PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Seno, K; Kishigami, A; Ihara, S; Maeda, T; Bondarenko, VA; Nishizawa, Y; Usukura, J; Yamazaki, A; Hayashi, F				Seno, K; Kishigami, A; Ihara, S; Maeda, T; Bondarenko, VA; Nishizawa, Y; Usukura, J; Yamazaki, A; Hayashi, F			A possible role of RGS9 in phototransduction - A bridge between the cGMP-phosphodiesterase system and the guanylyl cyclase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE ROD PHOTORECEPTORS; INHIBITORY SUBUNIT; PROTEIN-KINASE; CALCIUM; CLONING; PHOSPHORYLATION; SENSITIVITY; EXPRESSION; HYDROLYSIS; IONS	In the current concept of phototransduction, the concentration of cGMP in retinal rod outer segments is controlled by the balance of two enzyme activities: cGMP phosphodiesterase (PDE) and guanylyl cyclase (GC). However, no protein directly mediates these two enzyme systems. Here we show that RGS9, which is suggested to control PDE activity through regulation of transducin GTPase activity (He, W., Cowan, C. W., and Wensel, T, G. (1998) Neuron 20, 95-102), directly interacts with GC, When proteins in the Triton X-100-insoluble fraction of bovine rod outer segments were isolated by two-dimensional gel electrophoresis and binding of GC to these proteins was examined using a GC-specific antibody, proteins (55 and 32 kDa) were found to interact with GC. However, the activity of GC bound to the 55-kDa protein was not detected. This observation was elucidated by the finding that the 55-kDa protein inhibited GC activity in a dose-dependent manner. Amino acid sequence showed that five peptides derived from the 55-kDa protein were identical to corresponding peptides of RGS9. Together with other biochemical characterization of the 55-kDa protein, these observations indicate that the 55-kDa protein is RGS9 and that RGS9 inhibits GC. RGS9 may serve as a mediator between the PDE and GC systems.	Kobe Univ, Fac Sci, Dept Biol, Kobe, Hyogo 657, Japan; Kobe Univ, Grad Sch Sci & Technol, Kobe, Hyogo 657, Japan; Wayne State Univ, Sch Med, Dept Ophthalmol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Kresge Eye Inst, Detroit, MI 48201 USA; Nagoya Univ, Sch Med, Dept Anat, Nagoya, Aichi 466, Japan	Kobe University; Kobe University; Wayne State University; Wayne State University; Wayne State University; Nagoya University	Hayashi, F (corresponding author), Kobe Univ, Fac Sci, Dept Biol, Kobe, Hyogo 657, Japan.		Bondarenko, Vladimir/AFY-8370-2022; kishigami, Akio/B-5906-2018	kishigami, Akio/0000-0001-8333-5794; Usukura, Jiro/0000-0003-2286-5403	NEI NIH HHS [EY09631, EY07546] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009631, R01EY007546] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aparicio JG, 1996, J BIOL CHEM, V271, P27083, DOI 10.1074/jbc.271.43.27083; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; ERICKSON MA, 1992, SCIENCE, V257, P1255, DOI 10.1126/science.1519062; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; HAKKI S, 1990, BIOCHEMISTRY-US, V29, P1088, DOI 10.1021/bi00456a035; Harlow E, 1988, ANTIBODIES LABORATOR, P521; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4746, DOI 10.1073/pnas.88.11.4746; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; Li N, 1998, EUR J BIOCHEM, V252, P591, DOI 10.1046/j.1432-1327.1998.2520591.x; LIU XR, 1994, EXP EYE RES, V59, P761, DOI 10.1006/exer.1994.1162; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MATSUDAIRA P, 1993, PRACTICAL GUIDE PROT, P54; MOOS M, 1988, J BIOL CHEM, V263, P6005; NISHIZAWA Y, 1998, INVEST OPHTHALMOL  S, V39, P4855; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; TSUBOI S, 1994, J BIOL CHEM, V269, P15024; TSUBOI S, 1994, J BIOL CHEM, V269, P15016; Wolbring G, 1996, BIOCHEMISTRY-US, V35, P11013, DOI 10.1021/bi960699e; Yamazaki A, 1996, J BIOL CHEM, V271, P32495, DOI 10.1074/jbc.271.51.32495; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602	27	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22169	22172		10.1074/jbc.273.35.22169	http://dx.doi.org/10.1074/jbc.273.35.22169			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712827	hybrid			2022-12-25	WOS:000075616600003
J	Takei, Y; Tsujimoto, G				Takei, Y; Tsujimoto, G			Identification of a novel MCM3-associated protein that facilitates MCM3 nuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; DNA-REPLICATION; POSSIBLE INVOLVEMENT; IMPORTIN-ALPHA; RAT-LIVER; IN-VIVO; COMPLEX; EXPRESSION; CHROMATIN; COMPONENT	MCM3 is essential for the initiation of DNA replication and also participates in controls that ensure DNA replication is initiated once per cell cycle. In a two-hybrid screen for proteins that interact with human MCM3, we identified and cloned a novel protein of which the calculated molecular weight is 80,291. A specific antibody against the protein identified a 80-kDa protein in HeLa cell extract, indicating the protein actually expressed in cells. The interaction of these proteins was confirmed by immunoprecipitation assay. Moreover, we clarified a nuclear localization signal of human MCM3, and we find that mutagenesis on the nuclear localization signal of MCM3 affected the binding of newly isolated MCM3-assosiated protein, Map80. Map80 was expressed in Escherichia coli as a fusion with His, tag and purified with sequential column chromatographies. The addition of recombinant Map80 stimulated the amount of nuclear localized MCM3. These results suggest that Map80 is involved in the nuclear localization pathway of MCM3.	Natl Childrens Med Res Ctr, Dept Mol Cell Pharmacol, Setagaya Ku, Tokyo 154, Japan	National Center for Child Health & Development - Japan	Takei, Y (corresponding author), Natl Childrens Med Res Ctr, Dept Mol Cell Pharmacol, Setagaya Ku, Taishido 3-35-31, Tokyo 154, Japan.	ytakei@nch.go.jp						ADAM SA, 1991, METHOD CELL BIOL, V35, P469; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COLEMAN TR, 1996, SCIENCE, V270, P1667; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fujita M, 1997, J BIOL CHEM, V272, P10928; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; Kimura H, 1996, GENES CELLS, V1, P977, DOI 10.1046/j.1365-2443.1996.840284.x; KITADA K, 1992, GENETICS, V131, P21; Kohler M, 1997, FEBS LETT, V417, P104, DOI 10.1016/S0014-5793(97)01265-9; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Pemberton LF, 1997, J CELL BIOL, V139, P1645, DOI 10.1083/jcb.139.7.1645; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; TAKEI Y, 1992, J BIOL CHEM, V267, P5085; TAKEI Y, 1994, J BIOCHEM-TOKYO, V115, P578, DOI 10.1093/oxfordjournals.jbchem.a124378; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; Tsuji L, 1997, FEBS LETT, V416, P30, DOI 10.1016/S0014-5793(97)01092-2; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451; Young MR, 1997, MOL BIOL CELL, V8, P1587, DOI 10.1091/mbc.8.8.1587	28	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22177	22180		10.1074/jbc.273.35.22177	http://dx.doi.org/10.1074/jbc.273.35.22177			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712829	hybrid			2022-12-25	WOS:000075616600005
J	Arden, SR; Sinor, JD; Potthoff, WK; Aizenman, E				Arden, SR; Sinor, JD; Potthoff, WK; Aizenman, E			Subunit-specific interactions of cyanide with the N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONS IN-VITRO; REDOX MODULATORY SITE; INTRACELLULAR CALCIUM CONCENTRATIONS; CORTICAL-NEURONS; NMDA RECEPTOR; PYRROLOQUINOLINE QUINONE; OXIDIZED GLUTATHIONE; HIPPOCAMPAL CULTURES; MEDIATED RESPONSES; ZINC INHIBITION	Cyanide can potentiate N-methyl-D-aspartate receptor-mediated physiological responses in neurons. Here we show that this phenomenon may be attributable to a subunit-specific chemical modification of the receptor directly by the toxin. N-Methyl-D-aspartate (30 mu M)-induced whole cell responses in mature (22-29 days in vitro) rat cortical neurons were potentiated nearly a-fold by a 3-5-min treatment with 2 mM potassium cyanide, as did a similar treatment with 4 mM dithiothreitol. A 1-min incubation with the thiol oxidant 5,5'-dithio-bis(a-nitrobenzoic acid) (0.5 mM) readily reversed the potentiation induced by either cyanide or dithiothreitol. Cyanide did not increase further currents previously potentiated by dithiothreitol nor was it able to potentiate responses during brief co-application with the agonist. Transient expression studies in Chinese hamster ovary cells with wild-type and mutated recombinant N-methyl-D-aspartate subunits (NR) demonstrated that cyanide selectively potentiated NR1/NR2A receptors, presumably via the chemical reduction of NR2A. In contrast, currents mediated by NR1/NR2B receptors were somewhat diminished by the metabolic inhibitor. Some of the effects of cyanide on NR1/NR2B receptors may be mediated by the formation of a thiocyanate adduct with a cysteine residue located in NR1. Cyanide thus is able to distinguish chemically between two different N-methyl-D-aspartate receptor subtypes and produce diametrically opposing functional effects.	Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Aizenman, E (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurobiol, E1456-BST,3500 Terrace St, Pittsburgh, PA 15261 USA.		Aizenman, Elias/K-2726-2012	Aizenman, Elias/0000-0001-9610-4194	NINDS NIH HHS [NS29365] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029365] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIZENMAN E, 1995, NEUROSCI LETT, V189, P57, DOI 10.1016/0304-3940(95)11442-Y; AIZENMAN E, 1992, J NEUROSCI, V12, P2362; AIZENMAN E, 1990, NEURON, V5, P841, DOI 10.1016/0896-6273(90)90343-E; AIZENMAN E, 1994, NEUROSCI LETT, V168, P189, DOI 10.1016/0304-3940(94)90447-2; AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; AIZENMAN E, 1992, BRAIN RES, V585, P28, DOI 10.1016/0006-8993(92)91187-J; BOECKMAN FA, 1994, NEUROSCI LETT, V173, P189, DOI 10.1016/0304-3940(94)90180-5; Boeckman FA, 1996, J PHARMACOL EXP THER, V279, P515; Brimecombe JC, 1997, P NATL ACAD SCI USA, V94, P11019, DOI 10.1073/pnas.94.20.11019; CAI ZW, 1992, NEUROCHEM RES, V17, P803, DOI 10.1007/BF00969016; CATSIMPOOLAS N, 1964, J BIOL CHEM, V239, P4132; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chen NS, 1997, MOL PHARMACOL, V51, P1015, DOI 10.1124/mol.51.6.1015; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CORNELL NW, 1972, ANAL BIOCHEM, V47, P203, DOI 10.1016/0003-2697(72)90293-X; DUBINSKY JM, 1991, J NEUROSCI, V11, P2545; EMERSON D, 1993, J BACTERIOL, V175, P7819, DOI 10.1128/JB.175.24.7819-7827.1993; Ferreira IL, 1997, BRAIN RES, V768, P157, DOI 10.1016/S0006-8993(97)00634-3; GILBERT KR, 1991, NEUROSCI LETT, V133, P11, DOI 10.1016/0304-3940(91)90045-U; GOLDBERG MP, 1987, J PHARMACOL EXP THER, V243, P784; GOZLAN H, 1994, J NEUROPHYSIOL, V72, P3017, DOI 10.1152/jn.1994.72.6.3017; Hartnett KA, 1997, J NEUROCHEM, V68, P1836; KANTHASAMY AG, 1994, TOXICOL APPL PHARM, V126, P156, DOI 10.1006/taap.1994.1102; Kaplin AI, 1996, J NEUROSCI, V16, P2002; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KOHR G, 1994, NEURON, V12, P1031, DOI 10.1016/0896-6273(94)90311-5; LEHNINGER A, 1978, BIOCHEMISTRY-US, P477; MICHAELS RL, 1990, J NEUROSCI, V10, P283; MINTA A, 1989, J BIOL CHEM, V264, P8171; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; Paoletti P, 1997, J NEUROSCI, V17, P5711; PATEL MN, 1992, TOXICOL APPL PHARM, V115, P124, DOI 10.1016/0041-008X(92)90375-3; PATEL MN, 1993, NEUROTOXICOLOGY, V14, P35; PATEL MN, 1991, NEUROSCI LETT, V131, P42, DOI 10.1016/0304-3940(91)90332-N; PATEL MN, 1994, NEUROCHEM RES, V19, P1319, DOI 10.1007/BF01006824; PAUWELS PJ, 1989, MOL PHARMACOL, V36, P525; PECCI L, 1980, BIOCHIM BIOPHYS ACTA, V623, P348, DOI 10.1016/0005-2795(80)90262-7; Sinor J. D., 1997, Society for Neuroscience Abstracts, V23, P930; Sinor JD, 1997, BRAIN RES, V747, P297, DOI 10.1016/S0006-8993(96)01237-1; SUCHER NJ, 1991, J NEUROSCI RES, V30, P582, DOI 10.1002/jnr.490300316; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; Sun PW, 1997, J PHARMACOL EXP THER, V280, P1341; Sutcliffe MJ, 1996, BIOPHYS J, V70, P1575, DOI 10.1016/S0006-3495(96)79724-2; TANG LH, 1993, J PHYSIOL-LONDON, V465, P303, DOI 10.1113/jphysiol.1993.sp019678; TANG LH, 1993, NEURON, V11, P857, DOI 10.1016/0896-6273(93)90115-8; VANAMAN TC, 1970, J BIOL CHEM, V245, P3565; WAGNER PD, 1975, BIOCHEMISTRY-US, V14, P1900, DOI 10.1021/bi00680a015; Wo ZG, 1996, MOL PHARMACOL, V50, P770; ZEEVALK GD, 1992, J NEUROCHEM, V59, P1211, DOI 10.1111/j.1471-4159.1992.tb08430.x; ZHONG J, 1994, MOL PHARMACOL, V45, P846	51	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21505	21511		10.1074/jbc.273.34.21505	http://dx.doi.org/10.1074/jbc.273.34.21505			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705279	hybrid			2022-12-25	WOS:000075492600013
J	Fouts, DL; Stryker, GA; Gorski, KS; Miller, MJ; Nguyen, TV; Wrightsman, RA; Manning, JE				Fouts, DL; Stryker, GA; Gorski, KS; Miller, MJ; Nguyen, TV; Wrightsman, RA; Manning, JE			Evidence for four distinct major protein components in the paraflagellar rod of Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-COMPOSITION; SURFACE-ANTIGEN GENE; STRUCTURAL CLASSES; BRUCEI; STAGE; IDENTIFICATION; EXPRESSION; DROSOPHILA; SEQUENCE	The major structural proteins present inn the paraflagellar rod of Trypanosoma cruzi migrate on SDS-polyacrylamide gels as two distinct electrophoretic bands. The gene encoding a protein present in the faster migrating band, designated PAR 2, has been identified previously. Here we report the isolation and partial characterization of three genes, designated par I, par 3, and pal 4, that encode proteins present in the two paraflagellar rod protein bands. Peptide-specific polyclonal antibodies and monoclonal antibodies against the four proteins encoded by these genes shows that PAR 1 and PAR 3 are present only in the slower migrating paraflagellar rod band, and that PAR 2 and PAR 4 are present only in the faster migrating band. Analysis of the nucleotide sequence of these genes and the amino acid sequence of the conceptual proteins encoded by them indicates that par 2 shares high sequence similarity with par 3 and both are members of a common gene family, of which par I may be a distant member. Analysis of gene copy number and steady-state RNA levels suggest that the close stoichiometric ratio of the four PAR proteins is likely maintained by homeostatic regulation of RNA levels rather than gene dosage.	Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Manning, JE (corresponding author), Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA.			Stryker, Gabrielle/0000-0002-5658-0054; Miller, Mark/0000-0001-5676-389X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018873] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18873] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bastin P, 1996, PARASITOL TODAY, V12, P302, DOI 10.1016/0169-4758(96)10031-4; BEARD CA, 1988, MOL BIOCHEM PARASIT, V28, P227, DOI 10.1016/0166-6851(88)90007-2; BIRKETT CR, 1992, GENE, V110, P65, DOI 10.1016/0378-1119(92)90445-U; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; CHOU KC, 1992, EUR J BIOCHEM, V207, P429, DOI 10.1111/j.1432-1033.1992.tb17067.x; CHOU KC, 1995, PROTEINS, V21, P319, DOI 10.1002/prot.340210406; DEFLORIN J, 1994, J BIOL CHEM, V269, P28745; DELAFAILLE MAC, 1992, J BIOL CHEM, V267, P23839; DESOUZA W, 1980, J PARASITOL, V66, P229, DOI 10.2307/3280809; FOUTS DL, 1991, MOL BIOCHEM PARASIT, V46, P189, DOI 10.1016/0166-6851(91)90043-6; FOUTS DL, 1981, NUCLEIC ACIDS RES, V9, P7053, DOI 10.1093/nar/9.24.7053; GALLO JM, 1985, EUR J CELL BIOL, V36, P163; Hunger-Glaser I, 1997, MOL BIOCHEM PARASIT, V90, P347, DOI 10.1016/S0166-6851(97)00139-4; ISMACH R, 1989, J PROTOZOOL, V36, P616; KING RD, 1990, J MOL BIOL, V216, P441, DOI 10.1016/S0022-2836(05)80333-X; LEVIN JM, 1988, BIOCHIM BIOPHYS ACTA, V955, P283, DOI 10.1016/0167-4838(88)90206-3; MAO BY, 1994, PROTEIN ENG, V7, P319, DOI 10.1093/protein/7.3.319; Moore LL, 1996, MOL BIOCHEM PARASIT, V80, P125, DOI 10.1016/0166-6851(96)02688-6; PERRY DAD, 1995, INTERMEDIATE FILAMEN; ROZEK CE, 1983, CELL, V32, P23, DOI 10.1016/0092-8674(83)90493-2; SABORIO JL, 1990, EXP PARASITOL, V70, P411, DOI 10.1016/0014-4894(90)90125-V; SABORIO JL, 1989, J BIOL CHEM, V264, P4071; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLAEPPI K, 1989, J CELL BIOL, V109, P1695, DOI 10.1083/jcb.109.4.1695; Summers MD, 1987, MANUAL METHODS BACUL; WRIGHTSMAN RA, 1994, J IMMUNOL, V153, P3148; WRIGHTSMAN RA, 1986, INFECT IMMUN, V53, P235, DOI 10.1128/IAI.53.2.235-239.1986	28	33	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21846	21855		10.1074/jbc.273.34.21846	http://dx.doi.org/10.1074/jbc.273.34.21846			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705323	hybrid, Green Published			2022-12-25	WOS:000075492600057
J	Moriyama, T; Sather, SK; McGee, TP; Simoni, RD				Moriyama, T; Sather, SK; McGee, TP; Simoni, RD			Degradation of HMG-CoA reductase in vitro - Cleavage in the membrane domain by a membrane-bound cysteine protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; ENDOPLASMIC-RETICULUM; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; REGULATED DEGRADATION; APOLIPOPROTEIN B100; HEPG2 CELLS; PATHWAY; INHIBITOR; STEROL; ENZYME	We have recently shown that the endoplasmic reticulum (ER) membrane protein, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, is cleaved in isolated membrane fractions enriched for endoplasmic reticulum, Importantly, the cleavage rate is accelerated when the membranes are prepared from cells that have been pretreated with mevalonate or sterols, physiological regulators of the degradation process in vivo (McGee, T. P., Cheng, H. H., Kumagai, H., Omura, S., and Simoni, R. D. (1996) J. Biol. Chem. 271, 25630-25638). In the current study, we further characterize this in vitro cleavage of HMG-CoA reductase, E64, a specific inhibitor of cysteine-proteases, inhibits HMG-CoA reductase cleavage in vitro. In contrast, lactacystin, ale inhibitor of the proteasome, inhibits HMG-CoA reductase degradation in vivo but does not inhibit the in vitro cleavage. Purified ER fractions contain lactacystin-sensitive and E64-insensitive proteasome activity as measured by succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin hydrolysis. We removed the proteasome from purified ER fractions by solubilization with heptylthioglucoside and observed that the detergent extracted, proteasome-depleted membrane fractions retain regulated cleavage of HMG-CoA reductase, This indicates that ER-associated proteasome is not involved in degradation of HMG-CoA reductase in vitro. In order to determine the site(s) of proteolysis of HMG-CoA reductase in vitro, four antisera were prepared against peptide sequences representing various domains of HMG-CoA reductase and used for detection of proteolytic intermediates. The sizes and antibody reactivity of the intermediates suggest that HMG-CoA reductase is cleaved in the in vitro degradation system near the span 8 membrane region, which links the N-terminal membrane domain to the C-terminal catalytic domain of the protein. We conclude that HMG-CoA reductase can be cleaved in the membrane-span 8 region by a cysteine protease(s) tightly associated with ER membranes.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Simoni, RD (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	rdsimoni@leland.stanford.edu		McGee, Todd/0000-0002-3901-1001; Moriyama, Tatsuya/0000-0002-6861-926X	NHLBI NIH HHS [HL26502] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BIEDER T, 1997, SCIENCE, V278, P1801; CHUN KT, 1992, J BIOL CHEM, V267, P4236; CORRELL CC, 1994, J BIOL CHEM, V269, P633; EDWARDS PA, 1991, BIOCH LIPIDS LIPOPRO, P383; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; HANADA K, 1978, AGR BIOL CHEM TOKYO, V42, P523, DOI 10.1080/00021369.1978.10863014; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; INOUE S, 1992, J BIOL CHEM, V267, P9080; INOUE S, 1993, J BIOL CHEM, V268, P5894; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; LISCUM L, 1985, J BIOL CHEM, V260, P522; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; MEIGS TE, 1992, J BIOL CHEM, V267, P13547; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SKALNIK DG, 1985, J BIOL CHEM, V260, P1991; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; TANAKA RD, 1986, J LIPID RES, V27, P261; URADE R, 1992, J BIOL CHEM, V267, P15152; URBANI L, 1990, J BIOL CHEM, V265, P1919; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wu XJ, 1997, J BIOL CHEM, V272, P11575; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	39	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22037	22043		10.1074/jbc.273.34.22037	http://dx.doi.org/10.1074/jbc.273.34.22037			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705346	hybrid			2022-12-25	WOS:000075492600080
J	Najimi, M; Souaze, F; Mendez, M; Hermans, E; Berbar, T; Rostene, W; Forgez, P				Najimi, M; Souaze, F; Mendez, M; Hermans, E; Berbar, T; Rostene, W; Forgez, P			Activation of receptor gene transcription is required to maintain cell sensitization after agonist exposure - Study on neurotensin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-HYDROXYLASE GENE; BOND PSEUDOPEPTIDE ANALOGS; MESSENGER-RNA LEVELS; SMOOTH-MUSCLE CELLS; QUANTITATIVE RT-PCR; CALCIUM MOBILIZATION; DOWN-REGULATION; G-PROTEIN; DIFFERENTIAL REGULATION; RAPID DESENSITIZATION	Neurotensin (NT) acts through specific G protein-coupled receptors to induce effects in the central nervous system and periphery. In this study we have shown that in the human neuroblastoma cell Line CHP 212, an NT agonist, JMV 449, induced high affinity neurotensin receptor (NTR) gene activation. I-125-NT binding of cells challenged with JMV 449 rapidly decreased then reappeared and subsequently stabilized at 50% of the control values after 48 h of agonist exposure. These receptors, which reappeared at the cell surface, are as active as those found in control cells as demonstrated by Ca2+ mobilization. Furthermore, the tyrosine hydroxylase (TH) gene, a known NT target gene, remained activated after prolonged NT agonist exposure in this cell line. In the murine neuroblastoma cell line, N1E-115, NT did not stimulate NTR gene activation but induced NTR mRNA destabilization after long term agonist exposure. In this cell line, NT binding dropped to 15% of control values and remained at this value after agonist treatment. The TH expression, which was originally activated upon NT agonist exposure, decreased to control values after prolonged agonist exposure. These observations combined with the data obtained from a complementary study with HT-29 cells (Souaze, F., Rostene, W., and Forgez, P. (1997) J. Biol. Chem. 272, 10087-10094) revealed the crucial role of agonist-induced receptor gene transcription in the maintenance of cell sensitivity. A model for G protein-coupled receptor regulation induced by prolong and intense agonist stimulation is proposed.	Hop St Antoine, INSERM U339, F-75012 Paris, France; Univ Catholique Louvain, Pharmacol Lab, B-1200 Brussels, Belgium; Inst Mexicano Psiquiat, Mexico City 14370, DF, Mexico	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Catholique Louvain; Instituto Nacional de Psiquiatria Ramon de la Fuente Muniz	Forgez, P (corresponding author), Hop St Antoine, INSERM U339, 184 Rue Faubourg St Antoine, F-75012 Paris, France.		Hermans, Emmanuel/V-3040-2019; Hermans, Emmanuel/A-1654-2015; souazé, frédérique/AAE-6478-2021; Rostene, William/F-2754-2017; Souazé, Frédérique/K-7937-2015; FORGEZ, Patricia/N-2960-2018	Frederique, Souaze/0000-0003-0476-2603; ROSTENE, WILLIAM/0000-0003-0409-5361				AMAR S, 1987, J NEUROCHEM, V49, P999, DOI 10.1111/j.1471-4159.1987.tb09986.x; BOUDIN H, 1995, BIOCHEM J, V305, P277, DOI 10.1042/bj3050277; BOZOU JC, 1986, MOL PHARMACOL, V29, P489; BOZOU JC, 1989, BIOCHEM J, V264, P871, DOI 10.1042/bj2640871; BURGEVIN MC, 1992, NEUROSCIENCE, V49, P627, DOI 10.1016/0306-4522(92)90232-Q; CARRAWAY R, 1976, J BIOL CHEM, V251, P7045; Chae HD, 1996, J NEUROCHEM, V66, P1264; Chalon P, 1996, FEBS LETT, V386, P91, DOI 10.1016/0014-5793(96)00397-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; Clapham DE, 1996, NATURE, V379, P297, DOI 10.1038/379297a0; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; DIPAOLA ED, 1993, J PHARMACOL EXP THER, V264, P1; DOULUT S, 1992, PEPTIDE RES, V5, P30; FRASER CM, 1995, LIFE SCI, V56, P899, DOI 10.1016/0024-3205(95)00026-3; GULLY D, 1993, P NATL ACAD SCI USA, V90, P65, DOI 10.1073/pnas.90.1.65; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HEIN L, 1995, NEUROPHARMACOLOGY, V34, P357, DOI 10.1016/0028-3908(95)00018-2; HERMANS E, 1995, J NEUROCHEM, V64, P2518; HERMANS E, 1994, BIOCHEM BIOPH RES CO, V198, P400, DOI 10.1006/bbrc.1994.1056; HIREMAGALUR B, 1993, J BIOL CHEM, V268, P23704; HOSADA K, 1994, J NEUROCHEM, V63, P16345; IZZO NJ, 1990, P NATL ACAD SCI USA, V87, P6268, DOI 10.1073/pnas.87.16.6268; KARDOOR V, 1996, PROG NEUROBIOL, V48, P555; KASCKOW J, 1991, REGUL PEPTIDES, V36, P153, DOI 10.1016/0167-0115(91)90053-J; KITABGI P, 1987, EUR J PHARMACOL, V140, P285, DOI 10.1016/0014-2999(87)90285-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert PD, 1996, NEUROSCIENCE, V75, P1141, DOI 10.1016/0306-4522(96)00210-2; LUGRIN D, 1991, EUR J PHARMACOL, V205, P191, DOI 10.1016/0014-2999(91)90819-C; Mendez M, 1997, J MOL NEUROSCI, V9, P93, DOI 10.1007/BF02736853; NEMEROFF CB, 1980, BRAIN RES, V195, P69, DOI 10.1016/0006-8993(80)90867-7; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; RYDELEKFITZGERALD L, 1993, MOL CELL ENDOCRINOL, V92, P253, DOI 10.1016/0303-7207(93)90016-D; SATO M, 1991, DEV BRAIN RES, V58, P97, DOI 10.1016/0165-3806(91)90241-A; Scarceriaux V, 1996, J NEUROENDOCRINOL, V8, P587; SNIDER RM, 1986, J NEUROCHEM, V47, P1214; Souaze F, 1996, BIOTECHNIQUES, V21, P280; Souaze F, 1997, J BIOL CHEM, V272, P10087; STEEL MC, 1993, MOL PHARMACOL, V43, P694; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER JT, 1990, J PHARMACOL EXP THER, V253, P1049; VITA N, 1993, FEBS LETT, V317, P139, DOI 10.1016/0014-5793(93)81509-X; WESSELSREIKER M, 1993, J NEUROCHEM, V60, P1018, DOI 10.1111/j.1471-4159.1993.tb03250.x; Yu K, 1996, ENDOCRINOLOGY, V137, P3566, DOI 10.1210/en.137.8.3566	46	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21634	21641		10.1074/jbc.273.34.21634	http://dx.doi.org/10.1074/jbc.273.34.21634			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705296	Green Published, hybrid			2022-12-25	WOS:000075492600030
J	Singh, S; Tang, HK; Lee, JY; Saunders, GF				Singh, S; Tang, HK; Lee, JY; Saunders, GF			Truncation mutations in the transactivation region of PAX6 result in dominant-negative mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX-CONTAINING GENE; DNA-BINDING ACTIVITY; SMALL EYE SEY; PAIRED DOMAIN; ANIRIDIA GENE; EYELESS GENE; PROTEINS; MOUSE; CELLS; TRANSCRIPTION	PAX6 is a transcription factor with two DNA-binding domains (paired box and homeobox) and a proline-serine-threonine (PST)-rich transactivation domain. PAX6 regulates eye development in animals ranging from jellyfish to Drosophila to humans. Heterozygous mutations in the human PAX6 gene result in various phenotypes, including aniridia, Peter's anomaly, autosomal dominant keratitis, and familial foveal dysplasia, It is believed that the mutated allele of PAX6 produces an inactive protein and aniridia is caused due to genetic haploinsufficiency, However, several truncation mutations have been found to occur in the C-terminal half of PAX6 in patients with Aniridia resulting in mutant proteins that retain the DNA-binding domains but have lost most of the transactivation domain, It is not clear whether such mutants really behave as loss-of-function mutants as predicted by haploinsufficiency. Contrary to this theory, our data showed that these mutants are dominant-negative in transient transfection assays when they are coexpressed with wild-type PAX6. We found that the dominant-negative effects result from the enhanced DNA binding ability of these mutants. Kinetic studies of binding and dissociation revealed that various truncation mutants have 3-5-fold higher affinity to various DNA-binding sites when compared with the wild-type PAX6, These results provide a new insight into the role of mutant PAX6 in causing aniridia.	Univ Texas, MD Anderson Cancer Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Saunders, GF (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Biochem & Mol Biol, Box 117, Houston, TX 77030 USA.	saunders@odin.mdacc.tmc.edu			NCI NIH HHS [CA16672] Funding Source: Medline; NEI NIH HHS [EY09675, EY10608] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY010608, R01EY009675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDLEY UP, 1994, INVEST OPHTH VIS SCI, V35, P3094; Azuma N, 1996, NAT GENET, V13, P141, DOI 10.1038/ng0696-141; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHALEPAKIS G, 1994, DNA CELL BIOL, V13, P891, DOI 10.1089/dna.1994.13.891; CHISHOLM AD, 1995, NATURE, V377, P52, DOI 10.1038/377052a0; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; DAVIS A, 1993, HUM MOL GENET, V2, P2093, DOI 10.1093/hmg/2.12.2093; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Desplan C, 1997, CELL, V91, P861, DOI 10.1016/S0092-8674(00)80475-4; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; Glaser T., 1995, MOL GENETICS OCULAR, P51; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HANSON IM, 1993, HUM MOL GENET, V2, P915; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Holst BD, 1997, P NATL ACAD SCI USA, V94, P1465, DOI 10.1073/pnas.94.4.1465; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; LYONS LA, 1992, GENOMICS, V13, P925, DOI 10.1016/0888-7543(92)90002-A; MARTHA A, 1994, AM J HUM GENET, V54, P801; MARTHA AD, 1994, HUM MUTAT, V3, P297, DOI 10.1002/humu.1380030319; MATSUO T, 1993, NAT GENET, V3, P299, DOI 10.1038/ng0493-299; MINTZHITTNER HA, 1992, AM J OPHTHALMOL, V114, P700, DOI 10.1016/S0002-9394(14)74048-6; NELSON LB, 1984, SURV OPHTHALMOL, V28, P621, DOI 10.1016/0039-6257(84)90184-X; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; Prosser J, 1998, HUM MUTAT, V11, P93, DOI 10.1002/(SICI)1098-1004(1998)11:2<93::AID-HUMU1>3.0.CO;2-M; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Saunders GF, 1998, HUM MUTAT, pS207; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; SCHMAHL W, 1993, ACTA NEUROPATHOL, V86, P126, DOI 10.1007/BF00334879; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; Tang HK, 1997, HUM MOL GENET, V6, P381, DOI 10.1093/hmg/6.3.381; Tomarev SI, 1997, P NATL ACAD SCI USA, V94, P2421, DOI 10.1073/pnas.94.6.2421; TON CCT, 1992, GENOMICS, V13, P251, DOI 10.1016/0888-7543(92)90239-O; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; Vogan KJ, 1996, MOL CELL BIOL, V16, P6677; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WILKIE AOM, 1994, J MED GENET, V31, P89, DOI 10.1136/jmg.31.2.89; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Xu ZP, 1997, J BIOL CHEM, V272, P3430, DOI 10.1074/jbc.272.6.3430; ZHANG YH, 1995, NATURE, V377, P55, DOI 10.1038/377055a0	54	68	74	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21531	21541		10.1074/jbc.273.34.21531	http://dx.doi.org/10.1074/jbc.273.34.21531			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705283	hybrid			2022-12-25	WOS:000075492600017
J	Underwood, KW; Song, CZ; Kriz, RW; Chang, XJ; Knopf, JL; Lin, LL				Underwood, KW; Song, CZ; Kriz, RW; Chang, XJ; Knopf, JL; Lin, LL			A novel calcium-independent phospholipase A(2), cPLA(2)-gamma, that is prenylated and contains homology to cPLA(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE-A(2); P388D(1) MACROPHAGES; GENE-EXPRESSION; PROTEIN; CELLS; ACID; IDENTIFICATION; TRANSLOCATION; PURIFICATION; CYSTEINE	We report the cloning and characterization of a novel membrane-bound, calcium-independent PLA(2), named cPLA(2)-gamma. The sequence encodes a 541-amino acid protein containing a domain with significant homology to the catalytic domain of the 85-kDa cPLA(2) (cPLA(2)-alpha). cPLA(2)-gamma does not contain the regulatory calcium-dependent lipid binding (CaLB) domain found in cPLA(2)-alpha. However, cPLA(2)-gamma does contain two consensus motifs for lipid modification, a prenylation motif (-CCLA) at the C terminus and a myristoylation site at the N terminus. We present evidence that the isoprenoid precursor [H-3]mevalonolactone is incorporated into the prenylation motif of cPLA(2)-gamma. Interestingly, cPLA(2)-gamma demonstrates a preference for arachidonic acid at the sn-2 position of phosphatidylcholine as compared with palmitic acid. cPLA(2)-gamma encodes a 3-kilobase message, which is highly expressed in heart and skeletal muscle, suggesting a specific role in these tissues. identification of cPLA(2)-gamma reveals a newly defined family of phospholipases A(2) with homology to CPLA(2)-alpha.	Genet Inst, Small Mol Drug Discovery Grp, Cambridge, MA 02140 USA		Lin, LL (corresponding author), Genet Inst, Small Mol Drug Discovery Grp, 87 Cambridge Pk Dr, Cambridge, MA 02140 USA.							ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DAVIES MV, 1992, J VIROL, V66, P1924, DOI 10.1128/JVI.66.4.1924-1932.1992; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DEREWENDA ZS, 1993, TRENDS BIOCHEM SCI, V18, P20, DOI 10.1016/0968-0004(93)90082-X; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P5629; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; JOHNSON RD, 1994, ANNU REV BIOCHEM, V63, P869; KIM CM, 1992, J BIOL CHEM, V267, P23113; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; McHowat J, 1997, AM J PHYSIOL-HEART C, V272, pH1972, DOI 10.1152/ajpheart.1997.272.4.H1972; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otto JC, 1996, J BIOL CHEM, V271, P4569; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHARP JD, 1994, J BIOL CHEM, V269, P23250; Shen F, 1996, J BIOL CHEM, V271, P3692; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	31	200	211	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21926	21932		10.1074/jbc.273.34.21926	http://dx.doi.org/10.1074/jbc.273.34.21926			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705332	hybrid			2022-12-25	WOS:000075492600066
J	Camper, L; Hellman, U; Lundgren-Akerlund, E				Camper, L; Hellman, U; Lundgren-Akerlund, E			Isolation, cloning, and sequence analysis of the integrin subunit alpha 10, a beta 1-associated collages binding integrin expressed on chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; LEUKOCYTE ADHESION GLYCOPROTEIN; HUMAN ARTICULAR CHONDROCYTES; SMOOTH-MUSCLE CELLS; MOLECULAR-CLONING; CYTOPLASMIC DOMAINS; TISSUE DISTRIBUTION; DEPENDENT ADHESION; LAMININ RECEPTOR; MESSENGER-RNA	We have found that chondrocytes express a novel collagen type II-binding integrin, a new member of the beta 1-integrin family. The integrin alpha subunit, which has a M(r) of 160 kDa reduced, was isolated from bovine chondrocytes by collagen type II affinity purification. The human homologue was obtained by screening a human chondrocyte library with a bovine cDNA probe. Cloning and cDNA sequence analysis of the human integrin alpha subunit designated alpha 10 show that it shares the general structure of other integrin alpha subunits, The predicted amino acid sequence consists of a 1167-amino acid mature protein, including a signal peptide (22 amino acids), a long extracellular domain (1098 amino acids), a transmembrane domain (25 amino acids), and a short cytoplasmic domain (22 amino acids). The extracellular part contains a 7-fold repeated sequence, an I-domain (199 amino acids) and three putative divalent cation-binding sites. The deduced amino acid sequence of alpha 10 is 35% identical to the integrin subunit (alpha 2 and 37% identical to the integrin subunit alpha 1. Northern blot analysis shows a single mRNA of 5.4 kilobases in chondrocytes. A peptide antibody against the predicted sequence of the cytoplasmic domain of alpha 10 immunoprecipitated two proteins with masses of 125 and 160 kDa from chondrocyte lysates under reducing conditions. The peptide antibody specifically stained chondrocytes in tissue sections of human articular cartilage, showing that alpha 10 beta 1 is expressed in cartilage tissue.	Lund Univ, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, S-22100 Lund, Sweden; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Lund University; Ludwig Institute for Cancer Research	Camper, L (corresponding author), Lund Univ, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, POB 94, S-22100 Lund, Sweden.	lisbet.camper@medkem.lu.se	Haglund, Lisbet/N-3095-2013	Haglund, Lisbet/0000-0002-1288-2149				ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOTTGER BA, 1989, DIFFERENTIATION, V41, P158, DOI 10.1111/j.1432-0436.1989.tb00743.x; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; CALDERWOOD DA, 1995, BIOCHEM SOC T, V23, P504; Camper L, 1997, J CELL BIOL, V138, P1159, DOI 10.1083/jcb.138.5.1159; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; deMelker AA, 1997, BIOCHEM J, V328, P529, DOI 10.1042/bj3280529; DURR J, 1993, EXP CELL RES, V207, P235, DOI 10.1006/excr.1993.1189; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FORSBERG E, 1994, EXP CELL RES, V213, P183, DOI 10.1006/excr.1994.1189; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HAUSELMANN HJ, 1992, MATRIX, V12, P116; Hellman U, 1997, SPRING LAB MAN, P97; HEMLER ME, 1988, IMMUNOL TODAY, V9, P109, DOI 10.1016/0167-5699(88)91280-7; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HOLMVALL K, 1995, EXP CELL RES, V221, P496, DOI 10.1006/excr.1995.1401; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hynes RO, 1992, CURR OPIN GENET DEV, V2, P621, DOI 10.1016/S0959-437X(05)80182-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; LANGUINO LR, 1989, BLOOD, V73, P734; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LEE CH, 1995, CELL GROWTH DIFFER, V6, P347; MILLER EJ, 1972, BIOCHEMISTRY-US, V11, P4903, DOI 10.1021/bi00776a005; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P16580, DOI 10.1074/jbc.271.28.16580; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SALTER DM, 1992, BRIT J RHEUMATOL, V31, P231; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SCHNAPP LM, 1995, J CELL SCI, V108, P537; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SOMMARIN Y, 1983, BIOCHEM J, V214, P777, DOI 10.1042/bj2140777; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Towbin H, 1992, Biotechnology, V24, P145; Tuckwell DS, 1996, EUR J BIOCHEM, V241, P732, DOI 10.1111/j.1432-1033.1996.00732.x; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; TUCKWELL DS, 1994, CELL ADHES COMMUN, V2, P385, DOI 10.3109/15419069409004450; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WOODS VL, 1994, ARTHRITIS RHEUM, V37, P537, DOI 10.1002/art.1780370414; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Yokosaki Y, 1996, J BIOL CHEM, V271, P24144, DOI 10.1074/jbc.271.39.24144; ZIOBER BL, 1993, J BIOL CHEM, V268, P26773	64	189	211	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20383	20389		10.1074/jbc.273.32.20383	http://dx.doi.org/10.1074/jbc.273.32.20383			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685391	hybrid			2022-12-25	WOS:000075305400068
J	Fiskerstrand, T; Riedel, B; Ueland, PM; Seetharam, B; Pezacka, EH; Gulati, S; Bose, S; Banerjee, R; Berge, RK; Refsum, H				Fiskerstrand, T; Riedel, B; Ueland, PM; Seetharam, B; Pezacka, EH; Gulati, S; Bose, S; Banerjee, R; Berge, RK; Refsum, H			Disruption of a regulatory system involving cobalamin distribution and function in a methionine-dependent human glioma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLMALONYL-COA MUTASE; TRANSCOBALAMIN-II RECEPTOR; HOMOCYSTEINE REMETHYLATION; HUMAN-PLACENTA; EXPRESSION; METABOLISM; SYNTHASE; DEFICIENT; ENZYME; RAT	Cobalamin metabolism and function were investigated at the levels fi om transcobalamin II (TCII) receptor to the cobalamin-dependent enzymes, methionine synthase and methylnalonyl-CoA mutase, in a methionine-dependent (P60) and a methionine-independent (P60H) glioma cell line. Using P60H as reference, the P60 cells cultured in a methionine medium had slightly lower TCII receptor activity and normal total cobalamin content, a moderately reduced microsomal and mitochondrial cobalamin(LII) reductase activity but only trace amounts of the methylcobalamin and adenosylcobalamin cofactors. When transferred to a homocysteine medium without methionine, P60H cells showed a slightly enhanced TCII receptor activity, but the other cobalamin-related functions were essentially unchanged. In contrast, the methionine-dependent P60 cells responded to homocysteine medium with a nearly g-fold enhancement of TCII receptor expression and a doubling of both the hydroxycobalamin content and the microsomal reductase activity. The mitochondrial reductase and the cobalamin-related processes further down the pathway did not change markedly. In both cell lines, TCII receptor activity was further increased when growth in homocysteine medium was combined with N2O exposure. These data suggest that low methionine and/or high homocysteine exert a positive feedback control on TCII receptor activity. The concurrent increase in hydroxycobalamin content and in microsomal reductase activity are either subjected to similar regulation or secondary to increased cobalamin transport, This regulatory network is most prominent in the methionine-dependent P60 cells harboring a disruption of the network in the proximity of cobalamin(III) reductase.	Univ Bergen, Dept Pharmacol, N-5021 Bergen, Norway; Univ Bergen, Dept Clin Biochem, N-5021 Bergen, Norway; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Vet Affairs Med Ctr, Milwaukee, WI 53226 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Bergen; University of Bergen; Medical College of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Nebraska System; University of Nebraska Lincoln	Fiskerstrand, T (corresponding author), Univ Bergen, Dept Pharmacol, N-5021 Bergen, Norway.		Ueland, Per M/C-7340-2013; Refsum, Helga/A-4073-2010	Ueland, Per Magne/0000-0002-1903-0571	NIDDK NIH HHS [DK 45776, DK-50052] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045776, R01DK045776, R01DK050052] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKSLEN LA, 1988, ANTICANCER RES, V8, P797; AMAGASAKI T, 1990, BLOOD, V76, P1380; BOSE S, 1995, BIOCHEM J, V310, P923, DOI 10.1042/bj3100923; Bose S, 1997, METHOD ENZYMOL, V281, P281; BOSE S, 1995, J BIOL CHEM, V270, P8152, DOI 10.1074/jbc.270.14.8152; CARDINALE GJ, 1969, ARCH BIOCHEM BIOPHYS, V131, P92, DOI 10.1016/0003-9861(69)90108-8; CHRISTENSEN B, 1992, J PHARMACOL EXP THER, V261, P1096; DRUMMOND JT, 1994, BIOCHEMISTRY-US, V33, P3742, DOI 10.1021/bi00178a034; FENTON WA, 1978, ARCH BIOCHEM BIOPHYS, V189, P441, DOI 10.1016/0003-9861(78)90232-1; FISKERSTRAND T, 1994, CANCER RES, V54, P4899; Fiskerstrand T, 1997, INT J CANCER, V72, P301, DOI 10.1002/(SICI)1097-0215(19970717)72:2<301::AID-IJC17>3.3.CO;2-0; Gulati S, 1997, J BIOL CHEM, V272, P19171, DOI 10.1074/jbc.272.31.19171; HALL CA, 1987, J CELL PHYSIOL, V133, P187, DOI 10.1002/jcp.1041330125; HOFFMAN RM, 1985, ANTICANCER RES, V5, P1; Jacobsen D., 1979, Vitamin B12, P663; KENNEDY DG, 1990, BRIT J NUTR, V64, P721, DOI 10.1079/BJN19900074; KOLHOUSE JF, 1991, J BIOL CHEM, V266, P23010; KOLHOUSE JF, 1980, J BIOL CHEM, V255, P2708; LITEPLO RG, 1991, J CELL PHYSIOL, V149, P332, DOI 10.1002/jcp.1041490222; MELLMAN I, 1979, J BIOL CHEM, V254, P1847; MELLMAN I, 1997, P NATL ACAD SCI USA, V74, P916; PEZACKA EH, 1993, BIOCHIM BIOPHYS ACTA, V1157, P167, DOI 10.1016/0304-4165(93)90061-C; RIEDEL B, 1995, CLIN CHEM, V41, P1164; ROSENBLATT DS, 1990, BIOESSAYS, V12, P331, DOI 10.1002/bies.950120705; SELIGMAN PA, 1978, J BIOL CHEM, V253, P1766; VANKAPEL J, 1983, CLIN CHIM ACTA, V131, P211, DOI 10.1016/0009-8981(83)90090-6; Watanabe F, 1996, J NUTR, V126, P2947, DOI 10.1093/jn/126.12.2947; WATANABE F, 1994, BIOSCI BIOTECH BIOCH, V58, P556, DOI 10.1271/bbb.58.556; WATKINS D, 1989, AM J MED GENET, V34, P427, DOI 10.1002/ajmg.1320340320; WEISSBACH H, 1963, J BIOL CHEM, V238, P3318	30	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20180	20184		10.1074/jbc.273.32.20180	http://dx.doi.org/10.1074/jbc.273.32.20180			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685364	hybrid			2022-12-25	WOS:000075305400041
J	Song, J; Murakami, H; Tsutsui, H; Tang, XR; Matsumura, M; Itakura, K; Kanazawa, I; Sun, K; Yokoyama, KK				Song, J; Murakami, H; Tsutsui, H; Tang, XR; Matsumura, M; Itakura, K; Kanazawa, I; Sun, K; Yokoyama, KK			Genomic organization and expression of a human gene for myc-associated zinc finger protein (MAZ)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KI-RAS PROMOTER; C-MYC; INSITU HYBRIDIZATION; NUCLEAR FACTOR; RECEPTOR GENE; START SITES; TRANSCRIPTION; CELLS; SEQUENCES; BINDS	We have cloned and characterized the genomic structure of the human gene for Myc-associated zinc finger protein (MAZ), which is located on chromosome 16p11.2. This gene is transcribed as an mRNA of 2.7 kilobases (kb) that encodes a 60-kDa MAZ protein. A 40-kb cosmid clone was isolated that includes the promoter, five exons, four introns, and one 3'-untranslated region. All exon-intron junction sequences conform to the GT/AG rule. The promoter region has features typical of a housekeeping gene: a high G + C content (88.44%); a high frequency of CpG dinucleotides, in particular within the region 0.5 kb upstream of the site of initiation of translation; and the absence of canonical TATA and CAAT boxes. An S1 nuclease protection assay demonstrated the presence of multiple sites for initiation of transcription around a site 174 nucleotides (nt) upstream of the ATG codon and such expression was reflected by the promoter activity of a MAZ promoter/CAT (chloramphenicol acetyltransferase) reporter gene. Cis-acting positive and negative elements controlling basal transcription of the human MAZ gene were found from nucleotides (nt) -383 to -248 and nt -2500 to -948. Moreover, positive and negative autoregulatory elements were also identified in the regions from nt -248 to -189 and from nt -383 to -248 after co-transfection of HeLa cells with plasmids that carried the MAZ promoter/CAT construct and the MAZ-expression vector. Our results indicate that the 5'-end flanking sequences are responsible for the promoter activities of the MAZ gene.	RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 305, Japan; China Med Univ, Dept Med Genet, Shenyang 110001, Peoples R China; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 305, Japan; City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Genet, Duarte, CA 91010 USA; Univ Tokyo, Fac Med, Inst Brain Res, Dept Neurol, Tokyo 113, Japan	RIKEN; China Medical University; University of Tsukuba; City of Hope; Beckman Research Institute of City of Hope; University of Tokyo	Yokoyama, KK (corresponding author), RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, 3-1-1 Koyadai, Tsukuba, Ibaraki 305, Japan.	kazunari@rtc.riken.go.jp						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOCKAMP EO, 1995, BLOOD, V86, P1502, DOI 10.1182/blood.V86.4.1502.bloodjournal8641502; BONHAM K, 1993, ONCOGENE, V8, P1973; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; EVANS T, 1988, J MOL BIOL, V199, P61, DOI 10.1016/0022-2836(88)90379-8; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOU LH, 1983, METHOD ENZYMOL, V100, P60; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JORCYK CL, 1990, ONCOGENE, V6, P323; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KATOH S, 1990, EMBO J, V9, P127, DOI 10.1002/j.1460-2075.1990.tb08088.x; KAWAI J, 1989, J IMMUNOL, V142, P312; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; Komatsu M, 1997, ONCOGENE, V15, P1123, DOI 10.1038/sj.onc.1201283; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KOYANONAKAGAWA N, 1994, MOL CELL BIOL, V14, P5099, DOI 10.1128/MCB.14.8.5099; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MAVROTHALASSITIS GJ, 1990, ONCOGENE, V5, P1337; MOBERG KH, 1992, ONCOGENE, V7, P411; MOBERG KH, 1991, J CELL PHYSIOL, V148, P75, DOI 10.1002/jcp.1041480110; OZAWA K, 1992, GENOMICS, V12, P214, DOI 10.1016/0888-7543(92)90368-3; Parks CL, 1997, J VIROL, V71, P9600, DOI 10.1128/JVI.71.12.9600-9607.1997; Parks CL, 1996, J BIOL CHEM, V271, P4417; PATEL M, 1990, ONCOGENE, V5, P201; PESTOV DG, 1991, NUCLEIC ACIDS RES, V19, P6527, DOI 10.1093/nar/19.23.6527; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; Sambrook D.J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STEPHENS RM, 1992, J MOL BIOL, V228, P1124, DOI 10.1016/0022-2836(92)90320-J; Tsutsui H, 1996, BIOCHEM BIOPH RES CO, V226, P801, DOI 10.1006/bbrc.1996.1432	51	53	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20603	20614		10.1074/jbc.273.32.20603	http://dx.doi.org/10.1074/jbc.273.32.20603			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685418	hybrid			2022-12-25	WOS:000075305400095
J	Barley, RDC; Enns, L; Paterson, MC; Mirzayans, R				Barley, RDC; Enns, L; Paterson, MC; Mirzayans, R			Aberrant p21(WAF1)-dependent growth arrest as the possible mechanism of abnormal resistance to ultraviolet light cytotoxicity in Li-Fraumeni syndrome fibroblast strains heterozygous for TP53 mutations	ONCOGENE			English	Article						Li-Fraumeni syndrome; UV; apoptosis; DNA repair; p53; p21(WAF1)	CANCER-PRONE FAMILY; P53 TUMOR-SUPPRESSOR; TRANSCRIPTION-COUPLED REPAIR; WILD-TYPE P53; CELL-CYCLE; DNA-DAMAGE; EXCISION-REPAIR; ATAXIA-TELANGIECTASIA; PYRIMIDINE DIMERS; AFFECTED MEMBERS	The purpose of this study is to better understand the roles of the p53 tumor suppressor protein and the product of the p53-regulated gene p21(WAF1) in the response of diploid human dermal fibroblast cultures to 254 nm ultraviolet (UV) light. We report that Li - Fraumeni syndrome (LFS) fibroblast strains heterozygous for TP53 mutation at either codon 245 or 234 exhibit markedly reduced or no expression of p21(WAF1) following UV irradiation, respectively. These strains also exhibit defective nucleotide excision repair and pronounced inhibition of RNA synthesis following UV exposure, both of which are molecular hallmarks of cells derived from patients with the UV-sensitive syndrome xeroderma pigmentosum, In sharp contrast to xeroderma pigmentosum cells, however, the repair-deficient LFS cells show abnormal resistance, rather than hypersensitivity, to the killing effect of UV light. We further demonstrate that exposure of normal human fibroblasts to biologically relevant fluences (less than or equal to 15 J/m(2)) of UV does not induce apoptotic cell death, indicating that UV resistant phenotype displayed by LFS strains is not associated with deregulated apoptosis, In normal fibroblasts, such treatment results in a moderate (similar to threefold) up-regulation of p53 protein, induction of the p21(WAF1) gene, and a senescence-like growth arrest. On the other hand, exposure to greater than or equal to,20 J/m(2) UV results in a striking up-regulation of p53, inhibition of p21(WAF1) expression, and activation of an apoptotic pathway. We conclude that: (i) p21(WAF1)-mediated senescence is the principal mode of cell death induced by less than or equal to 15 J/m(2) UV light in normal human fibroblasts; (ii) there is a threshold effect for p53-dependent apoptosis and that, in normal human cells, this threshold level is induced upon exposure to similar to 20 J/m(2) UV; (iii) the p53 signaling pathway is malfunctional in the TP53 heterozygous LFS strains examined; and (iv) the enhanced resistance to UV-induced cell killing displayed by these LFS strains is a consequence of diminished growth arrest, which is presumably mediated by p21(WAF1) nd not abnormalities in an apoptotic pathway.	Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res MBC 03, Riyadh 11211, Saudi Arabia	University of Alberta; King Faisal Specialist Hospital & Research Center	Mirzayans, R (corresponding author), Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada.							ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ANDREWS AD, 1978, P NATL ACAD SCI USA, V75, P1984, DOI 10.1073/pnas.75.4.1984; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948; BECHHANSEN NT, 1981, LANCET, V1, P1335; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; Bristow RG, 1996, RADIOTHER ONCOL, V40, P197, DOI 10.1016/0167-8140(96)01806-3; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Chung DH, 1998, RADIAT RES, V149, P187, DOI 10.2307/3579929; Cistulli CA, 1998, CANCER RES, V58, P1993; DeFrank JS, 1996, CANCER RES, V56, P5365; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DOVER R, 1994, J CELL SCI, V107, P1181; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Enns L, 1998, RADIAT RES, V150, P11, DOI 10.2307/3579639; Ford JM, 1998, CANCER RES, V58, P599; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Gadbois DM, 1997, CANCER RES, V57, P1151; GALLOWAY AM, 1994, J BIOL CHEM, V269, P974; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; JARVIS WD, 1994, CANCER RES, V54, P1707; JONES JC, 1991, MUTAT RES, V255, P155, DOI 10.1016/0921-8777(91)90049-U; JUVAN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; LI CY, 1995, INT J ONCOL, V6, P233; LI Y, 1994, ONCOGENE, V9, P2261; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 1996, ONCOGENE, V13, P823; Loignon M, 1997, CANCER RES, V57, P3390; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Martin Seamus J., 1994, Current Opinion in Oncology, V6, P616, DOI 10.1097/00001622-199411000-00015; MEYN MS, 1995, CANCER RES, V55, P5991; Milas Luka, 1994, In Vivo (Attiki), V8, P665; MIRZAYANS R, 1992, INT J RADIAT BIOL, V62, P417, DOI 10.1080/09553009214552301; MIRZAYANS R, 1993, CARCINOGENESIS, V14, P2621, DOI 10.1093/carcin/14.12.2621; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; MIRZAYANS R, 1995, BRIT J CANCER, V71, P1221, DOI 10.1038/bjc.1995.237; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OConnor PM, 1997, CANCER RES, V57, P4285; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; PALCIC B, 1990, BIOINSTRUMENTATION D, P923; PARSHAD R, 1993, RADIAT RES, V136, P236, DOI 10.2307/3578616; PAVELETICH NP, 1993, GENE DEV, V7, P2556; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1997, CANCER RES, V57, P3434; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1993, ONCOGENE, V8, P2449; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; STRONG LC, 1992, AM J EPIDEMIOL, V135, P190, DOI 10.1093/oxfordjournals.aje.a116271; TOMMASI S, 1996, ONCOGENE, V13, P413; VARLEY JM, 1997, BRIT J CANCER, V75, P1; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Worner W, 1996, CANCER RES, V56, P1272; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2; Yount GL, 1996, CANCER RES, V56, P500	76	39	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					533	543		10.1038/sj.onc.1202271	http://dx.doi.org/10.1038/sj.onc.1202271			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704919				2022-12-25	WOS:000075195300001
J	Davison, TS; Yin, P; Nie, E; Kay, C; Arrowsmith, CH				Davison, TS; Yin, P; Nie, E; Kay, C; Arrowsmith, CH			Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome	ONCOGENE			English	Article						p53; oligomerization; Li-Fraumeni syndrome; DNA binding	TUMOR-SUPPRESSOR P53; TETRAMERIZATION DOMAIN; DNA-BINDING; MUTATIONS; GENE; INHIBITOR; KINASES; SYSTEM; P21	Recently two germline mutations in the oligomerization domain of p53 have been identified in patients with Li-Fraumeni and Li-Fraumeni-like Syndromes. We have used biophysical and biochemical methods to characterize these two mutants in order to better understand their functional defects and the role of the p53 oligomerization domain (residues 325 -355) in oncogenesis, We find that residues 310-360 of the L344P mutant are monomeric, apparently unfolded and cannot interact with wild-type (WT) p53. The full length L344P protein is unable to bind sequence specifically to DNA and is therefore an inactive, but not a dominant negative mutant, R337C, on the other hand, can form dimers and tetramers, can hetero-oligomerize with WTp53 and can bind to a p53 consensus element. However, the thermal stability of R337C is much lower than that of M'Tp53 and at physiological temperatures more than half of this mutant is less than tetrameric, Thus, the R337C mutant retains some functional activity yet leads to a predisposition to cancer, suggesting that even partial inactivation of p53 oligomerization is sufficient for accelerated tumour progression.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Alberta	Arrowsmith, CH (corresponding author), Univ Toronto, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Arrowsmith, Cheryl/0000-0002-4971-3250				CARIELLO NF, 1994, CANCER RES, V54, P4454; Casey G, 1996, ONCOGENE, V13, P1971; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lomax ME, 1997, ONCOGENE, V14, P1869, DOI 10.1038/sj.onc.1201133; LOMAX ME, 1998, IN PRESS ONCOGENE; MIYASHITA T, 1995, CELL, V80, P293; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sambrook J., 1989, MOL CLONING; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TARUNINA M, 1993, ONCOGENE, V8, P3165; Varley JM, 1996, ONCOGENE, V12, P2437; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Wagner P, 1995, FEBS LETT, V377, P155, DOI 10.1016/0014-5793(95)01329-6; Wagner P, 1998, ONCOGENE, V16, P105, DOI 10.1038/sj.onc.1201510; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	32	86	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					651	656		10.1038/sj.onc.1202062	http://dx.doi.org/10.1038/sj.onc.1202062			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704931				2022-12-25	WOS:000075195300013
J	Jaakkola, P; Kontusaari, S; Kauppi, T; Maatta, A; Jalkanen, M				Jaakkola, P; Kontusaari, S; Kauppi, T; Maatta, A; Jalkanen, M			Wound reepithelialization activates a growth factor-responsive enhancer in migrating keratinocytes	FASEB JOURNAL			English	Article						EGF FiRE; migration; syndecan-1; TGF-alpha; transcription	MOUSE SYNDECAN-1 GENE; TUMOR PROMOTER; MAP KINASE; EXPRESSION; INHIBITOR; CELLS; SKIN; ORGANIZATION; RECEPTORS; INDUCTION	Wound reepithelialization and keratinocyte migration require strictly ordered gene expression, which is assumed to be initiated by locally released mitogens and exposure of the cells to different matrix components. The mechanisms triggering gene expression specifically during reepithelialization are poorly understood. The far upstream AP-1-driven, FGF-inducible response element (FiRE) of the syndecan-1 gene was activated during cutaneous wound healing in transgenic mice, FiRE was induced selectively in migrating but not in proliferating keratinocytes at the wound edge, The activation was initiated at the start of the cell migration, was persistent throughout the merging and stratification phases, and was terminated after completion of reepithelialization. Although FiRE has been found within the gene of syndecan-1, the proximal promoter of syndecan-1 was not required for activation of FiRE in the migrating keratinocytes. The wounding induced activation was inhibited by blocking cell surface growth factor receptors with suramin, However, the activation of FiRE in resting skin required simultaneous growth factor- and stress-induced signals, but could also be elicited by the phosphatase inhibitor, okadaic acid, The activation by both wounding and chemical stimuli was blocked by inhibiting extracellular regulated kinase and p38 MAP kinases, suggesting the involvement of at least two parallel signal transduction pathways in wounding induced gene activation. As FiRE shows specificity for migrating keratinocytes only, it can be a useful tool for future wound healing studies and for targeting genes to injured tissues.	Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Univ Oulu, Dept Biochem, FIN-90571 Oulu, Finland; Univ Oulu, Biocenter Oulu, FIN-90571 Oulu, Finland	University of Turku; Abo Akademi University; Finland National Institute for Health & Welfare; University of Oulu; University of Oulu	Jalkanen, M (corresponding author), Univ Turku, Turku Ctr Biotechnol, Tykistokatu 6B,BioCity, FIN-20520 Turku, Finland.		Salonurmi, Tuire/L-3637-2018; Jaakkola, Panu M/B-4355-2012	Salonurmi, Tuire/0000-0001-5104-5792; Maatta, Arto/0000-0003-3759-1310; Jaakkola, Panu/0000-0002-2365-4985				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BEHRINGER RR, 1993, DEVELOPMENT, V117, P823; BENNETT NT, 1993, AM J SURG, V165, P728, DOI 10.1016/S0002-9610(05)80797-4; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BROWN GL, 1989, NEW ENGL J MED, V321, P76, DOI 10.1056/NEJM198907133210203; CHAMBERLAIN J, 1995, J ANAT, V186, P87; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAVIDSON JM, 1991, ANN NY ACAD SCI, V638, P306, DOI 10.1111/j.1749-6632.1991.tb49041.x; DLUGOSZ AA, 1994, CELL GROWTH DIFFER, V5, P1283; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; HANLEY T, 1991, BIOTECHNIQUES, V10, P56; Haynes J H, 1990, J Invest Surg, V3, P349, DOI 10.3109/08941939009140361; HINKES MT, 1993, J BIOL CHEM, V268, P11440; HOGAN B, 1986, MANIPULATING MOUSE E; Jaakkola P, 1997, MOL CELL BIOL, V17, P3210, DOI 10.1128/MCB.17.6.3210; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MARSHALL GM, 1992, VIROLOGY, V188, P373, DOI 10.1016/0042-6822(92)90768-K; MARTIN P, 1992, MECH DEVELOP, V38, P209, DOI 10.1016/0925-4773(92)90054-N; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Nanney LB, 1996, MOL CELLULAR BIOL WO, P171; NAVARRO JM, 1995, J BIOL CHEM, V270, P21362, DOI 10.1074/jbc.270.36.21362; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SEO S, 1995, SCIENCE, V270, P1988, DOI 10.1126/science.270.5244.1988; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; STOSCHECK CM, 1992, J INVEST DERMATOL, V99, P645, DOI 10.1111/1523-1747.ep12668143; TAKASAKI Y, 1981, J EXP MED, V154, P1899, DOI 10.1084/jem.154.6.1899; TSUBOI R, 1993, J INVEST DERMATOL, V101, P49, DOI 10.1111/1523-1747.ep12358892; VIHINEN T, 1993, J BIOL CHEM, V268, P17261; Vihinen T, 1996, J BIOL CHEM, V271, P12532, DOI 10.1074/jbc.271.21.12532; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; Woodley DT, 1996, MOL CELLULAR BIOL WO, P339	40	44	46	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					959	969		10.1096/fasebj.12.11.959	http://dx.doi.org/10.1096/fasebj.12.11.959			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707168				2022-12-25	WOS:000075372600006
J	Jaffrezou, JP; Maestre, N; de Mas-Mansat, V; Bezombes, C; Levade, T; Laurent, G				Jaffrezou, JP; Maestre, N; de Mas-Mansat, V; Bezombes, C; Levade, T; Laurent, G			Positive feedback control of neutral sphingomyelinase activity by ceramide	FASEB JOURNAL			English	Article						ERK; daunorubicin; TNF; C6-ceramide	DAUNORUBICIN-INDUCED APOPTOSIS; ACTIVATED PROTEIN-KINASE; GLIOMA-CELLS; STRESS; BCL-2; PATHWAY; DEATH; ACID	While ceramide has emerged as a potent signal transducer, inconsistencies in the kinetics of ceramide generation, or its absence, in response to stimuli have led to confusion and skepticism as to its potential role in apoptosis or proliferation. Here we show that in U937 and HL60 myeloid leukemia cells and in normal skin fibroblasts, cell-permeant ceramides can trigger neutral sphingomyelinase activation, sphingomyelin hydrolysis, and endogenous ceramide generation regardless of Bc12 overexpression, These observations identify neutral sphingomyelinase as a novel target for ceramide and show that this positive feedback mechanism is responsible for signal propagation, as exemplified by mitogen-activated protein kinase activation in daunorubicin-treated cells. This study provides insight into a fundamental process of cell biology. Indeed, such a sustained ceramide-mediated signal throughout the apoptotic process would ensure self-destruction, perhaps by overriding evolutionary conserved primal cell survival mechanisms.	Ctr Claudius Regaud, INSERM, CJF 9503, F-31052 Toulouse, France; Ctr Hosp Univ Rangueil, INSERM, Lab Biochim Med, F-31403 Toulouse, France; CHU Purpan, Serv Hematol, F-31059 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Jaffrezou, JP (corresponding author), Ctr Claudius Regaud, INSERM, CJF 9503, 20 Rue Pont St Pierre, F-31052 Toulouse, France.		Levade, Thierry/O-8948-2014; Bezombes, Christine/G-2743-2017; Bezombes, Christine/AAC-1724-2020; Bezombes, christine/X-8479-2019	Bezombes, christine/0000-0003-4079-4872				ALBOUZ S, 1983, NEUROSCI LETT, V36, P311, DOI 10.1016/0304-3940(83)90018-6; Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; ANDRIEU N, 1995, J BIOL CHEM, V270, P24518, DOI 10.1074/jbc.270.41.24518; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CHEN M, 1995, CANCER RES, V55, P991; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; IKEDA U, 1994, ATHEROSCLEROSIS, V110, P87, DOI 10.1016/0021-9150(94)90071-X; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JAFFREZOU JP, 1995, BBA-MOL CELL RES, V1266, P1, DOI 10.1016/0167-4889(94)00219-5; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; LEVADE T, 1993, FEBS LETT, V329, P306, DOI 10.1016/0014-5793(93)80243-N; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; MASSON M, 1989, J NEUROCHEM, V52, P1645, DOI 10.1111/j.1471-4159.1989.tb09221.x; NAUMOVSKI L, 1994, BLOOD, V83, P2261; NOKOLOVAKARAKAS.M, 1997, J BIOL CHEM, V272, P18718; OLIVEIRA S, 1992, J VEG SCI, V3, P267; QuilletMary A, 1996, LEUKEMIA, V10, P417; RAINES MA, 1993, J BIOL CHEM, V268, P14572; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	27	67	69	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					999	1006		10.1096/fasebj.12.11.999	http://dx.doi.org/10.1096/fasebj.12.11.999			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707172				2022-12-25	WOS:000075372600010
J	Pei, L				Pei, L			Molecular cloning of a novel transcriptional repressor protein of the rat type 1 vasoactive intestinal peptide receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-C; PREINITIATION COMPLEX; BINDING-PROTEIN; DNA-LIGASE; EXPRESSION; DOMAIN; DROSOPHILA; ELEMENT; SEQUENCE; SUBUNIT	This study demonstrates that the transcriptional repressor sequence of the rat vasoactive intestinal peptide receptor (VIPR) gene constitutes a 42-base pair core element that is the binding site for a nuclear protein. We showed that this element was able to confer transcriptional repression to a heterologous promoter and that deletion or point mutations within this element resulted in loss of transcriptional repression. Southwestern blot analysis indicated that the VIPR repressor element interacts specifically with a nuclear protein of about 72 kDa, By screening a rat lung expression library coupled with rapid amplification of cDNA ends polymerase chain reactions, we isolated a cDNA clone (designated as VIPR-RP) that contains an open reading frame of 656 amino acids. VIPR-RP is 78% identical to a previously characterized protein, differentiation-specific element-binding protein, which is a member of a family of proteins including components of the DNA replication factor C complex. However, VIPR-RP cDNA encodes for a much smaller protein than differentiation-specific element-binding protein because of a frameshift, VIPR-RP mRNA is expressed in multiple tissues, including lung, liver, brain, heart, kidney, spleen, and testis, VIPR-RP protein specifically interacts with the VIPR repressor element as demonstrated by gel shift assays. Transfection of VIP-RP expression vector into Cos cells resulted in transcriptional repression of a reporter construct containing multiple copies of the VIPR repressor element. These results indicate that VIPR-RP is a novel transcriptional repressor protein that regulates VIPR expression.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Endocrinol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pei, L (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Endocrinol, 8700 Beverly Blvd,D-3066, Los Angeles, CA 90048 USA.				NIDDK NIH HHS [DK-02346] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002346] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BROWN NL, 1995, CELL, V80, P879, DOI 10.1016/0092-8674(95)90291-0; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; JOHNSON FB, 1992, GENE DEV, V6, P2177, DOI 10.1101/gad.6.11.2177; LAUER G, 1991, J BACTERIOL, V173, P5047, DOI 10.1128/jb.173.16.5047-5053.1991; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LUCKOW B, 1994, MOL CELL BIOL, V14, P1626, DOI 10.1128/MCB.14.3.1626; MCGEHEE RE, 1995, MOL ENDOCRINOL, V9, P487, DOI 10.1210/me.9.4.487; Pei L, 1997, REGUL PEPTIDES, V71, P153, DOI 10.1016/S0167-0115(97)01012-4; PEI L, 1995, BIOCHEM J, V308, P719, DOI 10.1042/bj3080719; Pei L, 1996, J BIOL CHEM, V271, P20879; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHARK KB, 1992, FEMS MICROBIOL LETT, V96, P19, DOI 10.1111/j.1574-6968.1992.tb05387.x; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190	25	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19902	19908		10.1074/jbc.273.31.19902	http://dx.doi.org/10.1074/jbc.273.31.19902			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677428	hybrid			2022-12-25	WOS:000075125200080
J	Fulop, V; Colitti, CV; Genest, D; Berkowitz, RS; Yiu, GK; Ng, SW; Szepesi, J; Mok, SC				Fulop, V; Colitti, CV; Genest, D; Berkowitz, RS; Yiu, GK; Ng, SW; Szepesi, J; Mok, SC			DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases	ONCOGENE			English	Article						trophoblastic diseases; DOC-2; Dab2; tumor suppressor; cancer	PROLINE-RICH PEPTIDES; SUSCEPTIBILITY GENE; OVARIAN-CANCER; SH3 DOMAINS; BINDING; SEQUENCE; CLONING; PHOSPHOTYROSINE; IDENTIFICATION; PROTEINS	Gestational trophoblastic diseases comprise a spectrum of interrelated diseases including partial mole, complete mole and gestational choriocarcinoma, Using reverse transcriptase PCR (RT-PCR) analysis, we identified higher levels of DOC-2/hDab2 expression in the normal trophoblast cells in culture than in choriocarcinoma cell lines. Subsequent study using immunohistochemistry showed high levels of DOC-2/hDab2 protein expression in normal trophoblast tissues but significantly lower levels of expression in gestational trophoblastic disease tissues, particularly in complete mole and choriocarcinoma. When DOC-2/hDab2 was transfected into the choriocarcinoma cell lines, Jar, JEG and BeWo, the stable transfectants showed significantly reduced growth rate in culture. These data suggest that down regulation of DOC-2/hDab2 may play an important role in the development of gestational trophoblastic diseases.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol,Lab Gynecol Oncol, Boston, MA 02115 USA; Haymal Imre Univ Hlth Sci, Dept Obstet & Gynecol, Budapest, Hungary	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Mok, SC (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol,Lab Gynecol Oncol, Boston, MA 02115 USA.		Yiu, Glenn/AAF-2858-2020		NATIONAL CANCER INSTITUTE [R01CA069291, R01CA069453, R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA63381, R01CA69291, R01CA69453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEUNG ANY, 1993, J CLIN PATHOL, V46, P204, DOI 10.1136/jcp.46.3.204; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FULOP V, 1998, IN PRESS J REPROD ME; Hancock BW, 1997, GESTATIONAL TROPHOBL; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; MOK SC, 1998, IN PRESS ONCOGENE, V15; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; XU X, 1997, AM ASS CANC RES P, V38, P157; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	19	73	80	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	1998	17	4					419	424		10.1038/sj.onc.1201955	http://dx.doi.org/10.1038/sj.onc.1201955			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696034				2022-12-25	WOS:000075043000003
J	Petersen, S; Rudolf, J; Bockmuhl, U; Gellert, K; Wolf, G; Dietel, M; Petersen, I				Petersen, S; Rudolf, J; Bockmuhl, U; Gellert, K; Wolf, G; Dietel, M; Petersen, I			Distinct regions of allelic imbalance on chromosome 10q22-q26 in squamous cell carcinomas of the lung	ONCOGENE			English	Article						lung cancer; tumor genetics; loss of heterozygosity	PROSTATE-CANCER; HUMAN GLIOBLASTOMAS; LONG ARM; PROGRESSION; LOCI; HETEROZYGOSITY; GENE; HUMAN-CHROMOSOME-10; ADENOCARCINOMA; ABNORMALITIES	The genetic mechanisms underlying the progression to the metastatic phenotype of lung cancer are poorly understood. We recently showed that small cell lung cancer (SCLC) and metastasizing squamous cell carcinomas are characterized by an increased incidence of allelic loss on chromosome 10q, In the present study we performed a deletion mapping using 24 polymorphic markers on chromosome 10q22-q26 in 39 squamous cell carcinomas (SCC) of the lung identifying 14 metastatic carcinomas (74%) and three non-metastatic SCC (15%) with allelic imbalance. The allelotype analysis indicated three regions of allelic loss that were clustered at the loci Afm086/D10S541, D10S185 and D10S1782/D10S169. A localized microsatellite instability was observed in two carcinomas for the markers D10S1686 and D10S1782, In addition the PTEN/MMAC1 gene was analysed by direct DNA sequencing and Southern blot analysis in 25 and 28 carcinomas, respectively, without detecting any genomic alterations. Similarly, no altered transcript was detected in 15 tumor cell lines and 20 primary tumors by Northern blot analysis or RT-PCR, In summary, three distinct regions of allelic imbalance were identified suggesting that multiple tumor suppressor genes on chromosome 10q contribute to tumor progression and metastases formation of lung cancer.	Univ Hosp Charite, Inst Pathol, D-10098 Berlin, Germany; Univ Hosp Charite, Dept Otorhinolaryngol, D-10098 Berlin, Germany; Univ Hosp Charite, Dept Surg, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Petersen, I (corresponding author), Univ Hosp Charite, Inst Pathol, D-10098 Berlin, Germany.							Bockmuhl U, 1997, CANCER RES, V57, P5213; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; FONG KM, 1995, CANCER RES, V55, P28; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; GRAY IC, 1995, CANCER RES, V55, P4800; Guldberg P, 1997, CANCER RES, V57, P3660; HERBST RA, 1994, CANCER RES, V54, P3111; Ittmann M, 1996, CANCER RES, V56, P2143; KARLBOM AE, 1993, HUM GENET, V92, P169; Kerangueven F, 1997, ONCOGENE, V14, P339, DOI 10.1038/sj.onc.1200818; Komiya A, 1996, GENE CHROMOSOME CANC, V17, P245; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; MOIR DT, 1994, GENOMICS, V22, P1, DOI 10.1006/geno.1994.1338; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MORITA R, 1991, CANCER RES, V51, P5817; Nagase S, 1997, CANCER RES, V57, P1630; Nagase S, 1996, BRIT J CANCER, V74, P1979, DOI 10.1038/bjc.1996.663; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; NIHEI N, 1995, GENE CHROMOSOME CANC, V14, P112, DOI 10.1002/gcc.2870140205; PEIFFER SL, 1995, CANCER RES, V55, P1922; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Petersen I, 1997, CANCER RES, V57, P2331; Petersen S, 1998, BRIT J CANCER, V77, P270, DOI 10.1038/bjc.1998.43; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; RASHEED BKA, 1995, ONCOGENE, V10, P2243; REMPEL SA, 1993, CANCER RES, V53, P2386; Rhei E, 1997, CANCER RES, V57, P3657; SATO S, 1994, CANCER RES, V54, P5652; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; SPEAKS SL, 1992, GENE CHROMOSOME CANC, V5, P239, DOI 10.1002/gcc.2870050311; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; Teng DHF, 1997, CANCER RES, V57, P5221; TESTA JR, 1992, CANCER RES, V52, pS2702; THIBERVILLE L, 1995, CANCER RES, V55, P5133	40	48	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					449	454		10.1038/sj.onc.1201949	http://dx.doi.org/10.1038/sj.onc.1201949			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696038				2022-12-25	WOS:000075043000007
J	Yokomizo, A; Tindall, DJ; Drabkin, H; Gemmill, R; Franklin, W; Yang, P; Sugio, K; Smith, DI; Liu, WG				Yokomizo, A; Tindall, DJ; Drabkin, H; Gemmill, R; Franklin, W; Yang, P; Sugio, K; Smith, DI; Liu, WG			PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers	ONCOGENE			English	Article						PTEN/MMAC1; mutation; deletion; lung cancer; DHPLC	GENE; CHROMOSOME-10; HETEROZYGOSITY; PROGRESSION	A putative tumor suppressor, PTEN/MMAC1 gene at 10q23 was recently identified and found to be mutated in many different human tumors. To determine the role of the PTEN/MMAC1 gene in lung cancer, we screened 34 small cell lung cancer (SCLC) cell lines, 10 SCLC tumors, 13 non-small cell lung cancer (NSCLC) cell lines and 10 NSCLC tumors using Denaturing HPLC (DHPLC) and direct sequencing methods. In SCLC, six (18%) of the cell lines and one of the primary tumor samples (10%) showed alterations of the PTEN/ MMAC1 gene including point mutations, small fragment deletions, and homozygous deletions. All of the point mutations and small fragment deletions were observed in hemizygously deleted cell lines. In contrast to SCLC, none of the NSCLC tumors or cell lines had mutations in the PTEN/MMAC1 gene. These data indicate that PTEN/MMAC1 mutations contribute to the pathogenesis and neoplastic evolution in SCLC but not in NSCLC.	Mayo Clin & Mayo Fdn, Dept Pathol & Lab Med, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Urol, Rochester, MN 55905 USA; Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Kyushu Univ, Fac Med, Dept Surg 2, Fukuoka 81282, Japan	Mayo Clinic; Mayo Clinic; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Kyushu University	Liu, WG (corresponding author), Mayo Clin & Mayo Fdn, Dept Expt Pathol & Med, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL CANCER INSTITUTE [R01CA048031, P50CA058187] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031, CA58187] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartsch D, 1996, CANCER LETT, V102, P73, DOI 10.1016/0304-3835(96)04167-5; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; Giaccone G, 1996, CHEST, V109, pS130, DOI 10.1378/chest.109.5_Supplement.130S; Guldberg P, 1997, CANCER RES, V57, P3660; HERBST RA, 1994, CANCER RES, V54, P3111; JAMES CD, 1988, CANCER RES, V48, P5546; JOHNSON BE, 1995, LUNG CANCER-J IASLC, V12, pS5, DOI 10.1016/S0169-5002(10)80014-5; Kawamata N, 1996, PROSTATE, V29, P191, DOI 10.1002/1097-0045(199609)29:3<191::AID-PROS2990290305>3.0.CO;2-1; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; LEENSTRA S, 1994, BRIT J CANCER, V70, P684, DOI 10.1038/bjc.1994.373; LEVIN NA, 1995, GENE CHROMOSOME CANC, V13, P175, DOI 10.1002/gcc.2870130307; LEVIN NA, 1994, CANCER RES, V54, P5086; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LIU W, 1998, IN PRESS NUCL ACIDS; Liu WG, 1997, CANCER RES, V57, P5254; Liu WG, 1996, HUM MOL GENET, V5, P1581, DOI 10.1093/hmg/5.10.1581; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Oefner P. J., 1995, American Journal of Human Genetics, V57, pA266; OPHOFF RA, 1996, CELL, V87, P1; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PEIFFER SL, 1995, CANCER RES, V55, P1922; Pennisi E, 1997, SCIENCE, V275, P1876, DOI 10.1126/science.275.5308.1876; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; REMPEL SA, 1993, CANCER RES, V53, P2386; Rhei E, 1997, CANCER RES, V57, P3657; RIED T, 1994, CANCER RES, V54, P1801; Risinger JI, 1997, CANCER RES, V57, P4736; RSAHEED BKA, 1997, CANCER RES, V57, P4187; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Schwendel A, 1997, INT J CANCER, V74, P86, DOI 10.1002/(SICI)1097-0215(19970220)74:1<86::AID-IJC15>3.0.CO;2-G; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tashiro H, 1997, CANCER RES, V57, P3935; Testa JR, 1997, CANCER GENET CYTOGEN, V95, P20, DOI 10.1016/S0165-4608(96)00337-8; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; Underhill PA, 1996, P NATL ACAD SCI USA, V93, P196, DOI 10.1073/pnas.93.1.196; Wang SI, 1997, CANCER RES, V57, P4183	39	143	154	4	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					475	479		10.1038/sj.onc.1201956	http://dx.doi.org/10.1038/sj.onc.1201956			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696041				2022-12-25	WOS:000075043000010
J	Tamir, Y; Bengal, E				Tamir, Y; Bengal, E			p53 Protein is activated during muscle differentiation and participates with MyoD in the transcription of muscle creatine kinase gene	ONCOGENE			English	Article						p53; MyoD; cooperativity; muscle creatine kinase gene; muscle differentiation; transcriptional activation	WILD-TYPE P53; DNA-BINDING FUNCTION; CELL DIFFERENTIATION; SEQUENCE; EXPRESSION; ENHANCER; IDENTIFICATION; SUPPRESSOR; DISTINCT; ELEMENT	The p53 protein is a transcription factor involved in processes of cell growth and differentiation. The muscle creatine kinase (MCK) gene whose transcription is induced during muscle differentiation contains p53-binding sites. In this study we tested the involvement of p53 in the activation of MCK transcription during muscle differentiation of C2 cells. We have shown that the p53 protein is stabilized and its DNA binding and transcriptional activities are induced during muscle differentiation. At the stage of muscle-differentiation, p53 protein can induce the accurate transcription of a minimal p53-dependent MCK reporter gene. Moreover, p53 cooperates with MyoD in the induction of MCK transcription. The expression of a dominant negative p53 protein in muscle cells reduced the expression of endogenous MCK gene. The dominant negative p53 protein abolished the cooperativity of wild type p53 with MyoD. Amino and carboxy terminal residues of MyoD required for the cooperation with p53 in transcription were identified. The cooperativity between the two proteins occurs also at the stage of DNA binding. We suggest that p53 protein is activated during myoblast differentiation and participates with MyoD in the induction of MCK transcription.	Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, Dept Biochem, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Bengal, E (corresponding author), Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, Dept Biochem, Efron St,POB 9649, IL-31096 Haifa, Israel.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; BENGAL E, 1994, P NATL ACAD SCI USA, V91, P6221, DOI 10.1073/pnas.91.13.6221; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; JACKSON P, 1995, GENE EXPRESSION, V5, P19; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JAYNES JB, 1986, MOL CELL BIOL, V6, P2855, DOI 10.1128/MCB.6.8.2855; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum M, 1996, ONCOGENE, V13, P2527; Lu X, 1996, ONCOGENE, V13, P413; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; PROKOCIMER M, 1994, BLOOD, V84, P2391; REGIMOVE N, 1993, ONCOGENE, V8, P1183; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	51	50	50	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					347	356		10.1038/sj.onc.1201929	http://dx.doi.org/10.1038/sj.onc.1201929			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690516				2022-12-25	WOS:000074947500009
J	Bissonnette, N; Hunting, DJ				Bissonnette, N; Hunting, DJ			p21-induced cycle arrest in G(1) protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage	ONCOGENE			English	Article						DNA; p21(Waf1/Cip1); PARP; RNA polymerase III apoptosis; p53	CASEIN KINASE-II; CELLULAR TUMOR-ANTIGEN; HUMAN CANCER-CELLS; WILD-TYPE P53; DEPENDENT KINASES; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; P53-MEDIATED APOPTOSIS; ATAXIA-TELANGIECTASIA; POTENTIAL MEDIATOR	Cells expressing the R273H mutant of p53, which lacks sequence specific DNA binding capacity, do not undergo cell cycle arrest in G(1) following exposure to ionizing or UV radiation because of their inability to induce p21(Waf1/Cip1), a cyclin-dependent kinase inhibitor and downstream mediator of p53-dependent DNA damage-induced growth arrest. Following UV-irradiation or treatment with an inhibitor of RNA pol II, we observed a rapid induction of the apoptotic process, as evidenced by DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase. Using mimosine, a p21(Waf1/Cip1) inducer that bypasses the requirement for transcriptional transactivation by p53, we demonstrated that a G(1) cell cycle arrest can prevent apoptosis following UV-irradiation or treatment with an RNA polymerase II inhibitor, Serum starvation, which also synchronized cells in G(1) but did not induce p21(Waf1/Cip1), did not protect cells from apoptosis, These results demonstrate that restoring a late G(1) checkpoint by inducing p21(Waf1/Cip1) expression can protect cells from DNA damage induced apoptosis, Our results suggest that p21(Waf2/Cip1) can interrupt the apoptotic process at a point downstream from p53 accumulation but upstream from caspase-3 activation.	Univ Sherbrooke, Fac Med, MRC, Grp Radiat Sci, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Hunting, DJ (corresponding author), Univ Sherbrooke, Fac Med, MRC, Grp Radiat Sci, Sherbrooke, PQ J1H 5N4, Canada.							ADDISON C, 1990, ONCOGENE, V5, P423; Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Bissonnette N, 1997, BIOCHEM CELL BIOL, V75, P351, DOI 10.1139/bcb-75-4-351; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chernov MV, 1997, ONCOGENE, V14, P2503, DOI 10.1038/sj.onc.1201104; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DelSal G, 1996, ONCOGENE, V12, P177; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P85024; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1990, GENE DEV, V4, P74; FISCELLA M, 1994, ONCOGENE, V9, P3249; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Guerra B, 1997, ONCOGENE, V14, P2683, DOI 10.1038/sj.onc.1201112; Guillot C, 1997, ONCOGENE, V14, P45, DOI 10.1038/sj.onc.1200803; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kastan MB, 1996, BIOESSAYS, V18, P617, DOI 10.1002/bies.950180804; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KHANNA KK, 1995, ONCOGENE, V11, P609; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 1996, ONCOGENE, V13, P823; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MAYNE LV, 1982, CANCER RES, V42, P1473; McDonald E, 1996, CANCER RES, V56, P2250; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MIYASHITA T, 1995, CELL, V80, P293; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MOSCA PJ, 1992, MOL CELL BIOL, V12, P4375, DOI 10.1128/MCB.12.10.4375; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POLYAK D, 1994, GENE DEV, V10, P1945; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRICE BD, 1995, ONCOGENE, V11, P73; Schroter M, 1996, EUR J CELL BIOL, V69, P143; SELBY PC, 1997, NUCLEIC ACIDS RES, V25, P787; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STURZBECHER HW, 1990, ONCOGENE, V5, P795; Tarunina M, 1996, ONCOGENE, V13, P589; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WATSON JV, 1987, CYTOMETRY, V8, P1, DOI 10.1002/cyto.990080101; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZANDOMENI RO, 1989, BIOCHEM J, V262, P469, DOI 10.1042/bj2620469	82	132	134	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3461	3469		10.1038/sj.onc.1201899	http://dx.doi.org/10.1038/sj.onc.1201899			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692554				2022-12-25	WOS:000074544100013
J	Kunapuli, P; Lawson, JA; Rokach, JA; Meinkoth, JL; FitzGerald, GA				Kunapuli, P; Lawson, JA; Rokach, JA; Meinkoth, JL; FitzGerald, GA			Prostaglandin F-2 alpha (PGF(2 alpha)) and the isoprostane, 8,12-iso-isoprostane F-2 alpha-III, induce cardiomyocyte hypertrophy - Differential activation of downstream signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); CARDIAC MYOCYTE HYPERTROPHY; MUSCLE CELL HYPERTROPHY; STRESS IN-VIVO; PROTEIN-KINASE; GENE-EXPRESSION; OXIDANT STRESS; ALPHA(1)-ADRENERGIC RECEPTOR; 8-EPI PROSTAGLANDIN-F2-ALPHA; CORONARY REPERFUSION	Prostaglandin receptors may be activated by their cognate ligand or by free radical catalyzed isoprostanes, products of arachidonic acid peroxidation. For example, prostaglandin F-2 alpha (PGF(2 alpha)) causes hypertrophy of neonatal rat ventricular myocytes, via the PGF(2 alpha) receptor (FP). However, the FP may also be activated by the isoprostane, 8,12-iso-iPF(2 alpha)-III (Kunapuli, P., Lawson, J. A, Rokach, J., and FitzGerald, G. A. (1997) J. Biol. Chem 272, 27147-27154). Both ligands induce myocyte hypertrophy with overlapping potencies. Interestingly, the hypertrophic effects of these two agonists on cardiomyocytes are additive. Furthermore, the preference of these two agonists for activation of intracellular signal transduction pathways differs in several respects. Thus, PGF(2 alpha) and 8,12-iso-iPF(2 alpha)-III stimulate inositol phosphate formation with EC50 values of 50 +/- 12 nM and 3.5 +/- 0.6 mu M, respectively. Moreover, PGF(2 alpha) causes a robust activation (similar to 50-fold) of Erk2, whereas 9,12-iso-iPF(2 alpha)-III has no effect. Similarly, PGF(2 alpha) causes translocation of cytosolic phospholipase A, and also results in a 7-fold increment in the formation of 6-keto-PGF(1 alpha), whereas 8,12-iso-iPF(2 alpha)-III exerts no effect on this pathway. On the other hand, both agonists are equally potent in activating JNK1 and c-Jun, whereas neither activates the p38 kinase. Both PGF(2 alpha) and 8,12-iso-iPF(2 alpha)-III activate the p70S6 kinase (p70(S6K)), but not Akt, downstream of phosphatidylinositol-3-kinase (PI3K). However, both wortmannin, a PI3K inhibitor, and rapamycin, an inhibitor of p70(S6K) activity, inhibit 8,12-iso-iPF(2 alpha)-III-induced myocyte hypertrophy, with IC50 values of 60 +/- 12 and 3 +/- 1.7 nM, respectively, whereas neither compound abrogates the PGF(2 alpha)-mediated response. Thus, both PGF(2 alpha) and 8,12-iso-iPF(2 alpha)-III induce myocyte hypertrophy via discrete signaling pathways. Although both agonists signal via the JNK pathway to initiate changes in c-Jun-dependent gene transcription, PGF(2 alpha) preferentially activates the MEH-Erk2- cytosolic phospholipase A(2) pathway. In contrast, the PI3K-p70(S6K) pathway appears to be essential for 8,12-iso-iPF(2 alpha)-III-induced myocyte hypertrophy.	Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Florida Inst Technol, Claude Pepper Inst, Melbourne, FL 32901 USA; Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA	University of Pennsylvania; University of Pennsylvania; Florida Institute of Technology; Florida Institute of Technology	FitzGerald, GA (corresponding author), Univ Penn, Ctr Expt Therapeut, 153 Johnson Pavil, Philadelphia, PA 19104 USA.	garret@spirit.gcrc.upenn.edu	Meinkoth, Judy L/G-2900-2010; FitzGerald, Garret A/A-4222-2010	Rokach, Joshu/0000-0003-1814-7505	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044730, R01DK045696] Funding Source: NIH RePORTER; NHLBI NIH HHS [T-32-HL07843-02] Funding Source: Medline; NIDDK NIH HHS [DK45696, DK44730] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; Adams JW, 1996, J BIOL CHEM, V271, P1179, DOI 10.1074/jbc.271.2.1179; Adiyaman M, 1996, TETRAHEDRON LETT, V37, P4849, DOI 10.1016/0040-4039(96)00973-2; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Boluyt MO, 1997, CIRC RES, V81, P176, DOI 10.1161/01.RES.81.2.176; BRASS LF, 1977, THROMB HAEMOSTASIS, V77, P233; CHAZOV EI, 1979, CIRC RES, V45, P205, DOI 10.1161/01.RES.45.2.205; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CSEPLI J, 1975, PROSTAGLANDINS, V10, P689, DOI 10.1016/S0090-6980(75)80017-7; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Delanty N, 1997, CIRCULATION, V95, P2492, DOI 10.1161/01.CIR.95.11.2492; FRANCIS GS, 1993, EUR HEART J, V14, P49; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; FUKUNAGA M, 1993, BIOCHEM BIOPH RES CO, V195, P507, DOI 10.1006/bbrc.1993.2075; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Grammer TC, 1996, CANCER SURV, V27, P271; Hill MF, 1997, CIRCULATION, V96, P2414; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; Hwang SW, 1996, TETRAHEDRON LETT, V37, P779, DOI 10.1016/0040-4039(95)02390-9; ITO S, 1994, BIOCHEM BIOPH RES CO, V200, P756, DOI 10.1006/bbrc.1994.1515; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KARMAZYN M, 1989, CAN J PHYSIOL PHARM, V67, P912, DOI 10.1139/y89-144; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; KENTERA D, 1979, RESPIRATION, V37, P192, DOI 10.1159/000194026; Kinsella BT, 1997, J PHARMACOL EXP THER, V281, P957; KIRSHENBAUM LA, 1995, J MOL CELL CARDIOL, V27, P263, DOI 10.1016/S0022-2828(08)80025-9; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; Kunapuli P, 1997, J BIOL CHEM, V272, P27147, DOI 10.1074/jbc.272.43.27147; Lai J, 1996, AM J PHYSIOL-HEART C, V271, pH2197, DOI 10.1152/ajpheart.1996.271.6.H2197; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; MCCRACKEN JA, 1970, J CLIN ENDOCR METAB, V30, P544, DOI 10.1210/jcem-30-4-544; MENTZ P, 1988, BIOMED BIOCHIM ACTA, V47, pS244; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; OUDOT F, 1995, AM J PHYSIOL-HEART C, V268, pH308, DOI 10.1152/ajpheart.1995.268.1.H308; Page C, 1996, MOL CELL BIOCHEM, V157, P49; Pratico D, 1996, J BIOL CHEM, V271, P14916, DOI 10.1074/jbc.271.25.14916; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; Reilly M, 1996, CIRCULATION, V94, P19, DOI 10.1161/01.CIR.94.1.19; Reilly MP, 1997, CIRCULATION, V96, P3314; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, BIOCHEM BIOPH RES CO, V202, P1586, DOI 10.1006/bbrc.1994.2113; THORBURN J, 1994, J BIOL CHEM, V269, P30580; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; WATANABE T, 1995, J BIOL CHEM, V270, P8984, DOI 10.1074/jbc.270.15.8984	62	104	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22442	22452		10.1074/jbc.273.35.22442	http://dx.doi.org/10.1074/jbc.273.35.22442			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712868	hybrid			2022-12-25	WOS:000075616600044
J	Kramata, P; Downey, KM; Paborsky, LR				Kramata, P; Downey, KM; Paborsky, LR			Incorporation and excision of 9-(2-phosphonylmethoxyethyl)guanine (PMEG) by DNA polymerase delta and epsilon in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE ANALOGS; NUCLEOSIDE PHOSPHONATES; ENZYMOLOGIC MECHANISM; REPLICATION FORK; IN-VITRO; CELLS; ALPHA; INHIBITION; REPAIR; BETA	PMEG (9-(2-phosphonylmethoxyethyl)guanine) is an acyclic nucleotide analog being evaluated for its antiproliferative activity. We examined the inhibitory effects of PMEG diphosphate (PMEGpp) toward DNA polymerases (pol) delta and epsilon and found it to be a competitive inhibitor of both these enzymes. The apparent Ki values for PMEGpp were 3-4 times lower than the K(m) values for dGTP. The analog was shown to function as a substrate and to be incorporated into DNA by both enzymes. Examination of the ability of pol delta and pol epsilon to repair the incorporated PMEG revealed that pol epsilon could elongate PMEG-tterianated primers ire both matched and mismatched positions with an efficiency equal to 27 and 85% that observed for dGMP-terminated control template-primers. Because PMEG acts as an absolute DNA chain terminator, the elongation of PMEG-terminated primers is possible only by cooperation of the 3'-5'-exonuclease and DNA polymerase activities of the enzyme. In contrast to pol epsilon, pol delta exhibited negligible activity on these template-primers, indicating that pol epsilon, but not pol delta, can repair the incorporated analog.	Gilead Sci Inc, Foster City, CA 94404 USA; Univ Miami, Sch Med, Dept Med, Miami, FL 33101 USA	Gilead Sciences; University of Miami	Kramata, P (corresponding author), Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA.	Pavel_Kramata@gilead.com						APBORSKY LR, 1997, P AM ASSOC CANC RES, V38, P100; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUI G, 1995, J BIOL CHEM, V270, P7799, DOI 10.1074/jbc.270.14.7799; Cihlar T, 1997, ANTIVIR CHEM CHEMOTH, V8, P187, DOI 10.1177/095632029700800302; DECLERCQ E, 1991, BIOCHEM PHARMACOL, V42, P963, DOI 10.1016/0006-2952(91)90276-B; GANDHI V, 1995, CANCER RES, V55, P1517; HEINEMANN V, 1990, MOL PHARMACOL, V38, P567; HENTOSH P, 1990, J BIOL CHEM, V265, P4033; HO HT, 1992, ADV EXP MED BIOL, V312, P159; HOLY A, 1987, COLLECT CZECH CHEM C, V52, P2801, DOI 10.1135/cccc19872801; HUANG P, 1991, CANCER RES, V51, P6110; HUANG P, 1990, J BIOL CHEM, V265, P16617; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; Kamiya K, 1996, J BIOL CHEM, V271, P19428, DOI 10.1074/jbc.271.32.19428; Kramata P, 1996, MOL PHARMACOL, V49, P1005; KRIEDER JW, 1990, ANTIVIR RES, V14, P51; KUNKEL TA, 1992, BIOESSAYS, V14, P303, DOI 10.1002/bies.950140503; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Mozzherin DJ, 1996, BIOCHEMISTRY-US, V35, P3572, DOI 10.1021/bi952142p; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NG L, 1991, J BIOL CHEM, V266, P11699; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; Pisarev VM, 1997, MOL PHARMACOL, V52, P63, DOI 10.1124/mol.52.1.63; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; ROBBINS BL, 1995, MOL PHARMACOL, V47, P391; ROSE WC, 1990, J NATL CANCER I, V82, P510, DOI 10.1093/jnci/82.6.510; SABATINO RD, 1990, CANCER RES, V50, P5340; Sancar A, 1995, ANNU REV GENET, V29, P69, DOI 10.1146/annurev.ge.29.120195.000441; SYVAOJA J, 1989, J BIOL CHEM, V264, P2489; TAN CK, 1986, J BIOL CHEM, V261, P2310; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Xie KC, 1996, CANCER RES, V56, P3030; ZENG XR, 1994, J BIOL CHEM, V269, P13748; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x	37	39	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21966	21971		10.1074/jbc.273.34.21966	http://dx.doi.org/10.1074/jbc.273.34.21966			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705337	hybrid			2022-12-25	WOS:000075492600071
J	Liao, H; Li, YR; Brautigan, DL; Gundersen, GG				Liao, H; Li, YR; Brautigan, DL; Gundersen, GG			Protein phosphatase 1 is targeted to microtubules by the microtubule-associated protein Tau	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLASE-PHOSPHATASE; ALZHEIMERS-DISEASE; CATALYTIC SUBUNIT; OKADAIC ACID; MAP KINASE; DYNAMIC INSTABILITY; CELLULAR-REGULATION; P34(CDC2) KINASE; NERVOUS-SYSTEM; IN-VITRO	Phosphorylation has been implicated in the regulation of microtubule (MT) stability and function by controlling the interactions between MTs and MT-associated proteins. We found previously that protein phosphatase inhibitors selectively break down stable MTs, suggesting that protein phosphatases may be involved in regulating MT stability. To identify the protein phosphatases involved, we examined purified calf brain MTs and found a protein phosphatase activity that co-purified with MTs to constant stoichiometry, Western blot analysis and inhibitor profiles demonstrated that the MT-associated phosphatase was a type 1 protein phosphatase (PP1), which we named PP1(MT). Recombinant PP1 catalytic subunit (PP1c) did not bind to MTs, whereas PP1(MT) did bind, suggesting the presence of proteins that target PP1 to MTs, By Sepharose CL-GB chromatography, the phosphatase activity of PP1(MT) eluted as a large protein complex of similar to 400 kDa, High salt (2 RI NaCl) treatment followed by CL-GB chromatography dissociated PP1(MT) into PP1c and the MT-targeting subunit(s), The MT-targeting subunit was shown to be the MT-associated protein tau by PP1 blot overlays and other assays. Also, recombinant tau reconstituted the binding of PP1c to MTs, These results identify PPI as the first tau binding protein and suggest that tau is a novel PP1-targeting subunit.	Columbia Univ Coll Phys & Surg, Dept Anat & Cell Biol, New York, NY 10032 USA; Univ Virginia, Hlth Sci Ctr, Ctr Cell Signaling, Charlottesville, VA 22908 USA	Columbia University; University of Virginia	Gundersen, GG (corresponding author), Columbia Univ Coll Phys & Surg, Dept Anat & Cell Biol, 630 W 168th St, New York, NY 10032 USA.	ggg1@columbia.edu		JOHNSON, HEATHER/0000-0001-7468-0705	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056362] Funding Source: NIH RePORTER; NIA NIH HHS [AG10926] Funding Source: Medline; NIGMS NIH HHS [GM56362] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; BERLING B, 1994, EUR J CELL BIOL, V64, P120; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRANDT R, 1995, J CELL BIOL, V131, P1327, DOI 10.1083/jcb.131.5.1327; BRAUTIGAN DL, 1985, J BIOL CHEM, V260, P4295; BRAUTIGAN DL, 1993, ADV PROTEIN PHOSPHAT, V7, P43; BRION JP, 1988, NEUROSCIENCE, V25, P139, DOI 10.1016/0306-4522(88)90013-9; CASSIMERIS L, 1993, CELL MOTIL CYTOSKEL, V26, P275, DOI 10.1002/cm.970260402; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DEPENNART H, 1993, DEV BIOL, V157, P170, DOI 10.1006/dbio.1993.1121; DICKSON DW, 1992, NEUROBIOL AGING, V13, P179, DOI 10.1016/0197-4580(92)90027-U; DRESCHEL DN, 1992, MOL BIOL CELL, V3, P1141; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; FELLOUS A, 1994, INT J DEV BIOL, V38, P651; GARVER TD, 1994, J NEUROCHEM, V63, P2279; GLIKSMAN NR, 1992, J CELL BIOL, V119, P1271, DOI 10.1083/jcb.119.5.1271; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; GONG CX, 1994, FEBS LETT, V341, P94, DOI 10.1016/0014-5793(94)80247-5; GRATECOS D, 1977, BIOCHEMISTRY-US, V16, P4812, DOI 10.1021/bi00641a009; GRUPPUSO PA, 1985, J BIOL CHEM, V260, P4288; GURLAND G, 1993, P NATL ACAD SCI USA, V90, P8827, DOI 10.1073/pnas.90.19.8827; HIORKAWA N, 1991, NEURONAL CYTOSKELETO, P5; HIRANO K, 1995, J BIOL CHEM, V270, P19786, DOI 10.1074/jbc.270.34.19786; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; HIROKAWA N, 1985, J CELL BIOL, V101, P227, DOI 10.1083/jcb.101.1.227; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; JAMESON L, 1980, BIOCHEMISTRY-US, V19, P2472, DOI 10.1021/bi00552a027; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; LI HC, 1979, J BIOL CHEM, V254, P3368; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; MACCIONI RB, 1995, PHYSIOL REV, V75, P835, DOI 10.1152/physrev.1995.75.4.835; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; MATUS A, 1983, COLD SPRING HARB SYM, V48, P775, DOI 10.1101/SQB.1983.048.01.079; MATUS A, 1988, ANNU REV NEUROSCI, V466, P167; MorishimaKawashima M, 1996, MOL BIOL CELL, V7, P893, DOI 10.1091/mbc.7.6.893; NICHOLAS RH, 1995, FEBS LETT, V377, P295; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; RATTNER JB, 1990, CELL MOTIL CYTOSKEL, V17, P227, DOI 10.1002/cm.970170309; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SANO M, 1992, J NEUROCHEM, V59, P1263, DOI 10.1111/j.1471-4159.1992.tb08436.x; SCHOENFELD TA, 1994, INT REV CYTOL, V151, P67, DOI 10.1016/S0074-7696(08)62631-5; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SHELDEN E, 1993, J CELL BIOL, V120, P935, DOI 10.1083/jcb.120.4.935; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; Trojanowski JQ, 1995, FASEB J, V9, P1570, DOI 10.1096/fasebj.9.15.8529836; TU JL, 1995, EMBO J, V14, P5939, DOI 10.1002/j.1460-2075.1995.tb00282.x; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; VALLEE RB, 1986, METHOD ENZYMOL, V134, P116; YOSHITAKE S, 1979, EUR J BIOCHEM, V101, P395, DOI 10.1111/j.1432-1033.1979.tb19731.x; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	66	129	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21901	21908		10.1074/jbc.273.34.21901	http://dx.doi.org/10.1074/jbc.273.34.21901			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705329	hybrid			2022-12-25	WOS:000075492600063
J	Pan, CJ; Lei, KJ; Chou, JY				Pan, CJ; Lei, KJ; Chou, JY			Asparagine-linked oligosaccharides are localized to a luminal hydrophilic loop in human glucose-6-phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-STORAGE-DISEASE; ENDOPLASMIC-RETICULUM; ENZYME-DEFICIENT; GENE; MUTATIONS; 1A; GLYCOPROTEINS; MEMBRANE; TYPE-1A	yDeficiency of glucose-6-phosphatase (G6Pase), an endoplasmic reticulum transmembrane glycoprotein, causes glycogen storage disease type la, We have recently shown that human G6Pase contains an odd number of transmembrane segments, supporting a nine-transmembrane helical model for this enzyme. Sequence analysis predicts the presence of three potential asparagine (N)-linked glycosylation sites, (NTS)-T-96, N(203)AS, and (NSS)-S-276, conserved among mammalian G6Pases. According to this model, Asn(96), located in a 37-residue luminal loop, is a potential acceptor for oligosaccharides, whereas Asn(203) and Asn(276), located in a 12-residue cytoplasmic loop and helix 7, respectively, would not be utilized for this purpose. We therefore characterized mutant G6Pases lacking one, two, or all three potential N-linked glycosylation sites. Western blot and in vitro translation studies showed that G6Pase is glycosylated only at Asn(96), further validating the nine-transmembrane topology model. Substituting Asn96 with an Ala (N96A) moderately reduced enzymatic activity and had no effect on G6Pase synthesis or degradation, suggesting that oligosaccharide chains do not play a major role in protecting the enzyme from proteolytic degradation. Ln contrast, mutation of Asn(276) to an Ala (N276A) destabilized the enzyme and markedly reduced enzymatic activity. We present additional evidence suggesting that the integrity of transmembrane helices is essential for C6Pase stability and catalytic activity.	NICHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Chou, JY (corresponding author), NICHD, Heritable Disorders Branch, NIH, Bldg 10,Rm 98241, Bethesda, MD 20892 USA.	chou@helix.nih.gov						Ausubel FM, 1992, CURRENT PROTOCOLS MO; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; Chen Y-T, 1995, METABOLIC MOL BASES, P935; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; HERS H. G., 1964, ADVAN METAB DISORDERS, V1, P1; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Kishnani PS, 1997, BIOCHEM MOL MED, V61, P168, DOI 10.1006/bmme.1997.2600; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LEI KJ, 1995, J CLIN INVEST, V95, P234, DOI 10.1172/JCI117645; LEI KJ, 1995, J BIOL CHEM, V270, P11882, DOI 10.1074/jbc.270.20.11882; LEI KJ, 1995, AM J HUM GENET, V57, P766; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; MOSES SW, 1990, J PEDIATR GASTR NUTR, V11, P155, DOI 10.1097/00005176-199008000-00004; NILSSON I, 1993, J BIOL CHEM, V268, P5798; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, P349; OLDEN K, 1985, TRENDS BIOCHEM SCI, V10, P78, DOI 10.1016/0968-0004(85)90238-5; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; Parvari R, 1997, AM J MED GENET, V72, P286, DOI 10.1002/(SICI)1096-8628(19971031)72:3<286::AID-AJMG6>3.0.CO;2-P; Parvari R, 1997, EUR J HUM GENET, V5, P191, DOI 10.1159/000484762; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; STRUCK DK, 1977, J BIOL CHEM, V252, P1007; WADDELL ID, 1991, BIOCHEM J, V275, P133, DOI 10.1042/bj2750133	24	22	26	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21658	21662		10.1074/jbc.273.34.21658	http://dx.doi.org/10.1074/jbc.273.34.21658			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705299	hybrid			2022-12-25	WOS:000075492600033
J	Saha, C; Nigam, SK; Denker, BM				Saha, C; Nigam, SK; Denker, BM			Involvement of G alpha(i2) in the maintenance and biogenesis of epithelial cell tight junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INTRACELLULAR CALCIUM; ALPHA-SUBUNITS; IDENTIFICATION; MORPHOGENESIS; TERMINUS; NEPHRON	yPolarized epithelial cells have highly developed tight junctions (TJ) to maintain an impermeant barrier and segregate plasma membrane functions, but the mechanisms that promote TJ formation and maintain its integrity are only partially defined. Treatment of confluent monolayers of Madin-Darby canine kidney (MDCK) cells with AlF4- (activator of heterotrimeric G protein alpha subunits) results in a 3-4-fold increase in transepithelial resistances (TER), a reliable indicator of TJ integrity. MOCK cells transfected with activated G alpha(0) (Q205L) have acclerated TJ formation (Denker, B. M., Saha, C., Khawaja, S., and Nigam, S. J. (1996) J. Biol. Chem. 271, 25750-25753). G alpha(i2) has been localized within the tight junction, and a role for G alpha(i2) in the formation and/or maintenance of the tight junction was studied by transfection of MDCK cells with vector without insert (PC), wild type G alpha(i2), or a GTPase-deficient mutant (constitutively activated), Q205L alpha(i2). Tryptic conformational analysis confirmed expression of a constitutively active G alpha(i2) in Q205L alpha(i2)-MDCK cells, and confocal microscopy showed a similar pattern of G alpha(i2) localization in the three cell lines. Q205L alpha(i2)-MDCK cells had significantly higher base-line TER values than wild type G alpha(i2)- or PC-MDCK cells (1187 +/- 150 versus 576 +/- 89 (G alpha(i2)); 377 +/- 52 Omega . cm(2) (PC)), and both G alpha(i2)- and Q205L alpha(i2)-transfected cell lines more rapidly develop TER in the Ca2+ switch, a model widely used to study the mechanisms of junctional assembly. Treatment of cells with AlF4- during the Ca2+ switch had little effect on the kinetics of TER development in G alpha(i2)- or Q205L alpha(i2)-MDCK cells, but PC cells reached half-maximal TER significantly sooner in the presence of AlF4- (similar times to G alpha(i2)-transfected cells). Base-line TER values obtained after the switch were significantly higher for all three cell lines in the presence of AlF4-. These findings indicate that G alpha(i2) is important for both the maintenance and development of the TJ, although additional G alpha subunits are likely to play a role.	Harvard Univ, Inst Med, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Denker, BM (corresponding author), Harvard Univ, Inst Med, Sch Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	bdenker@rics.bwh.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055223, R29GM055223] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53507] Funding Source: Medline; NIGMS NIH HHS [GM55223] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; CEREIJIDO M, 1993, J CELL SCI, P127; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEALMEIDA JB, 1994, J CELL SCI, V107, P507; DENKER BM, 1992, J BIOL CHEM, V267, P9998; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DENKER BM, 1995, BIOCHEMISTRY-US, V34, P5544, DOI 10.1021/bi00016a028; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; Dodane V, 1996, J MEMBRANE BIOL, V149, P199, DOI 10.1007/s002329900020; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hamilton SE, 1997, BIOCHEM BIOPH RES CO, V234, P1, DOI 10.1006/bbrc.1997.6569; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NIGAM SK, 1992, P NATL ACAD SCI USA, V89, P6162, DOI 10.1073/pnas.89.13.6162; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Rosson D, 1997, J BIOL CHEM, V272, P14950, DOI 10.1074/jbc.272.23.14950; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; SENKFOR SI, 1993, J CLIN INVEST, V92, P786, DOI 10.1172/JCI116651; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; STEVENSON BR, 1984, J CELL BIOL, V98, P1209, DOI 10.1083/jcb.98.4.1209; Stuart RO, 1996, J BIOL CHEM, V271, P13636, DOI 10.1074/jbc.271.23.13636; STUART RO, 1994, J CELL PHYSIOL, V159, P423, DOI 10.1002/jcp.1041590306; STUART RO, 1995, SEMIN NEPHROL, V15, P315; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072	30	71	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21629	21633		10.1074/jbc.273.34.21629	http://dx.doi.org/10.1074/jbc.273.34.21629			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705295	hybrid			2022-12-25	WOS:000075492600029
J	Winkler, DG; Cutler, RE; Drugan, JK; Campbell, S; Morrison, DK; Cooper, JA				Winkler, DG; Cutler, RE; Drugan, JK; Campbell, S; Morrison, DK; Cooper, JA			Identification of residues in the cysteine-rich domain of Raf-1 that control Ras binding and Raf-1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; PLASMA-MEMBRANE; PROTEIN-KINASE; MAP KINASE; TYROSINE PHOSPHORYLATION; HA-RAS; ACTIVATION; 14-3-3-PROTEINS; TRANSFORMATION; COMPLEX	We have identified mutations in Raf-l that increase binding to Ras. The mutations were identified making use of three mutant forms of Ras that have reduced Raf-l binding (Winkler, D. G., Johnson, J. C., Cooper, J, A., and Vojtek, A. B. (1997) J. Biol, Chem. 272, 24402-24409). One mutation in Raf-l, N64L, suppresses the Ras mutant R41Q but not other Ras mutants, suggesting that this mutation structurally complements the Ras R41Q mutation. Missense substitutions of residues 143 and 144 in the Raf-l cysteine-rich domain were isolated multiple times. These Raf-l mutants, R143Q, R143W, and K144E, were general suppressors of three different Ras mutants and had increased interaction with non-mutant Ras. Each was slightly activated relative to wild-type Raf-1 in a transformation assay. In addition, two mutants, R143W and K144E, were active when tested for induction of germinal vesicle breakdown in Xenopus oocytes. Interestingly, all three cysteine-rich domain mutations reduced the ability of the Raf-1 N-terminal regulatory region to inhibit Xenopus oocyte germinal vesicle breakdown induced by the C-terminal catalytic region of Raf-l, We propose that a direct or indirect regulatory interaction between the N- and C-terminal regions of Raf-l is reduced by the R143W, R143Q, and K144E mutations, thereby increasing access to the Ras-binding regions of Raf-l and increasing Raf-l activity.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; NCI, Mol Basis Carcinogenesis Lab, ABL Basic Res, Frederick Canc Res & Dev Ctr, Frederick, MD 20702 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of North Carolina; University of North Carolina Chapel Hill	Cooper, JA (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N A2025,POB 9024, Seattle, WA 98109 USA.			campbell, sharon/0000-0003-0311-409X	NATIONAL CANCER INSTITUTE [R01CA070308, F32CA066281, R01CA054786] Funding Source: NIH RePORTER; NCI NIH HHS [CA70308, CA66281, CA54786] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; Cutler RE, 1997, EMBO J, V16, P1953, DOI 10.1093/emboj/16.8.1953; CUTLER RE, 1998, IN PRESS P NATL ACAD; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DIAZ R, 1997, MOL CELL BIOL, V17, P4509; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Rommel C, 1996, ONCOGENE, V12, P609; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Winkler DG, 1997, J BIOL CHEM, V272, P24402, DOI 10.1074/jbc.272.39.24402; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	48	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21578	21584		10.1074/jbc.273.34.21578	http://dx.doi.org/10.1074/jbc.273.34.21578			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705288	hybrid, Green Published			2022-12-25	WOS:000075492600022
J	Dobritzsch, D; Konig, S; Schneider, G; Lu, GG				Dobritzsch, D; Konig, S; Schneider, G; Lu, GG			High resolution crystal structure of pyruvate decarboxylase from Zymomonas mobilis - Implications for substrate activation in pyruvate decarboxylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE DEPENDENT ENZYME; THIAMIN DIPHOSPHATE; BREWERS-YEAST; TRANSKETOLASE; EQUILIBRIUM; SCATTERING; OXIDASE; RING; ION; PDC	The crystal structure of tetrameric pyruvate decarboxylase from Zymomonas nobilis has been determined at 1.9 Angstrom resolution and refined to a crystallographic R-factor of 16.2% and R-free of 19.7%, The subunit consists of three domains, all of the alpha/beta type. Two of the subunits form a tight dimer with an extensive interface area. The thiamin diphosphate binding site is located at the subunit-subunit interface, and the cofactor, bound in the V conformation, interacts with residues from the N-terminal domain of one subunit and the C-terminal domain of the second subunit, The S-fold symmetry generates the second thiamin diphosphate binding site in the dimer, Two of the dimers form a tightly packed tetramer with pseudo 222 symmetry. The interface area between the dimers is much larger in pyruvate decarboxylase from Z, mobilis than in the yeast enzyme, and structural differences in these parts result in a completely different packing of the subunits in the two enzymes. In contrast to other pyruvate decarboxylases, the enzyme from Z, mobilis is not subject to allosteric activation by the substrate. The tight packing of the dimers in the tetramer prevents large rearrangements in the quaternary structure as seen in the yeast enzyme and locks the enzyme in an activated conformation. The architecture of the cofactor binding site and the active site is similar in the two enzymes. However, the x-ray analysis reveals subtle but significant structural differences in the active site that might be responsible for variations in the biochemical properties in these enzymes.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Martin Luther Universitat Halle Wittenberg, Fachbereich Biochem Biotechnol 1, Inst Biochem, D-06099 Halle, Germany	Karolinska Institutet; Martin Luther University Halle Wittenberg	Lu, GG (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Doktorsringen 9, S-17177 Stockholm, Sweden.	guoguang@alfa.mbb.ki.se	Dobritzsch, Doreen/H-7334-2018; Koenig, Stephan/GRX-2480-2022	Schneider, Gunter/0000-0003-0622-5713				ARJUNAN P, 1986, J MOL BIOL, V355, P590; BABURINA I, 1994, BIOCHEMISTRY-US, V33, P5630, DOI 10.1021/bi00184a035; BRINGERMEYER S, 1986, ARCH MICROBIOL, V146, P105, DOI 10.1007/BF00402334; BRINGERMEYER S, 1988, BIOCATALYSIS, V1, P321; BRUHN H, 1995, EUR J BIOCHEM, V234, P650, DOI 10.1111/j.1432-1033.1995.650_b.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CONWAY T, 1987, J BACTERIOL, V169, P949, DOI 10.1128/jb.169.3.949-954.1987; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; DIEFENBACH RJ, 1991, BIOCHEM J, V276, P439, DOI 10.1042/bj2760439; Dietrich A, 1997, FEBS LETT, V400, P42, DOI 10.1016/S0014-5793(96)01326-9; DUCLOS JM, 1974, BIOCHEMISTRY-US, V13, P5358, DOI 10.1021/bi00723a016; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; FUREY W, 1996, BIOCH PHYSL THIAMIN, P103; HOLZER H, 1956, BIOCHEM Z, V327, P331; HUBNER G, 1988, BIOMED BIOCHIM ACTA, V47, P9; HUBNER G, 1990, FEBS LETT, V266, P17, DOI 10.1016/0014-5793(90)81495-A; HUBNER G, 1978, EUR J BIOCHEM, V92, P175, DOI 10.1111/j.1432-1033.1978.tb12735.x; JONES TA, 1992, P CCP4 STUD WEEK WAR, P99; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P100; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; KLEJWEGT G, 1994, ACTA CRYSTALLOGR S D, V50, P178; KONIG S, 1992, BIOCHEMISTRY-US, V31, P8726; KONIG S, 1990, BIOMED BIOCHIM ACTA, V49, P465; KONIG S, 1993, EUR BIOPHYS J BIOPHY, V22, P185; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; Lobell M, 1996, J AM CHEM SOC, V118, P1867, DOI 10.1021/ja951830t; Lu GA, 1996, PROTEIN DATA BANK Q, V78, P10; Lu GG, 1997, FEBS LETT, V403, P249, DOI 10.1016/S0014-5793(97)00057-4; MICZKA G, 1992, BIOTECHNOL APPL BIOC, V15, P192; MULLER YA, 1993, STRUCTURE, V1, P95, DOI 10.1016/0969-2126(93)90025-C; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEALE AD, 1987, NUCLEIC ACIDS RES, V15, P1753, DOI 10.1093/nar/15.4.1753; NEALE AD, 1987, J BACTERIOL, V169, P1024, DOI 10.1128/jb.169.3.1024-1028.1987; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; POHL M, 1995, BIOTECHNOL APPL BIOC, V22, P95; REYNEN M, 1988, J BACTERIOL, V170, P3310, DOI 10.1128/jb.170.7.3310-3313.1988; Schenk G, 1997, EUR J BIOCHEM, V248, P63, DOI 10.1111/j.1432-1033.1997.t01-1-00063.x; SUN SX, 1995, J AM CHEM SOC, V117, P7317, DOI 10.1021/ja00133a004; ZOLTEWICZ JA, 1980, J ORG CHEM, V45, P2104, DOI 10.1021/jo01299a015; 1994, ACTA CRYSTALLOGR S D, V50, P760	44	149	163	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20196	20204		10.1074/jbc.273.32.20196	http://dx.doi.org/10.1074/jbc.273.32.20196			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685367	hybrid			2022-12-25	WOS:000075305400044
J	Hayakawa, T; Noda, M; Yasuda, K; Yorifuji, H; Taniguchi, S; Miwa, I; Sakura, H; Terauchi, Y; Hayashi, J; Sharp, GWG; Kanazawa, Y; Akanuma, Y; Yazaki, Y; Kadowaki, T				Hayakawa, T; Noda, M; Yasuda, K; Yorifuji, H; Taniguchi, S; Miwa, I; Sakura, H; Terauchi, Y; Hayashi, J; Sharp, GWG; Kanazawa, Y; Akanuma, Y; Yazaki, Y; Kadowaki, T			Ethidium bromide-induced inhibition of mitochondrial gene transcription suppresses glucose-stimulated insulin release in the mouse pancreatic beta-cell line beta HC9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETES-MELLITUS; B-CELLS; POTASSIUM CHANNEL; K+ CHANNELS; SECRETION; DNA; EXPRESSION; MUTATION; ISLETS; RAT	Recently, a mitochondrial mutation was found to be associated with maternally inherited diabetes mellitus (Kadowaki, T., Kadowaki, H., Mori, Y., Tobe, K., Sakuta, R., Suzuki, Y., Tanabe, Y, Sakura, H., Awata, T., Goto, Y., Hayakawa, T., Matsuoka, K., Kawamori, R., Kamada, T., Horai, S., Nonaka, I., Hagura, R., Akanuma, Y., and Yazaki, Y. (1994) N. Engl. J. Med. 330, 962-968). In order to elucidate its etiology, we have investigated the involvement of mitochondrial function in insulin secretion. Culture of the pancreatic beta-cell line, beta HC9, with low dose ethidium bromide (EB) (0.4 mu g/ml) for 2-6 days resulted in a substantial decrease in the transcription level of mitochondrial DNA (to 10-20% of the control cells) without changing its copy number, whereas the transcription of nuclear genes was grossly unaffected. Electron microscopic analysis revealed that treatment by EB caused morphological changes only in mitochondria and not in other organelles such as nuclei, endoplasmic reticula, Golgi bodies, or secretory granules. When the cells were treated with EB for 6 days, glucose (20 mM) could no longer stimulate insulin secretion, while glibenclamide (1 mu M) Still did. When EB was removed after 3- or B-day treatment, mitochondrial gene transcription recovered within 2 days, and the profiles of insulin secretion returned to normal within 7 days. Studies with fura-2 indicated that in EB-treated cells, glucose (20 mM) failed to increase intracellular Ca2+ while the effect of glibenclamide (1 mu M) was maintained. Our system provides a unique way to investigate the relationship between mitochondrial function and insulin secretion.	Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 113, Japan; Jichi Med Sch, Omiya Med Ctr, Omiya, Saitama 330, Japan; Asahi Life Fdn, Inst Diabet Care & Res, Chiyoda Ku, Tokyo 100, Japan; Natl Def Med Coll, Dept Anat 2, Tokorozawa, Saitama 359, Japan; Meijo Univ, Fac Pharm, Dept Pathobiochem, Tenpaku Ku, Nagoya, Aichi 468, Japan; Univ Tsukuba, Inst Biol Sci, Ibaraki, Osaka 305, Japan; Cornell Univ, Coll Vet Med, Dept Pharmacol, Ithaca, NY 14853 USA	University of Tokyo; Jichi Medical University; Asahi Life Foundation; National Defense Medical College - Japan; Meijo University; University of Tsukuba; Cornell University	Yasuda, K (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Terauchi, Yasuo/AAO-4347-2020	NODA, Mitsuhiko/0000-0003-0413-4631				ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BRUN T, 1993, J BIOL CHEM, V268, P18905; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; CORDELL B, 1979, CELL, V18, P533, DOI 10.1016/0092-8674(79)90070-9; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; EFRAT S, 1993, DIABETES, V42, P901, DOI 10.2337/diabetes.42.6.901; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAYAKAWA T, 1979, J GEN APPL MICROBIOL, V25, P255, DOI 10.2323/jgam.25.255; HAYASHI J, 1990, BIOCHEM BIOPH RES CO, V167, P216, DOI 10.1016/0006-291X(90)91753-F; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; HOSOKAWA H, 1995, DIABETES, V44, P1328, DOI 10.2337/diabetes.44.11.1328; IDELLWENGER JA, 1978, J BIOL CHEM, V253, P4310; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; KADOWAKI H, 1993, LANCET, V341, P893, DOI 10.1016/0140-6736(93)93101-6; KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; LENZEN S, 1982, J BIOL CHEM, V257, P6631; LENZEN S, 1986, BIOSCIENCE REP, V6, P163, DOI 10.1007/BF01115002; Liang Y, 1996, AM J PHYSIOL-ENDOC M, V270, pE846, DOI 10.1152/ajpendo.1996.270.5.E846; LORY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD MJ, 1990, ARCH BIOCHEM BIOPHYS, V279, P104, DOI 10.1016/0003-9861(90)90468-E; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; MEDA P, 1990, J CLIN INVEST, V86, P759, DOI 10.1172/JCI114772; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; MISLER S, 1992, PFLUG ARCH EUR J PHY, V421, P289, DOI 10.1007/BF00374842; MIWA I, 1995, ENZYME PROTEIN, V48, P135; Noda M, 1996, DIABETES, V45, P1766, DOI 10.2337/diabetes.45.12.1766; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; SAKURADA M, 1993, ENDOCRINOLOGY, V132, P2659, DOI 10.1210/en.132.6.2659; Sambrook J., 2002, MOL CLONING LAB MANU; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; TRUS MD, 1981, DIABETES, V30, P911, DOI 10.2337/diabetes.30.11.911; TSUURA Y, 1993, DIABETES, V42, P1446, DOI 10.2337/diabetes.42.10.1446; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WELSH M, 1985, J BIOL CHEM, V260, P3590; ZYBLER E, 1969, J MOL BIOL, V44, P195	47	89	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20300	20307		10.1074/jbc.273.32.20300	http://dx.doi.org/10.1074/jbc.273.32.20300			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685380	hybrid			2022-12-25	WOS:000075305400057
J	Yonetani, T; Tsuneshige, A; Zhou, YX; Chen, XS				Yonetani, T; Tsuneshige, A; Zhou, YX; Chen, XS			Electron paramagnetic resonance and oxygen binding studies of alpha-nitrosyl hemoglobin - A novel oxygen carrier having no-assisted allosteric functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE HEMOGLOBIN; HYBRID HEMOGLOBINS; TREATED RATS; PHOTO-DISSOCIATION; ERYTHROCYTES; SUBUNITS; EQUILIBRIUM; SPECTRUM; HEMES; MODEL	alpha-Nitrosyl hemoglobin, alpha(Fe-NO)(2)beta(Fe)(2), which is frequently observed upon reaction of deoxy hemoglobin with limited quantities of NO in vitro as well as in vivo, has been synthetically prepared, and its reaction with O-2 has been investigation by EPR and thermodynamic equilibrium measurements. alpha-Nitrosyl hemoglobin is relatively stable under aerobic conditions and undergoes reversible O-2 binding at the heme sites of its beta-subunits. Its O-2 binding is coupled to the structural/functional transition between T- (low affinity extreme) and R- thigh affinity) states. This transition is linked to the reversible cleavage of the heme Fe-proximal His bonds in the alpha(Fe-NO) subunits and is sensitive to allosteric effectors, such as protons, 2,3-biphosphoglycerate, and inositol hexaphosphate. In fact, alpha(Fe-NO)(2)beta(Fe)(2) is exceptionally sensitive to protons, as it exhibits a highly enhanced Bohr effect. The total Bohr effect of alpha-nitrosyl hemoglobin is comparable to that of normal hemoglobin, despite the fact that the oxygenation process involves only two ligation steps. All of these structural and functional evidences have been further confirmed by examining the reactivity of the sulfhydryl group of the Cys(beta 93) toward 4,4'-dipyridyl disulfide of several alpha-nitrosyl hemoglobin derivatives over a wide pH range, as a probe for quaternary structure. Despite the halved O-2-carrying capacity, alpha-nitrosyl hemoglobin is fully functional (cooperative and allosterically sensitive) and could represent a versatile low affinity O-2 carrier with improved features that could deliver O-2 to tissues effectively even after NO is sequestered at the heme sites of the alpha-subunits. It is concluded that the NO bound to the heme sites of the alpha-subunits of hemoglobin acts as a negative allosteric effector of Hb and thus might play a role in O-2/CO2 transport in the blood under physiological conditions.	Univ Penn, Med Ctr, Dept Biochem & Biophys, Philadelphia, PA 19194 USA	University of Pennsylvania	Yonetani, T (corresponding author), Univ Penn, Med Ctr, Dept Biochem & Biophys, B605 Richards Bldg 6089,3700 Hamilton Walk, Philadelphia, PA 19194 USA.	yonetant@mail.med.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014508, R37HL014508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048130] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14508] Funding Source: Medline; NIGMS NIH HHS [GM48130] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMPULSKI RS, 1969, ANAL BIOCHEM, V32, P163, DOI 10.1016/0003-2697(69)90118-3; Barrick D, 1997, NAT STRUCT BIOL, V4, P78, DOI 10.1038/nsb0197-78; BERMAN M, 1971, ARCH BIOCHEM BIOPHYS, V145, P236; BUCCI E, 1965, J BIOL CHEM, V240, pP551; CANTILENA LR, 1992, J LAB CLIN MED, V120, P902; CHAMULITRAT W, 1994, MOL PHARMACOL, V46, P391; DRABKIN DL, 1946, J BIOL CHEM, V164, P703; ERIKSSON LEG, 1994, BIOCHEM BIOPH RES CO, V203, P176, DOI 10.1006/bbrc.1994.2165; FRIEDMAN JM, 1983, J BIOL CHEM, V258, P564; FUJII M, 1993, J BIOL CHEM, V268, P15386; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P197, DOI 10.1098/rspb.1965.0066; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; HAYASHI N, 1966, J BIOL CHEM, V241, P79; HENRY Y, 1973, J MOL BIOL, V73, P469, DOI 10.1016/0022-2836(73)90094-6; HILLE R, 1979, J BIOL CHEM, V254, P2110; HUANG TH, 1979, J BIOL CHEM, V254, P1467; HUOT AE, 1992, BIOCHEM BIOPH RES CO, V182, P151, DOI 10.1016/S0006-291X(05)80124-X; IMAI K, 1972, BIOCHEMISTRY-US, V11, P114, DOI 10.1021/bi00751a020; IMAI K, 1977, BIOCHIM BIOPHYS ACTA, V490, P1564; Imai K., 1982, ALLOSTERIC EFFECTS H; KON H, 1975, BIOCHIM BIOPHYS ACTA, V379, P103, DOI 10.1016/0005-2795(75)90012-4; Kosaka H, 1996, BIOCHEM BIOPH RES CO, V218, P749, DOI 10.1006/bbrc.1996.0133; KOSAKA H, 1994, AM J PHYSIOL, V266, pC1400, DOI 10.1152/ajpcell.1994.266.5.C1400; KRUSZYNA R, 1988, TOXICOL APPL PHARM, V94, P458, DOI 10.1016/0041-008X(88)90286-4; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAGAI K, 1978, BIOCHIM BIOPHYS ACTA, V532, P17, DOI 10.1016/0005-2795(78)90443-9; NAGAI K, 1980, P NATL ACAD SCI-BIOL, V77, P2033, DOI 10.1073/pnas.77.4.2033; ODA H, 1975, ARCH ENVIRON HEALTH, V30, P453, DOI 10.1080/00039896.1975.10666749; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; RALOFF J, 1995, SCI NEWS, V148, P247; REIN H, 1972, FEBS LETT, V24, P24, DOI 10.1016/0014-5793(72)80817-2; ROMBERG RW, 1970, BIOCHEMISTRY-US, V18, P5387; ROSE EJ, 1983, J AM CHEM SOC, V105, P2866, DOI 10.1021/ja00347a056; Scheidt W.R., 1987, METAL COMPLEXES TETR, V64, P1, DOI DOI 10.1007/BFB0036789; SCHEIDT WR, 1975, J AM CHEM SOC, V97, P17, DOI 10.1021/ja00834a005; SHIBAYAMA N, 1987, BIOCHEMISTRY-US, V26, P2194, DOI 10.1021/bi00382a019; SHIGA T, 1969, BIOCHEMISTRY-US, V8, P378, DOI 10.1021/bi00829a052; SHIMAZU M, 1984, INORG CHIM ACTA, V91, P210; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; SUZUKI T, 1965, BIOCHEM BIOPH RES CO, V19, P691, DOI 10.1016/0006-291X(65)90312-8; SZABO A, 1976, BIOCHEMISTRY-US, V15, P4427, DOI 10.1021/bi00665a013; TAKETA F, 1978, J BIOL CHEM, V253, P5448; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; TSUNESHIGE A, 1993, J BIOL CHEM, V268, P23031; Tsuneshige A, 1998, BIOPHYS J, V74, pA81; Tsuneshige A, 1998, BIOPHYS J, V74, pA80; WANG QZ, 1991, LIFE SCI, V49, pPL55, DOI 10.1016/0024-3205(91)90251-6; WAYLAND BB, 1974, J AM CHEM SOC, V96, P6037, DOI 10.1021/ja00826a013; YOSHIMURA T, 1997, CARDIOVASCULAR DIS G, V3, P1	50	121	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20323	20333		10.1074/jbc.273.32.20323	http://dx.doi.org/10.1074/jbc.273.32.20323			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685383	hybrid			2022-12-25	WOS:000075305400060
J	Zhu, T; Beckingham, K; Ikebe, M				Zhu, T; Beckingham, K; Ikebe, M			High affinity Ca2+ binding sites of calmodulin are critical for the regulation of myosin I beta motor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL CA2+-BINDING SITES; CALCIUM-BINDING; MUSCLE MYOSIN; LIGHT-CHAINS; DOMAIN; CONFORMATION; MUTATIONS	We coexpressed myosin IP heavy chain with three different calmodulin mutants in which the two Ca2+-binding sites of the two N-terminal domain (E12Q), C-terminal domain (E34Q), or all four sites (E1234Q) are mutated in order to define the importance of these Ca2+ binding sites to the regulation of myosin Tp. The! calmodulin mutated at the two Ca2+ binding sites in N-terminal domain and C-terminal domain lost its lower affinity Ca2+ binding site and higher affinity Ca2+ binding site, respectively, We found that, based upon the change in the actin-activated ATPase activities and actin translocating activities, myosin I beta with E12Q calmodulin has the regulatory characteristics similar to myosin IP containing wild-type calmodulin, while myosin IP with E34Q or E1234Q calmodulin lose all Ca2+ regulation. While the increase in myosin IP ATPase activity paralleled the dissociation of 1 mol of calmodulin from myosin Ip heavy chain for both wild type (above pCa 5) and E12Q calmodulin (above pCa 6), the Ca2+ level required for the inhibition of actin-translocating activity of myosin Ip was lower than that required for dissociation of calmodulin, suggesting that the conformational change induced by the binding of Ca2+ at the high affinity site but not the dissociation of calmodulin is critical for the inhibition of the motor activity. Our results suggest that the regulation of unconventional myosins by Ca2+ is directly mediated by the Ca2+ binding to calmodulin, and that the C-terminal pair of Ca2+-binding sites are critical for this regulation.	Univ Massachusetts, Med Ctr, Dept Physiol, Worcester, MA 01655 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	University of Massachusetts System; University of Massachusetts Worcester; Rice University	Ikebe, M (corresponding author), Univ Massachusetts, Med Ctr, Dept Physiol, Worcester, MA 01655 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056218, P01HL047530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 56218, HL 47530] Funding Source: Medline; NIAMS NIH HHS [AR 41653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; BECKINGHAM K, 1991, J BIOL CHEM, V266, P6027; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; COLUCCIO LM, 1994, J CELL SCI, V107, P2279; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Hasson T, 1996, J BIOL CHEM, V271, P16431, DOI 10.1074/jbc.271.28.16431; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; KELLER CH, 1982, CALCIUM CELL FUNCTIO, V3, P103; KLEE CB, 1988, MOL ASPECTS CELLULAR, V5, P35; LINSE S, 1991, J BIOL CHEM, V266, P8050; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Mukherjea P, 1996, PROTEIN SCI, V5, P468; POLLARD DP, 1991, ANNU REV PHYSIOL, V53, P653; REIZES O, 1994, P NATL ACAD SCI USA, V91, P6349, DOI 10.1073/pnas.91.14.6349; RUPPERT C, 1993, J CELL BIOL, V120, P1393, DOI 10.1083/jcb.120.6.1393; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; SHERR EH, 1993, J CELL BIOL, V120, P1405, DOI 10.1083/jcb.120.6.1405; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; Swindells MB, 1996, NAT STRUCT BIOL, V3, P501, DOI 10.1038/nsb0696-501; WAGNER MC, 1992, J CELL BIOL, V119, P163, DOI 10.1083/jcb.119.1.163; WOLENSKI JS, 1993, J CELL BIOL, V122, P613, DOI 10.1083/jcb.122.3.613; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c; ZHU T, 1994, FEBS LETT, V339, P31, DOI 10.1016/0014-5793(94)80378-1	31	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20481	20486		10.1074/jbc.273.32.20481	http://dx.doi.org/10.1074/jbc.273.32.20481			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685403	hybrid			2022-12-25	WOS:000075305400080
J	Lomax, ME; Barnes, DM; Hupp, TR; Picksley, SM; Camplejohn, RS				Lomax, ME; Barnes, DM; Hupp, TR; Picksley, SM; Camplejohn, RS			Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members	ONCOGENE			English	Article						p53; Li-Fraumeni syndrome; oligomerization domain; MDM2; apoptosis; transactivation	TUMOR-SUPPRESSOR P53; TETRAMERIZATION DOMAIN; DNA-BINDING; BAX GENE; IN-VIVO; EXPRESSION; CANCER; MDM2; APOPTOSIS; SARCOMAS	p53 is a tumour suppressor gene which functions as a transcription factor to upregulate genes for growth arrest and apoptosis following DNA damage. p53 mutations are associated with Li-Fraumeni and Li-Fraumeni like syndromes. Recently mutations of the oligomerization domain have been isolated from an LFS and an LFL family affecting respectively codon 344 (Leu to Pro) and 337 (Arg to Cys). The present study was designed to determine the affect of these mutations on the function of pJ3 protein, p53 344 Leu to Pro existed only in a monomeric form and could not bind to DIVA. It was inactive at inducing apoptosis, transactivating luciferase from a bax promoter and inhibiting cell growth. In contrast, p53 337 Arg to (Cys could form tetramers and could bind to DNA. However, p53 337 Arg to Cys was not fully active and could only induce apoptosis, transactivate luciferase from a bax promoter and inhibit cell growth with approximate to 60% of the ability of wild-type p53. Both mutant proteins had reduced ability to bind to MDM2, p53 337 Arg to Cys being more reduced than p53 344 Leu to Pro. These results indicate that point mutations in the oligomerization domain can disrupt p53 function. In addition, the value of LFS and LFL families for the further understanding of the biological and biochemical properties of p53 is demonstrated.	United Med & Dent Sch Guys & St Thomas Hosp, Richard Dimbleby Dept Canc Res, London SE1 7EH, England; Guys Hosp, Clin Oncol Unit, ICRF, London SE1 9RT, England; Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of Dundee; University of Bradford	Camplejohn, RS (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, Richard Dimbleby Dept Canc Res, Lambeth Palace Rd, London SE1 7EH, England.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BIRCH JM, 1994, EUR J CANCER, V30A, P1935, DOI 10.1016/0959-8049(94)00383-G; Casey G, 1996, ONCOGENE, V13, P1971; DAVISON T, UNPUB ONCOGENE SIMUL; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1995, ONCOGENE, V10, P1485; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KERN SE, 1991, SCIENCE, V251, P1708; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Lomax ME, 1997, ONCOGENE, V14, P1869, DOI 10.1038/sj.onc.1201133; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; Picksley SM, 1996, ACTA ONCOL, V35, P429, DOI 10.3109/02841869609109917; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1996, ONCOGENE, V12, P2437; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	34	78	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					643	649		10.1038/sj.onc.1201974	http://dx.doi.org/10.1038/sj.onc.1201974			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704930				2022-12-25	WOS:000075195300012
J	Qu, CK; Feng, GS				Qu, CK; Feng, GS			Shp-2 has a positive regulatory role in ES cell differentiation and proliferation	ONCOGENE			English	Article						tyrosine phosphatase; ES cell differentiation; cell proliferation; signal transduction	PROTEIN-TYROSINE-PHOSPHATASE; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; EMBRYONIC STEM-CELLS; FACTOR RECEPTOR-BETA; SIGNAL-TRANSDUCTION; MOTH-EATEN; ANTIGEN RECEPTOR; SH2 DOMAINS; IN-VITRO; SYP	Shp-2 is a ubiquitously expressed tyrosine phosphatase with two SH2 domains. Homozygous mutant mice with a targeted deletion of 65 amino acid residues in the N-terminal SH2 domain of Shp-2 die in utero at midgestation, with multiple defects in mesodermal patterning To surpass the embryonic lethality in dissecting the Shp-2 function in cell growth and differentiation, we established homozygous Shp-2 mutant embryonic stem (ES) cell lines. Our previous data showed a severe suppression of hematopoietic cell differentiation from Shp-2 mutant ES cells. Here rye demonstrate that development of cardiac muscle cells was dramatically delayed and impaired in embryoid bodies (EBs) of Shp-2 mutant origin. Shp-2 mutant ES cells failed to differentiate into epithelial and fibroblast cells in vitro. However, higher efficiency of secondary EB formation was observed from the mutant than the wild-type ES cells. Further, mutant ES cells were more sensitive than wild-type cells to the differentiation suppressing effect of leukemia inhibitory factor (LIF). In addition, mutant ES cells showed a reduced growth rate compared to wildtype cells. These results suggest that the Shp-2 tyrosine phosphatase is a positive regulator for both cell differentiation and proliferation, in contrast to the Src-family kinases which promote cell growth but block differentiation.	Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Feng, GS (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053660] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29GM53660] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOULTER CA, 1988, ONCOGENE, V2, P207; BOULTER CA, 1991, DEVELOPMENT, V111, P357; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MILLERHANCE WC, 1993, J BIOL CHEM, V268, P25244; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; THOMAS ML, 1995, J EXP MED, V181, P1953, DOI 10.1084/jem.181.6.1953; TSUI FWL, 1994, IMMUNOL REV, V138, P185, DOI 10.1111/j.1600-065X.1994.tb00852.x; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WOBUS AM, 1991, DIFFERENTIATION, V48, P173, DOI 10.1111/j.1432-0436.1991.tb00255.x; Wurst W., 1993, Gene targeting: a practical approach., P33; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577	43	63	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					433	439		10.1038/sj.onc.1201920	http://dx.doi.org/10.1038/sj.onc.1201920			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696036				2022-12-25	WOS:000075043000005
J	Lutz, W; Fulda, S; Jeremias, I; Debatin, KM; Schwab, M				Lutz, W; Fulda, S; Jeremias, I; Debatin, KM; Schwab, M			MycN and IFN gamma cooperate in apoptosis of human neuroblastoma cells	ONCOGENE			English	Article						oncogenes; amplification; APO-1; FAS; cytokines; CD95	BCL-2 HOMOLOG BAK; C-MYC; N-MYC; ORNITHINE DECARBOXYLASE; DEATH; ALPHA; PROTEIN; GROWTH; EXPRESSION; INDUCTION	Neuroblastomas undergo spontaneous regression at an unusually high rate. The mechanisms are not clear, but apoptosis may be involved. A large proportion of neuroblastomas is characterized by amplification of MYCN. Using human neuroblastoma cells harbouring tetracycline controlled expression of MYCN we have analysed the role of the MycN protein and IFN gamma in cell death decision. Neither conditional expression of MYCN nor treatment with IFN gamma alone was sufficient to trigger cell death. However, when acting in concert MycN and IFN gamma efficiently triggered cell death, which was accompanied by DNA fragmentation and required caspase activity, two hallmarks of apoptosis, MycN and IFN gamma may cooperate along at least two different pathways. First, IFN gamma increased the CD95 cell surface expression while MycN enhanced the cellular susceptibility for the CD95 mediated death signal. Second, IFN gamma, treatment induced expression of BAK mRNA while MycN and IFN gamma in combination increased the amount of Bax protein, another activator of apoptosis, without a concomitant increase in BAX mRNA. MycN also increased cell death in response to TRAIL and TNF alpha, suggesting that enforced MYCN expression in general increases the susceptibility of neuroblastoma cells towards a variety of death stimuli.	German Canc Res Ctr, Dept Cytogenet 0825, D-69120 Heidelberg, Germany; Heidelberg Univ, Childrens Hosp, Div Hematol Oncol, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Mol Oncol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Schwab, M (corresponding author), German Canc Res Ctr, Dept Cytogenet 0825, Neuheimer Feld 280, D-69120 Heidelberg, Germany.		Fulda, Simone/D-5864-2011; Jeremias, Irmela/C-6090-2015; Jeremias, Irmela/Q-5934-2019; Debatin, Klaus-Michael/J-9704-2014	Jeremias, Irmela/0000-0003-1773-7677; Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				ASKEW DS, 1991, ONCOGENE, V6, P1915; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BERTHOLD F, 1990, NEUROBLASTOMA TUMOR, P1; CASTLE VP, 1993, AM J PATHOL, V143, P1543; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P3823; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ikeda H, 1996, AM J SURG PATHOL, V20, P649, DOI 10.1097/00000478-199606000-00001; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; Lutz W, 1996, ONCOGENE, V13, P803; MIYASHITA T, 1995, CELL, V80, P293; Montaldo PG, 1997, CELL DEATH DIFFER, V4, P150, DOI 10.1038/sj.cdd.4400215; Nakagawara A, 1997, CANCER RES, V57, P4578; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OITVAI ZN, 1993, CELL, V74, P609; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PONZONI M, 1992, CANCER RES, V52, P931; PRITCHARD J, 1994, LANCET, V344, P869, DOI 10.1016/S0140-6736(94)92834-7; Sato T, 1997, BRIT J HAEMATOL, V97, P356, DOI 10.1046/j.1365-2141.1997.562704.x; Schwab M, 1995, NEUROSCIENTIST, V1, P277; SCHWAB M, 1998, BIOESSAYS        JUN; Schwab M, 1997, PATHOLOGY GENETICS T, P117; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P7227, DOI 10.1073/pnas.94.14.7227; ZORNIG M, 1995, ONCOGENE, V11, P2165; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	55	98	102	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	1998	17	3					339	346		10.1038/sj.onc.1200201	http://dx.doi.org/10.1038/sj.onc.1200201			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690515				2022-12-25	WOS:000074947500008
J	O'Brien, V; Campo, MS				O'Brien, V; Campo, MS			BPV-4 E8 transforms NIH3T3 cells, up-regulates cyclin A and cyclin A-associated kinase activity and de-regulates expression of the cdk inhibitor p27(Kip1)	ONCOGENE			English	Article						BPV-4; cell transformation; cyclin A; cyclin A-associated kinase; E8; p27(Kip1)	BOVINE PAPILLOMAVIRUS TYPE-4; PHASE-TRANSITION; GROWTH-FACTOR; PROTEIN; ONCOPROTEIN; INACTIVATION; FIBROBLASTS; RECEPTOR; GOLGI; BINDS	The E8 open reading frame of Bovine papillomavirus type 4 (BPV-4) encodes a small (42 amino acid) hydrophobic polypeptide localized to cellular membranes and capable of conferring an anchorage-independent (AI) growth phenotype on primary bovine cells co-transfected with BPV-4 E7 ORF and an activated ras gene. To further study the function of E8 independently of other viral gene products, we have expressed it in the murine fibroblast cell line, NIH3T3, Cells expressing E8 are capable of AI growth and escape growth arrest after serum withdrawal. E8 deregulates cyclin A expression, induces transactivation of the human cyclin A gene promoter and increases endogenous protein levels in cells maintained in short-term suspension culture and in low-serum (LS), Both these culture conditions promote downregulation of cyclin A in control cells. In LS growth conditions E8 permits sustained cyclin A-associated kinase activity but not cyclin E-cdk2 activity, Cyclin A-cdk2 activity and, in part, cyclin A gene expression are regulated by the cdk inhibitor p27(Kip1). Expression of this cdk inhibitor is also de-regulated in E8 cells, with high levels being detected under all culture conditions tested. These data suggest that the ability of BPV-4 E8 to transform NIH3T3 cells is associated with upregulation of cyclin A-associated kinase activity and de-regulated expression of the cdk inhibitor p27(Kip1) and does not rely on down-regulation of p27(Kip1) expression. Analysis of E8 mutants indicate that the hydrophilic 'tail' of the molecule (residues 31 - 42) is required for cell transformation, as assessed by anchorage-independent growth, while a form of E8 with expression restricted to the Endoplasmic Reticulum/cis-Golgi membranes by addition of a 'KDEL' retention signal revealed that the sub-cellular localization is an important determinant of E8 biological activity.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	O'Brien, V (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.			O'Brien, Vincent/0000-0002-2418-7768				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; CAMPO MS, 1994, CARCINOGENESIS, V15, P1597, DOI 10.1093/carcin/15.8.1597; CARMICHAEL J, 1987, CANCER RES, V47, P943; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GIRARD F, 1991, CELL, V67, P1; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Jackson ME, 1996, INT J ONCOL, V9, P1189; JAGGAR RT, 1990, J GEN VIROL, V71, P3041, DOI 10.1099/0022-1317-71-12-3041; Kramer A, 1996, J BIOL CHEM, V271, P6579; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PENNIE WD, 1993, VIROLOGY, V193, P614, DOI 10.1006/viro.1993.1169; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SETTLEMAN J, 1989, MOL CELL BIOL, V9, P5563, DOI 10.1128/MCB.9.12.5563; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPARKOWSKI J, 1995, EMBO J, V14, P3055, DOI 10.1002/j.1460-2075.1995.tb07308.x; THOME KZ, 1997, MOL CELL BIOL, V17, P407; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZerfassThome K, 1996, ONCOGENE, V13, P2323	33	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					293	301		10.1038/sj.onc.1201937	http://dx.doi.org/10.1038/sj.onc.1201937			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690511				2022-12-25	WOS:000074947500004
J	Ko, TC; Yu, WS; Sakai, T; Sheng, HM; Shao, JY; Beauchamp, RD; Thompson, EA				Ko, TC; Yu, WS; Sakai, T; Sheng, HM; Shao, JY; Beauchamp, RD; Thompson, EA			TGF-beta 1 effects on proliferation of rat intestinal epithelial cells are due to inhibition of cyclin D1 expression	ONCOGENE			English	Article						TGF-beta 1; cyclin D1; cyclin-dependent kinase; gut epithelial cells; antisense oligonucleotide	TGF-BETA RECEPTOR; GROWTH-FACTOR; GENE-EXPRESSION; DIFFERENTIAL SENSITIVITY; RETINOBLASTOMA PROTEIN; PRB PHOSPHORYLATION; POTENTIAL MEDIATOR; TRANSGENIC MICE; CARCINOMA-CELLS; CDK INHIBITORS	Transforming growth factor-beta 1 (TGF-beta 1) arrests intestinal epithelial cells (RIE-1 and IEC-6) in the G1 phase of the cell cycle and inhibits cyclin D1 expression, This report describes experiments designed to elucidate the mechanism of cyclin D1 inhibition and to determine whether inhibition of cyclin D1 expression is the cause, rather than the result, of TGF-beta 1-mediated cell cycle arrest, TGF-beta 1 inhibition of IEC-6 cell proliferation mas associated with a decrease in the abundance of cyclin D1/Cdk4 complexes and a corresponding decrease in Cdk4-dependent phosphorylation of the retinoblastoma protein, Metabolic labeling studies indicated that TGF-beta 1 inhibited cyclin D1 synthesis without altering the rate of cyclin DI protein degradation. Cyclin D1 antisense oligonucleotides blocked serum-stimulated induction of cyclin D1 and DNA synthesis, whereas cyclin D1 sense oligonucleotides had no effect. RIE-1 cells were engineered to overexpress human cyclin D1 under the control of a tetracycline-repressible promoter, These cells entered S phase in the presence of TGF-beta 1 only when human cyclin D1 was derepressed by the withdrawal of tetracycline. These data indicate that TGF-beta 1 inhibits the synthesis of cyclin D1 in gut epithelial cells and that this inhibition is the cause, rather than the result, of TGF-beta 1-mediated arrest of intestinal epithelial cell proliferation.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Vanderbilt Univ, Sch Med, Dept Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Showa Univ, Sch Med, Dept Internal Med 3, Tokyo 142, Japan	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Vanderbilt University; Vanderbilt University; Showa University	Thompson, EA (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.			Beauchamp, Robert Daniel/0000-0002-8446-4114	NCI NIH HHS [CA64191, CA64701, CA69457] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069457, R01CA064701, K08CA064191] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABAYATSKY MW, 1991, TXB GASTROENTEROLOGY, P475; AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Arber N, 1997, CANCER RES, V57, P1569; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; BARNARD JA, 1993, GASTROENTEROLOGY, V105, P67, DOI 10.1016/0016-5085(93)90011-Z; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BLAY J, 1985, J CELL PHYSIOL, V124, P107, DOI 10.1002/jcp.1041240117; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Bresnahan WA, 1996, VIROLOGY, V224, P150, DOI 10.1006/viro.1996.0516; CAIRNIE AB, 1965, EXP CELL RES, V39, P528, DOI 10.1016/0014-4827(65)90055-8; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIACCI C, 1993, GASTROENTEROLOGY, V105, P93, DOI 10.1016/0016-5085(93)90014-4; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FILMUS J, 1992, ONCOGENE, V7, P521; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; FROST GH, 1993, J BIOL CHEM, V268, P6748; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HALL PA, 1994, J CELL SCI, V107, P3569; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; Hung WC, 1996, BIOCHEM BIOPH RES CO, V220, P719, DOI 10.1006/bbrc.1996.0470; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KATO J, 1993, GENE DEV, V7, P331; KO TC, 1995, ONCOGENE, V10, P177; KO TC, 1994, AM J SURG, V167, P14, DOI 10.1016/0002-9610(94)90048-5; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; MANNING AM, 1991, ONCOGENE, V6, P1471; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MUNGER K, 1992, CELL GROWTH DIFFER, V3, P291; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; PALMERO I, 1993, ONCOGENE, V8, P1049; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Ramalingam A, 1997, MOL ENDOCRINOL, V11, P577, DOI 10.1210/me.11.5.577; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RHEE K, 1995, CANCER RES, V55, P4188; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TRABER PG, 1994, J LAB CLIN MED, V123, P467; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang T, 1997, CANCER RES, V57, P169; Zhang T, 1997, CANCER RES, V57, P1638	68	68	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3445	3454		10.1038/sj.onc.1201902	http://dx.doi.org/10.1038/sj.onc.1201902			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692552				2022-12-25	WOS:000074544100011
J	Carreira, CM; LaVallee, TM; Tarantini, F; Jackson, A; Lathrop, JT; Hampton, B; Burgess, WH; Maciag, T				Carreira, CM; LaVallee, TM; Tarantini, F; Jackson, A; Lathrop, JT; Hampton, B; Burgess, WH; Maciag, T			S100A13 is involved in the regulation of fibroblast growth factor-1 and p40 synaptotagmin-1 release in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; FACTOR-I; ANTIALLERGIC AGENT; ANNEXIN-II; SUBCELLULAR-DISTRIBUTION; PHOSPHOLIPID-BINDING; STRUCTURAL-ANALYSIS; CYSTEINE RESIDUES; NEURITE EXTENSION; SEQUENCE HOMOLOGY	We have previously characterized the release of the signal peptide sequence-less fibroblast growth factor (FGF) prototype, FGF-1, in vitro as a stress-induced pathway in which FGF-1 is released as a latent homodimer with the p40 extravesicular domain of p65 synaptotagmin (Syn)-1. To determine the biologic relevance of the FGF-1 release pathway in vivo, we sought to resolve and characterize fi om ovine brain a purified fraction that contained both FGF-1 and p40 Syn-1 and report that the brain-derived FGF-1:p40 Syn-1 aggregate is associated with the calcium-binding protein, S100A13, Since S100A13 binds the anti-inflammatory compound amlexanox and FGF-1 is involved in inflammation, we examined the effects of amlexanox on the release of FGF-1 and p40 Syn-1 in response to stress in vitro. We report that while amlexanox was able to repress the heat shock-induced release of FGF-1 and p40 Syn-1 in a concentration-dependent manner, it had no effect on the constitutive release of p40 Syn-1 from p40 Syn-1 NIH 3T3 cell transfectants. These data suggest the following: (i) FGF-1 is associated with Syn-1 and S100A13 in vivo; (ii) S100A13 may be involved in the regulation of FGF-1 and p40 Syn-1 release in response to temperature stress in vitro; and (iii) the FGF-1 release pathway may be accessible to pharmacologic regulation.	Maine Med Ctr, Res Inst, Ctr Mol Med, S Portland, ME 04106 USA; Amer Red Cross, Holland Lab, Dept Mol Biol, Rockville, MD 20855 USA	Maine Medical Center; American Red Cross	Maciag, T (corresponding author), Maine Med Ctr, Res Inst, Ctr Mol Med, 125 John Roberts Rd, S Portland, ME 04106 USA.	maciat@mail.mmc.org	Tarantini, Francesca/I-6332-2012; Hampton, Brian/G-8427-2015	Hampton, Brian/0000-0003-4650-2869; TARANTINI, FRANCESCA/0000-0002-1390-2965	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035627, P01HL054710, R01HL032348] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32348, HL35627, HL54710] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MK, 1993, J NEUROSCI, V13, P1701; Bergmeyer H.U., 1965, METHODS ENZYMATIC AN, P736, DOI [10.1016/b978-0-12-395630-9.50134-1, DOI 10.1016/B978-0-12-395630-9.50134-1]; BERMAN BA, 1983, CLIN REV ALLERG, V1, P105; Burgess W. H., 1996, P154; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COCHRAN AJ, 1993, MELANOMA RES, V3, P325, DOI 10.1097/00008390-199310000-00004; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DAMON DH, 1989, J CELL PHYSIOL, V138, P221, DOI 10.1002/jcp.1041380202; DAVIES BR, 1993, ONCOGENE, V8, P999; DINARELLO CA, 1991, CURR OPIN IMMUNOL, V3, P941, DOI 10.1016/S0952-7915(05)80018-4; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; DONATO R, 1990, ADV EXP MED BIOL, V269, P103; Donnelly SR, 1997, CELL MOL LIFE SCI, V53, P533, DOI 10.1007/s000180050068; EGERTON M, 1992, J IMMUNOL, V149, P1847; ENGLEKA KA, 1992, J BIOL CHEM, V267, P11307; FANO G, 1995, PROG NEUROBIOL, V46, P71, DOI 10.1016/0301-0082(94)00062-M; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; GOLDFARB AR, 1951, J BIOL CHEM, V193, P397; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; HEIZMAN CW, 1995, CALCIUM REGULATION C; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JOHNSSON N, 1990, PROG CLIN BIOL RES, V349, P123; KAHN HJ, 1983, AM J CLIN PATHOL, V79, P341, DOI 10.1093/ajcp/79.3.341; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; LACKMANN M, 1992, J BIOL CHEM, V267, P7499; LaVallee TM, 1998, J BIOL CHEM, V273, P22217, DOI 10.1074/jbc.273.35.22217; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MACIAG T, 1982, J BIOL CHEM, V257, P5333; MAKINO H, 1987, INT ARCH ALLER A IMM, V82, P66, DOI 10.1159/000234292; MERGIA A, 1989, BIOCHEM BIOPH RES CO, V164, P1121, DOI 10.1016/0006-291X(89)91785-3; NAKA M, 1994, BBA-MOL CELL RES, V1223, P348, DOI 10.1016/0167-4889(94)90094-9; NISHIKI T, 1994, J BIOL CHEM, V269, P10498; Oyama Y, 1997, BIOCHEM BIOPH RES CO, V240, P341, DOI 10.1006/bbrc.1997.7476; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Rammes A, 1997, J BIOL CHEM, V272, P9496; SAIJO T, 1985, INT ARCH ALLER A IMM, V78, P43, DOI 10.1159/000233861; SAIJO T, 1985, INT ARCH ALLER A IMM, V77, P315, DOI 10.1159/000233837; SAIJO T, 1986, INT ARCH ALLER A IMM, V79, P231, DOI 10.1159/000233978; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; SHAPIRO GG, 1985, PHARMACOTHERAPY, V5, P156; Shi JP, 1997, J BIOL CHEM, V272, P1142, DOI 10.1074/jbc.272.2.1142; TAGENAKA K, 1994, J CELL BIOL, V124, P757; TAGENAKA K, 1994, JPN J CANCER RES, V85, P831; TAGENAKA K, 1997, ONCOGENE, V14, P331; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; TARANTINI F, 1995, J BIOL CHEM, V270, P29039, DOI 10.1074/jbc.270.49.29039; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; THOMAS KA, 1986, TRENDS BIOCHEM SCI, V11, P81, DOI 10.1016/0968-0004(86)90271-9; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; WATANABE M, 1993, BIOCHEM BIOPH RES CO, V196, P1376, DOI 10.1006/bbrc.1993.2405; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; Wicki R, 1996, BIOCHEM BIOPH RES CO, V227, P594, DOI 10.1006/bbrc.1996.1551; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; ZENG FY, 1993, INT J BIOCHEM, V25, P1019, DOI 10.1016/0020-711X(93)90116-V; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	75	99	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22224	22231		10.1074/jbc.273.35.22224	http://dx.doi.org/10.1074/jbc.273.35.22224			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712836	hybrid			2022-12-25	WOS:000075616600012
J	Rajagopalan, PTR; Pei, D				Rajagopalan, PTR; Pei, D			Oxygen-mediated inactivation of peptide deformylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; METHIONYL-TRNA(F)(MET) FORMYLTRANSFERASE; TRANSLATION; ENZYMES	Peptide deformylase catalyzes the removal of the N-formyl group from newly synthesized polypeptides in prokaryotes. Its essential character and unique presence in prokaryotes make it an attractive target for antibacterial chemotherapy, However, purification and characterization of the peptide deformylase have remained a major challenge because this enzyme is extraordinarily labile under a variety of conditions (t(1/2) similar to 1 min at room temperature). In this work, we show that this unusual instability is because of oxidation of the catalytic Fe2+ ion of the deformylase into catalytically inactive Fe3+ ion by atmospheric oxygen. Oxidation of Fe2+ is accompanied by the conversion of O-2 into a yet unidentified reactive species, which covalently modifies the deformylase protein, most likely by oxidizing cysteine-90, a ligand residue of the Fe2+ ion, into a cysteine sulfonic acid. Enzymatic exclusion of O-2 from the deformylase assays renders the deformylase highly stable under otherwise identical conditions. An improved, readily reproducible purification procedure has been developed that produces approximately 10 mg of pure, fully active Fe2+ deformylase from a liter of cells. In addition, active peptide deformylase can be reconstituted in vitro from the denatured deformylase.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Pei, D (corresponding author), Ohio State Univ, Dept Chem, 100 W 18th Ave, Columbus, OH 43210 USA.		Pei, Dehua/P-4594-2016	Pei, Dehua/0000-0002-2057-6934	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040575] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40575] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS JM, 1968, J MOL BIOL, V33, P571, DOI 10.1016/0022-2836(68)90307-0; Becker A, 1998, J BIOL CHEM, V273, P11413, DOI 10.1074/jbc.273.19.11413; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan MK, 1997, BIOCHEMISTRY-US, V36, P13904, DOI 10.1021/bi9711543; ENGLANDER SW, 1987, ANAL BIOCHEM, V161, P300, DOI 10.1016/0003-2697(87)90454-4; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; KOZAK M, 1983, MICROBIOL REV, V47, P1; Larisch B, 1997, BIOORG MED CHEM LETT, V7, P2681, DOI 10.1016/S0960-894X(97)10056-7; LIVINGSTON DM, 1968, BIOCHEMISTRY-US, V8, P435; MAZEL D, 1994, EMBO J, V13, P914, DOI 10.1002/j.1460-2075.1994.tb06335.x; Meinnel T, 1996, J MOL BIOL, V262, P375, DOI 10.1006/jmbi.1996.0521; MEINNEL T, 1993, BIOCHIMIE, V75, P1061, DOI 10.1016/0300-9084(93)90005-D; MEINNEL T, 1994, J BACTERIOL, V176, P7387, DOI 10.1128/JB.176.23.7387-7390.1994; MEINNEL T, 1993, J BACTERIOL, V175, P7737, DOI 10.1128/JB.175.23.7737-7740.1993; Que L, 1996, CHEM REV, V96, P2607, DOI 10.1021/cr960039f; Rajagopalan PTR, 1997, BIOCHEMISTRY-US, V36, P13910, DOI 10.1021/bi971155v; Rajagopalan PTR, 1997, J AM CHEM SOC, V119, P12418, DOI 10.1021/ja9734096; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; STRYER L, 1981, BIOCHEMISTRY-US, P43; TAKEDA M, 1968, P NATL ACAD SCI USA, V60, P1487, DOI 10.1073/pnas.60.4.1487; Tsujimura M, 1997, J BIOL CHEM, V272, P29454, DOI 10.1074/jbc.272.47.29454; VOGEL AI, 1961, TXB QUANTITATIVE INO, P785; Wei YM, 1997, ANAL BIOCHEM, V250, P29, DOI 10.1006/abio.1997.2194; YAMAGUCHI K, 1987, METHOD ENZYMOL, V143, P395	24	80	83	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22305	22310		10.1074/jbc.273.35.22305	http://dx.doi.org/10.1074/jbc.273.35.22305			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712848	hybrid			2022-12-25	WOS:000075616600024
J	Stuart, JK; Myszka, DG; Joss, L; Mitchell, RS; McDonald, SM; Xie, ZH; Takayama, S; Reed, JC; Ely, KR				Stuart, JK; Myszka, DG; Joss, L; Mitchell, RS; McDonald, SM; Xie, ZH; Takayama, S; Reed, JC; Ely, KR			Characterization of interactions between the anti-apoptotic protein BAG-1 and Hsc70 molecular chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENTS; NUCLEOTIDE-EXCHANGE FACTOR; HEAT-SHOCK PROTEINS; PEPTIDE-BINDING; SECONDARY STRUCTURE; UNFOLDED PROTEINS; SELF-ASSOCIATION; ATPASE ACTIVITY; CELL-DEATH; CLONING	The anti-cell death protein BAG-1 binds to 70-kDa heat shock proteins (Hsp70/Hsc70) and modulates their chaperone activity. Among other facilitory roles, BAG-1 may serve as a nucleotide exchange factor for Hsp10/Hsc70 family proteins and thus represents the first example of a eukaryotic homologue of the bacterial co-chaperone GrpE. In this study, the interactions between BAG-1 and Hsc70 are characterized and compared with the analogous GrpE-DnaK bacterial system. In contrast to GrpE, which binds DnaK as a dimer, BAG-1 binds to Hsc70 as a monomer with a 1:1 stoichiometry. Dynamic light scattering, sedimentation equilibrium, and circular dichroism measurements provided evidence that BAG-1 exists as an elongated, highly helical monomer in solution. Isothermal titration microcalorimetry was used to determine the complex stoichiometry and an equilibrium dissociation constant, K-D, of 100 nM. Kinetic analysis using surface plasmon resonance yielded a K-D consistent with the calorimetrically determined value. Molecular modeling permitted a comparison of structural features between the functionally homologous BAG-1 and GrpE proteins. These data were used to propose a mechanism for BAG-1 in the regulation of Hsp70/Hsc70 chaperone activity.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	Sanford Burnham Prebys Medical Discovery Institute; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Ely, KR (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ely@burnham-inst.org			NATIONAL CANCER INSTITUTE [R01CA067329] Funding Source: NIH RePORTER; NCI NIH HHS [CA-67329] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Benaroudj N, 1996, J BIOL CHEM, V271, P18471, DOI 10.1074/jbc.271.31.18471; Benaroudj N, 1997, J BIOL CHEM, V272, P8744, DOI 10.1074/jbc.272.13.8744; Cantor C. R., 1980, BIOPHYSICAL CHEM 2, P560; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; COOK WJ, 1992, J BIOL CHEM, V267, P16467; Doyle ML, 1997, CURR OPIN BIOTECH, V8, P31, DOI 10.1016/S0958-1669(97)80154-1; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FERREDAMARE AR, 1994, STRUCTURE, V2, P357, DOI 10.1016/S0969-2126(00)00037-X; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Fung KL, 1996, J BIOL CHEM, V271, P21559, DOI 10.1074/jbc.271.35.21559; Gebauer M, 1997, FEBS LETT, V417, P109, DOI 10.1016/S0014-5793(97)01267-2; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; HA JH, 1995, BIOCHEMISTRY-US, V34, P11635, DOI 10.1021/bi00036a040; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOHFELD J, 1995, CELL, V83, P589; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Hu SM, 1996, ARCH BIOCHEM BIOPHYS, V332, P163, DOI 10.1006/abbi.1996.0328; Irmer H, 1997, J BIOL CHEM, V272, P2230; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; MacColl R, 1996, J BIOL CHEM, V271, P17157, DOI 10.1074/jbc.271.29.17157; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; MORTON TA, 1998, IN PRESS METHODS ENZ, V295; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Naylor DJ, 1996, FEBS LETT, V396, P181, DOI 10.1016/0014-5793(96)01100-3; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Takayama S, 1996, GENOMICS, V35, P494, DOI 10.1006/geno.1996.0389; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	53	96	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22506	22514		10.1074/jbc.273.35.22506	http://dx.doi.org/10.1074/jbc.273.35.22506			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712876	hybrid			2022-12-25	WOS:000075616600052
J	Morelon, E; Dautry-Varsat, A				Morelon, E; Dautry-Varsat, A			Endocytosis of the common cytokine receptor gamma(c) chain - Identification of sequences involved in internalization and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; TYROSINE KINASE-ACTIVITY; HUMAN T-LYMPHOCYTES; JAK-3 JANUS KINASE; BETA-CHAIN; IL-2 RECEPTOR; DOWN-REGULATION; INTERLEUKIN-2 RECEPTORS; CYTOPLASMIC DOMAIN; FUNCTIONAL COMPONENT	The common cytokine receptor gamma(c), shared by interleukin 2, 4, 7, 9, and 15 receptors, has a major role in lymphocyte proliferation and differentiation, leading, when mutated, to a genetic disease, X-linked severe combined immunodeficiency. In this study, we report that gamma(c) is internalized and degraded in lymphoid cells. To identify gamma(c) regions involved in sorting along the endocytic pathway, we have studied a chimeric protein composed of the extracellular part of interleukin 2-receptor alpha and transmembrane and intracellular part of gamma(c) alpha gamma gamma(wt). When transfected in Jurkat T cells, alpha gamma gamma(wt) is as efficiently internalized and degraded as gamma(c), demonstrating that the transmembrane and cytosolic tail of gamma(c) carry sequences involved in this process. To identify these motifs, we have analyzed the trafficking of chimeric proteins with serial truncations in their cytosolic tail. Internalization studies showed that the cytosolic tail of gamma(c) contains three regions located between cytosolic amino acids 1-35, 35-40, and 40-65 involved in gamma(c) endocytosis. Successive deletions of these motifs result in reduced endocytosis. One region containing the 5 cytosolic amino acids 36-40 is essential to direct gamma(c) to the degradation pathway. These sorting sequences, by participating in the fine tuning of cell surface gamma(c) expression, might somewhat regulate the cell responsiveness to interleukins whose receptors share this component.	Inst Pasteur, Unite Biol Interact Cellulaires, URA CNRS 1960, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Morelon, E (corresponding author), Inst Pasteur, Unite Biol Interact Cellulaires, URA CNRS 1960, 25 Rue Dr Roux, F-75724 Paris 15, France.							AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; ALCOVER A, 1988, EMBO J, V7, P1973, DOI 10.1002/j.1460-2075.1988.tb03035.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DISANTO JP, 1994, EUR J IMMUNOL, V24, P475, DOI 10.1002/eji.1830240232; DUPREZ V, 1988, J BIOL CHEM, V263, P12860; DUPREZ V, 1986, J BIOL CHEM, V261, P5450; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; HEMAR A, 1995, J CELL BIOL, V129, P55, DOI 10.1083/jcb.129.1.55; HEMAR A, 1994, EUR J IMMUNOL, V24, P1951, DOI 10.1002/eji.1830240902; HEMAR A, 1990, EUR J IMMUNOL, V20, P2629, DOI 10.1002/eji.1830201216; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LUND KA, 1990, J BIOL CHEM, V265, P15713; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; MORELON E, 1995, TRANSPLANT P, V27, P2477; Morelon E, 1996, BLOOD, V88, P1708; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; Nelson BH, 1996, MOL CELL BIOL, V16, P309; Noguchi M, 1997, P NATL ACAD SCI USA, V94, P11534, DOI 10.1073/pnas.94.21.11534; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SETIADI H, 1995, J BIOL CHEM, V270, P26818, DOI 10.1074/jbc.270.45.26818; Subtil A, 1998, EUR J BIOCHEM, V253, P525, DOI 10.1046/j.1432-1327.1998.2530525.x; Subtil A, 1997, J CELL BIOL, V136, P583, DOI 10.1083/jcb.136.3.583; SUBTIL A, 1994, J CELL SCI, V107, P3461; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VIJAYASARADHI S, 1995, J CELL BIOL, V130, P807, DOI 10.1083/jcb.130.4.807; Vincent V, 1997, J BIOL CHEM, V272, P7062, DOI 10.1074/jbc.272.11.7062; VOSS SD, 1992, J EXP MED, V176, P531, DOI 10.1084/jem.176.2.531; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YAMAGUCHI M, 1992, J BIOL CHEM, V267, P22035	50	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22044	22051		10.1074/jbc.273.34.22044	http://dx.doi.org/10.1074/jbc.273.34.22044			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705347	hybrid			2022-12-25	WOS:000075492600081
J	Ridderstrom, M; Cameron, AD; Jones, TA; Mannervik, B				Ridderstrom, M; Cameron, AD; Jones, TA; Mannervik, B			Involvement of an active-site Zn2+ ligand mechanism of human glyoxalase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIOSEPHOSPHATE ISOMERASE; PSEUDOMONAS-PUTIDA; GENE DUPLICATION; PROTEIN MODELS; REFINEMENT; CLONING; EXPRESSION; SEGMENTS; YEAST; METAL	The Zn2+ ligands glutamate 99 and glutamate 172 in the active site of human glyoxalase I were replaced, each in turn, by glutamines by site-directed mutagenesis to elucidate their potential significance for the catalytic properties of the enzyme. To compensate for the loss of the charged amino acid residue, another of the metal ligands, glutamine 33, was simultaneously mutated into glutamate. The double mutants and the single mutants Q33E, E99Q, and E172Q were expressed in Escherichia coli, purified on an S-hexylglutathione matrix, and characterized. Metal analysis demonstrated that mutant Q33E/E172Q contained 1.0 mel of zinc/mol of enzyme subunit, whereas mutant Q33E/E99Q contained only 0.3 mol of zinc/mol of subunit, No catalytic activity could be detected with the double mutant Q33E/E172Q (<10(-8) of the wild-type activity). The second double mutant Q33E/E99Q had 1.5% of the specific activity of the wild-type enzyme, whereas the values for mutants Q33E and E99Q were 1.3 and 0.1%, respectively; the E172Q mutant had less than 10(-5) times the specific activity of the wild-type. The crystal structure of the catalytically inactive double mutant Q33E/E172Q demonstrated that Zn2+ was bound without any gross changes or perturbations. The results suggest that the metal ligand glutamate 172 is directly involved in the catalytic mechanism of the enzyme, presumably serving as the base that abstracts a proton from the hemithioacetal substrate.	Uppsala Univ, Ctr Biomed, Dept Biochem, S-75123 Uppsala, Sweden; Uppsala Univ, Ctr Biomed, Dept Mol Biol, S-75124 Uppsala, Sweden	Uppsala University; Uppsala University	Mannervik, B (corresponding author), Uppsala Univ, Ctr Biomed, Dept Biochem, Box 576, S-75123 Uppsala, Sweden.	bengt.mannervik@biokem.uu.se	Cameron, Alexander/L-7288-2013	Cameron, Alexander/0000-0001-8776-3518				ARONSSON AC, 1981, BIOCHEM J, V197, P67, DOI 10.1042/bj1970067; ARONSSON AC, 1978, BIOCHEM BIOPH RES CO, V81, P1235, DOI 10.1016/0006-291X(78)91268-8; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARDSLEY WG, 1995, COMPUT CHEM, V19, P75, DOI 10.1016/0097-8485(95)00007-F; BJORNESTEDT R, 1992, BIOCHEM J, V282, P505; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR SYSTEM CRYSTA; Cameron AD, 1997, EMBO J, V16, P3386, DOI 10.1093/emboj/16.12.3386; Clugston SL, 1997, GENE, V186, P103, DOI 10.1016/S0378-1119(96)00691-9; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Espartero J, 1995, PLANT MOL BIOL, V29, P1223, DOI 10.1007/BF00020464; Inoue Y, 1996, J BIOL CHEM, V271, P25958, DOI 10.1074/jbc.271.42.25958; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLUM MW, 1978, ANAL BIOCHEM, V85, P586, DOI 10.1016/0003-2697(78)90258-0; KIM NS, 1993, J BIOL CHEM, V268, P11217; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LAN Y, 1995, J BIOL CHEM, V270, P12957, DOI 10.1074/jbc.270.22.12957; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; LU TF, 1994, GENE, V150, P93, DOI 10.1016/0378-1119(94)90864-8; Mannervik B., 1980, ENZYMATIC BASIS DETO, VVolume 2, P263; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; RACKER E, 1951, J BIOL CHEM, V190, P685; RANGANATHAN S, 1993, J BIOL CHEM, V268, P5661; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; Ridderstrom M, 1996, BIOCHEM J, V314, P463; Ridderstrom M, 1996, BIOCHEM J, V316, P1005, DOI 10.1042/bj3161005; Ridderstrom M, 1997, BIOCHEM J, V328, P231, DOI 10.1042/bj3280231; SELLIN S, 1982, J BIOL CHEM, V257, P23; SELLIN S, 1987, BIOCHEMISTRY-US, V26, P6779, DOI 10.1021/bi00395a030; SELLIN S, 1983, J BIOL CHEM, V258, P2091; SELLIN S, 1982, BIOCHEMISTRY-US, V21, P4850, DOI 10.1021/bi00263a004; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; Vander Jagt D.L., 1989, GLUTATHIONE CHEM, P597	37	66	68	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21623	21628		10.1074/jbc.273.34.21623	http://dx.doi.org/10.1074/jbc.273.34.21623			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705294	hybrid			2022-12-25	WOS:000075492600028
J	Zimmerman, JW; Lindermuth, J; Fish, PA; Palace, GP; Stevenson, TT; DeMong, DE				Zimmerman, JW; Lindermuth, J; Fish, PA; Palace, GP; Stevenson, TT; DeMong, DE			A novel carbohydrate-glycosphingolipid interaction between a beta-(1-3)-glucan immunomodulator, PGG-glucan, and lactosylceramide of human leukocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; RISK SURGICAL PATIENTS; CELL-LINES; BINDING CHARACTERISTICS; GALACTOSYL CERAMIDE; RESPONSE MODIFIER; RECEPTOR-BINDING; HUMAN MONOCYTES; ANTIGENS; VEROTOXIN-1	The immunomodulator Betafectin(R) PGG-glucan is a homopolymer of glucose derived from yeast cell walls which has been demonstrated to enhance leukocyte anti-infective activity in vitro and in vivo, without the induction of proinflammatory cytokines. We report here the purification of a PGG-glucan-binding element from human leukocytes and its identification as lactosylceramide, a major glycosphingolipid of neutrophils, which includes the CDw17 epitope, The binding of radiolabeled PGG-glucan to purified lactosylceramide was saturable, specific, and time- and temperature-dependent, Lactosylceramides from human leukocytes were fractionated by high performance liquid chromatography in order to analyze the effect of ceramide structure on binding, a variety of fatty acid chain lengths with varying degrees of unsaturation were found to support binding to radiolabeled PGG-glucan. However, DL-lactosylceramides containing dihydrosphingosine did not bind. Radiolabeled PGG-glucan bound several other neutral glycosphingolipids with a terminal galactose, including galactosylceramide, globotriaosylceramide, and gangliotetraosylceramide. The binding of radiolabeled PGG-glucan to lactosylceramide was not inhibited by glycogen, dextran, mannan, pustulan, laminarin, or a low molecular weight beta-(1-3)-glucan, but was inhibited by high molecular weight beta-(1-3)-glucans and by a monoclonal antibody to lactosylceramide. Although this glycosphingolipid has been shown in numerous reports to bind various microorganisms, this represents the first report of lactosylceramide binding to a a macromolecular carbohydrate.	Alpha Beta Technol Inc, Worcester, MA 01605 USA		Zimmerman, JW (corresponding author), Alpha Beta Technol Inc, 1 Innovat Dr, Worcester, MA 01605 USA.	jzimme@abti.com						Adams DS, 1997, J LEUKOCYTE BIOL, V62, P865, DOI 10.1002/jlb.62.6.865; ANDREWS RG, 1983, BLOOD, V62, P124; BABINEAU TJ, 1994, ANN SURG, V220, P601, DOI 10.1097/00000658-199411000-00002; BABINEAU TJ, 1994, ARCH SURG-CHICAGO, V129, P1204; Bast DJ, 1997, INFECT IMMUN, V65, P2019, DOI 10.1128/IAI.65.6.2019-2028.1997; Bhunia AK, 1996, J BIOL CHEM, V271, P10660, DOI 10.1074/jbc.271.18.10660; BLEICHER P, 1995, J BIOTECHNOL HEALTHC, V2, P207; Bohn JA, 1995, CARBOHYD POLYM, V28, P3, DOI 10.1016/0144-8617(95)00076-3; Chatterjee SB, 1997, GLYCOBIOLOGY, V7, P57, DOI 10.1093/glycob/7.1.57; ENGSTAD RE, 1994, DEV COMP IMMUNOL, V18, P397, DOI 10.1016/0145-305X(94)90005-1; Fantini J, 1997, J BIOL CHEM, V272, P7245, DOI 10.1074/jbc.272.11.7245; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; HAKOMORI S, 1972, METHOD ENZYMOL, V28, P232; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HERRMANN JE, 1995, J CLIN MICROBIOL, V33, P2511, DOI 10.1128/JCM.33.9.2511-2513.1995; HILDEBRAND J, 1971, J LIPID RES, V12, P361; IRIE A, 1990, J BIOCHEM-TOKYO, V108, P531, DOI 10.1093/oxfordjournals.jbchem.a123237; JIMENEZLUCHO V, 1990, INFECT IMMUN, V58, P2085, DOI 10.1128/IAI.58.7.2085-2090.1990; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KIARASH A, 1994, J BIOL CHEM, V269, P11138; Kniep B, 1998, J LEUKOCYTE BIOL, V63, P83, DOI 10.1002/jlb.63.1.83; KONOPSKI Z, 1994, BBA-MOL CELL RES, V1221, P61, DOI 10.1016/0167-4889(94)90216-X; Koshy KM, 1996, J BIOL CHEM, V271, P3496; KUSHI Y, 1989, ANAL BIOCHEM, V182, P405, DOI 10.1016/0003-2697(89)90615-5; LIANG J, 1998, IN PRESS INT J IMMUN; LUNDJOHANSEN F, 1992, J IMMUNOL, V148, P3221; MACHER BA, 1980, J BIOL CHEM, V255, P2092; MARCUS AJ, 1972, J CLIN INVEST, V51, P2602, DOI 10.1172/JCI107078; MCCLUER RH, 1986, ADV CHROMATOGR, V25, P309; MELICAN D, 1998, IN PRESS J LEUK BIOL; Muller A, 1996, J IMMUNOL, V156, P3418; ONDERDONK AB, 1992, INFECT IMMUN, V60, P1642, DOI 10.1128/IAI.60.4.1642-1647.1992; PATCHEN ML, 1998, IN PRESS STEM CELLS; Ramegowda B, 1996, INFECT IMMUN, V64, P1173, DOI 10.1128/IAI.64.4.1173-1180.1996; *REC NOM COMM INT, 1977, LIPIDS, V12, P455; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P348; STASHENKO P, 1995, J DENT RES, V74, P323, DOI 10.1177/00220345950740010701; STEIN KE, 1977, BIOCHEMISTRY-US, V16, P5285, DOI 10.1021/bi00643a019; STONE BA, 1992, CHEM BIOL 1 3 BETA G, P525; STROMBERG N, 1990, J BIOL CHEM, V265, P11244; SYMINGTON FW, 1985, J IMMUNOL, V134, P2498; SYMINGTON FW, 1986, LEUKOCYTE TYPING 2, V3, P47; SZABO T, 1995, J BIOL CHEM, V270, P2145, DOI 10.1074/jbc.270.5.2145; TAO RVP, 1973, J LIPID RES, V14, P16; TETTEROO PAT, 1986, LEUKOCYTE TYPING 2, V3, P27; Thornton BP, 1996, J IMMUNOL, V156, P1235; VANCE DE, 1967, J LIPID RES, V8, P621; vanSetten PA, 1996, BLOOD, V88, P174, DOI 10.1182/blood.V88.1.174.bloodjournal881174; WILLIAMS DL, 1991, CARBOHYD RES, V219, P203, DOI 10.1016/0008-6215(91)89052-H; YADNAK MA, 1994, MOL CHEM NEUROPATHOL, V21, P369; YAHI N, 1992, J VIROL, V66, P4848, DOI 10.1128/JVI.66.8.4848-4854.1992	51	185	203	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22014	22020		10.1074/jbc.273.34.22014	http://dx.doi.org/10.1074/jbc.273.34.22014			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705343	hybrid			2022-12-25	WOS:000075492600077
J	Geisler, C; Dietrich, J; Nielsen, BL; Kastrup, J; Lauritsen, JPH; Odum, N; Christensen, MD				Geisler, C; Dietrich, J; Nielsen, BL; Kastrup, J; Lauritsen, JPH; Odum, N; Christensen, MD			Leucine-based receptor sorting motifs are dependent on the spacing relative to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; COATED PIT ADAPTINS; FACTOR-II RECEPTOR; CYTOPLASMIC DOMAIN; CARBOXYL-TERMINUS; INVITRO BINDING; INVARIANT CHAIN; DOWN-REGULATION; INTERNALIZATION; CD3-GAMMA	Many integral membrane proteins contain leucine-based motifs within their cytoplasmic domains that mediate internalization and intracellular sorting. Two types of leucine-based motifs have been identified. One type is dependent on phosphorylation, whereas the other type, which includes an acidic amino acid, is constitutively active. In this study, we have investigated how the spacing relative to the plasma membrane affects the function of both types of leucine-based motifs, For phosphorylation-dependent leucine-based motifs, a minimal spacing of 7 residues between the plasma membrane and the phospho-acceptor was required for phosphorylation and thereby activation of the motifs. For constitutively active leucine-based motifs, a minimal spacing of 6 residues between the plasma membrane and the acidic residue was required for optimal activity of the motifs. In addition, we found that the acidic residue of leucine-based motifs must be located amino-terminal to the dileucine sequence for proper function of the motifs and that residues surrounding the motifs affect the activity of the motifs, Thus, our observations suggest that the position, the exact sequence, and surrounding residues are major determinants of the function of leucine-based receptor sorting motifs.	Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, DK-2200 Copenhagen, Denmark	University of Copenhagen	Geisler, C (corresponding author), Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, Bldg 18-3,Blegdamsvej 3C, DK-2200 Copenhagen, Denmark.	cgtcr@biobase.dk	Bartels, Mette Damkjær/AAY-5809-2020; Geisler, Carsten/A-7056-2012	Bartels, Mette Damkjær/0000-0002-8187-3684; Geisler, Carsten/0000-0002-8472-0771				BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BREMNES B, 1994, J CELL SCI, V107, P2021; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Dietrich J, 1996, J CELL BIOL, V132, P299, DOI 10.1083/jcb.132.3.299; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Dietrich J, 1996, J BIOL CHEM, V271, P11441, DOI 10.1074/jbc.271.19.11441; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; GEISLER C, 1992, J IMMUNOL, V148, P2437; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HAHN WC, 1993, GENE, V127, P267, DOI 10.1016/0378-1119(93)90731-H; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; MOTTA A, 1995, J BIOL CHEM, V270, P27165, DOI 10.1074/jbc.270.45.27165; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; ORR JW, 1994, J BIOL CHEM, V269, P8383; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Sheikh H, 1996, J BIOL CHEM, V271, P12185, DOI 10.1074/jbc.271.21.12185; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537	34	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21316	21323		10.1074/jbc.273.33.21316	http://dx.doi.org/10.1074/jbc.273.33.21316			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694892	hybrid			2022-12-25	WOS:000075386100085
J	O'Neill, H; Mayhew, SG; Butler, G				O'Neill, H; Mayhew, SG; Butler, G			Cloning and analysis of the genes for a novel electron-transferring flavoprotein from Megasphaera elsdenii - Expression and characterization of the recombinant protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZORHIZOBIUM-CAULINODANS ORS571; PEPTOSTREPTOCOCCUS-ELSDENII; PARACOCCUS-DENITRIFICANS; SECONDARY STRUCTURE; ADENINE-DINUCLEOTIDE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; NEURAL NETWORKS; FIXABC REGION; IDENTIFICATION	The genes that encode the two different subunits of the novel electron-transferring flavoprotein (ETF) from Megasphaera elsdenii were identified by screening a partial genomic DNA library with a probe that was generated by amplification of genomic sequences using the polymerase chain reaction. The cloned genes are arranged in tandem with the coding sequence for the beta-subunit in the position 5' to the alpha-subunit coding sequence. Amino acid sequence analysis of the two subunits revealed that there are two possible dinucleotide-binding sites on the alpha-subunit and one on the beta-subunit. Comparison of M. elsdenii ETF amino acid sequence to other ETFs and ETF-like proteins indicates that while homology occurs with the mitochondrial ETF and bacterial ETFs, the greatest similarity is with the putative ETFs from clostridia and with fixAB gene products from nitrogen-fixing bacteria. The recombinant ETF was isolated from extracts of Escherichia coli. It is a heterodimer with subunits identical in size to the native protein. The isolated enzyme contains approximately I mol of FAD, but like the native protein it binds additional flavin to ave a total of about 2 mol of FAD/dimer. It serves as an electron donor to butyryl-CoA dehydrogenase, and it also has NADH dehydrogenase activity.	Natl Univ Ireland Univ Coll Dublin, Dept Biochem, Dublin 4, Ireland	University College Dublin	Mayhew, SG (corresponding author), Natl Univ Ireland Univ Coll Dublin, Dept Biochem, Dublin 4, Ireland.	stephen.g.mayhew@ucd.ie		Butler, Geraldine/0000-0002-1770-5301; O'Neill, Hugh/0000-0003-2966-5527				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARIGONI F, 1991, MOL GEN GENET, V225, P514, DOI 10.1007/BF00261695; BALDWIN RL, 1964, BIOCHIM BIOPHYS ACTA, V92, P421, DOI 10.1016/0926-6569(64)90001-X; Bastiaens P I, 1991, J Fluoresc, V1, P95, DOI 10.1007/BF00865205; BECKER DF, 1993, BIOCHEMISTRY-US, V32, P10736, DOI 10.1021/bi00091a026; BEDZYK LA, 1993, J BIOL CHEM, V268, P20211; *BIOS TECHN, 1993, INS 2 VERS W 3 0 US; BROCKMAN HL, 1975, J BACTERIOL, V124, P1447, DOI 10.1128/JB.124.3.1447-1453.1975; BYRON CM, 1989, BIOCHEMISTRY-US, V28, P8582, DOI 10.1021/bi00447a047; CHEN DW, 1994, J BIOL CHEM, V269, P32120; DAVIDSON VL, 1986, J BACTERIOL, V166, P812, DOI 10.1128/jb.166.3.812-817.1986; DORVAL BC, 1991, J MOL BIOL, V221, P837, DOI 10.1016/0022-2836(91)80179-X; DUPLESSIS ER, 1994, BIOCHEM MOL BIOL INT, V32, P195; ELSDEN SR, 1956, J BACTERIOL, V72, P681, DOI 10.1002/path.1700720235; Eppink MHM, 1997, PROTEIN SCI, V6, P2454; FINOCCHIARO G, 1988, J BIOL CHEM, V263, P15773; FINOCCHIARO G, 1993, EUR J BIOCHEM, V213, P1003, DOI 10.1111/j.1432-1033.1993.tb17847.x; GHISLA S, 1976, EUR J BIOCHEM, V63, P373, DOI 10.1111/j.1432-1033.1976.tb10239.x; Ghisla S, 1980, Methods Enzymol, V66, P241; GOODMAN SI, 1994, EUR J BIOCHEM, V219, P277, DOI 10.1111/j.1432-1033.1994.tb19939.x; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GUBLER M, 1989, MOL MICROBIOL, V3, P141, DOI 10.1111/j.1365-2958.1989.tb01803.x; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HUSAIN M, 1985, J BACTERIOL, V163, P709, DOI 10.1128/JB.163.2.709-715.1985; IHARA S, 1987, ANAL BIOCHEM, V166, P349, DOI 10.1016/0003-2697(87)90584-7; JORNVALL H, 1977, EUR J BIOCHEM, V72, P443, DOI 10.1111/j.1432-1033.1977.tb11268.x; KAMINSKI PA, 1988, MOL GEN GENET, V214, P496, DOI 10.1007/BF00330486; LADD JN, 1959, BIOCHEM J, V71, P16, DOI 10.1042/bj0710016; LADD JN, 1959, BIOCHEM J, V71, P364, DOI 10.1042/bj0710364; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOEHR JP, 1990, PEDIATR RES, V27, P311, DOI 10.1203/00006450-199003000-00024; MAYHEW SG, 1971, BIOCHIM BIOPHYS ACTA, V235, P303, DOI 10.1016/0005-2744(71)90208-7; MAYHEW SG, 1974, EUR J BIOCHEM, V44, P579, DOI 10.1111/j.1432-1033.1974.tb03515.x; MCKIE JH, 1991, FEBS LETT, V279, P5, DOI 10.1016/0014-5793(91)80236-V; ONEILL HM, 1995, BIOCHEM SOC T, V23, pS379, DOI 10.1042/bst023379s; ONUALAIN EM, 1989, THESIS U COLLEGE DUB; ONUALLAIN EM, 1986, BIOCHEM SOC T, V14, P440, DOI 10.1042/bst0140440; ONUALLAIN EM, 1987, FLAVINS FLAVOPROTEIN, P361; PACE CP, 1987, BIOCHIM BIOPHYS ACTA, V911, P267, DOI 10.1016/0167-4838(87)90067-7; Roberts DL, 1996, P NATL ACAD SCI USA, V93, P14355, DOI 10.1073/pnas.93.25.14355; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1993, J BIOCHEM, V114, P215, DOI 10.1093/oxfordjournals.jbchem.a124157; Sharkey CT, 1997, ACTA CRYSTALLOGR D, V53, P461, DOI 10.1107/S0907444997000139; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; TSAI MH, 1995, RES MICROBIOL, V146, P397, DOI 10.1016/0923-2508(96)80285-3; WATMOUGH NJ, 1992, EUR J BIOCHEM, V205, P1089, DOI 10.1111/j.1432-1033.1992.tb16877.x; Weidenhaupt M, 1996, ARCH MICROBIOL, V165, P169, DOI 10.1007/s002030050312; WHITFIELD CD, 1974, J BIOL CHEM, V249, P2801; WHITFIELD CD, 1974, J BIOL CHEM, V249, P2811; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILSON K, 1994, CURRENT PROTOCOLS MO; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	61	25	27	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21015	21024		10.1074/jbc.273.33.21015	http://dx.doi.org/10.1074/jbc.273.33.21015			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694853	hybrid			2022-12-25	WOS:000075386100046
J	Geraghty, DS; Sucic, HB; Chen, J; Pederson, DS				Geraghty, DS; Sucic, HB; Chen, J; Pederson, DS			Evidence that partial unwrapping of DNA from nucleosomes facilitates the binding of heat shock factor following DNA replication in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RESPONSE ELEMENT; TRANSCRIPTION FACTOR; CHROMATIN STRUCTURE; SACCHAROMYCES-CEREVISIAE; IN-VIVO; POSITIONING SEQUENCES; PROMOTER; GENE; REPRESSION; PROTEIN	In the yeast Saccharomyces cerevisiae, heat shock transcription factor (HSF) binds heat shock element (HSE) DNA shortly after DNA replication, independently of its activation by heat shock. To determine if HSF binding occurs before newly replicated DNA is packaged into nucleosomes, we inserted an HSE into a DNA segment that normally forms a positioned nucleosome in vivo. Transcription from constructs designed to create steric competition between binding of HSF and histone H2A-H2B dimers was generally poor, suggesting that nucleosome assembly precedes and inhibits HSF binding. However, one such construct was as transcriptionally active as a nucleosome-free control. Structural analyses suggested that similar to 40 base pairs of DNA, including the HSE, had unwrapped from the 3' edge of the histone octamer, allowing HSF to bind; similar to 100 base pairs remained in association with the histone octamer, with the same translational and rotational orientation as was seen for the poorly transcribed constructs. Modeling studies suggest that the active and inactive constructs differ from one another in the ease with which the HSE and flanking sequences can adopt the curvature needed to form a stable nucleosome. These differences may influence the probability of DNA unwrapping from already assembled nucleosomes and the subsequent binding of HSF.	Univ Vermont, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA; Univ Vermont, Markey Ctr Mol Genet, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Pederson, DS (corresponding author), Univ Vermont, Dept Microbiol & Mol Genet, Stafford Bldg,Rom 302, Burlington, VT 05405 USA.	dpederso@zoo.uvm.edu						ALMOUZNI G, 1990, EMBO J, V9, P573, DOI 10.1002/j.1460-2075.1990.tb08145.x; ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; BECKER PB, 1991, P NATL ACAD SCI USA, V88, P4109, DOI 10.1073/pnas.88.10.4109; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; CHEN JJ, 1993, J BIOL CHEM, V268, P7442; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; COCKELL M, 1983, J MOL BIOL, V170, P423, DOI 10.1016/S0022-2836(83)80156-9; CUNNIFF NFA, 1993, J BIOL CHEM, V268, P8317; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Erkine AM, 1996, MOL CELL BIOL, V16, P7004; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FLICK KE, 1994, J BIOL CHEM, V269, P12475; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; Gasser R, 1996, J MOL BIOL, V258, P224, DOI 10.1006/jmbi.1996.0245; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GROSS DS, 1990, J MOL BIOL, V216, P611, DOI 10.1016/0022-2836(90)90387-2; GROSS DS, 1993, EMBO J, V12, P3931, DOI 10.1002/j.1460-2075.1993.tb06071.x; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; Holmes SG, 1996, GENE DEV, V10, P1021, DOI 10.1101/gad.10.8.1021; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; KRUDE T, 1991, MOL CELL BIOL, V11, P6257, DOI 10.1128/MCB.11.12.6257; LI Q, 1993, GENE DEV, V7, P2471, DOI 10.1101/gad.7.12a.2471; LI Q, 1995, MOL CELL BIOL, V15, P4375; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; MORSE RH, 1987, NUCLEIC ACIDS RES, V15, P10311, DOI 10.1093/nar/15.24.10311; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PATTERTON HG, 1995, NUCLEIC ACIDS RES, V23, P4170, DOI 10.1093/nar/23.20.4170; PEDERSON DS, 1984, NUCLEIC ACIDS RES, V12, P8489, DOI 10.1093/nar/12.22.8489; PEDERSON DS, 1994, MOL CELL BIOL, V14, P189, DOI 10.1128/MCB.14.1.189; PEDERSON DS, 1986, P NATL ACAD SCI USA, V83, P7206, DOI 10.1073/pnas.83.19.7206; PEDERSON DS, 1990, EMBO J, V9, P1873, DOI 10.1002/j.1460-2075.1990.tb08313.x; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Protacio RU, 1997, J MOL BIOL, V274, P708, DOI 10.1006/jmbi.1997.1440; PTASHNE M, 1987, GENETIC SWITCH, P109; Ramakrishnan V, 1997, ANNU REV BIOPH BIOM, V26, P83, DOI 10.1146/annurev.biophys.26.1.83; RANDALL SK, 1992, J BIOL CHEM, V267, P14259; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; SUSEK RE, 1989, MOL CELL BIOL, V9, P5265, DOI 10.1128/MCB.9.11.5265; Svaren J, 1996, CURR OPIN GENET DEV, V6, P164, DOI 10.1016/S0959-437X(96)80046-3; TANAKA S, 1992, EMBO J, V11, P1187, DOI 10.1002/j.1460-2075.1992.tb05159.x; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; THOMA F, 1985, NATURE, V315, P250, DOI 10.1038/315250a0; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; van Holde KE., 1989, SPRINGER SERIES MOL; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; Wolffe Alan P., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P167; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xu M, 1998, MOL CELL BIOL, V18, P1201, DOI 10.1128/MCB.18.3.1201	78	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20463	20472		10.1074/jbc.273.32.20463	http://dx.doi.org/10.1074/jbc.273.32.20463			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685401	hybrid			2022-12-25	WOS:000075305400078
J	Hresko, RC; Heimberg, H; Chi, MMY; Mueckler, M				Hresko, RC; Heimberg, H; Chi, MMY; Mueckler, M			Glucosamine-induced insulin resistance in 3T3-L1 adipocytes is caused by depletion of intracellular ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY CULTURED ADIPOCYTES; GLYCOGEN-SYNTHASE ACTIVITY; GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; HEXOSAMINE BIOSYNTHESIS; TRANSPORT SYSTEM; TRANSGENIC MICE; PHOSPHATIDYLINOSITOL 3-KINASE; SUBSTRATE PHOSPHORYLATION; INDUCED DESENSITIZATION; DIFFERENTIAL REGULATION	Glucosamine, which enters the hexosamine pathway downstream of the rate-limiting step, has been routinely used to mimic the insulin resistance caused by high glucose and insulin. We investigated the effect of glucosamine on insulin-stimulated glucose transport in 3T3-L1 adipocytes. The Delta-insulin (insulin-stimulated minus basal) value for S-deoxyglucose uptake was dramatically inhibited with increasing concentrations of glucosamine with an ED50 of 1.95 mM. Subcellular fractionation experiments demonstrated that reduction in insulin-stimulated 2-deoxyglucose uptake by glucosamine was due to an inhibition of translocation of both Glut 1 and Glut 4 from the low density microsomes (LDM) to the plasma membrane. Analysis of the insulin signaling cascade revealed that glucosamine impaired insulin receptor autophosphorylation, insulin receptor substrate (IRS-1) phosphorylation, IRS-l-associated PI 3-kinase activity in the LDM, and AKT-1 activation by insulin. Measurement of intracellular ATP demonstrated that the effects of glucosamine were highly correlated with its ability to reduce ATP levels. Reduction of intracellular ATP using azide inhibited Glut 1 and Glut 4 translocation from the LDM to the plasma membrane, insulin receptor autophosphorylation, and IRS-1 tyrosine phosphorylation. Additionally, both the reduction in intracellular ATP and the effects on insulin action caused by glucosamine could be prevented by the addition of inosine, which served as an alternative energy source in the medium. We conclude that direct administration of glucosamine can rapidly lower cellular ATP levels and affect insulin action in fat cells by mechanisms independent of increased intracellular UDP-N-acetylhexosamines and that increased metabolism of glucose via the hexosamine pathway may not represent the mechanism of glucose toxicity in fat cells.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Free Univ Brussels, Diabet Res Ctr, B-1090 Brussels, Belgium	Washington University (WUSTL); Universite Libre de Bruxelles; Vrije Universiteit Brussel	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Mueckler, Mike M/F-6115-2012	Heimberg, Harry/0000-0003-1954-7375	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050332, R01DK038495] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38495, DK50332] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BACKER JM, 1992, J BIOL CHEM, V267, P1367; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; Buse MG, 1996, J BIOL CHEM, V271, P23197, DOI 10.1074/jbc.271.38.23197; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEN H, 1997, MOL CELL ENDOCRINOL, V135, P66; CROOK ED, 1993, DIABETES, V42, P1289, DOI 10.2337/diabetes.42.9.1289; CROOK ED, 1995, DIABETES, V44, P314, DOI 10.2337/diabetes.44.3.314; Crook ED, 1996, DIABETES, V45, P322, DOI 10.2337/diabetes.45.3.322; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Filippis A, 1998, BIOCHEM J, V330, P405, DOI 10.1042/bj3300405; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GULVE EA, 1994, J BIOL CHEM, V269, P18366; Hawkins M, 1997, J BIOL CHEM, V272, P4889, DOI 10.1074/jbc.272.8.4889; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KOHANSKI RA, 1986, BIOCHEM BIOPH RES CO, V134, P1312, DOI 10.1016/0006-291X(86)90393-1; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LIMA FB, 1994, DIABETES, V43, P53, DOI 10.2337/diabetes.43.1.53; MARSHALL BA, 1994, AM J PHYSIOL-ENDOC M, V267, pE738, DOI 10.1152/ajpendo.1994.267.5.E738; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; MERCER RW, 1981, BIOCHIM BIOPHYS ACTA, V648, P63, DOI 10.1016/0005-2736(81)90124-3; Miles PDG, 1998, DIABETES, V47, P395, DOI 10.2337/diabetes.47.3.395; PASSONNEAU JV, 1993, ENZYMATIC ANAL PRACT, P10; PIPER RC, 1991, AM J PHYSIOL, V260, P570; QUON MJ, 1994, J BIOL CHEM, V269, P27920; RICHTER EA, 1988, BIOCHEM J, V252, P733, DOI 10.1042/bj2520733; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Thomson MJ, 1997, J BIOL CHEM, V272, P7759, DOI 10.1074/jbc.272.12.7759; TORDJMAN KM, 1990, BIOCHEM J, V271, P201, DOI 10.1042/bj2710201; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; TRAXINGER RR, 1991, J BIOL CHEM, V266, P10148; TRAXINGER RR, 1989, J BIOL CHEM, V264, P20910; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Wang HY, 1997, J BIOL CHEM, V272, P25731, DOI 10.1074/jbc.272.41.25731	42	114	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20658	20668		10.1074/jbc.273.32.20658	http://dx.doi.org/10.1074/jbc.273.32.20658			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685425	hybrid			2022-12-25	WOS:000075305400102
J	Kang, S; Liang, L; Parker, CD; Collawn, JF				Kang, S; Liang, L; Parker, CD; Collawn, JF			Structural requirements for major histocompatibility complex class II invariant chain endocytosis and lysosomal targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRANSFERRIN RECEPTOR; DI-LEUCINE MOTIF; MACROPHAGE FC-RECEPTORS; CYTOPLASMIC DOMAIN; RAPID INTERNALIZATION; INTRACELLULAR-TRANSPORT; CARBOXYL-TERMINUS; CELL-SURFACE; MOLECULES; SIGNAL	The invariant chain (Ii) targets newly synthesized major histocompatibility complex class II complexes to a lysosome-like compartment. Previously, we demonstrated that both the cytoplasmic tail (CT) and transmembrane (TM) domains of Ii were sufficient for this targeting and that the CT contains two di-leucine signals, (3)DQRDLI(8) and (12)EQLPML(17) (Odorizzi, C, G., Trowbridge, I. S,, Xue, L., Hopkins, C. R., Davis, C. D., and Collawn, J. F, (1994) J. Cell Biol. 126, 317-330). In the present study, we examined the relationship between signals required for endocytosis and those required for lysosomal targeting by analyzing Ii-transferrin receptor chimeras in quantitative transport assays. Analysis of the Ii CT signals indicates that although 3DQRDLI8 is necessary and sufficient for endocytosis, either dileucine signal is sufficient for lysosomal targeting. Deletions between the two signals reduced endocytosis without affecting lysosomal targeting. Transplantation of the DQRDLI sequence in place of the EQLPML signal produced a chimera that trafficked normally, suggesting that this di-leucine sequence coded for an independent structural motif. Structure-function analysis of the Ii TM region showed that when Ii TM residues 11-19 and 20-29 were individually substituted for the corresponding regions in the wild-type transferrin receptor, lysosomal targeting was dramatically enhanced, whereas endocytosis remained unchanged. Our results therefore demonstrate that the structural requirements for Ii endocytosis and lysosomal targeting are different.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Collawn, JF (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, BHSB 392,UAB Stn, Birmingham, AL 35294 USA.	jcollawn@uab.edu		Collawn, James/0000-0002-2528-2759; Kang, Sunghyun/0000-0003-1542-9750	NIDDK NIH HHS [R29-DK47339] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047339] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; ARNESON LS, 1995, J CELL BIOL, V129, P1217, DOI 10.1083/jcb.129.5.1217; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BREMNES B, 1994, J CELL SCI, V107, P2021; CALAFAT J, 1994, J CELL BIOL, V126, P967, DOI 10.1083/jcb.126.4.967; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; FernandezBorja M, 1996, INT IMMUNOL, V8, P625, DOI 10.1093/intimm/8.5.625; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HUGHES SH, 1990, J REPROD FERTIL, P39; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JADOT M, 1992, J BIOL CHEM, V267, P11069; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; Johnson AO, 1996, J CELL BIOL, V135, P1749, DOI 10.1083/jcb.135.6.1749; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAMB CA, 1992, J IMMUNOL, V148, P3478; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LINDERMAN JJ, 1988, J THEOR BIOL, V132, P203, DOI 10.1016/S0022-5193(88)80157-7; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MACHAMER CE, 1993, MOL BIOL CELL, V4, P695, DOI 10.1091/mbc.4.7.695; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MELLMAN I, 1984, J CELL BIOL, V98, P1163, DOI 10.1083/jcb.98.4.1163; MOTTA A, 1995, J BIOL CHEM, V270, P27165, DOI 10.1074/jbc.270.45.27165; NEWCOMB JR, 1993, J IMMUNOL, V151, P4153; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; Odorizzi G, 1997, J BIOL CHEM, V272, P11757, DOI 10.1074/jbc.272.18.11757; OGATA S, 1994, J BIOL CHEM, V269, P5210; OMARY MB, 1981, J BIOL CHEM, V256, P2888; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; PYTOWSKI B, 1995, J BIOL CHEM, V270, P9067, DOI 10.1074/jbc.270.16.9067; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ AL, 1986, J BIOL CHEM, V261, P5225; Simonsen A, 1997, J CELL SCI, V110, P597; SPIRO RC, 1989, J IMMUNOL, V143, P2589; SWIER K, 1995, J IMMUNOL, V155, P630; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; UKKONEN P, 1986, J EXP MED, V163, P952, DOI 10.1084/jem.163.4.952; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787	60	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20644	20652		10.1074/jbc.273.32.20644	http://dx.doi.org/10.1074/jbc.273.32.20644			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685423	hybrid			2022-12-25	WOS:000075305400100
J	Plescia, J; Conte, MS; VanMeter, G; Ambrosini, G; Altieri, DC				Plescia, J; Conte, MS; VanMeter, G; Ambrosini, G; Altieri, DC			Molecular identification of the cross-reacting epitope on alpha(m)beta(2) integrin I domain recognized by anti-alpha(IIb)beta(3) monoclonal antibody 7E3 and its involvement in leukocyte adherence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE CORONARY SYNDROMES; LIGAND-BINDING; RECEPTOR CD11B/CD18; BETA(3) SUBUNIT; ARTERY DISEASE; ADHESION; FIBRINOGEN; MAC-1; PATHOGENESIS; INHIBITION	The monoclonal antibody (mAb) 7E3 directed to the platelet integrin alpha(IIb)beta(3) was tested for its cross-reactivity with the homologous leukocyte integrin alpha(M)beta(2),. Nested recombinant fragments of alpha(M) I domain were expressed as glutathione S-transferase fusion proteins and analyzed for antibody recognition. In enzyme-linked immunosorbent assay, mAb 7E3 bound alpha(M) I domain fragments containing the amino-terminal sequence Cys(128)-Ser(172) whereas the carboxyl-terminal region Leu(173)-Pro(291) was ineffective. A synthetic peptide designated R1.1 and duplicating the alpha(M) sequence G(127)CPQEDSDIAFLIDGSGSIIPHDF(150) bound mAb 7E3, In contrast, the adjacent alpha(M) region F(150)RRMKEFVSTVMEQLKKSKTLFS(172) or a control peptide with a scrambled R1.1 sequence was not recognized by mAb 7E3, Binding of mAb 7E3 to alpha(M) I domain blocked monocyte and neutrophil adhesion to immobilized fibrinogen and fibrinogen-dependent leukocyte-endothelium bridging, indistinguishably from bona fide anti-beta(2) mAb IB4. In contrast, leukocyte binding to stable transfectants expressing intercellular adhesion molecule-1 was not affected by mAb 7E3, Balloon-mediated injury of iliofemoral arteries in rabbits resulted in prominent deposition of fibrinogen and increased monocyte adhesion to the injured vessel, in a reaction inhibited by mAb 7E3, but unaffected by control mAb 14E11. Through its cross-reactivity between alpha(IIb)beta(3) and alpha(M)beta(2), mAb 7E3 may initiate a new class of integrin antagonists, capable of simultaneously targeting platelet and leukocyte adhesion mechanisms in vascular injury.	Yale Univ, Sch Med, Dept Pathol, Boyer Ctr Mol Med, New Haven, CT 06536 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Vasc Surg,Harvard Inst Med, Boston, MA 02115 USA	Yale University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Altieri, DC (corresponding author), Yale Univ, Sch Med, Dept Pathol, Boyer Ctr Mol Med, BCMM 436B,295 Congress Ave, New Haven, CT 06536 USA.	dario.altieri@yale.edu			NHLBI NIH HHS [R01 HL43773, HL54131] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043773, R01HL054131, R37HL054131] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J IMMUNOL, V141, P2656; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; ALTIERI DC, 1991, J IMMUNOL, V147, P1891; ALTIERI DC, 1995, SEMIN CELL BIOL, V6, P269, DOI 10.1006/scel.1995.0036; ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; ARNAOUT MA, 1990, BLOOD, V75, P1037; BINI A, 1989, ARTERIOSCLEROSIS, V9, P109, DOI 10.1161/01.ATV.9.1.109; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; COLLER BS, 1995, THROMB HAEMOSTASIS, V74, P302; COLLER BS, 1994, SEMIN HEMATOL, V31, P301; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; Coller BS, 1997, J CLIN INVEST, V99, P1467, DOI 10.1172/JCI119307; CONTE MS, 1994, CIRCULATION, V89, P2161, DOI 10.1161/01.CIR.89.5.2161; DeNichilo MO, 1996, J IMMUNOL, V156, P284; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; Duperray A, 1997, J BIOL CHEM, V272, P435; FAN ST, 1991, J CLIN INVEST, V87, P50, DOI 10.1172/JCI115000; Frebelius S, 1996, ARTERIOSCL THROM VAS, V16, P1292, DOI 10.1161/01.ATV.16.10.1292; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GINSBERG MH, 1995, THROMB HAEMOSTASIS, V74, P352; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; Hatton MWC, 1996, ARTERIOSCL THROM VAS, V16, P1147, DOI 10.1161/01.ATV.16.9.1147; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; MARCUS AJ, 1995, THROMB HAEMOSTASIS, V74, P213; MATSUNO H, 1994, CIRCULATION, V90, P2203, DOI 10.1161/01.CIR.90.5.2203; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; Mesri M, 1998, J BIOL CHEM, V273, P744, DOI 10.1074/jbc.273.2.744; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; PEREZ RL, 1995, J IMMUNOL, V154, P1879; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Simon DI, 1997, ARTERIOSCL THROM VAS, V17, P528, DOI 10.1161/01.ATV.17.3.528; SKOGEN WF, 1988, BLOOD, V71, P1475; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; VEDDER NB, 1990, P NATL ACAD SCI USA, V87, P2643, DOI 10.1073/pnas.87.7.2643; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	44	29	30	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20372	20377		10.1074/jbc.273.32.20372	http://dx.doi.org/10.1074/jbc.273.32.20372			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685389	hybrid			2022-12-25	WOS:000075305400066
J	Smolenski, A; Bachmann, C; Reinhard, K; Honig-Liedl, P; Jarchau, T; Hoschuetzky, H; Walter, U				Smolenski, A; Bachmann, C; Reinhard, K; Honig-Liedl, P; Jarchau, T; Hoschuetzky, H; Walter, U			Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RICH FOCAL ADHESION; VASP IN-VITRO; HUMAN-PLATELETS; PURIFICATION; EXPRESSION; SUBSTRATE; CLONING; DOMAIN	The development and functional analysis of a monoclonal antibody (16C2) are reported; the antibody recognizes vasodilator-stimulated phosphoprotein (VASP; an established substrate of both cAMP- and cGMP-dependent protein kinase) only when serine 239 is phosphorylated. VASP serine 239 represents one of the best characterized cGMP-dependent protein kinase phosphorylation sites in vitro and in intact cells, Experiments with purified, recombinant human VASP and various VASP constructs with mutated phosphorylation sites (S157A, S239A, T278A) and experiments with intact cells (human/rat platelets and other cells) treated with cyclic nucleotide-elevating agents demonstrated the specificity of the monoclonal antibody 16C2. Quantitative analysis of the VASP shift from 46 to 50 kDa (indicating VASP serine 157 phosphorylation) and the appearance of VASP detected by the 16C2 monoclonal antibody (VASP serine 239 phosphorylation) in human platelets stimulated by selective protein kinase activators confirmed that serine 239 is the VASP phosphorylation site preferred by cGMP-dependent protein kinase in intact cells. Immunofluorescence experiments with human platelets treated with cGMP analogs showed that the 16C2 monoclonal antibody also detects VASP serine 239 phosphorylation in situ at established intracellular localization sites. Analysis of VASP serine 239 phosphorylation by the 16C2 antibody appears to be the best method presently available to measure cGMP-dependent protein kinase activation in intact cells. Also, the 16C2 antibody promises to be an excellent tool for the evaluation of VASP function in intact cells.	Inst Klin Biochem & Pathobiochem, Med Univ Klin, D-97080 Wurzburg, Germany; NanoTools Antikorpertech, D-79211 Denzlingen, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg	Walter, U (corresponding author), Inst Klin Biochem & Pathobiochem, Med Univ Klin, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	uwalter@klin-biochem.uni-wuerzburg.de	Walter, ulrich/W-2478-2017	Walter, ulrich/0000-0001-6784-2307; Smolenski, Albert/0000-0001-9210-9406				ABEL K, 1995, FEBS LETT, V370, P184, DOI 10.1016/0014-5793(95)00817-S; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; BUTT E, 1994, J BIOL CHEM, V269, P14509; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; Comer AR, 1998, MOL CELL BIOL, V18, P152, DOI 10.1128/MCB.18.1.152; DRAIJER R, 1995, CIRC RES, V77, P897, DOI 10.1161/01.RES.77.5.897; EIGENTHALER M, 1993, J BIOL CHEM, V268, P13526; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; FISCUS RR, 1988, METHOD ENZYMOL, V159, P150; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; HORSTRUP K, 1994, EUR J BIOCHEM, V225, P21, DOI 10.1111/j.1432-1033.1994.00021.x; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Lincoln T M, 1995, Adv Pharmacol, V34, P305; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; NOLTE C, 1991, J BIOL CHEM, V266, P14808; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; REINHARD M, 1998, IN PRESS GUIDEBOOK C; SANDBERG M, 1991, BIOCHEM J, V279, P521, DOI 10.1042/bj2790521; SMOLENSKI A, 1998, IN PRESS NAUNYNSCHMI; WALDMANN R, 1987, EUR J BIOCHEM, V167, P441, DOI 10.1111/j.1432-1033.1987.tb13357.x; WALTER U, 1980, J BIOL CHEM, V255, P3757; Zimmer M, 1996, GENOMICS, V36, P227, DOI 10.1006/geno.1996.0457	33	275	288	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20029	20035		10.1074/jbc.273.32.20029	http://dx.doi.org/10.1074/jbc.273.32.20029			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685341	hybrid			2022-12-25	WOS:000075305400018
J	Theis, S; Roemer, K				Theis, S; Roemer, K			c-Abl tyrosine kinase can mediate tumor cell apoptosis independently of the Rb and p53 tumor suppressors	ONCOGENE			English	Article						programmed cell death; tyrosine kinase; c-Abl; p53; retinoblastoma	RNA-POLYMERASE-II; RETINOBLASTOMA PROTEIN FUNCTION; TERMINAL REPEATED DOMAIN; GENE-PRODUCT; DNA-DAMAGE; BINDING; GROWTH; PHOSPHORYLATION; CYCLE; ONCOPROTEIN	Tumor cells frequently lack the p53 tumor suppressor because p53 mediates apoptosis in these cells. We report here that c-Abl, and to a greater extent a c-Abl mutant defective for DNA-binding, can provoke programmed cell death in p53-deficient tumor cells. Tyrosine kinase mutant K290R is less cytotoxic, In contrast, a C-terminal deletion mutant that lacks the RNA polymerase II (PolII)/actin interaction domain, fails to mediate apoptosis unless expressed to very high levels. Cytotoxicity is overcome by coexpression of the apoptosis antagonist E1B 19K protein, and partially overcome by full-length retinoblastoma protein (Rb) or the C pocket fragment of Rb (SE Delta) that associates with c-Abl, c-Abl is also highly toxic to Saos-2 cells that are deficient for both Rb and p53, indicating that cell death is not the result of inhibition through c-Abl of the anti-apoptotic function of Rb. Finally, p53 and c-Abl combined induce apoptosis stronger than either protein alone. Unlike Abl-mediated cell death, apoptosis by p53 is antagonized efficiently only by full-length Rb with intact A/B pocket but not by SE Delta. Mutant p53 inhibits apoptosis by p53 but not c-Abl, Thus, c-Abl with intact kinase and PolIII actin-binding domains can affect tumor cell survival independently of Rb and p53.	Univ Saarland, Sch Med, Dept Virol, D-66421 Homburg, Germany	Saarland University	Roemer, K (corresponding author), Univ Saarland, Sch Med, Dept Virol, Bldg 47, D-66421 Homburg, Germany.							Baskaran R, 1996, MOL CELL BIOL, V16, P3361; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GOGA A, 1995, ONCOGENE, V11, P791; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAUPT Y, 1995, ONCOGENE, V10, P1563; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; Miao YJ, 1996, J BIOL CHEM, V271, P22823, DOI 10.1074/jbc.271.37.22823; MIYASHITA T, 1995, CELL, V80, P293; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Roemer K, 1996, ONCOGENE, V12, P2069; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THEIS S, 1997, INT J CANCER, V72, P1; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	40	20	20	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					557	564		10.1038/sj.onc.1201973	http://dx.doi.org/10.1038/sj.onc.1201973			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704921				2022-12-25	WOS:000075195300003
J	Lecarpentier, Y; Chemla, D; Blanc, FX; Pourny, JC; Joseph, T; Riou, B; Coirault, C				Lecarpentier, Y; Chemla, D; Blanc, FX; Pourny, JC; Joseph, T; Riou, B; Coirault, C			Mechanics, energetics, and crossbridge kinetics of rabbit diaphragm during congestive heart failure	FASEB JOURNAL			English	Article						myosin; molecular motors; cardiac hypertrophy; muscle efficiency	RESPIRATORY MUSCLE STRENGTH; MYOSIN; CONTRACTION; MOLECULE; DISEASE; DYSPNEA; FORCE; MOTOR	Crossbridge (CB) properties were investigated in isolated diaphragm of rabbits during congestive heart failure (CHF, n = 9) induced by chronic volume and pressure overload. This model induced cardiac hypertrophy and heart failure. Controls (C) were prepared (n = 14). Compared to C, peak tension in CHF fell by 57% in twitch and by 40% in tetanus; V-max declined by 47% in twitch and by 48% in tetanus. Our study provided an analytical means of calculating from A. F. Huxley's equations the rate constants for CB attachment and detachment, CB single force (I-I), CB number per mm(3) (m'), peak mechanical efficiency (Eff,,), and turnover rate of myosin ATPase (k(cat)); m', Pi, and Eff(max) were lower in CHF than in C in both twitch and tetanus. The marked decline in m' and Pi accounted for the fall in diaphragm strength. In the overall population of C and CHF, Eff,, was linearly related to Pi. Conversely, there was no relationship between V-max and k(xat). Dissociation between V-max and k(cat) might be explained by the crucial role attributed to two apparently nonconserved surface 'loops' on the motor domain of myosin head.	LOA ENSTA Ecole Polytech, INSERM, U451, F-91120 Palaiseau, France; CHU Pitie Salpetriere, Dept Anesthesie Reanimat, Paris, France; CHU Bicetre, UFR Paris XI, Serv Physiol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP	Lecarpentier, Y (corresponding author), Hop Bicetre, Serv Physiol Cardiovasc & Resp, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.		Coirault, Catherine/I-2979-2016; Blanc, François-Xavier/D-7425-2015; Coirault, Catherine/S-2454-2019	Blanc, François-Xavier/0000-0001-7644-2188; Coirault, Catherine/0000-0002-5594-1057; CHEMLA, Denis/0000-0001-7479-9896				ANGER M, 1995, AM J PHYSIOL-HEART C, V268, pH1947, DOI 10.1152/ajpheart.1995.268.5.H1947; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; CHEMLA D, 1992, J PHARMACOL EXP THER, V262, P516; CHUA TP, 1995, BRIT HEART J, V74, P381; CLARK A, 1996, LUNG BIOL HEALTH DIS, V90, P263; Coirault C, 1997, AM J RESP CRIT CARE, V156, P959, DOI 10.1164/ajrccm.156.3.9701051; DETROYER A, 1980, AM J MED, V69, P867, DOI 10.1016/S0002-9343(80)80012-X; EISENBERG E, 1980, BIOPHYS J, V29, P195, DOI 10.1016/S0006-3495(80)85126-5; EVANS SA, 1995, THORAX, V50, P625, DOI 10.1136/thx.50.6.625; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; GILSON N, 1990, AM J PHYSIOL, V258, pH634, DOI 10.1152/ajpheart.1990.258.3.H634; HAMMOND MD, 1990, CHEST, V98, P1091, DOI 10.1378/chest.98.5.1091; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; HOWELL S, 1995, J APPL PHYSIOL, V79, P389, DOI 10.1152/jappl.1995.79.2.389; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; Lecarpentier Y, 1997, AM J RESP CRIT CARE, V155, P630, DOI 10.1164/ajrccm.155.2.9032205; Lindsay DC, 1996, EUR HEART J, V17, P1239; MANCINI DM, 1992, CIRCULATION, V86, P909, DOI 10.1161/01.CIR.86.3.909; MCPARLAND C, 1992, AM REV RESPIR DIS, V146, P467, DOI 10.1164/ajrccm/146.2.467; MUSCH TI, 1993, AM J PHYSIOL, V265, pH1721, DOI 10.1152/ajpheart.1993.265.5.H1721; NISHIZAKA T, 1995, NATURE, V377, P251, DOI 10.1038/377251a0; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SULLIVAN MJ, 1990, CIRCULATION, V81, P518, DOI 10.1161/01.CIR.81.2.518; SUPINSKI G, 1994, J APPL PHYSIOL, V76, P2707, DOI 10.1152/jappl.1994.76.6.2707; Tikunov B, 1997, CIRCULATION, V95, P910; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; Woledge RC, 1985, MONOGRAPHS PHYSL SOC, V41; YANAGIDA T, 1993, TRENDS BIOCHEM SCI, V18, P319, DOI 10.1016/0968-0004(93)90064-T	32	46	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					981	989		10.1096/fasebj.12.11.981	http://dx.doi.org/10.1096/fasebj.12.11.981			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707170				2022-12-25	WOS:000075372600008
J	Rouault, JP; Prevot, D; Berthet, C; Birot, AM; Billaud, M; Magaud, JP; Corbo, L				Rouault, JP; Prevot, D; Berthet, C; Birot, AM; Billaud, M; Magaud, JP; Corbo, L			Interaction of BTG1 and p53-regulated BTG2 gene products with mCaf1, the murine homolog of a component of the yeast CCR4 transcriptional regulatory complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL TRANSLOCATION GENE-1; NEURONAL PC12 CELLS; NERVE GROWTH-FACTOR; SACCHAROMYCES-CEREVISIAE; DEVELOPMENTAL EXPRESSION; PROTEIN; IDENTIFICATION; FAMILY; CLONING; SPT10	Both BTG1 and BTG2 are involved in cell-growth control. BTG2 expression is regulated by p53, and its inactivation in embryonic stem cells leads to the disruption of DNA damage-induced G(2)/M cell-cycle arrest. In order to investigate the mechanism underlying Btg-mediated functions, we looked for possible functional partners of Btg1 and Btg2. Using yeast two-hybrid screening, protein-binding assays, and transient transfection assays in HeLa cells, we demonstrated the physical in vitro and in vivo interaction of both Btg1 and Btg2 with the mouse protein mCaf1 (i.e. mouse CCR4-associated factor 1). mCaf1 was identified through its interaction with the CCR4 protein, a component of a general transcription multisubunit complex, which, in yeast, regulates the expression of different genes involved in cell-cycle regulation and progression, These data suggest that Btg proteins, through their association with mCaf1, may participate, either directly or indirectly, in the transcriptional regulation of the genes involved in the control of the cell cycle. Finally, we found that box B, one of two conserved domains which define the Btg family, plays a functional role, namely that it is essential to the Btg-mCaf1 interaction.	Ctr Leon Berard, INSERM, U453, F-69373 Lyon 08, France; Hop Edouard Herriot, Lab Cytogenet Mol, F-69373 Lyon, France; Univ Lyon 1, UMR 5641 CNRS, Genet Lab, F-69365 Lyon 1, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Corbo, L (corresponding author), Ctr Leon Berard, INSERM, U453, 28 Rue Laennec, F-69373 Lyon 08, France.		Billaud, Marc N/M-6954-2013; berthet, cyril/T-4842-2017	berthet, cyril/0000-0003-3166-3141				Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; DENIS CL, 1994, GENETICS, V138, P1005; DENIS CL, 1984, GENETICS, V108, P833; DENIS CL, 1990, GENETICS, V124, P283; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DOLLARD C, 1994, MOL CELL BIOL, V14, P5223, DOI 10.1128/MCB.14.8.5223; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; HARPER JW, 1993, CELL, V75, P805; Holland ND, 1997, DEV DYNAM, V210, P11, DOI 10.1002/(SICI)1097-0177(199709)210:1<11::AID-AJA2>3.0.CO;2-4; IACOPETTI P, 1994, MECH DEVELOP, V47, P127, DOI 10.1016/0925-4773(94)90085-X; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Liu HY, 1997, EMBO J, V16, P5289, DOI 10.1093/emboj/16.17.5289; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; Matsuda S, 1996, ONCOGENE, V12, P705; MCKENZIE EA, 1993, MOL GEN GENET, V240, P374, DOI 10.1007/BF00280389; MESNER PW, 1995, J NEUROSCI, V15, P7357; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; NATSOULIS G, 1991, NEW BIOL, V3, P1249; RABURN DJ, 1995, ENDOCRINOLOGY, V136, P5769, DOI 10.1210/en.136.12.5769; RIMOKH R, 1991, GENE CHROMOSOME CANC, V3, P24, DOI 10.1002/gcc.2870030106; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; SCHILD D, 1995, GENETICS, V140, P115; Suk K, 1997, IMMUNOLOGY, V91, P121, DOI 10.1046/j.1365-2567.1997.00235.x; Verdone L, 1997, J BIOL CHEM, V272, P30828, DOI 10.1074/jbc.272.49.30828; Waltzer L, 1996, J VIROL, V70, P5909, DOI 10.1128/JVI.70.9.5909-5915.1996; Wang SL, 1997, DEV BIOL, V188, P322, DOI 10.1006/dbio.1997.8655	35	119	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22563	22569		10.1074/jbc.273.35.22563	http://dx.doi.org/10.1074/jbc.273.35.22563			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712883	hybrid			2022-12-25	WOS:000075616600059
J	Ikeda, S; Biswas, T; Roy, R; Izumi, T; Boldogh, I; Kurosky, A; Sarker, AH; Seki, S; Mitra, S				Ikeda, S; Biswas, T; Roy, R; Izumi, T; Boldogh, I; Kurosky, A; Sarker, AH; Seki, S; Mitra, S			Purification and characterization of human NTH1, a homolog of Escherichia coli endonuclease III - Direct identification of Lys-212 as the active nucleophilic residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; 8-OXOGUANINE DNA GLYCOSYLASE; SACCHAROMYCES-CEREVISIAE; POLYMERASE-BETA; MAMMALIAN-CELLS; CLONING; PROTEIN; RECONSTITUTION; EXPRESSION; SEQUENCE	The human endonuclease III (hNTH1), a homolog of the Escherichia coli enzyme (Nth), is a DNA glycosylase with abasic (apurinic/apyrimidinic (AP)) lyase activity and specifically cleaves oxidatively damaged pyrimidines in DNA. Its cDNA was cloned, and the full-length enzyme (304 amino acid residues) was expressed as a glutathione S-transferase fusion polypeptide in E. coli. Purified wild-type protein with two additional amino acid residues and a truncated protein with deletion of 22 residues at the NH, terminus were equally active and had absorbance maxima at 280 and 410 nm, the latter due to the presence of a [4Fe-4S]cluster, as in E. coli Nth. The enzyme cleaved thymine glycol-containing form I plasmid DNA and a dihydrouracil (DHU)-containing oligonucleotide duplex. The protein had a molar extinction coefficient of 5.0 x 10(4) and a pi of 10. With the DHU-containing oligonucleotide duplex as substrate, the K-m was 47 nM, and k(cat) was similar to 0.6/min, independent of whether DHU paired with G or A. The enzyme carries out p-elimination and forms a Schiff base between the active site residue and the deoxyribose generated after base removal. The prediction of Lys-212 being the active site was confirmed by sequence analysis of the peptide-oligonucleotide adduct, Furthermore, replacing Lys-212 with Gin inactivated the enzyme. However, replacement with Arg-212 yielded an active enzyme with about 85-fold lower catalytic specificity than the wild-type protein. DNase I footprinting with hNTH1 showed protection of 10 nucleotides centered around the base lesion in the damaged strand and a stretch of 15 nucleotides (with the G opposite the lesion at the 5'-boundary) in the complementary strand. Immunological studies showed that HeLa cells contain a single hNTH species of the predicted size, localized in both the nucleus and the cytoplasm.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Immunol & Microbiol, Galveston, TX 77555 USA; Okayama Univ, Sch Med, Dept Biol Mol, Inst Mol & Cellular Biol, Okayama 700, Japan	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Okayama University	Mitra, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Route 1079, Galveston, TX 77555 USA.				NATIONAL CANCER INSTITUTE [R01CA053791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029261] Funding Source: NIH RePORTER; NCI NIH HHS [CA 53791] Funding Source: Medline; NIEHS NIH HHS [ES08457] Funding Source: Medline; NINDS NIH HHS [NS 29261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aburatani H, 1997, CANCER RES, V57, P2151; ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; BREIMER LH, 1984, J BIOL CHEM, V259, P5543; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; Cunningham RP, 1997, MUTAT RES-DNA REPAIR, V383, P189, DOI 10.1016/S0921-8777(97)00008-6; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; Hazra TK, 1997, BIOCHEMISTRY-US, V36, P5769, DOI 10.1021/bi963085i; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; KATCHER HL, 1983, BIOCHEMISTRY-US, V22, P4071, DOI 10.1021/bi00286a013; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Krokan HE, 1997, BIOCHEM J, V325, P1; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUHNLEIN U, 1976, P NATL ACAD SCI USA, V73, P1169, DOI 10.1073/pnas.73.4.1169; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MELAMEDE RJ, 1994, BIOCHEMISTRY-US, V33, P1255, DOI 10.1021/bi00171a028; Mitra S, 1997, MOL CELLS, V7, P305; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; OHANDLEY S, 1995, BIOCHEMISTRY-US, V34, P2528, DOI 10.1021/bi00008a017; RoldanArjona T, 1996, NUCLEIC ACIDS RES, V24, P3307, DOI 10.1093/nar/24.17.3307; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; Roy R, 1998, BIOCHEMISTRY-US, V37, P580, DOI 10.1021/bi972313l; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SEKI S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P287, DOI 10.1016/0167-4781(92)90027-W; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	40	211	217	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21585	21593		10.1074/jbc.273.34.21585	http://dx.doi.org/10.1074/jbc.273.34.21585			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705289	hybrid			2022-12-25	WOS:000075492600023
J	Schneider, A; Smith, RWP; Kautz, AR; Weisshart, K; Grosse, F; Nasheuer, HP				Schneider, A; Smith, RWP; Kautz, AR; Weisshart, K; Grosse, F; Nasheuer, HP			Primase activity of human DNA polymerase alpha-primase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER EMBRYOS; SPECIES-SPECIFIC REPLICATION; CALF THYMUS; IN-VITRO; MAMMALIAN PRIMASE; DIVALENT-CATIONS; ZINC MOTIF; PURIFICATION; BACTERIOPHAGE-T7; SUBUNIT	DNA polymerase alpha-primase consists of four subunits, p180, p68, p58, and p48, and comprises two essential enzymatic functions. To study the primase activity of the complex, we expressed cDNAs encoding for the human p58 and p48 subunits either as single proteins or together using Escherichia coli expression vectors, Coexpression of both primase subunits allowed the purification of a heterodimer in high yields that revealed stable primase activity. Purified recombinant p48 subunit showed enzyme activity, whereas purified p58 did not. In contrast to the heterodimer, the primase activity of p48 was unstable. The activity of p48 could be stabilized by the addition of the divalent cations Mg2+ and Mn2+ but not Zn2+. On a poly(dC) template the primase activity was hardly influenced by the monovalent cation potassium. However, by using poly(dT) as a template the recombinant p48 activity was sensitive to salt, whereas recombinant p58-p48 and the bovine DNA polymerase alpha-primase purified from thymus were less sensitive to the addition of monovalent cations, A complex of bacterially expressed primase and baculovirus-expressed p180 and p68 was assembled in vitro and shown to support replication of simian virus 40 DNA in a cell-free system.	Inst Mol Biotechnol, Biochem Abt, D-07745 Jena, Germany; Inst Mol Biotechnol, Abt Mol Cytol & Elektronenmikroskopie, D-07745 Jena, Germany		Nasheuer, HP (corresponding author), Inst Mol Biotechnol, Biochem Abt, Beutenbergstr 11, D-07745 Jena, Germany.	nasheuer@imb-jena.de	Smith, Richard/J-8117-2019; Nasheuer, Heinz P./B-9025-2008	Smith, Richard/0000-0002-6475-6910; Nasheuer, Heinz Peter/0000-0002-9218-9079				BAKKENIST CJ, 1994, J BIOL CHEM, V269, P26759; BICKLER SW, 1992, BIOTECHNIQUES, V13, P64; BISWAS EE, 1987, BIOCHEMISTRY-US, V26, P5377, DOI 10.1021/bi00391a024; BONET ML, 1992, INT J BIOCHEM, V24, P839; Boudker O, 1997, J MOL BIOL, V272, P770, DOI 10.1006/jmbi.1997.1263; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCKNER A, 1995, MOL CELL BIOL, V15, P1716; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P2523, DOI 10.1073/pnas.79.8.2523; Copeland WC, 1997, PROTEIN EXPRES PURIF, V9, P1, DOI 10.1006/prep.1996.0665; COPELAND WC, 1993, J BIOL CHEM, V268, P26179; ENGLER MJ, 1983, J BIOL CHEM, V258, P1165; Foiani M, 1997, TRENDS BIOCHEM SCI, V22, P424; FOIANI M, 1989, J BIOL CHEM, V264, P2189; GROSSE F, 1985, J BIOL CHEM, V260, P1881; GROSSE F, 1981, BIOCHEMISTRY-US, V20, P5470, DOI 10.1021/bi00522a019; HARTMANN GR, 1988, BIOL CHEM H-S, V369, P775; HINE AV, 1994, P NATL ACAD SCI USA, V91, P12327, DOI 10.1073/pnas.91.25.12327; HOLMES AM, 1986, J BIOL CHEM, V261, P1924; HUBSCHER U, 1983, EMBO J, V2, P133, DOI 10.1002/j.1460-2075.1983.tb01394.x; JAZWINSKI SM, 1985, J BIOL CHEM, V260, P4995; KAGUNI LS, 1983, J BIOL CHEM, V258, P9037; Kohn WD, 1997, J MOL BIOL, V267, P1039, DOI 10.1006/jmbi.1997.0930; KONIG H, 1983, EUR J BIOCHEM, V135, P435, DOI 10.1111/j.1432-1033.1983.tb07670.x; Kornberg A., 1991, DNA REPLICATION; Kusakabe T, 1997, J BIOL CHEM, V272, P12446, DOI 10.1074/jbc.272.19.12446; Kusakabe T, 1996, J BIOL CHEM, V271, P19563, DOI 10.1074/jbc.271.32.19563; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; Madern D, 1997, EUR J BIOCHEM, V249, P607, DOI 10.1111/j.1432-1033.1997.00607.x; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; NASHEUER HP, 1987, BIOCHEMISTRY-US, V26, P8458, DOI 10.1021/bi00399a064; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; PRUSSAK CE, 1989, J BIOL CHEM, V264, P4957; Rodriguez M, 1996, BIOCHEM MOL BIOL INT, V38, P783; ROTH YF, 1987, EUR J BIOCHEM, V165, P473, DOI 10.1111/j.1432-1033.1987.tb11463.x; Salas M., 1996, MECH PRIMING DNA SYN, P131; Sambrook J., 2002, MOL CLONING LAB MANU; SANTOCANALE C, 1993, J BIOL CHEM, V268, P1343; SEKIYA F, 1995, J BIOL CHEM, V270, P14325, DOI 10.1074/jbc.270.24.14325; SHEAFF RJ, 1993, BIOCHEMISTRY-US, V32, P3027, DOI 10.1021/bi00063a014; Sriram M, 1997, STRUCTURE, V5, P403, DOI 10.1016/S0969-2126(97)00197-4; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; Stadlbauer F, 1996, MOL CELL BIOL, V16, P94; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1987, J BIOL CHEM, V262, P15330; TSENG BY, 1983, J BIOL CHEM, V258, P9845; VISHWANATHA JK, 1986, NUCLEIC ACIDS RES, V14, P8467, DOI 10.1093/nar/14.21.8467; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG TSF, 1996, DNA REPLICATION EUKA, P461; WILSON FE, 1985, J BIOL CHEM, V260, P8173	51	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21608	21615		10.1074/jbc.273.34.21608	http://dx.doi.org/10.1074/jbc.273.34.21608			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705292	hybrid			2022-12-25	WOS:000075492600026
J	Bovolenta, C; Testolin, L; Benussi, L; Lievens, PMJ; Liboi, E				Bovolenta, C; Testolin, L; Benussi, L; Lievens, PMJ; Liboi, E			Positive selection of apoptosis-resistant cells correlates with activation of dominant-negative STAT5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; ERYTHROPOIETIN RECEPTOR; SIGNAL-TRANSDUCTION; INTERFERON-ALPHA; HOMEOBOX GENE; TRANSCRIPTION; EXPRESSION; PATHWAY; INTERLEUKIN-3; PROTEIN	The STATE activation has important roles in cell differentiation, cell cycle control, and development. However, the potential implications of STATE in the control of apoptosis remain unexplored. To evaluate any possible link between the erythropoietin receptor (EpoR) JAK2/STAT5 transduction pathway and apoptosis, we have investigated apoptosis-resistant cells (ApoR) that arose from positive selection of the erythroid-committed Ba/F3EpoR cells triggered to apoptosis by ectopic expression of the HOX-B8 homeotic gene, We show that JAK2 is normally activated by Epo in both Ba/F3EpoR and ApoR cells, In contrast, both STAT5a and STAT5b isoforms are uniquely activated in a C-truncated form (86 kDa) only in ApoR cells. Analysis of ApoR and Ba/F3EpoR subclones confirmed that the switch to the truncated STATE isoform coincides with apoptosis survival and that ApoR do not derive from preexisting cells with a shortened STATE. In addition, ApoR cells die in the absence of Epo, This indicates that resistance to apoptosis is not because of a general defect in the apoptotic pathway of ApoR cells. Furthermore, we show that the 86-kDa STATE protein presents a dominant-negative (DN) character. We hypothesize that the switch to a DN STATE may be part of a mechanism that allows ApoR cells to be selectively advantaged during apoptosis. In conclusion, we provide evidence for a functional correlation between a naturally occurring DN STATE and a biological response.	Univ Verona, Inst Biol Chem, I-37134 Verona, Italy; Univ Verona, Inst Anat, I-37134 Verona, Italy; Inst Neurol Sci C Besta, I-20137 Milano, Italy	University of Verona; University of Verona	Liboi, E (corresponding author), Univ Verona, Inst Biol Chem, I-37134 Verona, Italy.	LIBEL@borgoroma.univr.it	BENUSSI, LUISA/K-4409-2016	BENUSSI, LUISA/0000-0003-2836-8141				Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6394; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bovolenta C, 1996, FEBS LETT, V386, P239, DOI 10.1016/0014-5793(96)00453-X; BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Krishnaraju K, 1997, BLOOD, V90, P1840, DOI 10.1182/blood.V90.5.1840; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; MICHAELSON J, 1991, APOPTOSIS MOL BASIS, P31; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NAGATA S, 1994, PHILOS T ROY SOC B, V345, P281, DOI 10.1098/rstb.1994.0107; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PERKINS AC, 1993, EMBO J, V12, P3835, DOI 10.1002/j.1460-2075.1993.tb06062.x; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; REN HY, 1994, J BIOL CHEM, V269, P19633; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WALKER PR, 1994, EXP CELL RES, V213, P100, DOI 10.1006/excr.1994.1178; Wang DM, 1996, MOL CELL BIOL, V16, P6141	43	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20779	20784		10.1074/jbc.273.33.20779	http://dx.doi.org/10.1074/jbc.273.33.20779			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694822	hybrid			2022-12-25	WOS:000075386100015
J	Yu, DH; Qu, CK; Henegariu, O; Lu, XL; Feng, GS				Yu, DH; Qu, CK; Henegariu, O; Lu, XL; Feng, GS			Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SRC FAMILY KINASES; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; C-SRC; EXTRACELLULAR-MATRIX; RAS PATHWAY; NEURAL-TUBE; MAP KINASE; PHOSPHORYLATION	Shp-2, a widely expressed cytoplasmic tyrosine phosphatase with two SH2 domains, is believed to participate in signal relay downstream of growth factor receptors, We show here that this phosphatase also plays an important role in the control of cell spreading, migration, and cytoskeletal architecture. Fibroblast cells lacking a functional Shp-2 were impaired in their ability to spread and migrate on fibronectin compared with wild-type cells. Furthermore, Shp-2 mutant cells displayed an increased number of focal adhesions and condensed F-actin aggregation at the cell periphery, properties reminiscent of focal adhesion kinase (FAK)-deficient cells. This is consistent with our previous observations in vivo that mice homozygous for the Shp-2 mutation died at midgestation with similar phenotype to FAK and fibronectin-deficient embryos, having severe defects in mesodermal patterning, particularly the truncation of posterior structures. Biochemical analysis demonstrated that FAK dephosphorylation was significantly reduced in Shp-2 mutant cells in suspension. Furthermore, regulated association of Src SH2 domain with FAH and paxillin during cell attachment and detachment on fibronectin was disrupted in Shp-2 mutant cells. This report defines a unique role of the Shp-2 tyrosine phosphatase in cell motility, which might guide the design of a new strategy for pharmaceutical interference of tumor metastasis.	Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Feng, GS (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, 1044 W Walnut St,Rm 302, Indianapolis, IN 46202 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053660] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29GM53660] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard JD, 1996, DEVELOPMENT, V122, P1137; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FURUTA Y, 1995, ONCOGENE, V11, P1989; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Gilmore AP, 1996, STRUCTURE, V4, P647, DOI 10.1016/S0969-2126(96)00069-X; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Ilic D, 1997, J CELL SCI, V110, P401; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MILARSKI KL, 1994, J BIOL CHEM, V269, P2123; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Nojima Y, 1996, Hum Cell, V9, P169; OWENS LV, 1995, CANCER RES, V55, P2752; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; QU CK, 1998, IN PRESS ONCOGENE, V15; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Vuori K, 1996, MOL CELL BIOL, V16, P2606; XIAO S, 1994, J BIOL CHEM, V269, P21244; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	49	339	341	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21125	21131		10.1074/jbc.273.33.21125	http://dx.doi.org/10.1074/jbc.273.33.21125			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694867	hybrid			2022-12-25	WOS:000075386100060
J	Henry, KW; Yuan, XJ; Koszewski, NJ; Onda, H; Kwiatkowski, DJ; Noonan, DJ				Henry, KW; Yuan, XJ; Koszewski, NJ; Onda, H; Kwiatkowski, DJ; Noonan, DJ			Tuberous sclerosis gene 2 product modulates transcription mediated by steroid hormone receptor family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; THYROID-HORMONE; GLUCOCORTICOID RECEPTOR; CO-REPRESSOR; TRANSACTIVATION PROPERTIES; SIGNALING PATHWAYS; PROTEIN IMPORT; X-RECEPTOR; BINDING; PHOSPHORYLATION	Tuberous sclerosis (TSC) is a genetic disorder that results in the development of hamartomatous lesions in a variety of organ systems. Both the prevalence of the disease and the often devastating consequences of these tumors pose a serious health and medical care problem. The disease has been mapped to two distinct genetic loci in humans, and although the genes (TSC1 and TSC2) for both loci have recently been cloned, their function remains an enigma. Data presented here demonstrates that TSC2 protein can bind and selectively modulate transcription mediated by members of the steroid receptor superfamily of genes. These data place TSC2 into a growing list of nuclear receptor coregulators and strengthen the expanding body of evidence that these coregulators may play critical roles in cellular differentiation.	Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA; Univ Kentucky, Dept Internal Med, Lexington, KY 40536 USA; Brigham & Womens Hosp, Div Expt Med & Oncol, Boston, MA 02115 USA	University of Kentucky; University of Kentucky; Harvard University; Brigham & Women's Hospital	Noonan, DJ (corresponding author), Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA.							Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BERGER TS, 1992, J STEROID BIOCHEM, V41, P733, DOI 10.1016/0960-0760(92)90414-E; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CONSORTIUM TT, 1997, SCIENCE, V277, P805; Eggert M, 1995, J BIOL CHEM, V270, P30755, DOI 10.1074/jbc.270.51.30755; FRYER AE, 1987, LANCET, V1, P659; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Gomez MR, 1988, TUBEROUS SCLEROSIS; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENRY K, 1995, TOXICOL APPL PHARM, V132, P317, DOI 10.1006/taap.1995.1113; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KANDT RS, 1992, NAT GENET, V2, P37, DOI 10.1038/ng0992-37; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; KWIATKOWSKI DJ, 1994, ARCH DERMATOL, V130, P348, DOI 10.1001/archderm.130.3.348; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEFEBVRE P, 1995, J BIOL CHEM, V270, P10806, DOI 10.1074/jbc.270.18.10806; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NELLIST M, 1993, CELL, V75, P1305; ONATE SA, 1995, SCIENCE, V270, P1354; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125; PIKE JW, 1985, BIOCHEM BIOPH RES CO, V131, P378, DOI 10.1016/0006-291X(85)91813-3; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Tsuchiya H, 1996, CANCER RES, V56, P429; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	55	107	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20535	20539		10.1074/jbc.273.32.20535	http://dx.doi.org/10.1074/jbc.273.32.20535			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685410	hybrid			2022-12-25	WOS:000075305400087
J	Nakajima, T; Morita, K; Tsunoda, H; Imajoh-Ohmi, S; Tanaka, H; Yasuda, H; Oda, K				Nakajima, T; Morita, K; Tsunoda, H; Imajoh-Ohmi, S; Tanaka, H; Yasuda, H; Oda, K			Stabilization of p53 by adenovirus E1A occurs through its amino-terminal region by modification of the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE II-ALPHA; CELL-CYCLE ARREST; WILD-TYPE P53; AFFINITY PURIFICATION; E1A-INDUCED APOPTOSIS; IONIZING-RADIATION; TUMOR-SUPPRESSOR; PROTEIN LIGASE; DEGRADATION; INDUCTION	The human epidermoid carcinoma-derived cell line MA1, established by introduction of the adenovirus E1A 12 S cDNA linked to the hormone-inducible promoter, elicits apoptosis after induction of EIA,,, in response to dexamethasone. E1A expression caused accumulation of wild type p53 more than 10-fold within 24 h after dexamethasone treatment. The cell lines that express E1A mutants containing a deletion either in the amino terminus or the conserved region 1 were unable to accumulate p53, p53 accumulated was degraded efficiently in vitro in the S10-0 extract (S10-0) prepared from MA1 cells in an ATP and ubiquitin-dependent manner, but not in S10-24 prepared after treatment with dexamethasone for 24 h, The p53 polyubiquitination activity in S100-0 was calcium-dependent and reduced greatly in S100-24, Ubiquitin affinity chromatography revealed that p53 ubiquitination activity in eluates thought to contain ubiquitin-conjugating enzymes decreased greatly in S100-24 as compared with S100-0, The accumulation of p53 was accompanied by the increase in the level of Mdm2, which has been shown to degrade p53 through binding to it. The high p53 level, however, was maintained until the late stage of the apoptotic process, These results indicate that the stabilization of p53 by E1A occurs through modification of a ubiquitin-specific enzyme(s) in the ubiquitin-proteasome pathway.	Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 278, Japan; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 108, Japan; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Tokyo 19203, Japan	Tokyo University of Science; University of Tokyo; Tokyo University of Pharmacy & Life Sciences	Nakajima, T (corresponding author), Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 278, Japan.	nakajima@rs.noda.sut.ac.jp						ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; BAE IS, 1995, CANCER RES, V55, P2387; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; GOLL DE, 1992, BIOESSAYS, V14, P549, DOI 10.1002/bies.950140810; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; Harlow E., 1988, ANTIBODIES LAB MANUA; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; JAY G, 1981, P NATL ACAD SCI-BIOL, V78, P2932, DOI 10.1073/pnas.78.5.2932; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Maki CG, 1996, CANCER RES, V56, P2649; MAKI M, 1989, J BIOL CHEM, V264, P18866; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Nakajima T, 1996, J BIOL CHEM, V271, P24842, DOI 10.1074/jbc.271.40.24842; NAKAJIMA T, 1995, ONCOGENE, V10, P651; Nakajima T, 1997, BIOCHEM BIOPH RES CO, V239, P823, DOI 10.1006/bbrc.1997.7561; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang WL, 1997, ONCOGENE, V14, P255, DOI 10.1038/sj.onc.1200841	66	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20036	20045		10.1074/jbc.273.32.20036	http://dx.doi.org/10.1074/jbc.273.32.20036			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685342	hybrid			2022-12-25	WOS:000075305400019
J	Simmons, DT; Roy, R; Chen, L; Gai, DH; Trowbridge, PW				Simmons, DT; Roy, R; Chen, L; Gai, DH; Trowbridge, PW			The activity of topoisomerase I is modulated by large T antigen during unwinding of the SV40 origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-40 DNA-REPLICATION; LARGE TUMOR-ANTIGEN; RETINOBLASTOMA SUSCEPTIBILITY GENE; POLYMERASE-ALPHA-PRIMASE; CORE ORIGIN; PROTEIN-A; STRUCTURAL-CHANGES; PURIFIED PROTEINS; BINDING DOMAIN; VIRAL ORIGIN	When simian virus 40 (SV40) large T antigen binds to the virus origin of replication, it forms a double hexamer that functions as a helicase to unwind the DNA bidirectionally. We demonstrate in this report that T antigen can unwind and release an origin DNA single strand of less than full length in the presence of purified human topoisomerase I. The sites nicked by topoisomerase I in the strands released by T antigen during DNA unwinding were localized primarily to the "late" side of the origin, and the template for lagging strand synthesis was preferred significantly over the one for leading strand synthesis. Importantly, these sites were, for the most part, different from the sites nicked by topoisomerase I in the absence of T antigen. These data indicate that T antigen activates topoisomerase I nicking at discrete sites and releases these nicked strands during unwinding. We hypothesize that a single molecule of topoisomerase I can form a functional complex with a double hexamer of T antigen to simultaneously relax and unwind double-stranded origin-containing DNA.	Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA	University of Delaware	Simmons, DT (corresponding author), Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA.				NCI NIH HHS [CA36118] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036118] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEEN MD, 1984, BIOCHIM BIOPHYS ACTA, V782, P304, DOI 10.1016/0167-4781(84)90066-6; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1988, P NATL ACAD SCI USA, V85, P64, DOI 10.1073/pnas.85.1.64; BOROWIEC JA, 1991, J VIROL, V65, P1228, DOI 10.1128/JVI.65.3.1228-1235.1991; Bullock PA, 1997, VIROLOGY, V227, P460, DOI 10.1006/viro.1996.8347; Chen L, 1997, J VIROL, V71, P8743, DOI 10.1128/JVI.71.11.8743-8749.1997; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COVEY JM, 1989, CANCER RES, V49, P5016; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8267, DOI 10.1073/pnas.84.23.8267; DEAN FB, 1991, J BIOL CHEM, V266, P5062; DEB S, 1986, MOL CELL BIOL, V6, P4578, DOI 10.1128/MCB.6.12.4578; DEB S, 1986, MOL CELL BIOL, V6, P1663, DOI 10.1128/MCB.6.5.1663; DEB S, 1987, J VIROL, V61, P2143, DOI 10.1128/JVI.61.7.2143-2149.1987; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DELUCIA AL, 1983, J VIROL, V46, P143, DOI 10.1128/JVI.46.1.143-150.1983; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DORNREITER I, 1993, MOL CELL BIOL, V13, P809, DOI 10.1128/MCB.13.2.809; GJORUP OV, 1994, P NATL ACAD SCI USA, V91, P12125, DOI 10.1073/pnas.91.25.12125; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; GUTIERREZ C, 1990, MOL CELL BIOL, V10, P1719, DOI 10.1128/MCB.10.4.1719; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; MADDEN KR, 1992, CANCER RES, V52, P525; MALKAS LH, 1990, BIOCHEMISTRY-US, V29, P6362, DOI 10.1021/bi00479a004; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11008; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P2869, DOI 10.1073/pnas.83.9.2869; PARSONS R, 1990, J VIROL, V64, P509, DOI 10.1128/JVI.64.2.509-518.1990; POMMIER Y, 1998, IN PRESS BIOCHEMISTR; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; ROBERTS JM, 1989, P NATL ACAD SCI USA, V86, P3939, DOI 10.1073/pnas.86.11.3939; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; Simmons DT, 1996, VIROLOGY, V222, P365, DOI 10.1006/viro.1996.0433; Simmons DT, 1998, VIROLOGY, V242, P435, DOI 10.1006/viro.1997.9024; Smelkova NV, 1997, J VIROL, V71, P8766, DOI 10.1128/JVI.71.11.8766-8773.1997; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STAHL H, 1988, CANCER CELL, V6, P105; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; TJIAN R, 1978, CELL, V13, P165, DOI 10.1016/0092-8674(78)90147-2; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; Weisshart K, 1996, J VIROL, V70, P3509, DOI 10.1128/JVI.70.6.3509-3516.1996; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WUNKIM K, 1993, J VIROL, V67, P7608, DOI 10.1128/JVI.67.12.7608-7611.1993; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950	50	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20390	20396		10.1074/jbc.273.32.20390	http://dx.doi.org/10.1074/jbc.273.32.20390			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685392	hybrid			2022-12-25	WOS:000075305400069
J	Singh, I; Pahan, K; Khan, M; Singh, AK				Singh, I; Pahan, K; Khan, M; Singh, AK			Cytokine-mediated induction of ceramide production is redox-sensitive - Implications to proinflammatory cytokine-mediated apoptosis in demyelinating diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MULTIPLE-SCLEROSIS; NEUTRAL SPHINGOMYELINASE; TRANSCRIPTION FACTOR; PROTEIN-KINASE; ACTIVATION; PATHWAY; CELLS; GENE; DIFFERENTIATION	The present study underlines the importance of reactive oxygen species in cytokine-mediated degradation of sphingomyelin (SM) to ceramide, Treatment of rat primary astrocytes with tumor necrosis factor-alpha (TNF-alpha) Or interleukin-1 beta led to marked alteration in cellular redox (decrease in intracellular GSH) and rapid degradation of SM to ceramide. Interestingly, pretreatment of astrocytes with N-acetylcysteine (NAC), an antioxidant and efficient thiol source for glutathione, prevented cytokine-induced decrease in GSH and degradation of sphingomyelin to ceramide, whereas treatment of astrocytes with diamide, a thiol-depleting agent, alone caused degradation of SM to ceramide. Moreover, potent activation of SM hydrolysis and ceramide generation were observed by direct addition of an oxidant like hydrogen peroxide or a prooxidant like aminotriazole. Similar to NAG, pyrrolidinedithiocarbamate, another antioxidant, was also found to be a potent inhibitor of cytokine-induced degradation of SM to ceramide indicating that cytokine-induced hydrolysis of sphingomyelin is redox-sensitive, Besides astrocytes, NAC also blocked cytokine-mediated ceramide production in rat primary oligodendrocytes, microglia, and C-6 glial cells. Inhibition of TNF-alpha- and diamide-mediated depletion of GSH, elevation of ceramide level, and DNA fragmentation (apoptosis) in primary oligodendrocytes by NAG, and observed depletion of GSH, elevation of ceramide level, and apoptosis in banked human brains from patients with neuroinflammatory diseases (e.g. X-adrenoleukodystrophy and multiple sclerosis) suggest that the intracellular level of GSH may play a critical role in the regulation of cytokine-induced generation of ceramide leading to apoptosis of brain cells in these diseases.	Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA	Medical University of South Carolina	Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.		Singh, Ashok/HGF-2506-2022		NINDS NIH HHS [NS-37766, NS-34741, NS-22576] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS022576, R01NS037766, R01NS034741, R01NS022576] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Brugg B, 1996, J NEUROCHEM, V66, P733; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; GANSER AL, 1988, DEV NEUROSCI-BASEL, V10, P99, DOI 10.1159/000111961; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Guilian D, 1986, J NEUROSCI, V6, P2163; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KANTEY H, 1995, J BIOL CHEM, V270, P23780; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Laight DW, 1997, BRIT J PHARMACOL, V120, P1477, DOI 10.1038/sj.bjp.0701078; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; LAZO O, 1991, J NEUROCHEM, V56, P1343, DOI 10.1111/j.1471-4159.1991.tb11431.x; Linardic CM, 1996, CELL GROWTH DIFFER, V7, P765; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MAIMONE D, 1991, J NEUROIMMUNOL, V32, P67, DOI 10.1016/0165-5728(91)90073-G; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McGuinness MC, 1997, J NEUROIMMUNOL, V75, P174, DOI 10.1016/S0165-5728(97)00020-9; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; POWERS JM, 1992, J NEUROPATH EXP NEUR, V51, P630, DOI 10.1097/00005072-199211000-00007; PRIESS J, 1986, J BIOL CHEM, V261, P8597; RUDICK RA, 1992, ARCH NEUROL-CHICAGO, V49, P265, DOI 10.1001/archneur.1992.00530270079022; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHERTZER HG, 1995, CHEM RES TOXICOL, V8, P431, DOI 10.1021/tx00045a015; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; SPENCE MW, 1993, ADV LIPID RES, V26, P3; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TIKU ML, 1990, J IMMUNOL, V145, P690; TSUKADA N, 1991, J NEUROL SCI, V104, P230, DOI 10.1016/0022-510X(91)90315-X; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WEIGMAN K, 1992, CELL, V78, P1005; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; Wiessner C, 1996, ACTA NEUROCHIR SUPPL, V66, P1; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; ZHANG YH, 1995, ENDOCRINOLOGY, V136, P4157, DOI 10.1210/en.136.10.4157	49	179	181	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20354	20362		10.1074/jbc.273.32.20354	http://dx.doi.org/10.1074/jbc.273.32.20354			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685387	hybrid			2022-12-25	WOS:000075305400064
J	Swinnen, JV; Alen, P; Heyns, W; Verhoeven, G				Swinnen, JV; Alen, P; Heyns, W; Verhoeven, G			Identification of diazepam-binding inhibitor/acyl-CoA-binding protein as a sterol regulatory element-binding protein-responsive gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; CELL-LINE LNCAP; INDUCED INSULIN-SECRETION; AMINO-ACID SEQUENCE; ACYL-COA; MESSENGER-RNA; ADIPOCYTE DIFFERENTIATION; BENZODIAZEPINE RECEPTOR; ANDROGEN REGULATION; SYNTHASE PROMOTER	Diazepam-binding inhibitor/acyl-CoA-binding protein (DBI/ACBP), a highly conserved 10-kDa polypeptide, has been implicated in various physiological processes including gamma-aminobutyric acid type A receptor binding, acyl-CoA binding and transport, steroidogenesis, and peptide hormone release. Both in LNCaP prostate cancer cells and 3T3-L1 preadipocytes, the expression of DBI/ACBP is stimulated under conditions that promote lipogenesis (treatment with androgens and insulin, respectively) and that involve the activation of sterol regulatory element-binding proteins (SREBPs), Accordingly, we investigated whether DBI/ACBP expression is under the direct control of SREBPs, Analysis of the human and rat DBI/ACBP promoter revealed the presence of a conserved sterol regulatory element (SRE)-like sequence. Gel shift analysis confirmed that this sequence is able to bind SREBPs, In support of the functionality of SREBP binding, coexpression of SREBP-1a with a DBI/ACBP promoter-reporter gene resulted in a 50-fold increase in transcriptional activity in LNCaP cells. Disruption of the SRE decreased basal expression and abolished SREBP-1a-induced transcriptional activation. In agreement with the requirement of a co-regulator for SREBP function, transcriptional activation by SREBP-1a overexpression was severely diminished when a neighboring NF-Y site was mutated. Cholesterol depletion or androgen treatment, conditions that activate SREBP function in LNCaP cells, led to an increase in DBI/ACBP mRNA expression and SRE-dependent transcriptional activation. These findings indicate that the promoter for DBI/ACBP contains a functional SRE that allows DBI/ACBP to be coregulated with other genes involved in lipid metabolism.	Catholic Univ Louvain, Fac Med, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium; Catholic Univ Louvain, Fac Med, Div Biochem, B-3000 Louvain, Belgium	KU Leuven; Universite Catholique Louvain; Universite Catholique Louvain	Swinnen, JV (corresponding author), LEGENDO, Onderwijs Navorsing, Herestr 49, B-3000 Louvain, Belgium.	johan.swinnen@med.kuleuven.ac.be	Swinnen, Johannes V/AAA-2214-2022	Swinnen, Johannes V/0000-0002-7720-5077				AGERBERTH B, 1993, EUR J BIOCHEM, V216, P623, DOI 10.1111/j.1432-1033.1993.tb18182.x; APFEL R, 1992, MELANOMA RES, V2, P327, DOI 10.1097/00008390-199212000-00006; Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BISHOP RW, 1992, J LIPID RES, V33, P549; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; BORBONI P, 1991, NEUROPHARMACOLOGY, V30, P1399, DOI 10.1016/S0028-3908(11)80008-0; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; BROWN AS, 1991, BIOCHEM BIOPH RES CO, V180, P609; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHEN ZW, 1988, EUR J BIOCHEM, V174, P239, DOI 10.1111/j.1432-1033.1988.tb14088.x; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; DESTEFANIS P, 1995, REGUL PEPTIDES, V56, P153, DOI 10.1016/0167-0115(95)00002-S; Devos A, 1997, MOL ENDOCRINOL, V11, P1033, DOI 10.1210/me.11.8.1033; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; FERRERO P, 1984, NEUROPHARMACOLOGY, V23, P1359, DOI 10.1016/0028-3908(84)90061-3; FERRERO P, 1986, P NATL ACAD SCI USA, V83, P827, DOI 10.1073/pnas.83.3.827; GARNIER M, 1993, ENDOCRINOLOGY, V132, P444, DOI 10.1210/en.132.1.444; Guan GM, 1997, J BIOL CHEM, V272, P10295; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; GUIDOTTI A, 1983, P NATL ACAD SCI-BIOL, V80, P3531, DOI 10.1073/pnas.80.11.3531; HALL PF, 1988, INT CONGR SER, V799, P253; HANSEN HO, 1991, BIOCHEM J, V277, P341, DOI 10.1042/bj2770341; Herzig KH, 1996, P NATL ACAD SCI USA, V93, P7927, DOI 10.1073/pnas.93.15.7927; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Kawabe Y, 1996, BIOCHEM BIOPH RES CO, V219, P515, DOI 10.1006/bbrc.1996.0265; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; KNUDSEN J, 1989, BIOCHEM J, V262, P513, DOI 10.1042/bj2620513; KOLMER M, 1993, P NATL ACAD SCI USA, V90, P8439, DOI 10.1073/pnas.90.18.8439; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Magana MM, 1997, J LIPID RES, V38, P1630; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; MANDRUP S, 1992, J MOL BIOL, V228, P1011, DOI 10.1016/0022-2836(92)90888-Q; MANDRUP S, 1993, BIOCHEM J, V290, P369, DOI 10.1042/bj2900369; MEHTA KD, 1991, J BIOL CHEM, V266, P10415; MIKKELSEN J, 1987, BIOCHEM J, V245, P857, DOI 10.1042/bj2450857; MOGENSEN IB, 1987, BIOCHEM J, V241, P189, DOI 10.1042/bj2410189; Osborne TF, 1995, CRIT REV EUKAR GENE, V5, P317, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.50; OSTENSON CG, 1994, EUR J ENDOCRINOL, V131, P201, DOI 10.1530/eje.0.1310201; OSTENSON CG, 1990, REGUL PEPTIDES, V29, P143, DOI 10.1016/0167-0115(90)90077-A; PAPADOPOULOS V, 1995, J STEROID BIOCHEM, V53, P103, DOI 10.1016/0960-0760(95)00027-W; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; RASMUSSEN JT, 1994, BIOCHEM J, V299, P165, DOI 10.1042/bj2990165; RASMUSSEN JT, 1993, BIOCHEM J, V292, P907, DOI 10.1042/bj2920907; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; Swinnen JV, 1996, DNA CELL BIOL, V15, P197, DOI 10.1089/dna.1996.15.197; Swinnen JV, 1996, MOL CELL ENDOCRINOL, V118, P65, DOI 10.1016/0303-7207(96)03767-7; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; SWINNEN JV, 1994, MOL CELL ENDOCRINOL, V104, P153, DOI 10.1016/0303-7207(94)90118-X; Swinnen JV, 1996, ENDOCRINOLOGY, V137, P4468, DOI 10.1210/en.137.10.4468; Swinnen JV, 1997, CANCER RES, V57, P1086; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; YANAGIBASHI K, 1988, ENDOCRINOLOGY, V123, P2075, DOI 10.1210/endo-123-4-2075	62	57	60	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19938	19944		10.1074/jbc.273.32.19938	http://dx.doi.org/10.1074/jbc.273.32.19938			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685328	hybrid			2022-12-25	WOS:000075305400005
J	Tong, L; Warren, TC; Lukas, S; Schembri-King, J; Betageri, R; Proudfoot, JR; Jakes, S				Tong, L; Warren, TC; Lukas, S; Schembri-King, J; Betageri, R; Proudfoot, JR; Jakes, S			Carboxymethyl-phenylalanine as a replacement for phosphotyrosine in SH2 domain binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURES; MOLECULAR-REPLACEMENT; PEPTIDE; P56(LCK); INHIBITORS; MIMETICS; DESIGN	The crystal structure of human p56(lck) SH2 domain in complex with an inhibitor containing the singly charged p-(carboxymethyl)phenylalanine residue (cmF) as a phosphotyrosine (Tyr(P) or pY) replacement has been determined at 1.8 Angstrom resolution. The binding mode of the acetyl-cmF-Glu-Glu-Ile (cmFEEI) inhibitor is very similar to that of the pYEEI inhibitor, confirming that the cmFEEI inhibitor has a similar mechanism of SH2 domain inhibition despite its significantly reduced potency. Observed conformational differences in the side chain of the cmF residue can be interpreted in terms of maintaining similar interactions with the SH2 domain as the Tyr(P) residue. The crystal structure of the free p56(lck) SH2 domain has been determined at 1.9 Angstrom resolution and shows an open conformation for the BC loop and an open phosphotyrosine binding pocket, in contrast to earlier studies on the src SH2 domain that showed mostly closed conformation. The structural information presented here suggests that the carboxymethyl-phenylalanine residue may be a viable Tyr(P) replacement and represents an attractive starting point for the design and development of SH2 domain inhibitors with better pharmaceutical profiles.	Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA	Boehringer Ingelheim	Tong, L (corresponding author), Columbia Univ, Dept Biol Sci, 1212 Amsterdam Ave, New York, NY 10027 USA.	tong@como.bio.columbia.edu		Proudfoot, John/0000-0002-5922-2228; Tong, Liang/0000-0002-0563-6468				BRUGGE JS, 1993, SCIENCE, V260, P918, DOI 10.1126/science.8388123; BURKE TR, 1994, BIOCHEMISTRY-US, V33, P6490, DOI 10.1021/bi00187a015; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; Charifson PS, 1997, BIOCHEMISTRY-US, V36, P6283, DOI 10.1021/bi970019n; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; GILMER T, 1994, J BIOL CHEM, V269, P31711; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; MIKOL V, 1995, J MOL BIOL, V246, P344, DOI 10.1006/jmbi.1994.0089; MORELOCK MM, 1995, J MED CHEM, V38, P1309, DOI 10.1021/jm00008a009; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oligino L, 1997, J BIOL CHEM, V272, P29046, DOI 10.1074/jbc.272.46.29046; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Plummer MS, 1997, J MED CHEM, V40, P3719, DOI 10.1021/jm970402q; Shahripour A, 1996, BIOORG MED CHEM LETT, V6, P1209, DOI 10.1016/0960-894X(96)00208-9; TILLEY JW, 1991, J MED CHEM, V34, P1125, DOI 10.1021/jm00107a037; TONG L, 1993, J APPL CRYSTALLOGR, V26, P748, DOI 10.1107/S0021889893005631; Tong L, 1996, ACTA CRYSTALLOGR A, V52, P782, DOI 10.1107/S010876739600548X; Tong L, 1996, J MOL BIOL, V256, P601, DOI 10.1006/jmbi.1996.0112; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; YE B, 1995, J MED CHEM, V38, P4270, DOI 10.1021/jm00021a016; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	22	43	50	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20238	20242		10.1074/jbc.273.32.20238	http://dx.doi.org/10.1074/jbc.273.32.20238			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685372	hybrid			2022-12-25	WOS:000075305400049
J	Lu, XL; Qu, CK; Shi, ZQ; Feng, GS				Lu, XL; Qu, CK; Shi, ZQ; Feng, GS			Downregulation of platelet-derived growth factor receptor-beta in Shp-2 mutant fibroblast cell lines	ONCOGENE			English	Article						phosphatase; kinase; SH2 domain; signal transduction	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; PROTEIN-TYROSINE-PHOSPHATASE; FACTOR-ALPHA-RECEPTOR; MOTH-EATEN MICE; SIGNAL-TRANSDUCTION; DNA-SYNTHESIS; SH3 DOMAINS; SYP; SH-PTP2; ACTIVATION	The SH2-containing tyrosine phosphatase Shp-2 appears to function downstream of a variety of growth factor receptors and might play a positive role in cell proliferation, Here we report that expression of the beta subunit of platelet-derived growth factor receptor (PDGFR-beta) was specifically downregulated in mutant fibroblasts lacking a functional Shp-2, while the levels of PDGFR-alpha EGFR and IGFIR were not changed, PDGF-stimulated DNA synthesis and extracellular signal regulated kinase (Erk) activation was severely suppressed in mutant cells, RasGAP, that responds to activation of PDGFR-beta but not PDGFR-alpha, was not phosphorylated on tyrosine in mutant cells upon PDGF-treatment, Northern blot analysis failed to detect PDGFR-beta mRNA in mutant cells. The transcription initiation from the PDGFR-beta gene promoter was not significantly changed, but the half-life of its mRNA was shortened in Shp-2 mutant cells. These observations indicate that Shp-2 not only participates in transmission of signals from growth factor receptors but also plays a specific role in the control of the PDGFR-beta expression. We propose that this is an important mechanism for the positive control of cell proliferation by Shp-2.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Feng, GS (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.				NIGMS NIH HHS [R29GM53660] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053660] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; AUSUBEL FM, 1994, CURRENT PROTOCOLS, V1; BAZENET CE, 1994, ONCOGENE, V9, P517; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Lih CJ, 1996, P NATL ACAD SCI USA, V93, P4617, DOI 10.1073/pnas.93.10.4617; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PaasinenSohns A, 1997, ONCOGENE, V15, P1953, DOI 10.1038/sj.onc.1201366; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SHI ZQ, 1998, IN PRESS J BIOL CHEM; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WASILENKO WJ, 1990, MOL CELL BIOL, V10, P1254, DOI 10.1128/MCB.10.3.1254; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WILLIAMS DA, 1988, MOL CELL BIOL, V8, P3864, DOI 10.1128/MCB.8.9.3864; XIAO S, 1994, J BIOL CHEM, V269, P21244; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHANG QX, 1995, BBA-MOL CELL RES, V1266, P9, DOI 10.1016/0167-4889(94)00232-4	40	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					441	448		10.1038/sj.onc.1201988	http://dx.doi.org/10.1038/sj.onc.1201988			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696037				2022-12-25	WOS:000075043000006
J	Lafon, I; Carballes, F; Brewer, G; Poiret, M; Morello, D				Lafon, I; Carballes, F; Brewer, G; Poiret, M; Morello, D			Developmental expression of AUF1 and HuR, two c-myc mRNA binding proteins	ONCOGENE			English	Article						c-myc; AUF1 alternative exon; fetal liver; RNA stability	MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGIONS; TRANSGENIC MICE; RICH ELEMENTS; POSTTRANSCRIPTIONAL REGULATION; STABILITY INVITRO; CODING REGION; HALF-LIFE; GENE; SEQUENCE	Several proteins that may regulate c-myc mRNA posttranscriptionally were previously isolated and characterized. Two of them, HuR and AUF1, bind specifically to the 3' untranslated region (UTR) of c-myc mRNA. Because c-myc is regulated post-transcriptionally in various mouse tissues, including quiescent tissues, fetal liver and regenerating liver, we investigated whether HuR and AUF1 expression was also regulated in these tissues. Concerning AUF1, we analysed the expression of various mRNA and protein isoforms, We discovered a new AUF1 mRNA variant with a long AU-rich 3' UTR. We show that AUF1 expression, regardless of the RNA isoform considered, and HuR mRNA expression parallel C-myc expression in quiescent tissues and during liver development; their expression is high in lymphoid tissues and fetal liver and low in adult liver. However, no upregulation of HuR or AUF1 accompanies the upregulation of c-myc mRNA following partial hepatectomy. We discuss our results in relation to the current hypothesis that HuR and AUF1 act as mRNA destabilizing factors.	Univ Toulouse 3, CNRS UMR 5547, Ctr Dev Biol, F-31062 Toulouse 04, France; Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Wake Forest University; Wake Forest Baptist Medical Center	Morello, D (corresponding author), Univ Toulouse 3, CNRS UMR 5547, Ctr Dev Biol, 118 Rte Narbonne, F-31062 Toulouse 04, France.				NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NCI NIH HHS [CA52443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHEN X, 1993, BIOCHEM BIOPH RES CO, V191, P18, DOI 10.1006/bbrc.1993.1178; DeMaria CT, 1997, J BIOL CHEM, V272, P27635, DOI 10.1074/jbc.272.44.27635; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DREZEN JM, 1993, J IMMUNOL, V150, P2805; EHRENMAN K, 1994, GENE, V149, P315, DOI 10.1016/0378-1119(94)90168-6; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; LAVENU A, 1995, MOL CELL BIOL, V15, P4410; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MORELLO D, 1989, ONCOGENE, V4, P955; MORELLO D, 1985, IMMUNOGENETICS, V22, P441, DOI 10.1007/BF00418090; MORELLO D, 1993, ONCOGENE, V8, P1921; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Pistoi S, 1996, MOL CELL BIOL, V16, P5107; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; SOBCZAK J, 1989, ONCOGENE, V4, P1503; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WAGNER BJ, 1998, IN PRESS GENOMICS; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; Yeilding NM, 1997, MOL CELL BIOL, V17, P2698, DOI 10.1128/MCB.17.5.2698; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	44	60	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	1998	16	26					3413	3421		10.1038/sj.onc.1201895	http://dx.doi.org/10.1038/sj.onc.1201895			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692549				2022-12-25	WOS:000074544100008
J	King, JA; Bridger, JM; Lochelt, M; Lichter, P; Schulz, TF; Schirrmacher, V; Khazaie, K				King, JA; Bridger, JM; Lochelt, M; Lichter, P; Schulz, TF; Schirrmacher, V; Khazaie, K			Nucleocytoplasmic transport of HTLV-1 RNA is regulated by two independent LTR encoded nuclear retention elements	ONCOGENE			English	Article						HTLV-1; RxRE; CRS; nuclear export	VIRUS TYPE-I; STRUCTURAL GENE-EXPRESSION; REV-RESPONSIVE ELEMENT; CIS-ACTING ELEMENTS; ENV MESSENGER-RNA; PROTEIN; SEQUENCE; BINDING; EXPORT; IDENTIFICATION	Appropriate expression of HTLV-1 genes requires transcriptional transactivation by Tax and post-transcriptional regulation by Rex, both mediated by LTR encoded RNA sequences. Using a combination of deletion mutagenesis, Rex-reporter CAT assays, fluorescence in situ hybridization (FISH) and confocal laser scanning microscopy it was established that in the absence of Rex, CAT mRNAs harboring HTLV-1 LTR sequences were unable to leave the nucleus. Deletion of the known U5 encoded cis-acting repressing sequence (CRS) led to a partial release of nuclear retention. A novel regulatory element overlapping the 3' Rex responsive element (RxRE) region was shown to prevent export and expression of these transcripts. Deletion of both the 5' LTR encoded CRS and 3' LTR encoded downstream repressive sequence (3' CRS) led to constitutive mRNA nuclear export and gene expression, independently of Rex. The locations of the two regulatory elements indicate that while the 5' CRS selectively acts to hinder export of unspliced transcripts, the 3' CRS has the capacity to induce nuclear retention of all HTLV-1 transcripts, and therefore could potentially contribute to viral latency in infected cells.	German Canc Res Ctr, Dept Cellular Immunol, D-69120 Heidelberg, Germany; German Canc Res Ctr, Dept Org Complex Genomes, D-69120 Heidelberg, Germany; German Canc Res Ctr, Dept Retroviral Gene Express, D-69120 Heidelberg, Germany; Royal Liverpool Univ Hosp, Dept Med Microbiol & Genet Urinary Med, Liverpool L69 3BX, Merseyside, England; Dept Surg, Sect Mol Diag & Therapy, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Khazaie, K (corresponding author), German Canc Res Ctr, Dept Cellular Immunol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.			King, Jason/0000-0001-6886-8728; Schulz, Thomas/0000-0001-8792-5345				BLACK AC, 1991, VIROLOGY, V181, P433, DOI 10.1016/0042-6822(91)90875-C; BOGERD HP, 1992, J VIROL, V66, P7572, DOI 10.1128/JVI.66.12.7572-7575.1992; BRIGHTY DW, 1994, P NATL ACAD SCI USA, V91, P8314, DOI 10.1073/pnas.91.18.8314; CAMPBELL LH, 1994, J VIROL, V68, P5433, DOI 10.1128/JVI.68.9.5433-5438.1994; Chlichlia K, 1997, ONCOGENE, V14, P2265, DOI 10.1038/sj.onc.1201070; CHLICHLIA K, 1995, ONCOGENE, V10, P269; Churchill MJ, 1996, J VIROL, V70, P5786, DOI 10.1128/JVI.70.9.5786-5790.1996; COCHRANE AW, 1991, J VIROL, V65, P5305, DOI 10.1128/JVI.65.10.5305-5313.1991; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; HASELTINE WA, 1991, REGULATION HIV 1 REP; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; INOUE JI, 1986, FEBS LETT, V209, P187, DOI 10.1016/0014-5793(86)81108-5; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; Mikaelian I, 1996, J MOL BIOL, V257, P246, DOI 10.1006/jmbi.1996.0160; NASIOULAS G, 1994, J VIROL, V68, P2986, DOI 10.1128/JVI.68.5.2986-2993.1994; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Rehberger S, 1997, EXP CELL RES, V233, P363, DOI 10.1006/excr.1997.3562; SCHWARTZ S, 1992, J VIROL, V66, P150, DOI 10.1128/JVI.66.1.150-159.1992; SCHWARTZ S, 1992, J VIROL, V66, P7176, DOI 10.1128/JVI.66.12.7176-7182.1992; SEIKI M, 1990, VIROLOGY, V176, P81, DOI 10.1016/0042-6822(90)90232-G; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; Zhang GH, 1996, J CELL BIOL, V135, P9, DOI 10.1083/jcb.135.1.9; Zirbel RM, 1993, CHROMOSOME RES, V1, P93, DOI 10.1007/BF00710032	32	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3309	3316		10.1038/sj.onc.1201884	http://dx.doi.org/10.1038/sj.onc.1201884			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681830				2022-12-25	WOS:000074343600012
J	Guillonneau, X; Bryckaert, M; Launay-Longo, C; Courtois, Y; Mascarelli, F				Guillonneau, X; Bryckaert, M; Launay-Longo, C; Courtois, Y; Mascarelli, F			Endogenous FGF1-induced activation and synthesis of extracellular signal-regulated kinase 2 reduce cell apoptosis in retinal-pigmented epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE; FACTOR FAMILY; TYROSINE PHOSPHORYLATION; ENDOTHELIAL-CELLS; BINDING; RECEPTOR; INHIBITION; EXPRESSION	Retinal-pigmented epithelial (RPE) cell survival is critical to the maintenance of the function of the neural retinal and in the development of various retina degenerations. We investigated molecular mechanisms involved in this function by assessing apoptosis in RPE cells following serum deprivation. Apoptosis induced by serum withdrawal is lower in aged RPE cells because of higher endogenous acidic fibroblast growth factor (FGF1) synthesis and secretion. These experiments examined several aspects of FGF signaling and the contribution of endogenous FGF1 to activation of the extracellular signal-regulated kinase 2 (ERK2). In aged RPE cells, FGFR1 was rapidly activated, and its autophosphorylation followed the kinetics of endogenous FGF1 secretion, before the onset of apoptosis. ERK2 phosphorylation, activity, and de novo synthesis increased at the same time. In marked contrast, no de novo JNK1 synthesis was observed. MEK1 inhibition resulted in lower levels of ERK2 activation and synthesis and higher levels of apoptosis. Treatment with neutralizing anti-FGF1 or blocking anti-FGFR1 antibodies mimics these effects. Thus, this study strongly suggests that the survival-increasing effect of FGF1 in aged RPE cells is because of an autocrine/paracrine loop in which the ERK2 cascade plays a pivotal role.	CNRS, INSERM, U450, Assoc Claude Bernard, F-75016 Paris, France; INSERM, U348, IFR Circulat, F-75010 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Mascarelli, F (corresponding author), CNRS, INSERM, U450, Assoc Claude Bernard, 29 Rue Wilhem, F-75016 Paris, France.		Mascarelli, Frederic/L-8916-2018; guillonneau, xavier/AAF-9495-2021; Guillonneau, xavier/E-3995-2017	guillonneau, xavier/0000-0001-7379-3935; Guillonneau, xavier/0000-0001-7379-3935; Bryckaert, Marijke/0000-0003-3398-0976				ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CARUELLE D, 1989, J CELL BIOCHEM, V39, P117, DOI 10.1002/jcb.240390204; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COLLINS MKL, 1994, BIOESSAYS, V16, P133, DOI 10.1002/bies.950160210; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; Estival A, 1996, J BIOL CHEM, V271, P5663, DOI 10.1074/jbc.271.10.5663; FACTOROVICH EG, 1992, J NEUROSCI, V12, P3554; Fox JC, 1996, J BIOL CHEM, V271, P12578, DOI 10.1074/jbc.271.21.12578; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Guillonneau X, 1997, EXP CELL RES, V233, P198, DOI 10.1006/excr.1997.3542; Guillonneau X, 1996, J CELL PHYSIOL, V166, P170, DOI 10.1002/(SICI)1097-4652(199601)166:1<170::AID-JCP19>3.0.CO;2-J; Guillonneau X, 1998, GROWTH FACTORS, V15, P95, DOI 10.3109/08977199809117186; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JAYE M, 1986, SCIENCE, V233, P241; Konig A, 1997, LEUKEMIA, V11, P258, DOI 10.1038/sj.leu.2400556; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; MALECAZE F, 1993, J CELL PHYSIOL, V154, P631, DOI 10.1002/jcp.1041540323; MASCARELLI F, 1993, GROWTH FACTORS, V8, P211, DOI 10.3109/08977199309011024; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; Moscatelli D, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037499; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Oliver L, 1992, GROWTH FACTORS, V7, P97, DOI 10.3109/08977199209046399; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; PARTANEN J, 1992, Progress in Growth Factor Research, V4, P69, DOI 10.1016/0955-2235(92)90005-3; Renaud F, 1996, J BIOL CHEM, V271, P2801, DOI 10.1074/jbc.271.5.2801; RENAUD F, 1994, J CELL PHYSIOL, V158, P435, DOI 10.1002/jcp.1041580307; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; SATO Y, 1988, J CELL BIOL, V107, P1129; SCHWEIGERER L, 1987, BIOCHEM BIOPH RES CO, V143, P934, DOI 10.1016/0006-291X(87)90340-8; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; SIEVERS J, 1987, NEUROSCI LETT, V76, P157, DOI 10.1016/0304-3940(87)90708-7; STERNFELD MD, 1989, CURR EYE RES, V8, P1029, DOI 10.3109/02713688908997395; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; VENKATESWARAN S, 1992, HYBRIDOMA, V11, P729, DOI 10.1089/hyb.1992.11.729; VLODAVSKY I, 1982, EXP CELL RES, V140, P149, DOI 10.1016/0014-4827(82)90166-5; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	51	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22367	22373		10.1074/jbc.273.35.22367	http://dx.doi.org/10.1074/jbc.273.35.22367			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712857	hybrid			2022-12-25	WOS:000075616600033
J	Mazaki, Y; Uchida, H; Hino, O; Hashimoto, S; Sabe, H				Mazaki, Y; Uchida, H; Hino, O; Hashimoto, S; Sabe, H			Paxillin isoforms in mouse - Lack of the gamma isoform and developmentally specific beta isoform expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION PROTEIN; CELL-ADHESION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; BINDING; ACTIVATION; RECEPTOR; LIGAND; DOMAIN	Paxillin, a focal adhesion protein, exists as multiple isoforms in humans (alpha, beta, and gamma), To understand more about the physiological role of each isoform, we have employed the mouse system. We found that although the alpha and beta isoforms are present in the mouse, the gamma isoform is not. The alpha isoform protein was detected clearly in most adult tissues, whereas the beta isoform protein was almost undetectable except in spleen, testis, thymus, and lung. On the other hand, mRNAs of both isoforms were detectable in all tissues we examined. High levels of the beta isoform protein was detected in peritoneal exudate macrophage cells in adult mouse as well as in cultured fibroblasts, together with the alpha isoform, The alpha isoform was expressed at a constant level throughout the embryonic stages we examined, whereas the beta isoform protein was detected at the mid-stages of development and increased to levels almost equal to those of the a isoform during the late stages of embryogenesis, Therefore, unlike the alpha isoform, expression of the beta isoform protein is restricted in adult tissues. Moreover, we showed that alpha and beta isoforms were colocalized within the same focal adhesion plaques, and cytoplasmic pools of both isoforms exist in the perinuclear area, colocalized with the Gels apparatus.	Osaka Biosci Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan; Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Kyoto 61902, Japan; Kyoto Univ, Inst Virus Res, Kyoto 606, Japan; Keio Univ, Sch Med, Dept Obstet & Gynecol, Tokyo 160, Japan; Japanese Fdn Canc Res, Inst Canc, Tokyo 170, Japan	Japan Science & Technology Agency (JST); Kyoto University; Keio University; Japanese Foundation for Cancer Research	Sabe, H (corresponding author), Osaka Biosci Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan.	sabe@obi.or.jp	Sabe, Hisataka/GPF-4385-2022; Sabe, Hisataka/A-4066-2012	Mazaki, Yuichi/0000-0003-4192-0834				ARULANANDAM ARN, 1993, J EXP MED, V177, P1439, DOI 10.1084/jem.177.5.1439; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; DALTON SL, 1995, MOL BIOL CELL, V6, P1781, DOI 10.1091/mbc.6.12.1781; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; Gething M J, 1990, Semin Cell Biol, V1, P65; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HINO O, 1991, JPN J CANCER RES, V82, P1226, DOI 10.1111/j.1349-7006.1991.tb01785.x; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; LE PT, 1990, J IMMUNOL, V144, P4541; Mazaki Y, 1997, J BIOL CHEM, V272, P7437, DOI 10.1074/jbc.272.11.7437; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Muller RT, 1997, MOL BIOL CELL, V8, P2039, DOI 10.1091/mbc.8.10.2039; NAGATA T, 1989, 10TH P POST C SEM SM, V2, P1; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAUB TJ, 1989, EXP CELL RES, V184, P407, DOI 10.1016/0014-4827(89)90340-6; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sabe H, 1995, J BIOL CHEM, V270, P31219, DOI 10.1074/jbc.270.52.31219; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SAMBROOK J, 1989, MOL CLONING LAB MANA; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SINGER KH, 1990, J INVEST DERMATOL, V94, P85; STAUNTON DE, 1987, EMBO J, V6, P3695, DOI 10.1002/j.1460-2075.1987.tb02703.x; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tong X, 1997, J BIOL CHEM, V272, P33373, DOI 10.1074/jbc.272.52.33373; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; WALLNER BP, 1987, J EXP MED, V166, P923, DOI 10.1084/jem.166.4.923; WENG ZG, 1993, J BIOL CHEM, V268, P14956; Yamaguchi R, 1997, ONCOGENE, V15, P1753, DOI 10.1038/sj.onc.1201345	36	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22435	22441		10.1074/jbc.273.35.22435	http://dx.doi.org/10.1074/jbc.273.35.22435			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712867	hybrid			2022-12-25	WOS:000075616600043
J	McCallum, SJ; Erickson, JW; Cerione, RA				McCallum, SJ; Erickson, JW; Cerione, RA			Characterization of the association of the actin-binding protein, IQGAP, and activated Cdc42 with Golgi membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; ADP-RIBOSYLATION FACTOR; RASGAP-RELATED PROTEIN; RHO-FAMILY GTPASES; MOLECULAR CHARACTERIZATION; TYROSINE KINASE; MATRIX PROTEIN; BOVINE BRAIN; IDENTIFICATION; GTP	IQGAP is a recently identified actin-binding protein, which is a putative target for the Cdc42 and Rac GTP-binding proteins. Cdc42 was localized to the Golgi (Erickson, J. W., Zhang, C., Kahn, R. A., Evans, T., and Cerione, R. A. (1996) J. Biol. Chem. 271, 26850-26854), and here we show by immunofluorescence that IQGAP has a perinuclear localization, that it can be co-immunoprecipitated with Cdc42 from Golgi-enriched fractions, and that purified Golgi membranes are recognized by specific antibodies raised against IQGAP and Cdc42 in negative-stain immunogold electron microscopy experiments. Addition of activated, recombinant Cdc42 or solubilization of endogenous Cdc42 from Golgi membranes by the Rho-GDP dissociation inhibitor protein fails to solubilize IQGAP, suggesting that it associates with these membranes in a Cdc42-independent manner. Detergent solubilization of Golgi membranes leaves IQGAP and actin in an insoluble pellet but releases Cdc42 to the supernatant, whereas treatments that release actin from this detergent-insoluble pellet also release IQGAP. Addition of the COOH-terminal half of the IQGAP protein, which contains the Cdc42-binding domain, removes Cdc42 from Golgi membranes in a dose-dependent manner. These data suggest that IQGAP and Cdc42 are part of a cytoskeletal complex in Golgi membranes that may mediate Cdc42-regulated effects on the actin cytoskeleton in these membranes.	Cornell Univ, Ctr Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Biochem & Mol Cell Biol, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Ctr Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.							Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BACKLUND PS, 1993, BIOCHEM BIOPH RES CO, V196, P534, DOI 10.1006/bbrc.1993.2283; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BALCH WE, 1992, J BIOL CHEM, V267, P13053; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; BECK KA, 1994, J CELL BIOL, V127, P707, DOI 10.1083/jcb.127.3.707; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brill S, 1996, MOL CELL BIOL, V16, P4869; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CANO ML, 1992, J CELL BIOL, V116, P1123, DOI 10.1083/jcb.116.5.1123; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; EPP A, 1997, CURR BIOL, V7, P921; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Erlich R, 1996, J BIOL CHEM, V271, P8328, DOI 10.1074/jbc.271.14.8328; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; Fritzler MJ, 1995, J BIOL CHEM, V270, P31262, DOI 10.1074/jbc.270.52.31262; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1990, J BIOL CHEM, V265, P5990; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Jung E, 1996, EMBO J, V15, P1238, DOI 10.1002/j.1460-2075.1996.tb00465.x; KELLOKUMPU S, 1988, SCIENCE, V242, P1308, DOI 10.1126/science.2461589; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LEONARD D, 1992, J BIOL CHEM, V267, P22860; Lippincott J, 1998, J CELL BIOL, V140, P355, DOI 10.1083/jcb.140.2.355; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nomanbhoy TK, 1996, BIOCHEMISTRY-US, V35, P4602, DOI 10.1021/bi951743d; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; ROBERTSON D, 1986, J IMMUNOL, V136, P4565; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; UEDA T, 1990, J BIOL CHEM, V265, P9373; WEINER OH, 1993, J CELL BIOL, V123, P23, DOI 10.1083/jcb.123.1.23; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; WEST D W, 1981, Biochemical Society Transactions, V9, P77; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	54	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22537	22544		10.1074/jbc.273.35.22537	http://dx.doi.org/10.1074/jbc.273.35.22537			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712880	hybrid			2022-12-25	WOS:000075616600056
J	Meng, TC; Lin, MF				Meng, TC; Lin, MF			Tyrosine phosphorylation of c-ErbB-2 is regulated by the cellular form of prostatic acid phosphatase in human prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CARCINOMA-CELLS; NEU-ONCOGENE; PROTEIN-PHOSPHORYLATION; INSULIN-RECEPTOR; HUMAN-BREAST; EXPRESSION; HER-2/NEU; TRANSFORMATION; KINASES	Human Prostatic acid phosphatase (PAcP) is a prostate epithelium-specific differentiation antigen. In prostate carcinomas, the cellular PAcP is decreased. We investigated its functional role in these cells. Several lines of evidence support the hypothesis that cellular PAcP functions as a neutral protein-tyrosine phosphatase and is involved in regulating prostate cell growth. In this study, we identify its in vivo substrate. Our results demonstrated that, in different human prostate cancer cell lines, the phosphotyrosine (Tyr(P)) level of a 185-kDa phosphoprotein (pp185) inversely correlates with the cellular activity of PAcP. On SDS-PAGE, this pp185 comigrates with the c-ErbB-2 oncoprotein. Immunodepletion experiments revealed that c-ErbB-2 protein is the major pp185 in cells. Results from subclones of LNCaP cells indicated the lower the cellular PAcP activity, the higher the Tyr(P) levels of c-ErbB-2. This inverse correlation was further observed in PAcP cDNA-transfected cells. In clone 33 LNCaP cells, L-(+)-tartrate suppresses the cellular PAcP activity and causes an elevated Tyr(P) level of: c-ErbB-2 protein. Epidermal growth factor stimulates the proliferation of LNCaP cells, which concurs with a decreased cellular PAcP activity as well as an increased Tyr(P) level of c-ErbB-2. Biochemically, PAcP dephosphorylates c-ErbB-2 at pH 7.0. The results thus suggest that cellular PAcP down-regulates prostate cell growth by dephosphorylating Tyr(P) on c-ErbB-2 oncoprotein in those cells.	Univ Nebraska, Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Coll Med, Sect Urol Surg, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Canc Inst, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska, Med Ctr, Coll Med, Dept Biochem & Mol Biol, 600 S 42nd St, Omaha, NE 68198 USA.		Meng, Tzu-Ching/G-5426-2019	Meng, Tzu-Ching/0000-0001-7693-2021	NATIONAL CANCER INSTITUTE [R01CA072274] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72274] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad F, 1997, J BIOL CHEM, V272, P448; Arai Y, 1997, PROSTATE, V30, P195, DOI 10.1002/(SICI)1097-0045(19970215)30:3<195::AID-PROS8>3.0.CO;2-L; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DOUGALL WC, 1994, ONCOGENE, V9, P2109; FOTI AG, 1977, CANCER RES, V37, P4120; GARCIAARENAS R, 1995, MOL CELL ENDOCRINOL, V111, P29, DOI 10.1016/0303-7207(95)03544-H; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Gu KF, 1996, CANCER LETT, V99, P185, DOI 10.1016/0304-3835(95)04061-7; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Keane MM, 1996, CANCER RES, V56, P4236; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KUHN EJ, 1993, J UROLOGY, V150, P1427, DOI 10.1016/S0022-5347(17)35799-3; Landry F, 1996, J UROLOGY, V155, P386, DOI 10.1016/S0022-5347(01)66665-5; LATIL A, 1994, INT J CANCER, V59, P637, DOI 10.1002/ijc.2910590510; LI HC, 1984, EUR J BIOCHEM, V138, P45, DOI 10.1111/j.1432-1033.1984.tb07879.x; Lin MF, 1996, BIOCHEM BIOPH RES CO, V226, P206, DOI 10.1006/bbrc.1996.1334; LIN MF, 1988, MOL CELL BIOL, V8, P5477, DOI 10.1128/MCB.8.12.5477; LIN MF, 1986, MOL CELL BIOL, V6, P4753, DOI 10.1128/MCB.6.12.4753; LIN MF, 1993, ARCH BIOCHEM BIOPHYS, V300, P384, DOI 10.1006/abbi.1993.1052; LIN MF, 1986, BIOCHEM J, V235, P351, DOI 10.1042/bj2350351; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; LIN MF, 1992, CANCER RES, V52, P4600; LIN MF, 1994, DIFFERENTIATION, V57, P143, DOI 10.1046/j.1432-0436.1994.5720143.x; LIN MF, 1993, BIOCHEM BIOPH RES CO, V192, P413, DOI 10.1006/bbrc.1993.1431; LIN MF, 1983, BIOCHEMISTRY-US, V22, P1055, DOI 10.1021/bi00274a009; LOOR R, 1981, CANC LETT, V14, P61; MACOSKA JA, 1992, J UROLOGY, V147, P1142, DOI 10.1016/S0022-5347(17)37504-3; PEEHL DM, 1996, DEV BIOL, V22, P82; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; SADASIVAN R, 1993, J UROLOGY, V150, P126, DOI 10.1016/S0022-5347(17)35413-7; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; SHARIEF FS, 1989, BIOCHEM BIOPH RES CO, V160, P79, DOI 10.1016/0006-291X(89)91623-9; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; TESSIER S, 1989, MOL CELL ENDOCRINOL, V64, P87, DOI 10.1016/0303-7207(89)90068-3; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; VIHKO P, 1979, INVEST UROL, V16, P349; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; ZHAI YF, 1995, MOL CARCINOGEN, V14, P103, DOI 10.1002/mc.2940140206	46	77	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22096	22104		10.1074/jbc.273.34.22096	http://dx.doi.org/10.1074/jbc.273.34.22096			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705354	hybrid, Green Published			2022-12-25	WOS:000075492600088
J	Anton, IM; Lu, WG; Mayer, BJ; Ramesh, N; Geha, RS				Anton, IM; Lu, WG; Mayer, BJ; Ramesh, N; Geha, RS			The Wiskott-Aldrich syndrome protein-interacting protein (WIP) binds to the adaptor protein Nck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-3 DOMAINS; SH2 DOMAIN; NUCLEOTIDE EXCHANGE; TYROSINE; KINASE; PHOSPHORYLATION; PROFILIN; CELLS; THYMOSIN-BETA-4; ORGANIZATION	Nck is a ubiquitous adaptor molecule composed of three Src homology 3 (SH3) domains followed by a single SH2 domain, Nck links, via its SH2 domain, tyrosine-phosphorylated receptors to effector proteins that contain SH3-binding proline-rich sequences. In this report, we demonstrate that recombinant Nck precipitates endogenous WIP, a novel proline-rich protein that interacts with the Wiskott-Aldrich syndrome protein (WASP), from BJAB cell lysates, Nck binds through its second SH3 domain to WIP, and Nck binds to WIP at a site (amino acids 321-415) that differs from the WASP-binding site (amino acids 416-488), WIP has been shown to associate with the actin polymerization regulatory protein profilin and to induce actin polymerization and cytoskeletal reorganization in lymphoid cells. We demonstrate the presence of profilin in Nck precipitates suggesting that Nck may couple extracellular signals to the cytoskeleton via its interaction with WIP and profilin.	Harvard Univ, Div Immunol, Childrens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Geha, RS (corresponding author), Harvard Univ, Div Immunol, Childrens Hosp, Sch Med, Enders 8,300 Longwood Ave, Boston, MA 02115 USA.	geha@al.tch.harvard.edu	Anton, Ines M/G-6090-2015	Anton, Ines M/0000-0002-2935-5919	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037130] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-59561-01] Funding Source: Medline; NIAID NIH HHS [AI-37130] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; Choudhury GG, 1996, AM J PHYSIOL-RENAL, V270, pF295, DOI 10.1152/ajprenal.1996.270.2.F295; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; DONNELLY SFH, 1993, MOL MICROBIOL, V10, P585, DOI 10.1111/j.1365-2958.1993.tb00930.x; Finan PM, 1996, J BIOL CHEM, V271, P26291, DOI 10.1074/jbc.271.42.26291; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HU QJ, 1995, MOL CELL BIOL, V15, P1169; Kitamura T, 1996, BIOCHEM BIOPH RES CO, V219, P509, DOI 10.1006/bbrc.1996.0264; LAWE DC, 1997, 0NCOGENE, V14, P223; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matuoka K, 1997, BIOCHEM BIOPH RES CO, V239, P488, DOI 10.1006/bbrc.1997.7492; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; Perelroizen I, 1996, J BIOL CHEM, V271, P12302, DOI 10.1074/jbc.271.21.12302; Purich DL, 1997, BIOCHEM BIOPH RES CO, V231, P686, DOI 10.1006/bbrc.1997.6158; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	33	113	114	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20992	20995		10.1074/jbc.273.33.20992	http://dx.doi.org/10.1074/jbc.273.33.20992			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694849	hybrid			2022-12-25	WOS:000075386100042
J	Bellido, T; O'Brien, CA; Roberson, PK; Manolagas, SC				Bellido, T; O'Brien, CA; Roberson, PK; Manolagas, SC			Transcriptional activation of the p21(WAF1,CIP1,SDI1) gene by interleukin-6 type cytokines - A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; CYCLIN-DEPENDENT KINASES; HUMAN-MELANOMA CELLS; SIGNAL-TRANSDUCTION; BONE-MARROW; ONCOSTATIN-M; P21; INDUCTION; EXPRESSION; RECEPTORS	The cyclin-dependent kinase inhibitor p21(WAF1,CIP1,SDI1) plays a critical role in cell differentiation, and it has been shown to confer resistance to apoptosis. Based on this, and on evidence that activation of the gp130/signal transducer and activator of transcription (STAT) signal transduction pathway by interleukin (IL)-6 type cytokines promotes differentiation and prevents apoptosis in osteoblastic cells, we have investigated the possibility that p21 is a downstream effector of this signaling pathway in osteoblasts. We report that either oncostatin M (OSM) or IL-6 plus soluble IL-6 receptor increased the levels of p21 mRNA and protein in the osteoblast-like human osteosarcoma cell line MG63 and stimulated the activity of a 2.4-kilobase pair segment of the human p21 gene promoter. Further, nuclear extracts from cytokine-stimulated MG63 cells formed protein-DNA complexes with a 19-base pair nucleotide fragment of the p21 promoter containing a single STAT response element. The identity of the binding proteins as Stat3 and Stat1 was demonstrated with specific antibodies. In addition, and in support of a mediating role of STATs in the activation of the p21 promoter, overexpression of Stat3 potentiated the cytokine effect on the p21 promoter; whereas a dominant negative Stat3, or a mutation of the STAT response element on the promoter, significantly reduced the cytokine effect. Finally, antisense oligonucleotides complementary to p21 mRNA inhibited OSM-induced stimulation of alkaline phosphatase expression and antagonized the protective effect of OSM on anti-Fas-induced apoptosis. These results demonstrate that p21 is a downstream effector of gp130/Stat3 activation and a critical mediator of the pro-differentiating and anti-apoptotic effects of IL-6 type cytokines on human osteoblastic cells.	Univ Arkansas Med Sci, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA; McClellan Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; Geriatric Research Education & Clinical Center	Bellido, T (corresponding author), Univ Arkansas Med Sci, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, 4301 W Markham,Mail Slot 587, Little Rock, AR 72205 USA.	tmbellido@life.uams.edu	O'Brien, Charles A./AAL-5078-2020		NIAMS NIH HHS [R29AR43453] Funding Source: Medline; NIA NIH HHS [P01AG/AMS13918] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLAN EH, 1990, J CELL PHYSIOL, V145, P110, DOI 10.1002/jcp.1041450116; Bellido T, 1996, J CLIN INVEST, V97, P431, DOI 10.1172/JCI118432; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GIMBLE JM, 1994, J CELL BIOCHEM, V54, P122, DOI 10.1002/jcb.240540113; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HEREMANS H, 1978, ONCOLOGY, V35, P246, DOI 10.1159/000225298; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; JILKA RL, 1997, J BONE MINER RES, V12, pS455; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Majeska Robert J., 1996, P1229; MALIK N, 1995, MOL CELL BIOL, V15, P2349; Manolagas Stavros C., 1996, P701; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; METCALF D, 1989, P NATL ACAD SCI USA, V86, P5948, DOI 10.1073/pnas.86.15.5948; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Poluha W, 1996, MOL CELL BIOL, V16, P1335; RODAN SB, 1990, ENDOCRINOLOGY, V127, P1602, DOI 10.1210/endo-127-4-1602; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Stuart A., 1987, KENDALLS ADV THEORY; TAGUCHI T, 1998, IN PRESS P ASS AM PH; TAKAHASHI K, 1995, J BONE MINER RES, V10, pS317; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WARE CB, 1995, DEVELOPMENT, V121, P1283	49	189	195	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21137	21144		10.1074/jbc.273.33.21137	http://dx.doi.org/10.1074/jbc.273.33.21137			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694869	hybrid			2022-12-25	WOS:000075386100062
J	Hukovic, N; Panetta, R; Kumar, U; Rocheville, M; Patel, YC				Hukovic, N; Panetta, R; Kumar, U; Rocheville, M; Patel, YC			The cytoplasmic tail of the human somatostatin receptor type 5 is crucial for interaction with adenylyl cyclase and in mediating desensitization and internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; AGONIST-INDUCED DESENSITIZATION; PROTEIN-COUPLED RECEPTORS; CARBOXYL-TERMINUS; STIMULATED INTERNALIZATION; PEPTIDE RECEPTOR; PITUITARY-CELLS; MESSENGER-RNA; NPX(N)Y MOTIF; 2 ISOFORMS	We have investigated the role of the cytoplasmic tail (C-tail) of the human somatostatin receptor type 5 (hSSTR5) in regulating receptor coupling to adenylyl cyclase (AC) and in mediating agonist-dependent desensitization and internalization responses. Mutant receptors with progressive C-tail truncation (Delta 347, Delta 338, Delta 328, Delta 318), Cys(320) --> Ala substitution (to block palmitoylation), or Tyr(304) --> Ala substitution of a putative NPXYY internalization motif were stably expressed in Chinese hamster ovary K1 cells. Except for the Tyr(304) --> Ala mutant, which showed no binding, all other mutant receptors exhibited binding characteristics (K-d and B-max) and G protein coupling comparable with wild type (wt) hSSTR5. The C-tail truncation mutants displayed progressive reduction in coupling to AC, with the Delta 318 mutant showing complete loss of effector coupling. Agonist pretreatment of wt hSSTR5 led to uncoupling of AC inhibition, whereas the desensitization response of the C-tail deletion mutants was variably impaired. Compared with internalization (66% at 60 min) of wt hSSTR5, truncation of the C-tail to 318, 328, and 338 residues reduced receptor internalization to 46, 46, and 23%, respectively, whereas truncation to 347 residues slightly improved internalization (72%). Mutation of Cys(320) --> Ala induced a reduction in AC coupling, desensitization, and internalization. These studies show that the C-tail of hSSTR5 serves a multifunctional role in mediating effector coupling, desensitization, and internalization. Whereas coupling to AC is dependent on the length of the C-tail, desensitization and internalization require specific structural domains. Furthermore, internalization is regulated through both positive and negative molecular signals in the C-tail and can be dissociated from the signaling and acute desensitization responses of the receptor.	McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Neurol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Neurosurg, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Pharmacol & Therapeut, Montreal, PQ H3A 1A1, Canada; Montreal Neurol Inst, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University	Patel, YC (corresponding author), McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Med, Room M3-15,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.							AMHERDT M, 1989, J CLIN INVEST, V84, P412, DOI 10.1172/JCI114181; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENYA RV, 1994, MOL PHARMACOL, V46, P495; Bonifacino JS, 1996, P ASSOC AM PHYSICIAN, V108, P285; BOUVIER M, 1995, BIOCHEM SOC T, V23, P577, DOI 10.1042/bst0230577; BRUNO JF, 1994, BIOCHEM BIOPH RES CO, V202, P1738, DOI 10.1006/bbrc.1994.2136; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; DAY R, 1995, ENDOCRINOLOGY, V136, P5232, DOI 10.1210/en.136.11.5232; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GOLDMAN PS, 1994, J BIOL CHEM, V269, P15640; Greenwood MT, 1997, MOL PHARMACOL, V52, P807, DOI 10.1124/mol.52.5.807; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; HOFLAND LJ, 1995, ENDOCRINOLOGY, V136, P3698, DOI 10.1210/en.136.9.3698; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; Hukovic N, 1996, ENDOCRINOLOGY, V137, P4046, DOI 10.1210/en.137.9.4046; IRIE A, 1994, EUR J BIOCHEM, V224, P161, DOI 10.1111/j.1432-1033.1994.tb20007.x; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; KAWATE N, 1994, J BIOL CHEM, V269, P30651; Kumar U, 1997, ENDOCRINOLOGY, V138, P4473, DOI 10.1210/en.138.10.4473; Lamberts SWJ, 1996, NEW ENGL J MED, V334, P246, DOI 10.1056/NEJM199601253340408; Laporte SA, 1996, MOL PHARMACOL, V49, P89; MOREL G, 1985, ENDOCRINOLOGY, V116, P1615, DOI 10.1210/endo-116-4-1615; NG GYK, 1995, P NATL ACAD SCI USA, V92, P10157, DOI 10.1073/pnas.92.22.10157; Nouel D, 1997, ENDOCRINOLOGY, V138, P296, DOI 10.1210/en.138.1.296; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; Patel YC, 1997, TRENDS ENDOCRIN MET, V8, P398, DOI 10.1016/S1043-2760(97)00168-9; PATEL YC, 1994, J BIOL CHEM, V269, P1506; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; PRESKY DH, 1988, J BIOL CHEM, V263, P714; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; Roettger BF, 1997, MOL PHARMACOL, V51, P357; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; SLICE LW, 1994, J BIOL CHEM, V269, P21755; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; SULLIVAN SJ, 1988, ENDOCRINOLOGY, V122, P1137, DOI 10.1210/endo-122-3-1137; Tanaka K, 1998, ENDOCRINOLOGY, V139, P803, DOI 10.1210/en.139.2.803; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; Tolbert LM, 1998, J NEUROCHEM, V70, P113; VANETTI M, 1993, FEBS LETT, V331, P260, DOI 10.1016/0014-5793(93)80349-Y; XU Y, 1995, ENDOCRINOLOGY, V136, P5070, DOI 10.1210/en.136.11.5070	45	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21416	21422		10.1074/jbc.273.33.21416	http://dx.doi.org/10.1074/jbc.273.33.21416			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694905	hybrid			2022-12-25	WOS:000075386100098
J	Kelly, D; Kim, SJ; Rizzino, A				Kelly, D; Kim, SJ; Rizzino, A			Transcriptional activation of the type II transforming growth factor-beta receptor gene upon differentiation of embryonal carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATORY ELEMENT; SERINE THREONINE KINASE; ENDODERM-LIKE CELLS; EARLY MOUSE EMBRYOS; RNA POLYMERASE-II; TGF-BETA; NF-Y; MICROSATELLITE INSTABILITY; GROWTH-FACTOR-BETA-2 GENE; EXPRESSION CLONING	Previously, it has been shown that differentiation of embryonal carcinoma (EC) cells turns on the expression of functional transforming growth factor type-beta receptors, Here, we show that the type II receptor (T beta R-II) gene is activated at the transcriptional level when EC cells differentiate. We show that the differentiated cells, but not the parental EC cells, express transcripts for T beta R-II, In addition, the expression of T beta R-II promoter/ reporter gene constructs are elevated dramatically when EC cells differentiate and we identify at least two positive and two negative regulatory regions in the 5' flanking region of the T beta R-II gene. Moreover, we identify a cAMP response element/activating transcription factor site that acts as a positive cis-regulatory element in the T beta R-II promoter, and we demonstrate that the transcription factor ATF-1 binds to this site and strongly stimulates the expression of the T beta R-II promoter/reporter gene constructs when ATF-1 is overexpressed in EC-derived differentiated cells, Equally important, we identify a negative regulatory element in a 53-base pair region that had previously been shown to inhibit strongly the expression of T beta R-II promoter/reporter gene constructs, Specifically, we demonstrate that this region, which contains an inverted CCAAT box motif, binds the transcription factor complex NF-Y (also referred to as CBF) in vitro. Furthermore, expression of a dominant-negative NF-YA mutant protein, which prevents DNA binding by NF-Y, enhances TPR-II promoter expression. Together, these studies suggest that the transcription factors ATF-1 and NF-Y play important roles in the regulation of the T beta R-II gene.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; NCI, NIH, Bethesda, MD 20892 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rizzino, A (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 600 S 42nd St, Omaha, NE 68198 USA.				NATIONAL CANCER INSTITUTE [T32CA009476, P30CA036727, R01CA074771] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09476, CA 36727, CA 74771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; BOUCHER PD, 1993, J BIOL CHEM, V268, P17384; BOUCHER PD, 1995, MOL CELL BIOL, V15, P5144; BRYANS M, 1995, BIOCHEM BIOPH RES CO, V211, P5619; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CAMPBELL WJ, 1990, IN VITRO CELL DEV B, V26, P1181; deJonge RR, 1997, ONCOL RES, V9, P89; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; Guo YP, 1997, INT J CANCER, V71, P573, DOI 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.3.CO;2-1; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HASAN S, 1994, J BIOL CHEM, V269, P25042; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; HINKLEY C, 1992, MOL CELL BIOL, V12, P4400, DOI 10.1128/MCB.12.10.4400; HUMPHRIES DE, 1994, BIOCHEM BIOPH RES CO, V203, P1020, DOI 10.1006/bbrc.1994.2284; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; KAARTINEN V, 1995, NAT GENET, V11, P409; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; KELLY D, 1990, CYTOTECHNOLOGY, V4, P227, DOI 10.1007/BF00563783; KELLY D, 1992, DEV BIOL, V153, P172, DOI 10.1016/0012-1606(92)90102-M; KELLY D, 1995, MOL REPROD DEV, V40, P135, DOI 10.1002/mrd.1080400202; KELLY D, 1989, DIFFERENTIATION, V41, P34, DOI 10.1111/j.1432-0436.1989.tb00729.x; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSLEYKALLESE.M, 1996, IN VITRO CELL BIOL, V33, P294; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lamb KA, 1997, MOL REPROD DEV, V48, P301; Lazzereschi D, 1997, CANCER RES, V57, P2071; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MA YG, 1992, DEV BIOL, V154, P45, DOI 10.1016/0012-1606(92)90046-J; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MORIUCHI H, 1995, VIROLOGY, V214, P256, DOI 10.1006/viro.1995.9932; MUMMERY CL, 1990, DEV BIOL, V137, P161, DOI 10.1016/0012-1606(90)90017-D; MunozAntonia T, 1996, CANCER RES, V56, P4831; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11578; Osawa H, 1996, J BIOL CHEM, V271, P17296, DOI 10.1074/jbc.271.29.17296; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; PARIA BC, 1992, DEV BIOL, V151, P91, DOI 10.1016/0012-1606(92)90216-4; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; PELTON RW, 1990, DEVELOPMENT, V110, P609; Plet A, 1997, ONCOGENE, V14, P2575, DOI 10.1038/sj.onc.1201103; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; REITH W, 1994, J BIOL CHEM, V269, P20020; RIZZINO A, 1988, DEV BIOL, V130, P411, DOI 10.1016/0012-1606(88)90337-5; RIZZINO A, 1983, EXP CELL RES, V143, P143, DOI 10.1016/0014-4827(83)90116-7; RIZZINO A, 1980, P NATL ACAD SCI-BIOL, V77, P457, DOI 10.1073/pnas.77.1.457; RIZZINO A, 1985, IN VITRO CELL DEV B, V21, P531; RIZZINO A, 1987, CANCER RES, V47, P4386; RIZZINO A, 1989, GROWTH FACTORS MAMMA; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO; ROSENTHAL N, 1987, METHODS ENZYMOLOGY G; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SCHOLTZ B, 1995, MOL REPROD DEV, V41, P140, DOI 10.1002/mrd.1080410204; Scholtz B, 1996, DEV BIOL, V173, P420, DOI 10.1006/dbio.1996.0037; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHAPIRO IM, 1990, SOMAT CELL MOLEC GEN, V16, P1, DOI 10.1007/BF01650475; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SLAGER HG, 1991, DEV BIOL, V145, P205, DOI 10.1016/0012-1606(91)90120-R; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TIESMAN J, 1989, IN VITRO CELL DEV B, V25, P1193; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	77	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21115	21124		10.1074/jbc.273.33.21115	http://dx.doi.org/10.1074/jbc.273.33.21115			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694866	hybrid			2022-12-25	WOS:000075386100059
J	Ozbek, S; Grotzinger, J; Krebs, B; Fischer, M; Wollmer, A; Jostock, T; Mullberg, J; Rose-John, S				Ozbek, S; Grotzinger, J; Krebs, B; Fischer, M; Wollmer, A; Jostock, T; Mullberg, J; Rose-John, S			The membrane proximal cytokine receptor domain of the human interleukin-6 receptor is sufficient for ligand binding but not for gp130 association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; CRYSTAL-STRUCTURE; SIGNAL-TRANSDUCTION; BIOLOGICAL FUNCTION; ESCHERICHIA-COLI; TERMINAL DOMAIN; IL-6 RECEPTOR; ONCOSTATIN-M; EXPRESSION; CELLS	Interleukin-6 (IL-6) belongs to the family of the "four-helix bundle" cytokines. The extracellular parts of their receptors consist of several Ig- and fibronectin type III-like domains. Characteristic of these receptors is a cytokine-binding module consisting of two such fibronectin domains defined by a set of four conserved cysteines and a tryptophan-serine-X-tryptophan-serine (WSXWS) sequence motif. On target cells, IL-6 binds to a specific IL-6 receptor (IL-6R), and the complex of IL-6 IL-GR associates with the signal transducing protein gp130. The IL-GR consists of three extracellular domains. The NH2-terminal Ig-like domain is not needed for ligand binding and signal initiation. Here we have investigated the properties and functional role of the third membrane proximal domain. The protein can be efficiently expressed in bacteria, and the refolded domain is shown to be sufficient for IL-6 binding. When complexed with IL-6, however, it fails to associate with the gp130 protein. Since the second and the third domain together with IL-6 can bind to gp130 and induce signaling, our data demonstrate the ligand binding function of the third domain and point to an important role of the second domain in complex formation with gp130 and signaling.	Johannes Gutenberg Univ Mainz, Med Klin 1, Abt Pathophysiol, D-55101 Mainz, Germany; Rhein Westfal TH Aachen Klinikum, Inst Biochem, D-52057 Aachen, Germany	Johannes Gutenberg University of Mainz; RWTH Aachen University; RWTH Aachen University Hospital	Rose-John, S (corresponding author), Johannes Gutenberg Univ Mainz, Med Klin 1, Abt Pathophysiol, Obere Zahlbacher Str 63, D-55101 Mainz, Germany.	rosejohn@mail.uni-mainz.de	Özbek, Suat/D-3701-2014; Rose-John, Stefan/A-7998-2010	Rose-John, Stefan/0000-0002-7519-3279; Ozbek, Suat/0000-0003-2569-3942				ANAGUCHI H, 1995, J BIOL CHEM, V270, P27845, DOI 10.1074/jbc.270.46.27845; Baumann H, 1996, J IMMUNOL, V157, P284; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EHLERS M, 1994, J IMMUNOL, V153, P1744; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; GRISHINA IB, 1994, FARADAY DISCUSS, V99, P245, DOI 10.1039/fd9949900245; Grotzinger J, 1997, PROTEINS, V27, P96; GRUBE BJ, 1994, J BIOL CHEM, V269, P20791; Ichihara M, 1997, BLOOD, V90, P165; Krebs B, 1998, J BIOL CHEM, V273, P2858, DOI 10.1074/jbc.273.5.2858; KRUTTGEN A, 1990, FEBS LETT, V262, P323, DOI 10.1016/0014-5793(90)80219-9; LEEBEEK FWG, 1992, J BIOL CHEM, V267, P14832; Marz P, 1998, P NATL ACAD SCI USA, V95, P3251, DOI 10.1073/pnas.95.6.3251; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; MullerNewen G, 1997, EUR J BIOCHEM, V247, P425, DOI 10.1111/j.1432-1033.1997.00425.x; NEUBAUER P, 1995, BIOTECHNOL BIOENG, V47, P139, DOI 10.1002/bit.260470204; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SALVATI AL, 1995, J BIOL CHEM, V270, P12242, DOI 10.1074/jbc.270.20.12242; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Toniatti C, 1996, EMBO J, V15, P2726, DOI 10.1002/j.1460-2075.1996.tb00633.x; UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461; VANDAM M, 1993, J BIOL CHEM, V268, P15285; Vollmer P, 1996, J IMMUNOL METHODS, V199, P47, DOI 10.1016/S0022-1759(96)00163-9; WARD LD, 1994, J BIOL CHEM, V269, P23286; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	44	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21374	21379		10.1074/jbc.273.33.21374	http://dx.doi.org/10.1074/jbc.273.33.21374			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694899	hybrid			2022-12-25	WOS:000075386100092
J	Parthasarathy, N; Gotow, LF; Bottoms, JD; Kute, TE; Wagner, WD; Mulloy, B				Parthasarathy, N; Gotow, LF; Bottoms, JD; Kute, TE; Wagner, WD; Mulloy, B			Oligosaccharide sequence of human breast cancer cell heparan sulfate with high affinity for laminin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; LIPOPROTEIN-LIPASE; BINDING; PROTEOGLYCAN; CHAINS; PROTEIN; DOMAIN; GLYCOSAMINOGLYCANS; SYNDECAN-1; MEMBRANES	Laminin-1 is a basement membrane glycoprotein implicated in tumor-host adhesion, which involves the cell-binding domain(s) of laminin-l and tumor cell surface heparan sulfate (HS), The specific tumor cell surface HS oligosaccharide sequences that are necessary for binding to laminin-l have not been characterized. To identify this laminin-binding oligosaccharide sequence, Glc-NSO4-rich oligosaccharides terminating with [H-3]2,5-anhydromannitol (AMan(R)) residues were isolated from human breast cancer cell (MCF-7)-derived HS through hydrazinolysis/high pH (4.0) nitrous acid treatment/[H-3]NaBH4 reduction. These oligosaccharides were chromatographed on a laminin-l affinity column, A high affinity dodecasaccharide was isolated and characterized. Disaccharide analysis yielded IdoA(2-SO4) --> AMan(R)(6-SO4) as the only disaccharide upon treatment of this dodecasaccharide with nitrous acid at low pH (1.5), The sequence of laminin-binding high affinity oligosaccharide is therefore [IdoA(2-SO4 --> GlcNSO(4)(6-SO4)](5)[IdoA(2-SO4) --> AMan(R)(6-SO4)]. Low affinity dodecasaccharides composed of [IdoA(2-SO4) --> GlcNSO(4)(6-SO4)](5), [IdoA(2-SO4) --> GlcNSO(4)] were also isolated by laminin-l affinity chromatography, Molecular modeling studies indicate that a heparin-binding peptide sequence corresponding to amino acid residues 3010-3031 (KQNCLSSRASFRGCVRNLRLSR) in the G domain of laminin-l, modeled as a right-handed alpha-helix, carries an array of basic residues well placed to bind to clusters of sulfate groups on the high affinity dodecasaccharide.	Wake Forest Univ, Sch Med, Comparat Med Sect, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England	Wake Forest University; Wake Forest University; National Institute for Biological Standards & Control	Parthasarathy, N (corresponding author), Wake Forest Univ, Sch Med, Comparat Med Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA.	npartha@wfubmc.edu						ARUMUGHAM RG, 1988, CONNECT TISSUE RES, V18, P135, DOI 10.3109/03008208809008065; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1994, BIOCHEM J, V303, P81, DOI 10.1042/bj3030081; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BIENKOWSKI MJ, 1985, SEMIN THROMB HEMOST, V11, P86, DOI 10.1055/s-2007-1004363; CARLSON DM, 1968, J BIOL CHEM, V243, P616; Fromm JR, 1997, ARCH BIOCHEM BIOPHYS, V343, P92, DOI 10.1006/abbi.1997.0147; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HASCALL VC, 1994, METHOD ENZYMOL, V230, P390; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KATO M, 1994, J BIOL CHEM, V269, P18881; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, BIOCHEM SOC T, V22, P365, DOI 10.1042/bst0220365; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MATTER ML, 1994, J CELL BIOL, V124, P1083, DOI 10.1083/jcb.124.6.1083; MCGEE MP, 1995, J BIOL CHEM, V270, P26109, DOI 10.1074/jbc.270.44.26109; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; PARTHASARATHY N, 1982, ARCH BIOCHEM BIOPHYS, V213, P504, DOI 10.1016/0003-9861(82)90576-8; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; PEJLER G, 1987, J BIOL CHEM, V262, P5036; Pillarisetti S, 1997, J BIOL CHEM, V272, P15753, DOI 10.1074/jbc.272.25.15753; RAHMOUNE H, 1996, BIOCHEM SOC T, V24, P355; RODEN L, 1980, BIOCH GLYCOPROTEINS; SALMIVIRTA M, 1994, EXP CELL RES, V215, P180, DOI 10.1006/excr.1994.1330; SALMIVIRTA M, 1995, EXPERIENTIA, V51, P863, DOI 10.1007/BF01921737; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SHEN GQ, 1995, ARCH BIOCHEM BIOPHYS, V321, P83, DOI 10.1006/abbi.1995.1371; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; Sung U, 1997, EUR J BIOCHEM, V250, P138, DOI 10.1111/j.1432-1033.1997.00138.x; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; TURNBULL JE, 1993, BIOCHEM SOC T, V21, P477, DOI 10.1042/bst0210477; YURCHENCO PD, 1990, ANN NY ACAD SCI, V580, P195, DOI 10.1111/j.1749-6632.1990.tb17929.x	37	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21111	21114		10.1074/jbc.273.33.21111	http://dx.doi.org/10.1074/jbc.273.33.21111			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694865	hybrid			2022-12-25	WOS:000075386100058
J	Seimiya, H; Tsuruo, T				Seimiya, H; Tsuruo, T			Functional involvement of PTP-U2L in apoptosis subsequent to terminal differentiation of monoblastoid leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CHROMOSOMAL LOCALIZATION; HOMOPHILIC BINDING; MOLECULAR-CLONING; HL-60 CELLS; U937 CELLS; MOTH-EATEN; KINASE-C; RECEPTOR; EXPRESSION	A large family of protein tyrosine phosphatases (PTPs) bidirectionally regulate intracellular signaling pathways by reversing agonistic or antagonistic phosphorylation events derived from the action of protein tyrosine kinases. Receptor-like PTP PTP-U2 is expressed during phorbol ester-induced differentiation of monoblastoid leukemia U937 cells. We found that the shorter isoform, PTP-U2S, was expressed at an earlier phase in the course of differentiation and the longer isoform, PTP-U2L, was induced at a later phase. In the presence of 12-O-tetradecanoylphorbol-13-acetate, ectopic expression of PTP-U2L in U937 cells enhanced several characteristics of terminally differentiated cells. Most striking was that PTP-U2L enhanced apoptosis of the differentiated cells, which was only partially inhibited by caspase inhibitor Z-Asp-CH2-DCB. The catalytically inactive mutant PTP-U2L(C --> S) still retained the ability to enhance the differentiation but retained the ability to enhance the following apoptosis of the cells to a lesser extent. These data indicate a functional involvement of PTP-U2L in apoptosis subsequent to terminal differentiation of U937 cells. Since terminally differentiated blood cells often undergo apoptosis, the data also suggest that PTP-U2L might be involved in physiological turnover of hematopoietic cells in vivo.	Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	Japanese Foundation for Cancer Research; University of Tokyo	Tsuruo, T (corresponding author), Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, 1-37-1 Kami Ikebukoro, Tokyo 1708455, Japan.	hseimiya@jfcr.or.jp		Seimiya, Hiroyuki/0000-0003-3314-9736				Adachi M, 1996, CELL, V85, P15; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLUMBERG PM, 1988, CANCER RES, V48, P1; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BUTLER TM, 1990, CANCER RES, V50, P6323; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DAUM G, 1993, ANAL BIOCHEM, V211, P50, DOI 10.1006/abio.1993.1231; DENHERTOG J, 1992, BIOCHEM BIOPH RES CO, V184, P1241, DOI 10.1016/S0006-291X(05)80015-4; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; FRANK DA, 1988, CANCER RES, V48, P4299; FRANK DA, 1988, CANCER RES, V48, P52; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; GUNJI H, 1991, CANCER RES, V51, P741; HONDA H, 1994, BLOOD, V84, P4186, DOI 10.1182/blood.V84.12.4186.bloodjournal84124186; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KEENE P, 1987, BRIT J HAEMATOL, V67, P25, DOI 10.1111/j.1365-2141.1987.tb02291.x; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KREUTTER D, 1985, J BIOL CHEM, V260, P5979; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; PIXLEY FJ, 1995, J BIOL CHEM, V270, P27339, DOI 10.1074/jbc.270.45.27339; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; SAP J, 1994, MOL CELL BIOL, V14, P1; SEIMIYA H, 1995, ONCOGENE, V10, P1731; SEIMIYA H, 1993, CELL GROWTH DIFFER, V4, P1033; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SEIMIYA H, 1995, ONCOGENE, V11, P2047; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; THOMAS PE, 1994, J BIOL CHEM, V269, P19953; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; XIAO S, 1994, J BIOL CHEM, V269, P21244; Yahagi Y, 1996, NEUROSCI LETT, V211, P125, DOI 10.1016/0304-3940(96)12738-5; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007	52	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21187	21193		10.1074/jbc.273.33.21187	http://dx.doi.org/10.1074/jbc.273.33.21187			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694875	hybrid			2022-12-25	WOS:000075386100068
J	Thewke, DP; Panini, SR; Sinensky, M				Thewke, DP; Panini, SR; Sinensky, M			Oleate potentiates oxysterol inhibition of transcription from sterol regulatory element-1-regulated promoters and maturation of sterol regulatory element-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MONOUNSATURATED FATTY-ACIDS; COENZYME-A REDUCTASE; CHOLESTEROL-METABOLISM; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; TRANSGENIC MICE; 25-HYDROXYCHOLESTEROL; EXPRESSION; RECEPTOR; SREBP-2	Activation of genes containing SRE-1 (sterol regulatory element 1) sequences is known to be under the regulation of sterols through modulation of the proteolytic maturation of SREBPs (SRE-1-binding proteins). Previous work has demonstrated SREBP-mediated transcriptional activation of genes encoding enzymes of sterol and fatty acid biosynthesis. Because synthesis of both sterols and C18 fatty acids are required for cell growth, in the absence of exogenous supplements of these lipids, we examined the hypothesis that fatty acid can also be regulatory in SREBP maturation. Our data indicate that C18 fatty acids can potentiate the biological activities of a typical, regulatory sterol: 25-hydroxycholesterol. Inhibition of C18 fatty acid synthesis in cells cultured in serum-free medium renders them resistant to killing by 25-hydroxycholesterol. Repression of expression of reporter constructs driven by promoters bearing SRE-1 element(s) by 25-hydroxycholesterol is increased by C18 fatty acid supplementation. C18 fatty acids also increase the inhibitory effect of 25-hydroxycholesterol on proteolytic maturation and nuclear localization of SREBPs, Furthermore, we also show that C18 fatty acid supplementation can enhance the inhibitory effect of 25-hydroxycholesterol on sterol and fatty acid biosynthesis, These results demonstrate that maximal down-regulation of SREBP maturation and the consequent repression of SRE-1 promoters occurs in response to both a regulatory sterol and fatty acid.	E Tennessee State Univ, Dept Biochem & Mol Biol, James H Quillen Coll Med, Johnson City, TN 37614 USA	East Tennessee State University	Sinensky, M (corresponding author), E Tennessee State Univ, Dept Biochem & Mol Biol, James H Quillen Coll Med, Box 70581, Johnson City, TN 37614 USA.							BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Bollag D.M., 1991, PROTEIN METHODS; Brindley D. N, 1991, BIOCH LIPIDS LIPOPRO, P171; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHANG TY, 1981, ANAL BIOCHEM, V116, P298, DOI 10.1016/0003-2697(81)90360-2; CHANG TY, 1976, P NATL ACAD SCI USA, V73, P24, DOI 10.1073/pnas.73.1.24; CHIN J, 1981, J BIOL CHEM, V256, P6304; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; GOLDSTEIN JL, 1975, J BIOL CHEM, V250, P8487; Griffin ME, 1996, QJM-MON J ASSOC PHYS, V89, P211; GRUNDY SM, 1989, J NUTR, V119, P529, DOI 10.1093/jn/119.4.529; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; LEONARD S, 1988, BIOCHIM BIOPHYS ACTA, V947, P101, DOI 10.1016/0304-4157(88)90021-4; LIMANEK JS, 1978, P NATL ACAD SCI USA, V75, P5452, DOI 10.1073/pnas.75.11.5452; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; PANINI SR, 1990, J BIOL CHEM, V265, P14118; RUDEL LL, 1990, J LIPID RES, V31, P1873; Rudney Harry, 1993, Current Opinion in Lipidology, V4, P230, DOI 10.1097/00041433-199306000-00009; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; SINENSKY M, 1982, J CELL PHYSIOL, V113, P314, DOI 10.1002/jcp.1041130220; SINENSKY M, 1980, P NATL ACAD SCI-BIOL, V77, P6621, DOI 10.1073/pnas.77.11.6621; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; TABAS I, 1986, J BIOL CHEM, V261, P3147; TAM SP, 1992, ATHEROSCLEROSIS, V95, P137, DOI 10.1016/0021-9150(92)90017-B; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247	31	65	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21402	21407		10.1074/jbc.273.33.21402	http://dx.doi.org/10.1074/jbc.273.33.21402			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694903	Green Published, hybrid			2022-12-25	WOS:000075386100096
J	Wu, XL; Spiro, C; Owen, WG; McMurray, CT				Wu, XL; Spiro, C; Owen, WG; McMurray, CT			cAMP response element-binding protein monomers cooperatively assemble to form dimers on DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CREB; LEUCINE ZIPPER DOMAIN; NUCLEAR FACTOR CREB; X-RAY STRUCTURE; CYCLIC-AMP; SOMATOSTATIN GENE; BASIC REGION; COILED-COIL; PHOSPHORYLATION; FOS	We have analyzed the properties of cAMP response element-binding protein (CREB) in solution with emphasis on dimerization and effects of phosphorylation. Using a purified CREB fusion protein, a novel dye-label technique, and sedimentation equilibrium analysis, we directly and conclusively demonstrate that, unlike Jun and Fos, CREB dimerization is DNA-dependent. CREB exists primarily as a monomer in solution and cooperatively assembles on DNA to form dimers. Sedimentation equilibrium analysis also indicates that dimerization is unaffected by cAMP-dependent protein kinase-phosphorylation or by the symmetry of the cAMP-responsive element binding site. Filter binding assays reveal that CREB binding is unaffected by phosphorylation regardless of the symmetry of the cAMP-responsive element binding site. Our results suggest that structurally similar members of the same bZIP superfamily may differ significantly in their regulation at the level of dimerization.	Mayo Clin & Mayo Fdn, Dept Pharmacol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Grad Sch, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	McMurray, CT (corresponding author), Mayo Clin & Mayo Fdn, Dept Pharmacol, 200 1St St Sw, Rochester, MN 55905 USA.	mcmurray.cynthia@mayo.edu			NIDDK NIH HHS [DK 43694] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; Carroll AS, 1997, GENE DEV, V11, P2227, DOI 10.1101/gad.11.17.2227; COHEN DR, 1990, ONCOGENE, V5, P929; COLLINSHICOK J, 1994, MOL CELL BIOL, V14, P2837, DOI 10.1128/MCB.14.5.2837; DAVIES GF, 1995, ARCH BIOCHEM BIOPHYS, V323, P477, DOI 10.1006/abbi.1995.0070; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Foulkes NS, 1996, NATURE, V381, P83, DOI 10.1038/381083a0; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HU JC, 1993, PROTEIN SCI, V2, P1072, DOI 10.1002/pro.5560020701; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HURST HC, 1995, PROTEIN PROFILE, V2, P105; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; KATAGIRI F, 1992, MOL CELL BIOL, V12, P4809, DOI 10.1128/MCB.12.11.4809; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRAJEWSKI W, 1994, MOL CELL BIOL, V14, P7204, DOI 10.1128/MCB.14.11.7204; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE JC, 1974, ARCH BIOCHEM BIOPHYS, V165, P268, DOI 10.1016/0003-9861(74)90164-7; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657; MESELSON M, 1957, P NATL ACAD SCI USA, V43, P581, DOI 10.1073/pnas.43.7.581; Metallo SJ, 1997, NAT STRUCT BIOL, V4, P115, DOI 10.1038/nsb0297-115; Moitra J, 1997, BIOCHEMISTRY-US, V36, P12567, DOI 10.1021/bi971424h; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Pal S, 1997, P NATL ACAD SCI USA, V94, P5556, DOI 10.1073/pnas.94.11.5556; PAPPOULAS O, 1988, CURRENT PROTOCOLS MO; Parker D, 1996, MOL CELL BIOL, V16, P694; Press W. H., 1992, NUMERICAL RECIPES C, V2nd, P656; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUBERT F, 1990, NUCLEIC ACIDS RES, V18, P3427; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SPIRO C, 1993, P NATL ACAD SCI USA, V90, P4606, DOI 10.1073/pnas.90.10.4606; SPIRO C, 1995, J BIOL CHEM, V270, P27702, DOI 10.1074/jbc.270.46.27702; SUEOKA N, 1959, NATURE, V183, P1429, DOI 10.1038/1831429a0; SUN PQ, 1995, J BIOL CHEM, V270, P7041, DOI 10.1074/jbc.270.13.7041; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tully T, 1997, P NATL ACAD SCI USA, V94, P4239, DOI 10.1073/pnas.94.9.4239; van Holde K. E., 1985, PHYSICAL BIOCH, P110; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Walker WH, 1996, J BIOL CHEM, V271, P20145, DOI 10.1074/jbc.271.33.19668; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YUN Y, 1990, MOL ENDOCRINOL, V4, P931, DOI 10.1210/mend-4-6-931	59	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20820	20827		10.1074/jbc.273.33.20820	http://dx.doi.org/10.1074/jbc.273.33.20820			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694827	hybrid			2022-12-25	WOS:000075386100020
J	Zhou, ZF; Gong, QM; Epstein, ML; January, CT				Zhou, ZF; Gong, QM; Epstein, ML; January, CT			HERG channel dysfunction in human long QT syndrome - Intracellular transport and functional defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER K+ CHANNEL; POTASSIUM CHANNEL; CARDIAC-ARRHYTHMIA; QUALITY-CONTROL; MISSENSE MUTATION; SECRETORY PATHWAY; MOLECULAR-BASIS; PROTEIN; RESIDUES; FAMILY	Mutations in HERG are associated with human chromosome 7-linked congenital long QT (LQT-2) syndrome. We used electrophysiological, biochemical, and immunohistochemical methods to study the molecular mechanisms of HERG channel dysfunction caused by LQT-2 mutations. Wild type HERG and LQT-2 mutations were studied by stable and transient expression in HEK 293 cells. We found that some mutations (Y611H and V822M) caused defects in biosynthetic processing of HERO channels with the protein retained in the endoplasmic reticulum. Other mutations (I593R and G628S) were processed similarly to wild type HERO protein, but these mutations did not produce functional channels. In contrast, the T474I mutation expressed HERO current but with altered gating properties. These findings suggest that the loss of HERG channel function in LQT-2 mutations is caused by multiple mechanisms including abnormal channel processing, the generation of nonfunctional channels, and altered channel gating.	Univ Wisconsin, Dept Med, Cardiol Sect, Madison, WI 53792 USA; Univ Wisconsin, Dept Anat, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	January, CT (corresponding author), Univ Wisconsin, Hosp & Clin, Dept Med Cardiol, Room H6-352,600 Highland Ave, Madison, WI 53792 USA.	ctj@medicine.wisc.edu						Benson DW, 1996, CIRCULATION, V93, P1791, DOI 10.1161/01.CIR.93.10.1791; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; EBELING W, 1974, EUR J BIOCHEM, V47, P91, DOI 10.1111/j.1432-1033.1974.tb03671.x; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JANUARY CT, 1997, ELECTROCARDIOLOGY 96, P231; Kiehn J, 1996, CIRCULATION, V94, P2572, DOI 10.1161/01.CIR.94.10.2572; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martin MG, 1996, NAT GENET, V12, P216, DOI 10.1038/ng0296-216; Mohammad S, 1997, AM J PHYSIOL-HEART C, V273, pH2534, DOI 10.1152/ajpheart.1997.273.5.H2534; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; Nie L, 1998, BIOPHYS J, V74, pA213; PLANELLSCASES R, 1995, P NATL ACAD SCI USA, V92, P9422, DOI 10.1073/pnas.92.20.9422; Priori Silvia G., 1997, Circulation, V96, pI212; Rampe D, 1997, FEBS LETT, V417, P28, DOI 10.1016/S0014-5793(97)01249-0; Riezman H, 1997, SCIENCE, V278, P1728, DOI 10.1126/science.278.5344.1728; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; Satler CA, 1996, AM J MED GENET, V65, P27, DOI 10.1002/(SICI)1096-8628(19961002)65:1<27::AID-AJMG4>3.3.CO;2-J; Satler CA, 1998, HUM GENET, V102, P265, DOI 10.1007/s004390050690; SCHULTEIS CT, 1995, BIOCHEMISTRY-US, V34, P1725, DOI 10.1021/bi00005a029; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; Shi WM, 1997, J NEUROSCI, V17, P9423; Snyders DJ, 1996, MOL PHARMACOL, V49, P949; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; Tanaka T, 1997, CIRCULATION, V95, P565, DOI 10.1161/01.CIR.95.3.565; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Vesely Mark R., 1997, Circulation, V96, pI56; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1998, BIOPHYS J, V74, pA26	41	305	313	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21061	21066		10.1074/jbc.273.33.21061	http://dx.doi.org/10.1074/jbc.273.33.21061			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694858	hybrid			2022-12-25	WOS:000075386100051
J	Cao, WH; Garcia-Blanco, MA				Cao, WH; Garcia-Blanco, MA			A serine/arginine-rich domain in the human U1 70k protein is necessary and sufficient for ASF/SF2 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; 5' SPLICE-SITE; SMALL NUCLEAR RIBONUCLEOPROTEIN; SR PROTEINS; PREMESSENGER RNA; 5'-SPLICE-SITE RECOGNITION; DROSOPHILA-MELANOGASTER; ASSEMBLY PATHWAY; SNRNP PROTEIN; IDENTIFICATION	Critical protein-protein interactions among pre-mRNA splicing factors determine splicing efficiency and specificity. The serine/arginine proteins, a family of factors characterized by the presence of an RNA recognition motif and an arginine/serine domain, are essential for constitutive splicing and required for some alternative splicing decisions. ASF/SF2, SC35, and other members of the serine/arginine family, interact with the 70k protein of the U1 small nuclear ribonucleoprotein. The binding of this protein with ASF/SF2 is thought to enhance recognition of the 5' splice site of pre-mRNAs by the U1 small nuclear ribonucleoprotein. It has been clearly documented that the arginine/serine domain of ASF/SF2 is responsible for binding to the U1 70k protein. In this manuscript we characterize the segment in the human UI 70k protein that is both necessary and sufficient for ASF/SF2 binding. A domain within this segment, which begins with Arg(240) and ends with Asp(270), was shown to bind specifically to the arginine/serine domain of ASF/ SF2 using a yeast two-hybrid system and a far Western assay. Mutational analysis of this segment suggested that several arginines are critical for the interaction with ASF/SFS and for phosphorylation by SRPK1, Inspection of the sequence of the Arg(248) to Asp(270) region suggested this as an arsnine/serine-like domain in U1 70k protein, and the data presented in this manuscript strongly support this view. Inspection of the human U1 70k protein sequence, comparison with homologues in other animal species, and mutational analysis indicated the importance of the sequence Arg-Arg-Arg-Ser-Arg-Ser-Arg-Asp, which is found repeated twice in the region from Arg(248) to Asp(270) in the human protein.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Levine Sci Res Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Levine Sci Res Ctr, Dept Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Levine Sci Res Ctr, Dept Med, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Garcia-Blanco, MA (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Levine Sci Res Ctr, Box 3686, Durham, NC 27710 USA.							AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BILLINGS PB, 1982, J IMMUNOL, V128, P1176; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; Cao WH, 1997, RNA, V3, P1456; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; FU XD, 1995, RNA, V1, P663; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, P NATL ACAD SCI USA, V87, P3338, DOI 10.1073/pnas.87.9.3338; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; HILLEREN PJ, 1995, MOL CELL BIOL, V15, P6341; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MANCEBO R, 1990, MOL CELL BIOL, V10, P2492, DOI 10.1128/MCB.10.6.2492; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; PETZER S, 1997, RNA, V3, P344; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROSCIGNO RF, 1995, RNA, V1, P692; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10373, DOI 10.1093/nar/15.24.10373; SUNE C, 1995, J VIROL, V69, P3098; TARN WY, 1995, P NATL ACAD SCI USA, V92, P2504, DOI 10.1073/pnas.92.7.2504; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	49	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20629	20635		10.1074/jbc.273.32.20629	http://dx.doi.org/10.1074/jbc.273.32.20629			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685421	hybrid			2022-12-25	WOS:000075305400098
J	Le, H; Browning, KS; Gallie, DR				Le, H; Browning, KS; Gallie, DR			The phosphorylation state of the wheat translation initiation factors eIF4B, eIF4A, and eIF2 is differentially regulated during seed development and germination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; CASEIN KINASE-II; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; CONTROLLED REPRESSOR; ALPHA-SUBUNIT; GERM; BINDING; CELLS; YEAST	The translation initiation factors (eIF) 4B and eIF2 are phosphoproteins whose phosphorylation state differs between mature seed and leaves, We examined the isoforms of eIF4B and the alpha and beta subunits of eIF2 during the development and germination of wheat seed to determine whether the differences in their phosphorylation state are because of tissue-specific regulation or occur concomitant with changes in protein synthetic activity during development. eIF2 alpha underwent phosphorylation through several intermediate isoforms that correlated with the increase and subsequent reduction in protein synthetic activity characteristic of seed development. eIF2 beta and eIF4B, present as highly phosphorylated isoforms during early seed development, underwent dephosphorylation during late development. eIF4B was rapidly phosphorylated within 20 h of germination, whereas eIF2 alpha did not undergo dephosphorylation until 48-60 h of growth. A third factor, eIF4A, was predominantly nonphosphorylated throughout most of seed development and germination. These observations suggest that the phosphorylation state of eIF2 alpha, eIF2 beta, and eIF4B is developmentally regulated in a way that correlates with the changes in protein synthetic activity but that some differences were also observed.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of California System; University of California Riverside; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Gallie, DR (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	drgallie@citrus.ucr.edu						ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; BENNE R, 1980, EUR J BIOCHEM, V104, P109, DOI 10.1111/j.1432-1033.1980.tb04406.x; BENNETT MD, 1973, PHILOS T R SOC B, V266, P39, DOI 10.1098/rstb.1973.0036; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNING KS, 1989, J BIOL CHEM, V264, P8491; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; CHEN D, 1968, AGROCHIMICA, V12, P389; CLARKE RD, 1987, MOL CELL BIOCHEM, V74, P129; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; DELSENY M, 1994, STRESS INDUCED GENE, P25; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; EVERS AD, 1970, ANN BOT-LONDON, V34, P547, DOI 10.1093/oxfordjournals.aob.a084390; FENG L, 1994, MOL CELL BIOL, V14, P5139, DOI 10.1128/MCB.14.8.5139; GALLIE DR, 1995, PLANT PHYSIOL, V108, P1703, DOI 10.1104/pp.108.4.1703; Gallie DR, 1997, J BIOL CHEM, V272, P1046, DOI 10.1074/jbc.272.2.1046; GREENE FC, 1985, CEREAL CHEM, V62, P398; GREENE FC, 1983, PLANT PHYSIOL, V71, P40, DOI 10.1104/pp.71.1.40; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; JARAMILLO M, 1990, BIOCHIM BIOPHYS ACTA, V1050, P134, DOI 10.1016/0167-4781(90)90154-T; JEFFREY IW, 1990, BIOCHIMIE, V72, P751, DOI 10.1016/0300-9084(90)90160-I; KRAMER G, 1981, CURR TOP CELL REGUL, V20, P185; Lasko P., 1995, Molecular Biology of the Cell, V6, p80A; LAX SR, 1986, J BIOL CHEM, V261, P5632; Le H, 1997, EUR J BIOCHEM, V243, P350, DOI 10.1111/j.1432-1033.1997.0350a.x; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MARCUS A, 1964, P NATL ACAD SCI USA, V51, P1075, DOI 10.1073/pnas.51.6.1075; MARCUS A, 1966, PLANT PHYSIOL, V41, P1167, DOI 10.1104/pp.41.7.1167; MEHTA HB, 1986, J BIOL CHEM, V261, P6705; MERRICK WC, 1994, BIOCHIMIE, V76, P822, DOI 10.1016/0300-9084(94)90183-X; Metz AM, 1997, ARCH BIOCHEM BIOPHYS, V342, P187, DOI 10.1006/abbi.1997.0119; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; ROMERO DP, 1986, MOL CELL BIOL, V6, P1044, DOI 10.1128/MCB.6.4.1044; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SEAL SN, 1983, J BIOL CHEM, V258, P573; SPIEGEL S, 1975, NATURE, V256, P228, DOI 10.1038/256228a0; TERCELAFORGUE T, 1987, PHYSIOL PLANTARUM, V69, P105, DOI 10.1111/j.1399-3054.1987.tb01952.x; WEBSTER C, 1991, J BIOL CHEM, V266, P23341; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8	49	34	38	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20084	20089		10.1074/jbc.273.32.20084	http://dx.doi.org/10.1074/jbc.273.32.20084			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685349	hybrid			2022-12-25	WOS:000075305400026
J	Pease, JE; Wang, J; Ponath, PD; Murphy, PM				Pease, JE; Wang, J; Ponath, PD; Murphy, PM			The N-terminal extracellular segments of the chemokine receptors CCR1 and CCR3 are determinants for MIP-1 alpha and eotaxin binding, respectively, but a second domain is essential for efficient receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; AMINO TERMINUS; HIV-1 ENTRY; LIGAND; CHEMOATTRACTANT; RANTES; CXC; SELECTIVITY	CCR1 and CCR3 are seven-transmembrane domain G protein-coupled receptors specific for members of the CC chemokine subgroup of leukocyte chemoattractants, Both have been implicated in the inflammatory response, and CCR3, through its expression on eosinophils, basophils, and Th2 lymphocytes, may be especially important in allergic inflammation. CCR1 and CCR3 are 54% identical in amino acid sequence and share some ligands but not others. In particular, macrophage inflammatory protein la (MIP-la) is a ligand for CCR1 but not CCR3, and eotaxin is a ligand for CCR3 but not CCR1. To map ligand selectivity determinants and to guide rational antagonist design, we analyzed CCR1: CCR3 chimeric receptors, When expressed in mouse pre-B cells, chimeras in which the N-terminal extracellular segments were switched were both able to bind both MIP-1 alpha and eotaxin, but in each case, binding occurred via separate sites. Nevertheless, neither MIP-1 alpha nor eotaxin were effective agonists at either chimeric receptor in either calcium flux or chemotaxis assays. These data are consistent with a multi-site model for chemokine-chemokine receptor interaction in which one or more subsites determine chemokine selectivity, but others are needed for receptor activation. Agents that bind to the N-terminal segments of CCR1 and CCR3 may be useful in blocking receptor function.	Univ Sheffield, Krebs Inst, Sheffield S10 2TN, S Yorkshire, England; NIAID, Host Def Lab, Bethesda, MD 20892 USA; LeukoSite Inc, Cambridge, MA 02142 USA	University of Sheffield; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Ponath, PD (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Div Biomed Sci, Exhibit Rd, London SW7 2AZ, England.		Pease, James/X-4521-2018	Pease, James/0000-0003-3749-0341				Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Alkhatib G, 1997, J BIOL CHEM, V272, P19771, DOI 10.1074/jbc.272.32.19771; Alkhatib G, 1997, J BIOL CHEM, V272, P20420, DOI 10.1074/jbc.272.33.20420; ARAI H, 1997, P NATL ACAD SCI USA, V94, P14485; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Berger EA, 1997, AIDS, V11, pS3; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLUBB RT, 1994, FEBS LETT, V338, P93, DOI 10.1016/0014-5793(94)80123-1; COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673; COMBADIERE C, 1995, J BIOL CHEM, V270, P30235; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GAU JL, 1997, J EXP MED, V185, P1959; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; Gerard C, 1997, J CLIN INVEST, V100, P2022, DOI 10.1172/JCI119734; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LU ZH, 1995, J BIOL CHEM, V270, P26239; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Monteclaro FS, 1997, J BIOL CHEM, V272, P23186, DOI 10.1074/jbc.272.37.23186; MURPHY PM, 1996, CYTOKINE GROWTH F R, V12, P593; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; PEASE JE, 1998, IN PRESS SEMIN IMMUN; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Su SB, 1996, J LEUKOCYTE BIOL, V60, P658, DOI 10.1002/jlb.60.5.658; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373	44	91	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19972	19976		10.1074/jbc.273.32.19972	http://dx.doi.org/10.1074/jbc.273.32.19972			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685332	hybrid			2022-12-25	WOS:000075305400009
J	Ruckman, J; Green, LS; Beeson, J; Waugh, S; Gillette, WL; Henninger, DD; Claesson-Welsh, L; Janjic, N				Ruckman, J; Green, LS; Beeson, J; Waugh, S; Gillette, WL; Henninger, DD; Claesson-Welsh, L; Janjic, N			2 '-fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF(165)) - Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; HIGH-AFFINITY; CELL MITOGEN; IN-VIVO; CHEMICAL MODIFICATION; HAMMERHEAD RIBOZYMES; MESSENGER-RNAS; TUMOR-GROWTH; MOUSE MODEL; FACTOR-B	Vascular endothelial growth factor (VEGF) has been implicated in the pathological induction of new blood vessel growth in a variety of proliferative disorders. Using the SELEX process (Systematic evolution of ligands by exponential enrichment), we have isolated 2'-F-pyrimidine RNA oligonucleotide ligands (aptamers) to human VEGF(165). Representative aptamers from three distinct sequence families were truncated to the minimal sequence capable of high affinity binding to VEGF (23-29 nucleotides) and were further modified by replacement of 2'-O-methyl for 2'-OH at all ribopurine positions where the substitution was tolerated. Equilibrium dissociation constants for the interaction of VEGF with the truncated, 2'-O-methyl-modified aptamers range between 49 and 130 pM, These aptamers bind equally well to murine VEGF(164), do not bind to VEGF(121) or the smaller isoform of placenta growth factor (PlGF(129)), and show reduced, but significant affinity for the VEGF(165)/PlGF(129) heterodimer. Cysteine 137 in the exon 7-encoded domain of VEGF(165) forms a photo-inducible cross-link to a single uridine residue in each of the three aptamers. The aptamers potently inhibit the binding of VEGF to the human VEGF receptors, KDR and Flt-1, expressed by transfected porcine aortic endothelial cells. Furthermore, one of the aptamers is able to significantly reduce intradermal VEGF-induced vascular permeability in vivo.	NeXstar Pharmaceut Inc, Boulder, CO 80301 USA; Biomed Ctr, Dept Med & Physiol Chem, S-75123 Uppsala, Sweden		Ruckman, J (corresponding author), NeXstar Pharmaceut Inc, Boulder, CO 80301 USA.							ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; AURUP H, 1994, NUCLEIC ACIDS RES, V22, P20, DOI 10.1093/nar/22.1.20; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BEIGELMAN L, 1995, J BIOL CHEM, V270, P25702, DOI 10.1074/jbc.270.43.25702; Brown L F, 1997, EXS, V79, P233; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CUMMINS LL, 1995, NUCLEIC ACIDS RES, V23, P2019, DOI 10.1093/nar/23.11.2019; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; EATON BE, 1995, CHEM BIOL, V2, P633, DOI 10.1016/1074-5521(95)90023-3; EILINGTON A, 1990, NATURE, V346, P818; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; Fitzwater T, 1996, METHOD ENZYMOL, V267, P275; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GILL SC, 1991, J MOL BIOL, V220, P307, DOI 10.1016/0022-2836(91)90015-X; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GREEN L, 1995, J MOL BIOL, V247, P60, DOI 10.1006/jmbi.1994.0122; Green LS, 1996, BIOCHEMISTRY-US, V35, P14413, DOI 10.1021/bi961544+; GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2; GUSCHLBAUER W, 1980, NUCLEIC ACIDS RES, V8, P1421, DOI 10.1093/nar/8.6.1421; JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028; JENISON RD, 1998, IN PRESS ANTISENSE N, V8; Joukov V, 1996, EMBO J, V15, P290; KAKIUCHI N, 1982, J BIOL CHEM, V257, P1924; KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOCH AE, 1994, J IMMUNOL, V152, P4149; KONIGSBERG W, 1969, METHOD ENZYMOL, V13, P185; Kubik MF, 1997, J IMMUNOL, V159, P259; Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LESNIK EA, 1993, BIOCHEMISTRY-US, V32, P7832, DOI 10.1021/bi00081a031; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; Meisenheimer KM, 1997, CRIT REV BIOCHEM MOL, V32, P101, DOI 10.3109/10409239709108550; Melnyk O, 1996, CANCER RES, V56, P921; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MILLER PS, 1993, NUCLEOS NUCLEOT, V12, P785, DOI 10.1080/07328319308018549; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Norris CL, 1996, J AM CHEM SOC, V118, P5796, DOI 10.1021/ja9607852; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Pagratis NC, 1997, NAT BIOTECHNOL, V15, P68, DOI 10.1038/nbt0197-68; PARK JE, 1994, J BIOL CHEM, V269, P25646; PETERSHEIM M, 1983, BIOCHEMISTRY-US, V22, P256, DOI 10.1021/bi00271a004; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; TAKAHASHI A, 1994, CANCER RES, V54, P4233; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Yoshiji H, 1996, CANCER RES, V56, P2013	75	569	648	2	102	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20556	20567		10.1074/jbc.273.32.20556	http://dx.doi.org/10.1074/jbc.273.32.20556			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685413	hybrid			2022-12-25	WOS:000075305400090
J	Swanson, KD; Reigh, C; Landreth, GE				Swanson, KD; Reigh, C; Landreth, GE			ATP-stimulated activation of the mitogen-activated protein kinases through ionotrophic P2X2 purinoreceptors in PC12 cells - Difference in purinoreceptor sensitivity in two PC12 cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM INFLUX; PHEOCHROMOCYTOMA CELLS; NOREPINEPHRINE RELEASE; EXTRACELLULAR ATP; P-2 RECEPTORS; GROWTH-FACTOR; MAP KINASE; CHANNELS; ASTROCYTES; SECRETION	Extracellular purine nucleotides elicit a diverse range of biological responses through binding to specific cell surface receptors, The ionotrophic P2X subclass of purinoreceptors respond to ATP by stimulation of calcium ion permeability; however, it is unknown how P2X purinoreceptor activation is linked to intracellular signaling pathways. We report that stimulation of PC12 cells with ATP results in the activation of the mitogen-activated protein (MAP) kinases ERK1 and ERK2 and was wholly dependent upon extracellular calcium ions. Treatment of the cells with adenosine, AMP, ADP, UTP, or alpha,beta-methylene ATP was without effect; however, MAP kinase activation was abolished by pretreatment with suramin and reactive blue 2, The calcium-activated tyrosine kinase, Pyk2, acts as an upstream regulator of the MAP kinases and became tyrosine phosphorylated following treatment of the cells with ATP, We have ruled out the involvement of depolarization-mediated calcium influx because specific blockers of voltage-gated calcium channels did not affect MAP kinase activation. These data provide direct evidence that calcium influx through P2X2 receptors results in the activation of the MAP kinase cascade, Finally, we demonstrate that a different line of PC12 cells respond to ATP through P2Y2 purinoreceptors, providing an explanation for the conflicting findings of purine nucleotide responsiveness in PC12 cells.	Case Western Reserve Univ, Alzheimers Res Lab, Sch Med, Dept Neurol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Alzheimers Res Lab, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Landreth, GE (corresponding author), Case Western Reserve Univ, Alzheimers Res Lab, Sch Med, Dept Neurol, E504,10900 Euclid Ave, Cleveland, OH 44106 USA.				NIA NIH HHS [AG-00105] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRY VA, 1994, J CELL SCI, V107, P451; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brake AJ, 1996, ANNU REV CELL DEV BI, V12, P519, DOI 10.1146/annurev.cellbio.12.1.519; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Giniatullin R, 1996, BRIT J PHARMACOL, V119, P1045, DOI 10.1111/j.1476-5381.1996.tb15776.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; INOUE K, 1991, BRIT J PHARMACOL, V102, P581, DOI 10.1111/j.1476-5381.1991.tb12216.x; INOUE K, 1989, NEUROSCI LETT, V106, P294, DOI 10.1016/0304-3940(89)90179-1; KIM WK, 1994, J BIOL CHEM, V269, P6471; King BF, 1996, NEUROSCIENCE, V74, P1187, DOI 10.1016/0306-4522(96)00209-6; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MAJID MA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P283, DOI 10.1016/0167-4889(92)90118-U; Michel AD, 1996, N-S ARCH PHARMACOL, V354, P562; NEARY JT, 1994, NEUROREPORT, V5, P1617, DOI 10.1097/00001756-199408150-00019; NEARY JT, 1994, J NEUROCHEM, V63, P490; Neary JT, 1996, TRENDS NEUROSCI, V19, P13, DOI 10.1016/0166-2236(96)81861-3; NIKODIJEVIC B, 1994, CELL MOL NEUROBIOL, V14, P27, DOI 10.1007/BF02088587; RHOADS AR, 1993, J NEUROCHEM, V61, P1657, DOI 10.1111/j.1471-4159.1993.tb09800.x; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SELA D, 1991, J BIOL CHEM, V266, P17990; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Vulchanova L, 1996, P NATL ACAD SCI USA, V93, P8063, DOI 10.1073/pnas.93.15.8063; [No title captured]	30	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19965	19971		10.1074/jbc.273.32.19965	http://dx.doi.org/10.1074/jbc.273.32.19965			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685331	hybrid			2022-12-25	WOS:000075305400008
J	Genschel, J; Littman, SJ; Drummond, JT; Modrich, P				Genschel, J; Littman, SJ; Drummond, JT; Modrich, P			Isolation of MutS beta from human cells and comparison of the mismatch repair specificities of MutS beta and MutS alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TUMOR-CELLS; ENDOMETRIAL CANCER; NUCLEAR EXTRACTS; COLON-CANCER; MSH3 GENE; DNA; BINDING; HETERODIMER; MUTATIONS	A human MSH2-human MSH3 (hMSH2 . hMSH3) complex of approximately 1:1 stoichiometry (human MutS beta (hMutS beta)) has been demonstrated in several human tumor cell lines and purified to near homogeneity, In vitro, hMutS beta supports the efficient repair of insertion/deletion (I/D) heterologies of 2-8 nucleotides, is weakly active on a single-nucleotide I/D mispair, and is not detectably active on the eight base-base mismatches, Human MutS alpha (hMutS alpha), a heterodimer of hMSH2 and hMSH6, efficiently supports the repair of single-nucleotide IID mismatches, base-base mispairs, and all substrates tested that were repaired by hMutS beta, Thus, the repair specificities of hMutS alpha and hMutS beta are redundant with respect to the repair of I/D heterologies of 2-8 nucleotides. The hMutSa level in repair-proficient HeLa cells (1.5 mu g/mg nuclear extract) is approximately 10 times that of hMutS beta. In HCT-15 colorectal tumor cells, which do not contain hMSH6 and consequently lack hMutS alpha, the hMutS beta level is elevated severalfold relative to that in HeLa cells and is responsible for the repair of I/D mismatches that has been observed in this cell line. LoVo tumor cells, which are genetically deficient in hMSH2, lack both hMutS alpha and hMutS beta, and hMSH3 and hMSH6 levels are less than 4% of those found in repair-proficient cells. Coupled with previous findings (J. T. Drummond, J, Genschel, E. Wolf, and P. Modrich (1997) Proc. Natl. Acad Sci. U.S.A. 94, 10144-10149), these results suggest that hMSH2 partitions between available pools of hMSH3 and hMSH6 and indicate that hMSH2 positively modulates hMSH6 and hMSH3 levels, perhaps by stabilization of the polypeptides upon heterodimer formation.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Med Oncol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University	Modrich, P (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.			Modrich, Paul/0000-0001-8708-9885	NATIONAL CANCER INSTITUTE [K08CA071554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA71554] Funding Source: Medline; NIGMS NIH HHS [GM45190] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Akiyama Y, 1997, CANCER RES, V57, P3920; Alani E, 1996, MOL CELL BIOL, V16, P5604; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FUJII H, 1989, J BIOL CHEM, V264, P10057; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; Greene CN, 1997, MOL CELL BIOL, V17, P2844, DOI 10.1128/MCB.17.5.2844; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; INOKUCHI K, 1995, BIOCHEM BIOPH RES CO, V214, P171, DOI 10.1006/bbrc.1995.2271; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; Malkhosyan S, 1996, MUTAT RES-DNAGING G, V316, P249, DOI 10.1016/S0921-8734(96)90007-7; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Paques F, 1997, MOL CELL BIOL, V17, P6765, DOI 10.1128/MCB.17.11.6765; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; STRAND M, 1995, P NATL ACAD SCI USA, V92, P10418, DOI 10.1073/pnas.92.22.10418; SU SS, 1988, J BIOL CHEM, V263, P6829; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; Umar A, 1997, CANCER RES, V57, P3949; Yamamoto H, 1998, CANCER RES, V58, P997	44	320	325	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19895	19901		10.1074/jbc.273.31.19895	http://dx.doi.org/10.1074/jbc.273.31.19895			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677427	hybrid			2022-12-25	WOS:000075125200079
J	Froeschle, A; Alric, S; Kitzmann, M; Carnac, G; Aurade, F; Rochette-Egly, C; Bonnieu, A				Froeschle, A; Alric, S; Kitzmann, M; Carnac, G; Aurade, F; Rochette-Egly, C; Bonnieu, A			Retinoic acid receptors and muscle b-HLH proteins: partners in retinoid-induced myogenesis	ONCOGENE			English	Article						retinoic acid receptors; muscle b-HLH proteins; protein-protein interaction; myogenesis	THYROID-HORMONE RECEPTOR; HELIX-LOOP-HELIX; BOX TRANSCRIPTION FACTORS; LIGAND-BINDING DOMAIN; CELL-LINE BA-HAN-1C; X RECEPTOR; NUCLEAR RECEPTORS; RXR-ALPHA; ALL-TRANS; IN-VITRO	The results reported here indicate that retinoic acid (RA) induces growth arrest and differentiation only in MyoD-expressing muscle cells. Transient transfection assays reveal a functional interaction between MyoD, a key myogenic regulator and RA-receptors, principal mediators of RA actions, Interestingly, we demonstrate that RXR-MyoD-containing complexes are recruited at specific MyoD DNA-binding sites in muscle cells, Furthermore, we also demonstrate that RA-receptors and the muscle basic helix-loop-helix (b-HLH) proteins interact physically. Mutational analysis suggests that this interaction occurs via the basic region of muscle b-HLH proteins and the DIVA-binding domain of RA-receptors and is important for functional interactions between these two families of transcription factors. In conclusion, these results highlight novel interactions between two distinct groups of regulatory proteins that influence cell growth and differentiation.	INRA, Lab Differenciat Cellulaire & Croissance, F-34060 Montpellier 1, France; CNRS, CRBM, Cell Biol Unit, F-34033 Montpellier, France; Inst Pasteur, Dept Biol Mol, URA 1148 CNRS, F-75724 Paris 15, France; CU Strasbourg, GBMC, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	INRAE; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bonnieu, A (corresponding author), INRA, Lab Differenciat Cellulaire & Croissance, Pl Pierre Viala, F-34060 Montpellier 1, France.		Bonnieu, Anne/ABA-7182-2020; Carnac, Gilles/N-6744-2018	Carnac, Gilles/0000-0002-3518-8774				ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/j.1432-0436.1993.tb00632.x; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; ARNOLD HH, 1992, J CELL BIOL, V118, P877, DOI 10.1083/jcb.118.4.877; BENGAL E, 1994, P NATL ACAD SCI USA, V91, P6221, DOI 10.1073/pnas.91.13.6221; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DE LUCA LM, 1991, FASEB J, V5, P2924; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Froeschle A, 1996, ONCOGENE, V12, P411; GABBERT HE, 1988, CANCER RES, V48, P5264; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Groisman R, 1996, J BIOL CHEM, V271, P5258; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Gudas L. J., 1994, RETINOIDS BIOL CHEM, P443; HALEVY O, 1993, J CELL PHYSIOL, V154, P566, DOI 10.1002/jcp.1041540315; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hofmann Clementine, 1994, P387; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE IJ, 1994, P NATL ACAD SCI USA, V91, P1647, DOI 10.1073/pnas.91.5.1647; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MOMOI T, 1992, BIOCHEM BIOPH RES CO, V187, P245, DOI 10.1016/S0006-291X(05)81484-6; Montarras D, 1996, J CELL SCI, V109, P551; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; REZNIKOFF CA, 1973, CANCER RES, V33, P3239; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; VANDROMME M, 1995, P NATL ACAD SCI USA, V92, P4646, DOI 10.1073/pnas.92.10.4646; VOMBAUR E, 1995, EMBO J, V15, P110; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	79	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	1998	16	26					3369	3378		10.1038/sj.onc.1201894	http://dx.doi.org/10.1038/sj.onc.1201894			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692544				2022-12-25	WOS:000074544100003
J	Fukuda, K; Kawata, S; Tamura, S; Matsuda, Y; Inui, Y; Igura, T; Inoue, S; Kudara, T; Matsuzawa, Y				Fukuda, K; Kawata, S; Tamura, S; Matsuda, Y; Inui, Y; Igura, T; Inoue, S; Kudara, T; Matsuzawa, Y			Transforming growth factor-beta 1-induced degradation of activated Src tyrosine kinase in rat fibroblasts	ONCOGENE			English	Article						TGF-beta 1; c-Src; v-Src; MAPK; PDGF	HUMAN-COLON-CARCINOMA; FACTOR-BETA-RECEPTOR; SMOOTH-MUSCLE CELLS; ROUS-SARCOMA VIRUS; TGF-BETA; PHOSPHOLIPASE C-GAMMA-1; ANGIOTENSIN-II; CANCER CELLS; INHIBITION; FAMILY	Transforming growth factors-beta (TGF-beta s) play pivotal roles in the regulation of cell growth and differentiation, although little is known regarding the regulation of cytoplasmic components by TGF-beta s, Src tyrosine kinase is required for signal transduction of various cytokine receptors, including epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and G-protein coupled receptors, Moreover, Src tyrosine kinase is important in signal cross-talk between these receptors, To determine whether Src kinase is also involved in TGF-beta signaling,,ce examined the effects of TGF-beta 1 on Src in the rat fibroblast cell line 3Y1 and in v-Src-transformed 3Y1 (SR-3Y1), TGF-beta 1 inhibited mitogen-activated protein kinase activity and inhibited growth in SR-3Y1 cells, while it did not affect the growth of 3Y1 cells. TGF-beta 1 significantly decreased v-Src kinase activity and protein abundance in SR-3Y1 cells, mainly by accelerating the degradation of v-Src. In contrast, in 3Y1 cells, TGF-beta 1 did not affect c-Src abundance or kinase activity. However, upon activation of c-Src in 3Y1 cells by PDGF, TGF-beta 1 decreased Src abundance. Additionally, in 3Y1 cells transfected with an activated c-Src mutant which lacks the SH3 domain, its level was decreased by TGF-beta 1 treatment. These findings suggest that TGF-beta 1 specifically induces degradation of activated Src kinase, This may be a novel mechanism for cross-talk between growth factors and TGF-beta.	Osaka Univ, Sch Med, Dept Internal Med 2, Suita, Osaka 565, Japan	Osaka University	Fukuda, K (corresponding author), Osaka Univ, Sch Med, Dept Internal Med 2, 2-2 Yamadaoka, Suita, Osaka 565, Japan.							ATFI A, 1994, J BIOL CHEM, V269, P30688; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; FILMUS J, 1992, ONCOGENE, V7, P521; GRUPPUSO PA, 1991, J BIOL CHEM, V266, P3444; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HOWE PH, 1993, J BIOL CHEM, V268, P21448; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KISO S, 1994, HEPATOLOGY, V20, P1303, DOI 10.1016/0270-9139(94)90772-2; Knaus PI, 1996, MOL CELL BIOL, V16, P3480; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kumble S, 1997, GASTROENTEROLOGY, V112, P348, DOI 10.1053/gast.1997.v112.pm9024288; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LESCHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; MORI S, 1993, J BIOL CHEM, V268, P577; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; Oshikawa O, 1996, BIOCHEM BIOPH RES CO, V222, P770, DOI 10.1006/bbrc.1996.0819; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARK S, 1992, J BIOL CHEM, V267, P17194; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PENG ZY, 1995, ONCOGENE, V11, P1955; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Song QZ, 1996, J EXP MED, V184, P619, DOI 10.1084/jem.184.2.619; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	50	15	16	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3349	3356		10.1038/sj.onc.1201896	http://dx.doi.org/10.1038/sj.onc.1201896			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692542				2022-12-25	WOS:000074544100001
J	Carrere, S; Verger, A; Flourens, A; Stehelin, D; Duterque-Coquillaud, M				Carrere, S; Verger, A; Flourens, A; Stehelin, D; Duterque-Coquillaud, M			Erg proteins, transcription factors of the Ets family, form homo, heterodimers and ternary complexes via two distinct domains	ONCOGENE			English	Article						Ets family; protein interaction; transcription regulation	DNA-BINDING MOTIF; MURINE ETS-1; SECONDARY STRUCTURE; MOLECULAR-CLONING; GENE-EXPRESSION; ONCOGENE; MEMBER; CELLS; PEA3; PROTOONCOGENES	The ets genes family encodes a group of proteins which function as transcription factors under physiological conditions. We report here that the Erg proteins, members of the Ets family, form homo and heterodimeric complexes in vitro. We demonstrate that the Ergp55 protein isoform forms dimers,vith itself and with the two other isoforms, Ergp49 and Ergp38. Using a set of Erg protein deletion mutants, we define two distinct domains independently involved in dimerization. The first one is located in the amino-terminal part of the protein containing the pointed domain (PNT), conserved in a subset of Ets proteins. The second one resides within the ETS domain, the DNA-binding domain. We also show that the Erg protein central region behaves as an inhibitory domain of dimerization and its removal enhances the Ergp55 transactivation properties. Furthermore, Ergp55 forms heterodimers with some other Ets proteins. Among the latter, we show that Fli-1, Ets-2, Er81 and Pu-1 physically interact with Erg. Finally, rye show that the formation of the previously described ternary complex Ergp55/Fos/jun is mediated by ETS domain and Jun protein, while the ternary complex Ergp49/Fos/Jun is mediated by Fos protein.	Inst Biol, CNRS, UMR 319, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS)	Duterque-Coquillaud, M (corresponding author), Inst Biol, CNRS, UMR 319, BP447,1 Rue Calmette, F-59021 Lille, France.			verger, alexis/0000-0002-0299-2344; Duterque-Coquillaud, Martine/0000-0003-3943-5629				Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BAUD V, 1991, GENOMICS, V11, P223, DOI 10.1016/0888-7543(91)90124-W; Bornemann D, 1996, DEVELOPMENT, V122, P1621; Buttice G, 1996, ONCOGENE, V13, P2297; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GRAVES BJ, 1998, IN PRESS ADV CANC RE, V75; Grevin D, 1996, GENE, V174, P185, DOI 10.1016/0378-1119(96)00357-5; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; JEON IS, 1995, ONCOGENE, V10, P1229; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KHERROUCHE Z, 1998, ONCOGENE; KLAMBT C, 1993, DEVELOPMENT, V117, P163; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Melet F, 1996, MOL CELL BIOL, V16, P2708; MONTE D, 1994, ONCOGENE, V9, P1397; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; SETH A, 1990, ONCOGENE, V5, P1761; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920	42	88	91	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3261	3268		10.1038/sj.onc.1201868	http://dx.doi.org/10.1038/sj.onc.1201868			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681824				2022-12-25	WOS:000074343600006
J	Fotinou, C; Beauchamp, J; Emsley, P; deHaan, A; Schielen, WJG; Bos, E; Isaacs, NW				Fotinou, C; Beauchamp, J; Emsley, P; deHaan, A; Schielen, WJG; Bos, E; Isaacs, NW			Structure of an Fab fragment against a C-terminal peptide of hCG at 2.0 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; ANTIBODY-ANTIGEN INTERACTIONS; PROTEIN MODELS; BINDING-SITE; IMMUNOGLOBULINS	3A2 is an antibody raised against human chorionic gonadotropin and recognizes a linear epitope on the C-terminal peptide of the human chorionic gonadotropin P-subunit. Its three-dimensional structure has been determined to 2-Angstrom resolution using molecular replacement and refined to a conventional R-factor of 18.2%, The protein exhibits the typical immunoglobulin fold, and the model contains 944 ordered water molecules and one sulfate ion. A comparison of the complementarity-determining regions of the Fab3A2 with those from the Protein Data Bank following the canonical structure method reveals a canonical main chain conformation. This antibody belongs to the canonical structure class (combination of canonical conformations of the complementarity determining loops) that shows a preference for haptens and not for peptides, However, the shape of the surface of the antigen binding loops resembles that of an anti-peptide antibody.	Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland; NV Organon, Dept Biochem & Biotechnol, NL-5340 BH Oss, Netherlands; Organon Teknika BV, Chem Res Unit, NL-5280 AB Boxtel, Netherlands	University of Glasgow; Merck & Company	Isaacs, NW (corresponding author), Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland.	neil@chem.gla.ac.uk						AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banfield MJ, 1996, ACTA CRYSTALLOGR D, V52, P1107, DOI 10.1107/S0907444996007494; BERGER P, 1993, J CLIN ENDOCR METAB, V77, P347, DOI 10.1210/jc.77.2.347; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1988, XPLOR REFERENCE MANU; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Davies C, 1997, ACTA CRYSTALLOGR D, V53, P186, DOI 10.1107/S0907444996012048; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fotinou C, 1998, ACTA CRYSTALLOGR D, V54, P405, DOI 10.1107/S0907444997011074; HUSSA RO, 1981, LIGAND REV S2, V3, P6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABAT EA, 1991, 913242 NIH; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; MacCallum RM, 1996, J MOL BIOL, V262, P732, DOI 10.1006/jmbi.1996.0548; MANN K, 1983, CANCER, V52, P654, DOI 10.1002/1097-0142(19830815)52:4<654::AID-CNCR2820520415>3.0.CO;2-S; MARIUZZA RA, 1994, RES IMMUNOL, V145, P70, DOI 10.1016/S0923-2494(94)80048-0; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; Mikol V, 1996, ACTA CRYSTALLOGR D, V52, P534, DOI 10.1107/S0907444996000704; MORGAN FJ, 1975, J BIOL CHEM, V250, P5247; Murshudov GN, 1996, P CCP4 STUDY WEEKEND, P93; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1992, DATA COLLECTION PROC, P56; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; PADLAN EA, 1995, FASEB J, V9, P133, DOI 10.1096/fasebj.9.1.7821752; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RYAN RJ, 1987, RECENT PROG HORM RES, V43, P383; Shirai H, 1996, FEBS LETT, V399, P1, DOI 10.1016/S0014-5793(96)01252-5; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; VARGASMADRAZO E, 1995, J MOL BIOL, V254, P497, DOI 10.1006/jmbi.1995.0633; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; WU TT, 1993, PROTEINS, V16, P1, DOI 10.1002/prot.340160102	37	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22515	22518		10.1074/jbc.273.35.22515	http://dx.doi.org/10.1074/jbc.273.35.22515			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712877	hybrid			2022-12-25	WOS:000075616600053
J	Bishop, DK; Ear, U; Bhattacharyya, A; Calderone, C; Beckett, M; Weichselbaum, RR; Shinohara, A				Bishop, DK; Ear, U; Bhattacharyya, A; Calderone, C; Beckett, M; Weichselbaum, RR; Shinohara, A			Xrcc3 is required for assembly of Rad51 complexes in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; X-RAY RESISTANCE; SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; DNA-REPAIR; HOMOLOGOUS RECOMBINATION; ESCHERICHIA-COLI; RECA HOMOLOGS; IONIZING-RADIATION	Rad51 is a member of a family of eukaryotic proteins related to the bacterial recombinational repair protein RecA, Rad51 protein localizes to multiple subnuclear foci in Chinese hamster ovary cells. Subnuclear Rad51 foci are induced by ionizing radiation or the DNA crosslinking agent cisplatin. Formation of these foci is likely to reflect assembly of a multimeric form of Rad51 that promotes DNA repair. Formation of damage-induced Rad51 foci does not occur in the Chinese hamster ovary cell line irs1SF, which is sensitive to DNA damaging agents. The Rad51 focus formation defect of irs1SF cells is corrected by a construct that encodes the repair protein Xrcc3. Xrcc3 is a human homolog of Rad51 previously isolated by virtue of its ability to correct the radiation sensitivity of irs1SF cells. Changes in the steady state level of Rad51 protein do not account for the irs1SF defect nor do they account for the appearance of foci following DNA damage. These results suggest that Xrcc3 is required for the assembly or stabilization of a multimeric form of Rad51 during DNA repair. Cell Lines defective in two different components of DNA protein kinase formed Rad51 foci in response to damage, indicating DNA protein kinase is not required for damaged-induced mobilization of Rad51.	Univ Chicago, Med Ctr, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600055, Japan	University of Chicago; University of Chicago Medical Center; Osaka University	Bishop, DK (corresponding author), Univ Chicago, Med Ctr, Dept Radiat & Cellular Oncol, 5841 S Maryland Ave MC1105, Chicago, IL 60637 USA.	dbishop@midway.uchicago.edu						ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; Albala JS, 1997, GENOMICS, V46, P476, DOI 10.1006/geno.1997.5062; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ASHLEY T, 1995, CHROMOSOMA, V104, P19, DOI 10.1007/BF00352222; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; Errami A, 1996, MOL CELL BIOL, V16, P1519; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P435; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Habu T, 1996, NUCLEIC ACIDS RES, V24, P470, DOI 10.1093/nar/24.3.470; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; JACHYMCZYK WJ, 1981, MOL GEN GENET, V182, P196, DOI 10.1007/BF00269658; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRASIN F, 1977, J MOL BIOL, V116, P81, DOI 10.1016/0022-2836(77)90120-6; Li MJ, 1996, P NATL ACAD SCI USA, V93, P10222, DOI 10.1073/pnas.93.19.10222; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; LIU N, 1995, AM J HUM GENET S, V57, P147; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; Pittman DL, 1998, GENOMICS, V49, P103, DOI 10.1006/geno.1998.5226; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSS GM, 1995, CANCER RES, V55, P1235; Sato S, 1995, DNA Res, V2, P147, DOI 10.1093/dnares/2.3.147; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; STAHL FW, 1994, GENETICS, V138, P241; Stassen NY, 1997, CURR GENET, V31, P144, DOI 10.1007/s002940050189; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Tashiro S, 1996, ONCOGENE, V12, P2165; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; Thompson L. H., 1996, Environmental and Molecular Mutagenesis, V27, P68; THOMPSON LH, 1980, MUTAT RES, V74, P21, DOI 10.1016/0165-1161(80)90188-0; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Yamamoto A, 1996, MOL GEN GENET, V251, P1	56	235	239	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21482	21488		10.1074/jbc.273.34.21482	http://dx.doi.org/10.1074/jbc.273.34.21482			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705276	hybrid			2022-12-25	WOS:000075492600010
J	Heiska, L; Alfthan, K; Gronholm, M; Vilja, P; Vaheri, A; Carpen, O				Heiska, L; Alfthan, K; Gronholm, M; Vilja, P; Vaheri, A; Carpen, O			Association of ezrin with intercellular adhesion molecule-1 and -2 (ICAM-1 and ICAM-2) - Regulation by phosphatidylinositol 4,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING-SITE; ENDOTHELIAL-CELLS; ALPHA-ACTININ; INTRAMOLECULAR ASSOCIATION; INFLAMMATORY CYTOKINES; EXTRACELLULAR-MATRIX; SIGNALING PATHWAY; KINASE SUBSTRATE; MEMBRANE-PROTEIN; PLASMA-MEMBRANE	Ezrin is a cytoplasmic linker molecule between plasma membrane components and the actin-containing cytoskeleton. We studied whether ezrin is associated with intercellular adhesion molecule (ICAM)-1, 2, and -3. In transfected cells, ICAM-1 and ICAM-2 colocalized with ezrin in microvillar projections, whereas an ICAM-2 construct attached to cell membrane via a glycophosphatidyl-inositol anchor was uniformly distributed on the cell surface. An interaction of ICAM-2 and ezrin was seen by affinity precipitation, microtiter binding assay, coimmunoprecipitation, and surface plasmon resonance methods. The calculated K-D, value was 3.3 x 10(-7) M. Phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) induced an interaction of ezrin and ICAM-1 and enhanced the interaction of ezrin and ICAM-2, but ICAM-3 did not bind ezrin even in the presence of PtdIns(4,5)P-2. PtdIns(4,5)P-2 was shown to bind to cytoplasmic tails of ICAM-1 and ICAM-2, which are the first adhesion proteins demonstrated to interact with PtdIns(4,5)P-2. The results indicate an interaction of ezrin with ICAM-1 and ICAM-2 and suggest a regulatory role of phosphoinositide signaling pathways in regulation of ICAM-ezrin interaction.	Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; VTT Biotechnol & Food Res, FIN-02044 Espoo, Finland; Univ Tampere, Sch Med, FIN-33101 Tampere, Finland	University of Helsinki; University of Helsinki; VTT Technical Research Center Finland; Tampere University	Carpen, O (corresponding author), Univ Helsinki, Haartman Inst, Dept Pathol, POB 21 Haartmanink 3, FIN-00014 Helsinki, Finland.		Vaheri, Antti/AAV-1523-2020; Gronholm, Mikaela/B-4225-2010	Gronholm, Mikaela/0000-0002-2378-8924				ANDREOLI C, 1994, J CELL SCI, V107, P2509; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BERRYMAN M, 1993, J CELL SCI, V105, P1025; Bohling T, 1996, AM J PATHOL, V148, P367; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CAMPANERO MR, 1994, J CELL BIOL, V127, P867, DOI 10.1083/jcb.127.3.867; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DEFOUGEROLLES AR, 1994, J EXP MED, V179, P619, DOI 10.1084/jem.179.2.619; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DELPOZO MA, 1995, J CELL BIOL, V131, P495, DOI 10.1083/jcb.131.2.495; DIACOVO TG, 1994, J CLIN INVEST, V94, P1243, DOI 10.1172/JCI117442; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DUSTIN ML, 1986, J IMMUNOL, V137, P245; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; GILMORE AP, 1992, J CELL SCI, V103, P719; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Heiska L, 1996, J BIOL CHEM, V271, P26214, DOI 10.1074/jbc.271.42.26214; Helander TS, 1996, NATURE, V382, P265, DOI 10.1038/382265a0; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; LI R, 1993, J BIOL CHEM, V268, P17513; Lu PJ, 1997, J BIOL CHEM, V272, P466; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; McNamee HP, 1996, EXP CELL RES, V224, P116, DOI 10.1006/excr.1996.0118; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; NORTAMO P, 1991, EUR J IMMUNOL, V21, P2629, DOI 10.1002/eji.1830211049; NORTAMO P, 1991, J IMMUNOL, V146, P2530; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PAKKANEN R, 1988, EUR J CELL BIOL, V46, P435; PAKKANEN R, 1988, J CELL BIOCHEM, V38, P65, DOI 10.1002/jcb.240380107; Patey N, 1996, AM J PATHOL, V148, P465; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; SAMSON ML, 1989, CELL, V57, P1045, DOI 10.1016/0092-8674(89)90342-5; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TIISALA S, 1994, SCAND J IMMUNOL, V39, P249, DOI 10.1111/j.1365-3083.1994.tb03368.x; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TSUKITA S, 1997, CURR OPIN CELL BIOL, V9, P79; TURUNEN O, 1989, J BIOL CHEM, V264, P16727; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; Xian WJ, 1995, BIOPHYS J, V69, P2695, DOI 10.1016/S0006-3495(95)80140-2; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; YU FX, 1992, J BIOL CHEM, V267, P14616; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	62	271	276	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21893	21900		10.1074/jbc.273.34.21893	http://dx.doi.org/10.1074/jbc.273.34.21893			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705328	hybrid			2022-12-25	WOS:000075492600062
J	Pillutla, RC; Yue, ZY; Maldonado, E; Shatkin, AJ				Pillutla, RC; Yue, ZY; Maldonado, E; Shatkin, AJ			Recombinant human mRNA cap methyltransferase binds capping enzyme RNA polymerase IIo complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; GUANYLYLTRANSFERASE; PROTEIN; CELLS; GENE; 5'-TRIPHOSPHATASE; TRANSCRIPTION; PROMOTER; REOVIRUS	Guanine N-7 methylation is an essential step in the formation of the m(7)GpppN cap structure that is characteristic of eukaryotic mRNA 5' ends. The terminal 7-methylguanosine is recognized by cap-binding proteins that facilitate key events in gene expression including mRNA processing, transport, and translation. Here we describe the cloning, primary structure, and properties of human RNA (guanine-7-)methyltransferase. Sequence alignment of the 476-amino acid human protein with the corresponding yeast ABD1 enzyme demonstrated the presence of several conserved motifs known to be required for methyltransferase activity. We also identified a Drosophila open reading frame that encodes a putative RNA (guanine-7-)methyltransferase and contains these motifs. Recombinant human methyltransferase transferred a methyl group from S-adenosylmethionine to GpppG 5'ends, which are formed on RNA polymerase II transcripts by the sequential action of RNA 5'-triphosphatase and guanylyltransferase activities in the bifunctional mammalian capping enzyme. Binding studies demonstrated that the human cap methyltransferase associated with recombinant capping enzyme. Consistent with selective capping of RNA polymerase II transcripts, methyltransferase also formed ternary complexes with capping enzyme and the elongating form of RNA polymerase II.	Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Biol Celular & Mol, Santiago 7, Chile	Universidad de Chile	Shatkin, AJ (corresponding author), Ctr Adv Biotechnol & Med, 679 Hoes Ln, Piscataway, NJ 08854 USA.	shatkin@mbcl.rutgers.edu						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; COPPOLA JA, 1983, P NATL ACAD SCI-BIOL, V80, P1251, DOI 10.1073/pnas.80.5.1251; CORY S, 1975, J MOL BIOL, V99, P519, DOI 10.1016/S0022-2836(75)80170-7; EDERY I, 1985, P NATL ACAD SCI USA, V82, P7590, DOI 10.1073/pnas.82.22.7590; ENSINGER MJ, 1976, J BIOL CHEM, V251, P5283; FRIDERICI K, 1976, BIOCHEMISTRY-US, V15, P5234, DOI 10.1021/bi00669a006; FURUICHI Y, 1976, J BIOL CHEM, V251, P5043; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; Kuge H, 1995, EMBO J, V14, P6301, DOI 10.1002/j.1460-2075.1995.tb00320.x; LaGrandeur TE, 1998, EMBO J, V17, P1487, DOI 10.1093/emboj/17.5.1487; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; Lewis JD, 1997, EUR J BIOCHEM, V247, P461, DOI 10.1111/j.1432-1033.1997.00461.x; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MAO XD, 1995, MOL CELL BIOL, V15, P4167; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; Morley SJ, 1997, RNA, V3, P1085; Moss B., 1996, FIELDS VIROLOGY, P2637; PERRY RP, 1976, CELL, V8, P433, DOI 10.1016/0092-8674(76)90156-2; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; SCHIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; SHIMOTOHNO K, 1977, P NATL ACAD SCI USA, V74, P2734, DOI 10.1073/pnas.74.7.2734; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; SRIPATI CE, 1976, J BIOL CHEM, V251, P2898; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; YAGI Y, 1983, EMBO J, V2, P611, DOI 10.1002/j.1460-2075.1983.tb01471.x; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	38	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21443	21446		10.1074/jbc.273.34.21443	http://dx.doi.org/10.1074/jbc.273.34.21443			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705270	hybrid			2022-12-25	WOS:000075492600004
J	Blanchard, F; Raher, S; Duplomb, L; Vusio, P; Pitard, V; Taupin, JL; Moreau, JF; Hoflack, B; Minvielle, S; Jacques, Y; Godard, A				Blanchard, F; Raher, S; Duplomb, L; Vusio, P; Pitard, V; Taupin, JL; Moreau, JF; Hoflack, B; Minvielle, S; Jacques, Y; Godard, A			The mannose 6-phosphate/insulin-like growth factor II receptor is a nanomolar affinity receptor for glycosylated human leukemia inhibitory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-6 SIGNAL TRANSDUCER; 6-PHOSPHATE RECEPTOR; HUMAN INTERLEUKIN; BINDING-SITES; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; G-PROTEINS; DA CELLS; GP130; EXPRESSION	Comparison of the binding properties of non-glycosylated, glycosylated human leukemia inhibitory factor (LIF) and monoclonal antibodies (mAbs) directed at gp190/LIF-receptor beta subunit showed that most of the low affinity (nanomolar) receptors expressed by a variety of cell lines are not due to gp190, These receptors bind glycosylated LIF produced in Chinese hamster ovary cells (CHO LIF) (K-d, = 6.9 nM) but not Escherichia coli-derived LIF or CHO LIF treated with endoglycosidase F, CHO LIF binding to these receptors is neither affected by anti-gp190 mAbs nor by anti-gp130 mAbs and is specifically inhibited by low concentrations of mannose 6-phosphate (Man-6-P) (IC50 = 40 mu M), suggesting that they could be related to Man-B-P receptors, The identity of this LIF binding component with the Man-6-P/insulin-like growth factor-II receptor (Man-6-P/IGFII-R) was supported by several findings. (i) It has a molecular mass very similar to that of the Man-6-P/IGFII-R (270 kDa); (ii) the complex of LIF cross linked to this receptor is immunoprecipitated by a polyclonal anti-Man-6-P/IGFII-R antibody; (iii) this antibody inhibits LIF and IGFII binding to the receptor with comparable efficiencies; (iv) soluble Man-6-P/IGFII-R purified from serum binds glycosylated LIF (K-d = 4.3 nM) but not E. coli LIF. The potential role of Man-6-P/IGFII-R in LIF processing and biological activity is discussed.	Inst Biol, INSERM, U463, Grp Rech Cytokines Recepteurs Transduct, F-44035 Nantes 01, France; Inst Biol, IFR26, F-44035 Nantes, France; Univ Bordeaux 2, CNRS, UMR 5540, F-33076 Bordeaux, France; Inst Pasteur Lille, Inst Biol, EP CNRS 525, F-59021 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Jacques, Y (corresponding author), Inst Biol, INSERM, U463, Grp Rech Cytokines Recepteurs Transduct, 9 Quai Moncousu, F-44035 Nantes 01, France.		Minvielle, Stéphane/K-8251-2015; Blanchard, Frederic/AAS-1930-2021; Blanchard, Frederic/K-8018-2015; HOFLACK, Bernard/AAZ-6668-2020	Blanchard, Frederic/0000-0003-1055-2573; Blanchard, Frederic/0000-0003-1055-2573; Minvielle, Stephane/0000-0003-1389-312X; Duplomb, Laurence/0000-0002-5715-3759				Blanchard F, 1997, INT IMMUNOL, V9, P1775, DOI 10.1093/intimm/9.12.1775; CHEREL M, 1995, BLOOD, V86, P2534; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DEGROOTE D, 1994, J IMMUNOL METHODS, V167, P253, DOI 10.1016/0022-1759(94)90094-9; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; FELDMAN EL, 1991, BRAIN RES, V562, P111, DOI 10.1016/0006-8993(91)91194-6; FERRARA N, 1992, P NATL ACAD SCI USA, V89, P698, DOI 10.1073/pnas.89.2.698; GARMROUDI F, 1994, J BIOL CHEM, V269, P26944; GASCAN H, 1989, J BIOL CHEM, V264, P21509; GEARING DP, 1993, ADV IMMUNOL, V53, P31, DOI 10.1016/S0065-2776(08)60497-6; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GODARD A, 1992, J BIOL CHEM, V267, P3214; Groskopf JC, 1997, ENDOCRINOLOGY, V138, P2835, DOI 10.1210/en.138.7.2835; Hankins GR, 1996, ONCOGENE, V12, P2003; HERZOG V, 1987, EMBO J, V6, P555, DOI 10.1002/j.1460-2075.1987.tb04790.x; Heymann D, 1996, CYTOKINE, V8, P197, DOI 10.1006/cyto.1996.0028; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; IKEZU T, 1995, J BIOL CHEM, V270, P29224, DOI 10.1074/jbc.270.49.29224; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; JACQUES Y, 1996, CYTOKINES, P349; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; KIESS W, 1990, EUR J BIOCHEM, V190, P71, DOI 10.1111/j.1432-1033.1990.tb15547.x; KITAMURA T, 1994, TRENDS ENDOCRIN MET, V5, P8, DOI 10.1016/1043-2760(94)90115-5; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; KOMFELD S, 1992, ANNU REV BIOCHEM, V61, P307; KORNER C, 1995, J BIOL CHEM, V270, P287, DOI 10.1074/jbc.270.1.287; KOVACINA KS, 1989, BIOCHEM BIOPH RES CO, V160, P393, DOI 10.1016/0006-291X(89)91669-0; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LOBEL P, 1987, P NATL ACAD SCI USA, V84, P2233, DOI 10.1073/pnas.84.8.2233; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PAREKH RB, 1992, EUR J BIOCHEM, V203, P135, DOI 10.1111/j.1432-1033.1992.tb19838.x; Pitard V, 1997, J IMMUNOL METHODS, V205, P177, DOI 10.1016/S0022-1759(97)00074-4; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; Robledo O, 1997, J BIOL CHEM, V272, P4855, DOI 10.1074/jbc.272.8.4855; SAKANO KI, 1991, J BIOL CHEM, V266, P20626; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; TALLY M, 1987, BIOCHEM BIOPH RES CO, V148, P811, DOI 10.1016/0006-291X(87)90948-X; VAN SJ, 1989, J EXP MED, V169, P363; WARD LD, 1994, J BIOL CHEM, V269, P23286; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641	54	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20886	20893		10.1074/jbc.273.33.20886	http://dx.doi.org/10.1074/jbc.273.33.20886			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694835	hybrid			2022-12-25	WOS:000075386100028
J	Chen, XZ; Shayakul, C; Berger, UV; Tian, W; Hediger, MA				Chen, XZ; Shayakul, C; Berger, UV; Tian, W; Hediger, MA			Characterization of a rat Na+-dicarboxylate cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANES; GLUCOSE COTRANSPORTER; SUCCINATE TRANSPORT; CITRATE TRANSPORT; RENAL METABOLISM; VOLTAGE-CLAMP; VESICLES; ACID; PH; MICROENVIRONMENT	The metabolism of Krebs cycle intermediates is of fundamental importance for eukaryotic cells. In the kidney, these intermediates are transported actively into epithelial cells. Because citrate is a potent inhibitor for calcium stone formation, excessive uptake results in nephrolithiasis due to hypocitraturia. We report the cloning and characterization of a rat kidney dicarboxylate transporter (SDCT1). In situ hybridization revealed that SDCT1 mRNA is localized in 53 segments of kidney proximal tubules and in enterocytes lining the intestinal villi. Signals were also detected in lung bronchioli, the epididymis, and liver, When expressed in Xenopus oocytes, SDCT1 mediated electrogenic, sodium-dependent transport of most Krebs cycle intermediates (K-m = 20-60 ELM), including citrate, succinate, mu-ketoglutarate, and oxaloacetate. Of note, the acidic amino acids L- and D-glutamate and aspartate were also transported, although with lower affinity (K-m = 2-18 mM). Transport of citrate was pH-sensitive. At pH 7.5, the K-m for citrate was high (0.64 mM), whereas at pH 5.5, the K-m was low (57 mu M). This is consistent with the concept that the -2 form of citrate is the transported species. In addition, maximal currents at pH 5.5 were 70% higher than those at pH 7.5, and our data show that the -3 form acts as a competitive inhibitor. Simultaneous measurements of substrate-evoked currents and tracer uptakes under voltage-clamp condition, as well as a thermodynamic approach, gave a Na+ to citrate or a Na+ to succinate stoichiometry of 3 to 1. SDCT1-mediated currents were inhibited by phloretin. This plant glycoside also inhibited the SDCT1-specific sodium leak in the absence of substrate, indicating that at least one Na+ binds to the transporter before the substrate. The data presented provide new insights into the biophysical characteristics and physiological implications of a cloned dicarboxylate transporter.	Harvard Univ, Brigham & Womens Hosp, Inst Med, Div Renal, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Hediger, MA (corresponding author), Harvard Univ, Brigham & Womens Hosp, Inst Med, Div Renal, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	mhediger@rics.bwh.harvard.edu		Hediger, Matthias/0000-0003-1946-027X	NIDDK NIH HHS [DK43171] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043171] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER S, 1972, J LAB CLIN MED, V79, P505; ANAIZI NH, 1986, AM J PHYSIOL, V251, pF547, DOI 10.1152/ajprenal.1986.251.3.F547; ASPLIN JR, 1996, KIDNEY, P1893; BARACNIETO M, 1984, AM J PHYSIOL, V247, pF282, DOI 10.1152/ajprenal.1984.247.2.F282; BARUCH SB, 1975, MED CLIN N AM, V59, P569, DOI 10.1016/S0025-7125(16)32009-0; BRENNAN TS, 1986, AM J PHYSIOL, V251, pF683, DOI 10.1152/ajprenal.1986.251.4.F683; BURCKHARDT G, 1984, PFLUG ARCH EUR J PHY, V401, P254, DOI 10.1007/BF00582592; Castagna M, 1998, P NATL ACAD SCI USA, V95, P5395, DOI 10.1073/pnas.95.9.5395; Chen XZ, 1997, BIOPHYS J, V73, P2503, DOI 10.1016/S0006-3495(97)78278-X; Chen XZ, 1995, BIOPHYS J, V69, P2405, DOI 10.1016/S0006-3495(95)80110-4; Chen XZ, 1996, BIOPHYS J, V71, P2544, DOI 10.1016/S0006-3495(96)79447-X; FUKUHARA Y, 1983, AM J PHYSIOL, V245, pF374, DOI 10.1152/ajprenal.1983.245.3.F374; HAMM LL, 1990, KIDNEY INT, V38, P728, DOI 10.1038/ki.1990.265; HINTON BT, 1990, J ANDROL, V11, P498; HINTON BT, 1995, MICROSC RES TECHNIQ, V30, P67, DOI 10.1002/jemt.1070300106; HIRAYAMA B, 1986, PFLUG ARCH EUR J PHY, V407, pS174, DOI 10.1007/BF00584948; Hirayama BA, 1997, J BIOL CHEM, V272, P2110; JENKINS AD, 1985, AM J PHYSIOL, V249, pF590, DOI 10.1152/ajprenal.1985.249.4.F590; JORGENSEN KE, 1983, AM J PHYSIOL, V244, pF686, DOI 10.1152/ajprenal.1983.244.6.F686; KEIL M, 1979, ANDROLOGIA, V11, P385; Khatri IA, 1996, BBA-GENE STRUCT EXPR, V1309, P58, DOI 10.1016/S0167-4781(96)00138-8; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; LEVI M, 1991, AM J PHYSIOL, V261, pF767, DOI 10.1152/ajprenal.1991.261.5.F767; Melnick JZ, 1996, J CLIN INVEST, V98, P2381, DOI 10.1172/JCI119051; NICAR MJ, 1983, UROLOGY, V21, P8, DOI 10.1016/0090-4295(83)90113-9; NIETH H, 1966, NATURE, V209, P1244, DOI 10.1038/2091244a0; Pajor AM, 1996, AM J PHYSIOL-RENAL, V271, pF1093, DOI 10.1152/ajprenal.1996.271.5.F1093; Pajor AM, 1996, AM J PHYSIOL-RENAL, V270, pF642, DOI 10.1152/ajprenal.1996.270.4.F642; Pajor AM, 1996, AM J PHYSIOL-CELL PH, V271, pC1808, DOI 10.1152/ajpcell.1996.271.6.C1808; PAJOR AM, 1995, J BIOL CHEM, V270, P5779, DOI 10.1074/jbc.270.11.5779; PAK CYC, 1987, MINER ELECTROL METAB, V13, P257; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHELL RE, 1985, J PHYSIOL-LONDON, V360, P95, DOI 10.1113/jphysiol.1985.sp015605; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; Segel IH., 1975, ENZYME KINETICS, P227; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SIMPSON DP, 1983, AM J PHYSIOL, V244, pF223, DOI 10.1152/ajprenal.1983.244.3.F223; ULLRICH KJ, 1984, PFLUG ARCH EUR J PHY, V400, P241, DOI 10.1007/BF00581554; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0; WRIGHT EM, 1982, P NATL ACAD SCI-BIOL, V79, P7514, DOI 10.1073/pnas.79.23.7514; WRIGHT EM, 1985, ANNU REV PHYSIOL, V47, P127; WRIGHT SH, 1983, J BIOL CHEM, V258, P5456; WRIGHT SH, 1982, J BIOL CHEM, V257, P1773; WRIGHT SH, 1982, BIOCHIM BIOPHYS ACTA, V684, P287, DOI 10.1016/0005-2736(82)90019-0; WRIGHT SH, 1980, J MEMBRANE BIOL, V57, P73, DOI 10.1007/BF01868987; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF432, DOI 10.1152/ajprenal.1987.253.3.F432; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	48	101	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20972	20981		10.1074/jbc.273.33.20972	http://dx.doi.org/10.1074/jbc.273.33.20972			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694847	hybrid			2022-12-25	WOS:000075386100040
J	Liang, C; Rong, LW; Gotte, M; Li, XG; Quan, YD; Kleiman, L; Wainberg, MA				Liang, C; Rong, LW; Gotte, M; Li, XG; Quan, YD; Kleiman, L; Wainberg, MA			Mechanistic studies of early pausing events during initiation of HIV-1 reverse transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PRIMER BINDING-SITE; YEAST TY1 RETROTRANSPOSON; NUCLEOCAPSID PROTEIN; NUCLEOTIDE-SEQUENCE; DNA-SYNTHESIS; TRANSFER-RNA; SECONDARY STRUCTURE; TRNA(3)(LYS); ELONGATION	We have investigated the role of sequences that surround the primer binding site (PBS) in the reverse transcriptase-mediated initiation of (-) strand DNA synthesis in human immunodeficiency virus type I. In comparisons of reverse transcription initiated from either the cognate primer tRNALys.3 or a DNA primer D-Lys.3, bound to PBS sequences, we observed that a +3 pausing site occurred in both circumstances, However, the initiation reaction with tRNALys.3 was also characterized by a pausing event after incorporation of the first nucleotide, Alteration of sequences at the 5'-end instead of the 3'-end of the PBS resulted in elimination of the +3 pausing site, suggesting that this site was template sequence-dependent. In contrast, the pausing event at the +1 nucleotide position was still present in experiments that employed either of these mutated RNA templates. The mutations at the 5'-end of the PBS also caused a severely diminished rate of initiation and the strong arrest of reactions at the fl stage when tRNALys.3 was used as primer. Therefore, we propose that the ct pausing event is an initiation-specific event in regard to reactions primed by tRNALys.3 and that sequences at the 5'-end of the PBS may facilitate the release of reverse transcription from initiation to elongation.	McGill Univ, Jewish Gen Hosp, AIDS Ctr, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Microbiol, Montreal, PQ H3A 2B4, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Wainberg, MA (corresponding author), McGill Univ, Jewish Gen Hosp, AIDS Ctr, Lady Davis Inst Med Res, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.							ALYAR A, 1994, J VIROL, V68, P611; ALYAR A, 1992, J VIROL, V66, P2464; Berkhout B, 1997, NUCLEIC ACIDS RES, V25, P4013, DOI 10.1093/nar/25.20.4013; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; Essink BBO, 1996, J MOL BIOL, V264, P243, DOI 10.1006/jmbi.1996.0638; Friant S, 1996, NUCLEIC ACIDS RES, V24, P441, DOI 10.1093/nar/24.3.441; Ghosh M, 1997, BIOCHEMISTRY-US, V36, P5758, DOI 10.1021/bi963045e; GOTTE M, 1995, EMBO J, V14, P833, DOI 10.1002/j.1460-2075.1995.tb07061.x; HARADA F, 1979, J BIOL CHEM, V254, P979; HARADA F, 1975, J BIOL CHEM, V250, P3487; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang Y, 1997, J VIROL, V71, P726, DOI 10.1128/JVI.71.1.726-728.1997; Isel C, 1998, NUCLEIC ACIDS RES, V26, P1198, DOI 10.1093/nar/26.5.1198; ISEL C, 1993, J BIOL CHEM, V268, P25269; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; KATI WM, 1992, J BIOL CHEM, V267, P25988; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; Lanchy JM, 1996, BIOCHIMIE, V78, P1087, DOI 10.1016/S0300-9084(97)86734-X; Li XG, 1997, J VIROL, V71, P6003, DOI 10.1128/JVI.71.8.6003-6010.1997; Li XG, 1996, J VIROL, V70, P4996, DOI 10.1128/JVI.70.8.4996-5004.1996; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REARDON JE, 1993, J BIOL CHEM, V268, P8743; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMAMOTO T, 1993, J BIOL CHEM, V268, P2684; SKALKA A, 1993, REVERSE TRANSCRIPTAS; Skripkin E, 1996, NUCLEIC ACIDS RES, V24, P509, DOI 10.1093/nar/24.3.509; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WANG H, 1993, CELL, V75, P1071, DOI 10.1016/0092-8674(93)90317-J; WILHELM M, 1994, NUCLEIC ACIDS RES, V22, P4560, DOI 10.1093/nar/22.22.4560; WOHRL BM, 1993, J BIOL CHEM, V268, P13617; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6	39	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21309	21315		10.1074/jbc.273.33.21309	http://dx.doi.org/10.1074/jbc.273.33.21309			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694891	hybrid			2022-12-25	WOS:000075386100084
J	Rui, LY; Carter-Su, C				Rui, LY; Carter-Su, C			Platelet-derived growth factor (PDGF) stimulates the association of SH2-B beta with PDGF receptor and phosphorylation of SH2-B beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; INSULIN-RECEPTOR; SH2 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; HORMONE RECEPTOR; TRYPTOPHAN-HYDROXYLASE; PROTEIN; IDENTIFICATION; ACTIVATION	We recently identified SH2-B beta as a JAK2-binding protein and substrate involved in the signaling of receptors for growth hormone and interferon-gamma. In this work, we report that SH2-B beta also functions as a signaling molecule for platelet-derived growth factor (PDGF). SH2-B beta fused to glutathione S-transferase (GST) bound PDGF receptor (PDGFR) from PDGF-treated but not control cells. GST fusion protein containing only the SH2 domain of SH2-B beta also bound PDGFR from PDGF-treated cells. An Arg to Glu mutation within the FLVRQS motif in the SH2 domain of SH2-B beta inhibited GST-SH2-B beta binding to tyrosyl-phosphorylated PDGFR. The N-terminal truncated SH2-B beta containing the entire SH2 domain interacted directly with tyrosyl-phosphorylated PDGFR from PDGF-treated cells but not unphosphorylated PDGFR from control cells in a Far Western assay. These results suggest that the SH2 domain of SH2-B beta is necessary and sufficient to mediate the interaction between SH2-B beta and PDGFR. PDGF stimulated coimmunoprecipitation of endogenous SH2-B beta with endogenous PDGFR, in both 3T3-F442A and NIH3T3 cells. PDGF stimulated the rapid and transient phosphorylation of SH2-B beta on tyrosines and most likely on serines and/or threonines. Similarly, epidermal growth factor stimulated the phosphorylation of SH2-B beta; however, phosphorylation appears to be predominantly on serines and/or threonines. In response to PDGF, SH2-B beta associated with multiple tyrosyl-phosphorylated proteins, at least one of which (designated p84) does not bind to PI]GFR. Taken together, these data strongly argue that, in response to PDGF, SH2-B beta directly interacts with PDGFR and is phosphorylated on tyrosine and most likely on serines and/or threonines, and acts as a signaling protein for PDGFR.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Carter-Su, C (corresponding author), Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA.				NIAMS NIH HHS [P60-AR20557] Funding Source: Medline; NIDDK NIH HHS [P60-DK-20572, DK 34171, R01 DK034171] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034171, P60DK020572, R01DK034171] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Craparo A, 1997, J BIOL CHEM, V272, P11663; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; Ichimura T, 1997, FEBS LETT, V413, P273, DOI 10.1016/S0014-5793(97)00910-1; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; INUI H, 1994, J BIOL CHEM, V269, P30546; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LUBINUS M, 1994, J BIOL CHEM, V269, P9822; Ma HP, 1996, AM J PHYSIOL-RENAL, V271, pF994, DOI 10.1152/ajprenal.1996.271.5.F994; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; Ruusala A, 1998, J CELL SCI, V111, P111; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TANTI JF, 1994, J BIOL CHEM, V269, P6051; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHU GC, 1993, J BIOL CHEM, V268, P1775	36	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21239	21245		10.1074/jbc.273.33.21239	http://dx.doi.org/10.1074/jbc.273.33.21239			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694882	hybrid			2022-12-25	WOS:000075386100075
J	Carman, CV; Som, T; Kim, CM; Benovic, JL				Carman, CV; Som, T; Kim, CM; Benovic, JL			Binding and phosphorylation of tubulin by G protein-coupled receptor kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; ASSOCIATION; ACTIVATION; PURIFICATION; MICROTUBULES; EXPRESSION; MEMBRANES; ISOTYPE; ALPHA	Although the beta-adrenergic receptor kinase (beta ARK) mediates agonist-dependent phosphorylation and desensitization of G protein-coupled receptors, recent studies suggest additional cellular functions. During our attempts to identify novel beta ARK interacting proteins, we found that the cytoskeletal protein tubulin could specifially bind to a beta ARR-coupled affinity column. In vitro analysis demonstrated that beta ARK and G protein-coupled receptor kinase-5 (GRK5) mere able to stoichiometrically phosphorylate purified tubulin dimers with a preference for beta-tubulin and, under certain conditions, the beta III-isotype. Examination of the GRK/tubulin binding characteristics revealed that tubulin dimers and assembled microtubules bind GRKs, whereas the catalytic domain of beta ARK contains the primary tubulin binding determinants. In vivo interaction of GRK and tubulin was suggested by the following: (i) co-purification of beta ARK with tubulin from brain tissue; (ii) co-immunoprecipitation of beta ARR and tubulin from COS-l cells; and (iii) co-localization of beta ARK and GRK5 with microtubule structures in COS-l cells. In addition, GRK-phosphorylated tubulin was found preferentially associated with the microtubule fraction during in vitro assembly assays suggesting potential functional significance. These results suggest a novel link between the cytoskeleton and GRKs that may be important for regulating GRK and/or tubulin function.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Mol Pharmacol & Biochem, 233 S 10th St, Philadelphia, PA 19107 USA.		Carman, Christopher/L-8108-2016; Carman, Christopher V./AAX-8995-2020	Carman, Christopher/0000-0001-7358-2548; Carman, Christopher V./0000-0001-7358-2548	NATIONAL CANCER INSTITUTE [T32CA009662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NCI NIH HHS [5-T32-CA09662] Funding Source: Medline; NIGMS NIH HHS [GM47419, GM44944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE A, 1988, J BIOL CHEM, V263, P3029; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; Caron JM, 1997, MOL BIOL CELL, V8, P621, DOI 10.1091/mbc.8.4.621; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; DIAZNIDO J, 1990, J BIOL CHEM, V265, P13949; HARGREAVES AJ, 1986, NATURE, V323, P827, DOI 10.1038/323827a0; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KELLY WG, 1983, J CELL BIOL, V97, P1197; Khan IA, 1996, BIOCHEMISTRY-US, V35, P3704, DOI 10.1021/bi951247p; KIM CM, 1993, J BIOL CHEM, V268, P15412; KIM CM, 1993, RECEPTOR, V3, P39; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacRae TH, 1997, EUR J BIOCHEM, V244, P265, DOI 10.1111/j.1432-1033.1997.00265.x; MANDELKOW EM, 1992, CELL MOTIL CYTOSKEL, V22, P235, DOI 10.1002/cm.970220403; MCILVAIN JM, 1994, J BIOL CHEM, V269, P19176; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; NARISHIGE T, 1997, CIRCULATION, V96, P495; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; ONORATO JJ, 1995, J BIOL CHEM, V270, P21346, DOI 10.1074/jbc.270.36.21346; Pedrotti B, 1996, FEBS LETT, V388, P131, DOI 10.1016/0014-5793(96)00520-0; PFEFFER SR, 1983, J CELL BIOL, V97, P40, DOI 10.1083/jcb.97.1.40; Ping PP, 1997, AM J PHYSIOL-HEART C, V273, pH707, DOI 10.1152/ajpheart.1997.273.2.H707; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Popova JS, 1997, J BIOL CHEM, V272, P6760, DOI 10.1074/jbc.272.10.6760; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; Roychowdhury S, 1997, J BIOL CHEM, V272, P31576, DOI 10.1074/jbc.272.50.31576; RuizGomez A, 1997, J BIOL CHEM, V272, P9601; SATO H, 1997, J CELL BIOL, V139, P163; Saunders C, 1997, J BIOL CHEM, V272, P19035, DOI 10.1074/jbc.272.30.19035; SERRANO L, 1987, J CELL BIOL, V105, P1731, DOI 10.1083/jcb.105.4.1731; SERRANO L, 1989, EXP CELL RES, V181, P263, DOI 10.1016/0014-4827(89)90200-0; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; TSUTSUI H, 1994, CIRCULATION, V90, P533, DOI 10.1161/01.CIR.90.1.533; WANG N, 1990, J BIOL CHEM, V265, P1239; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1868; WHATLEY VJ, 1994, J BIOL CHEM, V269, P19546; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x	45	108	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20308	20316		10.1074/jbc.273.32.20308	http://dx.doi.org/10.1074/jbc.273.32.20308			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685381	hybrid			2022-12-25	WOS:000075305400058
J	Foster, LC; Arkonac, BM; Sibinga, NES; Shi, CW; Perrella, MA; Haber, E				Foster, LC; Arkonac, BM; Sibinga, NES; Shi, CW; Perrella, MA; Haber, E			Regulation of CD44 gene expression by the proinflammatory cytokine interleukin-1 beta in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; EXTRACELLULAR-MATRIX; GAMMA-INTERFERON; GROWTH-FACTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; ATHEROSCLEROTIC PLAQUES; ADHESION MOLECULE-1; ACTIVATION; HYALURONATE; TRANSCRIPTION	The CD44 gene codes for a family of alternatively spliced, multifunctional adhesion molecules that participate in extracellular matrix binding, lymphocyte activation, cell migration, and tumor metastasis. In a mouse model of transplant-associated arteriosclerosis, CD44 protein was induced in the neointima of allografted vessels and colocalized with a subset of proliferating vascular smooth muscle cells (SMC). To elucidate the molecular mechanisms regulating CD44 expression in this model, we investigated the regulation of CD44 gene expression by interleukin (IL)-1 beta. Treatment of rat aortic SMC with IL-1 beta resulted in a 5.3-fold increase in cell surface CD44 expression. Northern analysis showed that IL-1 beta promoted a dose- and time-dependent induction of CD44 mRNA which reached 6.6-fold after 48 h, and nuclear run-on analysis showed that IL-1 beta increased the rate of CD44 gene transcription within 8 h of stimulation. In transient reporter gene transfection experiments in rat aortic SMC, a 1.4-kilobase fragment of the mouse CD44 5'-flanking sequence mediated this response to IL-1 beta, Regulation of CD44 gene expression by the proinflammatory cytokine IL-1 beta may contribute to SMC phenotypic modulation in the pathogenesis of arteriosclerosis.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Perrella, MA (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 677 Huntington Ave, Boston, MA 02115 USA.	perrella@cvlab.harvard.edu	Sibinga, Nicholas/GOJ-8544-2022	Sibinga, Nicholas/0000-0003-4838-910X				ALHO AM, 1989, J CELL BIOL, V108, P1557, DOI 10.1083/jcb.108.4.1557; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6; COUFFINHAL T, 1994, CIRC RES, V74, P225, DOI 10.1161/01.RES.74.2.225; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; GAY CG, 1991, P NATL ACAD SCI USA, V88, P296, DOI 10.1073/pnas.88.1.296; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HANSSON GK, 1991, CIRCULATION, V84, P1266, DOI 10.1161/01.CIR.84.3.1266; HOFMANN M, 1993, CANCER RES, V53, P1516; Jain M, 1996, J CLIN INVEST, V97, P596, DOI 10.1172/JCI118455; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; LEIBSON HJ, 1984, NATURE, V309, P799, DOI 10.1038/309799a0; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; Maltzman JS, 1996, MOL CELL BIOL, V16, P2283; MOLOSSI S, 1995, J CELL PHYSIOL, V163, P19, DOI 10.1002/jcp.1041630104; MOYER CF, 1991, AM J PATHOL, V138, P951; NILSSON J, 1993, CARDIOVASC RES, V27, P1184, DOI 10.1093/cvr/27.7.1184; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; NOTTENBURG C, 1989, P NATL ACAD SCI USA, V86, P8521, DOI 10.1073/pnas.86.21.8521; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; PACE JL, 1983, J IMMUNOL, V130, P2011; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; PIERRES A, 1992, EUR J IMMUNOL, V22, P413, DOI 10.1002/eji.1830220219; PORRECA E, 1993, ATHEROSCLEROSIS, V99, P71, DOI 10.1016/0021-9150(93)90052-V; RAINES EW, 1993, BRIT HEART J, V69, pS30; Riessen R, 1996, CIRCULATION, V93, P1141, DOI 10.1161/01.CIR.93.6.1141; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHI CW, 1994, CIRC RES, V75, P199, DOI 10.1161/01.RES.75.2.199; Shi CW, 1996, P NATL ACAD SCI USA, V93, P4051, DOI 10.1073/pnas.93.9.4051; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; SIDMAN CL, 1984, NATURE, V309, P801, DOI 10.1038/309801a0; SKINNER MP, 1994, AM J PATHOL, V145, P1070; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; WARNER SJC, 1989, J CLIN INVEST, V83, P1174, DOI 10.1172/JCI113998; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Zhang M, 1997, J BIOL CHEM, V272, P14139, DOI 10.1074/jbc.272.22.14139; ZHOU DFH, 1989, J IMMUNOL, V143, P3390	48	35	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20341	20346		10.1074/jbc.273.32.20341	http://dx.doi.org/10.1074/jbc.273.32.20341			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685385	hybrid			2022-12-25	WOS:000075305400062
J	O'Bryan, JP; Lambert, QT; Der, CJ				O'Bryan, JP; Lambert, QT; Der, CJ			The Src homology 2 and phosphotyrosine binding domains of the ShcC adaptor protein function as inhibitors of mitogenic signaling by the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2 DOMAIN; AUTOPHOSPHORYLATION SITES; TYROSINE PHOSPHATASE; PHOSPHORYLATION; ASSOCIATION; KINASE; TRANSDUCTION; ACTIVATION; PATHWAYS; ASSAYS	Upon ligand activation, the epidermal growth factor receptor (EGFR) becomes tyrosine-phosphorylated, thereby recruiting intracellular signaling protei:ns such as Shc. EGFR binding of Shc proteins results in their tyrosine phosphorylation and subsequent activation of the Ras and Erk pathways. Shc interaction wi th activated receptor tyrosine kinases is mediated by two distinct phosphotyrosine interaction domains, an NH2-terminal phosphotyrosine binding (PTB) domain and a COOH-terminal Src homology 2 (SH2) domain. The relative importance of these two domains for EGFR binding was examined by determining if expression of the isolated SH2 or PTB domain of ShcC would inhibit EGFR signaling. The SH2 domain potently inhibited numerous aspects of EGFR signaling including activation of Erb2 and the Elk-1 transcription factor as well as EGFR-dependent transformation. Furthermore, the SH2 domain inhibited focus formation by the Neu oncoprotein, another EGFR family member. Surprisingly, inhibition of the EGFR by the SH2 domain did not involve stable association with the receptor. In contrast, the PTB domain associated quite well with the receptor yet had little effect on EGFR signaling. Although the EGFR cytoplasmic tail contains consensus binding sites for the PTB and SH2 domains of ShcC, and both domains of ShcC interact with the receptor in vitro, the SH2 domain is more potent for inhibiting receptor function in vivo. However, inhibition is not due to stable association with the receptor, suggesting that the SH2 domain is binding to a heretofore unknown protein(s) necessary for proper EGFR function.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	O'Bryan, JP (corresponding author), NIEHS, NIH, POB 12233,Bldg Rm 101-F332,MD F3-06, Res Triangle Pk, NC 27709 USA.	obryan@niehs.nih.gov		O'Bryan, John/0000-0001-5386-1080; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978, R29CA076570, F32CA068733] Funding Source: NIH RePORTER; NCI NIH HHS [CA76570, CA42978, CA68733] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BONFINI L, 1996, TRENDS BIOCHEM SCI, V21, P259; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1995, ONCOGENE, V11, P2525; HABIB T, 1994, J BIOL CHEM, V269, P25243; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; Hill RJ, 1996, CELL GROWTH DIFFER, V7, P1125; LI NX, 1994, ONCOGENE, V9, P3457; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nakamura T, 1996, ONCOGENE, V13, P1111; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OBryan JP, 1996, J BIOL CHEM, V271, P11787, DOI 10.1074/jbc.271.20.11787; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sasaoka T, 1996, J BIOL CHEM, V271, P20082, DOI 10.1074/jbc.271.33.20082; SOLER C, 1994, ONCOGENE, V9, P2207; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Xu YR, 1997, J BIOL CHEM, V272, P13463, DOI 10.1074/jbc.272.21.13463; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; YOUMING X, 1995, ONCOGENE, V10, P2409; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119	43	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20431	20437		10.1074/jbc.273.32.20431	http://dx.doi.org/10.1074/jbc.273.32.20431			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685397	Green Published, hybrid			2022-12-25	WOS:000075305400074
J	Poussin, C; Foti, M; Carpentier, JL; Pugin, J				Poussin, C; Foti, M; Carpentier, JL; Pugin, J			CD14-dependent endotoxin internalization via a macropinocytic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LPS-BINDING-PROTEIN; MONOCYTE DIFFERENTIATION ANTIGEN; LIPOPOLYSACCHARIDE LPS; SIGNAL-TRANSDUCTION; BACTERIAL LIPOPOLYSACCHARIDE; HUMAN-NEUTROPHILS; MEMBRANE DOMAINS; EPITHELIAL-CELLS; CD14; RECEPTOR	Gram-negative bacterial endotoxin (a lipopolysaccharide (LPS)) specifically binds to CD14, a glycosylphosphatidyl inositol (GPI)-anchored surface myeloid glycoprotein. This interaction leads to cell activation, but it also promotes LPS internalization and detoxification, In this work, we investigated the route of LPS and CD14 internalization and the relevance of CD14 GPI anchor in the endocytic pathway. In promonocytic THP-1 cells transfected with a GPI or a chimeric integral form of CD14, we showed by differential buoyancy in sucrose density gradients that these two forms of CD14 were sorted to different plasma membrane subdomains. However, both forms of CD14 associated preferentially with the same surface microfilament-enriched microvilli or ruffles. Electron microscopic studies indicated that CD14 internalized via macropinocytosis, a process resembling that of phagocytosis, different from "classical" receptor-mediated endocytic pathways, such as clathrin-coated pits or caveolae. With cell warming, the CD14-enriched ruffles fused and formed large vesicles. Later, these vacuoles made stacks and condensed into phago-lysosomes. CD14 was specifically associated with all of these structures, Radiolabeled LPS internalization paralleled CD14 internalization. Confocal microscopic studies confirmed the co-localization of LPS and CD14 both at the cell surface and in endosomal compartments. The microfilament-disrupting, macropinocytosis blocking agent cytochalasin D inhibited LPS and CD14 internalization but did not prevent LPS-dependent activation, indicating that these two processes are dissociated.	Univ Hosp Geneva, Dept Med, Div Med Intens Care, CH-1211 Geneva 14, Switzerland; Univ Geneva, Fac Med, Dept Morphol, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Pugin, J (corresponding author), Univ Hosp Geneva, Dept Med, Div Med Intens Care, 24 r Micheli du Crest, CH-1211 Geneva 14, Switzerland.			Foti, Michelangelo/0000-0001-7199-4135				ALLISON AC, 1971, NATURE-NEW BIOL, V232, P153; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; BAMEZAI A, 1989, J IMMUNOL, V143, P3107; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CARPENTIER JL, 1991, CELL REGUL, V2, P41, DOI 10.1091/mbc.2.1.41; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Detmers PA, 1996, J IMMUNOL, V157, P5589; DETMERS PA, 1987, J CELL BIOL, V105, P1137, DOI 10.1083/jcb.105.3.1137; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FRA AM, 1994, J BIOL CHEM, V269, P30745; FRANCIS CL, 1993, NATURE, V364, P639, DOI 10.1038/364639a0; GALLAY P, 1993, J IMMUNOL, V150, P5086; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; Grassme HUC, 1996, INFECT IMMUN, V64, P1621; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HAZIOT A, 1988, J IMMUNOL, V141, P547; HOREJSI V, 1988, FOLIA BIOL-PRAGUE, V34, P23; Ilangumaran S, 1996, ANAL BIOCHEM, V235, P49, DOI 10.1006/abio.1996.0090; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; KANG YH, 1990, J LEUKOCYTE BIOL, V48, P316, DOI 10.1002/jlb.48.4.316; Kitchens RL, 1998, J IMMUNOL, V160, P1920; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; KRIEGSMANN J, 1993, CELL MOL BIOL, V39, P791; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; MUNFORD RS, 1992, J IMMUNOL METHODS, V148, P115, DOI 10.1016/0022-1759(92)90164-O; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; OSHEA JJ, 1985, J IMMUNOL, V135, P1325; PETERSON PK, 1995, INFECT IMMUN, V63, P1598, DOI 10.1128/IAI.63.4.1598-1602.1995; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Pugin J, 1998, INFECT IMMUN, V66, P1174, DOI 10.1128/IAI.66.3.1174-1180.1998; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; RITTER TE, 1995, P NATL ACAD SCI USA, V92, P3824, DOI 10.1073/pnas.92.9.3824; Schiff DE, 1997, J LEUKOCYTE BIOL, V62, P786, DOI 10.1002/jlb.62.6.786; Shibata Y, 1996, J IMMUNOL, V156, P772; SIMMONS DL, 1989, BLOOD, V73, P284; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; TAUSK F, 1989, J IMMUNOL, V143, P3295; TOBIAS PS, 1993, J IMMUNOL, V150, P3011; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; Wang Ping-Yuan, 1995, Journal of Inflammation, V47, P126; WRIGHT SD, 1991, CURR OPIN IMMUNOL, V3, P83, DOI 10.1016/0952-7915(91)90082-C; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	49	96	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20285	20291		10.1074/jbc.273.32.20285	http://dx.doi.org/10.1074/jbc.273.32.20285			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685378	hybrid			2022-12-25	WOS:000075305400055
J	Yokoyama, K; Muneyuki, E; Amano, T; Mizutani, S; Yoshida, M; Ishida, M; Ohkuma, S				Yokoyama, K; Muneyuki, E; Amano, T; Mizutani, S; Yoshida, M; Ishida, M; Ohkuma, S			V-ATPase of Thermus thermophilus is inactivated during ATP hydrolysis but can synthesize ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; APPARENT NEGATIVE COOPERATIVITY; NUCLEOTIDE BINDING-SITES; MEMBRANE-BOUND ATPASE; VACUOLAR H+-ATPASE; BOVINE HEART; SULFOLOBUS-ACIDOCALDARIUS; ESCHERICHIA-COLI; CATALYTIC SITES; BACILLUS PS3	The ATP hydrolysis of the V-1-ATPase of Thermus thermophilus have been investigated with an ATP-regenerating system at 25 degrees C, The ratio of ATPase activity to ATP concentration ranged from 40 to 4000 mu M; from this, an apparent K-m of 240 +/- 24 mu M and a V-max of 5.2 +/-0.5 units/mg were deduced. An apparent negative cooperativity, which is frequently observed in case of F-1-ATPases, was not observed for the V-1-ATPase, Interestingly, the rate of hydrolysis decayed rapidly during ATP hydrolysis, and the ATP hydrolysis finally stopped. Furthermore, the inactivation of the V-1-ATPase was attained by a prior incubation with ADP-Mg. The inactivated V-1-ATPase contained 1.5 mol of ADP/mol of enzyme. Difference absorption spectra generated from addition of ATP-Mg to the isolated subunits revealed that the A subunit can bind ATP-Mg, whereas the B subunit cannot. The inability to bind ATP-Mg is consistent with the absence of Walker motifs in the B subunit, These results indicate that the inactivation of the V-1-ATPase during ATP hydrolysis is caused by entrapping inhibitory ADP-Mg in a catalytic site. Light-driven ATP synthesis by bacteriorhodopsin-VoV1-ATPase proteoliposomes was observed, and the rate of ATP synthesis was approximately constant. ATP synthesis occurred in the presence of an ADP-Mg of which concentration was high enough to induce complete inactivation of ATP hydrolysis of VoV1-ATPase, This result indicates that the ADP-Mg-inhibited form is not produced in ATP synthesis reaction.	Kanazawa Univ, Fac Pharmaceut Sci, Dept Biochem, Kanazawa, Ishikawa 920, Japan; Tokyo Inst Technol, Resources Utilizat Res Lab, Yokohama, Kanagawa 226, Japan; Tokyo Univ Fishers, Lab Biochem Marine Resources, Minato Ku, Tokyo 108, Japan	Kanazawa University; Tokyo Institute of Technology	Yokoyama, K (corresponding author), Kanazawa Univ, Fac Pharmaceut Sci, Dept Biochem, 13-1 Takara Machi, Kanazawa, Ishikawa 920, Japan.	yokoken@kenroku.kanazawa-u.ac.jp	ISHIDA, Masami/O-1909-2014; Yokoyama, Ken/AAJ-3582-2020	Yokoyama, Ken/0000-0002-6813-1096				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1988, J BIOL CHEM, V263, P8796; ARAI K, 1993, J BIOL CHEM, V268, P5649; Bald D, 1998, J BIOL CHEM, V273, P865, DOI 10.1074/jbc.273.2.865; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CROSS RL, 1982, J BIOL CHEM, V257, P2101; EBEL RE, 1975, J BIOL CHEM, V250, P191; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; HISABORI T, 1992, J BIOL CHEM, V267, P4551; HONER ZU, 1997, J BACTERIOL, V179, P1274; INATOMI K, 1986, J BACTERIOL, V167, P837, DOI 10.1128/jb.167.3.837-841.1986; Jault JM, 1996, J BIOL CHEM, V271, P28818, DOI 10.1074/jbc.271.46.28818; JAULT JM, 1993, J BIOL CHEM, V268, P1558; JAULT JM, 1994, J BIOL CHEM, V269, P319; KAKINUMA Y, 1990, FEBS LETT, V271, P97, DOI 10.1016/0014-5793(90)80381-R; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; KIBAK H, 1993, J BIOL CHEM, V268, P23325; KONISHI J, 1987, J BIOCHEM, V102, P1379, DOI 10.1093/oxfordjournals.jbchem.a122184; LUBBEN M, 1989, J BACTERIOL, V171, P6106; MATSUDA C, 1994, BIOCHEM BIOPH RES CO, V200, P671, DOI 10.1006/bbrc.1994.1503; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; MCKAY A, 1982, ARCH MICROBIOL, V131, P43, DOI 10.1007/BF00451497; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1987, J BIOL CHEM, V262, P14723; MUKOHATA Y, 1986, J BIOCH, V101, P1; MUNEYUKI E, 1988, FEBS LETT, V234, P455, DOI 10.1016/0014-5793(88)80137-6; Muneyuki E, 1996, J BIOCHEM-TOKYO, V120, P940; MUNEYUKI E, 1993, BIOCHIM BIOPHYS ACTA, V1144, P62, DOI 10.1016/0005-2728(93)90031-A; MUNEYUKI E, 1994, BBA-BIOENERGETICS, V1188, P108, DOI 10.1016/0005-2728(94)90028-0; NANBA T, 1987, J BIOCHEM-TOKYO, V102, P591, DOI 10.1093/oxfordjournals.jbchem.a122092; OESTERHELT D, 1973, P NATL ACAD SCI USA, V70, P2853, DOI 10.1073/pnas.70.10.2853; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; RICHARD P, 1995, J BIOL CHEM, V270, P21571, DOI 10.1074/jbc.270.37.21571; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; VASILYEVA E, 1997, J BIOL CHEM, V272, P12775; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; WONG SY, 1984, BIOCHEMISTRY-US, V23, P5004, DOI 10.1021/bi00316a027; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; YOKOYAMA K, 1994, J BIOL CHEM, V269, P12248; YOKOYAMA K, 1990, J BIOL CHEM, V265, P21946; YOSHIDA M, 1995, FEBS LETT, V359, P1, DOI 10.1016/0014-5793(94)01438-7; ZHANG JM, 1995, J BIOL CHEM, V270, P15494, DOI 10.1074/jbc.270.26.15494	45	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20504	20510		10.1074/jbc.273.32.20504	http://dx.doi.org/10.1074/jbc.273.32.20504			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685406	hybrid			2022-12-25	WOS:000075305400083
J	Carson-Walter, EB; Smith, DP; Ponder, BAJ; Baylin, SB; Nelkin, BD				Carson-Walter, EB; Smith, DP; Ponder, BAJ; Baylin, SB; Nelkin, BD			Post-transcriptional silencing of RET occurs, but is not required, during raf-1 mediated differentiation of medullary thyroid carcinoma cells	ONCOGENE			English	Article						RET; raf-1; differentiation	ACTIVATED PROTEIN-KINASE; NERVE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; NEOPLASIA TYPE 2B; PC12 CELLS; NEURONAL DIFFERENTIATION; TRANSFORMING GENE; RAS ONCOGENE; PROTOONCOGENE; MUTATIONS	Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor of the calcitonin secreting thyroid C-cells, Somatic and germline mutations in the RET proto-oncogene are associated with sporadic and inherited cases of MTC, respectively. The human MTC cell Line, TT, can be differentiated by activated raf-1, This differentiation is characterized, in part, by down-regulation of the RET proto-oncogene, We now show that raf-1 induction is followed by activation of the downstream kinases MEK1/2 and ERK1/2 and that differentiation is dependent on activation of MEK1/2, The concurrent down-regulation of RET appears to involve altered nuclear compartmentalization and transport of RET mRNA, Although RET is down-regulated during raf-1 mediated differentiation, overexpression of activated RET alleles which resist down-regulation does not alter the raf-1 mediated differentiation response. These data suggest that RET down-regulation is associated with, but not required, for raf-1 mediated MTC cell differentiation and that the raf-1 signal transduction pathway plays a dominant role in promoting MTC cell differentiation.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Program Human Genet & Mol Biol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Univ Cambridge, Human Canc Genet Grp, Cambridge CB2 2OQ, England	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; University of Cambridge	Nelkin, BD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21231 USA.				NCI NIH HHS [R01-CA47480] Funding Source: Medline; PHS HHS [2T32G07814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047480] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; CALIFANO D, 1995, ONCOGENE, V11, P107; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CARSON EB, 1995, CANCER RES, V55, P2048; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; HAZARD JB, 1959, J CLIN ENDOCR METAB, V19, P152, DOI 10.1210/jcem-19-1-152; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Holt KH, 1996, MOL CELL BIOL, V16, P577; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; Marsh DJ, 1996, CLIN ENDOCRINOL, V44, P249, DOI 10.1046/j.1365-2265.1996.681503.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NELKIN BD, 1990, BIOCHEM BIOPH RES CO, V170, P140, DOI 10.1016/0006-291X(90)91251-M; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Richardson GM, 1996, HUM ECOL RISK ASSESS, V2, P44, DOI 10.1080/10807039.1996.10387459; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	41	23	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					367	376		10.1038/sj.onc.1201938	http://dx.doi.org/10.1038/sj.onc.1201938			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690518				2022-12-25	WOS:000074947500011
J	Ghosh, S; Gachhui, R; Crooks, C; Wu, CQ; Lisanti, MP; Stuehr, DJ				Ghosh, S; Gachhui, R; Crooks, C; Wu, CQ; Lisanti, MP; Stuehr, DJ			Interaction between caveolin-1 and the reductase domain of endothelial nitric-oxide synthase - Consequences for catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; BINDING DOMAIN; L-ARGININE; CALMODULIN; TETRAHYDROBIOPTERIN; EXPRESSION; OXYGENASE; PROTEINS; CELLS; HEME	Endothelial nitric oxide synthase (eNOS) is targeted to caveoli through interaction with caveolin-1 (cav-l), cav-l binding to a consensus site in the eNOS oxygenase domain is proposed to antagonize calmodulin (CaM) binding and thereby inhibit eNOS nitric oxide (NO) synthesis. To study the mechanism, we examined how cav-l scaffolding domain peptide (amino acids 82-101; cav-1P) would affect NO synthesis, NADPH oxidation, cytochrome c reduction, and ferricyanide reduction by full-length eNOS or its isolated oxygenase and reductase domains, Cav-1P equivalently inhibited NO synthesis and NADPH oxidation by full-length eNOS in a manner reversible by CaM but did not affect NADPH-independent NO synthesis by full-length eNOS or its oxygenase domain, indicating inhibition required the reductase domain. Similar concentrations of cav-1P inhibited cytochrome c reduction by full-length eNOS or the reductase domain (amino acids 492-1205) in a CaM-reversible manner, indicating cav-1P interaction with reductase or full-length eNOS are equivalent. Ferricyanide reduction was unaffected by cav-1P in all cases. Immunoblotting showed that full-length eNOS, eNOS oxygenase, and eNOS reductase all bound to an immobilized glutathione S-transferase-cav-l fusion protein. Thus, cav-l interacts independently with both oxygenase and reductase domains of eNOS. The reductase interaction occurs independent of a cav-l binding motif, is CaM-reversible, and is of sufficient affinity to match cav-1P inhibition of NO synthesis by full-length eNOS. We propose that cav-l binding to eNOS reductase compromises its ability to bind CaM and to donate electrons to the eNOS heme, thereby inhibiting NO synthesis.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Cleveland Clinic Foundation; Yeshiva University; Albert Einstein College of Medicine	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018	Lisanti, Michael/0000-0003-2034-1382; Ghosh, Sanjay/0000-0001-8624-1494	NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER; NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHEN PF, 1994, J BIOL CHEM, V269, P25062; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; IGNARRO L, 1995, ADV PHARM, V34; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Presta A, 1997, NITRIC OXIDE-BIOL CH, V1, P74, DOI 10.1006/niox.1996.0110; PRESTA A, 1998, IN PRESS J AM CHEM S; PUFAHL RA, 1995, BIOCHEMISTRY-US, V34, P1930, DOI 10.1021/bi00006a014; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; SESSA WC, 1992, J BIOL CHEM, V267, P15274; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Wu CQ, 1996, BIOCHEM BIOPH RES CO, V222, P439, DOI 10.1006/bbrc.1996.0763	33	124	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22267	22271		10.1074/jbc.273.35.22267	http://dx.doi.org/10.1074/jbc.273.35.22267			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712842	hybrid			2022-12-25	WOS:000075616600018
J	LaVallee, TM; Tarantini, F; Gamble, S; Carreira, CM; Jackson, A; Maciag, T				LaVallee, TM; Tarantini, F; Gamble, S; Carreira, CM; Jackson, A; Maciag, T			Synaptotagmin-1 is required for fibroblast growth factor-1 release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; C-2-DOMAIN PROTEINS; BINDING; DOMAIN; CELLS; P65; IDENTIFICATION; FAMILY; FORMS	By using p65 synaptotagmin-1 and fibroblast growth factor (FGF)-1:beta-galactosidase (beta-gal) NIH 3T3 cell cotransfectants, we demonstrate that a proteolytic fragment consisting of the extravesicular domain of synaptotagmin-1 is released into the extracellular compartment in response to temperature stress with similar kinetics and pharmacological properties as FGF-1:beta-gal, Using a deletion mutant that lacks 95 amino acids from the extravesicular domain of synaptotagmin-1, neither synaptotagmin-1 nor FGF-1:beta-gal are able to access the stress-induced release pathway. Furthermore, the p40 extravesicular fragment of synaptotagmin-1 is constitutively released in p40 synaptotagmin-1 NIH 3T3 cell transfectants, and this release is potentiated when the cells are subjected to temperature stress. These data demonstrate that the p40 fragment derived from synaptotagmin-1 is able to utilize the FGF-1 non-classical exocytotic pathway and that the release of FGF-1 is dependent on synaptotagmin-1.	Maine Med Ctr, Res Inst, Ctr Mol Med, Portland, ME 04106 USA; Amer Red Cross, Holland Lab, Dept Mol Biol, Rockville, MD 20855 USA	Maine Medical Center; American Red Cross	Maciag, T (corresponding author), Maine Med Ctr, Res Inst, Ctr Mol Med, 125 John Roberts Rd, Portland, ME 04106 USA.	maciat@mail.mmc.org	Tarantini, Francesca/I-6332-2012	TARANTINI, FRANCESCA/0000-0002-1390-2965	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348, P01HL054710, R01HL035627] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54710, HL35627, HL32348] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1993, J NEUROSCI, V13, P1701; Bergmeyer H.U., 1965, METHODS ENZYMATIC AN, P736, DOI [10.1016/b978-0-12-395630-9.50134-1, DOI 10.1016/B978-0-12-395630-9.50134-1]; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; Cleves AE, 1996, J CELL BIOL, V133, P1017, DOI 10.1083/jcb.133.5.1017; Damer CK, 1996, J NEUROCHEM, V67, P1661; DAVKTOV B, 1993, J BIOL CHEM, V268, P6816; ENGLEKA KA, 1992, J BIOL CHEM, V267, P11307; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; Goldberg AL, 1997, BIOL CHEM, V378, P131; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; KELLY RB, 1995, CURR BIOL, V5, P257, DOI 10.1016/S0960-9822(95)00054-6; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; Kwon OJ, 1996, FEBS LETT, V378, P135, DOI 10.1016/0014-5793(95)01430-6; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MACH H, 1995, BIOCHEMISTRY-US, V34, P9913, DOI 10.1021/bi00031a013; MARTIN GM, 1970, LAB INVEST, V23, P86; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; Oyama Y, 1997, BIOCHEM BIOPH RES CO, V240, P341, DOI 10.1006/bbrc.1997.7476; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; Shi JP, 1997, J BIOL CHEM, V272, P1142, DOI 10.1074/jbc.272.2.1142; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; TARANTINI F, 1995, J BIOL CHEM, V270, P29039, DOI 10.1074/jbc.270.49.29039; TUGAL HB, 1991, BIOCHEM J, V279, P699, DOI 10.1042/bj2790699; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0	42	65	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22217	22223		10.1074/jbc.273.35.22217	http://dx.doi.org/10.1074/jbc.273.35.22217			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712835	hybrid			2022-12-25	WOS:000075616600011
J	Collins, M; Rojnuckarin, P; Zhu, YH; Bornstein, P				Collins, M; Rojnuckarin, P; Zhu, YH; Bornstein, P			A far upstream, cell type-specific enhancer of the mouse thrombospondin 3 gene is located within intron 6 of the adjacent metaxin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; MATRIX PROTEIN COMP; SYNERGISTIC ACTIVATION; RAT CHONDROSARCOMA; GAUCHER-DISEASE; BINDING PROTEIN; RECEPTOR; ELEMENT; EXPRESSION; PSEUDOACHONDROPLASIA	Thrombospondin 3 (TSP3) is a secreted, pentameric glycoprotein whose regulation of expression and function are not well understood. Mouse Thbs3 is located just downstream from the divergently transcribed metaxin gene (Mtx), which encodes an outer mitochondrial membrane import. protein. Although Thbs3 and Mtx share a common promoter region, previous studies showed that Mtx is regulated by proximal elements that had Little effect on Thbs3 expression. In this study, transient transfection. of rat chondrosarcoma cells and NIH-3T3 fibroblasts demonstrated that Thbs3 is regulated in a cell type-specific manner by a position- and orientation-independent far upstream enhancer located within intron 6 of Mtx. Despite its greater proximity to the transcription start site of Mtx, the Thbs3 enhancer did not have a significant effect on Mtx expression. Two DNA-protein complexes, which were both required for activity, were identified when nuclear extracts were assayed with a probe containing the enhancer sequence. The protein ire one of these complexes was identified as Spl, while the other DNA-protein complex remains uncharacterized. A B-kilobase pair promoter containing the enhancer was able to direct specific expression of the E. coli lacZ gene in transgenic mice, whereas a 2-kilobase pair promoter that lacked the enhancer was inactive. Thus, despite their close proximity, the genes of the Mtx/Thbs3 gene cluster are regulated independently.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Bornstein, P (corresponding author), Univ Washington, Dept Biochem, J-341-HSB,Box 357350, Seattle, WA 98195 USA.	bornsten@u.washington.edu	Collins, Malcolm/G-4046-2011	Collins, Malcolm/0000-0002-2564-0480	FIC NIH HHS [1 F05 TW05218-01] Funding Source: Medline; NIA NIH HHS [AG 13280] Funding Source: Medline; NIDCR NIH HHS [DE 08229] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW005218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG013280] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams J. C., 1995, THROMBOSPONDIN GENE; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; ARBER S, 1995, J CELL BIOL, V131, P1083, DOI 10.1083/jcb.131.4.1083; Armstrong LC, 1997, J BIOL CHEM, V272, P6510, DOI 10.1074/jbc.272.10.6510; BEUTLER E, 1995, ADV GENET, V32, P17; BORNSTEIN P, 1993, GENOMICS, V15, P607, DOI 10.1006/geno.1993.1114; BORNSTEIN P, 1995, P NATL ACAD SCI USA, V92, P4547, DOI 10.1073/pnas.92.10.4547; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; BORNSTEIN P, 1991, P NATL ACAD SCI USA, V88, P8636, DOI 10.1073/pnas.88.19.8636; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Chen SS, 1997, NUCLEIC ACIDS RES, V25, P3261, DOI 10.1093/nar/25.16.3261; CHOI HU, 1971, P NATL ACAD SCI USA, V68, P877, DOI 10.1073/pnas.68.5.877; Collins M, 1996, NUCLEIC ACIDS RES, V24, P3661, DOI 10.1093/nar/24.19.3661; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; HOGAN B, 1986, MANIPULATING MOUSE E; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lafeuillade B, 1996, J CELL PHYSIOL, V167, P164, DOI 10.1002/(SICI)1097-4652(199604)167:1<164::AID-JCP19>3.3.CO;2-0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAWLER J, 1993, J CELL BIOL, V120, P1059, DOI 10.1083/jcb.120.4.1059; LAWLER J, 1989, BLOOD, V74, P2022; LAWLER J, 1995, J BIOL CHEM, V270, P2809, DOI 10.1074/jbc.270.6.2809; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; QABAR A, 1995, J BIOL CHEM, V270, P12725, DOI 10.1074/jbc.270.21.12725; QABAR AN, 1994, J BIOL CHEM, V269, P1262; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Tucker RP, 1997, DEV DYNAM, V208, P326, DOI 10.1002/(SICI)1097-0177(199703)208:3<326::AID-AJA4>3.0.CO;2-K; TUCKER RP, 1995, DEV DYNAM, V203, P477, DOI 10.1002/aja.1002030410; TYBULEWICZ VLJ, 1992, NATURE, V357, P407, DOI 10.1038/357407a0; Urry LA, 1998, DEV DYNAM, V211, P390, DOI 10.1002/(SICI)1097-0177(199804)211:4<390::AID-AJA10>3.0.CO;2-8; VOS HL, 1995, MAMM GENOME, V6, P820, DOI 10.1007/BF00539013; VOS HL, 1992, J BIOL CHEM, V267, P12192	47	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21816	21824		10.1074/jbc.273.34.21816	http://dx.doi.org/10.1074/jbc.273.34.21816			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705320	hybrid			2022-12-25	WOS:000075492600054
J	Ho, PD; Zechner, DK; He, HP; Dillman, WH; Glembotski, CC; McDonough, PM				Ho, PD; Zechner, DK; He, HP; Dillman, WH; Glembotski, CC; McDonough, PM			The Raf-MEK-ERK cascade represents a common pathway for alteration of intracellular calcium by Ras and protein kinase C in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; VENTRICULAR MYOCYTES; PHORBOL ESTERS; HYPERTROPHY; HEART; ACTIVATION; CONTRACTION; STIMULATION; CELLS; CARDIOMYOCYTES	Ras and protein kinase C (PKC), which regulate the Raf-MEK-ERK cascade, may participate in the development of cardiac hypertrophy, a condition characterized by diminished and prolonged contractile calcium transients. To directly examine the influence of this pathway on intracellular calcium ([Ca2+](i)), cardiac myocytes were cotransfected with effectors of this pathway and with green fluorescent protein, which allowed the living transfected myocytes to be identified and examined for [Ca2+](i) via indo-1. Transfection with constitutively active Pas (Ha-Ras(V12)) increased cell size, decreased expression of the myofibrils and the calcium-regulatory enzyme SERCA2, and reduced the magnitude and prolonged the decay phase of the contractile [Ca2+](i) transients, Similar effects on [Ca2+](i) were obtained with Ha-Ras(V12S35), a Ras mutant that selectively couples to Raf, and with constitutively active Raf. in contrast, Ha-Ras(V12C40), a Ras mutant that activates the phosphatidylinositol 3-kinase pathway, had a lesser effect. The PKC-activating phorbol ester, phorbol 12-myristate 13-acetate, also prolonged the contractile [Ca2+](i) transients. Cotransfection with dnMEK inhibited the effects of Ha-RasV12, Raf, and phorbol 12-myristate 13-acetate on [Ca2+](i). The effects of Ha-Ras(V12) and Raf on [Ca2+]i were also counteracted by SERCA2 overexpression. Both Ras and PKC may thus regulate cardiac [Ca2+](i) via the Raf-MEK-ERK cascade, and this pathway may represent a critical determinant of cardiac physiological function.	San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University	McDonough, PM (corresponding author), San Diego State Univ, Dept Biol, 5500 Campanile Dr, San Diego, CA 92182 USA.	pmcdonough@biology.sdsu.edu			NHLBI NIH HHS [HL-46345, NL/HL-25073, HL-54030] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345, R01HL054030] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bailey BA, 1997, J MOL CELL CARDIOL, V29, P1823, DOI 10.1006/jmcc.1997.0422; BASSANI JWM, 1995, BIOPHYS J, V68, P1453, DOI 10.1016/S0006-3495(95)80318-8; Bogoyevitch MA, 1996, INT J BIOCHEM CELL B, V28, P1, DOI 10.1016/1357-2725(95)00142-5; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; Giordano FJ, 1997, CIRCULATION, V96, P400; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; Gotshall KR, 1997, P NATL ACAD SCI USA, V94, P4710, DOI 10.1073/pnas.94.9.4710; GU X, 1994, CIRC RES, V75, P926, DOI 10.1161/01.RES.75.5.926; Hartong R, 1996, J MOL CELL CARDIOL, V28, P2467, DOI 10.1006/jmcc.1996.0239; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Launay S, 1997, J BIOL CHEM, V272, P10746; MARON BJ, 1981, AM HEART J, V102, P95, DOI 10.1016/0002-8703(81)90419-1; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; MOSES RL, 1989, J CELL SCI, V93, P95; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; Qi M, 1996, AM J PHYSIOL-HEART C, V271, pH1031, DOI 10.1152/ajpheart.1996.271.3.H1031; Qi M, 1997, AM J PHYSIOL-HEART C, V272, pH2416, DOI 10.1152/ajpheart.1997.272.5.H2416; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SOMMER JR, 1995, J MOL CELL CARDIOL, V27, P19, DOI 10.1016/S0022-2828(08)80004-1; THORBURN A, 1993, J BIOL CHEM, V268, P2244; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; WANG JX, 1994, AM J PHYSIOL, V267, pH918, DOI 10.1152/ajpheart.1994.267.3.H918; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; WANKERL M, 1995, J MOL MED-JMM, V73, P487; WOODROW MA, 1993, J IMMUNOL, V150, P3853; Wu PSC, 1997, ENDOCRINOLOGY, V138, P114, DOI 10.1210/en.138.1.114; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; ZIMMER G, 1992, J AM COLL CARDIOL, V20, P1135, DOI 10.1016/0735-1097(92)90369-X; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	36	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21730	21735		10.1074/jbc.273.34.21730	http://dx.doi.org/10.1074/jbc.273.34.21730			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705309	hybrid			2022-12-25	WOS:000075492600043
J	Knaus, UG; Wang, Y; Reilly, AM; Warnock, D; Jackson, JH				Knaus, UG; Wang, Y; Reilly, AM; Warnock, D; Jackson, JH			Structural requirements for PAK activation by Rac GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; P21-ACTIVATED KINASE PAK1; RESPIRATORY BURST OXIDASE; NEUTROPHIL NADPH OXIDASE; CELL-CYCLE PROGRESSION; ACTIN STRESS FIBERS; TARGET PROTEINS; CDC42 GTPASES; TRANSFORMATION; RHO	The Rho family GTPases, Rad and Rac2, regulate a variety of cellular functions including cytoskeletal reorganization, the generation of reactive oxygen species, G(1) cell cycle progression and, in concert with Ras, oncogenic transformation, Among the many putative protein targets identified for Rac (and/or Cdc42), the Ser/Thr kinase pal-activated kinase (PAK) is a prime candidate for mediating some of Rac's cellular effects, This report shows that Rad binds to and stimulates the kinase activity of PAK1 approximately 2- and 4-5-fold, respectively, better than Rac2. Mutational analysis was employed to determine the structural elements on Rac and PAK that are important for optimal binding and activation. The most notable difference between the highly homologous Rac isomers is the composition of their C-terminal polybasic domains, Mutation of these six basic residues in Rac1 to neutral amino acids dramatically decreased the ability of Rad to bind PAK1 and almost completely abolished its ability to stimulate PAK activity. Moreover, replacing the highly charged polybasic domain of Rad with the less charged domain of Rac2 (and vice versa) completely reversed the PAK binding/activation properties of the two Rac isomers, Thus, polybasic domain differences account for the disparate abilities of Rac1 and Rac2 to activate PAK, PAH proteins also contain a basic region, consisting of three contiguous lysine residues (Lys(66)-Lys(67)-Lys(68)), which lies outside of the previously identified Cdc42/Rac-binding domain. Mutation of these Lys residues to neutral residues decreased PAK binding to activated Rad and Rac2 (but not Cdc42) and greatly reduced PAK1 activation by Rad, Rac2, and Cdc42 proteins in vivo, In contrast, mutation of lysines 66-68 to basic Arg residues did not decrease (and in some cases enhanced) the ability of Rac1, Rac2, and Cdc42 to bind and activate PAK1. Our studies suggest that the polybasic domain of Rac is a novel effector domain that may allow the two Rac isomers to activate different effector proteins. In addition, our results indicate that a basic region in PAK is required for PAR activation and that binding of Rac/Cdc42 to PAK is not sufficient for kinase activation.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Knaus, UG (corresponding author), Scripps Res Inst, Dept Immunol IMM14, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	uknaus@scripps.edu			NATIONAL CANCER INSTITUTE [R01CA054298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035947] Funding Source: NIH RePORTER; NCI NIH HHS [CA54298] Funding Source: Medline; NIAID NIH HHS [AI35947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JOSEPH G, 1995, J BIOL CHEM, V270, P29079, DOI 10.1074/jbc.270.49.29079; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kozma R, 1996, MOL CELL BIOL, V16, P5069; KRECK ML, 1994, J BIOL CHEM, V269, P4161; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SHIRATAKI H, 1991, J BIOL CHEM, V266, P20672; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TAUZON PT, 1984, J BIOL CHEM, V259, P541; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	44	96	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21512	21518		10.1074/jbc.273.34.21512	http://dx.doi.org/10.1074/jbc.273.34.21512			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705280	hybrid			2022-12-25	WOS:000075492600014
J	Hou, YM; McInnes, B; Hinek, A; Karpati, G; Mahuran, D				Hou, YM; McInnes, B; Hinek, A; Karpati, G; Mahuran, D			A Pro(504)-> Ser substitution in the beta-subunit of beta-hexosaminidase a inhibits alpha-subunit hydrolysis of G(M2) ganglioside, resulting in chronic Sandhoff disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAY-SACHS-DISEASE; GM2 ACTIVATOR PROTEIN; ADULT FORM; GM2-GANGLIOSIDOSIS-B1 VARIANT; SUBSTRATE-SPECIFICITY; JEWISH FAMILY; HEXB GENE; MUTATION; IDENTIFICATION; EXPRESSION	The G(M2) gangliosidoses are caused by mutations in the genes encoding the alpha- (Tay-Sachs) or beta- (Sandhoff) subunits of heterodimeric beta-hexosaminidase A (Hex A), or the G(M2) activator protein (AB variant), a substrate-specific co-factor for Hex A. Although the active site associated with the hydrolysis of G(M2) ganglioside, as well as part of the binding site for the ganglioside-activator complex, is associated with the alpha-subunit, elements of the beta-subunit are also involved. Missense mutations in these genes normally result in the mutant protein being retained in the endoplasmic reticulum and degraded. The mutations associated with the B1-variant of Tay-Sachs are rare exceptions that directly affect residues in the alpha-active site. We have previously reported two sisters with chronic Sandhoff disease who were heterozygous for the common HEXB deletion allele, Cells from these patients had higher than expected levels of mature beta-protein and residual Hex A activity, similar to 20%. We now identify these patients' second mutant allele as a C1510T transition encoding a beta-Pro(504) --> Ser substitution, Biochemical characterization of Hex A from both patient cells and cotransfected CHO cells demonstrated that this substitution (a) decreases the level of heterodimer transport out of the endoplasmic reticulum by similar to 45%, (b) lowers its heat stability, (c) does not affect its K-m, for neutral or charged artificial substrates, and (d) lowers the ratio of units of ganglioside/units of artificial substrate hydrolyzed by a factor of 3. We concluded that the beta-Pro(504) --> Ser mutation directly affects the ability of Hex A to hydrolyze its natural substrate but not its artificial substrates, The effect of the mutation on ganglioside hydrolysis, combined with its effect on intracellular transport, produces chronic Sandhoff disease.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2C4, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; McGill University; McGill University	Mahuran, D (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	hex@sickkids.on.ca	Hinek, Aleksander/V-8790-2019		Canadian Institutes of Health Research [10435] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		ANSON DS, 1992, BIOCHEM J, V284, P789, DOI 10.1042/bj2840789; Ashkenas J, 1997, AM J HUM GENET, V61, P267, DOI 10.1086/514865; BIKKER H, 1988, NUCLEIC ACIDS RES, V16, P8198, DOI 10.1093/nar/16.16.8198; BOLHUIS PA, 1993, BIOCHIM BIOPHYS ACTA, V1182, P142, DOI 10.1016/0925-4439(93)90134-M; BROWN CA, 1991, J BIOL CHEM, V266, P15855; BROWN CA, 1989, J BIOL CHEM, V264, P21705; BROWN CA, 1993, AM J HUM GENET, V53, P497; DAZZO A, 1984, J BIOL CHEM, V259, P1070; DeGasperi R, 1996, NEUROLOGY, V47, P547, DOI 10.1212/WNL.47.2.547; DEGASPERI R, 1995, BIOCHEM MOL MED, V56, P31, DOI 10.1006/bmme.1995.1053; DREYFUS JC, 1977, AM J HUM GENET, V29, P287; Fernandes Maria, 1992, Human Molecular Genetics, V1, P759, DOI 10.1093/hmg/1.9.759; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; Gravel R. A., 1995, METABOLIC MOL BASIS, P2839; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HENG HHQ, 1993, GENOMICS, V18, P429, DOI 10.1006/geno.1993.1491; Hinek A, 1996, EXP CELL RES, V225, P122, DOI 10.1006/excr.1996.0163; Hou YM, 1996, BIOCHEMISTRY-US, V35, P3963, DOI 10.1021/bi9524575; Hou YM, 1996, AM J HUM GENET, V59, P52; KLIMA H, 1993, BIOCHEM J, V292, P571, DOI 10.1042/bj2920571; KYTZIA HJ, 1983, EMBO J, V2, P1201, DOI 10.1002/j.1460-2075.1983.tb01567.x; KYTZIA HJ, 1985, J BIOL CHEM, V260, P7568; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEINEKUGEL P, 1992, HUM GENET, V88, P513, DOI 10.1007/BF00219337; LI SC, 1995, J BIOL CHEM, V270, P24246, DOI 10.1074/jbc.270.41.24246; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHURAN DJ, 1990, J BIOL CHEM, V265, P6794; MAHURAN DJ, 1991, BIOCHIM BIOPHYS ACTA, V1096, P87, DOI 10.1016/0925-4439(91)90044-A; MCINNES B, 1992, J CLIN INVEST, V90, P306, DOI 10.1172/JCI115863; MEIER EM, 1991, J BIOL CHEM, V266, P1879; NAKAI H, 1991, CYTOGENET CELL GENET, V56, P164, DOI 10.1159/000133077; NAVON R, 1989, SCIENCE, V243, P1471, DOI 10.1126/science.2522679; NEOTE K, 1990, J CLIN INVEST, V86, P1524, DOI 10.1172/JCI114871; NOVAK A, 1979, J LIPID RES, V20, P678; ODOWD BF, 1986, J BIOL CHEM, V261, P2680; OHNO K, 1988, J NEUROCHEM, V50, P316, DOI 10.1111/j.1471-4159.1988.tb13266.x; Pennybacker M, 1996, J BIOL CHEM, V271, P17377, DOI 10.1074/jbc.271.29.17377; PROIA RL, 1984, J BIOL CHEM, V259, P3350; RedonnetVernhet I, 1996, BBA-MOL BASIS DIS, V1317, P127, DOI 10.1016/S0925-4439(96)00044-0; RUBIN M, 1988, J NEUROL SCI, V87, P103, DOI 10.1016/0022-510X(88)90058-5; SANDHOFF K, 1995, METABOLIC MOL BASES, V2, P2427; Sandhoff K, 1989, METABOLIC BASIS INHE, VII, P1807; SmiljanicGeorgijev N, 1997, BBA-PROTEIN STRUCT M, V1339, P192, DOI 10.1016/S0167-4838(97)00002-2; TANAKA A, 1990, AM J HUM GENET, V46, P329; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; Tse R, 1996, BIOCHEMISTRY-US, V35, P7599, DOI 10.1021/bi960246+; Tse R, 1996, BIOCHEMISTRY-US, V35, P10894, DOI 10.1021/bi960503a; WU YY, 1994, J BIOL CHEM, V269, P16276	48	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21386	21392		10.1074/jbc.273.33.21386	http://dx.doi.org/10.1074/jbc.273.33.21386			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694901	hybrid			2022-12-25	WOS:000075386100094
J	Ishaq, M; Zhang, YM; Natarajan, V				Ishaq, M; Zhang, YM; Natarajan, V			Activation-induced down-regulation of retinoid receptor RXR alpha expression in human T lymphocytes - Role of cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARBITRARILY PRIMED PCR; DIFFERENTIAL DISPLAY; MONOCLONAL-ANTIBODIES; INDUCED APOPTOSIS; GENE-EXPRESSION; MESSENGER-RNA; ACID; PROTEIN; INHIBITION; INTERLEUKIN-2	A 5.4-kilobase mRNA, the expression of which is downregulated after treatment of human peripheral blood mononuclear cells (PBMCs) with various T cell-activating agents, was isolated using an mRNA differential display method. Nucleotide sequence analysis identified the 5' end of this RNA as human retinoid receptor RXR alpha mRNA. Here, we report the nucleotide sequence of 3.6 kilobases of this RNA, which represents the 3' end of RXR alpha mRNA, the sequence of which has not been previously described. Activated PBMCs also expressed lower levels of RXR alpha protein, and a DNA binding assay showed that the activation-induced loss of RXRa mRNA and protein expression correlated with the loss of DNA binding activity of this protein. We present evidence that the transition from G(0)/G(1) to S phase of the cell cycle results in the down-regulation of RXR alpha expression and that cell cycle inhibitors, which block the cells in G(1) phase, prevent this down-regulation. The decrease in the levels of RXR alpha mRNA was found to be regulated at the posttranscriptional level and involved new protein synthesis. These observations indicate that the levels of RXR alpha expression in T lymphocytes are coupled to cell cycle progression, and there is tight regulatory control of RXR alpha expression during the transition from G(0)/G(1) to S phase of the cell cycle.	NCI, Frederick Canc Res & Dev Ctr, Mol Cell Biol Lab, SAIC Frederick, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Mol Retrovirol, SAIC Frederick, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Ishaq, M (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Mol Cell Biol Lab, SAIC Frederick, Frederick, MD 21702 USA.				NCI NIH HHS [N01-CO-5600] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BHARGAVA AK, 1993, P NATL ACAD SCI USA, V90, P10260, DOI 10.1073/pnas.90.21.10260; BISSONNETTE RP, 1995, MOL CELL BIOL, V15, P5576; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHANG TW, 1981, P NATL ACAD SCI-BIOL, V78, P1805, DOI 10.1073/pnas.78.3.1805; COLIGAN JE, 1992, CURRENT PROTOCOLS IM, V2; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANAUSKEABEL HM, 1994, BBA-MOL CELL RES, V1221, P115, DOI 10.1016/0167-4889(94)90003-5; IMBODEN JB, 1985, IMMUNOL TODAY, V6, P328, DOI 10.1016/0167-5699(85)90129-X; IWATA M, 1992, J IMMUNOL, V149, P3302; KURRLE R, 1991, TRANSPLANT P, V23, P272; KVANTA A, 1992, CELL SIGNAL, V4, P275, DOI 10.1016/0898-6568(92)90067-I; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, CURR OPIN IMMUNOL, V7, P274, DOI 10.1016/0952-7915(95)80015-8; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; MAKOVER D, 1991, ONCOGENE, V6, P455; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1993, RECENT PROG HORM RES, V48, P99; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; MCCALLUM FS, 1985, BIOCHEM J, V232, P725, DOI 10.1042/bj2320725; MCCLELLAND M, 1995, TRENDS GENET, V11, P242, DOI 10.1016/S0168-9525(00)89058-7; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Prashar Y, 1996, P NATL ACAD SCI USA, V93, P659, DOI 10.1073/pnas.93.2.659; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEN RQ, 1995, P NATL ACAD SCI USA, V92, P6778, DOI 10.1073/pnas.92.15.6778; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; TERADA N, 1995, J IMMUNOL, V155, P3418; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VANWAUWE JP, 1980, J IMMUNOL, V124, P2708; VONWUSSOW P, 1981, J IMMUNOL, V127, P1197; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; YANG YL, 1993, P NATL ACAD SCI USA, V90, P6170, DOI 10.1073/pnas.90.13.6170; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	41	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21210	21216		10.1074/jbc.273.33.21210	http://dx.doi.org/10.1074/jbc.273.33.21210			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694878	hybrid			2022-12-25	WOS:000075386100071
J	Thiriet, C; Hayes, JJ				Thiriet, C; Hayes, JJ			Functionally relevant histone-DNA interactions extend beyond the classically defined nucleosome core region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVE TRANSCRIPTION FACTOR; RIBOSOMAL-RNA GENE; CHROMATIN STRUCTURE; FACTOR ACCESS; ZINC FINGERS; FACTOR-IIIA; XENOPUS; BINDING; ACETYLATION; COMPLEX	We demonstrate that core histones can affect the accessibility of a DNA element positioned outside of the classically defined nucleosome core region. The distance between a well positioned nucleosome and the binding site for the 5 S-specific transcription factor TFIIIA was systematically varied and the relative binding affinity for TFIIIA determined. We found that core histone-DNA interactions attenuate the affinity of TFIIIA for its cognate DNA element by a factor of 50-100-fold even when the critical binding region lies well outside of the classically defined nucleosome core region. These results have implications for the validity of parallels drawn between the accessibility of general nucleases to DNA sequences in chromatin and the activity of actual sequence-specific DNA binding factors.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Hayes, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA.	jjhs@uhura.cc.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052426] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52426] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; CHIPEV CC, 1992, MOL CELL BIOL, V12, P45, DOI 10.1128/MCB.12.1.45; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; CLEMENS KR, 1994, J MOL BIOL, V244, P23, DOI 10.1006/jmbi.1994.1701; DELRIO S, 1991, NUCLEIC ACIDS RES, V19, P6197; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FITZGERALD PC, 1985, J BIOL CHEM, V260, P5318; GODDE JS, 1995, NUCLEIC ACIDS RES, V23, P4557, DOI 10.1093/nar/23.22.4557; GRUNSTEIN M, 1997, NATURE, V389, P149; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HAYES JJ, 1992, BIOESSAYS, V14, P597, DOI 10.1002/bies.950140905; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; Hayes JJ, 1997, METHODS, V12, P2, DOI 10.1006/meth.1997.0441; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; Howe LW, 1998, MOL CELL BIOL, V18, P1156, DOI 10.1128/MCB.18.3.1156; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Li Q, 1997, METHODS, V12, P96, DOI 10.1006/meth.1997.0451; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; RAMSAY N, 1986, J MOL BIOL, V189, P179, DOI 10.1016/0022-2836(86)90389-X; ROMANIUK PJ, 1990, J BIOL CHEM, V265, P17593; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; TULLIUS TD, 1987, TRENDS BIOCHEM SCI, V12, P297, DOI 10.1016/0968-0004(87)90145-9; URA K, 1994, J BIOL CHEM, V269, P27171; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; van Holde KE., 1989, SPRINGER SERIES MOL; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wolffe A., 1995, CHROMATIN STRUCTURE; WOLFFE AP, 1993, METH MOL G, V2, P314; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O	44	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21352	21358		10.1074/jbc.273.33.21352	http://dx.doi.org/10.1074/jbc.273.33.21352			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694896	hybrid			2022-12-25	WOS:000075386100089
J	Yarovoi, SV; Lun, XP; Picard, N; Rungta, D; Rideout, D; Pfahl, M				Yarovoi, SV; Lun, XP; Picard, N; Rungta, D; Rideout, D; Pfahl, M			Selective activation of an apoptotic retinoid precursor in macrophage cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; ACID RECEPTOR-ALPHA; BREAST-CANCER CELLS; MOBILIZING PHOSPHOLIPASE-A2; CARCINOMA CELLS; N-(4-HYDROXYPHENYL)RETINAMIDE; INHIBITION; INDUCTION; ANALOGS; LIGANDS	Advances in the understanding of the retinoid signaling mechanism has allowed the discovery of highly selective retinoids that activate only one specific receptor class, subtype, or signaling pathway. These novel compounds lack certain of the common retinoid toxicities and therefore suggest promising new approaches for therapeutic applications. We describe here a new compound, 6-[3-(l-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid methyl ester (MX84), that is selectively activated in macrophages, leading to killing of only macrophage monocyte type cells in vitro. We provide evidence that MX84 is an inactive precursor that is converted into an active apoptosis-inducing retinoid in macrophages. The macrophage activity is also secreted, and our data suggest that the secreted activity is a phospholipase D type activity. Our observation may lead to the development of molecules that are highly macrophage-selective apoptosis inducers in vivo and that could represent important novel therapeutics against diseases caused by excessive macrophage activity.	Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Maxia Pharmaceut Inc, San Diego, CA 92121 USA		Pfahl, M (corresponding author), Sidney Kimmel Canc Ctr, 10835 Altman Row, San Diego, CA 92121 USA.				NCI NIH HHS [CA55681] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Beard RL, 1996, J MED CHEM, V39, P3556, DOI 10.1021/jm960386h; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; Darmon M., 1991, SEMINARS DEV BIOL, V2, P219; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; DELIA D, 1993, CANCER RES, V53, P6036; DIVINCI A, 1994, INT J CANCER, V59, P422, DOI 10.1002/ijc.2910590322; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; GRATAS C, 1993, ANTICANCER RES, V13, P1239; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; GROSS RW, 1995, J BIOL CHEM, V270, P14855, DOI 10.1074/jbc.270.25.14855; Hsieh TC, 1995, BIOCHEM MOL BIOL INT, V37, P499; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; JONG L, 1993, J MED CHEM, V36, P2605, DOI 10.1021/jm00070a003; KISS Z, 1995, BBA-LIPID LIPID MET, V1259, P105, DOI 10.1016/0005-2760(95)00148-6; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; Lu XP, 1997, NAT MED, V3, P686, DOI 10.1038/nm0697-686; MARTIN B, 1992, SKIN PHARMACOL, V5, P57; Morris-Kay G., 1992, RETINOIDS NORMAL DEV; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; NACCACHE PH, 1993, LAB INVEST, V69, P19; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; PONZONI M, 1995, CANCER RES, V55, P853; POWIS G, 1992, CANCER RES, V52, P2835; ROBERTS AB, 1984, RETINOIDS, V2, P209; SHADENDORF D, 1996, J CELL BIOL, V135, P1889; SHAO ZM, 1995, ONCOGENE, V11, P493; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; Supino R, 1996, INT J CANCER, V65, P491, DOI 10.1002/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D; Szondy Z, 1997, MOL PHARMACOL, V51, P972, DOI 10.1124/mol.51.6.972; TANAKA Y, 1989, ARCH BIOCHEM BIOPHYS, V272, P210, DOI 10.1016/0003-9861(89)90212-9; Wang TTY, 1996, CANCER LETT, V107, P65, DOI 10.1016/0304-3835(96)04344-3; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; WILCOX RW, 1987, LIPIDS, V22, P800, DOI 10.1007/BF02535534; XIE MS, 1994, BIOCHEM J, V297, P547, DOI 10.1042/bj2970547	46	4	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20852	20859		10.1074/jbc.273.33.20852	http://dx.doi.org/10.1074/jbc.273.33.20852			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694831	hybrid			2022-12-25	WOS:000075386100024
J	Sasaki, N; Shimada, T; Sutoh, K				Sasaki, N; Shimada, T; Sutoh, K			Mutational analysis of the switch II loop of Dictyostelium myosin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; MOTOR DOMAIN; PHENOTYPIC SELECTION; DISCOIDEUM; ACTIN; SUBFRAGMENT-1; INVITRO; BINDING; IDENTIFICATION; EXPRESSION	A loop comprising residues 454-459 of Dictyostelium myosin II is structurally and functionally equivalent to the switch II loop of the G-protein family. The consensus sequence of the "switch II loop" of the myosin family is DIXGFE, In order to determine the functions of each of the conserved residues, alanine scanning mutagenesis was carried out on the Dictyostelium myosin II heavy chain gene. Examination of in vivo and in vitro motor functions of the mutant myosins revealed that the I455A and S456A mutants retained those functions, whereas the D454A, G457A, F458A and E459A mutants lost them, Biochemical analysis of the latter myosins showed that the 6457A and E459A mutants lost the basal ATPase activity by blocking of the isomerization and hydrolysis steps of the ATPase cycle, respectively. The F458A mutant, however, lost the actin-activated ATPase activity without loss of the basal ATPase activity. These results are discussed in terms of the crystal structure of the Dictyostelium myosin motor domain.	Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 153, Japan	University of Tokyo	Sutoh, K (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Komaba 3-8-1, Tokyo 153, Japan.	cksutoh@komaba.ecc.u-tokyo.acjp						BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DELOZANNE A, 1985, P NATL ACAD SCI USA, V82, P6807, DOI 10.1073/pnas.82.20.6807; EGELHOFF TT, 1991, J CELL BIOL, V112, P677, DOI 10.1083/jcb.112.4.677; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KUBALEK EW, 1992, MOL BIOL CELL, V3, P1455, DOI 10.1091/mbc.3.12.1455; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; MANSTEIN DJ, 1989, SCIENCE, V246, P656, DOI 10.1126/science.2530629; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; OHALLORAN TJ, 1990, P NATL ACAD SCI USA, V87, P8110, DOI 10.1073/pnas.87.20.8110; Onishi H, 1997, BIOCHEMISTRY-US, V36, P3767, DOI 10.1021/bi9630772; PATTERSON B, 1995, GENETICS, V140, P505; Patterson B, 1996, GENETICS, V143, P801; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Ruppel KM, 1996, MOL BIOL CELL, V7, P1123, DOI 10.1091/mbc.7.7.1123; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; RUPPEL KM, 1990, ANN NY ACAD SCI, P147; Shimada T, 1997, BIOCHEMISTRY-US, V36, P14037, DOI 10.1021/bi971837i; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SUTOH K, 1993, PLASMID, V30, P150, DOI 10.1006/plas.1993.1042; TAN JL, 1991, J BIOL CHEM, V266, P16044; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; YOUNT RG, 1995, BIOPHYS J, V68, pS44	36	77	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20334	20340		10.1074/jbc.273.32.20334	http://dx.doi.org/10.1074/jbc.273.32.20334			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685384	hybrid			2022-12-25	WOS:000075305400061
J	Silverstein, AM; Grammatikakis, N; Cochran, BH; Chinkers, M; Pratt, WB				Silverstein, AM; Grammatikakis, N; Cochran, BH; Chinkers, M; Pratt, WB			P50(cdc37) binds directly to the catalytic domain of Raf as well as to a site on hsp90 that is topologically adjacent to the tetratricopeptide repeat binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; STEROID-RECEPTOR COMPLEXES; ROUS-SARCOMA VIRUS; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; FK506-BINDING PROTEIN; POLYCLONAL ANTIBODY; ESTROGEN-RECEPTOR; TERMINAL REGION; IMMUNOPHILIN	Several protein kinases (e.g. pp60(src), v-Raf) exist in heterocomplexes with hsp90 and a 50-kDa protein that is the mammalian homolog of the yeast cell cycle control protein Cdc37. In contrast, unliganded steroid receptors exist in heterocomplexes with hsp90 and a tetratri-copeptide repeat (TPR) domain protein, such as an immunophilin. Although p50(cdc37) and TPR domain proteins bind directly to hsp90, p50(cdc37) is, not present in native steroid receptor.hsp90 heterocomplexes. To obtain some insight as to how v-Raf selects predominantly hsp90.p50(cdc37) heterocomplexes, rather than hsp90 TPR protein heterocomplexes, we have examined the binding of p50(cdc37) to hsp90 and to Raf. We show that p50(cdc37) exists in separate hsp90 heterocomplexes from the TPR domain proteins and that intact TPR proteins compete for p50(cdc37) binding to hsp90 but a protein fragment containing a TPR domain does not. This suggests that the binding site for p50(cdc37) Lies topologically adjacent to the TPR acceptor site on the surface of hsp90. Also, we show that p50(cdc37) binds directly to v-Raf, with the catalytic domain of Raf being sufficient. We propose that the combination of exclusive binding of p50(cdc37) versus a TPR domain protein to hsp90 plus direct binding of p50(cdc37) to Raf allows the protein kinase to select for the dominant hsp90 p50(cdc37) composition that is observed with a variety of protein kinase heterocomplexes immunoadsorbed from cytosols.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	University of Michigan System; University of Michigan; Tufts University; Oregon Health & Science University	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.			Cochran, Brent/0000-0002-7598-5604	NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047063] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010] Funding Source: Medline; NHLBI NIH HHS [HL47063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; Carver LA, 1997, J BIOL CHEM, V272, P11452; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; CZAR MJ, 1995, MOL ENDOCRINOL, V9, P1549, DOI 10.1210/me.9.11.1549; Dey B, 1996, MOL BIOL CELL, V7, P1405, DOI 10.1091/mbc.7.9.1405; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; ERHART JC, 1988, ONCOGENE, V3, P595; GRAMMATIKAKIS N, 1995, J BIOL CHEM, V270, P16198, DOI 10.1074/jbc.270.27.16198; GRAMMATIKAKIS N, 1996, M CELL CYCL COLD SPR, P72; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; HOFFMANN K, 1995, BIOCHEM J, V307, P5, DOI 10.1042/bj3070005; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LEBIHAN S, 1993, BIOCHEM BIOPH RES CO, V195, P600, DOI 10.1006/bbrc.1993.2088; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; REHBERGER P, 1992, P NATL ACAD SCI USA, V89, P8001, DOI 10.1073/pnas.89.17.8001; RENOIR JM, 1995, P NATL ACAD SCI USA, V92, P4977, DOI 10.1073/pnas.92.11.4977; REXIN M, 1991, J BIOL CHEM, V266, P24601; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SEGNITZ B, 1995, P NATL ACAD SCI USA, V92, P2179, DOI 10.1073/pnas.92.6.2179; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, J BIOL CHEM, V268, P24270; SMITH DF, 1993, J BIOL CHEM, V268, P18365; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STANCATO LF, 1994, J BIOL CHEM, V269, P22157; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; SULLIVAN WP, 1993, J BIOL CHEM, V268, P20373; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; YEM AW, 1992, J BIOL CHEM, V267, P2868	53	109	114	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20090	20095		10.1074/jbc.273.32.20090	http://dx.doi.org/10.1074/jbc.273.32.20090			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685350	hybrid			2022-12-25	WOS:000075305400027
J	Tamai, I; Ohashi, R; Nezu, J; Yabuuchi, H; Oku, A; Shimane, M; Sai, Y; Tsuji, A				Tamai, I; Ohashi, R; Nezu, J; Yabuuchi, H; Oku, A; Shimane, M; Sai, Y; Tsuji, A			Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUVENILE VISCERAL STEATOSIS; BORDER-MEMBRANE-VESICLES; JVS MOUSE; DEFICIENCY; EXPRESSION; CLONING; DEFECT; KIDNEY; CARDIOMYOPATHY; FIBROBLASTS	Primary carnitine deficiency, because of a defect of the tissue plasma membrane carnitine transporters, causes critical symptoms. However, the transporter has not been molecularly identified. In this study, we screened a human kidney cDNA library and assembled a cDNA-encoding OCTN2 as a homologue of the organic cation transporter OCTN1, and then we examined the function of OCTN2 as a carnitine transporter. OCTN2-cDNA encodes a polypeptide of 557 amino acids with 75.8% similarity to OCTN1. Northern blot analysis showed that OCTN2 is strongly expressed in kidney, skeletal muscle, heart, and placenta in adult humans. When OCTN2 was expressed in HEK293 cells, uptake of L-[H-3]carnitine was strongly enhanced in a sodium-dependent manner with K-m value of 4.34 mu M, whereas typical substrates for previously known organic cation transporters, tetraethylammonium and guanidine, were not good substitutes. OCTN2-mediated L-[H-3]carnitine transport was inhibited by the D-isomer, acetyl-D,L-carnitine, and gamma-butyrobebaine with high affinity and by glycinebetaine with lower affinity, whereas choline, beta-hydroxybutyric acid, gamma-aminobutyric acid, lysine, and taurine were not inhibitory. Because the observed tissue distribution of OCTN2 is consistent with the reported distribution of carnitine transport activity and the functional characteristics of OCTN2 coincide with those reported for plasma membrane carnitine transport, we conclude that OCTN2 is a physiologically important, high affinity sodium-carnitine cotransporter in humans.	Kanazawa Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9200934, Japan; Chugai Res Inst Mol Med Inc, Ibaraki, Osaka 3004101, Japan	Kanazawa University	Tsuji, A (corresponding author), Kanazawa Univ, Fac Pharmaceut Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.		TAMAI, Ikumi/D-8412-2015; SAI, Yoshimichi/L-3828-2015	SAI, Yoshimichi/0000-0003-2954-1532				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; CARTER AL, 1995, J CHILD NEUROL, V10, P3; Chun JK, 1997, PHARMACEUT RES, V14, P936, DOI 10.1023/A:1012164203648; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; ENGEL AG, 1981, NEUROLOGY, V31, P819, DOI 10.1212/WNL.31.7.819; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; Hashimoto N, 1998, BIOCHEM PHARMACOL, V55, P1729, DOI 10.1016/S0006-2952(97)00670-9; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HORIUCHI M, 1993, FEBS LETT, V326, P267, DOI 10.1016/0014-5793(93)81805-A; HORIUCHI M, 1994, BBA-MOL BASIS DIS, V1226, P25, DOI 10.1016/0925-4439(94)90054-X; HUTH PJ, 1981, J NEUROCHEM, V36, P715, DOI 10.1111/j.1471-4159.1981.tb01647.x; KISPAL G, 1987, BIOCHIM BIOPHYS ACTA, V896, P96, DOI 10.1016/0005-2736(87)90360-9; KOIZUMI T, 1988, LAB ANIM, V22, P83, DOI 10.1258/002367788780746511; KULLAKUBLICK GA, 1995, GASTROENTEROLOGY, V109, P1274, DOI 10.1016/0016-5085(95)90588-X; KUWAJIMA M, 1991, BIOCHEM BIOPH RES CO, V174, P1090, DOI 10.1016/0006-291X(91)91532-H; Kuwajima M, 1996, BIOCHEM BIOPH RES CO, V223, P283, DOI 10.1006/bbrc.1996.0885; MOLSTAD P, 1978, BIOCHIM BIOPHYS ACTA, V512, P557, DOI 10.1016/0005-2736(78)90165-7; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; PONS R, 1995, J CHILD NEUROL, V10, P8; Prasad PD, 1996, BBA-BIOMEMBRANES, V1284, P109, DOI 10.1016/0005-2736(96)00126-5; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; REBOUCHE CJ, 1977, BIOCHIM BIOPHYS ACTA, V471, P145, DOI 10.1016/0005-2736(77)90402-3; REBOUCHE CJ, 1984, ARCH BIOCHEM BIOPHYS, V235, P393, DOI 10.1016/0003-9861(84)90212-1; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SHAW RD, 1983, AM J PHYSIOL, V245, pG376, DOI 10.1152/ajpgi.1983.245.3.G376; STANLEY CA, 1991, ANN NEUROL, V30, P709, DOI 10.1002/ana.410300512; STIEGER B, 1995, BIOCHEM J, V309, P643, DOI 10.1042/bj3090643; Tamai I, 1997, FEBS LETT, V419, P107, DOI 10.1016/S0014-5793(97)01441-5; TEIN I, 1990, PEDIATR RES, V28, P247, DOI 10.1203/00006450-199009000-00020; TREEM WR, 1988, NEW ENGL J MED, V319, P1331, DOI 10.1056/NEJM198811173192006; VARY TC, 1982, AM J PHYSIOL, V242, pH585, DOI 10.1152/ajpheart.1982.242.4.H585; Vivo D, 1990, INT PEDIAT, V5, P134; Walter JH, 1996, ARCH DIS CHILD, V74, P475, DOI 10.1136/adc.74.6.475; Zhang L, 1997, MOL PHARMACOL, V51, P913, DOI 10.1124/mol.51.6.913	38	562	578	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20378	20382		10.1074/jbc.273.32.20378	http://dx.doi.org/10.1074/jbc.273.32.20378			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685390	hybrid			2022-12-25	WOS:000075305400067
J	Petermann, R; Mossier, BM; Aryee, DNT; Khazak, V; Golemis, EA; Kovar, H				Petermann, R; Mossier, BM; Aryee, DNT; Khazak, V; Golemis, EA; Kovar, H			Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II	ONCOGENE			English	Article						ewing tumors; transcription; transformation; two-hybrid-system; sigma factors	EWINGS-SARCOMA TRANSLOCATION; TRANSCRIPTION FACTOR-TFIIB; BINDING PROTEIN; DNA-BINDING; CHROMOSOME-TRANSLOCATION; EWS GENE; MYXOID LIPOSARCOMA; MALIGNANT-MELANOMA; ACTIVATION DOMAIN; MYELOID-LEUKEMIA	As a result of the t(11;22)(q24;q12) chromosomal translocation characterizing the Ewing family of tumors (ET), the amino terminal portion of EWS, an RNA binding protein of unknown function, is fused to the DNA-binding domain of the ets transcription factor Fli1. The hybrid EWS-Fli1 protein acts as a strong transcriptional activator and, in contrast to wildtype Fli1, is a potent transforming agent. Similar rearrangements involving EWS or the highly homologous TLS with various transcription factors have been found in several types of human tumors. Employing yeast two-hybrid cloning we isolated the seventh largest subunit of human RNA polymerase II (hsRPB7) as a protein that specifically interacts with the amino terminus of EWS, This association was confirmed by in vitro immunocoprecipitation. In nuclear extracts, hsRPB7 was found to copurify with EWS-Fli1 but not with Fli1, Overexpression of recombinant hsRPB7 specifically increased gene activation by EWS-chimeric transcription factors. Replacement of the EWS portion by hsRPB7 in the oncogenic fusion protein restored the transactivating potential of the chimera. Our results suggest that the interaction of the amino terminus of EWS with hsRPB7 contributes to the transactivation function of EWS-Fli1 and, since hsRPB7 has characteristics of a regulatory subunit of RNA polymerase II, may influence promoter selectivity.	St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Saint Anna Children's Hospital; Fox Chase Cancer Center	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.			Kovar, Heinrich/0000-0001-6873-9109; Golemis, Erica/0000-0003-3618-3673	NIGMS NIH HHS [GM 708041] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alliegro MC, 1996, DEV BIOL, V174, P288, DOI 10.1006/dbio.1996.0074; [Anonymous], 1991, Methods Enzymol, V194, P1; AURIAS A, 1983, CR ACAD SCI III-VIE, V296, P1105; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BERTOLOTTI A, 1998, MOL CELL BIOL, V13, P6984; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CARE CT, 1983, C R SEANCES ACAD 3, V296, P1101; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; Clark J, 1996, ONCOGENE, V12, P229; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fujimura Y, 1996, ONCOGENE, V12, P159; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; Hackl W, 1996, J MOL BIOL, V264, P843, DOI 10.1006/jmbi.1996.0681; ICHIKAWA H, 1994, CANCER RES, V54, P2865; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEON IS, 1995, ONCOGENE, V10, P1229; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; KHAZAK V, 1998, IN PRESS MOL CELL BI; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; OHNO T, 1993, CANCER RES, V53, P5869; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAO VN, 1993, ONCOGENE, V8, P2167; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	49	109	124	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	1998	17	5					603	610		10.1038/sj.onc.1201964	http://dx.doi.org/10.1038/sj.onc.1201964			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704926				2022-12-25	WOS:000075195300008
J	Wicking, C; Simms, LA; Evans, T; Walsh, M; Chawengsaksophak, K; Beck, F; Chenevix-Trench, G; Young, J; Jass, J; Leggett, B; Wainwright, B				Wicking, C; Simms, LA; Evans, T; Walsh, M; Chawengsaksophak, K; Beck, F; Chenevix-Trench, G; Young, J; Jass, J; Leggett, B; Wainwright, B			CDX2, a human homologue of Drosophila caudal, is mutated in both alleles in a replication error positive colorectal cancer	ONCOGENE			English	Article						CDX2; caudal; colorectal cancer; microsatellite instability	MICROSATELLITE INSTABILITY; EXPRESSION; CARCINOMA; RECEPTOR; MUCIN; GENE	The Cdx2 gene is one of three murine homologues of the Drosophila homeobox gene caudal, Mice heterozygous for a null mutation in Cdx2 exhibit a variable phenotype including tail abnormalities, stunted growth and a homeotic shift of vertebrae. Most strikingly, however, 90% of heterozygous mice were reported to develop multiple intestinal adenomatous polyps, most notably in the proximal colon (Chawengsaksophak et al., 1997). These observations led us to propose that mutation of CDX2 may be involved in the genesis of some human colorectal tumours, A survey of DNA from 85 colorectal tumours revealed that one with extensive microsatellite instability (RER+ phenotype) has mutations in both alleles of CDX2, Both mutations occur in coding regions which contain repetitive elements and are consistent with those found in RER+ tumours.	Univ Queensland, Ctr Mol & Cellular Biol, St Lucia, Qld 4072, Australia; Bancroft Ctr, Glaxo Gastroenterol Lab, Herston, Qld 4029, Australia; Univ Queensland, Sch Med, Dept Pathol, Brisbane, Qld 4006, Australia; Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3052, Australia; Queensland Inst Med Res, Herston, Qld 4029, Australia	University of Queensland; University of Queensland; Florey Institute of Neuroscience & Mental Health; University of Melbourne; QIMR Berghofer Medical Research Institute	Wainwright, B (corresponding author), Univ Queensland, Ctr Mol & Cellular Biol, St Lucia, Qld 4072, Australia.		Young, Joanne P/H-7774-2014; Chawengsaksophak, Kallayanee/G-4427-2014; Leggett, Barbara A/D-3579-2011; Young, Joanne P/B-9981-2011; Wicking, Carol/J-1814-2014	Chawengsaksophak, Kallayanee/0000-0001-9401-2122; Wainwright, Brandon/0000-0003-0406-2092; Chenevix-Trench, Georgia/0000-0002-1878-2587; Evans, Timothy/0000-0001-7962-6863; Leggett, Barbara/0000-0003-2062-7380; Simms, Lisa/0000-0002-5387-7397; Wicking, Carol/0000-0002-7225-3803				Ajioka Y, 1996, J CLIN PATHOL, V49, P560, DOI 10.1136/jcp.49.7.560; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; EE HC, 1995, AM J PATHOL, V147, P586; JAMES R, 1994, J BIOL CHEM, V269, P15229; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; WALSH MD, 1993, J CLIN PATHOL, V46, P922, DOI 10.1136/jcp.46.10.922	9	89	96	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					657	659		10.1038/sj.onc.1201971	http://dx.doi.org/10.1038/sj.onc.1201971			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704932				2022-12-25	WOS:000075195300014
J	Fedele, M; Berlingieri, MT; Scala, S; Chiariotti, L; Viglietto, G; Rippel, V; Bullerdiek, J; Santoro, M; Fusco, A				Fedele, M; Berlingieri, MT; Scala, S; Chiariotti, L; Viglietto, G; Rippel, V; Bullerdiek, J; Santoro, M; Fusco, A			Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts	ONCOGENE			English	Article						lipoma; chromatin; oncogene; tumor	NUCLEAR PROTEINS; THYROID-CELLS; CDNA CLONING; Y PROTEINS; BETA GENE; EXPRESSION; BINDING; PHOSPHOPROTEIN; ORGANIZATION; ELEMENTS	Overexpression of the high mobility group I (HMGI) proteins is often associated with the malignant phenotype. Moreover, many benign human tumors, mainly of mesenchymal origin, are characterized by rearrangements of the HMGI-C gene. In most cases, HMGI-C alterations involve breaks within the third intron of the gene resulting in aberrant transcripts carrying exons from 1-3, which encode the three DNA binding domains, fused to ectopic sequences. Here, we show that the expression of a truncated form of HMGI-C protein carrying only the three DNA-binding domains, or of a fusion protein carrying the three DNA-binding domains of HMGI-C and the LIM domains of the lipoma preferred partner gene (LPP) protein, causes malignant transformation of NIH3T3 cells. The unrearranged wildtype HMGI-C cDNA did not exert any transforming activity. These findings indicate that rearranged forms of HMGI-C play a role in cell transformation.	Univ Reggio Calabria, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Ist Nazl Tumori, Fdn Senatore Pascale, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg Napoli, CNR,Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Bremen, Ctr Human Genet & Genet, Bremen, Germany	Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; IRCCS Fondazione Pascale; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Bremen	Fusco, A (corresponding author), Univ Reggio Calabria, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, Via Tommaso Campanella, I-88100 Catanzaro, Italy.		Viglietto, Giuseppe/AAC-2852-2019; Chiariotti, Lorenzo/AAC-5262-2022; Fedele, Monica/C-1417-2015; Scala, Stefania/K-1380-2016	Viglietto, Giuseppe/0000-0003-2327-7515; Fedele, Monica/0000-0002-9171-1312; Scala, Stefania/0000-0001-9524-2616; Fusco, Alfredo/0000-0003-3332-5197; CHIARIOTTI, Lorenzo/0000-0001-6097-4171				ASHAR HR, 1995, CELL, V82, P57; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Bol S, 1996, CANCER GENET CYTOGEN, V90, P88, DOI 10.1016/0165-4608(96)00062-3; CHAN KY, 1995, NUCLEIC ACIDS RES, V21, P4262; Chiappetta G, 1996, ONCOGENE, V13, P2439; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DU W, 1994, PNAS, V91, P113; ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; Fedele M, 1996, CANCER RES, V56, P1896; FERRANTI P, 1992, J BIOL CHEM, V267, P22486; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Kazmierczak B, 1996, ONCOGENE, V12, P515; LEWIS H, 1994, MOL CELL BIOL, V15, P3738; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Staats B, 1996, BREAST CANCER RES TR, V38, P299, DOI 10.1007/BF01806149; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	36	111	114	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					413	418		10.1038/sj.onc.1201952	http://dx.doi.org/10.1038/sj.onc.1201952			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696033				2022-12-25	WOS:000075043000002
J	Shao, NS; Chai, YL; Cui, JQ; Wang, N; Aysola, K; Reddy, ESP; Rao, VN				Shao, NS; Chai, YL; Cui, JQ; Wang, N; Aysola, K; Reddy, ESP; Rao, VN			Induction of apoptosis by Elk-1 and Delta Elk-1 proteins	ONCOGENE			English	Article						Elk-1; Delta Elk-1; apoptosis; calcium ionophore; breast cancer; MCF-7; Rat-1	SIGNAL-TRANSDUCTION PATHWAYS; ETS TRANSCRIPTION FACTOR; TERNARY COMPLEX FACTORS; SERUM RESPONSE ELEMENT; PROGRAMMED CELL-DEATH; ACTIVATION; FAMILY; GENE; PROTOONCOGENE; FIBROBLASTS	Elk-1, an ets related gene codes for at least two splice variants Elk-1, which regulates c-fos transcription and Delta Elk-1, both of which function as transcriptional activators. To investigate the role of Elk-1 and Delta Elk-1 proteins in apoptosis; we have developed rat fibroblast cell lines and human breast cancer cell lines expressing Delta Elk-1 and Delta Elk-1. The expression of Elk-1 and Delta Elk-1 proteins in the Elk-1/Delta Elk-1 transfectants were analysed by immunofluorescence, immunohistochemistry, and Western blot analysis. The Elk-1 unlike Delta Elk-1 transfectants showed a shortened and flattened morphology compared to the parental cells. We have found that calcium ionophore treatment of Rat-1 Elk-1, MCF-7 Elk-1, Rat-1 Delta Elk-1 and MCF-7 Delta Elk-1 transfectants resulted in programmed cell death. These results indicate that constitutive expression of Elk-1 and Delta Elk-1 proteins triggers apoptosis in Rat-1 fibroblasts and breast cancer cells when treated with calcium ionophore.	Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, Philadelphia, PA 19102 USA	Drexel University	Rao, VN (corresponding author), Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, MS 481,New Coll Bldg,Broad & Vine St, Philadelphia, PA 19102 USA.			Wang, Nan/0000-0003-0330-8636	NCI NIH HHS [CA57322, CA50507, CA58642] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050507, R01CA058642, R01CA057322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Athanasiou M, 1996, ONCOGENE, V12, P337; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COHEN JJ, 1984, J IMMUNOL, V132, P38; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JIMENEZ B, 1995, ONCOGENE, V10, P811; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; JOSEPH R, 1993, MOL BRAIN RES, V17, P70, DOI 10.1016/0169-328X(93)90074-Y; KONDO S, 1994, BRIT J CANCER, V70, P421, DOI 10.1038/bjc.1994.321; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MARIAS R, 1993, CELL, V73, P381; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Nozaki M, 1996, DNA CELL BIOL, V15, P855, DOI 10.1089/dna.1996.15.855; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Preston GA, 1996, MOL CELL BIOL, V16, P211; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAO VN, 1992, ONCOGENE, V7, P65; Rao VN, 1996, ONCOGENE, V12, P523; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SEARLE J, 1982, PATHOL ANNU, V17, P229; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; Shao NS, 1996, ONCOGENE, V13, P1; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YI HK, 1997, ONCOGENE, V14, P1250	42	40	43	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					527	532		10.1038/sj.onc.1201931	http://dx.doi.org/10.1038/sj.onc.1201931			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696047	Bronze			2022-12-25	WOS:000075043000016
J	Patel, AS; Schechter, GL; Wasilenko, WJ; Somers, KD				Patel, AS; Schechter, GL; Wasilenko, WJ; Somers, KD			Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro	ONCOGENE			English	Article						cortactin; overexpression; motility; invasion	HUMAN BREAST-CANCER; CYCLIN-DEPENDENT KINASES; TYROSINE PHOSPHORYLATION; ALTERED EXPRESSION; HUMAN CARCINOMAS; CONTACT SITES; AMPLIFICATION; CORTACTIN; SUBSTRATE; ONCOGENE	Cortactin, a p80/85 protein first identified as a src kinase substrate, is thought to be involved in the signaling pathway of mitogenic receptors and adhesion molecules mediating cytoskeletal reorganization. The cortactin gene, EMS1, maps to chromosome 11q13, a region amplified in head and neck squamous cell carcinomas (HNSCC) and breast cancer, which display lymph node metastasis and an unfavorable clinical outcome. To further address the role of cortactin in the malignant phenotype of cells, we stably overexpressed cortactin in NIH3T3 fibroblasts and evaluated the effects of elevated cortactin on cellular proliferation, motility and invasiveness. Cortactin overexpressing cells did not display any striking morphological changes, nor any significant differences in cell proliferation or saturation density as compared to control NIH3T3 cells. Furthermore, the cortactin overexpressing cells were anchorage dependent for growth. Interestingly, cortactin overexpressing cells were more motile and invasive in modified Boyden chamber assays. These results suggest that overexpression of cortactin may play a role in tumor progression by influencing tumor cell migration and invasion.	Eastern Virginia Med Sch, Dept Immunol Microbiol, Norfolk, VA 23501 USA; Eastern Virginia Med Sch, Dept Otolaryngol Head & Neck Surg, Head & Neck Tumor Biol Program, Norfolk, VA 23501 USA	Eastern Virginia Medical School; Eastern Virginia Medical School	Somers, KD (corresponding author), Eastern Virginia Med Sch, Dept Immunol Microbiol, Norfolk, VA 23501 USA.							ADELAIDE J, 1988, ONCOGENE, V2, P413; BATES S, 1994, ONCOGENE, V9, P71; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; CUNNINGHAM CC, 1992, CANCER METAST REV, V11, P69; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; FANTL V, 1993, CANCER SURV, V18, P77; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; LOVEC H, 1994, ONCOGENE, V9, P323; MAA MC, 1992, ONCOGENE, V7, P2429; MULLER D, 1994, ORAL ONCOL, V30B, P113; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Patel AM, 1996, ONCOGENE, V12, P31; PETERS G, 1995, BREAST CANCER RES TR, V33, P125, DOI 10.1007/BF00682720; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WILLIAMS ME, 1993, ARCH OTOLARYNGOL, V119, P1238; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; XU L, 1994, INT J CANCER, V59, P383, DOI 10.1002/ijc.2910590316; ZHAN X, 1993, J BIOL CHEM, V268, P24427	33	124	131	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3227	3232		10.1038/sj.onc.1201850	http://dx.doi.org/10.1038/sj.onc.1201850			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681820				2022-12-25	WOS:000074343600002
J	Bartoli, M; Monneron, A; Ladant, D				Bartoli, M; Monneron, A; Ladant, D			Interaction of calmodulin with striatin, a WD-repeat protein present in neuronal dendritic spines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITIES; NMDA RECEPTOR; KINASE-II; BINDING; SUBUNIT; IDENTIFICATION; MUTAGENESIS; EXPRESSION; FAMILY	Rat striatin, a quantitatively minor protein belonging to the WD-repeat family of proteins, is a Ca2+/calmodulin-binding protein mostly expressed in the striatum and in the motor and olfactory systems (Castets, F., Bartoli, M., Barnier, J. V., Baillat, G., Salin, P., Moqrich, A., Bourgeois, J. P., Denizot, F., Rougon, G., Calothy, G., and Monneron, A. (1996) J. Cell Biol. 134, 1051-1062). Generally associated with membranes, striatin is mostly found in dendritic spines where it is likely to play a role in Ca2+-signaling events. In this paper, we characterize its calmodulin-binding properties. By using deletion mapping and site-directed mutagenesis, we identified the sequence located between amino acids 149 and 166 as the main calmodulin-binding site. The predicted corresponding peptide is potentially able to form a basic amphiphilic helix, as is often the case for many known calmodulin-binding sites. Calmodulin binding to striatin is Ca2+-dependent, with half-maximal binding occurring around 0.5 mu M free Ca2+. In the presence of Ca2+, the equilibrium dissociation constant of calmodulin/striatin fusion protein complex is 40 +/- 5 nM. me also show that brain striatin subcellular localization, as studied by tissue fractionation, is Ca2+-dependent, this effect being probably mediated by calmodulin. Our results are in agreement with the hypothesis that striatin is a transducer involved in Ca2+ signaling or an adapter protein involved in regulating macromolecular assemblies within dendritic spines.	CNRS, UPR 9013, Lab Neurobiol Cellulaire & Fonct, F-13402 Marseille 20, France; Inst Pasteur, CNRS, URA 1129, Unite Biochim Cellulaire, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Monneron, A (corresponding author), CNRS, UPR 9013, Lab Neurobiol Cellulaire & Fonct, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	monneron@lnf.cnrs-mrs.fr	Bartoli, Marc/O-8893-2016; Bartoli, Marc/Q-5979-2017	Bartoli, Marc/0000-0003-3339-9858; Bartoli, Marc/0000-0003-3339-9858; LADANT, Daniel/0000-0003-1955-548X				Ansaldi M, 1996, ANAL BIOCHEM, V234, P110, DOI 10.1006/abio.1996.0060; Castets F, 1996, J CELL BIOL, V134, P1051, DOI 10.1083/jcb.134.4.1051; Denk W, 1996, CURR OPIN NEUROBIOL, V6, P372, DOI 10.1016/S0959-4388(96)80122-X; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GLENNEY JR, 1984, EUR J BIOCHEM, V144, P529, DOI 10.1111/j.1432-1033.1984.tb08498.x; GNEGY ME, 1993, ANNU REV PHARMACOL, V33, P45, DOI 10.1146/annurev.pa.33.040193.000401; GRAB DJ, 1979, J BIOL CHEM, V254, P8690; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; LADANT D, 1992, J BIOL CHEM, V267, P2244; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Liu MY, 1997, J BIOL CHEM, V272, P18801, DOI 10.1074/jbc.272.30.18801; MOQRICH A, 1998, IN PRESS GENOMICS; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Newbell BJ, 1997, BIOCHEMISTRY-US, V36, P1295, DOI 10.1021/bi962452n; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PATEL SN, 1988, BRAIN RES, V449, P34, DOI 10.1016/0006-8993(88)91021-9; Salin P, 1998, J COMP NEUROL, V397, P41; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SEGAL M, 1995, TRENDS NEUROSCI, V18, P468, DOI 10.1016/0166-2236(95)92765-I; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sonnenburg WK, 1995, J BIOL CHEM, V270, P30989, DOI 10.1074/jbc.270.52.30989; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; Suzuki T, 1997, J NEUROCHEM, V69, P436; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Warr CG, 1996, BIOCHEM J, V314, P497, DOI 10.1042/bj3140497; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I; Yoshimura Y, 1997, J BIOL CHEM, V272, P26354, DOI 10.1074/jbc.272.42.26354; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0	35	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22248	22253		10.1074/jbc.273.35.22248	http://dx.doi.org/10.1074/jbc.273.35.22248			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712839	hybrid			2022-12-25	WOS:000075616600015
J	Stuible, HP; Meier, S; Wagner, C; Hannappel, E; Schweizer, E				Stuible, HP; Meier, S; Wagner, C; Hannappel, E; Schweizer, E			A novel phosphopantetheine : protein transferase activating yeast mitochondrial acyl carrier protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHETASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; BIOCHEMICAL-CHARACTERIZATION; TRANSFORMATION; BIOSYNTHESIS; SYNTHASE; PEPTIDE; GENES; EXPRESSION	In Saccharomyces cerevisiae, the low molecular weight acyl carrier protein (ACP) of mitochondrial type ZI fatty acid synthase (FAS) and the cytoplasmic type I FAS multienzyme contain 4'-phosphopantetheine as a prosthetic group. Sequence alignment studies with the recently isolated phosphopantetheine:protein transferase (PPTase), Ppt1p, from Brevibacterium ammoniagenes revealed the yeast open reading frame, YPL148C, as a potential PPTase gene (25% identical and 43% conserved amino acids). In accordance with this similarity, pantetheinylation of mitochondrial ACP was lost upon disruption of YPL148C. In contrast, biosynthesis of cytoplasmic holo-FAS remained unaffected by this mutation. According to these characteristics, the newly identified gene was designated as PPT2. Similar to ACP null mutants, cellular lipoic acid synthesis and, hence, respiration were abolished in PPT2 deletants. ACP pantetheinylation, Lipoic acid synthesis, and respiratory competence were restored upon transformation of PPT2 mutants with cloned PPT2 DNA, In vitro, holo-ACP synthesis was achieved by incubating apo-ACP with coenzyme A in the presence of purified Ppt2p. The homologous yeast enzyme could be replaced, in this assay, by the ACP synthase (EC 2.7.8.7) of Escherichia coli but not by the type I FAS-specific PPTase of B. ammoniagenes, Ppt1p. These results conform with the inability of Ppt2p to activate the cytoplasmic type I FAS complex of yeast.	Univ Erlangen Nurnberg, Lehrstuhl Biochem, Fak Med, Inst Mikrobiol Biochem & Genet, D-91058 Erlangen, Germany; Univ Erlangen Nurnberg, Fak Med, Inst Biochem, D-91058 Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg	Schweizer, E (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Biochem, Fak Med, Inst Mikrobiol Biochem & Genet, Staudtstr 5, D-91058 Erlangen, Germany.							Bollag D.M., 1996, PROTEIN METHODS; BORELL CW, 1988, CURR GENET, V13, P299, DOI 10.1007/BF00424423; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; CHUMAN L, 1989, EUR J BIOCHEM, V184, P643, DOI 10.1111/j.1432-1033.1989.tb15061.x; FERNANDEZ MD, 1990, PLANT CELL, V2, P195, DOI 10.1105/tpc.2.3.195; Gehring AM, 1997, BIOCHEMISTRY-US, V36, P8495, DOI 10.1021/bi970453p; GUERRA DJ, 1988, J BIOL CHEM, V263, P4386; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HANNAPPEL E, 1988, ARCH BIOCHEM BIOPHYS, V260, P546, DOI 10.1016/0003-9861(88)90480-8; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V779, P65; HENSCHEN A, 1986, ADV METHODS PROTEIN, P244; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; Huang ME, 1997, YEAST, V13, P1181, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1181::AID-YEA169>3.3.CO;2-F; KEATING DH, 1995, J BIOL CHEM, V270, P22229, DOI 10.1074/jbc.270.38.22229; Kleinkauf H, 1996, EUR J BIOCHEM, V236, P335, DOI 10.1111/j.1432-1033.1996.00335.x; Ku J, 1997, CHEM BIOL, V4, P203, DOI 10.1016/S1074-5521(97)90289-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; LAMBALOT RH, 1995, J BIOL CHEM, V270, P24658, DOI 10.1074/jbc.270.42.24658; LYNEN F, 1980, EUR J BIOCHEM, V112, P431; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; PRESCOTT DJ, 1975, METHOD ENZYMOL, V25, P95; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; REED KE, 1993, J BACTERIOL, V175, P1325, DOI 10.1128/JB.175.5.1325-1336.1993; ROCK CO, 1979, J BIOL CHEM, V254, P9778; ROISE D, 1988, J BIOL CHEM, V263, P4509; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; SCHATZ G, 1987, EUR J BIOCHEM, V165, P1, DOI 10.1111/j.1432-1033.1987.tb11186.x; Schneider R, 1997, FEBS LETT, V407, P249, DOI 10.1016/S0014-5793(97)00360-8; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; SCHORR R, 1994, J PLANT PHYSIOL, V143, P407, DOI 10.1016/S0176-1617(11)81800-6; SCHULLER HJ, 1992, EUR J BIOCHEM, V203, P607, DOI 10.1111/j.1432-1033.1992.tb16590.x; Schwank S, 1997, CURR GENET, V31, P462, DOI 10.1007/s002940050231; SONI R, 1993, CURR GENET, V24, P455, DOI 10.1007/BF00351857; Stuible HP, 1997, EUR J BIOCHEM, V248, P481, DOI 10.1111/j.1432-1033.1997.00481.x; SULO P, 1993, J BIOL CHEM, V268, P17634; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; Wada H, 1997, P NATL ACAD SCI USA, V94, P1591, DOI 10.1073/pnas.94.4.1591	39	48	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22334	22339		10.1074/jbc.273.35.22334	http://dx.doi.org/10.1074/jbc.273.35.22334			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712852	hybrid			2022-12-25	WOS:000075616600028
J	van de Wal, M; D'Hulst, C; Vincken, JP; Buleon, A; Visser, R; Ball, S				van de Wal, M; D'Hulst, C; Vincken, JP; Buleon, A; Visser, R; Ball, S			Amylose is synthesized in vitro by extension of and cleavage from amylopectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALGA CHLAMYDOMONAS-REINHARDTII; STARCH SYNTHASE ACTIVITY; BRANCHING ENZYME; GRANULE; WAXY; BIOSYNTHESIS; BIOGENESIS; STORAGE; MUTANT	Amylose synthesis was obtained in vitro from purified Chlamydomonas reinhardtii starch granules. Labeling experiments clearly indicate that initially the major granule-bound starch synthase extends glucans available on amylopectin, Amylose synthesis occurs thereafter at rates approaching or exceeding those of net polysaccharide synthesis. Although these results suggested that amylose originates from cleavage of a pre-existing external amylopectin chain, such transfer of chains from amylopectin to amylose was directly evidenced from pulse-chase experiments. The structure of the in vitro synthesized amylose could not be distinguished from in vivo synthesized amylose by a variety of methods. Moreover high molecular mass branched amylose synthesis preceded that of the low molecular mass, suggesting that chain termination occurs consequently to glucan cleavage. Short pulses of synthesis followed by incubation in buffer with or without ADP-Glc prove that transfer requires the presence of the glucosyl-nucleotide. Taken together, these observations make a compelling case for amylopectin acting as the in vivo primer for amylose synthesis. They further prove that extension is followed by cleavage. A model is presented that can explain the major features of amylose synthesis in plants. The consequences of intensive amylose synthesis on the crystal organization of amylopectin are reported through wide angle x-ray analysis of the in vitro synthesized polysaccharides.	Univ Sci & Technol Lille, Chim Biol Lab, CNRS, UMR 111, F-59655 Villeneuve Dascq, France; INRA, Ctr Rech Agroalimentaires, F-44316 Nantes 03, France; Agr Univ Wageningen, Grad Sch Expt Plant Sci, Dept Plant Breeding, NL-6700 AJ Wageningen, Netherlands	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; INRAE; Wageningen University & Research	Ball, S (corresponding author), Univ Sci & Technol Lille, Chim Biol Lab, CNRS, UMR 111, F-59655 Villeneuve Dascq, France.	steven.ball@univ-lille1.fr	Visser, Richard GF/B-3423-2012; D'HULST, Christophe/B-2072-2012; Vincken, Jean-Paul/A-1778-2009; D'Hulst, Christophe/AAX-2809-2020	Visser, Richard GF/0000-0002-0213-4016; D'HULST, Christophe/0000-0002-5556-9099; D'Hulst, Christophe/0000-0002-5556-9099; Ball, Steven/0000-0003-1629-1650				BABA T, 1987, STARCH-STARKE, V39, P52, DOI 10.1002/star.19870390207; BALL S, 1991, PLANTA, V185, P17, DOI 10.1007/BF00194509; BALL SG, 1990, PLANT SCI, V66, P1, DOI 10.1016/0168-9452(90)90162-H; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BULEON A, 1982, STARKE, V34, P361, DOI 10.1002/star.19820341102; Buleon A, 1997, PLANT PHYSIOL, V115, P949, DOI 10.1104/pp.115.3.949; BULEON A, 1998, IN PRESS INT J BIOL; DEFEKETE MAR, 1960, NATURE, V187, P918, DOI 10.1038/187918a0; DELRUE B, 1992, J BACTERIOL, V174, P3612, DOI 10.1128/JB.174.11.3612-3620.1992; DENYER K, 1993, PLANT J, V4, P191, DOI 10.1046/j.1365-313X.1993.04010191.x; DENYER K, 1995, PLANT CELL ENVIRON, V18, P1019, DOI 10.1111/j.1365-3040.1995.tb00612.x; Denyer K, 1996, PLANT J, V10, P1135, DOI 10.1046/j.1365-313X.1996.10061135.x; ERIKSSON G, 1969, HEREDITAS-GENETISK A, V63, P180; FONTAINE T, 1993, J BIOL CHEM, V268, P16223; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; HOVENKAMPHERMELINK JHM, 1987, THEOR APPL GENET, V75, P217, DOI 10.1007/BF00249167; IMBERTY A, 1991, STARCH-STARKE, V43, P375, DOI 10.1002/star.19910431002; JANE JL, 1993, CARBOHYD RES, V247, P279, DOI 10.1016/0008-6215(93)84260-D; KONISHI Y, 1985, AGR BIOL CHEM TOKYO, V49, P1965, DOI 10.1080/00021369.1985.10867018; LELOIR LF, 1961, J BIOL CHEM, V236, P636; LIBESSART N, 1995, PLANT CELL, V7, P1117; MACDONALD FD, 1985, PLANT PHYSIOL, V78, P849, DOI 10.1104/pp.78.4.849; MADDELEIN ML, 1994, J BIOL CHEM, V269, P25150; MURATA T, 1965, BIOCHEM BIOPH RES CO, V18, P371, DOI 10.1016/0006-291X(65)90716-3; NAKAMURA T, 1995, MOL GEN GENET, V248, P253, DOI 10.1007/BF02191591; NELSON OE, 1962, BIOCHEM BIOPH RES CO, V9, P297, DOI 10.1016/0006-291X(62)90043-8; Planchot V, 1997, CARBOHYD RES, V298, P319, DOI 10.1016/S0008-6215(96)00317-5; PONSTEIN AS, 1991, STARCH-STARKE, V43, P208, DOI 10.1002/star.19910430603; Preiss J., 1996, PHOTOASSIMILATE DIST, V3, p63?96; RECONDO E, 1961, BIOCHEM BIOPH RES CO, V6, P85, DOI 10.1016/0006-291X(61)90389-8; Takata H, 1996, CARBOHYD RES, V295, P91, DOI 10.1016/S0008-6215(96)00217-0; Takata H, 1996, J BACTERIOL, V178, P1600, DOI 10.1128/jb.178.6.1600-1606.1996; VandenKoornhuyse N, 1996, J BIOL CHEM, V271, P16281, DOI 10.1074/jbc.271.27.16281; WAKELIN JH, 1959, J APPL PHYS, V30, P1654, DOI 10.1063/1.1735031; Weatherwax P, 1922, GENETICS, V7, P568	35	94	97	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22232	22240		10.1074/jbc.273.35.22232	http://dx.doi.org/10.1074/jbc.273.35.22232			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712837	Green Published, hybrid			2022-12-25	WOS:000075616600013
J	DeWitt, ND; dos Santos, CFT; Allen, KE; Slayman, CW				DeWitt, ND; dos Santos, CFT; Allen, KE; Slayman, CW			Phosphorylation region of the yeast plasma-membrane H+-ATPase - Role in protein folding and biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; DOMINANT LETHAL MUTATIONS; CYSTEINE-RICH REPEAT; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; CYSTIC-FIBROSIS; FAMILIAL HYPERCHOLESTEROLEMIA; DIRECTED MUTAGENESIS; SECRETORY VESICLES; GENE	Mutations at the phosphorylation site (Asp-378) of the yeast plasma-membrane H+-ATPase have been shown previously to cause misfolding of the ATPase, preventing normal movement along the secretory pathway; Asp-378 mutations also block the biogenesis of co-expressed wild-type ATPase and lead to a dominant lethal phenotype. To ask whether these defects are specific for Asp-378 or whether the phosphorylation region as a whole is involved, alanine-scanning mutagenesis has been carried out to examine the role of 11 conserved residues flanking Asp-378, In the sec6-4 expression system (Nakamoto, R.K., Rao, R., and Slayman, C. W. (1991) J. Biol. Chem. 266, 7940-7949), the mutant ATPases displayed varying abilities to reach the secretory vesicles that deliver plasma-membrane proteins to the cell surface. Indirect immunofluorescence of intact cells also gave evidence for a spectrum of behavior, ranging from mutant ATPases completely arrested (D378A, K379A, T380A, and T384A) or partially arrested in the endoplasmic reticulum to those that reached the plasma membrane in normal amounts (C376A, S377A, and G381A). Although the extent of ER retention varied among the mutants, the endoplasmic reticulum appeared to be the only secretory compartment in which the mutant ATPases accumulated. All of the mutant proteins that localized either partially or fully to the ER were also malfolded based ore their abnormal sensitivity to trypsin. Among them, the severely affected mutants had a dominant lethal phenotype, and even the intermediate mutants caused a visible slowing of growth when co-expressed with wild-type ATPase. The effects on growth could be traced to the trapping of the wild-type enzyme with the mutant enzyme in the ER, as visualized by double label immunofluorescence, Taken together, the results indicate that the residues surrounding Asp-378 are critically important for ATPase maturation and transport to the cell surface.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA	Yale University; Yale University	DeWitt, ND (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.				NIGMS NIH HHS [GM15761, GM18623] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015761, R37GM015761] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambesi A, 1997, ANAL BIOCHEM, V251, P127, DOI 10.1006/abio.1997.2257; Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; Brooks DA, 1997, FEBS LETT, V409, P115, DOI 10.1016/S0014-5793(97)00423-7; CHANG A, 1995, J CELL BIOL, V128, P39, DOI 10.1083/jcb.128.1.39; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; dExaerde AD, 1996, YEAST, V12, P907; Djordjevic JT, 1996, EUR J BIOCHEM, V239, P214, DOI 10.1111/j.1432-1033.1996.0214u.x; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOFF CG, 1984, GENE, V27, P35, DOI 10.1016/0378-1119(84)90236-1; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jensen HK, 1997, ATHEROSCLEROSIS, V131, P67, DOI 10.1016/S0021-9150(96)06059-5; Kolling R, 1996, EUR J BIOCHEM, V239, P356, DOI 10.1111/j.1432-1033.1996.0356u.x; LEITERSDORF E, 1988, P NATL ACAD SCI USA, V85, P7912, DOI 10.1073/pnas.85.21.7912; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Luo WJ, 1997, J CELL BIOL, V138, P731, DOI 10.1083/jcb.138.4.731; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; Nakamoto RK, 1998, J BIOL CHEM, V273, P7338, DOI 10.1074/jbc.273.13.7338; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NAO SQ, 1995, J BIOL CHEM, V270, P6815, DOI 10.1074/jbc.270.12.6815; PETROV VV, 1995, J BIOL CHEM, V270, P28535, DOI 10.1074/jbc.270.48.28535; Portillo F, 1997, FEBS LETT, V402, P136, DOI 10.1016/S0014-5793(96)01515-3; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; RAO R, 1993, J BIOL CHEM, V268, P6708; RAO R, 1992, ANN NY ACAD SCI, V671, P195, DOI 10.1111/j.1749-6632.1992.tb43796.x; RAO R, 1996, MYCOTA, V3, P29; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rose MD., 1990, METHODS YEAST GENETI; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; Seibert FS, 1996, J BIOL CHEM, V271, P15139, DOI 10.1074/jbc.271.25.15139; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SUPPLY P, 1993, J BIOL CHEM, V268, P19744; VERGERES G, 1993, J CELL SCI, V106, P249; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; WEIDMANN B, 1993, BIOCHIM BIOPHYS ACTA, V1153, P267, DOI 10.1016/0005-2736(93)90415-V; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WRIGHT R, 1988, J CELL BIOL, V130, P29; YU MH, 1988, J BIOL CHEM, V263, P1424	47	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21744	21751		10.1074/jbc.273.34.21744	http://dx.doi.org/10.1074/jbc.273.34.21744			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705311	hybrid			2022-12-25	WOS:000075492600045
J	Knudsen, BR; Lee, J; Lisby, M; Westergaard, O; Jayaram, M				Knudsen, BR; Lee, J; Lisby, M; Westergaard, O; Jayaram, M			Alcoholysis and strand joining by the Flp site-specific recombinase - Mechanistically equivalent reactions mediated by distinct catalytic configurations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEP-ARREST MUTANTS; DNA RECOMBINATION; TOPOISOMERASE-I; HALF-SITE; CLEAVAGE; PROTEIN; LIGATION; HOMOLOGY; MUTATIONS; TRANS	The strand joining step of recombination mediated by the Flp site-specific recombinase involves the attack of a 3'-phosphotyrosyl bond by a 5'-hydroxyl group from DNA, The nucleophile in this reaction, the 5'-OH, can be substituted by glycerol or other polyhydric alcohols, The strand joining and glycerolysis reactions are mechanistically equivalent and are competitive to each other. The target diester in strand joining can be a 3'-phosphate covalently linked either to a short tyrosyl peptide or to the whole Flp protein via Tyr-343. By contrast, only the latter type of 3'-phosphotyrosyl linkage is a substrate for glycerolysis. As a result, in activated DNA substrates (containing the scissile phosphate linked to a short Flp peptide), Flp(Y343F) can mediate the joining reaction utilizing the 5'-hydroxyl attack but fails to promote glycerolysis, Wild type Flp promotes both reactions in these substrates. The strand joining and glycerolysis reactions are absolutely dependent on the catalytic histidine sat position 305 of Flp. Our results fit into a model in which a Flp dimer, with one monomer covalently attached to the 3'-phosphate, is essential for orienting the target diester or the nucleophile (or both) during glycerolysis, The requirement for this dimeric complex is relaxed in the strand joining reaction because of the ability of DNA to orient the nucleophile (5'-OH) by complementary base pairing, The experimental outcomes described here have parallels to the "cleavage-dependent ligation" carried out by a catalytic variant of Flp, Flp(R308K) (Zhu, X.-D., and Sadowski, P.D. (1995) J. Biol. Chem. 270, 23044-23054).	Univ Texas, Dept Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cell Biol, Austin, TX 78712 USA; Aarhus Univ, Dept Mol & Struct Biol, DK-8000 Aarhus, Denmark; Cheju Univ, Fac Appl Marine Sci, Cheju 690756, South Korea	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Aarhus University; Jeju National University	Jayaram, M (corresponding author), Univ Texas, Dept Microbiol, Austin, TX 78712 USA.		Lisby, Michael/K-9814-2014; Lee, Jehee/AAS-3229-2021	Lisby, Michael/0000-0002-4830-5247; Lee, Jehee/0000-0001-9144-3648; Knudsen, Birgitta Ruth/0000-0002-3484-3802				Azam N, 1997, J BIOL CHEM, V272, P8731, DOI 10.1074/jbc.272.13.8731; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; CHEN JW, 1993, J BIOL CHEM, V268, P14417; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CHRISTIANSEN K, 1993, J BIOL CHEM, V268, P9690; GOU F, 1997, NATURE, V389, P40; JAYARAM M, 1994, NUCLEIC ACIDS MOL BI, V8, P268; KIMBALL AS, 1993, BIOCHEMISTRY-US, V32, P4698, DOI 10.1021/bi00069a002; Knudsen BR, 1997, J MOL BIOL, V266, P93, DOI 10.1006/jmbi.1996.0767; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; LEE J, 1993, J BIOL CHEM, V268, P17564; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LEE J, 1995, J BIOL CHEM, V270, P4042, DOI 10.1074/jbc.270.8.4042; LEE J, 1995, J BIOL CHEM, V270, P23203, DOI 10.1074/jbc.270.39.23203; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; PAN GH, 1992, J BIOL CHEM, V267, P12397; PAN GH, 1993, J BIOL CHEM, V268, P3683; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PRASAD PV, 1987, P NATL ACAD SCI USA, V84, P2189, DOI 10.1073/pnas.84.8.2189; PRASAD PV, 1988, P NATL ACAD SCI USA, V85, P1497; QIAN XH, 1992, J BIOL CHEM, V267, P7794; SADOWSKI PD, 1995, PROG NUCLEIC ACID RE, V51, P53, DOI 10.1016/S0079-6603(08)60876-4; SERRE MC, 1992, J MOL BIOL, V225, P643, DOI 10.1016/0022-2836(92)90391-V; SORRE MC, 1992, J MOL BIOL, V225, P621; Voziyanov Y, 1996, J MOL BIOL, V256, P720, DOI 10.1006/jmbi.1996.0120; Xu CJ, 1998, MOL CELL, V1, P729, DOI 10.1016/S1097-2765(00)80072-6; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534; ZHU XD, 1995, J BIOL CHEM, V270, P11646, DOI 10.1074/jbc.270.19.11646; ZHU XD, 1995, J BIOL CHEM, V270, P23044, DOI 10.1074/jbc.270.39.23044	30	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22028	22036		10.1074/jbc.273.34.22028	http://dx.doi.org/10.1074/jbc.273.34.22028			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705345	hybrid			2022-12-25	WOS:000075492600079
J	Sundaram, M; Yao, SYM; Ng, AML; Griffiths, M; Cass, CE; Baldwin, SA; Young, JD				Sundaram, M; Yao, SYM; Ng, AML; Griffiths, M; Cass, CE; Baldwin, SA; Young, JD			Chimeric constructs between human and rat equilibrative nucleoside transporters (hENT1 and rENT1) reveal hENT1 structural domains interacting with coronary vasoactive drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; FUNCTIONAL-CHARACTERIZATION; CLONING; NITROBENZYLTHIOINOSINE; EXPRESSION; ADENOSINE; PROTEIN; BINDING; ANALOGS; SYSTEM	We have recently isolated cDNAs from human placenta and rat jejunum encoding the prototypic human and rat equilibrative nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporters hENT1 and rENT1. The two proteins (456 and 457 residues, M-r 50,000) are 78% identical in amino acid sequence and contain 11 potential transmembrane segments (TMs) with a large putative extracellular loop between TMs 1 and 2 and a large cytoplasmic loop between TMs 6 and 7, When expressed in Xenopus oocytes, recombinant hENT1 and rENT1 transport both purine and pyrimidine nucleosides, including adenosine, and are inhibited by nanomolar concentrations of NBMPR. hENT1 is also potently inhibited by coronary vasodilator drugs (dipyridamole, dilazep, and draflazine), whereas rENT1 is insensitive to inhibition by these compounds (dipyridamole IC,, values 190 nM (hENT1) and greater than or equal to 10 mu M (rENT1) at 10 mu M uridine). In the present study, we have generated reciprocal chimeras between hENT1 and rENT1, using splice sites at residues 99 (end of TM. 2) and 231 (end of TM 6), to identify structural domains of hENT1 responsible for transport inhibition by vasoactive compounds. Transplanting the amino-terminal half of hENT1 into rENT1 converted rENT1 into a dipyridamole/dilazep-sensitive transporter, whereas the amino-terminal half of rENT1 rendered hENT1 dipyridamole/dilazep-insensitive, Domain swaps within the amino-terminal halves of hENT1 and rENT1 identified residues 100-231 (incorporating TMs 3-6) of hENT1 as the major site of vasodilator interaction. Since these drugs function as competitive inhibitors of nucleoside transport and NBMPR binding, TMs 3-6 are likely to form part of the substrate-binding site.	Univ Alberta, Dept Physiol, Membrane Transport Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Oncol, Membrane Transport Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Leeds	Young, JD (corresponding author), Univ Alberta, Dept Physiol, Membrane Transport Res Grp, 7-55 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; CLUMECK N, 1993, J ANTIMICROB CHEMOTH, V32, P133, DOI 10.1093/jac/32.suppl_A.133; CRAIG JE, 1994, MOL MICROBIOL, V11, P1159, DOI 10.1111/j.1365-2958.1994.tb00392.x; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Fang X, 1996, BIOCHEM J, V317, P457, DOI 10.1042/bj3170457; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; JACOBSON KA, 1990, PURINES CELLULAR SIG, P20; JARVIS SM, 1982, J PHYSIOL-LONDON, V324, P31, DOI 10.1113/jphysiol.1982.sp014099; JARVIS SM, 1986, MOL PHARMACOL, V30, P659; KWONG FYP, 1993, J BIOL CHEM, V268, P22127; PERIGAUD C, 1992, NUCLEOS NUCLEOT NUCL, V11, P903, DOI 10.1080/07328319208021748; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; SHI MM, 1986, BIOCHEM J, V240, P879, DOI 10.1042/bj2400879; SIVAPRASADARAO A, 1993, BIOCHEM J, V296, P209, DOI 10.1042/bj2960209; Wang J, 1997, AM J PHYSIOL-RENAL, V273, pF1058, DOI 10.1152/ajprenal.1997.273.6.F1058; Yao SYM, 1996, MOL PHARMACOL, V50, P1529; Yao SYM, 1996, MOL PHARMACOL, V50, P388; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	25	83	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21519	21525		10.1074/jbc.273.34.21519	http://dx.doi.org/10.1074/jbc.273.34.21519			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705281	hybrid			2022-12-25	WOS:000075492600015
J	Velasco, G; Geelen, MJH; del Pulgar, TG; Guzman, M				Velasco, G; Geelen, MJH; del Pulgar, TG; Guzman, M			Malonyl-CoA-independent acute control of hepatic carnitine palmitoyltransferase I activity - Role of Ca2+ calmodulin-dependent protein kinase II and cytoskeletal components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; INTERMEDIATE FILAMENTS; RAT HEPATOCYTES; OKADAIC ACID; BETA-OXIDATION; PHOSPHORYLATION; MITOCHONDRIA; LIVER; CARBOXYLASE; CELLS	The mechanism of malonyl-CoA-independent acute control of hepatic carnitine palmitoyltransferase I (CPT-I) activity was investigated. In a first series of experiments, the possible involvement of the cytoskeleton in the control of CPT-I activity was studied. The results of these investigations can be summarized as follows. (i) Very mild treatment of permeabilized hepatocytes with trypsin produced around 50% stimulation of CPT-I activity. This effect was absent in cells that had been pretreated with okadaic acid (OA) and seemed to be due to the action of trypsin on cell component(s) distinct from CPT-I, (ii) Incubation of intact hepatocytes with 3,3'-iminodipropionitrile, a disrupter of intermediate filaments, increased CPT-I activity in a non-additive manner with respect to OA, Taxol, a stabilizer of the cytoskeleton, prevented the OA- and 3,3'-iminodipropionitrile-induced stimulation of CPT-I, (iii) CPT-I activity in isolated mitochondria was depressed in a dose-dependent fashion by the addition of a total cytoskeleton fraction and a cytokeratin-enriched cytoskeletal fraction, the latter being 3 times more potent than the former. In a second series of experiments, the possible link between Ca2+/calmodulin-dependent protein kinase II (Ca2+/CM-PKII) and the cytoskeleton was studied in the context of CPT-I regulation. The data of these experiments indicate that (i) purified Ca2+/CM-PKII activated CPT-I in permeabilized hepatocytes but not in isolated mitochondria, (ii) purified Ca2+/CM-PKII abrogated the inhibition of CPT-I of isolated mitochondria induced by a cytokeratin-enriched fraction, and (iii) the Ca2+/CM-PKII inhibitor KN-62 prevented the OA-induced phosphorylation of cytokeratins in intact hepatocytes, Results thus support a novel mechanism of short-term control of hepatic CPT-I activity which may rely on the cascade Ca2+/CM-PKII activation --> cytokeratin phosphorylation --> CPT-I de-inhibition.	Univ Utrecht, Vet Biochem Lab, NL-3508 TD Utrecht, Netherlands; Univ Complutense Madrid, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain; Univ Utrecht, Inst Biomembranes, NL-3508 TD Utrecht, Netherlands	Utrecht University; Complutense University of Madrid; Utrecht University	Geelen, MJH (corresponding author), Univ Utrecht, Vet Biochem Lab, POB 80-176, NL-3508 TD Utrecht, Netherlands.	mgeelen@biochem.dgk.ruu.nl	Gomez del Pulgar, Teresa/GXV-5256-2022; Velasco, Guillermo/H-5260-2012; Velasco, Guillermo/AAU-9189-2020	Velasco, Guillermo/0000-0002-1994-2386; Velasco, Guillermo/0000-0002-1994-2386; Guzman, Manuel/0000-0001-7475-118X				ALMAHBOBI G, 1992, EXP CELL RES, V200, P361, DOI 10.1016/0014-4827(92)90184-A; AVRUCH J, 1978, J BIOL CHEM, V253, P4754; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; BERNIERVALENTIN F, 1982, J BIOL CHEM, V257, P7092; BEYNEN AC, 1981, BIOCHIM BIOPHYS ACTA, V665, P1, DOI 10.1016/0005-2760(81)90224-1; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; CADRIN M, 1992, CELL SIGNAL, V4, P715, DOI 10.1016/0898-6568(92)90052-A; COLLIER NC, 1993, J CELL BIOCHEM, V52, P297, DOI 10.1002/jcb.240520306; DeLoof A, 1996, INT REV CYTOL, V166, P1; Drynan L, 1996, BIOCHEM J, V317, P791, DOI 10.1042/bj3170791; Eaton S, 1996, BIOCHEM J, V320, P345, DOI 10.1042/bj3200345; ECKERT BS, 1986, CELL MOTIL CYTOSKEL, V6, P15, DOI 10.1002/cm.970060104; FEULLOLEY M, 1994, AM JPHYSL, V266, pE202; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; FONTAINE EM, 1995, BIOCHEM BIOPH RES CO, V213, P138, DOI 10.1006/bbrc.1995.2108; FORGACS G, 1995, J CELL SCI, V108, P2131; FRASER F, 1997, BIOCHEM J, V323, P411; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Geelen MJH, 1997, BIOCHEM BIOPH RES CO, V233, P253, DOI 10.1006/bbrc.1997.6437; Gualix J, 1996, J BIOL CHEM, V271, P1957, DOI 10.1074/jbc.271.4.1957; GUZMAN M, 1993, BIOCHIM BIOPHYS ACTA, V1167, P227, DOI 10.1016/0005-2760(93)90224-W; GUZMAN M, 1995, BIOCHEM J, V311, P853, DOI 10.1042/bj3110853; GUZMAN M, 1992, BIOCHEM J, V287, P487, DOI 10.1042/bj2870487; GUZMAN M, 1994, BIOCHEM J, V300, P693, DOI 10.1042/bj3000693; GUZMAN M, 1996, AM J PHYSIOL, V270, pG710; Ha J, 1996, P NATL ACAD SCI USA, V93, P11466, DOI 10.1073/pnas.93.21.11466; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P339, DOI 10.1111/j.1432-1033.1988.tb14202.x; HENEGOUWEN PMP, 1992, EXP CELL RES, V199, P90; HOLEN I, 1992, BIOCHEM J, V284, P633, DOI 10.1042/bj2840633; HOLLAND R, 1984, EUR J BIOCHEM, V140, P325, DOI 10.1111/j.1432-1033.1984.tb08105.x; Inagaki M, 1997, J BIOCHEM, V121, P407; KASHFI K, 1992, BIOCHEM J, V282, P909, DOI 10.1042/bj2820909; KU NO, 1994, J CELL BIOL, V127, P161, DOI 10.1083/jcb.127.1.161; LETERRIER JF, 1994, MICROSC RES TECHNIQ, V27, P233, DOI 10.1002/jemt.1070270305; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; Linden M, 1996, BIOCHEM BIOPH RES CO, V218, P833, DOI 10.1006/bbrc.1996.0148; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; OHSAWA K, 1983, ANAL BIOCHEM, V135, P409, DOI 10.1016/0003-2697(83)90703-0; OHTA T, 1992, CARCINOGENESIS, V13, P2443, DOI 10.1093/carcin/13.12.2443; Omary MB, 1997, HEPATOLOGY, V25, P1043, DOI 10.1002/hep.510250537; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; Spurway TD, 1997, BIOCHEM J, V323, P119, DOI 10.1042/bj3230119; STROMER MH, 1990, CELL MOTIL CYTOSKEL, V17, P11, DOI 10.1002/cm.970170104; Toivola DM, 1997, J CELL SCI, V110, P23; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Velasco G, 1997, BIOCHEM J, V321, P211, DOI 10.1042/bj3210211; Velasco G, 1996, BIOCHEM BIOPH RES CO, V224, P754, DOI 10.1006/bbrc.1996.1095; Velasco G, 1997, ARCH BIOCHEM BIOPHYS, V337, P169, DOI 10.1006/abbi.1996.9784; VELASCO G, 1998, IN PRESS BIOCH PHARM; Zammit V.A., 1994, DIABETES REV, V2, P132	54	31	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21497	21504		10.1074/jbc.273.34.21497	http://dx.doi.org/10.1074/jbc.273.34.21497			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705278	hybrid			2022-12-25	WOS:000075492600012
J	Valasek, L; Trachsel, H; Hasek, J; Ruis, H				Valasek, L; Trachsel, H; Hasek, J; Ruis, H			Rpg1, the Saccharomyces cerevisiae homologue of the largest subunit of mammalian translation initiation factor 3, is required for translational activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC PROTEIN-SYNTHESIS; GLOBIN MESSENGER-RNA; FACTOR EIF-3; SHUTTLE VECTORS; PRT1 PROTEIN; YEAST; COMPLEX; CELLS; PURIFICATION; MECHANISM	Eukaryotic initiation factor 3 (eIF3) consists of at least eight subunits and plays a key role in the formation of the 43 S preinitiation complex by dissociating 40 and 60 S ribosomal subunits, stabilizing the ternary complex, and promoting mRNA binding to 40 S ribosomal subunits. The product of the Saccharomyces cerevisiae RPG1 gene has been described as encoding a protein required for passage through the G(1) phase of the cell cycle and exhibiting significant sequence similarity to the largest subunit of human eIF3. Here we show that under nondenaturing conditions, Rpg1p copurifies with a known yeast eIF3 subunit, Prt1p. An anti-Rpg1p antibody co-immunoprecipitates Prt1p, and an antibody directed against the Myc tag of a tagged version of Prt1p co-immunoprecipitates Rpg1p, demonstrating that both proteins are present in the same complex. A cell-free translation system derived from the temperature-sensitive rpg1-1 mutant strain becomes inactivated by incubation at 37 degrees C, and its activity can be restored by the addition of the Rpg1-containing protein complex. Finally, the rpg1-1 temperature-sensitive mutant strain shows a dramatic reduction of the polysome/monosome ratio upon shift to the restrictive temperature. These data show that Rpg1p is an authentic eIF3 subunit and plays an important role in the initiation step of translation.	Inst Biochem & Mol Zellbiol, Vienna Bioctr, A-1030 Vienna, Austria; Ludwig Boltzmann Forschungsstelle Biochem, A-1030 Vienna, Austria; Univ Bern, Inst Biochem & Mol Biol, CH-3012 Bern, Switzerland; Acad Sci Czech Republ, Inst Microbiol, CR-14220 Prague, Czech Republic	Vienna Biocenter (VBC); Ludwig Boltzmann Institute; University of Bern; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Ruis, H (corresponding author), Inst Biochem & Mol Zellbiol, Vienna Bioctr, Dr Bohrgasse 9, A-1030 Vienna, Austria.	hr@abc.univie.ac.at	Valášek, Leoš Shivaya/I-5743-2014; Hasek, Jiri/H-2427-2014	Valášek, Leoš Shivaya/0000-0001-8123-8667; Hasek, Jiri/0000-0001-6634-2386				ALTMANN M, 1985, BIOCHEMISTRY-US, V24, P6085, DOI 10.1021/bi00343a009; Altmann M, 1997, METHODS, V11, P343, DOI 10.1006/meth.1996.0432; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; BENNE R, 1978, J BIOL CHEM, V253, P3078; BURKE DJ, 1991, MOL CELL BIOL, V11, P3691, DOI 10.1128/MCB.11.7.3691; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; GARCIABARRIO MT, 1995, GENE DEV, V9, P1781, DOI 10.1101/gad.9.14.1781; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOUMANS H, 1980, BIOCHIM BIOPHYS ACTA, V608, P39, DOI 10.1016/0005-2787(80)90131-8; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GU ZY, 1992, P NATL ACAD SCI USA, V89, P10355, DOI 10.1073/pnas.89.21.10355; GUPTA NK, 1990, POSTTRANSCRIPTIONAL, P521; HANNIG EM, 1995, BIOESSAYS, V17, P915, DOI 10.1002/bies.950171103; Hershey J, 1996, BIOCHIMIE, V78, P903, DOI 10.1016/S0300-9084(97)86711-9; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; Jirincova H, 1998, FOLIA BIOL-PRAGUE, V44, P73; Johnson KR, 1997, J BIOL CHEM, V272, P7106, DOI 10.1074/jbc.272.11.7106; Koller HT, 1996, YEAST, V12, P53, DOI 10.1002/(SICI)1097-0061(199601)12:1<53::AID-YEA886>3.0.CO;2-M; KOVACS D, 1993, SOCIOL RURALIS, V33, P100, DOI 10.1111/j.1467-9523.1993.tb00951.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LIPKE PN, 1976, J BACTERIOL, V127, P610, DOI 10.1128/JB.127.1.610-618.1976; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Merrick WC., 1996, TRANSLATION CONTROL, P31; MERRIL CR, 1990, NATURE, V343, P779, DOI 10.1038/343779a0; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; MOLDAVE K, 1988, GENETICS TRANSLATION, P271; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; Sherman F, 1986, LAB COURSE MANUAL ME; Si K, 1997, P NATL ACAD SCI USA, V94, P14285, DOI 10.1073/pnas.94.26.14285; SIKORSKI RS, 1989, GENETICS, V122, P19; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRACHSEL H, 1979, BIOCHIM BIOPHYS ACTA, V565, P305, DOI 10.1016/0005-2787(79)90207-7; TRACHSEL H, 1980, P NATL ACAD SCI-BIOL, V77, P770, DOI 10.1073/pnas.77.2.770; Verlhac MH, 1997, EMBO J, V16, P6812, DOI 10.1093/emboj/16.22.6812; WESTERMANN P, 1986, FEBS LETT, V205, P171, DOI 10.1016/0014-5793(86)80891-2; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248	44	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21253	21260		10.1074/jbc.273.33.21253	http://dx.doi.org/10.1074/jbc.273.33.21253			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694884	hybrid			2022-12-25	WOS:000075386100077
J	Halsted, CH; Ling, EH; Luthi-Carter, R; Villanueva, JA; Gardner, JM; Coyle, JT				Halsted, CH; Ling, EH; Luthi-Carter, R; Villanueva, JA; Gardner, JM; Coyle, JT			Folylpoly-gamma-glutamate carboxypeptidase from pig jejunum - Molecular characterization and relation to glutamate carboxypeptidase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ANTIGEN; PTEROYLPOLYGLUTAMATE HYDROLASE; MESSENGER-RNA; GENE; EXPRESSION; CLONING; ACID; DNA; AMINOPEPTIDASE; PURIFICATION	Jejunal folylpoly-gamma-glutamate carboxypeptidase hydrolyzes dietary folates prior to their intestinal absorption. The complete folylpoly-gamma-glutamate carboxypeptidase cDNA was isolated from a pig jejunal cDNA library using an amplified homologous probe incorporating primer sequences from prostate-specific membrane antigen, a protein capable of folate hydrolysis, The cDNA encodes a 751-amino acid polypeptide homologous to prostate-specific membrane antigen and rat brain N-acetylated alpha-linked acidic dipeptidase. PC3 transfectant membranes exhibited activities of folylpoly-gamma-carboxypeptidase and N-acetylated alpha-linked acidic dipeptidase, while immunoblots using monoclonal antibody to native folylpoly-gamma-glutamate carboxypeptidase identified a glycoprotein at 120 kDa and a polypeptide at 84 kDa, The kinetics of native folylpoly-gamma-carboxypeptidase were expressed in membranes of PC3 cells transfected with either pig folylpoly-gamma-carboxypeptidase or human prostate-specific membrane antigen. Folylpoly-gamma-carboxypeptidase transcripts were identified at 2.8 kilobase pairs in human and pig jejunum, human and rat brain, and human prostate cancer LNCaP cells. Thus, pig folylpoly-gamma-carboxypeptidase, rat N-acetylated alpha-linked acidic dipeptidase, and human prostate-specific membrane antigen appear to represent varied expressions of the same gene in different species and tissues. The discovery of the jejunal folylpoly-gamma-carboxypeptidase gene provides a framework for future studies on relationships among these proteins and on the molecular regulation of intestinal folate absorption.	Univ Calif Davis, Sch Med, Dept Internal Med, Davis, CA 95616 USA; Univ Calif Davis, Ctr Engn Plants Resistance Pathogens, Davis, CA 95616 USA; Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA	University of California System; University of California Davis; University of California System; University of California Davis; Harvard University; Harvard Medical School	Halsted, CH (corresponding author), Univ Calif Davis, Sch Med, Dept Internal Med, TB 156, Davis, CA 95616 USA.	chhalsted@ucdavis.edu			NIDDK NIH HHS [DK-45301, DK-35747] Funding Source: Medline; NIMH NIH HHS [MH-57201] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035747, R01DK045301] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; Bzdega T, 1997, J NEUROCHEM, V69, P2270; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; Carter RE, 1996, P NATL ACAD SCI USA, V93, P749, DOI 10.1073/pnas.93.2.749; CHANDLER C J, 1986, P539; CHANDLER CJ, 1991, AM J PHYSIOL, V260, pG865, DOI 10.1152/ajpgi.1991.260.6.G865; CHANDLER CJ, 1986, J BIOL CHEM, V261, P928; Chevrier B, 1996, EUR J BIOCHEM, V237, P393, DOI 10.1111/j.1432-1033.1996.0393k.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; DIXON KH, 1994, J BIOL CHEM, V269, P17; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Halsted C., 1990, FOLIC ACID METABOLIS, P23; ISRAELI RS, 1993, CANCER RES, V53, P227; ISRAELI RS, 1994, CANCER RES, V54, P1807; KRUMDIECK CL, 1970, ANAL BIOCHEM, V35, P123, DOI 10.1016/0003-2697(70)90017-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEK J, 1995, BRIT J CANCER, V72, P583, DOI 10.1038/bjc.1995.377; Luthi-Carter R, 1998, P NATL ACAD SCI USA, V95, P3215, DOI 10.1073/pnas.95.6.3215; Luthi-Carter R, 1998, J PHARMACOL EXP THER, V286, P1020; Maras B, 1996, EUR J BIOCHEM, V236, P843, DOI 10.1111/j.1432-1033.1996.00843.x; Matsudaira P, 1989, PRACTICAL GUIDE PROT; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; Nguyen TT, 1997, GASTROENTEROLOGY, V112, P783, DOI 10.1053/gast.1997.v112.pm9041240; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; Pinto JT, 1996, CLIN CANCER RES, V2, P1445; Rawlings ND, 1997, BBA-PROTEIN STRUCT M, V1339, P247, DOI 10.1016/S0167-4838(97)00008-3; RINKERSCHAEFFER CW, 1995, GENOMICS, V30, P105, DOI 10.1006/geno.1995.0019; ROBINSON MB, 1987, J BIOL CHEM, V262, P14498; Said HM, 1996, BBA-BIOMEMBRANES, V1281, P164, DOI 10.1016/0005-2736(96)00005-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Silver DA, 1997, CLIN CANCER RES, V3, P81; SLUSHER BS, 1992, J COMP NEUROL, V315, P217; SU SL, 1995, CANCER RES, V55, P1441; TROYER JK, 1995, INT J CANCER, V62, P552, DOI 10.1002/ijc.2910620511; VALLEE BL, 1993, P NATL ACAD SCI USA, V90, P2715, DOI 10.1073/pnas.90.7.2715; VanHoozen CM, 1996, BIOCHEM J, V319, P725; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WANG TTY, 1986, J BIOL CHEM, V261, P3551; Yao R, 1996, P NATL ACAD SCI USA, V93, P10134, DOI 10.1073/pnas.93.19.10134	44	80	85	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20417	20424		10.1074/jbc.273.32.20417	http://dx.doi.org/10.1074/jbc.273.32.20417			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685395	hybrid, Green Submitted			2022-12-25	WOS:000075305400072
J	Joseph, B; Orlian, M; Furneaux, H				Joseph, B; Orlian, M; Furneaux, H			p21(waf1) mRNA contains a conserved element in its 3 '-untranslated region that is bound by the Elav-like mRNA-stabilizing proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; CYCLIN-DEPENDENT KINASES; AU-RICH ELEMENTS; P53-INDEPENDENT INDUCTION; DROSOPHILA-MELANOGASTER; GROWTH-FACTOR; CELLS; EXPRESSION; DIFFERENTIATION; P21	The Elav-like proteins are specific mRNA-binding proteins that regulate mRNA stability. The neuronal members of this family (HuD, HuC, and Hel-N1) are required for neuronal differentiation. In this report, using purified HuD protein we have localized a high affinity HuD binding site to a 42-nucleotide region within a U-rich tract in the 3'-untranslated region p21(wafl) mRNA. The binding of HuD to this site is readily displaced by an RNA oligonucleotide encoding the HuD binding site of c-fos. The sequence of this binding site is well conserved in human, mouse, and rat p21(wafl) mRNA. p21(wafl) is an inhibitor of cyclin-dependent kinases and proliferating cell nuclear antigen and induces cell cycle arrest at G(1)/S, a requisite early step in cell differentiation. The identification of an Elav-like protein binding site in the 3'-untranslated region of p21(wafl) provides a novel link between the induction of differentiation, mRNA stability, and the termination of the cell cycle.	Mem Sloan Kettering Canc Ctr, Mol Neurooncol Lab, Program Mol Pharmacol & Therapeut, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Furneaux, H (corresponding author), Mem Sloan Kettering Canc Ctr, Mol Neurooncol Lab, Program Mol Pharmacol & Therapeut, 1275 York Ave, New York, NY 10021 USA.			furneaux, henry/0000-0003-2212-1017	NCI NIH HHS [P30-CA08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAMI K, 1995, J NEUROBIOL, V28, P82, DOI 10.1002/neu.480280108; CAMPOS AR, 1985, J NEUROGENET, V2, P197, DOI 10.3109/01677068509100150; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Chung SM, 1997, J BIOL CHEM, V272, P6593, DOI 10.1074/jbc.272.10.6593; DALMAU J, 1992, AM J PATHOL, V141, P881; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FURNEAUX HM, 1985, P NATL ACAD SCI USA, V82, P4351, DOI 10.1073/pnas.82.13.4351; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HARPER JW, 1993, CELL, V75, P805; HOMYK T, 1985, J NEUROGENET, V2, P309, DOI 10.3109/01677068509102326; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KING PH, 1994, J NEUROSCI, V14, P1943; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Li XS, 1996, CANCER RES, V56, P5055; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; SAKAI K, 1994, BIOCHEM BIOPH RES CO, V199, P1200, DOI 10.1006/bbrc.1994.1358; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; SHAO ZM, 1995, ONCOGENE, V11, P493; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wakamatsu Y, 1997, DEVELOPMENT, V124, P3449; Yan GZ, 1997, J NEUROSCI, V17, P6122; YAN GZ, 1995, J NEUROSCI, V15, P6200; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHANG W, 1995, CANCER RES, V55, P668	36	103	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20511	20516		10.1074/jbc.273.32.20511	http://dx.doi.org/10.1074/jbc.273.32.20511			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685407	hybrid			2022-12-25	WOS:000075305400084
J	Sattlegger, E; Hinnebusch, AG; Barthelmess, IB				Sattlegger, E; Hinnebusch, AG; Barthelmess, IB			cpc-3, the Neurospora crassa homologue of yeast GCN2, encodes a polypeptide with juxtaposed eIF2 alpha kinase and histidyl-tRNA synthetase-related domains required for general amino acid control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; FACTOR-2-ALPHA EIF-2-ALPHA KINASE; ARGININE BIOSYNTHETIC ENZYMES; CROSS-PATHWAY REGULATION; PROTEIN-KINASE; INITIATION FACTOR-2-ALPHA; SACCHAROMYCES-CEREVISIAE; TRANSLATIONAL CONTROL; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI	Based on characteristic amino acid sequences of kinases that phosphorylate the alpha subunit of eukaryotic translation initiation factor 2 (eIF2 alpha kinases), degenerate oligonucleotide primers were constructed and used to polymerase chain reaction-amplify from genomic DNA of Neurospora crassa a sequence encoding part of a putative protein kinase. With this sequence an open reading frame was identified encoding a predicted polypeptide with juxtaposed eIF2 alpha kinase and histidyl-tRNA synthetase-related domains. The 1646 amino acid sequence of this gene, called cpc-3, showed 35% positional identity over almost the entire sequence with GCN2 of yeast, which stimulates translation of the transcriptional activator of amino acid biosynthetic genes encoded by GCN4, Strains disrupted for cpc-3 were unable to induce increased transcription and derepression of amino acid biosynthetic enzymes in amino acid-deprived cells. The cpc-3 mutation did not affect the ability to up-regulate mRNA levels of cpc-1, encoding the GCN4 homologue and transcriptional activator of amino acid biosynthetic genes in N. crassa, but the mutation abolished the dramatic increase of CPC1 protein level in response to amino acid deprivation, These findings suggest that cpc-3 is the functional homologue of GCN2, being required for increased translation of cpc-1 mRNA in amino acid-starved cells.	NICHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA; Leibniz Univ Hannover, Inst Appl Genet, D-30419 Hannover, Germany	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Leibniz University Hannover	Sattlegger, E (corresponding author), NICHD, Lab Eukaryot Gene Regulat, NIH, Bldg 6A,Rm B1A-05, Bethesda, MD 20892 USA.	esattlegger@aghmac1.nichd.nih.gov						Aberg A, 1997, BIOCHEMISTRY-US, V36, P3084, DOI 10.1021/bi9618373; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arnez JG, 1997, P NATL ACAD SCI USA, V94, P7144, DOI 10.1073/pnas.94.14.7144; ARNEZ JG, 1995, EMBO J, V14, P4143, DOI 10.1002/j.1460-2075.1995.tb00088.x; BARTHELMESS IB, 1982, GENET RES, V39, P169, DOI 10.1017/S0016672300020863; BRUCHEZ JJP, 1993, FUNGAL GENETICS NEWS, V40, P85; CARSIOTIS M, 1974, J BACTERIOL, V119, P893, DOI 10.1128/JB.119.3.893-898.1974; CARSIOTIS M, 1974, J BACTERIOL, V119, P889, DOI 10.1128/JB.119.3.889-892.1974; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CATCHESIDE DEA, 1991, FUNGAL GENET NEWSL, V38, P71; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHOW TYK, 1993, FUNGAL GENET NEWSLET, V40, P25; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; DAVIS RH, 1979, GENETICS, V93, P557; DAVIS RH, 1962, ARCH BIOCHEM BIOPHYS, V97, P185, DOI 10.1016/0003-9861(62)90063-2; DAVIS RH, 1979, METHOD ENZYMOL, V57, P79; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOOLITTLE RF, 1986, URFS ORFS PRIMER ANA, P15; EBBOLE DJ, 1991, MOL CELL BIOL, V11, P928, DOI 10.1128/MCB.11.2.928; EDELMANN SE, 1994, EXP MYCOL, V18, P70, DOI 10.1006/emyc.1994.1007; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FLAVELL RB, 1968, J BACTERIOL, V95, P1063, DOI 10.1128/JB.95.3.1063-1068.1968; FLINT HJ, 1986, MOL GEN GENET, V203, P110, DOI 10.1007/BF00330391; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; GRANT CM, 1994, MOL CELL BIOL, V14, P606, DOI 10.1128/MCB.14.1.606; GURR SJ, 1981, GENE STRUCTURE EUKAR, P93; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HILTON JL, 1965, ARCH BIOCHEM BIOPHYS, V112, P544, DOI 10.1016/0003-9861(65)90093-7; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; ICELY PL, 1991, J BIOL CHEM, V266, P16073; IRELAN J, 1993, FUNGAL GENET NEWSL, V40, P24; JACOBS M, 1990, NUCLEIC ACIDS RES, V18, P1653, DOI 10.1093/nar/18.6.1653; KOLANUS J, 1990, MOL GEN GENET, V223, P443, DOI 10.1007/BF00264452; KRUGER D, 1990, CURR GENET, V18, P211, DOI 10.1007/BF00318383; KRUGER D, 1996, THESIS U HANNOVER GE; Lee S.B., 1988, FUNGAL GENET REP, V35, P23, DOI [10.4148/1941-4765.1531, DOI 10.4148/1941-4765.1531]; LUO ZG, 1995, MOL CELL BIOL, V15, P5235; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MELLOR H, 1994, J BIOL CHEM, V269, P10201; MELLOR H, 1994, BBA-GENE STRUCT EXPR, V1219, P693, DOI 10.1016/0167-4781(94)90229-1; METZENBERG RL, 1995, FUNGAL GENET NEWSLET, V42, P82; METZENBERG RL, 1984, NEUROSPORA NEWSL, V31, P35; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MULLER F, 1995, MOL GEN GENET, V248, P162, DOI 10.1007/BF02190797; ORBACH MJ, 1986, MOL CELL BIOL, V6, P2452, DOI 10.1128/MCB.6.7.2452; PALUH JL, 1988, P NATL ACAD SCI USA, V85, P3728, DOI 10.1073/pnas.85.11.3728; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Qiu HF, 1998, MOL CELL BIOL, V18, P2697, DOI 10.1128/MCB.18.5.2697; QU SM, 1994, GENE, V140, P239, DOI 10.1016/0378-1119(94)90550-9; RABEN N, 1992, NUCLEIC ACIDS RES, V20, P1075, DOI 10.1093/nar/20.5.1075; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; Robertson HD, 1996, BIOCHIMIE, V78, P909, DOI 10.1016/S0300-9084(97)86712-0; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; ROUSSOU I, 1988, MOL CELL BIOL, V8, P2132, DOI 10.1128/MCB.8.5.2132; Rudinger J, 1997, BIOORGAN MED CHEM, V5, P1001, DOI 10.1016/S0968-0896(97)00061-8; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Ruhlmann A, 1997, BIOCHEM BIOPH RES CO, V237, P192, DOI 10.1006/bbrc.1997.7108; SACHS MS, 1996, MYCOTA BIOCH MOL BIO, V4, P315; SAMBROOK J, 1989, MOL CLONING LABORATO, pE34; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Santoyo J, 1997, J BIOL CHEM, V272, P12544, DOI 10.1074/jbc.272.19.12544; SATTLEGGER E, 1996, THESIS U HANNOVER GE; Sokolovsky V., 1990, FUNGAL GENET NEWSLET, V37, P41; Sprinzl M., 1989, Nucleic Acids Research, V17, P1; Staben C, 1989, FUNGAL GENET NEWSL, V36, P79, DOI DOI 10.4148/1941-4765.1519; VOLLMER SJ, 1986, P NATL ACAD SCI USA, V83, P4867; Wang P, 1998, FUNGAL GENET BIOL, V23, P81, DOI 10.1006/fgbi.1997.1023; Wanke C, 1997, MOL MICROBIOL, V23, P23, DOI 10.1046/j.1365-2958.1997.1741549.x; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK SA, 1995, MOL CELL BIOL, V15, P4497; Yan W, 1996, BIOCHEMISTRY-US, V35, P6559, DOI 10.1021/bi952889f; ZABAROVSKY ER, 1990, NUCLEIC ACIDS RES, V18, P5912; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989; [No title captured]	86	45	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20404	20416		10.1074/jbc.273.32.20404	http://dx.doi.org/10.1074/jbc.273.32.20404			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685394	hybrid			2022-12-25	WOS:000075305400071
J	de Lau, WBM; Hurenkamp, J; Berendes, P; Touw, IP; Clevers, HC; van Dijk, MA				de Lau, WBM; Hurenkamp, J; Berendes, P; Touw, IP; Clevers, HC; van Dijk, MA			The gene encoding the granulocyte colony-stimulating factor receptor is a target for deregulation in pre-B ALL by the t(1;19)-specific oncoprotein E2A-Pbx1	ONCOGENE			English	Article						G-CSF receptor; cDNA subtraction; leukemia; chromosomal translocation	ACUTE LYMPHOBLASTIC-LEUKEMIA; REPRESENTATIONAL DIFFERENCE ANALYSIS; CHROMOSOMAL TRANSLOCATIONS; TRANSCRIPTIONAL ACTIVATOR; HOMEODOMAIN PROTEIN; MAMMALIAN-CELLS; MESSENGER-RNA; FUSION; PBX1; E2A	Approximately 25-30% of childhood pre-B cell acute lymphoblastic leukemias (pre-B ALL) is characterized by the presence of a (1;19)(q23;p13.3) translocation, The presence of this translocation is generally accompanied by a poor prognosis. The chimeric gene resulting from this chromosomal rearrangement encodes a hybrid transcription factor, E2A-Pbx1, In an attempt to delineate the genetic cascade initiated by E2A-Pbx1, we sought to identify genes that are deregulated by this transcription factor in t(1;19) pre-B ALL, We show here that the gene encoding the granulocyte colony-stimulating factor receptor (G-CSFr) is specifically upregulated in pre-B cells expressing E2A-Pbx1. G-CSFr is also expressed in cell lines established from t(1;19) pre-B cell leukemia and on primary t(1;19) tumor cells, but not on control cells. These data indicate that G-CSFr gene is a target for deregulation by E2A-Pbx1.	Acad Hosp Utrecht, Dept Immunol F03 821, NL-3508 GA Utrecht, Netherlands; Erasmus Univ, Dept Immunol, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Dept Hematol, NL-3000 DR Rotterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus University Rotterdam	van Dijk, MA (corresponding author), Acad Hosp Utrecht, Dept Immunol F03 821, POB 85500, NL-3508 GA Utrecht, Netherlands.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AVALOS BR, 1990, BLOOD, V75, P851; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; BERENDES P, 1995, LEUKEMIA, V9, P1321; BRADSTOCK K, 1993, BLOOD, V82, P3437; BRADSTOCK KF, 1995, LEUKEMIA LYMPHOMA, V18, P1, DOI 10.3109/10428199509064917; BURROWS PD, 1993, CURR OPIN IMMUNOL, V5, P201, DOI 10.1016/0952-7915(93)90005-D; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DONG F, 1995, NEW ENGL J MED, V333, P487, DOI 10.1056/NEJM199508243330804; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; DREXLER HG, 1995, LEUKEMIA, V9, P480; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; JACK I, 1986, CANCER GENET CYTOGEN, V19, P261, DOI 10.1016/0165-4608(86)90055-5; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1994, ONCOGENE, V9, P3159; KHWAJA A, 1993, BRIT J HAEMATOL, V85, P254, DOI 10.1111/j.1365-2141.1993.tb03164.x; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LIESCHKE GJ, 1994, BLOOD, V84, P1737; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LOWENBERG B, 1993, BLOOD, V81, P281; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MADSEN M, 1980, J IMMUNOL METHODS, V33, P323, DOI 10.1016/0022-1759(80)90003-4; Massari ME, 1996, MOL CELL BIOL, V16, P121; Matsushita K, 1997, BRIT J HAEMATOL, V96, P715, DOI 10.1046/j.1365-2141.1997.d01-2102.x; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; SCHUTTE M, 1995, NUCLEIC ACIDS RES, V23, P4127, DOI 10.1093/nar/23.20.4127; SETO Y, 1992, J IMMUNOL, V148, P259; TACHIBANA M, 1995, CANCER RES, V55, P3438; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	41	17	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					503	510		10.1038/sj.onc.1201967	http://dx.doi.org/10.1038/sj.onc.1201967			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696044				2022-12-25	WOS:000075043000013
J	Toma, L; Berninsone, P; Hirschberg, CB				Toma, L; Berninsone, P; Hirschberg, CB			The putative heparin-specific N-acetylglucosaminyl N-deacetylase/N-sulfotransferase also occurs in non-heparin-producing cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; SACCHAROMYCES-CEREVISIAE; SULFATE SULFOTRANSFERASE; GUANOSINE DIPHOSPHATASE; MOLECULAR-CLONING; GOLGI LUMEN; EXPRESSION; BINDING; PROTEOGLYCANS; PURIFICATION	N-Deacetylation and N-sulfation of N-acetylglucosamine of heparin and heparan sulfate are hypothesized to be mediated by different tissue-specific N-acetylglucosaminyl N-deacetylases/N-sulfotransferases, which in turn lead to the higher L-iduronic acid and sulfate content of heparin versus heparan sulfate. Furthermore, the putative heparin-specific N-acetylglucosaminyl N-deacetylase/N-sulfotransferase has been reported to require auxiliary proteins for its N-acetylglucosaminyl N-deacetylase activity in vivo based on its requirement of polycations in vitro, me have now found that cells derived from embryonic bovine trachea, a tissue that does not synthesize heparin, has a N-acetylglucosaminyl N-deacetylase/N-sulfotransferase, which has 95% amino acid sequence identity to the above enzyme postulated to be involved in the biosynthesis of heparin. Both enzymes also have very similar affinity for their substrates, The trachea enzyme does not require additional effecters for its N-acetylglucosaminyl N-deacetylase activity in vitro even though its biochemical characteristics are virtually the same as the enzyme previously isolated from cells of a heparin-producing mastocytoma tumor. The trachea enzyme, which is encoded by an abundant 4.6-kilobase mRNA, like mastocytoma cells, has 70% amino acid sequence identity with the corresponding enzyme from rat liver postulated to participate in the biosynthesis of heparan sulfate. Heparan sulfate synthesized by trachea cells has a higher content of sulfated iduronic acid than from other tissues, Together, the above results strongly suggest that the above enzymes from mastocytoma, liver, and trachea, per se, are not solely responsible for the selective tissue-specific synthesis of heparin or heparan sulfate; more likely cellular factors, additional enzymes, and availability of substrates in the Golgi lumen also play important roles in the differential synthesis of the above proteoglycans.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA	Boston University	Hirschberg, CB (corresponding author), Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA.			Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM34396] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAME KJ, 1991, J BIOL CHEM, V266, P12461; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONRAD HE, 1998, HEPARIN BINDING PROT, P175; DISCHE Z, 1947, J BIOL CHEM, V167, P189; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; KJELLEN L, 1992, ADV EXP MED BIOL, V313, P107; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LUPA MT, 1990, DEV BIOL, V142, P31, DOI 10.1016/0012-1606(90)90148-C; MANDON E, 1994, J BIOL CHEM, V269, P11729; Nader H. B., 1989, HEPARIN CHEM BIOL PR, P81; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; NADER HB, 1990, J BIOL CHEM, V265, P16807; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TERSARIOL ILS, 1994, BRAZ J MED BIOL RES, V27, P2097; Toma L, 1996, J BIOL CHEM, V271, P3897; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	37	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22458	22465		10.1074/jbc.273.35.22458	http://dx.doi.org/10.1074/jbc.273.35.22458			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712870	hybrid			2022-12-25	WOS:000075616600046
J	Lee, MJ; Thangada, S; Liu, CH; Thompson, BD; Hla, T				Lee, MJ; Thangada, S; Liu, CH; Thompson, BD; Hla, T			Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOSINE 1-PHOSPHATE; NEURITE RETRACTION; ADP-RIBOSYLATION; SURFACE-RECEPTOR; KINASE PATHWAY; CDC42 GTPASES; RHO; SPHINGOSINE-1-PHOSPHATE; CELLS; INHIBITION	EDG-1, an inducible G-protein-coupled receptor from vascular endothelial cells, is a high affinity receptor for sphingosine I-phosphate (SPP) (Lee, M-J., van Brocklyn, J. R., Thangada, S., Liu, C. H., Hand, A. R., Menzeleev, R., Spiegel, S., and Hla, T. (1998) Science 279, 1552-1555). In this study, we show that lysophosphatidic acid (LPA), a platelet-derived bioactive lipid structurally related to SPP, is an agonist for EDG-1. LPA binds to EDG-1 receptor with an apparent K-d of 2.3 mu M. In addition, LPA binding to EDG-1 induces receptor phosphorylation, mitogen-activated protein kinase activation, as well as Rho-dependent morphogenesis and P-cadherin expression. These data suggest that LPA is a low-affinity agonist for EDG-1. Activation of the endothelial receptor EDG-1 by platelet-derived lipids LPA and SPP may be important in thrombosis and angiogenesis, conditions in which critical platelet-endothelial interactions occur.	Univ Connecticut, Sch Med, Dept Physiol, Farmington, CT 06030 USA	University of Connecticut	Hla, T (corresponding author), Univ Connecticut, Sch Med, Dept Physiol, MC3505,263 Farmington Ave, Farmington, CT 06030 USA.		Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045659] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49094] Funding Source: Medline; NIDDK NIH HHS [DK45659] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander JS, 1998, AM J PHYSIOL-HEART C, V274, pH115, DOI 10.1152/ajpheart.1998.274.1.H115; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DURIEUX ME, 1993, TRENDS PHARMACOL SCI, V14, P249, DOI 10.1016/0165-6147(93)90021-B; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Erickson JP, 1998, J BIOL CHEM, V273, P1506, DOI 10.1074/jbc.273.3.1506; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HLA T, 1990, J BIOL CHEM, V265, P9308; Hung WC, 1996, BIOCHEM BIOPH RES CO, V229, P11, DOI 10.1006/bbrc.1996.1750; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; JALINK K, 1994, BBA-REV CANCER, V1198, P185, DOI 10.1016/0304-419X(94)90013-2; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; MOOLENAAR WH, 1994, TRENDS CELL BIOL, V4, P249; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; NAGY JA, 1989, BIOCHIM BIOPHYS ACTA, V948, P305, DOI 10.1016/0304-419X(89)90004-8; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; RESHKIN SJ, 1992, AM J PHYSIOL, V262, pF572, DOI 10.1152/ajprenal.1992.262.4.F572; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Yatomi Y, 1997, J BIOCHEM, V121, P969; Yatomi Y, 1997, J BIOL CHEM, V272, P5291, DOI 10.1074/jbc.272.8.5291; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	36	112	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22105	22112		10.1074/jbc.273.34.22105	http://dx.doi.org/10.1074/jbc.273.34.22105			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705355	hybrid			2022-12-25	WOS:000075492600089
J	Derfoul, A; Robertson, NM; Lingrel, JB; Hall, DJ; Litwack, G				Derfoul, A; Robertson, NM; Lingrel, JB; Hall, DJ; Litwack, G			Regulation of the human Na/K-ATPase beta 1 gene promoter by mineralocorticoid and glucocorticoid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTOR; RESPONSE ELEMENT; NA,K-ATPASE; EXPRESSION; ISOFORM; DNA; CORTICOSTEROIDS; COACTIVATOR; SUPERFAMILY; UPSTREAM	Expression of the human Na/K-ATPase beta 1 subunit is regulated by a mineralocorticoid- and glucocorticoid-responsive elements. Here we identified an MR and GR responsive element, at positions -650 to -630, within the beta 1 gene promoter that is required for both MR and GR activation. Independent expression of MR and GR activated by aldosterone or triamcinolone acetonide (TA) leads to significant transactivation of the beta 1 pro meter. Yet coexpression of both receptors activated by aldosterone plus TA or cortisol results in a much lower induction, indicating that coexpression of MR and GR is inhibitory. Gel shift mobility assay using an oligonucleotide including the al-base pair MRE/GRE with whole cell extracts prepared from CV-1 cells overexpressing MR or GR showed specific MR and GR binding to this sequence. Additionally, antibodies to both MR and GR effectively supershifted the protein-DNA complexes, indicating that these receptors bound to the DNA sequence. Finally, the 21-base pair MRE/GRE was capable of activating transcription from a heterologous promoter in response to both aldosterone and TA. Together these data indicate that the 21-base pair sequence represents a true MRE/GRE and that optimal activation of the human Na/K-ATPase beta 1 promoter is controlled by mineralocorticoid and glucocorticoid hormones, It appears that an interaction of MR with GR on the beta 1 promoter effectively down-regulates transcription.	Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	Jefferson University; University System of Ohio; University of Cincinnati	Litwack, G (corresponding author), Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Bluemle Life Sci Bldg,Rm 350,233 S 10th St, Philadelphia, PA 19107 USA.				NCI NIH HHS [CA67032] Funding Source: Medline; NIDDK NIH HHS [DK 44441] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALNEMRI ES, 1991, J BIOL CHEM, V266, P18072; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Bamberger CM, 1997, J STEROID BIOCHEM, V60, P43, DOI 10.1016/S0960-0760(96)00167-7; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EVANS RM, 1989, NEURON, V2, P1105, DOI 10.1016/0896-6273(89)90177-3; EWART HS, 1995, AM J PHYSIOL, pC295; FENG JI, 1993, NUCLEIC ACIDS RES, V21, P2619, DOI 10.1093/nar/21.11.2619; FUNDER JW, 1990, TRENDS ENDOCRIN MET, V1, P145, DOI 10.1016/1043-2760(90)90026-Y; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; IKEDA U, 1991, J BIOL CHEM, V266, P12058; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; LANE LK, 1989, GENOMICS, V5, P445, DOI 10.1016/0888-7543(89)90008-6; LINGREL JB, 1992, J BIOENERG BIOMEMBR, V24, P263; LINGREL JB, 1994, RENAL PHYSIOL BIOCH, V17, P198; Liu WH, 1995, P NATL ACAD SCI USA, V92, P12480, DOI 10.1073/pnas.92.26.12480; Liu WH, 1996, MOL ENDOCRINOL, V10, P1399, DOI 10.1210/me.10.11.1399; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; ONATE SA, 1995, SCIENCE, V270, P1354; ORLOWSKI J, 1990, J BIOL CHEM, V265, P3462; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; Verrey F, 1996, MINER ELECTROL METAB, V22, P279; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; WHORWOOD CB, 1994, ENDOCRINOLOGY, V135, P901, DOI 10.1210/en.135.3.901; WHORWOOD CB, 1995, J MOL ENDOCRINOL, V15, P93, DOI 10.1677/jme.0.0150093	30	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20702	20711		10.1074/jbc.273.33.20702	http://dx.doi.org/10.1074/jbc.273.33.20702			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694812	hybrid			2022-12-25	WOS:000075386100005
J	Kurashima, K; Szabo, EZ; Lukacs, G; Orlowski, J; Grinstein, S				Kurashima, K; Szabo, EZ; Lukacs, G; Orlowski, J; Grinstein, S			Endosomal recycling of the Na+/H+ exchanger NHE3 isoform is regulated by the phosphatidylinositol 3-kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; GROWTH-FACTOR; GLUCOSE-TRANSPORT; INTRACELLULAR PH; MOLECULAR-CLONING; PROTEIN-KINASE; NA/H EXCHANGER; WORTMANNIN; CELLS; INHIBITOR	The NHE3 isoform of the Na+/H+ exchanger localizes to both the plasmalemmal and endosomal compartments in polarized epithelial and transfected Chinese hamster ovary (AP-1) cells. It is unclear how the distribution of NHE3 between these compartments is regulated. In this study, we examined the potential involvement of phosphatidylinositol 3'-kinase (PI3-K) in regulating the activity and distribution of NHE3, as this lipid kinase has been implicated in modulating vesicular traffic in the endosomal recycling pathway. Wortmannin and LY294002, both potent inhibitors of PI3-K, markedly inhibited NHE3-mediated Ht extrusion across the plasma membrane in a concentration- and time-dependent manner. The subcellular distribution of the antiporters was monitored by transfecting epitope-tagged NHE3 into AP-1 cells. In parallel with the inhibition of transport, PIS-K antagonists induced a pronounced loss of NHE3 from the cell surface and its accumulation in an intracellular compartment, as assessed by immunofluorescence microscopy and enzyme-linked immunosorbent assays. Further analysis using cells transfected with antiporters bearing an external epitope tag revealed that the redistribution reflected primarily a decrease in the rate of recycling of intracellular NHE3 to the cell surface. The wortmannin-induced inhibition and redistribution of NHE3 were prevented when cells were incubated at 4 degrees C, consistent with the known temperature dependence of the endocytic process. These observations demonstrate that NHE3 activity is controlled by dynamic endocytic and recycling events that are modulated by PI3-K.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; Hosp Sick Children, Div Cell Biol, Cell Biol Programme, Res Inst, Toronto, ON M5G 1X8, Canada	McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Grinstein, S (corresponding author), Hosp Sick Children, Div Cell Biol, Cell Biol Programme, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	sga@sickkids.on.ca		Orlowski, John/0000-0001-7371-175X; Lukacs, Gergely/0000-0003-0900-0675				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; BORON WF, 1986, ANNU REV PHYSIOL, V48, P377; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; FIELD M, 1989, NEW ENGL J MED, V321, P879; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HENSLEY CB, 1989, AM J PHYSIOL, V257, pC637, DOI 10.1152/ajpcell.1989.257.4.C637; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KNICKELBEIN RG, 1988, J CLIN INVEST, V82, P2158, DOI 10.1172/JCI113838; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; MA YH, 1994, J BIOL CHEM, V269, P30734; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; OKADA T, 1994, J BIOL CHEM, V269, P3568; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SCHWARTZ MA, 1991, EXP CELL RES, V195, P533, DOI 10.1016/0014-4827(91)90407-L; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P535, DOI 10.1006/bbrc.1995.1846; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; SueAQuan AK, 1997, J CELL PHYSIOL, V172, P94, DOI 10.1002/(SICI)1097-4652(199707)172:1<94::AID-JCP11>3.0.CO;2-O; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; YANO H, 1993, J BIOL CHEM, V268, P25846; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; Zhang YB, 1996, AM J PHYSIOL-RENAL, V270, pF1004, DOI 10.1152/ajprenal.1996.270.6.F1004	48	147	148	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20828	20836		10.1074/jbc.273.33.20828	http://dx.doi.org/10.1074/jbc.273.33.20828			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694828	hybrid			2022-12-25	WOS:000075386100021
J	Maechler, P; Kennedy, ED; Wang, HY; Wollheim, CB				Maechler, P; Kennedy, ED; Wang, HY; Wollheim, CB			Desensitization of mitochondrial Ca2+ and insulin secretion responses in the beta cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLETS; CYTOSOLIC CA2+; ALPHA-TOXIN; INS-1 CELLS; B-CELLS; GLUCOSE; METABOLISM; CHANNELS; DEHYDROGENASE; AEQUORIN	The role of mitochondria in the desensitization of insulin secretion was investigated. In rat pancreatic beta cells, both insulin secretion and mitochondrial [Ca2+] increases were desensitized following two challenges with the mitochondrial substrate methyl succinate, In the beta cell line INS-1, similar results were observed when a B-min interval separated two 5-min pulses. In contrast, ATP generation monitored in luciferase-expressing INS-1 cells was stimulated to the same extent during both exposures to methyl succinate. Succinate, like alpha-glycerophosphate, activates the electron transport chain at complex II. As a consequence, the mitochondrial membrane hyperpolarizes, promoting ATP synthesis and Ca2+ influx into the mitochondria through the uniporter. The mitochondrial desensitization was further studied in permeabilized INS-1 cells. Increasing extramitochondrial [Ca2+] from 100 to 500 nM enhanced succinate oxidation 4-fold. At 500 nM Ca2+, 1 mM succinate caused a blunted mitochondrial [Ca2+] increase upon the second, compared with the first, stimulation. These effects were mimicked by alpha-glycerophosphate, and there was cross-desensitization between the two compounds. Succinate hyperpolarized the mitochondrial membrane during both the first and second applications. This suggests that the uniporter itself, rather than the respiratory chain, is desensitized. These results emphasize the key role of the mitochondria not only in the stimulation of insulin secretion, but also in its desensitization.	Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland	University of Geneva	Wollheim, CB (corresponding author), Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland.			Maechler, Pierre/0000-0002-2005-1433				Anello M, 1996, DIABETES, V45, P502, DOI 10.2337/diabetes.45.4.502; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Boden G, 1996, AM J PHYSIOL-ENDOC M, V270, pE251, DOI 10.1152/ajpendo.1996.270.2.E251; Civelek VN, 1996, BIOCHEM J, V318, P615, DOI 10.1042/bj3180615; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; GEMBAL M, 1993, J CLIN INVEST, V91, P871, DOI 10.1172/JCI116308; GILON P, 1993, J BIOL CHEM, V268, P22265; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; HANSFORD RG, 1985, REV PHYSIOL BIOCH P, V102, P1, DOI 10.1007/BFb0034084; IDAHL LA, 1995, BIOCHEM J, V312, P287, DOI 10.1042/bj3120287; JONAS JC, 1994, BIOCHEM J, V301, P523, DOI 10.1042/bj3010523; Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Kilpatrick ED, 1998, DIABETES, V47, P606, DOI 10.2337/diabetes.47.4.606; LEAHY JL, 1986, J CLIN INVEST, V77, P908, DOI 10.1172/JCI112389; Liang Y, 1996, AM J PHYSIOL-ENDOC M, V270, pE846, DOI 10.1152/ajpendo.1996.270.5.E846; Ling ZD, 1996, J CLIN INVEST, V98, P2805, DOI 10.1172/JCI119108; Litsky ML, 1997, BIOCHEMISTRY-US, V36, P7071, DOI 10.1021/bi970180y; MacDonald MJ, 1996, ARCH BIOCHEM BIOPHYS, V326, P79, DOI 10.1006/abbi.1996.0049; MACDONALD MJ, 1988, DIABETES, V37, P997, DOI 10.2337/diabetes.37.7.997; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; Magnus G, 1997, AM J PHYSIOL-CELL PH, V273, pC717, DOI 10.1152/ajpcell.1997.273.2.C717; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; NESHER R, 1987, ENDOCRINOLOGY, V121, P1017, DOI 10.1210/endo-121-3-1017; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Nilsson T, 1996, BIOCHEM J, V314, P91, DOI 10.1042/bj3140091; Nusse O, 1998, EMBO J, V17, P1279, DOI 10.1093/emboj/17.5.1279; OHTA M, 1990, J BIOL CHEM, V265, P17525; PALMER M, 1993, J BIOL CHEM, V268, P11959; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; ROBERTSON RP, 1994, DIABETES, V43, P1085, DOI 10.2337/diabetes.43.9.1085; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; SATIN LS, 1994, BIOPHYS J, V66, P141, DOI 10.1016/S0006-3495(94)80759-3; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; Sekine N, 1997, DIABETES, V46, P1424, DOI 10.2337/diabetes.46.9.1424; SENER A, 1990, BIOCHIM BIOPHYS ACTA, V1019, P42, DOI 10.1016/0005-2728(90)90122-K; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; TZAGOLOFF A, 1982, MITOCHONDRIA, P62; VOEST D, 1995, BIOCHEMISTRY-US, P538; WAYNER EA, 1993, J CELL BIOL, V121, P1141, DOI 10.1083/jcb.121.5.1141; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301; [No title captured]	51	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20770	20778		10.1074/jbc.273.33.20770	http://dx.doi.org/10.1074/jbc.273.33.20770			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694821	hybrid, Green Published			2022-12-25	WOS:000075386100014
J	Tomita, T; Tokuhiro, S; Hashimoto, T; Aiba, K; Saido, TC; Maruyama, K; Iwatsubo, T				Tomita, T; Tokuhiro, S; Hashimoto, T; Aiba, K; Saido, TC; Maruyama, K; Iwatsubo, T			Molecular dissection of domains in mutant presenilin 2 that mediate overproduction of amyloidogenic forms of amyloid beta peptides - Inability of truncated forms of PS2 with familial Alzheimer's disease mutation to increase secretion of A beta 42*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLGA GERMAN FAMILIES; PRECURSOR PROTEIN; MISSENSE MUTATIONS; MAMMALIAN-CELLS; WILD-TYPE; IN-VIVO; GENE; EXPRESSION; PATHOGENESIS; APOPTOSIS	Mutations in presenilin (PS) 1 or PS2 genes account for the majority of early-onset familial Alzheimer's disease, and these mutations have been shown to increase production of species of amyloid beta peptide (A beta) ending at residue 42, i.e. the most amyloidogenic form of A beta. To gain insight into the molecular mechanisms whereby mutant PS induces overproduction of A beta 42, we constructed cDNAs encoding mutant and/or truncated forms of PS2 and examined the secretion of A beta 42 hom COS or neuro2a cells transfected with these genes. Cells expressing full-length PS2 harboring both N141I and M239V mutations in the same polypeptide induced overproduction of A beta 42, although the levels of A beta 42 were comparable with those in cells engineered to express PS2 with one or the other of these PS2 mutations. In contrast, cells engineered to express partially truncated PS2 (eliminating the COOH-terminal third of PS2 while retaining the endoproteolytic NH2-terminal fragment) and harboring a N141I mutation, as well as cells expressing COOH-terminal fragments of PS2, did not overproduce A beta 42, and the levels of A beta 42 were comparable with those in cells that expressed full-length, wild-type PS2 or fragments thereof. These data indicate that: (i) the A beta 42-promoting effects of mutant PS2 proteins reach the maximum level with a given single amino acid substitution tie. N141I or M239V); and (ii) the expression of full-length mutant PS2 is required for the overproduction of A beta 42. Hence, cooperative interactions of NH2- and COOH-terminal fragments generated from full-length mutant PS2 may be important for the overproduction of A beta 42 that may underlie familial Alzheimer's disease.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 130033, Japan; RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan; Natl Inst Physiol Sci, Neurochem Lab, Okazaki, Aichi 4448585, Japan	University of Tokyo; RIKEN; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Iwatsubo, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 130033, Japan.		Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021; Tomita, Taisuke/L-5427-2015; Hashimoto, Tadafumi/A-7723-2013	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; Tomita, Taisuke/0000-0002-0075-5943; Hashimoto, Tadafumi/0000-0001-5442-4800				ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Baba M, 1998, AM J PATHOL, V152, P879; Baumeister R, 1997, Genes Funct, V1, P149; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1998, IN PRESS NEUROBIOL D; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Crook R, 1997, ANN NEUROL, V42, P124, DOI 10.1002/ana.410420121; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Janicki S, 1997, J CELL BIOL, V139, P485, DOI 10.1083/jcb.139.2.485; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Kwok JBJ, 1997, NEUROREPORT, V8, P1537, DOI 10.1097/00001756-199704140-00043; Levin BR, 1996, EMERG INFECT DIS, V2, P93, DOI 10.3201/eid0202.960203; LEVYLEHAD, 1995, SCIENCE, V269, P973; Mann DMA, 1997, ANN NEUROL, V41, P52, DOI 10.1002/ana.410410110; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SAIDO TC, 1994, J BIOL CHEM, V269, P15253; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shirotani K, 1997, BIOCHEM BIOPH RES CO, V240, P728, DOI 10.1006/bbrc.1997.7730; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208	44	75	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21153	21160		10.1074/jbc.273.33.21153	http://dx.doi.org/10.1074/jbc.273.33.21153			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694871	hybrid			2022-12-25	WOS:000075386100064
J	Um, S; Harbers, M; Benecke, A; Pierrat, B; Losson, R; Chambon, P				Um, S; Harbers, M; Benecke, A; Pierrat, B; Losson, R; Chambon, P			Retinoic acid receptors interact physically and functionally with the T : G mismatch-specific thymine-DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; NUCLEAR HORMONE RECEPTORS; ACTIVATION FUNCTION AF-2; HUMAN ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; X RECEPTOR; STEROID-RECEPTORS; CRYSTAL-STRUCTURE; REPAIR ENZYME; PROTEIN HMG-1	The pleiotropic effects of retinoids are mediated by nuclear receptors that are activated by 9-cis- or all-trans-retinoic acid to function as ligand-dependent transcription factors. In a yeast one-hybrid screen for proteins capable of interacting with native retinoic acid receptor (RAR), we have isolated the T:G mismatch-specific thymine-DNA glycosylase (TDG), which initiates the repair of T:G mismatches caused by spontaneous deamination of methylated cytosines. Here, we report that TDG can interact with RAR and the retinoid X receptor (RXR) in a ligand-independent manner, both in yeast and in vitro. Mapping of the binding sites revealed interaction with a region of the ligand binding domain harboring alpha-helix 1 in both RAR and RXR. In transient transfection experiments, TDG potentiated transactivation by RXR from a direct repeat element spaced by one nucleotide (DR1) and by RXR/RAR heterodimers from a direct repeat element spaced by five nucleotides (DR5). In vitro, TDG enhanced RXR and RXR/RAR binding to their response elements. These data indicate that TDG is not only a repair enzyme, but could also function in the control of transcription.	ULP, Coll France, Inst Genet & Biol Mol & Cellulaire, CNRS,INSERM, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chambon, P (corresponding author), ULP, Coll France, Inst Genet & Biol Mol & Cellulaire, CNRS,INSERM, BP 163, F-67404 Illkirch Graffenstaden, France.		Benecke, Arndt G./T-1079-2019	Harbers, Matthias/0000-0002-5613-7220				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHEN ZP, 1994, J BIOL CHEM, V269, P25770; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CLEAVER JE, 1995, CELL, V80, P825, DOI 10.1016/0092-8674(95)90283-X; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; HALL BL, 1993, P NATL ACAD SCI USA, V90, P6929, DOI 10.1073/pnas.90.15.6929; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HEERY DM, 1994, NUCLEIC ACIDS RES, V22, P726, DOI 10.1093/nar/22.5.726; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; Jones PA, 1996, CANCER RES, V56, P2463; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; ONATE SA, 1995, SCIENCE, V270, P1354; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PIERRAT B, 1992, GENE, V119, P237, DOI 10.1016/0378-1119(92)90277-V; Prendergast P, 1996, MOL ENDOCRINOL, V10, P393, DOI 10.1210/me.10.4.393; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; Verrier CS, 1997, MOL ENDOCRINOL, V11, P1009, DOI 10.1210/me.11.8.1009; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	72	103	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20728	20736		10.1074/jbc.273.33.20728	http://dx.doi.org/10.1074/jbc.273.33.20728			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694815	hybrid			2022-12-25	WOS:000075386100008
J	Kawamura, S; Abe, Y; Ueda, T; Masumoto, K; Imoto, T; Yamasaki, N; Kimura, M				Kawamura, S; Abe, Y; Ueda, T; Masumoto, K; Imoto, T; Yamasaki, N; Kimura, M			Investigation of the structural basis for thermostability of DNA-binding protein HU from Bacillus stearothermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE ELECTROSTATIC INTERACTIONS; HISTONE-LIKE PROTEIN; ESCHERICHIA-COLI; SALT BRIDGES; STABILITY; SPECTROSCOPY; SUBTILIS; SITE; HBSU	Site-directed mutagenesis was used to identify amino acid residues essential for the thermostability of the DNA-binding protein HU from the thermophile Bacillus stearothermophilus (BstHU), Two mutants, BstHU-A27S and BsfHU-V42I, in which Ala(27) and Val(42) in BstHU were replaced by the corresponding amino acids Ser(27) and Ile(42), respectively, in the homologue from a mesophile B. subtilis (BsuHU), were less stable than the wild-type BstHU (63.9 degrees C), showing T-m values of 58.4 degrees C and 60.1 degrees C, respectively, as estimated by circular dichroism (CD) analysis at pH 7.0. The denaturation of two mutants was further characterized using differential scanning calorimetry; the T-m values obtained by calorimetric analysis were in good agreement with those estimated by CD analysis. The results suggest that Ala(27) and Val(42) are partly responsible for enhancing the thermostability of BstHU, When considered together with previous results, it is revealed that Gly(15), Ala(27), Glu(34), Lys(38), and Val(42) are essential for the thermostability of thermophilic protein BstHU, Moreover, five thermostabilizing mutations were simultaneously introduced into BsuHU, which resulted in a quintuple mutant with a T-m value of 71.3 degrees C, which is higher than that of BstHU, and also resulted in insusceptibility to proteinase digestion.	Kyushu Univ, Biochem Lab, Fac Agr, Fukuoka 81281, Japan; Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 81281, Japan	Kyushu University; Kyushu University	Kimura, M (corresponding author), Kyushu Univ, Biochem Lab, Fac Agr, Fukuoka 81281, Japan.	mkimura@agr.kyushu-u.ac.jp	Abe, Yoshito/AAH-6141-2021; Abe, Yoshito/D-8370-2012	Abe, Yoshito/0000-0002-0016-8490; Abe, Yoshito/0000-0002-0016-8490				AKASAKO A, 1995, BIOCHEMISTRY-US, V34, P8115, DOI 10.1021/bi00025a018; CASTAING B, 1995, J BIOL CHEM, V270, P10291, DOI 10.1074/jbc.270.17.10291; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P7142, DOI 10.1021/bi00243a015; DRICA K, 1987, MICROBIOL REV, V51, P301; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; Hosaka H, 1997, STRUCTURE, V5, P1199, DOI 10.1016/S0969-2126(97)00270-0; HWANG DS, 1992, J BIOL CHEM, V267, P23083; IMBER R, 1987, EUR J BIOCHEM, V165, P547, DOI 10.1111/j.1432-1033.1987.tb11474.x; Imoto T, 1997, CELL MOL LIFE SCI, V53, P215, DOI 10.1007/PL00000593; IMOTO T, 1986, J MOL BIOL, V190, P647, DOI 10.1016/0022-2836(86)90250-0; Kawamura S, 1997, J BIOCHEM-TOKYO, V121, P448; Kawamura S, 1996, BIOCHEMISTRY-US, V35, P1195, DOI 10.1021/bi951581l; KAWAMURA S, 1995, BIOSCI BIOTECH BIOCH, V59, P126, DOI 10.1271/bbb.59.126; LAVOIE BD, 1994, J BIOL CHEM, V269, P15571; MATSUMURA M, 1986, NATURE, V323, P356, DOI 10.1038/323356a0; OGASAHARA K, 1985, EUR J BIOCHEM, V150, P17, DOI 10.1111/j.1432-1033.1985.tb08979.x; Querol E, 1996, PROTEIN ENG, V9, P265, DOI 10.1093/protein/9.3.265; SALI D, 1991, J MOL BIOL, V220, P779, DOI 10.1016/0022-2836(91)90117-O; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; Vieille C, 1996, TRENDS BIOTECHNOL, V14, P183, DOI 10.1016/0167-7799(96)10026-3; VIS H, 1994, BIOCHEMISTRY-US, V33, P14858, DOI 10.1021/bi00253a025; VIS H, 1995, J MOL BIOL, V254, P692, DOI 10.1006/jmbi.1995.0648; Vogt G, 1997, J MOL BIOL, V269, P631, DOI 10.1006/jmbi.1997.1042; WADA M, 1989, GENE, V76, P345, DOI 10.1016/0378-1119(89)90174-1; WELFLE H, 1993, EUR J BIOCHEM, V217, P849, DOI 10.1111/j.1432-1033.1993.tb18313.x; WELFLE H, 1992, EUR J BIOCHEM, V204, P1049, DOI 10.1111/j.1432-1033.1992.tb16727.x; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; WILSON KS, 1990, PROTEIN ENG, V4, P11, DOI 10.1093/protein/4.1.11	30	34	34	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19982	19987		10.1074/jbc.273.32.19982	http://dx.doi.org/10.1074/jbc.273.32.19982			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685334	hybrid			2022-12-25	WOS:000075305400011
J	Law, GL; Itoh, H; Law, DJ; Mize, GJ; Merchant, JL; Morris, DR				Law, GL; Itoh, H; Law, DJ; Mize, GJ; Merchant, JL; Morris, DR			Transcription factor ZBP-89 regulates the activity of the ornithine decarboxylase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; TUMOR SUPPRESSOR WT1; GENE-EXPRESSION; C-MYC; BINDING; GROWTH; CELLS; ACTIVATION; REPRESSION; SITE	Appropriate cellular levels of polyamines are required for cell growth and differentiation. Ornithine decarboxylase is a key regulatory enzyme in the biosynthesis of polyamines, and precise regulation of the expression of this enzyme is required, according to cellular growth state, A variety of mitogens increase the level of ornithine decarboxylase activity, and, in most cases, this elevation is due to increased levels of mRNA. A GC box in the proximal promoter of the ornithine decarboxylase gene is required for basal and induced transcriptional activity, and two proteins, Spl and NF-ODC1, bind to this region in a mutually exclusive manner, Using a yeast one-hybrid screening method, ZBP-89, a DNA-binding protein, was identified as a candidate for the protein responsible for NF-ODC1 binding activity. Three lines of evidence verified this identification; ZBP-89 co-purified with NF-ODC1 binding activity, ZBP-89 antibodies specifically abolished NF-ODC1 binding to the GC box, and binding affinities of 12 different double-stranded oligonucleotides were indistinguishable between NF-ODC1, in nuclear extract, and in vitro translated ZBP-89, ZBP-89 inhibited the activation of the ornithine decarboxylase promoter by Spl in Schneider's Drosophila line 2, consistent with properties previously attributed to NF-ODC1.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Akita Univ, Sch Med, Dept Biochem, Akita 010, Japan; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Washington; University of Washington Seattle; Akita University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute	Morris, DR (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.		Morris, David/G-4503-2011; Merchant, Juanita/AAF-8277-2019	Merchant, Juanita/0000-0002-6559-8184	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045729, R01DK045729] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08229] Funding Source: Medline; NIDDK NIH HHS [DK45729] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABMAYR SM, 1991, CURRENT PROTOCOLS MO; ABRAHAMSEN MS, 1992, J BIOL CHEM, V267, P18866; ABRAHAMSEN MS, 1991, PERSPECTIVES CELL RE, P107; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BLACK O, 1982, CANC LETT, V1, P87; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRASIER AR, 1991, CURRENT PROTOCOLS MO; CAO XM, 1993, J BIOL CHEM, V268, P16949; CONTURSI C, 1995, J BIOL CHEM, V270, P26570, DOI 10.1074/jbc.270.44.26570; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HEBY O, 1981, DIFFERENTIATION, V9, P1; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; JAGGI R, 1988, J STEROID BIOCHEM, V29, P457, DOI 10.1016/0022-4731(88)90179-3; JOHNSON AC, 1992, J BIOL CHEM, V267, P1689; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; KUMAR AP, 1995, J BIOL CHEM, V270, P4341, DOI 10.1074/jbc.270.39.22980; LAW GL, 1995, POLYAMINES REGULATIO, P5; LI RS, 1994, J BIOL CHEM, V269, P7941; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; MORRIS DR, 1991, J CELL BIOCHEM, V46, P102, DOI 10.1002/jcb.240460203; Moshier JA, 1996, NUCLEIC ACIDS RES, V24, P1149, DOI 10.1093/nar/24.6.1149; MOSHIER JA, 1993, CANCER RES, V53, P2618; OSTROWSKI J, 1993, NUCLEIC ACIDS RES, V21, P1045, DOI 10.1093/nar/21.4.1045; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PEGG AE, 1988, CANCER RES, V48, P759; PENA A, 1993, J BIOL CHEM, V268, P27277; SEILER N, 1990, CANCER RES, V50, P5077; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Taniuchi T, 1997, BIOCHEM BIOPH RES CO, V233, P154, DOI 10.1006/bbrc.1997.6310; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; YOSHIDA M, 1992, CANCER RES, V52, P6671	46	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19955	19964		10.1074/jbc.273.32.19955	http://dx.doi.org/10.1074/jbc.273.32.19955			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685330	hybrid			2022-12-25	WOS:000075305400007
J	Liu, QY; Wang, JC				Liu, QY; Wang, JC			Identification of active site residues in the "GyrA" half of yeast DNA topoisomerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; 2-GATE MECHANISM; FLP RECOMBINASE; CLEAVAGE; TRANSPORT; TYROSINE; PROTEIN; ENZYME; REPLICATION; FRAGMENT	Site-directed mutagenesis was carried out at 10 highly conserved polar residues within the C-terminal half of yeast DNA topoisomerase II, which corresponds to the A subunit of bacterial DNA gyrase, to identify amino acid side chains that augment the active site tyrosine Tyr-782 in the breakage and rejoining of DNA strands. Complementation tests show that alanine substitution at Arg-690, Asp-697, Lys-700, Arg-704, or Arg-781, but not at His-735, His-736, Glu-738, Gln-750, or Asn-828, inactivates the enzyme in vivo. Measurements of DNA relaxation and cleavage by purified mutant enzymes show that these activities are abolished in the R690A mutant and are much reduced in the mutants D697A, K700A, R704A, and R781A. When a Y782F polypeptide with a phenylalanine substituting for the active site tyrosine was expressed in cells that also express the R690A polypeptide, the resulting heterodimeric yeast DNA topoisomerase II was found to nick plasmid DNA, Thus in a dimeric wild-type enzyme, Tyr-782 in one protomer and Arg-690 in the other cooperate in trans in the catalysis of DNA cleavage. For the residues D697A, K700A, R704A, and R781A, their locations in the crystal structures of type II DNA topoisomerase fragments suggest that Arg-781 and Lys-700 might be involved in anchoring the 5' and 3' sides of the broken DNA, respectively, and the roles of Asp-697 and Arg-704 are probably less direct.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Wang, JC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.				NIGMS NIH HHS [GM24544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024544, R37GM024544] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BERGER JM, 1995, STRUCTURAL DETERMINA; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; CARON PR, 1994, DNA TOPOISOMERASES T, P271; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHAMPOUX JJ, 1981, J BIOL CHEM, V256, P4805; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; Chen SJ, 1998, J BIOL CHEM, V273, P6050, DOI 10.1074/jbc.273.11.6050; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P8289; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; Jayaram M, 1997, SCIENCE, V276, P49, DOI 10.1126/science.276.5309.49; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; Li W, 1997, J BIOL CHEM, V272, P31190, DOI 10.1074/jbc.272.49.31190; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU L, 1994, DNA TOPOISOMERASES T; LIU LF, 1983, J BIOL CHEM, V258, P5365; LIU LF, 1979, NATURE, V281, P456, DOI 10.1038/281456a0; Lue N, 1995, STRUCTURE, V3, P1315, DOI 10.1016/S0969-2126(01)00269-6; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; MILLER KG, 1981, J BIOL CHEM, V256, P9334; MORRISON A, 1979, CELL, V17, P175, DOI 10.1016/0092-8674(79)90305-2; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; QIAN XH, 1995, GENE DEV, V9, P2053, DOI 10.1101/gad.9.16.2053; REESE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROWE TC, 1984, J BIOL CHEM, V259, P9177; SANDER M, 1983, J BIOL CHEM, V258, P8421; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; STETLER GL, 1979, P NATL ACAD SCI USA, V76, P3737, DOI 10.1073/pnas.76.8.3737; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P15449, DOI 10.1021/bi00255a027; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; THOMAS CA, 1979, ANAL BIOCHEM, V93, P158, DOI 10.1016/S0003-2697(79)80130-X; TSE YC, 1980, J BIOL CHEM, V255, P5560; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1995, ANNU REV BIOPH BIOM, V24, P185, DOI 10.1146/annurev.bb.24.060195.001153; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	47	45	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20252	20260		10.1074/jbc.273.32.20252	http://dx.doi.org/10.1074/jbc.273.32.20252			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685374	hybrid			2022-12-25	WOS:000075305400051
J	Rodriguez-Cousino, N; Solorzano, A; Fujimura, T; Esteban, R				Rodriguez-Cousino, N; Solorzano, A; Fujimura, T; Esteban, R			Yeast positive-stranded virus-like RNA replicons - 20 S and 23 S RNA terminal nucleotide sequences and 3 ' end secondary structures resemble those of RNA coliphages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; REPLICATION; POLYMERASE; IDENTIFICATION; FORM; FAMILY	Saccharomyces cerevisiae strains carry single-stranded RNAs called 20 S RNA and 23 S RNA. These RNAs and their double-stranded counterparts, W and T dsRNAs, have been cloned and sequenced, A few nucleotides at both ends, however, remained unknown, These RNAs do not encode coat proteins but their own RNA-dependent RNA polymerases that share a high degree of conservation to each other. The polymerases are also similar to the replicases of RNA coliphages, such as Q beta, Here we have determined the nucleotide sequences of W and T dsRNAs at both ends using reverse transcriptase polymerase chain reaction-generated cDNA clones, We confirmed the terminal sequences by primer-extension and RNase protection experiments. Furthermore, these analyses demonstrated that W and T dsRNAs and their single-stranded RNA counterparts (i) are linear molecules, (ii) have identical nucleotide sequences at their ends, and (iii) have no poly(A) tails at their 3' ends. Both 20 S and 23 S RNAs have GGGGC at the 5' ends and the complementary 5-nucleotides sequence, GCCCC-OH, at their 3' ends. S1 and V1 secondary structure-mapping of the 3' ends of 20 S and 23 S RNAs shows the presence of a stem-loop structure that partially overlaps with the conserved 3' end sequence. Nucleotide sequences and stem-loop structures similar to those described here have been found at the 3' ends of RNA coliphages, These data, together with the similarity of the RNA-dependent RNA polymerases encoded among these RNAs and RNA coliphages, suggest that 20 S and 23 S RNAs are plus-strand single-stranded virus-like RNA replicons in yeast.	Univ Salamanca, Dept Genet & Microbiol, Inst Microbiol Bioquim, CSIC, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Esteban, R (corresponding author), Univ Salamanca, Dept Genet & Microbiol, Inst Microbiol Bioquim, CSIC, Edificio Dept Avda Campo Charro S-N, E-37007 Salamanca, Spain.		Rodríguez-Cousiño, Nieves/K-6465-2014; Fujimura, Tsutomu/K-5807-2014; Esteban, Rosa/K-4356-2014	Rodríguez-Cousiño, Nieves/0000-0002-6458-3677; Fujimura, Tsutomu/0000-0002-9457-6769; Esteban, Rosa/0000-0001-6804-7209; Solorzano, Alicia/0000-0003-0072-3463				ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BOEKE JD, 1991, MOL CELLULAR BIOL YE, P193; BRUENN JA, 1993, NUCLEIC ACIDS RES, V21, P5667, DOI 10.1093/nar/21.24.5667; Buck KW, 1996, ADV VIRUS RES, V47, P159, DOI 10.1016/S0065-3527(08)60736-8; CIGAN AM, 1987, GENE, V59, P1; ELSHERBEINI M, 1987, P NATL ACAD SCI USA, V84, P4293, DOI 10.1073/pnas.84.12.4293; ESTEBAN LM, 1992, J BIOL CHEM, V267, P10874; ESTEBAN LM, 1994, J BIOL CHEM, V269, P29771; ESTEBAN LM, 1993, THESIS U SALAMANCA S; ESTEBAN R, 1989, EMBO J, V8, P947, DOI 10.1002/j.1460-2075.1989.tb03456.x; ESTEBAN R, 1993, PROG NUCLEIC ACID RE, V46, P155, DOI 10.1016/S0079-6603(08)61021-1; Flores R, 1995, VIRUS TAXONOMY, P495; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; GARCIACUELLAR MP, 1995, J BIOL CHEM, V270, P20084, DOI 10.1074/jbc.270.34.20084; GarciaCuellar MP, 1997, RNA, V3, P27; HANNIG EM, 1985, NUCLEIC ACIDS RES, V13, P4379, DOI 10.1093/nar/13.12.4379; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; Koonin EV, 1992, SEMIN VIROL, V3, P327; Lamb Robert A., 1996, P605; MAIZELS N, 1993, RNA WORLD, P577; Maniatis T., 1982, MOL CLONING LAB MANU; MATSUMOTO Y, 1990, P NATL ACAD SCI USA, V87, P7628, DOI 10.1073/pnas.87.19.7628; MATSUMOTO Y, 1991, J BIOL CHEM, V266, P12779; MILLER WA, 1986, J MOL BIOL, V187, P537, DOI 10.1016/0022-2836(86)90332-3; Patton JT, 1996, J VIROL, V70, P3961, DOI 10.1128/JVI.70.6.3961-3971.1996; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PRIANO C, 1987, COLD SPRING HARB SYM, V52, P321, DOI 10.1101/SQB.1987.052.01.037; RODRIGUEZCOUSINO N, 1992, NUCLEIC ACIDS RES, V20, P2761, DOI 10.1093/nar/20.11.2761; RODRIGUEZCOUSINO N, 1991, J BIOL CHEM, V266, P12772; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOHE A, 1978, J BACTERIOL, V136, P1002, DOI 10.1128/JB.136.3.1002-1007.1978; WEJKSNORA PJ, 1978, J BACTERIOL, V134, P246, DOI 10.1128/JB.134.1.246-260.1978; WESOLOWSKI M, 1984, MOL CELL BIOL, V4, P181, DOI 10.1128/MCB.4.1.181; Wickner RB, 1996, MICROBIOL REV, V60, P250, DOI 10.1128/MMBR.60.1.250-265.1996; WIDNER WR, 1991, MOL CELL BIOL, V11, P2905, DOI 10.1128/MCB.11.5.2905; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	40	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20363	20371		10.1074/jbc.273.32.20363	http://dx.doi.org/10.1074/jbc.273.32.20363			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685388	hybrid			2022-12-25	WOS:000075305400065
J	Adachi, M; Mikami, B; Katsube, T; Utsumi, S				Adachi, M; Mikami, B; Katsube, T; Utsumi, S			Crystal structure of recombinant soybean beta-amylase complexed with beta-cyclodextrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; SWEET-POTATO; EXPRESSION; PROTEIN; CLONING; CRYSTALLIZATION; SUBSTRATE; ISOZYMES; BINDING	In order to study the interaction of soybean beta-amylase with substrate, we solved the crystal structure of beta-cyclodextrin-enzyme complex and compared it with that of alpha-cyclodextrin-enzyme complex. The enzyme was expressed in Escherichia coli at a high level as a soluble and catalytically active protein. The purified recombinant enzyme had properties nearly identical: to those of native soybean beta-amylase and formed the same crystals as the native enzyme. The crystal structure of recombinant enzyme complexed with beta-cyclodextrin was refined at 2.07-Angstrom resolution with a final crystallographic R value of 15.8% (R-free = 21.1%). The root mean square deviation in the position of C-alpha atoms between this recombinant enzyme and the native enzyme was 0.22 Angstrom. These results indicate that the expression system established here is suitable for studying structure-function relationships of beta-amylase, The conformation of the bound beta-cyclodextrin takes an ellipsoid shape in contrast to the circular shape of the bound alpha-cyclodextrin. The cyclodextrins shared mainly two glucose binding sites, 3 and 4. The glucose residue 4 was slightly shifted hom the maltose binding site. This suggests that the binding site of the cyclodextrins is important for its holding of a cleaved substrate, which enables the multiple attack:mechanism of beta-amylase.	Kyoto Univ, Food Sci Res Inst, Uji, Kyoto 6110011, Japan	Kyoto University	Mikami, B (corresponding author), Kyoto Univ, Food Sci Res Inst, Uji, Kyoto 6110011, Japan.	mikami@soya.food.kyoto-u.ac.jp						BAILEY JM, 1957, BIOCHEM J, V67, P540, DOI 10.1042/bj0670540; BAILEY JM, 1957, J BIOL CHEM, V226, P1; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEONG CG, 1995, PROTEINS, V21, P105, DOI 10.1002/prot.340210204; FRENCH D, 1961, NATURE, V190, P445, DOI 10.1038/190445a0; FRENCH D, 1950, J AM CHEM SOC, V72, P1866, DOI 10.1021/ja01160a537; FRENCH D, 1961, ENZYMES, V4, P345; IMBERTY A, 1988, J MOL BIOL, V201, P365, DOI 10.1016/0022-2836(88)90144-1; JI ES, 1990, AGR BIOL CHEM TOKYO, V54, P3065, DOI 10.1080/00021369.1990.10870425; KATSUBE T, 1995, PLANT PHYSIOL, V109, P722; KAWAZU T, 1987, J BACTERIOL, V169, P1564, DOI 10.1128/jb.169.4.1564-1570.1987; KIM CS, 1990, PROTEIN ENG, V3, P725, DOI 10.1093/protein/3.8.725; KITAMOTO N, 1988, J BACTERIOL, V170, P5848, DOI 10.1128/jb.170.12.5848-5854.1988; KREIS M, 1987, EUR J BIOCHEM, V169, P517, DOI 10.1111/j.1432-1033.1987.tb13640.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MARSHALL JJ, 1973, EUR J BIOCHEM, V33, P494, DOI 10.1111/j.1432-1033.1973.tb02708.x; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; MIKAMI B, 1982, AGR BIOL CHEM TOKYO, V46, P943, DOI 10.1080/00021369.1982.10865177; MIKAMI B, 1986, J BIOCHEM-TOKYO, V100, P513, DOI 10.1093/oxfordjournals.jbchem.a121741; MIKAMI B, 1993, BIOCHEMISTRY-US, V32, P6836, DOI 10.1021/bi00078a006; MIKAMI B, 1994, BIOCHEMISTRY-US, V33, P7779, DOI 10.1021/bi00191a005; MONROE JD, 1991, PLANT PHYSIOL, V97, P1599, DOI 10.1104/pp.97.4.1599; MORITA Y, 1975, J BIOCHEM-TOKYO, V77, P343, DOI 10.1093/oxfordjournals.jbchem.a130731; MORITA Y, 1976, J BIOCHEM, V79, P591, DOI 10.1093/oxfordjournals.jbchem.a131102; NITTA Y, 1989, J BIOCHEM-TOKYO, V105, P573, DOI 10.1093/oxfordjournals.jbchem.a122706; NITTA Y, 1983, J BIOCHEM-TOKYO, V93, P1195, DOI 10.1093/oxfordjournals.jbchem.a134245; NOMURA K, 1986, J BIOCHEM-TOKYO, V100, P1175, DOI 10.1093/oxfordjournals.jbchem.a121821; RHODES C, 1987, NUCLEIC ACIDS RES, V15, P3934, DOI 10.1093/nar/15.9.3934; RORAT T, 1991, THEOR APPL GENET, V83, P257, DOI 10.1007/BF00226260; SAENGER W, 1983, BIOCHEM SOC T, V11, P136, DOI 10.1042/bst0110136; SHARFF AJ, 1993, BIOCHEMISTRY-US, V32, P10553, DOI 10.1021/bi00091a004; SIGGENS KW, 1987, MOL MICROBIOL, V1, P86, DOI 10.1111/j.1365-2958.1987.tb00531.x; SIGGENS KW, 1988, MOL MICROBIOL, V1, P170; STEINER T, 1994, J AM CHEM SOC, V116, P5122, DOI 10.1021/ja00091a014; SUGANUMA T, 1980, AGR BIOL CHEM TOKYO, V44, P1111, DOI 10.1080/00021369.1980.10864080; THOMA JA, 1960, J AM CHEM SOC, V82, P3329, DOI 10.1021/ja01498a025; THOMA JA, 1971, ENZYMES, V5, P115; TOTSUKA A, 1994, EUR J BIOCHEM, V221, P649, DOI 10.1111/j.1432-1033.1994.tb18777.x; Totsuka A, 1996, EUR J BIOCHEM, V240, P655, DOI 10.1111/j.1432-1033.1996.0655h.x; TOTSUKA A, 1993, EUR J BIOCHEM, V214, P787, DOI 10.1111/j.1432-1033.1993.tb17981.x; Utsumi S, 1992, Adv Food Nutr Res, V36, P89, DOI 10.1016/S1043-4526(08)60105-9; YOSHIDA N, 1991, J BIOCHEM-TOKYO, V110, P196, DOI 10.1093/oxfordjournals.jbchem.a123556; YOSHIGI N, 1995, J BIOCHEM, V118, P562, DOI 10.1093/oxfordjournals.jbchem.a124946; YOSHIGI N, 1994, BIOSCI BIOTECH BIOCH, V58, P1080, DOI 10.1271/bbb.58.1080	48	45	48	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19859	19865		10.1074/jbc.273.31.19859	http://dx.doi.org/10.1074/jbc.273.31.19859			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677422	hybrid			2022-12-25	WOS:000075125200074
J	Klotzsche, O; Etzrodt, D; Hohenberg, H; Bohn, W; Deppert, W				Klotzsche, O; Etzrodt, D; Hohenberg, H; Bohn, W; Deppert, W			Cytoplasmic retention of mutant tsp53 is dependent on an intermediate filament protein (Vimentin) scaffold	ONCOGENE			English	Article						nuclear exclusion; cytoplasmic anchorage; temperature sensitive mutant p53; vimentin; intermediate filaments; C6 rat glioma cells	HEAT-SHOCK PROTEINS; P53 PROTEIN; NUCLEAR EXCLUSION; CELL-LINES; KINASE-C; LOCALIZATION; MUTATIONS; PHOSPHORYLATION; ASSOCIATION; EXPRESSION	The temperature-sensitive mutant tsp(val135) accumulates in the cytoplasm of cells kept at the non-permissive temperature (39 degrees C), but is rapidly transported into the cell nucleus at the permissive temperature (30 degrees C). tsp53 thus may serve as a model for analysing cellular parameters influencing the subcellular location of p53. Here we provide evidence that retention of tsp53 in the cytoplasm at the non-permissive temperature is due to cytoskeletal anchorage of the p53 protein. Two sublines of C6 rat glioma cells differing in their expression of the intermediate filament protein vimentin (vimentin expressing or vimentin negative cells) were stably transfected with a vector encoding tsp53, Whereas cells of vimentin expressing C6 subclones retained tsp53 in the cytoplasm at the non-permissive temperature, cells of vimentin negative subclones exclusively harbored the tsp53 within their nuclei. Intermediate filament deficient cells that had been reconstituted with a full length vimentin protein again shelved a cytoplasmic localization of tsp53, whereas in cells expressing a C-terminally truncated (tail-less) vimentin tsp53 localized to the nucleus, We conclude that cytoplasmic sequestration of tsp53 requires an intact intermediate filament system.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Bohn, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							ALBERS K, 1992, INT REV CYTOL, V134, P243, DOI 10.1016/S0074-7696(08)62030-6; ALI IU, 1994, CANCER RES, V54, P1; BADER BL, 1991, J CELL BIOL, V115, P1293, DOI 10.1083/jcb.115.5.1293; BOHN W, 1992, EXP CELL RES, V201, P1, DOI 10.1016/0014-4827(92)90341-5; BOHN W, 1993, J STRUCT BIOL, V111, P48, DOI 10.1006/jsbi.1993.1035; CHENG TJ, 1994, J CELL BIOCHEM, V54, P100, DOI 10.1002/jcb.240540111; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CIESIELSKITRESKA J, 1991, J NEUROSCI RES, V29, P362, DOI 10.1002/jnr.490290312; Deppert W, 1996, J CELL BIOCHEM, V62, P172, DOI 10.1002/(SICI)1097-4644(199608)62:2<172::AID-JCB5>3.0.CO;2-P; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DEPPERT W, 1994, INT CONGR SER, V1050, P11; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ECKELT A, 1992, EUR J CELL BIOL, V58, P319; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; Foisner R, 1995, J STRUCT BIOL, V115, P304, DOI 10.1006/jsbi.1995.1055; GANNON JV, 1991, NATURE, V349, P802; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HEINS S, 1994, CURR OPIN CELL BIOL, V6, P25, DOI 10.1016/0955-0674(94)90112-0; HENNEKES H, 1990, MOL GEN GENET, V221, P33, DOI 10.1007/BF00280364; HERRMANN H, 1992, J MOL BIOL, V223, P637, DOI 10.1016/0022-2836(92)90980-X; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; Knippschild U, 1996, ONCOGENE, V12, P1755; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIAO J, 1995, J BIOL CHEM, V270, P915, DOI 10.1074/jbc.270.2.915; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCCORMICK MB, 1993, J CELL BIOL, V122, P395, DOI 10.1083/jcb.122.2.395; MEDCALF EA, 1992, ONCOGENE, V7, P71; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Nebe B, 1997, CYTOMETRY, V28, P66, DOI 10.1002/(SICI)1097-0320(19970501)28:1<66::AID-CYTO8>3.0.CO;2-F; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; OKABE S, 1988, J CELL BIOL, V107, P651, DOI 10.1083/jcb.107.2.651; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PORTER PL, 1992, AM J PATHOL, V140, P145; ROSER K, 1991, EXP CELL RES, V197, P200, DOI 10.1016/0014-4827(91)90423-R; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; STAUFENBIEL M, 1983, EUR J CELL BIOL, V31, P341; STEINMEYER K, 1988, ONCOGENE, V3, P501; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TAKAHASHI K, 1994, ONCOGENE, V9, P183; TRAUB P, 1983, J CELL SCI, V63, P43; TRONCOSO JC, 1990, J STRUCT BIOL, V103, P2, DOI 10.1016/1047-8477(90)90080-V; ZERRAHN J, 1992, ONCOGENE, V7, P1371	60	47	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3423	3434		10.1038/sj.onc.1202155	http://dx.doi.org/10.1038/sj.onc.1202155			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692550				2022-12-25	WOS:000074544100009
J	Lee, NH; Malek, RL				Lee, NH; Malek, RL			Nerve growth factor regulation of m4 muscarinic receptor mRNA stability but not gene transcription requires mitogen-activated protein kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; INDUCED DOWN-REGULATION; 3' UNTRANSLATED REGION; ACETYLCHOLINE-RECEPTOR; PC12 CELLS; PC-12 CELLS; POSTTRANSCRIPTIONAL REGULATION; NEURONAL DIFFERENTIATION; 3'-UNTRANSLATED REGION; INDUCED STABILIZATION	Nerve growth factor (NGF) up-regulated steady-state levels of m4 muscarinic acetylcholine receptor (mAChR) mRNA in PC12 cells. Up-regulation of mRNA levels was associated with a corresponding increase in mAChR binding sites. Two other growth factors, basic fibroblast growth factor (bFGP) and epidermal growth factor (EGF), up regulated m4 mRNA and mAChR binding sites. Treatment of PC12 cells with NGF and bFGF, but not EGF, has previously been demonstrated to result in sustained activation of mitogen activated protein kinase (MAPK), Analogously, NGF and bFGF, but not EGF, increased the stability of m4 mRNA in PC12 cells. In HER-PC12 cells, a clonal PC12 cell transfectant overexpressing EGF receptors and displaying sustained MAPK activation upon receptor stimulation, EGF treatment stabilized the m4 transcript, A synthetic inhibitor of MAPK kinase, PD98059, inhibited growth factor-induced stabilization of the m4 transcript in both PC12 and HER-PC12 cells. These findings demonstrate that the MAPK pathway is involved in transcript stabilization. Cycloheximide pretreatment abolished the posttranscriptional effect of NGF, indicating that de novo protein synthesis was required for the observed increase in m4 mRNA stability, By contrast, cycloheximide had no discernible post-transcriptional effect if added after NGF treatment, suggesting that an inducible yet stable protein factor was involved in m4 mRNA decay, An unusually well conserved 137 nucleotides of m4 3'-untranslated region has been identified by sequence comparison with other mRNAs that are post-transcriptionally regulated by NGF. In PC12 cells that heterologously overexpress this region, we demonstrate that NGF no longer stabilizes endogenous m4 mRNA This conserved region probably represents an NGF-responsive element involved in mRNA stability regulation, Finally, transcription of the m4 gene can be induced by all three growth factors but is not dependent on MAPK activity, unlike growth factor-induced m4 mRNA stabilization.	Inst Genom Res, Dept Mol & Cellular Biol, Rockville, MD 20850 USA	J. Craig Venter Institute	Lee, NH (corresponding author), Inst Genom Res, Dept Mol & Cellular Biol, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	nhlee@tigr.org			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035231] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35231] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATWATER JA, 1994, ANNU REV GENET, V24, P519; BASI GS, 1987, CELL, V49, P785, DOI 10.1016/0092-8674(87)90616-7; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; CAVALLARO S, 1995, MOL PHARMACOL, V48, P56; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung SM, 1997, J BIOL CHEM, V272, P6593, DOI 10.1074/jbc.272.10.6593; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; EVA C, 1992, MOL BRAIN RES, V14, P344, DOI 10.1016/0169-328X(92)90102-H; FRASER CM, 1994, PROG NUCLEIC ACID RE, V49, P113; FRASER CM, 1995, LIFE SCI, V56, P899, DOI 10.1016/0024-3205(95)00026-3; FUKAMAUCHI F, 1993, MOL PHARMACOL, V44, P940; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HABECKER BA, 1992, P NATL ACAD SCI USA, V89, P5035, DOI 10.1073/pnas.89.11.5035; HADCOCK JR, 1993, J NEUROCHEM, V60, P1, DOI 10.1111/j.1471-4159.1993.tb05816.x; Haddad EB, 1996, MOL PHARMACOL, V49, P781; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; Irwin N, 1997, NUCLEIC ACIDS RES, V25, P1281, DOI 10.1093/nar/25.6.1281; JUMBLATT JE, 1982, NATURE, V297, P152, DOI 10.1038/297152a0; KIJIMA K, 1995, BIOCHEM BIOPH RES CO, V216, P359, DOI 10.1006/bbrc.1995.2632; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; Lee NH, 1996, MOL PHARMACOL, V50, P140; LEE NH, 1994, J BIOL CHEM, V269, P4291; LEE NH, 1995, MOL B INT U, P247; LEE NH, 1996, PHOSPHOINOSITIDASE C, P133; LENZ W, 1994, N-S ARCH PHARMACOL, V350, P507, DOI 10.1007/BF00173020; LINDENBAUM MH, 1988, J BIOL CHEM, V263, P5662; LUDLAM WH, 1994, DEV BIOL, V164, P528, DOI 10.1006/dbio.1994.1221; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mieda M, 1996, J BIOL CHEM, V271, P5177; NARAYANAN CS, 1992, J BIOL CHEM, V267, P17296; NISHIZAWA K, 1994, BIOCHEM BIOPH RES CO, V200, P789, DOI 10.1006/bbrc.1994.1520; NISHIZAWA K, 1994, BIOCHEM BIOPH RES CO, V205, P1380, DOI 10.1006/bbrc.1994.2818; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pepitoni S, 1997, J BIOL CHEM, V272, P17112, DOI 10.1074/jbc.272.27.17112; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PERRONEBIZZOZERO NI, 1993, J CELL BIOL, V120, P1263, DOI 10.1083/jcb.120.5.1263; Rosoff ML, 1996, P NATL ACAD SCI USA, V93, P14889, DOI 10.1073/pnas.93.25.14889; ROUSELL J, 1995, J BIOL CHEM, V270, P7213, DOI 10.1074/jbc.270.13.7213; Smith MA, 1997, J BIOL CHEM, V272, P15675, DOI 10.1074/jbc.272.25.15675; STEEL MC, 1993, MOL PHARMACOL, V43, P694; Szeberenyi J., 1996, Neurobiology (Budapest), V4, P1; Tholanikunnel BG, 1997, J BIOL CHEM, V272, P11471; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Tsai KC, 1997, J NEUROSCI, V17, P1950; TWISS JL, 1995, J NEUROCHEM, V64, P550; WANG SZ, 1990, FEBS LETT, V276, P185, DOI 10.1016/0014-5793(90)80538-T; Wood IC, 1995, J BIOL CHEM, V270, P30933, DOI 10.1074/jbc.270.52.30933; Wood IC, 1996, J BIOL CHEM, V271, P14221, DOI 10.1074/jbc.271.24.14221; Yan GZ, 1997, J NEUROSCI, V17, P6122	55	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22317	22325		10.1074/jbc.273.35.22317	http://dx.doi.org/10.1074/jbc.273.35.22317			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712850	hybrid			2022-12-25	WOS:000075616600026
J	Marks-Konczalik, J; Chu, SC; Moss, J				Marks-Konczalik, J; Chu, SC; Moss, J			Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor kappa B-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PROTEOLYTIC DEGRADATION; SIGNAL-TRANSDUCTION; MOUSE MACROPHAGES; INTERFERON-GAMMA; P50 SUBUNIT; JUN-D; PROMOTER; FOS; CELLS	The involvement of AP-1 and NF-kappa B transcription factors in cytokine-mediated induction of human inducible nitric oxide synthase (hiNOS) promoter activity was examined. Luciferase reporter plasmids, containing mutations in AP-1 and NF-kappa B sites, in a hiNOS promoter extending from -8.3 kilobase pairs (kb) to +168, were transiently expressed in A549 cells, and promoter activity was determined after treatment with a cytokine mixture (CM) containing interleukin 1-beta, interferon-gamma, and tumor necrosis factor-alpha. Mutation of the AP-1 heptad located -5301 base pairs upstream decreased gene activation by 90% in a -8.3-kb promoter and a shorter -5.574-kb promoter. Disruption of AP-1 (at -5115) or NF-kappa B (at -115 and -8283) sites reduced promoter activity by 45, 67, and 52%, respectively. Responsiveness to CM was decreased by 85% in constructs mutated in both NF-kappa B sites. By gel retardation analyses, CM increased AP-1- and NF-kappa B binding. Supershift analysis identified Jun D and Fra-2 as components of AP-1 complexes. Each kappa B Site bound different complements of NF-kappa B/Rel family members (downstream site, Rel A/p50; upstream site, Rel A/Rel A). Rel A was maximally, whereas I kappa B-alpha was minimally, expressed in nuclei after 1 h of CM treatment, corresponding with the peak in NF-kappa B inding activity. Thus, AP-1 and NF-kappa B are important cis-elements for induction of hiNOS gene transcription.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Marks-Konczalik, J (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10,Rm 6D03,10 Ctr Dr,MSC 1590, Bethesda, MD 20892 USA.	markrsj@gwgate.nhlbi.nih.gov						ADDOCK IM, 1994, BIOCHEM SOC T, V22, P186; AMOAHAPRAKU B, 1995, KIDNEY INT, V48, P674, DOI 10.1038/ki.1995.337; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEDOYA FJ, 1995, BIOCHEM BIOPH RES CO, V210, P816, DOI 10.1006/bbrc.1995.1731; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHU SC, 1995, J BIOL CHEM, V270, P10625, DOI 10.1074/jbc.270.18.10625; Chu SC, 1998, BIOCHEM BIOPH RES CO, V248, P871, DOI 10.1006/bbrc.1998.9062; CORBETT JA, 1991, J BIOL CHEM, V266, P21351; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; EBERHARDT W, 1994, BIOCHEM BIOPH RES CO, V200, P163, DOI 10.1006/bbrc.1994.1429; Eissa NT, 1996, J BIOL CHEM, V271, P27184, DOI 10.1074/jbc.271.43.27184; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Farivar RS, 1996, J BIOL CHEM, V271, P31585, DOI 10.1074/jbc.271.49.31585; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; FORSTERMANN U, 1995, N-S ARCH PHARMACOL, V352, P351; GARDNER K, 1994, J BIOL CHEM, V269, P32963; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KLEEMANN R, 1993, FEBS LETT, V328, P9, DOI 10.1016/0014-5793(93)80954-S; KONE BC, 1995, AM J PHYSIOL-RENAL, V269, pF718, DOI 10.1152/ajprenal.1995.269.5.F718; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nunokawa Y, 1996, BIOCHEM BIOPH RES CO, V223, P347, DOI 10.1006/bbrc.1996.0897; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; Rahmsdorf HJ, 1996, J MOL MED, V74, P725, DOI 10.1007/s001090050077; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Spitsin SV, 1996, MOL MED, V2, P226, DOI 10.1007/BF03401619; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; Suzuki T, 1996, J BIOL CHEM, V271, P1626, DOI 10.1074/jbc.271.3.1626; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VODOVOTZ Y, 1994, J IMMUNOL, V152, P4110; WEINBERG JB, 1994, J EXP MED, V179, P651, DOI 10.1084/jem.179.2.651; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1994, J LEUKOCYTE BIOL, V56, P576, DOI 10.1002/jlb.56.5.576; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YANG Z, 1990, P NATL ACAD SCI USA, V87, P9226, DOI 10.1073/pnas.87.23.9226; YOON JK, 1994, MOL CELL BIOL, V14, P7731, DOI 10.1128/MCB.14.12.7731; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A	65	264	273	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22201	22208		10.1074/jbc.273.35.22201	http://dx.doi.org/10.1074/jbc.273.35.22201			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712833	hybrid			2022-12-25	WOS:000075616600009
J	Brewster, NK; Johnston, GC; Singer, RA				Brewster, NK; Johnston, GC; Singer, RA			Characterization of the CP complex, an abundant dimer of Cdc68 and Pob3 proteins that regulates yeast transcriptional activation and chromatin repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; SHUTTLE VECTORS; NUCLEAR-PROTEIN; ESSENTIAL GENE; EXPRESSION; MUTATIONS; SUPPRESS; ENCODES; SPT5	The Cdc68 protein of the yeast Saccharomyces cerevisiae is an essential nuclear protein that has been shown to be necessary for the tl-ans-activation of many genes as well as for the maintenance of chromatin-mediated repression in the absence of trans-activation, These activities implicate, the Cdc68 protein in the regulation of chromatin structure and/or function, Here we report that Cdc68 is found in association with another essential nuclear protein, Pob3, in what we term the CP complex. This dimer of Cdc68 with Pob3 is stable to partial purification, so that the functions of gene activation and repression that are assigned to Cdc68 are likely to be properties of the CP complex. The CP complex is highly abundant, suggesting that it may be widespread throughout chromatin.	Dalhousie Univ, Dept Biochem, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Med, Halifax, NS B3H 4H7, Canada	Dalhousie University; Dalhousie University; Dalhousie University	Singer, RA (corresponding author), Dalhousie Univ, Dept Biochem, Halifax, NS B3H 4H7, Canada.	rasinger@is.dal.ca						BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; Chiang PW, 1996, GENOMICS, V38, P421, DOI 10.1006/geno.1996.0646; Chiang PW, 1996, GENOMICS, V34, P328, DOI 10.1006/geno.1996.0294; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; CLARKADAMS CD, 1987, MOL CELL BIOL, V7, P679, DOI 10.1128/MCB.7.2.679; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; DRAPER MP, 1994, MOL CELL BIOL, V14, P4522, DOI 10.1128/MCB.14.7.4522; FASSLER JS, 1988, GENETICS, V118, P203; HAPPEL AM, 1991, GENETICS, V128, P69; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; JIANG YW, 1995, GENETICS, V140, P103; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LYCAN D, 1994, MOL CELL BIOL, V14, P7455, DOI 10.1128/MCB.14.11.7455; MALONE EA, 1991, MOL CELL BIOL, V11, P5710, DOI 10.1128/MCB.11.11.5710; NEIGEBORN L, 1986, GENETICS, V112, P741; NEIGEBORN L, 1984, GENETICS, V108, P845; NEIGEBORN L, 1987, MOL CELL BIOL, V7, P672, DOI 10.1128/MCB.7.2.672; NISHIWAKI K, 1993, MOL GEN GENET, V239, P313, DOI 10.1007/BF00276929; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; PRELICH G, 1993, GENETICS, V135, P665; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; ROWLEY A, 1991, MOL CELL BIOL, V11, P5718, DOI 10.1128/MCB.11.11.5718; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Stachora AA, 1997, FEBS LETT, V409, P74, DOI 10.1016/S0014-5793(97)00486-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWANSON MS, 1991, MOL CELL BIOL, V11, P4286, DOI 10.1128/MCB.11.8.4286; SWANSON MS, 1991, MOL CELL BIOL, V11, P3009, DOI 10.1128/MCB.11.6.3009; SWANSON MS, 1992, GENETICS, V132, P325; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Winston, 1992, TRANSCRIPTIONAL REGU, P1271; WINSTON F, 1984, GENETICS, V107, P179; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wittmeyer J, 1997, MOL CELL BIOL, V17, P4178, DOI 10.1128/MCB.17.7.4178; XU QL, 1995, MOL CELL BIOL, V15, P6025; XU QL, 1993, MOL CELL BIOL, V13, P7553, DOI 10.1128/MCB.13.12.7553	46	73	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21972	21979		10.1074/jbc.273.34.21972	http://dx.doi.org/10.1074/jbc.273.34.21972			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705338	hybrid			2022-12-25	WOS:000075492600072
J	Junemann, S; Heathcote, P; Rich, PR				Junemann, S; Heathcote, P; Rich, PR			On the mechanism of quinol oxidation in the bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C REDUCTASE; IRON-SULFUR PROTEIN; INHIBITOR; UBIQUINONE; SITE; UBIHYDROQUINONE; OXIDOREDUCTASE; ANTIMYCIN; ELECTRON; BINDING	The question of whether significant levels of a semiquinone can be generated in the Q(o) site of the be, complex under conditions of oxidant-induced reduction is relevant to the mechanism of bifurcation of electron transfer in this site. It has already been reported that beef heart submitochondrial particles under such conditions exhibit an EPR-detectable semiquinone, which is distinct from Q(i)((.) over bar) and which was attributed to a semiquinone in the Q(o) site (de Vries, S., Albracht, S. P. J., Berden, J. A., and Slater, E. C. (1981) J. Biol. Chem. 256, 11996-11998). However, we show here that this signal, which can be generated to a level of around 0.1 per bc(1) monomer, is insensitive to the Q(o) site inhibitors myxothiazol, E-beta-methoxyacrylate-stilbene, and stigmatellin, indicating that it does not arise from a Q(o)((.) over bar) species. Based on sensitivities to inhibitors of other Q sites, up to 60% of the signal may arise from semiquinones of complexes I and II. We further show that the iron-sulfur center remains EPR silent under oxidant-induced reduction conditions. Overall, the results indicate that, under conditions of oxidant-induced reduction, the Q(o) site is occupied primarily by quinol with the iron-sulfur center oxidized, or, possibly, by an antiferromagnetically coupled semiquinone/reduced iron-sulfur center pair, which are EPR silent. This is discussed in relation to proposed mechanisms of quinol oxidation in the Q(o) site, and we describe a minimal intermediate-controlled bifurcation model based on rate constants by which bifurcated electron transfer at the Q(o) site might occur.	UCL, Glynn Lab Bioenerget, Dept Biol, London WC1E 6BT, England; Queen Mary Univ London, Sch Biol Sci, London E1 4NS, England	University of London; University College London; University of London; Queen Mary University London	Rich, PR (corresponding author), UCL, Glynn Lab Bioenerget, Dept Biol, Gower St, London WC1E 6BT, England.	prr@ucl.ac.uk	Heathcote, Peter/B-3749-2011		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Brandt U, 1998, BBA-BIOENERGETICS, V1365, P261, DOI 10.1016/S0005-2728(98)00078-4; BRANDT U, 1991, J BIOL CHEM, V266, P19958; BRANDT U, 1991, EUR J BIOCHEM, V195, P163, DOI 10.1111/j.1432-1033.1991.tb15690.x; Brandt U, 1996, FEBS LETT, V387, P1, DOI 10.1016/0014-5793(96)00436-X; Clark W. M., 1960, OXIDATION REDUCTION; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; DEVRIES S, 1981, J BIOL CHEM, V256, P1996; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; Hartzell C R, 1978, Methods Enzymol, V53, P54; LEE IY, 1972, BIOCHIM BIOPHYS ACTA, V283, P395, DOI 10.1016/0005-2728(72)90257-5; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; MALKIN R, 1981, FEBS LETT, V131, P169, DOI 10.1016/0014-5793(81)80912-X; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Moody A. J., 1997, BIOELECTROCHEMISTRY, P419; RICH PR, 1990, BIOCHIM BIOPHYS ACTA, V1018, P29, DOI 10.1016/0005-2728(90)90106-E; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; RIESKE JS, 1976, BIOCHIM BIOPHYS ACTA, V456, P195, DOI 10.1016/0304-4173(76)90012-4; SLATER EC, 1973, BIOCHIM BIOPHYS ACTA, V301, P129, DOI 10.1016/0304-4173(73)90002-5; SLATER EC, 1980, NATURE, V288, P717, DOI 10.1038/288717a0; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; WIKSTROM MK, 1972, BIOCHIM BIOPHYS ACTA, V283, P403, DOI 10.1016/0005-2728(72)90258-7; WILLIAMSSMITH DL, 1978, BIOCHEM J, V170, P365, DOI 10.1042/bj1700365; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	27	100	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21603	21607		10.1074/jbc.273.34.21603	http://dx.doi.org/10.1074/jbc.273.34.21603			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705291	hybrid			2022-12-25	WOS:000075492600025
J	Spalding, TA; Burstein, ES; Henderson, SC; Ducote, KR; Brann, MR				Spalding, TA; Burstein, ES; Henderson, SC; Ducote, KR; Brann, MR			Identification of a ligand-dependent switch within a muscarinic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; RANDOM SATURATION MUTAGENESIS; ACETYLCHOLINE-RECEPTOR; CONSTITUTIVE ACTIVATION; TRANSMEMBRANE HELICES; ANTAGONIST BINDING; RHODOPSIN; SUBTYPES; EXPRESSION	G-protein-coupled receptors spontaneously switch between active and inactive conformations. Agonists stabilize the active conformation, whereas antagonists stabilize the inactive conformation. In a systematic search for residues that participate in receptor function, several regions of the m5 muscarinic receptor were randomly mutated and tested for their functional properties. Mutations spanning one face of transmembrane 6 (TM6) were found to induce high levels of receptor activity in the absence of agonists (constitutive activity). The same face of TM6 contained several residues crucial for receptor activation by agonists and one residue identified as a contact site for both agonists and antagonists. In addition, one mutation induced agonist-like responses from the receptor when exposed to classical antagonists. These results suggest that TMB is a switch that defines the activation state of the receptor, and that ligand interactions with TM6 stabilize the receptor in either an active or an inactive conformation.	ADADIA Pharmaceut Inc, San Diego, CA 92121 USA; Univ Vermont, Dept Psychiat, Mol Neuropharmacol Sect, Burlington, VT 05405 USA; Univ Vermont, Dept Pharmacol, Mol Neuropharmacol Sect, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Spalding, TA (corresponding author), ADADIA Pharmaceut Inc, 3911 Sorrento Valley Blvd, San Diego, CA 92121 USA.	tspalding@acadia-pharm.com			NIGMS NIH HHS [R01 GM52737] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052737] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BLUML K, 1994, J BIOL CHEM, V269, P18870; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRANN MR, 1993, LIFE SCI, V52, P405, DOI 10.1016/0024-3205(93)90295-E; Brauner-Osborne H, 1996, EUR J PHARMACOL, V295, P93, DOI 10.1016/0014-2999(95)00639-7; Burstein ES, 1998, BIOCHEMISTRY-US, V37, P4052, DOI 10.1021/bi972132j; Burstein ES, 1996, J BIOL CHEM, V271, P2882, DOI 10.1074/jbc.271.6.2882; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; Burstein ES, 1997, MOL PHARMACOL, V51, P312, DOI 10.1124/mol.51.2.312; BURSTEIN ES, 1995, FEBS LETT, V363, P261, DOI 10.1016/0014-5793(95)00323-2; CHABRE M, 1985, ANNU REV BIOPHYS BIO, V14, P331, DOI 10.1146/annurev.biophys.14.1.331; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FRASER CM, 1989, MOL PHARMACOL, V36, P840; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HILF G, 1992, EUR J PHARM-MOLEC PH, V225, P245, DOI 10.1016/0922-4106(92)90026-R; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; Jakubik J, 1995, FEBS LETT, V377, P275, DOI 10.1016/0014-5793(95)01360-1; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; MATSUI H, 1995, MOL PHARMACOL, V47, P88; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SPALDING TA, 1994, J BIOL CHEM, V269, P4092; Spalding TA, 1997, BIOCHEMISTRY-US, V36, P10109, DOI 10.1021/bi970565g; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; WESS J, 1990, MOL PHARMACOL, V38, P517; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x	35	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21563	21568		10.1074/jbc.273.34.21563	http://dx.doi.org/10.1074/jbc.273.34.21563			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705286	hybrid			2022-12-25	WOS:000075492600020
J	Tabor, DE; Kim, JB; Spiegelman, BM; Edwards, PA				Tabor, DE; Kim, JB; Spiegelman, BM; Edwards, PA			Transcriptional activation of the stearoyl-CoA desaturase 2 gene by sterol regulatory element-binding protein/adipocyte determination and differentiation factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL DIPHOSPHATE SYNTHASE; MUTANT HAMSTER-CELLS; 3T3-L1 PREADIPOCYTES; FATTY-ACIDS; EXPRESSION; CHOLESTEROL; PROMOTER; PROTEIN; METABOLISM; MYC	To identify genes that are transcriptionally activated by sterol regulatory element-binding proteins (SREBPs), we utilized mRNA differential display and mutant cells that express either high car low levels of transcriptionally active SREBP. This approach identified stearoyl-CoA desaturase 2 (SCD2) as a new SREBP-regulated gene. Cells were transiently transfected with reporter genes blinder the control of different fragments of the mouse SCD2 promoter. Constructs containing >199 base pairs of the SCD2 proximal promoter were activated following incubation of cells in sterol-depleted medium or as a result of co-expression of SREBP-1a, SREBP-2, or rat adipocyte determination and differentiation factor 1 (ADD1). Electromobility shift assays and DNase I footprint analysis demonstrated that recombinant SREBP-1a hound to a novel cis element (5'-AGCAGATTGTG-3') in the proximal promoter of the SCD2 gene. The finding that the endogenous SCD2 mRNA Bevels were induced when wild-type Chinese hamster ovary fibroblasts were incubated in sterol-deficient medium is consistent with a role for SREBP in regulating transcription of the gene. These studies identify SCD2 as a new member of the family of genes that are transcriptionally regulated in response to changing levels of nuclear SREBP/ADD1. In addition, the sterol regulatory element in the SCD2 promoter is distinct from all previously characterized motifs that confer SREBP- and ADD1-dependent transcriptional activation.	Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Edwards, PA (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, CHS 33-257, Los Angeles, CA 90095 USA.	pedwards@medicine.medsch.ucla.edu		KIM, Jae Bum/0000-0003-2337-6935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Athanikar JN, 1998, P NATL ACAD SCI USA, V95, P4935, DOI 10.1073/pnas.95.9.4935; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHIN J, 1982, BIOCHEMISTRY-US, V21, P3196, DOI 10.1021/bi00256a025; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; EVANS MJ, 1993, MOL CELL BIOL, V13, P5175, DOI 10.1128/MCB.13.9.5175; Guan GM, 1997, J BIOL CHEM, V272, P10295; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; Jackson SM, 1996, J LIPID RES, V37, P1712; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Liang P, 1997, Methods Mol Biol, V85, P3; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Maniatis T., 1989, MOL CLONING LAB MANU; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; NTAMBI JM, 1995, PROG LIPID RES, V34, P139, DOI 10.1016/0163-7827(94)00010-J; PANINI SR, 1990, J BIOL CHEM, V265, P14118; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SCHNITZERPOLOKOFF R, 1983, ARCH BIOCHEM BIOPHYS, V227, P71, DOI 10.1016/0003-9861(83)90348-X; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; Tabor DE, 1998, MAMM GENOME, V9, P341, DOI 10.1007/s003359900765; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152	32	93	94	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22052	22058		10.1074/jbc.273.34.22052	http://dx.doi.org/10.1074/jbc.273.34.22052			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705348	hybrid, Green Published			2022-12-25	WOS:000075492600082
J	Grima, J; Wong, CCS; Zhu, LJ; Zong, SD; Cheng, CY				Grima, J; Wong, CCS; Zhu, LJ; Zong, SD; Cheng, CY			Testin secreted by Sertoli cells is associated with the cell surface, and its expression correlates with the disruption of Sertoli-germ cell junctions but not the inter-Sertoli tight junction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; ANDROGEN-BINDING-PROTEIN; RAT TESTIS; DEVELOPMENTAL-CHANGES; EXTRACELLULAR-MATRIX; SEMINIFEROUS TUBULE; OCCLUDING JUNCTIONS; SPERMATID BINDING; ENDOTHELIAL-CELLS; CANCER METASTASIS	Testin is a testosterone-responsive Sertoli cell secretory product. In the present study, we demonstrated that the amount of testin secreted by Sertoli cells in vitro was comparable with several other Sertoli cell secretory products. However, virtually no testin was found in the luminal fluid and cytosols of the testis and epididymis when the intercellular junctions were not previously disrupted, suggesting that secreted testin may be reabsorbed by testicular cells in vivo. Studies using Sertoli cells with and without a cell surface cross-inker and radioiodination in conjunction with immunoprecipitation illustrated the presence of two polypeptides of 28 and 45 kDa, which constitute a binding protein complex that anchors testin onto the cell surface, The 28- and 45-kDa peptide appear to be residing on and inside the cell surface, respectively. Immunogold EM studies illustrated testin was abundantly localized on the Sertoli cell side of the ectoplasmic specialization (a modified adherens junction) surrounding developing spermatids. In contrast, very few testin gold particles were found at the site of inter-Sertoli tight junctions. When the inter-Sertoli tight junctions were formed or disrupted, no significant change in testin expression was noted. This is in sharp contrast to the disruption of Sertoli-germ cell junctions, which is accompanied by a surge in testin expression. These results demonstrate the usefulness of testin in examining Sertoli-germ cell interactions.	Populat Council, New York, NY 10021 USA; Univ Hong Kong, Dept Zool, Hong Kong, Hong Kong	Population Council; University of Hong Kong	Cheng, CY (corresponding author), Populat Council, 1230 York Ave, New York, NY 10021 USA.	yan@popcbr.rockefeller.edu		Cheng, C Yan/0000-0003-3117-3791	NICHD NIH HHS [HD-13541] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; Aravindan GR, 1996, J CELL PHYSIOL, V168, P123; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BILLIG H, 1995, ENDOCRINOLOGY, V136, P5, DOI 10.1210/en.136.1.5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; Byers S., 1993, SERTOLI CELL, P461; BYERS S, 1993, SERTOLI CELL, P431; CAMERON DF, 1991, J CELL SCI, V100, P623; CHENG CY, 1986, J ANDROL, V7, P175; CHENG CY, 1984, ENDOCRINOLOGY, V114, P1386, DOI 10.1210/endo-114-4-1386; CHENG CY, 1988, BIOCHEMISTRY-US, V27, P4079, DOI 10.1021/bi00411a026; CHENG CY, 1987, J BIOL CHEM, V262, P12768; CHENG CY, 1993, BIOCHEM BIOPH RES CO, V191, P224, DOI 10.1006/bbrc.1993.1206; Chung SSW, 1998, ENDOCRINOLOGY, V139, P1853, DOI 10.1210/en.139.4.1853; CLARKE MSF, 1995, CIRC RES, V76, P927, DOI 10.1161/01.RES.76.6.927; CLAUDE P, 1978, J MEMBRANE BIOL, V39, P219, DOI 10.1007/BF01870332; Diamond J M, 1977, Physiologist, V20, P10; EDDY EM, 1981, GAMETE RES, V4, P333, DOI 10.1002/mrd.1120040407; ENDERS GC, 1988, J CELL SCI, V90, P105; ENDERS GC, 1993, SERTOLI CELL, V90, P105; ENDERS GC, 1993, SERTOLI CELL, P488; ENG F, 1994, J ANDROL, V15, P311; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRITZ IB, 1993, SERTOLI CELL, P217; Galdieri M, 1981, J ANDROL, V5, P249; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GRIMA J, 1990, ENDOCRINOLOGY, V126, P2989, DOI 10.1210/endo-126-6-2989; Grima J, 1997, J BIOL CHEM, V272, P6499, DOI 10.1074/jbc.272.10.6499; GRIMA J, 1992, MOL CELL ENDOCRINOL, V89, P127, DOI 10.1016/0303-7207(92)90219-V; GRIMA J, 1995, BIOL REPROD, V52, P340, DOI 10.1095/biolreprod52.2.340; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; HAN IS, 1993, MOL ENDOCRINOL, V7, P889, DOI 10.1210/me.7.7.889; HOWARDS SS, 1975, FERTIL STERIL, V26, P13; HUCHKINS C, 1978, ANAT REC, V190, P905; JEGOU B, 1993, ENDOCRINOLOGY, V132, P2557, DOI 10.1210/en.132.6.2557; KERR JB, 1992, J REPROD FERTIL, V95, P825, DOI 10.1530/jrf.0.0950825; LARSEN WJ, 1988, TISSUE CELL, V20, P809, DOI 10.1016/0040-8166(88)90025-0; LI AHY, 1994, BIOL REPROD, V50, P1287, DOI 10.1095/biolreprod50.6.1287; MARTINEZPALOMO A, 1980, J CELL BIOL, V87, P736, DOI 10.1083/jcb.87.3.736; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; McNeil Paul L., 1993, Trends in Cell Biology, V3, P302, DOI 10.1016/0962-8924(93)90012-P; MCNEIL PL, 1992, AM J PATHOL, V140, P1097; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; McNeil PL, 1997, J CELL BIOL, V137, P1, DOI 10.1083/jcb.137.1.1; MELDOLESI J, 1978, J CELL BIOL, V79, P156, DOI 10.1083/jcb.79.1.156; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; Mruk D, 1997, J ANDROL, V18, P612; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; NICOLSON GL, 1982, BIOCHIM BIOPHYS ACTA, V695, P113, DOI 10.1016/0304-419X(82)90020-8; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; ONODA M, 1990, BIOL REPROD, V43, P672, DOI 10.1095/biolreprod43.4.672; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PEDERSEN RA, 1988, PHYSL REPROD, V1, P187; PINEAU C, 1993, J ANDROL, V14, P87; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; RUSSELL LD, 1987, ENDOCRINOLOGY, V120, P1615, DOI 10.1210/endo-120-4-1615; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; STAHLER MS, 1991, ENDOCRINOLOGY, V128, P2805, DOI 10.1210/endo-128-6-2805; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; WIEBE JP, 1984, CONTRACEPTION, V29, P291, DOI 10.1016/S0010-7824(84)80009-8; WIEBE JP, 1984, LIFE SCI, V34, P1747, DOI 10.1016/0024-3205(84)90574-5; WRIGHT WW, 1989, ANN NY ACAD SCI, V564, P173, DOI 10.1111/j.1749-6632.1989.tb25896.x; YU QC, 1992, AM J PATHOL, V141, P1349; Zhu LJ, 1997, BIOL REPROD, V56, P1330, DOI 10.1095/biolreprod56.5.1330; ZIPARO E, 1980, AM J ANAT, V159, P385, DOI 10.1002/aja.1001590404; ZONG SD, 1992, BIOL REPROD, V47, P568, DOI 10.1095/biolreprod47.4.568; ZONG SD, 1994, BIOL REPROD, V51, P843, DOI 10.1095/biolreprod51.5.843	69	94	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21040	21053		10.1074/jbc.273.33.21040	http://dx.doi.org/10.1074/jbc.273.33.21040			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694856	hybrid			2022-12-25	WOS:000075386100049
J	Mizushima, T; Takaki, T; Kubota, T; Tsuchiya, T; Miki, T; Katayama, T; Sekimizu, K				Mizushima, T; Takaki, T; Kubota, T; Tsuchiya, T; Miki, T; Katayama, T; Sekimizu, K			Site-directed mutational analysis for the ATP binding of DnaA protein - Functions of two conserved amino acids (Lys-178 and Asp-235) located in the ATP-binding domain of DnaA protein in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; REPLICATION ORIGIN; INITIATOR PROTEIN; IN-VITRO; AFFINITY; MUTANTS; SECA; SEQUENCES; TOPOLOGY	DnaA protein, the initiator of chromosomal DNA replication in Escherichia coli, is activated by binding to ATP in vitro. We introduced site-directed mutations into two amino acids of the protein conserved among various ATP-binding proteins and examined functions of the mutated DnaA proteins, in vitro and in vivo. Both mutated DnaA proteins (Lys-178 --> Ile or Asp-235 --> Asn) lost the affinity for both ATP and ADP but did maintain binding activity for oriC. Specific activities in an oriC DNA replication system in vitro were less than one-tenth those of the wild-type protein. Assay of the generation of oriC sites sensitive to P1 nuclease, using the mutated DnaA proteins, revealed a defect in induction of the duplex opening at oriC. On the other hand, expression of each mutated DnaA protein in the temperature-sensitive dnaA46 mutant did not complement the temperature sensitivity. We suggest that Lys-178 and Asp-235 of DnaA protein are essential for the activity needed to initiate oriC DNA replication in vitro and in vivo and that ATP binding to DnaA. protein is required for DNA replication-related functions.	Kyushu Univ, Fac Pharmaceut Sci, Fukuoka 8128582, Japan; Okayama Univ, Fac Pharmaceut Sci, Okayama 7008530, Japan	Kyushu University; Okayama University	Sekimizu, K (corresponding author), Kyushu Univ, Fac Pharmaceut Sci, Fukuoka 8128582, Japan.	sekimizu@bisei.pharm.kyushu-u.ac.jp		Katayama, Tsutomu/0000-0001-9994-1684				BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; Carr KM, 1996, MOL MICROBIOL, V20, P1307, DOI 10.1111/j.1365-2958.1996.tb02649.x; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HUPP TR, 1993, J BIOL CHEM, V268, P13128; HWANG DS, 1988, J BIOL CHEM, V263, P10633; KATAYAMA T, 1994, J BIOL CHEM, V269, P12698; KATAYAMA T, 1994, J BIOL CHEM, V269, P22075; Kubota T, 1997, BIOCHEM BIOPH RES CO, V232, P130, DOI 10.1006/bbrc.1997.6244; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MATSUYAMA S, 1995, ADV CELL MOL BIOL M, V4, P61; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Mizushima T, 1997, EMBO J, V16, P3724, DOI 10.1093/emboj/16.12.3724; Mizushima T, 1996, J BIOL CHEM, V271, P3633; Mizushima T, 1996, J BIOL CHEM, V271, P25178, DOI 10.1074/jbc.271.41.25178; Mizushima T, 1997, J BIOL CHEM, V272, P21195, DOI 10.1074/jbc.272.34.21195; Mizushima T, 1996, BIOCHEMISTRY-US, V35, P11512, DOI 10.1021/bi953088f; Sato K, 1996, J BIOL CHEM, V271, P17439, DOI 10.1074/jbc.271.29.17439; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SHINPUKU T, 1995, BIOCHEM BIOPH RES CO, V212, P84, DOI 10.1006/bbrc.1995.1939; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; VANDERWOLK JPW, 1995, J BIOL CHEM, V270, P18975, DOI 10.1074/jbc.270.32.18975; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WOLK JV, 1993, MOL MICROBIOL, V8, P31; YOSHIDA M, 1995, FEBS LETT, V359, P1, DOI 10.1016/0014-5793(94)01438-7; YUNG BYM, 1989, J BIOL CHEM, V264, P6146	29	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20847	20851		10.1074/jbc.273.33.20847	http://dx.doi.org/10.1074/jbc.273.33.20847			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694830	hybrid			2022-12-25	WOS:000075386100023
J	Molloy, DP; Milner, AE; Yakub, IK; Chinnadurai, G; Gallimore, PH; Grand, RJA				Molloy, DP; Milner, AE; Yakub, IK; Chinnadurai, G; Gallimore, PH; Grand, RJA			Structural determinants present in the c-terminal binding protein binding site of adenovirus early region 1A proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; ZINC-FINGER; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; CRYSTAL-STRUCTURE; WATER SOLUTION; E1A PROTEINS; PEPTIDE; DOMAIN; TRANSFORMATION	The C-terminal binding protein (CtBP) has previously been shown to bind to a highly conserved six-amino acid motif very close to the C terminus of adenovirus early region 1A (Ad EIA) proteins. We have developed an enzyme-linked immunosorbent assay that has facilitated the screening of synthetic peptides identical or similar to the binding site on Ad E1A for their ability to bind CtBP and thus inhibit its interaction with Ad12 Elk It has been shown that amino acids both C-terminal and N-terminal to the original proposed binding site contribute to the interaction of peptides with CtBP, Single amino acid substitutions across the binding site appreciably alter the K-d of the peptide for CtBP, indicative of a marked reduction in the affinity of the peptide for CtBP, The solution structures of synthetic peptides equivalent to the C termini of both Ad5 and Ad12 E1A and two substituted forms of these have been determined by proton NMR spectroscopy. Both the Ad12 and Ad5 peptides dissolved in trifluoroethanol/water mixtures were found to adopt regular secondary structural conformations seen as a series of beta-turns. An Ad12 peptide bearing a substitution that resulted in only very weak binding to CtBP (Ad12 L258G) was found to be random coil in solution, However, a second mutant (Ad12 V256K), which bound to CtBP rather more strongly (although not as well as the wild type), adopted a conformation similar to that of the wild type, We conclude that secondary structure (beta-turns) and an appropriate series of amino acid side chains are necessary for recognition by CtBP.	Univ Birmingham, Inst Canc Studies, Canc Res Campaign, Birmingham B15 2TA, W Midlands, England; St Louis Univ, Med Ctr, Inst Mol Virol, St Louis, MO 63110 USA	University of Birmingham; Saint Louis University	Molloy, DP (corresponding author), Univ Birmingham, Inst Canc Studies, Canc Res Campaign, Birmingham B15 2TA, W Midlands, England.	D.P.Molloy@cancer.bham.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACKARYA KR, 1991, J MOL BIOL, V221, P571; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CULP JS, 1988, P NATL ACAD SCI USA, V85, P6450, DOI 10.1073/pnas.85.17.6450; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; GARRATT RC, 1985, FEBS LETT, V188, P59, DOI 10.1016/0014-5793(85)80874-7; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; GOURNARIDES JS, 1994, BIOPOLYMERS, V34, P709; Grand RJA, 1998, VIROLOGY, V244, P230, DOI 10.1006/viro.1998.9081; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAUBLE H, 1994, J MOL BIOL, V237, P437, DOI 10.1006/jmbi.1994.1246; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; LUI F, 1990, CELL, V61, P1217; LUI F, 1994, NATURE, V368, P520; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; Malinski JA, 1996, J BIOL CHEM, V271, P12919, DOI 10.1074/jbc.271.22.12919; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; Mitra SN, 1997, BIOPOLYMERS, V41, P97, DOI 10.1002/(SICI)1097-0282(199701)41:1<97::AID-BIP9>3.0.CO;2-Y; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NAIDER F, 1992, BIOPOLYMERS, V32, P335, DOI 10.1002/bip.360320407; PEI R, 1989, J VIROL, V63, P3499, DOI 10.1128/JVI.63.8.3499-3506.1989; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; RICHARDSON JS, 1988, PROTEINS, V4, P229, DOI 10.1002/prot.340040402; ROSEN S, 1985, PROBL COMMUNISM, V34, P1; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Saudek V., 1994, BRUKER REPORT, V140/94, P6; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SHIN HC, 1993, BIOCHEMISTRY-US, V32, P6356, DOI 10.1021/bi00076a008; SMITH CK, 1995, SCIENCE, V270, P980, DOI 10.1126/science.270.5238.980; Smith KJ, 1996, J BIOL CHEM, V271, P16703, DOI 10.1074/jbc.271.28.16703; SMITH LJ, 1994, STRUCTURE, V2, P703, DOI 10.1016/S0969-2126(00)00071-X; SOLLERBRANT K, 1996, NUCLEIC ACIDS RES, V24, P3347; SWIFT HJ, 1991, ACTA CRYSTALLOGR B, V47, P535, DOI 10.1107/S0108768191001970; WANG JM, 1990, BIOCHEMISTRY-US, V29, P7160, DOI 10.1021/bi00483a003; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; WEBSTER LC, 1991, P NATL ACAD SCI USA, V88, P9989, DOI 10.1073/pnas.88.22.9989; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WINKLER FK, 1991, J MOL BIOL, V217, P235, DOI 10.1016/0022-2836(91)90536-F; WRIGHT CS, 1990, J MOL BIOL, V215, P635, DOI 10.1016/S0022-2836(05)80174-3; Wuthrich K, 1986, NMR NUCL ACIDS PROTE; YAO J, 1994, J MOL BIOL, V243, P754, DOI 10.1016/0022-2836(94)90045-0	54	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20867	20876		10.1074/jbc.273.33.20867	http://dx.doi.org/10.1074/jbc.273.33.20867			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694833	hybrid			2022-12-25	WOS:000075386100026
J	Sheikh, S; O'Handley, SF; Dunn, CA; Bessman, MJ				Sheikh, S; O'Handley, SF; Dunn, CA; Bessman, MJ			Identification and characterization of the Nudix hydrolase from the Archaeon, Methanococcus jannaschii, as a highly specific ADP-ribose pyrophosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MUTT; MOLECULAR-CLONING; MUTAGENIC SUBSTRATE; CATALYTIC DOMAIN; DNA-SYNTHESIS; SEQUENCE; PROTEINS; PURIFICATION; FAMILY; MUTATOR	The MJ1149 gene from the Archaeon, Methanococcus jannaschii, has been cloned and expressed in Escherichia coli, The 19-kDa protein containing the Nudix box, GX(5)EX(7)REUXEEXGU, has been purified and identified as a highly specific enzyme catalyzing the Mg2+-dependent hydrolysis of ADP-ribose according to the equation: ADP-ribose + H2O --> AMP + ribose-5-phosphate. The enzyme retains full activity when heated to 80 degrees C, and the rate of hydrolysis is 15-fold higher at 75 degrees C than at 37 degrees C in keeping with the thermophilicity of the organism. This is the first Nudix hydrolase identified from the Archaea, indicating that the family of enzymes containing the Nudix signature sequence is represented in all three kingdoms.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Bessman, MJ (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.	zoot@jhu.edu		Dunn, Christopher/0000-0001-7899-0110; O'Handley, Suzanne/0000-0001-8373-0065	NIGMS NIH HHS [GM18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMES BN, 1960, J BIOL CHEM, V235, P769; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; Cleland W W, 1979, Methods Enzymol, V63, P103; COX EC, 1969, J BACTERIOL, V100, P390, DOI 10.1128/JB.100.1.390-397.1969; FOWLER RG, 1994, J BACTERIOL, V176, P7727, DOI 10.1128/JB.176.24.7727-7729.1994; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; Hankin S, 1997, INT J BIOCHEM CELL B, V29, P317, DOI 10.1016/S1357-2725(96)00153-7; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HILZ H, 1986, P NATL ACAD SCI USA, V83, P6267, DOI 10.1073/pnas.83.17.6267; HONJO T, 1968, J BIOL CHEM, V243, P3553; JACOBSON EL, 1994, MOL CELL BIOCHEM, V138, P207, DOI 10.1007/BF00928463; JONES WJ, 1983, ARCH MICROBIOL, V136, P254, DOI 10.1007/BF00425213; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P4847, DOI 10.1093/nar/21.20.4847; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Maksel D, 1998, BIOCHEM J, V329, P313, DOI 10.1042/bj3290313; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; MOSS J, 1994, MOL CELL BIOCH FOCUS, V138; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; OLIVERA BM, 1989, ADP RIBOSE TRANSFER, P353; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Sambrook J., 1989, MOL CLONING LAB MANU, V2; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; Villeret V, 1998, P NATL ACAD SCI USA, V95, P2801, DOI 10.1073/pnas.95.6.2801; WITTENBERG J, 1953, J BIOL CHEM, V202, P431	35	53	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20924	20928		10.1074/jbc.273.33.20924	http://dx.doi.org/10.1074/jbc.273.33.20924			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694840	hybrid			2022-12-25	WOS:000075386100033
J	Timpel, C; Strahl-Bolsinger, S; Ziegelbauer, K; Ernst, JF				Timpel, C; Strahl-Bolsinger, S; Ziegelbauer, K; Ernst, JF			Multiple functions of Pmt1p-mediated protein O-mannosylation in the fungal pathogen Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; ENDOTHELIAL-CELLS; HYPHAL FORMATION; GENE FAMILY; GLYCOSYLATION; MUTANTS; MANNOSYLTRANSFERASE; VIRULENCE; GROWTH; OLIGOSACCHARIDES	Protein mannosylation by Pmt proteins initiates O-glycosylation in fungi, We have identified the PMT1 gene and analyzed the function of Pmt1p in the fungal human pathogen Candida albicans. Mutants defective in PMT1 alleles lacked Pmt in vitro enzymatic activity, showed reduced growth rates, and tended to for-m cellular aggregates. In addition, multiple specific deficiencies not known in Saccharomyces cerevisiae (including defective hyphal morphogenesis; supersensitivity to the antifungal agents hygromycin B, G418, clotrimazole, and calcofluor white; and reduced adherence to Caco-2 epithelial cells) were observed in pmt1 mutants. PMT1 deficiency also led to faster electrophoretic mobility of the Als1p cell wall protein and to elevated extracellular activities of chitinase. Homozygous pmt1 mutants were avirulent in a mouse model of systemic infection, while heterozygous PMT1/pmt1 strains showed reduced virulence. The results indicate that protein O-mannosylation by Pmt proteins occurs in different fungal species, where PMT1 deficiency can lead to defects in multiple cellular functions.	Univ Dusseldorf, Inst Mikrobiol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Biol Med Forschungszentrum, D-40225 Dusseldorf, Germany; Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany; Bayer AG, Lehrstuhl Zellbiol & Pflanzenphysiol, D-42117 Wuppertal, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; University of Regensburg; Bayer AG	Ernst, JF (corresponding author), Univ Dusseldorf, Inst Mikrobiol, Univ Str 1-26-12, D-40225 Dusseldorf, Germany.	joachim.ernst@uni-duesseldorf.de						BACHER A, 1992, EXP CELL RES, V200, P97, DOI 10.1016/S0014-4827(05)80076-X; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; BECKER JM, 1995, INFECT IMMUN, V63, P4515, DOI 10.1128/IAI.63.11.4515-4518.1995; Bourdineaud JP, 1998, MOL MICROBIOL, V27, P85, DOI 10.1046/j.1365-2958.1998.00660.x; BRETTHAUER RK, 1975, ARCH BIOCHEM BIOPHYS, V167, P151, DOI 10.1016/0003-9861(75)90451-8; BULAWA CE, 1995, P NATL ACAD SCI USA, V92, P10570, DOI 10.1073/pnas.92.23.10570; Chiba A, 1997, J BIOL CHEM, V272, P2156; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; CUTLER JE, 1991, ANNU REV MICROBIOL, V45, P187, DOI 10.1146/annurev.mi.45.100191.001155; DELBRUCK S, 1993, MOL MICROBIOL, V10, P859, DOI 10.1111/j.1365-2958.1993.tb00956.x; ELORZA MV, 1994, ARCH MICROBIOL, V161, P145, DOI 10.1007/s002030050034; Finck M, 1996, GLYCOBIOLOGY, V6, P313, DOI 10.1093/glycob/6.3.313; FONZI WA, 1993, GENETICS, V134, P717; Fratti RA, 1996, INFECT IMMUN, V64, P4714, DOI 10.1128/IAI.64.11.4714-4718.1996; Fu Y, 1998, INFECT IMMUN, V66, P1783, DOI 10.1128/IAI.66.4.1783-1786.1998; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; Gentzsch M, 1995, FEBS LETT, V377, P128, DOI 10.1016/0014-5793(95)01324-5; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GOLD MH, 1976, BIOCHEMISTRY-US, V15, P1808, DOI 10.1021/bi00654a004; GOW NAR, 1994, P NATL ACAD SCI USA, V91, P6216, DOI 10.1073/pnas.91.13.6216; Guerreiro P, 1996, YEAST, V12, P273, DOI 10.1002/(SICI)1097-0061(19960315)12:3<273::AID-YEA898>3.0.CO;2-1; HASELBECK A, 1983, FEBS LETT, V158, P335, DOI 10.1016/0014-5793(83)80608-5; HAYETTE MP, 1992, J CLIN MICROBIOL, V30, P411, DOI 10.1128/JCM.30.2.411-417.1992; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HOYER LL, 1995, MOL MICROBIOL, V15, P39, DOI 10.1111/j.1365-2958.1995.tb02219.x; IMMERVOLL T, 1995, YEAST, V11, P1345, DOI 10.1002/yea.320111403; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KELLY R, 1988, MOL GEN GENET, V214, P24, DOI 10.1007/BF00340174; Kohler JR, 1996, P NATL ACAD SCI USA, V93, P13223, DOI 10.1073/pnas.93.23.13223; KRUSIUS T, 1986, J BIOL CHEM, V261, P8237; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; Leberer E, 1996, P NATL ACAD SCI USA, V93, P13217, DOI 10.1073/pnas.93.23.13217; LEHLE L, 1995, GLYCOPROTEINS, P475; LETOUBLON R, 1974, FEBS LETT, V46, P214, DOI 10.1016/0014-5793(74)80371-6; LIU HP, 1994, SCIENCE, V266, P1723, DOI 10.1126/science.7992058; LUSSIER M, 1995, J BIOL CHEM, V270, P2770, DOI 10.1074/jbc.270.6.2770; MartinBlanco E, 1996, P NATL ACAD SCI USA, V93, P6048, DOI 10.1073/pnas.93.12.6048; MCCREATH KJ, 1995, P NATL ACAD SCI USA, V92, P2544, DOI 10.1073/pnas.92.7.2544; MONK BC, 1991, J BACTERIOL, V173, P6826, DOI 10.1128/jb.173.21.6826-6836.1991; Odds FC., 1988, CANDIDA CANDIDOSIS; RAM AFJ, 1994, YEAST, V10, P1019, DOI 10.1002/yea.320100804; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; ROTROSEN D, 1985, J INFECT DIS, V152, P1264, DOI 10.1093/infdis/152.6.1264; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; SANGLARD D, 1995, ANTIMICROB AGENTS CH, V39, P2378, DOI 10.1128/AAC.39.11.2378; Sherman F., 1986, METHODS YEAST GENETI; Stoldt VR, 1997, EMBO J, V16, P1982, DOI 10.1093/emboj/16.8.1982; STRAHLBOLSINGER S, 1993, P NATL ACAD SCI USA, V90, P8164, DOI 10.1073/pnas.90.17.8164; STRAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185, DOI 10.1111/j.1432-1033.1991.tb15802.x; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; Vai M, 1996, YEAST, V12, P361, DOI 10.1002/(SICI)1097-0061(19960330)12:4<361::AID-YEA920>3.0.CO;2-T; WESTON A, 1993, EUR J BIOCHEM, V215, P845, DOI 10.1111/j.1432-1033.1993.tb18101.x; ZHU JD, 1985, BIO-TECHNOL, V3, P451, DOI 10.1038/nbt0585-451	56	140	144	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20837	20846		10.1074/jbc.273.33.20837	http://dx.doi.org/10.1074/jbc.273.33.20837			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694829	hybrid			2022-12-25	WOS:000075386100022
J	Dorner, C; Ciossek, T; Muller, S; Moller, NPH; Ullrich, A; Lammers, R				Dorner, C; Ciossek, T; Muller, S; Moller, NPH; Ullrich, A; Lammers, R			Characterization of KIF1C, a new kinesin-like protein involved in vesicle transport from the Golgi apparatus to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTEROGRADE AXONAL-TRANSPORT; TYROSINE-PHOSPHATASE; BREFELDIN-A; CYTOPLASMIC DYNEIN; HEAVY-CHAIN; IN-VIVO; RETROGRADE TRANSPORT; SYNAPTIC VESICLES; MEMBRANE-BINDING; 2-HYBRID SYSTEM	Kinesins comprise a large family of microtubule-based motor proteins, of which individual members mediate specific types of motile processes. Using the ezrin domain of the protein-tyrosine phosphatase PTPD1 as a bait in a yeast two-hybrid screen, we identified a new kinesin-like protein, KIF1C. KIF1C represents a member of the Unc104 subfamily of kinesin-like proteins that are involved in the transport of mitochondria or synaptic vesicles in axons, Like its homologues, the 1103-amino acid protein KIF1C consists of an amino-terminal motor domain followed by a U104 domain and probably binds to target membranes through carboxyl-terminal sequences. Interestingly, KIF1C was tyrosine-phosphorylated after peroxovanadate stimulation when overexpressed in 293 or NIH3T3 fibroblasts or in native C2C12 cells. Using immunofluorescence, we found that KIF1C is localized primarily at the Golgi apparatus. In brefeldin A-treated cells, the Golgi membranes and KIF1C redistributed to the endoplasmic reticulum (ER). This brefeldin A-induced flow of Golgi membranes into the ER was inhibited in cells transiently overexpressing catalytically inactive KIF1C. In conclusion, our data suggest an involvement of tyrosine phosphorylation in the regulation of the Golgi to ER membrane flow and describe a new kinesin-like motor protein responsible for this transport.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Lammers, R (corresponding author), Univ Tubingen, Med Klin 4, Otfried Muller Str 10, D-72076 Tubingen, Germany.	rrlammer@med.uni-tuebingen.de						AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; Allan V, 1996, SEMIN CELL DEV BIOL, V7, P335, DOI 10.1006/scdb.1996.0043; Alphey L, 1997, J CELL BIOL, V138, P395, DOI 10.1083/jcb.138.2.395; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Furlong RA, 1996, GENOMICS, V33, P421, DOI 10.1006/geno.1996.0217; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; Hanlon DW, 1997, NEURON, V18, P439, DOI 10.1016/S0896-6273(00)81244-1; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; HOLLENBECK PJ, 1993, J NEUROCHEM, V60, P2265, DOI 10.1111/j.1471-4159.1993.tb03513.x; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; Hunter T, 1996, BIOCHEM SOC T, V24, P307, DOI 10.1042/bst0240307; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MURPHY DB, 1989, J CELL BIOL, V109, P80; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; NAKATA T, 1995, J CELL BIOL, V131, P1039, DOI 10.1083/jcb.131.4.1039; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; OKADA Y, 1995, J NEUROSCI, V15, P3053; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P265, DOI 10.1016/S0968-0004(00)89040-4; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; ROGALSKI AA, 1984, J CELL BIOL, V99, P1092, DOI 10.1083/jcb.99.3.1092; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; SMITH AL, 1995, BIOCHEM BIOPH RES CO, V209, P959, DOI 10.1006/bbrc.1995.1591; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEHLAND J, 1983, J CELL BIOL, V97, P1476, DOI 10.1083/jcb.97.5.1476; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	60	103	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20267	20275		10.1074/jbc.273.32.20267	http://dx.doi.org/10.1074/jbc.273.32.20267			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685376	hybrid			2022-12-25	WOS:000075305400053
J	Gromer, S; Arscott, LD; Williams, CH; Schirmer, RH; Becker, K				Gromer, S; Arscott, LD; Williams, CH; Schirmer, RH; Becker, K			Human placenta thioredoxin reductase - Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-DERIVED FACTOR; GLUTATHIONE-REDUCTASE; ESCHERICHIA-COLI; MECHANISM; PURIFICATION; SELENOCYSTEINE; LYMPHOCYTES; MUTAGENESIS; EXPRESSION; ENZYME	Human thioredoxin reductase is a pyridine nucleotide-disulfide oxidoreductase closely related to glutathione reductase but differing from the latter in having a Cys-SeCys (selenocysteine) sequence as an additional redox center. Because selenoproteins cannot be expressed yet in heterologous systems, we optimized the purification of the protein from placenta with respect to final yield (1-2 mg from one placenta), specific activity (42 units/mg), and selenium content (0.94 +/- 0.03 mol/mol subunit). The steady state kinetics showed that the enzyme operates by a ping-pong mechanism; the value of k(cat) was 3330 +/- 882 min(-1), and the K-m values were 18 mu M for NADPH and 25 mu M for Escherichia coli thioredoxin. The activation energy of the reaction was found to be 53.2 kJ/mol, which allows comparisons of the steady state data with previous pre-steady state measurements. In its physiological, NADPH-rednced form, the enzyme is strongly inhibited by organic gold compounds that are widely used in the treatment of rheumatoid arthritis; for auranofin, the K-i was 4 nM when measured in the presence of 50 mu M thioredoxin. At 1000-fold higher concentrations, that is at micromolar levels, the drugs also inhibited human glutathione reductase and the selenoenzyme glutathione peroxidase.	Heidelberg Univ, Ctr Biochem, D-69120 Heidelberg, Germany; Univ Michigan, Med Ctr, Dept Vet Affairs, Ann Arbor, MI 48105 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48105 USA	Ruprecht Karls University Heidelberg; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Schirmer, RH (corresponding author), Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	schirmer.@urz.uni-heidelberg.de			NIGMS NIH HHS [GM21444] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson M, 1996, J BIOL CHEM, V271, P10116, DOI 10.1074/jbc.271.17.10116; [Anonymous], 1989, COENZYMES COFACTORS; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; BERRY A, 1989, BIOCHEMISTRY-US, V28, P1264, DOI 10.1021/bi00429a047; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; Beutler E, 1984, RED CELL METABOLISM, P74; BUCHELER US, 1992, NUCLEIC ACIDS RES, V20, P3127, DOI 10.1093/nar/20.12.3127; CHAUDIERE J, 1984, J INORG BIOCHEM, V20, P313, DOI 10.1016/0162-0134(84)85030-8; GASDASKA JR, 1995, CELL GROWTH DIFFER, V6, P1643; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gromer S, 1997, FEBS LETT, V412, P318, DOI 10.1016/S0014-5793(97)00816-8; Gromer S, 1998, BIOCHEM J, V332, P591, DOI 10.1042/bj3320591; GROMER S, 1998, THESIS HEIDELBERG U; Hill KE, 1997, BIOCHEM BIOPH RES CO, V234, P293, DOI 10.1006/bbrc.1997.6618; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; KAIM W, 1991, BIOANORGANISCHE CHEM, P325; Larsen PR, 1997, BIOCHEM SOC T, V25, P588, DOI 10.1042/bst0250588; LENNON BW, 1995, BIOCHEMISTRY-US, V34, P3670, DOI 10.1021/bi00011a023; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MASSEY V, 1960, BIOCHEM J, V77, P341, DOI 10.1042/bj0770341; MOORE EC, 1964, J BIOL CHEM, V239, P3453; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Mulrooney SB, 1997, PROTEIN EXPRES PURIF, V9, P372, DOI 10.1006/prep.1996.0698; OBLONG JE, 1993, BIOCHEMISTRY-US, V32, P7271, DOI 10.1021/bi00079a025; RIETVELD P, 1994, BIOCHEMISTRY-US, V33, P13888, DOI 10.1021/bi00250a043; Saito I, 1996, ARTHRITIS RHEUM, V39, P773, DOI 10.1002/art.1780390509; SCHALLREUTER KU, 1990, BIOCHIM BIOPHYS ACTA, V1054, P14, DOI 10.1016/0167-4889(90)90199-N; SCOTT AJ, 1976, REG SCI URBAN ECON, V6, P147, DOI 10.1016/0166-0462(76)90024-7; SEWELL DL, 1995, CLIN MICROBIOL REV, V8, P389, DOI 10.1128/CMR.8.3.389; SIMON TM, 1981, CANCER RES, V41, P94; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WILLIAMS CH, 1995, FASEB J, V9, P1267, DOI 10.1096/fasebj.9.13.7557016; WILLIAMS CH, 1967, J BIOL CHEM, V242, P5226; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; ZVAIFLER NJ, 1983, AM J MED, V75, P3, DOI 10.1016/0002-9343(83)90469-2	39	447	453	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20096	20101		10.1074/jbc.273.32.20096	http://dx.doi.org/10.1074/jbc.273.32.20096			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685351	hybrid			2022-12-25	WOS:000075305400028
J	Lackmann, M; Oates, AC; Dottori, M; Smith, FM; Do, C; Power, M; Kravets, L; Boyd, AW				Lackmann, M; Oates, AC; Dottori, M; Smith, FM; Do, C; Power, M; Kravets, L; Boyd, AW			Distinct subdomains of the EphA3 receptor mediate ligand binding and receptor dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EPIDERMAL GROWTH-FACTOR; IMMUNOGLOBULIN-LIKE DOMAINS; FACTOR PDGF RECEPTORS; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; CELL LINES; IN-VITRO; GENE; EXPRESSION	Eph receptor tyrosine kinases and their ligands (ephrins) are highly conserved protein families implicated in patterning events during development, particularly in the nervous system. In a number of functional studies, strict conservation of structure and function across distantly related vertebrate species has been confirmed. In this study we make use of the observation that soluble human EphA3 (HEK) exerts a dominant negative effect on somite formation and axial organization during zebrafish embryogenesis to probe receptor function. Based on exon structure we have dissected the extracellular region of EphA3 receptor into evolutionarily conserved subdomains and used kinetic BIAcore analysis, mRNA injection into zebrafish embryos, and receptor transphosphorylation analysis to study their function. We show that ligand binding is restricted to the N-terminal region encoded by exon III, and we identify an independent, C-terminal receptor-dimerization domain. Recombinant proteins encoding either region in isolation can function as receptor antagonists in zebrafish. We propose a two-step mechanism of Eph receptor activation with distinct ligand binding and ligand-independent receptor-receptor oligomerization events.	Royal Brisbane Hosp, Queensland Inst Med Res, Bancroft Ctr, Brisbane, Qld 4029, Australia; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Branch, Melbourne, Vic 3050, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Boyd, AW (corresponding author), Royal Brisbane Hosp, Queensland Inst Med Res, Bancroft Ctr, Brisbane, Qld 4029, Australia.	andrewBo@qimr.edu.au	Boyd, Andrew/G-2083-2010	Dottori, Mirella/0000-0003-0598-4195				BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BOYD AW, 1992, J BIOL CHEM, V267, P3262; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Brennan C, 1997, DEVELOPMENT, V124, P655; Cerretti DP, 1995, MOL IMMUNOL, V32, P1197, DOI 10.1016/0161-5890(95)00108-5; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Connor RJ, 1995, ONCOGENE, V11, P2429; Cooper HM, 1995, ONCOGENE, V11, P2243; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FJOSE A, 1994, DEVELOPMENT, V120, P71; Flanagan JG, 1997, CELL, V90, P403; FRATTALI AL, 1992, J BIOL CHEM, V267, P19521; Frisen J, 1998, NEURON, V20, P235, DOI 10.1016/S0896-6273(00)80452-3; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HERREN B, 1993, J BIOL CHEM, V268, P15088; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; Labrador JP, 1997, EMBO J, V16, P3889, DOI 10.1093/emboj/16.13.3889; Lackmann M, 1996, P NATL ACAD SCI USA, V93, P2523, DOI 10.1073/pnas.93.6.2523; Lackmann M, 1997, J BIOL CHEM, V272, P16521, DOI 10.1074/jbc.272.26.16521; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LEVYTOLEDANO R, 1994, EMBO J, V13, P835, DOI 10.1002/j.1460-2075.1994.tb06326.x; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; OLDBERG A, 1986, J BIOL CHEM, V261, P2113; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; SAJJADI FG, 1991, NEW BIOL, V3, P769; SALVARIS E, 1992, LEUKEMIA RES, V16, P655, DOI 10.1016/0145-2126(92)90016-Z; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; UENO H, 1993, J BIOL CHEM, V268, P22814; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; Weinberg ES, 1996, DEVELOPMENT, V122, P271; WESTERFIELD M, 1995, ZEBRAFISH BOOK; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0; Xu QL, 1995, DEVELOPMENT, V121, P4005	62	83	94	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20228	20237		10.1074/jbc.273.32.20228	http://dx.doi.org/10.1074/jbc.273.32.20228			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685371	hybrid			2022-12-25	WOS:000075305400048
J	Shetty, KM; Kurada, P; O'Tousa, JE				Shetty, KM; Kurada, P; O'Tousa, JE			Rab6 regulation of rhodopsin transport in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; RETINAL-DEGENERATION; ENDOPLASMIC-RETICULUM; PHOTORECEPTOR CELLS; VESICULAR TRANSPORT; OUTER SEGMENT; OPSIN GENE; GOLGI; MEMBRANE; MUTATION	Rab6 is a GTP binding protein that regulates vesicular trafficking within the Golgi and post-Golgi compartments. We overexpressed wild-type, a GTPase defective (Q71L), and a guanine nucleotide binding defective (N125I) Rab6 protein in Drosophila photoreceptors to assess the in vivo role of Rab6 in the trafficking of rhodopsin and other proteins. Expression of Drab6(Q71L) greatly reduced the steady state levels of two rhodopsins, Rh1 and Rh3, whereas Drab6(wt) and Drab6(N125I) showed weaker effects. Analysis of a strain carrying Rh1 rhodopsin under a heat shock promoter showed that Drab6(Q71L), but not Drab6(wt) or Drab6(N125I), prevents the maturation of rhodopsin beyond an immature 40 kDa form. Drab6(Q71L) is a GTPase defective mutant, indicating that anterograde transport of rhodopsin requires Rab6 GTPase function. The three Drab6 strains had no effect on the expression of several other photoreceptor proteins. The Drab6(Q71L) photoreceptors show marked histological defects at young ages and degenerate over a two week time span. These results establish that rhodopsin is transported via a Rab6 regulated pathway and that defects in trafficking pathways lead to retinal degeneration.	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA	University of Notre Dame	O'Tousa, JE (corresponding author), Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.			O'Tousa, Joseph/0000-0001-9754-6816	NEI NIH HHS [EY06808] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; Blest A. D., 1980, EFFECTS CONSTANT LIG, P217; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; DERETIC D, 1993, J CELL SCI, V106, P803; FEILER R, 1992, J NEUROSCI, V12, P3862; HUBER A, 1994, EUR J CELL BIOL, V63, P219; Ivessa NE, 1997, J BIOL CHEM, V272, P20828, DOI 10.1074/jbc.272.33.20828; JASMIN BJ, 1992, NEUROSCIENCE, V49, P849, DOI 10.1016/0306-4522(92)90361-5; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; KURADA P, 1995, NEURON, V14, P571, DOI 10.1016/0896-6273(95)90313-5; Kurada P, 1998, VISUAL NEUROSCI, V15, P693, DOI 10.1017/S0952523898154093; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; LEONARD DS, 1992, J NEUROBIOL, V23, P605, DOI 10.1002/neu.480230602; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MATSUMOTO H, 1987, P NATL ACAD SCI USA, V84, P985, DOI 10.1073/pnas.84.4.985; McConlogue L, 1996, J BIOL CHEM, V271, P1343, DOI 10.1074/jbc.271.3.1343; MISMER D, 1987, GENETICS, V116, P565; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OTOUSA JE, 1989, J NEUROGENET, V6, P41, DOI 10.3109/01677068909107099; OZAKI K, 1993, NEURON, V10, P1113, DOI 10.1016/0896-6273(93)90059-Z; Pak W.L., 1979, P67; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PORTER JA, 1992, J CELL BIOL, V116, P683, DOI 10.1083/jcb.116.3.683; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; SAPP RJ, 1991, EXP EYE RES, V53, P73, DOI 10.1016/0014-4835(91)90147-7; Satoh AK, 1997, FEBS LETT, V404, P65, DOI 10.1016/S0014-5793(97)00094-X; Satoh AK, 1997, J CELL SCI, V110, P2943; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; SUNG CH, 1994, J NEUROSCI, V14, P5818; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TIXIERVIDAL A, 1993, J CELL SCI, V105, P935; VIHTELIC TS, 1993, J CELL BIOL, V122, P1013, DOI 10.1083/jcb.122.5.1013; WASHBURN T, 1992, GENETICS, V130, P585; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	49	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20425	20430		10.1074/jbc.273.32.20425	http://dx.doi.org/10.1074/jbc.273.32.20425			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685396	hybrid			2022-12-25	WOS:000075305400073
J	Salvat, C; Jariel-Encontre, I; Acquaviva, C; Omura, S; Piechaczyk, M				Salvat, C; Jariel-Encontre, I; Acquaviva, C; Omura, S; Piechaczyk, M			Differential directing of c-Fos and c-Jun proteins to the proteasome in serum-stimulated mouse embryo fibroblasts	ONCOGENE			English	Article						c-Fos; c-Jun; ubiquitin; proteasome; stimulation for growth	UBIQUITIN-ACTIVATING ENZYME; TEMPERATURE-SENSITIVE MUTANTS; CELL-CYCLE; TRANSCRIPTION FACTORS; V-FOS; MICROBIAL METABOLITE; G0-TO-G1 TRANSITION; NEUROBLASTOMA-CELLS; DNA-SYNTHESIS; TS85 CELLS	c-Fos and c-Jun proteins are highly unstable transcription factors that heterodimerize within the AP-1 transcription complex. Their accumulation is transilently induced at the beginning of the G(0)-to-S phase transition in quiescent cells stimulated for growth. To address the mechanisms responsible for rapid clearance of c-Fos and c-Jun proteins under these experimental conditions, we have used the ts20 mouse embryo fibroblasts which express a thermosensitive mutant of the E1 enzyme of the ubiquitin pathway. The use of cell-permeant protease inhibitors indicates that both proteins are degraded by the proteasome and excludes any major contribution for calpains and lysosomes during the G(0)-to-S phase transition. Synchronisation of ts20 cells at the non permissive temperature blocks the degradation of c-Jun, indicating that this process is E1-dependent. In contrast, c-Fos is broken down according to an apparently E1-independent pathway in ts20 cells, although a role for ubiquitinylation in this process cannot be formally ruled out. Interestingly, c-Jun is highly unstable in c-Fos-null mouse embryo fibroblasts stimulated for growth. Taken together, these observations show that in vivo during a G(0)-to-S phase transition (i) the precise mechanisms triggering c-Fos and c-Jun directing to the proteasome are not identical, (ii) the presence of c-Fos is not an absolute prerequisite for the degradation of c-Jun and (iii) the degradation of c-Jun is not required for that of c-Fos.	CNRS, UMR5535, Inst Med Genet, F-34293 Montpellier 05, France; Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, Tokyo 108, Japan; Kitasato Univ, Kitasato Inst, Biol Funct Res Ctr, Minato Ku, Tokyo 108, Japan	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Kitasato University; Kitasato University	Piechaczyk, M (corresponding author), CNRS, UMR5535, Inst Med Genet, 1919 Route Mende, F-34293 Montpellier 05, France.		Acquaviva, Claire/N-4306-2017; PIECHACZYK, Marc/E-7896-2013	Acquaviva, Claire/0000-0002-0227-9813; PIECHACZYK, Marc/0000-0003-1367-2597				Angel P. E., 1994, FOS JUN FAMILIES TRA; Aniento F, 1996, FEBS LETT, V390, P47, DOI 10.1016/0014-5793(96)00625-4; Carillo S, 1996, BIOCHEM J, V313, P245, DOI 10.1042/bj3130245; CARILLO S, 1994, ONCOGENE, V9, P1679; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Curran T, 1988, ONCOGENE HDB, P307; DEVERAUX Q, 1990, J BIOL CHEM, V265, P6323; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fuchs SY, 1996, ONCOGENE, V13, P1531; HARLOW E, 1988, ANTIBODIES; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HOPSUHAVU VK, 1997, PROTEOLYSIS CELL FUN; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; JENNISSEN HP, 1995, EUR J BIOCHEM, V231, P1; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; KULKA RG, 1988, J BIOL CHEM, V263, P15726; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Mils V, 1997, ONCOGENE, V14, P1555, DOI 10.1038/sj.onc.1200991; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; MORI M, 1993, J BIOL CHEM, V268, P16803; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; RABOY B, 1986, EMBO J, V5, P863, DOI 10.1002/j.1460-2075.1986.tb04296.x; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; ROUX P, 1994, C FOS C JUN FAMILIES, P87; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SLATER ML, 1976, CELL, V7, P289, DOI 10.1016/0092-8674(76)90028-3; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Steff AM, 1997, BIOCHEM J, V323, P685, DOI 10.1042/bj3230685; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092; ZENG GC, 1984, MOL CELL BIOL, V4, P1815, DOI 10.1128/MCB.4.9.1815; Zhang WL, 1997, ONCOGENE, V14, P255, DOI 10.1038/sj.onc.1200841	64	38	38	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					327	337		10.1038/sj.onc.1201922	http://dx.doi.org/10.1038/sj.onc.1201922			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690514				2022-12-25	WOS:000074947500007
J	Whittaker, MM; Whittaker, JW				Whittaker, MM; Whittaker, JW			A glutamate bridge is essential for dimer stability and metal selectivity in manganese superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ANION BINDING-PROPERTIES; ESCHERICHIA-COLI-B; X-RAY STRUCTURE; PROPIONIBACTERIUM-SHERMANII; THERMUS-THERMOPHILUS; PSEUDOMONAS-OVALIS; CRYSTAL-STRUCTURES; PH-DEPENDENCE; IRON	In Escherichia coli manganese superoxide dismutase (MnSOD), the absolutely conserved Glu(170) Of one monomer is hydrogen-bonded to the Mn Ligand His(171) Of th, other monomer, forming a double bridge at the dimer interface. Point mutation of Glu(170) --> Ala destabilizes the dimer structure, and the mutant protein occurs as a mixture of dimer and monomer species, The purified E170A MnSOD contains exclusively Fe and is devoid of superoxide dismutase activity. E170A Fe-2-MnSOD closely resembles authentic FeSOD in terms of spectroscopic properties, anion interactions and pH titration behavior. Reconstitution of E170A Fe2-MnSOD with Mn(II) salts does not restore superoxide dismutase activity despite the spectroscopic similarity between E170A Mn-2-MnSOD and wild type Mn-2-MnSOD. Growth of sodA(+) and sodA(-) E. coli containing the mutant plasmid pDT1-5(E170A) is impaired, suggesting that expression of mutant protein is toxic to the host cells.	Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Portland, OR 97291 USA		Whittaker, JW (corresponding author), Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, POB 91000, Portland, OR 97291 USA.	jim@bmb.ogi.edu			NIGMS NIH HHS [GM 42680] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042680] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEYER WF, 1991, J BIOL CHEM, V266, P303; BEYER WF, 1989, BIOCHEMISTRY-US, V28, P4403, DOI 10.1021/bi00436a042; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; BULL C, 1985, J AM CHEM SOC, V107, P3295, DOI 10.1021/ja00297a040; Bunting K, 1998, EUR J BIOCHEM, V251, P795, DOI 10.1046/j.1432-1327.1998.2510795.x; CARLIOZ A, 1988, J BIOL CHEM, V263, P1555; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; COOPER JB, 1995, J MOL BIOL, V246, P531, DOI 10.1006/jmbi.1994.0105; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Edwards RA, 1998, J BIOL INORG CHEM, V3, P161, DOI 10.1007/s007750050217; FARR SB, 1986, P NATL ACAD SCI USA, V83, P8268, DOI 10.1073/pnas.83.21.8268; FEE JA, 1981, ISRAEL J CHEM, V21, P54, DOI 10.1002/ijch.198100014; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; Griffith J.S., 1964, THEORY TRANSITION ME; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; Huggett ASG, 1957, BIOCHEM J, V66, P12; Hunter T, 1997, BIOCHEMISTRY-US, V36, P4925, DOI 10.1021/bi9629541; Lim JH, 1997, J MOL BIOL, V270, P259, DOI 10.1006/jmbi.1997.1105; Liochev SI, 1997, ARCH BIOCHEM BIOPHYS, V346, P263, DOI 10.1006/abbi.1997.0298; LUDWIG ML, 1991, J MOL BIOL, V219, P335, DOI 10.1016/0022-2836(91)90569-R; MARTIN ME, 1986, J BIOL CHEM, V261, P9361; McCord J M, 1976, Adv Exp Med Biol, V74, P540; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCCORD JM, 1988, FREE RADICAL BIO MED, V5, P363, DOI 10.1016/0891-5849(88)90109-8; MEIER B, 1995, BIOCHEM J, V310, P945, DOI 10.1042/bj3100945; Meier B, 1997, FEBS LETT, V414, P122, DOI 10.1016/S0014-5793(97)00960-5; OSE DE, 1979, ARCH BIOCHEM BIOPHYS, V194, P360, DOI 10.1016/0003-9861(79)90628-3; PARBOOSINGH JS, 1995, NEUROMUSCULAR DISORD, V5, P7, DOI 10.1016/0960-8966(94)E0022-Z; PARKER MW, 1987, PROTEIN ENG, V1, P393, DOI 10.1093/protein/1.5.393; PARKER MW, 1988, FEBS LETT, V229, P377, DOI 10.1016/0014-5793(88)81160-8; PARKER MW, 1988, J MOL BIOL, V199, P649, DOI 10.1016/0022-2836(88)90308-7; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; Schmidt M, 1996, J BIOL INORG CHEM, V1, P532, DOI 10.1007/s007750050089; SLYKHOUSE TO, 1976, J BIOL CHEM, V251, P5472; STALLINGS WC, 1983, P NATL ACAD SCI-BIOL, V80, P3884, DOI 10.1073/pnas.80.13.3884; STODDARD BL, 1990, PROTEIN ENG, V4, P113, DOI 10.1093/protein/4.2.113; STODDARD BL, 1990, BIOCHEMISTRY-US, V29, P8885, DOI 10.1021/bi00490a002; TOUATI D, 1983, J BACTERIOL, V155, P1078, DOI 10.1128/JB.155.3.1078-1087.1983; Vance CK, 1998, J AM CHEM SOC, V120, P461, DOI 10.1021/ja972060j; WAGNER UG, 1993, PROTEIN SCI, V2, P814, DOI 10.1002/pro.5560020511; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WERBER MM, 1991, FREE RADICAL RES COM, V12-3, P335, DOI 10.3109/10715769109145803; WHITTAKER JW, 1991, J AM CHEM SOC, V113, P5528, DOI 10.1021/ja00015a003; Whittaker MM, 1997, BIOCHEMISTRY-US, V36, P8923, DOI 10.1021/bi9704212; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; YAMAKURA F, 1995, EUR J BIOCHEM, V227, P700, DOI 10.1111/j.1432-1033.1995.tb20191.x; YAMAKURA F, 1994, INT CONGR SER, V1058, P115; YOST FJ, 1973, J BIOL CHEM, V248, P4905; Youn HD, 1996, BIOCHEM J, V318, P889, DOI 10.1042/bj3180889	50	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22188	22193		10.1074/jbc.273.35.22188	http://dx.doi.org/10.1074/jbc.273.35.22188			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712831	hybrid			2022-12-25	WOS:000075616600007
J	Gotoh, K; Yokota, H; Kikuya, E; Watanabe, T; Oishi, M				Gotoh, K; Yokota, H; Kikuya, E; Watanabe, T; Oishi, M			Genomic structure of MUNC18-1 protein, which is involved in docking and fusion of synaptic vesicles in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SITES; CAENORHABDITIS-ELEGANS; ROP; YEAST; GENE; SECRETION; INTERACTS; SELECTION; REGULATOR; SYNTAXIN	MUNC18-1 (n-Sec1) is a brain-specific protein and is known to play a role in neurotransmitter release by mediating docking and fusion of synaptic vesicles to presynaptic membranes. The protein is also implicated in the cellular excretion process of hormones and other biological substances in other mammalian tissues and yeasts. We have studied the structure of mouse munc18-1 gene by sequencing the genomic munc18-1 gene and its 5'-flanking region, munc18-1 gene comprises 19 exons whose size ranges from 50 base pairs (2nd exon) to 1676 base pairs (19th exon) with a total gene size of approximately 56 kilobases. In the 5'-flanking region, there are several transcription factor binding sites such as for HSF2, Lyf-1, and Spl but no TATA or CAAT sequences, munc18-1 gene was mapped on mouse chromosome 2 between two anchor markers D2Mit152 and D2Mit242. Transfection experiments employing these and upstream sequences suggest the presence of a sequence(s) that negatively regulates the expression of munc18-1 gene.	Kazusa DNA Res Inst, Chiba, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 113, Japan; Daiichi Pharmaceut Co Ltd, Tokyo 134, Japan; Tohoku Univ, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 980, Japan	Kazusa DNA Research Institute; University of Tokyo; Daiichi Sankyo Company Limited; Tohoku University	Oishi, M (corresponding author), Kazusa DNA Res Inst, 1532-3 Yana, Chiba, Japan.							BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BRENNER S, 1974, GENETICS, V77, P71; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GREEN MR, 1980, CELL, V22, P231, DOI 10.1016/0092-8674(80)90171-3; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; KATOHSEMBA R, 1987, J NEUROSCI RES, V17, P36, DOI 10.1002/jnr.490170106; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; Mount SM, 1996, SCIENCE, V271, P1690, DOI 10.1126/science.271.5256.1690; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203	22	4	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21642	21647		10.1074/jbc.273.34.21642	http://dx.doi.org/10.1074/jbc.273.34.21642			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705297	hybrid			2022-12-25	WOS:000075492600031
J	Guittet, O; Ducastel, B; Salem, JS; Henry, Y; Rubin, H; Lemaire, G; Lepoivre, M				Guittet, O; Ducastel, B; Salem, JS; Henry, Y; Rubin, H; Lemaire, G; Lepoivre, M			Differential sensitivity of the tyrosyl radical of mouse ribonucleotide reductase to nitric oxide and peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; R2 PROTEIN; ADENOCARCINOMA CELLS; PHOTOSYSTEM-II; IRON CENTER; SUPEROXIDE; MACROPHAGES; SUBUNIT; INHIBITION; SITE	Ribonucleotide reductase is essential for DNA synthesis in cycling cells. It has been previously shown that the catalytically competent tyrosyl free radical of its small R2 subunit (R2-Y-.) is scavenged in tumor cells co-cultured with macrophages expressing a nitric oxide synthase II activity. We now demonstrate a loss of R2-Y-. induced either by (NO)-N-. or peroxynitrite in vitro. The (NO)-N-. effect is reversible and followed by an increase in ferric iron release from mouse protein R2. A similar increased iron lability in radical-free, diferric metR2 protein suggests reciprocal stabilizing interactions between R2-Y-. and the diiron center in the mouse protein. Scavenging of R2-Y-. by peroxynitrite is irreversible and paralleled to an irreversible loss of R2 activity. Formation of nitrotyrosine and dihydroxyphenylalanine was also detected in peroxynitrite-modified protein R2. In R2-overexpressing tumor cells co-cultured with activated murine macrophages, scavenging of R2-Y-. following NO synthase II induction was fully reversible, even when endogenous production of peroxynitrite was induced by triggering NADPH oxidase activity with a phorbol ester. Our results did not support the involvement of peroxynitrite in R2-Y-. scavenging by macrophage (NO)-N-. synthase II activity. They confirmed the preponderant physiological role of (NO)-N-. in the process.	Univ Paris Sud, CNRS, U571, F-91405 Orsay, France; Inst Curie, INSERM, U350, Orsay, France; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Pennsylvania	Guittet, O (corresponding author), Univ Paris Sud, CNRS, U571, ERS 571,Bat 430, F-91405 Orsay, France.	michel.lepoivre@bbmpc.u-psud.fr	Lepoivre, Michel/J-8578-2013; Guittet, Olivier/J-8642-2013					Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bouton C, 1996, J BIOL CHEM, V271, P2300, DOI 10.1074/jbc.271.4.2300; Bouton C, 1997, J BIOL CHEM, V272, P19969, DOI 10.1074/jbc.272.32.19969; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; CROW JP, 1995, BIOCHEMISTRY-US, V34, P3544, DOI 10.1021/bi00011a008; Davydov A, 1996, BIOCHEM BIOPH RES CO, V219, P213, DOI 10.1006/bbrc.1996.0207; Davydov R, 1996, BIOCHEMISTRY-US, V35, P5571, DOI 10.1021/bi952836y; EISERICH JP, 1995, BIOCHEM J, V310, P745, DOI 10.1042/bj3100745; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; Fan HZ, 1996, FEBS LETT, V382, P145, DOI 10.1016/0014-5793(96)00143-3; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; Gaudu P, 1996, FEBS LETT, V387, P137, DOI 10.1016/0014-5793(96)00480-2; Gerez C, 1997, EUR J BIOCHEM, V249, P401, DOI 10.1111/j.1432-1033.1997.t01-2-00401.x; GRANDPERRET T, 1986, EUR J IMMUNOL, V16, P332, DOI 10.1002/eji.1830160403; GRASLUND A, 1982, J BIOL CHEM, V257, P5711; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; Han JY, 1997, J BIOL INORG CHEM, V2, P287, DOI 10.1007/s007750050134; HASKIN CJ, 1995, BIOCHEMISTRY-US, V34, P11090, DOI 10.1021/bi00035a014; HENRIKSEN MA, 1994, J AM CHEM SOC, V116, P9773, DOI 10.1021/ja00100a062; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; JANZEN EG, 1993, J ORG CHEM, V58, P3597, DOI 10.1021/jo00066a001; Kauppi B, 1996, J MOL BIOL, V262, P706, DOI 10.1006/jmbi.1996.0546; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LEPOIVRE M, 1992, J BIOL CHEM, V267, P22994; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; LEPOIVRE M, 1982, J IMMUNOL, V129, P860; LEPOIVRE M, 1994, J BIOL CHEM, V269, P21891; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MONCADA S, 1991, PHARMACOL REV, V43, P109; NOCEK JM, 1988, BIOCHEMISTRY-US, V27, P1014, DOI 10.1021/bi00403a026; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; NYHOLM S, 1993, J BIOL CHEM, V268, P26200; ORMO M, 1995, J BIOL CHEM, V270, P6570, DOI 10.1074/jbc.270.12.6570; PAZ MA, 1991, J BIOL CHEM, V266, P689; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; ROY B, 1995, BIOCHEMISTRY-US, V34, P5411, DOI 10.1021/bi00016a012; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SALEM JS, 1993, FEBS LETT, V323, P93, DOI 10.1016/0014-5793(93)81455-9; Sanakis Y, 1997, BIOCHEMISTRY-US, V36, P1411, DOI 10.1021/bi9622074; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; Szabo C, 1996, FEBS LETT, V381, P82, DOI 10.1016/0014-5793(96)00087-7; Szalai VA, 1996, BIOCHEMISTRY-US, V35, P15080, DOI 10.1021/bi961117w; THELANDER L, 1983, BIOCHEM BIOPH RES CO, V110, P859, DOI 10.1016/0006-291X(83)91040-9; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954	58	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22136	22144		10.1074/jbc.273.34.22136	http://dx.doi.org/10.1074/jbc.273.34.22136			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705359	hybrid			2022-12-25	WOS:000075492600093
J	Milev, P; Monnerie, H; Popp, S; Margolis, RK; Margolis, RU				Milev, P; Monnerie, H; Popp, S; Margolis, RK; Margolis, RU			The core protein of the chondroitin sulfate proteoglycan phosphacan is a high-affinity ligand of fibroblast growth factor-2 and potentiates its mitogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; CENTRAL-NERVOUS-SYSTEM; TYROSINE-PHOSPHATASE; EXTRACELLULAR VARIANT; NEUROCAN; BRAIN; TISSUE	Using a radioligand binding assay we have demonstrated that phosphacan, a chondroitin sulfate proteoglycan of nervous tissue that also represents the extracellular domain of a receptor-type protein tyrosine phosphatase, shows saturable, reversible, high-affinity binding (K-d similar to 6 nM) to fibroblast growth factor-a (FGF-S), Binding was reduced by only similar to 35% following chondroitinase treatment of the proteoglycan, indicating that the interaction is mediated primarily through the core protein rather than the glycosaminoglycan chains. Immunocytochemical studies also showed an overlapping localization of FGF-S and phosphacan in the developing central nervous system. At concentrations of 10 mu g protein/ml, both native phosphacan and the core protein obtained by chondroitinase treatment potentiated the mitogenic effect of FGF-2 (5 ng/ml) on NIH/3T3 cells by 75-90%, which is nearly the same potentiation as that produced by heparin at an equivalent concentration. Although studies on the role of proteoglycans in mediating the binding and mitogenic effects of FGF-S have previously focused on cell surface heparan sulfate, our results indicate that the core protein of a chondroitin sulfate proteoglycan may also regulate the access of FGF-S to cell surface signaling receptors in nervous tissue.	NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA; SUNY Hlth Sci Ctr, Dept Pharmacol, Brooklyn, NY 11203 USA	New York University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Margolis, RU (corresponding author), NYU, Med Ctr, Dept Pharmacol, 550 1st Ave, New York, NY 10016 USA.				NIMH NIH HHS [MH-00129] Funding Source: Medline; NINDS NIH HHS [NS-09348, NS-13876] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013876, R01NS009348] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baird Andrew, 1994, Current Opinion in Neurobiology, V4, P78, DOI 10.1016/0959-4388(94)90035-3; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CADAY CG, 1990, DEV BRAIN RES, V52, P241, DOI 10.1016/0165-3806(90)90240-Y; GIORDANO S, 1992, DEV BIOL, V152, P293, DOI 10.1016/0012-1606(92)90136-5; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Margolis RK, 1996, PERSPECT DEV NEUROBI, V3, P273; Margolis RU, 1997, CELL TISSUE RES, V290, P343, DOI 10.1007/s004410050939; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MEYERPUTTLITZ B, 1995, J NEUROCHEM, V65, P2327; MeyerPuttlitz B, 1996, J COMP NEUROL, V366, P44, DOI 10.1002/(SICI)1096-9861(19960226)366:1<44::AID-CNE4>3.0.CO;2-K; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MILEV PV, 1992, J BIOTECHNOL, V22, P299, DOI 10.1016/0168-1656(92)90148-3; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; RAUCH U, 1991, J BIOL CHEM, V266, P14785; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SENSENBRENNER M, 1993, PROG NEUROBIOL, V41, P683, DOI 10.1016/0301-0082(93)90031-M; SUZU S, 1994, BLOOD, V83, P3113, DOI 10.1182/blood.V83.11.3113.bloodjournal83113113	20	83	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21439	21442		10.1074/jbc.273.34.21439	http://dx.doi.org/10.1074/jbc.273.34.21439			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705269	hybrid			2022-12-25	WOS:000075492600003
J	Posner, BA; Mixon, MB; Wall, MA; Sprang, SR; Gilman, AG				Posner, BA; Mixon, MB; Wall, MA; Sprang, SR; Gilman, AG			The A326S mutant of G(i alpha 1) as an approximation of the receptor-bound state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; BETA-GAMMA; MOLECULAR REPLACEMENT; ADENYLATE-CYCLASE; BINDING; GTP; MECHANISM; MG-2+	Agonist-bound heptahelical receptors activate heterotrimeric G proteins by catalyzing exchange of GDP for GTP on their alpha subunits. In search of an approximation of the receptor-alpha subunit complex, we have considered the properties of A326S G(i alpha 1), a mutation discovered originally in G(s alpha) (Iiri, T., Herzmark, P., Nakamoto, J. M., Van Dop, C., and Bourne, H. R. (1994) Nature 371, 164-168) that mimics the effect of receptor on nucleotide exchange. The mutation accelerates dissociation of GDP from the alpha(i1)beta(1)gamma(2) heterotrimer by 250-fold. Nevertheless, affinity of mutant G(i alpha 1) for GTP gamma S is high in the presence of Mg2+, and the mutation has no effect on the intrinsic GTPase activity of the alpha subunit. The mutation also uncouples two activities of beta gamma stabilization of the GDP-bound alpha subunit (which is retained) and retardation of GDP dissociation from the heterotrimer (which is lost). For wild-type and mutant G(i alpha 1), beta gamma prevents irreversible inactivation of the alpha subunit at 30 degrees C. However, the mutation accelerates irreversible inactivation of alpha at 37 degrees C despite the presence of beta gamma, Structurally, the mutation weakens affinity for GTP gamma S by steric crowding: a 2-fold increase in the number of close contacts between the protein and the purine ring of the nucleotide, By contrast, we observe no differences in structure at the GDP binding site between wild-type heterotrimers and those containing A326S G(i alpha 1). However, the GDP binding site is only partially occupied ill crystals of G protein heterotrimers containing A326S G(i alpha 1). In contrast to original speculations about the structural correlates of receptor-catalyzed nucleotide exchange, rapid dissociation of GDP can be observed in the absence of substantial structural alteration of a G(alpha) subunit in the GDP-bound state.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gilman, AG (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046371, R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497, F32GM017530] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46371] Funding Source: Medline; NIGMS NIH HHS [GM34497, GM17530] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO T, 1984, BIOCHEMISTRY-US, V23, P5467, DOI 10.1021/bi00318a014; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; Johnson R A, 1979, Adv Cyclic Nucleotide Res, V10, P135; JONES TA, 1996, O VERSION 5 1; KATADA T, 1986, J BIOL CHEM, V261, P8182; LEE E, 1994, METHOD ENZYMOL, V237, P146; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Sambrook J., 2002, MOL CLONING LAB MANU; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	25	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21752	21758		10.1074/jbc.273.34.21752	http://dx.doi.org/10.1074/jbc.273.34.21752			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705312	hybrid			2022-12-25	WOS:000075492600046
J	Sheng, HM; Williams, CS; Shao, JY; Liang, P; DuBois, RN; Beauchamp, RD				Sheng, HM; Williams, CS; Shao, JY; Liang, P; DuBois, RN; Beauchamp, RD			Induction of cyclooxygenase-2 by activated Ha-ras oncogene in rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; SYNTHASE-2 GENE-EXPRESSION; GROWTH-FACTOR; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTOR; PLASMA-MEMBRANE; PC12 CELLS; C-JUN	Elevated cyclooxygenase-2 (COX-2) expression and activity have been observed in several different transformed cell types that express mutated ras genes. To investigate the mechanism of increased COX-2 expression following Ras-mediated transformation, Rat-1:iRas cell line was transfected with an Ha-Ras(Val-12) cDNA expressions vector that is under the transcriptional control of the lac operon and is inducible with isopropyl-1-thio-beta-D-galactopyranoside (IPTG). IPTG treatment caused parallel increases in the levels of Ha-Ras and COX-2 proteins in Rat-1:iRas cells. The increased expression of COX-2 was accompanied by increased prostaglandin E-2 production. Selective inhibition of COX-2 activity suppressed the production of prostaglandin E-2 by >90% but did not alter the progress of the morphological transformation. The Bevel of COX-2 mRNA was up-regulated by activated Ha-Ras. Induction of Ras increased the transcription of COX-2 by 44.3 +/- 10.1% and increased the half-life of COX-2 mRNA by similar to 3.5-fold. A specific mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) inhibitor (PD 98059) caused a delay in both the activation of ERK1/2 and the induction of COX-2 in IPTG-induced Rat-1:iRas cells. Inhibition of ERK activity by PD 98059 also suppressed the induction of COX-2 by epidermal growth factor in intestinal epithelial cells and significantly reduced the expression of COX-2 in Ha-Ras-transformed rat intestinal epithelial cells. ERK activity appears to be required for induction of COX-2 by Ras.	Vanderbilt Univ, Ctr Med, Ctr Canc, Dept Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Med, Ctr Canc, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Med, Ctr Canc, Dept Cell Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Beauchamp, RD (corresponding author), Vanderbilt Univ, Ctr Med, Ctr Canc, Dept Surg, CC-2306,Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA.		Williams, christopher S/A-1186-2009; DuBois, Raymond N./AAX-8869-2020	Beauchamp, Robert Daniel/0000-0002-8446-4114	NATIONAL CANCER INSTITUTE [R01CA069457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047297, R01DK052334, R37DK047297] Funding Source: NIH RePORTER; NCI NIH HHS [CA-69457] Funding Source: Medline; NIDDK NIH HHS [DK-47297, DK-52334] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barrie AP, 1997, J BIOL CHEM, V272, P19666, DOI 10.1074/jbc.272.32.19666; BEAUCHAMP RD, 1992, MOL ENDOCRINOL, V6, P1789, DOI 10.1210/me.6.11.1789; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5291; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; COLEMAN WB, 1994, CARCINOGENESIS, V15, P1005, DOI 10.1093/carcin/15.5.1005; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FILMUS J, 1992, ONCOGENE, V7, P521; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KO TC, 1995, ONCOGENE, V10, P177; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Masferrer JL, 1996, GASTROENTEROL CLIN N, V25, P363, DOI 10.1016/S0889-8553(05)70252-1; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; Mestre JR, 1997, CANCER RES, V57, P2890; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHWARZ LC, 1988, CANCER RES, V48, P6999; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 1997, CELL GROWTH DIFFER, V8, P463; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; YAN MH, 1994, NATURE, V372, P798; Zhang R, 1997, ONCOGENE, V14, P1607, DOI 10.1038/sj.onc.1200957; ZHAO JM, 1993, EXP CELL RES, V204, P82, DOI 10.1006/excr.1993.1011	58	170	174	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22120	22127		10.1074/jbc.273.34.22120	http://dx.doi.org/10.1074/jbc.273.34.22120			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705357	hybrid			2022-12-25	WOS:000075492600091
J	Vandorpe, DH; Shmukler, BE; Jiang, LW; Lim, B; Maylie, J; Adelman, JP; de Franceschi, L; Cappellini, MD; Brugnara, C; Alper, SL				Vandorpe, DH; Shmukler, BE; Jiang, LW; Lim, B; Maylie, J; Adelman, JP; de Franceschi, L; Cappellini, MD; Brugnara, C; Alper, SL			cDNA cloning and functional characterization of the mouse Ca2+-gated K+ channel, mIK1 - Roles in regulatory volume decrease and erythroid differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL DISEASE; ACTIVATED POTASSIUM CHANNELS; HUMAN RED-CELLS; XENOPUS-OOCYTES; ANION-EXCHANGER; IN-VITRO; CALCIUM; CLOTRIMAZOLE; DEHYDRATION; INHIBITION	We have cloned from murine erythroleukemia (MEL) cells, thymus, and stomach the cDNA encoding the Ca2+-gated K+ (K-Ca) channel, mIK1, the mouse homolog of hIK1 (Ishii, T. M., Silvia, C., Hirschberg, B., Bond, C. T., Adelman, J. P., and Maylie, J. (1997) Proc. Natl. Acad. Sci.(U. S. A. 94, 11651-11656), mIK1 mRNA was detected at varied levels in many tissue types. mIK1 K-Ca channel activity expressed in Xenopus oocytes closely resembled the K-Ca of red cells (Grardos channel) and MEL cells in its single channel conductance, lack of voltage-sensitivity of activation, inward rectification, and Ca2+ concentration dependence. mIK1 also resembled the erythroid channel in its pharmacological properties, mediating whole cell and unitary currents sensitive to low nM concentrations of both clotrimazole (CLT) and its des-imidazolyl metabolite, 2-chlorophenyl-bisphenyl-methanol, and to low nM concentrations of iodocharybdotoxin, Whereas control oocytes subjected to hypotonic swelling remained swollen, mIK1 expression conferred on oocytes a novel, Ca2+-dependent, CLT-sensitive regulatory volume decrease response. Hypotonic swelling of voltage-clamped mIK1-expressing oocytes increased outward currents that were Ca2+-dependent, CLT-sensitive, and reversed near the K+ equilibrium potential. mIK1 mRNA levels in ES cells increased steadily during erythroid differentiation in culture, in contrast to other K-Ca mRNAs examined. Low nanomolar concentrations of CLT inhibited proliferation and erythroid differentiation of peripheral blood stem cells in Liquid culture.	Beth Israel Med Ctr, Mol Med Unit, Boston, MA 02215 USA; Beth Israel Med Ctr, Renal Unit, Boston, MA 02215 USA; Beth Israel Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA; Harvard Univ, Inst Med, Boston, MA 02215 USA; Oregon Hlth Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Univ Verona, Dept Internal Med, I-37100 Verona, Italy; Univ Verona, Dept Gen Pathol, I-37100 Verona, Italy; Univ Milan, IRCCS, Maggiore Hosp, Dept Internal Med, I-20122 Milan, Italy; Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Oregon Health & Science University; Oregon Health & Science University; University of Verona; University of Verona; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Alper, SL (corresponding author), Beth Israel Med Ctr, Mol Med Unit, RW763,Beth Israel Deaconess Med Ctr E Campus,330, Boston, MA 02215 USA.	salper@bih.harvard.edu	Brugnara, Carlo/A-8041-2010; CAPPELLINI, MARIA DOMENICA/B-4475-2017	Brugnara, Carlo/0000-0001-8192-8713; CAPPELLINI, MARIA DOMENICA/0000-0001-8676-6864	NHLBI NIH HHS [HL15157] Funding Source: Medline; NIDDK NIH HHS [DK51059, DK47636] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047636, R01DK051059] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMAN MJ, 1994, J GEN PHYSIOL, V103, P153, DOI 10.1085/jgp.103.2.153; ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; ARCANGELI A, 1987, BIOCHEM BIOPH RES CO, V146, P1450, DOI 10.1016/0006-291X(87)90812-6; ARMSBY CC, 1995, AM J PHYSIOL-CELL PH, V268, pC894, DOI 10.1152/ajpcell.1995.268.4.C894; BENZAQUEN LR, 1995, NAT MED, V1, P534, DOI 10.1038/nm0695-534; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; Brugnara C, 1997, Curr Opin Hematol, V4, P122; BRUGNARA C, 1995, J PHARMACOL EXP THER, V273, P266; Brugnara C, 1996, J CLIN INVEST, V97, P1227, DOI 10.1172/JCI118537; Brugnara C, 1995, Ann N Y Acad Sci, V763, P262, DOI 10.1111/j.1749-6632.1995.tb32411.x; BRUGNARA C, 1993, J CLIN INVEST, V92, P520, DOI 10.1172/JCI116597; BULBARELLI A, 1998, IN PRESS BLOOD; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Chernova MN, 1997, BBA-BIOMEMBRANES, V1329, P111, DOI 10.1016/S0005-2736(97)00090-4; Chernova MN, 1997, J GEN PHYSIOL, V109, P345, DOI 10.1085/jgp.109.3.345; CHRISTOPHERSEN P, 1991, J MEMBRANE BIOL, V119, P75, DOI 10.1007/BF01868542; De Franceschi L., 1997, Blood, V90, p264A; DeFranceschi L, 1997, J CLIN INVEST, V100, P1847, DOI 10.1172/JCI119713; DEFRANCESCHI L, 1994, J CLIN INVEST, V93, P1670, DOI 10.1172/JCI117149; DEUTSCH C, 1993, P NATL ACAD SCI USA, V90, P10036, DOI 10.1073/pnas.90.21.10036; DEUTSCH C, 1991, J BIOL CHEM, V266, P3668; Devor DC, 1997, AM J PHYSIOL-CELL PH, V273, pC531, DOI 10.1152/ajpcell.1997.273.2.C531; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; FIBACH E, 1989, BLOOD, V73, P100; Franco RS, 1996, BLOOD, V88, P4359; Furukawa T, 1998, AM J PHYSIOL-CELL PH, V274, pC500, DOI 10.1152/ajpcell.1998.274.2.C500; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P653, DOI 10.1016/0006-3002(58)90124-0; GRYGORCZYK R, 1983, CELL CALCIUM, V4, P499, DOI 10.1016/0143-4160(83)90025-8; GRYGORCZYK R, 1984, BIOPHYS J, V45, P693, DOI 10.1016/S0006-3495(84)84211-3; GRYGORCZYK R, 1985, EUR BIOPHYS J BIOPHY, V12, P57, DOI 10.1007/BF00260428; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guillemot JC, 1996, BLOOD, V88, P2722, DOI 10.1182/blood.V88.7.2722.bloodjournal8872722; HALPERIN JA, 1989, J CLIN INVEST, V83, P1466, DOI 10.1172/JCI114039; HAMIL OP, 1981, J PHYSL, V319, P97; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hartzell HC, 1996, J GEN PHYSIOL, V108, P157, DOI 10.1085/jgp.108.3.157; Hatton CJ, 1996, AM J PHYSIOL-CELL PH, V271, pC85, DOI 10.1152/ajpcell.1996.271.1.C85; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jiang LW, 1997, AM J PHYSIOL-CELL PH, V272, pC191, DOI 10.1152/ajpcell.1997.272.1.C191; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KELLY SM, 1995, COMP BIOCHEM PHYS A, V111, P681, DOI 10.1016/0300-9629(95)00046-A; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LEINDERS T, 1992, BIOCHIM BIOPHYS ACTA, V1112, P67, DOI 10.1016/0005-2736(92)90255-K; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Li Q, 1996, J BIOL CHEM, V271, P18651, DOI 10.1074/jbc.271.31.18651; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; LUCCHESI K, 1989, J MEMBRANE BIOL, V109, P269, DOI 10.1007/BF01870284; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; MCDOUGALL A, 1995, CURR BIOL, V5, P318, DOI 10.1016/S0960-9822(95)00062-5; MOZZARELLI A, 1987, SCIENCE, V237, P500, DOI 10.1126/science.3603036; OHNISHI ST, 1989, BIOCHIM BIOPHYS ACTA, V1010, P199; PARKER I, 1994, CELL CALCIUM, V15, P276, DOI 10.1016/0143-4160(94)90067-1; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Rufo PA, 1996, J CLIN INVEST, V98, P2066, DOI 10.1172/JCI119012; Rufo PA, 1997, J CLIN INVEST, V100, P3111, DOI 10.1172/JCI119866; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Shirihai O, 1996, PFLUG ARCH EUR J PHY, V431, P632, DOI 10.1007/s004240050045; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; WULF GM, 1993, EMBO J, V12, P5065, DOI 10.1002/j.1460-2075.1993.tb06200.x; Zolotarev AS, 1996, AM J PHYSIOL-GASTR L, V271, pG311, DOI 10.1152/ajpgi.1996.271.2.G311	66	174	181	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21542	21553		10.1074/jbc.273.34.21542	http://dx.doi.org/10.1074/jbc.273.34.21542			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705284	hybrid			2022-12-25	WOS:000075492600018
J	Noll, M; Petrukhin, K; Lutsenko, S				Noll, M; Petrukhin, K; Lutsenko, S			Identification of a novel transcription regulator from Proteus mirabilis, PMTR, revealed a possible role of YJAI protein in balancing zinc in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ENCODES; METAL; TRANSPORTER; RESISTANCE; SEQUENCE; CADMIUM	Zinc is an essential trace element required for structural integrity and functional activity of numerous proteins, yet mechanisms by which cells regulate zinc concentration are poorly understood. Here, we identified a gene from Proteus mirabilis that encodes a 135-amino acid residue protein, PMTR (P. mirabilis transcription regulator), a new member of the MerR family of transcription activators. Transformation of Escherichia coli with PMTR-carrying vectors specifically increases cell tolerance to zinc, suggesting the role of PMTR in zinc homeostasis. In response to zinc, PMTR-containing cells robustly accumulate a 12-kDa protein, the amount of which correlates with the cells' ability to grow at high zinc concentrations. The 12-kDa protein is not induced in the presence of Ni2+, Co2+, Cd2+, Mn2+, or Fe2+, indicating that the PMTR-dependent expression of the 12-kDa protein is specifically regulated by zinc. The 12-kDa protein was identified as the C-terminal fragment off. coli protein YJAI, and was shown to contain two zinc-binding motifs, Metal-affinity chromatography and Zn-65 blotting assay confirmed the ability of the 12-kDa protein to bind zinc specifically (zinc > cobalt much greater than cadmium). We propose that YJAI is an important component of the zinc-balancing mechanism in E. coli, the up-regulation of which with PMTR results in an increased tolerance to zinc.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Lutsenko, S (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.			Petrukhin, Konstantin/0000-0002-5545-6924				ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; Bartsevich VV, 1996, J BIOL CHEM, V271, P26057, DOI 10.1074/jbc.271.42.26057; Beard SJ, 1997, MOL MICROBIOL, V25, P883, DOI 10.1111/j.1365-2958.1997.mmi518.x; BROCKLEHURST K, 1997, ASBMB FALL S; CHANG LW, 1990, J TOXICOL SCI, V4, P125; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; FEINBERG H, 1993, J CHEM INF COMP SCI, V33, P501, DOI 10.1021/ci00013a030; Goyer RA, 1997, ANNU REV NUTR, V17, P37, DOI 10.1146/annurev.nutr.17.1.37; Hagenmaier S, 1997, J BACTERIOL, V179, P2073, DOI 10.1128/jb.179.6.2073-2076.1997; HARRIS TJR, 1986, MOL BIOL MED, V3, P272; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; HOGSTRAND C, 1996, J EXP BIOL, V199, P2453; HOLMES DJ, 1993, EMBO J, V12, P3183, DOI 10.1002/j.1460-2075.1993.tb05987.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NAKANO Y, 1991, J BIOCHEM-TOKYO, V109, P223; NIES DH, 1992, PLASMID, V27, P17, DOI 10.1016/0147-619X(92)90003-S; NOLL M, 1998, P 4 WORLD C FOODB IN; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; SADOWSKY MJ, 1991, P NATL ACAD SCI USA, V88, P637, DOI 10.1073/pnas.88.2.637; Silver S, 1996, ANNU REV MICROBIOL, V50, P753, DOI 10.1146/annurev.micro.50.1.753; UNDERWOOD EJ, 1981, J HUM NUTR, V35, P37; UPHOFF TS, 1990, J BACTERIOL, V172, P1206, DOI 10.1128/jb.172.3.1206-1216.1990; Zhang FL, 1996, BIOCHEMISTRY-US, V35, P8166, DOI 10.1021/bi960574+; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	28	40	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21393	21401		10.1074/jbc.273.33.21393	http://dx.doi.org/10.1074/jbc.273.33.21393			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694902	hybrid			2022-12-25	WOS:000075386100095
J	Rosenberg, K; Olsson, H; Morgelin, M; Heinegard, D				Rosenberg, K; Olsson, H; Morgelin, M; Heinegard, D			Cartilage oligomeric matrix protein shows high affinity zinc-dependent interaction with triple helical collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH PLATE CARTILAGE; RAY-EMISSION SRIXE; ELECTRON-MICROSCOPY; ARTICULAR-CARTILAGE; BINDING-SITE; II COLLAGEN; CALCIUM; THROMBOSPONDIN; DECORIN; COMP	Cartilage and tendon extracellular matrices are composed of collagens, proteoglycans, and a number of noncollagenous proteins. Cartilage oligomeric matrix protein (COMP) is a prominent such protein, structurally related to the thrombospondins. We found that native COMP binds to collagen I/II and procollagen I/II and that the interaction is dependent on the divalent cations Zn2+ or Ni2+, whereas Ca2+, Mg2+, and Mn2+ did not promote binding. Using a solid phase assay, Scatchard analysis identified one class of binding site with a dissociation constant (K-d) close to 1.5 nM in the presence of Zn2+. The results were confirmed by studies using surface plasmon resonance. Furthermore, metal chelate chromatography demonstrated that COMP bound Zn2+ and Ni2+. Electron microscopy showed that the interaction occurred at four defined sites on the 300-nm collagen and procollagen molecules. Two were located close to each end, and two at 126 and 206 nm, respectively, from the C-terminal, COMP interacted via its C-terminal globular domain and significantly only in the presence of Zn2+.	Lund Univ, Dept Cell & Mol Biol, Sect Connect Tissue Biol, S-22100 Lund, Sweden	Lund University	Heinegard, D (corresponding author), Lund Univ, Dept Cell & Mol Biol, Sect Connect Tissue Biol, POB 94, S-22100 Lund, Sweden.	Dick.Heinegard@medkem.lu.se		Olsson, Henric/0000-0002-5101-8871				ARNOLD FH, 1991, SCIENCE, V252, P1796, DOI 10.1126/science.1648261; BOEDTKER H, 1956, J AM CHEM SOC, V78, P4267, DOI 10.1021/ja01598a024; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; CHATEAUVERT JMD, 1989, J RHEUMATOL, V16, P1098; CURRAN S, 1982, BIOCHEMISTRY-US, V21, P1482, DOI 10.1021/bi00536a003; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; DICESARE PE, 1995, J ORTHOPAED RES, V13, P422, DOI 10.1002/jor.1100130316; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; DZAMBA BJ, 1993, J CELL BIOL, V121, P1165, DOI 10.1083/jcb.121.5.1165; EFIMOV VP, 1994, FEBS LETT, V341, P54, DOI 10.1016/0014-5793(94)80239-4; Ekman S, 1997, CALCIFIED TISSUE INT, V60, P547, DOI 10.1007/s002239900278; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; GALVIN NJ, 1987, J CELL BIOL, V104, P1413, DOI 10.1083/jcb.104.5.1413; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HARGEST TE, 1985, J HISTOCHEM CYTOCHEM, V33, P275, DOI 10.1177/33.4.3980981; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KUHN K, 1987, STRUCTURE FUNCTION C, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLER J, 1986, ANN NY ACAD SCI, V485, P273, DOI 10.1111/j.1749-6632.1986.tb34589.x; LAWLER J, 1983, J BIOL CHEM, V258, P2098; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; Maroudas, 1979, ADULT ARTICULAR CART, P219; MISENHEIMER TM, 1995, J BIOL CHEM, V270, P1729, DOI 10.1074/jbc.270.4.1729; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; NEWTON G, 1994, GENOMICS, V24, P435, DOI 10.1006/geno.1994.1649; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; PRITZKER KPH, 1987, J RHEUMATOL, V14, P806; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; RIZZO R, 1995, J EXP ZOOL, V273, P82, DOI 10.1002/jez.1402730111; ROSENBERG L, 1991, J BIOL CHEM, V266, P7016; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Shen ZX, 1995, MATRIX BIOL, V14, P773, DOI 10.1016/S0945-053X(05)80020-4; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; Smith RKW, 1997, MATRIX BIOL, V16, P255, DOI 10.1016/S0945-053X(97)90014-7; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; STENFLO J, 1991, ANN NY ACAD SCI, V614, P11, DOI 10.1111/j.1749-6632.1991.tb43688.x; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VITTUR F, 1992, BIOCHEM BIOPH RES CO, V188, P1010, DOI 10.1016/0006-291X(92)91332-K; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Zaia J, 1997, J BIOL CHEM, V272, P14120, DOI 10.1074/jbc.272.22.14120	52	264	277	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20397	20403		10.1074/jbc.273.32.20397	http://dx.doi.org/10.1074/jbc.273.32.20397			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685393	hybrid			2022-12-25	WOS:000075305400070
J	Lloyd, BH; Platt-Higgins, A; Rudland, PS; Barraclough, R				Lloyd, BH; Platt-Higgins, A; Rudland, PS; Barraclough, R			Human S100A4(p9Ka) induces the metastatic phenotype upon benign tumour cells	ONCOGENE			English	Article						breast cancer; calcium-binding protein; metastasis; p9Ka; S100A4	CALCIUM-BINDING PROTEIN; HUMAN BREAST-CANCER; RAT MAMMARY-GLAND; MESSENGER-RNA; MYOEPITHELIAL CELLS; MOLECULAR-CLONING; NONMUSCLE MYOSIN; GENE; P9KA; TRANSFECTION	The rodent S100-related calcium-binding protein, S100A4 induces metastasis in non-metastatic rat and mouse benign mammary cells and co-operates with benign-tumour-inducing changes in two transgenic mouse models, to yield metastatic mammary tumours, Cotransfection of the human gene for S100A4 with pSV2neo into the benign rat mammary cell line, Rama 37, yielded cells which expressed a low level of the endogenous S100A4 mRNA, and either high or undetectable levels of human S100A4 mRNA. The cells which expressed a high level of human S100A4 mRNA induced metastasis in the benign rat mammary cell line Rama 37 in an in vivo assay, whereas the cells which expressed an undetectable level of human S100A4 did not induce any detectable metastases. The primary tumours arising from the S100A4-expressing cells contained high levels of immunocytochemically-detected S100A4 and this high level of S100A4 and the metastatic potential were maintained when cells from a metastasis were re-injected into syngeneic rats, The results show that the human S100A4 possesses metastasis-inducing capabilities.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7BZ, Merseyside, England	University of Liverpool	Barraclough, R (corresponding author), Univ Liverpool, Sch Biol Sci, POB 147, Liverpool L69 7BZ, Merseyside, England.		Barraclough, Roger/AAH-6516-2020	Barraclough, Roger/0000-0002-7203-1194				Ambartsumian NS, 1996, ONCOGENE, V13, P1621; BARRACLOUGH R, 1987, J CELL PHYSIOL, V131, P393, DOI 10.1002/jcp.1041310311; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BARRACLOUGH R, 1984, BIOCHEM BIOPH RES CO, V120, P351, DOI 10.1016/0006-291X(84)91261-0; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V21, P8097; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIES BR, 1993, ONCOGENE, V8, P999; DAVIES BR, 1994, CANCER RES, V54, P2785; Davies MPA, 1996, ONCOGENE, V13, P1631; DAVIES MPA, 1993, THESIS U LIVERPOOL; DEVILEE P, 1991, CANCER RES, V51, P1020; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; DUNNINGTON DJ, 1984, J NATL CANCER I, V72, P455; DUNNINGTON DJ, 1984, THESIS U LONDON; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ENGELKAMP D, 1992, BIOCHEMISTRY-US, V31, P10258, DOI 10.1021/bi00157a012; ENGELKAMP D, 1993, P NATL ACAD SCI USA, V90, P6547, DOI 10.1073/pnas.90.14.6547; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Flynn AM, 1996, BIOCHEM SOC T, V24, pS341, DOI 10.1042/bst024341s; FORD HL, 1995, ONCOGENE, V10, P1597; GENDLER SJ, 1990, INT J CANCER, V45, P431, DOI 10.1002/ijc.2910450309; GIBBS FEM, 1995, J HISTOCHEM CYTOCHEM, V43, P169, DOI 10.1177/43.2.7822773; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grigorian M, 1996, INT J CANCER, V67, P831, DOI 10.1002/(SICI)1097-0215(19960917)67:6<831::AID-IJC13>3.0.CO;2-4; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; JAMIESON S, 1990, INT J CANCER, V46, P1071, DOI 10.1002/ijc.2910460621; JAMIESON S, 1990, PATHOBIOLOGY, V58, P329, DOI 10.1159/000163605; JAMIESON S, 1987, THESIS U LONDON; KAMBY C, 1990, CANCER TREAT REV, V17, P37, DOI 10.1016/0305-7372(90)90075-Q; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MERLO GR, 1989, CANCER RES, V49, P6966; MICALE MA, 1994, HUM PATHOL, V25, P29, DOI 10.1016/0046-8177(94)90167-8; NEWMAN RA, 1979, J NATL CANCER I, V63, P1339; PANDIS N, 1992, GENE CHROMOSOME CANC, V5, P235, DOI 10.1002/gcc.2870050310; RAMAEKERS FCS, 1983, P NATL ACAD SCI-BIOL, V80, P2618, DOI 10.1073/pnas.80.9.2618; RUDLAND PS, 1993, HISTOL HISTOPATHOL, V8, P385; Sambrook J., 2002, MOL CLONING LAB MANU; SLOANE J, 1981, CANCER, V41, P1786; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, TRANSCRIPTION TRANSL, P1; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; WARBURTON MJ, 1982, J HISTOCHEM CYTOCHEM, V30, P667, DOI 10.1177/30.7.6179984; WARBURTON MJ, 1989, HISTOCHEM J, V21, P679, DOI 10.1007/BF01002489; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	51	104	109	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					465	473		10.1038/sj.onc.1201948	http://dx.doi.org/10.1038/sj.onc.1201948			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696040				2022-12-25	WOS:000075043000009
J	Dejardin, E; Deregowski, V; Greimers, R; Cai, ZZ; Chouaib, S; Merville, MP; Bours, V				Dejardin, E; Deregowski, V; Greimers, R; Cai, ZZ; Chouaib, S; Merville, MP; Bours, V			Regulation of major histocompatibility complex class I expression by NF-kappa B-related proteins in breast cancer cells	ONCOGENE			English	Article						MHC class I; NF-kappa B, breast cancer	MHC CLASS-I; EMBRYONAL CARCINOMA-CELLS; TRANSCRIPTION FACTORS; GENE-EXPRESSION; DOWN-REGULATION; ONCOPROTEIN BCL-3; ALPHA PROTEOLYSIS; FACTOR BINDING; REL ONCOGENE; TAX-PROTEIN	Downregulation of MHC Class I antigens has been observed in many cancers and usually results from a decreased gene transcription. A reporter CAT gene dependent on the MHC Class I kappa B site or on a longer promoter is transactivated by NF-kappa B complexes containing p65 or RelB. p100 as well as I kappa B-alpha are potent inhibitors of this transcription and p100 sequesters RelB and p65 complexes in the cytoplasm of breast cancer cells. However, although p100 is highly expressed in a number of breast cancer cell lines, MHC Class I antigen expression was observed on all the cell lines we analysed and could be further induced by stimulation with the cytokines IFN-gamma or TNF-alpha. Stable transfection of a unresponsive mutated I kappa B-alpha Ser 32-36 expression vector showed that TNF-alpha induced MHC Cl I expression in an NF-kappa B-dependent way while IFN-gamma did it independently of any NF-kappa B activation.	Univ Liege, Lab Med Chem Med Oncol, B-4000 Liege, Belgium; Univ Liege, Pathol Lab, B-4000 Liege, Belgium; Inst Gustave Roussy, INSERM, CJF Cytokines & Immun Antitumorale 9411, F-94805 Villejuif, France	University of Liege; University of Liege; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Bours, V (corresponding author), Univ Liege, Lab Med Chem Med Oncol, B-4000 Liege, Belgium.		Dejardin, Emmanuel/AAE-9076-2021; Chouaib, Salem/F-7939-2016					ACCOLLA RS, 1995, IMMUNOL TODAY, V16, P8, DOI 10.1016/0167-5699(95)80063-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BLANCHET O, 1992, P NATL ACAD SCI USA, V89, P3488, DOI 10.1073/pnas.89.8.3488; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Cai ZZ, 1997, J BIOL CHEM, V272, P96; CORDONCARDO C, 1991, CANCER RES, V51, P6372; DANIELVEDELE F, 1985, IMMUNOGENETICS, V21, P601, DOI 10.1007/BF00395884; DEJARDIN E, 1995, ONCOGENE, V11, P1835; DOBRZANSKI P, 1995, ONCOGENE, V10, P1003; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; Drew PD, 1995, J INTERF CYTOK RES, V15, P1037, DOI 10.1089/jir.1995.15.1037; DREW PD, 1993, J IMMUNOL, V150, P3300; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; Garrido F, 1995, ADV CANCER RES, V67, P155, DOI 10.1016/S0065-230X(08)60713-7; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; Liu XH, 1996, MOL CELL BIOL, V16, P398; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PLASKIN D, 1993, J EXP MED, V177, P1651; POTTER DA, 1993, J BIOL CHEM, V268, P18882; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHOUTEN GJ, 1995, EMBO J, V14, P1498, DOI 10.1002/j.1460-2075.1995.tb07136.x; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Weih F, 1996, ONCOGENE, V12, P445; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x	55	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3299	3307		10.1038/sj.onc.1201879	http://dx.doi.org/10.1038/sj.onc.1201879			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681829	Green Published			2022-12-25	WOS:000074343600011
J	Meerovitch, K; Wing, S; Goltzman, D				Meerovitch, K; Wing, S; Goltzman, D			Proparathyroid hormone-related protein is associated with the chaperone protein BiP and undergoes proteasome-mediated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID-HORMONE; ENDOPLASMIC-RETICULUM; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; APOLIPOPROTEIN B100; PEPTIDE PRODUCTION; SECRETORY PROTEIN; ER DEGRADATION; HEAVY-CHAIN; CELL-DEATH; PATHWAY	Parathyroid hormone-related peptide (PTHrP) is an important causal factor for hypercalcemia associated with malignancy. In addition to the endocrine functions attributed to secretory forms of the peptide, PTHrP also plays a local role as a mediator of cellular growth and differentiation presumably at least in part through intracellular pathways. In studying the post-translational regulation of PTHrP, we observed that PTHrP was conjugated to multiple ubiquitin moieties. We report here that the proteasome is responsible for the degradation of the endoplasmic reticulum-associated precursor, pro-PTHrP. Cells expressing prepro-PTHrP and exposed to lactacystin accumulate pro-PTHrP assessed by anti-pro specific antibodies. Brefeldin A-treated cells also accumulate pro-PTHrP suggesting that degradation does not occur in the endoplasmic reticulum (ER) lumen. Subcellular fractionation of both lactacystin and brefeldin A-treated cells indicated that accumulated pro-PTHrP resides in microsomal fractions with a portion of the protein exposed to the cytosolic side of the ER membrane as assessed by protease protection experiments. Immunoprecipitation and Western blot analysis identified pro-PTHrP in association with the ER molecular chaperone protein BiP. We conclude that pro-PTHrP from the ER can gain access to the cytoplasmic side of the ER membrane where it can undergo ubiquitination and degradation by the proteasome.	McGill Univ, Calcium Res Lab, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Polypeptide Lab, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University	Goltzman, D (corresponding author), Royal Victoria Hosp, Calcium Res Lab, Rm H4-67,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.							ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; Amizuka N, 1996, ENDOCRINOLOGY, V137, P5055, DOI 10.1210/en.137.11.5055; Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BONIFACINO JS, 1994, CELL PROTEOLYTIC SYS; BROADUS AE, 1994, PARATHYROIDS; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLTZMAN D, 1997, ENDOCRINE NEOPLASMS; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Henderson JE, 1996, J CELL PHYSIOL, V169, P33, DOI 10.1002/(SICI)1097-4652(199610)169:1<33::AID-JCP4>3.0.CO;2-F; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; ISAKSSON A, 1996, BIOCHIM BIOPHYS ACTA, V1288, P21; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KAISER SM, 1992, J BIOL CHEM, V267, P13623; KAISER SM, 1994, MOL ENDOCRINOL, V8, P139, DOI 10.1210/me.8.2.139; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LI X, 1993, CANCER RES, V53, P2980; LIU B, 1993, ENDOCRINOLOGY, V132, P1658, DOI 10.1210/en.132.4.1658; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; Meerovitch K, 1997, J BIOL CHEM, V272, P6706, DOI 10.1074/jbc.272.10.6706; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; RABBANI SA, 1995, ENDOCRINOLOGY, V136, P5416, DOI 10.1210/en.136.12.5416; RIVETT AJ, 1993, BIOCHEM J, V291, P1; Roberts BJ, 1997, J BIOL CHEM, V272, P9771; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	49	41	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21025	21030		10.1074/jbc.273.33.21025	http://dx.doi.org/10.1074/jbc.273.33.21025			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694854	hybrid			2022-12-25	WOS:000075386100047
J	Muhlbauer, SK; Eichacker, LA				Muhlbauer, SK; Eichacker, LA			Light-dependent formation of the photosynthetic proton gradient regulates translation elongation in chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED PEA-CHLOROPLASTS; SPINACH-CHLOROPLASTS; PHOTOSYSTEM-I; ELECTRON-TRANSPORT; PROTEIN-SYNTHESIS; MESSENGER-RNAS; BINDING; ACCUMULATION; D1; PLASTOQUINONE	Upon transfer of lysed chloroplasts from darkness to light, the accumulation of membrane and stromal chloroplast proteins is strictly regulated at the level of translation elongation. In darkness, translation elongation is retarded even in the presence of exogenously added ATP and dithiothreitol. In the light, addition of the electron transport inhibitor 3-(3,4-dichlorophenyl)-1,1-dimethyl urea inhibits translation elongation even in the presence of ATP. This inhibition can be overcome by addition of artificial electron donors in the presence of light, but not in darkness. Electron flow between photo-system II and I induced by far red light of 730 nm is sufficient for the activation of translation elongation. This activation can also be obtained by electron donors to photosystem I, which transport protons into the thylakoid lumen, Release of the proton gradient by uncouplers prevents the Light-dependent activation of translation elongation. Also, the induction of translation activation is switched off rapidly upon transfer from light to darkness. Hence, we propose that the formation of a photosynthetic proton gradient across the thylakoid membrane activates translation elongation in chloroplasts.	Univ Munich, Dept Bot, D-80638 Munich, Germany	University of Munich	Eichacker, LA (corresponding author), Univ Munich, Dept Bot, Menzinger Str 67, D-80638 Munich, Germany.							ALLEN CA, 1995, REDOX REP, V1, P119, DOI 10.1080/13510002.1995.11746969; ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; BERRY JO, 1988, P NATL ACAD SCI USA, V85, P4190, DOI 10.1073/pnas.85.12.4190; BHAYA D, 1984, PLANT PHYSIOL, V75, P832, DOI 10.1104/pp.75.3.832; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; Eichacker LA, 1996, J BIOL CHEM, V271, P32174, DOI 10.1074/jbc.271.50.32174; GAL A, 1990, J BIOL CHEM, V265, P19742; HAEHNEL W, 1977, BIOCHIM BIOPHYS ACTA, V459, P418, DOI 10.1016/0005-2728(77)90043-3; HATTORI T, 1986, ARCH BIOCHEM BIOPHYS, V244, P630; Hauser CR, 1996, J BIOL CHEM, V271, P1486, DOI 10.1074/jbc.271.3.1486; INAGAKI N, 1992, FEBS LETT, V300, P5, DOI 10.1016/0014-5793(92)80152-7; IZAWA S, 1978, BIOCHEM BIOPH RES CO, V83, P1171, DOI 10.1016/0006-291X(78)91518-8; Izawa S., 1980, METHODS ENZYMOL    C, P413; JUNGE W, 1977, ANNU REV PLANT PHYS, V28, P503, DOI 10.1146/annurev.pp.28.060177.002443; Kim JM, 1997, SCIENCE, V278, P1954, DOI 10.1126/science.278.5345.1954; KIM JM, 1991, J BIOL CHEM, V266, P14931; KIRK MM, 1985, CELL, V41, P419, DOI 10.1016/S0092-8674(85)80015-5; Klaff P, 1995, PHOTOSYNTH RES, V46, P235, DOI 10.1007/BF00020436; KLEIN RR, 1986, J BIOL CHEM, V261, P1138; Kuroda H, 1996, PLANT CELL PHYSIOL, V37, P754, DOI 10.1093/oxfordjournals.pcp.a029010; MCCARTY RE, 1980, METHOD ENZYMOL, V69, P719; MICHAELS A, 1990, BIOCHEM BIOPH RES CO, V170, P1082, DOI 10.1016/0006-291X(90)90503-F; ORLICH G, 1980, EUR J BIOCHEM, V111, P525, DOI 10.1111/j.1432-1033.1980.tb04968.x; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; STAUB JM, 1993, EMBO J, V12, P601, DOI 10.1002/j.1460-2075.1993.tb05692.x; TANAKA A, 1994, PLANTA, V192, P92; TANIGUCHI M, 1993, FEBS LETT, V317, P57, DOI 10.1016/0014-5793(93)81491-H; vanWijk KJ, 1996, FEBS LETT, V388, P89, DOI 10.1016/0014-5793(96)00540-6; WOOD PM, 1976, EUR J BIOCHEM, V61, P337, DOI 10.1111/j.1432-1033.1976.tb10027.x	30	55	60	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20935	20940		10.1074/jbc.273.33.20935	http://dx.doi.org/10.1074/jbc.273.33.20935			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694842	hybrid			2022-12-25	WOS:000075386100035
J	Sheridan, SD; Benham, CJ; Hatfield, GW				Sheridan, SD; Benham, CJ; Hatfield, GW			Activation of gene expression by a novel DNA structural transmission mechanism that requires supercoiling-induced DNA duplex destabilization in an upstream activating sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; SUPERHELICAL DNA; GEL-ELECTROPHORESIS; ILVGMEDA OPERON; RICH REGIONS; TRANSCRIPTION; PROTEIN; PROMOTER; TRANSITIONS	We have previously demonstrated that integration host factor (IHF)-mediated activation of transcription from the ilvP(G) promoter of Escherichia coli requires a supercoiled DNA template and occurs in the absence of specific interactions between IHF and RNA polymerase. In this report, we describe a novel, supercoiling-dependent, DNA structural transmission mechanism for this activation. We provide theoretical evidence for a supercoiling-induced DNA duplex destabilized (SIDD) structure in the A + T-rich, ilvP(G) regulatory region between base pair positions +1 and -160, We show that the region of this SIDD sequence immediately upstream of an IHF binding site centered at base pair position -92 is, in fact, destabilized by superhelical stress and that this duplex destabilization is inhibited by IHF binding. Thus, in the presence of IHF, the negative superhelical twist normally absorbed by this DNA structure in the promoter distal half of the SIDD sequence is transferred to the downstream portion of the SIDD sequence containing the ilvP(G) promoter site. This IHF-mediated translocation of superhelical energy facilitates duplex destabilization in the -10 region of the downstream ilvP(G) promoter and activates transcription by increasing the rate of open complex formation.	Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; CUNY Mt Sinai Sch Med, Dept Biomath Sci, New York, NY 10029 USA	University of California System; University of California Irvine; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Hatfield, GW (corresponding author), Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.		Benham, Craig J/G-1512-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047012] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55073, GM07311, GM47012] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULELA F, 1992, J BIOL CHEM, V267, P1776; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Barton MC, 1997, P NATL ACAD SCI USA, V94, P7257, DOI 10.1073/pnas.94.14.7257; BENHAM CJ, 1979, P NATL ACAD SCI USA, V76, P3870, DOI 10.1073/pnas.76.8.3870; BENHAM CJ, 1992, J MOL BIOL, V225, P835, DOI 10.1016/0022-2836(92)90404-8; BENHAM CJ, 1990, J CHEM PHYS, V92, P6294, DOI 10.1063/1.458353; BENHAM CJ, 1993, P NATL ACAD SCI USA, V90, P2999, DOI 10.1073/pnas.90.7.2999; Benham CJ, 1996, J MOL BIOL, V255, P425, DOI 10.1006/jmbi.1996.0035; BOWATER R, 1992, METHOD ENZYMOL, V212, P105; BOWATER RP, 1994, NUCLEIC ACIDS RES, V22, P2042, DOI 10.1093/nar/22.11.2042; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; Fyfe JAM, 1998, J BACTERIOL, V180, P2152, DOI 10.1128/JB.180.8.2152-2159.1998; HAUGHN GW, 1986, J BACTERIOL, V166, P1113, DOI 10.1128/jb.166.3.1113-1117.1986; HIGGINS NP, 1989, J BIOL CHEM, V264, P3035; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; LAWTHER RP, 1987, NUCLEIC ACIDS RES, V15, P2137, DOI 10.1093/nar/15.5.2137; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; NISHI T, 1986, GENE, V44, P29, DOI 10.1016/0378-1119(86)90039-9; PAGEL JM, 1992, J MOL BIOL, V224, P919, DOI 10.1016/0022-2836(92)90460-2; PALECEK E, 1992, METHOD ENZYMOL, V212, P139; Parekh BS, 1996, J BIOL CHEM, V271, P20258, DOI 10.1074/jbc.271.34.20258; Parekh BS, 1996, P NATL ACAD SCI USA, V93, P1173, DOI 10.1073/pnas.93.3.1173; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; RAHMOUNI AR, 1992, J MOL BIOL, V223, P131, DOI 10.1016/0022-2836(92)90721-U; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Sambrook J., 2002, MOL CLONING LAB MANU; SHINDO H, 1995, BIOL PHARM BULL, V18, P1328; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; STECK TR, 1993, MOL MICROBIOL, V10, P473, DOI 10.1111/j.1365-2958.1993.tb00920.x; VANRIJN PA, 1988, NUCLEIC ACIDS RES, V16, P4595, DOI 10.1093/nar/16.10.4595; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	36	77	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21298	21308		10.1074/jbc.273.33.21298	http://dx.doi.org/10.1074/jbc.273.33.21298			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694890	hybrid			2022-12-25	WOS:000075386100083
J	Dimitriadis, EK; Prasad, R; Vaske, MK; Chen, L; Tomkinson, AE; Lewis, MS; Wilson, SH				Dimitriadis, EK; Prasad, R; Vaske, MK; Chen, L; Tomkinson, AE; Lewis, MS; Wilson, SH			Thermodynamics of human DNA ligase I trimerization and association with DNA polymerase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; DOMAIN; IDENTIFICATION; RESIDUES; BINDING; SITE	The interaction between human DNA polymerase beta (pol beta) and DNA Ligase I, which appear to be responsible for the gap filling and nick ligation steps in short patch or simple base excision repair, has been examined by affinity chromatography and analytical ultracentrifugation. Domain mapping studies revealed that complex formation is mediated through the non-catalytic N-terminal domain of DNA ligase I and the N-terminal 8-kDa domain of pol beta that interacts with the DNA template and excises 5'-deoxyribose phosphate residue. Intact pol beta, a 39-kDa bi-domain enzyme, undergoes indefinite self-association, forming oligomers of many sizes. The binding sites for self-association reside within the C-terminal 31-kDa domain. DNA ligase I undergoes self-association to form a homotrimer, At temperatures over 18 degrees C, three pol beta monomers attached to the DNA ligase I trimer, forming a stable heterohexamer, In contrast, at lower temperatures (<18 degrees C), pol beta and DNA ligase I formed a stable 1:1 binary complex only. In agreement with the domain mapping studies, the 8-kDa domain of pol beta interacted with DNA ligase I, forming a stable 3:3 complex with DNA ligase I at all temperatures, whereas the 31-kDa domain of pol beta did not. Our results indicate that the association between pol beta and DNA ligase I involves both electrostatic binding and an entropy-driven process. Electrostatic binding dominates the interaction mediated by the 8-kDa domain of pol beta, whereas the entropy-driven aspect of interprotein binding appears to be contributed by the 31-kDa domain.	NIEHS, LSB, NIH, Res Triangle Pk, NC 27709 USA; NIH, Biomed Engn & Phys Sci Program, Bethesda, MD 20892 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; University of Texas System; University of Texas Health San Antonio	Wilson, SH (corresponding author), NIEHS, LSB, NIH, POB 12233,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.		Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047251, R29GM047251] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM047251, GM47251] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beard WA, 1995, METHOD ENZYMOL, V262, P98; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; CHUN PW, 1995, J BIOL CHEM, V270, P13925; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Dimitriadis EK, 1997, PROG COLL POL SCI S, V107, P20; Eykhoff P., 1974, SYSTEM IDENTIFICATIO; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; KIM SJ, 1994, J MOL BIOL, V244, P224, DOI 10.1006/jmbi.1994.1720; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Mackey ZB, 1997, MOL CELL BIOL, V17, P989, DOI 10.1128/MCB.17.2.989; MANUKIAN EB, 1986, MODERN CONCEPTS THEO; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Papoulis A., 1991, PROBABILITY RANDOM V; Parikh SS, 1997, STRUCTURE, V5, P1543, DOI 10.1016/S0969-2126(97)00303-1; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; PRASAD R, 1993, J BIOL CHEM, V268, P22746; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Rao C.R., 1965, LINEAR STAT INFERENC, V2nd; RON D, 1992, BIOTECHNIQUES, V13, P866; Samson LD, 1992, ESSAYS BIOCHEM, V27, P69; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SRIVASTAVA DK, 1998, IN PRESS J BIOL CHEM, V273; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	33	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20540	20550		10.1074/jbc.273.32.20540	http://dx.doi.org/10.1074/jbc.273.32.20540			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685411	hybrid			2022-12-25	WOS:000075305400088
J	Drissi, H; Lasmoles, F; Le Mellay, V; Marie, PJ; Lieberherr, M				Drissi, H; Lasmoles, F; Le Mellay, V; Marie, PJ; Lieberherr, M			Activation of phospholipase C-beta 1 via G alpha(q/11) during calcium mobilization by calcitonin gene-related peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; CYCLIC-AMP FORMATION; BETA-GAMMA-SUBUNITS; SIGNAL-TRANSDUCTION; ADENYLATE-CYCLASE; COS-7 CELLS; C ISOZYMES; RECEPTOR; GQ; IDENTIFICATION	Interaction of calcitonin gene-related peptide (CGRP) with its receptors leads to stimulation of adenylyl cyclase and/or phospholipase C (PLC), While regulation of adenylyl cyclase is thought to involve the G-protein G(s), it is not known whether activation of PLC results from coupling the receptor to G(q) family proteins or whether beta gamma subunits released from receptor-activated G(s) activate PLC. We used human bone cells OHS-4 bearing CORP receptors in which CORP activates only the PLC signaling pathway to determine how CORP acts. CORP increased the concentration of intracellular calcium ([Ca2+](i)) within 5 s via a Ca2+ influx through voltage-gated calcium channels and by mobilizing calcium from the endoplasmic reticulum. The activation of effecters, like PLC coupled to G-proteins, is the early event in the pathway leading to inositol 1,4,5-trisphosphate formation, which is responsible for Ca2+ mobilization. Western blotting demonstrated a range of PLC-beta isoforms (beta 1, beta 3, beta 4, but not beta 2) and G-proteins (G alpha(q/11) and G alpha(s)). Only phospholipase C-beta 1 is involved in the mobilization of Ca2+ from the endoplasmic reticulum of Fura-2-loaded confluent OHS-4 cells and the formation of inositol 1,4,5-trisphosphate by CORP; PLC-gamma have no effect. Activation of PLC-beta 1 by CORP involves the G alpha(q/11) subunit, which is insensitive to pertussis toxin, but not G beta gamma subunits. We therefore believe that CORP causes the activation of two separate G-proteins.	INRA, CNRS, UPR 1524, F-78350 Jouy En Josas, France; Hop Lariboisiere, INSERM, U349, Paris, France	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Lieberherr, M (corresponding author), INRA, CNRS, UPR 1524, Batiment 221, F-78350 Jouy En Josas, France.	lieberhe@diamant.jouy.inra.fr		drissi, hicham/0000-0002-3322-281X				Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRNBAUMER L, 1995, J RECEPT SIGNAL TR R, V15, P213; BJURHOLM A, 1992, J BONE MINER RES, V7, P1011; BLEASDALE JE, 1989, ADV PROSTAG THROMB L, V19, P590; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAROZZI A, 1993, FEBS LETT, V315, P340, DOI 10.1016/0014-5793(93)81190-B; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DEFTOS LJ, 1989, BONE MINERAL RES, V6, P267; Drissi H, 1997, J BONE MINER RES, V12, pF391; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; FARLEY JR, 1993, METABOLISM, V42, P97, DOI 10.1016/0026-0495(93)90179-R; FOURNIER B, 1991, J CELL BIOL, V114, P577, DOI 10.1083/jcb.114.3.577; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GOLTZMAN D, 1985, SCIENCE, V227, P1343, DOI 10.1126/science.2983422; GRAY DW, 1991, BRIT J PHARMACOL, V107, P691; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Han ZQ, 1997, J MOL ENDOCRINOL, V18, P267, DOI 10.1677/jme.0.0180267; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; JAMES SR, 1994, BIOCHEM J, V304, P359, DOI 10.1042/bj3040359; JOSEPH SK, 1989, ARCH BIOCHEM BIOPHYS, V273, P1, DOI 10.1016/0003-9861(89)90156-2; Kapas S, 1995, BIOCHEM BIOPH RES CO, V217, P832, DOI 10.1006/bbrc.1995.2847; KAWASE T, 1995, BONE, V16, pS379, DOI 10.1016/8756-3282(95)00016-7; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; KUPPE A, 1990, BIOCHIM BIOPHYS ACTA, V1047, P41, DOI 10.1016/0005-2760(90)90258-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUFER R, 1989, J BIOL CHEM, V264, P2683; LEE CW, 1994, J BIOL CHEM, V269, P25335; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LeMellay V, 1997, J BIOL CHEM, V272, P11902, DOI 10.1074/jbc.272.18.11902; MARTIN TFJ, 1991, PHARMACOL THERAPEUT, V49, P329, DOI 10.1016/0163-7258(91)90062-Q; MICHELANGELI VP, 1986, CALCIFIED TISSUE INT, V39, P44, DOI 10.1007/BF02555739; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NELSON MT, 1990, NATURE, V344, P770, DOI 10.1038/344770a0; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566; OLIVEIRA L, 1994, TRENDS PHARMACOL SCI, V15, P170, DOI 10.1016/0165-6147(94)90137-6; Parsons AM, 1997, SYNAPSE, V26, P235, DOI 10.1002/(SICI)1098-2396(199707)26:3<235::AID-SYN5>3.3.CO;2-#; POYNER DR, 1992, PHARMACOL THERAPEUT, V56, P32; PRENTKI M, 1986, FEBS LETT, V197, P285, DOI 10.1016/0014-5793(86)80343-X; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STANGL D, 1993, ENDOCRINOLOGY, V132, P744, DOI 10.1210/en.132.2.744; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THIEBAUD D, 1991, J BONE MINER RES, V6, P1137; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UI M, 1990, ADP RIBOSYLATING TOX, P45; Vignery A, 1996, BONE, V18, P331, DOI 10.1016/8756-3282(96)00017-8; WU DQ, 1992, J BIOL CHEM, V267, P1811	57	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20168	20174		10.1074/jbc.273.32.20168	http://dx.doi.org/10.1074/jbc.273.32.20168			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685362	hybrid			2022-12-25	WOS:000075305400039
J	Frank, O; Schwanbeck, R; Wisniewski, JR				Frank, O; Schwanbeck, R; Wisniewski, JR			Protein footprinting reveals specific binding modes of a high mobility group protein I to DNAs of different conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-BETA GENE; 4-WAY JUNCTION DNA; HMG-I; VIRUS INDUCTION; RNA-POLYMERASE; CDC2 KINASE; EXPRESSION; HMG-I(Y); DOMAINS; CDNA	The high mobility group proteins I and Y (HMGI/Y) are abundant components of chromatin. They are thought to derepress chromatin, affect the assembly and activity of the transcriptional machinery, and associate with constitutive heterochromatin during mitosis. HMGI/Y protein molecules contain three potential DNA-binding. motifs (AT-hooks), but the extent of contacts between DNA and the entire protein has not been determined, We have used a protein-footprinting procedure to map regions of the Chironomus HMGI protein molecule that are involved in contacts with DNA, We find that in the presence of double-stranded DNA all AT-hook motifs are protected against hydroxyl radical proteolysis. In contrast, only two motifs were protected in the presence of four-wag junction DNA. Large regions that flank the AT-hook motifs were found to be strongly protected against proteolysis in complexes with interferon-beta promoter DNA, suggesting amino acid residues outside the AT-hooks considerably contribute to DNA binding.	Univ Gottingen, Zool Inst Entwicklungsbiol 3, D-37073 Gottingen, Germany	University of Gottingen	Wisniewski, JR (corresponding author), Univ Gottingen, Zool Inst Entwicklungsbiol 3, Humboldtallee 34A, D-37073 Gottingen, Germany.	jwisnie@gwdg.de	Schwanbeck, Ralf/A-2648-2008	Schwanbeck, Ralf/0000-0003-0925-929X				ASHLEY CT, 1989, J BIOL CHEM, V264, P8394; Bagga R, 1997, GENE DEV, V11, P629, DOI 10.1101/gad.11.5.629; Baichoo N, 1997, BIOCHEMISTRY-US, V36, P10830, DOI 10.1021/bi970714v; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Berner JM, 1997, ONCOGENE, V14, P2935, DOI 10.1038/sj.onc.1201135; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; Bornstein P, 1977, Methods Enzymol, V47, P132; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CLAUS P, 1994, J BIOL CHEM, V269, P33042; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Ghidelli S, 1997, CHROMOSOMA, V105, P369, DOI 10.1007/BF02529752; GRASSER KD, 1995, PLANT J, V7, P185, DOI 10.1046/j.1365-313X.1995.7020185.x; Greiner DP, 1996, P NATL ACAD SCI USA, V93, P71, DOI 10.1073/pnas.93.1.71; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; Heyduk E, 1997, J BIOL CHEM, V272, P19763, DOI 10.1074/jbc.272.32.19763; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; Hill DA, 1997, NUCLEIC ACIDS RES, V25, P3523, DOI 10.1093/nar/25.17.3523; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1990, EXP CELL RES, V187, P60; LEHN DA, 1988, BIOCHEM INT, V16, P963; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; Nicolas FJ, 1996, P NATL ACAD SCI USA, V93, P6881, DOI 10.1073/pnas.93.14.6881; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; RAM TG, 1993, CANCER RES, V53, P2655; Reeves R, 1996, BIOCHEMISTRY-US, V35, P5063, DOI 10.1021/bi952424p; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwanbeck R, 1997, J BIOL CHEM, V272, P27476, DOI 10.1074/jbc.272.43.27476; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Tkachenko A, 1997, CANCER RES, V57, P2276; VANHOLDE K, 1994, CHROMATIN STRUCTURE, P1; VARGAWEISZ P, 1993, J BIOL CHEM, V268, P20699; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; Wisniewski JR, 1997, EUR J BIOCHEM, V243, P151, DOI 10.1111/j.1432-1033.1997.0151a.x; Wisniewski JR, 1996, INT J DEV BIOL, V40, P177; XIAO D, 1997, CBHUNG KUO I HSUEH K, V18, P79; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649	50	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20015	20020		10.1074/jbc.273.32.20015	http://dx.doi.org/10.1074/jbc.273.32.20015			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685339	hybrid			2022-12-25	WOS:000075305400016
J	Gokmen-Polar, Y; Fields, AP				Gokmen-Polar, Y; Fields, AP			Mapping of a molecular determinant for protein kinase C beta(II) isozyme function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; NUCLEAR-MEMBRANE; MIXED MICELLES; LEUKEMIA-CELLS; LAMIN-B; CALCIUM; PHOSPHATIDYLSERINE; DIFFERENTIATION; DIACYLGLYCEROL	In human erythroleukemia (K562) cells, the highly related protein kinase C (PRC) alpha and PKC beta(II) isozymes serve distinct functions in cellular differentiation and proliferation, respectively. Previous studies using two domain switch PRC chimera revealed that the catalytic domains of PHC alpha and beta(II) contain molecular determinants important for isozyme-specific function (Walker, S. D,, Murray, N, R,, Burns, D, J,, and Fields, A. P, (1995) Proc. Natl, Acad, Sci. U.S.A. 92, 9156-9160), We have now analyzed a panel of PKC chimeras to determine the specific region within the catalytic domain important for PKC beta(II) function. A cellular assay for PKC beta(II) function was devised based on the finding that PKC beta(II) selectively translocates to the nucleus and phosphorylates nuclear lamin B in response to the PKC activator bryostatin, This response is strictly dependent upon expression of PKC beta(II) or a PKC chimera that functions like PKC beta(II). We demonstrate that a PKC alpha/beta(II) chimera containing only the carboxyl-terminal 13 amino acids from PRC beta(II) (beta(II) V5) is capable of nuclear translocation and lamin B phosphorylation. These results are consistent with our recent observation that the PRC beta(II) V5 region binds to phosphatidylglycerol (PG), a potent and selective PRC beta(II) activator present in the nuclear membrane (Murray, N, R,, and Fields, A. P, (1998) J. Biol. Chem. 273, 11514-11520). Soluble beta(II) V5 peptide selectively inhibits PG-stimulated PKC beta(II) activity in a dose-dependent fashion, indicating that PG-mediated activation of PKC beta(II) involves interactions with the beta(II) V5 region of the enzyme. We conclude that beta(II) V5 is a major determinant for PKC beta(II) nuclear function and suggest a model in which binding of PG to the beta(II) V5 region stimulates nuclear PKC beta(II) activity during G(2) phase of the cell cycle.	Univ Texas, Med Branch, Sealy Ctr Oncol & Haematol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pharmacol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Fields, AP (corresponding author), Univ Texas, Med Branch, Sealy Ctr Oncol & Haematol, Med Res Bldg,Rm 9-104,301 Univ Blvd, Galveston, TX 77555 USA.		Gokmen-Polar, Yesim/AAX-4001-2021	Gokmen-Polar, Yesim/0000-0001-9927-4893	NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NCI NIH HHS [CA56869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; CLEMENS MJ, 1992, J CELL SCI, V103, P881; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; Fields A P, 1995, Prog Cell Cycle Res, V1, P271; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; GOSS VL, 1994, J BIOL CHEM, V269, P19074; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HEPLER PK, 1994, CELL CALCIUM, V16, P322, DOI 10.1016/0143-4160(94)90096-5; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KIKKAWA U, 1989, ANN REV BIOCH, V58, P32; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; MURRAY NR, 1997, PROTEIN KINASE C MOL; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; RATAN RR, 1988, J CELL BIOL, V107, P993, DOI 10.1083/jcb.107.3.993; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Sun B, 1997, J BIOL CHEM, V272, P26313, DOI 10.1074/jbc.272.42.26313; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156	38	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20261	20266		10.1074/jbc.273.32.20261	http://dx.doi.org/10.1074/jbc.273.32.20261			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685375	hybrid			2022-12-25	WOS:000075305400052
J	Tsao, HS; Zhang, X; Benoit, E; Haluska, FG				Tsao, HS; Zhang, X; Benoit, E; Haluska, FG			Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines	ONCOGENE			English	Article						cancer; genetics; mutation; PTEN/MMAC1; melanoma	PRIMARY CUTANEOUS MELANOMA; FAMILIAL MELANOMA; HETEROZYGOSITY; DELETIONS; MUTATIONS; GLIOMAS; NEVI; P16	A novel tumor suppressor gene, PTEN/MMAC1, has been recently shown to be mutated in gliomas, breast, prostate, kidney cancers and melanomas, Loss-of-heterozygosity studies in melanoma have suggested the presence of at least one chromosome 10q locus lost early in tumor progression. In this study, we screened 45 melanoma cell lines and 17 paired uncultured metastatic melanoma and peripheral blood specimens for PTEN/MMAC1 alterations using PCR-SSCP and direct sequencing. We found nine melanoma cell lines with homozygous deletions (five with intragenic loss) and four cell lines with mutations (one nonsense and one frameshift; two intronic); from among our uncultured melanoma specimens, me found one tumor with a somatic 17 bp duplication in exon 7 leading to a premature stop codon and one tumor with a possible homozygous deletion. Furthermore, we ha ce identified a novel intragenic polymorphism within intron 4 of PTEN/MMAC1. Taken together, these data suggest that PTEN/MMAC1 may be a chromosome 10q tumor suppressor important in melanoma turner formation or progression.	Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA; Dana Farber Partners Canc Care, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute	Haluska, FG (corresponding author), Massachusetts Gen Hosp, Dept Dermatol, Fruit St, Boston, MA 02114 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007098] Funding Source: NIH RePORTER; NIAMS NIH HHS [5T32AR07098-23] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albarosa R, 1996, AM J HUM GENET, V58, P1260; Bartkova J, 1996, CANCER RES, V56, P5475; Dahia PLM, 1997, CANCER RES, V57, P4710; DREYLING MH, 1995, CANCER RES, V55, P984; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FRIEND SH, 1993, SCIENCE, V259, P774, DOI 10.1126/science.8430329; FULTS D, 1990, CANCER RES, V50, P5784; Guldberg P, 1997, CANCER RES, V57, P3660; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; Healy E, 1996, CANCER RES, V56, P589; HERBST RA, 1994, CANCER RES, V54, P3111; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Ohta M, 1996, INT J CANCER, V65, P762, DOI 10.1002/(SICI)1097-0215(19960315)65:6<762::AID-IJC9>3.0.CO;2-X; PARMITER AH, 1988, CANCER GENET CYTOGEN, V30, P313, DOI 10.1016/0165-4608(88)90200-2; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Rasheed BKA, 1997, CANCER RES, V57, P4187; Rhei E, 1997, CANCER RES, V57, P3657; RICHMOND A, 1986, J INVEST DERMATOL, V86, P295, DOI 10.1111/1523-1747.ep12285452; Risinger JI, 1997, CANCER RES, V57, P4736; SHAPIRO SD, 1988, INT J DERMATOL, V27, P232, DOI 10.1111/j.1365-4362.1988.tb03214.x; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENES CHROMOSOM CANC, V12, P235; WALKER GJ, 1995, GENE CHROMOSOME CANC, V12, P134, DOI 10.1002/gcc.2870120208	30	188	189	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3397	3402		10.1038/sj.onc.1201881	http://dx.doi.org/10.1038/sj.onc.1201881			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692547				2022-12-25	WOS:000074544100006
J	Askwith, CC; Kaplan, J				Askwith, CC; Kaplan, J			Site-directed mutagenesis of the yeast multicopper oxidase Fet3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON UPTAKE; SACCHAROMYCES-CEREVISIAE; FERRIC REDUCTASE; CERULOPLASMIN; GENE; FERROXIDASE; TRANSPORT; HOMOLOG	High affinity iron transport in yeast is mediated by two proteins, Fet3p and Ftr1p. The multicopper oxidase Fet3p is thought to convert extracellular ferrous iron to ferric iron, which then crosses the plasma membrane through the permease Ftr1p, Fet3p is capable of oxidizing other substrates, such as p-phenylenediamine, and there is still a question of whether it is the ferroxidase activity that is essential for iron transport. Fet3p is also required for Ftr1p localization to the cell surface, making it difficult to prove a direct role for Fet3p oxidase in high affinity iron transport. In an attempt to generate Fet3p specifically lacking ferroxidase activity, we used site-directed mutagenesis to alter residues within Fet3p that had been suggested to impart iron oxidase activity. These substitutions resulted in either a loss or retention of both p-phenylenediamine and ferroxidase activities, indicating that the ability of Fet3p to act as a ferroxidase involves other amino acids. Inactive Fet3p, however, did mediate Ftr1p localization to the cell surface but did not mediate high affinity iron transport. These observations indicate that the ferroxidase activity of Fet3p is intrinsically required for high affinity iron transport.	Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, 50 N Med Dr, Salt Lake City, UT 84132 USA.				NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030534, R01DK030534] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007464] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42014] Funding Source: Medline; NIDDK NIH HHS [DK30534] Funding Source: Medline; NIGMS NIH HHS [T32 GM07464] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; deSilva D, 1997, J BIOL CHEM, V272, P14208, DOI 10.1074/jbc.272.22.14208; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; EIDE D, 1992, J BIOL CHEM, V267, P20774; FRIEDEN B, 1976, EXP BIOL MED, V74, P505; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; Murphy MEP, 1997, PROTEIN SCI, V6, P761; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; WILLIAMS DM, 1974, AM J PHYSIOL, V227, P1094, DOI 10.1152/ajplegacy.1974.227.5.1094; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	13	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22415	22419		10.1074/jbc.273.35.22415	http://dx.doi.org/10.1074/jbc.273.35.22415			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712864	hybrid			2022-12-25	WOS:000075616600040
J	Li, LT; Kaplan, J				Li, LT; Kaplan, J			Defects in the yeast high affinity iron transport system result in increased metal sensitivity because of the increased expression of transporters with a broad transition metal specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE ENCODES; COPPER DETOXIFICATION; VACUOLAR FUNCTION; GENE; PROTEIN; MUTANTS; RESISTANCE; NRAMP2	Yeast with defects in vacuolar pH show increased sensitivity to high concentrations of transition metals. This sensitivity has been presumed to result from defective metal storage. We demonstrate that mutations that result in a defective high affinity iron transport system, such as a deletion in the surface ferroxidase FET3, also result in increased metal sensitivity independent of vacuolar function. Multiple copies of transition metal transporter resistance genes, such as COTI or ZRC1, do not reduce the metal sensitivity of fet3 mutations. Increased metal sensitivity is because of an increased cellular accumulation of transition metals resulting from the increased activity of low affinity iron transporters, such as FET4, that mediates the transport of other transition metals. In cells lacking a high affinity iron transport system, the increased transition metal uptake can be prevented by increased extracellular iron. These results suggest that vacuolar function may not be required for transition metal sequestration.	Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA.				NCI NIH HHS [CA 42014] Funding Source: Medline; NIDDK NIH HHS [DK-30534] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030534, R01DK030534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMBERG DC, 1995, YEAST, V11, P1275, DOI 10.1002/yea.320111307; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BODE HP, 1995, EUR J BIOCHEM, V228, P337; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; DIX DR, 1994, J BIOL CHEM, V269, P26092; EIDE DJ, 1993, MOL GEN GENET, V241, P447, DOI 10.1007/BF00284699; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Gaxiola RA, 1998, P NATL ACAD SCI USA, V95, P4046, DOI 10.1073/pnas.95.7.4046; GREENE JR, 1993, MOL GEN GENET, V241, P542, DOI 10.1007/BF00279896; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; KITAMOTO K, 1988, J BACTERIOL, V170, P2687, DOI 10.1128/jb.170.6.2687-2691.1988; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Liu XF, 1997, J BIOL CHEM, V272, P11763, DOI 10.1074/jbc.272.18.11763; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; Radisky DC, 1997, P NATL ACAD SCI USA, V94, P5662, DOI 10.1073/pnas.94.11.5662; Ramsay LM, 1997, FEMS MICROBIOL LETT, V152, P293, DOI 10.1016/S0378-1097(97)00213-9; Sambrook J., 2002, MOL CLONING LAB MANU; SHERMAN F, 1989, METHODS YEAST GENETI; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Szczypka MS, 1997, YEAST, V13, P1423, DOI 10.1002/(SICI)1097-0061(199712)13:15<1423::AID-YEA190>3.3.CO;2-3; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	30	132	139	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22181	22187		10.1074/jbc.273.35.22181	http://dx.doi.org/10.1074/jbc.273.35.22181			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712830	hybrid			2022-12-25	WOS:000075616600006
J	Sastre, M; Turner, RS; Levy, E				Sastre, M; Turner, RS; Levy, E			X11 interaction with beta-amyloid precursor protein modulates its cellular stabilization and reduces amyloid beta-protein secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; ALZHEIMERS-DISEASE; HIPPOCAMPAL-NEURONS; CYTOPLASMIC DOMAIN; NEURITE OUTGROWTH; TRANSGENIC MICE; DISTINCT SITES; GROWTH-FACTOR; FE65 PROTEIN; PC12 CELLS	The protein interaction domain of the neuronal protein X11 binds to the YENPTY motif within the cytoplasmic domain of beta-amyloid precursor protein (beta APP). Amyloid-beta protein (A beta), the major constituent of the amyloid deposited in brain of Alzheimer's disease patients, is generated by proteolytic processing of beta APP, which occurs in part following beta APP internalization. Because the YENPTY motif has a role in the internalization of beta APP, the effect of X11 binding on beta APP processing was studied in mouse neuroblastoma N2a, human embryonic kidney 293, monkey kidney COS-1, and human glial U251 cell lines transfected with wild type or mutated beta APP cDNAs. Secretion of soluble beta APP via alpha-secretase activity increased significantly in cells transfected with beta APP variants containing mutations that impair interaction with X11 when compared with cells transfected with wild type cDNA Cotransfection of beta APP and X11 caused retention of cellular beta APP, decreased secretion of s beta APP alpha, and decreased AP secretion. Thus, beta APP interaction with the protein interaction domain of X11 stabilizes cellular beta APP and thereby participates in the regulation of beta APP processing pathways.	NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA; NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; Univ Michigan, Med Ctr, Dept Neurol, Ann Arbor, MI 48109 USA	New York University; New York University; University of Michigan System; University of Michigan	Levy, E (corresponding author), NYU, Med Ctr, Dept Pharmacol, 550 1st Ave, New York, NY 10016 USA.		Turner, Raymond Scott/G-2263-2011	Turner, Raymond Scott/0000-0001-7534-2935	NATIONAL INSTITUTE ON AGING [P50AG008671, R01AG013705] Funding Source: NIH RePORTER; NIA NIH HHS [P50 AG008671, AG13705] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; DYRKS T, 1994, FEBS LETT, V349, P210, DOI 10.1016/0014-5793(94)00671-7; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FARAONIO R, 1994, NUCLEIC ACIDS RES, V22, P4876, DOI 10.1093/nar/22.23.4876; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Koo EH, 1997, MOL MED, V3, P204, DOI 10.1007/BF03401673; KOO EH, 1994, J BIOL CHEM, V269, P17386; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; LARNER AJ, 1995, BIOESSAYS, V17, P819, DOI 10.1002/bies.950170912; LEBLANC AC, 1994, BIOCHEM BIOPH RES CO, V204, P1371, DOI 10.1006/bbrc.1994.2615; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1994, J NEUROBIOL, V25, P439, DOI 10.1002/neu.480250409; McLoughlin DM, 1996, FEBS LETT, V397, P197; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; NINOMIYA H, 1993, J CELL BIOL, V121, P879, DOI 10.1083/jcb.121.4.879; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; Peraus GC, 1997, J NEUROSCI, V17, P7714; QIU WQ, 1995, J NEUROSCI, V15, P2157, DOI 10.1523/JNEUROSCI.15-03-02157.1995; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHDOJI M, 1992, SCIENCE, V258, P126; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; VASILAKOS JP, 1994, FEBS LETT, V354, P289, DOI 10.1016/0014-5793(94)01142-7; Wei LH, 1998, J BIOL CHEM, V273, P11806, DOI 10.1074/jbc.273.19.11806; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; Yamazaki T, 1996, J CELL SCI, V109, P999; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141	62	127	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22351	22357		10.1074/jbc.273.35.22351	http://dx.doi.org/10.1074/jbc.273.35.22351			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712855	hybrid			2022-12-25	WOS:000075616600031
J	Berg, TO; Fengsrud, M; Stromhaug, PE; Berg, T; Seglen, PO				Berg, TO; Fengsrud, M; Stromhaug, PE; Berg, T; Seglen, PO			Isolation and characterization of rat liver amphisomes - Evidence for fusion of autophagosomes with both early and late endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VINBLASTINE-INDUCED AUTOPHAGOCYTOSIS; LYSOSOMAL ACID-PHOSPHATASE; CATHEPSIN-C SUBSTRATE; PROTEIN-DEGRADATION; ENDOCYTIC PATHWAYS; MOUSE-LIVER; ASIALOGLYCOPROTEIN ENDOCYTOSIS; PRELYSOSOMAL COMPARTMENT; HEPATOCYTIC AUTOPHAGY; LEUPEPTIN TREATMENT	Amphisomes, the autophagic vacuoles (AVs) formed upon fusion between autophagosomes and endosomes, have so far only been characterized in indirect, functional terms. To enable a physical distinction between autophagosomes and amphisomes, the latter were selectively density-shifted in sucrose gradients following fusion with AOM-gold-loaded endosomes (endosomes made dense by asialoorosomucoid-conjugated gold particles, endocytosed by isolated rat hepatocytes prier to subcellular fractionation). Whereas amphisomes, by this criterion, accounted for only a minor fraction of the AVs in control hepatocytes, treatment of the cells with leupeptin (an inhibitor of lysosomal protein degradation) caused an accumulation of amphisomes to about one-half of the AV population. A quantitative electron microscopic study confirmed that leupeptin induced a severalfold increase in the number of hepatocytic amphi somes (recognized by their gold particle contents; otherwise, their ultrastructure was quite similar to autophagosomes), Leupeptin caused, furthermore, a selective retention of endocytosed AOM-gold in the amphisomes at the expense of the lysosomes, consistent with an inhibition of amphisome-lysosome fusion. The electron micrographs suggested that autophagosomes could undergo multiple independent fusions, with multivesicular (late) endosomes to form amphisomes and with small lysosomes to form large autolysosomes. A biochemical comparison between autophagosomes and amphisomes, purified by a novel procedure, showed that the amphisomes were enriched in early endosome markers (the asialoglycoprotein receptor and the early endosome-associated protein I) as well as in a late endosome marker (the cation-independent mannose 6-phosphate receptor). Amphisomes would thus seem to be capable of receiving inputs both from early and late endosomes.	Norwegian Radium Hosp, Dept Cell Biol, Inst Canc Res, N-0310 Oslo, Norway; Univ Oslo, Dept Biol, Div Mol Cell Biol, N-0316 Oslo, Norway	University of Oslo; University of Oslo	Seglen, PO (corresponding author), Norwegian Radium Hosp, Dept Cell Biol, Inst Canc Res, N-0310 Oslo, Norway.		Brinchmann, Monica Fengsrud/C-2916-2012	Brinchmann, Monica Fengsrud/0000-0002-1222-0743				Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; ARSTILA AU, 1968, AM J PATHOL, V53, P687; BERG T, 1985, EXP CELL RES, V161, P285, DOI 10.1016/0014-4827(85)90086-2; BERG TO, 1994, BIOCHEM J, V300, P229, DOI 10.1042/bj3000229; BERG TO, 1994, EUR J BIOCHEM, V221, P595, DOI 10.1111/j.1432-1033.1994.tb18771.x; BERGMEYER HU, 1974, METHODEN ENZYMATISCH; BERTHIAUME EP, 1995, J CELL BIOL, V129, P989, DOI 10.1083/jcb.129.4.989; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; BOLENDER RP, 1973, J CELL BIOL, V56, P746, DOI 10.1083/jcb.56.3.746; COURTOY PJ, 1984, J CELL BIOL, V98, P870, DOI 10.1083/jcb.98.3.870; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1979, J BIOL CHEM, V254, P4191; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; ERICSSON JL, 1969, EXP CELL RES, V56, P393, DOI 10.1016/0014-4827(69)90030-5; FENGSRUD M, 1995, EXP CELL RES, V221, P504, DOI 10.1006/excr.1995.1402; FERRIS AL, 1987, J CELL BIOL, V105, P2703, DOI 10.1083/jcb.105.6.2703; FURUNO K, 1982, J BIOCHEM-TOKYO, V91, P1485, DOI 10.1093/oxfordjournals.jbchem.a133840; FURUNO K, 1990, EXP CELL RES, V189, P261, DOI 10.1016/0014-4827(90)90245-6; FUTTER CE, 1989, J CELL SCI, V94, P685; GORDON PB, 1992, BIOCHEM J, V283, P361, DOI 10.1042/bj2830361; GORDON PB, 1987, BIOCHEM J, V243, P655, DOI 10.1042/bj2430655; GORDON PB, 1988, BIOCHEM BIOPH RES CO, V151, P40, DOI 10.1016/0006-291X(88)90556-6; GORDON PB, 1982, EXP CELL RES, V142, P1, DOI 10.1016/0014-4827(82)90402-5; GRIFFITHS G, 1990, J CELL SCI, V95, P441; GRINDE B, 1981, H-S Z PHYSIOL CHEM, V362, P549, DOI 10.1515/bchm2.1981.362.1.549; HIMENO M, 1991, BIOCHEM BIOPH RES CO, V180, P1483, DOI 10.1016/S0006-291X(05)81363-4; HOLEN I, 1995, J BIOL CHEM, V270, P12823, DOI 10.1074/jbc.270.21.12823; HOLEN I, 1995, BIOCHEM J, V311, P317, DOI 10.1042/bj3110317; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HOYVIK H, 1991, J CELL BIOL, V113, P1305, DOI 10.1083/jcb.113.6.1305; HOYVIK H, 1986, EXP CELL RES, V166, P1, DOI 10.1016/0014-4827(86)90503-3; HOYVIK H, 1987, BIOCHEM SOC T, V15, P964, DOI 10.1042/bst0150964; ISHIKAWA T, 1983, EXP CELL RES, V144, P15, DOI 10.1016/0014-4827(83)90436-6; KOLSET SO, 1979, EXP CELL RES, V122, P159, DOI 10.1016/0014-4827(79)90570-6; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOVACS AL, 1982, EXP CELL RES, V137, P191, DOI 10.1016/0014-4827(82)90020-9; LAWRENCE BP, 1992, J CELL SCI, V102, P515; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; LUIKEN JJFP, 1992, FEBS LETT, V304, P93, DOI 10.1016/0014-5793(92)80596-9; MARZELLA L, 1908, LYSOSOMES THEIR ROLE, P319; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; MULLOCK BM, 1994, J CELL BIOL, V126, P1173, DOI 10.1083/jcb.126.5.1173; PFEIFER U, 1978, J CELL BIOL, V78, P152, DOI 10.1083/jcb.78.1.152; Pfeifer U., 1987, LYSOSOMES THEIR ROLE, P3; PUNNONEN EL, 1993, EUR J CELL BIOL, V61, P54; PUNNONEN EL, 1989, CELL TISSUE RES, V258, P269; RABOUILLE C, 1993, J CELL BIOL, V120, P897, DOI 10.1083/jcb.120.4.897; REUNANEN H, 1985, HISTOCHEMISTRY, V83, P513, DOI 10.1007/BF00492453; REUNANEN H, 1983, HISTOCHEMISTRY, V79, P59, DOI 10.1007/BF00494342; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; SEGLEN O, 1975, BIOCHEM BIOPH RES CO, V66, P44, DOI 10.1016/S0006-291X(75)80292-0; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SEGLEN PO, 1985, EXP CELL RES, V157, P550, DOI 10.1016/0014-4827(85)90141-7; SEGLEN PO, 1977, EXP CELL RES, V107, P207, DOI 10.1016/0014-4827(77)90402-5; SEGLEN PO, 1986, BIOMED BIOCHIM ACTA, V45, P1647; SEGLEN PO, 1980, MOL PHARMACOL, V18, P468; SEGLEN PO, 1979, EUR J BIOCHEM, V95, P215, DOI 10.1111/j.1432-1033.1979.tb12956.x; SEGLEN PO, 1976, EXP CELL RES, V100, P276, DOI 10.1016/0014-4827(76)90148-8; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Seglen PO, 1987, LYSOSOMES THEIR ROLE, P369; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; STROMHAUG PE, 1993, BIOCHEM J, V291, P115, DOI 10.1042/bj2910115; TOLLESHAUG H, 1979, BIOCHIM BIOPHYS ACTA, V585, P71, DOI 10.1016/0304-4165(79)90326-X; TOLLESHAUG H, 1981, EXP CELL RES, V134, P207, DOI 10.1016/0014-4827(81)90478-X; TOOZE J, 1990, J CELL BIOL, V111, P329, DOI 10.1083/jcb.111.2.329; VANDYKE RW, 1993, AM J PHYSIOL, V265, pC901, DOI 10.1152/ajpcell.1993.265.4.C901; YOKOTA S, 1995, EUR J CELL BIOL, V66, P15; ZACHGO S, 1992, J CELL SCI, V103, P811	74	287	295	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21883	21892		10.1074/jbc.273.34.21883	http://dx.doi.org/10.1074/jbc.273.34.21883			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705327	hybrid			2022-12-25	WOS:000075492600061
J	Schmidt, PP; Rova, U; Katterle, B; Thelander, L; Graslund, A				Schmidt, PP; Rova, U; Katterle, B; Thelander, L; Graslund, A			Kinetic evidence that a radical transfer pathway in protein R2 of mouse ribonucleotide reductase is involved in generation of the tyrosyl free radical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HERPES-SIMPLEX VIRUS; ESCHERICHIA-COLI; ELECTRON-TRANSFER; RADICAL-DIIRON(III) COFACTOR; MOSSBAUER SPECTROSCOPIES; 3-DIMENSIONAL STRUCTURE; FE2+ REACTION; SUBUNIT; EPR	Class I ribonucleotide reductases consist of two subunits, R1 and R2, The active site is located in B1; active R2 contains a diferric center and a tyrosyl free radical (Tyr(.)), both essential for enzymatic activity. The proposed mechanism for the enzymatic reaction includes the transport of a reducing equivalent, i.e. electron or hydrogen radical, across a 35-Angstrom distance between Tyr(.) in R2 and the active site in R1, which are connected by a hydrogen-bonded chain of conserved, catalytically essential amino acid residues. Asp(266) and Trp(103) in mouse R2 are part of this radical transfer pathway. The differic/Tyr(.) site in R2 is reconstituted spontaneously by mixing iron-free apoR2 with Fe(II) and O-2. The reconstitution reaction requires the delivery of an external reducing equivalent to form the diferric/Tyr(.) site. Reconstitution kinetics were investigated in mouse ape-wild type R2 and the three mutants D266A, W103Y, and W103F by rapid freeze-quench electron paramagnetic resonance with greater than or equal to 4 Fe(II)/R2 at various reaction temperatures. The kinetics of Tyr(.) formation in D266A and W103Y is on average 20 times slower than in wild type R2, More strikingly, Tyr(.) formation is completely suppressed in W103F, No change in the reconstitution kinetics was found starting from Fe(II)-preloaded proteins, which shows that the mutations do not affect the rate of iron binding. Our results are consistent with a reaction mechanism using Asp266 and Trp(103) for delivery of the external reducing equivalent. Further, the results with W103F suggest that an intact hydrogen-bonded chain is crucial for the reaction, indicating that the external reducing equivalent is a H-.. Finally, the formation of Tyr(.) is not the slowest step of the reaction as it is in Escherichia coli R2, consistent with a stronger interaction between Tyr(.) and the iron center in mouse R2, A new electron paramagnetic resonance visible intermediate named mouse X, strikingly similar to species X found in E. coli R2, was detected only in small amounts under certain conditions. We propose that it may be an intermediate in a side reaction leading to a diferric center without forming the neighboring Tyr ..	Univ Stockholm, Dept Biophys, S-10691 Stockholm, Sweden; Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden; Univ Stockholm, Dept Mol Biol, S-10691 Stockholm, Sweden	Stockholm University; Umea University; Stockholm University	Graslund, A (corresponding author), Univ Stockholm, Dept Biophys, S-10691 Stockholm, Sweden.							ABERG A, 1993, BIOCHEMISTRY-US, V32, P9845; ATTA M, 1994, J AM CHEM SOC, V116, P6429, DOI 10.1021/ja00093a051; Ballou D P, 1978, Methods Enzymol, V54, P85; BENDER CJ, 1989, J AM CHEM SOC, V111, P8076, DOI 10.1021/ja00203a002; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8015, DOI 10.1021/ja00097a008; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8024, DOI 10.1021/ja00097a009; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; Davydov R, 1996, BIOCHEMISTRY-US, V35, P5571, DOI 10.1021/bi952836y; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Edmondson DE, 1996, INORG CHIM ACTA, V252, P399, DOI 10.1016/S0020-1693(96)05427-8; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; GERFEN GJ, 1993, J AM CHEM SOC, V115, P6420, DOI 10.1021/ja00067a071; Graslund A, 1996, ANNU REV BIOPH BIOM, V25, P259; HALES BJ, 1993, METHOD ENZYMOL, V227, P384; Katterle B, 1997, J BIOL CHEM, V272, P10414; Kauppi B, 1996, J MOL BIOL, V262, P706, DOI 10.1006/jmbi.1996.0546; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; OCHIAI EI, 1990, J BIOL CHEM, V265, P15758; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; SAHLIN M, 1995, J BIOL CHEM, V270, P12361, DOI 10.1074/jbc.270.21.12361; Schmidt PP, 1996, J BIOL CHEM, V271, P23615, DOI 10.1074/jbc.271.39.23615; Shu LJ, 1997, SCIENCE, V275, P515, DOI 10.1126/science.275.5299.515; Siegbahn PEM, 1997, THEOR CHEM ACC, V97, P289, DOI 10.1007/s002140050264; Sjoberg B. M., 1995, NUCLEIC ACIDS MOL BI, V9, P192; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; Sturgeon BE, 1996, J AM CHEM SOC, V118, P7551, DOI 10.1021/ja960399k; THELANDER L, 1994, MET IONS BIOL SYST, V30, P109; Tong WH, 1996, J AM CHEM SOC, V118, P2107, DOI 10.1021/ja952764y; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; van Dam PJ, 1998, J AM CHEM SOC, V120, P5080, DOI 10.1021/ja9737127; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; [No title captured]	38	52	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21463	21472		10.1074/jbc.273.34.21463	http://dx.doi.org/10.1074/jbc.273.34.21463			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705274	hybrid			2022-12-25	WOS:000075492600008
J	Sakakibara, M; Inoue, H; Yoshioka, T				Sakakibara, M; Inoue, H; Yoshioka, T			Evidence for the involvement of inositol trisphosphate but not cyclic nucleotides in visual transduction in Hermissenda eye	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMULUS VENTRAL PHOTORECEPTORS; INVERTEBRATE PHOTORECEPTORS; PHOSPHOLIPASE-C; SQUID PHOTORECEPTORS; ION CHANNELS; EXCITATION; LIGHT; DROSOPHILA; CALCIUM; PHOTOTRANSDUCTION	Although several second messengers are known to be involved in invertebrate photoresponses, the mechanism underlying invertebrate phototransduction remains unclear. In the present study, brief injection of inositol trisphosphate into Hermissenda photoreceptors induced a transient Na+ current followed by burst activity, which accurately reproduced the native photoresponse. Injection of Ca2+ did not induce a significant change in the membrane potential but potentiated the native photoresponse, Injection of a Ca2+ chelator decreased the response amplitude and increased the response latency. Injection of cGMP induced a Ca2+-dependent, transient depolarization with a short latency. cAMP injection evoked Na+-dependent action potentials without a rise in membrane potential. Taken together, these results suggest that phototransduction in Hermissenda is mediated by Na+ channels that are directly activated by inositol trisphosphate without mobilization of cytosolic Ca2+.	Tokai Univ, Dept Biol Sci & Technol, Sch High Technol Human Welf, Numazu 41003, Japan; Waseda Univ, Dept Mol Neurobiol, Sch Human Sci, Tokorozawa, Saitama 359, Japan	Tokai University; Waseda University	Sakakibara, M (corresponding author), Tokai Univ, Dept Biol Sci & Technol, Sch High Technol Human Welf, Numazu 41003, Japan.							Acharya JK, 1997, NEURON, V18, P881, DOI 10.1016/S0896-6273(00)80328-1; ALKON DL, 1973, J GEN PHYSIOL, V61, P444, DOI 10.1085/jgp.61.4.444; ALKON DL, 1972, J GEN PHYSIOL, V60, P631, DOI 10.1085/jgp.60.6.631; ALKON DL, 1978, J NEUROPHYSIOL, V41, P1328, DOI 10.1152/jn.1978.41.5.1328; ALKON DL, 1976, J GEN PHYSIOL, V67, P197, DOI 10.1085/jgp.67.2.197; ALKON DL, 1985, BIOPHYS J, V48, P983, DOI 10.1016/S0006-3495(85)83861-3; BACIGALUPO J, 1991, P NATL ACAD SCI USA, V88, P7938, DOI 10.1073/pnas.88.18.7938; BACIGALUPO J, 1995, J NEUROSCI, V15, P7196; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOLSOVER SR, 1985, J PHYSIOL-LONDON, V364, P381, DOI 10.1113/jphysiol.1985.sp015751; BROWN JE, 1992, EXP EYE RES, V54, P403, DOI 10.1016/0014-4835(92)90052-T; BROWN JE, 1984, J PHYSIOL-LONDON, V353, P523, DOI 10.1113/jphysiol.1984.sp015349; BROWN JE, 1984, NATURE, V311, P160, DOI 10.1038/311160a0; BROWN JE, 1987, BIOCHEM J, V247, P293, DOI 10.1042/bj2470293; DENNIS M J, 1967, Journal of Neurophysiology (Bethesda), V30, P1439; DETWILER PB, 1976, J PHYSIOL-LONDON, V256, P691, DOI 10.1113/jphysiol.1976.sp011346; ETCHEBERRIGARAY R, 1991, J EXP BIOL, V156, P619; FADDIS MN, 1993, J GEN PHYSIOL, V101, P909, DOI 10.1085/jgp.101.6.909; FEIN A, 1984, NATURE, V311, P157, DOI 10.1038/311157a0; FENG JJ, 1991, BRAIN RES, V552, P291, DOI 10.1016/0006-8993(91)90094-C; FRANK TM, 1991, J GEN PHYSIOL, V97, P697, DOI 10.1085/jgp.97.4.697; GOMEZ MD, 1995, NEURON, V15, P607, DOI 10.1016/0896-6273(95)90149-3; GROSSMAN Y, 1981, COMP BIOCHEM PHYS A, V68, P487, DOI 10.1016/0300-9629(81)90079-7; HARDIE RC, 1995, J NEUROSCI, V15, P889; HARDIE RC, 1993, NATURE, V366, P113, DOI 10.1038/366113a0; HATT H, 1994, P NATL ACAD SCI USA, V91, P6264, DOI 10.1073/pnas.91.14.6264; Honda E, 1995, BRAIN RES, V703, P79, DOI 10.1016/0006-8993(95)01072-6; INOUE H, 1985, BIOCHEM BIOPH RES CO, V132, P513, DOI 10.1016/0006-291X(85)91163-5; JOHNSON EC, 1986, NATURE, V324, P468, DOI 10.1038/324468a0; JOHNSON EC, 1995, J NEUROSCI, V15, P6586; LEVY S, 1985, J GEN PHYSIOL, V85, P805, DOI 10.1085/jgp.85.6.805; MCKAY RR, 1995, J BIOL CHEM, V270, P13271, DOI 10.1074/jbc.270.22.13271; NAGY K, 1991, Q REV BIOPHYS, V24, P165, DOI 10.1017/S0033583500003401; NOMURA K, 1990, J MEMBRANE BIOL, V115, P241, DOI 10.1007/BF01868639; ODAY PM, 1989, J GEN PHYSIOL, V93, P473, DOI 10.1085/jgp.93.3.473; PAK WL, 1991, PHOTOCHEM PHOTOBIOL, V53, P871, DOI 10.1111/j.1751-1097.1991.tb09901.x; PAYNE R, 1986, J GEN PHYSIOL, V88, P107, DOI 10.1085/jgp.88.1.107; PAYNE R, 1986, J GEN PHYSIOL, V87, P243, DOI 10.1085/jgp.87.2.243; PAYNE R, 1986, J GEN PHYSIOL, V88, P127, DOI 10.1085/jgp.88.1.127; SAIBIL HR, 1984, FEBS LETT, V168, P213, DOI 10.1016/0014-5793(84)80248-3; SAKAKIBARA M, 1994, BIOCHEM BIOPH RES CO, V202, P299, DOI 10.1006/bbrc.1994.1927; SHIN JH, 1993, NEURON, V11, P845, DOI 10.1016/0896-6273(93)90114-7; SOMASUNDARAM B, 1995, J BIOL CHEM, V270, P16638, DOI 10.1074/jbc.270.28.16638; STEIVE H, 1992, VISION RES, V32, P403; SZUTS EZ, 1986, BIOCHEM J, V240, P929, DOI 10.1042/bj2400929; TAKEDA T, 1982, VISION RES, V22, P303, DOI 10.1016/0042-6989(82)90130-4; THIO CL, 1993, J NEUROSCI, V13, P4889; TOYOSHIMA S, 1990, J BIOL CHEM, V265, P14842; UKHANOV KY, 1995, J GEN PHYSIOL, V105, P95, DOI 10.1085/jgp.105.1.95; WECKSTROM M, 1988, ACTA PHYSIOL SCAND, V132, P103, DOI 10.1111/j.1748-1716.1988.tb08303.x; WOOD SF, 1989, J BIOL CHEM, V264, P12970; YOSHIOKA T, 1983, BIOCHEM BIOPH RES CO, V111, P567, DOI 10.1016/0006-291X(83)90344-3; YOSHIOKA T, 1983, BIOCHIM BIOPHYS ACTA, V755, P50, DOI 10.1016/0304-4165(83)90271-4	53	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20795	20801		10.1074/jbc.273.33.20795	http://dx.doi.org/10.1074/jbc.273.33.20795			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694824	hybrid			2022-12-25	WOS:000075386100017
J	Eckhardt, M; Gotza, B; Gerardy-Schahn, R				Eckhardt, M; Gotza, B; Gerardy-Schahn, R			Mutants of the CMP-sialic acid transporter causing the Lec2 phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-MANNOSIDASE-II; MOLECULAR-CLONING; ENDOPLASMIC-RETICULUM; GLYCOSYLATION MUTANTS; GOLGI-APPARATUS; SIALYLATION; TOPOGRAPHY; EXPRESSION; DEFICIENT; GALACTOSE	Chinese hamster ovary (CHO) mutants belonging to the Lec2 complementation group are unable to translocate CMP-sialic acid to the lumen of the Golgi apparatus. Complementation cloning in these cells has recently been used to isolate cDNAs encoding the CMP-sialic acid transporter from mouse and hamster. The present study was carried out to determine the molecular defects leading to the inactivation of CMP-sialic acid transport, To this end, CMP-sialic acid transporter cDNAs derived from five independent clones of the Lec2 complementation group, were analyzed. Deletions in the coding region were observed for three clones, and single mutants were found to contain an insertion and a point mutation. Epitope-tagged variants of the wild-type transporter protein and of the mutants were used to investigate the effect of the structural changes on the expression and subcellular targeting of the transporter proteins. Mutants derived from deletions showed reduced protein expression and in immunofluorescence showed a diffuse staining throughout the cytoplasm in transiently transfected cells, while the translation product derived from the point mutated cDNA (G189E) was expressed at the level of the wild-type transporter and co-localized with the Golgi marker cu-mannosidase ll. This mutation therefore seems to directly affect the transport activity. Site-directed mutagenesis was used to change glycine 189 into alanine, glutamine, and isoleucine, respectively. While the G189A mutant was able to complement CMP-sialic acid transport-deficient Chinese hamster ovary mutants, the exchange of glycine 189 into glutamine or isoleucine dramatically affected the transport activity of the CMP-sialic acid transporter.	MHH, Inst Med Mikrobiol, D-30625 Hannover, Germany	Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf	Gerardy-Schahn, R (corresponding author), MHH, Inst Med Mikrobiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	rgs@mikrobio.h.shuttle.de						Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; Berninsone P, 1997, J BIOL CHEM, V272, P12616, DOI 10.1074/jbc.272.19.12616; Bresalier RS, 1996, GASTROENTEROLOGY, V110, P1354, DOI 10.1053/gast.1996.v110.pm8613039; BRILES EB, 1977, J BIOL CHEM, V252, P1107; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 1997, EUR J BIOCHEM, V248, P187, DOI 10.1111/j.1432-1033.1997.00187.x; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; Gorelik E, 1997, CANCER RES, V57, P332; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARVEY BE, 1992, CANCER RES, V52, P1775; HARVEY BE, 1993, BIOCHEM BIOPH RES CO, V190, P571, DOI 10.1006/bbrc.1993.1086; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; Hirschberg CB, 1996, SOC GEN PHY, V51, P105; Ishida N, 1996, J BIOCHEM, V120, P1074; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; ROST B, 1995, PROTEIN SCI, V4, P521; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITOH O, 1992, J BIOL CHEM, V267, P5700; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTER UV, 1989, EUR J BIOCHEM, V181, P249, DOI 10.1111/j.1432-1033.1989.tb14719.x; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; Tabuchi M, 1997, BIOCHEM BIOPH RES CO, V232, P121, DOI 10.1006/bbrc.1997.6239; TAKANO R, 1994, GLYCOBIOLOGY, V4, P665, DOI 10.1093/glycob/4.5.665; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VERBERT A, 1987, BIOCHIMIE, V69, P91, DOI 10.1016/0300-9084(87)90240-9	35	88	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20189	20195		10.1074/jbc.273.32.20189	http://dx.doi.org/10.1074/jbc.273.32.20189			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685366	hybrid			2022-12-25	WOS:000075305400043
J	Hyytiainen, M; Taipale, J; Heldin, CH; Keski-Oja, J				Hyytiainen, M; Taipale, J; Heldin, CH; Keski-Oja, J			Recombinant latent transforming growth factor beta-binding protein 2 assembles to fibroblast extracellular matrix and is susceptible to proteolytic processing and release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONNECTIVE-TISSUE MICROFIBRILS; FACTOR-LIKE DOMAINS; MARFAN-SYNDROME; CALCIUM-BINDING; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; TGF-BETA; FIBRILLIN; COMPONENT; GENE	Latent transforming growth factor P-binding protein 2 (LTBP-2) belongs to the fibrillin-LTBP gene family and is a component of 10-nm microfibrils. LTBP-2 consists mainly of domains of 8-cysteine and EGF-Like repeats linked by proline-rich regions. To characterize the biochemical properties of LTBP-2, its assembly to the extracellular matrix, and its proteolytic release from the matrix, LTBP-2 was expressed recombinantly in Chinese hamster ovary cells and purified to homogeneity under nondenaturing conditions. Purified LTBP-2 bound calcium and was glycosylated at the central domain of EGF-like repeats. Antibodies made against the recombinant LTBP-2 decorated fibrillar structures in fibroblast extracellular matrix. Treatment of matrices with plasmin or elastase released a soluble similar to 160-kDa LTBP-2 fragment. Processing of LTBP-2 was studied by treating purified LTBP-2 with plasmin or porcine pancreatic elastase. LTBP-2 was processed with these proteases initially to a similar to 160-kDa fragment, and with higher concentrations to a protease-resistant similar to 120-kDa fragment. Processing sites were localized by amino acid sequencing to proline-rich regions at the N-terminal part of LTBP-2, suggesting that the matrix binding sites locate to the N-terminal similar to 500 amino acids of LTBP-2. Purified and biotinylated LTBP-2 could be assembled to fibrillar structures in fibroblast extracellular matrix during cell cultivation, indicating that LTBP-2 assembly to the matrix is not strictly linked to cells that make it and suggesting that microfibril assembly may involve soluble intermediates.	Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	University of Helsinki; Ludwig Institute for Cancer Research	Keski-Oja, J (corresponding author), Univ Helsinki, Haartman Inst, Dept Virol, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.							DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539; DAVIS EC, 1994, J CELL SCI, V107, P727; DAVIS EC, 1993, CELL TISSUE RES, V272, P211, DOI 10.1007/BF00302726; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HORRIGAN SK, 1992, J BIOL CHEM, V267, P10087; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KIELTY CM, 1994, FEBS LETT, V351, P85, DOI 10.1016/0014-5793(94)00818-3; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MOREN A, 1994, J BIOL CHEM, V269, P32469; Nakajima Y, 1997, J CELL BIOL, V136, P193, DOI 10.1083/jcb.136.1.193; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; Olofsson A, 1995, J BIOL CHEM, V270, P31294, DOI 10.1074/jbc.270.52.31294; Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097-218; Peters D. M. P., 1994, EXTRACELLULAR MATRIX, P315; PROCKOP DJ, 1994, EXTRACELLULAR MATRIX, P47; PUTNAM EA, 1995, NAT GENET, V11, P456, DOI 10.1038/ng1295-456; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; Saharinen J, 1998, J BIOL CHEM, V273, P18459, DOI 10.1074/jbc.273.29.18459; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sakamoto H, 1996, J BIOL CHEM, V271, P4916; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	43	60	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20669	20676		10.1074/jbc.273.32.20669	http://dx.doi.org/10.1074/jbc.273.32.20669			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685426	hybrid			2022-12-25	WOS:000075305400103
J	Zambrano, N; Minopoli, G; de Candia, P; Russo, T				Zambrano, N; Minopoli, G; de Candia, P; Russo, T			The Fe65 adaptor protein interacts through its PID1 domain with the transcription factor CP2/LSF/LBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; BINDING DOMAIN; DNA-BINDING; IN-VITRO; MOTIF; SHC; PHOSPHORYLATION; ASSOCIATION; DISTINCT	The neural protein Fe65 possesses three putative protein-protein interaction domains: one WRY domain and two phosphotyrosine interaction/phosphotyrosine binding domains (PID1 and PID2); the most C-terminal of these domains (PHD2) interacts in vivo with the Alzheimer's beta-amyloid precursor protein, whereas the WW domain binds to Mena, the mammalian homolog of Drosophila-enabled protein. By the interaction trap procedure, we isolated a cDNA clone encoding a possible ligand of the N-terminal PID/PTB domain of Fe65 (PID1), Sequence analysis of this clone revealed that this ligand corresponded to the previously identified transcription factor CP2/LSF/LBP1, Co-immunoprecipitation experiments demonstrated that the interaction between Fe65 and CP2/LSF/LBP1 also takes place in vivo between the native molecules. The localization of both proteins was studied using fractionated cellular extracts. These experiments demonstrated that the various isoforms of CP2/LSF/LBP1 are differently distributed among subcellular fractions. At least one isoform, derived from alternative splicing (LSF-ID), is present outside the nucleus; Fe65 was found in both fractions. Furthermore, transfection experiments with an HA-tagged CP2/LSF/LBP1 cDNA demonstrated that Fe65 interacts also with the nuclear form of CP2/LSF/LBP1. Considering that the analysis of Fe65 distribution in fractionated cell extracts demonstrated that this protein is present both in nuclear and non-nuclear fractions, we examined the expression of Fe65 deletion mutants in the two fractions. This analysis allowed us to observe that a small region N-terminal to the WW domain is phosphorylated and is necessary for the presence of Fe65 in the nuclear fraction.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy	University of Naples Federico II	Russo, T (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.		de Candia, Paola/HGC-8826-2022; Russo, Tommaso/K-1331-2016; Zambrano, Nicola/B-9352-2014; de Candia, Paola/Z-1498-2019	de Candia, Paola/0000-0003-4767-446X; Russo, Tommaso/0000-0003-4426-0106; Zambrano, Nicola/0000-0001-9395-3481; de Candia, Paola/0000-0003-4767-446X	Telethon [E.0522] Funding Source: Medline	Telethon(Fondazione Telethon)		ADAM LP, 1993, FEBS LETT, V322, P56, DOI 10.1016/0014-5793(93)81110-L; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Chow NW, 1996, J BIOL CHEM, V271, P11339, DOI 10.1074/jbc.271.19.11339; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; FARAONIO R, 1994, NUCLEIC ACIDS RES, V22, P4876, DOI 10.1093/nar/22.23.4876; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; FIORE F, 1995, CELL CYCLE MATERIALS, P211; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Giambarella U, 1997, EMBO J, V16, P4897, DOI 10.1093/emboj/16.16.4897; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Li JH, 1995, P NATL ACAD SCI USA, V92, P12180, DOI 10.1073/pnas.92.26.12180; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; ONODA K, 1993, J BIOL CHEM, V268, P4106; PARADA CA, 1995, J BIOL CHEM, V270, P2274, DOI 10.1074/jbc.270.5.2274; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; QUINTO I, 1993, J BIOL CHEM, V268, P26719; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHIRRA MK, 1994, MOL CELL BIOL, V14, P5076, DOI 10.1128/MCB.14.8.5076; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SIMEONE A, 1994, DEV NEUROSCI-BASEL, V16, P53, DOI 10.1159/000112088; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Volker JL, 1997, GENE DEV, V11, P1435, DOI 10.1101/gad.11.11.1435; WINEY M, 1993, J CELL BIOL, V122, P743, DOI 10.1083/jcb.122.4.743; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399	43	136	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20128	20133		10.1074/jbc.273.32.20128	http://dx.doi.org/10.1074/jbc.273.32.20128			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685356	hybrid			2022-12-25	WOS:000075305400033
J	Huang, JH; Logsdon, N; Schmieg, FI; Simmons, DT				Huang, JH; Logsdon, N; Schmieg, FI; Simmons, DT			p53-mediated transcription induces resistance of DNA to UV inactivation	ONCOGENE			English	Article						p53; DNA repair; transcriptional activation; genetic reactivation	WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; CELL NUCLEAR ANTIGEN; LI-FRAUMENI SYNDROME; TUMOR-SUPPRESSOR; PYRIMIDINE DIMER; GENE-PRODUCT; HOMOLOGOUS RECOMBINATION	A possible role of p53-dependent transcription in the induction of DIVA repair was explored by transfecting a UV-irradiated chloramphenicol acetyl transferase (CAT) reporter plasmid (pRGC.FOS.CAT), containing a minimal FOS promoter driven by a consensus p53 binding site, into a p53 negative-mouse cell line [(10)1], When a p53-expressing plasmid (pSV.p53) was cotransfected into these cells, CAT expression levels persisted even after prolonged UV irradiation. In comparison, CAT expression from pSV2.CAT, which lacks a p53-responsive element in its SV40 promoter, dropped off much more precipitously after UV irradiation in the absence or presence of WT p53 expression. A similar sharp drop was observed with three other constructs when the reporter gene was under the control of the ras, beta-actin or fos promoter. Mouse cells (A1-5) that constitutively express a temperature-sensitive mutant (135 AV) of mouse p53 also generated, at 32 degrees C, higher levels of enzyme expressed from UV-irradiated pRGC,FOS,CAT than from UV-irradiated pSV2.CAT. The frequency of cyclobutane pyrimidine dimers in UV-irradiated pRGC,FOS,CAT was determined with T4 endo V, and the probability of having an undamaged CAT coding strand was calculated by the Poisson distribution for various times of UV-irradiation, The observed relative CAT expression levels from irradiated pSV2,CAT and pRGC,FOS,CAT in the absence of p53 were consistent with those numbers. These results show that WT p53-mediated transcription directs a resistance of the transcribed DNA to UV inactivation and reactivates the reporter gene. Furthermore, some single point substitution mutants of p53 that maintain a near normal ability to activate transcription had lost their ability to extend CAT gene expression after UV irradiation. Conversely, other mutants with reduced transcriptional activity retained this ability. This indicates that although resistance to UV inactivation is transcriptionally-dependent, these two activities are genetically distinct. These data, taken together, suggest that the transcription of UV-damaged DNA by a p53-dependent process promotes its repair.	Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA	University of Delaware	Simmons, DT (corresponding author), Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA.				NATIONAL CANCER INSTITUTE [R55CA055234] Funding Source: NIH RePORTER; NCI NIH HHS [CA55234] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTON NK, 1979, NATURE, V282, P864, DOI 10.1038/282864a0; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13465; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAVRE PA, 1995, CANCER RES, V55, P4420; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KERN SE, 1991, SCIENCE, V252, P1707; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li G, 1997, AM J PATHOL, V150, P1457; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LINK CJ, 1991, CANCER CELL-MON REV, V3, P427; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; MCKEEL KL, 1997, ONCOGENE, V14, P1847; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MIRZAYANS R, 1995, ONCOGENE, V11, P1597; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; NAKABEPPU Y, 1982, J BIOL CHEM, V257, P2556; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PROTIC M, 1988, SOMAT CELL MOLEC GEN, V14, P351, DOI 10.1007/BF01534643; PROTICSABLJIC M, 1985, P NATL ACAD SCI USA, V82, P6622, DOI 10.1073/pnas.82.19.6622; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; RADANY EH, 1980, NATURE, V286, P182, DOI 10.1038/286182a0; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SCHMIEG FI, 1993, ONCOGENE, V8, P2043; SELBY CP, 1994, MICROBIOL REV, V58, P317, DOI 10.1128/MMBR.58.3.317-329.1994; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wiesmuller L, 1996, J VIROL, V70, P737; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YUAN JL, 1995, CARCINOGENESIS, V16, P2295, DOI 10.1093/carcin/16.10.2295; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAO JQ, 1994, MOL CELL BIOL, V14, P8483, DOI 10.1128/MCB.14.12.8483	94	17	17	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	1998	17	4					401	411		10.1038/sj.onc.1201951	http://dx.doi.org/10.1038/sj.onc.1201951			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696032				2022-12-25	WOS:000075043000001
J	Crump, MP; Rajarathnam, K; Kim, KS; Clark-Lewis, I; Sykes, BD				Crump, MP; Rajarathnam, K; Kim, KS; Clark-Lewis, I; Sykes, BD			Solution structure of eotaxin, a chemokine that selectively recruits eosinophils in allergic inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; CC-CHEMOKINE; NEUTROPHIL ACTIVATION; MOLECULAR-CLONING; NMR ASSIGNMENTS; RECEPTOR; IDENTIFICATION; INTERLEUKIN-8; EXPRESSION; RANTES	The solution structure of the CCR3-specific chemokine, eotaxin, has been determined by NMR spectroscopy. The quaternary structure of eotaxin was investigated by ultracentrifugation and NMR, and it was found to be in equilibrium between monomer and dimer under a wide range of conditions. At pH less than or equal to 5 and low ionic strength, eotaxin was found to be predominantly a monomer, The three dimensional structure of the eotaxin monomer solved at pH 5.0 revealed that it has a typical chemokine fold, which includes a 3-stranded beta-sheet and an overlying alpha-helix, Except for the N-terminal residues (residues 1-8), the core of the protein is well defined. The eotaxin structure is compared with the chemokines regulated upon activation, normal T-cell expressed and secreted (RANTES) and monocyte chemoattractant protein-1 (MCP-1); eotaxin binds only CC chemokine receptor CCR3, whereas RANTES binds many receptors including CCR3, and MCP-1 binds a distinct receptor, CCR2. The RMSD of the eotaxin ensemble of structures with the RANTES average minimized monomeric subunit is 5.52 +/- 0.87 Angstrom over all backbone atoms and 1.14 +/- 0.09 Angstrom over backbone atoms of residues 11-28 and 34-65, The most important difference between the structures is in the N-terminal residues that are unstructured in eotaxin but structured in RANTES and MCP-1, Several residues in the loop region of RANTES show similar packing in eotaxin (residues 11-17), As the N-terminal and loop regions have been shown to be critical for receptor binding and signaling, this structure will be useful for determining the basis for CCR3 selectivity of the eotaxin.	Univ Alberta, Prot Engn Network Ctr Excellence, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Korea Inst Sci & Technol, Struct Biol Ctr, Seoul 130650, South Korea; Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of Alberta; University of Alberta; Korea Institute of Science & Technology (KIST); University of British Columbia; University of British Columbia	Sykes, BD (corresponding author), Univ Alberta, Prot Engn Network Ctr Excellence, Edmonton, AB T6G 2S2, Canada.	bds@polaris.biochem.ualberta.ca		Crump, Matthew/0000-0002-7868-5818				Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Beall CJ, 1996, BIOCHEM J, V313, P633, DOI 10.1042/bj3130633; Brunger A. T, 1993, XPLOR MANUAL VERSION; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; Kim KS, 1996, FEBS LETT, V395, P277, DOI 10.1016/0014-5793(96)01024-1; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; Mattoli S, 1997, BIOCHEM BIOPH RES CO, V236, P299, DOI 10.1006/bbrc.1997.6958; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; PAOLINI JF, 1994, J IMMUNOL, V153, P2704; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Rajarathnam K, 1997, J BIOL CHEM, V272, P1725, DOI 10.1074/jbc.272.3.1725; Rajarathnam K, 1997, METHOD ENZYMOL, V287, P89; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; RAJARATHNAM K, 1994, BIOCHEMISTRY-US, V33, P6623, DOI 10.1021/bi00187a032; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	40	88	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22471	22479		10.1074/jbc.273.35.22471	http://dx.doi.org/10.1074/jbc.273.35.22471			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712872	hybrid			2022-12-25	WOS:000075616600048
J	Tretiakova, A; Gallia, GL; Shcherbik, N; Jameson, B; Johnson, EM; Amini, S; Khalili, K				Tretiakova, A; Gallia, GL; Shcherbik, N; Jameson, B; Johnson, EM; Amini, S; Khalili, K			Association of Pur alpha with RNAs homologous to 7 SL determines its binding ability to the myelin basic protein promoter DNA sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; DYSMYELINATING MUTANT MICE; MOUSE-BRAIN; INSITU HYBRIDIZATION; ALU REPEAT; DEVELOPMENTAL EXPRESSION; INDUCED TRANSFORMATION; GENE-TRANSCRIPTION; RECEPTOR COMPLEXES; ESTROGEN-RECEPTOR	Cell type and developmental stage expression of the myelin basic protein (MBP) gene in mouse brain is regulated at the transcriptional level. Earlier studies from our laboratory have led to the identification of a DNA binding protein from mouse brain, named Pur alpha, which interacts with the MB1 regulatory motif of the MBP and stimulates its transcription in glial cells. In this report, we demonstrate that a cellular RNA, with significant homology to 7 SL RNA is associated with Pur alpha, Results from band shift competition studies indicate that Pur alpha-associated RNA (PU-RNA), inhibits the interaction of immunopurified Pur alpha with the MB1 DNA sequence, Re suits from Northern blot studies indicated that PU-RNA is expressed during various stages of brain development. Of interest, this RNA was found in association with Pur alpha that was produced in the mouse brain at the early stage of brain development. Results from Northwestern analysis using a PU-RNA probe identified the regions within Pur alpha that are important for Pur alpha/PU-RNA association. Production of Purer at the early stage of brain development and its association with PU-RNA at this stage, when Pur alpha exhibits poor binding ability to the MB1 DNA sequence, suggests that PU-RNA may function as a co-factor that negatively regulates Pur alpha interaction with the MBP promoter sequence.	Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, Philadelphia, PA 19102 USA; CUNY Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA	Drexel University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Khalili, K (corresponding author), Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, Broad & Vine,MS 406, Philadelphia, PA 19102 USA.							ALMENOFF JS, 1994, J BIOL CHEM, V269, P16610; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; Bovia F, 1996, J CELL SCI, V109, P2601; BRITTEN RJ, 1994, P NATL ACAD SCI USA, V91, P5992, DOI 10.1073/pnas.91.13.5992; CAMPAGNONI AT, 1988, MOL NEUROBIOL, V2, P41, DOI 10.1007/BF02935632; CARSON JH, 1983, DEV BIOL, V96, P485, DOI 10.1016/0012-1606(83)90185-9; Chang DY, 1996, NUCLEIC ACIDS RES, V24, P4165, DOI 10.1093/nar/24.21.4165; CHEN NN, 1995, J VIROL, V69, P5843, DOI 10.1128/JVI.69.9.5843-5848.1995; Cheng JG, 1996, DNA CELL BIOL, V15, P549, DOI 10.1089/dna.1996.15.549; CHUANG LM, 1988, BIOCHEM BIOPH RES CO, V156, P1287, DOI 10.1016/S0006-291X(88)80772-1; Clawson GA, 1996, CELL GROWTH DIFFER, V7, P635; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; FRENCH BT, 1984, CANCER LETT, V23, P45, DOI 10.1016/0304-3835(84)90060-0; GIAMBIAGI N, 1989, LIFE SCI, V44, P2067, DOI 10.1016/0024-3205(89)90353-6; GIORDANO T, 1992, MECH AGEING DEV, V64, P13, DOI 10.1016/0047-6374(92)90092-R; HAAS S, 1993, MOL CELL BIOL, V13, P3103, DOI 10.1128/MCB.13.5.3103; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; Herault Yann, 1995, Gene Expression, V4, P85; Ishizaki J, 1996, NAT MED, V2, P1386, DOI 10.1038/nm1296-1386; JANG KL, 1992, J ACQ IMMUN DEF SYND, V5, P1142; KOHNOE S, 1987, BIOCHIM BIOPHYS ACTA, V909, P107, DOI 10.1016/0167-4781(87)90032-7; Krachmarov CP, 1996, P NATL ACAD SCI USA, V93, P14112, DOI 10.1073/pnas.93.24.14112; KRAUSE MO, 1986, CANCER RES, V46, P1990; KRISTENSSON K, 1986, J HISTOCHEM CYTOCHEM, V34, P467, DOI 10.1177/34.4.2419396; KURZ J, 1988, BIOCHEM BIOPH RES CO, V152, P753, DOI 10.1016/S0006-291X(88)80102-5; LASHGARI MS, 1990, J CLIN INVEST, V86, P1671, DOI 10.1172/JCI114890; LIU WM, 1995, NUCLEIC ACIDS RES, V23, P1758, DOI 10.1093/nar/23.10.1758; LUKIW WJ, 1992, NEUROCHEM RES, V17, P591, DOI 10.1007/BF00968788; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; MA ZW, 1994, GENE, V149, P311, DOI 10.1016/0378-1119(94)90167-8; MARTIGNETTI JA, 1993, P NATL ACAD SCI USA, V90, P11563, DOI 10.1073/pnas.90.24.11563; QUENTIN Y, 1994, GENETICA, V93, P203, DOI 10.1007/BF01435252; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; ROSSINI GP, 1990, LIFE SCI, V47, P743, DOI 10.1016/0024-3205(90)90630-A; ROSSINI GP, 1989, J STEROID BIOCHEM, V32, P633, DOI 10.1016/0022-4731(89)90507-4; SAKAMOTO K, 1991, J BIOL CHEM, V266, P3031; SHARP PA, 1983, NATURE, V301, P471, DOI 10.1038/301471a0; SHIOTA C, 1991, J NEUROCHEM, V56, P818, DOI 10.1111/j.1471-4159.1991.tb01997.x; SORG BA, 1987, J NEUROCHEM, V49, P1146, DOI 10.1111/j.1471-4159.1987.tb10005.x; STRUB K, 1991, MOL CELL BIOL, V11, P3949, DOI 10.1128/MCB.11.8.3949; THOMAS T, 1985, J STEROID BIOCHEM, V23, P19, DOI 10.1016/0022-4731(85)90255-9; THOMAS T, 1986, J STEROID BIOCHEM, V24, P505, DOI 10.1016/0022-4731(86)90112-3; TIERCY JM, 1985, EXPERIENTIA, V41, P82, DOI 10.1007/BF02005887; VERITY AN, 1988, J NEUROSCI RES, V21, P238, DOI 10.1002/jnr.490210216; WATSON JB, 1987, MOL CELL BIOL, V7, P3324, DOI 10.1128/MCB.7.9.3324; WIKTOROWICZ M, 1991, DEV NEUROSCI-BASEL, V13, P143, DOI 10.1159/000112152; Zamore PD, 1996, CURR BIOL, V6, P773, DOI 10.1016/S0960-9822(02)00591-2; ZELLER NK, 1984, P NATL ACAD SCI-BIOL, V81, P18, DOI 10.1073/pnas.81.1.18	50	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22241	22247		10.1074/jbc.273.35.22241	http://dx.doi.org/10.1074/jbc.273.35.22241			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712838	hybrid			2022-12-25	WOS:000075616600014
J	Megidish, T; Cooper, J; Zhang, LX; Fu, HA; Hakomori, S				Megidish, T; Cooper, J; Zhang, LX; Fu, HA; Hakomori, S			A novel sphingosine-dependent protein kinase (SDK1) specifically phosphorylates certain isoforms of 14-3-3 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SIGNALING PATHWAYS; TYROSINE PHOSPHORYLATION; SPHINGOLIPID METABOLITES; CELLULAR PROLIFERATION; LIPID 2ND-MESSENGERS; MOLECULAR-CLONING; HUMAN-PLATELETS; T-CELLS; BRAIN; INHIBITION	Protein kinases activated by sphingosine or N,N'-di-methylsphingosine, but not by other lipids, have been detected and are termed sphingosine-dependent protein kinases (SDKs), These SDKs were previously shown to phosphorylate endogenous 14-3-3 proteins (Megidish, T., White, T., Takio, K., Titani, K., Igarashi, Y., and Hakomori, S. (1995) Biochem. Biophys. Res. Commun. 216, 739-747). We have now partially purified one SDK, termed SDK1, from cytosol of mouse Balb/c 3T3(A31) fibroblasts. SDK1 is a serine kinase with molecular mass 50-60 kDa that is strongly activated by N,N'-dimethylsphingosine and sphingosine, but not by ceramide, sphingosine 1-phosphate, or other sphingo-, phospho-, or glycerolipids tested. Its activity is inhibited by the protein kinase C activator phosphatidylserine. Activity of SDK1 is clearly distinct from other types of serine kinases tested, including casein kinase II, the alpha and zeta isoforms of protein kinase C, extracellular signal-regulated mitogene-activated protein kinase 1 (Erk-1), Erk-2, and Raf-1. SDK1 specifically phosphorylates certain isoforms of 14-3-3 (eta, beta, zeta) but not others (sigma, tau). The phosphorylation site was identified as Ser* in the sequence Arg-Arg-Ser-Ser*-Trp-Arg in 14-3-3 beta. The sigma and tau isoforms of 14-3-3 lack serine at this position, potentially explaining their lack of phosphorylation by SDK1. Interestingly, the phosphorylation site is located on the dimes interface of 14-3-3. Phosphorylation of this site by SDK1 was studied in 14-3-3 mutants. Mutation Of a lysine residue, located 9 amino acids N-terminal to the phosphorylation site, abolished 14-3-3 phosphorylation. Furthermore, co-immunoprecipitation experiments demonstrate an association between ate SDK and 14-3-3 in sifts. Exogenous N,N'-dimethylsphingosine stimulates 14-3-3 phosphorylation in Balb/c 3T3 fibroblasts, suggesting that SDK1 may phosphorylate 14-3-3 in situ. These data support a biological sole of SDK1 activation and consequent phosphorylation of specific 14-3-3 isoforms that regulate signal transduction. In view of the three-dimensional structure of 14-3-3, it is likely that phosphorylation by SDK1 would alter dimerization of 14-3-3, and/or induce conformational changes that alter 14-3-3 association with other kinases involved in signal transduction.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Emory University	Hakomori, S (corresponding author), Pacific NW Res Inst, Seattle, WA 98122 USA.	hakomori@u.washington.edu		Zhang, Lixin/0000-0003-0894-9520	NATIONAL CANCER INSTITUTE [R01CA054786, R35CA042505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053165, R29GM053165] Funding Source: NIH RePORTER; NCI NIH HHS [CA42505, CA54786] Funding Source: Medline; NIGMS NIH HHS [GM53165] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELGHANY M, 1992, BIOCHIM BIOPHYS ACTA, V1137, P349, DOI 10.1016/0167-4889(92)90156-6; AITKEN A, 1995, MOL CELL BIOCHEM, V149, P41, DOI 10.1007/BF01076562; AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; ARNOLD RS, 1991, BIOCHEMISTRY-US, V30, P7747, DOI 10.1021/bi00245a011; Blakesley VA, 1997, J BIOL CHEM, V272, P16211, DOI 10.1074/jbc.272.26.16211; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; IGARASHI Y, 1990, J BIOL CHEM, V265, P5385; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; IGARASHI Y, 1989, BIOCHEM BIOPH RES CO, V164, P1411, DOI 10.1016/0006-291X(89)91827-5; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOBAYASHI T, 1988, EUR J BIOCHEM, V172, P747, DOI 10.1111/j.1432-1033.1988.tb13952.x; LAVIE Y, 1994, BBA-MOL CELL RES, V1220, P323, DOI 10.1016/0167-4889(94)90156-2; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Mano N, 1997, ANAL BIOCHEM, V244, P291, DOI 10.1006/abio.1996.9891; MARTIN H, 1994, J NEUROCHEM, V63, P2259; MCDONALD OB, 1991, J BIOL CHEM, V266, P21773; MEGIDISH T, 1995, BIOCHEM BIOPH RES CO, V216, P739, DOI 10.1006/bbrc.1995.2684; Meller N, 1996, MOL CELL BIOL, V16, P5782; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHTA H, 1995, CANCER RES, V55, P691; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Perego L, 1997, MOL REPROD DEV, V47, P370, DOI 10.1002/(SICI)1098-2795(199708)47:4&lt;370::AID-MRD3&gt;3.0.CO;2-H; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; RADUNZ HE, 1988, LIEBIGS ANN CHEM, P1103; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; Rommel C, 1996, ONCOGENE, V12, P609; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; WATANABE M, 1994, MOL BRAIN RES, V25, P113, DOI 10.1016/0169-328X(94)90285-2; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yatomi Y, 1997, BIOCHEM BIOPH RES CO, V231, P848, DOI 10.1006/bbrc.1997.6207; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHANG H, 1990, J BIOL CHEM, V265, P76; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	56	111	124	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21834	21845		10.1074/jbc.273.34.21834	http://dx.doi.org/10.1074/jbc.273.34.21834			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705322	hybrid			2022-12-25	WOS:000075492600056
J	Crabb, JW; Nie, ZQ; Chen, Y; Hulmes, JD; West, KA; Kapron, JT; Ruuska, SE; Noy, N; Saari, JC				Crabb, JW; Nie, ZQ; Chen, Y; Hulmes, JD; West, KA; Kapron, JT; Ruuska, SE; Noy, N; Saari, JC			Cellular retinaldehyde-binding protein ligand interactions - GLN-210 and LYS-221 are in the retinoid binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	68th Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology	APR, 1996	FT LAUDERDALE, FLORIDA	Assoc Res Vis & Ophthalmol			SITE-DIRECTED MUTAGENESIS; BOVINE RETINA; X-RECEPTORS; ACID; RHODOPSIN; CLONING; GENE; DETERMINANTS; TRANSDUCIN; CRALBP	Cellular retinaldehyde-binding protein (CRALBP) carries Il-cis-retinal and/or Il-cis-retinol as endogenous ligands in the retinal pigment epithelium (RPE) and Muller cells of the retina and has been linked with autosomal recessive retinitis pigmentosa, Ligand interactions determine the physiological role of CRALBP in the RPE where the protein is thought to function as a substrate carrier for Il-cis-retinol dehydrogenase in the synthesis of Il-cis-retinal for visual pigment regeneration. However, CRALBP is also present in optic nerve and brain where its natural ligand and function are not yet known. We have characterized the interactions of retinoids with native bovine CRALBP, human recombinant CRALBP (rCRALBP) and five mutant rCRALBPs. Efforts to trap and/or identify a Schiff base in the dark, under a variety of reducing, denaturing, and pH conditions were unsuccessful, suggesting the lack of covalent interactions between CRALBP and retinoid. Buried and solvent-exposed lysine residues were identified in bovine CRALBP by reductive methylation of the holoprotein followed by denaturation and reaction with [H-3]acetic anhydride, Radioactive lysine residues were identified by Edman degradation and electrospray mass spectrometry following proteolysis and purification of modified peptides, Human rCRALBP mutants K152A, K221A, and K294A were prepared to investigate possible retinoid interactions with buried or partially buried lysines. Two other rCRALBP mutants, I162V and Q210R, were also prepared to identify substitutions altering the retinoid binding properties of a random mutant. The structures of all the mutants were verified by amino acid and mass spectral analyses and retinoid binding properties evaluated by W-visible and fluorescence spectroscopy. AU of the mutants bound Il-cis-retinal essentially like the wild type protein, indicating that the proteins were not grossly misfolded, Three of the mutants bound 9-cis-retinal like the wild type protein; however, Q210R and K221A bound less than stoichiometric amounts of the g-cis-isomer and exhibited lower affinity for this retinoid relative to wild type rCRALBP. Residues Gin-210 and Lys-221 are located within a region of CRALBP exhibiting sequence homology with the ligand binding cavity of yeast phosphatidylinositol-transfer protein, The data implicate Gin-210 and Lys-221 as components of the CRALBP retinoid binding cavity and are discussed in the context of ligand interactions in structurally or functionally related proteins with known crystallographic structures.	Adirondack Biomed Res Inst, Lake Placid, NY 12946 USA; Univ Washington, Dept Biochem & Ophthalmol, Seattle, WA 98195 USA; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	University of Washington; University of Washington Seattle; Cornell University	Crabb, JW (corresponding author), Adirondack Biomed Res Inst, 10 Old Barn Rd, Lake Placid, NY 12946 USA.	jcrabb@cell-science.org			NATIONAL EYE INSTITUTE [P30EY001730] Funding Source: NIH RePORTER; NEI NIH HHS [EY02317, EY01730, EY06603] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; ASENJO AB, 1994, NEURON, V12, P1131, DOI 10.1016/0896-6273(94)90320-4; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen Y, 1996, J BIOL CHEM, V271, P20507, DOI 10.1074/jbc.271.34.20507; CHEN Y, 1994, TECHNIQUES PROTEIN C, V5, P371; CHENG L, 1991, J BIOL CHEM, V266, P24404; CRABB JW, 1988, J BIOL CHEM, V263, P18678; Crabb JW, 1998, METH MOL B, V89, P91; Crabb JW, 1998, PROTEIN SCI, V7, P746, DOI 10.1002/pro.5560070324; CRABB JW, 1988, J BIOL CHEM, V263, P18688; Crabb JW, 1996, INVEST OPHTH VIS SCI, V37, P3691; CRABB JW, 1991, J BIOL CHEM, V266, P16674; CRABB JW, 1997, CURRENT PROTOCOLS PR, V7; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FUTTERMAN S, 1977, J BIOL CHEM, V252, P3267; INTRES R, 1994, J BIOL CHEM, V269, P25411; JACOBY IV, 1993, BIOCHEMISTRY-US, V32, P872; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; KAPRON JT, 1995, PROTEIN SCI S2, V4, P147; KAPRON JT, 1997, PROTEIN SCI, V6, P1; Kennedy BN, 1998, J BIOL CHEM, V273, P5591, DOI 10.1074/jbc.273.10.5591; KENNEDY BN, 1998, INVEST OPHTH VIS SCI, V39, P539; Kersten S, 1996, BIOCHEMISTRY-US, V35, P3816, DOI 10.1021/bi952737k; LONGSTAFF C, 1985, BIOCHEMISTRY-US, V25, P6311; Luck LA, 1997, TECH PROT CHEM, V8, P439, DOI 10.1016/S1080-8914(97)80044-0; Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; NEWCOMER ME, 1995, FASEB J, V9, P229, DOI 10.1096/fasebj.9.2.7781925; Norris AW, 1998, METH MOL B, V89, P123; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; Ong David E., 1994, P283; SAARI JC, 1982, J BIOL CHEM, V257, P13329; SAARI JC, 1994, BIOCHEMISTRY-US, V33, P3106, DOI 10.1021/bi00176a045; Saari JC, 1997, GLIA, V21, P259; SAARI JC, 1987, J BIOL CHEM, V262, P7618; SAARI JC, 1988, EXP EYE RES, V46, P569, DOI 10.1016/S0014-4835(88)80013-7; SAARI JC, 1982, BIOCHIM BIOPHYS ACTA, V716, P266, DOI 10.1016/0304-4165(82)90277-X; Saari John C., 1994, P351; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; STUBBS GW, 1979, J BIOL CHEM, V254, P8529; ZHANG JH, 1992, PROTEINS, V13, P87, DOI 10.1002/prot.340130202; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431	45	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20712	20720		10.1074/jbc.273.33.20712	http://dx.doi.org/10.1074/jbc.273.33.20712			9	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694813	hybrid			2022-12-25	WOS:000075386100006
J	Gimenez-Roqueplo, AP; Celerier, J; Lucarelli, G; Corvol, P; Jeunemaitre, X				Gimenez-Roqueplo, AP; Celerier, J; Lucarelli, G; Corvol, P; Jeunemaitre, X			Role of N-glycosylation in human angiotensinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HUMAN RENIN; LINKED OLIGOSACCHARIDES; RAT ANGIOTENSINOGEN; HUMAN HYPERTENSION; EXPRESSION; PROTEIN; PLASMA; RADIOIMMUNOASSAY; HETEROGENEITY	Human angiotensinogen, the specific substrate of renin, is a heterogeneous glycoprotein constitutively secreted by the liver. Different glycosylation levels may be responsible for its heterogeneity. It contains four putative asparagine-linked glycosylation sites (Asn-X-Ser/Thr), Systematic site-directed mutagenesis (Asn replaced with Gin) of these four sites was undertaken, and 11 (single, double, triple, and quadruple (N-4)) mutants were produced in COS-7 and/or CHO-K1 cells and characterized. All of the sites were N-glycosylated with preferential glycosylation of the Asn(14) and the Asn(271). The suppression of the Asn(14) glycosylation site led to 5 times lower K-m and a 10 times lower k(cat). Angiotensinogen heterogeneity was much lower for the N-4 mutant protein, which produced a single form at 48 kDa. Pulse-chase experiments showed slight intracellular retention (15%) of the deglycosylated protein after 24 h, Interestingly, the N-4 mutant had a higher catalytic efficiency (k(cat)/K-m = 5.0 versus 1.6 mu M-1 . s(-1)) than the wild-type protein. The thermal stability of the N-4 protein was unaffected by deglycosylation, suggesting that it was correctly folded. This deglycosylated recombinant human angiotensinogen could be of value for x-ray crystallography studies.	Coll France, INSERM U36, Chair Med Expt & Endocrinol Renale, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Gimenez-Roqueplo, AP (corresponding author), Coll France, INSERM U36, Chair Med Expt & Endocrinol Renale, 3 Rue Ulm, F-75005 Paris, France.	jeunemaitre@hbroussais.fr	GIMENEZ-ROQUEPLO, Anne-Paule/T-6752-2018; JEUNEMAITRE, Xavier/AAQ-4853-2021	GIMENEZ-ROQUEPLO, Anne-Paule/0000-0002-4816-670X; JEUNEMAITRE, Xavier/0000-0001-5925-381X				CAMPBELL CJ, 1987, BIOCHEM J, V243, P121, DOI 10.1042/bj2430121; CAMPBELL DJ, 1984, ENDOCRINOLOGY, V114, P776, DOI 10.1210/endo-114-3-776; CLOUSTON W M, 1988, Genomics, V2, P240, DOI 10.1016/0888-7543(88)90008-0; Cohen P, 1996, J CLIN ENDOCR METAB, V81, P3505, DOI 10.1210/jc.81.10.3505; Corvol P, 1997, ENDOCR REV, V18, P662, DOI 10.1210/er.18.5.662; CUMIN F, 1987, BIOCHIM BIOPHYS ACTA, V913, P10, DOI 10.1016/0167-4838(87)90226-3; DO YS, 1984, J BIOL CHEM, V262, P1037; DOOLITTLE RF, 1983, SCIENCE, V222, P417, DOI 10.1126/science.6604942; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FENG W, 1995, J BIOL CHEM, V270, P11851, DOI 10.1074/jbc.270.20.11851; FERNLEY RT, 1986, EUR J BIOCHEM, V154, P597, DOI 10.1111/j.1432-1033.1986.tb09440.x; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GAILLARD I, 1989, DNA-J MOLEC CELL BIO, V8, P87, DOI 10.1089/dna.1.1989.8.87; GENAIN C, 1984, J CLIN ENDOCR METAB, V59, P478, DOI 10.1210/jcem-59-3-478; GimenezRoqueplo AP, 1996, J BIOL CHEM, V271, P9838, DOI 10.1074/jbc.271.16.9838; GOULD AB, 1971, CARDIOVASC RES, V5, P86, DOI 10.1093/cvr/5.1.86; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HILGENFELDT U, 1987, MOL CELL ENDOCRINOL, V51, P211, DOI 10.1016/0303-7207(87)90030-X; HILGENFELDT U, 1988, MOL CELL ENDOCRINOL, V56, P91, DOI 10.1016/0303-7207(88)90012-3; INOUE I, 1995, J BIOL CHEM, V270, P11430, DOI 10.1074/jbc.270.19.11430; Inoue I, 1997, J CLIN INVEST, V99, P1786, DOI 10.1172/JCI119343; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; Kaetzel DM, 1996, BBA-PROTEIN STRUCT M, V1298, P250, DOI 10.1016/S0167-4838(96)00136-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mathews S, 1996, PROTEIN EXPRES PURIF, V7, P81, DOI 10.1006/prep.1996.0012; MENARD J, 1972, ENDOCRINOLOGY, V90, P422, DOI 10.1210/endo-90-2-422; MOFFETT RB, 1987, BIOCHIM BIOPHYS ACTA, V912, P73; NAGASE M, 1994, BIOSCI BIOTECH BIOCH, V58, P1884, DOI 10.1271/bbb.58.1884; OKHUBO H, 1983, P NATL ACAD SCI USA, V80, P2196; PRINTZ MP, 1977, J BIOL CHEM, V252, P1654; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROITSCH T, 1989, EUR J BIOCHEM, V181, P525, DOI 10.1111/j.1432-1033.1989.tb14755.x; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; SKEGGS LT, 1963, J EXP MED, V118, P73, DOI 10.1084/jem.118.1.73; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TEWKSBURY DA, 1981, BIOCHEM BIOPH RES CO, V99, P1311, DOI 10.1016/0006-291X(81)90762-2; TEWKSBURY DA, 1990, HYPERTENSION PATHOPH, P1197; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; vanBerkel PHC, 1996, BIOCHEM J, V319, P117, DOI 10.1042/bj3190117; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WEI L, 1988, BIOCHEM BIOPH RES CO, V156, P1103, DOI 10.1016/S0006-291X(88)80746-0	42	32	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21232	21238		10.1074/jbc.273.33.21232	http://dx.doi.org/10.1074/jbc.273.33.21232			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694881	hybrid			2022-12-25	WOS:000075386100074
J	Graham, JE; Richardson, JP				Graham, JE; Richardson, JP			rut sites in the nascent transcript mediate rho-dependent transcription termination in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRO MESSENGER-RNA; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; HELICASE ACTIVITY; DNA INTERACTIONS; PROTEIN; ANTITERMINATION; BINDING; SEQUENCE; REQUIREMENT	The in vitro function of the coliphage lambda tR1 Rho-dependent terminator is governed primarily by a tripartite upstream sequence element designated rut. To determine the contribution of the different components of the rut site to terminator function in the normal context of coupled translation of the nascent cro message, tR1 variants lacking different rut site sequences were tested for terminator function in vivo. Intact rutA and rutB sequences were both necessary for efficient termination. However, deletion of the upstream rutA was far more detrimental than deletion of rutB. The intervening boxB, which encodes a short RNA stem and loop, could be deleted without reducing termination or detectably altering Rho's interaction with the corresponding cro transcript. The relative importance of these sequence elements was also the same in a minimal in vitro termination assay system. Rut sequences are therefore essential for terminator function in vivo and rutA contributes substantially more to tR1 function than does rutB. The relative contribution of these elements can be ascribed to differences in Rho's binding affinity for the encoded transcripts. If other cellular factors also bind the rut element RNA, they do not alter the relative contribution of its two regions to Rho-dependent transcription termination in vivo.	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Richardson, JP (corresponding author), Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.	jrichard@bio.indiana.edu			NIAID NIH HHS [AI01042] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALIFANO P, 1991, CELL, V64, P553; ANDREWS C, 1985, J BIOL CHEM, V260, P5826; CERUZZI MAF, 1985, J BIOL CHEM, V260, P9412; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; CHEN CYA, 1986, CELL, V46, P1023, DOI 10.1016/0092-8674(86)90701-4; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; COURT D, 1980, J MOL BIOL, V138, P231, DOI 10.1016/0022-2836(80)90285-5; DAMBLY-CHAUDIERE C, 1983, Journal of Molecular and Applied Genetics, V2, P45; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; FAUS I, 1990, J MOL BIOL, V212, P53, DOI 10.1016/0022-2836(90)90304-5; FRIEDMAN DI, 1983, CELL, V34, P143, DOI 10.1016/0092-8674(83)90144-7; FRIEDMAN DI, 1995, MOL MICROBIOL, V18, P191, DOI 10.1111/j.1365-2958.1995.mmi_18020191.x; FRIEDMAN DI, 1988, BACTERIOPHAGES, V2, P263; GALLUPPI G, 1976, RNA POLYMERASE, P657; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HART CM, 1991, J BIOL CHEM, V266, P24140; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOWARD BH, 1976, J BIOL CHEM, V251, P2520; JAEGER JA, 1990, METHODS ENZYMOL, V183, P281; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAU LF, 1982, P NATL ACAD SCI-BIOL, V79, P6171, DOI 10.1073/pnas.79.20.6171; LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/nar/18.15.4631; LINN T, 1990, J BACTERIOL, V172, P1077, DOI 10.1128/jb.172.2.1077-1084.1990; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; Miller J. H., 1972, EXPT MOL GENETICS, pXVI; MILLER JH, 1992, SHORT COURSE BACTERI, P268; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; NODWELL JR, 1993, CELL, V72, P261, DOI 10.1016/0092-8674(93)90665-D; Nowatzke W, 1996, METHOD ENZYMOL, V274, P353; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; PATTERSON TA, 1994, J MOL BIOL, V236, P217, DOI 10.1006/jmbi.1994.1131; QIAN L, 1991, BIOTECHNIQUES, V10, P736; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; Richardson LV, 1996, J BIOL CHEM, V271, P21597, DOI 10.1074/jbc.271.35.21597; ROBERT J, 1987, CELL, V51, P483, DOI 10.1016/0092-8674(87)90644-1; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; ROBERTS JW, 1993, CELL, V72, P653, DOI 10.1016/0092-8674(93)90394-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNEIDER D, 1993, FASEB J, V7, P201, DOI 10.1096/fasebj.7.1.7678562; SQUIRES CL, 1993, P NATL ACAD SCI USA, V90, P970, DOI 10.1073/pnas.90.3.970; STEINMETZ EJ, 1994, P NATL ACAD SCI USA, V91, P1401, DOI 10.1073/pnas.91.4.1401; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Walstrom KM, 1997, BIOCHEMISTRY-US, V36, P7980, DOI 10.1021/bi963179s; WARREN F, 1984, P NATL ACAD SCI-BIOL, V81, P3612, DOI 10.1073/pnas.81.12.3612; Washburn RS, 1996, J MOL BIOL, V260, P347, DOI 10.1006/jmbi.1996.0405; ZALATAN F, 1992, J BIOL CHEM, V267, P19082; ZALATAN F, 1993, J BIOL CHEM, V268, P17051; ZOU LL, 1991, J BIOL CHEM, V266, P10201	51	27	28	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20764	20769		10.1074/jbc.273.33.20764	http://dx.doi.org/10.1074/jbc.273.33.20764			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694820	hybrid			2022-12-25	WOS:000075386100013
J	Rane, MJ; Arthur, JM; Prossnitz, ER; McLeish, KR				Rane, MJ; Arthur, JM; Prossnitz, ER; McLeish, KR			Activation of mitogen-activated protein kinases by formyl peptide receptors is regulated by the cytoplasmic tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HUMAN NEUTROPHILS; SIGNAL-TRANSDUCTION; HL-60 CELLS; BETA-2-ADRENERGIC RECEPTOR; CHEMOATTRACTANT RECEPTOR; LEUCYL-PHENYLALANINE; COUPLED RECEPTORS; PHYSICAL COMPLEX; C5A RECEPTOR	Wild type formyl peptide receptors (FPRwt) and receptors deleted of the carboxyl-terminal 45 amino acids (FPRdel) were stably expressed in undifferentiated HL-60 promyelocytes. Expression of FPRwt reconstituted N-formylmethionyl-leucyl-phenylalanine (FMLP)-stimulated extracellular signal-regulated kinase (ERK) and p38 kinase activity. Expression of FPRdel resulted in a 2-5-fold increase in basal ERK and p38 kinase activity, whereas FMLP failed to stimulate either mitogen-activated protein kinase (MAPK). Pertussis toxin abolished FMLP stimulation of both MAPKs in FPRwt cells but had no effect on either basal or FMLP-stimulated MAPK activity in FPRdel cells. FMLP stimulated a concentration-dependent increase in guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) binding in membranes from FPRwt but not FPRdel cells. GTP gamma S inhibited FMLP binding to FPRwt but not FPRdel membranes. Photoaffinity labeling with azidoanilide-[gamma-P-32]GTP in the presence or absence of FMLP showed increased labeling only in FPRwt membranes. Immunoprecipitation of alpha(i2) and alpha(q/11) from solubilized, photolabeled membranes showed that FPRwt were coupled to alpha(i2) but not to alpha(q/11). FPRwt cells demonstrated calcium mobilization following stimulation with FMLP, whereas FPRdel cells showed no increase in intracellular calcium. We conclude that the carboxyl-terminal tail of FPRs is necessary for ligand-mediated activation of G(i) proteins and MAPK cascades. Deletion of the carboxyl-terminal tail results in constitutive activation of ERK and p38 kinase through a G(i2)-independent pathway.	Univ Louisville, Kidney Dis Program, Hlth Sci Ctr, Dept Med, Louisville, KY 40202 USA; Univ Louisville, Hlth Sci Ctr, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Vet Affairs Med Ctr, Louisville, KY 40202 USA; Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA	University of Louisville; University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of New Mexico; University of New Mexico's Health Sciences Center	McLeish, KR (corresponding author), Univ Louisville, Kidney Dis Program, Hlth Sci Ctr, Dept Med, 615 S Floyd St, Louisville, KY 40202 USA.		Prossnitz, Eric R./B-4543-2008; McLeish, Kenneth R./B-9819-2013	McLeish, Kenneth R./0000-0002-7816-3286; Arthur, John/0000-0003-4342-4762; Prossnitz, Eric/0000-0001-9190-8302	NIAID NIH HHS [AI36357] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036357, R01AI036357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALI H, 1994, J BIOL CHEM, V269, P24557; AMATRUDA TT, 1995, J BIOL CHEM, V270, P28010; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; Arthur JM, 1997, AM J PHYSIOL-RENAL, V273, pF129, DOI 10.1152/ajprenal.1997.273.1.F129; Avdi NJ, 1996, J BIOL CHEM, V271, P33598, DOI 10.1074/jbc.271.52.33598; BOMMAKANTI RK, 1993, J LEUKOCYTE BIOL, V54, P572, DOI 10.1002/jlb.54.6.572; BOMMAKANTI RK, 1992, J BIOL CHEM, V267, P7576; BOMMAKANTI RK, 1995, BIOCHEMISTRY-US, V34, P6720, DOI 10.1021/bi00020a017; BUHL AM, 1995, J BIOL CHEM, V270, P19828, DOI 10.1074/jbc.270.34.19828; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; GIERSCHIK P, 1989, EUR J PHARM-MOLEC PH, V172, P481, DOI 10.1016/0922-4106(89)90031-X; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; JACOBS AA, 1995, J LEUKOCYTE BIOL, V57, P679, DOI 10.1002/jlb.57.4.679; Klinker JF, 1996, GEN PHARMACOL, V27, P33, DOI 10.1016/0306-3623(95)00107-7; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MCLEISH KR, 1989, BIOCHEM J, V260, P427, DOI 10.1042/bj2600427; MCLEISH KR, 1989, MOL PHARMACOL, V36, P384; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; Pillinger MH, 1996, J BIOL CHEM, V271, P12049, DOI 10.1074/jbc.271.20.12049; Prossnitz ER, 1997, J BIOL CHEM, V272, P15213, DOI 10.1074/jbc.272.24.15213; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; PROSSNITZ ER, 1993, J IMMUNOL, V151, P5704; Rane MJ, 1997, J IMMUNOL, V159, P5070; Sambrook J., 2002, MOL CLONING LAB MANU; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHEPERS TM, 1992, J BIOL CHEM, V267, P159; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; Shi LC, 1996, J NEUROCHEM, V67, P1478; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; Xie W, 1997, J BIOL CHEM, V272, P24948, DOI 10.1074/jbc.272.40.24948; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	42	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20916	20923		10.1074/jbc.273.33.20916	http://dx.doi.org/10.1074/jbc.273.33.20916			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694839	hybrid			2022-12-25	WOS:000075386100032
J	Sugimoto, R; Yae, Y; Akaiwa, M; Kitajima, S; Shibata, Y; Sato, H; Hirata, J; Okochi, K; Izuhara, K; Hamasaki, N				Sugimoto, R; Yae, Y; Akaiwa, M; Kitajima, S; Shibata, Y; Sato, H; Hirata, J; Okochi, K; Izuhara, K; Hamasaki, N			Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; MANNOSE-BINDING PROTEIN; MOLECULAR-CLONING; FIBRINOGEN-LIKE; BAND-3 PROTEIN; COLLAGEN-LIKE; COLLECTINS; DOMAINS; COMPLEMENT; FICOLINS	The Hakata antigen is a novel, thermolabile beta(2)-macro-glycoprotein that reacts with sera from patients suffering from systemic lupus erythematosus. In this study we present the structure and the function of the Hakata antigen. We have identified cDNA clones encoding the Hakata antigen and analyzed its function. The cDNA included a possible open reading frame of 897 nucleotides, encoding 299 amino acids. The Hakata antigen consisted of a collagen-like domain in the middle section and a fibrinogen-like domain in the COOH terminus, both of which are homologous to human ficolin-1 and opsonin P35, indicating that these three molecules form a distinct family, The molecular mass of the Hakata antigen expressed in transfected cells was 35 kDa under reduced conditions, and it formed ladder bands under nonreducing conditions compatible with the previous result that the Hakata antigen exists in serum as homopolymers, Purified Hakata antigen sustained lectin activity, showing affinity with GalNAc, GlcNAc, D-fucose as mono/oligosaccharide, and lipopolysaccharides from Salmonella typhimurium and Salmonella minnesota. These results suggest that the Hakata antigen, a new member of the ficolin/opsonin P35 family, plays a role in the serum exerting lectin activity under physiological conditions.	Kyushu Univ, Dept Clin Chem & Lab Med, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Dept Anat, Fac Med, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Hamasaki, N (corresponding author), Kyushu Univ, Dept Clin Chem & Lab Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	hamasaki@cclm.med.kyushu-u.ac.jp						Davies EJ, 1997, J RHEUMATOL, V24, P485; EPSTEIN WV, 1973, ARTHRITIS RHEUM-US, V16, P43, DOI 10.1002/art.1780160107; Fukutomi T, 1996, CLIN CHIM ACTA, V255, P93, DOI 10.1016/0009-8981(96)06393-0; Hamasaki N, 1997, J BIOCHEM-TOKYO, V122, P577; HARUMIYA S, 1995, J BIOCHEM-TOKYO, V117, P1029, DOI 10.1093/oxfordjournals.jbchem.a124802; Harumiya S, 1996, J BIOCHEM-TOKYO, V120, P745; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; ICHIJO H, 1993, J BIOL CHEM, V268, P14505; INABA S, 1990, Fukuoka Acta Medica, V81, P284; Inaba S., 1978, IGAKU AYUM, V107, P690; KAWANO Y, 1988, J BIOL CHEM, V263, P8232; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; LU J, 1990, J IMMUNOL, V144, P2287; MALHOTRA R, 1992, EUR J IMMUNOL, V22, P1437, DOI 10.1002/eji.1830220616; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; Ohashi T, 1997, J BIOL CHEM, V272, P14220, DOI 10.1074/jbc.272.22.14220; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SASTRY K, 1993, CURR OPIN IMMUNOL, V5, P59, DOI 10.1016/0952-7915(93)90082-4; THIEL S, 1992, IMMUNOPHARMACOLOGY, V24, P91, DOI 10.1016/0162-3109(92)90015-5; TURNER MW, 1994, BIOCHEM SOC T, V22, P88, DOI 10.1042/bst0220088; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; YAE Y, 1991, BIOCHIM BIOPHYS ACTA, V1078, P369, DOI 10.1016/0167-4838(91)90158-V	27	181	200	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20721	20727		10.1074/jbc.273.33.20721	http://dx.doi.org/10.1074/jbc.273.33.20721			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694814	hybrid			2022-12-25	WOS:000075386100007
J	Rapaport, D; Brunner, M; Neupert, W; Westermann, B				Rapaport, D; Brunner, M; Neupert, W; Westermann, B			Fzo1p is a mitochondrial outer membrane protein essential for the biogenesis of functional mitochondria in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST REQUIRES; INHERITANCE; DNA; MAINTENANCE; CHAPERONE; DYNAMIN; FUSION; GENE; SNAP	Fzo1p is a novel component required for the biogenesis of functional mitochondria in the yeast Saccharomyces cerevisiae. The protein is homologous to Drosophila Fzo, the first known protein mediator of mitochondrial fusion. Deletion of the FZO1 gene results in a petite phenotype, loss of mitochondrial DNA, and a fragmented mitochondrial morphology. Fzo1p is an integral protein of the mitochondrial outer membrane exposing its major part to the cytosol, It is imported into the outer membrane in a receptor-dependent manner. Fzo1p is part of a larger protein complex of 800 kDa, and presumably is the first identified component of the yeast mitochondrial fusion machinery.	Univ Munchen, Inst Physiol Chem Physikal Biochem & Zellbiol, D-80336 Munchen, Germany	University of Munich	Neupert, W (corresponding author), Univ Munchen, Inst Physiol Chem Physikal Biochem & Zellbiol, Goethestr 33, D-80336 Munchen, Germany.	neupert@bio.med.uni-muenchen.de	Westermann, Benedikt/H-7766-2013	Westermann, Benedikt/0000-0002-2991-1604; Brunner, Michael/0000-0001-9798-3047				Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; Bereiter-Hahn J., 1990, International Review of Cytology, V122, P1, DOI 10.1016/S0074-7696(08)61205-X; Berger KH, 1997, J CELL BIOL, V136, P545, DOI 10.1083/jcb.136.3.545; BURGESS SM, 1994, J CELL BIOL, V126, P1375, DOI 10.1083/jcb.126.6.1375; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUAN KL, 1993, CURR GENET, V24, P141, DOI 10.1007/BF00324678; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; HELM R, 1995, NATURE, V373, P663; Hermann GJ, 1997, J CELL BIOL, V137, P141, DOI 10.1083/jcb.137.1.141; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; HERRMANN JM, 1994, J CELL BIOL, V127, P893, DOI 10.1083/jcb.127.4.893; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MCCONNELL SJ, 1993, SCIENCE, V260, P687, DOI 10.1126/science.8480179; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; PON L, 1991, MOL CELLULAR BIOL YE, P333; Rep M, 1996, CURR GENET, V30, P367, DOI 10.1007/s002940050145; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; Sambrook J., 2002, MOL CLONING LAB MANU; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON VR, 1995, J CELL BIOL, V130, P345, DOI 10.1083/jcb.130.2.345; SOGO LF, 1994, J CELL BIOL, V126, P1361, DOI 10.1083/jcb.126.6.1361; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Stevens B., 1981, MOL BIOL YEAST SACCH, V11, P471; STEWART LC, 1991, J CELL BIOL, V115, P1249, DOI 10.1083/jcb.115.5.1249; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yaffe MP, 1997, CURR BIOL, V7, pR782, DOI 10.1016/S0960-9822(06)00404-0	33	285	295	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20150	20155		10.1074/jbc.273.32.20150	http://dx.doi.org/10.1074/jbc.273.32.20150			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685359	hybrid			2022-12-25	WOS:000075305400036
J	Sepp-Lorenzino, L; Rosen, N				Sepp-Lorenzino, L; Rosen, N			A farnesyl-protein transferase inhibitor induces p21 expression and G(1) block in p53 wild type tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; DNA-DAMAGE; FARNESYLTRANSFERASE INHIBITORS; NUCLEAR ANTIGEN; GROWTH; REPLICATION; MICE; PCNA; SUPPRESSION; RESISTANCE	Farnesylation is required for the membrane partition and function of several proteins, including Ras. Farnesyl-protein transferase inhibitors (FTIs) were developed to prevent Ras processing and thus to be effective agents for the treatment of cancers harboring mutated ras. However, FTIs inhibit the growth of most tumor cells and several xenograft models, irrespective of whether they possess mutated ras, Furthermore, the antiproliferative effect is not correlated with inhibition of Ki-Ras processing; tumors with wild type ras are inhibited, and FTIs are not particularly toxic. These data suggest that the mechanism of FTI action is complex and may involve other targets besides Ras, To begin to understand how FTIs work, we investigated the mechanism of growth inhibition. FTI causes G(1) arrest in a subset of sensitive lines. This is accomplished by transcriptional induction of p21, which mediates the inhibition of cyclin E-associated protein kinase activity, pRb hypophosphorylation and inhibition of DNA replication. Induction of p21 is p53-dependent; it does not occur in cells with mutant p53 or in cells expressing human papillomavirus E6, However, neither p53 nor p21 are required for inhibition of cell proliferation. FTI still blocks the growth of cells deficient in these proteins. In the absence of p21, G(1) block is relaxed, DNA replication is not affected, and cells become polyploid and undergo apoptosis. These results suggest that farnesylated protein(s) may be involved in regulating p53 function and in coordinating entrance into S, and that the consequences of FTI treatment are a function of the other mutations found in the tumor cell.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Sepp-Lorenzino, L (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 333, New York, NY 10021 USA.	l-sepp@ski.mskcc.org	Rosen, Neal/ABF-2677-2020		NATIONAL CANCER INSTITUTE [P50CA068425] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA68425-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEN X, 1995, CANCER RES, P4257; Coleman P S, 1997, Subcell Biochem, V28, P363; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; DelSal G, 1996, ONCOGENE, V12, P177; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Leonardo A, 1997, CANCER RES, V57, P1013; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GIARETTI W, 1994, METHOD CELL BIOL, V41, P389; Gibbs JB, 1996, BREAST CANCER RES TR, V38, P75, DOI 10.1007/BF01803786; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; Guillot C, 1997, ONCOGENE, V14, P45, DOI 10.1038/sj.onc.1200803; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Li XS, 1996, CANCER RES, V56, P5055; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maki CG, 1996, CANCER RES, V56, P2649; Miquel K, 1997, CANCER RES, V57, P1846; NUSSE M, 1990, CYTOMETRY, V11, P813, DOI 10.1002/cyto.990110707; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Prendergast GC, 1996, CANCER RES, V56, P2626; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SEPPLORENZINO L, 1994, CELL GROWTH DIFFER, V5, P1077; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SPITKOVSKY D, 1995, ONCOGENE, V10, P2421; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TAKAHASHI K, 1993, INT J CANCER, V55, P453, DOI 10.1002/ijc.2910550322; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; VOJTESEK B, 1993, J CELL SCI, V105, P607; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; Zhang FL, 1997, J BIOL CHEM, V272, P10232; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	46	101	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20243	20251		10.1074/jbc.273.32.20243	http://dx.doi.org/10.1074/jbc.273.32.20243			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685373	hybrid			2022-12-25	WOS:000075305400050
J	Trocme, C; Gaudin, P; Berthier, S; Barro, C; Zaoui, P; Morel, F				Trocme, C; Gaudin, P; Berthier, S; Barro, C; Zaoui, P; Morel, F			Human B lymphocytes synthesize the 92-kDa gelatinase, matrix metalloproteinase-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; IV COLLAGENASE GELATINASE; HUMAN T-LYMPHOCYTES; IN-VITRO; NEUTROPHIL GELATINASE; CYTOKINE REGULATION; BASEMENT-MEMBRANE; TISSUE INHIBITOR; GENE-EXPRESSION; CELLS	Matrix metalloproteinases (MMPs) are involved in the remodeling of connective tissue as well as in disease states associated with acute and chronic inflammation or tumoral metastatic processes. Despite detailed and extensive studies of the mechanisms of lymphocyte extravasation, remarkably little is known about the expression and regulation of metalloproteinases involved in the migratory process. By using zymography and reverse transcription-polymerase chain reaction experiments, we have demonstrated that Epstein-Barr virus-immortalized B lymphocytes are able to secrete a 92-kDa metalloproteinase with gelatinolytic activity which has been purified and identified as being MMP-9. Moreover, the tissue inhibitor of metalloproteinase was shown to be constitutively expressed by the B cells. The expression of 92-kDa gelatinase is mediated by cytokines, growth factors, lipopolysaccharide, concanavalin A, and the tumor promotor phorbol 12-myristate 13-acetate. Time dependence activity increased rapidly up to 24 h of incubation with lipopolysaccharide or concanavalin A stimulation while it requires a delay and more time to have an optimum effect when cytokines were the stimulating agents; transforming growth factor-p abolished 92-kDa gelatinase production. Both staurosporine and wortmannin are inductive stimuli, and the level of MMP-9 secreted into the media is greater than that observed with other agents except concanavalin A. Elicitation of the chemotactic migration of B cells through a model basement membrane by lipopolysaccharide was shown to be correlated with gelatinase expression and inhibited by 7 mM captopril. Our study indicates that Epstein-Barr virus-B lymphocytes express 92-kDa gelatinase, the production of which can be modified by a variety of physiological and pharmacological signals which have been shown to differ according to the cell type.	CHU Albert Michallon, Enzymol Lab, UPR ES EA 2019, GREPI, F-38043 Grenoble 9, France; CHU Albert Michallon, Serv Rhumatol, F-38043 Grenoble 9, France; CHU Albert Michallon, Serv Nephrol, F-38043 Grenoble 9, France	CHU Grenoble Alpes; CHU Grenoble Alpes; CHU Grenoble Alpes	Morel, F (corresponding author), CHU Albert Michallon, Enzymol Lab, UPR ES EA 2019, GREPI, BP 217, F-38043 Grenoble 9, France.							AUMAILLEY M, 1993, M S-MED SCI, V9, P926, DOI 10.4267/10608/3013; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Buisson AC, 1996, J CELL PHYSIOL, V166, P413, DOI 10.1002/(SICI)1097-4652(199602)166:2<413::AID-JCP20>3.0.CO;2-A; BUSIEK DF, 1995, J IMMUNOL, V154, P6484; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHENTANUGI L, 1991, EUR J BIOCHEM, V202, P649, DOI 10.1111/j.1432-1033.1991.tb16419.x; Delclaux C, 1996, AM J RESP CELL MOL, V14, P288, DOI 10.1165/ajrcmb.14.3.8845180; FABRY Z, 1995, J IMMUNOL, V155, P325; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; Goetzl EJ, 1996, J IMMUNOL, V156, P1; Houde M, 1996, BBA-MOL CELL RES, V1310, P193, DOI 10.1016/0167-4889(95)00167-0; ITOH Y, 1995, J BIOL CHEM, V270, P16518, DOI 10.1074/jbc.270.28.16518; LACRAZ S, 1994, J BIOL CHEM, V269, P22027; LACRAZ S, 1995, J CLIN INVEST, V96, P2304, DOI 10.1172/JCI118286; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEPPERT D, 1995, J IMMUNOL, V154, P4379; LYONS JG, 1993, J BIOL CHEM, V268, P19143; MAINARDI CL, 1988, CONTROL TISSUE DAMAG, P139; MASURE S, 1991, EUR J BIOCHEM, V198, P391, DOI 10.1111/j.1432-1033.1991.tb16027.x; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MERTZ PM, 1994, J BIOL CHEM, V269, P21322; MONTGOMERY AMP, 1993, BIOCHIM BIOPHYS ACTA, V1176, P265, DOI 10.1016/0167-4889(93)90054-S; MOREL F, 1993, BIOCHEM BIOPH RES CO, V191, P269, DOI 10.1006/bbrc.1993.1212; MOREL F, 1994, BBA-GEN SUBJECTS, V1201, P373, DOI 10.1016/0304-4165(94)90065-5; MURPHY G, 1995, METHOD ENZYMOL, V248, P470; Okada S, 1997, AM J RESP CELL MOL, V17, P519, DOI 10.1165/ajrcmb.17.4.2877; OWEN CA, 1995, SEMIN CELL BIOL, V6, P367, DOI 10.1016/S1043-4682(05)80007-8; POURMOTABBED T, 1994, BBA-PROTEIN STRUCT M, V1204, P97, DOI 10.1016/0167-4838(94)90038-8; Powell WC, 1996, CURR TOP MICROBIOL, V213, P1; RIES C, 1995, BIOL CHEM H-S, V376, P345; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; Sato T, 1996, FEBS LETT, V392, P175, DOI 10.1016/0014-5793(96)00808-3; SHOSHAN MC, 1992, J CELL BIOCHEM, V55, P496; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smith WB, 1996, J IMMUNOL, V157, P360; SORBI D, 1993, KIDNEY INT, V44, P1266, DOI 10.1038/ki.1993.378; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Volpert OV, 1996, J CLIN INVEST, V98, P671, DOI 10.1172/JCI118838; WEEKS BS, 1993, J CELL PHYSIOL, V157, P644, DOI 10.1002/jcp.1041570326; WERB Z, 1989, TXB RHEUMATOLOGY, P248; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINWOOD PJ, 1995, HEPATOLOGY, V22, P304; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOESSNER JF, 1995, METHOD ENZYMOL, V248, P510; Xia MH, 1996, J IMMUNOL, V156, P160; Yao PM, 1996, J BIOL CHEM, V271, P15580, DOI 10.1074/jbc.271.26.15580; Zaoui P, 1996, BBA-GEN SUBJECTS, V1290, P101, DOI 10.1016/0304-4165(96)00008-6; ZHOU H, 1993, BIOCHIM BIOPHYS ACTA, V1177, P174, DOI 10.1016/0167-4889(93)90037-P	51	79	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20677	20684		10.1074/jbc.273.32.20677	http://dx.doi.org/10.1074/jbc.273.32.20677			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685427	hybrid			2022-12-25	WOS:000075305400104
J	Baccetti, B; Collodel, G; Costantino-Ceccarini, E; Eshkol, A; Gambera, L; Moretti, E; Strazza, M; Piomboni, P				Baccetti, B; Collodel, G; Costantino-Ceccarini, E; Eshkol, A; Gambera, L; Moretti, E; Strazza, M; Piomboni, P			Localization of human follicle-stimulating hormone in the testis	FASEB JOURNAL			English	Article						FSHR mRNA; FSH antibody; human testis cells; mouse testis cells; ultrastructure	RECEPTOR MESSENGER-RNA; RAT TESTIS; FSH RECEPTOR; IMMUNOCYTOCHEMICAL LOCALIZATION; CELL-PROLIFERATION; SERTOLI CELLS; EXPRESSION; INTERNALIZATION; CLONING	Localization of the follicle-stimulating hormone (FSH) molecule and its receptor (FSHR), as well as the role of FSH in Sertoli cell mitosis and maturation, has been demonstrated by several investigators in human and murine testis by detecting the localization of anti-FSH antibodies or [I-131]-labeled FSH and by detecting FSH receptor (FSHR) mRNA by in situ hybridization, or FSHR by anti-FSHR antibodies. The presence of FSH in germinal cells is controversial or, in humans, excluded. We have investigated the distribution of the human FSH molecule and its receptor in human and mouse testicular cells under different experimental conditions, at the submicroscopical level, by using a better antigenicity conservative procedure. Thus, the distribution of FSH and of the messenger RNA for its receptor in Sertoli cells has now been clarified, In germinal cells, our observations demonstrate the presence of FSH and the FSHR mRNA: the first on the plasma membrane and in endocytotic vesicles, and the second scattered in the cytoplasm. The cells presenting the higher amount of positivity ranged from spermatogonia to spermatocytes, including round spermatids. Penetration was by the endocytosis via membrane vesicles in which the FSHR is present, whereas its messenger is largely present in the cytoplasm and is responsible for the binding and subsequent internalization of the FSH molecule. As a control, human FSH was administered in vitro to the Y1 mouse cell line, which was stably transfected with cDNA for FSHR and devoid of endogenous FSH. The FSH molecule has been localized by monoclonal antibodies on plasma membranes and vesicles, and the FSHR mRNA was found scattered in the cytoplasm after in situ hybridization. We can now conclude that FSH is present in Sertoli cells and in round germinal cells, both expressing the FSHR. FSH penetrates in a similar way in both kinds of cells via endocytosis, and is therefore subsequently localized in the same membranous organelles.	Univ Siena, Inst Gen Biol, I-53100 Siena, Italy; CNR, Ctr Study Germinal Cells, I-53100 Siena, Italy; Ares Serv SA, CH-1211 Geneva 20, Switzerland	University of Siena; Consiglio Nazionale delle Ricerche (CNR)	Baccetti, B (corresponding author), Univ Siena, Inst Gen Biol, Via T Pendola 62, I-53100 Siena, Italy.		piomboni, paola/AAB-9868-2019; collodel, giulia/AAW-5217-2021	collodel, giulia/0000-0003-1587-0159; Moretti, Elena/0000-0002-9467-0501				BACCETTI B, 1995, ZYGOTE, V3, P207, DOI 10.1017/S0967199400002604; BOCKERS TM, 1994, CELL TISSUE RES, V278, P595; BOITANI C, 1993, BIOL REPROD, V48, P761, DOI 10.1095/biolreprod48.4.761; CARLEMALM E, 1985, J MICROSC-OXFORD, V140, P55, DOI 10.1111/j.1365-2818.1985.tb02660.x; CASTRO AE, 1970, P SOC EXP BIOL MED, V133, P582; CASTRO AE, 1972, J ENDOCRINOL, V52, P129, DOI 10.1677/joe.0.0520129; DATTATREYAMURTY B, 1993, ENDOCRINOLOGY, V133, P1593, DOI 10.1210/en.133.4.1593; Fritz I., 1978, BIOCHEM ACTION HORM, V5, P249; HECKERT L, 1993, RECENT PROG HORM RES, V48, P61; HECKERT LL, 1991, MOL ENDOCRINOL, V5, P670, DOI 10.1210/mend-5-5-670; HON CA, 1983, AM J ANAT, V167, P441, DOI 10.1002/aja.1001670403; KELTON CA, 1992, MOL CELL ENDOCRINOL, V89, P141, DOI 10.1016/0303-7207(92)90220-Z; KLIESCH S, 1992, MOL CELL ENDOCRINOL, V84, pR45, DOI 10.1016/0303-7207(92)90039-9; KULKARNI SA, 1992, ARCH ANDROLOGY, V29, P87, DOI 10.3109/01485019208987713; MANCINI RE, 1967, J HISTOCHEM CYTOCHEM, V15, P516, DOI 10.1177/15.9.516; MEHTA MK, 1995, INT J FERTIL MENOP S, V40, P39; MINEGISH T, 1991, BIOCHEM BIOPH RES CO, V175, P1125, DOI 10.1016/0006-291X(91)91682-3; ORTH J, 1977, ENDOCRINOLOGY, V101, P262, DOI 10.1210/endo-101-1-262; ORTH J, 1978, ENDOCRINOLOGY, V103, P1944, DOI 10.1210/endo-103-5-1944; ORTH JM, 1984, ENDOCRINOLOGY, V115, P1248, DOI 10.1210/endo-115-4-1248; Sallese M, 1997, J BIOL CHEM, V272, P10188; SHIMIZU A, 1989, J BIOL CHEM, V264, P13632; SHIMIZU A, 1987, ENDOCRINOL JAPON, V34, P431; WAHLSTROM T, 1983, J CLIN ENDOCR METAB, V57, P825, DOI 10.1210/jcem-57-4-825; YOON DJ, 1987, ACTA ENDOCRINOL-COP, V116, P333, DOI 10.1530/acta.0.1160333	25	32	36	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1998	12	11					1045	1054		10.1096/fasebj.12.11.1045	http://dx.doi.org/10.1096/fasebj.12.11.1045			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707177				2022-12-25	WOS:000075372600015
J	Dollinger, MM; Howie, SEM; Plevris, JN; Graham, AM; Hayes, PC; Harrison, DJ				Dollinger, MM; Howie, SEM; Plevris, JN; Graham, AM; Hayes, PC; Harrison, DJ			Intrahepatic proliferation of 'naive' and 'memory' T cells during liver allograft rejection: primary immune response within the allograft	FASEB JOURNAL			English	Article						T lymphocytes; liver allograft rejection; transplantation; leukocyte	RENAL-ALLOGRAFTS; RECEPTOR; TRANSPLANTATION; INFILTRATION; EXPRESSION; APOPTOSIS; CD45RO; ALPHA	Liver allograft rejection is mediated by a primary response of T lymphocytes, followed by infiltration of the graft with a mixed inflammatory reaction. Using single and double label immunocytochemistry, we examined the proliferation index and the phenotype of leukocytes on liver biopsies from 10 patients with acute rejection before and after treatment with i.v. steroids, 10 patients with chronic rejection, 10 patients without rejection posttransplant, and 15 nongrafted, nonimmunosuppressed patients. Proliferation of mononuclear leukocytes (assessed by expression of Ki-67, a nuclear antigen associated with the cell cycle) inside the allograft was a prominent feature of acute and chronic rejection and was down-regulated by steroid treatment. Leukocytes in cell cycle were located predominantly in the portal tracts at the site of the inflammatory infiltrate. The majority of 'naive' (CD45RA+) and 'memory' (CD45RO+) CD4+ T lymphocytes were also periportally distributed. In contrast, CD8+ T lymphocytes, CD57+ natural killer cells, and CD68+ macrophages were located intraparenchymally throughout the liver lobules, whereas CD20+ B lymphocytes were only present in some of the portal tracts. Predominantly CD4+ and occasionally CD8+ lymphocytes were proliferating (assessed by double staining). The proliferating CD4+ cells were of both naive (CD4+, CD45RA+) and memory (CD4+, CD45RO+) phenotypes. To our knowledge, this is the first description of proliferating naive T lymphocytes in situ in Liver allografts. These findings suggest that there may be a primary immune response generated within the allograft as well as in draining lymphatic tissue. This implicates not only intrahepatic proliferation of T lymphocytes as a prominent feature of rejection, but also suggests that the liver has a special immunological status comparable to that of lymphatic tissue.	Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Royal Infirm, Dept Med, Liver Unit, Edinburgh EH3 9YW, Midlothian, Scotland	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Dollinger, MM (corresponding author), Univ Edinburgh, Sch Med, Dept Pathol, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	M.Dollinger@ed.ac.uk	Plevris, John N/O-3517-2014	harrison, david/0000-0001-9041-9988				ABBAS AK, 1994, CELLULAR MOL IMMUNOL, P431; BALAN V, 1997, HEPATOLOGY S4, V26, pA124; Bianchi E, 1997, IMMUNOL TODAY, V18, P586, DOI 10.1016/S0167-5699(97)01162-6; BREZINSCHEK RI, 1995, J IMMUNOL, V154, P3062; CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; Coates PJ, 1996, J PATHOL, V178, P71; Collins C, 1996, EUR J IMMUNOL, V26, P3114, DOI 10.1002/eji.1830261243; Crispe IN, 1996, IMMUNOL TODAY, V17, P522, DOI 10.1016/S0167-5699(96)80906-6; DEMETRIS AJ, 1991, AM J PATHOL, V138, P609; Dollinger M. M., 1998, Journal of Hepatology, V28, P61, DOI 10.1016/S0168-8278(98)80442-X; Dollinger M. M., 1997, Journal of Hepatology, V26, P149; Fabre JW, 1996, IMMUNOL REV, V154, P21, DOI 10.1111/j.1600-065X.1996.tb00928.x; Fisher L R, 1995, Liver Transpl Surg, V1, P10, DOI 10.1002/lt.500010104; FORBES RDC, 1986, J EXP MED, V164, P1239, DOI 10.1084/jem.164.4.1239; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; GERDES J, 1984, J IMMUNOL, V133, P1710; HAYRY P, 1983, TRANSPLANTATION CLIN, V15, P124; IBRAHIM S, 1993, AM J PATHOL, V142, P1794; IBRAHIM S, 1995, TRANSPLANTATION, V59, P724, DOI 10.1097/00007890-199503150-00015; ITOH N, 1993, J IMMUNOL, V151, P621; KAMADA N, 1981, NATURE, V292, P840, DOI 10.1038/292840a0; Knolle PA, 1997, HEPATOLOGY, V26, P1267; Legendre C, 1997, NEW ENGL J MED, V337, P822, DOI 10.1056/NEJM199709183371204; LUDWIG J, 1995, HEPATOLOGY, V22, P648; MACKAY CR, 1993, CURR OPIN IMMUNOL, V5, P423, DOI 10.1016/0952-7915(93)90063-X; MAKINO Y, 1993, J EXP MED, V177, P1399, DOI 10.1084/jem.177.5.1399; NEMLANDER A, 1982, J EXP MED, V156, P1087, DOI 10.1084/jem.156.4.1087; NEUBERGER J, 1995, J HEPATOL, V23, P54; OppenheimerMarks N, 1997, IMMUNOL TODAY, V18, P456, DOI 10.1016/S0167-5699(97)82723-5; Pape KA, 1997, IMMUNOL REV, V156, P67, DOI 10.1111/j.1600-065X.1997.tb00959.x; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; QUIAN S, 1997, J IMMUNOL, V158, P4654; SATO K, 1995, J EXP MED, V182, P759, DOI 10.1084/jem.182.3.759; SAYEGH MH, 1994, TRANSPLANTATION, V58, P125; Starzl TE, 1996, IMMUNOL TODAY, V17, P577, DOI 10.1016/S0167-5699(96)10070-0; SZEKANECZ Z, 1992, J CELL SCI, V101, P885; VONWILLEBRAND E, 1983, TRANSPLANT P, V15, P1195; WOO J, 1994, TRANSPLANTATION, V58, P484, DOI 10.1097/00007890-199408270-00015	38	26	26	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					939	947		10.1096/fasebj.12.11.939	http://dx.doi.org/10.1096/fasebj.12.11.939			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707166				2022-12-25	WOS:000075372600004
J	Spinella, MJ; Kitareewan, S; Mellado, B; Sekula, D; Khoo, KS; Dmitrovsky, E				Spinella, MJ; Kitareewan, S; Mellado, B; Sekula, D; Khoo, KS; Dmitrovsky, E			Specific retinoid receptors cooperate to signal growth suppression and maturation of human embryonal carcinoma cells	ONCOGENE			English	Article						retinoic acid; differentiation; embryonal carcinoma; teratocarcinoma; retinoid receptors	ACUTE PROMYELOCYTIC LEUKEMIA; 2ND PRIMARY TUMORS; ACID RECEPTOR; NEURONAL DIFFERENTIATION; HUMAN TERATOCARCINOMAS; SELECTIVE LIGANDS; RESPONSE ELEMENT; BINDING-PROTEIN; CO-REPRESSOR; ALPHA	This study addresses the contributions of specific retinoid receptors during all-trans-retinoic acid (RA)-mediated differentiation and growth suppression of human embryonal carcinoma cells. The pleiotropic effects of RA are mediated bg retinoic acid receptors (RARs) and retinoid, X receptors (RXRs), members of the nuclear receptor family of transcription factors, After RA-treatment the multipotent human embryonal carcinoma cell line NTERA-2 clone D1 (NT2/D1) displays limited proliferative potential, reduced tumorigenicity, and morphologic and immunophenotypic neuronal maturation. RAR gamma over-expression in NT2/D1 cells signals mesenchymal NT2/D1 terminal differentiation while RAR alpha and RAR beta do not and RAR gamma overcomes retinoid resistance in an NT2/D1 clone (NT2/D1-R1) having deregulated RAR gamma expression, Since RAR gamma transfectants do not display neuronal maturation, this study sought to identify cooperating retinoid receptors engaged in NT2/D1 differentiation. Through gain of function experiments, this report highlights RXR beta as playing an important role along with RAR gamma in signaling differentiation of NTZ/DI cells. Stable over-expression of RXR beta, but not RXR alpha or RXR gamma, was found to signal NT2/D1 growth suppression and to induce a non-neuronal morphology and immunophenotype pe. Notably, co-transfection of RAR gamma, and RXR beta resulted in marked growth suppression and for the first time, expression of typical neuronal markers of NT2/D1 differentiation. To clarify the role of RXR beta and RAR gamma in this differentiation program, a modified transient fibroblast growth factor-4 (FGF4) promoter-enhancer reporter assay that reflects effective RA-mediated differentiation of NT2/D1 cells was employed, Transfection of RAR gamma or RXR beta in NT2/D1 cells augments transcriptional repression of the FGF4 reporter and RAR gamma and RXR beta co-transfection markedly repressed reporter activity, indicating the combined role of these receptors in RA-induced NT2/D1 differentiation. Taken together, these findings reveal specific retinoid receptors must cooperate to signal terminal growth suppression and maturation of NT2/D1 cells. Since the transcriptional repression of FGF4 is coupled to the effective maturation of human embryonal carcinoma cells, the described co-transfection strategy should prove useful to identify genes with positive or negative effects on the differentiation program of these tumor cells.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Mem Hosp & Mol Pharmacol & Therapeut Program, Dept Med,Lab Mol Med, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Spinella, MJ (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Mem Hosp & Mol Pharmacol & Therapeut Program, Dept Med,Lab Mol Med, New York, NY 10021 USA.		Spinella, Michael/B-7210-2014		NCI NIH HHS [R01-CA54494-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn MJ, 1995, ONCOGENE, V11, P2357; AHN MJ, 1995, ONCOGENE, V10, P2307; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1986, DIFFERENTIATION, V31, P119, DOI 10.1111/j.1432-0436.1986.tb00392.x; ANGULO A, 1995, J VIROL, V69, P3831, DOI 10.1128/JVI.69.6.3831-3837.1995; BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; BOUILLET P, 1995, DEV BIOL, V170, P420, DOI 10.1006/dbio.1995.1226; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; Collignon J, 1996, DEVELOPMENT, V122, P509; Costa SL, 1996, EXP CELL RES, V225, P35, DOI 10.1006/excr.1996.0154; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; DOLLE P, 1990, DEVELOPMENT, V110, P1133; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; Horn V, 1996, FASEB J, V10, P1071, DOI 10.1096/fasebj.10.9.8801169; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JETTEN AM, 1979, NATURE, V278, P180, DOI 10.1038/278180a0; Kastner P, 1997, DEVELOPMENT, V124, P313; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KRUYT FAE, 1991, MECH DEVELOP, V33, P171, DOI 10.1016/0925-4773(91)90025-2; KURIE JM, 1993, DIFFERENTIATION, V54, P123; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LaVistaPicard N, 1996, MOL CELL BIOL, V16, P4137; Lei W, 1997, J MOL ENDOCRINOL, V18, P167, DOI 10.1677/jme.0.0180167; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LOTAN R, 1995, CANCER RES, V55, P232; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MILLER WH, 1990, ONCOGENE, V5, P511; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; Mills KJ, 1996, CELL GROWTH DIFFER, V7, P327; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; Muto Y, 1996, NEW ENGL J MED, V334, P1561, DOI 10.1056/NEJM199606133342402; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; ONATE SA, 1995, SCIENCE, V270, P1354; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Sporn M.B., 1994, RETINOIDS BIOL CHEM; TIESMAN J, 1989, IN VITRO CELL DEV B, V25, P1193; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WILLIAMS JB, 1985, P NATL ACAD SCI USA, V82, P4658, DOI 10.1073/pnas.82.14.4658; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V157, P618, DOI 10.1016/S0006-291X(88)80295-X; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	66	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	1998	16	26					3471	3480		10.1038/sj.onc.1201876	http://dx.doi.org/10.1038/sj.onc.1201876			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692555				2022-12-25	WOS:000074544100014
J	de Haan, JB; Bladier, C; Griffiths, P; Kelner, M; O'Shea, RD; Cheung, NS; Bronson, RT; Silvestro, MJ; Wild, S; Zheng, SS; Beart, PM; Hertzog, PJ; Kola, I				de Haan, JB; Bladier, C; Griffiths, P; Kelner, M; O'Shea, RD; Cheung, NS; Bronson, RT; Silvestro, MJ; Wild, S; Zheng, SS; Beart, PM; Hertzog, PJ; Kola, I			Mice with a homozygous null mutation for the most abundant glutathione peroxidase, Gpx1, show increased susceptibility to the oxidative stress-inducing agents paraquat and hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU/ZN-SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; ENZYME-ACTIVITY; KNOCKOUT MICE; FREE-RADICALS; GSHPX-GI; SELENIUM; GENE; EXPRESSION; CELLS	Glutathione peroxidases have been thought to function in cellular antioxidant defense. However, some recent studies on Gpx1 knockout (-/-) mice have failed to show a role for Gpx1 under conditions of oxidative stress such as hyperbaric oxygen and the exposure of eye lenses to high levels of H2O2. These findings have, unexpectedly, raised the issue of the role of Gpx1, especially under conditions of oxidative stress. Here we demonstrate a role for Gpx1 in protection against oxidative stress by showing that Gpx1 (-/-) mice are highly sensitive to the oxidant paraquat. Lethality was already detected within 24 h in mice exposed to paraquat at 10 mg . kg(-1) (approximately 1/7 the LD50 of wild-type controls). The effects of paraquat were dose-related. In the 30 mg . kg(-1)-treated group, 100% of mice died within 5 h, whereas the controls showed no evidence of toxicity. me further demonstrate that paraquat transcriptionally upregulates Gpx1 in normal cells, reinforcing a role for Gpzl in protection against paraquat toxicity. Finally, we show that cortical neurons from Gpx1 (-/-) mice are more susceptible to H2O2; 30% of neurons from Gpx1 (-/-) mice were killed when exposed to 65 mu M H2O2, whereas the wild-type controls were unaffected. These data establish a function for Gpx1 in protection against some oxidative stressors and in protection of neurons against H2O2. Further, they emphasize the need to elucidate the role of Gpx1 in protection against different oxidative stressors and in different disease states and suggest that Gpx1 (-/-) mice may be valuable for studying the role of H2O2 in neurodegenerative disorders.	Monash Med Ctr, Inst Reprod & Dev, Mol Genet & Dev Grp, Clayton, Vic 3168, Australia; Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; Monash Univ, Dept Pharmacol, Clayton, Vic 3168, Australia; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA	Monash University; University of California System; University of California San Diego; Monash University; Tufts University	Kola, I (corresponding author), Monash Med Ctr, Inst Reprod & Dev, Mol Genet & Dev Grp, 246 Clayton Rd, Clayton, Vic 3168, Australia.		O'Shea, Ross D/B-5426-2012; Hertzog, Paul J/I-7053-2013; Kola, Ismail/C-5254-2013; de Haan, Judy/E-8778-2010	O'Shea, Ross D/0000-0002-8178-8797; Hertzog, Paul J/0000-0002-1373-8472; de Haan, Judy B./0000-0002-2749-7833	NIEHS NIH HHS [R01ES04989] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004989] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BALDIER C, 1997, CELL GROWTH DIFFER, V8, P589; BarPeled O, 1996, P NATL ACAD SCI USA, V93, P8530, DOI 10.1073/pnas.93.16.8530; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; BUS JS, 1976, TOXICOL APPL PHARM, V35, P501, DOI 10.1016/0041-008X(76)90073-9; BUS JS, 1974, BIOCHEM BIOPH RES CO, V58, P749, DOI 10.1016/S0006-291X(74)80481-X; BUSCIGLIO J, 1995, NATURE, V378, P777; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; Cheng WH, 1997, J NUTR, V127, P1445, DOI 10.1093/jn/127.8.1445; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU FF, 1992, BLOOD, V79, P3233; CHU FF, 1990, NUCLEIC ACIDS RES, V18, P1531, DOI 10.1093/nar/18.6.1531; CHU FF, 1993, J BIOL CHEM, V268, P2571; CHU FF, 1995, ARCH BIOCHEM BIOPHYS, V323, P288, DOI 10.1006/abbi.1995.9962; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DE R, 1979, TOXICOL APPL PHARM, V48, P479; DEHAAN JB, 1995, BIOCHEM MOL BIOL INT, V35, P1281; deHaan JB, 1996, HUM MOL GENET, V5, P283, DOI 10.1093/hmg/5.2.283; DEHAAN JB, 1992, MOL BRAIN RES, V13, P179, DOI 10.1016/0169-328X(92)90025-7; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; FREEMAN BA, 1982, LAB INVEST, V47, P412; Fuchs O, 1997, NEOPLASMA, V44, P184; GHYSELINCK NB, 1993, MOL ENDOCRINOL, V7, P258, DOI 10.1210/me.7.2.258; GIRI SN, 1983, TOXICOL APPL PHARM, V71, P132, DOI 10.1016/0041-008X(83)90052-2; Halliwel B, 1989, FREE RADICALS BIOL M; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HASSAN HM, 1979, ARCH BIOCHEM BIOPHYS, V196, P385, DOI 10.1016/0003-9861(79)90289-3; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; HORNSBY PJ, 1985, J CELL PHYSIOL, V123, P33, DOI 10.1002/jcp.1041230106; Hussain S, 1995, INT J DEV NEUROSCI, V13, P811, DOI 10.1016/0736-5748(95)00071-2; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; JONES DP, 1981, ARCH BIOCHEM BIOPHYS, V210, P505, DOI 10.1016/0003-9861(81)90215-0; Jornot L, 1997, BIOCHEM J, V326, P117, DOI 10.1042/bj3260117; KEELING PL, 1982, BIOCHIM BIOPHYS ACTA, V716, P249, DOI 10.1016/0304-4165(82)90275-6; KELNER MJ, 1990, FREE RADICAL BIO MED, V9, P149, DOI 10.1016/0891-5849(90)90118-3; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; KHAN AU, 1995, CHEM BIOL, V2, P437; Kola I, 1997, HUM MOL GENET, V6, P1713, DOI 10.1093/hmg/6.10.1713; Larm JA, 1997, J NEUROCHEM, V69, P617; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; MAIORINO M, 1991, FREE RADICAL RES COM, V12-3, P131, DOI 10.3109/10715769109145777; MAKINO N, 1994, J BIOL CHEM, V269, P1020; MARTINDALE, 1978, EXTRA PHARMACOPOEIA, P794; MOSCOW JA, 1992, J BIOL CHEM, V267, P5949; NICHOLLS P, 1972, BIOCHIM BIOPHYS ACTA, V279, P306, DOI 10.1016/0304-4165(72)90147-X; POOT M, 1991, MUTAT RES, V256, P117; RAHMAN IU, 1992, FREE RADICAL BIO MED, V12, P323, DOI 10.1016/0891-5849(92)90119-2; Reddy VN, 1997, OPHTHALMOLOGICA, V211, P192, DOI 10.1159/000310788; Sagara Y, 1996, J NEUROSCI, V16, P497; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUCKELT R, 1991, FREE RADICAL RES COM, V14, P343, DOI 10.3109/10715769109093424; Sies H., 1991, OXIDATIVE STRESS OXI; SOHAL RS, 1990, MECH AGEING DEV, V53, P217, DOI 10.1016/0047-6374(90)90040-M; Spector A, 1996, EXP EYE RES, V62, P521, DOI 10.1006/exer.1996.0063; Spector A, 1997, EXP EYE RES, V64, P477, DOI 10.1006/exer.1996.0250; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; URSINI F, 1987, CHEM PHYS LIPIDS, V44, P255, DOI 10.1016/0009-3084(87)90053-3; VERNET P, 1996, CELL BIOL, V74, P125; Yoshida T, 1997, CIRCULATION, V96, P216; YOSHIMURA S, 1991, J BIOCHEM-TOKYO, V109, P918, DOI 10.1093/oxfordjournals.jbchem.a123480	62	354	361	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22528	22536		10.1074/jbc.273.35.22528	http://dx.doi.org/10.1074/jbc.273.35.22528			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712879	hybrid, Green Published			2022-12-25	WOS:000075616600055
J	Kurdi-Haidar, B; Heath, D; Aebi, S; Howell, SB				Kurdi-Haidar, B; Heath, D; Aebi, S; Howell, SB			Biochemical characterization of the human arsenite-stimulated ATPase (hASNA-I)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ARS OPERON; RESISTANCE; BINDING; PURIFICATION; SUBUNITS; HOMOLOG	Arsenic is a potent toxin and carcinogen. In pro karyotes, arsenic detoxification is accomplished by chromosomal and plasmid-borne operon-encoded efflux systems. We have previously reported the cloning of hASNA-I, a human homologue of arsA encoding the ATPase component of the Escherichia coli arsenite transporter. Purified glutathione S-transferase (GST)hASNA-I fusion protein was biochemically characterized, and its properties were compared with those of ArsA. The GST-hASNA-I exhibited a basal level of ATPase activity of 18.5 +/- 8 nmol/min/mg in the absence of arsenite. Arsenite produced a 1.6 +/- 0.1-fold stimulation of activity (p = 0.0044), which was related to an increase in V-max; antimonite did not stimulate activity. Two lines of evidence suggest that an oligomer is the most likely native form of hASNA-I, First, lysates of human embryo kidney 293 cells overproducing recombinant hASNA-I produced a single monomeric 37-kDa band on SDS-polyacrylamide gel electrophoresis (PAGE) and two distinct species when analyzed using nondenaturing PAGE. Second, chemical cross-linking of the 63-kDa GST-hASNA-I resulted in the formation of dimeric and tetrameric protein forms, The results indicate that hASNA-I is a distinct human arsenite-stimulated ATPase belonging to the same superfamily of ATPases represented by the E. coli ArsA protein.	Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Bern, Dept Med Oncol, CH-3010 Bern, Switzerland	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Bern	Kurdi-Haidar, B (corresponding author), Univ Calif San Diego, Ctr Canc, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Aebi, Stefan/F-2004-2010	Aebi, Stefan/0000-0002-3383-9449	NATIONAL CANCER INSTITUTE [R01CA069004] Funding Source: NIH RePORTER; NCI NIH HHS [CA69004] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIN A, 1995, J BACTERIOL, V177, P981, DOI 10.1128/jb.177.4.981-986.1995; DIORIO C, 1995, J BACTERIOL, V177, P2050, DOI 10.1128/jb.177.8.2050-2056.1995; DUPUIS A, 1985, BIOCHEMISTRY-US, V24, P734, DOI 10.1021/bi00324a030; GLADYSHEVA TB, 1994, BIOCHEMISTRY-US, V33, P7288, DOI 10.1021/bi00189a033; HEDGES RW, 1973, J BACTERIOL, V115, P459, DOI 10.1128/JB.115.1.459-460.1973; HSU CM, 1989, J BIOL CHEM, V264, P17349; HSU CM, 1991, J BIOL CHEM, V266, P2327; JI GY, 1992, J BACTERIOL, V174, P3684, DOI 10.1128/JB.174.11.3684-3694.1992; KOONIN EV, 1993, J MOL BIOL, V229, P1165, DOI 10.1006/jmbi.1993.1115; KurdiHaidar B, 1996, GENOMICS, V36, P486, DOI 10.1006/geno.1996.0494; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; NAKATSUJI T, 1981, ANAL BIOCHEM, V112, P52, DOI 10.1016/0003-2697(81)90258-X; NOVICK RP, 1968, J BACTERIOL, V95, P1335, DOI 10.1128/JB.95.4.1335-1342.1968; OLEARY KA, 1988, ARCH BIOCHEM BIOPHYS, V264, P1, DOI 10.1016/0003-9861(88)90563-2; ROSEN BP, 1990, BIOCHIM BIOPHYS ACTA, V1018, P203, DOI 10.1016/0005-2728(90)90249-4; ROSENSTEIN R, 1992, J BACTERIOL, V174, P3676, DOI 10.1128/JB.174.11.3676-3683.1992; SMITH DB, 1992, CURRENT PROTOCOLS MO, V2; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; Wang ZL, 1996, TOXICOL APPL PHARM, V137, P112, DOI 10.1006/taap.1996.0062	21	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22173	22176		10.1074/jbc.273.35.22173	http://dx.doi.org/10.1074/jbc.273.35.22173			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712828	hybrid, Green Published			2022-12-25	WOS:000075616600004
J	Rivera, I; Harhaj, EW; Sun, SC				Rivera, I; Harhaj, EW; Sun, SC			Involvement of NF-AT in type I human T-cell leukemia virus tax-mediated Fas ligand promoter transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; TRANSCRIPTION FACTOR NFAT1; RECEPTOR GENE-EXPRESSION; KAPPA-B-ALPHA; HTLV-I; C-REL; INTERLEUKIN-2 PROMOTER; NUCLEAR-LOCALIZATION; RESPONSE ELEMENT; ACTIVATOR TAX	Human T-cell leukemia virus type I (HTLV-I)-infected T-cells constitutively express surface Fas ligand (FasL), which may serve as a mechanism of viral pathogenesis. HTLV-I induces transcription of FasL gene through the viral transactivator Tax, although the underlying molecular mechanism remains unclear. In the present study, we have analyzed both the cis-activating element and transactivating factors involved in Tax activation of the Fast promoter. We show that the 486-base pair upstream region of the human Fast gene is sufficient for Tax-mediated transactivation in Jurkat T-cells. Interestingly, a palindromic DNA sequence (GGAAACTTCC) covering the consensus NF-ATp binding site (GGAAA), is required for Tax activation of Fast promoter. The involvement of NF-AT in this transactivation event is suggested by the finding that Tax fails to activate the Fast promoter in a Jurkat T-cell line defective in capacitative calcium entry, a signaling mechanism involved in NF-AT activation. Furthermore, activation of Fast promoter by Tax is largely attenuated in the nonlymphoid F9 embryonal and COS kidney cells deficient in NF-ATE, expression. DNA-protein interaction assays reveal that the NF-AT-like motif in the Fast promoter is bound by both NF-ATp and NF-AT4 in Jurkat T-cells expressing Tax. The binding of NF-ATp, although not NF-AT4, to this enhancer also occurs along with HTLV-I-mediated infection of human peripheral blood T-cells. Furthermore, exogenously transfected NF-ATp binds to the NF-AT-like enhancer and participates in Tax-mediated Fast promoter transactivation. These results suggest an important role for proteins of the NF-AT family in HTLV-1 Tax-mediated Fast gene transactivation.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.	sxs70@psu.edu			NCI NIH HHS [1 R01 CA68471-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; BALLARD D W, 1989, New Biologist, V1, P83; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Chen XL, 1997, J GEN VIROL, V78, P3277, DOI 10.1099/0022-1317-78-12-3277; CHLICHLIA K, 1995, ONCOGENE, V10, P269; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1054; CRENON I, 1993, ONCOGENE, V8, P867; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; Curtiss VE, 1996, MOL CELL BIOL, V16, P3567; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GESSAIN A, 1985, LANCET, V2, P407; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; Green DR, 1997, P NATL ACAD SCI USA, V94, P5986, DOI 10.1073/pnas.94.12.5986; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Himes SR, 1996, J VIROL, V70, P4001, DOI 10.1128/JVI.70.6.4001-4008.1996; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Latinis KM, 1997, J IMMUNOL, V158, P4602; LI M, 1993, MOL CELL BIOL, V13, P6490, DOI 10.1128/MCB.13.10.6490; Loh C, 1996, MOL CELL BIOL, V16, P3945; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; Maggirwar SB, 1997, MOL CELL BIOL, V17, P2605, DOI 10.1128/MCB.17.5.2605; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MERL S, 1984, BLOOD, V64, P967; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MIYOSHI I, 1981, GANN, V72, P978; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NISHIOKA K, 1993, RHEUM DIS CLIN N AM, V19, P489; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OSAME M, 1986, LANCET, V1, P1031; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; PERSAUD D, 1995, J VIROL, V69, P6297, DOI 10.1128/JVI.69.10.6297-6303.1995; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1996, MOL CELL BIOL, V16, P1058; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; VERWEIJ CL, 1991, J BIOL CHEM, V266, P14179; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; Xu XN, 1997, J EXP MED, V186, P7, DOI 10.1084/jem.186.1.7; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	83	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22382	22388		10.1074/jbc.273.35.22382	http://dx.doi.org/10.1074/jbc.273.35.22382			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712859	hybrid			2022-12-25	WOS:000075616600035
J	Hesslinger, C; Kremmer, E; Hultner, L; Ueffing, M; Ziegler, I				Hesslinger, C; Kremmer, E; Hultner, L; Ueffing, M; Ziegler, I			Phosphorylation of GTP cyclohydrolase I and modulation of its activity in rodent mast cells - GTP cyclohydrolase I hyperphosphorylation is coupled to high affinity IgE receptor signaling and involves protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; TETRAHYDROBIOPTERIN SYNTHESIS; INTERFERON-GAMMA; IMMUNOGLOBULIN-E; SENSITIVE ASSAY; MESSENGER-RNA; RAT; ACTIVATION; EXPRESSION; SUBSTRATE	GTP cyclohydrolase I controls the de novo pathway for the synthesis of tetrahydrobiopterin, which is the essential cofactor for tryptophan 5-monooxygenase and thus, for serotonin production. In mouse bone marrow-derived mast cells, the kit Ligand selectively up-regulates GTP cyclohydrolase I activity (Ziegler, I., Hultner, L., Egger, D., Kempkes, B., Mailhammer, R., Gillis, S., and Rodl, W. (1993) J. Biol. Chem. 268, 12544-12551), Immunoblot analysis now confirms that this long term enhancement is caused by increased expression of the enzyme. Furthermore we show that GTP cyclohydrolase I is subject to modification at the post-translational level. In vivo labeling with [P-32]orthophosphate demonstrates that in primary mast cells and in transfected RBL-2H3 cells overexpressing GTP cyclohydrolase I, the enzyme exists in a phosphorylated form, Antigen binding to the high affinity receptor for IgE triggers an additional and transient phosphorylation of GTP cyclohydrolase I with a concomitant rise in its activity, and in consequence, cellular tetrahydrobiopterin levels increase, These events culminate 8 min after stimulation and call be mimicked by phorbol ester. The hyperphosphorylation is greatly reduced by the protein kinase C inhibitor Ro-31-8220. In vitro phosphorylation studies indicate that GTP cyclohydrolase I is a substrate for both casein kinase II and protein kinase C.	GSF, Inst Klin Mol Biol & Tumorgenet, D-81377 Munich, Germany; GSF, Inst Immunol, D-81377 Munich, Germany; GSF, Inst Expt Hamatol, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Hesslinger, C (corresponding author), GSF, Inst Klin Mol Biol & Tumorgenet, Marchioninistr 25, D-81377 Munich, Germany.	hesslinger@gsf.de						ALBER G, 1992, J IMMUNOL, V149, P2428; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENHAMOU M, 1997, IGE RECEPTOR FCERI F, P33; DAVIS MD, 1988, EUR J BIOCHEM, V173, P345, DOI 10.1111/j.1432-1033.1988.tb14004.x; DIRKS W, 1993, GENE, V128, P247, DOI 10.1016/0378-1119(93)90569-O; DUTCH DS, 1991, J NUTR BIOCH, V2, P411; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GERMANO P, 1994, J BIOL CHEM, V269, P23102; Gutlich M, 1996, BIOCHEM J, V314, P95; GUTLICH M, 1992, BIOCHIM BIOPHYS ACTA, V1171, P133, DOI 10.1016/0167-4781(92)90112-D; GUTLICH M, 1994, BIOCHEM BIOPH RES CO, V203, P1675, DOI 10.1006/bbrc.1994.2379; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HendricksTaylor LR, 1997, J BIOL CHEM, V272, P1363, DOI 10.1074/jbc.272.2.1363; HULTNER L, 1989, IMMUNOLOGY, V67, P408; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; KAUFMAN S, 1972, OXYGENASES, P285; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KERLER F, 1989, BIOCHIM BIOPHYS ACTA, V990, P15, DOI 10.1016/S0304-4165(89)80005-4; KERLER F, 1990, J CELL PHYSIOL, V142, P268, DOI 10.1002/jcp.1041420208; Kieser A, 1996, GENE DEV, V10, P1455, DOI 10.1101/gad.10.12.1455; KIHARA H, 1994, J BIOL CHEM, V269, P22427; KREMMER E, 1995, VIROLOGY, V208, P336, DOI 10.1006/viro.1995.1157; KUHN DM, 1980, ARCH BIOCHEM BIOPHYS, V199, P355, DOI 10.1016/0003-9861(80)90291-X; KULCZYCKI A, 1974, J EXP MED, V139, P600, DOI 10.1084/jem.139.3.600; LEVENBERG B, 1959, J BIOL CHEM, V234, P955; MAIER J, 1995, BIOCHEM BIOPH RES CO, V212, P705, DOI 10.1006/bbrc.1995.2026; Milstien S, 1996, J BIOL CHEM, V271, P19743, DOI 10.1074/jbc.271.33.19743; Nar H, 1995, P NATL ACAD SCI USA, V92, P12120, DOI 10.1073/pnas.92.26.12120; NIXON JS, 1992, BIOCHEM SOC T, V20, P419, DOI 10.1042/bst0200419; Pluss C, 1996, BIOCHEM J, V318, P665; REMBOLD H, 1969, BIOCHIM BIOPHYS ACTA, V184, P589, DOI 10.1016/0304-4165(69)90273-6; RIVERA J, 1997, IGE RECEPTOR FCERI F, P107; SAWADA M, 1986, ANAL BIOCHEM, V154, P361, DOI 10.1016/0003-2697(86)90537-3; SCHOEDON G, 1987, EUR J BIOCHEM, V166, P303, DOI 10.1111/j.1432-1033.1987.tb13515.x; SCHOTT K, 1992, EXP CELL RES, V200, P105, DOI 10.1016/S0014-4827(05)80077-1; SCHOTT K, 1993, J CELL PHYSIOL, V156, P12, DOI 10.1002/jcp.1041560103; SEIDL J, 1986, BIOCHEM BIOPH RES CO, V141, P494, DOI 10.1016/S0006-291X(86)80200-5; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; WURSTER B, 1981, J BACTERIOL, V148, P183, DOI 10.1128/JB.148.1.183-192.1981; Yoneyama T, 1997, J BIOL CHEM, V272, P9690; ZANDOMENI R, 1984, J BIOL CHEM, V259, P4804; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; ZIEGLER I, 1990, J BIOL CHEM, V265, P17026; ZIEGLER I, 1985, J CELL BIOCHEM, V28, P197, DOI 10.1002/jcb.240280303; ZIEGLER I, 1993, ADV EXP MED BIOL, V338, P211; ZIEGLER I, 1993, J BIOL CHEM, V268, P12544; ZIEGLER I, 1992, FEBS LETT, V307, P147, DOI 10.1016/0014-5793(92)80755-6	49	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21616	21622		10.1074/jbc.273.34.21616	http://dx.doi.org/10.1074/jbc.273.34.21616			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705293	hybrid			2022-12-25	WOS:000075492600027
J	Moyer, BD; Loffing, J; Schwiebert, EM; Loffing-Cueni, D; Halpin, PA; Karlson, KH; Ismailov, II; Guggino, WB; Langford, GM; Stanton, BA				Moyer, BD; Loffing, J; Schwiebert, EM; Loffing-Cueni, D; Halpin, PA; Karlson, KH; Ismailov, II; Guggino, WB; Langford, GM; Stanton, BA			Membrane trafficking of the cystic fibrosis gene product, cystic fibrosis transmembrane conductance regulator, tagged with green fluorescent protein in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING CHLORIDE CHANNELS; EPITHELIAL-CELLS; PLASMA-MEMBRANE; VIRAL GLYCOPROTEINS; COLLECTING DUCT; XENOPUS-OOCYTES; LIPID BILAYERS; MDCK CELLS; 2 STRAINS; CFTR	The mechanism by which cAMP stimulates cystic fibrosis transmembrane conductance regulator (CFTR)-mediated chloride (Cl-) secretion is cell type-specific. By using Madin-Darby canine kidney (MDCK) type I epithelial cells as a model, we tested the hypothesis that cAMP stimulates Cl- secretion by stimulating CFTR Cl- channel trafficking from an intracellular pool to the apical plasma membrane. To this end, we generated a green fluorescent protein (GFP)-CFTR expression vector in which GFP was linked to the N terminus of CFTR, GFP did not alter CFTR function in whole cell patch-clamp or planar lipid bilayer experiments. In stably transfected MDCK type I cells, GFP-CFTR localization was substratum dependent. In cells grown on glass coverslips, GFP-CFTR was polarized to the basolateral membrane, whereas in cells grown on permeable supports, GFP-CFTR was polarized to the apical membrane. Quantitative confocal fluorescence microscopy and surface biotinylation experiments demonstrated that cAMP did not stimulate detectable GFP-CFTR translocation from an intracellular pool to the apical membrane or regulate GFP-CFTR endocytosis. Disruption of the microtubular cytoskeleton with colchicine did not affect cAMP-stimulated Cl- secretion or GFP-CFTR expression in the apical membrane. We conclude that cAMP stimulates CFTR-mediated Cl- secretion in MDCK type I cells by activating channels resident in the apical plasma membrane.	Dartmouth Med Sch, Dept Physiol, Hanover, NH 03755 USA; Dartmouth Med Sch, Dept Biol, Hanover, NH 03755 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA	Dartmouth College; Dartmouth College; Johns Hopkins University; University of Alabama System; University of Alabama Birmingham	Stanton, BA (corresponding author), Dartmouth Med Sch, Dept Physiol, Hanover, NH 03755 USA.	Bruce.A.Stanton@Dartmouth.edu	Loffing, Johannes/ABG-9973-2020	Langford, George/0000-0001-9737-2182; Loffing, Johannes/0000-0002-9415-6588	NCI NIH HHS [CA 23108] Funding Source: Medline; NIDDK NIH HHS [DK-45881, DK-51067] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045881, R01DK051067] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BRADBURY NA, 1994, AM J PHYSIOL, V267, pC1, DOI 10.1152/ajpcell.1994.267.1.C1; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CLIFF WH, 1992, AM J PHYSIOL, V262, pC1154, DOI 10.1152/ajpcell.1992.262.5.C1154; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DAndrea L, 1996, J BIOL CHEM, V271, P28969, DOI 10.1074/jbc.271.46.28969; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; GEKLE M, 1994, PFLUG ARCH EUR J PHY, V428, P157, DOI 10.1007/BF00374853; Gerdes HH, 1996, FEBS LETT, V389, P44, DOI 10.1016/0014-5793(96)00586-8; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; GOTTLIEB TA, 1986, J CELL BIOL, V102, P1242, DOI 10.1083/jcb.102.4.1242; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; Hanaoka K, 1996, AM J PHYSIOL-CELL PH, V270, pC389, DOI 10.1152/ajpcell.1996.270.1.C389; HANSSON GC, 1986, EMBO J, V5, P483, DOI 10.1002/j.1460-2075.1986.tb04237.x; Howard M, 1996, KIDNEY INT, V49, P1642, DOI 10.1038/ki.1996.239; HOWARD MB, 1996, PED PULMONOL S, V13, P231; Hug MJ, 1997, PFLUG ARCH EUR J PHY, V434, P779, DOI 10.1007/s004240050465; HUSTED RF, 1995, J CLIN INVEST, V95, P644, DOI 10.1172/JCI117709; JILING T, 1997, INT REV CYTOL, V172, P193; JOVOV B, 1995, J BIOL CHEM, V270, P1521, DOI 10.1074/jbc.270.4.1521; JOVOV B, 1995, J BIOL CHEM, V270, P29194, DOI 10.1074/jbc.270.49.29194; KAETHER C, 1995, FEBS LETT, V369, P267, DOI 10.1016/0014-5793(95)00765-2; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; KUWAHARA M, 1995, J BIOL CHEM, V270, P10384, DOI 10.1074/jbc.270.18.10384; Lehrich RW, 1998, J CLIN INVEST, V101, P737, DOI 10.1172/JCI803; LIM CR, 1995, J BIOCHEM-TOKYO, V118, P13, DOI 10.1093/oxfordjournals.jbchem.a124868; Ling BN, 1997, J BIOL CHEM, V272, P594; LippincottSchwartz J, 1997, CURR OPIN NEUROBIOL, V7, P631, DOI 10.1016/S0959-4388(97)80082-7; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; Lukacs GL, 1997, BIOCHEM J, V328, P353; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; Makhina EN, 1998, J BIOL CHEM, V273, P3369, DOI 10.1074/jbc.273.6.3369; Maples CJ, 1997, J BIOL CHEM, V272, P6741, DOI 10.1074/jbc.272.10.6741; MARPLES D, 1995, AM J PHYSIOL-CELL PH, V269, pC655, DOI 10.1152/ajpcell.1995.269.3.C655; MARSHALL J, 1994, J BIOL CHEM, V269, P2987; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; Mohamed A, 1997, BIOCHEM J, V322, P259, DOI 10.1042/bj3220259; Morris RG, 1998, AM J PHYSIOL-RENAL, V274, pF300, DOI 10.1152/ajprenal.1998.274.2.F300; MOYER BD, 1997, EXPRESSIONS, V4, P6; NICHOLS GE, 1986, BIOCHIM BIOPHYS ACTA, V887, P1, DOI 10.1016/0167-4889(86)90115-1; OSTEDGAARD LS, 1992, J BIOL CHEM, V267, P26142; PEREZ G, 1994, BIOPHYS J, V66, P1022, DOI 10.1016/S0006-3495(94)80883-5; PRINCE LS, 1993, AM J PHYSIOL, V264, pC491, DOI 10.1152/ajpcell.1993.264.2.C491; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; Rice JE, 1996, BIOCHEM SOC T, V24, P540, DOI 10.1042/bst0240540; RICHARDSON JCW, 1981, BIOCHIM BIOPHYS ACTA, V673, P26, DOI 10.1016/0304-4165(81)90307-X; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; RIORDAN JR, 1989, SCIENCE, V245, P1066; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P2674, DOI 10.1073/pnas.95.5.2674; SCHWIEBERT EM, 1994, AM J PHYSIOL, V266, pC1464, DOI 10.1152/ajpcell.1994.266.5.C1464; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Stanton BA, 1997, WIEN KLIN WOCHENSCHR, V109, P457; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TILLY BC, 1992, J BIOL CHEM, V267, P9470; Torres RJ, 1996, AM J PHYSIOL-CELL PH, V271, pC1574, DOI 10.1152/ajpcell.1996.271.5.C1574; Tousson A, 1996, J CELL SCI, V109, P1325; Valentich J D, 1981, Ann N Y Acad Sci, V372, P384, DOI 10.1111/j.1749-6632.1981.tb15490.x; VANDORPE D, 1995, AM J PHYSIOL-CELL PH, V269, pC683, DOI 10.1152/ajpcell.1995.269.3.C683; WARD CL, 1994, J BIOL CHEM, V269, P25710; WESTERMEIER R, 1993, ELECTROPHORESIS PRAC, P167; Zhang GH, 1996, BIOCHEM BIOPH RES CO, V227, P707, DOI 10.1006/bbrc.1996.1573	68	143	145	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21759	21768		10.1074/jbc.273.34.21759	http://dx.doi.org/10.1074/jbc.273.34.21759			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705313	hybrid			2022-12-25	WOS:000075492600047
J	Bai, M; Trivedi, S; Lane, CR; Yang, YH; Quinn, SJ; Brown, EM				Bai, M; Trivedi, S; Lane, CR; Yang, YH; Quinn, SJ; Brown, EM			Protein kinase C phosphorylation of threonine at position 888 in Ca-0(2+)-sensing receptor (CaR) inhibits coupling to Ca2+ store release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PARATHYROID CELLS; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; NEONATAL SEVERE HYPERPARATHYROIDISM; CA2+-SENSING RECEPTOR; HORMONE RELEASE; SENSING RECEPTOR; CALCIUM RECEPTOR; RAT HIPPOCAMPUS; ACTIVATION; SECRETION	Previous studies in parathyroid cells, which express the G protein-coupled, extracellular calcium-sensing receptor (CaR), showed that activation of protein kinase C (PKC) blunts high extracellular calcium (Ca-o(2+))-evoked stimulation of phospholipase C and the associated increases in cytosolic calcium (Ca-i(2+)), suggesting that PKC may directly modulate the coupling of the CaR to intracellular signaling systems, In this study, we examined the role of PKC in regulating the coupling of the CaR to Ca-i(2+) dynamics in fura-2-loaded human embryonic kidney cells (HEK293 cells) transiently transfected with the human parathyroid CaR, We demonstrate that several PKC activators exert inhibitory effects on CaR-mediated increases in Ca-i(2+) due to release of Ca2+ from intracellular stores. Consistent with the effect being mediated by activation of PKC, the inhibitory effect of PRC activators on Ca2+ release can be blocked by a PKC inhibitor. The use of site-directed mutagenesis reveals that threonine at amino acid position 888 is the major PKC site that mediates the inhibitory effect of PKC activators on Ca2+ mobilization, The effect of PKC activation can be maximally blocked by mutating three PKC sites (Thr(888), Ser(895), and Ser(915)) or all five PKC sites. In vitro phosphorylation shows that Thr(888) is readily phosphorylated by PKC, Our results suggest that phosphorylation of the CaR, is the molecular basis for the previously described effect of PKC activation on Ca-o(2+)-evoked changes in Ca-i(2+) dynamics in parathyroid cells.	Brigham & Womens Hosp, Div Endocrine Hypertens, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Childrens Hosp, Dept Cardiol, Res Lab, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Bai, M (corresponding author), Brigham & Womens Hosp, Div Endocrine Hypertens, Dept Med, 221 Longwood Ave, Boston, MA 02115 USA.				NIDDK NIH HHS [DK48330, DK09436, DK41415] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009436, R01DK048330, R01DK041415] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIDA K, 1995, J CLIN ENDOCR METAB, V80, P2594, DOI 10.1210/jc.80.9.2594; Bai M, 1997, J CLIN INVEST, V99, P1917, DOI 10.1172/JCI119359; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; BROWN EM, 1995, CELL, V83, P679, DOI 10.1016/0092-8674(95)90180-9; CHANG WH, 1995, AM J PHYSIOL-ENDOC M, V269, pE864, DOI 10.1152/ajpendo.1995.269.5.E864; CLARKE BL, 1993, ENDOCRINOLOGY, V132, P1168, DOI 10.1210/en.132.3.1168; COLINO A, 1993, EUR J NEUROSCI, V5, P1198, DOI 10.1111/j.1460-9568.1993.tb00974.x; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; FAJTOVA VT, 1991, AM J PHYSIOL, V261, pE151, DOI 10.1152/ajpendo.1991.261.1.E151; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Gogusev J, 1997, KIDNEY INT, V51, P328, DOI 10.1038/ki.1997.41; GUERINEAU NC, 1995, J NEUROSCI, V15, P4395; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; ISHIZUKA T, 1987, ENDOCRINOL JAPON, V34, P965; Kifor O, 1996, J CLIN ENDOCR METAB, V81, P1598, DOI 10.1210/jc.81.4.1598; KIFOR O, 1990, J BONE MINER RES, V5, P1003; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacrezLepretre N, 1997, J BIOL CHEM, V272, P5261, DOI 10.1074/jbc.272.8.5261; MEMBRENO L, 1989, ENDOCRINOLOGY, V124, P789, DOI 10.1210/endo-124-2-789; MORRISSEY JJ, 1988, AM J PHYSIOL, V254, pE63, DOI 10.1152/ajpendo.1988.254.1.E63; MUFF R, 1988, ARCH BIOCHEM BIOPHYS, V265, P128, DOI 10.1016/0003-9861(88)90378-5; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; RACKE FK, 1993, J PHYSIOL-LONDON, V468, P141, DOI 10.1113/jphysiol.1993.sp019764; RACKE FK, 1993, J PHYSIOL-LONDON, V468, P163, DOI 10.1113/jphysiol.1993.sp019765; RACKE FK, 1994, AM J PHYSIOL, V267, pE429, DOI 10.1152/ajpendo.1994.267.3.E429; Ribeiro CMP, 1996, J BIOL CHEM, V271, P21522, DOI 10.1074/jbc.271.35.21522; RIDEFELT P, 1992, ACTA ENDOCRINOL-COP, V126, P505, DOI 10.1530/acta.0.1260505; SAXE AW, 1987, SURGERY, V102, P932; SHOBACK DM, 1990, ENDOCRINOLOGY, V127, P141, DOI 10.1210/endo-127-1-141; SUN GY, 1988, NEUROCHEM INT, V12, P69, DOI 10.1016/0197-0186(88)90150-7; WATSON PH, 1992, J BONE MINER RES, V7, P667; WONGSURAWAT N, 1987, EXP GERONTOL, V22, P263, DOI 10.1016/0531-5565(87)90005-2; Ye CP, 1996, BIOCHEM BIOPH RES CO, V226, P572, DOI 10.1006/bbrc.1996.1396	37	119	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21267	21275		10.1074/jbc.273.33.21267	http://dx.doi.org/10.1074/jbc.273.33.21267			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694886	hybrid			2022-12-25	WOS:000075386100079
J	Cao, LG; Zhang, L; Ruiz-Lozano, P; Yang, QC; Chien, KR; Graham, RM; Zhou, MD				Cao, LG; Zhang, L; Ruiz-Lozano, P; Yang, QC; Chien, KR; Graham, RM; Zhou, MD			A novel putative protein-tyrosine phosphatase contains a BRO1-like domain and suppresses Ha-ras-mediated transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PATHWAYS; CELL HYPERTROPHY; XENOPUS OOCYTES; PTP-PEST; GROWTH; EXPRESSION; CLONING; GENE; MYOCYTES; DIFFERENTIATION	To investigate a potential role of protein-tyrosine phosphatases (PTPases) in myocardial growth and signaling, a degenerate primer-based reverse transcription-polymerase chain reaction approach was used to isolate cDNAs for proteins that contain a PTPase catalytic domain. Among the 16 cDNA clones isolated by reverse transcription-polymerase chain reaction from total neonatal rat cardiomyocyte RNA, one, designated PTP-TD14, was unique. Subsequent isolation and sequencing of a full-length PTP-TD14 cDNA confirmed that it encodes a novel 164-kDa protein, p164(PTP-TD14) The C-terminal region contains the PTP-like domain, whereas the N-terminal region shows no homology to any known mammalian protein. However, this region is homologous to a yeast protein, BRO1, that is involved in the mitogen-activated protein kinase signaling pathway. Like BRO1, p164(PTP-TD14) contains a proline-rich region with two putative SH3-domain binding sites. By Northern blot analysis, PTP-TD14 is expressed as a 5.3-kilobase pair transcript, not only in neonatal heart but also in many adult rat tissues. When expressed in either COS-7 or NIH-3T3 cells, p164(PTP-TD14) localizes to the cytoplasm in association with vesicle-like structures. Expression of p164(PTP-TD14) in NIH-3T3 cells inhibits Ha ras-mediated transformation more than 3-fold. This inhibitory activity is localized to the C-terminal PTPase homology domain, since no inhibition of Ha-ras-mediated focus formation was observed with a PTP-TD14 mutant, in which the putative catalytic activity was presumably inactivated by a point mutation. These findings indicate that PTP-TD14 encodes a novel protein that may be critically involved in regulating Ha-ras-dependent cell growth.	St Vincents Hosp, Victor Chang Cardiac Res Inst, Darlinghurst, NSW 2010, Australia; Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; Immusol Inc, San Diego, CA 92121 USA	St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute; University of New South Wales Sydney; University of California System; University of California San Diego	Zhou, MD (corresponding author), Victor Chang Cardiac Res Inst, 384 Victoria St,Level 6, Darlinghurst, NSW 2010, Australia.	m.zhou@victorchang.unsw.edu.au						AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BILSEN VM, 1993, CARDIVASC RES, V27, P1140; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; Byon JCH, 1997, P SOC EXP BIOL MED, V216, P1; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIEN KR, 1993, SCIENCE, V260, P916, DOI 10.1126/science.8493528; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; HERTOG JD, 1992, BIOCHEM BIOPH RES CO, V184, P1241; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; HUNTER T, 1995, ANN REV BIOCH, V54, P897; KAMBAYASHI Y, 1995, BIOCHEM J, V306, P331, DOI 10.1042/bj3060331; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Liu QQ, 1996, CIRC RES, V79, P716, DOI 10.1161/01.RES.79.4.716; MCGILL CJ, 1995, CARDIOVASC RES, V30, P557, DOI 10.1016/S0008-6363(95)00113-1; NegreteUrtasun S, 1997, J BACTERIOL, V179, P1832, DOI 10.1128/jb.179.5.1832-1835.1997; Nickas ME, 1996, MOL CELL BIOL, V16, P2585; SAITO H, 1992, BIOCHEM SOC T, V20, P165, DOI 10.1042/bst0200165; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; STONE RL, 1994, J BIOL CHEM, V269, P31323; TAKEKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P1223, DOI 10.1016/0006-291X(92)92335-U; THORBURN A, 1993, J BIOL CHEM, V268, P2244; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TONKS NK, 1992, COLD SPRING HARB SYM, V57, P87, DOI 10.1101/SQB.1992.057.01.012; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; UENO H, 1988, J CELL BIOL, V107, P1911, DOI 10.1083/jcb.107.5.1911; YANG Q, 1993, J BIOL CHEM, V268, P6622; ZAK R, 1974, CIRC RES, V35, P17; Zhang K, 1996, J BIOL CHEM, V271, P3884; ZHOU MD, 1995, P NATL ACAD SCI USA, V92, P7391, DOI 10.1073/pnas.92.16.7391	38	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21077	21083		10.1074/jbc.273.33.21077	http://dx.doi.org/10.1074/jbc.273.33.21077			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694860	hybrid			2022-12-25	WOS:000075386100053
J	Cuozzo, JW; Tao, K; Cygler, M; Mort, JS; Sahagian, GG				Cuozzo, JW; Tao, K; Cygler, M; Mort, JS; Sahagian, GG			Lysine-based structure responsible for selective mannose phosphorylation of cathepsin D and cathepsin L defines a common structural motif for lysosomal enzyme targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCAN; PROCATHEPSIN-D; 6-PHOSPHATE RECEPTOR; PORCINE PEPSINOGEN; CRYSTAL-STRUCTURES; PROTEIN STABILITY; 1.8-A RESOLUTION; GENETIC-ANALYSIS; MAMMALIAN-CELLS; ADHESION DOMAIN	Previous studies have shown that lysine residues on the surface of cathepsins and other lysosomal proteins are a shared component of the recognition structure involved in mannose phosphorylation, In this study, the involvement of specific lysine residues in mannose phosphorylation of cathepsin D was explored by site-directed mutagenesis, Mutation of two lysine residues in the mature portion of the protein, Lys-203 and Lys-293, cooperated to inhibit mannose phosphorylation by 70%. Other positively charged residues could not substitute for lysine at these positions, and comparison of thermal denaturation curves for the wild type and mutant proteins indicated that the inhibition could not be explained by alterations in protein folding. Structural comparisons of the two lysine residues with those required for phosphorylation of cathepsin L, using models generated from recently acquired crystal structures, revealed several relevant similarities. On both molecules, the lysine residues were positioned approximately 34 Angstrom apart (34.06 Angstrom for cathepsin D and 33.80 Angstrom for cathepsin L), When the lysine pairs were superimposed, N-linked glycosylation sites on the two proteins were found to be oriented so that oligosaccharides extending out from the sites could share a common region of space. Further similarities in the local environments of the critical lysines were also observed. These results provide details for a common lysosomal targeting structure based on a specific arrangement of lysine residues with respect to each other and to glycosylation sites on the surface of lysosomal proteins.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Shriners Hosp Children, Joint Dis Lab, Montreal, PQ H3G 1A6, Canada	Tufts University; National Research Council Canada; McGill University	Sahagian, GG (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	gsahagia@opal.tufts.edu		Cuozzo, John/0000-0002-6229-0395				ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; Bao M, 1996, J BIOL CHEM, V271, P31437, DOI 10.1074/jbc.271.49.31437; Bao M, 1996, J BIOL CHEM, V271, P31446, DOI 10.1074/jbc.271.49.31446; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; CUMMING DA, 1987, BIOCHEMISTRY-US, V26, P6664, DOI 10.1021/bi00395a016; CUMMING DA, 1987, BIOCHEMISTRY-US, V26, P6655, DOI 10.1021/bi00395a015; CUOZZO JW, 1994, J BIOL CHEM, V269, P14490; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; Dittmer F, 1997, J BIOL CHEM, V272, P852, DOI 10.1074/jbc.272.2.852; DONG JM, 1990, J BIOL CHEM, V265, P4210; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; FAUST PL, 1987, J CELL BIOL, V105, P1947, DOI 10.1083/jcb.105.5.1947; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FERSHT A, 1977, ENZYME STRUCTURE MEC, P1; GLICKMAN JN, 1993, J CELL BIOL, V123, P99, DOI 10.1083/jcb.123.1.99; GULNIK S, 1992, J MOL BIOL, V227, P265, DOI 10.1016/0022-2836(92)90696-H; HASILIK A, 1980, J BIOL CHEM, V255, P4946; HECHT MH, 1984, P NATL ACAD SCI-BIOL, V81, P5685, DOI 10.1073/pnas.81.18.5685; HECHT MH, 1983, P NATL ACAD SCI-BIOL, V80, P2676, DOI 10.1073/pnas.80.9.2676; HORST M, 1991, BIOCHEM J, V273, P355, DOI 10.1042/bj2730355; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KOELSCH G, 1995, ADV EXP MED BIOL, V362, P273; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAHM A, 1991, J MOL BIOL, V222, P645, DOI 10.1016/0022-2836(91)90502-W; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; Matthews BW, 1996, FASEB J, V10, P35, DOI 10.1096/fasebj.10.1.8566545; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Nishikawa A, 1997, J BIOL CHEM, V272, P19408, DOI 10.1074/jbc.272.31.19408; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; SCHOREY JS, 1995, J CELL SCI, V108, P2007; SIELECKI AR, 1990, J MOL BIOL, V214, P143, DOI 10.1016/0022-2836(90)90153-D; SIELECKI AR, 1991, J MOL BIOL, V219, P671, DOI 10.1016/0022-2836(91)90664-R; STEARNS NA, 1990, ARCH BIOCHEM BIOPHYS, V283, P447, DOI 10.1016/0003-9861(90)90666-M; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; TONG PY, 1989, J BIOL CHEM, V264, P7962; VARKI A, 1983, J BIOL CHEM, V258, P2808; VARKI A, 1980, J BIOL CHEM, V255, P8398; WOODS RJ, 1995, CURR OPIN STRUC BIOL, V5, P591, DOI 10.1016/0959-440X(95)80049-2; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; WYSS DF, 1995, BIOCHEMISTRY-US, V34, P1622, DOI 10.1021/bi00005a019	50	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21067	21076		10.1074/jbc.273.33.21067	http://dx.doi.org/10.1074/jbc.273.33.21067			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694859	hybrid			2022-12-25	WOS:000075386100052
J	Nass, R; Rao, R				Nass, R; Rao, R			Novel localization of a Na+/H+ exchanger in a late endosomal compartment of yeast - Implications for vacuole biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT RENAL-CORTEX; SACCHAROMYCES-CEREVISIAE; PREVACUOLAR COMPARTMENT; SYNTAXIN HOMOLOG; H+ EXCHANGE; PROTEIN; ANTIPORTER; MITOCHONDRIA; COMPONENTS; TRANSPORT	Na+/H+ exchangers catalyze the electrically silent countertransport of Na+ and H+, controlling the transmembrane movement of salt, water, and acid-base equivalents, and are therefore critical for Na+ tolerance, cell volume control, and pH regulation. In contrast to numerous well studied plasma membrane isoforms (NHE1-4), much less is known about intracellular Na+/H+ exchangers, and thus far no vertebrate isoform has been shown to have an exclusively endosomal distribution. In this context, me show that the yeast NHE homologue, Nhx1 (Nass, R., Cunningham, K. W., and Rao, R. (1997) J. Biol. Chem. 272, 26145-26152), localizes uniquely to prevacuolar compartments, equivalent to late endosomes of animal cells. In living yeast, we show that these compartments closely abut the vacuolar membrane in a striking bipolar distribution, suggesting that vacuole biogenesis occurs at distinct sites. Nhx1 is the founding member of a newly emergent cluster of exchanger homologues, from yeasts, worms, and humans that may share a common intracellular localization. By compartmentalizing Na+, intracellular exchangers play an important role in halotolerance; furthermore, we hypothesize that salt and water movement into vesicles may regulate vesicle volume and pH and thus contribute to vacuole biogenesis.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Rao, R (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.	rajini_rao@qmail.bs.jhu.edu						Anderie I, 1996, J MEMBRANE BIOL, V152, P195, DOI 10.1007/s002329900097; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Barkla B J, 1994, Symp Soc Exp Biol, V48, P141; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; Dibrov P, 1997, FEBS LETT, V405, P119, DOI 10.1016/S0014-5793(97)00169-5; GARLID KD, 1991, J BIOL CHEM, V266, P6518; GARLID KD, 1978, BIOCHEM BIOPH RES CO, V83, P1450, DOI 10.1016/0006-291X(78)91383-9; GRIFFITHS G, 1989, J CELL BIOL, V90, P40; GRINSTEIN S, 1982, FEBS LETT, V148, P1, DOI 10.1016/0014-5793(82)81230-1; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; GURICH RW, 1986, AM J PHYSIOL, V251, pF702, DOI 10.1152/ajprenal.1986.251.4.F702; HAIGH JR, 1989, BIOCHEM J, V257, P499, DOI 10.1042/bj2570499; Hechenberger M, 1996, J BIOL CHEM, V271, P33632, DOI 10.1074/jbc.271.52.33632; HENSLEY CB, 1990, KIDNEY INT, V37, P707, DOI 10.1038/ki.1990.37; Hicke L, 1997, MOL BIOL CELL, V8, P13, DOI 10.1091/mbc.8.1.13; HILDEN SA, 1990, AM J PHYSIOL, V258, pF1311; Nakamura N, 1997, J BIOL CHEM, V272, P11344; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SATIR B, 1973, J CELL BIOL, V56, P153, DOI 10.1083/jcb.56.1.153; SCHAEPER TJ, 1986, BRIT J EIGHTEENTH-C, V9, P1; Serrano R, 1996, INT REV CYTOL, V165, P1, DOI 10.1016/S0074-7696(08)62219-6; Sorin A, 1997, J BIOL CHEM, V272, P9895; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; TSE CM, 1994, CELL PHYSIOL BIOCHEM, V4, P282, DOI 10.1159/000154731; VANDYKE RW, 1995, AM J PHYSIOL-CELL PH, V269, pC943, DOI 10.1152/ajpcell.1995.269.4.C943; Wada Y, 1997, J CELL SCI, V110, P1299; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WELIHINDA AA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P367, DOI 10.1016/0005-2728(93)90122-V	38	173	183	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21054	21060		10.1074/jbc.273.33.21054	http://dx.doi.org/10.1074/jbc.273.33.21054			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694857	hybrid			2022-12-25	WOS:000075386100050
J	Srivastava, DK; Vande Berg, BJ; Prasad, R; Molina, JT; Beard, WA; Tomkinson, AE; Wilson, SH				Srivastava, DK; Vande Berg, BJ; Prasad, R; Molina, JT; Beard, WA; Tomkinson, AE; Wilson, SH			Mammalian abasic site base excision repair - Identification of the reaction sequence and rate-determining steps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-BETA; DEOXYRIBOSE-PHOSPHATE RESIDUES; BOVINE TESTIS; LIGASE-III; XRCC1; RECONSTITUTION; PATHWAY; GENE; ENDONUCLEASE; REPLICATION	Base excision repair (BER) is one of the cellular defense mechanisms repairing damage to nucleoside 5'-monophosphate residues in genomic DNA. This repair pathway is initiated by spontaneous or enzymatic N-glycosidic bond cleavage creating an abasic or apurinic-apyrimidinic (AP) site in double-stranded DNA. Class II AP endonuclease, deoxyribonucleotide phosphate (dRP) lyase, DNA synthesis, and DNA ligase activities complete repair of the AP site. In mammalian cell nuclear extract, BER can be mediated by a macromolecular complex containing DNA polymerase beta (beta-pol) and DNA ligase I. These two enzymes are capable of contributing the latter three of the four BER enzymatic activities. In the present study, we found that AP site BER can be reconstituted in vitro using the following purified human proteins:AP endonuclease, beta-pol, and DNA ligase I. Examination of the individual enzymatic steps in BER allowed us to identify an ordered reaction pathway: subsequent to 5' "nicking" of the AP site-containing DNA strand by AP endonuclease, beta-pol performs DNA synthesis prior to removal of the 5'-dRP moiety in the gap. Removal of the (dRP flap is strictly required for DNA ligase I to seal the resulting nick, Additionally, the catalytic rate of the reconstituted BER system and the individual enzymatic activities was measured. The reconstituted BER system performs repair of AP site DNA at a rate that is slower than the respective rates of AP endonuclease, DNA synthesis, and ligation, suggesting that these steps are not rate-determining in the overall reconstituted BER system, Instead, the rate-limiting step in the reconstituted system was found to be removal of dRP tie. dRP lyase), catalyzed by the amino-terminal domain of beta-pol, This work is the first to measure the rate of BER in an in vitro reaction. The potential significance of the dRP-containing intermediate in the regulation of BER is discussed.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Hlth Sci Ctr, Ctr Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Health San Antonio	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, 111 Alexander Dr,Bldg 101,Rm B246, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Wilson, Samuel H/E-6644-2019; Srivastava, Deo Kumar/P-2435-2017	Wilson, Samuel H/0000-0002-1702-5293; Srivastava, Deo Kumar/0000-0001-6693-8120				Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DIMITRIADIS EK, 1998, IN PRESS J BIOL CHEM, V273; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P135; FROSINA G, 1994, BIOCHEM J, V304, P699, DOI 10.1042/bj3040699; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KLUNGLAND A, 1997, EMBO J, V16, P334; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOEB LA, 1985, CELL, V40, P483, DOI 10.1016/0092-8674(85)90191-6; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1991, MOL CELL BIOL, V11, P4441, DOI 10.1128/MCB.11.9.4441; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; Nicholl ID, 1997, BIOCHEMISTRY-US, V36, P7557, DOI 10.1021/bi962950w; Parikh SS, 1997, STRUCTURE, V5, P1543, DOI 10.1016/S0969-2126(97)00303-1; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; TEO IA, 1983, MUTAT RES, V107, P371, DOI 10.1016/0027-5107(83)90177-X; TERAOKA H, 1983, BIOCHIM BIOPHYS ACTA, V747, P117, DOI 10.1016/0167-4838(83)90129-2; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; ZHOU W, 1993, P NATL ACAD SCI USA, V90, P6601, DOI 10.1073/pnas.90.14.6601	43	330	344	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21203	21209		10.1074/jbc.273.33.21203	http://dx.doi.org/10.1074/jbc.273.33.21203			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694877	hybrid			2022-12-25	WOS:000075386100070
J	Tsai, SC; Adamik, R; Hong, JX; Moss, J; Vaughan, M; Kanoh, H; Exton, JH				Tsai, SC; Adamik, R; Hong, JX; Moss, J; Vaughan, M; Kanoh, H; Exton, JH			Effects of arfaptin 1 on guanine nucleotide-dependent activation of phospholipase D and cholera toxin by ADP-ribosylation factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGE PROTEIN; BREFELDIN-A; BOVINE BRAIN; FACTOR ARF; GTP; GOLGI; PURIFICATION; STIMULATION; CONTAINS; DOMAINS	Arfaptin 1, a similar to 39-kDa protein based on the deduced amino acid sequence, had been initially identified in a yeast two-hybrid screen using dominant active ARF3 (Q71L) as bait with an HL-60 cDNA library. It was suggested that arfaptin 1 may be involved in Golgi functions, since the FLAG-tagged protein was associated with Golgi membranes when expressed in COS-7 cells and could be bound to Golgi in vitro in an ADP-ribosylation factor (ARF)- and GTP gamma S-dependent, brefeldin A-inhibited fashion. Arfaptin 2, found in the same two-hybrid screen as arfaptin 1, is 60% identical in amino acid sequence and may or may not have an analogous function. We now report some effects of arfaptin 1 on ARF activation of phospholipase D and cholera toxin ADP-ribosyltransferase, Arfaptin 1 inhibited activation of both enzymes in a concentration-dependent manner and was without effect in the absence of ARF. Two ARF1 mutants that activated the toxin, one lacking 13 N-terminal amino acids and the other, in which 73 residues at the N terminus were replaced with the analogous sequence from ARL1, were not inhibited by arfaptin, consistent with the conclusion that arfaptin interaction requires the N terminus of ARF. This region has also been implicated in phospholipase D activation, but whether the two proteins interact with the same structural elements in ARF remains to be determined, Arfaptin inhibition of the action of ARF5 and ARF6 was less than that of ARF1 and ARF3; its effects were less on nanmyristoylated than myristoylated ARFs. Arfaptin effects on guanine nucleotide binding by ARFs were minimal whether or not a purified ARF guanine nucleotide-exchange protein was present. These findings indicate that arfaptin acts as an inhibitor of ARF actions in vitro, raising the possibility that it has a similar role in vivo.	NHLBI, NIH, Pulm Crit Care Med Branch, Bethesda, MD 20892 USA; Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Physiol & Biophys & Pharmacol, Nashville, TN 37232 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Howard Hughes Medical Institute; Vanderbilt University	Tsai, SC (corresponding author), NHLBI, NIH, Pulm Crit Care Med Branch, Rm 5N-307,Bldg 10,10 Ctr Dr,MSC 1434, Bethesda, MD 20892 USA.							BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; Ding M, 1996, J BIOL CHEM, V271, P24005, DOI 10.1074/jbc.271.39.24005; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HONG JX, 1994, J BIOL CHEM, V269, P9743; Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TSAI SC, 1988, J BIOL CHEM, V263, P1768; Tsai SC, 1996, P NATL ACAD SCI USA, V93, P305, DOI 10.1073/pnas.93.1.305; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; TSAI SC, 1993, J BIOL CHEM, V268, P10820; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	21	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20697	20701		10.1074/jbc.273.33.20697	http://dx.doi.org/10.1074/jbc.273.33.20697			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694811	hybrid			2022-12-25	WOS:000075386100004
J	Amendt, BA; Sutherland, LB; Semina, EV; Russo, AF				Amendt, BA; Sutherland, LB; Semina, EV; Russo, AF			The molecular basis of Rieger syndrome - Analysis of Pitx2 homeodomain protein activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; HOMEOBOX GENES; TRANSCRIPTION; RECOGNITION; HELIX; ULTRABITHORAX; MUTATION; EMBRYO	Rieger syndrome is an autosomal-dominant developmental disorder that includes glaucoma and mild craniofacial dysmorphism in humans. Mutations in the Pitx2 homeobox gene have been linked to Rieger syndrome. We have characterized wild type and mutant Pitx2 activities using electrophoretic mobility shift assays, protein binding, and transient transfection assays. Pitx2 preferentially binds the bicoid homeodomain binding site and transactivates reporter genes containing this site. The combination of Pitx2 and another homeodomain protein, Pit-1, yielded a synergistic 55-fold activation of the prolactin promoter in transfection assays. Addition of Pit-1 increased Pitx2 binding to the bicoid element in electrophoretic mobility shift assays. Furthermore, we demonstrate specific binding of Pit-1 to Pitx2 in vitro. Thus, wild type Pitx2 DNA binding activity is modulated by protein-protein interactions. We next studied two Rieger mutants. A threonine to proline mutation (T68P) in the second helix of the homeodomain retained DNA binding activity with the same apparent K-D and only about a a-fold reduction in the B-max. However, this mutant did not transactivate reporter genes containing the bicoid site. The mutant Pitx2 protein binds Pit-1, but there was no detectable synergism on the prolactin promoter. A second mutation (L54Q) in a highly conserved residue in helix 1 of the homeodomain yielded an unstable protein. Our results provide insights into the potential mechanisms underlying the developmental defects in Rieger syndrome.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Amendt, BA (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.			Amendt, Brad A./0000-0001-6524-1006; Russo, Andrew/0000-0002-8156-5649	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE009170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007018, P30DK025295] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE09170] Funding Source: Medline; NIDDK NIH HHS [DK07018, DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEACHY PA, 1988, CELL, V55, P1069, DOI 10.1016/0092-8674(88)90251-6; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; Hassan B, 1997, P NATL ACAD SCI USA, V94, P10991, DOI 10.1073/pnas.94.20.10991; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JIN YS, 1994, NATURE, V372, P780, DOI 10.1038/372780a0; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; KUMMAR J, 1997, GENE DEV, V11, P2023; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Lanigan TM, 1997, J BIOL CHEM, V272, P18316, DOI 10.1074/jbc.272.29.18316; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; Ma L, 1996, HUM MOL GENET, V5, P1915, DOI 10.1093/hmg/5.12.1915; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Mucchielli ML, 1996, MOL CELL NEUROSCI, V8, P258, DOI 10.1006/mcne.1996.0062; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; Rieger H, 1935, Z AUGENHEILKD, V86, P333; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; STARK MR, 1994, NATURE, V371, P429, DOI 10.1038/371429a0; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; TREISMAN J, 1992, BIOESSAYS, V14, P145, DOI 10.1002/bies.950140302; TREISMAN J, 1989, CELL, V59, P553; TVERBERG LA, 1993, J BIOL CHEM, V268, P15965; Wilson DS, 1996, P NATL ACAD SCI USA, V93, P6886, DOI 10.1073/pnas.93.14.6886; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0	43	114	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20066	20072		10.1074/jbc.273.32.20066	http://dx.doi.org/10.1074/jbc.273.32.20066			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685346	hybrid			2022-12-25	WOS:000075305400023
J	McKay, BC; Ljungman, M; Rainbow, AJ				McKay, BC; Ljungman, M; Rainbow, AJ			Persistent DNA damage induced by ultraviolet light inhibits p21(waf1) and bax expression: implications for DNA repair, UV sensitivity and the induction of apoptosis	ONCOGENE			English	Article						apoptosis; DNA repair; E2F-1; E2F-4; viral tumour antigens; p21(waf1)	TRANSCRIPTION-COUPLED REPAIR; CYCLIN-DEPENDENT KINASES; LI-FRAUMENI SYNDROME; PIGMENTOSUM GROUP-C; LARGE T-ANTIGEN; CELL-CYCLE; XERODERMA-PIGMENTOSUM; EXCISION-REPAIR; G(1) ARREST; P53-DEPENDENT APOPTOSIS	Ultraviolet light (UV) induced DNA lesions efficiently block transcript elongation and induce the p53 response. Although p53 contributes to transcriptional activation of the p21(WAF1) and bax genes, accumulation of these proteins requires that these genes are free of UV induced pyrimidine dimers. We assessed the level of expression of p53 and the p53 regulated p21(WAF1) and bax gene products in normal diploid fibroblasts (NDF) and several nucleotide excision repair deficient fibroblasts following UV-irradiation. At low UV fluences, increased expression of p53, p21(WAF1) and bax was only observed in fibroblasts deficient in transcription coupled repair (TCR). Whereas p53 protein levels increased in all cell types at high UV fluences, p21(WAF1) levels initially decreased and then recovered in a manner dependent on TCR. At later times, expression of p21(WAF1) and bax was only elevated in TCR-proficient cells. The lack of TCR strongly correlated with an enhanced induction of apoptosis. Furthermore, we assessed the effect of modulation of the p53/p21(WAF1)/pRb pathway on clonogenic survival following UV irradiation. Expression of E2F-1, E2F-4, and the large tumour antigens of SV40 and Polyomavirus conferred UV sensitivity to NDF whereas p21(WAF1) protected cells against UV treatment. We propose that the fluence dependent attenuation of protective functions of p53 by blockage of transcription favours apoptosis following UV exposure.	McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; Univ Michigan, Ctr Comprehens Canc, Div Canc Biol, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	McMaster University; University of Michigan System; University of Michigan	Rainbow, AJ (corresponding author), McMaster Univ, Dept Biol Life Sci, Bldg 218A,1280 Main St W, Hamilton, ON L8S 4K1, Canada.		McKay, Bruce C/I-4081-2013	McKay, Bruce C/0000-0002-7921-1331				Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARREAU M, 1992, MUTAT RES, V274, P57, DOI 10.1016/0921-8777(92)90043-3; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; deLaat A, 1996, PHOTOCHEM PHOTOBIOL, V63, P492; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Doherty J, 1997, ONCOGENE, V14, P1923, DOI 10.1038/sj.onc.1201025; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; EASTHAM JA, 1995, CANCER RES, V55, P5151; EVANS MK, 1993, J BIOL CHEM, V268, P4839; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gluzman Y., 1982, EUKARYOTIC VIRAL VEC, P187; GomezManzano C, 1997, J NATL CANCER I, V89, P1036, DOI 10.1093/jnci/89.14.1036; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GRAHAM F, 1991, GENE TRANSFER EXPRES, V7; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IMRAY P, 1983, MUTAT RES, V112, P301, DOI 10.1016/0167-8817(83)90005-6; KARENTZ D, 1986, MUTAT RES, V165, P165, DOI 10.1016/0167-8817(86)90051-9; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1994, MUTAT RES, V314, P67, DOI 10.1016/0921-8777(94)90062-0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ljungman M, 1996, ONCOGENE, V13, P823; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu X, 1996, ONCOGENE, V13, P413; Luna RMDO, 1996, GENOMICS, V33, P352, DOI 10.1006/geno.1996.0210; MASSIE B, 1986, MOL CELL BIOL, V6, P2872, DOI 10.1128/MCB.6.8.2872; MAYNE LV, 1982, CANCER RES, V42, P1473; McDonald E, 1996, CANCER RES, V56, P2250; McKay BC, 1997, PHOTOCHEM PHOTOBIOL, V66, P659, DOI 10.1111/j.1751-1097.1997.tb03203.x; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; MIYASHITA T, 1995, CELL, V80, P293; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORSY MA, 1993, J CLIN INVEST, V92, P1580, DOI 10.1172/JCI116739; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SMITH ML, 1995, ONCOGENE, V10, P1053; Tolbert DM, 1996, CANCER RES, V56, P3324; Tu YQ, 1997, J BIOL CHEM, V272, P20747, DOI 10.1074/jbc.272.33.20747; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; vanLaar T, 1995, BIOCHEM BIOPH RES CO, V217, P769, DOI 10.1006/bbrc.1995.2839; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; ZEIGLER A, 1994, NATURE, V372, P773	73	85	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					545	555		10.1038/sj.onc.1201963	http://dx.doi.org/10.1038/sj.onc.1201963			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704920				2022-12-25	WOS:000075195300002
J	Wolff, GL; Kodell, RL; Moore, SR; Cooney, CA				Wolff, GL; Kodell, RL; Moore, SR; Cooney, CA			Maternal epigenetics and methyl supplements affect agouti gene expression in A(vy)/a mice	FASEB JOURNAL			English	Article						maternal diet; methyl supplementation; DNA methylation; epigenetic regulation of gene expression; yellow mice	X-CHROMOSOME INACTIVATION; NEURAL-TUBE DEFECTS; DNA METHYLTRANSFERASE; MOUSE; PARTICLE; MUTATION; CHOLINE; INHERITANCE; METABOLISM; METHIONINE	'Viable yellow' (A(vy)/alpha) mice are larger, obese, hyperinsulinemic, more susceptible to cancer, and, on average, shorter lived than their non-yellow siblings. They are epigenetic mosaics ranging from a yellow phenotype with maximum ectopic agouti overexpression, through a continuum of mottled agouti/yellow phenotypes with partial agouti overexpression, to a pseudoagouti phenotype with minimal ectopic expression. Pseudoagouti A(vy)/a mice are lean, healthy, and longer lived than their yellow siblings. Here we report that feeding pregnant black a/a dams methyl-supplemented diets alters epigenetic regulation of agouti expression in their offspring, as indicated by increased agouti/black mottling in the direction of the pseudoagouti phenotype, We also present confirmatory evidence that epigenetic phenotypes are maternally heritable. Thus A(vy) expression, already known to be modulated by imprinting, strain-specific modification, and maternal epigenetic inheritance, is also modulated by maternal diet. These observations suggest, at least in this special case, that maternal dietary supplementation may positively affect health and longevity of the offspring, Therefore, this experimental system should be useful for identifying maternal factors that modulate epigenetic mechanisms, especially DNA methylation, in developing embryos.	US FDA, Div Biochem Toxicol, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA; US FDA, Div Biometry & Risk Assessment, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA; Univ Arkansas Med Sci, Dept Biochem Mol Biol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Pharmacol Interdisciplinary Toxicol, Little Rock, AR 72205 USA; Bionet Corp, Jefferson, AR 72079 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Wolff, GL (corresponding author), US FDA, Div Biochem Toxicol, Natl Ctr Toxicol Res, 3900 NCTR Rd, Jefferson, AR 72079 USA.			Cooney, Craig/0000-0003-4279-557X				Adams R. L. P., 1985, MOL BIOL DNA METHYLA; ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; Argeson AC, 1996, GENETICS, V142, P557; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BULTMAN SJ, 1994, GENE DEV, V8, P481, DOI 10.1101/gad.8.4.481; Chuang LSH, 1996, J MOL BIOL, V257, P935, DOI 10.1006/jmbi.1996.0213; Conover William Jay, 1998, PRACTICAL NONPARAMET, V350; COONEY CA, 1993, GROWTH DEVELOP AGING, V57, P261; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; FEENSTRA A, 1986, NUCLEIC ACIDS RES, V14, P4343, DOI 10.1093/nar/14.10.4343; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; FUNG KY, 1994, RISK ANAL, V14, P639, DOI 10.1111/j.1539-6924.1994.tb00277.x; GARNER SC, 1995, J NUTR, V125, P2851; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; Henikoff S, 1997, TRENDS GENET, V13, P293, DOI 10.1016/S0168-9525(97)01219-5; Jablonka E., 1995, EPIGENETIC INHERITAN; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; Jamieson RV, 1996, INT J DEV BIOL, V40, P1065; Jaspan JB, 1996, J CLIN ENDOCR METAB, V81, P2271, DOI 10.1210/jc.81.6.2271; John RM, 1996, CURR OPIN CELL BIOL, V8, P348, DOI 10.1016/S0955-0674(96)80008-1; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Koetsier PA, 1996, TRANSGENIC RES, V5, P235, DOI 10.1007/BF01972877; LANDIS RJ, 1978, INT STAT REV, V46, P237; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; Martin David I. K., 1996, Bioessays, V18, P919, DOI 10.1002/bies.950181111; MAYSHOOPES LL, 1983, MOL CELL BIOL, V3, P1371, DOI 10.1128/MCB.3.8.1371; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; Mills JL, 1996, J NUTR, V126, pS756, DOI 10.1093/jn/126.suppl_3.756S; Miltenberger RJ, 1997, J NUTR, V127, pS1902, DOI 10.1093/jn/127.9.1902S; MINTZ B, 1991, P NATL ACAD SCI USA, V88, P9643, DOI 10.1073/pnas.88.21.9643; Moephuli SR, 1997, P NATL ACAD SCI USA, V94, P543, DOI 10.1073/pnas.94.2.543; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Petronis A, 1996, BIOESSAYS, V18, P587, DOI 10.1002/bies.950180710; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; Roemer I, 1997, CURR BIOL, V7, P277, DOI 10.1016/S0960-9822(06)00124-2; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; *SAS I INC, 1993, SAS STAT US GUID, V2; SELLER MJ, 1994, CIBA F SYMP, V181, P161; Shemer R, 1997, P NATL ACAD SCI USA, V94, P10267, DOI 10.1073/pnas.94.19.10267; SPERGEL G, 1975, METABOLISM, V24, P1311, DOI 10.1016/0026-0495(75)90048-7; Stewart CL, 1997, REPROD TOXICOL, V11, P309; VANSTRAATEN HWM, 1995, J NUTR, V125, P2733; Walker BE, 1997, CARCINOGENESIS, V18, P791, DOI 10.1093/carcin/18.4.791; Weichman K, 1997, MOL CELL BIOL, V17, P5269, DOI 10.1128/MCB.17.9.5269; WOLFF GL, 1987, CARCINOGENESIS, V8, P1889, DOI 10.1093/carcin/8.12.1889; Wolff GL, 1996, FUND APPL TOXICOL, V29, P176, DOI 10.1006/faat.1996.0019; WOLFF GL, 1978, GENETICS, V88, P529; Wu M, 1997, P NATL ACAD SCI USA, V94, P890, DOI 10.1073/pnas.94.3.890; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zeisel SH, 1996, ADV EXP MED BIOL, V399, P131	53	757	779	3	96	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					949	957		10.1096/fasebj.12.11.949	http://dx.doi.org/10.1096/fasebj.12.11.949			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707167				2022-12-25	WOS:000075372600005
J	Austen, M; Cerni, C; Luscher-Firzlaff, JM; Luscher, B				Austen, M; Cerni, C; Luscher-Firzlaff, JM; Luscher, B			YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc	ONCOGENE			English	Article						transformation; c-Myc; YY1; Myc/Max DNA-binding; protein-protein interaction; gene transcription	ADENOVIRUS E1A PROTEINS; ZINC-FINGER PROTEIN; N-TERMINAL DOMAIN; CASEIN KINASE-II; TRANSCRIPTIONAL ACTIVATION; VIRAL ONCOPROTEINS; BURKITTS-LYMPHOMA; TUMOR-SUPPRESSOR; FOS PROMOTER; NF-E1 YY-1	The proto-oncoprotein c-Myc and the multifunctional transcriptional regulator YY1 have been shown previously to interact directly in a manner that excludes Max from the complex (Shrivastava et al., 1993). As binding to Max is necessary for all known c-Myc activities we have analysed the influence of YY1 on c-Myc function. We demonstrate that YY1 is a potent inhibitor of c-Myc transforming activity. The region in YY1 required for inhibition corresponds to a functional DNA-binding domain and is distinct from the domains necessary for direct binding to c-Myc. Furthermore the transactivation domain of YY1 was not necessary suggesting that gene regulation by YY1, for example through DNA bending or displacement of regulators from DNA, could be the cause for the negative regulation of c-Myc. This model of indirect regulation of c-Myc by YY1 was supported by the finding that although YY1 did not bind to the c-Myc transactivation domain (TAD) in vitro it was able to inhibit transactivation by Gal4-MycTAD fusion proteins in transient transfections. As for the inhibition of transformation, an intact DNA-binding domain of YY1 was necessary and sufficient for this effect. In addition YY1 did not alter c-Myc/Max DNA binding, further supporting an indirect mode of action. Our findings point to a role of YY1 as a negative regulator of cell growth with a possible involvement in tumor suppression.	Hannover Med Sch, Inst Mol Biol, D-30623 Hannover, Germany; Univ Vienna, Inst Tumorbiol & Krebsforsch, A-1090 Vienna, Austria	Hannover Medical School; University of Vienna	Luscher, B (corresponding author), Hannover Med Sch, Inst Mol Biol, D-30623 Hannover, Germany.		Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709				ALBERT T, 1994, ONCOGENE, V9, P759; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BASU A, 1993, J BIOL CHEM, V268, P4188; BECKER KG, 1994, GENE, V150, P259, DOI 10.1016/0378-1119(94)90435-9; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BUSHMEYER S, 1995, J BIOL CHEM, V270, P30213; CERNI C, 1995, ONCOGENE, V11, P587; CERNI C, 1989, P NATL ACAD SCI USA, V86, P3266, DOI 10.1073/pnas.86.9.3266; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GASTON K, 1994, FEBS LETT, V347, P289, DOI 10.1016/0014-5793(94)00567-2; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HAHN S, 1992, Current Biology, V2, P152, DOI 10.1016/0960-9822(92)90268-F; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Houbaviy HB, 1996, P NATL ACAD SCI USA, V93, P13577, DOI 10.1073/pnas.93.24.13577; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1992, NUCLEIC ACIDS RES, P3317; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutterbach B, 1997, ONCOGENE, V14, P967, DOI 10.1038/sj.onc.1200920; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; NEVINS JR, 1992, SCIENCE, V258, P424; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PISANESCHI G, 1994, BIOCHEM BIOPH RES CO, V205, P1236, DOI 10.1006/bbrc.1994.2797; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1997, RETROVIRAL ONCOGENES, V1, P1; PULVERER BJ, 1994, ONCOGENE, V9, P59; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; SHENK T, 1991, ADV CANCER RES, V57, P47; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; YANO T, 1993, ONCOGENE, V8, P2741; ZHOU QJ, 1995, J VIROL, V69, P7402, DOI 10.1128/JVI.69.12.7402-7409.1995	87	68	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	1998	17	4					511	520		10.1038/sj.onc.1201968	http://dx.doi.org/10.1038/sj.onc.1201968			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696045				2022-12-25	WOS:000075043000014
J	Blaydes, JP; Wynford-Thomas, D				Blaydes, JP; Wynford-Thomas, D			The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2	ONCOGENE			English	Article						p53; mdm2; p21(WAF-1); cell proliferation	TUMOR-SUPPRESSOR GENE; TRANSCRIPTIONAL ACTIVATION; ONCOPROTEIN MDM2; MUTANT P53; PROTEIN; TRANSACTIVATION; SENESCENCE; EXPRESSION; INDUCTION; MUTATIONS	Loss of function of the tumour suppressor gene p53 is a key event in most human cancers. Although usually occurring through mutation, in some tumour types this appears to be achieved via an indirect mechanism involving inappropriate expression of functional inhibitor, mdm2, which binds to the transactivation domain of p53. This interaction offers an ideal potential target for novel cancer therapies. However, therapeutic specificity may depend on the extent to which this p53-inhibitory action of mdm2 is also required by normal cells. Transgenic data have already established that mdm2 is needed to prevent embryonic lethality, but the situation in adult cells is still unclear. Here we show that micro-injection of normal human fibroblasts with an antibody directed against the p53-binding domain of mdm2 induces expression of p53-responsive genes, and furthermore results in p53-dependent growth arrest. We conclude that normal cell proliferation can be dependent on negative regulation of p53 by mdm2, a finding which raises an important note of caution for mdm2-directed cancer therapies.	Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Wynford-Thomas, D (corresponding author), Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Heath Pk, Cardiff CF4 4XN, S Glam, Wales.		Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				ABARZUA P, 1995, CANCER RES, V55, P3490; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1994, ONCOGENE, V9, P1885; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Bottger V, 1996, ONCOGENE, V13, P2141; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; MARCHETTI A, 1995, J PATHOL, V175, P31, DOI 10.1002/path.1711750106; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OCALUAN RM, 1995, NATURE, V378, P203; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Wynford-Thomas D, 1998, CARCINOGENESIS, V19, P29, DOI 10.1093/carcin/19.1.29; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	32	58	58	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3317	3322		10.1038/sj.onc.1201880	http://dx.doi.org/10.1038/sj.onc.1201880			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681831				2022-12-25	WOS:000074343600013
J	Lee, H; Maihle, NJ				Lee, H; Maihle, NJ			Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell lines and normal human tissues	ONCOGENE			English	Article						c-erbB3; alternative processing; truncated growth factor receptors; gene structure; epidermal growth factor receptor homologues	GROWTH-FACTOR RECEPTOR; GENE ENCODES; CAENORHABDITIS-ELEGANS; MONOCLONAL-ANTIBODY; TYROSINE KINASE; TRUNCATED FORM; LET-23 GENE; PROTEIN; TUMORS; DOMAIN	ErbB-3 is a member of the epidermal growth factor receptor (EGFR/ErbB) family. In addition to the previously reported 6.2 kb full-length and 1.4 kb truncated c-erbB3 transcripts, we have observed a 1.7 kb c-erbB3 human transcript in Northern blots that specifically hybridizes to a probe of the extracellular domain of the receptor. Using 3'-RACE we have isolated four novel c-erbB3 cDNA clones of 1.6, 1.7, 2.1 and 2.3 kb from a human ovarian carcinoma-derived cell line. All four alternate transcripts are synthesized by readthrough of an intron and use of an alternative polyadenylation signal within this intron. Identical c-erbB3 transcripts are expressed in normal human placental tissues. Expression of these alternate transcripts is tissue-specific as indicated by Northern blot and RNase protection analyses. Fibroblasts transfected with expression vectors carrying these alternate c-erbB3 cDNA clones stably express truncated ErbB-3 products. Three of these four cDNA clones express a receptor product that is secreted. Immunoprecipitation analysis of primary cultures of human ovarian carcinomas also demonstrate the expression of a 90 kDa ErbB-3 related protein that is secreted. Furthermore, we demonstrate conservation of the exon-intron junctions between members of the erbB gene family in those regions of the gene encoding the extracellular domain. This gene structure is also conserved in the c-erbB1 homologues of Drosophila and C. elegans. Growth regulatory roles for related truncated ErbB products recently have been reported. It is, therefore, possible that the products of these four alternate c-erbB3 transcripts may also play important growth regulatory roles in normal and transformed cells.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Maihle, NJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.				NCI NIH HHS [CA65800, CA09441, CA57534] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009441, R01CA057534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT FW, 1980, CELL, V20, P381; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BUICK RN, 1985, CANCER RES, V45, P3668; CALLAGHAN T, 1993, ONCOGENE, V8, P2939; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; CLIFFORD R, 1994, GENETICS, V137, P531; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; Frohman Michael A., 1994, P14; KAN JLC, 1995, J BIOL CHEM, V270, P1823, DOI 10.1074/jbc.270.4.1823; KATOH M, 1993, BIOCHEM BIOPH RES CO, V192, P1189, DOI 10.1006/bbrc.1993.1542; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; MAIHLE NJ, 1991, P NATL ACAD SCI USA, V88, P1825, DOI 10.1073/pnas.88.5.1825; MAIHLE NJ, 1988, MOL CELL BIOL, V8, P1970; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PLET A, 1995, ONCOGENE, V10, P319; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; RAJKUMAR T, 1993, J PATHOL, V170, P271, DOI 10.1002/path.1711700309; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; Reiter JL, 1996, NUCLEIC ACIDS RES, V24, P4050, DOI 10.1093/nar/24.20.4050; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Sakai T, 1996, J MOL BIOL, V256, P548, DOI 10.1006/jmbi.1996.0107; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; SIMPSON BJB, 1995, BRIT J CANCER, V71, P758, DOI 10.1038/bjc.1995.147; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	30	51	68	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3243	3252		10.1038/sj.onc.1201866	http://dx.doi.org/10.1038/sj.onc.1201866			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681822				2022-12-25	WOS:000074343600004
J	Uchimura, K; Muramatsu, H; Kadomatsu, K; Fan, QW; Kurosawa, N; Mitsuoka, C; Kannagi, R; Habuchi, O; Muramatsu, T				Uchimura, K; Muramatsu, H; Kadomatsu, K; Fan, QW; Kurosawa, N; Mitsuoka, C; Kannagi, R; Habuchi, O; Muramatsu, T			Molecular cloning and characterization of an N-acetylglucosamine-6-O-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; N-LINKED OLIGOSACCHARIDES; FUCOSYL-TRANSFERASE GENE; L-SELECTIN; CHONDROITIN 6-SULFOTRANSFERASE; CARBOHYDRATE CHAINS; ACETYLGLUCOSAMINE RESIDUES; EXPRESSION; SULFATE; LIGAND	We isolated a cDNA clone encoding mouse N-acetyl-glucosamine-6-O-sulfotransferase based on sequence homology to the previously cloned mouse chondroitin B-sulfotransferase. The cDNA clone contained an open reading frame that predicts a type II transmembrane protein composed of 483 amino acid residues. The expressed enzyme transferred sulfate to the 6 position of nonreducing GlcNAc in GlcNAc beta 1-3Gal beta 1-4GlcNAc. Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4GlcNAc and various glycosaminoglycans did not serve as accepters. Expression of the cDNA in COS-7 cells resulted in production of a cell-surface antigen, the epitope of which was NeuAc alpha 2-3Gal beta 1-4(SO4-6)GlcNAc; double transfection with fucosyltransferase IV yielded Gal beta 1-4(Fuc alpha 1-3) (SO4-6)Glc-NAc antigen. The sulfotransferase mRNA was strongly expressed in the cerebrum, cerebellum, eye, pancreas, and lung of adult mice. In situ hybridization revealed that the mRNA was localized in high endothelial venules of mesenteric lymph nodes. The sulfotransferase was concluded to be involved in biosynthesis of glycoconjugates bearing the 6-sulfo N-acetyllactosamine structure such as 6-sulfo sialyl Lewis X. The products of the sulfo transferase probably include glycoconjugates with intercellular recognition signals; one candidate of such a glycoconjugate is an L-selectin ligand.	Nagoya Univ, Sch Med, Dept Biochem, Nagoya, Aichi 466, Japan; Aichi Canc Ctr, Res Inst, Program Expt Pathol, Nagoya, Aichi 464, Japan; Aichi Univ Educ, Dept Life Sci, Kariya, Aichi 448, Japan	Nagoya University; Aichi Cancer Center; Aichi University Education	Muramatsu, T (corresponding author), Nagoya Univ, Sch Med, Dept Biochem, Nagoya, Aichi 466, Japan.	tmurama@tsuru.med.nagoya-u.ac.jp	Uchimura, Kenji/C-9635-2014; Muramatsu, Hideki/ABA-3376-2021; Muramatsu, Hideki/I-3763-2012; Kannagi, Reiji/Q-6459-2018; Kadomatsu, Kenji/G-8083-2012; Uchimura, Kenji/AFV-1802-2022	Uchimura, Kenji/0000-0003-3009-248X; Muramatsu, Hideki/0000-0002-8801-0021; Kannagi, Reiji/0000-0003-4202-2921; Uchimura, Kenji/0000-0003-3009-248X; Kurosawa, Nobuyuki/0000-0002-1548-4541				ARUFFO A, 1991, CURRENT PROTOCOL S14, V14; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EDGE ASB, 1984, J BIOL CHEM, V259, P4710; Fan QW, 1998, NEUROSCI RES, V30, P53, DOI 10.1016/S0168-0102(97)00119-3; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GREEN ED, 1986, MOL CELL BIOCHEM, V72, P81; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; Habuchi O, 1996, GLYCOBIOLOGY, V6, P51, DOI 10.1093/glycob/6.1.51; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; IMAI Y, 1993, NATURE, V361, P555; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; KAMEYAMA A, 1991, CARBOHYD RES, V209, pC1, DOI 10.1016/0008-6215(91)80171-I; KIYOHARA T, 1976, J BIOCHEM, V80, P9, DOI 10.1093/oxfordjournals.jbchem.a131263; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Komba S, 1996, CARBOHYD RES, V285, pC1, DOI 10.1016/S0008-6215(96)90188-3; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MAKITA A, 1985, NEW COMPREHENSIVE BI, V10, P1; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Mitsuoka C, 1997, BIOCHEM BIOPH RES CO, V230, P546, DOI 10.1006/bbrc.1996.6012; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; NOGUCHI S, 1992, EUR J BIOCHEM, V209, P883, DOI 10.1111/j.1432-1033.1992.tb17361.x; Ohmoto H, 1996, J MED CHEM, V39, P1339, DOI 10.1021/jm9506478; OHOMORI K, 1993, BLOOD, V82, P2797; OSHINO K, 1997, J MED CHEM, V40, P455; Ozawa M, 1996, J BIOCHEM-TOKYO, V119, P302; ROUX L, 1988, J BIOL CHEM, V263, P8879; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHILATIFARD A, 1993, J VIROL, V67, P943, DOI 10.1128/JVI.67.2.943-952.1993; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Spiro RG, 1996, BIOCHEM J, V319, P209, DOI 10.1042/bj3190209; STRECKER G, 1989, CARBOHYD RES, V185, P1, DOI 10.1016/0008-6215(89)84016-9; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; Uchimura K, 1998, GLYCOBIOLOGY, V8, P489, DOI 10.1093/glycob/8.5.489	48	138	143	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22577	22583		10.1074/jbc.273.35.22577	http://dx.doi.org/10.1074/jbc.273.35.22577			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712885	hybrid			2022-12-25	WOS:000075616600061
J	Brown, GW; Kelly, TJ				Brown, GW; Kelly, TJ			Purification of Hsk1, a minichromosome maintenance protein kinase from fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE CDC7; DNA-POLYMERASE-ALPHA; CELL-CYCLE CONTROL; S-PHASE; SCHIZOSACCHAROMYCES-POMBE; MCM PROTEINS; REPLICATION ORIGINS; BUDDING YEAST; COMPLEX; GENE	Members of the Cdc7 family of protein kinases are essential for the initiation of DNA replication in all eukaryotes, but their precise biochemical function is unclear. We have purified the fission yeast Cdc7 homologue Hsk1 approximately 30,000-fold, to near homogeneity. Purified Hsk1 has protein kinase activity on several substrates and is capable of autophosphorylation, Point mutations in highly conserved regions of Hsk1 inactivate the kinase in vitro and in vivo, Overproduction of two of the mutant hsk1 alleles blocks initiation of DNA replication and deranges the mitotic checkpoint, a phenotype consistent with a role for Hsk1 in the early stages of initiation. The purified Hsk1 kinase can be separated into two active forms, a Hsk1 monomer and a heterodimer consisting of Hsk1 complexed with a copurifying polypeptide, Dfp1. Association with Dfp1 stimulates phosphorylation of exogenous substrates but has little effect on autokinase activity. We have identified Dfp1 as the fission yeast homologue of budding yeast Dbf4. Purified Hsk1 phosphorylates the Cdc19 (Mcm2) subunit of the six-member minichromosome maintenance protein complex purified from fission yeast, Since minichromosome maintenance proteins have been implicated in the initiation of DNA replication, the essential function of Hsk1 at the G(1)/S transition may be mediated by phosphorylation of Cdc19. Furthermore, the phosphorylation of critical substrates by Hsk1 kinase is likely regulated by association with a Dbf4-like co-factor.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Johns Hopkins University	Kelly, TJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.	tom_kelly@qmail.bs.jhu.edu		Brown, Grant/0000-0002-9002-5003	NATIONAL CANCER INSTITUTE [T32CA009139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050806] Funding Source: NIH RePORTER; NCI NIH HHS [CA09139] Funding Source: Medline; NIGMS NIH HHS [GM50806] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Brown GW, 1997, P NATL ACAD SCI USA, V94, P6142, DOI 10.1073/pnas.94.12.6142; BUCK V, 1991, MOL GEN GENET, V227, P452, DOI 10.1007/BF00273937; CHAPMAN JW, 1989, EXP CELL RES, V180, P419, DOI 10.1016/0014-4827(89)90068-2; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; DURSO G, 1995, J CELL SCI, V108, P3109; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Forsburg SL, 1997, GENE, V191, P191, DOI 10.1016/S0378-1119(97)00058-9; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; HARTWELL LH, 1973, J BACTERIOL, V115, P966, DOI 10.1128/JB.115.3.966-974.1973; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; Hess GF, 1998, GENE, V211, P133, DOI 10.1016/S0378-1119(98)00094-8; HOLLINGSWORTH RE, 1990, P NATL ACAD SCI USA, V87, P6272, DOI 10.1073/pnas.87.16.6272; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jiang W, 1997, P NATL ACAD SCI USA, V94, P14320, DOI 10.1073/pnas.94.26.14320; JOHNSTON LH, 1982, MOL GEN GENET, V186, P445, DOI 10.1007/BF00729467; Kearsey SE, 1996, BIOESSAYS, V18, P183, DOI 10.1002/bies.950180305; KEENEY JB, 1994, GENETICS, V136, P849; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KITADA K, 1992, GENETICS, V131, P21; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; MASAI H, 1995, EMBO J, V14, P3094, DOI 10.1002/j.1460-2075.1995.tb07312.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MuziFalconi F, 1996, CURR BIOL, V6, P229, DOI 10.1016/S0960-9822(02)00464-5; Ohtoshi A, 1997, MOL GEN GENET, V254, P562, DOI 10.1007/s004380050452; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SCLAFANI RA, 1994, MOL MICROBIOL, V11, P805, DOI 10.1111/j.1365-2958.1994.tb00358.x; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; YOON HJ, 1991, P NATL ACAD SCI USA, V88, P3574, DOI 10.1073/pnas.88.9.3574; YOON HJ, 1993, MOL BIOL CELL, V4, P195, DOI 10.1091/mbc.4.2.195	48	102	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22083	22090		10.1074/jbc.273.34.22083	http://dx.doi.org/10.1074/jbc.273.34.22083			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705352	hybrid			2022-12-25	WOS:000075492600086
J	Callebaut, C; Blanco, J; Benkirane, N; Krust, B; Jacotot, E; Guichard, G; Seddiki, N; Svab, J; Dam, E; Muller, S; Briand, JP; Hovanessian, AG				Callebaut, C; Blanco, J; Benkirane, N; Krust, B; Jacotot, E; Guichard, G; Seddiki, N; Svab, J; Dam, E; Muller, S; Briand, JP; Hovanessian, AG			Identification of V3 loop-binding proteins as potential receptors implicated in the binding of HIV particles to CD4(+) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LINE-ADAPTED HIV-1; ENVELOPE GLYCOPROTEIN; NEUTRALIZING ANTIBODIES; MONOCLONAL-ANTIBODIES; TYPE-1 GP120; PHOSPHATASE 2A; AMINO-ACIDS; HISTONE H3; T-CELLS	The binding of human immunodeficiency virus (HIV) type 1 particles to CD4(+) cells could be blocked either by antibodies against the V3 loop domain of the viral external envelope glycoprotein gp120, or by the V3 loop mimicking pseudopeptide 5[K psi(CH2N)PR]-TASP, which forms a stable complier with a cell-surface-expressed 95-kDa protein, Here, by using an affinity matrix containing 5[K psi(CH2N)PR]-TASP and cytoplasmic extracts from human CEM cells, we purified three V3 loop-binding proteins of 95, 40, and 30 kDa, which after microsequencing were revealed to be as nucleolin, putative HLA class II-associated protein (PHAP) II, and PHAP I, respectively. The 95-kDa cell-surface protein was also isolated and found to be nucleolin, We show that recombinant preparations of gp120 bind the purified preparations containing the V3 loop-binding proteins with a high affinity, comparable to the binding of gp120 to soluble CD4, Such binding is inhibited either by 5[K psi(CH2N)PR]-TASP or antibodies against the V3 loop. Moreover, these purified preparations inhibit HIV entry into CD4+ cells as efficiently as soluble CD4, Taken together, our results suggest that nucleolin, PHAP II, and PHAP I appear to be functional as potential receptors in the HIV binding process by virtue of their capacity to interact with the V3 loop of gp120.	Inst Pasteur, Unite Virol & Immunol Cellulaire, ERS 572 CNRS, F-75724 Paris 15, France; Inst Biol Mol & Cellulaire, UPR 9021 CNRS, F-67084 Strasbourg, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)	Hovanessian, AG (corresponding author), Inst Pasteur, Unite Virol & Immunol Cellulaire, ERS 572 CNRS, 28 Rue Dr Roux, F-75724 Paris 15, France.	arahovan@pasteur.fr	Blanco, Julià/A-5347-2008; Benkirane-Jessel, Nadia/H-6438-2016; GUICHARD, Gilles/I-3858-2016; Muller, Sylviane/J-5319-2014	Blanco, Julià/0000-0002-2225-0217; GUICHARD, Gilles/0000-0002-2584-7502; /0000-0002-5301-1569; Benkirane-Jessel, Nadia/0000-0003-3059-3559; Seddiki, Nabila/0000-0002-0379-8527				ADACHI Y, 1994, J BIOL CHEM, V269, P2258; AVRIL LE, 1994, FEBS LETT, V345, P81, DOI 10.1016/0014-5793(94)00410-2; Battini JL, 1996, J VIROL, V70, P4387, DOI 10.1128/JVI.70.7.4387-4393.1996; BENKIRANE N, 1995, J BIOL CHEM, V270, P11921, DOI 10.1074/jbc.270.20.11921; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BORMAN AM, 1995, J VIROL, V69, P2058, DOI 10.1128/JVI.69.4.2058-2067.1995; BOUR S, 1995, MICROBIOL REV, V59, P63, DOI 10.1128/MMBR.59.1.63-93.1995; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; Callebaut C, 1996, VIROLOGY, V218, P181, DOI 10.1006/viro.1996.0178; Callebaut C, 1998, EXP CELL RES, V241, P352, DOI 10.1006/excr.1998.4063; Callebaut C, 1997, J BIOL CHEM, V272, P7159, DOI 10.1074/jbc.272.11.7159; Callebaut C, 1996, RES VIROLOGY, V147, P67, DOI 10.1016/0923-2516(96)80241-X; CALLEBAUT C, 1994, RETROVIRUSES HUMAN A, V237, P141; CHIN LT, 1995, IMMUNOL LETT, V44, P25, DOI 10.1016/0165-2478(94)00192-T; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Deng JS, 1996, MOL BIOL REP, V23, P191, DOI 10.1007/BF00351168; DEVERDUGO UR, 1995, J VIROL, V69, P6751, DOI 10.1128/JVI.69.11.6751-6757.1995; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; HOOK WA, 1991, J IMMUNOL, V147, P2670; Jacotot E, 1996, VIROLOGY, V223, P318, DOI 10.1006/viro.1996.0483; JAVAHERIAN K, 1995, AIDS RES HUM RETROV, V11, P1163, DOI 10.1089/aid.1995.11.1163; Jordan P, 1996, MOL BIOL REP, V22, P63, DOI 10.1007/BF00996307; KINNEYTHOMAS E, 1988, AIDS, V2, P25; LAMAN JD, 1992, J VIROL, V66, P1823, DOI 10.1128/JVI.66.3.1823-1831.1992; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; Leydet A, 1996, J MED CHEM, V39, P1626, DOI 10.1021/jm950358j; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; LINSLEY PS, 1988, J VIROL, V62, P3695, DOI 10.1128/JVI.62.10.3695-3702.1988; MATSUOKA K, 1994, P NATL ACAD SCI USA, V91, P9670, DOI 10.1073/pnas.91.21.9670; MCKEATING JA, 1992, VIROLOGY, V190, P134, DOI 10.1016/0042-6822(92)91199-5; Mebatsion T, 1997, CELL, V90, P841, DOI 10.1016/S0092-8674(00)80349-9; MOORE JP, 1991, AIDS, V5, P455, DOI 10.1097/00002030-199104000-00017; MOORE JP, 1993, VIRAL FUSION MECHANI, P233; Niwa Y, 1996, EUR J BIOCHEM, V237, P64, DOI 10.1111/j.1432-1033.1996.0064n.x; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Oravecz T, 1996, J IMMUNOL, V157, P1329; ORAVECZ T, 1995, NAT MED, V1, P919, DOI 10.1038/nm0995-919; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; RODERIQUEZ G, 1995, J VIROL, V69, P2233, DOI 10.1128/JVI.69.4.2233-2239.1995; Schnell MJ, 1997, CELL, V90, P849, DOI 10.1016/S0092-8674(00)80350-5; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; SRIVASTAVA M, 1989, FEBS LETT, V250, P99, DOI 10.1016/0014-5793(89)80692-1; Stemmer C, 1996, J BIOL CHEM, V271, P21257, DOI 10.1074/jbc.271.35.21257; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; UGEN KE, 1993, VACCINES, V93, P215; Ugolini S, 1997, J EXP MED, V186, P1287, DOI 10.1084/jem.186.8.1287; VAESEN M, 1994, BIOL CHEM H-S, V375, P113, DOI 10.1515/bchm3.1994.375.2.113; Valenzuela A, 1997, J VIROL, V71, P8289, DOI 10.1128/JVI.71.11.8289-8298.1997; Valenzuela A, 1997, J IMMUNOL, V158, P3721; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; YU Y, 1995, AIDS RES HUM RETROV, V11, P563	63	65	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21988	21997		10.1074/jbc.273.34.21988	http://dx.doi.org/10.1074/jbc.273.34.21988			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705340	hybrid			2022-12-25	WOS:000075492600074
J	Kifor, O; Diaz, R; Butters, R; Kifor, I; Brown, EM				Kifor, O; Diaz, R; Butters, R; Kifor, I; Brown, EM			The calcium-sensing receptor is localized in caveolin-rich plasma membrane domains of bovine parathyroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; EXTRACELLULAR CA2+-SENSING RECEPTOR; SIGNAL-TRANSDUCTION; CARDIAC MYOCYTES; ALPHA-SUBUNITS; EXPRESSION; PROTEIN; INTERNALIZATION; SURFACE; HYPERPARATHYROIDISM	Parathyroid cells have an intracellular machinery for parathyroid hormone (PTH) secretion that is inversely regulated by the extracellular calcium concentration (Ca-0(2+)). The recently characterized Ca-0(2+)-semsing receptor (CaR) is a G protein-coupled, seven-transmembrane receptor mediating the inhibitory effects of high Ca-0(2+) on PTH secretion. The CaR's precise cell surface localization and the signal transducation pathway(s) mediating its inhibitory effects on PTH secretion have not been characterized fully. Here, we demonstrate that the CaR resides within caveolin-rich membrane domains in bovine parathyroid cells. Chief cells within bovine parathyroid glands exhibit a similar pattern of staining for caveolin-1 and for alkaline phosphatase, a glucosylphosphatidylinositol-anchored protein often enriched in caveolae. Purified caveolin-enriched membrane fractions (CEMF) from bovine parathyroid cells are highly enriched in the CaR. and alkaline phosphatase. Other signaling proteins, including G(q/11), eNOS, and several protein kinase C isoforms (i.e. alpha, delta, and zeta, are also present in CEMF, Activation of the CaR by high Ca-0(2+) increases tyrosine phosphorylation of caveolin-1 in CEMF, suggesting that CaR-mediated signal transduction potentially involved in Ca-0(2+)-regulated processes in parathyroid cells occur in caveolae-like domains.	Brigham & Womens Hosp, Div Endocrine Hypertens, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Childrens Hosp, Div Endocrine, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital	Kifor, O (corresponding author), Brigham & Womens Hosp, Div Endocrine Hypertens, 221 Longwood Ave, Boston, MA 02115 USA.		Vehi, Josep/D-6602-2013	Vehi, Josep/0000-0001-6884-9789	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044588, K08DK002530, R01DK052005] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44588, DK02530, DK52005] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Brown Edward M., 1994, P15; BROWN EM, 1976, ENDOCRINOLOGY, V99, P1582, DOI 10.1210/endo-99-6-1582; BROWN EM, 1995, NEW ENGL J MED, V333, P234, DOI 10.1056/NEJM199507273330407; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; Chattopadhyay N, 1996, ENDOCR REV, V17, P289, DOI 10.1210/er.17.4.289; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FOX J, 1993, J BONE MINER RES, V8, pS181; GARDNER DG, 1979, ENDOCRINOLOGY, V105, P360, DOI 10.1210/endo-105-2-360; GARRETT JE, 1995, ENDOCRINOLOGY, V136, P5202, DOI 10.1210/en.136.11.5202; Gogusev J, 1997, KIDNEY INT, V51, P328, DOI 10.1038/ki.1997.41; HEIDIN CH, 1995, CELL, V80, P213; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Isshiki M, 1998, P NATL ACAD SCI USA, V95, P5009, DOI 10.1073/pnas.95.9.5009; Kifor O, 1997, J BONE MINER RES, V12, P715, DOI 10.1359/jbmr.1997.12.5.715; Kifor O, 1996, J CLIN ENDOCR METAB, V81, P1598, DOI 10.1210/jc.81.4.1598; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Mineo C, 1996, MOL BIOL CELL, V7, P1604; MITHAL A, 1995, ENDOCRINOLOGY, V136, P3087, DOI 10.1210/en.136.7.3087; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; PEARCE S, 1995, J CLIN INVEST, V52, P736; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Ross ME, 1996, METHOD ENZYMOL, V269, P408; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Tang ZL, 1997, J BIOL CHEM, V272, P2437, DOI 10.1074/jbc.272.4.2437; TSUCHIYA T, 1980, HISTOCHEMISTRY, V65, P321, DOI 10.1007/BF00493182; VARRAULT A, 1995, ENDOCRINOLOGY, V136, P4390, DOI 10.1210/en.136.10.4390; WILD P, 1995, MICROSC RES TECHNIQ, V32, P120, DOI 10.1002/jemt.1070320207; WILD P, 1990, HISTOCHEMISTRY, V94, P409	53	112	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21708	21713		10.1074/jbc.273.34.21708	http://dx.doi.org/10.1074/jbc.273.34.21708			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705306	hybrid			2022-12-25	WOS:000075492600040
J	Song, CS; Jung, MH; Kim, SC; Hassan, T; Roy, AK; Chatterjee, B				Song, CS; Jung, MH; Kim, SC; Hassan, T; Roy, AK; Chatterjee, B			Tissue-specific and androgen-repressible regulation of the rat dehydroepiandrosterone sulfotransferase gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTION FACTOR; NF-KAPPA-B; DNA-BINDING; HYDROXYSTEROID SULFOTRANSFERASE; MOLECULAR-CLONING; MESSENGER-RNA; RECEPTOR GENE; LIVER; PROTEIN; HORMONE	Dehydroepiandrosterone sulfotransferase (Std) catalyzes sulfonation of androgenic steroids and certain aromatic procarcinogens, In rats, this enzyme is selectively expressed in the fiver, and its expression is strongly repressed by androgens, DNase I footprinting and electrophoretic mobility shift analyses revealed two hepatocyte nuclear factor-1 (HNF1), three CCAAT/enhancer-binding protein (C/EBP), and one consensus palindromic thyroid hormone response elements within the first 215 base pairs (bp) of the promoter sequence of sat Std. This promoter is normally inactive in fibroblast-derived NIH 3T3 cells. However, overexpression of HNF1 and C/EBP resulted in synergistic activation of the Std promoter in this cell type, indicating essential roles of these two trans-regulators in liver-selective expression of the rat Std gene. On the other hand, point mutations at any one of five cis elements proximal to the -215 bp region markedly reduced reporter gene expression, suggesting that all of these sites are important for overall promoter function. Androgenic repression of the Std gene in rat liver can be recapitulated in androgen receptor (AR)-negative HepG2 hepatoma cells after co-transfection with an AR expression plasmid. Functional assay of a nested set of 5'-deleted promoters mapped the negative androgen response region between positions -235 and -310, Antibody supershift and oligonucleotide competition identified three OCT-1 and two C/EBP elements between bp -231 and -292, An additional OCT-1 site was found to overlap with a C/EBP element at the -262/-252 position. Mutational inactivation of any one of five cis elements within the -231/-292 region abolished negative androgen response, However, none of these cis elements showed DNase I protection by recombinant AR in footprinting assay, suggesting the absence of a direct AR-DNA interaction. Thus, these studies on rat Std promoter function indicate that (i) HNF1 and C/EBP are responsible for Liver specificity of the rat Std gene; (ii) androgenic repression of the gene requires the presence of all of the OCT-1 and C/EBP elements between positions -231 and -292; and (iii) AR may exert its negative regulatory effect indirectly through transcriptional interference of OCT-1 and C/EBP rather than through a direct DNA-AR interaction.	Univ Texas, Hlth Sci Ctr, Dept Struct & Cellular Biol, San Antonio, TX 78284 USA; Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Chatterjee, B (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Struct & Cellular Biol, San Antonio, TX 78284 USA.				NATIONAL INSTITUTE ON AGING [R01AG003527] Funding Source: NIH RePORTER; NIA NIH HHS [AG-03527] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan J, 1998, CHEM-BIOL INTERACT, V109, P267, DOI 10.1016/S0009-2797(97)00138-5; Chatterjee B, 1996, P NATL ACAD SCI USA, V93, P728, DOI 10.1073/pnas.93.2.728; CHATTERJEE B, 1987, J BIOL CHEM, V262, P822; CHEN C, 1987, MOL CELL BIOL, V7, P2031; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; DEMYAN WF, 1992, MOL ENDOCRINOL, V6, P589, DOI 10.1210/me.6.4.589; Flesher JW, 1997, BIOCHEM BIOPH RES CO, V234, P554, DOI 10.1006/bbrc.1997.6679; Glatt H, 1997, FASEB J, V11, P314, DOI 10.1096/fasebj.11.5.9141497; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; Heckert LL, 1997, MOL ENDOCRINOL, V11, P1497, DOI 10.1210/me.11.10.1497; HO AN, 1989, GENE, V77, P51; HOBKIRK R, 1993, TRENDS ENDOCRIN MET, V4, P69, DOI 10.1016/S1043-2760(05)80018-9; HOMMA H, 1994, CHEM-BIOL INTERACT, V92, P15, DOI 10.1016/0009-2797(94)90049-3; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; LABRIE Y, 1994, ENDOCRINOLOGY, V134, P1693, DOI 10.1210/en.134.4.1693; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; OGURA K, 1990, BIOCHEM BIOPH RES CO, V166, P1494, DOI 10.1016/0006-291X(90)91036-R; Osada S, 1996, J BIOL CHEM, V271, P3891; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; OTTERNESS DM, 1995, DNA CELL BIOL, V14, P331, DOI 10.1089/dna.1995.14.331; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; PASQUALINI JR, 1992, EUR J CANCER, V28A, P758, DOI 10.1016/0959-8049(92)90110-N; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; Roy AK, 1999, VITAM HORM, V55, P309; ROY AK, 1992, P SOC EXP BIOL MED, V199, P265; Samadani U, 1996, MOL CELL BIOL, V16, P6273; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SONG CS, 1993, BIOCHEM J, V294, P779, DOI 10.1042/bj2940779; SONG CS, 1990, BIOCHEMISTRY-US, V29, P542, DOI 10.1021/bi00454a031; Sourla A, 1998, ENDOCRINOLOGY, V139, P753, DOI 10.1210/en.139.2.753; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Strott CA, 1996, ENDOCR REV, V17, P670, DOI 10.1210/er.17.6.670; Suh DS, 1997, MOL ENDOCRINOL, V11, P1822, DOI 10.1210/me.11.12.1822; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; WILSON JD, 1993, ENDOCR REV, V14, P577, DOI 10.1210/er.14.5.577; XIE YB, 1992, J BIOL CHEM, V267, P4939; YAMAZOE Y, 1989, MOL PHARMACOL, V35, P707; YANUKAKASHLES O, 1994, MOL CELL BIOL, V14, P7124, DOI 10.1128/MCB.14.11.7124	49	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21856	21866		10.1074/jbc.273.34.21856	http://dx.doi.org/10.1074/jbc.273.34.21856			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705324	hybrid			2022-12-25	WOS:000075492600058
J	Xu, Y; Wong, SH; Tang, BL; Subramaniam, VN; Zhang, T; Hong, WJ				Xu, Y; Wong, SH; Tang, BL; Subramaniam, VN; Zhang, T; Hong, WJ			A 29-kilodalton Golgi soluble N-ethylmaleimide-sensitive factor attachment protein receptor (Vti1-rp2) implicated in protein trafficking in the secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; SYNTAXIN FAMILY; CIS-GOLGI; SNARE; COMPLEX; YEAST; VESICLES; FUSION	Expressed sequence tags coding for a potential SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) were revealed during data base searches. The deduced amino acid sequence of the complete coding region predicts a 217-residue protein with a COOH-terminal hydrophobic membrane anchor. Affinity-purified antibodies raised against the cytoplasmic region of this protein specifically detect a 29-kilo-dalton integral membrane protein enriched in the Golgi membrane. Indirect immunofluorescence microscopy reveals that this protein is mainly associated with the Golgi apparatus. When detergent extracts of the Golgi membrane are incubated with immobilized glutathione S-transferase a soluble N-ethylmaleimide-sensitive factor attachment protein (GST-alpha-SNAP), this protein was specifically retained. This protein has been independently identified and termed Vtil-rp2, and it is homologous to Vti1p, a yeast Golgi SNARE. We further show that Vti1-rp2 can be qualitatively coimmunoprecipitated with Golgi syntaxin 5 and syntaxin 6, suggesting that Vti1-rp2 exists in at least two distinct Golgi SNARE complexes. In cells microinjected with antibodies against Vti1-rp2, transport of the envelope protein (G-protein) of vesicular stomatitis virus from the endoplasmic reticulum to the plasma membrane was specifically arrested at the Golgi apparatus, providing further evidence for functional importance of Vtil-rpa in protein trafficking in the secretory pathway.	Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hong, WJ (corresponding author), Inst Mol & Cell Biol, Membrane Biol Lab, 30 Med Dr, Singapore 117609, Singapore.	mcbhwj@imcb.nus.edu.sg	Subramaniam, V. Nathan/A-1901-2010; HONG, Wanjin/E-9927-2010; Tang, Bor Luen/E-4548-2012	Subramaniam, V. Nathan/0000-0002-4583-7790; Tang, Bor Luen/0000-0002-1925-636X				Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; DASCHER C, 1994, J BIOL CHEM, V269, P29363; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HAY JC, 1997, CELL, V89, P147; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; Lowe SL, 1996, J CELL SCI, V109, P209; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; Lupashin VV, 1997, MOL BIOL CELL, V8, P2659, DOI 10.1091/mbc.8.12.2659; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHELLER RH, 1995, NEURON, V14, P893; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Subramaniam VN, 1997, J BIOL CHEM, V272, P25441, DOI 10.1074/jbc.272.41.25441; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; SUBRAMANIAM VN, 1995, J CELL SCI, V108, P2405; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; von Mollard GF, 1998, J BIOL CHEM, V273, P2624, DOI 10.1074/jbc.273.5.2624; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P84; Wong SH, 1998, J BIOL CHEM, V273, P375, DOI 10.1074/jbc.273.1.375; Xu Y, 1997, J BIOL CHEM, V272, P20162, DOI 10.1074/jbc.272.32.20162; Zhang T, 1997, J CELL BIOL, V139, P1157, DOI 10.1083/jcb.139.5.1157	40	52	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21783	21789		10.1074/jbc.273.34.21783	http://dx.doi.org/10.1074/jbc.273.34.21783			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705316	hybrid			2022-12-25	WOS:000075492600050
J	Bolhuis, A; Broekhuizen, CP; Sorokin, A; van Roosmalen, ML; Venema, G; Bron, S; Quax, WJ; van Dijl, JM				Bolhuis, A; Broekhuizen, CP; Sorokin, A; van Roosmalen, ML; Venema, G; Bron, S; Quax, WJ; van Dijl, JM			SecDF of Bacillus subtilis, a molecular Siamese twin required for the efficient secretion of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL PEPTIDASE-I; TEMPORALLY CONTROLLED EXPRESSION; COLI INNER MEMBRANE; ESCHERICHIA-COLI; PREPROTEIN TRANSLOCATION; EXPORT; GENE; ATP; INSERTION; HOMOLOG	In the present studies, we show that the SecD and SecF equivalents of the Gram-positive bacterium Bacillus subtilis are jointly present in one polypeptide, denoted SecDF, that is required to maintain a high capacity for protein secretion. Unlike the SecD subunit of the pre-protein translocase of Escherichia coli, SecDF of B. subtilis was not required for the release of a mature secretory protein from the membrane, indicating that SecDF is involved in earlier translocation steps. Strains lacking intact SecDF showed a cold-sensitive phenotype, which was exacerbated by high level production of secretory proteins, indicating that protein translocation in B. subtilis is intrinsically cold-sensitive. Comparison with SecD and SecF proteins from other organisms revealed the presence of 10 conserved regions in SecDF, some of which appear to be important for SecDF function. Interestingly, the SecDF protein of B. subtilis has 12 putative transmembrane domains. Thus, SecDF does not only show sequence similarity but also structural similarity to secondary solute transporters. Our data suggest that SecDF of B. subtilis represents a novel type of the SecD and SecF proteins, which seems to be present in at least two other organisms.	Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands; Genencor Int, NL-2288 GJ Rijswijk, Netherlands; INRA, Lab Genet Microbienne, F-78352 Jouy En Josas, France; Univ Groningen, Dept Pharmaceut Biol, NL-9713 AV Groningen, Netherlands	University of Groningen; INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of Groningen	van Dijl, JM (corresponding author), Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	j.m.van.dijl@biol.rug.nl	Bolhuis, Albert/E-9932-2010; van Dijl, Jan Maarten/G-1205-2013; Quax, Wim/O-2875-2019; Quax, Wim/K-2802-2012; Sorokin, Alexei/AAV-4666-2020	Bolhuis, Albert/0000-0001-9307-0515; Quax, Wim/0000-0002-5162-9947; Quax, Wim/0000-0002-5162-9947; Sorokin, Alexei/0000-0002-8653-9896				ARKOWITZ RA, 1994, EMBO J, V13, P954, DOI 10.1002/j.1460-2075.1994.tb06340.x; Bolhuis A, 1996, MOL MICROBIOL, V22, P605, DOI 10.1046/j.1365-2958.1996.d01-4676.x; Chambliss Glenn H., 1993, P213; denBlaauwen T, 1996, BIOCHEMISTRY-US, V35, P11994, DOI 10.1021/bi9605088; DRIESSEN AJM, 1992, TRENDS BIOCHEM SCI, V17, P219, DOI 10.1016/0968-0004(92)90381-I; DRIESSEN AJM, 1996, HDB BIOL PHYS, V2, P759; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Ferrari Eugenio, 1993, P917; GARDEL C, 1987, J BACTERIOL, V169, P1286, DOI 10.1128/jb.169.3.1286-1290.1987; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; Jander G, 1996, J BACTERIOL, V178, P3049, DOI 10.1128/jb.178.11.3049-3058.1996; JEONG SM, 1993, MOL MICROBIOL, V10, P133, DOI 10.1111/j.1365-2958.1993.tb00910.x; Kim L, 1996, GENE, V181, P71, DOI 10.1016/S0378-1119(96)00466-0; KIM YJ, 1994, CELL, V78, P845; KONTINEN VP, 1988, J GEN MICROBIOL, V134, P2333; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; KUNST F, 1995, J BACTERIOL, V177, P2403, DOI 10.1128/jb.177.9.2403-2407.1995; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; NAKAMURA K, 1990, J BIOCHEM-TOKYO, V107, P603; PALVA I, 1982, GENE, V19, P81, DOI 10.1016/0378-1119(82)90191-3; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; POGLIANO KJ, 1993, GENETICS, V133, P763; POGLIANO KJ, 1994, J BACTERIOL, V176, P804, DOI 10.1128/jb.176.3.804-814.1994; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; REUTER K, 1991, J BACTERIOL, V173, P2256, DOI 10.1128/JB.173.7.2256-2264.1991; SADAIE Y, 1991, GENE, V98, P101; Sambrook F., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SUH JW, 1990, MOL MICROBIOL, V4, P305, DOI 10.1111/j.1365-2958.1990.tb00597.x; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; TJALSMA H, 1998, IN PRESS GENES DEV; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1991, J GEN MICROBIOL, V137, P2073, DOI 10.1099/00221287-137-9-2073; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; YANSURA DG, 1984, GENETICS BIOCH BACIL, P249	48	103	110	4	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21217	21224		10.1074/jbc.273.33.21217	http://dx.doi.org/10.1074/jbc.273.33.21217			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694879	Green Published, hybrid			2022-12-25	WOS:000075386100072
J	Eppink, MHM; Schreuder, HA; van Berkel, WJH				Eppink, MHM; Schreuder, HA; van Berkel, WJH			Interdomain binding of NADPH in p-hydroxybenzoate hydroxylase as suggested by kinetic, crystallographic and modeling studies of histidine 162 and arginine 269 variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-FLUORESCENS; CRYSTAL-STRUCTURE; ISOCITRATE DEHYDROGENASE; CHEMICAL MODIFICATION; 4-HYDROXYBENZOATE HYDROXYLASE; CIBACRON BLUE; ACTIVE-SITE; PURIFICATION; SEQUENCE; COMPLEX	The conserved residues His-162 and Arg-269 of the flavoprotein p-hydroxybenzoate hydroxylase (EC 1.14.13.2) are located at the entrance of the interdomain cleft that leads toward the active site. To study their putative role in NADPH binding, His-162 and Arg-269 were selectively changed by site-specific mutagenesis, The catalytic properties of H162R, H162Y, and R269K were similar to the wild-type enzyme. However, less conservative His-162 and Arg-269 replacements strongly impaired NADPH binding without affecting the conformation of the flavin ring and the efficiency of substrate hydroxylation, The crystal structures of H162R and R269T in complex with 4-hydroxybenzoate were solved at 3.0 and 2.0 Angstrom resolution, respectively. Both structures are virtually indistinguishable from the wild-type enzyme-substrate complex except for the substituted side chains, In contrast to wild-type p-hydroxybenzoate hydroxylase, H162R is not inactivated by diethyl pyrocarbonate, NADPH protects wild-type p-hydroxybenzoate hydroxylase from diethylpyrocarbonate inactivation, suggesting that His-162 is involved in NADPH binding, Based on these results and GRID calculations we propose that the side chains of His-162 and Arg-269 interact with the pyrophosphate moiety of NADPH, An interdomain binding mode for NADPH is proposed which takes a novel sequence motif (Eppink, M, H, M,, Schreuder, H, A., and van Berkel, W, J, H, (1997) Protein Sci, 6, 2454-2458) into account.	Agr Univ Wageningen, Biochem Lab, Dept Biomol Sci, NL-6703 HA Wageningen, Netherlands; Hoechst Marion Roussel, Core Res Funct, D-65926 Frankfurt, Germany	Wageningen University & Research; Sanofi-Aventis	van Berkel, WJH (corresponding author), Agr Univ Wageningen, Biochem Lab, Dept Biomol Sci, Dreijenlaan 3, NL-6703 HA Wageningen, Netherlands.	willem.vanberkel@fad.bc.wau.nl	Eppink, Michel/AAB-6866-2022; van Berkel, Willem J.H./O-2431-2014	Eppink, Michel/0000-0001-8297-9985; van Berkel, Willem J.H./0000-0002-6551-2782; Schreuder, Herman/0000-0003-2249-2782				Bell CE, 1997, PROTEIN SCI, V6, P2084; BREITER DR, 1994, PROTEIN SCI, V3, P2023, DOI 10.1002/pro.5560031115; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ENTSCH B, 1991, J BIOL CHEM, V266, P17341; ENTSCH B, 1995, FASEB J, V9, P476, DOI 10.1096/fasebj.9.7.7737455; ENTSCH B, 1990, METHOD ENZYMOL, V188, P138; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; EPPINK MHM, 1995, EUR J BIOCHEM, V231, P157, DOI 10.1111/j.1432-1033.1995.0157f.x; Eppink MHM, 1997, PROTEIN SCI, V6, P2454; Eppink MHM, 1998, EUR J BIOCHEM, V253, P194, DOI 10.1046/j.1432-1327.1998.2530194.x; EPPINK MHM, 1997, FLAVINS FLAVOPROTEIN, V12, P315; ESCHRICH K, 1993, EUR J BIOCHEM, V216, P137, DOI 10.1111/j.1432-1033.1993.tb18125.x; ESCHRICH K, 1990, FEBS LETT, V277, P197, DOI 10.1016/0014-5793(90)80843-8; FITA I, 1985, P NATL ACAD SCI USA, V82, P1604, DOI 10.1073/pnas.82.6.1604; GATTI DL, 1994, SCIENCE, V266, P110, DOI 10.1126/science.7939628; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; HOWELL LG, 1972, J BIOL CHEM, V247, P4340; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1994, STRUCTURE, V2, P1007, DOI 10.1016/S0969-2126(94)00104-9; HUSAIN M, 1979, J BIOL CHEM, V254, P6657; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MANSTEIN DJ, 1986, BIOCHEMISTRY-US, V25, P6807, DOI 10.1021/bi00370a012; MAS MT, 1984, BIOCHEMISTRY-US, V23, P1675, DOI 10.1021/bi00303a015; MULLER F, 1983, BIOCHEM INT, V7, P115; MULLER F, 1979, EUR J BIOCHEM, V101, P235, DOI 10.1111/j.1432-1033.1979.tb04236.x; MULLER F, 1982, EUR J BIOCHEM, V128, P21; Palfey BA, 1997, BIOCHEMISTRY-US, V36, P15713; PRESTERA T, 1992, BIOCHEMISTRY-US, V31, P824, DOI 10.1021/bi00118a027; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; Seibold B, 1996, EUR J BIOCHEM, V239, P469, DOI 10.1111/j.1432-1033.1996.0469u.x; SHUMAN B, 1993, J BIOL CHEM, V268, P17057; SPECTOR T, 1972, J BIOL CHEM, V247, P4679; Stanier R Y, 1973, Adv Microb Physiol, V9, P89; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9310, DOI 10.1021/bi00087a008; STURA EA, 1983, J MOL BIOL, V170, P529, DOI 10.1016/S0022-2836(83)80160-0; SUBRAMANIAN S, 1984, CRC CR REV BIOCH MOL, V16, P169, DOI 10.3109/10409238409102302; SUZUKI K, 1995, J BIOCHEM-TOKYO, V117, P579, DOI 10.1093/oxfordjournals.jbchem.a124747; THOMPSON ST, 1976, P NATL ACAD SCI USA, V73, P361, DOI 10.1073/pnas.73.2.361; VANBERKEL W, 1992, EUR J BIOCHEM, V210, P411; VANBERKEL WJH, 1989, EUR J BIOCHEM, V179, P307; VANBERKEL WJH, 1987, EUR J BIOCHEM, V167, P35; VANBERKEL WJH, 1988, EUR J BIOCHEM, V176, P449; VANBERKEL WJH, 1994, PROTEIN SCI, V3, P2245, DOI 10.1002/pro.5560031210; VANBERKEL WJH, 1997, FLAVINS FLAVOPROTEIN, V12, P305; VANDERLAAN JM, 1989, BIOCHEMISTRY-US, V28, P7199, DOI 10.1021/bi00444a011; WIERENGA RK, 1979, J MOL BIOL, V131, P55, DOI 10.1016/0022-2836(79)90301-2; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; WIJNANDS RA, 1982, BIOCHEMISTRY-US, V21, P6639, DOI 10.1021/bi00269a005; WIJNANDS RA, 1987, EUR J BIOCHEM, V163, P535, DOI 10.1111/j.1432-1033.1987.tb10901.x; WIJNANDS RA, 1984, EUR J BIOCHEM, V139, P637, DOI 10.1111/j.1432-1033.1984.tb08051.x; XIONG JP, 1994, NAT STRUCT BIOL, V1, P695, DOI 10.1038/nsb1094-695; YOU KS, 1985, CRC CR REV BIOCH MOL, V17, P313, DOI 10.3109/10409238509113625	58	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21031	21039		10.1074/jbc.273.33.21031	http://dx.doi.org/10.1074/jbc.273.33.21031			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694855	hybrid			2022-12-25	WOS:000075386100048
J	Nash, P; Whitty, A; Handwerker, J; Macen, J; McFadden, G				Nash, P; Whitty, A; Handwerker, J; Macen, J; McFadden, G			Inhibitory specificity of the anti-inflammatory myxoma virus serpin, SERP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEINASE-INHIBITOR; REACTIVE CENTER LOOP; KINETIC CHARACTERIZATION; PLASMINOGEN-ACTIVATOR; CONFORMATIONAL CHANGE; PROTEASE INHIBITORS; SUICIDE SUBSTRATE; FIBROMA VIRUS; MECHANISM; COMPLEX	SERP-1 is a myxoma virus-encoded serpin, secreted from infected cells, that is required for virulence and has anti-inflammatory activity. We report that purified recombinant SERP-1 forms SDS-stable complexes with urokinase-type plasminogen activator (uPA), tissue-type plasminogen activator (tPA), plasmin, thrombin, and factor Xa, N-terminal sequencing confirmed Arg(319)-Asn(320) as the site of reaction. Mutation of these residues to Ala-Ala abolished inhibitory activity but had no effect on the specific cleavage at Thr(315)-Leu(316) Seen with elastase and with cathepsin G, Kinetic analysis of the reactions with uPA, tPA, plasmin, thrombin, Xa, and Cls showed second-order rate constants to vary over 3 logs, from k(inh) = 3 x 10(5) M(-1) s(-1) with thrombin to similar to 600 M(-1) s(-1) with Cls, while steady-state inhibition constants ranged from K(I) = 10 pM with thrombin to similar to 100 nM with C1s. Stoichiometries of inhibition varied between SI = 1.4 +/- 0.1 for uPA to SI = 13 +/- 3 for thrombin, Analysis of the variations in inhibition kinetics shows that when serpins act at ion: concentrations, comparable with the target protease or with K(I) (as appears likely for SERP-1 in vivo), inhibitory specificity becomes less dominated by It,, and is increasingly dependent on partitioning within the branched reaction mechanism and on the lifetime of the inhibited complex.	Robarts Res Inst, London, ON N6G 2V4, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Biogen Inc, Dept Prot Engn, Cambridge, MA 02142 USA; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6G 2V4, Canada	Western University (University of Western Ontario); University of Alberta; Biogen; Western University (University of Western Ontario)	McFadden, G (corresponding author), Robarts Res Inst, 1400 Western Rd,SDRI 133, London, ON N6G 2V4, Canada.							BLOCK W, 1985, VIROLOGY, V140, P113, DOI 10.1016/0042-6822(85)90450-7; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CHRISTENSEN S, 1995, J BIOL CHEM, V270, P14859, DOI 10.1074/jbc.270.25.14859; DAVISON AJ, 1990, NUCLEIC ACIDS RES, V18, P4285, DOI 10.1093/nar/18.14.4285; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; Fenner F., 1978, Viruses and environment, P539; FENNER F, 1965, MYXOMATOSIS; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; GHENDLER Y, 1994, EXP PARASITOL, V78, P121, DOI 10.1006/expr.1994.1013; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gils A, 1997, J BIOL CHEM, V272, P12662, DOI 10.1074/jbc.272.19.12662; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; JAMESON GW, 1973, BIOCHEM J, V131, P101; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LOMAS DA, 1993, J BIOL CHEM, V268, P516; Lucas A, 1996, CIRCULATION, V94, P2890, DOI 10.1161/01.CIR.94.11.2890; MACEN JL, 1993, VIROLOGY, V195, P348, DOI 10.1006/viro.1993.1385; Maksymowych WP, 1996, J RHEUMATOL, V23, P878; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MCFADDEN G, 1995, J LEUKOCYTE BIOL, V57, P731, DOI 10.1002/jlb.57.5.731; MCFADDEN G, 1995, VIROCEPTORS VIROKINE; MORGENSTERN KA, 1994, BIOCHEMISTRY-US, V33, P3432, DOI 10.1021/bi00177a037; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MULDBJERG M, 1993, BLOOD COAGUL FIBRIN, V4, P47, DOI 10.1097/00001721-199304010-00008; Nash P, 1997, ADV EXP MED BIOL, V425, P195; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OMalley KM, 1997, J BIOL CHEM, V272, P5354, DOI 10.1074/jbc.272.8.5354; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PATSTON PA, 1994, THROMB HAEMOSTASIS, V72, P166; PATSTON PA, 1994, SEMIN THROMB HEMOST, V20, P410, DOI 10.1055/s-2007-1001929; Patston PA, 1996, FEBS LETT, V383, P87, DOI 10.1016/0014-5793(96)00231-1; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; Rubin H, 1996, NAT MED, V2, P632, DOI 10.1038/nm0696-632; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P100; Schechter NM, 1997, J BIOL CHEM, V272, P24499, DOI 10.1074/jbc.272.39.24499; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STONE SR, 1995, BIOCHEMISTRY-US, V34, P5164, DOI 10.1021/bi00015a030; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Turner PC, 1995, VIROCEPTORS VIROKINE, P67; UPTON C, 1990, VIROLOGY, V179, P618, DOI 10.1016/0042-6822(90)90129-F; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WRIGHT HT, 1994, PROTEIN-STRUCT FUNCT, V22, P210; YENBUTR P, 1995, INFECT IMMUN, V63, P1745, DOI 10.1128/IAI.63.5.1745-1753.1995; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	51	77	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20982	20991		10.1074/jbc.273.33.20982	http://dx.doi.org/10.1074/jbc.273.33.20982			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694848	hybrid			2022-12-25	WOS:000075386100041
J	Zhao, ZW; Weiner, JH				Zhao, ZW; Weiner, JH			Interaction of 2-n-heptyl-4-hydroxyquinoline-N-oxide with dimethyl sulfoxide reductase of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR MOLYBDOENZYME; DIMETHYLSULFOXIDE REDUCTASE; LACTATE DEHYDROGENASE; SUBSTRATE-SPECIFICITY; FUMARATE REDUCTASE; BINDING; COMPLEX; SITE; TITRATION; MEMBRANE	colinWe have studied the interaction of the menaquinol analog 2-n-heptyl-4-hydroxyquinoline-N-oxide (HOQNO) with dimethyl sulfoxide reductase (DmsABC) and the effect of a mutation in the DmsC subunit (DmsABC(H65R)) using fluorescence titration and stopped-flow methods. The titration data show that the HOQNO fluorescence is quenched when HOQNO binds to DmsABC. The binding stoichiometry is determined to be about 1:1. The mutant DmsABCH65R blocks HOQNO binding to the protein. It is therefore proposed that there is one high-affinity HOQNO binding site per DmsABC molecule located in the DmsC subunit. Stopped-flow kinetic studies show that the interaction can be described by a two-step equilibrium model, a fast bimolecular step followed by a slow unimolecular step. The quenching of HOQNO fluorescence occurs in the bimolecular step. The rates for the forward and reverse reaction of the first equilibrium are determined to be k(1) = (3.9 +/- 0.3) x 10(5) M-1 s(-1) and k(2) = 0.10 +/- 0.01 s(-1) respectively. The dissociation constant for the first equilibrium, K-dI = k(2)/k(1) is calculated to be about 260 nM. The upper limit of the overall dissociation constant is estimated to be 6 nM.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Medical Research Council Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Weiner, JH (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.	joel.weiner@ualberta.ca		Zhao, Zhongwei/0000-0003-4081-7077				BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; BILOUS PT, 1985, J BACTERIOL, V162, P1151, DOI 10.1128/JB.162.3.1151-1155.1985; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRANDT U, 1991, EUR J BIOCHEM, V195, P163, DOI 10.1111/j.1432-1033.1991.tb15690.x; Buc J, 1995, EUR J BIOCHEM, V234, P766, DOI 10.1111/j.1432-1033.1995.766_a.x; CAMMACK R, 1990, BIOCHEMISTRY-US, V29, P8410, DOI 10.1021/bi00488a030; CECCHINI G, 1995, J BACTERIOL, V177, P4587, DOI 10.1128/jb.177.16.4587-4592.1995; CORNFORTH JW, 1956, BIOCHEM J, V63, P124, DOI 10.1042/bj0630124; Giordani R, 1997, EUR J BIOCHEM, V250, P567, DOI 10.1111/j.1432-1033.1997.0567a.x; HALFORD SE, 1975, BIOCHEM J, V149, P411, DOI 10.1042/bj1490411; HAMMES GG, 1982, ENZYME CATALYSIS REG, P61; HIROMI K, 1979, KINETICS FAST ENZYME, P187; Holland LZ, 1997, BIOCHEMISTRY-US, V36, P3207, DOI 10.1021/bi962664k; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KOTIK M, 1992, BIOCHEMISTRY-US, V31, P7787, DOI 10.1021/bi00149a007; Magalon A, 1998, J BIOL CHEM, V273, P10851, DOI 10.1074/jbc.273.18.10851; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; PAULSEN KE, 1993, METHOD ENZYMOL, V227, P396; Rothery RA, 1996, BIOCHEMISTRY-US, V35, P3247, DOI 10.1021/bi951584y; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; Rothery RA, 1998, EUR J BIOCHEM, V254, P588, DOI 10.1046/j.1432-1327.1998.2540588.x; ROY C, 1997, STRUCTURE LOND, V5, P1339; Sambrook J., 2002, MOL CLONING LAB MANU; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22934; SimalaGrant JL, 1996, MICROBIOL-SGM, V142, P3231, DOI 10.1099/13500872-142-11-3231; TRIEBER CA, 1994, J BIOL CHEM, V269, P7103; VANARK G, 1977, BIOCHIM BIOPHYS ACTA, V459, P119, DOI 10.1016/0005-2728(77)90014-7; VanHellemond JJ, 1995, J BIOL CHEM, V270, P31065, DOI 10.1074/jbc.270.52.31065; WEINER JH, 1992, BIOCHIM BIOPHYS ACTA, V1102, P1, DOI 10.1016/0167-4838(92)90493-W; WEINER JH, 1988, J BACTERIOL, V170, P1505, DOI 10.1128/jb.170.4.1505-1510.1988; WEINER JH, 1993, J BIOL CHEM, V268, P3238; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WESTENBERG DJ, 1990, J BIOL CHEM, V265, P19560; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60	34	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20758	20763		10.1074/jbc.273.33.20758	http://dx.doi.org/10.1074/jbc.273.33.20758			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694819	hybrid			2022-12-25	WOS:000075386100012
J	Edgerton, M; Koshlukova, SE; Lo, TE; Chrzan, BG; Straubinger, RM; Raj, PA				Edgerton, M; Koshlukova, SE; Lo, TE; Chrzan, BG; Straubinger, RM; Raj, PA			Candidacidal activity of salivary histatins - Identification of a histatin 5-binding protein on Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-RICH POLYPEPTIDES; HUMAN-PAROTID SECRETION; BLASTOSPORE VIABILITY; HELICAL CONFORMATION; ANTIFUNGAL ACTIVITY; FUNCTIONAL DOMAIN; HIV-INFECTION; ORAL CANDIDA; PEPTIDE; INHIBITION	Candida albicans is the predominant species of yeast isolated from patients with oral candidiasis, which is frequently a symptom of human immunodeficiency virus infection and is a criterion for staging and progression of AIDS, Salivary histatins (Hsts) are potent in vitro antifungal agents and have great promise as therapeutic agents in humans with oral candidiasis, The molecular mechanisms by which Hsts kill yeast cells are not known. We report here, that unlike other antimicrobial proteins, Hsts do not display lytic activities to lipid membranes, measured by release and dequenching of the fluorescent dye calcein, Analysis of the magnitude and time course of Hst-induced calcein release from C. albicans cells further showed that loss of cell integrity was a secondary effect following cell death, rather than the result of primary disruption of the yeast cell membrane. I-125-Hst 5 binding studies indicated that C. albicans expressed a class of saturable binding sites (K-D = 1 ELM), numbering 8.6 x 10(5) sites/cell. Both Hst 3 and Hst 4 competed for these binding sites with similar affinities, which is consistent with the micromolar concentration of Hsts required for candidacidal activity. Specific I-125-Hst 5 binding was not detected to C. albicans spheroplasts, which were 14-fold less susceptible to Hst 5 killing, compared with intact cells in candidacidal assays. in overlay experiments, I-125-Hst 5 bound to a 67-kDa protein detected in C, albicans whole cell lysates and crude membrane fractions, but not in the yeast cell wall fraction. Consistent with the overlay data, cross-linking of I-125-Hst 5 to C. albicans resulted in the appearance of a specific 73-kDa I-125-Hst B-containing complex that was not detected in the cell wall. I-125-Hst B-binding protein of similar size was also observed in susceptible S, cerevisiae strain TI#20, This is the first description of Hst 5 binding sites on C, albicans which mediate cell killing and identification of a 67-kDa yeast Hst 5-binding protein. The binding characteristics of Hst 5 are in agreement with the observed potency of its biological effect and provide crucial information to the use of Hst 5 as a therapeutic agent. The presence of a specific C. albicans Hst 5-binding protein provides further insight into the potential mechanism of yeast killing and suggests a basis for differential activity between yeast killing and the nontoxic nature of Hsts to humans.	SUNY Buffalo, Dept Oral Biol, Sch Dent Med, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Restorat Dent, Sch Dent Med, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Pharmaceut, Buffalo, NY 14214 USA; MIT, Div Toxicol, Cambridge, MA 02139 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Massachusetts Institute of Technology (MIT)	Edgerton, M (corresponding author), SUNY Buffalo, Dept Oral Biol, Sch Dent Med, 310 Foster Hall,3435 Main St, Buffalo, NY 14214 USA.	mira_edgerton@sdm.buffalo.edu	RAJ, PROFESSORDES/AAA-1007-2020	RAJ, PROFESSORDES/0000-0002-4050-4778	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR027232] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012159, R29DE010641, P50DE004898] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BALZI E, 1994, BBA-BIOENERGETICS, V1187, P152, DOI 10.1016/0005-2728(94)90102-3; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BEGGS WH, 1994, ANTIMICROB AGENTS CH, V38, P363, DOI 10.1128/AAC.38.2.363; Bolard J., 1991, Candida albicans. Cellular and molecular biology., P214; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; Bossche H. vanden, 1991, Candida albicans. Cellular and molecular biology., P239; BOUCHARA JP, 1990, INFECT IMMUN, V58, P48, DOI 10.1128/IAI.58.1.48-54.1990; BOURDINEAUD JP, 1990, MOL MICROBIOL, V4, P1737, DOI 10.1111/j.1365-2958.1990.tb00551.x; CALDERONE RA, 1988, INFECT IMMUN, V56, P252, DOI 10.1128/IAI.56.1.252-258.1988; CALDERONE RA, 1991, MICROBIOL REV, V55, P1; CANNON RD, 1995, J DENT RES, V74, P1152, DOI 10.1177/00220345950740050301; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; COLEMAN DC, 1993, CRIT REV MICROBIOL, V19, P61, DOI 10.3109/10408419309113523; DECOTTIGNIES A, 1994, J BIOL CHEM, V269, P12797; Driscoll J, 1996, GENE, V177, P29, DOI 10.1016/0378-1119(96)00265-X; DUCLOHIER H, 1994, TOXICOLOGY, V87, P175, DOI 10.1016/0300-483X(94)90160-0; EDGERTON M, 1995, J BIOMED MATER RES, V29, P1277, DOI 10.1002/jbm.820291015; EDGERTON M, 1993, INFECT IMMUN, V61, P2644, DOI 10.1128/IAI.61.6.2644-2652.1993; Evans LJA, 1996, J MOL BIOL, V255, P559, DOI 10.1006/jmbi.1996.0047; FRANK RW, 1990, J BIOL CHEM, V265, P18871; GABAY JE, 1994, SCIENCE, V264, P373, DOI 10.1126/science.8153623; GAZIT E, 1994, BIOCHEMISTRY-US, V33, P10681, DOI 10.1021/bi00201a016; GEORGOPAPADAKOU NH, 1994, SCIENCE, V264, P371, DOI 10.1126/science.8153622; GREENSPAN D, 1994, ORAL SURG ORAL MED O, V78, P211, DOI 10.1016/0030-4220(94)90149-X; HOLLO Z, 1994, BBA-BIOMEMBRANES, V1191, P384, DOI 10.1016/0005-2736(94)90190-2; HOSTETTER MK, 1994, CLIN MICROBIOL REV, V7, P29, DOI 10.1128/CMR.7.1.29-42.1994; JAZWINSKI SM, 1990, METHOD ENZYMOL, V182, P154; KITAMURA K, 1972, J GEN APPL MICROBIOL, V18, P57, DOI 10.2323/jgam.18.57; LAL K, 1992, J ACQ IMMUN DEF SYND, V5, P904; LAZDUNSKI CJ, 1995, MOL MICROBIOL, V16, P1059, DOI 10.1111/j.1365-2958.1995.tb02331.x; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; Lubkowitz MA, 1997, MICROBIOL-UK, V143, P387, DOI 10.1099/00221287-143-2-387; MACKAY BJ, 1984, INFECT IMMUN, V44, P695, DOI 10.1128/IAI.44.3.695-701.1984; MEITNER SW, 1990, INFECT IMMUN, V58, P2228, DOI 10.1128/IAI.58.7.2228-2236.1990; MURAKAMI Y, 1991, FEMS MICROBIOL LETT, V82, P253; NEGRE E, 1994, J BIOL CHEM, V269, P22039; OConnell BC, 1996, HUM GENE THER, V7, P2255, DOI 10.1089/hum.1996.7.18-2255; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; OPPENHEIM FG, 1986, J BIOL CHEM, V261, P1177; PARK NG, 1992, BIOCHEMISTRY-US, V31, P12241, DOI 10.1021/bi00163a038; POLLOCK JJ, 1984, INFECT IMMUN, V44, P702, DOI 10.1128/IAI.44.3.702-707.1984; RAJ PA, 1990, J BIOL CHEM, V265, P3898; RAJ PA, 1994, J BIOL CHEM, V269, P9610; Raj PA, 1998, BIOPOLYMERS, V45, P51, DOI 10.1002/(SICI)1097-0282(199801)45:1<51::AID-BIP5>3.0.CO;2-Y; Raj PA, 1996, BIOCHEMISTRY-US, V35, P4314, DOI 10.1021/bi951681r; Raj Periathamby Anthony, 1995, FEBS Letters, V368, P526, DOI 10.1016/0014-5793(95)00712-I; RUHR E, 1985, ANTIMICROB AGENTS CH, V27, P841, DOI 10.1128/AAC.27.5.841; SABATINI LM, 1989, BIOCHEM BIOPH RES CO, V160, P495, DOI 10.1016/0006-291X(89)92460-1; SANTARPIA RP, 1988, ARCH ORAL BIOL, V33, P567, DOI 10.1016/0003-9969(88)90131-8; SANTARPIA RP, 1990, ORAL MICROBIOL IMMUN, V5, P226, DOI 10.1111/j.1399-302X.1990.tb00651.x; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; STRAHILEVITZ J, 1994, BIOCHEMISTRY-US, V33, P10951, DOI 10.1021/bi00202a014; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TROXLER RF, 1990, J DENT RES, V69, P2, DOI 10.1177/00220345900690010101; Tsai H, 1997, ANTIMICROB AGENTS CH, V41, P2224, DOI 10.1128/AAC.41.10.2224; Tsai HY, 1996, INFECT IMMUN, V64, P5000, DOI 10.1128/IAI.64.12.5000-5007.1996; VANBELKUM MJ, 1991, J BACTERIOL, V173, P7934, DOI 10.1128/jb.173.24.7934-7941.1991; VANDENBOSSCHE H, 1987, CRIT REV MICROBIOL, V15, P57; XU L, 1993, ARCH ORAL BIOL, V38, P277, DOI 10.1016/0003-9969(93)90133-7; XU T, 1991, INFECT IMMUN, V59, P2549, DOI 10.1128/IAI.59.8.2549-2554.1991; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YPHANTIS DA, 1967, J BACTERIOL, V94, P1509, DOI 10.1128/JB.94.5.1509-1515.1967; ZUO Y, 1995, GENE, V161, P87, DOI 10.1016/0378-1119(95)00237-Z; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	71	159	165	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20438	20447		10.1074/jbc.273.32.20438	http://dx.doi.org/10.1074/jbc.273.32.20438			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685398	hybrid			2022-12-25	WOS:000075305400075
J	Escola, JM; Kleijmeer, MJ; Stoorvogel, W; Griffith, JM; Yoshie, O; Geuze, HJ				Escola, JM; Kleijmeer, MJ; Stoorvogel, W; Griffith, JM; Yoshie, O; Geuze, HJ			Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; SPAN-TRANSMEMBRANE PROTEIN; INVARIANT CHAIN COMPLEXES; GROWTH-FACTOR RECEPTOR; LEUKEMIA-VIRUS TYPE-1; T-CELL ACTIVATION; SYNCYTIUM FORMATION; HLA-DR; LYSOSOMAL COMPARTMENTS; LYMPHOBLASTOID CELLS	Association of major histocompatibility complex (MHC) class II molecules with peptides occurs in a series of endocytic vacuoles, termed MHC class II-enriched compartments (MIICs). Morphological criteria have defined several types of MIICs, including multivesicular MIICs, which are composed of 50-60-nm vesicles surrounded by a limiting membrane. Multivesicular MIICs can fuse with the plasma membrane, thereby releasing their internal vesicles into the extracellular space. The externalized vesicles, termed exosomes, carry MHC class II and can stimulate T-cells in, vitro. In this study, we show that exosomes are enriched in the co-stimulatory molecule CD86 and in several tetraspan proteins, including CD37, CD53, CD63, CD81, and CD82, Interestingly, subcellular localization of these molecules revealed that they were concentrated on the internal membranes of multivesicular MIICs, In contrast to the tetraspans, other membrane proteins of MIICs, such as HLA-DM, Lamp-1, and Lamp-a, were mainly localized to the limiting membrane and mere hardly detectable on the internal membranes of MIICs nor on exosomes, Because internal vesicles of multivesicular MIICs are thought to originate from inward budding of the limiting membrane, the differential distribution of membrane proteins on the internal and limiting membranes of MIICs has to be driven by active protein sorting.	Univ Utrecht, Sch Med, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Shionogi Inst Med Sci, Osaka 566, Japan	Utrecht University; Shionogi & Company Limited	Geuze, HJ (corresponding author), Univ Utrecht, Sch Med, Dept Cell Biol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	H.J.Geuze@lab.azu.nl	Eckhardt, Erik/G-1567-2010	Yoshie, Osamu/0000-0003-4353-5809				ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Boismenu R, 1996, SCIENCE, V271, P198, DOI 10.1126/science.271.5246.198; Cibotti R, 1997, IMMUNITY, V6, P245, DOI 10.1016/S1074-7613(00)80327-1; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GEUZE H, 1994, EUR J CELL BIOL, V64, P3; GEUZE HJ, 1981, J CELL BIOL, V89, P653, DOI 10.1083/jcb.89.3.653; Glickman JN, 1996, J CELL BIOL, V132, P769, DOI 10.1083/jcb.132.5.769; HAMMOND C, IN PRESS J IMMUNOL; HARDING CV, 1993, J IMMUNOL, V151, P3988; HARDING CV, 1992, J CELL BIOL, V119, P531, DOI 10.1083/jcb.119.3.531; IMAI T, 1992, J IMMUNOL, V149, P2879; IMAI T, 1993, J IMMUNOL, V151, P6470; IMAI T, 1995, J IMMUNOL, V155, P1229; JOHNSTONE RM, 1992, BIOCHEM CELL BIOL, V70, P179, DOI 10.1139/o92-028; JOHNSTONE RM, 1991, J CELL PHYSIOL, V147, P27, DOI 10.1002/jcp.1041470105; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; Kleijmeer Monique J., 1996, Methods (Orlando), V10, P191, DOI 10.1006/meth.1996.0095; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAMB CA, 1992, J IMMUNOL, V148, P3478; Lazo PA, 1997, CELL IMMUNOL, V178, P132, DOI 10.1006/cimm.1997.1139; LEBELBINAY S, 1995, J IMMUNOL, V155, P101; LEBELBINAY S, 1995, J LEUKOCYTE BIOL, V57, P956, DOI 10.1002/jlb.57.6.956; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Maecker HT, 1997, J EXP MED, V185, P1505, DOI 10.1084/jem.185.8.1505; Mannion BA, 1996, J IMMUNOL, V157, P2039; Morkowski S, 1997, EUR J IMMUNOL, V27, P609, DOI 10.1002/eji.1830270306; MORTON PA, 1995, J IMMUNOL, V154, P137; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NIJMAN HW, 1995, J EXP MED, V182, P163, DOI 10.1084/jem.182.1.163; NOJIMA Y, 1993, CELL IMMUNOL, V152, P249, DOI 10.1006/cimm.1993.1285; PATERSON DJ, 1987, J EXP MED, V165, P1, DOI 10.1084/jem.165.1.1; PATERSON DJ, 1987, J EXP MED, V166, P1603, DOI 10.1084/jem.166.5.1603; PETERS PJ, 1989, EUR J IMMUNOL, V19, P1469, DOI 10.1002/eji.1830190819; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; Radford KJ, 1996, BIOCHEM BIOPH RES CO, V222, P13, DOI 10.1006/bbrc.1996.0690; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; RAPOSO G, 1997, WEIRS HDB EXPT IMMUN; REILLY PL, 1995, J IMMUNOL, V155, P529; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; RIBERDY JM, 1994, J CELL BIOL, V125, P1225, DOI 10.1083/jcb.125.6.1225; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Sanderson F, 1996, IMMUNITY, V4, P87, DOI 10.1016/S1074-7613(00)80301-5; Sanderson F, 1995, CURR BIOL, V5, P1372, DOI 10.1016/S0960-9822(95)00274-0; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; Todd SC, 1996, J EXP MED, V184, P2055, DOI 10.1084/jem.184.5.2055; TOOTHILL VJ, 1990, J IMMUNOL, V145, P283; VANDEURS B, 1993, EUR J CELL BIOL, V61, P208; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411; Wubbolts R, 1996, J CELL BIOL, V135, P611, DOI 10.1083/jcb.135.3.611	63	847	892	2	66	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20121	20127		10.1074/jbc.273.32.20121	http://dx.doi.org/10.1074/jbc.273.32.20121			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685355	hybrid			2022-12-25	WOS:000075305400032
J	Freeman, JLR; De La Cruz, EM; Pollard, TD; Lefkowitz, RJ; Pitcher, JA				Freeman, JLR; De La Cruz, EM; Pollard, TD; Lefkowitz, RJ; Pitcher, JA			Regulation of G protein-coupled receptor kinase 5 (GRK5) by actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEINS; SKELETAL-MUSCLE; F-ACTIN; PURIFICATION; IDENTIFICATION; ACTIVATION; CALMODULIN; FAMILY; POLYMERIZATION; ASSOCIATION	Gr protein-coupled receptor kinases (GRKs) initiate pathways leading to the desensitization of agonist-occupied G-protein-coupled receptors (GPCRs), Here we report that the cytoskeletal protein actin binds and inhibits GRK5, Actin inhibits the kinase activity directly, reducing GRK5-mediated phosphorylation of both membrane-bound GPCRs and soluble substrates, GRK5 binds actin monomers with a K-d of 0.6 mu M and actin filaments with a K-d of 0.2 mu M. Mutation of 6 amino acids near the amino terminus of GRK5 eliminates actin-mediated inhibition of GRK5. Calmodulin has previously been shown to bind to the amino terminus of GRK5 (Pronin, A. N., and Benovic, J. L. (1997) J. Biol, Chem. 272, 3806-3812) and here we show calmodulin displaces GRK5 from actin. Calmodulin inhibits GRK5-mediated phosphorylation of GPCRs, but not soluble substrates such as casein. Thus in the presence of actin, calmodulin determines the substrate specificity of GRK5 by preferentially allowing phosphorylation of soluble substrates over membrane-bound substrates.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Salk Institute	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.		Pitcher, Julie/ABH-2078-2020; Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [HL 16737] Funding Source: Medline; NIGMS NIH HHS [GM26338] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026338] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; ARNOLD H, 1970, EUR J BIOCHEM, V15, P360, DOI 10.1111/j.1432-1033.1970.tb01016.x; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; Brown N G, 1993, Eur J Biochem, V212, P840; CHEN CY, 1993, J BIOL CHEM, V268, P7825; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; COOPER JA, 1985, BIOCHEMISTRY-US, V24, P793, DOI 10.1021/bi00324a039; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FREEDMAN NJ, 1996, RECENT PROG HORM RES, V51, P352; Haga K, 1997, BIOCHEMISTRY-US, V36, P1315, DOI 10.1021/bi961613k; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HITCHCOCKDEGREGORI SE, 1988, BIOCHEMISTRY-US, V27, P9182, DOI 10.1021/bi00426a016; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; JARRETT HW, 1995, J BIOL CHEM, V270, P5578, DOI 10.1074/jbc.270.10.5578; Karino A, 1996, FEBS LETT, V398, P317, DOI 10.1016/S0014-5793(96)01266-5; KIM CM, 1993, RECEPTOR, V3, P39; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEISER M, 1986, J BIOL CHEM, V261, P1904; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1984, J CELL BIOL, V99, P1970, DOI 10.1083/jcb.99.6.1970; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; Sallese M, 1997, J BIOL CHEM, V272, P10188; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; WALSH TP, 1977, BIOCHEM J, V165, P165, DOI 10.1042/bj1650165	36	43	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20653	20657		10.1074/jbc.273.32.20653	http://dx.doi.org/10.1074/jbc.273.32.20653			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685424	hybrid			2022-12-25	WOS:000075305400101
J	Knudsen, KE; Arden, KC; Cavenee, KK				Knudsen, KE; Arden, KC; Cavenee, KK			Multiple G(1) regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; D-TYPE CYCLINS; CANCER-CELLS; PROTEIN FUNCTION; KINASE-ACTIVITY; ATPASE ACTIVITY; T-ANTIGEN; LNCAP; FIBROBLASTS; PHASE	Prostatic epithelial cells and most primary prostate tumors are dependent on androgen for growth, but how androgen regulates cellular proliferation remains unsolved. Using poorly understood mechanisms, recurrent tumor cells evade the androgen requirement. We utilized androgen-dependent prostatic tumor cells to demonstrate that androgen exerts its effect on the cell cycle by influencing specific aspects of G(1)-S progression. Androgen depletion of these cells results in early G(1) arrest, characterized by reduced cyclin dependent kinase activity, and underphosphorylated retinoblastoma tumor suppressor protein (RB), The reduction in kinase activity was partially attributed to reduction of specific G(1) cyclins and alternate regulation of cyclin-dependent kinase inhibitors, Using this information, we developed a reliable assay to assess the ability of specific G(1) regulatory proteins to circumvent these controls and promote androgen-independent growth. As expected, inactivation of RE was required for progression through the cell cycle. Surprisingly, overexpression of G(1) cyclins, which drives RE phosphorylation, was insufficient to promote androgen-independent cell cycle progression. Introduction of viral oncoproteins did promote G(1)-S progression in the absence of androgen, dependent on their ability to sequester RE and related proteins. These results provide the first evidence that multiple elements governing the G(1)-S transition dictate androgen-dependent growth, and the formation of androgen-independent prostatic tumors may be because of misregulation of these processes.	Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Cavenee, KK (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.			Knudsen, Karen/0000-0002-1301-890X				Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BERCHEM GJ, 1995, CANCER RES, V55, P735; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; Chen Y, 1996, ONCOGENE, V13, P1765; Conzen SD, 1995, ONCOGENE, V11, P2295; Cunningham JM, 1996, CANCER RES, V56, P4475; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Denmeade SR, 1996, PROSTATE, V28, P251; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; HERMAN JG, 1995, CANCER RES, V55, P4525; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JENSTER G, 1992, J STEROID BIOCHEM, V41, P671, DOI 10.1016/0960-0760(92)90402-5; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, CANCER RES, V58, P2042; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 1996, P NATL ACAD SCI USA, V93, P8278, DOI 10.1073/pnas.93.16.8278; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; MONTGOMERY BT, 1992, PROSTATE, V21, P63, DOI 10.1002/pros.2990210107; MONTIE JE, 1994, UROLOGY, V43, P892, DOI 10.1016/0090-4295(94)90163-5; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Mymryk JS, 1996, ONCOGENE, V13, P1581; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PEEPER DS, 1994, BBA-REV CANCER, V1198, P215, DOI 10.1016/0304-419X(94)90015-9; PHILLIPS SMA, 1994, BRIT J CANCER, V70, P1252, DOI 10.1038/bjc.1994.482; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAVENNA L, 1995, PROSTATE, V26, P290, DOI 10.1002/pros.2990260604; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SAROFF J, 1980, ONCOLOGY-BASEL, V37, P46, DOI 10.1159/000225401; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SONNENSCHEIN C, 1989, CANCER RES, V49, P3474; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Theodorescu D, 1997, J UROLOGY, V158, P131, DOI 10.1097/00005392-199707000-00040; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; WALL D, 1994, J BIOL CHEM, V269, P5446; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WENDEROTH UK, 1983, ENDOCRINOLOGY, V113, P569, DOI 10.1210/endo-113-2-569; WILDING G, 1995, CANCER SURV, V23, P43; ZHU JY, 1991, J VIROL, V65, P2778, DOI 10.1128/JVI.65.6.2778-2790.1991	67	163	171	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20213	20222		10.1074/jbc.273.32.20213	http://dx.doi.org/10.1074/jbc.273.32.20213			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685369	hybrid			2022-12-25	WOS:000075305400046
J	McGinnis, KM; Whitton, MM; Gnegy, ME; Wang, KKW				McGinnis, KM; Whitton, MM; Gnegy, ME; Wang, KKW			Calcium/calmodulin-dependent protein kinase IV is cleaved by caspase-3 and calpain in SH-SY5Y human neuroblastoma cells undergoing apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; HUMAN HEPATOMA-CELLS; POLY(ADP-RIBOSE) POLYMERASE; CYSTEINE PROTEASE; CA2+-ATPASE INHIBITOR; NEURONAL APOPTOSIS; MOLECULAR-CLONING; ACTIVATION; PHOSPHORYLATION; EXPRESSION	We have previously demonstrated cleavage of alpha-spectrin by caspase-3 and calpain during apoptosis in SH-SY5Y neuroblastoma cells (Nath, R, Raser, K, J., Stafford, D., Hajimohammadreza, I., Posner, A., Alien, H,, Talanian, R, V,, Yuen, P,, Gilbertsen, R. B,, and Wang, K, K, (1996) Biochem. J, 319, 683-690). We demonstrate here that calcium/calmodulin-dependent protein kinase IV (CaMK TV) is cleaved during apoptosis by caspase-3 and calpain, We challenged SH-SY5Y cells with the pro-apoptotic agent thapsigargin. Western blot analysis revealed major CaMK IV breakdown. products of 40, 38, and 33 kDa, Digestion of control SH-SY5Y lysate with purified caspase-3 produced a 38-kDa CaMK IV fragment; digestion with purified calpain produced a major fragment of 40 kDa, Pretreatment with carbobenzoxy-Asp-CH2OC(O)-2,6-dichlorobenzene or Z-Val-Ala-Asp-fluoromethylketone was able to block the caspase-3-mediated production of the 38-kDa fragment both in situ and in vitro. Calpain inhibitor II similarly blocked formation of the calpain-mediated 40-kDa fragment both in situ and in vitro. Digestion of recombinant CaMK TV by other caspase family members revealed that only caspase-3 produces a fragmentation pattern consistent to that seen in situ. The major caspase-3 and calpain cleavage sites are respectively identified as PAPD(176)*A and CG(201)*A, both within the CaMK TV catalytic domain. Furthermore, calmodulin-stimulated protein kinase activity decreases within 6 h in thapsigargin-treated SH-SY5Y, The loss of activity precedes cell death.	Warner Lambert Co, Dept Neurosci Therapeut, Lab Neurobiochem, Parke Davis Pharmaceut Res Div, Ann Arbor, MI 48105 USA; Warner Lambert Co, Dept Chem, Lab Neurobiochem, Parke Davis Pharmaceut Res Div, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	Pfizer; Pfizer; University of Michigan System; University of Michigan	Wang, KKW (corresponding author), Warner Lambert Co, Dept Neurosci Therapeut, Lab Neurobiochem, Parke Davis Pharmaceut Res Div, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.			Wang, Kevin/0000-0002-9343-6473	NIGMS NIH HHS [5T32GM07767] Funding Source: Medline; NIMH NIH HHS [MH36044] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH036044] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alevizopoulos A, 1997, BIOESSAYS, V19, P581, DOI 10.1002/bies.950190709; Alevizopoulos A, 1997, J BIOL CHEM, V272, P23597, DOI 10.1074/jbc.272.38.23597; Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Cain K, 1996, BIOCHEM J, V314, P27, DOI 10.1042/bj3140027; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; CHURN SB, 1995, J NEUROSCI, V15, P3200; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENSLEN H, 1995, BIOCHEM BIOPH RES CO, V207, P1038, DOI 10.1006/bbrc.1995.1289; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HARRIS AS, 1989, J BIOL CHEM, V264, P17401; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; Ho N, 1996, J EXP MED, V184, P101, DOI 10.1084/jem.184.1.101; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; Ji RR, 1996, BRAIN RES, V721, P167, DOI 10.1016/0006-8993(95)01316-4; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KANEKO Y, 1994, CANCER LETT, V79, P147, DOI 10.1016/0304-3835(94)90253-4; Kawamura KI, 1996, BIOCHEM PHARMACOL, V52, P1903, DOI 10.1016/S0006-2952(96)00692-2; KITANI T, 1994, J BIOCHEM-TOKYO, V115, P637, DOI 10.1093/oxfordjournals.jbchem.a124387; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1995, J BIOCHEM-TOKYO, V117, P686, DOI 10.1093/oxfordjournals.jbchem.a124764; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Posmantur R, 1997, J NEUROCHEM, V68, P2328; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; TOMBES RM, 1995, CELL GROWTH DIFFER, V6, P1063; TSUKAMOTO A, 1993, CELL BIOL INT, V17, P969, DOI 10.1006/cbir.1993.1021; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Wang KKW, 1996, BIOTECHNIQUES, V20, P662; Watanabe S, 1996, J BIOL CHEM, V271, P6903, DOI 10.1074/jbc.271.12.6903; Wayman GA, 1996, MOL CELL BIOL, V16, P6075; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	70	87	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19993	20000		10.1074/jbc.273.32.19993	http://dx.doi.org/10.1074/jbc.273.32.19993			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685336	hybrid			2022-12-25	WOS:000075305400013
J	Du, Q; Melnikova, IN; Gardner, PD				Du, Q; Melnikova, IN; Gardner, PD			Differential effects of heterogeneous nuclear ribonucleoprotein K on Sp1- and Sp3-mediated transcriptional activation of a neuronal nicotinic acetylcholine receptor promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; SUBUNIT MESSENGER-RNAS; BINDING-PROTEIN; GENE PROMOTER; ALPHA-3 GENE; POU DOMAIN; RAT; DNA; BETA-4; BRAIN	The neuronal nicotinic acetylcholine receptor gene family consists of II members, alpha 2-alpha 9 and beta 2-beta 4, Three of the genes, those encoding the alpha 3, alpha 5, and beta 4 subunits, are clustered tightly within the genome. These three subunits constitute the predominant acetylcholine receptor subtype expressed in the peripheral nervous system. The genomic proximity of the three genes suggests a regulatory mechanism ensuring their coordinate expression. However, it is likely that gene-specific regulatory mechanisms are also functioning because the expression patterns of the three genes, although similar, are not identical. Previously we identified regulatory elements within the beta 4 promoter region and demonstrated that these elements interact specifically with nuclear proteins. One of these elements, E1, interacts with the regulatory factor Pur alpha as well as three other unidentified DNA-binding proteins with. molecular masses of 31, 65, and 114 kDa, Another element, E2, interacts with Spl and Sp3, Because El and E2 are immediately adjacent to one another, we postulated that the proteins that bind to the elements interact to regulate beta 4 gene expression. Here we report the identification of the 65-kDa El-binding protein as heterogeneous nuclear ribonucleoprotein K and demonstrate that it affects the transactivation of beta 4 promoter activity by Spl and Sp3 differentially.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Gardner, PD (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	gardner@uthscsa.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030243] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30243, R01 NS030243] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMADOR M, 1995, J NEUROSCI, V15, P4525; BESSIS A, 1993, NUCLEIC ACIDS RES, V21, P2185, DOI 10.1093/nar/21.9.2185; Bigger CB, 1996, J BIOL CHEM, V271, P32842, DOI 10.1074/jbc.271.51.32842; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; BOULTER J, 1990, J BIOL CHEM, V265, P4472; Boyd RT, 1996, NEUROSCI LETT, V208, P73, DOI 10.1016/0304-3940(96)12561-1; BOYD RT, 1994, J NEUROBIOL, V25, P960, DOI 10.1002/neu.480250806; CONROY WG, 1992, NEURON, V9, P679, DOI 10.1016/0896-6273(92)90031-8; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Criado M, 1997, J NEUROSCI, V17, P6554; DAUBAS P, 1993, P NATL ACAD SCI USA, V90, P2237, DOI 10.1073/pnas.90.6.2237; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINELEYMILLER K, 1992, MOL BRAIN RES, V16, P339, DOI 10.1016/0169-328X(92)90244-6; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; Fornasari D, 1997, MOL PHARMACOL, V51, P250, DOI 10.1124/mol.51.2.250; Fyodorov D, 1996, MOL CELL BIOL, V16, P5004; Gerzanich V, 1997, MOL PHARMACOL, V51, P320, DOI 10.1124/mol.51.2.320; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAMMOND DN, 1990, BRAIN RES, V512, P190, DOI 10.1016/0006-8993(90)90626-M; HERNANDEZ MC, 1995, J BIOL CHEM, V270, P3224, DOI 10.1074/jbc.270.7.3224; HU MJ, 1995, J BIOL CHEM, V270, P4497, DOI 10.1074/jbc.270.19.11619; HU MJ, 1994, J NEUROCHEM, V62, P392; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; Lee MH, 1996, J BIOL CHEM, V271, P3420; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MATTER JM, 1995, J NEUROSCI, V15, P5919; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; McDonough J, 1997, J NEUROSCI, V17, P2273; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; Melnikova IN, 1996, CELL GROWTH DIFFER, V7, P1067; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MILTON NGN, 1995, J BIOL CHEM, V270, P15143, DOI 10.1074/jbc.270.25.15143; Milton NGN, 1996, BIOCHEM J, V317, P419, DOI 10.1042/bj3170419; PATRICK J, 1993, PROG BRAIN RES, V98, P113; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; WADA E, 1990, BRAIN RES, V526, P46; WinzerSerhan UH, 1997, J COMP NEUROL, V386, P540, DOI 10.1002/(SICI)1096-9861(19971006)386:4<540::AID-CNE2>3.0.CO;2-2; Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4; Yan GZ, 1997, J NEUROSCI, V17, P6122; YANG X, 1997, J NEUROBIOL, V28, P311; YANG XD, 1994, J BIOL CHEM, V269, P10252; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514; ZOLI M, 1995, J NEUROSCI, V15, P1912, DOI 10.1523/JNEUROSCI.15-03-01912.1995	62	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19877	19883		10.1074/jbc.273.31.19877	http://dx.doi.org/10.1074/jbc.273.31.19877			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677424	hybrid			2022-12-25	WOS:000075125200076
J	Hossain, A; Tsuchiya, S; Minegishi, M; Osada, M; Ikawa, S; Tezuka, F; Kaji, M; Konno, T; Watanabe, M; Kikuchi, H				Hossain, A; Tsuchiya, S; Minegishi, M; Osada, M; Ikawa, S; Tezuka, F; Kaji, M; Konno, T; Watanabe, M; Kikuchi, H			The Ah receptor is not involved in 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated apoptosis in human leukemic T cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON HYDROXYLASE; PROTEIN-TYROSINE KINASES; TRANSCRIPTION FACTOR; ICE/CED-3 PROTEASE; EXPRESSION; INDUCTION; ACTIVATION; TOXICITY; DEATH; GENES	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a common environmental pollutant causing public concern. Its toxic effects include disruption of the immune, endocrine, and reproductive systems, impairment of fetal development, carcinogenicity, and lethality in rodents. Here, we report that TCDD induces apoptosis in two cultured human leukemic lymphoblastic T cell lines. This cell death was found not to be dependent on an aryl hydrocarbon receptor and to be inhibited by the inhibitor of tyrosine kinases and caspases. Apoptosis-linked c-Jun N-terminal kinase is rapidly activated in these cells by the treatment with TCDD. A dominant-negative mutant of c-Jun N-terminal kinase prevented cell death in the treatment with TCDD. Furthermore, TCDD decreases the Bcl-2 protein level in. these cell lines. These findings will help in the understanding of the molecular mechanism underlying TCDD-mediated immunotoxicity.	Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Pediat Oncol, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Pathol, Sendai, Miyagi 9808575, Japan; Natl Sendai Hosp, Dept Pathol, Miyagino Ku, Sendai, Miyagi 983, Japan	Tohoku University; Tohoku University; Tohoku University	Kikuchi, H (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, 4-1 Seiryomachi, Sendai, Miyagi 9808575, Japan.		井川, 俊太郎/L-5911-2015					Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BERGHARD A, 1990, J BIOL CHEM, V265, P21086; BOMBICK DW, 1988, P NATL ACAD SCI USA, V85, P4128, DOI 10.1073/pnas.85.12.4128; Bronte V, 1996, BIOCHEM BIOPH RES CO, V218, P344, DOI 10.1006/bbrc.1996.0060; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVITO MJ, 1995, TOXICOLOGY, V102, P115, DOI 10.1016/0300-483X(95)03040-M; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; GARDIN K, 1994, J BIOL CHEM, V269, P23800; GASIEWICZ TA, 1984, MOL PHARMACOL, V26, P90; GREENLEE WF, 1985, TOXICOL APPL PHARM, V79, P112, DOI 10.1016/0041-008X(85)90373-4; HARRIS M, 1989, CANCER RES, V49, P4531; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Hoffer A, 1996, TOXICOL APPL PHARM, V141, P238; HUFF J, 1994, ANNU REV PHARMACOL, V34, P343; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; KNUTSON JC, 1980, TOXICOL APPL PHARM, V54, P377, DOI 10.1016/0041-008X(80)90163-5; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lee DC, 1996, TOXICOL APPL PHARM, V137, P90, DOI 10.1006/taap.1996.0060; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; MA X, 1992, BIOCHEM BIOPH RES CO, V189, P5965; Martin Seamus J., 1993, Trends in Cell Biology, V3, P141, DOI 10.1016/0962-8924(93)90128-N; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; MCCABE MJ, 1993, BIOCHEM BIOPH RES CO, V194, P944, DOI 10.1006/bbrc.1993.1912; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MIGITA K, 1994, J IMMUNOL, V153, P3457; MINEGISHI M, 1995, LEUKEMIA RES, V19, P433, DOI 10.1016/0145-2126(95)00016-H; Morita S, 1996, LEUKEMIA, V10, P102; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; Park JYK, 1996, P NATL ACAD SCI USA, V93, P2322, DOI 10.1073/pnas.93.6.2322; POLAND A, 1980, MOL PHARMACOL, V17, P86; POLAND A, 1977, MOL PHARMACOL, V13, P924; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rhile MJ, 1996, TOXICOLOGY, V110, P153, DOI 10.1016/0300-483X(96)83962-X; SILVERSTONE AE, 1994, TOXICOL APPL PHARM, V126, P248, DOI 10.1006/taap.1994.1114; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; WHITLOCK JP, 1996, FASEB J, V10, P808; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	46	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19853	19858		10.1074/jbc.273.31.19853	http://dx.doi.org/10.1074/jbc.273.31.19853			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677421	hybrid			2022-12-25	WOS:000075125200073
J	Sharma, SV				Sharma, SV			Rapid recruitment of p120RasGAP and its associated protein, p190RhoGAP, to the cytoskeleton during integrin mediated cell-substrate interaction	ONCOGENE			English	Article						p120RasGAP; p190RhoGAP; cell-substrate interaction; integrins; cytoskeleton	FOCAL ADHESION KINASE; GTPASE-ACTIVATING PROTEIN; ACTIN STRESS FIBERS; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; RHO-FAMILY; DEPHOSPHORYLATION; INSULIN	The interaction of cells with their substrate triggers cascades of signal transduction that result in profound changes in cell morphology. The nature of these signals and how they are integrated to orchestrate changes in cell shape are beginning to be elucidated. In particular, adhesive interactions between cells and their substrate, mediated by cell-surface integrins and extracellular matrix (ECM) proteins, appear to result in massive rearrangement of the cell cytoskeleton via the small G-protein, Rho. Here we show that in mouse fibroblasts, the interaction between cells and their substrate results in the rapid recruitment to the cytoskeleton of RasGAP (p120RasGAP), its associated protein of 190 kilodaltons, the GTPase activating protein for RhoA (p190RhoGAP) and the focal adhesion kinase (p125FAK). Similar results were obtained when cells were plated on ECM proteins, such as fibronectin, suggesting that the phenomenon is integrin mediated. These studies suggest that in fibroblasts, cell-substrate interaction triggered by integrin engagement result in the recruitment to the cytoskeleton of signaling molecules such as p120RasGAP, p190RhoGAP and p125FAK and may be involved in the formation of membrane cytoskeleton-associated signaling complexes that are important in cytoarchitectural reorganization.	Univ Tennessee, Ctr Hlth Sci, Dept Microbiol & Immunol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Sharma, SV (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Microbiol & Immunol, Memphis, TN 38163 USA.				NCI NIH HHS [CA55983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BARRY ST, 1994, J CELL SCI, V107, P2033; BENZEEV A, 1979, CELL, V17, P859, DOI 10.1016/0092-8674(79)90326-X; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; Bottazzi ME, 1997, TRENDS CELL BIOL, V7, P348, DOI 10.1016/S0962-8924(97)01114-8; Burbelo PD, 1995, J BIOL CHEM, V270, P30919, DOI 10.1074/jbc.270.52.30919; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Bussey H, 1996, SCIENCE, V272, P224, DOI 10.1126/science.272.5259.224; Bussey H, 1996, SCIENCE, V273, P203, DOI 10.1126/science.273.5272.203; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CARRAWAY KL, 1995, BIOESSAYS, V17, P171, DOI 10.1002/bies.950170212; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CHANG JH, 1993, ONCOGENE, V8, P959; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gille J, 1996, ANN NY ACAD SCI, V797, P93, DOI 10.1111/j.1749-6632.1996.tb52952.x; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Hotchin NA, 1996, CANCER SURV, V27, P311; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Juliano Rudy, 1996, Bioessays, V18, P911, DOI 10.1002/bies.950181110; Konstantopoulos N, 1996, BIOCHEM J, V314, P387, DOI 10.1042/bj3140387; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PATCH LA, 1995, J CELL SCI, V108, P1371; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1989, P NATL ACAD SCI USA, V86, P4525, DOI 10.1073/pnas.86.12.4525; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Sharma SV, 1997, ONCOGENE, V14, P2641, DOI 10.1038/sj.onc.1201115; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tobe K, 1996, MOL CELL BIOL, V16, P4765; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wang DZM, 1997, CANCER RES, V57, P2478; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; ZHAO JF, 1995, ONCOGENE, V11, P161; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	75	33	34	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	1998	17	3					271	281		10.1038/sj.onc.1201921	http://dx.doi.org/10.1038/sj.onc.1201921			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690509				2022-12-25	WOS:000074947500002
J	Tarantini, F; LaVallee, T; Jackson, A; Gamble, S; Carreira, CM; Garfinkel, S; Burgess, WH; Maciag, T				Tarantini, F; LaVallee, T; Jackson, A; Gamble, S; Carreira, CM; Garfinkel, S; Burgess, WH; Maciag, T			The extravesicular domain of synaptotagmin-1 is released with the latent fibroblast growth factor-1 homodimer in response to neat shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 C2 DOMAINS; FACTOR-I; PROTEIN-KINASE; RAT-BRAIN; CELLS; BINDING; IDENTIFICATION; MEMBRANES; RECEPTOR; FORMS	The heparin-binding fibroblast growth factor (FGF) prototypes lack a classical signal sequence, yet their presence is required in the extracellular compartment for the activation of cell-surface receptor-dependent signaling. Early studies with FGF-1 demonstrated its presence in bovine brain as a novel high molecular weight complex, and subsequent studies identified a second heparin-binding protein that co-purified with FGF-1. Polypeptide sequence analysis revealed that this heparin-binding protein corresponded to the extravesicular domain of bovine synaptotagmin (Syn)-1, a transmembrane component of synaptic vesicles involved in the regulation of organelle traffic. Since FGF-1 is released in response to heat shock as a mitogenically inactive Cys-SO homodimer, we sought to determine whether this heparin-binding protein was involved in the release of FGF-1. We report that a proteolytic fragment of the extravesicular domain of Syn-1 is associated with FGF-1 in the extracellular compartment of FGF-l-transfected NIH 3T3 cells following temperature stress. By using heparin-Sepharose affinity to discriminate between the monomer and homodimer forms of FGF-1 and resolution by conventional and limited denaturant gel shift immunoblot analysis, it was possible to identify FGF-1 and Syn-1 as potential components of a denaturant- and reducing agent-sensitive extracellular complex. It was also possible to demonstrate that the expression of an antisense-Syn-l gene represses the release of FGF-1 in response to heat shock. These data indicate that FGF-1 may be able to utilize the cytosolic face of conventional exocytotic vesicles to traffic to the inner surface of the plasma membrane where it may gain access to the extracellular compartment as a complex with Syn-1.	Maine Med Ctr, Res Inst, Ctr Mol Med, S Portland, ME 04106 USA; Amer Red Cross, Holland Lab, Dept Mol Biol, Rockville, MD 20855 USA	Maine Medical Center; American Red Cross	Maciag, T (corresponding author), Maine Med Ctr, Res Inst, Ctr Mol Med, 125 John Roberts Rd, S Portland, ME 04106 USA.		Tarantini, Francesca/I-6332-2012	TARANTINI, FRANCESCA/0000-0002-1390-2965	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035627, R01HL032348, P01HL054710] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54710, HL35627, HL32348] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1993, J NEUROSCI, V13, P1701; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DAMER CK, 1994, J BIOL CHEM, V269, P31115; ENGLEKA KA, 1992, J BIOL CHEM, V267, P11307; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GARFINKEL S, 1992, J BIOL CHEM, V267, P24375; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Kwon OJ, 1996, FEBS LETT, V378, P135, DOI 10.1016/0014-5793(95)01430-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MACH H, 1995, BIOCHEMISTRY-US, V34, P9913, DOI 10.1021/bi00031a013; NISHIKI T, 1994, J BIOL CHEM, V269, P10498; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SAMUEL CE, 1992, PHARMACOL THERAPEUT, V54, P307, DOI 10.1016/0163-7258(92)90005-K; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; Shi JP, 1997, J BIOL CHEM, V272, P1142, DOI 10.1074/jbc.272.2.1142; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TARANTINI F, 1995, J BIOL CHEM, V270, P29039, DOI 10.1074/jbc.270.49.29039; TUGAL HB, 1991, BIOCHEM J, V279, P699, DOI 10.1042/bj2790699; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zimrin AB, 1996, J BIOL CHEM, V271, P32499, DOI 10.1074/jbc.271.51.32499	27	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22209	22216		10.1074/jbc.273.35.22209	http://dx.doi.org/10.1074/jbc.273.35.22209			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712834	hybrid, Green Published			2022-12-25	WOS:000075616600010
J	Gross, CN; Irrinki, A; Feder, JN; Enns, CA				Gross, CN; Irrinki, A; Feder, JN; Enns, CA			Co-trafficking of HFE, a nonclassical major histocompatibility complex class I protein, with the transferrin receptor implies a role in intracellular iron regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED GLYCOSYLATION SITE; HEREDITARY HEMOCHROMATOSIS; INSULIN-RECEPTORS; HLA-H; ANTIGENS; ASSOCIATION; EXPRESSION; CELLS; GENE; TETRACYCLINE	The mechanism by which a novel major histocompatibility compiler class I protein, HFE, regulates iron uptake into the body is not known. HFE is the product of the gene that is mutated in >80% of hereditary hemochromatosis patients. It was recently found to coprecipitate with the transferrin receptor (Feder, J. N., Penny, D. M., Irrinki, A., Lee, V. K., Lebron, J. A., Watson, N., Tsuchihashi, Z., Sigal, E., Bjorkman, P. J., and Schatzman, R. C. (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 1472-1477; Parkkila, S., Waheed, A., Britton, R. S., Bacon, B. R., Zhou, X. Y., Tomatsu, S., Fleming, R.E., and Sly, W. S. (1997) Proc. Natl. Acad Sci. U.S.A. 94, 13198-13202) and to decrease the affinity of transferrin for the transferrin receptor (Feder et al.). In this study, HeLa cells were transfected with HFE: under the control of the tetracycline-repressible promoter. We demonstrate that HFE: and the transferrin receptor are capable of associating with each other within 30 min of their synthesis with pulse-chase experiments. HFE and the transferrin receptor co-immunoprecipitate throughout the biosynthetic pathway. Excess HFE is rapidly degraded, whereas the HFE-transferrin receptor complex is stable. Immunofluorescence experiments indicate that they salse endocytose into transferrin-positive compartments. Combined, these results suggest a role for the transferrin receptor in HFE trafficking, Cells expressing HFE have modestly increased levels of transferrin receptor and drastically reduced levels of ferritin. These results implicate HFE further in the modulation of iron levels in the cell.	Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA; Progenitor Inc, Menlo Park, CA 94025 USA	Oregon Health & Science University	Enns, CA (corresponding author), Oregon Hlth Sci Univ, Dept Cell & Dev Biol, L215, Portland, OR 97201 USA.				NHLBI NIH HHS [T32-HL00781] Funding Source: Medline; NIDDK NIH HHS [DK 40608] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040608] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON GJ, 1990, GASTROENTEROLOGY, V98, P576, DOI 10.1016/0016-5085(90)90276-7; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Bonkovsky HL, 1996, HEPATOLOGY, V24, P718, DOI 10.1053/jhep.1996.v24.ajhep0240718; BOTHWELL TH, 1995, METABOLIC MOL BASIS, V2, P1433; DUE C, 1986, P NATL ACAD SCI USA, V83, P6007, DOI 10.1073/pnas.83.16.6007; Enns C.A., 1996, BIOMEMBRANE, V4, P255, DOI [10.1016/S1874-5342(96)80012-2, DOI 10.1016/S1874-5342(96)80012-2]; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feder JN, 1997, J BIOL CHEM, V272, P14025, DOI 10.1074/jbc.272.22.14025; FEHLMANN M, 1985, P NATL ACAD SCI USA, V82, P8634, DOI 10.1073/pnas.82.24.8634; Ghetie V, 1997, IMMUNOL TODAY, V18, P592, DOI 10.1016/S0167-5699(97)01172-9; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P2534, DOI 10.1073/pnas.94.6.2534; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; PHILLIPS ML, 1986, P NATL ACAD SCI USA, V83, P3474, DOI 10.1073/pnas.83.10.3474; POWELL LW, 1970, GUT, V11, P727, DOI 10.1136/gut.11.9.727; RECKHOW CL, 1988, J BIOL CHEM, V263, P7297; RUTLEDGE EA, 1991, J BIOL CHEM, V266, P21125; RUTLEDGE EA, 1994, BLOOD, V83, P580; SCHREIBER AB, 1984, J CELL BIOL, V98, P725, DOI 10.1083/jcb.98.2.725; VERLAND S, 1989, J IMMUNOL, V143, P945; Warren RA, 1997, J BIOL CHEM, V272, P2116; WILLIAMS AM, 1991, J BIOL CHEM, V266, P17648; WILLIAMS AM, 1993, J BIOL CHEM, V268, P12780; YANG B, 1993, J BIOL CHEM, V268, P7435	28	193	195	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22068	22074		10.1074/jbc.273.34.22068	http://dx.doi.org/10.1074/jbc.273.34.22068			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705350	hybrid			2022-12-25	WOS:000075492600084
J	Haeseleer, F; Huang, J; Lebioda, L; Saari, JC; Palczewski, K				Haeseleer, F; Huang, J; Lebioda, L; Saari, JC; Palczewski, K			Molecular characterization of a novel short-chain dehydrogenase/reductase that reduces all-trans-retinal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-ALPHA-HYDROXYSTEROID DEHYDROGENASES; ALCOHOL DEHYDROGENASES; BIOCHEMICAL ASPECTS; PIGMENT EPITHELIUM; VISUAL PROCESS; BOVINE RETINA; PROTEINS; RHODOPSIN; RAT; IDENTIFICATION	The reduction of all-trans-retinal in photoreceptor outer segments is the first step in the regeneration of bleached visual pigments. We report here the cloning of a dehydrogenase, retSDR1, that belongs to the short-chain dehydrogenase/reductase superfamily and localizes predominantly in cone photoreceptors. retSDR1 expressed in insect cells displayed substrate specificities of the photoreceptor all-trans-retinol dehydrogenase. Homology modeling of retSDR1 using the carbonyl reductase structure as a scaffold predicted a classical Rossmann fold for the nucleotide binding and an N-terminal extension that could facilitate binding of the enzyme to the cell membranes. The presence of retSDR1 in a subset of inner retinal neurons and in other tissues suggests that the enzyme may also be involved in retinol metabolism outside of photoreceptors.	Univ Washington, Dept Ophthalmol, Sch Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA; Univ S Carolina, Dept Biochem & Chem, Columbia, SC 29208 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Sch Med, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu			NATIONAL EYE INSTITUTE [R01EY009339, P30EY001730] Funding Source: NIH RePORTER; NEI NIH HHS [EY09339, EY02317, EY01730] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALPERN M, 1971, J PHYSIOL-LONDON, V217, P447, DOI 10.1113/jphysiol.1971.sp009580; ALPERN M, 1971, VISION RES, V11, P539, DOI 10.1016/0042-6989(71)90075-7; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BOERMAN MHE, 1995, BIOCHEMISTRY-US, V34, P1027; Boll F., 1876, MONATSBERICHTE KONIG, P783; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHAYKIN S, 1966, BIOCHIM BIOPHYS ACTA, V124, P1, DOI 10.1016/0304-4165(66)90307-2; DAVIS JT, 1995, BIOL REPROD, V52, P356, DOI 10.1095/biolreprod52.2.356; Dowling J. E., 1987, RETINA APPROACHABLE; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; EDELHOFF S, 1994, ONCOGENE, V9, P665; FUTTERMAN SIDNEY, 1963, JOUR BIOL CHEM, V238, P1145; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KROZOWSKI Z, 1994, J STEROID BIOCHEM, V51, P125, DOI 10.1016/0960-0760(94)90084-1; KUHNE W, 1877, UNTERS PHYSL I U HEI, V1, P1; LAW WC, 1989, J AM CHEM SOC, V111, P793, DOI 10.1021/ja00184a090; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; Milam AH, 1997, VISUAL NEUROSCI, V14, P601, DOI 10.1017/S0952523800012256; NAKAJIMA N, 1989, J BIOCHEM-TOKYO, V106, P515, DOI 10.1093/oxfordjournals.jbchem.a122884; OttoBruc A, 1997, P NATL ACAD SCI USA, V94, P4727, DOI 10.1073/pnas.94.9.4727; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; Palczewski K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3; Penning TM, 1996, STEROIDS, V61, P508, DOI 10.1016/S0039-128X(96)00093-1; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Rando RR, 1996, CHEM BIOL, V3, P255, DOI 10.1016/S1074-5521(96)90105-2; REES DC, 1994, MEMBRANE PROTEIN STR, P1; ROSSMANN MG, 1978, MOL CELL BIOCHEM, V21, P161; SAARI JC, 1982, J BIOL CHEM, V257, P13329; Saari JC, 1997, GLIA, V21, P259; SAARI JC, 1993, ANAL BIOCHEM, V213, P128, DOI 10.1006/abio.1993.1395; SAARI JC, 1998, VISION RES, V44, P17; Saari John C., 1994, P351; Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; TANAKA N, 1995, J BIOCHEM-TOKYO, V118, P871, DOI 10.1093/jb/118.5.871; Tsigelny I, 1996, BIOCHEM BIOPH RES CO, V226, P118, DOI 10.1006/bbrc.1996.1320; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; Zhao XY, 1998, J BIOL CHEM, V273, P5124, DOI 10.1074/jbc.273.9.5124; ZIMMERMAN WF, 1974, NATURE, V250, P66, DOI 10.1038/250066a0; ZIMMERMAN WF, 1975, EXP EYE RES, V21, P325, DOI 10.1016/0014-4835(75)90043-3	49	143	148	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21790	21799		10.1074/jbc.273.34.21790	http://dx.doi.org/10.1074/jbc.273.34.21790			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705317	hybrid			2022-12-25	WOS:000075492600051
J	Hamza, I; Chauhan, S; Hassett, R; O'Brian, MR				Hamza, I; Chauhan, S; Hassett, R; O'Brian, MR			The bacterial Irr protein is required for coordination of heme biosynthesis with iron availability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOLEVULINIC-ACID DEHYDRATASE; SYNTHASE MESSENGER-RNA; SOYBEAN ROOT-NODULES; BRADYRHIZOBIUM-JAPONICUM; ESCHERICHIA-COLI; TETRAPYRROLE SYNTHESIS; TRANSLATIONAL CONTROL; REGULATORY PROTEIN-2; NITRIC-OXIDE; GENE	Heme is a ubiquitous macromolecule that serves as the active group of proteins involved in many cellular processes. The multienzyme pathway for heme formation culminates with the insertion of iron into a protoporphyrin ring. The cytotoxicity of porphyrins suggests the need for coordination of its biosynthesis with iron availability. We isolated a mutant strain of the bacterium Bradyrhizobium japonicum that, under iron limitation, accumulated protoporphyrin and showed aberrantly high expression of hemB, an iron-regulated gene encoding the heme synthesis enzyme delta-aminolevulinic acid dehydratase. The strain carries a loss of function mutation in irr, a newly described gene that encodes a putative member of the GntR family of bacterial transcriptional regulators. Irr accumulated only under iron limitation, and turned over rapidly upon an increase in iron availability. A separate role for Irr in controlling the cellular iron level was inferred based on a deficiency in high affinity iron transport activity in the irr strain, and suggests that regulation of the heme pathway is coordinated with iron homeostasis. A high level of protoporphyrin accumulation is not a normal consequence of nutritional iron deprivation, thus a mechanism for iron-dependent control of heme biosynthesis may be present in other organisms.	SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	O'Brian, MR (corresponding author), SUNY Buffalo, Dept Biochem, 140 Farber Hall, Buffalo, NY 14214 USA.			Hamza, Iqbal/0000-0003-0045-0610				BHASKER CR, 1993, J BIOL CHEM, V268, P12699; Braun V., 1991, HDB MICROBIAL IRON C, P107; Camilli A, 1995, MOL MICROBIOL, V18, P671, DOI 10.1111/j.1365-2958.1995.mmi_18040671.x; Chauhan S, 1997, J BACTERIOL, V179, P3706, DOI 10.1128/jb.179.11.3706-3710.1997; Chauhan S, 1997, J BACTERIOL, V179, P5516, DOI 10.1128/jb.179.17.5516-5520.1997; CHAUHAN S, 1995, J BIOL CHEM, V270, P19823, DOI 10.1074/jbc.270.34.19823; DELORENZO V, 1987, J BACTERIOL, V169, P2624, DOI 10.1128/jb.169.6.2624-2630.1987; FRUSTACI JM, 1991, J BACTERIOL, V173, P1145, DOI 10.1128/jb.173.3.1145-1150.1991; FRUSTACI JM, 1995, J BIOL CHEM, V270, P7387, DOI 10.1074/jbc.270.13.7387; FRUSTACI JM, 1992, J BACTERIOL, V174, P4223, DOI 10.1128/JB.174.13.4223-4229.1992; GARRET S, 1994, ACTA HAEMATOL-BASEL, V91, P21; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; HAMILTON JW, 1991, ARCH BIOCHEM BIOPHYS, V289, P387, DOI 10.1016/0003-9861(91)90428-L; HANTKE K, 1987, MOL GEN GENET, V210, P135, DOI 10.1007/BF00337769; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; KAPPAS A, 1995, METABOLIC MOL BASES, V3, P2103; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; MENDEZ R, 1992, J BIOL CHEM, V267, P11500; Mock HP, 1997, PLANT PHYSIOL, V113, P1101, DOI 10.1104/pp.113.4.1101; MOSTELLER RD, 1980, J BIOL CHEM, V255, P2524; NAKAHIGASHI K, 1991, P NATL ACAD SCI USA, V88, P10520, DOI 10.1073/pnas.88.23.10520; OBrian MR, 1996, J BACTERIOL, V178, P2471, DOI 10.1128/jb.178.9.2471-2478.1996; PAGE KM, 1994, J BACTERIOL, V176, P1535, DOI 10.1128/jb.176.5.1535-1538.1994; PAGE KM, 1995, J BACTERIOL, V177, P3979, DOI 10.1128/jb.177.14.3979-3984.1995; REIZER A, 1991, MOL MICROBIOL, V5, P1081, DOI 10.1111/j.1365-2958.1991.tb01880.x; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; SANGWAN I, 1991, SCIENCE, V251, P1220, DOI 10.1126/science.251.4998.1220; SCHILKE BA, 1995, J BACTERIOL, V177, P1929, DOI 10.1128/jb.177.8.1929-1937.1995; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; Smith K.M., 1975, PORPHYRINS METALLOPO; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Wang JY, 1996, P NATL ACAD SCI USA, V93, P10434, DOI 10.1073/pnas.93.19.10434; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541; ZHANG L, 1994, GENE DEV, V8, P2110, DOI 10.1101/gad.8.17.2110	41	129	134	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21669	21674		10.1074/jbc.273.34.21669	http://dx.doi.org/10.1074/jbc.273.34.21669			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705301	hybrid			2022-12-25	WOS:000075492600035
J	Matsushita, M; Nairn, AC				Matsushita, M; Nairn, AC			Characterization of the mechanism of regulation of Ca2+/calmodulin-dependent protein kinase I by calmodulin and by Ca2+/calmodulin-dependent protein kinase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; HIGH-AFFINITY INTERACTION; CRYSTAL-STRUCTURE; RAT-BRAIN; SUBSTRATE RECOGNITION; PEPTIDE SUBSTRATE; CATALYTIC SUBUNIT; SWITCH-LIKE; PHOSPHORYLATION; ACTIVATION	Ca2+/calmodulin-dependent protein kinase I (CaMKI) is maintained in an autoinhibited state by the interaction of a COOH-terminal helix-loop-helix (Ile(286)-Met(316)) regulatory domain with the catalytic core. Activation of the enzyme by calmodulin (CaM) also allows CaMKI to be phosphorylated and activated by a second enzyme, CaMK kinase (CaMKK). To more thoroughly characterize the regulation of CaMKI by CaM and its interrelationship with phosphorylation by CaMKK, we have carried out a detailed structure-function analysis using recombinant wild-type (WT) and mutant forms of CaMKI and CaMKK. CaMKI-WT, in the absence of CaM, or CaMKI-299 and CaMKI-298 were autoinhibited and could not be phosphorylated by CaMKK-433 (a truncated constitutively active form of CaMKK). Removal of Phe(298) (CaMK-297) generated a constitutively active form of CaMKI that was also phosphorylated by CaMKK-433. CaMKI-WT was essentially inactive in the absence of CaM (K-0.5 for activation by CaM similar to 30 nM). Mutation of Ile(294) and Phe(298) to alanine (CaMKI-2A) resulted in measurable basal enzyme activity. Additional mutation of Ile(286) and Val(290) to alanine (CaMKI-4A) increased this basal activity. Mutation of Trp(303) (CaMKI-W303S) resulted in a large increase in the K-0.5 for CaM (similar to 100 mu M), supporting a role for this residue as an initial target for CaM. Mutation of Phe(307) (CaMKI-F307A) resulted in increased basal enzyme activity, supporting a role for this residue in autoinhibition of CaMKI. Together these studies demonstrate the critical role of specific amino acids in the autoinhibition of CaMKI and also in its activation by CaM and phosphorylation by CaMKK.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA	Rockefeller University	Nairn, AC (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA.			Nairn, Angus/0000-0002-7075-0195				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; Chin D, 1997, J BIOL CHEM, V272, P31235, DOI 10.1074/jbc.272.50.31235; Clancy CE, 1997, J BIOL CHEM, V272, P11812, DOI 10.1074/jbc.272.18.11812; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cote GP, 1997, J BIOL CHEM, V272, P6846, DOI 10.1074/jbc.272.11.6846; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; Ferrell JE, 1997, TRENDS BIOCHEM SCI, V22, P288, DOI 10.1016/S0968-0004(97)82217-7; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; GALLAGHER PJ, 1993, J BIOL CHEM, V268, P26578; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GRAND RJA, 1979, BIOCHEM J, V177, P521, DOI 10.1042/bj1770521; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Hata Y, 1996, J NEUROSCI, V16, P2488; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1990, PEPTIDES PROTEIN PHO; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KONG CT, 1988, BIOCHEMISTRY-US, V27, P4795, DOI 10.1021/bi00413a032; LEE JC, 1995, BIOCHEM BIOPH RES CO, V210, P631, DOI 10.1006/bbrc.1995.1705; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MOCHIZUKI H, 1993, BIOCHEM BIOPH RES CO, V197, P1595, DOI 10.1006/bbrc.1993.2661; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; Okuno S, 1996, J BIOCHEM-TOKYO, V119, P1176; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1995, J BIOCHEM-TOKYO, V117, P686, DOI 10.1093/oxfordjournals.jbchem.a124764; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1996, INTRACELLULAR SIGNAL, P251; Redpath NT, 1996, J BIOL CHEM, V271, P17547, DOI 10.1074/jbc.271.29.17547; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHACTER E, 1984, J BIOL CHEM, V259, P2252; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SMITH MK, 1992, J BIOL CHEM, V267, P1761; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUGITA R, 1994, BIOCHEM BIOPH RES CO, V203, P694, DOI 10.1006/bbrc.1994.2238; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851	65	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21473	21481		10.1074/jbc.273.34.21473	http://dx.doi.org/10.1074/jbc.273.34.21473			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705275	hybrid			2022-12-25	WOS:000075492600009
J	Tripathi, S; Kloss, PS; Mankin, AS				Tripathi, S; Kloss, PS; Mankin, AS			Ketolide resistance conferred by short peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							23S RIBOSOMAL-RNA; ESCHERICHIA-COLI; ERYTHROMYCIN RESISTANCE; TRANSLATION	Clones expressing pentapeptides conferring resistance to a ketolide antibiotic, HMR3004, were selected from a random pentapeptide mini-gene library. The pentapeptide MRFFV conferred the highest level of resistance and was encoded in three different mini-genes. Comparison of amino acid sequences of peptides conferring resistance to a ketolide with those conferring resistance to erythromycin reveals a correspondence between the peptide sequence and the chemical structure of macrolide antibiotic, indicating possible interaction between the peptide and the drag on the ribosome. Based on these observations, a "bottle brush" model of action of macrolide resistance peptides is proposed, in which newly translated peptide interacts with the macrolide molecule on the ribosome and actively displaces it from its binding site. Temporal "cleaning" of the ribosome from the bound antibiotic may be sufficient to allow continuation of protein synthesis even despite the presence of the drug in the medium.	Univ Illinois, Ctr Pharmaceut Biotechnol, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mankin, AS (corresponding author), Univ Illinois, Ctr Pharmaceut Biotechnol, M-C 870,900 S Ashland Ave, Chicago, IL 60607 USA.							Agouridas C, 1997, ANTIMICROB AGENTS CH, V41, P2149, DOI 10.1128/AAC.41.10.2149; CHITTUM HS, 1995, CURR MICROBIOL, V30, P273, DOI 10.1007/BF00295501; CHITTUM HS, 1994, J BACTERIOL, V176, P6192, DOI 10.1128/jb.176.20.6192-6198.1994; Cundliffe E., 1972, MOLECULAR BASIS ANTI, P278; Dam M, 1996, J MOL BIOL, V259, P1, DOI 10.1006/jmbi.1996.0296; ENDIE LM, 1997, ANTIMICROB AGENTS CH, V41, P1033; MENNINGER JR, 1994, MOL GEN GENET, V243, P225, DOI 10.1007/BF00280320; MENNINGER JR, 1982, ANTIMICROB AGENTS CH, V21, P810; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; OLEINICK NL, 1975, ANTIBIOTICS, V3, P396; OTAKA T, 1975, P NATL ACAD SCI USA, V72, P2649, DOI 10.1073/pnas.72.7.2649; PESTKA S, 1974, ANTIMICROB AGENTS CH, V5, P255, DOI 10.1128/AAC.5.3.255; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SIGMUND CD, 1982, P NATL ACAD SCI-BIOL, V79, P5602, DOI 10.1073/pnas.79.18.5602; Tenson T, 1995, BIOCHEM CELL BIOL, V73, P1061, DOI 10.1139/o95-114; Tenson T, 1997, J BIOL CHEM, V272, P17425, DOI 10.1074/jbc.272.28.17425; Tenson T, 1996, P NATL ACAD SCI USA, V93, P5641, DOI 10.1073/pnas.93.11.5641; TERAOKA H, 1978, J MOL BIOL, V126, P185, DOI 10.1016/0022-2836(78)90358-3; Vazquez D., 1975, ANTIBIOTICS MECHANIS, P459; WEISBLUM B, 1995, ANTIMICROB AGENTS CH, V39, P577, DOI 10.1128/AAC.39.3.577; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	21	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20073	20077		10.1074/jbc.273.32.20073	http://dx.doi.org/10.1074/jbc.273.32.20073			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685347	hybrid			2022-12-25	WOS:000075305400024
J	Vande Berg, BJ; Sancar, GB				Vande Berg, BJ; Sancar, GB			Evidence for dinucleotide flipping by DNA photolyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PHOTOLYASE; PYRIMIDINE DIMERS; CRYSTAL-STRUCTURE; CIS-SYN; SACCHAROMYCES-CEREVISIAE; ACTION MECHANISM; PHR1 PHOTOLYASE; THYMINE DIMERS; ENZYME; SUBSTRATE	DNA photolyases repair pyrimidine dimers via a reaction in which light energy drives electron donation from a catalytic chromophore, FADH(-), to the dimer. The crystal structure of Escherichia coli photolyase suggested that the pyrimidine dimer is flipped out of the DNA helix and into a cavity that leads from the surface of the enzyme to FADH-. We have tested this model using the Saccharomyces cerevisiae Phr1 photolyase which is >50% identical to E. coli photolyase over the region comprising the DNA binding domain. By using the bacterial photolyase as a starting point, we modeled the region encompassing amino acids 383-530 of the yeast enzyme. The model retained the cavity leading to FADH- as well as the band of positive electrostatic potential which defines the DNA binding surface. We found that alanine substitution mutations at sites within the cavity reduced both substrate binding and discrimination, providing direct support for the dinucleotide flip model. The roles of three residues predicted to interact with DNA flanking the dimer were also tested. Arg(452) was found to be particularly critical to substrate binding, discrimination, and photolysis, suggesting a role in establishing or maintaining the dimer in the flipped state. A structural model for photolyase-dimer interaction is presented.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sancar, GB (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	gsancar.biochem@mhs.unc.edu			NIGMS NIH HHS [GM35123] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035123] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAER M, 1989, MOL CELL BIOL, V9, P4777, DOI 10.1128/MCB.9.11.4777; BAER ME, 1993, J BIOL CHEM, V268, P16717; BRASH DE, 1985, J BIOL CHEM, V260, P1438; BROYDE S, 1980, BIOPOLYMERS, V19, P1695, DOI 10.1002/bip.1980.360190913; CADET J, 1985, BIOPOLYMERS, V24, P897, DOI 10.1002/bip.360240512; HAYES FN, 1971, J AM CHEM SOC, V93, P4940, DOI 10.1021/ja00748a065; HUSAIN I, 1987, J BIOL CHEM, V262, P13188; HUSAIN I, 1987, NUCLEIC ACIDS RES, V15, P1109; KIENER A, 1989, J BIOL CHEM, V264, P13880; Kim Sang-Tae, 1993, Biochemistry, V32, P7065, DOI 10.1021/bi00079a001; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; KIM ST, 1992, P NATL ACAD SCI USA, V89, P900, DOI 10.1073/pnas.89.3.900; LI YF, 1990, BIOCHEMISTRY-US, V29, P5698, DOI 10.1021/bi00476a009; Maxam A M, 1980, Methods Enzymol, V65, P499; Nakajima S, 1998, NUCLEIC ACIDS RES, V26, P638, DOI 10.1093/nar/26.2.638; OGara M, 1996, J MOL BIOL, V261, P634, DOI 10.1006/jmbi.1996.0489; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Patrick MH., 1976, PHOTOCHEM PHOTOBIOL, V2, P35, DOI [10.1016/B978-0-12-734602-1.50008-3, DOI 10.1016/B978-0-12-734602-1.50008-3]; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P5706, DOI 10.1021/bi00476a010; PEARLMAN DA, 1985, SCIENCE, V227, P1304, DOI 10.1126/science.3975615; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SANCAR GB, 1987, J BIOL CHEM, V262, P15457; SANCAR GB, 1987, J BIOL CHEM, V262, P492; SANCAR GB, 1985, NUCLEIC ACIDS RES, V13, P8231, DOI 10.1093/nar/13.22.8231; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TAYLOR JS, 1987, J AM CHEM SOC, V109, P6735, DOI 10.1021/ja00256a030; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; Uchida N, 1997, PHOTOCHEM PHOTOBIOL, V65, P964, DOI 10.1111/j.1751-1097.1997.tb07955.x; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x; Zhao XD, 1997, J BIOL CHEM, V272, P32580, DOI 10.1074/jbc.272.51.32580	39	56	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20276	20284		10.1074/jbc.273.32.20276	http://dx.doi.org/10.1074/jbc.273.32.20276			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685377	hybrid, Green Published			2022-12-25	WOS:000075305400054
J	Care, A; Silvani, A; Meccia, E; Mattia, G; Peschle, C; Colombo, MP				Care, A; Silvani, A; Meccia, E; Mattia, G; Peschle, C; Colombo, MP			Transduction of the SkBr3 breast carcinoma cell line with the HOXB7 gene induces bFGF expression, increases cell proliferation and reduces growth factor dependence	ONCOGENE			English	Article						bFGF; homeobox gene, SkBr3 cell line; retroviral vector; intracrine loop	HOMEOBOX GENES; TUMORS; MICE; LEUKEMIA; PROMOTER; CANCER	Several melanomas, carcinomas, glioblastomas and leukemias showed coordinated expression of HOXB7 and bFGF with exception of the SkBr3 mammary carcinoma that was negative for both. Transduction of HOXB7 gene into SkBr3 cells, induced bFGF expression, increased growth rate, independence from serum withdrawal and ability to form colonies in semisolid medium. ELISA assay showed that most of bFGF was associated to cell lysate when cells were cultured at 1% serum whereas in cells kept to 10% serum bFGF was detected both within cell lysate or secreted into cell supernatants. Antisense oligos to bFGF inhibited the growth of cells cultured in 1%, indicating that beside the possible activation of additional genes other than bFGF by HOXB7 transduction, only bFGF induction accounts for the observed results. Moreover, since inhibition of cell proliferation occurred in cells kept in 1% but not 10% serum, a bFGF intracrine loop appears operative in serum starved SkBr3/HOXB7 cells. Also, these results further indicate bFGF as target of HOXB7.	Ist Nazl Studio & Cura Tumori, Div Expt Oncol D, I-20133 Milan, Italy; Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Istituto Superiore di Sanita (ISS)	Colombo, MP (corresponding author), Ist Nazl Studio & Cura Tumori, Div Expt Oncol D, Via Venezian 1, I-20133 Milan, Italy.		Colombo, Mario P./V-7166-2017; Silvani, Antonio/AAA-4600-2019; CARE', Alessandra/H-5090-2016; Mattia, Gianfranco/K-5194-2016; felli, nadia/G-2088-2012	Colombo, Mario P./0000-0003-0042-7955; Silvani, Antonio/0000-0002-4791-1042; CARE', Alessandra/0000-0003-4106-3342; Mattia, Gianfranco/0000-0001-7047-6360; felli, nadia/0000-0001-6763-3361; meccia, ettore/0000-0003-2076-5951				CARE A, 1994, MOL CELL BIOL, V14, P4872, DOI 10.1128/MCB.14.7.4872; Care A, 1996, MOL CELL BIOL, V16, P4842; CILLO C, 1992, INT J CANCER, V51, P892, DOI 10.1002/ijc.2910510610; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DEGUCHI Y, 1993, CANCER RES, V53, P373; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; FERNIG DG, 1993, INT J CANCER, V54, P629, DOI 10.1002/ijc.2910540418; FLAMME I, 1992, DEVELOPMENT, V116, P435; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; GOOMER RS, 1994, P NATL ACAD SCI USA, V91, P7985, DOI 10.1073/pnas.91.17.7985; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; KERBEL RS, 1992, AM J PATHOL, V141, P519; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; MAVILIO F, 1993, EUR J BIOCHEM, V212, P273, DOI 10.1111/j.1432-1033.1993.tb17660.x; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; PEYRAT JP, 1992, J STEROID BIOCHEM, V43, P87, DOI 10.1016/0960-0760(92)90191-K; Quaranta MT, 1996, J IMMUNOL, V157, P2462; Sambrook J., 2002, MOL CLONING LAB MANU; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; STCHOWIAK EK, 1997, ONCOGENE, V14, P2201; TREMPE G, 1973, IN VITRO CELL DEV B, V8, P433	28	78	81	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3285	3289		10.1038/sj.onc.1201875	http://dx.doi.org/10.1038/sj.onc.1201875			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681827				2022-12-25	WOS:000074343600009
J	Marzesco, AM; Galli, T; Louvard, D; Zahraoui, A				Marzesco, AM; Galli, T; Louvard, D; Zahraoui, A			The rod cGMP phosphodiesterase delta subunit dissociates the small GTPase Rab13 from membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP/GTP EXCHANGE PROTEIN; EPITHELIAL-CELLS; BINDING PROTEINS; SNARE ACTIVATION; DOMAIN; INHIBITOR; TRANSPORT; EFFECTOR; RABAPTIN-5; COMPLEXES	Small Rab GTPases are involved in the regulation of membrane trafficking. They cycle between cytosolic and membrane-bound forms. These membrane association/dissociation are tightly controlled by regulatory proteins. To search for proteins interacting with Rab13, a small GTPase associated with vesicles in fibroblasts and predominantly with tight junctions in epithelial cells, we screened a HeLa two-hybrid cDNA Library and isolated a clone encoding a protein of 17.4 kDa. This protein, almost identical to the bovine rod cGMP phosphodiesterase delta subunit, was named human delta-PDE. The delta-PDE binds specifically to Rab13. It exhibits two putative C-terminal sequences necessary for the interaction with PDZ (PSD95, Dig, ZO-1) domains contained in many proteins localized to specific plasma membrane microdomains. Immunofluorescence microscopic studies revealed that the vesicular stomatitis virus (VSV)tagged F-PDE is localized in vesicular structures accumulated near the plasma membrane in epithelial cells. Deletion of the PDZ binding motifs impair VSV-S-PDE subcellular distribution. Purified recombinant S-PDE had the capacity to dissociate Rab13 from cellular membranes. Our data support the proposal that S-PDE, but not GDP dissociation inhibitor, may serve to control the dynamic of the association of Rab13 with cellular membranes.	Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Zahraoui, A (corresponding author), Inst Curie, CNRS, UMR 144, 26 Rue Ulm, F-75248 Paris 05, France.		Galli, Thierry/G-8842-2011; Galli, Thierry/Q-2249-2019	Galli, Thierry/0000-0001-8514-7455; Galli, Thierry/0000-0001-8514-7455				ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; Ayad N, 1997, EMBO J, V16, P4497, DOI 10.1093/emboj/16.15.4497; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; DIRAC SA, 1997, EMBO J, V16, P465; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; JOBERTY G, 1993, FEBS LETT, V330, P323, DOI 10.1016/0014-5793(93)80897-4; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LOUVARD D, 1980, P NATL ACAD SCI-BIOL, V77, P4132, DOI 10.1073/pnas.77.7.4132; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101	34	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22340	22345		10.1074/jbc.273.35.22340	http://dx.doi.org/10.1074/jbc.273.35.22340			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712853	hybrid			2022-12-25	WOS:000075616600029
J	Bresnahan, WA; Albrecht, T; Thompson, EA				Bresnahan, WA; Albrecht, T; Thompson, EA			The cyclin E promoter is activated by human cytomegalovirus 86-kDa immediate early protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IE2 86-KILODALTON PROTEIN; BOX-BINDING-PROTEIN; CELL-CYCLE; TATA-BOX; RETINOBLASTOMA PROTEIN; TRANSCRIPTIONAL ACTIVATION; CDK2 ACTIVITY; GENE-PRODUCT; IE86 PROTEIN; INTERACTS	Human cytomegalovirus (HCMV) activates cyclin E/Cdk2, which regulates cell cycle progression in G(1) and S phase of the cell cycle. HCMV activation of cyclin E/Cdk2 can be demonstrated in cells that are refractory to normal mitotic stimuli. This observation suggests that the virus has some means to overcome the stringent control on expression of cell cycle progression factors that is characteristic of cells in the G(0) state. One of the mechanisms involved in activation of cyclin E/Cdk2 is the induction of cyclin E expression. We report here that HCMV induces cyclin E expression through a transcriptional mechanism. The cyclin E gene is activated by the HCMV 86-kDa immediate early gene product (IE86), which directly binds to nucleotide sequences within the cyclin E promoter. An IE86 DNA-binding mutant neither binds nor activates the cyclin E promoter. IE86-binding sites within the cyclin E promoter are required for IE86-mediated activation, and deletion of the IE86-binding site inhibits IE86 activation of the cyclin E promoter. We also demonstrate that mutation of the known E2F-binding sites in the cyclin E promoter does not block activation by HCMV or IE86. These data provide a molecular mechanism for HCMV induction of cyclin E and represent the first report of IE86 directly binding to a cellular promoter.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Thompson, EA (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.	athompso@utmb.edu			NCI NIH HHS [CA24347] Funding Source: Medline; NIDCR NIH HHS [DE11389] Funding Source: Medline; NIEHS NIH HHS [ES06676] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA024347, R01CA024347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARLT H, 1994, J VIROL, V68, P4117, DOI 10.1128/JVI.68.7.4117-4125.1994; BOLDOGH I, 1990, SCIENCE, V247, P961; Botz J, 1996, MOL CELL BIOL, V16, P3401; Bresnahan WA, 1997, J GEN VIROL, V78, P1993, DOI 10.1099/0022-1317-78-8-1993; Bresnahan WA, 1997, VIROLOGY, V231, P239, DOI 10.1006/viro.1997.8489; Bresnahan WA, 1996, VIROLOGY, V224, P150, DOI 10.1006/viro.1996.0516; Bresnahan WA, 1996, CELL GROWTH DIFFER, V7, P1283; CASWELL R, 1993, J GEN VIROL, V74, P2691, DOI 10.1099/0022-1317-74-12-2691; CHOI KS, 1995, VIROLOGY, V208, P450, DOI 10.1006/viro.1995.1175; Dittmer D, 1997, J VIROL, V71, P1629, DOI 10.1128/JVI.71.2.1629-1634.1997; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; FURNARI BA, 1993, J VIROL, V67, P4981, DOI 10.1128/JVI.67.8.4981-4991.1993; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Geng Y, 1996, ONCOGENE, V12, P1173; HAGEMEIER C, 1994, EMBO J, V13, P2897, DOI 10.1002/j.1460-2075.1994.tb06584.x; HAGEMEIER C, 1992, J GEN VIROL, V73, P2385, DOI 10.1099/0022-1317-73-9-2385; HAGEMEIER C, 1992, J VIROL, V66, P4452, DOI 10.1128/JVI.66.7.4452-4456.1992; JAULT FM, 1995, J VIROL, V69, P6697, DOI 10.1128/JVI.69.11.6697-6704.1995; JUPP R, 1993, J VIROL, V67, P5595, DOI 10.1128/JVI.67.9.5595-5604.1993; JUPP R, 1993, J VIROL, V67, P7539, DOI 10.1128/JVI.67.12.7539-7546.1993; KINGSTON RE, 1996, INTRO DNA MAMMALIAN; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LANG D, 1993, J VIROL, V67, P323, DOI 10.1128/JVI.67.1.323-331.1993; LANG D, 1994, NUCLEIC ACIDS RES, V22, P3331, DOI 10.1093/nar/22.16.3331; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Lu MS, 1996, J VIROL, V70, P8850, DOI 10.1128/JVI.70.12.8850-8857.1996; LUKAC DM, 1994, J VIROL, V68, P5184, DOI 10.1128/JVI.68.8.5184-5193.1994; MARGOLIS MJ, 1995, J VIROL, V69, P7759, DOI 10.1128/JVI.69.12.7759-7767.1995; MONICK MM, 1992, AM J RESP CELL MOL, V7, P251, DOI 10.1165/ajrcmb/7.3.251; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OHTSUBO M, 1995, P NATL ACAD SCI USA, V92, P12146; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SANTOMENNA LD, 1988, J VIROL, V166, P217; SCHWARTZ R, 1994, J VIROL, V68, P5613, DOI 10.1128/JVI.68.9.5613-5622.1994; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SOMMER MH, 1994, J VIROL, V68, P6223, DOI 10.1128/JVI.68.10.6223-6231.1994; Spector DH, 1996, INTERVIROLOGY, V39, P361, DOI 10.1159/000150507; Stenberg RM, 1996, INTERVIROLOGY, V39, P343, DOI 10.1159/000150505; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WATHEN MW, 1982, J VIROL, V41, P462, DOI 10.1128/JVI.41.2.462-477.1982; Yoo YD, 1996, J VIROL, V70, P7062, DOI 10.1128/JVI.70.10.7062-7070.1996	45	78	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22075	22082		10.1074/jbc.273.34.22075	http://dx.doi.org/10.1074/jbc.273.34.22075			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705351	hybrid			2022-12-25	WOS:000075492600085
J	Kamitani, H; Geller, M; Eling, T				Kamitani, H; Geller, M; Eling, T			Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN COLON-CANCER; HAMSTER EMBRYO FIBROBLASTS; SODIUM-BUTYRATE; NORDIHYDROGUAIARETIC ACID; ALVEOLAR MACROPHAGES; MOLECULAR-CLONING; EPITHELIAL-CELLS; ARACHIDONIC-ACID; SYNTHASE-2 GENE; PHORBOL ESTER	We studied arachidonic acid metabolism and the expression of cyclooxygenase(Cox) and 15-lipoxygenase (15-LO) in the human colorectal carcinoma cell line, Caco-2, which undergo apoptosis and cell differentiation in the presence of sodium butyrate (NaBT), Caco-2 cells expressed very low levels of Cox-1 but highly expressed Cox-a. NaBT treatment shifted the arachidonic acid metabolites by cell lysates from prostaglandins to 15-hydroxyeicosatetraenoic acid, indicating the presence of a 15-LO. Linoleic acid, an excellent substrate for 15-LO, was metabolized poorly by the Caco-2 cells, but NaBT treatment shifted metabolism to 15-LO metabolite, 13(S)-hydroxyoctadecadienoic acid. Caco-2 cells expressed a 15-LO but only after treatment with NaBT, as determined by Northern blotting. Immunoblotting with anti-human 15-LO antibody detected a 72-kDa band in NaBT-treated Caco-2 cells. Expression of 15-LO mRNA was dependent on the duration of NaBT treatment, with the highest expression observed between 10 and 24 h, Results from expression and metabolism studies with arachidonic and linoleic acid cells indicated Cox-a was responsible for the lipid metabolism in control cells, whereas 15-LO was the major enzyme responsible after NaBT induction of apoptosis and cell differentiation. The 15-LO in Caco-2 cells was characterized as human reticulocyte 15-LO by reverse transcription-polymerase chain reaction and restriction enzyme analysis. The expression of 15-LO and 15-hydroxyeicosatetraenoic acid or 13(S)-hydroxyoctadecadienoic acid formation correlates with cell differentiation or apoptosis in Caco-2 cells induced by NaBT, The addition of nordihydroguaiaretic acid, a lipoxygenase inhibitor, significantly increased NaBT-induced apoptosis, whereas the addition of indomethacin did not alter NaBT-induced apoptosis in the Caco-2 cells. However, indomethacin treatment decreased the expression of Cox-a in NaBT-treated cells and significantly increased the expression of 15-LO during NaBT treatment, These studies suggest a role for 15-LO, in addition to Cox-a, in modulating NaBT-induced apoptosis and cell differentiation in human colorectal carcinoma cells.	NIEHS, Eicosanoid Biochem Sect, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Eling, T (corresponding author), NIEHS, Eicosanoid Biochem Sect, Mol Carcinogenesis Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.							AUGERON C, 1984, CANCER RES, V44, P3961; Boolbol SK, 1996, CANCER RES, V56, P2556; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brinckmann R, 1996, BIOCHEM J, V318, P305, DOI 10.1042/bj3180305; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; Glasgow WC, 1996, MOL PHARMACOL, V49, P1042; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; Glasgow WC, 1997, J BIOL CHEM, V272, P19269, DOI 10.1074/jbc.272.31.19269; HAGUE A, 1995, INT J CANCER, V60, P400, DOI 10.1002/ijc.2910600322; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hamberg M, 1998, ARCH BIOCHEM BIOPHYS, V349, P376, DOI 10.1006/abbi.1997.0443; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; HENKE DC, 1984, ANAL BIOCHEM, V162, P156; Hill EM, 1998, AM J RESP CELL MOL, V18, P662, DOI 10.1165/ajrcmb.18.5.2985; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; JONES DA, 1993, J BIOL CHEM, V268, P9049; KARGMAN SL, 1995, CANCER RES, V55, P2556; KELLETT GL, 1993, BIOCHEM PHARMACOL, V45, P1932, DOI 10.1016/0006-2952(93)90454-5; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LEVY BD, 1993, J CLIN INVEST, V92, P1572, DOI 10.1172/JCI116738; Mandal M, 1997, CARCINOGENESIS, V18, P229, DOI 10.1093/carcin/18.1.229; MATSUMOTO H, 1990, GASTROENTEROLOGY, V98, P1199, DOI 10.1016/0016-5085(90)90334-W; Mestre JR, 1997, CANCER RES, V57, P1081; Mestre JR, 1997, CANCER RES, V57, P2890; Mirzoeva OK, 1996, FEBS LETT, V396, P266, DOI 10.1016/0014-5793(96)01111-8; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NASSAR GM, 1994, J BIOL CHEM, V269, P27631; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; PAVANI M, 1994, BIOCHEM PHARMACOL, V48, P1935, DOI 10.1016/0006-2952(94)90592-4; PIAZZA GA, 1995, CANCER RES, V55, P3110; Piazza GA, 1997, CANCER RES, V57, P2452; PRESCOTT SM, 1996, CELL, V87, P159; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; SANO H, 1995, CANCER RES, V55, P3785; SHANNON VR, 1991, AM J PHYSIOL, V261, pL399, DOI 10.1152/ajplung.1991.261.6.L399; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; SIGAL E, 1992, AM J PHYSIOL, V262, pL392, DOI 10.1152/ajplung.1992.262.4.L392; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SIGAL E, 1990, J BIOL CHEM, V265, P5113; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SOBERMAN RJ, 1985, J BIOL CHEM, V260, P4508; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; Tang DG, 1997, J CELL PHYSIOL, V172, P155, DOI 10.1002/(SICI)1097-4652(199708)172:2<155::AID-JCP3>3.0.CO;2-N; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; ZHAO HL, 1995, J LIPID RES, V36, P2444	53	136	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21569	21577		10.1074/jbc.273.34.21569	http://dx.doi.org/10.1074/jbc.273.34.21569			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705287	hybrid			2022-12-25	WOS:000075492600021
J	Su, C; Sahlin, M; Oliw, EH				Su, C; Sahlin, M; Oliw, EH			A protein radical and ferryl intermediates are generated by linoleate diol synthase, a ferric hemeprotein with dioxygenase and hydroperoxide isomerase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	5th International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Related Diseases	SEP 17-20, 1997	LA JOLLA, CALIFORNIA				PROSTAGLANDIN-H SYNTHASE; FUNGUS GAEUMANNOMYCES-GRAMINIS; HIGHER OXIDATION-STATES; COLI RIBONUCLEOTIDE REDUCTASE; TYROSYL RADICALS; PEROXIDASE REACTION; 5,8,11-EICOSATRIENOIC ACID; ENDOPEROXIDE SYNTHASE; ASPERGILLUS-NIDULANS; REACTION-MECHANISMS	Linoleate diol synthase (LDS) was isolated as a hemeprotein from the fungus Gaeumannomyces graminis, LDS converts linoleate sequentially to 8R-hydroperoxylinoleate (8-HPODE) through an 8-dioxygenase by insertion of molecular oxygen and to 7S,8S-dihydroxylinoleate through a hydroperoxide isomerase by intramolecular oxygen transfer. Light absorption and EPR spectra of LDS indicated that the heme iron was ferric and mainly high spin. Oxygen consumption during catalysis started after a short time lag which was reduced by 8-HPODE, Catalysis declined due to suicide inactivation. Stopped flow studies with LDS and 8-HPODE at 13 degrees C showed a rapid decrease in light absorption at 406 nm within 35 ms with a first order rate constant of 90-120 s(-1). Light absorption at 406 nm then increased at a rate of similar to 4 s(-1), whereas the absorption at 421 nm increased after a lag time of similar to 5 ms at a rate of similar to 70 s(-1). EPR spectra at 77 K of LDS both with linoleic acid and 8-HPODE showed a transient doublet when quenched after incubation on ice for 3 s (major hyperfine splitting 2.3 millitesla; g = 2.005), indicating a protein radical. The relaxation properties of the protein radical suggested interaction with a metal center. 8-HPODE generated about twice as much radical as linoleic acid, and the 8-HPODE-induced radical appeared to be stable. Our results suggest that LDS may form, in analogy with prostaglandin Ii synthases, ferryl intermediates and a protein radical during catalysis.	Uppsala Univ, Uppsala Biomed Ctr, Dept Pharmaceut Sci, S-75124 Uppsala, Sweden; Stockholm Univ, Arrhenius Labs, Dept Mol Biol, S-10691 Stockholm, Sweden	Uppsala University; Stockholm University	Oliw, EH (corresponding author), Uppsala Univ, Uppsala Biomed Ctr, Dept Pharmaceut Sci, POB 591, S-75124 Uppsala, Sweden.			Oliw, Ernst/0000-0002-7986-8130				ABELSON PH, 1995, SCIENCE, V269, P1027, DOI 10.1126/science.269.5227.1027; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN, P13; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODOWSKY ID, 1992, J BIOL CHEM, V267, P14738; CHAMPE SP, 1989, J BACTERIOL, V171, P3982, DOI 10.1128/jb.171.7.3982-3988.1989; CHAMULITRAT W, 1989, J BIOL CHEM, V264, P20968; Coves J, 1996, BIOCHEMISTRY-US, V35, P8595, DOI 10.1021/bi960355o; DEGRAY JA, 1992, J BIOL CHEM, V267, P23583; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; ELLIOTT WJ, 1986, J BIOL CHEM, V261, P6719; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; Hamberg M, 1997, ARCH BIOCHEM BIOPHYS, V344, P194, DOI 10.1006/abbi.1997.0194; HAMBERG M, 1994, ARCH BIOCHEM BIOPHYS, V309, P77, DOI 10.1006/abbi.1994.1087; Himo F, 1997, BIOPHYS J, V72, P1556, DOI 10.1016/S0006-3495(97)78803-9; Hoganson CW, 1997, SCIENCE, V277, P1953, DOI 10.1126/science.277.5334.1953; HOLLENBERG PF, 1992, FASEB J, V6, P686, DOI 10.1096/fasebj.6.2.1537457; Ivancich A, 1996, J AM CHEM SOC, V118, P12852, DOI 10.1021/ja9628361; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; Licht S, 1996, SCIENCE, V271, P477, DOI 10.1126/science.271.5248.477; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; Marnett Lawrence J., 1995, P49; MAZUR P, 1990, TETRAHEDRON LETT, V31, P3837, DOI 10.1016/S0040-4039(00)97482-3; OLIW EH, 1993, ARCH BIOCHEM BIOPHYS, V305, P288, DOI 10.1006/abbi.1993.1425; Oliw EH, 1997, J CHROMATOGR B, V690, P332, DOI 10.1016/S0378-4347(96)00372-6; OMalley PJ, 1995, BBA-BIOENERGETICS, V1232, P175, DOI 10.1016/0005-2728(95)00102-6; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SAHLIN M, 1995, J BIOL CHEM, V270, P12361, DOI 10.1074/jbc.270.21.12361; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SAHLIN M, 1994, J BIOL CHEM, V269, P11699; SCHENKMAN JB, 1982, HEPATIC CYTOCHROME P, P587; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SJOBERG BM, 1994, STRUCTURE, V2, P793, DOI 10.1016/S0969-2126(94)00080-8; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Su C, 1996, J BIOL CHEM, V271, P14112, DOI 10.1074/jbc.271.24.14112; SU C, 1995, LIPIDS, V30, P43, DOI 10.1007/BF02537040; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; Tsai AL, 1998, J BIOL CHEM, V273, P3888, DOI 10.1074/jbc.273.7.3888; TSAI AL, 1993, J BIOL CHEM, V268, P8554; Tsai AL, 1997, J BIOL CHEM, V272, P8885; van der Ouderaa F J, 1980, Adv Prostaglandin Thromboxane Res, V6, P139; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WEI CH, 1995, BIOCHEMISTRY-US, V34, P8499, DOI 10.1021/bi00026a034; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u; Young P, 1996, J BIOL CHEM, V271, P20770, DOI 10.1074/jbc.271.34.20770	48	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20744	20751		10.1074/jbc.273.33.20744	http://dx.doi.org/10.1074/jbc.273.33.20744			8	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694817	hybrid			2022-12-25	WOS:000075386100010
J	Stephens, G; O'Luanaigh, N; Reilly, D; Harriott, P; Walker, B; Fitzgerald, D; Moran, N				Stephens, G; O'Luanaigh, N; Reilly, D; Harriott, P; Walker, B; Fitzgerald, D; Moran, N			A sequence within the cytoplasmic tail of GpIIb independently activates platelet aggregation and thromboxane synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; INTEGRIN-ALPHA; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ALPHA(IIB)BETA(3); LIGAND; COMPLEX; SUBUNIT; DOMAIN; CALRETICULIN	All integrin alpha subunits contain a highly conserved KXGFFKR motifin their cytoplasmic domains that plays a crucial role in the regulation of integrin affinity for their ligands, We show that a lipid-modified peptide corresponding to the cytoplasmic region, 989-995, of the platelet integrin subunit glycoprotein GpIIb (alpha IIb), palmitoyl-KVGFFKR (Ppep; 10 mu m), but not a similarly modified scrambled peptide (palmitoyl-FKFVRGK), can specifically induce platelet activation and aggregation equivalent to that of strong agonists such as thrombin, Ppep-induced aggregation is also associated with indices of platelet activation including thromboxane A(2) (TXA(2)) synthesis (EC50 = 45 +/- 5 mu M), secretion of alpha-granules detected as enhanced surface expression of P-selectin (EC50 = 52 +/- 8 mu M), and conformational changes in GpIIb/IIIa measured by the monoclonal antibody, PAC-1 (EC50 = 3.7 +/- 1 mu M). The TXA(2) receptor antagonist, SQ29548, PGE(1), and the ADP scavenger, apyrase, differentially inhibit the aggregation response and TXA(2) synthesis in response to Ppep, Similarly, GpIIb/IIIa antagonists (RO-449883 and integrelin), which inhibit aggregation by greater than 90%, have little effect on peptide-induced TXA(2) synthesis, suggesting that this event is independent of fibrinogen binding to GpIIb/IIIa, Alanine-stepping of the Ppep sequence identifies GFFK(991-994) as the critical residues in all peptide-mediated events. We conclude that this peptide can imitate the cytoplasmic domain of GpIIb and initiate parallel but independent signaling pathways, one leading to ligand binding and platelet aggregation and the other to intracellular signaling events such as TXA(2) synthesis and secretion.	Royal Coll Surg Ireland, Dept Clin Pharmacol, Ctr Cardiovasc Sci, Dublin 2, Ireland; Queens Univ Belfast, Dept Biochem, Belfast BT9 7BL, Antrim, North Ireland	Royal College of Surgeons - Ireland; Trinity College Dublin; Queens University Belfast	Moran, N (corresponding author), Royal Coll Surg Ireland, Dept Clin Pharmacol, Ctr Cardiovasc Sci, St Stephens Green, Dublin 2, Ireland.		Walker, Brian/C-5263-2008; Moran, Niamh/F-4188-2012	Moran, Niamh/0000-0002-8614-3242	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BRIESEWITZ R, 1993, MOL BIOL CELL, V4, P593, DOI 10.1091/mbc.4.6.593; BRUCHER KH, 1990, VIROLOGY, V178, P617, DOI 10.1016/0042-6822(90)90365-X; CHARO IF, 1992, CIRCULATION S1, V86, P1034; COLLER BS, 1995, THROMB HAEMOSTASIS, V74, P302; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; DELANTY N, 1993, CIRCULATION, V88, pA1319; DU XP, 1993, J BIOL CHEM, V268, P23087; FitzGerald G A, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P87; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; FOX JEB, 1994, ANN NY ACAD SCI, V714, P75, DOI 10.1111/j.1749-6632.1994.tb12032.x; Haas TA, 1996, J BIOL CHEM, V271, P6017, DOI 10.1074/jbc.271.11.6017; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HARRISON P, 1993, BLOOD REV, V7, P52, DOI 10.1016/0268-960X(93)90024-X; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; JONES CR, 1993, THROMB HAEMOSTASIS, V69, P560; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LEONG L, 1995, J CELL SCI, V108, P3817; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; Loh E, 1996, J BIOL CHEM, V271, P30233, DOI 10.1074/jbc.271.47.30233; MENDELSOHN ME, 1991, P NATL ACAD SCI USA, V88, P11212, DOI 10.1073/pnas.88.24.11212; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PERUTELLI P, 1992, Recenti Progressi in Medicina, V83, P100; Peter K, 1996, BLOOD COAGUL FIBRIN, V7, P233, DOI 10.1097/00001721-199603000-00031; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1986, BLOOD, V68, P1224; SONG A, 1992, CIRCULATION, V86, pA1410; STEINER B, 1993, THROMB HAEMOSTASIS, V69, P782; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; THIAGARAJAN P, 1987, BIOCHIM BIOPHYS ACTA, V924, P127, DOI 10.1016/0304-4165(87)90079-1; vanWilligen G, 1996, BIOCHEM J, V314, P769, DOI 10.1042/bj3140769; Weitzman JB, 1997, EUR J IMMUNOL, V27, P78, DOI 10.1002/eji.1830270112; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	41	69	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20317	20322		10.1074/jbc.273.32.20317	http://dx.doi.org/10.1074/jbc.273.32.20317			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685382	hybrid			2022-12-25	WOS:000075305400059
J	Yuan, Y; Li, DM; Sun, H				Yuan, Y; Li, DM; Sun, H			PIR1, a novel phosphatase that exhibits high affinity to RNA ribonucleoprotein complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASE; SPLICING FACTORS; MAP KINASE; IN-VIVO; PROTEIN; ENCODES	Protein tyrosine phosphatases are involved in the regulation of important cellular processes such as signal transduction, cell cycle progression, and tumor suppression. Here we report the cloning and characterization of PIR1, a novel member in the dual-specificity phosphatase subfamily of the protein tyrosine phosphatases. PIR1 also contains two stretches of arginine-rich sequences. We have shown that the recombinant PIR1 protein possessed an intrinsic phosphatase activity on phosphotyrosine-containing substrate. A unique feature of this phosphatase is that it binds directly to RNA in vitro with high affinity. In addition, we have found that PIR1 interacted with splicing factors 9G8 and SRp30C, possibly through an RNA intermediate during a yeast two-hybrid screen. PIR1 exhibited a nuclear-staining pattern that was sensitive to RNase A, but not to DNase I, suggesting that PIR1 in the cells are associated with RNA and/or ribonucleoprotein particles. Furthermore, a fraction of PIR1 showed a speckle-staining pattern that superimposed with that of the splicing factor, SC35. Taken together, our data suggest that PIR1 is a novel phosphatase that may participate in nuclear mRNA metabolism.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA	Yale University	Sun, H (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06520 USA.			Yuan, Yu/0000-0003-1075-1628				ALESSI DR, 1993, ONCOGENE, V8, P2015; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Dreyfuss G, 1996, CELL, V85, P963, DOI 10.1016/S0092-8674(00)81298-2; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HUANG S, 1994, J CELL BIOL, V126, P877, DOI 10.1083/jcb.126.4.877; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; POLYAK K, 1994, CELL, V78, P56; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	25	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20347	20353		10.1074/jbc.273.32.20347	http://dx.doi.org/10.1074/jbc.273.32.20347			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685386	hybrid			2022-12-25	WOS:000075305400063
J	Zhu, WJ; Eicher, A; Leber, B; Andrews, DW				Zhu, WJ; Eicher, A; Leber, B; Andrews, DW			At the onset of transformation polyomavirus middle-T recruits shc and src to a perinuclear compartment coincident with condensation of endosomes	ONCOGENE			English	Article						middle-T antigen; polyomavirus; perinuclear; shc; transformation	SIZED TUMOR-ANTIGEN; CELLULAR-LOCALIZATION; PROTEIN PHOSPHATASE; MEMBRANE-PROTEINS; EGF RECEPTOR; RAT-CELLS; VIRUS; BINDING; ASSOCIATION; ACTIVATION	To examine the early cellular changes that accompany transformation, middle-T antigen (the transforming protein of polyomavirus), was expressed from an inducible promoter in Rat2 fibroblasts and in normal diploid human fibroblast (MRCS) cells using a replication defective adenovirus vector. The earliest detectable expression of middle-T antigen correlated closely with the initial changes in cellular morphology. At this time, expression of middle-T antigen resulted in the redistribution of shc and src to a brefeldin A resistant perinuclear compartment coincident with the formation of kinase active complexes containing middle-T antigen, she and src. The first detectable changes directly related to altered morphology was reorganization of actin filaments, and the condensation of tubular endosomes in the perinuclear region of the cell. These results suggest a potential role for perinuclear localized mT molecules in some of the morphologic changes associated with the initial phase of cellular transformation.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Andrews, DW (corresponding author), McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada.			Andrews, David/0000-0002-9266-7157; Leber, Brian/0000-0001-5502-1480				AGUZZI A, 1991, ONCOGENE, V6, P113; ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; BALLMERHOFER K, 1985, EMBO J, V4, P2321, DOI 10.1002/j.1460-2075.1985.tb03933.x; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BEVAN AP, 1995, J BIOL CHEM, V270, P10784, DOI 10.1074/jbc.270.18.10784; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; Brewster CEP, 1997, J VIROL, V71, P5512, DOI 10.1128/JVI.71.7.5512-5520.1997; BRUNETTI CR, 1995, J VIROL, V69, P3517, DOI 10.1128/JVI.69.6.3517-3528.1995; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CARLEY WW, 1981, J CELL BIOL, V90, P797, DOI 10.1083/jcb.90.3.797; CARMICHAEL GG, 1982, P NATL ACAD SCI-BIOL, V79, P3579, DOI 10.1073/pnas.79.11.3579; CHENG SH, 1990, MOL CELL BIOL, V10, P5569, DOI 10.1128/MCB.10.10.5569; CHENG SH, 1990, EMBO J, V7, P384; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COOK DN, 1990, J VIROL, V64, P2392, DOI 10.1128/JVI.64.5.2392-2395.1990; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1986, EMBO J, V5, P491, DOI 10.1002/j.1460-2075.1986.tb04238.x; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; DRUCKER B, 1990, J VIROL, V64, P4454; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GRIFFIN BE, 1983, ADV CANCER RES, V39, P183, DOI 10.1016/S0065-230X(08)61036-2; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; ITO Y, 1977, P NATL ACAD SCI USA, V74, P4666, DOI 10.1073/pnas.74.10.4666; JELINEK MA, 1992, ONCOGENE, V7, P1687; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; Kim PK, 1997, BIOCHEMISTRY-US, V36, P8873, DOI 10.1021/bi970090t; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KORNBLUTH S, 1997, J VIROL, V64, P1584; KRAUZEWICZ N, 1994, ONCOGENE, V9, P2283; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; Messerschmitt A, 1996, J GEN VIROL, V77, P17, DOI 10.1099/0022-1317-77-1-17; OKAMURA H, 1994, ONCOGENE, V9, P2293; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; RASSOULZADEGAN M, 1990, ONCOGENE, V5, P1507; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SCHAFFHAUSEN BS, 1982, MOL CELL BIOL, V2, P1187, DOI 10.1128/MCB.2.10.1187; SEGAWA K, 1982, P NATL ACAD SCI-BIOL, V79, P6812, DOI 10.1073/pnas.79.22.6812; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TEMPLETON D, 1984, MOL CELL BIOL, V4, P282, DOI 10.1128/MCB.4.2.282; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; TUCKER RW, 1978, CELL, V13, P629, DOI 10.1016/0092-8674(78)90213-1; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Yi XD, 1997, J VIROL, V71, P6279, DOI 10.1128/JVI.71.9.6279-6286.1997; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	61	10	10	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					565	576		10.1038/sj.onc.1201979	http://dx.doi.org/10.1038/sj.onc.1201979			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704922				2022-12-25	WOS:000075195300004
J	Matsuo, T; Thiele, CJ				Matsuo, T; Thiele, CJ			p27(Kip1): a key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line	ONCOGENE			English	Article						neuroblastoma; retinoids; cell cycle; p27(Kip1); N-myc; G1 cyclin; cdk	DEPENDENT KINASE INHIBITOR; HUMAN NEURO-BLASTOMA; POTENTIAL MEDIATOR; CDK2 ACTIVITY; CYCLIN-E; DIFFERENTIATION; EXPRESSION; INDUCTION; G(1); ACTIVATION	Retinoic acid (RA) treatment of SMS-KCNR neuroblastoma (NB) cells leads to G1 growth arrest and neuronal differentiation. To investigate the molecular mechanisms by which RA alters cell growth, we analysed the expression and activity of components of the cell cycle machinery after culture in RA. Within 2 days of RA treatment and prior to the arrest of NE cells in the G1 phase of the cell cycle, there is a complete downregulation of G1 cyclin/Cdk activities. Protein levels for the G1 cyclin/Cdks were essentially unchanged during this time although there was a decrease in the steady-state levels of p67(N-Myc) and hyperphosphorylated Rb proteins. The Cdk inhibitors, p21(Cipl) and p27(Kip1) were constitutively expressed in KCNR while p15(INK4B) and p16(INK4A) were not detected. RA induced an increase in the expression of p27(Kip1) but not p21(Cip1). Furthermore, coincident with the decrease in kinase activity there was an increase in G1 cyclin/Cdk bound p27(Kip1). These results indicate that changes in the level of p27(Kip1) and its binding to G1 cyclin/Cdks may play a key role in RA induced growth arrest of NB cells.	NCI, Cell & Mol Biol Sect, Pediat Oncol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thiele, CJ (corresponding author), NCI, Cell & Mol Biol Sect, Pediat Oncol Branch, 10 Ctr Dr,MSC-1928, Bethesda, MD 20892 USA.							COHEN PS, 1995, CANCER RES, V55, P2380; Cushing H, 1927, AM J PATHOL, V3, P203; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gaetano C, 1997, J BIOL CHEM, V272, P12195, DOI 10.1074/jbc.272.18.12195; GAETANO C, 1992, CANCER RES, V52, P4402; GAETANO C, 1991, CELL GROWTH DIFFER, V2, P487; Giannini G, 1997, J BIOL CHEM, V272, P26693, DOI 10.1074/jbc.272.42.26693; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Iavarone A, 1997, NATURE, V387, P417; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KNUDSON AG, 1980, NEW ENGL J MED, V302, P1254, DOI 10.1056/NEJM198005293022210; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SIDELL N, 1982, J NATL CANCER I, V68, P589; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang QM, 1996, CANCER RES, V56, P264; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142	44	75	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3337	3343		10.1038/sj.onc.1201830	http://dx.doi.org/10.1038/sj.onc.1201830			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681834				2022-12-25	WOS:000074343600016
J	Ketchum, CJ; Nakamoto, RK				Ketchum, CJ; Nakamoto, RK			A mutation in the Escherichia coli F0F1-ATP synthase rotor, gamma E208K, perturbs conformational coupling between transport and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1F0 ATP SYNTHASE; TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; POLAR LOOP REGION; SUBUNIT-C; EPSILON-SUBUNIT; GAMMA-SUBUNIT; H+-ATPASE; BETA-SUBUNIT; F-0 PARTS; F1-ATPASE	Cross-Linking studies on the Escherichia coli F0F1-ATP synthase indicated a site of interaction involving gamma and epsilon subunits in F-1 and subunit c in F-0 (Watts, S. D., Tang, C., and Capaldi, R. A. (1996) J. Biol. Chem. 271, 28341-28347), To assess the function of these interactions, we introduced random mutations in this region of the gamma subunit (gamma 194-213). One mutation, gamma Glu-208 to Lys (gamma E208K), caused a temperature-sensitive defect in oxidative phosphorylation-dependent growth. ATP hydrolytic rates of the gamma E208K F0F1 enzyme became increasingly uncoupled from H+ pumping above 28 degrees C. In contrast, Arrhenius plot of steady-state ATP hydrolysis of the mutant enzyme was Linear from 20 to 50 degrees C, Analysis of this plot revealed a significant increase in the activation energy of the catalytic transition state to a value very similar to soluble, epsilon subunit-inhibited F-1 and suggested that the mutation blocked normal release of epsilon inhibition of ATP hydrolytic activity upon binding of F-1 to F-0. The difference in temperature dependence suggested that the gamma E208K mutation perturbed release of inhibition via a different mechanism than it did energy coupling. Suppressor mutations in the polar loop of subunit c restored ATP-dependent H+ pumping and transition state thermodynamic parameters close to wild-type values indicating that interactions between gamma and c subunits mediate release of epsilon inhibition and communication of coupling information.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA	University of Virginia	Nakamoto, RK (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, POB 10011, Charlottesville, VA 22906 USA.				NIGMS NIH HHS [R01-GM50957, R01 GM050957] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050957] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AlShawi MK, 1997, J BIOL CHEM, V272, P2300; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; AlShawi MK, 1997, BIOCHEMISTRY-US, V36, P12961, DOI 10.1021/bi971478r; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUNCAN TM, 1985, J BIOL CHEM, V260, P4901; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FRAGA D, 1991, J BACTERIOL, V173, P2639, DOI 10.1128/jb.173.8.2639-2643.1991; FRAGA D, 1989, J BIOL CHEM, V264, P6797; FRAGA D, 1994, J BIOL CHEM, V269, P7532; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; GIRVIN ME, 1995, BIOCHEMISTRY-US, V34, P1635, DOI 10.1021/bi00005a020; GIRVIN ME, 1994, BIOCHEMISTRY-US, V33, P665, DOI 10.1021/bi00169a006; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kaibara C, 1996, J BIOL CHEM, V271, P2433, DOI 10.1074/jbc.271.5.2433; Ketchum CJ, 1998, BIOCHEM J, V330, P707; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KUKI M, 1988, J BIOL CHEM, V263, P17437; Kuo PH, 1998, FEBS LETT, V426, P217, DOI 10.1016/S0014-5793(98)00337-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER MJ, 1989, J BIOL CHEM, V264, P305; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; NAKAMOTO RK, 1995, J BIOL CHEM, V270, P14042, DOI 10.1074/jbc.270.23.14042; Nakamoto RK, 1996, J MEMBRANE BIOL, V151, P101, DOI 10.1007/s002329900061; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; SMITH JB, 1977, BIOCHEMISTRY-US, V16, P306, DOI 10.1021/bi00621a023; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; TAKEYAMA M, 1990, J BIOL CHEM, V265, P21279; VIK SB, 1994, J BIOL CHEM, V269, P30364; Watts SD, 1997, J BIOL CHEM, V272, P15065, DOI 10.1074/jbc.272.24.15065; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; XIONG H, 1995, J BIOL CHEM, V270, P23300, DOI 10.1074/jbc.270.40.23300; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZHANG Y, 1994, J BIOL CHEM, V269, P10221; [No title captured]	48	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22292	22297		10.1074/jbc.273.35.22292	http://dx.doi.org/10.1074/jbc.273.35.22292			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712846	hybrid			2022-12-25	WOS:000075616600022
J	Pohl, E; Holmes, RK; Hol, WGJ				Pohl, E; Holmes, RK; Hol, WGJ			Motion of the DNA-binding domain with respect to the core of the diphtheria toxin repressor (DtxR) revealed in the crystal structures of apo- and holo-DtxR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE R-VALUE; CORYNEBACTERIUM-DIPHTHERIAE; SEQUENCE-ANALYSIS; MET REPRESSOR; IRON; PROTEIN; IDENTIFICATION; ACTIVATION; CLONING; HOMOLOG	The diphtheria toxin repressor (DtxR) from Corynebacterium diphtheriae is a divalent metal-activated repressor of chromosomal genes that encode proteins responsible for siderophore-mediated iron uptake and also of the gene of certain corynebacteriophages that encodes diphtheria toxin. DtxR consists of two 25.3-kDa three-domain subunits and is a member of a family of related repressor proteins in several Gram-positive bacterial species, some of which are important human pathogens. In this paper, we report on the first high resolution crystal structures of apo-DtxR in two related space groups. In addition, crystal structures of Zn-DtxR were determined in the same two space groups. The resolutions of the structures range from 2.2 to 2.4 Angstrom. The four refined models of the apo- and the hoIo-repressor exhibit quite similar metal binding centers, which do, however, show higher thermal motion in the ape-structures. All four structures reported differ from each other in one important aspect. The N-terminal DNA-binding domain and the last 20 residues of the dimerization domain of each subunit move significantly with respect to the core of the DtxR dimer, which consists of residues 74-120 from both subunits. These results provide the first indication of a conformational change that may occur upon binding of the hole-repressor to DNA.	Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hol, WGJ (corresponding author), Univ Washington, Howard Hughes Med Inst, Hlth Sci Bldg,Rm K-428,Box 357742, Seattle, WA 98195 USA.		Pohl, Ehmke/I-2408-2012	Pohl, Ehmke/0000-0002-9949-4471	NCI NIH HHS [R01CA65656] Funding Source: Medline; NIAID NIH HHS [R01AI4107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065656] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Ding X, 1996, NAT STRUCT BIOL, V3, P382, DOI 10.1038/nsb0496-382; DOUKHAN L, 1995, GENE, V165, P67, DOI 10.1016/0378-1119(95)00427-8; GUNTERSEEBOTH K, 1995, GENE, V166, P117, DOI 10.1016/0378-1119(95)00628-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee JH, 1997, INFECT IMMUN, V65, P4273, DOI 10.1128/IAI.65.10.4273-4280.1997; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OGUIZA JA, 1995, J BACTERIOL, V177, P465, DOI 10.1128/jb.177.2.465-467.1995; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK COL; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PHILLIPS K, 1994, STRUCTURE, V2, P309, DOI 10.1016/S0969-2126(00)00032-0; Pohl E, 1997, PROTEIN SCI, V6, P1114, DOI 10.1002/pro.5560060519; Qiu XY, 1996, BIOCHEMISTRY-US, V35, P12292, DOI 10.1021/bi960861d; QIU XY, 1995, STRUCTURE, V3, P87, DOI 10.1016/S0969-2126(01)00137-X; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHIERING N, 1995, P NATL ACAD SCI USA, V92, P9843, DOI 10.1073/pnas.92.21.9843; Schmidt F.L., 1992, CURRENT DIRECTIONS P, V1, P89, DOI [DOI 10.1111/1467-8721.EP10768758, 10.1111/1467-8721.ep10768758]; SCHMITT MP, 1993, MOL MICROBIOL, V9, P173, DOI 10.1111/j.1365-2958.1993.tb01679.x; SCHMITT MP, 1991, INFECT IMMUN, V59, P1899, DOI 10.1128/IAI.59.6.1899-1904.1991; Schmitt MP, 1997, INFECT IMMUN, V65, P4634, DOI 10.1128/IAI.65.11.4634-4641.1997; Schmitt MP, 1997, INFECT IMMUN, V65, P5364, DOI 10.1128/IAI.65.12.5364-5367.1997; SCHMITT MP, 1995, INFECT IMMUN, V63, P4284, DOI 10.1128/IAI.63.11.4284-4289.1995; SCHMITT MP, 1994, J BACTERIOL, V176, P1141, DOI 10.1128/JB.176.4.1141-1149.1994; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; STOJILJKOVIC I, 1994, J MOL BIOL, V236, P531, DOI 10.1006/jmbi.1994.1163; TAO X, 1993, P NATL ACAD SCI USA, V90, P8524, DOI 10.1073/pnas.90.18.8524; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; WEINBERG ED, 1993, PERSPECT BIOL MED, V36, P215; XU T, 1992, J BIOL CHEM, V267, P21761; ZHANG XJ, 1995, J APPL CRYSTALLOGR, V28, P624, DOI 10.1107/S0021889895001063; 1994, ACTA CRYSTALLOGR, V50, P760	37	49	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22420	22427		10.1074/jbc.273.35.22420	http://dx.doi.org/10.1074/jbc.273.35.22420			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712865	hybrid			2022-12-25	WOS:000075616600041
J	Ugarova, TP; Solovjov, DAS; Zhang, L; Loukinov, DI; Yee, VC; Medved, LV; Plow, EF				Ugarova, TP; Solovjov, DAS; Zhang, L; Loukinov, DI; Yee, VC; Medved, LV; Plow, EF			Identification of a novel recognition sequence for integrin alpha(M)beta(2) within the gamma-chain of fibrinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL INHIBITORY FACTOR; MAC-1 CD11B CD18; MONOCLONAL-ANTIBODIES; I-DOMAIN; LEUKOCYTE ADHESION; PLASMA FIBRONECTIN; BINDING-SITE; RECEPTOR; FIBRIN(OGEN); GLYCOPROTEIN	The interaction of leukocyte integrin alpha(M)beta(2) (CD11b/CD18, Mac-1) with fibrinogen has been implicated in the inflammatory response by contributing to leukocyte adhesion to the endothelium and subsequent transmigration. Previously, it has been demonstrated that a peptide, P1, corresponding to residues 190-202 in the gamma-chain of fibrinogen, binds to alpha(M)beta(2) and blocks the interaction of fibrinogen with the receptor and that Asp(199) within P1 is important to activity. We have demonstrated, however, that a double mutation of Asp(199)-Gly(200) to Gly-Ala in the recombinant gamma-module of fibrinogen, spanning region 148-411, did not abrogate alpha(M)beta(2) recognition and considered that other binding sites in the gamma-module may participate in the receptor recognition. We have found that synthetic peptide P2, duplicating gamma 377-395, inhibited adhesion of alpha(M)beta(2)-transfected cells to immobilized D-100 fragment of fibrinogen in a dose-dependent manner. In addition, immobilized Pa directly supported efficient adhesion of the alpha(M)beta(2)-expressing cells, including activated and non-activated monocytoid cells. The I domain of alpha(M)beta(2) was implicated in recognition of P2, as the biotinylated recombinant alpha(M)I domain specifically bound to both P2 and P1 peptides, Analysis of overlapping peptides spanning P2 demonstrated that it may contain two functional sequences: gamma 377-386 (P2-N) and gamma 383-395 (P2-C), with the latter sequence being more active. In the three-dimensional structure of the gamma-module, gamma 190-202 and gamma 377-395 reside in close proximity, forming two antiparallel beta strands. The juxtapositioning of these two sequences may form an unique and complex binding site for alpha(M)beta(2).	Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Amer Red Cross, Jerome H Holland Lab, Rockville, MD 20855 USA	Cleveland Clinic Foundation; American Red Cross	Ugarova, TP (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA.			Medved, Leonid/0000-0002-3665-9849	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054924, R01HL056051] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54924, HL-56051, R01 HL056051] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; AMAOUT MA, 1990, BLOOD, V75, P1037; AOTA S, 1994, J BIOL CHEM, V269, P24756; BINI A, 1989, ARTERIOSCLEROSIS, V9, P109, DOI 10.1161/01.ATV.9.1.109; DANA N, 1986, J IMMUNOL, V137, P3259; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; GUSTAFSON EJ, 1989, J CELL BIOL, V109, P377, DOI 10.1083/jcb.109.1.377; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANGUINO LR, 1995, P NATL ACAD SCI USA, V92, P1505, DOI 10.1073/pnas.92.5.1505; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; Medved L, 1997, BIOCHEMISTRY-US, V36, P4685, DOI 10.1021/bi962795l; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; MOYLE M, 1994, J BIOL CHEM, V269, P10008; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; PLOW EF, 1987, BIOCHEM PHARMACOL, V36, P4035, DOI 10.1016/0006-2952(87)90558-2; PLOW EF, 1981, J BIOL CHEM, V256, P9477; PROCYK R, 1991, BLOOD, V77, P1469; SHATTIL SJ, 1987, BLOOD, V70, P307; SIMON DI, 1993, BLOOD, V82, P2414; Spraggon G, 1997, NATURE, V389, P455, DOI 10.1038/38947; Sriramarao P, 1996, BLOOD, V88, P3416, DOI 10.1182/blood.V88.9.3416.bloodjournal8893416; TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147; Tang LP, 1996, J CLIN INVEST, V97, P1329, DOI 10.1172/JCI118549; UGAROVA TP, 1992, J BIOL CHEM, V267, P13687; VALENZUELA R, 1992, AM J PATHOL, V141, P861; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8; ZAMARRON C, 1991, J BIOL CHEM, V266, P16193; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	39	134	138	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22519	22527		10.1074/jbc.273.35.22519	http://dx.doi.org/10.1074/jbc.273.35.22519			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712878	hybrid			2022-12-25	WOS:000075616600054
J	Contreres, JO; Faure, R; Baquiran, G; Bergeron, JJ; Posner, BI				Contreres, JO; Faure, R; Baquiran, G; Bergeron, JJ; Posner, BI			ATP-dependent desensitization of insulin binding and tyrosine kinase activity of the insulin receptor kinase - The role of endosomal acidification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; DIABETES-MELLITUS; SIGNAL-TRANSDUCTION; AFRICAN CHILDREN; CHLOROQUINE; DEGRADATION; ACTIVATION; INVIVO; INTERNALIZATION; PROTEIN	Incubating endosomes with ATP decreased binding of I-125-insulin but not I-125-labeled human growth hormone. Increasing ATP concentrations from 0.1 to 1 mM increased P-subunit tyrosine phosphorylation and insulin receptor kinase (IRK) activity assayed after partial purification. At higher (5 mM) ATP concentrations P-subunit tyrosine phosphorylation and IRK activity were markedly decreased. This was not observed with nonhydrolyzable analogs of ATP, nor with plasma membrane IRK, nor with endosomal epidermal growth factor receptor kinase autophosphorylation. The inhibition of endosomal IRK tyrosine phosphorylation and activity was completely reversed by bafilomycin A(1), indicating a role for endosomal proton pump(s), The inhibition of IRK was not due to serine/threonine phosphorylation nor was it influenced by the inhibition of phosphotyrosyl phosphatase using bisperoxo(1,10-phenanthroline)oxovanadate anion, Prior phosphorylation of the beta-subunit with 1 mM ATP did not prevent the inhibition of IRK activity on incubating with 5 mM ATP, To evaluate conformational change we incubated endosomes with dithiothreitol (DTT) followed by SDS-polyacrylamide gel electrophoresis under nonreducing conditions. Without DTT the predominant species of IRK observed was alpha(2)beta(2). With DTT the alpha beta dimer predominated but on co-incubation with 5 mM ATP the alpha(2)beta(2) form predominated. Thus, ATP-dependent endosomal acidification contributes to the termination of transmembrane signaling by, among other processes, effecting a deactivating conformational change of the IRK.	McGill Univ, Polypeptide Hormone Lab, Montreal, PQ, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada; Univ Laval, CHUL, Dept Med, Quebec City, PQ G1V 4G2, Canada; Univ Laval, CHUL, Ctr Rech, Quebec City, PQ G1V 4G2, Canada	McGill University; McGill University; Laval University; Laval University	Posner, BI (corresponding author), McGill Univ, Polypeptide Hormone Lab, Strathcona Anat & Dent Bdg,3640 Univ St,Rm W315, Montreal, PQ, Canada.	mc85@musica.mcgill.ca	Posner, Barry/B-6733-2008; Bergeron, John/AAW-1893-2021					ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; AUTHIER F, 1994, J BIOL CHEM, V269, P3010; AUTHIER F, 1994, CELLULAR PROTEOLYTIC, P89; BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; BACKER JM, 1990, J BIOL CHEM, V265, P14828; BERGERON JJM, 1986, BIOCHEMISTRY-US, V25, P1756, DOI 10.1021/bi00355a046; BERGERON JJM, 1982, J CELL BIOL, V92, P139, DOI 10.1083/jcb.92.1.139; Bevan AP, 1996, TRENDS ENDOCRIN MET, V7, P13, DOI 10.1016/1043-2760(95)00179-4; Bevan AP, 1997, J BIOL CHEM, V272, P26833, DOI 10.1074/jbc.272.43.26833; BEVAN AP, 1995, J BIOL CHEM, V270, P10784, DOI 10.1074/jbc.270.18.10784; BLAZAR BR, 1984, DIABETES, V33, P1133, DOI 10.2337/diabetes.33.12.1133; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; BURGESS JW, 1992, EXP CLIN ENDOCRINOL, V11, P67; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; Courtoy P J, 1993, Subcell Biochem, V19, P29; DESBUQUOIS B, 1990, EUR J BIOCHEM, V193, P501, DOI 10.1111/j.1432-1033.1990.tb19365.x; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; DURRER P, 1995, J BIOL CHEM, V270, P17575, DOI 10.1074/jbc.270.29.17575; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GALLOWAY CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3334, DOI 10.1073/pnas.80.11.3334; GAUDIN Y, 1993, J VIROL, V67, P1365, DOI 10.1128/JVI.67.3.1365-1372.1993; HAMEL FG, 1988, J BIOL CHEM, V263, P6703; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; ILARDE A, 1994, DRUG AGING, V4, P470, DOI 10.2165/00002512-199404060-00004; KAY DG, 1986, J BIOL CHEM, V261, P8473; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KHAN MN, 1985, DIABETES, V34, P1025, DOI 10.2337/diabetes.34.10.1025; Krueger KM, 1997, J BIOL CHEM, V272, P5; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; LAI WH, 1989, J CELL BIOL, V109, P2741, DOI 10.1083/jcb.109.6.2741; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LEVY JR, 1988, J BIOL CHEM, V263, P6101; LEWIS RE, 1994, J BIOL CHEM, V269, P26259; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MEYER RA, 1982, AM J PHYSIOL, V242, pC1, DOI 10.1152/ajpcell.1982.242.1.C1; MILLER DS, 1986, J BIOL CHEM, V261, P13911; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; PAPINI E, 1993, J BIOL CHEM, V268, P1567; PASVOL G, 1991, AM J TROP MED HYG, V45, P702, DOI 10.4269/ajtmh.1991.45.702; POSNER BI, 1980, J BIOL CHEM, V255, P735; POSNER BI, 1994, J BIOL CHEM, V269, P4596; POSNER BI, 1982, J BIOL CHEM, V257, P5789; POWRIE JK, 1991, AM J PHYSIOL, V260, pE897, DOI 10.1152/ajpendo.1991.260.6.E897; QUATRARO A, 1988, DIABETES METAB, V14, P666; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SMITH GD, 1987, BRIT MED J, V294, P465, DOI 10.1136/bmj.294.6570.465; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; SUSSMAN I, 1980, BIOCHIM BIOPHYS ACTA, V591, P209, DOI 10.1016/0005-2728(80)90153-X; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; TRISCHITTA V, 1984, METABOLISM, V33, P577, DOI 10.1016/0026-0495(84)90015-5; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; WHITE NJ, 1987, LANCET, V1, P708	58	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22007	22013		10.1074/jbc.273.34.22007	http://dx.doi.org/10.1074/jbc.273.34.22007			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705342	hybrid			2022-12-25	WOS:000075492600076
J	Gosling, M; Harley, SL; Turner, RJ; Carey, N; Powell, JT				Gosling, M; Harley, SL; Turner, RJ; Carey, N; Powell, JT			Human saphenous vein endothelial cells express a tetrodotoxin-resistant, voltage-gated sodium current	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION CHANNELS; NA+ CURRENT; MUSCLE CELLS; PATCH-CLAMP; MEMBRANE; CALCIUM; HEART; ARTERY; LINE	Whole-cell patch-clamp electrophysiological investigation of endothelial cells cultured from human saphenous vein (HSVECs) has identified a voltage-gated Na+ current with a mean peak magnitude of -595 +/- 49 pA (n = 75). This current was inhibited by tetrodotoxin (TTX) in a concentration-dependent manner, with an IC50 value of 4.7 mu M, suggesting that it was of the TTX-resistant subtype, An antibody directed against the highly conserved intracellular linker region between domains III and IV of known Na+ channel alpha-subunits was able to retard current inactivation when applied intracellularly. This antibody identified a 245-kDa protein from membrane lysates on Western blotting and positively immunolabeled both cultured HSVECs and intact venous endothelium, HSVECs were also shown by reverse transcription-polymerase chain reaction to contain transcripts of the hH1 sodium channel gene. The expression of Na+ channels by HSVECs was shown using electrophysiology and cell-based enzyme-linked immunosorbent assay to be dependent on the concentration and source of human serum. Together, these results suggest that TTX-resistant Na+ channels of the hill isoform are expressed in human saphenous vein endothelium and that the presence of these channels is controlled by a serum factor.	Charing Cross Hosp, Imperial Coll, Dept Vasc Surg, Sch Med, London W6 8RF, England	Imperial College London	Gosling, M (corresponding author), Charing Cross Hosp, Imperial Coll, Dept Vasc Surg, Sch Med, Fulham Palace Rd, London W6 8RF, England.		Powell, Janet/AAW-8669-2021	Powell, Janet/0000-0002-3905-1468				ADAMS DJ, 1989, FASEB J, V3, P2389, DOI 10.1096/fasebj.3.12.2477294; Beny JL, 1997, PFLUG ARCH EUR J PHY, V433, P364; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; BKAILY G, 1991, J MOL CELL CARDIOL, V23, P25, DOI 10.1016/0022-2828(91)90036-L; BOSSU JL, 1989, FEBS LETT, V255, P377, DOI 10.1016/0014-5793(89)81126-3; BOSSU JL, 1992, PFLUG ARCH EUR J PHY, V420, P200, DOI 10.1007/BF00374991; BROWN AM, 1981, J PHYSIOL-LONDON, V318, P479; Chahine M, 1996, AM J PHYSIOL-HEART C, V271, pH498, DOI 10.1152/ajpheart.1996.271.2.H498; Cohen S A, 1993, Int Rev Cytol, V137C, P55; COHEN-ARMON M, 1993, J BIOL CHEM, V268, P9824; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GORDIENKO DV, 1994, PFLUG ARCH EUR J PHY, V428, P91, DOI 10.1007/BF00374756; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; JAFFE EA, 1985, ANN NY ACAD SCI, V454, P279, DOI 10.1111/j.1749-6632.1985.tb11868.x; KALLEN RG, 1990, NEURON, V4, P232; KOSTYUK PG, 1981, NEUROSCIENCE, V6, P2423, DOI 10.1016/0306-4522(81)90088-9; KUSAKA M, 1994, AM J PHYSIOL-CELL PH, V267, pC1288; MARSDEN PA, 1991, J AM SOC NEPHROL, V1, P931; Quignard JF, 1997, CIRC RES, V80, P377, DOI 10.1161/01.res.0000435853.85322.af; RENAUD JF, 1983, J BIOL CHEM, V258, P8799; REVEST PA, 1992, TRENDS PHARMACOL SCI, V13, P404, DOI 10.1016/0165-6147(92)90124-O; SAGE SO, 1991, J PHYSIOL-LONDON, V440, P569, DOI 10.1113/jphysiol.1991.sp018725; SCULPTOREANU A, 1992, AM J PHYSIOL, V262, pC724, DOI 10.1152/ajpcell.1992.262.3.C724; SONTHEIMER H, 1992, J NEUROPHYSIOL, V68, P1001, DOI 10.1152/jn.1992.68.4.1001; Sontheimer H, 1996, TRENDS NEUROSCI, V19, P325, DOI 10.1016/0166-2236(96)10039-4; VANHOUTTE PM, 1986, ANNU REV PHYSIOL, V48, P307; WATSKY MA, 1991, PFLUG ARCH EUR J PHY, V419, P454, DOI 10.1007/BF00370788; Ying XY, 1996, CIRC RES, V79, P898, DOI 10.1161/01.RES.79.4.898	31	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21084	21090		10.1074/jbc.273.33.21084	http://dx.doi.org/10.1074/jbc.273.33.21084			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694861	hybrid			2022-12-25	WOS:000075386100054
J	Honsho, M; Mitoma, JY; Ito, A				Honsho, M; Mitoma, JY; Ito, A			Retention of cytochrome b(5) in the endoplasmic reticulum is transmembrane and luminal domain-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER PROTEINS; MEDIATED RETRIEVAL; SECRETORY PATHWAY; MEMBRANE-PROTEIN; GOLGI; YEAST; TRANSPORT; CLONING; SIGNAL; CDNA	Cytochrome b(5) (b5), a typical tail-anchored protein of the endoplasmic reticulum (ER) membrane, is composed of three functionally different domains: amino-terminal heme-containing catalytic, central hydrophobic membrane-anchoring, and carboxyl-terminal ER-targeting domains (Mitoma, J., and Ito, A. (1992) EMBO J. 11, 4197-4203), To analyze the potential retention signal of b5, mutant proteins were prepared to replace each domain with natural or artificial sequences, and subcellular localizations were examined using immunofluorescence microscopy and cell fractionation. The transmembrane domain functioned to retain the cytochrome in the ER, and the mutation of all or part of the transmembrane domain with an artificial hydrophobic sequence had practically no effect on intracellular distribution of the cytochrome. However, when the transmembrane domain was extended systematically, a substantial portion of the protein with the domain of over 22 amino acid residues leaked from the organelle, Thus, the transmembrane length functions as the retention signal. When cytochromes with mutations at the carboxyl-terminal end were overexpressed in cells, a substantial portion of the protein was transported to the plasma membrane, indicating that the carboxyl-terminal luminal domain also has a role in retention of b5 in the ER. Carbohydrate moiety of the glycosylatably-mutated b5 was sensitive to endoglycosidase H but resistant to endoglycosidase D. Therefore, both transmembrane and carboxyl-terminal portions seems to function as the static retention signal.	Kyushu Univ, Fac Sci, Dept Chem, Higashi Ku, Fukuoka 8128581, Japan	Kyushu University	Ito, A (corresponding author), Kyushu Univ, Fac Sci, Dept Chem, Higashi Ku, Fukuoka 8128581, Japan.			Honsho, Masanori/0000-0001-6165-4516				ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DESILVESTRIS M, 1995, FEBS LETT, V370, P69, DOI 10.1016/0014-5793(95)00797-D; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; HABIG WH, 1974, J BIOL CHEM, V249, P7130; INOUE A, 1992, J BIOL CHEM, V267, P10613; ITO A, 1980, J BIOCHEM, V87, P63, DOI 10.1093/oxfordjournals.jbchem.a132753; ITO A, 1990, BIOCHEM INT, V22, P235; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kuroda R, 1996, J BIOCHEM-TOKYO, V120, P828; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; MIYAUCHI K, 1991, J BIOL CHEM, V266, P19536; MIZUOCHI T, 1984, J BIOCHEM-TOKYO, V95, P1209, DOI 10.1093/oxfordjournals.jbchem.a134711; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NILSSON I, 1993, J BIOL CHEM, V268, P5798; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NISHIKAWA S, 1993, P NATL ACAD SCI USA, V90, P8179, DOI 10.1073/pnas.90.17.8179; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; Pedrazzini E, 1996, P NATL ACAD SCI USA, V93, P4207, DOI 10.1073/pnas.93.9.4207; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SHIMER SB, 1990, P NATL ACAD SCI USA, V87, P5148; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VERGERES G, 1995, J BIOL CHEM, V270, P3414, DOI 10.1074/jbc.270.7.3414; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; ZHANG H, 1988, ARCH BIOCHEM BIOPHYS, V264, P343, DOI 10.1016/0003-9861(88)90603-0	40	51	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20860	20866		10.1074/jbc.273.33.20860	http://dx.doi.org/10.1074/jbc.273.33.20860			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694832	hybrid			2022-12-25	WOS:000075386100025
J	Maki, S; Hashimoto, K; Ohara, T; Sugino, A				Maki, S; Hashimoto, K; Ohara, T; Sugino, A			DNA polymerase II (epsilon) of Saccharomyces cerevisiae dissociates from the DNA template by sensing single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-C; CELL NUCLEAR ANTIGEN; ESCHERICHIA-COLI; S-PHASE; YEAST; CHECKPOINT; SUBUNIT; REPAIR; DELTA; RECONSTITUTION	Two forms of DNA polymerase II (epsilon) of Saccharomyces cerevisiae, Pol II* and Pol II, were purified to near homogeneity from yeast cells. Pol II* is a four-subunit complex containing a 256-kDa catalytic polypeptide, whereas Pol II consists solely of a 145-kDa polypeptide derived from the N-terminal half of the 256-kDa polypeptide of Pol II*. We show that Pol II* and Pol II are indistinguishable with respect to the processivity and rate of DNA-chain elongation. The equilibrium dissociation constants of the complexes of Pol II* and Pol II with the DNA template showed that the stability of these complexes is almost the same. However, when the rates of dissociation of the Pol II* and Pol II from the DNA template were measured using single-stranded DNA as a trap for the dissociated polymerase, Pol II* dissociated 75-fold faster than Pol II. Furthermore, the rate of dissociation of Pol II* from the DNA template became faster as the concentration of the single-stranded DNA was increased. These results indicate that the rapid dissociation of Pol II* from the DNA template is actively promoted by single-stranded DNA, The dissociation of Pol II from the DNA template was also shown to be promoted by single-stranded DNA, although at a much slower rate. These results suggest that the site for sensing single stranded DNA resides within the 145-kDa N-terminal portion of the catalytic subunit and that the efficiency for sensing single-stranded DNA by this site is positively modulated by either the C-terminal half of the catalytic subunit and/or the other subunits.	Osaka Univ, Microbial Dis Res Inst, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan	Osaka University	Sugino, A (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Biochem & Mol Biol, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.							Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CAMPBELL JL, 1993, J BIOL CHEM, V268, P25261; EKI T, 1992, J BIOL CHEM, V267, P7284; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; Hashimoto K, 1998, NUCLEIC ACIDS RES, V26, P477, DOI 10.1093/nar/26.2.477; KESTI T, 1993, J BIOL CHEM, V268, P10238; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LEE SH, 1991, J BIOL CHEM, V266, P22707; MAGA G, 1995, BIOCHEMISTRY-US, V34, P891, DOI 10.1021/bi00003a023; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MORRISON A, 1993, PROG NUCLEIC ACID RE, V46, P93, DOI 10.1016/S0079-6603(08)61019-3; Mozzherin DJ, 1996, BIOCHEMISTRY-US, V35, P3572, DOI 10.1021/bi952142p; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; Sugimoto K, 1997, MOL CELL BIOL, V17, P5905, DOI 10.1128/MCB.17.10.5905; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; TUUSA J, 1995, NUCLEIC ACIDS RES, V23, P2178, DOI 10.1093/nar/23.12.2178; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; YODER BL, 1991, J BIOL CHEM, V266, P22689; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	40	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21332	21341		10.1074/jbc.273.33.21332	http://dx.doi.org/10.1074/jbc.273.33.21332			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694894	hybrid			2022-12-25	WOS:000075386100087
J	Murphy, GM; Yang, L; Cordell, B				Murphy, GM; Yang, L; Cordell, B			Macrophage colony-stimulating factor augments beta-amyloid-induced interleukin-1, interleukin-6, and nitric oxide production by microglial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN FETAL ASTROCYTES; ALZHEIMERS-DISEASE; FACTOR-I; SCAVENGER RECEPTOR; CULTURED MICROGLIA; PLAQUE EVOLUTION; INTERFERON-GAMMA; GENE-EXPRESSION; FACTOR-ALPHA	In Alzheimer's disease (AD), a chronic cerebral inflammatory state is thought to lead to neuronal injury. Microglia, intrinsic cerebral immune effector cells, are likely to be key in the pathophysiology of this inflammatory state. We showed that macrophage colony-stimulating factor, a microglial activator found at increased levels in the central nervous system in AD, dramatically augments beta-amyloid peptide (beta AP)-induced microglial production of interleukin-l, interleukin-6, and nitric oxide. In contrast, granulocyte macrophage colony-stimulating factor, another hematopoietic cytokine found in the AD brain, did not augment beta AP-induced microglial secretory activity. These results indicate that increased macrophage colony-stimulating factor levels in AD could magnify beta AP-induced microglial inflammatory cytokine and nitric oxide production, which in turn could intensify the cerebral inflammatory state by activating astrocytes and additional microglia, as well as directly injuring neurons.	Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Neurosci Res Labs, Stanford, CA 94305 USA; Scios Inc, Sunnyvale, CA 94086 USA	Stanford University; Scios	Murphy, GM (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Neurosci Res Labs, Stanford, CA 94305 USA.	greer.murphy@stanford.edu						AKIYAMA H, 1994, BRAIN RES, V639, P171, DOI 10.1016/0006-8993(94)91779-5; ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; Bitting L, 1996, J BIOL CHEM, V271, P16084, DOI 10.1074/jbc.271.27.16084; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; CHUNG Y, 1994, J NEUROIMMUNOL, V52, P9; DERYUGINA EI, 1995, BLOOD, V86, P2568; DICKSON DW, 1991, LAB INVEST, V64, P135; Ding MZ, 1997, J BIOL CHEM, V272, P11327; ElKhoury J, 1996, NATURE, V382, P716; FUNG MC, 1992, J IMMUNOL METHODS, V149, P97, DOI 10.1016/S0022-1759(12)80053-6; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; GIULIAN D, 1988, J NEUROSCI, V8, P4707; GOODWIN JL, 1995, BRAIN RES, V692, P207, DOI 10.1016/0006-8993(95)00646-8; GRIFFIN WST, 1995, J NEUROPATH EXP NEUR, V54, P276; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Hamilton JA, 1997, IMMUNOL TODAY, V18, P313, DOI 10.1016/S0167-5699(97)01084-0; HAO C, 1990, J NEUROSCI RES, V27, P314, DOI 10.1002/jnr.490270310; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Ii M, 1996, BRAIN RES, V720, P93, DOI 10.1016/0006-8993(96)00156-4; KLEGERIS A, 1994, BIOCHEM BIOPH RES CO, V199, P984, DOI 10.1006/bbrc.1994.1326; Kloss CUA, 1997, J NEUROSCI RES, V49, P248; LEE SC, 1993, J IMMUNOL, V150, P594; LEE SC, 1994, GLIA, V12, P309, DOI 10.1002/glia.440120407; LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R; Lorton D, 1996, J NEUROIMMUNOL, V67, P21, DOI 10.1016/S0165-5728(96)00030-6; MARCINKIEWICZ J, 1995, EUR J IMMUNOL, V25, P947, DOI 10.1002/eji.1830250414; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; MCMILLIAN M, 1995, BIOCHEM BIOPH RES CO, V215, P572, DOI 10.1006/bbrc.1995.2503; Meda L, 1996, J IMMUNOL, V157, P1213; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MIYAJIMA A, 1993, BLOOD, V82, P1960; MRAK RE, 1995, HUM PATHOL, V26, P816, DOI 10.1016/0046-8177(95)90001-2; MURPHY GM, 1993, J NEUROSCI RES, V35, P643, DOI 10.1002/jnr.490350607; NOHAVA K, 1992, EUR J IMMUNOL, V22, P2539, DOI 10.1002/eji.1830221012; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; Personett DA, 1996, J NEUROSCI METH, V65, P77, DOI 10.1016/0165-0270(95)00150-6; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7; SAWADA M, 1990, BRAIN RES, V509, P119, DOI 10.1016/0006-8993(90)90317-5; SEBIRE G, 1993, J IMMUNOL, V150, P1517; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SHADDUCK RK, 1993, EXP HEMATOL, V21, P515; SHAFITZAGARDO B, 1993, INT J DEV NEUROSCI, V11, P189, DOI 10.1016/0736-5748(93)90078-R; Sheng JG, 1997, ACTA NEUROPATHOL, V94, P1, DOI 10.1007/s004010050664; Singh VK, 1997, J PSYCHIAT RES, V31, P657, DOI 10.1016/S0022-3956(97)00023-X; Smith MA, 1997, J NEUROSCI, V17, P2653; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; THERY C, 1992, J NEUROCHEM, V59, P1183, DOI 10.1111/j.1471-4159.1992.tb08366.x; VIGNE P, 1993, BRAIN RES, V606, P332, DOI 10.1016/0006-8993(93)91003-B; WALKER DG, 1995, J NEUROSCI RES, V40, P478, DOI 10.1002/jnr.490400407; Wishnok JS, 1996, METHOD ENZYMOL, V268, P130; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	62	107	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20967	20971		10.1074/jbc.273.33.20967	http://dx.doi.org/10.1074/jbc.273.33.20967			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694846	hybrid			2022-12-25	WOS:000075386100039
J	Okkenhaug, K; Rottapel, R				Okkenhaug, K; Rottapel, R			Grb2 forms an inducible protein complex with CD28 through a Src homology 3 domain-proline interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; RECEPTOR TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE ASSOCIATION; GUANINE-NUCLEOTIDE EXCHANGE; LYMPHOCYTE SURFACE-RECEPTOR; C-CBL PROTOONCOGENE; SH3 DOMAIN; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; COSTIMULATORY RECEPTOR	CD28 provides a costimulatory signal that results in optimal activation of T cells. The signal transduction pathways necessary for CD28-mediated co-stimulation are presently unknown. Engagement of CD28 leads to its tyrosine phosphorylation and subsequent binding to Src homology 2 (SH2)-containing proteins including the p85 subunit of phosphatidylinositol 3'-kinase (PI3K); however, the contribution of PI3K to CD28-dependent costimulation remains controversial. Here we show that CD28 is capable of binding the Src homology 3 (SH3) domains of several proteins, including Grb2. The interaction between Grb2 and CD28 is mediated by the binding of Grb2-SH3 domains to the C-terminal diproline motif present in the cytoplasmic domain of CD28. While the affinity of the C-terminal SH3 domain of Grb2 for CD28 is greater than that of the N-terminal SH3 domain, optimal binding requires both SH3 domains. Ligation of CD28, but not tyrosine-phosphorylation, is required for the SH3-mediated binding of Grb2 to CD28. We propose a model whereby the association of Grb2 with CD28 occurs via an inducible SH3-mediated interaction and leads to the recruitment of tyrosine-phosphorylated proteins such as p52(shc) bound to the SH2 domain of Grb2. The inducible interaction of Grb2 to the C-terminal region of CD28 may form the basis for PI3K-independent signaling through CD28.	Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 1A2, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A2, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto	Okkenhaug, K (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	Rottapel@oci.utoronto.ca	Okkenhaug, Klaus/H-3154-2019; Okkenhaug, Klaus/D-5149-2012	Okkenhaug, Klaus/0000-0002-9432-4051; Okkenhaug, Klaus/0000-0002-9432-4051; Rottapel, Robert/0000-0002-6024-5558				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Boussiotis VA, 1996, J EXP MED, V184, P365, DOI 10.1084/jem.184.2.365; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BOUSSIOTIS VA, 1993, J EXP MED, V178, P1753, DOI 10.1084/jem.178.5.1753; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI YC, 1995, IMMUNITY, V3, P417, DOI 10.1016/1074-7613(95)90171-X; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; CROOKS MEC, 1995, MOL CELL BIOL, V15, P6820; DEN HJ, 1996, EMBO J, V15, P3016; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gibson S, 1996, J BIOL CHEM, V271, P7079, DOI 10.1074/jbc.271.12.7079; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HUTCHCROFT JE, 1994, P NATL ACAD SCI USA, V91, P3260, DOI 10.1073/pnas.91.8.3260; Hutchcroft JE, 1996, J BIOL CHEM, V271, P13362, DOI 10.1074/jbc.271.23.13362; HUTCHCROFT JE, 1995, P NATL ACAD SCI USA, V92, P8808, DOI 10.1073/pnas.92.19.8808; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kim HH, 1998, J BIOL CHEM, V273, P296, DOI 10.1074/jbc.273.1.296; Klasen S, 1998, INT IMMUNOL, V10, P481, DOI 10.1093/intimm/10.4.481; LAHESMAA R, 1995, J IMMUNOL, V155, P3815; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LIU Y, 1992, P NATL ACAD SCI USA, V89, P3845, DOI 10.1073/pnas.89.9.3845; LU YL, 1992, J IMMUNOL, V149, P24; LU YL, 1995, EUR J IMMUNOL, V25, P533, DOI 10.1002/eji.1830250234; LU YL, 1994, EUR J IMMUNOL, V24, P2732, DOI 10.1002/eji.1830241124; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Marengere LEM, 1997, J IMMUNOL, V159, P3220; MAROC N, 1993, ONCOGENE, V8, P909; McGuire KL, 1997, J IMMUNOL, V159, P1319; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; Noel PJ, 1996, J IMMUNOL, V157, P636; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; Pages F, 1996, J BIOL CHEM, V271, P9403, DOI 10.1074/jbc.271.16.9403; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; Radvanyi LG, 1996, J IMMUNOL, V156, P1788; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHAPIROVS, 1997, MOL CELL BIOL, V17, P4051; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SPERLING AI, 1995, J EXP MED, V182, P139, DOI 10.1084/jem.182.1.139; STEIN PH, 1994, MOL CELL BIOL, V14, P3392, DOI 10.1128/MCB.14.5.3392; Truitt KE, 1996, J IMMUNOL, V156, P4539; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; WARD SG, 1995, EUR J IMMUNOL, V25, P526, DOI 10.1002/eji.1830250233; WEISS A, 1986, J IMMUNOL, V137, P819; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	78	58	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21194	21202		10.1074/jbc.273.33.21194	http://dx.doi.org/10.1074/jbc.273.33.21194			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694876	hybrid			2022-12-25	WOS:000075386100069
J	Strack, S; Colbran, RJ				Strack, S; Colbran, RJ			Autophosphorylation-dependent targeting of calcium/calmodulin-dependent protein kinase II by the NR2B subunit of the N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; POSTSYNAPTIC DENSITY PROTEIN; GLUTAMATE RECEPTORS; NMDA RECEPTORS; CALCIUM; PHOSPHORYLATION; EXPRESSION; SYNAPSES; IDENTIFICATION; PHOSPHATASE-1	Activation and Thr(286) autophosphorylation of calcium/calmodulindependent kinase II (CaMKII) following Ca2+ influx via N-methyl-D-aspartate (NMDA)-type glutamate receptors is essential for hippocampal long term potentiation (LTP), a widely investigated cellular model of learning and memory. Here, we show that NR2B, but not NR2A or NR1, subunits of NMDA receptors are responsible for autophosphorylation-dependent targeting of CaMKII. CaMKII and NMDA receptors colocalize in neuronal dendritic spines, and a CaMKII.NMDA receptor complex can be isolated from brain extracts. Autophosphorylation induces direct high-affinity binding of CaMKII to a 50 amino acid domain in the NR2B cytoplasmic tail; little or no binding is observed to NR2A and NR1 cytoplasmic tails. Specific colocalization of CaMKII with NR2B-containing NMDA receptors in transfected cells depends on receptor activation, Ca2+ influx, and Thr(286) autophosphorylation. Translocation of CaMKII because of interaction with the NMDA receptor Ca2+ channel may potentiate kinase activity and provide exquisite spatial and temporal control of postsynaptic substrate phosphorylation.	Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Colbran, RJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA.	roger.colbran@mcmail.vanderbilt.edu	Colbran, Roger/AAU-7708-2021	Colbran, Roger/0000-0001-7401-8244; Strack, Stefan/0000-0002-6175-7280	NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NIGMS NIH HHS [GM47973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593, P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047973] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Buchs PA, 1996, P NATL ACAD SCI USA, V93, P8040, DOI 10.1073/pnas.93.15.8040; Colbran RJ, 1997, J NEUROCHEM, V69, P920; DOSEMECI A, 1993, J NEUROCHEM, V61, P550; Flint AC, 1997, J NEUROSCI, V17, P2469; FONG YL, 1989, J BIOL CHEM, V264, P16759; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; GEINISMAN Y, 1991, BRAIN RES, V566, P77, DOI 10.1016/0006-8993(91)91683-R; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Grant ER, 1997, J BIOL CHEM, V272, P647; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; LOVINGER DM, 1995, J PHARMACOL EXP THER, V274, P164; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; Otmakhov N, 1997, J NEUROSCI, V17, P5357; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; Rema V, 1996, J COMP NEUROL, V368, P165; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Shi J, 1997, J NEUROSCI, V17, P6264; SHIELDS SM, 1985, J NEUROSCI, V5, P3414; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SODERLING TR, 1995, ADV SEC MESS PHOSPH, V30, P175; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; Strack S, 1997, J NEUROCHEM, V68, P2119; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	32	353	365	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20689	20692		10.1074/jbc.273.33.20689	http://dx.doi.org/10.1074/jbc.273.33.20689			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694809	hybrid			2022-12-25	WOS:000075386100002
J	Uhlik, M; Good, L; Xiao, GT; Harhaj, EW; Zandi, E; Karin, M; Sun, SC				Uhlik, M; Good, L; Xiao, GT; Harhaj, EW; Zandi, E; Karin, M; Sun, SC			NF-kappa B-inducing kinase and I kappa B kinase participate in human T-cell leukemia virus I tax-mediated NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HTLV-I; TRANSACTIVATOR TAX; DNA-BINDING; TRANSCRIPTIONAL ACTIVATOR; 21-BASE-PAIR REPEATS; LYMPHOMA VIRUS; BZIP PROTEINS; ALPHA; TRANSFORMATION; DEGRADATION	The tax gene product of human T-cell leukemia virus I induces aberrant expression of various cellular genes, which contributes to transformation of host cells. Induction of many Tax target genes is mediated through transcription factor NF-kappa B. Here we show that Tax triggers activation of cellular protein kinases, I kappa B kinase alpha (IKK alpha) and IKK beta, which phosphorylate the NF-kappa B inhibitory protein I kappa B alpha, resulting in its degradation and NF-kappa B activation. Constitutive IKK activation occurs in both Tax-transfected and human T-cell leukemia virus I-infected T cells. We further demonstrate that Tax-mediated NF-kappa B signaling also requires the NF-kappa B-inducing kinase (NIK). Consistently, inactive forms of either IKKs or NIK. attenuate Tax-mediated NF-kappa B activation. Therefore, Tax activates NF-kappa B by targeting cellular signaling molecules, including both IKKs and NIK.	Penn State Univ, Coll Med, Dept Immunol & Microbiol, Hershey, PA 17033 USA; Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of California System; University of California San Diego	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Immunol & Microbiol, 500 Univ Dr, Hershey, PA 17033 USA.				NATIONAL CANCER INSTITUTE [F32CA071108, R01CA068471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006376] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA 71108-01A1, 1 R01 CA68471-03] Funding Source: Medline; NIEHS NIH HHS [ES06376-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GAZDAR AF, 1980, BLOOD, V55, P409; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; GRILLI M, 1993, INT REV CYTOL, V143, P1; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; KANNO T, 1995, J BIOL CHEM, V270, P11745, DOI 10.1074/jbc.270.20.11745; KOEFFLER HP, 1984, BLOOD, V64, P482; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MAGGIRWAR SB, 1995, ONCOGENE, V11, P993; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERL S, 1984, BLOOD, V64, P967; MIYOSHI I, 1981, GANN, V72, P978; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PERSAUD D, 1995, J VIROL, V69, P6297, DOI 10.1128/JVI.69.10.6297-6303.1995; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1996, MOL CELL BIOL, V16, P1058; SUZUKI T, 1994, ONCOGENE, V9, P3099; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WORONICZ JD, 1997, SCIENCE, V278, P868; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	59	145	146	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21132	21136		10.1074/jbc.273.33.21132	http://dx.doi.org/10.1074/jbc.273.33.21132			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694868	hybrid			2022-12-25	WOS:000075386100061
J	Dumonteil, E; Laser, B; Constant, I; Philippe, J				Dumonteil, E; Laser, B; Constant, I; Philippe, J			Differential regulation of the glucagon and insulin I gene promoters by the basic helix-loop-helix transcription factors E47 and BETA2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; ENHANCER-BINDING PROTEINS; DNA-BINDING; E-BOX; ELEMENTS; COMPLEXES; SEQUENCES; MYOD; E2A; REGION	The insulin and glucagon genes are expressed in the beta and alpha cells of the islets of Langerhans, respectively, The factors controlling their cell- and islet-specific expression are poorly known. Insulin-enhancer factor-1 (IEF1) has previously been shown to interact with the E boxes of the rat insulin I and II genes and was proposed to play a critical role in beta cell-specific expression. BETA2, a recently identified basic helix-loop-helix (bHLH) protein, binds with high affinity and transactivates the rat insulin II gene upon dimerization with the ubiquitous bHLH protein E47, We show here that the heterodimer E47/BETA2 also binds and transactivates the rat insulin I and glucagon genes and exhibits the same characteristics as IEF1. In transfection experiments, the E boxes of the insulin I and glucagon genes confer transcriptional activity in both insulin- and glucagon-producing cells, which is increased by overexpression of E47 and BETA2, However, overexpression of E47 inhibits only E box-mediated glucagon gene expression, whereas it activates insulin gene transcription, indicating that the E boxes of the insulin and glucagon genes display gene-specific characteristics. We conclude that the heterodimer E47/BETA2 represents an islet-specific factor that controls both insulin and glucagon gene transcription and that the E47/BETA2 ratio may be important for regulated gene expression.	Ctr Med Univ, Unite Diabetol Clin, CH-1211 Geneva 4, Switzerland	University of Geneva	Philippe, J (corresponding author), Ctr Med Univ, Unite Diabetol Clin, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	Philippe@cmu.unige.ch		Dumonteil, Eric/0000-0001-9376-0209				APONE S, 1995, J BIOL CHEM, V270, P21420, DOI 10.1074/jbc.270.36.21420; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CORDIERBUSSAT M, 1995, MOL CELL BIOL, V15, P3904; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; DANDOYDRON F, 1991, NUCLEIC ACIDS RES, V19, P4925, DOI 10.1093/nar/19.18.4925; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; DRUCKER DJ, 1987, T ASS AM PHYSICIAN C, P109; Dumonteil E, 1996, DIABETES METAB, V22, P164; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; ERICKSON JW, 1993, GENE DEV, V7, P1688, DOI 10.1101/gad.7.9.1688; FISCHER F, 1992, EMBO J, V11, P4103; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HWUNG YP, 1990, MOL CELL BIOL, V10, P1784, DOI 10.1128/MCB.10.4.1784; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KARLSSON O, 1989, MOL CELL BIOL, V9, P823, DOI 10.1128/MCB.9.2.823; LASER B, 1997, ADV MOL CELLULAR END, V1, P203; Miyamoto A, 1996, MOL CELL BIOL, V16, P2394; MOREL C, 1995, J BIOL CHEM, V270, P3046, DOI 10.1074/jbc.270.7.3039; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; OHLSSON H, 1988, P NATL ACAD SCI USA, V85, P4228, DOI 10.1073/pnas.85.12.4228; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; PEYTON M, 1994, J BIOL CHEM, V269, P25936; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Sloan SR, 1996, MOL CELL BIOL, V16, P6900; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; VIERRA CA, 1995, MOL ENDOCRINOL, V9, P64, DOI 10.1210/me.9.1.64; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WEINTRAUB H, 1994, GENE DEV, V8, P2203, DOI 10.1101/gad.8.18.2203; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1	40	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19945	19954		10.1074/jbc.273.32.19945	http://dx.doi.org/10.1074/jbc.273.32.19945			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685329	hybrid			2022-12-25	WOS:000075305400006
J	Itoh, T; Ijuin, T; Takenawa, T				Itoh, T; Ijuin, T; Takenawa, T			A novel phosphatidylinositol-5-phosphate 4-kinase (phosphatidylinositol-phosphate kinase II gamma) is phosphorylated in the endoplasmic reticulum in response to mitogenic signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-PHOSPHATE 5-KINASE; GTP ANALOGS; 4,5-BISPHOSPHATE; CELLS; POLYPHOSPHOINOSITIDES; PLATELETS; ISOFORMS; FAMILY; RHO	Here, we identify a novel rat phosphatidylinositol-5-phosphate 4-kinase, phosphatidylinositol-phosphate kinase II gamma (PIPKII gamma). PIPKII gamma comprises 420 amino acids with a molecular mass of 47,048 Ha, showing greater homology to the type II alpha and II beta isoforms (61.1 and 63.7% amino acid identities, respectively) of phosphatidylinositol-phosphate kinase than to the type I isoforms. It is predominantly expressed in kidney, with low expression in almost all other tissues. PIPKII gamma was found to have phosphatidylinositol-5-phosphate 4-kinase activity as demonstrated in other type II kinases such as PIPKII alpha. The PIPKII gamma that is present endogenously in rat fibroblasts, PC12 cells, and rat whole brain lysate or that is exogenously overexpressed in COS-7 cells shows a doublet migrating pattern on SDS-polyacrylamide gel electrophoresis. Alkaline phosphatase treatment and metabolic labeling in [P-32]orthophosphate experiments revealed that PIPKII gamma is phosphorylated in vivo, resulting in a shift in its electrophoretic mobility. Phosphorylation is induced by treatment of mitogens such as serum and epidermal growth factor. Immunostaining experiments and subcellular fractionation revealed that PIPKII gamma localizes dominantly in the endoplasmic reticulum (ER). Phosphorylation also occurs in the ER. Thus, PIPKII gamma may have an important role in the synthesis of phosphatidylinositol bisphosphate in the ER.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 108, Japan	University of Tokyo	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 108, Japan.	takenawa@ims.u-tokyo.ac.jp	Ijuin, Takeshi/H-7016-2017	Ijuin, Takeshi/0000-0002-0618-1776				BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; Carvajal JJ, 1996, NAT GENET, V14, P157, DOI 10.1038/ng1096-157; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HALENDA SP, 1984, BIOCHEM BIOPH RES CO, V124, P507, DOI 10.1016/0006-291X(84)91583-3; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HELMS JB, 1991, J BIOL CHEM, V266, P21368; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; Hinchliffe KA, 1998, BIOCHEM J, V329, P115; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; LUNDBERG GA, 1988, FEBS LETT, V240, P171, DOI 10.1016/0014-5793(88)80362-4; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MORRIS SJ, 1990, BIOCHIM BIOPHYS ACTA, V1022, P339, DOI 10.1016/0005-2736(90)90283-T; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; PAYRASTRE B, 1990, BIOCHEM J, V272, P665, DOI 10.1042/bj2720665; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; SCHACHT J, 1978, J LIPID RES, V19, P1063; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; SMITH CD, 1989, J BIOL CHEM, V264, P3206; STEPHENS L, 1993, BIOCHEM J, V296, P481, DOI 10.1042/bj2960481; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; URUMOW T, 1990, FEBS LETT, V264, P15; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236	28	71	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20292	20299		10.1074/jbc.273.32.20292	http://dx.doi.org/10.1074/jbc.273.32.20292			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685379	hybrid			2022-12-25	WOS:000075305400056
J	Pap, M; Cooper, GM				Pap, M; Cooper, GM			Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EMBRYOS; GROWTH-FACTOR; INHIBITION; APOPTOSIS; INSULIN; REQUIREMENT; WORTMANNIN; ACTIVATION; EXPRESSION; PROTEASE	Growth factor-dependent survival of a variety of mammalian cells is dependent on the activation of phosphatidylinositol (PI) 3-kinase and its downstream effector, the protein kinase Akt. Glycogen synthase kinase-3 (GSK-3) has been previously identified as a physiological target of Akt, which is inhibited by phosphorylation, so we have investigated the role of GSK-3 in cell survival. Overexpression of catalytically active GSK-3 induced apoptosis of both Rat-1 and PC12 cells, whereas dominant-negative GSK-3 prevented apoptosis following inhibition of PI 3-kinase. GSK-3 thus plays a critical role in regulation of apoptosis and represents a key downstream target of the PI 3-kinase/Akt survival signaling pathway.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Cooper, GM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.	gmcooper@bio.bu.edu	Roszak, Joanna/F-4003-2010		NCI NIH HHS [R01 CA18689] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; CAI YC, 1995, IMMUNITY, V3, P417, DOI 10.1016/1074-7613(95)90171-X; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEMELLO SR, 1997, J NEUROSCI, V17, P1548; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; GonzalezGarcia A, 1997, J BIOL CHEM, V272, P10220; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Miller TM, 1997, J BIOL CHEM, V272, P9847; Minshall C, 1996, J IMMUNOL, V156, P939; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PESO LD, 1997, SCIENCE, V278, P687; PIERCE SB, 1995, DEVELOPMENT, V121, P755; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	35	922	965	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19929	19932		10.1074/jbc.273.32.19929	http://dx.doi.org/10.1074/jbc.273.32.19929			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685326	hybrid			2022-12-25	WOS:000075305400003
J	Thuerauf, DJ; Arnold, ND; Zechner, D; Hanford, DS; DeMartin, KM; McDonough, PM; Prywes, R; Glembotski, CC				Thuerauf, DJ; Arnold, ND; Zechner, D; Hanford, DS; DeMartin, KM; McDonough, PM; Prywes, R; Glembotski, CC			p38 mitogen-activated protein kinase mediates the transcriptional induction of the atrial natriuretic factor gene through a serum response element - a potential role for the transcription factor ATF6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN PROMOTER; DNA-BINDING ACTIVITY; MAP KINASE; TERNARY COMPLEX; GROWTH; PATHWAYS; SRF; EXPRESSION; STRESS; 3PK	In various cell types certain stresses can stimulate p38 mitogen-activated protein kinase (p38 MAPK), leading to the transcriptional activation of genes that contribute to appropriate compensatory responses, In this report the mechanism of p38-activated transcription was studied in cardiac myocytes where this MAPK is a key regulator of the cell growth and the cardiac-specific gene induction that occurs in response to potentially stressful stimuli. In the cardiac atrial natriuretic factor (ANF) gene, a promoter-proximal serum response element (SRE), which binds serum response factor (SRF), was shown to be critical for ANF induction in primary cardiac myocytes transfected with the selective p38 MAPK activator, MKK6 (Glu). This ANF SRE does not possess sequences typically required for the binding of the Ets-related ternary complex factors (TCFs), such as Elk-l, indicating that p38-mediated induction through this element may take place independently of such TCFs. Although p38 did not phosphorylate SRF in vitro, it efficiently phosphorylated ATF6, a newly discovered SRF-binding protein that is believed to serve as a coactivator of SRF-inducible transcription at SREs, Expression of an ATF6 antisense RNA blocked p38-mediated ANF induction through the ANF SRE. Moreover, when fused to the Gal4 DNA-binding domain, an N-terminal 273-amino acid fragment of ATF6 was sufficient to support trans-activation of Gal4/luciferase expression in response to p38 but not the other stress kinase, N-terminal Jun kinase (JNK); p38-activating cardiac growth promoters also stimulated ATF6 trans-activation. These results indicate that through ATF6, p38 can augment SRE-mediated transcription independently of Ets-related TCFs, representing a novel mechanism of SRF-dependent transcription by MAP kinases.	San Diego State Univ, Dept Biol, Inst Mol Biol, San Diego, CA 92182 USA	California State University System; San Diego State University	Glembotski, CC (corresponding author), San Diego State Univ, Dept Biol, Inst Mol Biol, San Diego, CA 92182 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056861, P01HL046345] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46345, HL-56861] Funding Source: Medline; NINDS NIH HHS [NS/HL-25073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MOSS JB, 1994, J BIOL CHEM, V269, P12731; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Sithanandam G, 1996, MOL CELL BIOL, V16, P868; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thuerauf DJ, 1997, J BIOL CHEM, V272, P7464, DOI 10.1074/jbc.272.11.7464; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	39	105	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20636	20643		10.1074/jbc.273.32.20636	http://dx.doi.org/10.1074/jbc.273.32.20636			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685422	hybrid			2022-12-25	WOS:000075305400099
J	Wang, JY; Frenzel, KE; Wen, DZ; Falls, DL				Wang, JY; Frenzel, KE; Wen, DZ; Falls, DL			Transmembrane neuregulins interact with LIM kinase 1, a cytoplasmic protein kinase implicated in development of visuospatial cognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU DIFFERENTIATION FACTOR; GLIAL GROWTH-FACTOR; ZINC-FINGER; NERVOUS-SYSTEM; NEUROMUSCULAR-JUNCTIONS; WILLIAMS-SYNDROME; TGF-ALPHA; RECEPTOR; GENE; IDENTIFICATION	The neuregulins are receptor tyrosine kinase ligands that play a critical role in the development of the heart, nervous system, and breast, Unlike many extracellular signaling molecules, such as the neurotrophins, most neuregulins are synthesized as transmembrane proteins. To determine the functions of the highly conserved neuregulin cytoplasmic tail, a yeast two-hybrid screen was performed to identify proteins that interact with the 157-amino acid sequence common to the cytoplasmic tails of all transmembrane neuregulin isoforms, This screen revealed that the neuregulin cytoplasmic tail interacts with the LIM domain region of the nonreceptor protein kinase LIM kinase 1 (LLMK1). Interaction between the neuregulin cytoplasmic tail and full-length LIMK1 was demonstrated by in vitro binding and coimmunoprecipitation assays, Transmembrane neuregulins with each of the three known neuregulin cytoplasmic tail isoforms interacted with LIMK1. In contrast, the cytoplasmic tail of TGF-alpha did not interact with LIMK1. In vivo, neuregulin and LIMK1 are co-localized at the neuromuscular synapse, suggesting that LIMK1, like neuregulin, may play a role in synapse formation and maintenance. To our knowledge, LIMK1 is the first identified protein shown to interact with the cytoplasmic tail of a receptor tyrosine kinase ligand.	Emory Univ, Dept Biol, Atlanta, GA 30322 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	Emory University; Amgen	Falls, DL (corresponding author), Emory Univ, Dept Biol, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM056337] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 56337] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartel P.L., 1993, CELLULAR INTERACTION; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; Bosenberg MW, 1993, CURR OPIN CELL BIOL, V5, P832, DOI 10.1016/0955-0674(93)90032-L; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Burden SJ, 1998, GENE DEV, V12, P133, DOI 10.1101/gad.12.2.133; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; Busfield SJ, 1997, MOL CELL BIOL, V17, P4007, DOI 10.1128/MCB.17.7.4007; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Carraway KL, 1996, BIOESSAYS, V18, P263, DOI 10.1002/bies.950180403; Carroll SL, 1997, J NEUROSCI, V17, P1642; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CHEN MS, 1994, J COMP NEUROL, V349, P389, DOI 10.1002/cne.903490306; CHENG AK, 1995, MECH DEVELOP, V52, P187, DOI 10.1016/0925-4773(95)00400-U; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; Frangiskakis JM, 1996, CELL, V86, P59, DOI 10.1016/S0092-8674(00)80077-X; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Gassmann M, 1997, CURR OPIN NEUROBIOL, V7, P87, DOI 10.1016/S0959-4388(97)80125-0; GOODEARL ADJ, 1993, J BIOL CHEM, V268, P18095; GOODEARL ADJ, 1995, J CELL BIOL, V130, P1423, DOI 10.1083/jcb.130.6.1423; Grimm S, 1997, J EXP MED, V185, P1137, DOI 10.1084/jem.185.6.1137; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Higuchi O, 1996, FEBS LETT, V396, P81, DOI 10.1016/0014-5793(96)01072-1; Higuchi O, 1997, ONCOGENE, V14, P1819, DOI 10.1038/sj.onc.1201020; Hiraoka J, 1996, FEBS LETT, V399, P117, DOI 10.1016/S0014-5793(96)01303-8; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; Kopp DM, 1997, J NEUROSCI, V17, P6697; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; LU HS, 1995, J BIOL CHEM, V270, P4775, DOI 10.1074/jbc.270.9.4775; LUPA MT, 1989, J NEUROSCI, V9, P3937; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MATSUDAIRA P, 1993, PRACTICAL GUIDE PROT, P49; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MIZUNO K, 1994, ONCOGENE, V9, P1605; Monaco AP, 1996, CURR BIOL, V6, P1396, DOI 10.1016/S0960-9822(96)00740-3; Mori T, 1997, MOL BRAIN RES, V45, P247, DOI 10.1016/S0169-328X(96)00257-4; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; Ng YP, 1997, MOL CELL NEUROSCI, V9, P132, DOI 10.1006/mcne.1997.0613; NUNOUE K, 1995, ONCOGENE, V11, P701; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PFEFFER S, 1985, NATURE, V313, P184, DOI 10.1038/313184a0; PROSCHEL C, 1995, ONCOGENE, V11, P1271; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SANDROCK AW, 1995, J NEUROSCI, V15, P6124; Shum L, 1996, J BIOL CHEM, V271, P28502, DOI 10.1074/jbc.271.45.28502; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; Tassabehji M, 1996, NAT GENET, V13, P272, DOI 10.1038/ng0796-272; Trachtenberg JT, 1996, NATURE, V379, P174, DOI 10.1038/379174a0; Trachtenberg JT, 1997, J NEUROSCI, V17, P6243; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; Verdi JM, 1996, NEURON, V16, P515, DOI 10.1016/S0896-6273(00)80071-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Yang X, 1998, NEURON, V20, P255, DOI 10.1016/S0896-6273(00)80454-7; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x	71	59	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20525	20534		10.1074/jbc.273.32.20525	http://dx.doi.org/10.1074/jbc.273.32.20525			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685409	hybrid			2022-12-25	WOS:000075305400086
J	Chacko, G; Ling, Q; Hajjar, KA				Chacko, G; Ling, Q; Hajjar, KA			Induction of acute translational response genes by homocysteine - Elongation factors-1 alpha, -beta, and -delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-1-GAMMA MESSENGER-RNA; PROTEIN-C ACTIVATION; SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; PLASMINOGEN-ACTIVATOR; FACTOR EF-1-ALPHA; VASCULAR-DISEASE; ANNEXIN-II; ENDOPLASMIC-RETICULUM; DIFFERENTIAL DISPLAY	The thiol amino acid homocysteine (HC) accumulates in homocystinuria and homocyst(e)inemia, and is associated with a wide variety of clinical manifestations. To determine whether HC influences the cell's program of gene expression, vascular endothelial cells were treated with HC for 6-42 h and analyzed by differential display. We found a 3-7-fold, time-dependent induction of a 220-base pair fragment, which demonstrated complete sequence identity with elongation factor-1 delta (EF-1 delta), a member of the multimeric complex regulating mRNA translation. Fibroblasts from cystathionine beta-synthase -/- individuals also showed up to 3.0-fold increased levels of mRNA for EF-1 alpha, -beta, and -delta when compared with normal cells, and treatment of normal cells with the HC precursor, methionine, induced a 1.5-2.0-fold increase in EF-1 alpha, -beta, and -delta mRNA. This induction was completely inhibited by cycloheximide and reflected a doubling in the rate of gene transcription in nuclear run-on analyses. In HC-treated endothelial cells, pulse-chase studies revealed a doubling in the rate of synthesis of the thiol-containing protein, annexin II, but no change in synthesis of the cysteineless protein, plasminogen activator inhibitor-1. Thus, HC induces expression of a family of acute translational response genes through a protein synthesis-dependent transcriptional mechanism. This process may mediate accelerated synthesis of free thiol-containing proteins in response to HC-induced oxidative stress.	Cornell Univ, Coll Med, Dept Pediat, Div Hematol Oncol, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Med, Div Hematol Oncol, New York, NY 10021 USA	Cornell University; Cornell University	Hajjar, KA (corresponding author), Cornell Univ, Coll Med, Dept Pediat, Div Hematol Oncol, 1300 York Ave,Box 45, New York, NY 10021 USA.	khajjar@mail.med.cornell.edu			NHLBI NIH HHS [HL 46403, HL 42493, HL 58981] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042493, P01HL046403, R01HL058981] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Blazquez M, 1996, J BIOL CHEM, V271, P18638, DOI 10.1074/jbc.271.31.18638; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Burger A, 1996, J MOL BIOL, V257, P839, DOI 10.1006/jmbi.1996.0205; CAVALLIUS J, 1986, EXP GERONTOL, V21, P149, DOI 10.1016/0531-5565(86)90068-9; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327; GOLDSTRAW P, 1992, DIAGN ONCOL, V2, P9; GONEN H, 1994, P NATL ACAD SCI USA, V91, P7648, DOI 10.1073/pnas.91.16.7648; GRANT AG, 1992, INT J CANCER, V50, P740, DOI 10.1002/ijc.2910500513; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HABBEN JE, 1995, P NATL ACAD SCI USA, V92, P8640, DOI 10.1073/pnas.92.19.8640; Hajjar KA, 1998, J BIOL CHEM, V273, P9987, DOI 10.1074/jbc.273.16.9987; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; HUANG LE, 1994, J BIOL CHEM, V269, P30718; JUNG M, 1994, CANCER RES, V54, P2541; Kato MV, 1997, BLOOD, V90, P1373, DOI 10.1182/blood.V90.4.1373.1373_1373_1378; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; KRAUS JP, 1994, J INHERIT METAB DIS, V17, P383, DOI 10.1007/BF00711354; LENTZ SR, 1993, BLOOD, V81, P683; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Loscalzo J, 1996, J CLIN INVEST, V98, P5, DOI 10.1172/JCI118776; MCCULLY KS, 1993, ANN CLIN LAB SCI, V23, P477; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; MIMORI K, 1995, CANCER, V75, P1446, DOI 10.1002/1097-0142(19950315)75:6+<1446::AID-CNCR2820751509>3.0.CO;2-P; Mimori K, 1996, GUT, V38, P66, DOI 10.1136/gut.38.1.66; MORRIS DR, 1995, PROG NUCLEIC ACID RE, V51, P339, DOI 10.1016/S0079-6603(08)60883-1; MUDD SH, 1985, AM J HUM GENET, V37, P1; MUDD SH, 1995, METABOLIC MOL BASES, V1, P1279; PATTON WF, 1995, J BIOL CHEM, V270, P21404, DOI 10.1074/jbc.270.36.21404; PROUD CG, 1994, MOL BIOL REP, V19, P161, DOI 10.1007/BF00986958; RATAN RR, 1994, J NEUROSCI, V14, P4385; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RIJKEN DC, 1986, J BIOL CHEM, V261, P3098; RODGERS GM, 1990, BLOOD, V75, P895; SAMBROOK J, 1989, MOL CLONING, V1, P7; Sanders J, 1996, J CELL SCI, V109, P1113; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHEPHERD JCW, 1989, P NATL ACAD SCI USA, V86, P7520, DOI 10.1073/pnas.86.19.7520; SONG JM, 1989, MOL CELL BIOL, V9, P4571, DOI 10.1128/MCB.9.10.4571; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; TANIGUCHI S, 1991, NUCLEIC ACIDS RES, V19, P6949, DOI 10.1093/nar/19.24.6949; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; Tsai JC, 1996, J CLIN INVEST, V97, P146, DOI 10.1172/JCI118383; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; Voller A., 1976, AM SOC MICROBIOL, V17, P506; WAKABAYASHIITO N, 1994, J BIOL CHEM, V269, P29831; Wang H, 1997, J BIOL CHEM, V272, P25380, DOI 10.1074/jbc.272.40.25380	56	24	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19840	19846		10.1074/jbc.273.31.19840	http://dx.doi.org/10.1074/jbc.273.31.19840			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677419	hybrid			2022-12-25	WOS:000075125200071
J	Castagnino, P; Soriano, JV; Montesano, R; Bottaro, DP				Castagnino, P; Soriano, JV; Montesano, R; Bottaro, DP			Induction of tissue inhibitor of metalloproteinases-3 is a delayed early cellular response to hepatocyte growth factor	ONCOGENE			English	Article						hepatocyte growth factor; TIMP-3; metalloproteinase; cell proliferation; gene induction	ERYTHROID-POTENTIATING ACTIVITY; FACTOR SCATTER FACTOR; RECEPTOR TYROSINE KINASE; CHICKEN-EMBRYO FIBROBLASTS; MET PROTOONCOGENE PRODUCT; HUMAN SKIN FIBROBLASTS; KIDNEY-CELLS REQUIRES; TIMP GENE FAMILY; NIH 3T3 CELLS; EPITHELIAL-CELLS	Hepatocyte growth factor (HGF) stimulates mitogenic, motogenic, and morphogenic responses in various cell types. We analysed HGF-responsive cells by differential display PCR to identify HGF-induced genes that mediate these biological events. One of the genes identified encoded a member of the tissue inhibitor of metalloproteinases (TIMP) family, TIMP3. HGF transiently induced TIMP-3 mRNA in keratinocytes as well as kidney and mammary epithelial cells maximally between 4 and 6 h post-stimulation. Increased TIMP3 protein secretion returned to basal levels within 18 h, while the expression of gelatinases A and B remained unchanged, suggesting that temporary suppression of matrix degradation is a delayed early response to HGF. Ectopic overexpression of TIMP-3 in cultured leiomyosarcoma cells conferred an epithelial morphology, reduced cell growth rate, anchorage-independent growth, and matrix invasion in vitro. Antisense suppression of TIMP3 was associated with a scattered, fibroblastic cell morphology, as well as enhanced proliferation, anchorage-independent growth, and matrix invasion. A survey of tumor cell lines revealed an inverse relationship between metastatic potential and TIMP3 expression level. These data suggest that early, transient TIMP3 expression mediates specific HGF-induced phenotypic changes, and that loss of TIMP3 expression may enhance the invasion potential of certain tumors.	NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Ctr Med Univ Geneva, Dept Morphol, Geneva, Switzerland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Geneva	Bottaro, DP (corresponding author), NCI, Cellular & Mol Biol Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.		Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				ALBINI A, 1987, CANCER RES, V47, P3239; ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; AVALOS BR, 1988, BLOOD, V71, P1721; BARDELLI A, 1992, ONCOGENE, V7, P1973; BERTAUX B, 1990, PATHOL BIOL, V38, P1029; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; BLENIS J, 1984, J BIOL CHEM, V259, P1563; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DOWRICK PG, 1991, CYTOKINE, V3, P299, DOI 10.1016/1043-4666(91)90498-3; Dunsmore SE, 1996, J BIOL CHEM, V271, P24576, DOI 10.1074/jbc.271.40.24576; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GOHDA E, 1994, CYTOKINE, V6, P633, DOI 10.1016/1043-4666(94)90051-5; GOLDE DW, 1980, P NATL ACAD SCI-BIOL, V77, P593, DOI 10.1073/pnas.77.1.593; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; Hurskainen T, 1996, J HISTOCHEM CYTOCHEM, V44, P1379, DOI 10.1177/44.12.8985130; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; JONES SE, 1994, FEBS LETT, V352, P171, DOI 10.1016/0014-5793(94)00951-1; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LONGATI P, 1994, ONCOGENE, V9, P49; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; PELICCI G, 1995, ONCOGENE, V10, P1631; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PONZETTO C, 1991, J BIOL CHEM, V266, P22087; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RON D, 1993, J BIOL CHEM, V268, P2984; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SAKURAI H, 1997, AM J PHYSIOL, V272, P139; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Soloway PD, 1996, ONCOGENE, V13, P2307; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SPONSEL HT, 1994, AM J PHYSIOL, V267, pF257, DOI 10.1152/ajprenal.1994.267.2.F257; Stahl SJ, 1997, BIOCHEM J, V326, P763, DOI 10.1042/bj3260763; STASKUS PW, 1991, J BIOL CHEM, V266, P449; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; STOKER M, 1985, J CELL SCI, V77, P209; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WATANABE S, 1994, BIOCHEM BIOPH RES CO, V199, P1453, DOI 10.1006/bbrc.1994.1394; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WESTBROOK CA, 1984, J BIOL CHEM, V259, P9992; WICK M, 1994, J BIOL CHEM, V269, P18953; WOJTA J, 1994, BLOOD, V84, P151; YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; ZHU H, 1994, J BIOL CHEM, V269, P29943	81	23	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					481	492		10.1038/sj.onc.1201957	http://dx.doi.org/10.1038/sj.onc.1201957			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696042	Green Published			2022-12-25	WOS:000075043000011
J	Krosl, J; Baban, S; Krosl, G; Rozenfeld, S; Largman, C; Sauvageau, G				Krosl, J; Baban, S; Krosl, G; Rozenfeld, S; Largman, C; Sauvageau, G			Cellular proliferation and transformation induced by HOXB4 and HOXB3 proteins involves cooperation with PBX1	ONCOGENE			English	Article						oncogenes; proliferation; Hox; Pbx; cancer	HOMEODOMAIN-DNA INTERACTIONS; ACUTE MYELOID-LEUKEMIA; HOMEOBOX GENES; CRYSTAL-STRUCTURE; GROWTH-FACTOR; PRE-B; TRANSLOCATION; EXPRESSION; E2A-PBX1; BINDING	The products of PBX homeobox genes, which mere initially discovered in reciprocal translocations occurring in human leukemias, have been shown to cooperate in the in vitro DNA binding with HOX proteins. Despite the growing body of data implicating Hox genes in the development of various cancers, little is known about the role of HOX-PBX interactions in the regulation of proliferation and induction of transformation of mammalian cells. We build on the existing model of Hox-induced transformation of Rat-1 cells to show that both cellular transformation and proliferation induced by Hoxb4 and Hoxb3 are greatly modulated by the levels of available PBX1 present in these cells. Furthermore, we show that the transforming capacity of these two HOX proteins depends on their conserved tetrapeptide and homeodomain regions which mediate binding to PBX and DNA, respectively. Taken together, results of this study demonstrate that cooperation between HOX and PBX proteins modulates cellular proliferation and strongly suggest that cooperative DIVA binding by these two groups of proteins represent the basis for Hox-induced cellular transformation.	Clin Res Inst Montreal, Lab Mol Genet Hemopoiet Stem Cells, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3J 3J7, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3G 1A4, Canada; Univ Calif San Francisco, Dept Med, Vet Affairs Med Ctr, San Francisco, CA 94121 USA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Sauvageau, G (corresponding author), Clin Res Inst Montreal, Lab Mol Genet Hemopoiet Stem Cells, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.			Sauvageau, Guy/0000-0002-4333-7266				BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Care A, 1996, MOL CELL BIOL, V16, P4842; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; JIANG W, 1993, ONCOGENE, V8, P3447; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; Maconochie MK, 1997, GENE DEV, V11, P1885, DOI 10.1101/gad.11.14.1885; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NEUTEBOOM ST, 1995, P NATL ACAD SCI USA, V92, P9196; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PERKINS AC, 1993, EMBO J, V12, P3835, DOI 10.1002/j.1460-2075.1993.tb06062.x; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; ROCCO GD, 1997, EMBO J, V16, P3644; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; Shen WF, 1996, NUCLEIC ACIDS RES, V24, P898, DOI 10.1093/nar/24.5.898; SUN B, 1995, EMBO J, V14, P520, DOI 10.1002/j.1460-2075.1995.tb07028.x; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; Zhao JJG, 1996, EMBO J, V15, P1313, DOI 10.1002/j.1460-2075.1996.tb00473.x	40	71	78	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3403	3412		10.1038/sj.onc.1201883	http://dx.doi.org/10.1038/sj.onc.1201883			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692548				2022-12-25	WOS:000074544100007
J	Kohno, T; Shinmura, K; Tosaka, M; Tani, M; Kim, SR; Sugimura, H; Nohmi, T; Kasai, H; Yokota, J				Kohno, T; Shinmura, K; Tosaka, M; Tani, M; Kim, SR; Sugimura, H; Nohmi, T; Kasai, H; Yokota, J			Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA	ONCOGENE			English	Article						8-hydroxyguanine; DNA repair; genetic polymorphism; alternative splicing; hOGG1 gene	CELL LUNG-CARCINOMA; TUMOR-SUPPRESSOR GENE; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; GLYCOSYLASE; CANCER; PROTEIN; 7,8-DIHYDRO-8-OXOGUANINE; 8-OXOGUANINE; MUTATIONS	The hOGG1 gene encodes a DNA glycosylase that excises 8-hydroxyguanine (oh(8)Gua) from damaged DNA, Structural analyses of the hOGG1 gene and its transcripts were performed in normal and lung cancer cells. Due to a genetic polymorphism at codon 326, hOGG1-Ser(326) and hOGG1-Cys(326) proteins were produced in human cells. Activity in the repair of oh8Gua was greater in hOGG1-Ser(326) protein than in hOGG1-Cys(326) protein in the complementation assay of an E, coli mutant defective in the repair of oh8Gua. Two isoforms of hOGG1 transcripts produced by alternative splicing encoded distinct hOGG1 proteins: one with and the other without a putative nuclear localization signal. Loss of heterozygosity at the hOGG1 locus was frequently (15/ 23, 62.2%) detected in lung cancer cells, and a cell Line NCI-H526 had a mutation leading to the formation of the transcripts encoding a truncated hOGG1 protein. However, the oh(8)Gua levels in nuclear DNA were similar among lung cancer cells and leukocytes irrespective of the type of hOGG1 proteins expressed. These results suggest that the oh(8)Gua levels are maintained at a steady level, even though multiple hOGG1 proteins are produced due to genetic polymorphisms, mutations and alternative splicing of the hOGG1 gene.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 104, Japan; Natl Inst Hlth Sci, Div Genet & Mutagenesis, Setagaya Ku, Tokyo 158, Japan; Hamamatsu Univ Sch Med, Dept Pathol 1, Hamamatsu, Shizuoka 43131, Japan; Univ Occupat & Environm Hlth, Dept Environm Oncol, Yahatanishi Ku, Kitakyushu, Fukuoka 807, Japan	National Cancer Center - Japan; National Institute of Health Sciences - Japan; Hamamatsu University School of Medicine; University of Occupational & Environmental Health - Japan	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 104, Japan.		Shinmura, Kazuya/K-8940-2012	Shinmura, Kazuya/0000-0003-4963-746X				Aburatani H, 1997, CANCER RES, V57, P2151; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; Asami S, 1996, CANCER RES, V56, P2546; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BABA S, 1995, HUM MOL GENET, V4, P1083, DOI 10.1093/hmg/4.6.1083; BESSHO T, 1993, J BIOL CHEM, V268, P19416; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; Garuti R, 1996, J LIPID RES, V37, P1459; GAZDAR AF, 1994, ANTICANCER RES, V14, P261; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HIBI K, 1992, ONCOGENE, V7, P445; HOSOE S, 1994, LUNG CANCER-J IASLC, V10, P297, DOI 10.1016/0169-5002(94)90659-9; HUANG CH, 1993, J BIOL CHEM, V268, P25902; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; KASAI H, 1991, OXIDATIVE STRESS OXI, P99; KOHNO T, 1995, HUM MOL GENET, V4, P667, DOI 10.1093/hmg/4.4.667; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MALINS DC, 1991, CANCER RES, V51, P5430; Maniatis T., 1982, MOL CLONING LAB MANU; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; Nakajima M, 1996, CARCINOGENESIS, V17, P787, DOI 10.1093/carcin/17.4.787; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Otsuka T, 1996, GENE CHROMOSOME CANC, V16, P113, DOI 10.1002/(SICI)1098-2264(199606)16:2<113::AID-GCC5>3.0.CO;2-2; Perera FP, 1996, JNCI-J NATL CANCER I, V88, P496, DOI 10.1093/jnci/88.8.496; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Shinmura K, 1997, MUTAT RES-DNA REPAIR, V385, P75, DOI 10.1016/S0921-8777(97)00041-4; SHISEKI M, 1994, CANCER RES, V54, P5643; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; SUZUKI M, 1995, IN PRESS MUT RES; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	41	388	409	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3219	3225		10.1038/sj.onc.1201872	http://dx.doi.org/10.1038/sj.onc.1201872			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681819				2022-12-25	WOS:000074343600001
J	Xu, XM; Ng, S; Wu, ZL; Nguyen, D; Homburger, S; Seidel-Dugan, C; Ebens, A; Luo, YL				Xu, XM; Ng, S; Wu, ZL; Nguyen, D; Homburger, S; Seidel-Dugan, C; Ebens, A; Luo, YL			Human semaphorin K1 is glycosylphosphatidylinositol-linked and defines a new subfamily of viral-related semaphorins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-NERVE PROJECTION; COLLAPSIN-1 MESSENGER-RNA; GROWTH CONE GUIDANCE; SPINAL-CORD; LUNG-CANCER; MURINE SEMAPHORIN; DEVELOPING CHICK; GENE FAMILY; IN-SITU; EXPRESSION	The semaphorin family contains a large number of secreted and transmembrane proteins, some of which are known to act as repulsive axon guidance cues during development or to be involved in immune function. We report here on the identification of semaphorin K1 (sema K1), the first semaphorin known to be associated with cell surfaces via a glycosylphosphatidylinositol linkage. Sema K1 is highly homologous to a viral semaphorin and can interact with specific immune cells, suggesting that like its viral counterpart, sema K1 could play an important role in regulating immune function. Sema K1 does not bind to neuropilin-1 or neuropilin-2, the two receptors implicated in mediating the repulsive action of several secreted semaphorins, and thus it likely acts through a novel receptor. In contrast to most previously described semaphorins, sema K1 is only weakly expressed during development but is present at high levels in postnatal and adult tissues, particularly brain and spinal cord.	Exelixis Pharmaceut Inc, San Francisco, CA 94080 USA	Exelixis, Inc.	Luo, YL (corresponding author), Exelixis Pharmaceut Inc, 260 Littlefield Ave, San Francisco, CA 94080 USA.	yluo@exelixis.com						Adams RH, 1996, MECH DEVELOP, V57, P33, DOI 10.1016/0925-4773(96)00525-4; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barron KD, 1995, J NEUROL SCI, V134, P57, DOI 10.1016/0022-510X(95)00209-K; BOUGERET C, 1992, J IMMUNOL, V148, P318; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Eickholt BJ, 1997, MOL CELL NEUROSCI, V9, P358, DOI 10.1006/mcne.1997.0636; ENSSER A, 1995, J GEN VIROL, V76, P1063, DOI 10.1099/0022-1317-76-4-1063; Ensser A, 1997, J VIROL, V71, P6517, DOI 10.1128/JVI.71.9.6517-6525.1997; FAN JH, 1995, NEURON, V14, P263, DOI 10.1016/0896-6273(95)90284-8; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; Hall KT, 1996, P NATL ACAD SCI USA, V93, P11780, DOI 10.1073/pnas.93.21.11780; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kikuchi K, 1997, MOL BRAIN RES, V51, P229, DOI 10.1016/S0169-328X(97)00251-9; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kobayashi H, 1997, J NEUROSCI, V17, P8339; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Koppel AM, 1997, NEURON, V19, P531, DOI 10.1016/S0896-6273(00)80369-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; LUO YL, 1995, NEURON, V14, P1131, DOI 10.1016/0896-6273(95)90261-9; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; Puschel AW, 1996, MOL CELL NEUROSCI, V7, P419, DOI 10.1006/mcne.1996.0030; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; Roche J, 1996, ONCOGENE, V12, P1289; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Shepherd I, 1996, DEV BIOL, V173, P185, DOI 10.1006/dbio.1996.0016; Shepherd IT, 1997, DEVELOPMENT, V124, P1377; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; Spriggs MK, 1996, ANNU REV IMMUNOL, V14, P101, DOI 10.1146/annurev.immunol.14.1.101; Taniguchi M, 1997, NEURON, V19, P519, DOI 10.1016/S0896-6273(00)80368-2; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Wong JTW, 1997, DEVELOPMENT, V124, P3597; WRIGHT DE, 1995, J COMP NEUROL, V361, P321, DOI 10.1002/cne.903610209; Xiang RH, 1996, GENOMICS, V32, P39, DOI 10.1006/geno.1996.0074; Yamada T, 1997, P NATL ACAD SCI USA, V94, P14713, DOI 10.1073/pnas.94.26.14713; Yu HH, 1998, NEURON, V20, P207, DOI 10.1016/S0896-6273(00)80450-X; Zhou L, 1997, MOL CELL NEUROSCI, V9, P26, DOI 10.1006/mcne.1997.0607	48	98	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22428	22434		10.1074/jbc.273.35.22428	http://dx.doi.org/10.1074/jbc.273.35.22428			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712866	hybrid			2022-12-25	WOS:000075616600042
J	Giraudo, E; Primo, L; Audero, E; Gerber, HP; Koolwijk, P; Soker, S; Klagsbrun, M; Ferrara, N; Bussolino, F				Giraudo, E; Primo, L; Audero, E; Gerber, HP; Koolwijk, P; Soker, S; Klagsbrun, M; Ferrara, N; Bussolino, F			Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; INDUCED ANGIOGENESIS; TYROSINE KINASE; TNF-ALPHA; IN-VIVO; MOLECULAR MECHANISMS; RHEUMATOID-ARTHRITIS; VEGF RECEPTORS; MESSENGER-RNA; GLIOMA-CELLS	Tumor necrosis factor-alpha (TNF-alpha) modulates gene expression in endothelial cells and is angiogenic in vivo, TNF-alpha does not activate in vitro migration and proliferation of endothelium, and its angiogenic activity is elicited by synthesis of direct angiogenic inducers or of proteases, Here, we show that TNF-alpha up-regulates in a dose- and time-dependent manner the expression and the function of vascular endothelial growth factor receptor-2 (VEGFR-2) as well as the expression of its coreceptor neuropilin-1 in human endothelium, As inferred by nuclear run-on assay and transient expression of VEGFR-2 promoter-based reporter gene construct, the cytokine increased the transcription of the VEGFR-2 gene. Mithramycin, an inhibitor of binding of nuclear transcription factor Spl to the promoter consensus sequence, blocked activation of VEGFR-2, suggesting that the up-regulation of the receptor required Spl binding sites. TNF-alpha increased the cellular amounts of VEGFR-2 protein and tripled the high affinity I-125-VEGF-A(165) capacity without affecting the K-d of ligand-receptor interaction. As a consequence, TNF-alpha enhanced the migration and the wound healing triggered by VEGF-A(165). Since VEGFR-2 mediates angiogenic signals in endothelium, our data indicate that its up-regulation is another mechanism by which TNF-alpha is angiogenic and may provide insight into the mechanism of neovascularization as occurs in TNF-alpha-mediated pathological settings.	Univ Turin, Sch Med, Dept Genet Biol & Biochem, Vasc Biol Lab, I-10126 Turin, Italy; Genentech Inc, Dept Cardiovasc Res, S San Francisco, CA 94080 USA; Lab TNO PG, Dept Vasc & Connect Tissue Res Gaubius, NL-2333 CK Leiden, Netherlands; Harvard Univ, Childrens Hosp, Sch Med, Dept Urol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of Turin; Roche Holding; Genentech; Netherlands Organization Applied Science Research; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Bussolino, F (corresponding author), Univ Turin, Sch Med, Dept Genet Biol & Biochem, Vasc Biol Lab, I-10126 Turin, Italy.	Bussol@molinette.unito.it	Giraudo, Enrico/K-3192-2016; Giraudo, Enrico/K-6441-2019; Bussolino, Federico/AES-3951-2022; Bussolino, Federico/K-2500-2016	Giraudo, Enrico/0000-0003-4128-4786; Giraudo, Enrico/0000-0003-4128-4786; PRIMO, Luca/0000-0002-1294-0441; Bussolino, Federico/0000-0002-5348-1341; Audero, Enrica/0000-0002-6138-244X	NCI NIH HHS [CA 37392] Funding Source: Medline; PHS HHS [45548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA037392, R56CA037392, R01CA037392] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BARLEON B, 1994, J CELL BIOCHEM, V54, P56, DOI 10.1002/jcb.240540107; Basile A, 1997, J BIOL CHEM, V272, P8172, DOI 10.1074/jbc.272.13.8172; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CAMUSSI G, 1995, J IMMUNOL, V154, P6492; CAMUSSI G, 1991, EUR J BIOCHEM, V202, P3, DOI 10.1111/j.1432-1033.1991.tb16337.x; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Gaudry M, 1997, BLOOD, V90, P4153, DOI 10.1182/blood.V90.10.4153; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; KOCH AE, 1994, J IMMUNOL, V152, P4149; Koolwijk P, 1996, J CELL BIOL, V132, P1177, DOI 10.1083/jcb.132.6.1177; LEAVITT J, 1984, MOL CELL BIOL, V4, P1961, DOI 10.1128/MCB.4.10.1961; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Lupia E, 1996, EUR J IMMUNOL, V26, P1690, DOI 10.1002/eji.1830260804; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MILES DW, 1994, INT J CANCER, V56, P777, DOI 10.1002/ijc.2910560603; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377; NAWROTH P, 1986, J EXP MED, V167, P740; OKAMURA K, 1991, J BIOL CHEM, V266, P19162; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Patterson C, 1997, J BIOL CHEM, V272, P8410, DOI 10.1074/jbc.272.13.8410; Patterson C, 1996, J CLIN INVEST, V98, P490, DOI 10.1172/JCI118816; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROESSLER K, 1995, J NEUROSURG, V83, P291, DOI 10.3171/jns.1995.83.2.0291; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Sambrook J., 2002, MOL CLONING LAB MANU; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; TERMAN BI, 1991, ONCOGENE, V6, P1677; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VANHINSBERGH VWM, 1990, BLOOD, V75, P1991; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Yamamoto S, 1997, BRIT J CANCER, V76, P1221, DOI 10.1038/bjc.1997.537; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015	59	216	228	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22128	22135		10.1074/jbc.273.34.22128	http://dx.doi.org/10.1074/jbc.273.34.22128			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705358	Green Published, hybrid			2022-12-25	WOS:000075492600092
J	Griggs, DW; Schmidt, CM; Carron, CP				Griggs, DW; Schmidt, CM; Carron, CP			Characteristics of cation binding to the I domains of LFA-1 and MAC-1 - The LFA-1 I domain contains a Ca2+-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; INTEGRIN ALPHA-2-BETA-1 VLA-2; LIGAND-BINDING; LEUKOCYTE ADHESION; A-DOMAIN; EXTRACELLULAR-MATRIX; REGULATED EXPRESSION; VONWILLEBRAND-FACTOR; CRYSTAL-STRUCTURE; CR3 CD11B/CD18	The crystal structures of the I domains of integrins MAC-1 (alpha(M)beta(2); CD11lb/CD18) and LFA-1 (alpha(L)beta(2); CD11a/CD18) show that a single conserved cation-binding site is present in each protein. Purified recombinant I domains have intrinsic ligand binding activity, and in several systems this interaction has been demonstrated to be cation-dependent, It has been proposed that the I domain cation-binding site represents a general metal ion-dependent adhesion motif utilized for binding protein ligands, Here we show that the purified recombinant I domain of LFA-I (alpha(L)I) binds cations, but with significantly different characteristics compared with the I domain of MAC-1 (alpha(M)I) Both alpha(L)I and alpha(M)I bind Mn-54(2+) in a conformation-dependent manner, and in general, cations with charge and size characteristics similar to Mn2+ most effectively inhibit Mn-54(2+) binding. Surprisingly, however, physiological levels of Ca2+ (1-2 mM) inhibited Mn-54(2+) binding to purified alpha(L)I, but not to alpha(M)I. Using Ca-45(2+) and Mn-54(2+) in direct binding studies, the dissociation constants (K-D) for the interactions between these cations and alpha(L)I were estimated to be 5-6 x 10(-5) and 1-2 x 10(-5) M, respectively. Together with the available structural information, the data suggest differential affinities for Mn2+ and Ca2+ binding to the single conserved site within alpha(L)I. Antagonism of LFA-1, but not MAC-1, -mediated cell adhesion by Ca2+ may be related to the Ca2+ binding activity of the LFA-1 I domain.	Monsanto Co, Searle Res & Dev, Discovery Pharmacol, St Louis, MO 63198 USA	Monsanto; Pfizer	Carron, CP (corresponding author), Monsanto Co, Searle Res & Dev, Discovery Pharmacol, AA3C,700 Chesterfield Village Pkwy, St Louis, MO 63198 USA.							ADAMS DH, 1994, LANCET, V343, P831, DOI 10.1016/S0140-6736(94)92029-X; ALTIERI DC, 1991, J IMMUNOL, V147, P1891; ARNAOUT MA, 1990, BLOOD, V75, P1037; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; COLOMBATTI A, 1991, BLOOD, V77, P2305; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; GRAHAM IL, 1991, J IMMUNOL, V146, P685; GRZESIAK JJ, 1995, J CLIN INVEST, V95, P227, DOI 10.1172/JCI117644; Henry J.B, 1996, CLIN DIAGNOSIS MANAG, V9th; JACKSON AM, 1994, IMMUNOLOGY, V81, P120; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KERN A, 1994, J BIOL CHEM, V269, P22811; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LANGE TS, 1994, EXP CELL RES, V214, P381, DOI 10.1006/excr.1994.1271; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MILLER LJ, 1986, J IMMUNOL, V137, P2891; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; Petruzzelli L, 1998, J IMMUNOL, V160, P4208; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RANDI AM, 1994, J BIOL CHEM, V269, P12395; ROSS GD, 1983, J EXP MED, V158, P334, DOI 10.1084/jem.158.2.334; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P600; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SHIMIZU Y, 1993, J IMMUNOL, V151, P4106; SMITH JW, 1994, J BIOL CHEM, V269, P960; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; Towbin H, 1979, 10 1073 PNAS 76 9 43, V76, P4350, DOI [10.1073/pnas.76.9.4350, DOI 10.1073/PNAS.76.9.4350]; TUCKWELL D, 1995, J CELL SCI, V108, P1629; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	43	25	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22113	22119		10.1074/jbc.273.34.22113	http://dx.doi.org/10.1074/jbc.273.34.22113			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705356	hybrid			2022-12-25	WOS:000075492600090
J	Maksymowych, AB; Simpson, LL				Maksymowych, AB; Simpson, LL			Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; TOXIN TYPE-A; CLOSTRIDIAL NEUROTOXINS; TETANUS TOXIN; CACO-2 CELLS; TRANSPORT; PROTEINS; ANTAGONIZES; MONOLAYERS; INDUCTION	T-84 and Caco-2 human colon carcinoma cells and Madin-Darby canine kidney (MDCK) cells were used to study binding and transcytosis of iodinated. Clostridium botulinum neurotoxin serotypes A, B, and C, as well as tetanus toxin. Specific binding and transcytosis were demonstrated for serotypes A and B in intestinal cells. Using serotype A as an example, the rate of transcytosis by T-84 cells was determined in both apical to basolateral (11.34 fmol/h/cm(2)) as well as basolateral to apical (8.98 fmol/h/cm(2)) directions, and by Caco-2 cells in the apical to basolateral (8.42 fmol/h/cm(2)) direction. Serotype A retained intact di-chain structure during transit through T-84 or Caco-2 cells, and when released on the basolateral side was toxic in vivo to mice and in vitro on mouse phrenic nerve-hemidiaphragm preparations. Serotype C and tetanus toxin did mot bind effectively to T-84 cells, nor were they efficiently transcytosed (8-10% of serotype A). MDCK cells did not bind or efficiently transcytose (0.32 fmol/h/cm(2)) botulinum toxin, Further characterization demonstrated that the rate of transcytosis for serotype A in T-84 cells was increased 66% when vesicle sea-sting was disrupted by 5 mu M brefeldin A, decreased 42% when microtubules were disrupted by 10 mu M nocodazole, and decreased 74% art 18 degrees C. Drugs that antagonize toxin action at the nerve terminal, such as bafilomycin A, (which prevents acidification of endosomes) and methylamine HCl (which neutralizes acidification of endosomes), produced only a modest inhibitory effect on the rate of transcytosis (17-22%). These results may provide an explanation for the mechanism by which botulinum toxin escapes the human gastrointestinal tract, and they may also explain why specific serotypes cause human disease and others do not.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Simpson, LL (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, 1020 Locust St,Rm 314,Jefferson Alumni Hall, Philadelphia, PA 19107 USA.	lance.simpson@mail.tju.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022153] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-22153] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Acheson DWK, 1996, INFECT IMMUN, V64, P3294, DOI 10.1128/IAI.64.8.3294-3300.1996; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BENLOUNES N, 1995, BIOL NEONATE, V67, P254, DOI 10.1159/000244173; BONVENTRE PF, 1979, REV INFECT DIS, V1, P663; Coffield JA, 1997, J PHARMACOL EXP THER, V280, P1489; DASGUPTA BR, 1968, J BIOL CHEM, V243, P1065; DASGUPTA BR, 1984, TOXICON, V22, P415, DOI 10.1016/0041-0101(84)90085-0; DESHPANDE D, 1994, PHARMACEUT RES, V11, P1121, DOI 10.1023/A:1018980630675; DIX CJ, 1990, GASTROENTEROLOGY, V98, P1272, DOI 10.1016/0016-5085(90)90344-Z; Gebert A, 1996, INT REV CYTOL, V167, P91, DOI 10.1016/S0074-7696(08)61346-7; Hamad ARA, 1997, J EXP MED, V185, P1447, DOI 10.1084/jem.185.8.1447; Hatheway CL, 1995, CURR TOP MICROBIOL, V195, P55; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; Jahn R, 1995, COLD SPRING HARB SYM, V60, P329, DOI 10.1101/SQB.1995.060.01.037; Kiyatkin N, 1997, INFECT IMMUN, V65, P4586, DOI 10.1128/IAI.65.11.4586-4591.1997; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANNA C, 1967, J INFECT DIS, V117, P327, DOI 10.1093/infdis/117.4.327; LENCER WI, 1993, J CLIN INVEST, V92, P2941, DOI 10.1172/JCI116917; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; MATTER K, 1990, EMBO J, V9, P3163, DOI 10.1002/j.1460-2075.1990.tb07514.x; MIGITA K, 1994, EUR J IMMUNOL, V24, P2081, DOI 10.1002/eji.1830240922; Montecucco C, 1996, ARCH TOX S, V18, P342; MONTECUCCO C, 1994, FEBS LETT, V346, P92, DOI 10.1016/0014-5793(94)00449-8; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; Obiso RJ, 1997, INFECT IMMUN, V65, P1431, DOI 10.1128/IAI.65.4.1431-1439.1997; OBISO RJ, 1995, INFECT IMMUN, V63, P3820, DOI 10.1128/IAI.63.10.3820-3826.1995; OGUMA K, 1995, MICROBIOL IMMUNOL, V39, P161, DOI 10.1111/j.1348-0421.1995.tb02184.x; RAMANUJAM KS, 1991, AM J PHYSIOL, V260, pG416, DOI 10.1152/ajpgi.1991.260.3.G416; RODEWALD R, 1984, J CELL BIOL, V99, pS159, DOI 10.1083/jcb.99.1.159s; ROSSETTO O, 1995, J PHYSIOLOGY-PARIS, V89, P43, DOI 10.1016/0928-4257(96)80550-X; SAKAGUCHI G, 1982, PHARMACOL THERAPEUT, V19, P165, DOI 10.1016/0163-7258(82)90061-4; SANDERS AB, 1983, J FAM PRACTICE, V16, P987; Schiavo G, 1995, CURR TOP MICROBIOL, V195, P257; Shah D, 1996, J PHARM SCI-US, V85, P1306, DOI 10.1021/js9601400; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; SIMPSON LL, 1988, METHOD ENZYMOL, V165, P76; SIMPSON LL, 1993, J PHARMACOL EXP THER, V267, P720; SIMPSON LL, 1988, J PHARMACOL EXP THER, V245, P867; SIMPSON LL, 1981, PHARMACOL REV, V33, P155; SIMPSON LL, 1986, ANNU REV PHARMACOL, V26, P427, DOI 10.1146/annurev.pa.26.040186.002235; SIMPSON LL, 1980, J PHARMACOL EXP THER, V212, P16; SIMPSON LL, 1994, J PHARMACOL EXP THER, V269, P256; SIMPSON LL, 1983, J PHARMACOL EXP THER, V225, P546; SUGII S, 1977, INFECT IMMUN, V17, P491, DOI 10.1128/IAI.17.3.491-496.1977; ZHANG RE, 1995, GENE, V159, P293, DOI 10.1016/0378-1119(95)00152-V	45	95	104	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21950	21957		10.1074/jbc.273.34.21950	http://dx.doi.org/10.1074/jbc.273.34.21950			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705335	hybrid			2022-12-25	WOS:000075492600069
J	Nielsen, LB; Kahn, D; Duell, T; Weier, HUG; Taylor, S; Young, SG				Nielsen, LB; Kahn, D; Duell, T; Weier, HUG; Taylor, S; Young, SG			Apolipoprotein B gene expression in a series of human apolipoprotein B transgenic mice generated with recA-assisted restriction endonuclease cleavage-modified bacterial artificial chromosomes - An intestine-specific enhancer element is located between 54 and 62 kilobases 5 ' to the structural gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; BETA-GLOBIN GENE; RARE CLEAVAGE; TYROSINASE GENE; DNA; PROMOTER; LIVER; LIPOPROTEIN(A); DISEASE; DISTANT	Prior studies have established that the expression of the human apolipoprotein B (apoB) gene in the intestine is dependent on DNA sequences located a great distance from the structural gene. To identify the location of those sequences, we used recA-assisted restriction endonuclease (RARE) cleavage to truncate the 5'- or 3'-flanking sequences from a 145-kilobase (kb) bacterial artificial chromosome spanning the entire human apoB gene. Seven RARE cleavage- modified bacterial artificial chromosomes with different lengths of flanking sequences were used to generate transgenic mice. An analysis of those mice revealed that as little as 1.5 kb of 3' sequences or 5 kb of 5' sequences were sufficient to confer apoB expression in the liver. in contrast, apoB gene expression in the intestine required DNA sequences 54-62 kb 5' to the structural gene. Those sequences retained their ability to direct apoB expression hn the intestine when they were moved closer to the gene. These studies demonstrate that the intestinal expression of the apoB gene is dependent on DNA sequences located an extraordinary distance from the structural gene and that the RARE cleavage/transgenic expression strategy is a powerful approach for analyzing distant gene-regulatory sequences.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Young, SG (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.		Kahn, Daniel/B-9393-2013	Kahn, Daniel/0000-0001-8093-0854; Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allan CM, 1997, J BIOL CHEM, V272, P29113, DOI 10.1074/jbc.272.46.29113; Boren J, 1996, GENOME RES, V6, P1123, DOI 10.1101/gr.6.11.1123; CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CALLOW MJ, 1994, NUCLEIC ACIDS RES, V22, P4348, DOI 10.1093/nar/22.20.4348; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; Duell T, 1997, CYTOGENET CELL GENET, V79, P64, DOI 10.1159/000134685; ECCLES S, 1990, New Biologist, V2, P801; FAN J, 1995, CIRCULATION, V92, P104; Ferrin L J, 1995, Genet Eng (N Y), V17, P21; FERRIN LJ, 1994, NAT GENET, V6, P379, DOI 10.1038/ng0494-379; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Gregg Richard E., 1994, Current Opinion in Lipidology, V5, P81, DOI 10.1097/00041433-199404000-00003; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; Havel RJ, 1995, METABOLIC MOL BASES, V7th, P1841, DOI [10.1036/ommbid.142, DOI 10.1036/OMMBID.142]; Hug BA, 1996, MOL CELL BIOL, V16, P2906; JONES BK, 1995, MOL CELL BIOL, V15, P7010; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; LEVYWILSON B, 1995, PROG NUCLEIC ACID RE, V50, P161, DOI 10.1016/S0079-6603(08)60814-4; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; LINTON MF, 1993, J LIPID RES, V34, P521; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P143; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; McCormick SPA, 1996, J BIOL CHEM, V271, P11963, DOI 10.1074/jbc.271.20.11963; McCormick SPA, 1996, TRENDS CARDIOVAS MED, V6, P16, DOI 10.1016/1050-1738(95)00125-5; MCCORMICK SPA, 1994, GENET ANAL-BIOMOL E, V11, P158, DOI 10.1016/1050-3862(94)90036-1; MCCORMICK SPA, 1997, TRANSGENIC ANIMALS G, P273; Montoliu L, 1996, EMBO J, V15, P6026, DOI 10.1002/j.1460-2075.1996.tb00991.x; Nielsen LB, 1997, J BIOL CHEM, V272, P29752, DOI 10.1074/jbc.272.47.29752; PAUL M, 1994, ANNU REV PHYSIOL, V56, P811, DOI 10.1146/annurev.ph.56.030194.004115; PAULWEBER B, 1991, J BIOL CHEM, V266, P21956; PAULWEBER B, 1991, J BIOL CHEM, V266, P24161; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; SCHEDL A, 1993, NUCLEIC ACIDS RES, V21, P4783, DOI 10.1093/nar/21.20.4783; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; SHACHTER NS, 1993, J LIPID RES, V34, P1699; Silver L.M., 1995, MOUSE GENETICS CONCE; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SIMONET WS, 1990, T ASSOC AM PHYSICIAN, V103, P119; STAMATOYANNOPOULOS JA, 1995, EMBO J, V14, P106, DOI 10.1002/j.1460-2075.1995.tb06980.x; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; STRICH D, 1993, J PEDIATR GASTR NUTR, V16, P257, DOI 10.1097/00005176-199304000-00006; TAYLOR JM, 1993, CURR OPIN LIPIDOL, V4, P84, DOI 10.1097/00041433-199304000-00002; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; WALSH A, 1993, J LIPID RES, V34, P617; WEIER HUG, 1995, HUM MOL GENET, V4, P1903; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574; YOUNG SG, 1994, WESTERN J MED, V160, P153; YOUNG SG, 1998, IN PRESS MOL BASIS H	51	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21800	21807		10.1074/jbc.273.34.21800	http://dx.doi.org/10.1074/jbc.273.34.21800			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705318	Green Submitted, hybrid			2022-12-25	WOS:000075492600052
J	Quan, YD; Inouye, P; Liang, C; Rong, LW; Gotte, M; Wainberg, MA				Quan, YD; Inouye, P; Liang, C; Rong, LW; Gotte, M; Wainberg, MA			Dominance of the E89G substitution in HIV-1 reverse transcriptase in regard to increased polymerase processivity and patterns of pausing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HIGH-LEVEL RESISTANCE; ANGSTROM RESOLUTION; REDUCED SENSITIVITY; KINETIC-PROPERTIES; INVITRO SELECTION; CRYSTAL-STRUCTURE; CROSS-RESISTANCE; DRUG-RESISTANT; GLU-89 RESIDUE	The substitution of a glycine for glutamic acid at position 89 in human immunodeficiency virus-1 (HIV-1) reverse transcriptase (RT) (E89G) confers resistance to several nucleoside and non-nucleoside inhibitors of RT. As residue 89 contacts the template strand, it has been suggested that this mutation may modulate the conformation of the RT.template/primer complex. in addition, certain mutations in RT that confer resistance to nucleoside analogs, such as M184V, ape located near the polymerase active site. To characterize further these substitutions, we performed processivity assays alongside era analysis of pausing profiles with wild-type (nt) RT and recombinant RTs containing substitutions at E89G, M184V, or both, We now show that E89G RT has higher processivity thats wt enzyme as well as a different pattern of pausing sites. Similar findings were obtained with the doubly mutated RT, although enzyme containing only the M184V mutation had lower processivity thats wt. Consistent with these observations, and from a mechanistic standpoint, both E89G-containing as well as doubly mutated RT had decreased dissociation constants from a complex consisting of RT and template-primer, in comparison with either mt RT or M184V-containing RT. No significant differences were observed among the various enzymes in regard to K-m values for the heteropolymeric RNA template used in these studies. Viruses containing the E89G mutation synthesized longer strand DNA products than either wt viruses or viruses containing only the M184V mutation in endogenous RT assays. Thus, the E89G substitution is a dominant determinant in regard to each of the k(off) values from an RT.template/primer complex, RT processivity, and specific patterns of pausing during DNA polymerization.	McGill Univ, Lady Davis Inst Med Res, McGill AIDS Ctr, Sir Mortimer B Davis Jewish Hosp, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University	Wainberg, MA (corresponding author), McGill Univ, Lady Davis Inst Med Res, McGill AIDS Ctr, Sir Mortimer B Davis Jewish Hosp, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	mdwa@musica.mcgill.ca						Arion D, 1996, J BIOL CHEM, V271, P19860, DOI 10.1074/jbc.271.33.19860; ARTS EJ, 1994, J BIOL CHEM, V269, P14672; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOUCHER CAB, 1993, ANTIMICROB AGENTS CH, V37, P2231, DOI 10.1128/AAC.37.10.2231; BOYER JC, 1992, P NATL ACAD SCI USA, V89, P6919, DOI 10.1073/pnas.89.15.6919; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; BOYER PL, 1995, ANTIMICROB AGENTS CH, V39, P1624, DOI 10.1128/AAC.39.7.1624; Caliendo AM, 1996, J VIROL, V70, P2146, DOI 10.1128/JVI.70.4.2146-2153.1996; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEBOUCK C, 1987, P NATL ACAD SCI USA, V84, P8903, DOI 10.1073/pnas.84.24.8903; Drosopoulos WC, 1996, J VIROL, V70, P4834, DOI 10.1128/JVI.70.7.4834-4838.1996; Essink BBO, 1997, NUCLEIC ACIDS RES, V25, P3212, DOI 10.1093/nar/25.16.3212; GAO Q, 1992, J VIROL, V66, P12, DOI 10.1128/JVI.66.1.12-19.1992; GAO Q, 1993, ANTIMICROB AGENTS CH, V37, P1390, DOI 10.1128/AAC.37.6.1390; GU ZX, 1992, J VIROL, V66, P7128, DOI 10.1128/JVI.66.12.7128-7135.1992; GU ZX, 1994, J BIOL CHEM, V269, P28118; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; Hsu ML, 1997, NUCLEIC ACIDS RES, V25, P4532, DOI 10.1093/nar/25.22.4532; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JAPOUR AJ, 1991, P NATL ACAD SCI USA, V88, P3092, DOI 10.1073/pnas.88.8.3092; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KEW Y, 1994, J BIOL CHEM, V269, P15331; Kew Y, 1996, ANTIMICROB AGENTS CH, V40, P1711, DOI 10.1128/AAC.40.7.1711; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Kornberg A., 1992, DNA REPLICATION; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; LARDER BA, 1991, J VIROL, V65, P5232, DOI 10.1128/JVI.65.10.5232-5236.1991; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; MCHENRY CS, 1989, MOL BIOL CHROMOSOME, P97; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; Perach M, 1997, J MOL BIOL, V268, P648, DOI 10.1006/jmbi.1997.0927; PRASAD VR, 1991, P NATL ACAD SCI USA, V88, P11363, DOI 10.1073/pnas.88.24.11363; Preston BD, 1996, TRENDS MICROBIOL, V4, P16, DOI 10.1016/0966-842X(96)81500-9; Quan YD, 1996, J VIROL, V70, P5642, DOI 10.1128/JVI.70.8.5642-5645.1996; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; SONG QG, 1992, J VIROL, V66, P7568, DOI 10.1128/JVI.66.12.7568-7571.1992; Sousa R, 1996, TRENDS BIOCHEM SCI, V21, P186, DOI 10.1016/S0968-0004(96)10023-2; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; WAKEFIELD JK, 1992, J VIROL, V66, P6806, DOI 10.1128/JVI.66.11.6806-6812.1992; WANG J, 1994, P NATL ACAD SCI USA, V91, P7242, DOI 10.1073/pnas.91.15.7242; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P18682; ZHANG D, 1994, ANTIMICROB AGENTS CH, V38, P282, DOI 10.1128/AAC.38.2.282	56	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21918	21925		10.1074/jbc.273.34.21918	http://dx.doi.org/10.1074/jbc.273.34.21918			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705331	hybrid			2022-12-25	WOS:000075492600065
J	Ruckemann, K; Fairbanks, LD; Carrey, EA; Hawrylowicz, CM; Richards, DF; Kirschbaum, B; Simmonds, HA				Ruckemann, K; Fairbanks, LD; Carrey, EA; Hawrylowicz, CM; Richards, DF; Kirschbaum, B; Simmonds, HA			Leflunomide inhibits pyrimidine de Novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOSUPPRESSIVE AGENT LEFLUNOMIDE; DIHYDROOROTIC ACID DEHYDROGENASE; TYROSINE KINASE-ACTIVITY; PROLIFERATION IN-VITRO; DE-NOVO; NUCLEOTIDE BIOSYNTHESIS; BREQUINAR SODIUM; CELLS; TRANSPLANTATION; PHOSPHORYLATION	The mode of action of Leflunomide, an immunomodulatory drug used in rheumatoid arthritis, is debated, This study, using C-14-labeled de novo purine and pyrimidine synthesis precursors, proves conclusively that the prime target in proliferating human T-lymphocytes is pyrimidine biosynthesis at the level of dihydroorotic-acid dehydrogenase. Leflunomide (25 and 50 mu M), like Brequinar (0.5 and 1 mu M), a demonstrated dihydroorotic-acid dehydrogenase inhibitor, was cytostatic, not cytotoxic, with proliferation being halted in the G(1) phase. Both drugs restricted the normal 4-8-fold mitogen-induced expansion of pyrimidine pools over 72 h to concentrations found in nonstimulated T-cells and [C-14]bicarbonate incorporation into UTP, ATP, and GTP. Uridine (50 mu M) restored expansion of all pools, but [C-14]bicarbonate incorporation into ATP and GTP only, not UTP, [C-14]Hypoxanthine salvage was also restricted, indicating that purine salvage pathways are compromised likewise by both inhibitors, [C-14]Glycine studies confirmed that restriction of de novo purine synthesis occurred secondary to inhibition of proliferation since this was reversed by uridine rescue, except at 100 mu M Leflunomide. 100 mu M Leflunomide markedly depleted ATP and GTP pools also, which would have serious consequences for ATP-dependent enzymes essential to the immune response, thereby explaining non-pyrimidine-related effects reported for Leflunomide at 100 mu M and above.	Guys Hosp, UMDS, Purine Res Lab, London SE1 9RT, England; Guys Hosp, UMDS, Dept Allergy & Resp Med, London SE1 9RT, England; St Thomas Hosp, UMDS, Dept Allergy & Resp Med, London SE1 9RT, England; St Thomas Hosp, UMDS, Purine Res Lab, London SE1 9RT, England; Royal Free Hosp, Sch Med, Dept Biochem & Mol Biol, London NW3 2PF, England; Hoechst Marion Roussel, D-65926 Frankfurt, Germany	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Sanofi-Aventis	Simmonds, HA (corresponding author), Guys Hosp, UMDS, Purine Res Lab, 5th Floor Thomas Guy House, London SE1 9RT, England.		Hawrylowicz, Catherine/Q-8483-2017	Hawrylowicz, Catherine/0000-0002-2337-7463; Ruckemann-Dziurdzinska, Katarzyna/0000-0002-5018-0818				Barinaga M, 1997, SCIENCE, V278, P1036, DOI 10.1126/science.278.5340.1036; Bartlett Robert R., 1994, P349; BARTLETT RR, 1991, AGENTS ACTIONS, V32, P10, DOI 10.1007/BF01983301; BOFILL M, 1995, J BIOL CHEM, V270, P29690, DOI 10.1074/jbc.270.50.29682; CHERWINSKI HM, 1995, J PHARMACOL EXP THER, V275, P1043; CHERWINSKI HM, 1995, INFLAMM RES, V44, P317, DOI 10.1007/BF01796261; CHERWINSKI HM, 1995, J PHARMACOL EXP THER, V272, P460; Chong ASF, 1996, TRANSPLANTATION, V61, P140, DOI 10.1097/00007890-199601150-00026; CHRISTOPHERSON RI, 1979, J BIOL CHEM, V254, P2506; CLEAVELAND ES, 1995, BIOCHEM PHARMACOL, V49, P947, DOI 10.1016/0006-2952(95)00009-O; Elder RT, 1997, J IMMUNOL, V159, P22; EUGUI EM, 1991, SCAND J IMMUNOL, V33, P161, DOI 10.1111/j.1365-3083.1991.tb03746.x; FAIRBANKS LD, 1995, J BIOL CHEM, V270, P29682; GREENE S, 1995, BIOCHEM PHARMACOL, V50, P861, DOI 10.1016/0006-2952(95)00255-X; HEMMENS B, 1994, EUR J BIOCHEM, V225, P845, DOI 10.1111/j.1432-1033.1994.0845b.x; KEMP AJ, 1986, J BIOL CHEM, V261, P4891; Knecht W, 1996, EUR J BIOCHEM, V240, P292, DOI 10.1111/j.1432-1033.1996.0292h.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKOWKA L, 1993, IMMUNOL REV, V136, P51, DOI 10.1111/j.1600-065X.1993.tb00654.x; MARIJNEN YMT, 1989, BIOCHIM BIOPHYS ACTA, V1012, P148, DOI 10.1016/0167-4889(89)90088-8; MATTAR T, 1993, FEBS LETT, V334, P161, DOI 10.1016/0014-5793(93)81704-4; MLADENOVIC V, 1995, ARTHRITIS RHEUM-US, V38, P1595, DOI 10.1002/art.1780381111; NAIR RV, 1995, IMMUNOL LETT, V47, P171, DOI 10.1016/0165-2478(95)00074-5; NIKCEVICH DA, 1994, AGENTS ACTIONS, V41, pC279, DOI 10.1007/BF01987669; PETERS GJ, 1990, CANCER RES, V50, P4644; PETERS GJ, 1987, INVEST NEW DRUGS B, V253, P375; PETERS GJ, 1992, BRIT J CANCER, V365, P229; SAMELSON LE, 1986, NATURE, V324, P674, DOI 10.1038/324674a0; SASVARISZEKELY M, 1993, BIOCHEM BIOPH RES CO, V194, P966, DOI 10.1006/bbrc.1993.1915; SEBESTA I, 1994, CLIN CHIM ACTA, V224, P45, DOI 10.1016/0009-8981(94)90119-8; Siemasko KF, 1996, TRANSPLANTATION, V61, P635, DOI 10.1097/00007890-199602270-00020; Silva H T Jr, 1997, Expert Opin Investig Drugs, V6, P51, DOI 10.1517/13543784.6.1.51; Silva HT, 1997, TRANSPL P, V29, P1292, DOI 10.1016/S0041-1345(96)00523-4; Simmonds H., 1991, TECHNIQUES DIAGNOSTI, P397; Simmonds HA, 1995, BIOCHEM SOC T, V23, P877, DOI 10.1042/bst0230877; SIMON P, 1993, TRANSPLANT P, V25, P77; SOKOLOSKI JA, 1987, INT J CANCER, V39, P764, DOI 10.1002/ijc.2910390618; VANDENBERG AA, 1994, LEUKEMIA, V8, P1375; WEBSTER DR, 1995, METABOLIC MOL BASIS, P1725; WILLIAMSON RA, 1995, J BIOL CHEM, V270, P22467, DOI 10.1074/jbc.270.38.22467; Xu XL, 1997, J IMMUNOL, V159, P167; XU XL, 1995, J BIOL CHEM, V270, P12398, DOI 10.1074/jbc.270.21.12398; Xu XL, 1996, BIOCHEM PHARMACOL, V52, P527, DOI 10.1016/0006-2952(96)00303-6; Zielinski T., 1995, Inflammation Research, V44, pS207, DOI 10.1007/BF01778336; ZIELINSKI T, 1994, AGENTS ACTIONS, V41, P205	45	214	226	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21682	21691		10.1074/jbc.273.34.21682	http://dx.doi.org/10.1074/jbc.273.34.21682			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705303	hybrid			2022-12-25	WOS:000075492600037
J	Singh, U; Rogers, JB				Singh, U; Rogers, JB			The novel core promoter element GAAC in the hgl5 gene of Entamoeba histolytica is able to direct a transcription start site independent of TATA or initiator regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; BINDING PROTEIN; EXPRESSION; DNA; TRANSFECTION; RECOGNITION; COMPLEX; BOX	Entamoeba histolytica, an enteric protozoa, is the third leading parasitic cause of death worldwide. Investigation of the transcriptional machinery of this eukaryotic pathogen has revealed an unusual core promoter structure that consists of nonconsensus TATA and initiator regions and a novel third conserved core promoter sequence, the GAAC element. Mutation of this region in the hgl5 promoter decreases reporter gene expression and alters the transcription start site. Using positional analysis of this element, we have now demonstrated that it is able to direct a new transcription start site, 2-7 bases downstream of itself, independent of TATA and Inr regions. The GAAC region was also shown to control the rate of transcription via nuclear run on analysis and an amebic nuclear protein was demonstrated to specifically interact with this sequence. This is the first description in the eukaryotic literature of a third conserved core promoter element, distinct from TATA or initiator regions, that is able to direct a transcription start site. We have formulated two models for the role of the GAAC region: (i) the GAAC-binding protein is a part of the TFIID complex and (ii) the GAAC-binding protein functions to "tether" TATA-binding protein to the TATA box.	Univ Virginia, Hlth Sci Ctr, Dept Med, Charlottesville, VA 22908 USA	University of Virginia	Singh, U (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Med, Rm 2115,MR 4 Bldg,300 Pk Pl, Charlottesville, VA 22908 USA.			Singh, Upinder/0000-0003-0630-0306	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037941, K08AI001453] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI-37941, K08-AI 01453] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRUCHHAUS I, 1993, DNA CELL BIOL, V12, P925, DOI 10.1089/dna.1993.12.925; BURATOWSKI S, 1997, CURRENT PROTOCOLS MO; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; CHORY J, 1997, CURRENT PROTOCOLS MO; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; DVORAK JA, 1995, J EUKARYOT MICROBIOL, V42, P610, DOI 10.1111/j.1550-7408.1995.tb05915.x; GELDERMAN AH, 1971, J PARASITOL, V57, P906, DOI 10.2307/3277826; Gilchrist CA, 1998, INFECT IMMUN, V66, P2383, DOI 10.1128/IAI.66.5.2383-2386.1998; Gomez C, 1998, J BIOL CHEM, V273, P7277, DOI 10.1074/jbc.273.13.7277; GREENBERG ME, 1997, CURRENT PROTOCOLS MO; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; Jiang JG, 1997, MOL CELL BIOL, V17, P5758, DOI 10.1128/MCB.17.10.5758; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; LIOUTAS C, 1995, MOL BIOCHEM PARASIT, V73, P259, DOI 10.1016/0166-6851(95)00101-6; MCANDREW MB, 1993, GENE, V124, P165, DOI 10.1016/0378-1119(93)90390-O; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; Perez DG, 1998, J BIOL CHEM, V273, P7285, DOI 10.1074/jbc.273.13.7285; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; Purdy JE, 1996, MOL BIOCHEM PARASIT, V78, P91, DOI 10.1016/S0166-6851(96)02614-X; PURDY JE, 1994, P NATL ACAD SCI USA, V91, P7099, DOI 10.1073/pnas.91.15.7099; Ramakrishnan G, 1997, MOL BIOCHEM PARASIT, V84, P93, DOI 10.1016/S0166-6851(96)02784-3; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Singh U, 1997, P NATL ACAD SCI USA, V94, P8812, DOI 10.1073/pnas.94.16.8812; TANNICH E, 1992, J MOL EVOL, V34, P272, DOI 10.1007/BF00162976; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; VINES RR, 1995, MOL BIOCHEM PARASIT, V71, P265, DOI 10.1016/0166-6851(95)00057-8; Yanai K, 1996, J BIOL CHEM, V271, P15981, DOI 10.1074/jbc.271.27.15981; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841	30	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21663	21668		10.1074/jbc.273.34.21663	http://dx.doi.org/10.1074/jbc.273.34.21663			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705300	hybrid			2022-12-25	WOS:000075492600034
J	Yasuda, H; Lindorfer, MA; Myung, CS; Garrison, JC				Yasuda, H; Lindorfer, MA; Myung, CS; Garrison, JC			Phosphorylation of the G protein gamma(12) subunit regulates effector specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-BETA-GAMMA; BACULOVIRUS EXPRESSION SYSTEM; HETEROTRIMERIC G-PROTEINS; TRIMERIC G-PROTEINS; PHOSPHOLIPASE-C; KINASE-C; ADENOSINE RECEPTORS; ADENYLYL CYCLASES; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT	Although the G protein beta gamma dimer is an important mediator in cell signaling, the mechanisms regulating its activity have not been widely investigated. The gamma(12) subunit is a known substrate for protein kinase C, suggesting phosphorylation as a potential regulatory mechanism. Therefore, recombinant beta(1)gamma(12) dimers were overexpressed using the baculovirus/Sf9 insect cell system,, purified, and phosphorylated stoichiometrically with protein kinase C alpha. Their ability to support coupling of the G(il) alpha subunit to the A1 adenosine receptor and to activate type II adenylyl cyclase or phospholipase C-beta was examined, Phosphorylation of the beta(1)gamma(12) dimer increased its potency in the receptor coupling assay from 6.4 to 1 nM, change the K-act for stimulation of type II adenylyl cyclase from 14 to 37 nM, and decreased its maximal efficacy by 50%. In contrast, phosphorylation of the dimer had no effect on its ability to activate phospholipase C-beta. The native beta(1)gamma(10) dimer, which has 4 similar amino acids in the phosphorylation site at the N terminus, was not phosphorylated by protein kinase C alpha. Creation of a phosphorylation site in the N terminus of the protein (Gly(4) --> Lys) resulted in a beta(1)gamma(10G4K) dimer which could be phosphorylated. The activities of this beta gamma dimer were similar to those of the phosphorylated beta(1)gamma(12) dimer Thus, phosphorylation of the beta(1)gamma(12) dimer ore the gamma subunit with protein kinase C alpha regulates its activity in an effector-specific fashion. Because the gamma(12) subunit is widely expressed, phosphorylation may be an important mechanism for integration of the multiple signals generated by receptor activation.	Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia	Garrison, JC (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Box 448, Charlottesville, VA 22908 USA.	jcg8w@virginia.edu		Myung, Chang-Seon/0000-0002-6292-2911	NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA 40042] Funding Source: Medline; NIDDK NIH HHS [R01-DK-19952] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asano T, 1998, EUR J BIOCHEM, V251, P314, DOI 10.1046/j.1432-1327.1998.2510314.x; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Figler RA, 1996, MOL PHARMACOL, V50, P1587; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FUNG BKK, 1983, J BIOL CHEM, V258, P495; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRABER SG, 1994, METHOD ENZYMOL, V237, P212; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRABER SG, 1996, METH NEUROSCI, V29, P207; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HAWES BE, 1994, J BIOL CHEM, V269, P29825; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE CH, 1995, J BIOL CHEM, V270, P8779, DOI 10.1074/jbc.270.15.8779; LEE RH, 1990, J BIOL CHEM, V265, P15860; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; Morishita R, 1997, J NEUROCHEM, V68, P820; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; Muller S, 1996, J BIOL CHEM, V271, P11781, DOI 10.1074/jbc.271.20.11781; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Robeva AS, 1996, BIOCHEM PHARMACOL, V51, P545, DOI 10.1016/0006-2952(95)02235-X; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; SPRING DJ, 1994, J BIOL CHEM, V269, P22882; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; Ueda H, 1997, J CELL SCI, V110, P1503; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050; Zimmermann G, 1996, J BIOL CHEM, V271, P27161, DOI 10.1074/jbc.271.43.27161	69	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21958	21965		10.1074/jbc.273.34.21958	http://dx.doi.org/10.1074/jbc.273.34.21958			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705336	hybrid			2022-12-25	WOS:000075492600070
J	Zhang, M; Stauffacher, CV; Lin, DY; Van Etten, RL				Zhang, M; Stauffacher, CV; Lin, DY; Van Etten, RL			Crystal structure of a human low molecular weight phosphotyrosyl phosphatase - Implications for substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; ACID-PHOSPHATASE; BOVINE HEART; ACP1; SEQUENCE; ISOZYMES; EXPRESSION; TUNGSTATE; RESIDUES; CLONING	The low molecular weight phosphotyrosine phosphatases (PTPases) constitute a distinctive class of phosphotyrosine phosphatases that is widely distributed among vertebrate and invertebrate organisms, In vertebrates, two isoenzymes of these low molecular weight PTPases are commonly expressed. The two human isoenzymes, HCPTPA and HCPTPB, differ in an alternatively spliced sequence (residues 40-73) referred to as the variable loop, resulting in isoenzymes that have different substrate specificities and inhibitor/activator responses. We present here the x-ray crystallographic structure of a human low molecular weight PT-Pase solved by molecular replacement to 2.2 Angstrom. The structure of human Bow molecular weight PTPase is compared with a structure representing the other isoenzyme in this PTPase class, in each case with a sulfonate inhibitor bound to the active site. Possible aromatic residue interactions with the phosphotyrosine substrate are proposed from an examination of the binding site of the inhibitors. Differences are observed in the variable loop region, which forms one wall and the floor of a long crevice leading from the active-site loop. A set of residues lying along this crevice (amino acids 49, 50, and 53) is suggested to be responsible for differences in substrate specificity in these two enzymes.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Van Etten, RL (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.				NIGMS NIH HHS [GM 27003] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027003] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; BRYSON GLM, 1995, GENOMICS, V30, P133; CAVALLISFORZA L, 1994, HIST GEOGRAPHY HUMAN, P185; Cirri P, 1996, J BIOL CHEM, V271, P2604, DOI 10.1074/jbc.271.5.2604; DISSING J, 1992, BIOCHIM BIOPHYS ACTA, V1121, P261, DOI 10.1016/0167-4838(92)90155-7; DISSING J, 1993, BIOCHIM BIOPHYS ACTA, V1162, P275, DOI 10.1016/0167-4838(93)90291-X; DISSING J, 1991, J BIOL CHEM, V266, P20619; Evans B, 1996, BIOCHEMISTRY-US, V35, P13609, DOI 10.1021/bi9605651; Fauman EB, 1996, J BIOL CHEM, V271, P18780, DOI 10.1074/jbc.271.31.18780; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; HOPKINSON DA, 1963, NATURE, V199, P969, DOI 10.1038/199969a0; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; LAZARUK KDA, 1993, BIOCHEM BIOPH RES CO, V196, P440, DOI 10.1006/bbrc.1993.2269; LOGAN TM, 1994, BIOCHEMISTRY-US, V33, P11087, DOI 10.1021/bi00203a005; NAVAZA J, 1987, ACTA CRYSTALLOGR A, V43, P645, DOI 10.1107/S0108767387098787; OTWINOWSKI A, 1993, DATA COLLECTION PROC, P66; RAMPONI G, 1994, ADV PROT PHOSPHATASE, V8, P1; SCHUBERT HL, 1995, PROTEIN SCI, V4, P1904, DOI 10.1002/pro.5560040924; SOKAL RR, 1991, NATURE, V351, P143, DOI 10.1038/351143a0; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; STEIN E, 1997, ASBMB SAT M SEATTL W; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Tailor P, 1997, J BIOL CHEM, V272, P5371, DOI 10.1074/jbc.272.9.5371; Tishmack PA, 1997, BIOCHEMISTRY-US, V36, P11984, DOI 10.1021/bi9712448; WAHEED A, 1988, BIOCHEMISTRY-US, V27, P4265, DOI 10.1021/bi00412a010; WO WYP, 1992, THESIS PURDUE U; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; WO YYP, 1992, J BIOL CHEM, V267, P10856; YOSHIHARA CM, 1980, AM J HUM GENET, V32, P898; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; Zhang M, 1997, BIOCHEMISTRY-US, V36, P15, DOI 10.1021/bi961804n; ZHANG M, 1995, ADV PROTEIN PHOSPHAT, V9, P1; ZHANG ZT, 1994, J BIOL CHEM, V269, P25947; ZHOU MM, 1993, BIOCHEMISTRY-US, V32, P8479, DOI 10.1021/bi00084a012	38	73	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21714	21720		10.1074/jbc.273.34.21714	http://dx.doi.org/10.1074/jbc.273.34.21714			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705307	hybrid			2022-12-25	WOS:000075492600041
J	He, B; Gross, M; Roizman, B				He, B; Gross, M; Roizman, B			The gamma(1)34.5 protein of herpes simplex virus 1 has the structural and functional attributes of a protein phosphatase I regulatory subunit and is present in a high molecular weight complex with the enzyme in infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY RESPONSE GENE; AMINO-ACID-SEQUENCE; PREMATURE SHUTOFF; SKELETAL-MUSCLE; GROWTH ARREST; BRAIN-TUMORS; L-COMPONENT; DNA-DAMAGE; PHOSPHORYLATION; NEUROVIRULENCE	The carboxyl-terminal domain of the gamma(1)34.5 protein of the herpes simplex virus 1 binds to protein phosphatase 1 alpha (PP1) and is required to prevent the shut-off of protein synthesis resulting from phosphorylation of the alpha subunit of eIF-2 by the double-stranded RNA-activated protein kinase. The corresponding domain of the conserved GADD34 protein homologous to gamma(1)34.5 functionally substitutes for y(1)34.5, This report shows that y(1)34.5 and PPI form a complex in the infected cells, that fractions containing this complex specifically dephosphorylate eIF-2 alpha, and that both gamma(1)34.5 and GADD34 proteins contain the amino acid sequence motif common to subunits of PPI that is required for binding to the PPI catalytic subunit, An oligopeptide containing this motif competes with gamma(1)34.5 for binding to PPI, Substitution of Val(193) and Phe(195) in the PPI-binding motif abolished activity. These results suggest that the carboxyl-terminal domain of gamma(1)34.5 protein has the structural and functional attributes of a subunit of PP1 specific for eIF-2 alpha, that it has evolved to preclude shut-off of protein synthesis, and that GADD34 may have a similar function.	Univ Chicago, Marjorie B Kovler Viral Oncol Labs, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Roizman, B (corresponding author), Univ Chicago, Marjorie B Kovler Viral Oncol Labs, 910 E 58th St, Chicago, IL 60637 USA.	bernard@kovler.uchicago.edu			NATIONAL CANCER INSTITUTE [R35CA047451] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024009] Funding Source: NIH RePORTER; NCI NIH HHS [CA47451] Funding Source: Medline; NHLBI NIH HHS [HL30121] Funding Source: Medline; NIAID NIH HHS [AI24009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMANN M, 1986, J VIROL, V58, P843, DOI 10.1128/JVI.58.3.843-850.1986; AITKEN A, 1982, FEBS LETT, V147, P54, DOI 10.1016/0014-5793(82)81010-7; Andreansky S, 1997, CANCER RES, V57, P1502; Andreansky SS, 1996, P NATL ACAD SCI USA, V93, P11313, DOI 10.1073/pnas.93.21.11313; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; CHOU J, 1986, J VIROL, V57, P629, DOI 10.1128/JVI.57.2.629-637.1986; CHOU J, 1990, SCIENCE, V250, P1262, DOI 10.1126/science.2173860; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CHOU J, 1995, P NATL ACAD SCI USA, V92, P10516, DOI 10.1073/pnas.92.23.10516; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; CHOU J, 1990, J VIROL, V64, P1014, DOI 10.1128/JVI.64.3.1014-1020.1990; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; EJERCITO PM, 1968, J GEN VIROL, V2, P357, DOI 10.1099/0022-1317-2-3-357; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GROSS M, 1987, J BIOL CHEM, V262, P6899; GROSS M, 1980, J BIOL CHEM, V255, P6270; GROSS M, 1973, BIOCHEM BIOPH RES CO, V50, P832, DOI 10.1016/0006-291X(73)91320-X; GROSS M, 1983, BIOCHIM BIOPHYS ACTA, V740, P255, DOI 10.1016/0167-4781(83)90134-3; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; Hirano K, 1996, FEBS LETT, V389, P191, DOI 10.1016/0014-5793(96)00577-7; HIRANO K, 1995, J BIOL CHEM, V270, P19786, DOI 10.1074/jbc.270.34.19786; Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; LAGUNOFF M, 1995, J VIROL, V69, P3615, DOI 10.1128/JVI.69.6.3615-3623.1995; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; MCGEOCH DJ, 1991, J GEN VIROL, V72, P3057, DOI 10.1099/0022-1317-72-12-3057; MCGEOCH DJ, 1991, NATURE, V353, P609, DOI 10.1038/353609b0; POST LE, 1981, CELL, V25, P227, DOI 10.1016/0092-8674(81)90247-6; SHELDRICK P, 1974, COLD SPRING HARB SYM, V39, P667, DOI 10.1101/SQB.1974.039.01.080; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SUSSMAN MD, 1992, J VIROL, V66, P5586, DOI 10.1128/JVI.66.9.5586-5589.1992; TANG PM, 1991, J BIOL CHEM, V266, P15782; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; WADSWORTH S, 1975, J VIROL, V15, P1487, DOI 10.1128/JVI.15.6.1487-1497.1975; WHITLEY RJ, 1993, J CLIN INVEST, V91, P2837, DOI 10.1172/JCI116527; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	44	133	138	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20737	20743		10.1074/jbc.273.33.20737	http://dx.doi.org/10.1074/jbc.273.33.20737			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694816	hybrid			2022-12-25	WOS:000075386100009
J	Hirao, K; Hata, Y; Ide, N; Takeuchi, M; Irie, M; Yao, I; Deguchi, M; Toyoda, A; Sudhof, TC; Takai, Y				Hirao, K; Hata, Y; Ide, N; Takeuchi, M; Irie, M; Yao, I; Deguchi, M; Toyoda, A; Sudhof, TC; Takai, Y			A novel multiple PDZ domain-containing molecule interacting with N-methyl-D-aspartate receptors and neuronal cell adhesion proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; TUMOR-SUPPRESSOR PROTEIN; GUANYLATE KINASE; WW DOMAIN; SEPTATE JUNCTIONS; PSD-95 FAMILY; HUMAN BRAIN; GENE; CHANNEL; HOMOLOG	At synaptic junctions, pre- and postsynaptic membranes are connected by cell adhesion and have distinct structures for specialized functions. The presynaptic membranes have a machinery for fast neurotransmitter release, and the postsynaptic membranes have clusters of neurotransmitter receptors, The molecular mechanism of the assembly of synaptic junctions is not yet clear. Pioneering studies identified postsynaptic density (PSD)-95/SAP90 as a prototypic synaptic scaffolding protein to maintain the structure of synaptic junctions. PSD-95/SAP90 belongs to a family of membrane-associated guanylate kinases and binds N-methyl-D-aspartate receptors, potassium channels, and neuroligins through the PDZ domains and GKAP/SAPAP/DAP through the guanylate kinase (GK) domain. We performed here a yeast two-hybrid screening for SAPAP-interacting molecules and identified a novel protein that has an inverse structure of membrane-associated guanylate kinases with an NH2-terminal GK-like domain followed by two WW and five PDZ domains. It binds SAPAP through the GH-like domain and NMDA receptors and neuroligins through the PDZ domains. We named this protein S-SCAM (synaptic scaffolding molecule) because S-SCAM may assemble receptors and cell adhesion proteins at synaptic junctions.	Osaka Univ, Sch Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan; Univ Texas, SW Med Ctr, Dept Mol Genet, Howard Hughes Med Inst, Dallas, TX 75235 USA; JCR Pharmaceut Co Ltd, ERATO, Japan Sci & Technol Corp, Tokai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan	Osaka University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Biochem & Mol Biol, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	ytakai@moIbio.med.osak-u.ac.jp	Toyoda, Atsushi/AAA-5885-2020	Toyoda, Atsushi/0000-0002-0245-3244				Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; DONG H, 1997, NATURE, V386, P379; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Hata Y, 1996, J NEUROSCI, V16, P2488; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Kennedy M B, 1993, Curr Opin Neurobiol, V3, P732, DOI 10.1016/0959-4388(93)90145-O; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; LA SA, 1991, NATURE, V352, P77; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Margolis RL, 1997, HUM GENET, V100, P114, DOI 10.1007/s004390050476; Margolis RL, 1996, MOL BRAIN RES, V36, P219, DOI 10.1016/0169-328X(95)00241-J; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Naisbitt S, 1997, J NEUROSCI, V17, P5687; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; Niethammer M, 1996, J NEUROSCI, V16, P2157; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7	44	243	258	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21105	21110		10.1074/jbc.273.33.21105	http://dx.doi.org/10.1074/jbc.273.33.21105			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694864	hybrid			2022-12-25	WOS:000075386100057
J	Linnik, KM; Herscovitz, H				Linnik, KM; Herscovitz, H			Multiple molecular chaperones interact with apolipoprotein B during its maturation - The network of endoplasmic reticulum-resident chaperones (ERp72, GRP94, calreticulin, and BiP) interacts with apolipoprotein B regardless of its lipidation state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; THIOL-DEPENDENT REDUCTASE; MAMMARY-DERIVED CELLS; STRESS PROTEINS; BETA-SUBUNIT; DEGRADATION; SECRETION; BINDING; LIPOPROTEINS; GLYCOPROTEINS	The present study was undertaken to identify and characterize molecular chaperones that assist in the folding of apolipoprotein (apo) B, a secretory protein that requires assembly with lipids (lipidation) for its secretion. Both HepG2 cells, normally secreting full-length apoB (apoB-100), and C127 cells transfected to secrete truncated forms of apoB, apoB-41, apoB-29, and apoB-17, respectively, were employed. C127 cells were used to determine whether chaperone binding is dependent on apoB lipidation as they secrete both unlipidated and lipidated apoB forms despite their lack of microsomal triglyceride transfer protein (MTP), which mediates lipidation of apoB in HepG2 cells. The endoplasmic reticulum (ER)-resident molecular chaperones GRP94, calreticulin, and ERp72 were co-immunoprecipitated with apoB-100 from HepG2 cell lysates following cross-linking of proteins in living cells. The same chaperones including BiP/GRP78 were also associated with all truncated forms of apoB. Sequential immunoprecipitation with antibodies to MTP and apoB revealed the presence of ternary complexes containing apoB-100, MTP, and ERp72. However, MTP is not obligatory for the binding of ERp72 as it was associated with all truncated forms of apoB in C127 cells that lack MTP. The interactions between apoB-100 and ERp72 or GRP94 persisted for at least 2 h following a 30-min pulse. Thus, BiP/GRP78, calreticulin, ERp72, and GRP94 may participate in critical steps in the folding of apoB before any substantial lipidation occurs. ERp72 and GRP94 may also mediate the folding of more advanced folding intermediates and/or target the misfolded underlipidated pool of apoB for degradation.	Boston Univ, Sch Med, Dept Biophys, Ctr Adv Biomed Res, Boston, MA 02118 USA	Boston University	Herscovitz, H (corresponding author), Boston Univ, Sch Med, Dept Biophys, Ctr Adv Biomed Res, 715 Albany St, Boston, MA 02118 USA.			Herscovitz, Haya/0000-0001-8067-6091	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058833, R01HL058833, P01HL026335] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58833-02, HL26335-18] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adeli K, 1997, J BIOL CHEM, V272, P22489, DOI 10.1074/jbc.272.36.22489; Baksh S, 1995, J BIOL CHEM, V270, P31338, DOI 10.1074/jbc.270.52.31338; Beggah A, 1996, J BIOL CHEM, V271, P20895, DOI 10.1074/jbc.271.34.20895; Bercovich B, 1997, J BIOL CHEM, V272, P9002; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Burch WL, 1996, CIRCULATION, V94, P867; Bush KT, 1997, J BIOL CHEM, V272, P9086; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; Feng WJ, 1996, J BIOL CHEM, V271, P18543, DOI 10.1074/jbc.271.31.18543; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Ginsberg HN, 1997, CLIN EXP PHARMACOL P, V24, pA29, DOI 10.1111/j.1440-1681.1997.tb03051.x; HAMMOND C, 1993, CURR BIOL, V3, P884, DOI 10.1016/0960-9822(93)90226-E; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; HERSCOVITZ H, 1995, P NATL ACAD SCI USA, V92, P659, DOI 10.1073/pnas.92.3.659; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; Huang XF, 1997, J BIOL CHEM, V272, P31872, DOI 10.1074/jbc.272.50.31872; KANE JP, 1983, METABOLIC BASIS INHE, P1139; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE AQ, 1994, J BIOL CHEM, V269, P7514; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; Luz J M, 1996, EXS, V77, P97; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Shelness GS, 1996, J LIPID RES, V37, P408; Small DM, 1997, CIRCULATION, V96, P3; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Tran K, 1998, J BIOL CHEM, V273, P7244, DOI 10.1074/jbc.273.13.7244; URADE R, 1992, J BIOL CHEM, V267, P15152; URADE R, 1993, J BIOL CHEM, V268, P22004; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; Yao ZM, 1997, J LIPID RES, V38, P1937; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220	58	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21368	21373		10.1074/jbc.273.33.21368	http://dx.doi.org/10.1074/jbc.273.33.21368			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694898	hybrid			2022-12-25	WOS:000075386100091
J	Okamoto, K; Nakayama, K; Kadowaki, T; Abe, N; Ratnayake, DB; Yamamoto, K				Okamoto, K; Nakayama, K; Kadowaki, T; Abe, N; Ratnayake, DB; Yamamoto, K			Involvement of a lysine-specific cysteine proteinase in hemoglobin adsorption and heme accumulation by Porphyromonas gingivalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLACK-PIGMENTED BACTEROIDES; ARG-GINGIPAIN; COLLAGENOLYTIC ACTIVITY; BACTERICIDAL ACTIVITY; PERIODONTAL-DISEASE; MOLECULAR-CLONING; PURIFICATION; PROTEASE; VIRULENCE; COMPLEMENT	The oral anaerobic bacterium Porphyromonas gingivalis, a major pathogen of advanced adult periodontitis, produces a novel class of cysteine proteinases in both cell-associated and secretory forms. A lysine-specific cysteine proteinase (Lys-gingipain, KGP), as well as an arginine-specific cysteine proteinase (Arg-gingipain), is a major trypsin-like proteinase of the organism. Recent studies indicate that the secreted KGP is implicated in the destruction of periodontal tissue and the disruption of host defense mechanisms. In this study, we have constructed a KGP-deficient mutant to determine whether the cell-associated KGP is important for pathophysiology of the organism. Although the mutant retained the strong ability to disrupt the bactericidal activity of polymorphonuclear leukocytes, its hemagglutination activity was reduced to about one-half that observed with the wild-type strain. More important, the mutant did not form black-pigmented colonies on blood agar plates, indicating the defect of hemoglobin adsorption and heme accumulation. Immunoblot analysis showed that the expression of a 19-kDa hemoglobin receptor protein, which is thought to be responsible for hemoglobin binding by the organism, was greatly retarded in this mutant. The mutant also showed a marked decrease in the ability to degrade fibrinogen, These results suggest the possible involvement of RGP in the hemoglobin binding and heme accumulation of the organism and in the bleeding tendency in periodontal pockets.	Kyushu Univ, Fac Dent, Dept Microbiol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Dent, Dept Pharmacol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Yamamoto, K (corresponding author), Kyushu Univ, Fac Dent, Dept Microbiol, Higashi Ku, Fukuoka 8128582, Japan.	kyama@dent.kyushu-u.ac.jp						Abe N, 1998, J BIOCHEM, V123, P305; BarkocyGallagher GA, 1996, J BACTERIOL, V178, P2734, DOI 10.1128/jb.178.10.2734-2741.1996; BEDI GS, 1994, J BIOL CHEM, V269, P599; BIRKEDALHANSEN H, 1988, J PERIODONTAL RES, V23, P258, DOI 10.1111/j.1600-0765.1988.tb01369.x; CHU L, 1991, INFECT IMMUN, V59, P1932, DOI 10.1128/IAI.59.6.1932-1940.1991; CIBOROWSKI P, 1994, J BACTERIOL, V176, P4549, DOI 10.1128/JB.176.15.4549-4557.1994; FRANDSEN EVG, 1987, INFECT IMMUN, V55, P631, DOI 10.1128/IAI.55.3.631-638.1987; Fujimura S, 1996, INFECT IMMUN, V64, P2339, DOI 10.1128/IAI.64.6.2339-2342.1996; Genco CA, 1996, TRENDS MICROBIOL, V4, P179, DOI 10.1016/0966-842X(96)10029-9; GIBBONS RJ, 1960, J BACTERIOL, V80, P164, DOI 10.1128/JB.80.2.164-170.1960; GRENIER D, 1989, ORAL MICROBIOL IMMUN, V4, P12, DOI 10.1111/j.1399-302X.1989.tb00400.x; GRENIER D, 1992, INFECT IMMUN, V60, P1854, DOI 10.1128/IAI.60.5.1854-1857.1992; Han NM, 1996, INFECT IMMUN, V64, P4000, DOI 10.1128/IAI.64.10.4000-4007.1996; HINODE D, 1992, ARCH ORAL BIOL, V37, P859, DOI 10.1016/0003-9969(92)90120-W; IMAMURA T, 1995, INFECT IMMUN, V63, P4877, DOI 10.1128/IAI.63.12.4877-4882.1995; IMAMURA T, 1994, J CLIN INVEST, V94, P361, DOI 10.1172/JCI117330; KADOWAKI T, 1994, J BIOL CHEM, V269, P21371; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON DA, 1992, INFECT IMMUN, V60, P1524, DOI 10.1128/IAI.60.4.1524-1529.1992; Lee SW, 1996, INFECT IMMUN, V64, P4802, DOI 10.1128/IAI.64.11.4802-4810.1996; LINDEGREN CC, 1955, SCIENCE, V121, P605, DOI 10.1126/science.121.3147.605; LIPPKE JA, 1987, APPL ENVIRON MICROB, V53, P2588, DOI 10.1128/AEM.53.10.2588-2589.1987; MCKEE AS, 1988, J MED MICROBIOL, V27, P59, DOI 10.1099/00222615-27-1-59; Nakayama K, 1996, J BACTERIOL, V178, P2818, DOI 10.1128/jb.178.10.2818-2824.1996; NAKAYAMA K, 1995, J BIOL CHEM, V270, P23619, DOI 10.1074/jbc.270.40.23619; Nakayama K, 1997, MICROBIOL IMMUNOL, V41, P185, DOI 10.1111/j.1348-0421.1997.tb01189.x; Nakayama K, 1998, MOL MICROBIOL, V27, P51, DOI 10.1046/j.1365-2958.1998.00656.x; NIEKRASH CE, 1986, J PERIODONTAL RES, V21, P233; Okamoto K, 1996, J BIOCHEM-TOKYO, V120, P398; OKAMOTO K, 1995, ARCH BIOCHEM BIOPHYS, V316, P917, DOI 10.1006/abbi.1995.1123; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; Pavloff N, 1997, J BIOL CHEM, V272, P1595, DOI 10.1074/jbc.272.3.1595; POTEMPA J, 1995, INFECT IMMUN, V63, P1176, DOI 10.1128/IAI.63.4.1176-1182.1995; SCHENKEIN HA, 1988, J PERIODONTAL RES, V23, P187, DOI 10.1111/j.1600-0765.1988.tb01356.x; SCOTT CF, 1993, J BIOL CHEM, V268, P7935; SHAH HN, 1989, FEMS MICROBIOL LETT, V61, P213, DOI 10.1016/0378-1097(89)90199-7; SHAH HN, 1979, BIOCHEM J, V180, P45, DOI 10.1042/bj1800045; SHAH HN, 1989, ORAL MICROBIOL IMMUN, V4, P19, DOI 10.1111/j.1399-302X.1989.tb00401.x; SOJAR HT, 1993, INFECT IMMUN, V61, P2369, DOI 10.1128/IAI.61.6.2369-2376.1993; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUNDQVIST G, 1988, ORAL MICROBIOL IMMUN, V3, P103, DOI 10.1111/j.1399-302X.1988.tb00093.x; SUNDQVIST G, 1987, J PERIODONTAL RES, V22, P300, DOI 10.1111/j.1600-0765.1987.tb01589.x; SUNDQVIST GK, 1984, SCAND J DENT RES, V92, P14; TODA K, 1984, J PERIODONTAL RES, V19, P372, DOI 10.1111/j.1600-0765.1984.tb01010.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Travis J, 1997, J PERIODONTAL RES, V32, P120, DOI 10.1111/j.1600-0765.1997.tb01392.x; UITTO VJ, 1989, INFECT IMMUN, V57, P213, DOI 10.1128/IAI.57.1.213-218.1989; Yamamoto K, 1997, BIOM HLTH R, V15, P139; YONEDA M, 1990, INFECT IMMUN, V58, P406, DOI 10.1128/IAI.58.2.406-411.1990	50	134	136	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21225	21231		10.1074/jbc.273.33.21225	http://dx.doi.org/10.1074/jbc.273.33.21225			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694880	hybrid			2022-12-25	WOS:000075386100073
J	Torrance, H; Giffin, W; Rodda, DJ; Pope, L; Hache, RJG				Torrance, H; Giffin, W; Rodda, DJ; Pope, L; Hache, RJG			Sequence-specific binding of Ku autoantigen to single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; LONG TERMINAL REPEAT; DEPENDENT PROTEIN-KINASE; MULTIPLE REGULATORY ELEMENTS; RNA POLYMERASE-II; ALPHA-ACTIN GENE; TRANSCRIPTION FACTOR; V(D)J RECOMBINATION; MMTV PROMOTER; MEDIATES INDUCTION	Glucocorticoid-induced transcription of mouse mammary tumor virus is repressed by Ku antigen/DNA-dependent protein kinase (DNA-PK) through a DNA sequence element (NRE1) in the viral long terminal repeat. Nuclear factors binding to the separated single strands of NRE1 have been identified that may also be important for transcriptional regulation through this element. We report the separation of the upper-stranded NRE1 binding activity in Jurkat T cell nuclear extracts into two components. One component was identified as Ku antigen. The DNA sequence preference for Ku binding to single-stranded DNA closely paralleled the sequence requirements of Ku for double-stranded DNA. Recombinant Ku bound the single, upper strand of NRE1 with an affinity that was 3-4-fold lower than its affinity for double-stranded NRE1, Sequence-specific single-stranded Ku binding occurred rapidly (t(1/2) on = 2.0 min) and was exceptionally stable, with an off rate of t(1/2) = 68 min. While Ku70 cross-linked to the upper strand of NRE1 when Ku was bound to double-stranded and single-stranded DNAs, the Ku80 subunit only crosslinked to single-stranded NRE1, Intriguingly, addition of Mg2+ and ATP, the cofactors required for Ku helicase activity, induced the cross-linking of Ku80 to a double-stranded NRE1-containing oligonucleotide, without completely unwinding the two strands.	Univ Ottawa, Dept Med, Ottawa Civic Hosp, Loeb Inst Med Res, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa Civic Hosp, Loeb Inst Med Res, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Grad Program Biochem, Ottawa Civic Hosp, Loeb Inst Med Res, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Hache, RJG (corresponding author), Univ Ottawa, Dept Med, Ottawa Civic Hosp, Loeb Inst Med Res, 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.	hache@civich.ottawa.on.ca						ALTIOK S, 1993, MOL CELL BIOL, V13, P7303, DOI 10.1128/MCB.13.12.7303; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BALL JK, 1988, J VIROL, V62, P2985, DOI 10.1128/JVI.62.8.2985-2993.1988; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Bliss TM, 1997, J BIOL CHEM, V272, P5765, DOI 10.1074/jbc.272.9.5765; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CAO QP, 1994, BIOCHEMISTRY-US, V33, P8548, DOI 10.1021/bi00194a021; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; Chavez S, 1997, P NATL ACAD SCI USA, V94, P2885, DOI 10.1073/pnas.94.7.2885; COGAN JG, 1995, J BIOL CHEM, V270, P11310, DOI 10.1074/jbc.270.19.11310; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DICROCE PA, 1995, P NATL ACAD SCI USA, V92, P10137, DOI 10.1073/pnas.92.22.10137; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY JP, 1986, J VIROL, V57, P385, DOI 10.1128/JVI.57.1.385-388.1986; DVIR A, 1993, J BIOL CHEM, V268, P10440; FALZON M, 1993, J BIOL CHEM, V268, P10546; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GERSTLE JT, 1993, ELECTROPHORESIS, V14, P725, DOI 10.1002/elps.11501401115; GIFFIN W, 1994, J BIOL CHEM, V269, P1449; Giffin W, 1995, DNA CELL BIOL, V14, P1025, DOI 10.1089/dna.1995.14.1025; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GIFIN W, 1997, J BIOL CHEM, V272, P5647; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GOUILLEUX F, 1991, NUCLEIC ACIDS RES, V19, P1563, DOI 10.1093/nar/19.7.1563; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; HSU CLL, 1988, J VIROL, V62, P4644, DOI 10.1128/JVI.62.12.4644-4652.1988; JANSENDURR P, 1992, NUCLEIC ACIDS RES, V20, P1243, DOI 10.1093/nar/20.6.1243; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; KADANOGA JT, 1986, P NATL ACAD SCI USA, V83, P5889; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; Kelm RJ, 1996, J BIOL CHEM, V271, P24278, DOI 10.1074/jbc.271.39.24278; KIM MH, 1995, J VIROL, V69, P4717, DOI 10.1128/JVI.69.8.4717-4726.1995; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; KUSK P, 1995, MOL ENDOCRINOL, V9, P1180, DOI 10.1210/me.9.9.1180; Kusk P, 1996, J BIOL CHEM, V271, P31269, DOI 10.1074/jbc.271.49.31269; Laskowski M., 1971, HYDROLYSIS, V4, P289; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; LEE JW, 1991, J BIOL CHEM, V266, P24101; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; LIU ES, 1991, NUCLEIC ACIDS RES, V19, P5425, DOI 10.1093/nar/19.19.5425; MAY G, 1991, J BIOL CHEM, V266, P3052; MCCORMICK L, 1992, J VIROL, V66, P3435, DOI 10.1128/JVI.66.6.3435-3447.1992; MESSIER H, 1993, P NATL ACAD SCI USA, V90, P2685, DOI 10.1073/pnas.90.7.2685; MINK S, 1990, NUCLEIC ACIDS RES, V18, P2017, DOI 10.1093/nar/18.8.2017; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MOORE S, 1981, ENZYMES A, V14, P281; MORLEY KL, 1987, NUCLEIC ACIDS RES, V15, P6973, DOI 10.1093/nar/15.17.6973; MUKHERJEE R, 1993, NUCLEIC ACIDS RES, V21, P2655, DOI 10.1093/nar/21.11.2655; NORDSTROM LA, 1993, J BIOL CHEM, V268, P13193; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ochem AE, 1997, J BIOL CHEM, V272, P29919, DOI 10.1074/jbc.272.47.29919; OKUMURA K, 1994, FEBS LETT, V356, P94, DOI 10.1016/0014-5793(94)01243-1; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; PINA B, 1990, MOL CELL BIOL, V10, P625, DOI 10.1128/MCB.10.2.625; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P391; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RODDA DJ, 1995, BIOCHEM BIOPH RES CO, V209, P379, DOI 10.1006/bbrc.1995.1514; Romero F, 1996, MOL CELL BIOL, V16, P37; Sakatsume O, 1996, J BIOL CHEM, V271, P31322, DOI 10.1074/jbc.271.49.31322; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; STEWART TA, 1988, MOL CELL BIOL, V8, P473, DOI 10.1128/MCB.8.1.473; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TANUMA Y, 1995, MOL CELL BIOL, V15, P517, DOI 10.1128/MCB.15.1.517; THEUNISSEN HJM, 1989, J VIROL, V63, P3466, DOI 10.1128/JVI.63.8.3466-3471.1989; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VANOOYEN A, 1990, J VIROL, V64, P4043; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; YANAGAWA SI, 1993, J VIROL, V67, P112, DOI 10.1128/JVI.67.1.112-118.1993; YANAGAWA SI, 1990, J VIROL, V64, P2474, DOI 10.1128/JVI.64.6.2474-2483.1990; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	88	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20810	20819		10.1074/jbc.273.33.20810	http://dx.doi.org/10.1074/jbc.273.33.20810			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694826	hybrid			2022-12-25	WOS:000075386100019
J	Rim, JS; Atta, MG; Dahl, SC; Berry, GT; Handler, JS; Kwon, HM				Rim, JS; Atta, MG; Dahl, SC; Berry, GT; Handler, JS; Kwon, HM			Transcription of the sodium/myo-inositol cotransporter gene is regulated by multiple tonicity-responsive enhancers spread over 50 kilobase pairs in the 5 '-flanking region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTONIC STRESS; ALDOSE REDUCTASE; OSMOTIC-STRESS; MESSENGER-RNA; RAT-KIDNEY; IN-VIVO; EXPRESSION; CELLS; DEHYDROGENASE; OSMOLYTES	The sodium/myo-inositol cotransporter is a plasma membrane protein responsible for concentrative cellular accumulation of myo-inositol in a variety of tissues. When cells in kidney and brain are exposed to a hyperosmolar salt condition (hypertonicity) due to the operation of urinary concentration mechanism and pathological conditions, respectively; they survive the stress of hypertonicity by raising the cellular concentration of myo-inositol. Transcription of the sodium/myo-inositol cotransporter gene is markedly stimulated in response to hypertonicity, leading to an increase in the activity of the cotransporter, which in turn drives the osmoprotective accumulation of myo-inositol. To understand the molecular mechanisms by which hypertonicity stimulates transcription, we analyzed the BI-flanking region of the cotransporter gene for cis-acting regulatory sequences. We identified five tonicity-responsive enhancers that are scattered over 50 kilobase pairs. All the enhancers are variations of the same type of enhancer interacting with the transcription factor named tonicity-responsive enhancer binding protein. In vivo methylation experiments demonstrated that exposure of cells to hypertonicity increases the binding of tonicity-responsive enhancer binding protein to the enhancer sites, indicating that all of these enhancers are involved in the transcriptional stimulation. We conclude that the sodium/myo-inositol cotransporter gene is regulated by a large region (similar to 50 kilobase pairs) upstream of the gene.	Johns Hopkins Univ, Sch Med, Div Nephrol, Baltimore, MD 21205 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	Johns Hopkins University; University of Pennsylvania	Kwon, HM (corresponding author), 963 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.		Lee-Kwon, Whaseon/D-6021-2011	Berry, Gerard/0000-0001-5299-3313	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042479, F32DK009469, T32DK007712] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32 DK009469-01, F32 DK009469, DK42479, DK07712, DK09469] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Ferraris JD, 1996, AM J PHYSIOL-CELL PH, V270, pC650, DOI 10.1152/ajpcell.1996.270.2.C650; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.me.44.020193.001445; HAGER K, 1995, J MEMBRANE BIOL, V143, P103; Ibsen L, 1996, AM J PHYSIOL-RENAL, V271, pF877, DOI 10.1152/ajprenal.1996.271.4.F877; ISHITANI M, 1995, PLANT MOL BIOL, V27, P307, DOI 10.1007/BF00020185; Kitamura H, 1998, KIDNEY INT, V53, P146, DOI 10.1046/j.1523-1755.1998.00747.x; Kitamura H, 1997, AM J PHYSIOL-RENAL, V272, pF267, DOI 10.1152/ajprenal.1997.272.2.F267; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; KWON HM, 1992, J BIOL CHEM, V267, P6297; KWON HM, 1995, CURR OPIN CELL BIOL, V7, P465, DOI 10.1016/0955-0674(95)80002-6; KWON HM, 1993, CELLULAR MOL PHYSL C, P383; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LUCHT JM, 1994, J BIOL CHEM, V269, P6578; Mallee JJ, 1997, GENOMICS, V46, P459, DOI 10.1006/geno.1997.5055; Minami Y, 1996, MOL BRAIN RES, V40, P64; Miyakawa H, 1998, AM J PHYSIOL-RENAL, V274, pF753, DOI 10.1152/ajprenal.1998.274.4.F753; Morimura H, 1996, MOL BRAIN RES, V35, P333, DOI 10.1016/0169-328X(95)00245-N; Rim JS, 1997, ARCH BIOCHEM BIOPHYS, V341, P193, DOI 10.1006/abbi.1997.9950; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; UCHIDA S, 1989, AM J PHYSIOL, V256, pC614, DOI 10.1152/ajpcell.1989.256.3.C614; UCHIDA S, 1991, J CLIN INVEST, V88, P656, DOI 10.1172/JCI115350; UCHIDA S, 1993, J CLIN INVEST, V91, P1604, DOI 10.1172/JCI116367; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; YAMAUCHI A, 1995, J CLIN INVEST, V96, P1195, DOI 10.1172/JCI118151; YAMAUCHI A, 1994, J AM SOC NEPHROL, V5, P62; YAMAUCHI A, 1993, AM J PHYSIOL, V264, pF20, DOI 10.1152/ajprenal.1993.264.1.F20; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; ZHOU C, 1997, EXP EYE RES, V35, P349	31	140	141	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20615	20621		10.1074/jbc.273.32.20615	http://dx.doi.org/10.1074/jbc.273.32.20615			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685419	hybrid, Green Accepted			2022-12-25	WOS:000075305400096
J	Seybold, J; Newton, R; Wright, L; Finney, PA; Suttorp, N; Barnes, PJ; Adcock, IM; Giembycz, MA				Seybold, J; Newton, R; Wright, L; Finney, PA; Suttorp, N; Barnes, PJ; Adcock, IM; Giembycz, MA			Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and G(s)-coupled receptor agonists - Potential role in beta(2)-adrenoreceptor desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP-PHOSPHODIESTERASE; CAMP-SPECIFIC PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; MESSENGER-RNA; NUCLEOTIDE PHOSPHODIESTERASE; MOLECULAR-CLONING; DROSOPHILA-MELANOGASTER; HORMONAL-REGULATION; ASTHMA; GENE	In this study, a potential mechanism of beta(2)-adrenoreceptor desensitization has been explored that is based upon the enhanced degradation of cAMP by phosphodiesterase (PDE), Pretreatment of Jurkat T-cells with 8-bromo cAMP (8-Br-cAMP) or prostaglandin E-2 increased PDE3 and PDE4 activity in an actinomycin D- and cycloheximide-sensitive manner. This effect was associated with increased expression of HSPDE3B, HSPDE4A4, HSPDE4D1, HSPDE4D2, and HSPDE4D3 mRNA transcripts. Western analysis reproducibly labeled a band of immunoreactivity in vehicle-treated cells that corresponded to HSPDE4A4 (125 kDa). Although the intensity of this band was unchanged in cells treated with 8-Br-cAMP, additional 68-72-kDa proteins (HSPDE4D2, HSPDE4D1) were labeled that were not detected after vehicle. Similar results were obtained with T-lymphocytes exposed to 8-Br-cAMP and fenoterol, However, in those experiments HSPDE4A4 and HSPDE4D1 appeared to be equally expressed in vehicle- and treated cells, whereas HSPDE4D2 (72 kDa) was detected only after 8-Br-cAMP. The up-regulation of PDE activity in Jurkat T-cells abolished the ability of isoproterenol to elevate cAMP, which was partially reversed by the non-selective PDE inhibitor, 3-isobutyl-1-methyl-xanthine, and by the PDE3 and PDE4 inhibitors, Org 9935 and rolipram, respectively. Collectively, these data suggest that chronic treatment of T-cells with cAMP-elevating agents compromises beta(2)-adrenoreceptor-mediated cAMP accumulation by increasing the expression of HSPDE3B and HSPDE4D gene products.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England	Imperial College London	Giembycz, MA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	m.giembycz@ic.ac.uk	Newton, Robert/C-6814-2012; Adcock, Ian/L-3217-2019	Newton, Robert/0000-0002-4919-8498; Adcock, Ian/0000-0003-2101-8843; Suttorp, Norbert/0000-0002-3958-1151; Barnes, Peter/0000-0002-5122-4018; Seybold, Joachim/0000-0003-1444-8976				ALVAREZ R, 1995, MOL PHARMACOL, V48, P616; BAECKER PA, 1994, GENE, V138, P253, DOI 10.1016/0378-1119(94)90818-4; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; Bloom TJ, 1996, P NATL ACAD SCI USA, V93, P14188, DOI 10.1073/pnas.93.24.14188; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; Bolger GB, 1997, BIOCHEM J, V328, P539; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; CHERRY JA, 1995, J NEUROBIOL, V28, P102, DOI 10.1002/neu.480280109; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; DENT G, 1995, CLIN IMMUNOTHER, V3, P423, DOI 10.1007/BF03259062; ENGELS P, 1994, FEBS LETT, V350, P291, DOI 10.1016/0014-5793(94)00788-8; ENGELS P, 1995, FEBS LETT, V358, P305, DOI 10.1016/0014-5793(94)01460-I; GARDINER PV, 1994, AM J RESP CRIT CARE, V150, P1006, DOI 10.1164/ajrccm.150.4.7921429; GETTYS TW, 1988, J BIOL CHEM, V263, P10359; Giembycz MA, 1996, BRIT J PHARMACOL, V118, P1945, DOI 10.1111/j.1476-5381.1996.tb15629.x; Giembycz MA, 1996, TRENDS PHARMACOL SCI, V17, P331, DOI 10.1016/0165-6147(96)10039-0; GIEMBYCZ MA, 1992, BIOCHEM PHARMACOL, V43, P2041, DOI 10.1016/0006-2952(92)90160-K; GIEMBYCZ MA, 1994, METHYLXANTHINES PHOS, P27; ICHIMURA M, 1993, BIOCHEM BIOPH RES CO, V193, P985, DOI 10.1006/bbrc.1993.1722; Kochetkova M, 1995, BIOCHEM PHARMACOL, V50, P2033, DOI 10.1016/0006-2952(95)02104-3; KOVALA T, 1994, J BIOL CHEM, V269, P8680; KUEHL FA, 1987, AM REV RESPIR DIS, V136, P210, DOI 10.1164/ajrccm/136.1.210; LIVI GP, 1990, MOL CELL BIOL, V10, P2678, DOI 10.1128/MCB.10.6.2678; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; Manning CD, 1996, J PHARMACOL EXP THER, V276, P810; MANOLITSAS ND, 1995, AM J RESP CRIT CARE, V151, P1925, DOI 10.1164/ajrccm.151.6.7767541; MCLAUGHLIN MM, 1993, J BIOL CHEM, V268, P6470; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; MICHAELI T, 1993, J BIOL CHEM, V268, P12925; Miki T, 1996, GENOMICS, V36, P476, DOI 10.1006/geno.1996.0493; Mirabet M, 1997, BRIT J PHARMACOL, V122, P1075, DOI 10.1038/sj.bjp.0701495; MONACO L, 1994, J BIOL CHEM, V269, P347; Nemoz G, 1996, FEBS LETT, V384, P97, DOI 10.1016/0014-5793(96)00300-6; OBERNOLTE R, 1993, GENE, V129, P239, DOI 10.1016/0378-1119(93)90274-7; PARSONS WJ, 1988, MOL PHARMACOL, V34, P37; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; SETTE C, 1994, MOL CELL ENDOCRINOL, V100, P75, DOI 10.1016/0303-7207(94)90282-8; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; SETTE C, 1994, J BIOL CHEM, V269, P18271; SHAHID M, 1991, BRIT J PHARMACOL, V102, pP314; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; SULLIVAN M, 1994, CELL SIGNAL, V6, P793, DOI 10.1016/0898-6568(94)00039-5; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; Taylor DR, 1996, MED CLIN N AM, V80, P719, DOI 10.1016/S0025-7125(05)70465-X; TENOR H, 1995, CLIN EXP ALLERGY, V25, P616, DOI 10.1111/j.1365-2222.1995.tb01109.x; TENOR H, 1995, J INVEST DERMATOL, V105, P70, DOI 10.1111/1523-1747.ep12313330; TORPHY TJ, 1992, J PHARMACOL EXP THER, V263, P1195; TORPHY TJ, 1995, J BIOL CHEM, V270, P23598, DOI 10.1074/jbc.270.40.23598; TORPHY TJ, 1991, THORAX, V46, P512, DOI 10.1136/thx.46.7.512; TORPHY TJ, 1994, ENVIRON HEALTH PERSP, V102, P79, DOI 10.2307/3432220; VERGHESE MW, 1995, MOL PHARMACOL, V47, P1164	61	88	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20575	20588		10.1074/jbc.273.32.20575	http://dx.doi.org/10.1074/jbc.273.32.20575			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685415	hybrid			2022-12-25	WOS:000075305400092
J	Waters, TR; Swann, PF				Waters, TR; Swann, PF			Kinetics of the action of thymine DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; MISMATCH REPAIR; CHROMATOGRAPHIC-SEPARATION; STRUCTURAL BASIS; HELA-CELLS; URACIL; PURIFICATION; EXTRACTS; O-6-METHYLGUANINE; SPECIFICITY	The time course of removal of thymine by thymine DNA glycosylase has been measured in vitro. Each molecule of thymine DNA glycosylase removes only one molecule of thymine from DNA containing a G.T mismatch because it binds tightly to the apurinic DNA site left after removal of thymine. The 5'-flanking base pair to G.T mismatches influences the rate of removal of thymine: k(cat) values with C.G, T.A, G.C, and A.T as the 5'-base pair were 0.91, 0.023, 0.0046, and 0.0013 min(-l), respectively. Thymine DNA glycosylase can also remove thymine from mismatches with S(6)-methylthioguanine, but, unlike G.T mismatches, a 5'-C.G does not have a striking effect on the rate: k(cat) values for removal of thymine from (SMe)G.T With C.G, T.A, G.C, and A.T as the 5'-base pair were 0.026, 0.018, 0.0017, and 0.0010 min(-l), respectively. Thymine removal is fastest when it is from a G.T mismatch with a 5'-flanking C.G pair, suggesting that the rapid reaction of this substrate involves contacts between the enzyme and oxygen 6 or the N-l hydrogen of the mismatched guanine as well as the 5'-flanking C.G pair. Disrupting either of these sets of contacts (i,e. replacing the 5'-flanking C.G base pair with a T.A or replacing the G.T mismatch with (SMe)G.T) has essentially the same effect on rate as disrupting both sets (i,e. replacing CpG.T with Tp(Sme)G.T), and so these contacts are probably cooperative. The glycosylase removes uracil from G.U, C.U, and T.U base pairs faster than it removes thymine from G.T. It can even remove uracil from A.U base pairs, although at a very much lower rate. Thus, thymine DNA glycosylase may play a backup role to the more efficient general uracil DNA glycosylase.	Univ London Univ Coll, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of London; University College London	Waters, TR (corresponding author), Univ London Univ Coll, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.	t.waters@biochem.ucl.ac.uk						AFEYAN NB, 1990, J CHROMATOGR, V519, P1, DOI 10.1016/0021-9673(90)85132-F; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Ceccotti S, 1996, CURR BIOL, V6, P1528, DOI 10.1016/S0960-9822(96)00758-0; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; GRIFFIN S, 1994, BIOCHEMISTRY-US, V33, P4787, DOI 10.1021/bi00182a006; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; Karran P, 1996, CHEM BIOL, V3, P875, DOI 10.1016/S1074-5521(96)90175-1; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Krokan HE, 1997, BIOCHEM J, V325, P1; MAXAM AM, 1977, P NATL ACAD SCI USA, V91, P1642; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; PEGG AE, 1990, CANCER RES, V50, P6119; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; Scharer OD, 1997, P NATL ACAD SCI USA, V94, P4878, DOI 10.1073/pnas.94.10.4878; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SIBGHATULLAH, 1995, BIOCHEMISTRY-US, V34, P6869, DOI 10.1021/bi00020a034; SibghatUllah, 1996, BIOCHEMISTRY-US, V35, P12926, DOI 10.1021/bi961022u; Singh J, 1996, J BIOL CHEM, V271, P28391, DOI 10.1074/jbc.271.45.28391; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; Waters TR, 1997, BIOCHEMISTRY-US, V36, P2501, DOI 10.1021/bi9621573; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; XU YZ, 1992, ANAL BIOCHEM, V204, P185, DOI 10.1016/0003-2697(92)90159-5	32	134	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20007	20014		10.1074/jbc.273.32.20007	http://dx.doi.org/10.1074/jbc.273.32.20007			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685338	hybrid			2022-12-25	WOS:000075305400015
J	Xu, SQ; Tang, DH; Chamberlain, S; Pronk, G; Masiarz, FR; Kaur, S; Prisco, M; Zanocco-Marani, T; Baserga, R				Xu, SQ; Tang, DH; Chamberlain, S; Pronk, G; Masiarz, FR; Kaur, S; Prisco, M; Zanocco-Marani, T; Baserga, R			The granulin/epithelin precursor abrogates the requirement for the insulin-like growth factor 1 receptor for growth in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERM DNA TOPOISOMERASE; FACTOR-I RECEPTOR; GRANULIN PRECURSOR; POLYACRYLAMIDE GELS; EPITHELIN PRECURSOR; CELL-GROWTH; MAP KINASE; E-DOMAIN; GENE; PURIFICATION	3T3 cells null for the type 1 insulin-like growth factor receptor are refractory to stimulation by a variety of purified growth factors that are known to be required for the stimulation of other 3T3 cells. However, these cells, known as R- cells, grow in serum-supplemented medium and also in media conditioned by certain cell lines. We report here the purification of a growth factor that stimulates DNA synthesis (and growth) of R- cells. The growth factor, purified to homogeneity by SDS-polyacrylamide gel electrophoresis, was identified as the granulin/epithelin precursor by an accurate determination of the masses of endoproteinase Lys-C peptides using matrix-assisted laser desorption ionization mass spectrometry, followed by a data base search. The granulin/epithelin precursor is a little known growth factor, secreted by a variety of epithelial and hemopoietic cells. It is at present the only purified growth factor that can stimulate the growth of mouse embryo fibroblasts null for the type 1 insulin-like growth factor receptor.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Calif San Francisco, Chiron Corp, San Francisco, CA 94608 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94608 USA	Jefferson University; Novartis; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.		Zanocco Marani, Tommaso/D-5801-2015	Zanocco Marani, Tommaso/0000-0002-9911-7078	NIA NIH HHS [AG 00378] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BABA T, 1993, FEBS LETT, V322, P89, DOI 10.1016/0014-5793(93)81544-A; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BATEMAN A, 1990, BIOCHEM BIOPH RES CO, V173, P1161, DOI 10.1016/S0006-291X(05)80908-8; BELCOURT DR, 1993, J BIOL CHEM, V268, P9230; Bhandari V, 1996, BIOCHEM J, V319, P441, DOI 10.1042/bj3190441; BHANDARI V, 1992, P NATL ACAD SCI USA, V89, P1715, DOI 10.1073/pnas.89.5.1715; BHANDARI V, 1992, BIOCHEM BIOPH RES CO, V188, P57, DOI 10.1016/0006-291X(92)92349-3; BHANDARI V, 1993, ENDOCRINOLOGY, V133, P2682, DOI 10.1210/en.133.6.2682; Bucan M, 1996, MAMM GENOME, V7, P704, DOI 10.1007/s003359900212; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P10458; DANGELIS T, 1995, J CELL PHYSL, V164, P214; DULAK NC, 1973, J CELL PHYSIOL, V81, P161, DOI 10.1002/jcp.1040810205; DYNAN WS, 1981, J BIOL CHEM, V256, P5860; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; Hrabal R, 1996, NAT STRUCT BIOL, V3, P747, DOI 10.1038/nsb0996-747; HYLKA VW, 1990, BIOCHIM BIOPHYS ACTA, V1051, P6, DOI 10.1016/0167-4889(90)90167-C; HYLKA VW, 1985, J BIOL CHEM, V260, P4417; ISHII K, 1983, J BIOL CHEM, V258, P2728; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Parnell PG, 1992, GROWTH FACTORS, V7, P65, DOI 10.3109/08977199209023938; PARNELL PG, 1995, J RECEPT SIGNAL TR R, V15, P747, DOI 10.3109/10799899509079904; PLOWMAN GD, 1992, J BIOL CHEM, V267, P13073; Rechler MM, 1997, ENDOCRINOLOGY, V138, P2645, DOI 10.1210/en.138.7.2645; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; Sparro G, 1997, PROTEIN EXPRES PURIF, V10, P169, DOI 10.1006/prep.1997.0726; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xu SQ, 1997, CELL PROLIFERAT, V30, P295; ZHOU J, 1993, J BIOL CHEM, V268, P10863; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	45	82	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20078	20083		10.1074/jbc.273.32.20078	http://dx.doi.org/10.1074/jbc.273.32.20078			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685348	hybrid, Green Published			2022-12-25	WOS:000075305400025
J	Yoneyama, T; Hatakeyama, K				Yoneyama, T; Hatakeyama, K			Decameric GTP cyclohydrolase I forms complexes with two pentameric GTP cyclohydrolase I feedback regulatory proteins in the presence of phenylalanine or of a combination of tetrahydrobiopterin and GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS; PURIFICATION; DEFICIENCY; CLONING; ENZYME	The activity of GTP cyclohydrolase I is inhibited by (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) and stimulated by phenylalanine through complex formation with GTP cyclohydrolase I feedback regulatory protein (GFRP). Gel filtration experiments as well as enzyme activity measurements showed that the number of subunits of GFRP in both the inhibitory and stimulatory complexes is equal to that of GTP cyclohydrolase I. Because GFRP is a pentamer and GTP cyclohydrolase I was shown here by cross-linking experiments to be a decamer, the results indicate that two molecules of a pentameric GFRP associate with one molecule of GTP cyclohydrolase I. Gel filtration analysis suggested that the complex has a radius of gyration similar to that of the enzyme itself. These observations support our model that one molecule of GFRP binds to each of the two outer faces of the torus-shaped GTP cyclohydrolase I. For formation of the inhibitory protein complex, both BH4, and GTP were required; the median effective concentrations of BH4 and GTP were 2 and 26 mu M, respectively. BH4 was the most potent of biopterins with different oxidative states. Among GTP analogues, dGTP as well as guanosine 5'-O-(3'-thiotriphosphate) exhibited similar inducibility compared with GTP, whereas other nucleotide triphosphates had no effect. On the other hand, phenylalanine alone was enough for formation of the stimulatory protein complex, and positive cooperativity was found for the phenylalanine-induced protein complex formation. Phenylalanine was the most potent of the aromatic amino acids.	Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hatakeyama, K (corresponding author), Univ Pittsburgh, Dept Surg, Kaufman Bldg,Suite 300,3471 5th Ave, Pittsburgh, PA 15213 USA.		Yoneyama, Tohru/ABG-2670-2020		NIDDK NIH HHS [DK51257] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051257] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENESADOUN A, 1976, ANAL BIOCHEM, V70, P241; DHONDT JL, 1983, EUR J PEDIATR, V141, P92, DOI 10.1007/BF00496797; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HATAKEYAMA K, 1989, J BIOL CHEM, V264, P21660; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; HATAKEYAMA K, 1997, METHOD MOL BIOL, V100, P267; KATZENMEIER G, 1991, BIOL CHEM H-S, V372, P991, DOI 10.1515/bchm3.1991.372.2.991; KAUFMAN S, 1985, BIOCHEM SOC T, V13, P433, DOI 10.1042/bst0130433; KAUFMAN S, 1978, NEW ENGL J MED, V299, P673, DOI 10.1056/NEJM197809282991301; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEMING RJ, 1976, ARCH DIS CHILD, V51, P771, DOI 10.1136/adc.51.10.771; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Milstien S, 1996, J BIOL CHEM, V271, P19743, DOI 10.1074/jbc.271.33.19743; NAR H, 1995, STRUCTURE, V3, P459, DOI 10.1016/S0969-2126(01)00179-4; NEWMANN U, 1996, PROTEIN PROTOCOLS HD, P173; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; Weber K., 1975, PROTEINS, VI, P179; Yoneyama T, 1997, J BIOL CHEM, V272, P9690	18	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20102	20108		10.1074/jbc.273.32.20102	http://dx.doi.org/10.1074/jbc.273.32.20102			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685352	hybrid			2022-12-25	WOS:000075305400029
J	Espanel, X; Le Cam, L; North, S; Sardet, C; Brun, G; Gillet, G				Espanel, X; Le Cam, L; North, S; Sardet, C; Brun, G; Gillet, G			Regulation of E2F-1 gene expression in avian cells	ONCOGENE			English	Article						E2F; retina; differentiation; transcription; genomic footprinting	UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTION FACTOR; S-PHASE; DIFFERENTIATION; PROLIFERATION; DEGRADATION; APOPTOSIS; INDUCTION; ELEMENTS; PROMOTER	E2F-1 is the prototype of a family of transcription factors playing a central role in the control of cell proliferation and apoptosis, E2F DNA binding activity is down-regulated during cellular differentiation, which is correlated with cell division arrest. We report here that the expression of E2F-1 itself is down-regulated in the developing quail neural retina between embryonic days E8-E10, This event occurs just after the massive arrest of the quail neuroretina cell division (E7-E8), To gain further insight into the regulatory mechanisms monitoring E2F-1 expression in differentiating neurons, we have cloned the quail E2F-1 promoter. In vivo DNA footprintings of this promoter have shown that a number of potential SP-1 and C/EBP response elements are constitutively occupied in the entire quail neuroretina of E5 and E14, whereas the two consensus palindromic E2F binding sites are only protected at E5, This suggests that these E2F elements participate in down-regulation of E2F-1 gene expression during avian neuroretina development. CAT reporter assays have shown that E2F-1 in association with its partner DP-1 transactivates its own promoter, whereas p105(Rb) inhibits the E2F-1 promoter. Both E2F-1/DP-1 and pl05(Rb) require the presence of the E2F binding sites to mediate their effects. However, experiments performed with deletion mutants of the promoter strongly suggest that other regions located upstream of the E2F binding sites also mediate part of the E2F-1 transactivating effect on its own promoter. Altogether, these results suggest that the down-regulation of E2F-1 gene expression in differentiating neurons could be due, in part, to the E2F/Rb complexes binding to the E2F-1 promoter.	Inst Biol & Chim Prot, UPR 412 CNRS, F-69367 Lyon 07, France; Ecole Normale Super Lyon, UMR 49 CNRS, Lab Biol Mol & Cellulaire, F-69364 Lyon 07, France; CNRS, UMR 9942, Ctr Mol Genet, F-34033 Montpellier 01, France	Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS)	Gillet, G (corresponding author), Inst Biol & Chim Prot, UPR 412 CNRS, 7 Passage Vercors, F-69367 Lyon 07, France.		Le Cam, Laurent/O-1408-2016; gillet, germain/A-9095-2013	GILLET, Germain/0000-0002-1514-327X; LE CAM, Laurent/0000-0003-0325-878X				ALTSHULER DM, 1991, P RET RES F, V3, P37; ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; CORBEIL HB, 1995, ONCOGENE, V11, P909; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; Espanel X, 1997, INT J DEV BIOL, V41, P469; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GILLET G, 1993, ONCOGENE, V8, P565; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUGUES SH, 1987, J VIROL, V61, P3004; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kaisse Ellen M., 1985, PHONOLOGY YB, V2, P1, DOI DOI 10.1017/S0952675700000361; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; Lin SY, 1996, MOL CELL BIOL, V16, P1668; METIVIER C, 1993, ONCOGENE, V8, P2311; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; Neuman E, 1996, GENE, V173, P163, DOI 10.1016/0378-1119(96)00184-9; North S, 1996, CELL GROWTH DIFFER, V7, P339; PASTEAU S, 1995, ONCOGENE, V11, P1475; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARDET C, 1997, E2FS RETINOBLASTOMA; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	36	7	8	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	1998	17	5					585	594		10.1038/sj.onc.1201962	http://dx.doi.org/10.1038/sj.onc.1201962			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704924				2022-12-25	WOS:000075195300006
J	Cavallaro, U; Wu, ZH; Di Palo, A; Montesano, R; Pepper, MS; Maier, JAM; Soria, MR				Cavallaro, U; Wu, ZH; Di Palo, A; Montesano, R; Pepper, MS; Maier, JAM; Soria, MR			FGF-2 stimulates migration of Kaposi's sarcoma-like vascular cells by HGF-dependent relocalization of the urokinase receptor	FASEB JOURNAL			English	Article						TTB cell migration; hepatocyte growth factor; FGF; uPAR relocalization	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; C-MET PROTOONCOGENE; ENDOTHELIAL-CELLS; TRANSGENIC MICE; PLASMINOGEN-ACTIVATOR; SPINDLE CELLS; TAT PROTEIN; IN-VITRO; EXPRESSION	The spindle-shaped cell line TTB was recently isolated from highly vascularized skin lesions of BKV/HIV-1 tat transgenic mice and shown to possess an autocrine loop for hepatocyte growth factor (HGF), We show that fibroblast growth factor-2 (FGF-2) stimulates TTB cell migration and promotes polarization of uPAR at the leading edge of migrating cells. FGF-stimulated TTB cells presented the typical migratory phenotype, with a triangular cell shape and concomitant breakdown of actin stress fibers and smooth muscle-specific actin isoform, FGF-2-stimulated migration was blocked by antibodies against urokinase-type plasminogen activator (uPA) or uPA receptor (uPAR) and by neutralizing anti-HGF antibodies, The latter also inhibited uPAR relocalization at the cell surface of FGF-2-treated TTB cells. This points to a crosstalk between FGF-2 and HGF that might mediate TTB cell migration by modulating the localization of cell surface uPAR.	San Raffaele Sci Inst, Dept Biol & Technol Res, Dibit, I-20132 Milan, Italy; Univ Geneva, Med Ctr, Dept Morphol, Geneva, Switzerland; Univ Milan, Dept Biomed Sci & Technol, Milano, Italy	University of Geneva; University of Milan	Cavallaro, U (corresponding author), San Raffaele Sci Inst, Dept Biol & Technol Res, Dibit, Via Olgettina 58, I-20132 Milan, Italy.		Maier, Jeanette AM/H-4820-2012; Cavallaro, Ugo/J-9745-2012; Pepper, Michael S./M-6143-2014	Maier, Jeanette AM/0000-0002-6326-9221; Cavallaro, Ugo/0000-0002-0884-6460; Pepper, Michael S./0000-0001-6406-2380				Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; Borset M, 1996, J BIOL CHEM, V271, P24655, DOI 10.1074/jbc.271.40.24655; CAMPIONI D, 1995, AIDS RES HUM RETROV, V11, P1039, DOI 10.1089/aid.1995.11.1039; Cavallaro U, 1996, AIDS, V10, P1211, DOI 10.1097/00002030-199609000-00006; Cavallaro U., 1993, DRUG DELIV, V1, P119, DOI 10.3109/10717549309022765; CORALLINI A, 1993, CANCER RES, V53, P5569; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Ganem D, 1996, SEMIN VIROL, V7, P325, DOI 10.1006/smvy.1996.0040; GOHDA E, 1994, CYTOKINE, V6, P633, DOI 10.1016/1043-4666(94)90051-5; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; KENAGY RD, 1995, THROMB RES, V77, P55, DOI 10.1016/0049-3848(95)90864-C; Maier JAM, 1996, ONCOGENE, V13, P1009; Maier JAM, 1996, FIBRINOLYSIS, V10, P309, DOI 10.1016/S0268-9499(96)80012-9; MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; Nakamura Y, 1996, J HYPERTENS, V14, P1067, DOI 10.1097/00004872-199609000-00004; Nakamura Y, 1996, HYPERTENSION, V28, P409, DOI 10.1161/01.HYP.28.3.409; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; ODEKON LE, 1992, J CELL PHYSIOL, V150, P258, DOI 10.1002/jcp.1041500206; OKADA SS, 1995, EXP CELL RES, V217, P180, DOI 10.1006/excr.1995.1077; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; PERANTONI AO, 1995, P NATL ACAD SCI USA, V92, P4696, DOI 10.1073/pnas.92.10.4696; POLVERINI PJ, 1995, ADV CANCER RES, V66, P235, DOI 10.1016/S0065-230X(08)60256-0; PYKE C, 1991, AM J PATHOL, V138, P1059; REUNING U, 1994, BLOOD, V84, P3700, DOI 10.1182/blood.V84.11.3700.bloodjournal84113700; Roletto F, 1996, J CELL PHYSIOL, V166, P105, DOI 10.1002/(SICI)1097-4652(199601)166:1<105::AID-JCP12>3.0.CO;2-E; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SLAVIN J, 1995, CELL BIOL INT, V19, P431, DOI 10.1006/cbir.1995.1087; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0	40	17	19	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					1027	1034		10.1096/fasebj.12.11.1027	http://dx.doi.org/10.1096/fasebj.12.11.1027			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707175				2022-12-25	WOS:000075372600013
J	Okamoto, T; Yamamoto, S; Watanabe, Y; Ohta, T; Hanaoka, F; Roeder, RG; Ohkuma, Y				Okamoto, T; Yamamoto, S; Watanabe, Y; Ohta, T; Hanaoka, F; Roeder, RG; Ohkuma, Y			Analysis of the role of TFIIE in transcriptional regulation through structure-function studies of the TFIIE beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; INITIATION COMPLEX-FORMATION; BASAL TRANSCRIPTION; IMMEDIATELY UPSTREAM; PROMOTER CLEARANCE; HUMAN COACTIVATOR; TERMINAL DOMAIN; BINDING; SITE; ACTIVATION	The general transcription factor TFIIE plays important roles at two distinct but sequential steps in transcription as follows: preinitiation complex formation and activation (open complex formation), and the transition from initiation to elongation. The large subunit of human TFIIE (TFIIE alpha) binds to and facilitates the enzymatic functions of TFIIH, but TFIIE also functions independently from TFIIH. To determine functional roles of the small subunit of human TFIIE (TFIIE beta), deletion mutations were systematically introduced into putative structural motifs and characteristic sequences. Here we show that all of these structures that lie within the central 227-amino acid region of TFIIE beta are necessary and sufficient for both basal and activated transcription. We further demonstrate that two C-terminal basic regions are essential for physical interaction with both TFIIE alpha and single-stranded DNA, as well as with other transcription factors including the Drosophila transcriptional regulator Kruppel. In addition, we analyzed the effects of the TFIIE beta deletion mutations on TFIIH-dependent phosphorylation of the C-terminal domain of RNA polymerase II and on wild type TFIIE beta-driven basal transcription. Both responsible regions also mapped within the essential 227-amino acid region. Our results suggest that TFIIE engages in communication with both transcription factors and promoter DNA via the TFIIE beta subunit.	Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	Osaka University; Rockefeller University	Ohkuma, Y (corresponding author), Osaka Univ, Inst Mol & Cellular Biol, 1-3 Yamada Oka, Suita, Osaka 5650871, Japan.	ohkumay@imeb.osaka-u.ac.jp			NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI37327] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; IMHOF A, 1997, CURR BIOL, V7, P889; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KIM TK, 1993, J BIOL CHEM, V268, P20866; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; OHKUMA Y, 1995, MOL CELL BIOL, V15, P4856; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; OHKUMA Y, 1992, NUCLEIC ACIDS RES, V20, P4363, DOI 10.1093/nar/20.16.4363; Ohkuma Y, 1997, J BIOCHEM-TOKYO, V122, P481; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PAN GH, 1994, J BIOL CHEM, V269, P30101; PETERSON MG, 1991, NATURE, V354, P369; Robert F, 1996, J BIOL CHEM, V271, P8517, DOI 10.1074/jbc.271.15.8517; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TJIAN R, 1994, CELL, V77, P6; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; WANG BQ, 1994, PROTEIN EXPRES PURIF, V5, P476, DOI 10.1006/prep.1994.1067; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	52	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19866	19876		10.1074/jbc.273.31.19866	http://dx.doi.org/10.1074/jbc.273.31.19866			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677423	hybrid			2022-12-25	WOS:000075125200075
J	Battista, S; de Nigris, F; Fedele, M; Chiappetta, G; Scala, S; Vallone, D; Pierantoni, GM; Megar, T; Santoro, M; Viglietto, G; Verde, P; Fusco, A				Battista, S; de Nigris, F; Fedele, M; Chiappetta, G; Scala, S; Vallone, D; Pierantoni, GM; Megar, T; Santoro, M; Viglietto, G; Verde, P; Fusco, A			Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo	ONCOGENE			English	Article						transformation; AP-1; fra-1; thyroid carcinomas	C-JUN; TRANSCRIPTIONAL ACTIVATION; NEOPLASTIC TRANSFORMATION; BINDING-ACTIVITY; DELETION MUTANT; DNA-BINDING; EXPRESSION; FOS; ONCOGENE; LINE	We have recently reported that neoplastic transformation of two rat thyroid epithelial cell lines by retroviruses carrying the v-mos and v-ras Ki oncogenes is associated with a drastic increase of AP-1 activity. The most important effects were represented by the dramatic junB and fra-1 gene induction, which was abolished by the block of the transformation-induced HMGI-C protein synthesis. Here, we have further characterized the transformation-dependent AP-1 activity, by analysing the expression of different jun- and fos-related components, in rat thyroid cell lines transformed by several oncogenes, in human thyroid carcinoma cell lines, and in naturally occurring human thyroid rumours. A significant increase of Fra-1 and JunB protein levels was detected in all oncogene transformed rat thyroid cell lines, Fra-1 gene induction was demonstrated to occur also in human thyroid carcinoma cell lines and tissues, Conversely, c-Jun and JunD proteins, rather than JunB, accumulated in human thyroid carcinoma cell lines. An induction of AP-1 target genes was also detected both in rat and human thyroid transformed cell lines. Therefore, in vivo and in vitro thyroid cell transformation is associated with important compositional changes in the AP-1 complex and an increased transcriptional activity.	Ist Nazl Tumori, Fdn Senatore Pascale Oncol Sperimentale D & E, I-80131 Naples, Italy; CNR, Ist Int Genet & Biofis, I-80125 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Reggio Calabria, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria	Fusco, A (corresponding author), Ist Nazl Tumori, Fdn Senatore Pascale Oncol Sperimentale D & E, Via M Semmola, I-80131 Naples, Italy.		Pierantoni, Giovanna Maria/O-7527-2015; Battista, Sabrina/AAY-2981-2020; Fedele, Monica/C-1417-2015; Scala, Stefania/K-1380-2016; Viglietto, Giuseppe/AAC-2852-2019	Pierantoni, Giovanna Maria/0000-0003-4078-8528; Battista, Sabrina/0000-0001-5899-9759; Fedele, Monica/0000-0002-9171-1312; Scala, Stefania/0000-0001-9524-2616; Viglietto, Giuseppe/0000-0003-2327-7515; Fusco, Alfredo/0000-0003-3332-5197; de nigris, filomena/0000-0002-2322-1557				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; BERLINGIERI MT, 1988, MOL CELL BIOL, V8, P2261, DOI 10.1128/MCB.8.5.2261; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN PH, 1993, ONCOGENE, V8, P877; Cerutti J, 1996, CLIN CANCER RES, V2, P119; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURCIO F, 1994, P NATL ACAD SCI USA, V91, P9004, DOI 10.1073/pnas.91.19.9004; DECESARE D, 1995, ONCOGENE, V11, P365; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GACK S, 1994, J BIOL CHEM, V269, P10363; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; GRUDA MC, 1994, ONCOGENE, V9, P2537; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Joseloff E, 1997, MOL CARCINOGEN, V18, P26, DOI 10.1002/(SICI)1098-2744(199701)18:1<26::AID-MC4>3.0.CO;2-P; KARDALINOU E, 1993, J CELL BIOCHEM, V52, P375, DOI 10.1002/jcb.240520402; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Li JJ, 1996, CANCER RES, V56, P483; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MATSUI M, 1990, ONCOGENE, V5, P249; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; NOMURA N, 1990, NUCLEIC ACIDS RES, V18, P3047, DOI 10.1093/nar/18.10.3047; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Rosenberger SF, 1996, ONCOGENE, V12, P2301; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SITTMAN DB, 1983, P NATL ACAD SCI-BIOL, V80, P1849, DOI 10.1073/pnas.80.7.1849; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TOKUNAGA K, 1987, CANCER RES, V47, P5616; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Vandel L, 1996, MOL CELL BIOL, V16, P1881; VIGLIETTO G, 1995, ONCOGENE, V11, P1569	49	54	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	1998	17	3					377	385		10.1038/sj.onc.1201953	http://dx.doi.org/10.1038/sj.onc.1201953			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690519				2022-12-25	WOS:000074947500012
J	Kondo, S; Kondo, Y; Li, GY; Silverman, RH; Cowell, JK				Kondo, S; Kondo, Y; Li, GY; Silverman, RH; Cowell, JK			Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA	ONCOGENE			English	Article						telomerase; brain tumors; nude mice; RNAse L; apoptosis	IMMORTAL CELLS; TUMOR; ACTIVATION; CHIMERAS	Telomerase is the RNA-protein complex which elongates telomeric DNA (TTAGGG)(n) and appears to play an important role in cellular immortalization. The almost exclusive expression of telomerase in tumor cells, and not in most normal cells, offers an exciting opportunity for therapy by inhibiting its function. Here, we have investigated the effect of inhibition of telomerase on the growth and survival of human malignant glioma cells in vitro and in vivo by using a 19-mer antisense oligonucleotide against human telomerase RNA linked to a 2',5'-oligoadenylate (2-5A), 2-5A antisense functions by activating the endoribonuclease, RNase L, resulting in the degradation of single stranded, targeted RNA. We have shown that the 2-5A antisense treatment effectively suppressed tumor cell growth and survival in vitro. Furthermore, treatment of tumors grown in nude mice with the antisense oligonucleotide inhibited survival of the tumor cells. TUNEL assays suggest that this effect is mediated through the induction of apoptosis. Targeting telomerase RNA with 2-5A antisense, therefore, may represent an effective and novel approach for treatment of a broad range of cancers.	Cleveland Clin Fdn, Dept Neurosurg, Brain Tumor Ctr, Ctr Canc, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurosci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Cowell, JK (corresponding author), Cleveland Clin Fdn, Dept Neurosurg, Brain Tumor Ctr, Ctr Canc, Cleveland, OH 44195 USA.			Cowell, John/0000-0002-2079-5950	NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NCI NIH HHS [1 PO1 CA 62220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Cirino NM, 1997, P NATL ACAD SCI USA, V94, P1937, DOI 10.1073/pnas.94.5.1937; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DEEN DF, 1993, J NEURO-ONCOL, V16, P243, DOI 10.1007/BF01057041; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DONG BH, 1994, J BIOL CHEM, V269, P14153; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kondo S., UNPUB; KRAUSE D, 1986, J BIOL CHEM, V261, P6836; LANGFORD LA, 1995, LANCET, V346, P1267, DOI 10.1016/S0140-6736(95)91865-5; LESIAK K, 1993, BIOCONJUGATE CHEM, V4, P467, DOI 10.1021/bc00024a008; MAHALEY MS, 1989, J NEUROSURG, V71, P826, DOI 10.3171/jns.1989.71.6.0826; MAITRA RK, 1995, J BIOL CHEM, V270, P15071, DOI 10.1074/jbc.270.25.15071; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; SALSER W, 1977, COLD SPRING HARB SYM, V42, P985; SCHOENBERG BS, 1983, ONCOLOGY NERVOUS SYS, P1; Silverman R., 1997, RIBONUCLEASES STRUCT, P515; TORRENCE PF, 1993, P NATL ACAD SCI USA, V90, P1300, DOI 10.1073/pnas.90.4.1300; XIAO W, 1994, BIOORG MED CHEM LETT, V4, P2609, DOI 10.1016/S0960-894X(01)80294-8; Xiao W, 1996, ANTISENSE NUCLEIC A, V6, P247, DOI 10.1089/oli.1.1996.6.247; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	32	177	202	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	1998	16	25					3323	3330		10.1038/sj.onc.1201885	http://dx.doi.org/10.1038/sj.onc.1201885			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681832	Bronze			2022-12-25	WOS:000074343600014
J	Grant, GA; Xu, XL				Grant, GA; Xu, XL			Probing the regulatory domain interface of D-3-phosphoglycerate dehydrogenase with engineered tryptophan residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODULATED ALLOSTERIC REGULATION; PHOSPHOGLYCERATE DEHYDROGENASE; EFFECTOR-BINDING; MECHANISM; ENZYME; SITE	D-3-Phosphoglycerate dehydrogenase from Escherichia coli is a homotetrameric enzyme which is allosterically regulated by the end product of its pathway, L-serine, The enzyme binds 4 L-serine molecules at two interfaces formed by the noncovalent association of the regulatory domains. The two domains that comprise each interface are related by an approximately 180 degrees axis of symmetry, and two serine molecules bind at each interface by forming a hydrogen bond network between the domains. A model has been proposed that suggests that serine functions by drawing adjacent domains together and that this in turn translates a conformational change to the active site. A tryptophan residue has been engineered into the helices flanking the regulatory interfaces that displays significant quenching in response to serine binding. Residues on the adjacent subunit appear to be primarily responsible for the tryptophan quenching and thus support the hypothesis that serine binding leads to an increase in the proximity between residues on neighboring subunits, Serine binding studies show that this quenching, as well as inhibition of enzymatic activity, are essentially complete when only two of the four serine binding sites are occupied. The requirement for only one serine per interface is consistent with the notion that the interface is formed by relatively rigid domains and that hydrogen bonding at only a single site is all that is required to substantially close the interface. The fluorescence quenching in response to L-serine binding generally correlates with enzymatic inhibition, but there appears to be a slight lag in inhibition relative to quenching at low serine concentrations. The observed fluorescence quenching of residues in the regulatory domains of D-3-phosphoglycerate dehydrogenase provide the first direct evidence for a conformational change in response to effector binding and provide a means to monitor the first step in the allosteric mechanism.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Grant, GA (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056676] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 56676] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AlRabiee R, 1996, J BIOL CHEM, V271, P23235, DOI 10.1074/jbc.271.38.23235; AlRabiee R, 1996, J BIOL CHEM, V271, P13013, DOI 10.1074/jbc.271.22.13013; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORMACK B, 1991, CURRENT PROTOCOLS MO; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Grant GA, 1996, PROTEIN SCI, V5, P34; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; SCHULLER DJ, 1989, J BIOL CHEM, V264, P2645; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2090; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; TOBEY KL, 1986, J BIOL CHEM, V261, P2179; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996	13	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22389	22394		10.1074/jbc.273.35.22389	http://dx.doi.org/10.1074/jbc.273.35.22389			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712860	hybrid			2022-12-25	WOS:000075616600036
J	Kametaka, S; Okano, T; Ohsumi, M; Ohsumi, Y				Kametaka, S; Okano, T; Ohsumi, M; Ohsumi, Y			Apg14p and Apg6/Vps30p form a protein complex essential for autophagy in the yeast, Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVITRO MUTAGENESIS; VACUOLAR HYDROLASES; TARGETING PATHWAY; AMINOPEPTIDASE-I; SORTING RECEPTOR; MUTANT YEAST; GENE; TRANSPORT; CYTOPLASM; MEMBRANE	Mutation in the Saccharomyces cerevisiae APG14 gene causes a defect in autophagy, Cloning and structural analysis of the APG14 gene revealed that APG14 encodes a novel hydrophilic protein with a predicted molecular mass of 40.5 kDa, and that Apg14p has a coiled-coil motif at its N terminus region, We found that overproduction of Apg14p partially reversed the defect in autophagy induced by the apg6-1 mutation. The apg6-1 mutant was found to be defective not only in autophagy but also in sorting of carboxypeptidase Y (CPY), a vacuolar-soluble hydrolase, to the vacuole, However, overexpression of APG14 did not alter the CPY sorting defect of the apg6-1 mutant, nor did the apg14 null mutation affect the CPY sorting pathway. Structural analysis of APG6 revealed that APG6 is identical to VPS30, which is involved in a retrieval step of the CPY receptor, Vps10p, to the late-Golgi from the endosome (Seaman, M. N. J., Marcusson, E. G., Cereghino, J. L., and Emr, S. D. (1997) J. Cell Biol. 137, 79-92), Subcellular fractionation indicated that Apg14p and Apg6p peripherally associated with a membrane structure(s), Apg14p was co-immunoprecipitated with Apg6p, suggesting that they form a stable protein complex. These results imply that Apg6/Vps30p has two distinct functions in the autophagic process and the vacuolar protein sorting pathway. Apg14p may be a component specifically required for the function of Apg6/Vps30p through the autophagic pathway.	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Teikyo Univ Sci & Technol, Fac Engn Sci, Dept Biosci, Yamanashi 4090193, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Ohsumi, Y (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan.	yohsumi@nibb.ac.jp	Kametaka, Satoshi/GVT-6091-2022; Ohsumi, Yoshinori/C-6449-2009	Ohsumi, Yoshinori/0000-0003-2384-2166; Kametaka, Satoshi/0000-0003-0659-6426				Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Baba M, 1995, CELL STRUCT FUNCT, V20, P465, DOI 10.1247/csf.20.465; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Funakoshi T, 1997, GENE, V192, P207, DOI 10.1016/S0378-1119(97)00031-0; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; HENIKOFF S, 1990, NUCLEIC ACIDS RES, V18, P2961, DOI 10.1093/nar/18.10.2961; Horazdovsky BF, 1996, J BIOL CHEM, V271, P33607, DOI 10.1074/jbc.271.52.33607; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Kametaka S, 1996, GENE, V178, P139, DOI 10.1016/0378-1119(96)00354-X; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; MORTIMORE GE, 1977, NATURE, V270, P174, DOI 10.1038/270174a0; Nakamura N, 1997, J BIOL CHEM, V272, P11344; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; PARAVICINI G, 1992, MOL BIOL CELL, V3, P415, DOI 10.1091/mbc.3.4.415; Piper RC, 1997, J CELL BIOL, V138, P531, DOI 10.1083/jcb.138.3.531; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Rose MD., 1990, METHODS YEAST GENETI; SAMBROOK J, 1989, MOL CLINING LAB MANU; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79; SEGLEN PO, 1987, LYSOSOMES THEIR ROLE, P371; Shirahama K, 1997, CELL STRUCT FUNCT, V22, P501, DOI 10.1247/csf.22.501; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214	47	207	220	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22284	22291		10.1074/jbc.273.35.22284	http://dx.doi.org/10.1074/jbc.273.35.22284			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712845	hybrid			2022-12-25	WOS:000075616600021
J	Lepperdinger, G; Strobl, B; Kreil, G				Lepperdinger, G; Strobl, B; Kreil, G			HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; MURINE MACROPHAGES; MEMBRANE-PROTEIN; PH-20; SPERM; ACID; DEGRADATION; SECONDARY; CLONING; EMBRYOS	Using Expressed Sequence Tags (ESTs) deposited in the data banks, a cDNA has been assembled that encodes a protein related to the hyaluronidases from bee venom and mammalian sperm. Expression of this cDNA yielded a polypeptide termed HYAL2, which is located in lysosomes, The HYAL2 protein was shown to have hyaluronidase activity below pH 4, However, it only hydrolyzed hyaluronan of high molecular mass from umbilical cord, rooster comb, and a Streptococcus strain. The reaction product was a polysaccharide of about 20 kDa, which was further hydrolyzed to small oligosaccharides by the sperm hyaluronidase. Conversely, hyaluronan fragments from vitreous humor, which had a molecular mass of about 20 kDa, were not cleaved by the HYAL2 enzyme to any detectable extent. These results provide evidence for the existence of structural domains in hyaluronan, which are resistant to the action of this enzyme, The structural and functional implications of these findings are discussed.	Austrian Acad Sci, Inst Mol Biol, A-5020 Salzburg, Austria	Austrian Academy of Sciences	Kreil, G (corresponding author), Austrian Acad Sci, Inst Mol Biol, Billrothstr 11, A-5020 Salzburg, Austria.	gkreil@oeaw.ac.at		Lepperdinger, Gunter/0000-0002-4265-4489; Strobl, Birgit/0000-0001-5716-3212				ARNOTT S, 1983, J MOL BIOL, V169, P861, DOI 10.1016/S0022-2836(83)80140-5; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Cherr GN, 1996, DEV BIOL, V175, P142, DOI 10.1006/dbio.1996.0102; DALY MC, 1993, ONCOGENE, V8, P1721; DORFMAN A, 1955, METHOD ENZYMOL, V1, P166, DOI 10.1016/0076-6879(55)01023-9; Frost GI, 1997, BIOCHEM BIOPH RES CO, V236, P10, DOI 10.1006/bbrc.1997.6773; Frost GL, 1996, TRENDS GLYCOSCI GLYC, V8, P419, DOI 10.4052/tigg.8.419; GMACHL M, 1993, P NATL ACAD SCI USA, V90, P3569, DOI 10.1073/pnas.90.8.3569; GMACHL M, 1993, FEBS LETT, V336, P545, DOI 10.1016/0014-5793(93)80873-S; KREIL G, 1995, PROTEIN SCI, V4, P1666, DOI 10.1002/pro.5560040902; LATHROP WF, 1990, J CELL BIOL, V111, P2939, DOI 10.1083/jcb.111.6.2939; Latif F, 1997, HUM GENET, V99, P334, DOI 10.1007/s004390050368; LAURENT T, 1989, CIBA F SYMP, V143, P1; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Lepperdinger G, 1996, PROTEIN SCI, V5, P1250, DOI 10.1002/pro.5560050704; LIN Y, 1994, J CELL BIOL, V125, P1157, DOI 10.1083/jcb.125.5.1157; Liu DC, 1996, P NATL ACAD SCI USA, V93, P7832, DOI 10.1073/pnas.93.15.7832; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; MEYER K, 1971, HYALURONIDASES, V5; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; MITRA AK, 1983, J MOL BIOL, V169, P813, DOI 10.1016/S0022-2836(83)80138-7; Natowicz MR, 1996, CLIN CHIM ACTA, V245, P1, DOI 10.1016/0009-8981(95)06182-7; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; REISSIG JL, 1955, J BIOL CHEM, V217, P959; SAMPSON PM, 1992, J CLIN INVEST, V90, P1492, DOI 10.1172/JCI116017; SCOTT JE, 1990, INT J BIOL MACROMOL, V12, P180, DOI 10.1016/0141-8130(90)90029-A; SCOTT JE, 1991, BIOCHEM J, V274, P699, DOI 10.1042/bj2740699; SCOTT JE, 1989, CIBA F SYMP, V143, P6; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; SZAFARZ BF, 1989, SOMAT CELL MOLEC GEN, V15, P79; VAES G, 1966, METHOD ENZYMOL, V8, P509; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340	33	240	248	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22466	22470		10.1074/jbc.273.35.22466	http://dx.doi.org/10.1074/jbc.273.35.22466			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712871	hybrid			2022-12-25	WOS:000075616600047
J	Oka, T; Yamamoto, R; Futai, M				Oka, T; Yamamoto, R; Futai, M			Multiple genes for vacuolar-type ATPase proteolipids in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; SACCHAROMYCES-CEREVISIAE; SUBUNIT-C; URINARY ACIDIFICATION; B-SUBUNIT; EXPRESSION; CLONING; PROTEIN; CELLS; INACTIVATION	In the vacuolar-type Hf-ATPase (V-ATPase), highly hydrophobic subunits known as the proteolipids are components of the integral membrane V-0 sector. Previously, we described the identification of three different proteolipid genes in Caenorhabditis elegans (Oka, T., Yamamoto, R., and Futai, M. (1997) J. Biol. Chem. 272, 24387-24392): vha-l and vha-2 encoded 16-kDa subunits, and vha-4, a 23-kDa isoform. me report here that a third 16-kDa gene, vha-3, has been identified on chromosome IV. This is the first example in which four proteolipid genes have been found in a single organism, vha-2 and vha-3 exhibited 85% nucleotide identity within the open reading frames which encoded the identical amino acid sequence. Northern blot analysis indicated that all four genes were expressed in a similar pattern during the worm life cycle; however, studies with transgenic worms indicated that the vha-3 gene was expressed differently from other proteolipid genes in a cell-specific manner. These results implied that the isoforms of the proteolipids may be related to functional differences of V-ATPases in various cell types. Another new gene, vha-11, contained seven exons and was found to be located immediately downstream of vha-3. The two genes constitute a single transcriptional unit. The VHA-11 protein had 384 amino acids and shared strong sequence similarities with the C subunit, a component of the peripheral V-1 sector of the V-ATPase, from yeast, bovine, and human. Expression of the Dha-II cDNA complemented a null mutation of VMA5, the yeast C subunit gene, thus demonstrating that vha-11 was the functional C subunit of C. elegans.	Osaka Univ, Japan Sci & Technol Corp, CREST, Inst Sci & Ind Res,Div Biol Sci, Ibaraki, Osaka 5670047, Japan	Japan Science & Technology Agency (JST); Osaka University	Futai, M (corresponding author), Osaka Univ, Japan Sci & Technol Corp, CREST, Inst Sci & Ind Res,Div Biol Sci, Ibaraki, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp						ANRAKU Y, 1996, HDB BIOL PHYS, V2, P93; BELTRAN C, 1992, J BIOL CHEM, V267, P774; Breton S, 1996, NAT MED, V2, P470, DOI 10.1038/nm0496-470; CHATTERJEE D, 1992, J EXP BIOL, V172, P193; Davies SA, 1996, J BIOL CHEM, V271, P30677, DOI 10.1074/jbc.271.48.30677; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUTAI M, 1998, IN PRESS J BIOCH; FUTAI M, 1996, HDB BIOL PHYS, V2, P47; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; HASEBE M, 1992, BIOCHEM BIOPH RES CO, V183, P856, DOI 10.1016/0006-291X(92)90562-Y; HASENFRATZ MP, 1995, PLANT PHYSIOL, V108, P1395, DOI 10.1104/pp.108.4.1395; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HO MN, 1993, J BIOL CHEM, V268, P221; KLIONSKY DJ, 1992, J EXP BIOL, V172, P83; KRAUSE M, 1995, CAENORHABDITIS ELEGA, P482; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; MELLMAN I, 1992, J EXP BIOL, V172, P39; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NELSON FK, 1983, J ULTRA MOL STRUCT R, V82, P156; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1990, J BIOL CHEM, V265, P20390; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; Oka T, 1997, J BIOL CHEM, V272, P24387, DOI 10.1074/jbc.272.39.24387; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; SPIETH J, 1991, MOL CELL BIOL, V11, P4651, DOI 10.1128/MCB.11.9.4651; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Sulston J., 1988, NEMATODE CAENORHABDI, P587; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Tomochika K, 1997, FEBS LETT, V404, P61, DOI 10.1016/S0014-5793(97)00090-2; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; VANHILLE B, 1993, BIOCHEM BIOPH RES CO, V197, P15, DOI 10.1006/bbrc.1993.2434; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	37	39	48	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22570	22576		10.1074/jbc.273.35.22570	http://dx.doi.org/10.1074/jbc.273.35.22570			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712884	hybrid			2022-12-25	WOS:000075616600060
J	Kallstrom, H; Islam, MS; Berggren, PO; Jonsson, AB				Kallstrom, H; Islam, MS; Berggren, PO; Jonsson, AB			Cell signaling by the type IV pili of pathogenic Nisseria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPITHELIAL-CELLS; NEISSERIA-GONORRHOEAE; ENDOTHELIAL-CELLS; SALMONELLA-TYPHIMURIUM; SELECTIVE INHIBITOR; ESCHERICHIA-COLI; PROTEIN-KINASE; IN-VITRO; ADHERENCE; TRANSDUCTION	Neisseria gonorrhoeae and Neisseria meningitidis are Gram-negative bacterial pathogens that infect human mucosal epithelia. Type TV pilus-mediated adherence of these bacteria is a crucial early event for establishment of infection. In this work, we show that the type IV pill transduce a signal into the eucaryotic host cell. Purified adherent pill, but not pill from a low binding mutant, trigger an increase in the cytosolic free calcium ([Ca2+](i)) in target epithelial cells, a signal known to control many cellular responses. The [Ca2+](i) increase was blocked by antibodies against CD46, a putative pilus receptor, suggesting a role for this protein in signal transduction. Pilus-mediated attachment was inhibited by depletion of host cell intracellular Ca2+ stores but not by removal of extracellular Ca2+. Further, kinase inhibition studies showed that pilus-mediated adherence is dependent on casein kinase II. In summary, these data reveal a novel function of the type IV pill, namely induction of signal transduction pathways in host cells.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Karolinska Hosp, Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Jonsson, AB (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.	Ann-Beth.Jonsson@mtc.ki.se	Islam, Shahidul/K-3295-2019	Islam, Shahidul/0000-0002-9016-1881; Berggren, Per-Olof/0000-0001-8991-413X				BALDWIN TJ, 1991, INFECT IMMUN, V59, P1599, DOI 10.1128/IAI.59.5.1599-1604.1991; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; CHEN JCR, 1991, MOL MICROBIOL, V5, P1531, DOI 10.1111/j.1365-2958.1991.tb00800.x; CHEN T, 1995, J EXP MED, V182, P511, DOI 10.1084/jem.182.2.511; Chen T, 1996, P NATL ACAD SCI USA, V93, P14851, DOI 10.1073/pnas.93.25.14851; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DYTOC M, 1994, GASTROENTEROLOGY, V106, P1150, DOI 10.1016/0016-5085(94)90004-3; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; GrayOwen SD, 1997, EMBO J, V16, P3435, DOI 10.1093/emboj/16.12.3435; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; ISLAM MS, 1995, BIOCHEM J, V306, P679, DOI 10.1042/bj3060679; JONSSON AB, 1991, EMBO J, V10, P477, DOI 10.1002/j.1460-2075.1991.tb07970.x; JONSSON AB, 1994, MOL MICROBIOL, V13, P403, DOI 10.1111/j.1365-2958.1994.tb00435.x; Kallstrom H, 1997, MOL MICROBIOL, V25, P639, DOI 10.1046/j.1365-2958.1997.4841857.x; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; KELLOGG DS, 1968, J BACTERIOL, V96, P596, DOI 10.1128/JB.96.3.596-605.1968; LISZEWSKI MK, 1994, J BIOL CHEM, V269, P10776; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; MITTLEMAN B, 1983, J MOL BIOL, V165, P461, DOI 10.1016/S0022-2836(83)80213-7; NASSIF X, 1994, P NATL ACAD SCI USA, V91, P3769, DOI 10.1073/pnas.91.9.3769; NASSIF X, 1993, MOL MICROBIOL, V8, P719, DOI 10.1111/j.1365-2958.1993.tb01615.x; Naumann M, 1997, J EXP MED, V186, P247, DOI 10.1084/jem.186.2.247; OMURA S, 1995, J ANTIBIOT, V48, P535, DOI 10.7164/antibiotics.48.535; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PATTON C, 1996, MAXCHELATOR; PETERSON G, 1995, J NUTR, V125, pS784, DOI 10.1093/jn/125.suppl_3.784S; Rahman M, 1997, MOL MICROBIOL, V25, P11, DOI 10.1046/j.1365-2958.1997.4601823.x; RODRIGUEZ A, 1995, J CELL BIOL, V129, P1263, DOI 10.1083/jcb.129.5.1263; ROSENSHINE I, 1993, BIOESSAYS, V15, P17, DOI 10.1002/bies.950150104; RUDEL T, 1992, MOL MICROBIOL, V6, P3439, DOI 10.1111/j.1365-2958.1992.tb02211.x; RUDEL T, 1995, NATURE, V373, P357, DOI 10.1038/373357a0; RUDEL T, 1995, MOL MICROBIOL, V17, P1057, DOI 10.1111/j.1365-2958.1995.mmi_17061057.x; RUSCHKOWSKI S, 1992, FEMS MICROBIOL LETT, V95, P121; SCHULZ I, 1990, METHOD ENZYMOL, V192, P280; SWANSON J, 1987, J EXP MED, V165, P1344, DOI 10.1084/jem.165.5.1344; SWANSON J, 1973, J EXP MED, V137, P571, DOI 10.1084/jem.137.3.571; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANPUTTEN JPM, 1995, EMBO J, V14, P2144, DOI 10.1002/j.1460-2075.1995.tb07208.x; VANWINKLE WB, 1976, SCIENCE, V193, P1130, DOI 10.1126/science.959824; VIRJI M, 1993, MOL MICROBIOL, V10, P1013, DOI 10.1111/j.1365-2958.1993.tb00972.x; Virji M, 1996, MOL MICROBIOL, V22, P941, DOI 10.1046/j.1365-2958.1996.01551.x; VIRJI M, 1992, MOL MICROBIOL, V6, P1271, DOI 10.1111/j.1365-2958.1992.tb00848.x	43	120	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21777	21782		10.1074/jbc.273.34.21777	http://dx.doi.org/10.1074/jbc.273.34.21777			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705315	hybrid			2022-12-25	WOS:000075492600049
J	Pini, A; Viti, F; Santucci, A; Carnemolla, B; Zardi, L; Neri, P; Neri, D				Pini, A; Viti, F; Santucci, A; Carnemolla, B; Zardi, L; Neri, P; Neri, D			Design and use of a phage display library - Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMOBILIZED PH GRADIENTS; BY-PASSING IMMUNIZATION; FIBRONECTIN ISOFORM; MONOCLONAL-ANTIBODIES; SYNTHETIC REPERTOIRES; ESCHERICHIA-COLI; ANTIGEN-BINDING; LIGHT-CHAINS; ELECTROPHORESIS; FRAGMENTS	We report the construction and the use of a phage display human antibody library (>3 x 10(8) clones) based on principles of protein design. A large repertoire of functional antibodies with similar properties was produced by appending short variable complementarity-determining region 3 (CDR3) onto the two antibody germ line segments most frequently found in human antibodies. With this strategy we concentrated sequence diversity in regions of the antibody structure that are centrally located in the antigen binding site, while leaving residues in more peripheral positions available for further mutagenesis aimed at improving the affinity of the selected antibodies. In addition, the library was tested by selecting antibodies against six biologically relevant antigens, Using only 0.3 mu g of antigen eluted from a two-dimensional gel spot, we isolated binders specific for the ED-B domain of fibronectin, a marker of angiogenesis. These antibodies recognize the native antigen with affinities in the 10(7-)10(8) M-1 range, and perform well in immunosorbent assays, in two-dimensional Western blotting and in immunohistochemistry, The affinity of one anti-ED-B antibody was improved by 27-fold by combinatorially mutating six strategically selected residues in the heavy chain variable domain. A further 28-fold affinity improvement could be achieved by mutating residues 32 and 50 of the light chain. The resulting antibody, L19, bound to the ED-B domain of fibronectin with very high affinity (K-d = 54 pM), as determined by real-time interaction analysis with surface plasmon resonance detection, band shift analysis, and by competition experiments with electrochemiluminescent detection.	ETH Honggerberg, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland; Univ Siena, Dipartimento Biol Mol, Sez Biochim, I-53100 Siena, Italy; Ist Nazl Ric Canc, I-16132 Genoa, Italy	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Siena; University of Genoa; IRCCS AOU San Martino IST	Neri, D (corresponding author), ETH Honggerberg, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland.		Santucci, Annalisa/K-1932-2018; Pini, Alessandro/R-1359-2018; Neri, Dario/P-4368-2016	Santucci, Annalisa/0000-0001-6976-9086; Pini, Alessandro/0000-0002-3832-8349; Neri, Dario/0000-0001-5234-7370				Anderson NG, 1996, ELECTROPHORESIS, V17, P443, DOI 10.1002/elps.1150170303; BALZA E, 1993, FEBS LETT, V332, P39, DOI 10.1016/0014-5793(93)80479-E; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; Borsi L, 1998, EXP CELL RES, V240, P244, DOI 10.1006/excr.1998.3946; Carnemolla B, 1996, INT J CANCER, V68, P397, DOI 10.1002/(SICI)1097-0215(19961104)68:3<397::AID-IJC20>3.3.CO;2-D; CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; COX JPL, 1994, EUR J IMMUNOL, V24, P827, DOI 10.1002/eji.1830240409; DEAVER DR, 1995, NATURE, V377, P758, DOI 10.1038/377758a0; DEKRUIF J, 1995, P NATL ACAD SCI USA, V92, P3938, DOI 10.1073/pnas.92.9.3938; Dunn MJ, 1996, METHOD ENZYMOL, V271, P177; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HELMERCITTERICH M, 1994, J MOL BIOL, V235, P1021, DOI 10.1006/jmbi.1994.1054; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P; HUANG H, 1997, SCIENCE, V275, P547; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Ignatovich O, 1997, J MOL BIOL, V268, P69, DOI 10.1006/jmbi.1997.0956; ITO W, 1995, J MOL BIOL, V248, P729, DOI 10.1006/jmbi.1995.0255; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KAHN P, 1995, SCIENCE, V270, P369, DOI 10.1126/science.270.5235.369; KIRKHAM PM, 1992, EMBO J, V11, P603, DOI 10.1002/j.1460-2075.1992.tb05092.x; LAVOIE TB, 1992, J IMMUNOL, V148, P503; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MARKS JD, 1993, BIO-TECHNOL, V11, P1145, DOI 10.1038/nbt1093-1145; Neri D, 1996, TRENDS BIOTECHNOL, V14, P465, DOI 10.1016/S0167-7799(96)10067-6; Neri D, 1996, J INVEST DERMATOL, V107, P164, DOI 10.1111/1523-1747.ep12329566; Neri D, 1996, BIOTECHNIQUES, V20, P708; Neri D, 1997, NAT BIOTECHNOL, V15, P1271, DOI 10.1038/nbt1197-1271; NERI D, 1996, NAT BIOTECHNOL, V14, P385; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; Pereira S, 1997, J IMMUNOL METHODS, V203, P11, DOI 10.1016/S0022-1759(97)00005-7; Pini A, 1997, J IMMUNOL METHODS, V206, P171, DOI 10.1016/S0022-1759(97)00107-5; Righetti PG, 1996, METHOD ENZYMOL, V270, P235; Sanchez JC, 1997, ELECTROPHORESIS, V18, P324, DOI 10.1002/elps.1150180305; Schier R, 1996, GENE, V169, P147, DOI 10.1016/0378-1119(95)00821-7; TOMLINSON IM, 1995, EMBO J, V14, P4628, DOI 10.1002/j.1460-2075.1995.tb00142.x; Tomlinson IM, 1996, J MOL BIOL, V256, P813, DOI 10.1006/jmbi.1996.0127; TOMLINSON IM, 1992, J MOL BIOL, V227, P776, DOI 10.1016/0022-2836(92)90223-7; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; Watters JM, 1997, IMMUNOTECHNOLOGY, V3, P21, DOI 10.1016/S1380-2933(96)00056-5; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x	55	358	480	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21769	21776		10.1074/jbc.273.34.21769	http://dx.doi.org/10.1074/jbc.273.34.21769			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705314	Green Published, hybrid			2022-12-25	WOS:000075492600048
J	Roberts, R; Sciorra, VA; Morris, AJ				Roberts, R; Sciorra, VA; Morris, AJ			Human type 2 phosphatidic acid phosphohydrolases - Substrate specificity of the type 2a, 2b, and 2c enzymes and cell surface activity of the 2a isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PHOSPHOLIPASE-D; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; SF9 CELLS; RAT-LIVER; IDENTIFICATION; PURIFICATION; PROTEIN; SPHINGOSINE	Phosphatidic acid (PA), lysophosphatidic acid, ceramide l-phosphate (CIP), and sphingosine l-phosphate (S1P) are lipid mediators generated by phospholipases, sphingomyelinases, and lipid kinases, The major pathway for degradation of these lipids is dephosphorylation catalyzed by members of two classes (types 1 and 2) of phosphohydrolase activities (PAPs), cDNAs encoding two type 2 PAPs, PAP-2a and -2b, have been expressed by transient transfection and shown to catalyze hydrolysis of PA, CIP, and SIP (Kai, M., Wada, I., Imai, S., Sakane, F. and Kanoh, H. (1997) J. Biol. Chem. 272, 24572-24578), We report the cloning and expression of a third type 2 PAP enzyme (288 amino acids, predicted molecular mass of 32.6 kDa), PAP-2c, which exhibits 54 and 43% sequence homology to PAPs 2a and 2b. Expression of HA epitope-tagged PAP-2a, -2b, and 2c in HEK293 cells produced immunoreactive proteins and increased membrane-associated PAP activity. Sf9 insect cells contain very low endogenous PAP activity. Recombinant expression of the three PAP enzymes using baculovirus vectors produces dramatic increases in membrane-associated Mg2+-independent, N-ethylmaleimide-insensitive PAP activity, Expression of PAP-2a but not PAP-2b or -2c resulted in high levels of cell surface PAP activity in intact insect cells. Kinetic analysis of PAP-2a, -2b, and -2c activity against PA, lysophosphatidic acid, C1P, and S1P presented in mixed micelles of Triton X-100 revealed differences in substrate specificity and susceptibility to inhibition by sphingosine, Zn2+, and propranol.	SUNY Stony Brook, Hlth Sci Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; SUNY Stony Brook, Hlth Sci Ctr, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Morris, AJ (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.	andrew@pharm.sunysb.edu	Morris, Andrew/B-7869-2010		NIGMS NIH HHS [GM50388] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050388] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barila D, 1996, J BIOL CHEM, V271, P29928, DOI 10.1074/jbc.271.47.29928; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; Brindley DN, 1996, CHEM PHYS LIPIDS, V80, P45, DOI 10.1016/0009-3084(96)02545-5; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; FLEMING IN, 1995, BIOCHEM J, V308, P983, DOI 10.1042/bj3080983; FROHMAN MA, 1994, PCR METH APPL, V4, pS40; GOMEZMUNOZ A, 1992, BIOCHIM BIOPHYS ACTA, V1127, P49, DOI 10.1016/0005-2760(92)90200-F; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; JAIN MK, 1995, METHOD ENZYMOL, V249, P567; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; Kai M, 1997, J BIOL CHEM, V272, P24572, DOI 10.1074/jbc.272.39.24572; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; KANOH H, 1992, J BIOL CHEM, V267, P25309; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LIN YP, 1990, J BIOL CHEM, V265, P166; LINDAU M, 1991, BIOCHIM BIOPHYS ACTA, V1071, P429, DOI 10.1016/0304-4157(91)90006-I; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; MARTIN JB, 1949, ANAL CHEM, V21, P965, DOI 10.1021/ac60032a024; Messerschmidt A, 1996, P NATL ACAD SCI USA, V93, P392, DOI 10.1073/pnas.93.1.392; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Neuwald AF, 1997, PROTEIN SCI, V6, P1764, DOI 10.1002/pro.5560060817; OLIVERA A, 1994, ANAL BIOCHEM, V223, P306, DOI 10.1006/abio.1994.1589; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P107; PAGANO RE, 1985, J BIOL CHEM, V260, P1909; PERRY DK, 1993, J BIOL CHEM, V268, P25302; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Stukey J, 1997, PROTEIN SCI, V6, P469; TAUSSIG R, 1994, METHOD ENZYMOL, V238, P95; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; WAGGONER DW, 1995, J BIOL CHEM, V270, P19422, DOI 10.1074/jbc.270.33.19422; XIE MS, 1994, ARCH BIOCHEM BIOPHYS, V312, P254, DOI 10.1006/abbi.1994.1307; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0	39	147	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22059	22067		10.1074/jbc.273.34.22059	http://dx.doi.org/10.1074/jbc.273.34.22059			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705349	hybrid			2022-12-25	WOS:000075492600083
J	Sato, T; Konno, H; Tanaka, Y; Kataoka, T; Nagai, K; Wasserman, HH; Ohkuma, S				Sato, T; Konno, H; Tanaka, Y; Kataoka, T; Nagai, K; Wasserman, HH; Ohkuma, S			Prodigiosins as a new group of H+/Cl- symporters that uncouple proton translocators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; FLUORESCEIN ISOTHIOCYANATE-DEXTRAN; MEDIATED EXCHANGE DIFFUSION; H+-ATPASE; PHOSPHOLIPID-VESICLES; RAT-LIVER; 2.8-ANGSTROM RESOLUTION; TRIPHENYLTIN COMPOUNDS; GLUCOSE TRANSPORTER; HYDROXIDE EXCHANGE	We reported previously (Kataoka, T., Muroi, M., Ohkuma, S., Waritani, T., Magae, J., Takatsuki, A., Kondo, S., Yamasaki, M., and Nagai, K. (1995) FEES Lett. 359, 53-59) that prodigiosin 25-C uncoupled vacuolar H+-ATPase, inhibited vacuolar acidification, and affected glycoprotein processing. In the present study we show that prodigiosins (prodigiosin, metacycloprodigiosin and prodigiosin 25-C) inhibit the acidification activity of H+-ATPase chloride dependently, but not membrane potential formation or ATP hydrolysis activity, and suggest that they promote H+/Cl- symport (or OH-/Cl- exchange, in its equivalence) across vesicular membranes. In fact, prodigiosins displayed H+/Cl- symport activity on liposomal membranes. First of all, they decreased the internal pH of liposomes depending on the external chloride, and raised it depending on the internal chloride when external buffer was free from chloride. Second, their effect was electroneutral and not seriously affected by the application of an inside positive membrane potential generated by K+ and valinomycin, Finally, they promoted the uptake of [Cl-36] from external buffers with concomitant intraliposomal acidification when external pH was acidic relative to liposome interior. As prodisosins hardly inhibit the catalytic activity (ATP hydrolysis) unlike well known OH-/Cl- exchangers (for example, tributyltin chloride), they should provide powerful tools for the study of molecular machinery and cellular activities involving transport of protons and/or chloride.	Kanazawa Univ, Fac Pharmaceut Sci, Dept Mol & Cell Biol, Biochem Lab, Kanazawa, Ishikawa 9200934, Japan; Tokyo Inst Technol, Dept Bioengn, Midori Ku, Yokohama, Kanagawa 2260026, Japan; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Kanazawa University; Tokyo Institute of Technology; Yale University	Ohkuma, S (corresponding author), Kanazawa Univ, Fac Pharmaceut Sci, Dept Mol & Cell Biol, Biochem Lab, Takaramachi 13-1, Kanazawa, Ishikawa 9200934, Japan.	ohkuma@kenroku.kanazawa-u.ac.jp						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; [Anonymous], 1977, ADV PHYS ORG CHEM; ANTONENKO YN, 1990, J MEMBRANE BIOL, V113, P109, DOI 10.1007/BF01872884; ARAI K, 1991, J BIOCHEM, V110, P541, DOI 10.1093/oxfordjournals.jbchem.a123616; ARAI K, 1993, J BIOL CHEM, V268, P5649; ASH RP, 1977, J AM CHEM SOC, V99, P4471, DOI 10.1021/ja00455a043; BARRANCO J, 1981, BIOCHEM BIOPH RES CO, V100, P1402, DOI 10.1016/0006-291X(81)91980-X; BOGER DL, 1987, TETRAHEDRON LETT, V28, P2499, DOI 10.1016/S0040-4039(00)95451-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIN K, 1977, BIOCHEM J, V162, P575, DOI 10.1042/bj1620575; CHAN KM, 1986, ANAL BIOCHEM, V157, P375, DOI 10.1016/0003-2697(86)90640-8; CHANIOTAKIS NA, 1988, ANAL CHEM, V60, P185, DOI 10.1021/ac00153a020; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1534, DOI 10.1021/bi00509a019; DAlessio R, 1996, SYNLETT, P513; DIAZ RS, 1994, MOL PHARMACOL, V46, P1210; DIETRICH B, 1988, J CHEM SOC CHEM COMM, P691, DOI 10.1039/c39880000691; ElEtri M, 1996, AM J PHYSIOL-LUNG C, V270, pL386, DOI 10.1152/ajplung.1996.270.3.L386; EMANUEL EL, 1984, BIOCHIM BIOPHYS ACTA, V766, P209, DOI 10.1016/0005-2728(84)90233-0; FARROW BG, 1978, EUR J BIOCHEM, V86, P85, DOI 10.1111/j.1432-1033.1978.tb12287.x; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; GOULD JM, 1976, EUR J BIOCHEM, V62, P567, DOI 10.1111/j.1432-1033.1976.tb10191.x; GRABE CG, 1983, ANAL BIOCHEM, V130, P287; HARASHIMA K, 1967, AGR BIOL CHEM TOKYO, V31, P481, DOI 10.1080/00021369.1967.10858824; HIGUTI T, 1993, NEW FUNCTIONALITY MA, P131; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; KALM G, 1995, J MOL BIOL, V253, P726; KANO K, 1978, BIOCHIM BIOPHYS ACTA, V509, P289, DOI 10.1016/0005-2736(78)90048-2; KARNISKI LP, 1992, J BIOL CHEM, V267, P19218; KASAHARA M, 1977, J BIOL CHEM, V252, P7384; KATAOKA T, 1992, J ANTIBIOT, V45, P1618, DOI 10.7164/antibiotics.45.1618; KATAOKA T, 1995, FEBS LETT, V359, P53, DOI 10.1016/0014-5793(94)01446-8; KONDO S, 1988, J ANTIBIOT, V41, P1196, DOI 10.7164/antibiotics.41.1196; KOVACIC H, 1993, J PHARMACOL EXP THER, V267, P1509; LEE MH, 1995, BIOSCI BIOTECH BIOCH, V59, P1417, DOI 10.1271/bbb.59.1417; Magae J, 1996, J ANTIBIOT, V49, P86, DOI 10.7164/antibiotics.49.86; MORIYAMA Y, 1984, J BIOCHEM-TOKYO, V95, P995, DOI 10.1093/oxfordjournals.jbchem.a134726; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MORIYAMA Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P278, DOI 10.1006/abbi.1993.1423; MUKOHATA Y, 1981, ARCH BIOCHEM BIOPHYS, V206, P72, DOI 10.1016/0003-9861(81)90067-9; NAKAMURA A, 1989, TRANSPLANTATION, V47, P1013, DOI 10.1097/00007890-198906000-00019; NAKAMURA A, 1986, J ANTIBIOT, V39, P1155, DOI 10.7164/antibiotics.39.1155; NAKAMURA K, 1970, CHEM COMMUN, P1135; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OHKUMA S, 1983, J BIOCHEM, V94, P1935, DOI 10.1093/oxfordjournals.jbchem.a134547; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; Ohkuma S, 1997, CELL STRUCT FUNCT, V22, P253, DOI 10.1247/csf.22.253; OHKUMA S, 1989, METHOD ENZYMOL, V174, P131; OHKUMA S, 1996, JPN BIOENERG GROUP A, V22, P28; Rothmaier M, 1996, ANAL CHIM ACTA, V327, P17, DOI 10.1016/0003-2670(96)00055-4; SARTI P, 1995, BIOCHEM J, V312, P643, DOI 10.1042/bj3120643; SASAKI J, 1995, SCIENCE, V269, P73, DOI 10.1126/science.7604281; SASE S, 1982, J BIOL CHEM, V257, P1100; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SELWYN MJ, 1970, EUR J BIOCHEM, V14, P120, DOI 10.1111/j.1432-1033.1970.tb00268.x; SESSLER JL, 1991, J CHEM SOC CHEM COMM, P1733, DOI 10.1039/c39910001733; SINGH AP, 1986, BIOCHEM CELL BIOL, V64, P647, DOI 10.1139/o86-089; STARKS CM, 1985, ACS SYM SER, V326, P1; STOCKDAL.M, 1970, EUR J BIOCHEM, V15, P342, DOI 10.1111/j.1432-1033.1970.tb01013.x; TOSTESON MT, 1979, J GEN PHYSIOL, V73, P789, DOI 10.1085/jgp.73.6.789; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; UDAGAWA T, 1986, J BIOL CHEM, V261, P2616; USTA J, 1993, APPL ORGANOMET CHEM, V7, P193, DOI 10.1002/aoc.590070306; VERKMAN AS, 1989, BIOCHEMISTRY-US, V28, P4240, DOI 10.1021/bi00436a018; WASSERMAN HH, 1989, TETRAHEDRON LETT, V30, P1725, DOI 10.1016/S0040-4039(00)99566-2; WASSERMAN HH, 1984, TETRAHEDRON LETT, V25, P1387, DOI 10.1016/S0040-4039(01)80165-9; WASSERMAN HH, 1976, TETRAHEDRON, V32, P1867, DOI 10.1016/0040-4020(76)85188-5; WASSERMAN HH, 1966, TETRAHEDRON        S, V8, P647; WIETH JO, 1979, J GEN PHYSIOL, V73, P765, DOI 10.1085/jgp.73.6.765; Williams R.P., 1967, BIOSYNTHESIS, P410; Woo JT, 1997, BIOSCI BIOTECH BIOCH, V61, P400, DOI 10.1271/bbb.61.400; WULF RG, 1975, ARCH BIOCHEM BIOPHYS, V167, P176, DOI 10.1016/0003-9861(75)90454-3	72	135	136	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21455	21462		10.1074/jbc.273.34.21455	http://dx.doi.org/10.1074/jbc.273.34.21455			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705273	hybrid			2022-12-25	WOS:000075492600007
J	Trujillo, KM; Yuan, SSF; Lee, EYHP; Sung, P				Trujillo, KM; Yuan, SSF; Lee, EYHP; Sung, P			Nuclease activities in a complex of human recombination and DNA repair factors Rad50, Mre11, and p95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; MEIOSIS; GENES; ROLES	Genetic studies in yeast have indicated a role of the RAD50 and MRE11 genes in homologous recombination, telomere length maintenance, and DNA repair processes. Here, we purify from nuclear extract of Raji cells a complex consisting of human Rad50, Mre11, and another protein factor with a size of about 95 kDa (p95), which is likely to be Nibrin, the protein encoded by the gene mutated in Nijmegen breakage syndrome, We show that the Rad50-Mre11-p95 complex possesses manganese-dependent single-stranded DNA endonuclease and 3' to 5' exonuclease activities. These nuclease activities are likely to be important for recombination, repair, and genomic stability.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Sung, P (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA.	sung@uthscsa.edu		yuan, shyng-shiou/0000-0002-4753-788X	NCI NIH HHS [CA49649] Funding Source: Medline; NIEHS NIH HHS [ES07061] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049649, R29CA049649, R37CA049649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; Cox MM, 1997, P NATL ACAD SCI USA, V94, P11764, DOI 10.1073/pnas.94.22.11764; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Kanaar R, 1998, NATURE, V391, P335, DOI 10.1038/34790; Klein HL, 1997, GENETICS, V147, P1533; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; SCHIESTL RH, 1994, MOL CELL BIOL, V14, P4493, DOI 10.1128/MCB.14.7.4493; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; Shinohara M, 1997, GENETICS, V147, P1545; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5	18	312	327	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21447	21450		10.1074/jbc.273.34.21447	http://dx.doi.org/10.1074/jbc.273.34.21447			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705271	hybrid			2022-12-25	WOS:000075492600005
J	Deng, KP; Zhang, L; Kachurin, AM; Yu, L; Xia, D; Kim, H; Deisenhofer, J; Yu, CA				Deng, KP; Zhang, L; Kachurin, AM; Yu, L; Xia, D; Kim, H; Deisenhofer, J; Yu, CA			Activation of a matrix processing peptidase from the crystalline cytochrome bc(1) complex of bovine heart mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C OXIDOREDUCTASE COMPLEX; SACCHAROMYCES-CEREVISIAE; POTATO MITOCHONDRIA; ELECTRON-TRANSPORT; ENHANCING PROTEIN; SUBUNIT-II; UBIQUINOL; REDUCTASE; GENE; SEQUENCE	No mitochondrial processing peptidase (MPP) activity is detected in crystalline bovine heart mitochondrial cytochrome be, complex, which possesses full electron transfer activity. However, when the complex is treated with increasing concentrations of Triton X-100 at 37 degrees C, the electron transfer activity decreases, whereas peptidase activity increases. Maximum MPP activity is obtained when the electron transfer activity in the complex is completely inactivated with 1.5 mar of Triton X-100, This result supports our suggestion that the lack of MPP activity in the mammalian cytochrome be, complex is because of binding of an inhibitor polypeptide to the active site of MPP located at the interface of core subunits I and II. This suggestion is based on the three-dimensional structural information for the be, complex and the sequence homology between subunits of MPP and the core subunits of the beef complex. Triton X-100, at concentrations that disrupt the structural integrity of the be, complex as indicated by the loss of its electron transfer activity, weakens the binding of inhibitor polypeptide to the active site of MPP in core subunits, thus activating MPP, The Triton X-100-activated MPP is pH-, buffer system-, ionic strength-, and temperature-dependent. Maximum activity is observed with an assay mixture containing 15 mM Tris-HCl buffer at neutral pH (6.5-8.5) and at 37 degrees C, Activated MPP is completely inhibited by metal ion chelators such as EDTA and o-phenanthroline and partially inhibited by myxothiazol (58%), ferricyanide (28%), and dithiothreitol (81%). The metal ion chelator-inhibited activity can be partially restored by the addition of divalent cations such as Zn2+ (68%), Mg2+ (44%), Mn2+ (54%), Co2+ (62%), and Fe2+ (92%), indicating that metal ion is required for MPP activity. The cleavage site specificity of activated MPP depends more on the length of amino acid sequence from the mature protein portion and less on the presequence portion, when a synthetic peptide composed of NH2-terminal residues of a mature protein and the COOH-terminal residues of its presequence is used as a substrate.	Oklahoma State Univ, Stillwater, OK 74078 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	Oklahoma State University System; Oklahoma State University - Stillwater; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yu, CA (corresponding author), Oklahoma State Univ, Stillwater, OK 74078 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRY EA, 1992, J MOL BIOL, V224, P1161, DOI 10.1016/0022-2836(92)90476-Z; BRANDT U, 1993, J BIOL CHEM, V268, P8387; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; BRAUN HP, 1995, J BIOENERG BIOMEMBR, V27, P423, DOI 10.1007/BF02110005; DENG K, 1996, BIOPHYS J, V72, pA319; EMMERMANN M, 1993, PLANT PHYSIOL, V103, P615, DOI 10.1104/pp.103.2.615; EMMERMANN M, 1993, BIOCHIM BIOPHYS ACTA, V1142, P306, DOI 10.1016/0005-2728(93)90158-C; EMMERMANN M, 1993, J BIOL CHEM, V268, P18936; ERIKSSON AC, 1992, BIOCHIM BIOPHYS ACTA, V1140, P208, DOI 10.1016/0005-2728(92)90010-Y; ERIKSSON AC, 1996, J BIOENERG BIOMEMBR, V28, P283; GENCIC S, 1991, EUR J BIOCHEM, V199, P123, DOI 10.1111/j.1432-1033.1991.tb16099.x; GLASER E, 1994, FEBS LETT, V346, P83, DOI 10.1016/0014-5793(94)00312-2; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; KALOUSEK F, 1992, EMBO J, V11, P2803, DOI 10.1002/j.1460-2075.1992.tb05347.x; KIM H, 1998, IN PRESS P NATL ACAD; KITADA S, 1995, J BIOCHEM-TOKYO, V117, P1148, DOI 10.1093/oxfordjournals.jbchem.a124836; KUBOTA T, 1991, J MOL BIOL, V221, P379, DOI 10.1016/0022-2836(91)80059-4; MAARSE AC, 1988, EUR J BIOCHEM, V172, P179, DOI 10.1111/j.1432-1033.1988.tb13870.x; OU W, 1988, EMBO J, V8, P2605; OUDSHOORN P, 1987, EUR J BIOCHEM, V163, P97, DOI 10.1111/j.1432-1033.1987.tb10741.x; PHILLIPS JD, 1990, J BIOL CHEM, V265, P20813; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; SCHMITT ME, 1990, J BIOL CHEM, V265, P17005; SCHOPPINK PJ, 1989, BIOCHIM BIOPHYS ACTA, V974, P192, DOI 10.1016/S0005-2728(89)80372-X; Striebel HM, 1996, ARCH BIOCHEM BIOPHYS, V335, P211, DOI 10.1006/abbi.1996.0500; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANG XH, 1988, J BIOL CHEM, V263, P11962; YU CA, 1994, J MOL BIOL, V243, P802, DOI 10.1016/0022-2836(94)90051-5; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YU CA, 1982, BIOCHEMISTRY-US, V21, P4096, DOI 10.1021/bi00260a028; YUE WH, 1991, BIOCHEMISTRY-US, V30, P2303, DOI 10.1021/bi00223a002	34	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20752	20757		10.1074/jbc.273.33.20752	http://dx.doi.org/10.1074/jbc.273.33.20752			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694818	hybrid			2022-12-25	WOS:000075386100011
J	Ekberg, M; Potsch, S; Sandin, E; Thunnissen, M; Nordlund, P; Sahlin, M; Sjoberg, BM				Ekberg, M; Potsch, S; Sandin, E; Thunnissen, M; Nordlund, P; Sahlin, M; Sjoberg, BM			Preserved catalytic activity in an engineered ribonucleotide reductase R2 protein with a nonphysiological radical transfer pathway - The importance of hydrogen bond connections between the participating residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; SITE-DIRECTED MUTAGENESIS; ELECTRON-TRANSFER COMPLEX; ESCHERICHIA-COLI; 2'-AZIDO-2'-DEOXYURIDINE 5'-DIPHOSPHATE; HYPOTHETICAL MODEL; PROMOTER SYSTEM; R1; MECHANISM; KINETICS	A hydrogen-bonded catalytic radical transfer pathway in Escherichia coli ribonucleotide reductase (RNR) is evident from the three-dimensional structures of the R1 and R2 proteins, phylogenetic studies, and site-directed mutagenesis experiments, Current knowledge of electron transfer processes is difficult to apply to the very long radical transfer pathway in RNR, To explore the importance of the hydrogen bonds between the participating residues, we converted the protein R2 residue Asp(237), one of the conserved residues along the radical transfer route, to an asparagine and a glutamate residue in two separate mutant proteins. In this study, me show that the D237E mutant is catalytically active and has hydrogen bond connections similar to that of the wild type protein. This is the first reported mutant protein that affects the radical transfer pathway while catalytic activity is preserved. The D237N mutant is catalytically inactive, and its tyrosyl radical is unstable, although the mutant can form a diferric-oxo iron center and a R1-R2 complex. The data strongly support our hypothesis that an absolute requirement for radical transfer during catalysis in ribonucleotide reductase is an intact hydrogen-bonded pathway between the radical site in protein R2 and the substrate binding site in R1, Our data thus strongly favor the idea that the electron transfer mechanism in RNR is coupled with proton transfer, i.e. a radical transfer mechanism.	Univ Stockholm, Dept Mol Biol, S-10691 Stockholm, Sweden; Univ Stockholm, Dept Biophys, S-10691 Stockholm, Sweden	Stockholm University; Stockholm University	Sjoberg, BM (corresponding author), Univ Stockholm, Dept Mol Biol, S-10691 Stockholm, Sweden.	Britt-Marie.Sjoberg@molbio.su.se	Thunnissen, Marjolein MGM/B-9366-2011	Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8015, DOI 10.1021/ja00097a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; DEREGE PJF, 1995, SCIENCE, V269, P1409, DOI 10.1126/science.7660123; DOBELN UV, 1976, J BIOL CHEM, V251, P3616; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; HAZZARD JT, 1987, BIOCHEMISTRY-US, V26, P2836, DOI 10.1021/bi00384a027; HO PS, 1985, J AM CHEM SOC, V107, P1070, DOI 10.1021/ja00290a059; Katterle B, 1997, J BIOL CHEM, V272, P10414; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LASSMANN G, 1992, BIOCHEM BIOPH RES CO, V188, P879, DOI 10.1016/0006-291X(92)91138-G; Logan DT, 1996, STRUCTURE, V4, P1053, DOI 10.1016/S0969-2126(96)00112-8; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NORDLUND P, 1989, FEBS LETT, V258, P251, DOI 10.1016/0014-5793(89)81666-7; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Persson AL, 1997, J BIOL CHEM, V272, P31533, DOI 10.1074/jbc.272.50.31533; Persson BO, 1996, J BIOL INORG CHEM, V1, P247, DOI 10.1007/s007750050050; PERSSON BO, 1997, THESIS STOCKHOLM U S; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1980, J BIOL CHEM, V255, P322; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SALOWE S, 1993, BIOCHEMISTRY-US, V32, P12749, DOI 10.1021/bi00210a026; SCHMIDT PP, 1998, IN PRESS J BIOL CHEM, V273; Siegbahn PEM, 1997, THEOR CHEM ACC, V97, P289, DOI 10.1007/s002140050264; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SJOBERG BM, 1983, J BIOL CHEM, V258, P8060; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1976, J BIOL CHEM, V251, P1398; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; VANDERDONK WA, 1995, J AM CHEM SOC, V117, P8908, DOI 10.1021/ja00140a003; WALDMEYER B, 1982, J BIOL CHEM, V257, P6073; WANG JM, 1990, BIOCHEMISTRY-US, V29, P7160, DOI 10.1021/bi00483a003	50	64	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21003	21008		10.1074/jbc.273.33.21003	http://dx.doi.org/10.1074/jbc.273.33.21003			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694851	hybrid			2022-12-25	WOS:000075386100044
J	Furuchi, T; Anderson, RGW				Furuchi, T; Anderson, RGW			Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; DENSITY-LIPOPROTEIN RECEPTOR; PLASMA-MEMBRANE; MEDIATED TRANSPORT; MA104 CELLS; SR-BI; PROTEIN; GROWTH; COMPONENT; BINDING	Previously we showed that activation of Erk in quiescent cells occurs in the caveolae fraction isolated from fibroblasts. Since the structure and function of caveolae is sensitive to the amount of cholesterol in the membrane, it might be that a direct link exists between the concentration of membrane cholesterol and mitogen-activated protein (LAP) kinase activation. We acutely lowered the cholesterol level of the caveolae fraction by incubating Rat-1 cells in the presence of either cyclodextrin or progesterone, Cholesterol-depleted caveolae had a reduced amount of several key protein components of the MAP kinase complex, including Pas, GrbB, Erk2, and Src. Incubation of these cells in the presence of epidermal growth factor (EGF) caused a rapid loss of EGF receptor from the caveolae fraction, but the usual recruitment of c-Raf was markedly inhibited. Despite the reduced amount of c-Raf and Erk2 in the cholesterol-depleted caveolae fraction, EGF caused a hyperactivation of the remaining caveolae Erk isoenzymes. This was followed by an increase in the amount of active Erk in the cytoplasm, The increased amount of activated Erk produced under these conditions was linked to a 8-fold higher level of EGF-stimulated DNA synthesis. Even cholesterol depletion by itself stimulated Erk activation and DNA synthesis. These results suggest that the MAP kinase pathway can connect the cholesterol level of caveolae membrane to the control of cell division.	Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Anderson, RGW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052016] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 52016] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; ANDERSON RGW, 1998, IN PRESS ANN REV BIO, V67; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Baorto DM, 1997, NATURE, V389, P636, DOI 10.1038/39376; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Burack WR, 1997, BIOCHEMISTRY-US, V36, P5929, DOI 10.1021/bi970535d; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Fielding PE, 1996, BIOCHEMISTRY-US, V35, P14932, DOI 10.1021/bi9613382; GAMBLE W, 1978, J LIPID RES, V19, P1068; IALTABA AR, 1997, CELL, V90, P193; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; Pomerantz KB, 1997, BIOCHEMISTRY-US, V36, P9523, DOI 10.1021/bi963069l; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J CELL BIOL, V134, P1169, DOI 10.1083/jcb.134.5.1169; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554	38	327	332	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21099	21104		10.1074/jbc.273.33.21099	http://dx.doi.org/10.1074/jbc.273.33.21099			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694863	hybrid			2022-12-25	WOS:000075386100056
J	Liu, ST; Chang, WZ; Cao, HM; Hu, HL; Chen, ZH; Ni, FD; Lu, HF; Hong, GF				Liu, ST; Chang, WZ; Cao, HM; Hu, HL; Chen, ZH; Ni, FD; Lu, HF; Hong, GF			A HU-like protein binds to specific sites within nod promoters of Rhizobium leguminosarum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-LIKE PROTEINS; ESCHERICHIA-COLI; GENE-EXPRESSION; RNA-POLYMERASE; LAC PROMOTER; DNA; NODULATION; COMPLEXES; MELILOTI; CHROMATOGRAPHY	Nodulation genes (nod) of rhizobia are essential for establishment of its symbiosis with specific legume hosts and are usually located on the Sym(biosis) megaplasmid, In this work we identified a new Sym plasmid independent protein in Rhizobium leguminosarum, Pr, by its ability to bind to nod promoters and induce DNA bending. Depending upon its concentrations relative to DNA templates, Pr could either stimulate or inhibit in vitro transcription of the major regulatory nodulation gene nodD. This may result from its property to bind to specific sites within nod promoters at lower concentration or in the presence of competitor calf thymus DNA but nonspecifically associate with DNA at higher levels or in the absence of competitors. Its binding sites within nodD and nodF promoters were determined by DNase I footprinting but showed no sequence consensus. N-terminal sequencing and Western blot revealed that Pr belongs to the HU class of prokaryotic histone-like proteins. Its binding feature and functioning mechanism were discussed in the Light of this discovery.	Chinese Acad Sci, Shanghai Inst Biochem, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Hong, GF (corresponding author), Chinese Acad Sci, Shanghai Inst Biochem, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.		Liu, Song-Tao/Y-4732-2019; chen, zehua/H-1260-2011	Liu, Song-Tao/0000-0002-9623-8579				Aki T, 1997, EMBO J, V16, P3666, DOI 10.1093/emboj/16.12.3666; BAGDASARIAN M, 1981, GENE, V16, P237, DOI 10.1016/0378-1119(81)90080-9; BIANCHI ME, 1994, MOL MICROBIOL, V14, P1, DOI 10.1111/j.1365-2958.1994.tb01261.x; BONNEFOY E, 1994, J MOL BIOL, V242, P116, DOI 10.1006/jmbi.1994.1563; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CAO HM, 1992, CHINESE SCI BULL, V37, P951; CASTAING B, 1995, J BIOL CHEM, V270, P10291, DOI 10.1074/jbc.270.17.10291; CHANG WZ, 1997, CHIN J BIOTECHNOL, V13, P83; CHANG WZ, 1996, THESIS CHINESE ACAD; Denarie J, 1996, ANNU REV BIOCHEM, V65, P503, DOI 10.1146/annurev.bi.65.070196.002443; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FLASHNER Y, 1988, CELL, V54, P713, DOI 10.1016/S0092-8674(88)80016-3; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HONG GF, 1987, NUCLEIC ACIDS RES, V15, P9677, DOI 10.1093/nar/15.23.9677; KAJITANI M, 1983, NUCLEIC ACIDS RES, V11, P671, DOI 10.1093/nar/11.3.671; KHANAKA H, 1985, EUR J BIOCHEM, V147, P343, DOI 10.1111/j.1432-1033.1985.tb08755.x; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KONDOROSI E, 1989, EMBO J, V8, P1331, DOI 10.1002/j.1460-2075.1989.tb03513.x; KONDOROSI E, 1991, J MOL BIOL, V222, P885, DOI 10.1016/0022-2836(91)90583-R; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAMB JW, 1985, GENE, V34, P235, DOI 10.1016/0378-1119(85)90132-5; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LI M, 1993, TRANSCRIPTION FACTOR, P49; MAVRIDOU A, 1995, MICROBIOL-UK, V141, P103, DOI 10.1099/00221287-141-1-103; OGAWA J, 1995, GENE DEV, V9, P714, DOI 10.1101/gad.9.6.714; PEREZMARTIN J, 1994, MICROBIOL REV, V58, P268; PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x; PREOBRAJENSKAYA O, 1994, MOL MICROBIOL, V13, P459, DOI 10.1111/j.1365-2958.1994.tb00440.x; Pueppke SG, 1996, CRIT REV BIOTECHNOL, V16, P1, DOI 10.3109/07388559609146599; ROSSEN L, 1985, EMBO J, V4, P3369, DOI 10.1002/j.1460-2075.1985.tb04092.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHALLER H, 1972, EUR J BIOCHEM, V26, P474, DOI 10.1111/j.1432-1033.1972.tb01789.x; SCHLAMAN HRM, 1992, J BACTERIOL, V174, P5177, DOI 10.1128/JB.174.16.5177-5182.1992; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; SERRANO M, 1993, TRENDS BIOCHEM SCI, V18, P202, DOI 10.1016/0968-0004(93)90187-R; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; SHEARMAN CA, 1986, EMBO J, V5, P647, DOI 10.1002/j.1460-2075.1986.tb04262.x; SHINDO H, 1992, NUCLEIC ACIDS RES, V20, P1553, DOI 10.1093/nar/20.7.1553; STERNBACH H, 1975, EUR J BIOCHEM, V60, P51, DOI 10.1111/j.1432-1033.1975.tb20974.x; TAGAMI H, 1995, NUCLEIC ACIDS RES, V23, P599, DOI 10.1093/nar/23.4.599; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VANRHIJN P, 1995, MICROBIOL REV, V59, P124, DOI 10.1128/MMBR.59.1.124-142.1995; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; Yasukawa H, 1997, MOL GEN GENET, V254, P548, DOI 10.1007/s004380050450; YELTON MM, 1987, J BACTERIOL, V169, P3094, DOI 10.1128/jb.169.7.3094-3098.1987	46	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20568	20574		10.1074/jbc.273.32.20568	http://dx.doi.org/10.1074/jbc.273.32.20568			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685414	hybrid			2022-12-25	WOS:000075305400091
J	Sawaya, BE; Khalili, K; Mercer, WE; Denisova, L; Amini, S				Sawaya, BE; Khalili, K; Mercer, WE; Denisova, L; Amini, S			Cooperative actions of HIV-1 Vpr and p53 modulate viral gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; LONG TERMINAL REPEAT; WILD-TYPE P53; CELL-CYCLE; VIRION INCORPORATION; MUTATIONAL ANALYSIS; PROTEIN; ACTIVATION; ARRESTS; DOMAIN	Transcription of the human immunodeficiency virus type-1 (HIV-1) genome is controlled by cooperative interaction of viral encoded proteins and host regulatory proteins. In this study, we have examined the capacity of the viral auxiliary protein, Vpr, to modulate transcriptional activity of the HIV-1 promoter sequence located within the long terminal repeat (LTR), We demonstrate that ectopic expression of Vpr in human astrocytic cells, U-87MG, enhances the basal activity of the viral promoter in transfected cells and that the GC-rich sequences, spanning nucleotides -80 to -43, are important for this activity. Since this region serves as the target for p53-induced suppression of LTR activity and interacts with the ubiquitous transcription factor, Spl, we examined the cooperative activity of Vpr, p53, and Spl upon LTR transcription. Results from co-transfection studies indicated that overexpression of wild type p53, but not mutant p53, decreases the level of activation of the LTR by Vpr. Transcriptional activation of the LTR by Vpr required the presence of Spl since overexpression of Vpr in cells with no endogenous Spl failed to augment LTR activity. Results from protein-protein interaction studies indicated that Vpr is associated with both p53 and Spl in cells with ectopic expression of these proteins. Moreover, it was evident that p53 and Spl interact with each other in these cells. These functional and structural studies provided a working model on the cooperative interaction of Vpr with cellular proteins Spl and p53 and control of viral gene transcription at immediate early stage of infection prior to the participation of other viral regulatory proteins.	Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, Philadelphia, PA 19102 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Drexel University; Jefferson University	Amini, S (corresponding author), Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, 245 N 15th St,Mailstop 406, Philadelphia, PA 19102 USA.	amini@auhs.edu						Agostini I, 1996, J MOL BIOL, V261, P599, DOI 10.1006/jmbi.1996.0485; ARRIGO SJ, 1990, J VIROL, V64, P4585, DOI 10.1128/JVI.64.9.4585-4588.1990; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Kundu M, 1997, J BIOL CHEM, V272, P29468, DOI 10.1074/jbc.272.47.29468; Kundu M, 1998, J BIOL CHEM, V273, P8130, DOI 10.1074/jbc.273.14.8130; LEGROS Y, 1994, ONCOGENE, V9, P2071; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; MACREADIE IG, 1995, P NATL ACAD SCI USA, V92, P2770, DOI 10.1073/pnas.92.7.2770; MAHALINGAM S, 1995, P NATL ACAD SCI USA, V92, P3794, DOI 10.1073/pnas.92.9.3794; MAHALINGAM S, 1995, VIROLOGY, V207, P297, DOI 10.1006/viro.1995.1081; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; Miller RH, 1997, NAT MED, V3, P389, DOI 10.1038/nm0497-389; MOEREMANS M, 1985, ANAL BIOCHEM, V145, P315, DOI 10.1016/0003-2697(85)90368-9; OGAWA K, 1989, J VIROL, V63, P4110, DOI 10.1128/JVI.63.9.4110-4114.1989; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Serio D, 1997, P NATL ACAD SCI USA, V94, P3346, DOI 10.1073/pnas.94.7.3346; Shaw PH, 1996, PATHOL RES PRACT, V192, P669, DOI 10.1016/S0344-0338(96)80088-4; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZEICHNER SL, 1991, J VIROL, V65, P2436, DOI 10.1128/JVI.65.5.2436-2444.1991; Zhao YQ, 1996, J VIROL, V70, P5821, DOI 10.1128/JVI.70.9.5821-5826.1996; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	46	84	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20052	20057		10.1074/jbc.273.32.20052	http://dx.doi.org/10.1074/jbc.273.32.20052			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685344	hybrid			2022-12-25	WOS:000075305400021
J	Steffensen, B; Bigg, HF; Overall, CM				Steffensen, B; Bigg, HF; Overall, CM			The involvement of the fibronectin type II-like modules of human gelatinase A in cell surface localization and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; IV COLLAGENASE; 72-KDA GELATINASE; TISSUE INHIBITOR; EXTRACELLULAR-MATRIX; PROGELATINASE-A; BINDING; EXPRESSION; METALLOPROTEINASES; 92-KDA	Recombinant collagen-binding domain (rCBD) comprising the three fibronectin type II-like modules of human gelatinase A was found to compete the zymogen form of this matrix metalloproteinase from the cell surface of normal human fibroblasts in culture. Upon concanavalin A treatment of cells, the induced cellular activation of gelatinase A was markedly elevated in the presence of the rCBD. Therefore, the mechanistic aspects of gelatinase A binding to cells by this domain were further studied using cell attachment assays. Fibroblasts attached to rCBD-coated microplate wells in a manner that was inhibited by soluble rCBD, blocking antibodies to the beta(1)-integrin subunit but not the cu,integrin subunit, and bacterial collagenase treatment. Addition of soluble collagen rescued the attachment of collagenase-treated cells to the rCBD. As a probe on ligand blots of octyl-beta-D-thioglucopyranoside-solubilized cell membrane extracts, the rCBD bound 140- and 160-kDa protein bands. Their identities were likely procollagen chains being both bacterial collagenase-sensitive and also converted upon pepsin digestion to 112- and 126-kDa bands that co-migrated with collagen arl(I) and alpha 2(I) chains. A rCBD mutant protein (Lys(263) --> Ala) with reduced collagen affinity showed less cell attachment, whereas a heparin-binding deficient mutant (Lys(357) --> Ala), heparinase treatment, or heparin addition did not alter attachment. Thus, a cell-binding mechanism for gelatinase A is revealed that does not involve the hemopexin COOH domain. Instead, an attachment complex comprising gelatinase A-native type I collagen-beta(1)-integrin forms as a result of interactions involving the collagen-binding domain of the enzyme. Moreover, this distinct pool of cell collagen-bound proenzyme appears recalcitrant to cellular activation.	Univ British Columbia, Fac Dent, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Fac Med, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Overall, CM (corresponding author), Univ British Columbia, Fac Dent, 2199 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.							BANYAI L, 1991, FEBS LETT, V282, P23, DOI 10.1016/0014-5793(91)80436-7; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BROWN PD, 1990, CANCER RES, V50, P6184; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CORCORAN ML, 1995, J BIOL CHEM, V270, P13453, DOI 10.1074/jbc.270.22.13453; CRABBE T, 1993, EUR J BIOCHEM, V218, P431, DOI 10.1111/j.1432-1033.1993.tb18393.x; EMONARD HP, 1992, CANCER RES, V52, P5845; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; HEMLER ME, 1988, IMMUNOL TODAY, V9, P109, DOI 10.1016/0167-5699(88)91280-7; KEUNG W, 1989, ANAL BIOCHEM, V182, P16; Kolkenbrock H, 1997, BIOL CHEM, V378, P71, DOI 10.1515/bchm.1997.378.2.71; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; MURPHY G, 1994, J BIOL CHEM, V269, P6632; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OVERALL CM, 1988, BIOCHEM J, V256, P965, DOI 10.1042/bj2560965; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; OVERALL CM, 1998, IN PRESS INHIBITORS; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; SEFTOR REB, 1993, CANCER RES, V53, P3411; Shipley JM, 1996, J BIOL CHEM, V271, P4335; SODEK J, 1981, CALCIFIED TISSUE INT, V33, P255, DOI 10.1007/BF02409446; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; ZUCKER S, 1987, BIOCHIM BIOPHYS ACTA, V924, P225, DOI 10.1016/0304-4165(87)90091-2	37	80	80	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20622	20628		10.1074/jbc.273.32.20622	http://dx.doi.org/10.1074/jbc.273.32.20622			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685420	hybrid			2022-12-25	WOS:000075305400097
J	Uchida, T; Ishikawa, H; Takahashi, S; Ishimori, K; Morishima, I; Ohkubo, K; Nakajima, H; Aono, S				Uchida, T; Ishikawa, H; Takahashi, S; Ishimori, K; Morishima, I; Ohkubo, K; Nakajima, H; Aono, S			Heme environmental structure of CooA is modulated by the target DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ACTIVATOR PROTEIN; CARBON-MONOXIDE DEHYDROGENASE; RESONANCE RAMAN-SCATTERING; RHODOSPIRILLUM-RUBRUM; CYTOCHROME-C; TRANSCRIPTIONAL ACTIVATOR; B-DNA; COMPLEX; DISTAL; HYDROGENASE	In order to investigate the gene activation mechanism triggered by the CO binding to CooA, a heme-containing transcriptional activator, the heme environmental structure and the dynamics of the CO rebinding and dissociation have been examined in the absence and presence of its target DNA. In the absence of DNA, the Fe-CO and C=O stretching Raman lines of the GO-bound CooA were observed at 487 and 1969 cm(-l), respectively, suggesting that a neutral histidine is an axial ligand trans to CO. The frequency of nu(Fe-CO) implies an open conformation of the distal heme pocket, indicating that the Ligand replaced by CO is located away from the bound CO. When the target DNA was added to GO-bound CooA, an appearance of a new nu(Fe-CO) line at 519 cm(-l) and narrowing of the main line at 486 cm(-1) were observed. Although the rate of the CO dissociation was insensitive to the additions of DNA, the CO rebinding was decelerated in the presence of the target DNA, but not in the presence of nonsense DNA. These observations demonstrate the structural alterations in the heme distal site in response to binding of the target DNA and support the activation mechanism proposed for CooA, which is triggered by the movement of the heme distal ligand to modify the conformation of the DNA binding domain.	Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan; Japan Adv Inst Sci & Technol, Sch Mat Sci, Tatsunokuchi, Ishikawa 9231292, Japan	Kyoto University; Japan Advanced Institute of Science & Technology (JAIST)	Morishima, I (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan.		Ishimori, Koichiro/AAQ-4434-2021; Asano, Yasuhisa/K-5898-2016; Ohkubo, Kei/L-5002-2019; Ishikawa, Haruto/B-1562-2012; Ishimori, Koichiro/S-1247-2016; Aono, Shigetoshi/ABD-7618-2020; Ohkubo, Kei/E-5127-2012; Uchida, Takeshi/A-6455-2017	Ishimori, Koichiro/0000-0002-5868-0462; Asano, Yasuhisa/0000-0003-3645-3952; Ohkubo, Kei/0000-0001-8328-9249; Ishikawa, Haruto/0000-0001-6362-5719; Ishimori, Koichiro/0000-0002-5868-0462; Aono, Shigetoshi/0000-0002-2870-3694; Ohkubo, Kei/0000-0001-8328-9249; Uchida, Takeshi/0000-0001-9270-8329				Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Aono S, 1997, BIOCHEM BIOPH RES CO, V240, P783, DOI 10.1006/bbrc.1997.7746; Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; BONAM D, 1989, J BACTERIOL, V171, P3102, DOI 10.1128/jb.171.6.3102-3107.1989; DAWSON JH, 1983, J BIOL CHEM, V258, P3637; Fox JD, 1996, J BACTERIOL, V178, P1515, DOI 10.1128/jb.178.6.1515-1524.1996; Fox JD, 1996, J BACTERIOL, V178, P6200, DOI 10.1128/jb.178.21.6200-6208.1996; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; HU SZ, 1993, J AM CHEM SOC, V115, P12446, DOI 10.1021/ja00079a028; JEWSBURY P, 1994, BIOPHYS J, V67, P2236, DOI 10.1016/S0006-3495(94)80708-8; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; KERBY RL, 1992, J BACTERIOL, V174, P5284, DOI 10.1128/JB.174.16.5284-5294.1992; Kerby RL, 1997, J BACTERIOL, V179, P2259, DOI 10.1128/jb.179.7.2259-2266.1997; KITAGAWA T, 1975, J BIOCHEM-TOKYO, V78, P719, DOI 10.1093/oxfordjournals.jbchem.a130960; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; LOU BS, 1993, BIOCHIM BIOPHYS ACTA, V1144, P403, DOI 10.1016/0005-2728(93)90127-2; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; Millikan GA, 1936, PROC R SOC SER B-BIO, V120, P366, DOI 10.1098/rspb.1936.0041; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; OLDFIELD E, 1991, J AM CHEM SOC, V113, P7537, DOI 10.1021/ja00020a014; PARK KD, 1991, BIOCHEMISTRY-US, V30, P2333, DOI 10.1021/bi00223a007; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; SMULEVICH G, 1994, INORG CHEM, V33, P4629, DOI 10.1021/ic00099a012; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; STRITTMATTER P, 1956, J BIOL CHEM, V221, P253; TAKAHASHI M, 1989, J MOL BIOL, V207, P783, DOI 10.1016/0022-2836(89)90244-1; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; Uchida T, 1997, J BIOL CHEM, V272, P30108, DOI 10.1074/jbc.272.48.30108; UNO T, 1987, J BIOL CHEM, V262, P4549; WALLACE CJA, 1992, J BIOL CHEM, V267, P3852; WEBER IT, 1984, P NATL ACAD SCI-BIOL, V81, P3973, DOI 10.1073/pnas.81.13.3973; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WITTENBERG BA, 1965, ARCH BIOCHEM BIOPHYS, V111, P576, DOI 10.1016/0003-9861(65)90237-7; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39	37	63	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19988	19992		10.1074/jbc.273.32.19988	http://dx.doi.org/10.1074/jbc.273.32.19988			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685335	hybrid			2022-12-25	WOS:000075305400012
J	Erickson, S; Sangfelt, O; Heyman, M; Castro, J; Einhorn, S; Grander, D				Erickson, S; Sangfelt, O; Heyman, M; Castro, J; Einhorn, S; Grander, D			Involvement of the Ink4 proteins p16 and p15 in T-lymphocyte senescence	ONCOGENE			English	Article						T-lymphocytes; p16; p15 senescence	DEPENDENT KINASE INHIBITORS; CELL-CYCLE CONTROL; REPLICATIVE SENESCENCE; TUMOR SUPPRESSION; HUMAN-FIBROBLASTS; MAMMALIAN-CELLS; TGF-BETA; EXPRESSION; GENE; INACTIVATION	Little is known about the molecular background to senescence in T-lymphocytes. In fibroblast systems replicative senescence has been shown to correlate with a number of changes in the expression of the proteins normally regulating progression through the G1 phase of the cell cycle, and recently the Ink4 inhibitor p16 was implicated as a central regulator of replicative senescence in human fibroblasts. It has, however, been claimed that p16 is not expressed in T-lymphocytes, In the present study we have analysed G1 regulating proteins in ageing human T-lymphocytes, We show that PHA and IL-2 stimulated T-lymphocytes cease to proliferate after around 20 population doublings, these cells can not thereafter be restimulated to growth, and were also found to exhibit markers for senescence, We found that T-lymphocytes accumulate p16 and p15 protein during successive population doublings and display high levels of these proteins as they enter into replicative senescence. There was also an increased binding of p16 to the Cdk6 kinase in senescent cells, and a decreased Cdk6 as well as Cdk2 kinase activity. The levels of other G1 regulating proteins were also altered in the senescent cells, such as slightly elevated levels of p21/WAF1, and downregulation of Cdk2 and cyclinD3, The levels off p27/Kipl is down regulated in proliferating cells but rise to approximately 15% of the levels in un-stimulated quiescent cells. As a high proportion of T-cell childhood acute lymphoblastic leukaemias have deletions of both p15 and p16, our data suggest that inactivation of these genes makes it possible for leukemic cells to avoid senescence.	Karolinska Hosp & Inst, Dept Pathol & Oncol, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Grander, D (corresponding author), Karolinska Hosp & Inst, Dept Pathol & Oncol, S-17176 Stockholm, Sweden.							Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ATADJA P, 1995, P NATL ACAD SI US, V92, P8328; Batova A, 1997, CANCER RES, V57, P832; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Effros RB, 1996, EXP GERONTOL, V31, P21, DOI 10.1016/0531-5565(95)00017-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GOLDSTEIN S, 1994, J CELL PHYSIOL, V161, P571, DOI 10.1002/jcp.1041610321; GRANA X, 1995, ONCOGENE, V11, P211; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Herman JG, 1996, CANCER RES, V56, P722; Heyman M, 1996, LEUKEMIA LYMPHOMA, V23, P235, DOI 10.3109/10428199609054826; HIRAMA T, 1995, BLOOD, V86, P841; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Kamb A, 1994, Nat Genet, V8, P23; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; LOIS AF, 1995, CANCER RES, V55, P4010; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PERILLO NL, 1993, EXP CELL RES, V207, P131, DOI 10.1006/excr.1993.1171; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Reznikoff CA, 1996, CANCER RES, V56, P2886; RYAN QC, 1993, CELL IMMUNOL, V149, P65, DOI 10.1006/cimm.1993.1136; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; SONODA Y, 1995, ONCOGENE, V11, P2145; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TAM SW, 1994, CANCER RES, V54, P5816; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; ULLBERG M, 1983, SCAND J IMMUNOL, V17, P365, DOI 10.1111/j.1365-3083.1983.tb00801.x	44	82	85	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					595	602		10.1038/sj.onc.1201965	http://dx.doi.org/10.1038/sj.onc.1201965			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704925				2022-12-25	WOS:000075195300007
J	Lee, SK; Qing, WG; Mar, W; Luyengi, L; Mehta, RG; Kawanishi, K; Fong, HHS; Beecher, CWW; Kinghorn, AD; Pezzuto, JM				Lee, SK; Qing, WG; Mar, W; Luyengi, L; Mehta, RG; Kawanishi, K; Fong, HHS; Beecher, CWW; Kinghorn, AD; Pezzuto, JM			Angoline and chelerythrine, benzophenanthridine alkaloids that do not inhibit protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE ACTIVITY; MITOCHONDRIAL-FRACTION; PHORBOL ESTERS; RAT RETINA; CELLS; ACTIVATION; POTENT; PHOSPHORYLATION; INVOLVEMENT; EXPRESSION	Starting with an extract derived from the I;tem of Macleaya cordata (Papaveraceae) that was active in the process of inhibiting phorbol 12,13-dibutyrate binding to partially purified protein kinase C (PI(C), the benzophenanthridine alkaloid angoline was isolated and identified. This discovery appeared in context, as a related benzophenanthridine alkaloid, chelerythrine, has been reported to mediate a variety of biological activities, including potent and selective inhibition of protein kinase C (PKC). However, in our studies, angoline was not observed to function as a potent inhibitor of PHC. Moreover, we were unable to confirm the reported inhibitory activity of chelerythrine. In a comprehensive series of studies performed with various PKC isozymes derived from a variety of mammalian species, neither chelerythrine nor angoline inhibited activity with high potency. To the contrary, chelerythrine stimulated PKC activity in the cytosolic fractions of rat and mouse brain in concentrations up to 100 mu M. In addition, chelerythrine and angoline did not inhibit [H-3]phorbol 12,13-dibutyrate binding to the regulatory domain of PKC at concentrations up to 40 mu g/ml, and no significant; alteration of PKC-alpha, -beta, or -gamma translocation was observed with human leukemia (HL-60) cells in culture. Fur ther, chelerythrine did not inhibit 12-O-tetradecanoylphorbol 13-acetate-induced ornithine decarboxylase activity with cultured mouse 308 cells, but angoline was active in this capacity with an IC50 value of 1.0 mu g/ml. AI relatively large number of biological responses have been reported in studies conducted with chelerythrine, and alteration of PI(C activity has been considered as a potential mechanism of action. In light of the current report, mechanisms independent of PKC inhibition should be considered as responsible for these effects.	Univ Illinois, Coll Pharm, Program Collaborat Res Pharmaceut Sci, Chicago, IL 60612 USA; Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Surg Oncol, Chicago, IL 60612 USA; Seoul Natl Univ, Inst Nat Prod Res, Seoul 110460, South Korea; Kobe Pharmaceut Univ, Kobe, Hyogo 658, Japan	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Seoul National University (SNU); Kobe Pharmaceutical University	Pezzuto, JM (corresponding author), Univ Illinois, Coll Pharm, Program Collaborat Res Pharmaceut Sci, M-C 877,833 S Wood St, Chicago, IL 60612 USA.			Kinghorn, A. Douglas/0000-0002-6647-8707	NATIONAL CANCER INSTITUTE [P01CA048112] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA48112] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COSTAGNA M, 1987, BIOL CELL, V59, P3; DASILVA C, 1990, CANCER RES, V50, P2081; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEVRIES DJ, 1988, BIOCHEM PHARMACOL, V37, P4069, DOI 10.1016/0006-2952(88)90097-4; FONZES L, 1968, PHYTOCHEMISTRY, V7, P1889, DOI 10.1016/S0031-9422(00)86668-6; Gopalakrishna R., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P615; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HERBERT JM, 1993, THROMB RES, V71, P487, DOI 10.1016/0049-3848(93)90122-5; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; Hoelting T, 1997, CANCER LETT, V119, P1, DOI 10.1016/S0304-3835(97)00242-5; KO FN, 1990, BIOCHIM BIOPHYS ACTA, V1052, P360, DOI 10.1016/0167-4889(90)90144-3; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KRANE BD, 1984, J NAT PROD, V47, P1, DOI 10.1021/np50031a001; LARSEN AK, 1994, BBA-MOL CELL RES, V1222, P477, DOI 10.1016/0167-4889(94)90057-4; LENFELD J, 1981, PLANTA MED, V43, P161, DOI 10.1055/s-2007-971493; LICHTI U, 1982, J CELL PHYSIOL, V113, P433, DOI 10.1002/jcp.1041130312; Lombardini JB, 1996, BIOCHEM PHARMACOL, V52, P253, DOI 10.1016/0006-2952(96)00202-X; LOMBARDINI JB, 1995, BRAIN RES, V673, P194, DOI 10.1016/0006-8993(94)01369-S; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; MCLEAN DB, 1969, CAN J CHEM, V47, P1951; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OTTE AP, 1992, CELL, V68, P1021, DOI 10.1016/0092-8674(92)90074-M; SHARMA PN, 1979, INDIAN J CHEM B, V17, P299; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TSENG CP, 1994, CARCINOGENESIS, V15, P707, DOI 10.1093/carcin/15.4.707; VERMA AK, 1986, CANCER RES, V46, P6149; VONSTEBUT E, 1994, AGENTS ACTIONS, V41, pC56; WALTEROVA D, 1981, J MED CHEM, V24, P1103; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; WOLFF J, 1993, BIOCHEMISTRY-US, V32, P13334, DOI 10.1021/bi00211a047; ZOUKHRI D, 1993, AM J PHYSIOL, V264, pC1045, DOI 10.1152/ajpcell.1993.264.4.C1045	37	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19829	19833		10.1074/jbc.273.31.19829	http://dx.doi.org/10.1074/jbc.273.31.19829			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677417	hybrid			2022-12-25	WOS:000075125200069
J	Fenstermaker, RA; Ciesielski, MJ; Castiglia, GJ				Fenstermaker, RA; Ciesielski, MJ; Castiglia, GJ			Tandem duplication of the epidermal growth factor receptor tyrosine kinase and calcium internalization domains in A-172 glioma cells	ONCOGENE			English	Article						epidermal growth factor receptor; mutation; genetic recombination; glioma; intron; oncogene	HUMAN GLIOBLASTOMA; EGF-RECEPTOR; MALIGNANT GLIOMAS; BRAIN-TUMORS; FACTOR-ALPHA; C-MYB; GENE; EXPRESSION; TRANSFORMATION; AMPLIFICATION	Amplification and rearrangement of the epidermal growth factor receptor (EGFR) gene occur frequently in malignant gliomas. Rearrangement may also lead to the expression of potentially oncogenic EGFR deletion mutants. Data presented here indicate the existence of a 190 kDa mutant form of the EGFR in A-172 glioma cells that is substantially different from the deletion mutants characterized previously. The EC;FR-like protein is expressed along with the 170 kDa wild type EGFR. It is detectable with antibodies to both extracellular and intracellular regions of the EGFR, but is not crossreactive with other HER-family members, The wild type and mutant receptors undergo phosphorylation in response to treatment with TGF alpha and are associated with expression of both 10.5 kb and 11.5 kb EGFR-related transcripts. Combined reverse transcription-polymerase chain reaction (RT-PCR) identifies a unique transcript in A-172 cells that encodes an in-frame, tandem duplication of both tyrosine kinase and calcium internalization (TK/CAIN) domains (exons 18 through 26). The duplication of these domains is associated with a specific genomic rearrangement between potential v-myb and c-myb consensus binding sites within introns 26 and 17 of the EGFR gene resulting in the formation of a chimeric intron.	Roswell Pk Canc Inst, Dept Neurosurg, Buffalo, NY 14263 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14209 USA	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Fenstermaker, RA (corresponding author), Roswell Pk Canc Inst, Dept Neurosurg, Elm & Carlton St, Buffalo, NY 14263 USA.				NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056-21] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGNES F, 1994, GENE, V145, P283, DOI 10.1016/0378-1119(94)90021-3; BASAU A, 1989, MOL CELL BIOL, V9, P671; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; BIGNER SH, 1990, CANCER RES, V50, P8017; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; BOGLER O, 1995, CANCER RES, V55, P2746; CALLAGHAN T, 1993, ONCOGENE, V8, P2939; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; Deng QL, 1996, NUCLEIC ACIDS RES, V24, P766, DOI 10.1093/nar/24.4.766; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Frisa PS, 1996, CELL GROWTH DIFFER, V7, P223; HALEY JD, 1989, ONCOGENE, V4, P273; HernandezMunain C, 1996, J EXP MED, V183, P289, DOI 10.1084/jem.183.1.289; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; HUMPHREY PA, 1991, BIOCHEM BIOPH RES CO, V178, P1413, DOI 10.1016/0006-291X(91)91051-D; HUMPHREY PA, 1988, CANCER RES, V48, P2231; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; LUNDJOHANSEN M, 1990, CANCER RES, V50, P6039; MAHALEY MS, 1991, J NEURO-ONCOL, V11, P85, DOI 10.1007/BF02390173; MARUNO M, 1991, J NEUROSURG, V75, P97, DOI 10.3171/jns.1991.75.1.0097; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; Moscatello DK, 1996, ONCOGENE, V13, P85; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PANNEERSELVAM K, 1995, EUR J BIOCHEM, V230, P951, DOI 10.1111/j.1432-1033.1995.tb20641.x; PELLEY RJ, 1988, J VIROL, V54, P304; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; RASHEED BKA, 1994, CANCER RES, V54, P1324; SCHLEGEL J, 1994, INT J CANCER, V56, P72; STECK PA, 1988, CANCER RES, V48, P5433; SU HHJ, 1997, J BIOL CHEM, V272, P2927; Ueki K, 1996, CANCER RES, V56, P150; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WELTER C, 1990, CANCER LETT, V52, P57, DOI 10.1016/0304-3835(90)90077-B; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAMOMOTO T, 1983, CELL, V34, P225; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812	47	27	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3435	3443		10.1038/sj.onc.1202156	http://dx.doi.org/10.1038/sj.onc.1202156			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692551				2022-12-25	WOS:000074544100010
J	Marchetti, D; Parikh, N; Sudol, M; Gallick, GE				Marchetti, D; Parikh, N; Sudol, M; Gallick, GE			Stimulation of the protein tyrosine kinase c-Yes but not c-Src by neurotrophins in human brain-metastatic melanoma cells	ONCOGENE			English	Article						c-Yes, c-Src; neurotrophins; nerve growth factor; neurotrophin-3; brain-metastatic melanoma	NERVE GROWTH-FACTOR; HUMAN-MALIGNANT MELANOMA; ELEVATED EXPRESSION; HUMAN MELANOCYTES; TUMOR-METASTASIS; NUDE-MICE; PP60C-SRC; PARACRINE; RECEPTOR; INVASION	The c-Yes proto-oncogene (pp62(c-Yes)) encodes a nonreceptor-type protein tyrosine kinase (NRPTK) of the Src family. c-Yes activities and protein levels are elevated in human melanoma and melanocyte cell lines. Because the neurotrophins (NT) are important in the progression of melanoma to the brain-metastatic phenotype, we determined whether NT stimulate c-Yes activity in human MeWo melanoma cells and two variant sublines with opposite metastatic capabilities, 3 S 5 and 70W, The highly brain-metastatic 70W subline had an intrinsically higher c-Yes activity than parental MeWo or poorly metastatic 3 S 5 cells, c-Yes kinase was further induced by the prototypic human NT, nerve growth factor (NGF) in a dose and time-dependent manner. In contrast, c-Src activity (pp60(c-Src)) was similar in all these cells and unaffected by NGF exposure. Additionally, human NGF and neurotrophin-3 stimulated c-Yes in brain-metastatic 70W cells. The magnitude of c-Yes activation correlated with the degree of invasion of 70 W cells following incubation of these neurotrophins. To further examine NT stimulation of c-Yes in melanoma cells, three additional cell lines were examined. Metastatic TXM-13 and TXM-18 increased c-Yes activity in response to NGF. In contrast, no increase was observed in low-metastatic TXM-40 cells. Together, these data suggest that altered c-Yes expression may play a role in the malignant progression of the human melanocyte towards the brain-metastatic phenotype and that NT enhance the activity of c-Yes in signaling penetration into the matrix of NT-rich stromal microenvironments such as the brain.	Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	University of Texas System; UTMD Anderson Cancer Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Marchetti, D (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA.				NCI NIH HHS [CA 63617, R-29 CA 64178, CA 01605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064178] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKSLEN LA, 1987, INVAS METAST, V7, P253; ALBINO AP, 1991, CANCER RES, V51, P4815; BARBACID M, 1993, ONCOGENE, V8, P2033; BARNEKOW A, 1987, CANCER RES, V47, P235; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; FANNING P, 1992, CANCER RES, V52, P1457; GOLDEN A, 1988, SRC ONCOGENE ONCOGEN, P149; GRANDORI C, 1991, ONCOGENE, V6, P1063; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUTMAN M, 1994, ANTICANCER RES, V14, P1759; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HERLYN M, 1985, CANCER RES, V45, P5670; HERRMANN JL, 1993, MOL BIOL CELL, V4, P1205, DOI 10.1091/mbc.4.11.1205; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; ISHIKAWA M, 1988, CANCER RES, V48, P665; ISHIKAWA M, 1988, CANCER RES, V48, P4897; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LOGANZO F, 1993, ONCOGENE, V8, P2637; Marchetti D, 1996, CANCER RES, V56, P2856; MARCHETTI D, 1993, INT J CANCER, V55, P692, DOI 10.1002/ijc.2910550430; Marchetti D, 1997, ADV ENZYME REGUL, V37, P111, DOI 10.1016/S0065-2571(96)00019-2; Marchetti D, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P99, DOI 10.1038/jidsymp.1997.19; MARCHETTI D, 1995, INT J ONCOL, V7, P87; NICOLSON GL, 1993, EXP CELL RES, V204, P171, DOI 10.1006/excr.1993.1022; NICOLSON GL, 1986, INT J CANCER, V38, P289, DOI 10.1002/ijc.2910380221; NICOLSON GL, 1993, CANCER METAST REV, V12, P325, DOI 10.1007/BF00665961; NICOLSON GL, 1994, CRIT REV ONCOGENESIS, V5, P451, DOI 10.1615/CritRevOncog.v5.i5.20; NICOLSON GL, 1994, J NEURO-ONCOL, V18, P139, DOI 10.1007/BF01050420; OCONNOR TJ, 1992, CELL GROWTH DIFFER, V3, P435; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Steck Peter A., 1993, P371; SUDOL M, 1988, BRAIN RES REV, V13, P391, DOI 10.1016/0165-0173(88)90014-8; SUDOL M, 1989, MOL CELL BIOL, V9, P4545, DOI 10.1128/MCB.9.10.4545; SUDOL M, 1992, MOL BASIS HUMAN CANC; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; WHITTEMORE SR, 1987, BRAIN RES REV, V12, P439, DOI 10.1016/0165-0173(87)90008-7; WRIGHT DC, 1989, CANCER PRINCIPLES PR, P2245; ZHANG RD, 1991, CANCER RES, V51, P2029; ZHAO YH, 1990, ONCOGENE, V5, P1629	49	39	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	1998	16	25					3253	3260		10.1038/sj.onc.1201877	http://dx.doi.org/10.1038/sj.onc.1201877			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681823	Bronze			2022-12-25	WOS:000074343600005
J	Varley, JM; Chapman, P; McGown, G; Thorncroft, M; White, GRM; Greaves, MJ; Scott, D; Spreadborough, A; Tricker, KJ; Birch, JM; Evans, DGR; Reddel, R; Camplejohn, RS; Burn, J; Boyle, JM				Varley, JM; Chapman, P; McGown, G; Thorncroft, M; White, GRM; Greaves, MJ; Scott, D; Spreadborough, A; Tricker, KJ; Birch, JM; Evans, DGR; Reddel, R; Camplejohn, RS; Burn, J; Boyle, JM			Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family	ONCOGENE			English	Article						Li-Fraumeni; TP53; splicing	CANCER-PRONE FAMILY; P53 MUTATIONS; BREAST-CANCER; IRRADIATION; POLYMORPHISM; GENOME; BLOOD; ASSAY	We report an extensive Li-Fraumeni-like family in which there is an unusual spectrum of tumours at relatively late onset. A germline TP53 splice donor mutation in exon 4 is present in all affected family members available for testing. The mutation abolishes correct splicing of intron 4 and techniques of RT-PCR have identified three different aberrant transcripts from the mutant TP53 allele. Using the yeast functional assay to analyse transcripts in cells from a number of family members with the mutant allele, TP53 appears wild-type, Functional studies have been carried out on cells from patients with and without cancer who carry the germline mutation, and on cells from unaffected individuals from the same family who do not carry the mutation. Using a number of functional endpoints known to distinguish between cells carrying mutant or wild-type TP53 alleles, we were unable to discriminate normal (wt/wt) from heterozygous (wt/mut) cells by lymphocyte apoptosis and fibroblast survival following low dose rate ionising radiation exposure. However germline mutation carriers show increased sensitivity to radiation-induced chromosome damage in the G(2) phase of the cell cycle, and decreased transient and permanent G(1) arrest. These studies demonstrate the importance of fully characterising the effects of TP53 germline mutations, and may explain some of the phenotypic features of this family.	Paterson Inst Canc Res, CRC, Mol Genet Sect, Manchester M20 9BX, Lancs, England; Univ Newcastle Upon Tyne, Dept Human Genet, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Paterson Inst Canc Res, CRC, Paediat & Familial Canc Res Grp, Manchester M20 9BX, Lancs, England; St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England; Childrens Med Res Inst, Sydney, NSW 2145, Australia; St Thomas Hosp, Richard Dimbleby Dept Canc Res, London SE1 7EH, England	Paterson Institute for Cancer Research; Newcastle University - UK; Paterson Institute for Cancer Research; University of Manchester; Children's Medical Research Institute - Australia; University of Sydney; Guy's & St Thomas' NHS Foundation Trust	Varley, JM (corresponding author), Paterson Inst Canc Res, CRC, Mol Genet Sect, Wilmslow Rd, Manchester M20 9BX, Lancs, England.		Reddel, Roger R/A-6635-2014; Evans, D Gareth/AAB-4308-2022	Reddel, Roger R/0000-0002-6302-6107; Evans, D Gareth/0000-0002-8482-5784; Burn, John/0000-0002-9823-2322				BIRCH JM, 1994, CANCER RES, V54, P1298; BOYLE JM, 1998, IN PRESS BR J CANC; CAMPLEJOHN RS, 1995, BRIT J CANCER, V72, P654, DOI 10.1038/bjc.1995.390; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FREBOURG T, 1995, AM J HUM GENET, V56, P608; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; Heineman EF, 1996, CANCER, V77, P549, DOI 10.1002/(SICI)1097-0142(19960201)77:3<549::AID-CNCR18>3.0.CO;2-4; HOGGARD N, 1995, GENE CHROMOSOME CANC, V12, P24, DOI 10.1002/gcc.2870120105; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Lomax ME, 1997, ONCOGENE, V14, P1869, DOI 10.1038/sj.onc.1201133; MACGEOCH C, 1995, J MED GENET, V32, P186, DOI 10.1136/jmg.32.3.186; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mitchell ELD, 1997, INT J RADIAT BIOL, V72, P435, DOI 10.1080/095530097143202; PARSHAD R, 1993, RADIAT RES, V136, P236, DOI 10.2307/3578616; SCOTT D, 1993, NATO ASI SERIES H, V77, P101; Sproston ARM, 1996, INT J RADIAT BIOL, V70, P145, DOI 10.1080/095530096145139; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; WARNEFORD S, 1991, CELL GROWTH DIFFER, V2, P439; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; Williams KJ, 1997, ONCOGENE, V14, P277, DOI 10.1038/sj.onc.1200838	27	45	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3291	3298		10.1038/sj.onc.1201878	http://dx.doi.org/10.1038/sj.onc.1201878			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681828				2022-12-25	WOS:000074343600010
J	Langen, R; Isas, JM; Luecke, H; Haigler, HT; Hubbell, WL				Langen, R; Isas, JM; Luecke, H; Haigler, HT; Hubbell, WL			Membrane-mediated assembly of annexins studied by site-directed spin labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; T4 LYSOZYME; MOTION; RESOLUTION; DYNAMICS	Annexins are soluble proteins that bind to membranes in the presence of Ca2+. Crystal structures have been determined for some soluble forms, but little is known about the important membrane-bound state. We employed site-directed spin labeling to demonstrate that 1) annexin XII assumes a trimer configuration similar to the crystal structure when bound to bilayers under physiological conditions; 2) trimer assembly on bilayers is remarkably rapid, occurring on a millisecond time scale, whereas subunit exchange requires hours; and 3) different annexins can mix to form heterotrimers. The rapid assembly and heterotrimer formation have important implications concerning the cellular functions of annexins.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Haigler, HT (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.		Luecke, Hartmut/F-4712-2012; Haigler, Harry/C-3788-2011	Luecke, Hartmut/0000-0002-4938-0775; 	NATIONAL EYE INSTITUTE [R01EY005216, R37EY005216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055651, R01GM056445] Funding Source: NIH RePORTER; NEI NIH HHS [EY05216] Funding Source: Medline; NIGMS NIH HHS [GM55651, GM56445] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CONCHA NO, 1992, FEBS LETT, V314, P159, DOI 10.1016/0014-5793(92)80964-I; CONCHA NO, 1993, SCIENCE, V261, P1321, DOI 10.1126/science.8362244; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; HUBBELL WL, 1987, REV SCI INSTRUM, V58, P1879, DOI 10.1063/1.1139536; HUBBELL WL, 1994, CURR OPIN STRUC BIOL, V4, P566, DOI 10.1016/S0959-440X(94)90219-4; Hubbell WL, 1996, STRUCTURE, V4, P779, DOI 10.1016/S0969-2126(96)00085-8; Hustedt EJ, 1997, BIOPHYS J, V72, P1861, DOI 10.1016/S0006-3495(97)78832-5; Liemann S, 1997, J MOL BIOL, V270, P79, DOI 10.1006/jmbi.1997.1091; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; Mailliard WS, 1997, BIOCHEMISTRY-US, V36, P9045, DOI 10.1021/bi970749v; Mchaourab HS, 1997, BIOCHEMISTRY-US, V36, P307, DOI 10.1021/bi962114m; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; MEHAOURAB HS, 1997, BIOCHEMISTRY-US, V36, P307; OLOFSSON A, 1994, J STRUCT BIOL, V113, P199, DOI 10.1006/jsbi.1994.1054; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; Seaton B. A., 1996, ANNEXINS MOL STRUCTU; SOPKOVA J, 1993, J MOL BIOL, V234, P816, DOI 10.1006/jmbi.1993.1627; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281; WENG XW, 1993, PROTEIN SCI, V2, P448	20	80	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22453	22457		10.1074/jbc.273.35.22453	http://dx.doi.org/10.1074/jbc.273.35.22453			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712869	hybrid			2022-12-25	WOS:000075616600045
J	Tang, XB; Fujinaga, J; Kopito, R; Casey, JR				Tang, XB; Fujinaga, J; Kopito, R; Casey, JR			Topology of the region surrounding Glu(681) of human AE1 protein, the erythrocyte anion exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; PROTEOLYTIC CLEAVAGE SITES; BAND-3 PROTEIN; DIRECTED MUTAGENESIS; MEMBRANE TOPOLOGY; TRANSPORT PROTEIN; LOCALIZATION; RESIDUES; GLYCOPROTEIN; ORIENTATION	AE1 protein transports Cl- and HCO3- across the erythrocyte membrane by an electroneutral exchange mechanism, Glu(681) Of human AE1 may form part of the anion translocation apparatus and the permeability barrier. We have therefore studied the structure of the sequence surrounding Glu(681), using scanning cysteine mutagenesis, Residues of the Ser(643) (adjacent to the glycosylation site) to Ser(690) region of cysteineless mutant (AE1C(-)) were replaced individually with cysteine, The ability of mutants to mediate Cl-/HCO3- exchange in transfected HEK293 cells revealed that extracellular mutants, W648C, I650C, P652C, L655C, and F659C have an important role in transport. By contrast, only transmembrane mutation E681C fully blocked anion exchange activity, The topology of the region was investigated by comparing cysteine labeling with the membrane-permeant cysteine-directed reagent 3-(N-maleimidylpropionyl)biocytin, with or without prior labeling with membrane-impermeant lucifer yellow iodoacetamide (LYIA), Two regions readily label with 3-(N-maleimidylpropionyl)biocytin (Ser(643)-Met(663) and Ile(684)-Ser(690)), We propose that poorly labeled Met(664)-Gln(683) corresponds to transmembrane segment 8 of AE1, Regions Ser(643)-Met(663) and Ile(684)-Ser(690) localize, respectively, to extracellular and intracellular sites on the basis of accessibility to LYIA. On the basis of LYIA accessibility, we propose that the Arg(656)-Met(663) region forms a "vestibule" that leads anions to the transport channel, Glu(681) is located 3 amino acids from the C terminus of transmembrane segment 8, which places the membrane permeability barrier within 5 Angstrom of the intracellular surface of the membrane.	Univ Alberta, Dept Physiol, Edmonton, AB T6G 2H7, Canada; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	University of Alberta; Stanford University	Casey, JR (corresponding author), Univ Alberta, Dept Physiol, Edmonton, AB T6G 2H7, Canada.	joe.casey@ualberta.ca	Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CASEY JR, 1995, J BIOL CHEM, V270, P8521, DOI 10.1074/jbc.270.15.8521; Catizone A, 1996, CELL MOL BIOL, V42, P1229; COYLE DA, 1998, SCIENCE, V280, P69; CREIGHTON TE, 1983, PROTEINS STRUCTURES, P171; EIDELMAN O, 1991, AM J PHYSIOL, V260, pC1094, DOI 10.1152/ajpcell.1991.260.5.C1094; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GERSHONI JM, 1985, ANAL BIOCHEM, V146, P59, DOI 10.1016/0003-2697(85)90395-1; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Hamasaki N, 1997, J BIOCHEM-TOKYO, V122, P577; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JENNINGS ML, 1990, J GEN PHYSIOL, V96, P991, DOI 10.1085/jgp.96.5.991; JENNINGS ML, 1986, J BIOL CHEM, V261, P9002; JENNINGS ML, 1987, J BIOL CHEM, V262, P1691; JENNINGS ML, 1989, ANION TRANSPORT PROT, P59; Kimura T, 1997, J BIOL CHEM, V272, P580; Kimura T, 1998, J BIOL CHEM, V273, P5243, DOI 10.1074/jbc.273.9.5243; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1991, J BIOL CHEM, V266, P11448; LIEBERMAN DM, 1988, J BIOL CHEM, V263, P10022; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; REITHMEIER RAF, 1996, TRANSPORT PROCESSES, V2, P281; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SEKLER I, 1995, J BIOL CHEM, V270, P28751, DOI 10.1074/jbc.270.48.28751; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; TANNER MJA, 1989, METHOD ENZYMOL, V173, P423; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAINWRIGHT SD, 1990, BIOCHEM J, V272, P265, DOI 10.1042/bj2720265; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053	38	86	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22545	22553		10.1074/jbc.273.35.22545	http://dx.doi.org/10.1074/jbc.273.35.22545			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712881	hybrid			2022-12-25	WOS:000075616600057
J	Ahn, T; Kim, H				Ahn, T; Kim, H			Effects of nonlamellar-prone lipids on the ATPase activity of SecA bound to model membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE-TRANSITION TEMPERATURE; ESCHERICHIA-COLI; ACIDIC PHOSPHOLIPIDS; PROTEIN TRANSLOCATION; DIGLYCERIDE KINASE; PLASMA-MEMBRANE; BILAYER; BINDING; PHOSPHATIDYLETHANOLAMINES; PENETRATION	The effect of nonlamellar-prone lipids, diacylglycerol (DG) and phosphatidylethanolamine (PE), on the ATPase activity of SecA was examined. When Escherichia coli PE of the standard vesicles composed of 60 mol% of this lipid and 40 mol% of dioleoylphosphatidylglycerol (DOPG) is gradually replaced with either dioleoylglycerol (DOG) or dioeloyl PE (DOPE), the ATPase activity of SecA present together increased appreciably. On the other hand, when E. coli PE of the standard vesicles was replaced with DOG analogs, the SecA ATPase activity decreased slightly, and when replaced activity was more appreciable. When DOPE or E. coli PE was added to PC vesicles, the SecA ATPase activity was enhanced only slightly, suggesting that the hexagonal II structure per se is not important for the ATPase activity increase. It was observed that DOG induced phase separation of PG, and the lamellar-hexagonal II (L-H-II) 10 degrees C. The DOG analogs had no effect on these properties, suggesting the importance of the phase separation of PG and the decrease of L-H-II transition temperature of lipid bilayers to the SecA ATPase activity. The phase separation of PG by Ca2+ also brought about increased ATPase activity of SecA, underlining the importance of phase separation of PG for the enzyme activity. The incorporation of DOG or DOPE in the vesicle also increased the amount of SecA penetration into the membrane. Studies with vesicles without SecA showed increased exposure of hydrophobic acyl chains when the DOG was present. Taken together, these observations suggest that the phase separation of PG and/or the bilayer penetration of SecA are mainly responsible for the enhanced SecA-vesicle interaction with concomitant increase in SecA ATPase activity.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Yusong Gu, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Kim, H (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Yusong Gu, 373-1 Kusong Dong, Taejon 305701, South Korea.							Ahn T, 1996, J BIOL CHEM, V271, P12372, DOI 10.1074/jbc.271.21.12372; AHN T, 1994, BIOCHEM BIOPH RES CO, V203, P326, DOI 10.1006/bbrc.1994.2185; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BROWN MF, 1994, CHEM PHYS LIPIDS, V73, P159, DOI 10.1016/0009-3084(94)90180-5; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CHONG PLG, 1985, BIOPHYS J, V47, P613, DOI 10.1016/S0006-3495(85)83957-6; DAS S, 1986, BIOCHEMISTRY-US, V25, P2882, DOI 10.1021/bi00358a022; ELLENS H, 1986, BIOCHEMISTRY-US, V25, P285, DOI 10.1021/bi00350a001; EPAND RM, 1985, BIOCHEMISTRY-US, V24, P7092, DOI 10.1021/bi00346a011; EPAND RM, 1988, BIOCHIM BIOPHYS ACTA, V944, P144, DOI 10.1016/0005-2736(88)90427-0; GALLA HJ, 1980, CHEM PHYS LIPIDS, V27, P199, DOI 10.1016/0009-3084(80)90036-5; GRAHAM I, 1985, BIOCHEMISTRY-US, V24, P7123, DOI 10.1021/bi00346a016; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; HONG KL, 1988, BIOCHEMISTRY-US, V27, P3947, DOI 10.1021/bi00411a009; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; KELLER SL, 1993, BIOPHYS J, V65, P23, DOI 10.1016/S0006-3495(93)81040-3; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LI L, 1995, CHEM PHYS LIPIDS, V76, P135, DOI 10.1016/0009-3084(95)02437-N; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Mizushima T, 1996, J BIOL CHEM, V271, P3633; Park SK, 1997, BIOCHEM BIOPH RES CO, V235, P593, DOI 10.1006/bbrc.1997.6834; Price A, 1996, J BIOL CHEM, V271, P31580, DOI 10.1074/jbc.271.49.31580; RAETZ CRH, 1978, J BIOL CHEM, V253, P3882; RAETZ CRH, 1979, J BACTERIOL, V137, P860, DOI 10.1128/JB.137.2.860-868.1979; RIETVELD AG, 1995, EMBO J, V14, P5506, DOI 10.1002/j.1460-2075.1995.tb00237.x; SIEGEL DP, 1989, BIOCHEMISTRY-US, V28, P5010, DOI 10.1021/bi00438a016; SOMERHARJU PJ, 1985, BIOCHEMISTRY-US, V24, P2773, DOI 10.1021/bi00332a027; Song M, 1997, J BIOCHEM-TOKYO, V122, P1010; Starling AP, 1996, BIOCHEM J, V320, P309, DOI 10.1042/bj3200309; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; VASKOVSKY VE, 1975, J CHROMATOGR, V114, P129, DOI 10.1016/S0021-9673(00)85249-8	35	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21692	21698		10.1074/jbc.273.34.21692	http://dx.doi.org/10.1074/jbc.273.34.21692			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705304	hybrid			2022-12-25	WOS:000075492600038
J	McEnery, MW; Copeland, TD; Vance, CL				McEnery, MW; Copeland, TD; Vance, CL			Altered expression and assembly of N-type calcium channel alpha(1B) and beta subunits in epileptic lethargic (lh/lh) mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OMEGA-CONOTOXIN GVIA; MUTANT MICE; ABSENCE SEIZURES; CA2+ CHANNELS; RAT-BRAIN; ATAXIA; HETEROGENEITY; RECEPTOR; CLONING; BINDING	Voltage-dependent calcium channels (VDCC) are multisubunit complexes whose expression and targeting require the assembly of the pore-forming alpha(1) with auxiliary beta and alpha(2)/delta subunits, The developmentally regulated expression and differential assembly of beta isoforms with the cu,, subunit to form N-type VDCC suggested a unique role for the beta 4 isoform in VDCC maturation (Vance, C. L., Begg, C. M., Lee, W.-L., Haase, H., Copeland, T. D., and McEnery, M. W. (1998) J, Biol. Chem, 273, 14495-14502), The focus of this study is the expression and assembly of alpha(1B) and beta isoforms in the epileptic mouse, lethargic (lh/lh), a mutant anticipated to produce a truncated beta 4 subunit (Burgess, D, L,, Jones, J, M., Meisler, M. H., and Noebels, J, L, (1997) Cell 88, 385-392), In this report, we demonstrate that neither full-length nor truncated beta 4 protein is expressed in lh/lh mice. The absence of beta 4 in lh/lh mice is associated with decreased expression of N-type VDCC in forebrain and cerebellum. The most surprising characteristic of the lh/lh mouse is increased expression of beta 1b protein. This result suggests a previously unidentified cellular mechanism wherein expression of the total pool of available beta subunits is under tight metabolic regulation. As a consequence of increased beta 1b expression, the beta 1b is increased in its incorporation into alpha(1B)/beta complexes relative to wild type. Thus, in striking similarity to the population of N-type VDCC present in immature rat brain, the population of N-type VDCC present in adult lh/lh mice is characterized by the absence of beta 4 with increased beta 1b expression and assembly into N-type VDCC, It is intriguing to speculate that the increased excitability and susceptibility to seizures observed in the lh/lh mouse arises from the inappropriate expression of an immature population of N-type VDCC throughout neuronal development.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA	Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	McEnery, MW (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	mwm4@po.cwru.edu						Brice NL, 1997, EUR J NEUROSCI, V9, P749, DOI 10.1111/j.1460-9568.1997.tb01423.x; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; COULTER DA, 1990, BRIT J PHARMACOL, V100, P800, DOI 10.1111/j.1476-5381.1990.tb14095.x; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Doyle J, 1997, MAMM GENOME, V8, P113, DOI 10.1007/s003359900369; DUNG HC, 1971, TEX REP BIOL MED, V29, P273; DUNG HC, 1972, TEX REP BIOL MED, V30, P23; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Hosford DA, 1997, EPILEPSIA, V38, P408, DOI 10.1111/j.1528-1157.1997.tb01729.x; Kraus RL, 1998, J BIOL CHEM, V273, P5586, DOI 10.1074/jbc.273.10.5586; LITZINGER MJ, 1994, J CHILD NEUROL, V9, P77, DOI 10.1177/088307389400900120; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; MAEDA N, 1989, BRAIN RES, V489, P21, DOI 10.1016/0006-8993(89)90004-8; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; McEnery MW, 1997, FEBS LETT, V420, P74, DOI 10.1016/S0014-5793(97)01490-7; MCENERY MW, 1993, MOL CELLULAR BIOL PH, P3; MCENERY MW, 1998, IN PRESS J BIOENERG, V40; Noebels J L, 1986, Adv Neurol, V44, P97; PATIL P, 1998, NEURON, V20, P1; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; Sander T, 1998, EPILEPSY RES, V29, P115, DOI 10.1016/S0920-1211(97)00073-9; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; Smith SM, 1998, BIOPHYS J, V74, pA120; SNEAD OC, 1995, ANN NEUROL, V37, P146, DOI 10.1002/ana.410370204; Stevanin G, 1997, NEUROLOGY, V49, P1243, DOI 10.1212/WNL.49.5.1243; TANAKA O, 1995, MOL BRAIN RES, V30, P1, DOI 10.1016/0169-328X(94)00265-G; Vance CL, 1998, J BIOL CHEM, V273, P14495, DOI 10.1074/jbc.273.23.14495; VANCE CL, 1998, IN PRESS NEUROSCIENC; WAGNER JA, 1988, J NEUROSCI, V8, P3354; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	33	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21435	21438		10.1074/jbc.273.34.21435	http://dx.doi.org/10.1074/jbc.273.34.21435			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705268	hybrid			2022-12-25	WOS:000075492600002
J	Subbaramaiah, K; Chung, WJ; Michaluart, P; Telang, N; Tanabe, T; Inoue, H; Jang, MS; Pezzuto, JM; Dannenberg, AJ				Subbaramaiah, K; Chung, WJ; Michaluart, P; Telang, N; Tanabe, T; Inoue, H; Jang, MS; Pezzuto, JM; Dannenberg, AJ			Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN COLON-CANCER; PROTEIN-KINASE-C; ENDOPEROXIDE SYNTHASE-2 GENE; MOUSE FIBROBLAST CELLS; SELECTIVE-INHIBITION; RESPONSE ELEMENT; AP-1 ACTIVITY; EXPRESSION; PROSTAGLANDIN; GROWTH	We determined whether resveratrol, a phenolic anti-oxidant found in grapes and other food products, inhibited phorbol ester (PMA)-mediated induction of COX-2 in human mammary and oral epithelial cells. Treatment of cells with PMA induces COX-2 and causes a marked increase in the production of prostaglandin E-2. These effects were inhibited by resveratrol, Resveratrol suppressed PMA-mediated increases in COX-2 mRNA and protein. Nuclear run-offs revealed increased rates of COX-2 transcription after treatment with PMA, an effect that was inhibited by resveratrol, PMA caused about a 6-fold increase in COX-2 promoter activity, which was suppressed by resveratrol, Transient transfections utilizing COX-2 promoter deletion constructs and COX-2 promoter constructs, in which specific enhancer elements were mutagenized, indicated that the effects of PMA and resveratrol were mediated via a cyclic AMP response element. Resveratrol inhibited PMA-mediated activation of protein kinase C, Overexpressing protein kinase C-alpha, ERK1, and c-Jun led to 4.7-, 5.1-, and C-fold increases in COX-2 promoter activity, respectively. These effects also were inhibited by resveratrol, Resveratrol blocked PMA-dependent activation of AP-l-mediated gene expression. In addition to the above effects on gene expression, we found that resveratrol also directly inhibited the activity of COX-2, These data are likely to be important for understanding the anti-cancer and anti-inflammatory properties of resveratrol.	Cornell Univ, Med Ctr, New York Hosp, Div Digest Dis,Dept Med, New York, NY 10021 USA; Cornell Univ, Med Ctr, New York Hosp, Dept Surg, New York, NY 10021 USA; Strang Canc Prevent Ctr, Anne Fisher Nutr Ctr, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, Head & Neck Serv, New York, NY 10021 USA; Natl Cardiovasc Ctr, Res Inst, Dept Pharmacol, Osaka, Japan; Univ Illinois, Coll Med, Dept Surg Oncol, Chicago, IL 60612 USA; Univ Illinois, Coll Pharm, Program Collaborat Res Pharmaceu Sci, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA	Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital; Memorial Sloan Kettering Cancer Center; National Cerebral & Cardiovascular Center - Japan; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Dannenberg, AJ (corresponding author), Cornell Univ, Med Ctr, New York Hosp, Div Digest Dis,Dept Med, Room F-231,1300 York Ave, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [P01CA029502, R01CA068136, P01CA048112] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA48112, CA68136, P01 CA29502] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; BENNETT A, 1986, PROG LIPID RES, V25, P539, DOI 10.1016/0163-7827(86)90109-8; Caponigro F, 1997, ANTI-CANCER DRUG, V8, P26, DOI 10.1097/00001813-199701000-00003; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; GOODWIN JS, 1983, J CLIN IMMUNOL, V3, P295, DOI 10.1007/BF00915791; Gordge PC, 1996, EUR J CANCER, V32A, P2120, DOI 10.1016/S0959-8049(96)00255-9; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; JONES DA, 1993, J BIOL CHEM, V268, P9049; JUNG TTK, 1985, LARYNGOSCOPE, V95, P307; KARGMAN SL, 1995, CANCER RES, V55, P2556; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KAWAMORI T, 1998, CANCER RES, V58, P4809; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SF, 1997, NUTR CANCER, V28, P177, DOI 10.1080/01635589709514572; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lupulescu A, 1996, PROSTAG LEUKOTR ESS, V54, P83, DOI 10.1016/S0952-3278(96)90064-2; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; Mestre JR, 1997, CANCER RES, V57, P1081; Mestre JR, 1997, CANCER RES, V57, P2890; MULLERDECKER K, 1995, MOL CARCINOGEN, V12, P31, DOI 10.1002/mc.2940120106; OBRIAN CA, 1989, CANCER RES, V49, P3215; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PARETT ML, 1997, INT J ONCOL, V10, P503; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Ristimaki A, 1997, CANCER RES, V57, P1276; ROLLAND PH, 1980, JNCI-J NATL CANCER I, V64, P1061; Sacks PG, 1996, CANCER METAST REV, V15, P27, DOI 10.1007/BF00049486; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1998, CANCER RES, V58, P362; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Subbaramaiah K, 1996, CANCER RES, V56, P4424; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TIANO H, 1997, P AM ASSOC CANC RES, V38, P1727; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREJO J, 1994, J BIOL CHEM, V269, P21682; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; WAGNER H, 1986, PLANTA MED, V52, P184; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; ZHAI YF, 1993, CANCER RES, V53, P2272	49	672	694	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21875	21882		10.1074/jbc.273.34.21875	http://dx.doi.org/10.1074/jbc.273.34.21875			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705326	hybrid			2022-12-25	WOS:000075492600060
J	Suzuki, T; Park, H; Kitajima, K; Lennarz, WJ				Suzuki, T; Park, H; Kitajima, K; Lennarz, WJ			Peptides glycosylated in the endoplasmic reticulum of yeast are subsequently deglycosylated by a soluble peptide: N-glycanase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-DEGRADATION; GLYCOPEPTIDE EXPORT; MOLECULAR-CLONING; QUALITY-CONTROL; ANIMAL-CELLS; IDENTIFICATION; REMODIFICATION; GLYCOAMIDASE; GLYCOSIDASE	Several lines of evidence suggest that soluble peptide: N-glycanase (PNGase) is involved in the quality control system for newly synthesized glycoproteins in mammalian cells. Here we report the occurrence of a soluble PNGase activity in Saccharomyces cerevisiae. The enzyme, which was recovered in the cytosolic fraction, has a neutral pH optimum, and dithiothreitol is required for activity. All of these properties were similar to those of earlier described for mammalian PNGases, Interestingly, the yeast enzyme activity was found to be present almost exclusively in cells in stationary phase; little activity was detected in logarithmic growth phase cells, Upon incubation of a glycosylatable peptide R-Asn-X-Thr-R' with permeabilized yeast spheroplasts, we detected formation of both,glycosylated peptide and the peptide product expected from PNGase-mediated deglycosylation of this glycopeptide, namely, R-Asp-X-Thr-R'. Recent findings that yeast have an active system for the retrograde transport of unfolded (glyco)proteins and glycopeptides out of the endoplasmic reticulum (ER) into the cytosol raise the possibility that this PNGase may participate in an early step in degradation of these molecules following their export from the ER.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 46401, Japan; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Nagoya University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lennarz, WJ (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.		Suzuki, Tadashi/AAX-5707-2021; Suzuki, Tadashi/I-4536-2014	Suzuki, Tadashi/0000-0003-1030-7631; 	NIGMS NIH HHS [GM33184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033184] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BELARD M, 1988, BIOCHEM J, V255, P235; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Chang T, 1997, FASEB J, V11, pA1247; Cresswell P, 1997, CURR BIOL, V7, pR552, DOI 10.1016/S0960-9822(06)00279-X; DUNN B, 1990, CURRENT PROTOCOLS MO; Fan JQ, 1997, J BIOL CHEM, V272, P27058, DOI 10.1074/jbc.272.43.27058; FtouhiPaquin N, 1997, J BIOL CHEM, V272, P22960, DOI 10.1074/jbc.272.36.22960; HANOVER JA, 1982, J BIOL CHEM, V257, P2787; INOUE S, 1990, TRENDS GLYCOSCI GLYC, V2, P225; INOUE S, 1997, GLYCOPROTEINS, V2, P143; KITAJIMA K, 1995, ARCH BIOCHEM BIOPHYS, V319, P393, DOI 10.1006/abbi.1995.1309; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Ploegh HL, 1997, IMMUNOL TODAY, V18, P269, DOI 10.1016/S0167-5699(97)80021-7; ROMISCH K, 1992, P NATL ACAD SCI USA, V89, P7227, DOI 10.1073/pnas.89.15.7227; Romisch K, 1997, P NATL ACAD SCI USA, V94, P6730, DOI 10.1073/pnas.94.13.6730; ROOS J, 1994, P NATL ACAD SCI USA, V91, P1485, DOI 10.1073/pnas.91.4.1485; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SEKO A, 1991, J BIOL CHEM, V266, P22110; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; SUZUKI T, 1993, BIOCHEM BIOPH RES CO, V194, P1124, DOI 10.1006/bbrc.1993.1938; Suzuki T, 1997, P NATL ACAD SCI USA, V94, P6244, DOI 10.1073/pnas.94.12.6244; SUZUKI T, 1995, GLYCOCONJUGATE J, V12, P183, DOI 10.1007/BF00731318; SUZUKI T, 1994, GLYCOCONJUGATE J, V11, P469, DOI 10.1007/BF00731283; SUZUKI T, 1995, J BIOL CHEM, V270, P15181, DOI 10.1074/jbc.270.25.15181; SUZUKI T, 1994, GLYCOBIOLOGY, V4, P777, DOI 10.1093/glycob/4.6.777; SUZUKI T, 1997, GLYCOSCIENCES STATUS, P121; TAKAHASHI N, 1977, BIOCHEM BIOPH RES CO, V76, P1194, DOI 10.1016/0006-291X(77)90982-2; TAKAHASHI N, 1992, CRC HDB ENDOGLYCOSID, P183; TARENTINO AL, 1990, J BIOL CHEM, V265, P6961; TARENTINO AL, 1993, TRENDS GLYCOSCI GLYC, V5, P163; Wang LX, 1997, J AM CHEM SOC, V119, P11137, DOI 10.1021/ja9712027; Weng S, 1997, BIOCHEM J, V322, P655, DOI 10.1042/bj3220655	37	84	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21526	21530		10.1074/jbc.273.34.21526	http://dx.doi.org/10.1074/jbc.273.34.21526			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705282	hybrid			2022-12-25	WOS:000075492600016
J	Yamada, M; Inbe, H; Tanaka, M; Sumi, K; Matsushita, K; Adachi, O				Yamada, M; Inbe, H; Tanaka, M; Sumi, K; Matsushita, K; Adachi, O			Mutant isolation of the Escherichia coli quinoprotein glucose dehydrogenase and analysis of crucial residues Asp-730 and His-775 for its function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHANOL DEHYDROGENASE; ACINETOBACTER-CALCOACETICUS; PYRROLOQUINOLINE QUINONE; NUCLEOTIDE-SEQUENCE; PARACOCCUS-DENITRIFICANS; GLUCONOBACTER-SUBOXYDANS; ALCOHOL-DEHYDROGENASE; UBIQUINONE REDUCTION; ELECTRON-TRANSPORT; RESPIRATORY-CHAIN	Several mutants of quinoprotein glucose dehydrogenase (GDH) in Escherichia coli were obtained and characterized. Of these, significant mutants were further characterized by kinetic analysis after purification or by site-directed mutagenesis to introduce different amino acid substitutions. H775R and H775A showed a pronounced reduction of affinity for a prosthetic group, pyrroloquinoline quinone (PQQ), suggesting that His775 may directly interact with PQQ, D730N and D730A showed low glucose oxidase activity without influence on the affinity for PQQ, Mg2+, or substrate, but D730R showed reduced affinity for PQQ, The spectrum of tryptophan fluorescence revealed that the local structure surrounding PQQ was not changed by D730N mutation. Based on these data, we assume that Asp-730 may occur close to PQQ and function as a proton (and also electron) donor to PQQ or acceptor from PQQH(2). Substitutions of Gly-689, that are located at the end of a unique segment of GDH among homologous quinoprotein dehydrogenases, directed reduction of the affinity for PQQ or GDH activity. Therefore, the unique segment and Asp-730 may play a specific role for GDH, which might be related to the intramolecular electron transfer from PQQ to ubiquinone.	Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yamaguchi 7538515, Japan	Yamaguchi University	Yamada, M (corresponding author), Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yamaguchi 7538515, Japan.	yamada@agr.yamaguchi-u.ac.jp		Yamada, Mamoru/0000-0003-4354-7324				AMEYAMA M, 1986, AGR BIOL CHEM TOKYO, V50, P49, DOI 10.1080/00021369.1986.10867348; AMEYAMA M, 1985, AGR BIOL CHEM TOKYO, V49, P1227, DOI 10.1080/00021369.1985.10866884; AMEYAMA M, 1981, FEBS LETT, V130, P179, DOI 10.1016/0014-5793(81)81114-3; Anthony C., 1993, P221; ANTHONY C, 1992, INT J BIOCHEM, V24, P29, DOI 10.1016/0020-711X(92)90226-Q; BLAKE CCF, 1994, NAT STRUCT BIOL, V1, P102, DOI 10.1038/nsb0294-102; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLETONJANSEN AM, 1991, MOL GEN GENET, V229, P206, DOI 10.1007/BF00272157; CLETONJANSEN AM, 1988, NUCLEIC ACIDS RES, V16, P6228, DOI 10.1093/nar/16.13.6228; CLETONJANSEN AM, 1990, J BACTERIOL, V172, P6308, DOI 10.1128/jb.172.11.6308-6315.1990; CLETONJANSEN AM, 1989, MOL GEN GENET, V217, P430, DOI 10.1007/BF02464914; Cozier GE, 1995, BIOCHEM J, V312, P679, DOI 10.1042/bj3120679; DUINE JA, 1979, FEBS LETT, V108, P443, DOI 10.1016/0014-5793(79)80584-0; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FRIEDRICH T, 1990, FEBS LETT, V265, P37, DOI 10.1016/0014-5793(90)80878-M; HARMS N, 1987, J BACTERIOL, V169, P3969, DOI 10.1128/jb.169.9.3969-3975.1987; HOMMES RWJ, 1984, FEMS MICROBIOL LETT, V24, P329, DOI 10.1016/0378-1097(84)90274-X; INOUE T, 1989, J BACTERIOL, V171, P3115, DOI 10.1128/jb.171.6.3115-3122.1989; MACHLIN SM, 1988, J BACTERIOL, V170, P4739, DOI 10.1128/jb.170.10.4739-4747.1988; MANAYAN R, 1988, J BACTERIOL, V170, P1290, DOI 10.1128/jb.170.3.1290-1296.1988; Maniatis T., 1982, MOL CLONING LAB MANU; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Matsushita K, 1996, J BIOL CHEM, V271, P4850; MATSUSHITA K, 1989, J BIOCHEM, V105, P633, DOI 10.1093/oxfordjournals.jbchem.a122716; MATSUSHITA K, 1987, J BACTERIOL, V169, P205, DOI 10.1128/jb.169.1.205-209.1987; Matsushita K, 1997, MICROBIOL-UK, V143, P3149, DOI 10.1099/00221287-143-10-3149; MATSUSHITA K, 1989, BIOCHEMISTRY-US, V28, P6276, DOI 10.1021/bi00441a020; Miller J.H., 1992, SHORT COURSE BACTERI, P150; SAIER MH, 1972, J BIOL CHEM, V247, P972; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SODE K, 1994, BIOTECHNOL LETT, V16, P455, DOI 10.1007/BF01023325; VANSCHIE BJ, 1985, J BACTERIOL, V163, P493, DOI 10.1128/JB.163.2.493-499.1985; VANSPANNING RJM, 1991, J BACTERIOL, V173, P6948, DOI 10.1128/jb.173.21.6948-6961.1991; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WHITE S, 1993, BIOCHEMISTRY-US, V32, P12955, DOI 10.1021/bi00211a002; XIA ZX, 1992, J BIOL CHEM, V267, P22289; YAMADA M, 1993, J BIOL CHEM, V268, P12812; YAMADA M, 1993, J BACTERIOL, V175, P568, DOI 10.1128/JB.175.2.568-571.1993; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	40	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22021	22027		10.1074/jbc.273.34.22021	http://dx.doi.org/10.1074/jbc.273.34.22021			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705344	hybrid			2022-12-25	WOS:000075492600078
J	Grandori, R; Khalifah, P; Boice, JA; Fairman, R; Giovanielli, K; Carey, J				Grandori, R; Khalifah, P; Boice, JA; Fairman, R; Giovanielli, K; Carey, J			Biochemical characterization of WrbA, founding member of a new family of multimeric flavodoxin-like proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH-SULFITE REDUCTASE; ESCHERICHIA-COLI; TRP REPRESSOR; CLONED GENES; DNA; SEQUENCE; FLAVOPROTEIN; YEAST	The protein WrbA had been identified as an Escherichia coli stationary-phase protein that copurified and coimmunoprecipitated with the tryptophan repressor. Sequences homologous to WrbA have been reported in several species of yeast and plants. We previously showed that this new family of proteins displays low but structurally significant sequence similarity with flavodoxins and that its members are predicted to share the alpha/beta core of the flavodoxin fold but with a short conserved insertion unique to the new family, which could account for reports that some family members may be dimeric in solution. The general sequence similarity to flavodoxins suggests that the members of the new family might bind FMN, but their wide evolutionary distribution indicates that, unlike the flavodoxins, these proteins may be ubiquitous. In this paper, we report the purification and biochemical characterization of WrbA, demonstrating that the protein binds FMN specifically and is a multimer in solution. The FMN binding constant is weaker than for many flavodoxins, being similar to 2 mu M at 25 degrees C in 0.1 mM sodium phosphate, pH 7.2, The protein participates in a dimer-tetramer equilibrium over a wide range of solution conditions, with a midpoint at approximately 1.4 mu M. One FMN binds per monomer and has no apparent effect on the multimerization equilibrium. WrbA has no effect on the affinity or mode of DNA binding by the tryptophan repressor; thus, its physiological role remains unclear. Although many proteins with flavodoxin-like domains are known to be multimers, WrbA is apparently the first characterized case in which multimerization is associated directly with the flavodoxin-like domain itself.	Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Bristol Myers Squibb Pharmaceut Res Inst, Princeton, NJ 08543 USA	Princeton University; Bristol-Myers Squibb	Carey, J (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.			Khalifah, Peter/0000-0002-2216-0377	NIGMS NIH HHS [GM-43558] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043558, R29GM043558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENEDICT RC, 1981, BIOPHYS CHEM, V13, P245, DOI 10.1016/0301-4622(81)80006-3; BUJALOWSKI W, 1991, J BIOL CHEM, V266, P1616; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; ESCHENBRENNER M, 1995, FEBS LETT, V374, P82, DOI 10.1016/0014-5793(95)01081-O; Giebeler R, 1992, ANAL ULTRACENTRIFUGA, P16; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRANDORI R, 1994, PROTEIN SCI, V3, P2185, DOI 10.1002/pro.5560031204; GRANDORI R, 1994, TRENDS BIOCHEM SCI, V19, P72, DOI 10.1016/0968-0004(94)90037-X; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOIE TA, 1996, THESIS PRINCETON U; Mayhew S. G., 1992, CHEM BIOCH FLAVOENZY, V3, P389; Mayhew S.G., 1975, ENZYMES, V12, P57; NICHOLS BP, 1983, METHOD ENZYMOL, V101, P155; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PALUH JL, 1986, NUCLEIC ACIDS RES, V14, P7851, DOI 10.1093/nar/14.20.7851; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; Tollin G., 1980, METHOD ENZYMOL, V69, P392; VERVOORT J, 1994, METHOD ENZYMOL, V243, P188; WEBER G, 1994, PROTEIN INTERACTIONS, P16; WHITBY LG, 1953, BIOCHEM J, V54, P437, DOI 10.1042/bj0540437; Yang J, 1996, J MOL BIOL, V258, P37, DOI 10.1006/jmbi.1996.0232; YANG WP, 1993, P NATL ACAD SCI USA, V90, P5796, DOI 10.1073/pnas.90.12.5796	27	52	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20960	20966		10.1074/jbc.273.33.20960	http://dx.doi.org/10.1074/jbc.273.33.20960			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694845	hybrid			2022-12-25	WOS:000075386100038
J	Scantlebury, T; Maslowska, M; Cianflone, K				Scantlebury, T; Maslowska, M; Cianflone, K			Chylomicron-specific enhancement of acylation stimulating protein and precursor protein C3 production in differentiated human adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING PROTEIN; HUMAN ADIPOSE-TISSUE; LIPOPROTEIN-LIPASE; GENE-EXPRESSION; THYROID-HORMONE; 3T3-L1 ADIPOCYTES; MESSENGER-RNA; ACID; PATHWAY; ADIPSIN	Acylation stimulating protein (ASP) is a potent stimulator of adipocyte triacylglycerol storage. In vivo studies have shown that ASP production by adipocytes increases locally after a fat meal. Initial. in vitro studies demonstrated increased production of ASP in the presence of chylomicrons (CHYLO). The present aim was to define the CHYLO component responsible. None of the apoproteins tested (AT, AII, AIV, CI, CII, CIII, and E) were capable of stimulating C3 (the precursor protein) or ASP production. Rather, the active component is a nonlipid, loosely associated, trypsin-sensitive molecule. High pressure liquid chromatography fractionation of the CHYLO infranate proteins identified the critical protein as transthyretin (TTR), which binds retinol-binding protein and complexes thyroxine and retinol. Addition of TTR alone, with lipid emulsion, or with respun CHYLO to human differentiated adipocytes had little effect on C3 and ASP production. Ey contrast, when transthyretin was added to CHYLO, C3 and ASP production were substantially enhanced up to 75- and 7.5-fold respectively, compared with the effect of native CHYLO alone. Finally, a polyclonal antibody against TTR could inhibit stimulation of C3 and ASP production by CHYLO (by 98 and 100%, respectively) and by CHYLO infranate proteins (by 99 and 94%, respectively). We hypothesize that TTR. mediates the transfer of the active components from CHYLO to adipocytes, which then stimulates increased C3 and ASP production. Thus the CHYLO provides the physiologic trigger of the ASP pathway.	McGill Univ, Royal Victoria Hosp, Ctr Hlth, Mike Rosenbloom Lab Cardiovasc Res, Montreal, PQ H3A 1A1, Canada; Concordia Univ, Dept Chem & Biochem, Montreal, PQ H3M 1M8, Canada	McGill University; Royal Victoria Hospital; Concordia University - Canada	Scantlebury, T (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Mike Rosenbloom Lab Cardiovasc Res, Rm H7-35,687 Pine Ave, Montreal, PQ H3A 1A1, Canada.	mdkc@musica.mcgill.ca						AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; ANTRASFERRY J, 1994, BIOCHEM J, V302, P943, DOI 10.1042/bj3020943; BALDO A, 1993, J CLIN INVEST, V92, P1543, DOI 10.1172/JCI116733; BALDO A, 1995, J LIPID RES, V36, P1415; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASSIS LA, 1988, HYPERTENSION, V11, P591, DOI 10.1161/01.HYP.11.6.591; CHOY LN, 1992, J BIOL CHEM, V267, P12736; Cianflone K, 1997, CLIN BIOCHEM, V30, P301, DOI 10.1016/S0009-9120(97)00011-8; CIANFLONE K, 1995, EUR J CLIN INVEST, V25, P817, DOI 10.1111/j.1365-2362.1995.tb01690.x; CIANFLONE K, 1994, BIOCHEMISTRY-US, V33, P9489, DOI 10.1021/bi00198a014; FLORESDELGADO G, 1987, MOL CELL BIOCHEM, V76, P35; GALTON DJ, 1991, HYPERLIPIDAEMIA PRAC, P1; GERMINARIO R, 1993, METABOLISM, V42, P574, DOI 10.1016/0026-0495(93)90215-A; HAUNER H, 1989, J CLIN INVEST, V84, P1663, DOI 10.1172/JCI114345; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hunter J, 1996, MOL CELL ENDOCRINOL, V116, P213, DOI 10.1016/0303-7207(95)03717-9; JIANG XC, 1991, J BIOL CHEM, V266, P4631; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; Kern PA, 1996, J LIPID RES, V37, P2332; LABRIE F, 1991, INT J OBESITY, V15, P91; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malpeli G, 1996, BBA-PROTEIN STRUCT M, V1294, P48, DOI 10.1016/0167-4838(95)00264-2; Maslowska M, 1997, INT J OBESITY, V21, P261, DOI 10.1038/sj.ijo.0800396; Maslowska M, 1997, J LIPID RES, V38, P1; OKUNO M, 1995, J LIPID RES, V36, P137; Peake PW, 1997, EUR J CLIN INVEST, V27, P922, DOI 10.1046/j.1365-2362.1997.2090759.x; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PETERSON J, 1990, P NATL ACAD SCI USA, V87, P909, DOI 10.1073/pnas.87.3.909; Saleh J, 1998, J LIPID RES, V39, P884; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; Tao YH, 1997, BBA-LIPID LIPID MET, V1344, P221, DOI 10.1016/S0005-2760(96)00144-0; ZECHNER R, 1991, J BIOL CHEM, V266, P10583; ZOVICH DC, 1992, J BIOL CHEM, V267, P13884	36	84	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20903	20909		10.1074/jbc.273.33.20903	http://dx.doi.org/10.1074/jbc.273.33.20903			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694837	hybrid			2022-12-25	WOS:000075386100030
J	Du, HS; Babitzke, P				Du, HS; Babitzke, P			trp RNA-binding attenuation protein-mediated long distance RNA refolding regulates translation of trpE in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 REGA PROTEIN; MESSENGER-RNA; SECONDARY STRUCTURE; ESCHERICHIA-COLI; LEADER RNA; TRAP; INITIATION; OPERON; EXPRESSION; SEQUENCE	Expression of the trpEDCFBA operon is regulated at both the transcriptional and translational levels by the trp RNA-binding attenuation protein (TRAP) of Bacillus subtilis, When cells contain sufficient levels of tryptophan to activate TRAP, the protein binds to trp operon transcripts as they are being synthesized, most often causing transcription termination. However, termination is never 100% efficient, and transcripts that escape termination are subject to translational control. We determined that TRAP-mediated translational control of trpE can occur via a novel RNA conformational switch mechanism. When TRAP binds to the 5'-untranslated leader segment of a trp operon read-through transcript, it can disrupt a large secondary structure containing a portion of the TRAP binding target. This promotes refolding of the RNA such that the trpE Shine-Dalgarno sequence, located more than 100 nucleotides downstream from the TRAP binding site, becomes sequestered in a stable RNA hairpin. Results from cell-free translation, ribosome toeprint, and RNA structure mapping experiments demonstrate that formation of this structure reduces TrpE synthesis by blocking ribosome access to the trpE ribosome binding site. The role of the Shine-Dalgarno blocking hairpin in controlling translation of trpE was confirmed by examining the effect of multiple nucleotide substitutions that abolish the structure without altering the Shine-Dalgarno sequence itself. The possibility of protein-mediated RNA refolding as a general mechanism in controlling gene expression is discussed.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Babitzke, P (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	pxb28@psu.edu	Babitzke, Paul/AAL-3048-2020	Babitzke, Paul/0000-0003-2481-1062	NIGMS NIH HHS [R01 GM052840, GM52840] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052840] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; ANTSON AA, 1994, J MOL BIOL, V244, P1, DOI 10.1006/jmbi.1994.1698; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; Babitzke P, 1996, J BACTERIOL, V178, P5159, DOI 10.1128/jb.178.17.5159-5163.1996; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; Babitzke P, 1997, MOL MICROBIOL, V26, P1, DOI 10.1046/j.1365-2958.1997.5541915.x; BRUNEL C, 1995, J MOL BIOL, V253, P277, DOI 10.1006/jmbi.1995.0552; CHANG JHT, 1995, J BACTERIOL, V177, P6560, DOI 10.1128/jb.177.22.6560-6567.1995; CHRISTENSEN T, 1984, EMBO J, V3, P1609, DOI 10.1002/j.1460-2075.1984.tb02018.x; CLIMIE SC, 1988, J BIOL CHEM, V263, P15166; DESMIT MH, 1990, PROG NUCLEIC ACID RE, V38, P1; Du HS, 1997, J BACTERIOL, V179, P2582, DOI 10.1128/jb.179.8.2582-2586.1997; HATTMAN S, 1991, P NATL ACAD SCI USA, V88, P10027, DOI 10.1073/pnas.88.22.10027; Henner Dennis, 1993, P269; HENNER DJ, 1985, GENE, V34, P169, DOI 10.1016/0378-1119(85)90125-8; Hensold JO, 1997, NUCLEIC ACIDS RES, V25, P2869, DOI 10.1093/nar/25.14.2869; Hess MA, 1996, NUCLEIC ACIDS RES, V24, P2441, DOI 10.1093/nar/24.12.2441; Jackson RJ, 1997, CURR OPIN GENET DEV, V7, P233, DOI 10.1016/S0959-437X(97)80133-5; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; Kaminski A, 1994, Genet Eng (N Y), V16, P115; KANE JF, 1977, J BACTERIOL, V132, P419, DOI 10.1128/JB.132.2.419-425.1977; Klaff P, 1996, PLANT MOL BIOL, V32, P89, DOI 10.1007/BF00039379; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; Lindahl L, 1992, CURR OPIN GENET DEV, V2, P720, DOI 10.1016/S0959-437X(05)80132-7; LOWMAN HB, 1986, J BIOL CHEM, V261, P5396; MA CK, 1994, MOL MICROBIOL, V14, P1033, DOI 10.1111/j.1365-2958.1994.tb01337.x; MERINO E, 1995, J BACTERIOL, V177, P6362, DOI 10.1128/jb.177.22.6362-6370.1995; Miller JH., 1972, EXPT MOL GENETICS; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; PANTOPOULOS K, 1994, PROG NUCLEIC ACID RE, V48, P181, DOI 10.1016/S0079-6603(08)60856-9; Perkins John B., 1993, P319; Poot RA, 1997, P NATL ACAD SCI USA, V94, P10110, DOI 10.1073/pnas.94.19.10110; SEKIGUCHI J, 1975, J BACTERIOL, V121, P688, DOI 10.1128/JB.121.2.688-694.1975; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; SLOCK J, 1990, J BACTERIOL, V172, P7211, DOI 10.1128/jb.172.12.7211-7226.1990; SPIZIZEN J, 1958, P NATL ACAD SCI USA, V44, P1072, DOI 10.1073/pnas.44.10.1072; STEITZ JA, 1975, P NATL ACAD SCI USA, V72, P4734, DOI 10.1073/pnas.72.12.4734; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; UNNITHAN S, 1990, NUCLEIC ACIDS RES, V18, P7083, DOI 10.1093/nar/18.23.7083; WEBSTER KR, 1989, NUCLEIC ACIDS RES, V17, P10047, DOI 10.1093/nar/17.23.10047; WULCZYN FG, 1991, CELL, V65, P259, DOI 10.1016/0092-8674(91)90160-Z; Yang DC, 1997, VIROLOGY, V228, P63, DOI 10.1006/viro.1996.8366; YANG M, 1995, J BACTERIOL, V177, P4272, DOI 10.1128/jb.177.15.4272-4278.1995; Yang M, 1997, J MOL BIOL, V270, P696, DOI 10.1006/jmbi.1997.1149; ZENGEL JM, 1994, PROG NUCLEIC ACID RE, V47, P331, DOI 10.1016/S0079-6603(08)60256-1	48	77	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20494	20503		10.1074/jbc.273.32.20494	http://dx.doi.org/10.1074/jbc.273.32.20494			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685405	hybrid			2022-12-25	WOS:000075305400082
J	Guo, HC; Xu, Q; Buckley, D; Guan, C				Guo, HC; Xu, Q; Buckley, D; Guan, C			Crystal structures of Flavobacterium glycosylasparaginase - An N-terminal nucleophile hydrolase activated by intramolecular proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							20S PROTEASOME; LYSOSOMAL ASPARTYLGLUCOSAMINIDASE; MOLECULAR-CLONING; SUBUNITS; ASPARTYLGLYCOSAMINURIA; BIOCHEMISTRY; COMPLEX; SERINE	Glycosylasparaginase (GA) is a member of a novel family of N-terminal nucleophile hydrolases that catalytically use an N-terminal residue as both a polarizing base and a nucleophile. These enzymes are activated from a single chain precursor by intramolecular autoproteolysis to yield the N-terminal nucleophile. A deficiency of GA results in the human genetic disorder known as aspartylglycosaminuria. In this study, we report the crystal structure of recombinant GA from Flavobacterium meningosepticum, Similar to the human structure, the bacterial GA forms an alpha beta alpha sandwich. However, some significant differences are observed between the Flavobacterium and human structures. The active site of Flavobacterium glycosylasparaginase is in an open conformation when compared with the human structure. We also describe the structure of a mutant wherein the N-terminal nucleophile Thr(152) is, substituted by a cysteine. In the bacterial GA crystals, we observe a heterotetrameric structure similar to that found in the human structure, as well as that observed in solution for eukaryotic glycosylasparaginases. The results confirm the suitability of the bacterial enzyme as a model to study the consequences of mutations in aspartylglycosaminuria patients. They also suggest that further studies are necessary to understand the detail mechanism of this enzyme. The presence of the heterotetrameric structure in the crystals is significant because dimerization of precursors has been suggested in the human enzyme to be a prerequisite to trigger autoproteolysis.	Boston Univ, Sch Med, Dept Biophys, Boston, MA 02118 USA; New England Biolabs Inc, Beverly, MA 01915 USA	Boston University	Guo, HC (corresponding author), Boston Univ, Sch Med, Dept Biophys, 715 Albany St, Boston, MA 02118 USA.							[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Aronson NN, 1996, GLYCOBIOLOGY, V6, P669, DOI 10.1093/glycob/6.7.669; BARRETT AJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P247, DOI 10.1006/abbi.1995.1227; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR MANUAL SYSTEM; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; FISHER KJ, 1993, FEBS LETT, V323, P271, DOI 10.1016/0014-5793(93)81355-4; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; HALILA R, 1991, BIOCHEM J, V276, P251, DOI 10.1042/bj2760251; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu Y, 1996, GLYCOBIOLOGY, V6, P527, DOI 10.1093/glycob/6.5.527; Liu Y, 1998, J BIOL CHEM, V273, P9688, DOI 10.1074/jbc.273.16.9688; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; MONONEN I, 1993, FASEB J, V7, P1247, DOI 10.1096/fasebj.7.13.8405810; MONONEN I, 1995, FASEB J, V9, P428, DOI 10.1096/fasebj.9.5.7896015; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; Riikonen A, 1996, J BIOL CHEM, V271, P21340, DOI 10.1074/jbc.271.35.21340; RIIKONEN A, 1995, J BIOL CHEM, V270, P4903, DOI 10.1074/jbc.270.9.4903; RISLEY JM, 1996, FASEB J, V10, P1104; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; TARENTINO AL, 1995, ARCH BIOCHEM BIOPHYS, V316, P399, DOI 10.1006/abbi.1995.1053; TOLLERSRUD OK, 1992, BIOCHEM J, V282, P891, DOI 10.1042/bj2820891; TOONE EJ, 1994, CURR OPIN STRUC BIOL, V4, P719, DOI 10.1016/S0959-440X(94)90170-8	39	53	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20205	20212		10.1074/jbc.273.32.20205	http://dx.doi.org/10.1074/jbc.273.32.20205			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685368	Green Submitted, hybrid			2022-12-25	WOS:000075305400045
J	Ivanovic, A; Reilander, H; Laube, B; Kuhse, J				Ivanovic, A; Reilander, H; Laube, B; Kuhse, J			Expression and initial characterization of a soluble glycine binding domain of the N-Methyl-D-aspartate receptor NR1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE RECEPTORS; NMDA-RECEPTORS; H-3 MDL-105,519; PROTEINS; SITE; LIGAND; NEURONS; BRAIN; IDENTIFICATION; CHANNEL	Glycine is an essential co-agonist of the excitatory N-methyl-D-aspartate (NMDA) receptor, a subtype of the ionotropic glutamate receptor family. The glycine binding site of this hetero-oligomeric ion channel protein is formed by two distinct extracellular regions, S1 and S2, of the NR1 subunit, whereas the homologous domains of the NR2 subunit mediate glutamate binding. Here, segments SI and S2 of the NR1 polypeptide were fused via a linker peptide followed by N-. and C-terminally tagging with Flag and His, epitopes, respectively. Infection of High Five insect cells with a recombinant baculovirus containing this glycine binding site construct resulted in efficient secretion of a soluble fusion protein of about 53 kDa. After affinity purification to near-homogeneity, the fusion protein bound the competitive glycine site antagonist [H-3]MDL105,519 with high affinity (K-d = 5.22 +/- 0.13 nM) similar to that determined with rat brain membrane fractions. This high affinity binding could be competed by the glycine site antagonist 7-chlorokynurenic acid as well as the agonists glycine and D-serine but not by L-glutamate. This indicates that the S1 and S2 domains of the NR1 subunit are sufficient for the formation of a glycine binding site that displays pharmacological properties similar to those of the NMDA receptor in vivo.	Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany; Max Planck Inst Biophys, Dept Mol Membrane Biol, D-60528 Frankfurt, Germany	Max Planck Society; Max Planck Society	Kuhse, J (corresponding author), Max Planck Inst Brain Res, Dept Neurochem, Deutschordenstr 46, D-60528 Frankfurt, Germany.	kuhse@mpih-frankfurt.mpg.de	Kuhse, Jochen/T-3864-2019					Anson LC, 1998, J NEUROSCI, V18, P581; Arvola M, 1996, J BIOL CHEM, V271, P15527, DOI 10.1074/jbc.271.26.15527; Baron BM, 1996, J PHARMACOL EXP THER, V279, P62; Chen GQ, 1997, P NATL ACAD SCI USA, V94, P13431, DOI 10.1073/pnas.94.25.13431; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Everts I, 1997, MOL PHARMACOL, V52, P861, DOI 10.1124/mol.52.5.861; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; Grunewald S, 1996, BIOCHEMISTRY-US, V35, P15149, DOI 10.1021/bi9607564; HASEGAWA Y, 1994, STROKE, V25, P1241, DOI 10.1161/01.STR.25.6.1241; Hirai H, 1996, P NATL ACAD SCI USA, V93, P6031, DOI 10.1073/pnas.93.12.6031; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Lenhard T, 1996, GENE, V169, P187, DOI 10.1016/0378-1119(95)00831-4; LODGE D, 1994, NMDA RECEPTOR, P105; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OH BH, 1993, J BIOL CHEM, V268, P11348; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P124; Paas Y, 1996, NEURON, V17, P979, DOI 10.1016/S0896-6273(00)80228-7; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Siegel BW, 1996, EUR J PHARMACOL, V312, P357, DOI 10.1016/0014-2999(96)00477-3; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; UCHINO S, 1992, FEBS LETT, V308, P253, DOI 10.1016/0014-5793(92)81286-U; WAFFORD KA, 1993, NEUROREPORT, V4, P1347, DOI 10.1097/00001756-199309150-00015; Wenzel A, 1995, NEUROREPORT, V7, P45, DOI 10.1097/00001756-199512290-00010	36	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19933	19937		10.1074/jbc.273.32.19933	http://dx.doi.org/10.1074/jbc.273.32.19933			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685327	hybrid			2022-12-25	WOS:000075305400004
J	Morrow, CS; Smitherman, PK; Diah, K; Schneider, E; Townsend, AJ				Morrow, CS; Smitherman, PK; Diah, K; Schneider, E; Townsend, AJ			Coordinated action of glutathione S-Transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification - Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CLASS; CANCER-CELLS; CONFERS RESISTANCE; ALKYLATING-AGENTS; LEUKOTRIENE C-4; EXPORT PUMP; PI-CLASS; GENE; EXPRESSION; SENSITIVITY	To examine the role of multidrug resistance protein 1 (MRP1) and glutathione S-transferases (GSTs) in cellular resistance to antineoplastic drugs, derivatives of MCF7 breast carcinoma cells were developed that express MRP1 in combination with one of three human cytosolic isozymes of GST, Expression of MRP1 alone confers resistance to several drugs representing the multidrug resistance phenotype, drugs including doxorubicin, vincristine, etoposide, and mitoxantrone. However, co-expression with MRP1 of any of the human GST isozymes Al-l, M1-1, or P1-1 failed to augment MRP1-associated resistance to these drugs. In contrast, combined expression of MRP1 and GST Al-l conferred similar to 4-fold resistance to the anticancer drug chlorambucil. Expression of MRP1 alone failed to confer resistance to chlorambucil, showing that the observed protection from chlorambucil cytotoxicity was absolutely dependent upon GST Al-l protein. Moreover, using inhibitors of GST (dicumarol) or MRP1 (sulfinpyrazone), it was shown that in MCF7 cells resistance to chlorambucil requires both intact MRP1-dependent efflux pump activity and, for full protection, GST Al-l catalytic activity. These results are the first demonstration that GST Al-l and MRP1 can act in synergy to protect cells from the cytotoxicity of a nitrogen mustard, chlorambucil.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wadsworth Ctr, Albany, NY 12201 USA	Wake Forest University; Wadsworth Center	Morrow, CS (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, Med Ctr Blvd, Winston Salem, NC 27157 USA.				NCI NIH HHS [CA70338] Funding Source: Medline; NIEHS NIH HHS [ES06006] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R55ES006006, R01ES006006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMSTRONG DK, 1992, CANCER RES, V52, P1416; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Awasthi S, 1996, DRUG METAB DISPOS, V24, P371; Barnouin K, 1998, BRIT J CANCER, V77, P201, DOI 10.1038/bjc.1998.34; BERHANE K, 1993, CANCER RES, V53, P4257; BLACK SM, 1991, PHARMACOL THERAPEUT, V51, P139, DOI 10.1016/0163-7258(91)90044-M; BLACK SM, 1990, BIOCHEM J, V268, P309, DOI 10.1042/bj2680309; BOLTON MG, 1991, CANCER RES, V51, P2410; BULLER AL, 1987, MOL PHARMACOL, V31, P575; Bunting KD, 1996, J BIOL CHEM, V271, P11884, DOI 10.1074/jbc.271.20.11884; CIACCIO PJ, 1991, BIOCHEM PHARMACOL, V42, P1504, DOI 10.1016/0006-2952(91)90468-K; CIACCIO PJ, 1990, CANCER COMMUN, V2, P279, DOI 10.3727/095535490820874263; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; Davis LG, 1994, BASIC METHODS MOL BI; DIRVEN HAAM, 1995, CANCER RES, V55, P1701; DIRVEN HAAM, 1994, CANCER RES, V54, P6215; DULIK DM, 1986, BIOCHEM PHARMACOL, V35, P3405, DOI 10.1016/0006-2952(86)90444-2; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HIPFNER DR, 1994, CANCER RES, V54, P5788; Jedlitschky G, 1996, CANCER RES, V56, P988; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; Kool M, 1997, CANCER RES, V57, P3537; LEIER I, 1994, J BIOL CHEM, V269, P27807; LEWIS AD, 1988, P NATL ACAD SCI USA, V85, P8511, DOI 10.1073/pnas.85.22.8511; LEYLANDJONES BR, 1991, CANCER RES, V51, P587; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MAYS JB, 1992, BIOCHEM PHARMACOL, V44, P921, DOI 10.1016/0006-2952(92)90124-2; MEWS K, 1993, CANCER RES, V53, P5135; MEYER DJ, 1993, XENOBIOTICA, V23, P823, DOI 10.3109/00498259309059411; MEYER DJ, 1992, BRIT J CANCER, V66, P433, DOI 10.1038/bjc.1992.292; Morrow CS, 1998, CARCINOGENESIS, V19, P109, DOI 10.1093/carcin/19.1.109; MORROW CS, 1990, CANCER CELL-MON REV, V2, P15; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; MOSCOW JA, 1988, P NATL ACAD SCI USA, V85, P6518, DOI 10.1073/pnas.85.17.6518; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; RHOADS DM, 1987, BIOCHEM BIOPH RES CO, V145, P474, DOI 10.1016/0006-291X(87)91345-3; SCHECTER RL, 1993, CANCER RES, V53, P4900; SCHNEIDER E, 1994, CANCER RES, V54, P152; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SMITH MT, 1989, CANCER RES, V49, P2621; TEW KD, 1994, CANCER RES, V54, P4313; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TOWNSEND AJ, 1992, MOL PHARMACOL, V41, P230; TU CPD, 1986, BIOCHEM BIOPH RES CO, V141, P229, DOI 10.1016/S0006-291X(86)80358-8; WOLF CR, 1986, BIOCHEM PHARMACOL, V35, P1577, DOI 10.1016/0006-2952(86)90127-9; YANG WZ, 1992, MOL PHARMACOL, V41, P625	51	124	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20114	20120		10.1074/jbc.273.32.20114	http://dx.doi.org/10.1074/jbc.273.32.20114			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685354	hybrid			2022-12-25	WOS:000075305400031
J	Savel'ev, AS; Novikova, LA; Kovaleva, IE; Luzikov, VN; Neupert, W; Langer, T				Savel'ev, AS; Novikova, LA; Kovaleva, IE; Luzikov, VN; Neupert, W; Langer, T			ATP-dependent proteolysis in mitochondria - m-AAA protease and PIM1 protease exert overlapping substrate specificities and cooperate with the mtHsp70 system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SIGMA(32); RAT-LIVER MITOCHONDRIA; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; SACCHAROMYCES-CEREVISIAE; INNER MEMBRANE; LON PROTEASE; CYTOCHROME-C; DNAJ HOMOLOG; DEGRADATION	To analyze protein degradation in mitochondria and the role of molecular chaperone proteins in this process, bovine apocytochrome P450scc was employed as a model protein. When imported into isolated yeast mitochondria, P450scc was mislocalized to the matrix and rapidly degraded. This proteolytic breakdown was mediated by the ATP-dependent PIM1 protease, a Lon-like protease in the mitochondrial matrix, in cooperation with the mtHsp70 system. In addition, a derivative of P450scc was studied to which a heterologous transmembrane region was fused at the amino terminus. This protein became anchored to the inner membrane upon import and was degraded by the membrane-embedded, ATP-dependent m-AAA protease, Again, degradation depended on the mtHsp70 system; it was inhibited at nonpermissive temperature in mitochondria carrying temperature-sensitive mutant forms of Ssc1p, Mdj1p, or Mge1p. These results demonstrate overlapping substrate specificities of PIM1 and the m-AAA protease, and they assign a central role to the mtHsp70 system during the degradation of misfolded polypeptides by both proteases.	Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia	University of Munich; Lomonosov Moscow State University	Langer, T (corresponding author), Univ Munich, Inst Physiol Chem, Goethestr 33, D-80336 Munich, Germany.	Langer@bio.med.uni-muenchen.de	Novikova, Ludmila A/A-3427-2014; Kovaleva, Irina/K-1217-2013	Saveliev, Alexander/0000-0003-0840-4774; Langer, Thomas/0000-0003-1250-1462				Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Beyer A, 1997, PROTEIN SCI, V6, P2043; BLASZCZAK A, 1995, EMBO J, V14, P5085, DOI 10.1002/j.1460-2075.1995.tb00190.x; Brodsky JL, 1996, TRENDS BIOCHEM SCI, V21, P122, DOI 10.1016/0968-0004(96)20010-6; Dekker PJT, 1997, J MOL BIOL, V270, P321, DOI 10.1006/jmbi.1997.1131; DESAUTELS M, 1982, J BIOL CHEM, V257, P1673; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Guelin E, 1996, FEBS LETT, V381, P42, DOI 10.1016/0014-5793(96)00074-9; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Jubete Y, 1996, J BIOL CHEM, V271, P30798, DOI 10.1074/jbc.271.48.30798; KELLER JA, 1988, MOL MICROBIOL, V2, P31, DOI 10.1111/j.1365-2958.1988.tb00004.x; KUNAU WH, 1993, BIOCHIMIE, V75, P209, DOI 10.1016/0300-9084(93)90079-8; KUTEJOVA E, 1993, FEBS LETT, V329, P47, DOI 10.1016/0014-5793(93)80190-6; Langer T, 1996, EXPERIENTIA, V52, P1069, DOI 10.1007/BF01952104; LANGER T, 1994, BIOL HEAT SHOCK PROT, P53; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; Miao BJ, 1997, J MOL BIOL, V265, P541, DOI 10.1006/jmbi.1996.0762; NAKAI T, 1995, MOL CELL BIOL, V15, P4441; OMURA T, 1991, METHOD ENZYMOL, V206, P75; OU W, 1986, J BIOCHEM-TOKYO, V100, P1287, DOI 10.1093/oxfordjournals.jbchem.a121835; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PEARCE DA, 1995, J BIOL CHEM, V270, P20879, DOI 10.1074/jbc.270.36.20879; PripBuus C, 1996, FEBS LETT, V380, P142, DOI 10.1016/0014-5793(96)00049-X; RASSOW J, 1995, TRENDS CELL BIOL, V5, P207, DOI 10.1016/S0962-8924(00)89001-7; Rep M, 1996, CURR GENET, V30, P367, DOI 10.1007/s002940050145; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; Rep M, 1996, CURR GENET, V30, P206, DOI 10.1007/s002940050122; ROJO EE, 1995, EMBO J, V14, P3445, DOI 10.1002/j.1460-2075.1995.tb07350.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Savelev AS, 1997, BIOCHEMISTRY-MOSCOW+, V62, P779; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SEQUIREAL B, 1993, EMBO J, V12, P2211, DOI 10.1002/j.1460-2075.1993.tb05869.x; SHERMAN MY, 1992, EMBO J, V11, P71; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; USANOV SA, 1990, FEBS LETT, V275, P33, DOI 10.1016/0014-5793(90)81432-N; van Dyck L, 1998, GENE DEV, V12, P1515, DOI 10.1101/gad.12.10.1515; VANDYCK L, 1994, J BIOL CHEM, V269, P238; VOOS W, 1994, MOL CELL BIOL, V14, P6627, DOI 10.1128/MCB.14.10.6627; Wagner I, 1997, EMBO J, V16, P7317, DOI 10.1093/emboj/16.24.7317; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; WANG N, 1994, J BIOL CHEM, V269, P29308; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; Weber ER, 1996, MOL BIOL CELL, V7, P307, DOI 10.1091/mbc.7.2.307; WESTERMANN B, 1995, EMBO J, V14, P3452, DOI 10.1002/j.1460-2075.1995.tb07351.x; Westermann B, 1996, MOL CELL BIOL, V16, P7063; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	70	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20596	20602		10.1074/jbc.273.32.20596	http://dx.doi.org/10.1074/jbc.273.32.20596			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685417	hybrid			2022-12-25	WOS:000075305400094
J	Vallet, VS; Casado, M; Henrion, AA; Bucchini, D; Raymondjean, M; Kahn, A; Vaulont, S				Vallet, VS; Casado, M; Henrion, AA; Bucchini, D; Raymondjean, M; Kahn, A; Vaulont, S			Differential roles of upstream stimulatory factors 1 and 2 in the transcriptional response of liver genes to glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE; FACTOR USF; CARBOHYDRATE REGULATION; TRANSGENIC MICE; C-MYC; PROMOTER; PROTEINS; RAT; ORGANIZATION; EXPRESSION	USF1 and USF2 are ubiquitous transcription factors of the basic helix-loop-helix leucine zipper family. They form homo- and heterodimers and recognize a CACGTG motif termed E box. In the liver, USF binding activity is mainly accounted for by the USF1/USF2 heterodimer, which binds irt vitro the glucose/carbohydrate response elements (GlRE/ChoRE) of glucose-responsive genes. To assign a physiological role of USFs in vivo, we have undertaken the disruption of USF1 and USF2 genes in mice. We present here the generation of USF1-deficient mice. In the liver of these mice, we demonstrate that USFS remaining dimers can compensate for glucose responsiveness, even though the level of total USF binding activity is reduced by half as compared with wild type mice. The residual USF1 binding activity was similarly reduced in the previously reported USF2 -/- mice in which an impaired glucose responsiveness was observed (Vallet, V, S,, Henrion, A, A., Bucchini, D., Casado, M., Raymondjean, M., Kahn, A., and Vaulont, S. (1997) J. Biol. Chem. 272, 21944-21949). Taken together, these results clearly suggest differential transactivating efficiencies of USF1 and USF2 in promoting the glucose response. Furthermore, they support the view that USF2 is the functional transactivator of the glucose-responsive complex.	Universite Rene Descartes, INSERM, U129, Unite Rech Physiol & Pathol Genet & Mol, F-75014 Paris, France; Universite Rene Descartes, Inst Cochin Genet Mol, F-75014 Paris, France; Universite Rene Descartes, INSERM, U257, Lab Genet Cellulaire & Mol, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Vaulont, S (corresponding author), Universite Rene Descartes, INSERM, U129, Unite Rech Physiol & Pathol Genet & Mol, 24 Rue Faubourg, F-75014 Paris, France.	vaulont@cochin.inserm.fr	Vaulont, Sophie/O-6732-2017; Caude, Alexandra A Henrion/I-2778-2016; Casado, Marta/L-2078-2014	Caude, Alexandra A Henrion/0000-0002-8170-2260; Casado, Marta/0000-0001-6457-4650				Aperlo C, 1996, GENOMICS, V37, P337, DOI 10.1006/geno.1996.0568; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Carter RS, 1997, MOL CELL BIOL, V17, P18, DOI 10.1128/MCB.17.1.18; CUIF MH, 1993, J BIOL CHEM, V268, P13769; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; Dear TN, 1997, ONCOGENE, V14, P891, DOI 10.1038/sj.onc.1200912; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; Henrion AA, 1996, MAMM GENOME, V7, P803, DOI 10.1007/s003359900241; HENRION AA, 1995, GENOMICS, V25, P36, DOI 10.1016/0888-7543(95)80107-W; Joyner AL, 1993, GENE TARGETING PRACT; Kennedy HJ, 1997, J BIOL CHEM, V272, P20636, DOI 10.1074/jbc.272.33.20636; Kurschner C, 1997, BIOCHEM BIOPH RES CO, V231, P333, DOI 10.1006/bbrc.1997.6097; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LIAW CW, 1984, J BIOL CHEM, V259, P7253; LIN Q, 1994, J BIOL CHEM, V269, P23894; LITTLEWOOD TD, 1995, PROTEIN PROFILE, V2, P621; LONE YC, 1986, FEBS LETT, V195, P97, DOI 10.1016/0014-5793(86)80138-7; Lun Y, 1997, CELL GROWTH DIFFER, V8, P275; Moriizumi S, 1998, GENE EXPRESSION, V7, P103; MOUNTFORD PS, 1995, TRENDS GENET, V11, P179, DOI 10.1016/S0168-9525(00)89040-X; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SHIH HM, 1992, J BIOL CHEM, V267, P13222; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Takahashi Y, 1997, BIOCHEM BIOPH RES CO, V240, P293, DOI 10.1006/bbrc.1997.7651; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405	36	110	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20175	20179		10.1074/jbc.273.32.20175	http://dx.doi.org/10.1074/jbc.273.32.20175			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685363	hybrid			2022-12-25	WOS:000075305400040
J	Vecchi, M; Rudolph-Owen, LA; Brown, CL; Dempsey, PJ; Carpenter, G				Vecchi, M; Rudolph-Owen, LA; Brown, CL; Dempsey, PJ; Carpenter, G			Tyrosine phosphorylation and proteolysis - Pervanadate-induced, metalloprotease-dependent cleavage of the ErbB-4 receptor and amphiregulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; KINASE-C-DELTA; NEU DIFFERENTIATION FACTOR; PHORBOL ESTER; CELL-SURFACE; FACTOR-ALPHA; T-CELLS; PROTEIN; ACTIVATION; LIGAND	Enhancement of tyrosine phosphorylation in cells by the application of pervanadate, an extremely potent phosphotyrosine phosphatase inhibitor, provokes the rapid metalloprotease-dependent cleavage of ErbB-4, a transmembrane receptor tyrosine kinase. The pervanadate-induced proteolysis occurs in NIH 3T3 cells expressing transfected human ErbB-4 and in several cell lines that express endogenous ErbB-4. One product of this proteolytic event is a membrane-anchored molecule of approximately 80 kDa, which is heavily tyrosine phosphorylated and which possesses tyrosine kinase catalytic activity toward an exogenous substrate in vitro. This response to pervanadate is not dependent on protein kinase C activation, which has previously been demonstrated to also activate ErbB-4 cleavage. Hence, the pervanadate and 12- O-tetradecanoylphorbol-13-acetate-induced proteolytic cleavage of ErbB-4 seem to proceed by different mechanisms, although both require metalloprotease activity. Moreover, pervanadate activation of ErbB-4 cleavage, but not that of 12-O-tetradecanoylphorbol-13-acetate, is blocked by the oxygen radical scavenger pyrrolidine dithiocarbomate. A second phosphotyrosine phosphatase inhibitor, phenylarsine oxide, also stimulates a similar cleavage of ErbB-4 but, unlike pervanadate, is not sensitive to pyrrolidine dithiocarbomate. Last, pervanadate is shown to stimulate the proteolytic cell surface processing of a second and unrelated transmembrane molecule: the precursor for amphiregulin, an epidermal growth factor-related molecule. Amphiregulin cleavage by pervanadate occurred in the absence of a cytoplasmic domain and:tyrosine phosphorylation of this substrate.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA.		Vecchi, Manuela/L-3502-2017	Vecchi, Manuela/0000-0002-2750-9160	NATIONAL CANCER INSTITUTE [R01CA046413, R01CA024071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007491] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA24071, R01 CA46413] Funding Source: Medline; NIAMS NIH HHS [T32 AR07491] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; Baulida J, 1996, J BIOL CHEM, V271, P5251; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BRIZZI MF, 1994, ONCOGENE, V9, P1583; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GRASSMAN M, 1995, NATURE, V378, P390; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HORSTMAN DA, 1995, PROTEIN EXPRES PURIF, V6, P278, DOI 10.1006/prep.1995.1036; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Kadotani M, 1997, J BIOCHEM-TOKYO, V121, P1047; Kamat Asha, 1997, Cytokine and Growth Factor Reviews, V8, P109, DOI 10.1016/S1359-6101(97)00003-8; Komurasaki T, 1997, ONCOGENE, V15, P2841, DOI 10.1038/sj.onc.1201458; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Krejsa CM, 1997, J BIOL CHEM, V272, P11541; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; LIAO K, 1991, J BIOL CHEM, V266, P6544; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Reiland J, 1996, BIOCHEM J, V319, P39, DOI 10.1042/bj3190039; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SLACK BE, 1995, J BIOL CHEM, V270, P8337, DOI 10.1074/jbc.270.14.8337; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; THORNE BA, 1994, MOL CELL BIOL, V14, P1635, DOI 10.1128/MCB.14.3.1635; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YEE NS, 1993, J BIOL CHEM, V268, P14189; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	61	79	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20589	20595		10.1074/jbc.273.32.20589	http://dx.doi.org/10.1074/jbc.273.32.20589			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685416	hybrid			2022-12-25	WOS:000075305400093
J	Schwartz, MA; Meredith, JE; Kiosses, WB				Schwartz, MA; Meredith, JE; Kiosses, WB			An activated Rac mutant functions as a dominant negative for membrane ruffling	ONCOGENE			English	Article						Rho family small GTP binding protein; signal transduction; actin cytoskeleton	CELL-CYCLE PROGRESSION; PROTEIN-KINASE; ACTIN POLYMERIZATION; SMALL GTPASES; CDC42; RHO; CASCADE	Previous studies have shown that point mutations in the effector domain of Rad block specific downstream pathways such as PAK, JNK/SAPK kinases and membrane ruffling, Specifically, the F37A mutation, made in a constitutively activated Q61L background, activates PAK but fails to induce membrane ruffles. We now show that Q61L/F37A Rac not only fails to induce ruffling but potently blocks membrane ruffling induced by serum or PDGF, In the presence of serum, cells do extend filopodia, suggesting that this mutant only blocks a subset of the effecters that induce cytoskeletal reorganization. At later times, this rac mutant induces membrane blebbing, but not apoptosis, These results show that Q61L/F37A Rac, is constitutively activated with respect to PAK activation but functions as a dominant negative for another pathway, membrane ruffling, That an effector domain point mutant can simultaneously function as a dominant negative and dominant positive for different pathways implies that effects of these variants on cell functions must be interpreted with caution.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schwartz, MA (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			schwartz, martin/0000-0002-2071-1243	NIGMS NIH HHS [R01 GM27214] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; Fedier A, 1997, CELL MOTIL CYTOSKEL, V37, P326; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	15	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					625	629		10.1038/sj.onc.1201977	http://dx.doi.org/10.1038/sj.onc.1201977			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704928				2022-12-25	WOS:000075195300010
J	Howie, SEM; Cotton, GJ; Heslop, I; Martin, NJ; Harrison, DJ; Ramage, R				Howie, SEM; Cotton, GJ; Heslop, I; Martin, NJ; Harrison, DJ; Ramage, R			Synthetic peptides representing discontinuous CD4 binding epitopes of HIV-1 gp120 that induce T cell apoptosis and block cell death induced by gp120	FASEB JOURNAL			English	Article						TFA; phycoerythrin; IgG; optical density	IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN GP120; CONFORMATIONAL SWITCH; CROSS-LINKING; RECEPTOR; INFECTION; AIDS; LYMPHOCYTES; ANTIGEN; REGION	A vaccine against HIV-1 virus would block initial infection and must target conserved residues. Since initial infection depends on binding of the viral envelope protein gp120 to CD4 on the cell surface, the CD4 binding site of gp120 is a target for vaccine design, To identify the optimal biologically active site, we synthesized a series of 32-mer peptides, based on conserved residues in the C3 and C4 regions of gp120. These included three of five sequence discontinuous residues known to be involved in CD4 binding, one or two of which were substituted with alanine, We also synthesized a 44-mer peptide with an additional branch to incorporate an extra C4 region sequence including a fourth CD4 binding residue. All these peptides used an oxidized Cys-X-Cys bridge to link the discontinuous sequence elements in a manner suggested by the known conserved disulfide bridges in gp120, Polyclonal sera raised to these peptides indicate that they all contain both B and T lymphocyte epitopes, Binding of the peptides to CD4-transfected HeLa cells reveals a hierarchy dependent on the number of relevant CD4 binding residues present. Furthermore, antibody cross-linking of peptides bound to the surface of human T cells results in apoptosis that is similar to the known properties of gp120, The peptide incorporating three CD4 binding residues competitively inhibited gp120-induced T lymphocyte apoptosis, Thus, we have synthesized novel, branched peptides incorporating conserved discontinuous sequences from two different conserved domains of HIV-1 gp120 that contain T and B lymphocyte epitopes and mimic biological functions of the native protein, These synthetic peptides are candidates for future vaccine development.	Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Ctr Prot Technol, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Howie, SEM (corresponding author), Univ Edinburgh, Sch Med, Dept Pathol, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	s.e.m.howie@ed.ac.uk						AMEISEN JC, 1994, IMMUNOL REV, V142, P9, DOI 10.1111/j.1600-065X.1994.tb00882.x; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BYCROFT BW, 1993, J CHEM SOC CHEM COMM, V5, P283; CORBEIL J, 1995, J GEN VIROL, V76, P681, DOI 10.1099/0022-1317-76-3-681; CORDONNIER A, 1989, NATURE, V340, P574; Cotton GJ, 1996, MOL IMMUNOL, V33, P171, DOI 10.1016/0161-5890(95)00110-7; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DOWBENKO D, 1988, J VIROL, V62, P4703, DOI 10.1128/JVI.62.12.4703-4711.1988; FUJII N, 1989, J CHEM SOC CHEM COMM, P283, DOI 10.1039/c39890000283; FUJII N, 1987, J CHEM SOC CHEM COMM, P1676, DOI 10.1039/c39870001676; FYFE L, 1991, IMMUNOLOGY, V74, P467; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P553, DOI 10.1089/aid.1993.9.553; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HOWIE SEM, 1994, IMMUNOL REV, V142, P141, DOI 10.1111/j.1600-065X.1994.tb00887.x; HOWIE SEM, 1994, CLIN EXP IMMUNOL, V95, P195; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LAURENTCRAWFORD AG, 1993, AIDS RES HUM RETROV, V9, P761, DOI 10.1089/aid.1993.9.761; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; MALDARELLI F, 1995, J VIROL, V69, P6457, DOI 10.1128/JVI.69.10.6457-6465.1995; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; OYAIZU N, 1993, BLOOD, V82, P3392; OYAIZU N, 1994, BLOOD, V84, P2622; POLLARD SR, 1992, EMBO J, V11, P585, DOI 10.1002/j.1460-2075.1992.tb05090.x; RAMAGE R, 1994, BIOCHEM J, V299, P151, DOI 10.1042/bj2990151; REED J, 1991, BIOCHEMISTRY-US, V30, P4521, DOI 10.1021/bi00232a022; REED J, 1993, P NATL ACAD SCI USA, V90, P6761, DOI 10.1073/pnas.90.14.6761; SYU WJ, 1990, P NATL ACAD SCI USA, V87, P3695, DOI 10.1073/pnas.87.10.3695; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; THALI M, 1991, J VIROL, V65, P6188, DOI 10.1128/JVI.65.11.6188-6193.1991; vonStosch AG, 1996, BIOCHEMISTRY-US, V35, P411, DOI 10.1021/bi952045w; WANG ZQ, 1994, EUR J IMMUNOL, V24, P1553, DOI 10.1002/eji.1830240715; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	37	14	26	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1998	12	11					991	998		10.1096/fasebj.12.11.991	http://dx.doi.org/10.1096/fasebj.12.11.991			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707171				2022-12-25	WOS:000075372600009
J	Varga, K; Wagner, JA; Bridgen, DT; Kunos, G				Varga, K; Wagner, JA; Bridgen, DT; Kunos, G			Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension	FASEB JOURNAL			English	Article						anandamide; 2-arachidonyl glyceride; CB1 cannabinoid receptors; vasodilation	NEUROBLASTOMA-CELLS; ENZYMATIC-SYNTHESIS; IMMUNE FUNCTION; ANANDAMIDE; RECEPTOR; BRAIN; RAT; CB1; BIOSYNTHESIS; DEGRADATION	Macrophages are the primary cellular targets of bacterial lipopolysaccharide (LPS), but the role of macrophage-derived cytokines in LPS-induced septic shock is uncertain. Recent evidence indicates that activation of peripheral CB1 cannabinoid receptors contributes to hemorrhagic hypotension and that macrophage-derived anandamide as well as unidentified platelet-derived substances may be contributing factors. Here we demonstrate that rat platelets contain the endogenous cannabinoid 2-arachidonyl glyceride (2-AG), as identified by reverse phase high-performance liquid chromatography, gas chromatography, and mass spectrometry, and that in vitro exposure of platelets to LPS (200 mu g/ml) markedly increases 2-AG levels, LPS-stimulated, but not control, macrophages contain anandamide, which is undetectable in either control or LPS-stimulated platelets. Prolonged hypotension and tachycardia are elicited in urethane-anesthetized rats treated 1) with LPS (15 mg/kg i.v.); 2) with macrophages plus platelets isolated from 3 ml of blood from an LPS-treated donor rat; or 3) with rat macrophages or 4) platelets preincubated in vitro with LPS (200 mu g/ml). In all four cases, the hypotension but not the tachycardia is prevented by pretreatment of the recipient rat with the CB1 receptor antagonist SR141716A (3 mg/kg i.v.), which also inhibits the hypotensive response to anandamide or 2-AG, The hypotension elicited by LPS-treated macrophages or platelets remains unchanged in the absence of sympathetic tone or after blockade of nitric oxide synthase, These findings indicate that platelets and macrophages generate different endogenous cannabinoids, and that both 2-AG and anandamide may be paracrine mediators of endotoxin-induced hypotension via activation of vascular CB1 receptors.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Virginia Commonwealth University	Kunos, G (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, POB 980613, Richmond, VA 23298 USA.				NHLBI NIH HHS [HL 59257] Funding Source: Medline; NIAAA NIH HHS [AA-09719] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009719] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AMRUTHESH SC, 1992, J NEUROCHEM, V58, P503, DOI 10.1111/j.1471-4159.1992.tb09749.x; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Bisogno T, 1997, BIOCHEM J, V322, P671, DOI 10.1042/bj3220671; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Cadas H, 1997, J NEUROSCI, V17, P1226; Calignano A, 1997, EUR J PHARMACOL, V337, pR1, DOI 10.1016/S0014-2999(97)01297-1; Cummings CJ, 1997, AM J RESP CRIT CARE, V156, P431, DOI 10.1164/ajrccm.156.2.9509017; DENTENER MA, 1993, J IMMUNOL, V150, P2885; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; Di Marzo V, 1998, BIOCHEM J, V331, P15; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; diMarzo V, 1996, BIOCHEM J, V316, P977, DOI 10.1042/bj3160977; DORMAN T, 1994, CRIT CARE MED, V22, P1069, DOI 10.1097/00003246-199407000-00001; Ellis EF, 1995, AM J PHYSIOL-HEART C, V269, pH1859, DOI 10.1152/ajpheart.1995.269.6.H1859; GEBREMEDHIN G, 1996, FASEB J, V10, pA302; HALLING JL, 1992, INFECT IMMUN, V60, P845, DOI 10.1128/IAI.60.3.845-852.1992; Hillard CJ, 1997, J NEUROCHEM, V69, P631, DOI 10.1046/j.1471-4159.1997.69020631.x; Ishac EJN, 1996, BRIT J PHARMACOL, V118, P2023, DOI 10.1111/j.1476-5381.1996.tb15639.x; Junger WG, 1996, J TRAUMA, V40, P702, DOI 10.1097/00005373-199605000-00004; KUMAR GS, 1998, FEBS LETT, V422, P69; Lake KD, 1997, J PHARMACOL EXP THER, V281, P1030; LEE M, 1995, J PHARMACOL EXP THER, V275, P529; Malinowska B, 1997, N-S ARCH PHARMACOL, V356, P197, DOI 10.1007/PL00005041; McCuskey RS, 1996, CARDIOVASC RES, V32, P752, DOI 10.1016/S0008-6363(96)00113-7; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; Patrini G, 1997, J NEUROIMMUNOL, V80, P143, DOI 10.1016/S0165-5728(97)00149-5; Peitzman AB, 1995, CURR PROB SURG, V32, P927; Plane F, 1997, BRIT J PHARMACOL, V121, P1509, DOI 10.1038/sj.bjp.0701361; Pratt PF, 1998, AM J PHYSIOL-HEART C, V274, pH375, DOI 10.1152/ajpheart.1998.274.1.H375; PRESCOTT SM, 1983, J BIOL CHEM, V258, P764; Randall MD, 1996, BIOCHEM BIOPH RES CO, V229, P114, DOI 10.1006/bbrc.1996.1766; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V284, P644; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Schatz AR, 1997, TOXICOL APPL PHARM, V142, P278, DOI 10.1006/taap.1996.8034; SHERRY B, 1988, J CELL BIOL, V107, P1269, DOI 10.1083/jcb.107.4.1269; Stein EA, 1996, BRIT J PHARMACOL, V119, P107, DOI 10.1111/j.1476-5381.1996.tb15683.x; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; STONE R, 1994, SCIENCE, V264, P365, DOI 10.1126/science.8153620; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sun XM, 1997, AM J PHYSIOL-GASTR L, V273, pG56, DOI 10.1152/ajpgi.1997.273.1.G56; VARGA K, 1995, EUR J PHARMACOL, V278, P279, DOI 10.1016/0014-2999(95)00181-J; Varga K, 1996, HYPERTENSION, V28, P682, DOI 10.1161/01.HYP.28.4.682; Wagner JA, 1997, NATURE, V390, P518, DOI 10.1038/37371; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	49	344	349	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					1035	1044		10.1096/fasebj.12.11.1035	http://dx.doi.org/10.1096/fasebj.12.11.1035			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707176				2022-12-25	WOS:000075372600014
J	Landgren, E; Klint, P; Yokote, K; Claesson-Welsh, L				Landgren, E; Klint, P; Yokote, K; Claesson-Welsh, L			Fibroblast growth factor receptor 1 mediates chemotaxis independently of direct SH2 domain protein binding	ONCOGENE			English	Article						FGF receptor; chemotaxis	PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; SIGNAL-TRANSDUCTION; POINT MUTATION; AUTOPHOSPHORYLATION SITES; KINASE INSERT; CDNA CLONING; ACTIVATION; EXPRESSION; FAMILY	Endothelial cells expressing fibroblast growth factor receptor-1 (FGFR-1) migrate and proliferate in response to treatment with FGF. We analysed ligand-induced migration and proliferation of porcine aortic endothelial cells expressing wild-type FGFR-1, point-mutated Y766F FGFR-1, unable to activate phospholipase C-gamma 1 (PLC-gamma 1), or carboxyl-terminally truncated FGFR-1, lacking either 48 (from amino acid 774 in the FGFR-1 sequence) or 63 (from amino acid 759) amino acid residues of the C-terminal tail. The truncated CT63 FGFR-1 mutant failed to mediate chemotaxis, but was in response to ligand stimulation capable of mediating proliferation of the cells, stimulation of MAP kinase activity and tyrosine phosphorylation of FRS2, an FGFR-1 specific signaling molecule. The defect in migration-capacity of CT63 was not due to loss of Y766, and thereby PLC-gamma 1 activation, since cells expressing the mutant Y7766F FGFR-1 migrated as efficiently as the wild-type receptor cells. Induction of phospholipase A(2) (PLA(2)) activity by the activated FGFR-1 was dependent on the presence of Y766, and was therefore also not critical for the chemotactic response. Although the FGFR-1 only very inefficiently mediates activation of phosphatidylinositol 3' kinase (PI 3-kinase), the PI 3-kinase inhibitor wortmannin suppressed wild-type FGFR-1 mediated migration. We conclude that the signal transduction pathway for FGFR-1 mediated migration is independent of phosphotyrosine residues in the receptor and requires activation of a wortmannin-sensitive enzyme.	Biomed Ctr, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Chiba Univ, Sch Med, Dept Internal Med, Chuo Ku, Chiba 260, Japan	Chiba University	Claesson-Welsh, L (corresponding author), Biomed Ctr, Dept Med Biochem & Microbiol, Box 575, S-75123 Uppsala, Sweden.							ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; AUERBACH R, 1991, PHARMACOL THERAPEUT, V51, P1, DOI 10.1016/0163-7258(91)90038-N; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLYMAN RI, 1994, CELL ADHES COMMUN, V1, P333, DOI 10.3109/15419069409097264; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LANDGREN E, 1995, ONCOGENE, V10, P2027; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Roghani M, 1996, J BIOL CHEM, V271, P31154, DOI 10.1074/jbc.271.49.31154; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SA G, 1994, J BIOL CHEM, V269, P3219; SHAOUL E, 1995, ONCOGENE, V10, P1553; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; WENNSTROM S, 1994, ONCOGENE, V9, P651; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816	34	42	42	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					283	291		10.1038/sj.onc.1201936	http://dx.doi.org/10.1038/sj.onc.1201936			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690510				2022-12-25	WOS:000074947500003
J	Marron-Terada, PG; Brzycki-Wessell, MA; Dahms, NM				Marron-Terada, PG; Brzycki-Wessell, MA; Dahms, NM			The two mannose 6-phosphate binding sites of the insulin-like growth factor-II mannose 6-phosphate receptor display different ligand binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCURONIDASE; LYSOSOMAL-ENZYMES; DICTYOSTELIUM-DISCOIDEUM; SEQUENCE-ANALYSIS; CATHEPSIN-D; CARBOHYDRATE-RECOGNITION; CYTOPLASMIC DOMAIN; CARBOXYL-TERMINUS; ARGININE RESIDUES; HUMAN-FIBROBLASTS	The two mannose 6-phosphate (Man-6-P) binding sites of the insulin-like growth factor-II/mannose 6-phosphate receptor (IGF-II/MPR) have been localized to domains 1-3 and 7-9, and studies have shown that Arg(435) in, domain 3 and Arg(1334) in domain 9 are essential for Man-6-P binding. To determine whether the IGF-II/MPR containing a single Man-6-P binding site is functional, clonal mouse L cell Lines stably transfected with either mutant bovine IGF-II/MPR cDNA, containing substitutions at position 435 and/or 1334, or the wild type receptor cDNA were assayed for their ability to sort lysosomal enzymes to the lysosome. Mutant receptors containing a single Man-6-P binding site were similar to 50% less efficient than the wild type receptor in the overall targeting of lysosomal enzymes to the lysosome. Mutant receptors containing a substitution at Arg(1334) (Dom9(Ala)), in contrast to those containing a substitution at Arg(435) (Dom3(Ala)), were unable to target cathepsin D and beta-hexosaminidase to the lysosome. Equilibrium binding assays using I-125-labeled beta-glucuronidase demonstrated that Dom3(Ala) and Dom9(Ala) had a K-d of 2.0 and 4.3 nM, respectively. In addition, Dom3(Ala), unlike Dom9(Ala), was unable to completely dissociate from ligand under acidic pH conditions. These data indicate that the two Man-B-P binding sites of the IGF-II/MPR are not functionally equivalent.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Dahms, NM (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042667, R01DK042667, R56DK042667] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42667] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAPAT B, 1988, FEBS LETT, V237, P191, DOI 10.1016/0014-5793(88)80199-6; BECCARI T, 1992, BIOCHEM J, V285, P593, DOI 10.1042/bj2850593; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; FISCHER HD, 1980, J BIOL CHEM, V255, P5069; FREEZE HH, 1983, J BIOL CHEM, V258, P8928; FREEZE HH, 1980, J BIOL CHEM, V255, P1081; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GABEL CA, 1984, J BIOL CHEM, V259, P3762; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GLASER JH, 1973, J LAB CLIN MED, V82, P969; GOLDBERG DE, 1981, J BIOL CHEM, V256, P3060; GOLDSTEIN JL, 1977, CELL, V12, P629, DOI 10.1016/0092-8674(77)90263-X; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; GRUSBY MJ, 1990, NUCLEIC ACIDS RES, V18, P4008, DOI 10.1093/nar/18.13.4008; JADOT M, 1992, J BIOL CHEM, V267, P11069; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LI M, 1990, ARCH BIOCHEM BIOPHYS, V283, P150, DOI 10.1016/0003-9861(90)90625-9; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MA ZM, 1992, J BIOL CHEM, V267, P19017; MunierLehmann H, 1996, BIOCHEM SOC T, V24, P133, DOI 10.1042/bst0240133; NOLAN CM, 1990, CELL REGUL, V1, P197, DOI 10.1091/mbc.1.2.197; PARK JE, 1991, SOMAT CELL MOLEC GEN, V17, P137, DOI 10.1007/BF01232971; PERDUE JF, 1983, J BIOL CHEM, V258, P7800; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; SHIPLEY JM, 1993, J BIOL CHEM, V268, P12193; Sleat DE, 1997, J BIOL CHEM, V272, P731, DOI 10.1074/jbc.272.2.731; STEIN M, 1987, BIOL CHEM H-S, V368, P413, DOI 10.1515/bchm3.1987.368.1.413; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; TAIT JF, 1981, J BIOL CHEM, V256, P1086; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TONG PY, 1988, J BIOL CHEM, V263, P2585; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1988, BIOCHEM BIOPH RES CO, V152, P1248, DOI 10.1016/S0006-291X(88)80419-4; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WENDLAND M, 1991, J BIOL CHEM, V266, P2917; WENK J, 1991, BIOCHEM INT, V23, P723; WESTCOTT KR, 1987, J BIOL CHEM, V262, P6101; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X	52	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22358	22366		10.1074/jbc.273.35.22358	http://dx.doi.org/10.1074/jbc.273.35.22358			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712856	hybrid			2022-12-25	WOS:000075616600032
J	Sellers, VM; Wang, KF; Johnson, MK; Dailey, HA				Sellers, VM; Wang, KF; Johnson, MK; Dailey, HA			Evidence that the fourth ligand to the [2Fe-2S] cluster in animal ferrochelatase is a cysteine - Characterization of the enzyme from Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HUMAN ERYTHROPOIETIC PROTOPORPHYRIA; IRON-SULFUR PROTEIN; MAMMALIAN FERROCHELATASE; ESCHERICHIA-COLI; IN-VIVO; BOVINE FERROCHELATASE; MOLECULAR DEFECT; LIVER-FAILURE; IDENTIFICATION	In a previous study, site-directed mutagenesis experiments identified three of the four ligands to the [2Fe-2S] cluster in animal ferrochelatase as conserved cysteines in the COOH terminal extension, Cys-403, Cys-406, and Cys-411 in human ferrochelatase (Crouse, B. R., Sellers, V. M., Finnegan, M. G., Dailey, H. A. & Johnson, M. K. (1996) Biochemistry 35, 16222-16229), The nature of the fourth ligand was left unresolved, and spectroscopic studies raised the possibility of one noncysteinyl, oxygenic ligand, In this work, we report two lines of evidence that strongly suggest the fourth ligand is a cysteine residue. Cysteine at position 196 in human recombinant ferrochelatase when changed to a serine results in an inactive enzyme that is lacking the [2Fe-2S] cluster. Furthermore, whole cell EPR studies demonstrate that in the C196S mutant the cluster fails to assemble. Additionally, the cloning and expression of Drosophila melanogaster ferrochelatase has allowed the identification, by EPR and UV-visible spectroscopy, of a [2Fe-2S](2+) cluster with properties analogous to those of animal ferrochelatases. The observation that Drosophila ferrochelatase contains only four conserved cysteines at positions 196, 403, 406, and 411, is in accord with the proposal that these residues function as cluster ligands, In the case of the ferrochelatase iron-sulfur cluster ligands, NH2-Cys-X-206-Cys-X-2-Cys-X-2-Cys-COOH, the position distant from other ligands may lead to a spatial positioning of the cluster near the enzyme active site or at the interface of two domains, thereby explaining the loss of enzyme activity that accompanies cluster degradation and reinforcing the idea that the cluster functions as a regulatory switch.	Univ Georgia, Dept Microbiol, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Dept Chem, Athens, GA 30602 USA; Univ Georgia, Ctr Metalloenzyme Studies, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Dailey, HA (corresponding author), Univ Georgia, Dept Microbiol, Athens, GA 30602 USA.	dailey@bscr.uga.edu			NIDDK NIH HHS [R56 DK032303, DK32303] Funding Source: Medline; NIGMS NIH HHS [GM51962] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032303, R01DK032303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051962] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Karadaghi S, 1997, STRUCTURE, V5, P1501, DOI 10.1016/S0969-2126(97)00299-2; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Blackwood ME, 1997, J AM CHEM SOC, V119, P12170, DOI 10.1021/ja971619c; BRENNER DA, 1991, P NATL ACAD SCI USA, V88, P849, DOI 10.1073/pnas.88.3.849; Crouse BR, 1996, BIOCHEMISTRY-US, V35, P16222, DOI 10.1021/bi9620114; Dailey HA, 1997, J BIOL INORG CHEM, V2, P411, DOI 10.1007/s007750050151; DAILEY HA, 1994, J BIOL CHEM, V269, P390; DAILEY HA, 1983, J BIOL CHEM, V258, P1453; DAILEY HA, 1994, BIOCHEMISTRY-US, V33, P403, DOI 10.1021/bi00168a003; DAILEY HA, 1996, MECH METALLOCENTER A, P77; Dailey TA, 1996, PROTEIN SCI, V5, P98; DAY AL, 1998, IN PRESS ARCH BIOCH; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Ding HG, 1997, P NATL ACAD SCI USA, V94, P8445, DOI 10.1073/pnas.94.16.8445; DUNIN EC, 1997, BIOCHEMISTRY-US, V36, P11811; FERREIRA GC, 1994, J BIOL CHEM, V269, P7062; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; FRUSTACI JM, 1993, J BACTERIOL, V175, P2154, DOI 10.1128/JB.175.7.2154-2156.1993; Gaudu P, 1997, J BIOL CHEM, V272, P5082, DOI 10.1074/jbc.272.8.5082; Gora M, 1996, J BIOL CHEM, V271, P11810, DOI 10.1074/jbc.271.20.11810; JOHNSON MK, 1994, ENCY INORGANIC CHEM, P1896; Jordan PA, 1997, FEBS LETT, V416, P349, DOI 10.1016/S0014-5793(97)01219-2; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; KOHNO H, 1994, BBA-PROTEIN STRUCT M, V1209, P95, DOI 10.1016/0167-4838(94)90142-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; NAKAHASHI Y, 1992, P NATL ACAD SCI USA, V89, P281, DOI 10.1073/pnas.89.1.281; NAKAHASHI Y, 1993, HUM MOL GENET, V2, P1069, DOI 10.1093/hmg/2.7.1069; NAKAHASHI Y, 1993, HUM GENET, V91, P303; NAKAHIGASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P784; Rouault TA, 1996, J BIOL INORG CHEM, V1, P494, DOI 10.1007/s007750050083; SARKANY RPE, 1994, LANCET, V343, P1394, DOI 10.1016/S0140-6736(94)92525-9; SARKANY RPE, 1994, J INVEST DERMATOL, V102, P481, DOI 10.1111/1523-1747.ep12373073; SCHRODER I, 1991, J BIOL CHEM, V266, P13572; Sellers VM, 1996, BIOCHEMISTRY-US, V35, P2699, DOI 10.1021/bi952631p; Sellers VM, 1998, BLOOD, V91, P3980; Sellers VM, 1997, METHOD ENZYMOL, V281, P378; SHIBUYA H, 1995, BBA-BIOENERGETICS, V1231, P117, DOI 10.1016/0005-2728(95)00077-V; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; TAKETANI S, 1990, J BIOL CHEM, V265, P19377	41	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22311	22316		10.1074/jbc.273.35.22311	http://dx.doi.org/10.1074/jbc.273.35.22311			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712849	hybrid			2022-12-25	WOS:000075616600025
J	Wang, ZG; Benkovic, SJ				Wang, ZG; Benkovic, SJ			Purification, characterization, and kinetic studies of a soluble Bacteroides fragilis metallo-beta-lactamase that provides multiple antibiotic resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROMONAS-HYDROPHILA AE036; CLINICAL ISOLATE; GENE; IMIPENEM; CLONING; CCRA; CLASSIFICATION; MECHANISMS; REVEALS; TAL3636	Resistance to multiple beta-lactam antibiotics traced to the expression of Zn(II) requiring metallo-beta-lactamases has emerged in clinical isolates of several bacterial strains including Bacteroides fragilis, a pathogen commonly found in suppurative/surgical infections. A soluble B. fragilis metallo-beta-lactamase has been purified to homogeneity from the cell growth medium after expression as a secretory protein in Escherichia coli. The enzyme requires two tightly bound Zn(II) ions for full activity, and the Zn(II) ions can be removed by EDTA hom the enzyme. The apoenzyme is reactivated by stoichiometric amounts of Zn(II) and Co(II) ions. The Co(II)substituted enzyme exhibits a UV-visible spectrum characterized by strong Co(II) d-d transitions at 510, 548, 615, and 635 nm and an EPR spectrum with g values of 5.52, 4.25, and 2.01: features that serve as useful spectroscopic handles for the mechanistic studies of the enzyme. Although steady-state and transient-state kinetic studies of the soluble Zn(II) enzyme with nitrocefin as substrate found no ionizable groups with pK(a) values between 5.25 and 10.0 involved in catalysis, a kinetically significant proton transfer step in turnover was implicated by studies in deuterium oxide. These studies also detected the accumulation of an enzyme-bound intermediate and provide the basis for a minimal kinetic scheme describing metallo-beta-lactamase-catalyzed nitrocefin hydrolysis.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Benkovic, SJ (corresponding author), Penn State Univ, Dept Chem, 152 Davey Lab, University Pk, PA 16802 USA.	sjb1@psu.edu			NIGMS NIH HHS [GM18061] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018061] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBER RP, 1985, FEBS LETT, V189, P207; AULD DS, 1988, METHOD ENZYMOL, V158, P40; BALDWIN GS, 1978, BIOCHEM J, V175, P441, DOI 10.1042/bj1750441; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Bertini I, 1984, Adv Inorg Biochem, V6, P71; BROOK I, 1989, ANN CLIN LAB SCI, V19, P360; BUSH K, 1989, ANTIMICROB AGENTS CH, V33, P271, DOI 10.1128/AAC.33.3.271; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Christianson DW, 1996, ACCOUNTS CHEM RES, V29, P331, DOI 10.1021/ar9501232; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Crowder MW, 1996, BIOCHEMISTRY-US, V35, P12126, DOI 10.1021/bi960976h; DAVIES RB, 1974, BIOCHEM J, V143, P129, DOI 10.1042/bj1430129; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FERSHT A, 1984, ENZYME STRUCTURE MEC, P101; FRERE JM, 1995, MOL MICROBIOL, V16, P385, DOI 10.1111/j.1365-2958.1995.tb02404.x; FRERE JM, 1991, RES MICROBIOL, V142, P705, DOI 10.1016/0923-2508(91)90084-N; FRERE JM, 1995, BIOCHIM BIOPHYS ACTA, V1246, P109; HUSSAIN M, 1985, J BACTERIOL, V164, P223, DOI 10.1128/JB.164.1.223-229.1985; KNOWLES JR, 1985, ACCOUNTS CHEM RES, V18, P97, DOI 10.1021/ar00112a001; Lever A. B. P., 1984, INORGANIC ELECT SPEC; Lew J, 1997, BIOCHEMISTRY-US, V36, P6717, DOI 10.1021/bi963164u; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; MASSIDDA O, 1991, J BACTERIOL, V173, P4611, DOI 10.1128/jb.173.15.4611-4617.1991; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; OSANO E, 1994, ANTIMICROB AGENTS CH, V38, P71, DOI 10.1128/AAC.38.1.71; PAGE MI, 1984, ACCOUNTS CHEM RES, V17, P144, DOI 10.1021/ar00100a005; PAYNE DJ, 1993, J MED MICROBIOL, V39, P93, DOI 10.1099/00222615-39-2-93; POSNER B, 1993, GENE, V128, P111, DOI 10.1016/0378-1119(93)90161-U; RASMUSSEN BA, 1990, ANTIMICROB AGENTS CH, V34, P1590, DOI 10.1128/AAC.34.8.1590; Rasmussen BA, 1997, ANTIMICROB AGENTS CH, V41, P223, DOI 10.1128/AAC.41.2.223; Rasmussen BA, 1993, CLIN INFECT DIS, V16, P390; SEGATORE B, 1993, ANTIMICROB AGENTS CH, V37, P1324, DOI 10.1128/AAC.37.6.1324; THOMPSON JS, 1990, J BACTERIOL, V172, P2584, DOI 10.1128/jb.172.5.2584-2593.1990; Toney JH, 1997, PROTEIN EXPRES PURIF, V9, P355, DOI 10.1006/prep.1996.0718; TURNER P, 1995, LANCET, V345, P1275, DOI 10.1016/S0140-6736(95)90927-3; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; WALSH TR, 1994, BBA-GENE STRUCT EXPR, V1218, P199, DOI 10.1016/0167-4781(94)90011-6; YANG YJ, 1992, ANTIMICROB AGENTS CH, V36, P1155, DOI 10.1128/AAC.36.5.1155; [No title captured]	40	105	109	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22402	22408		10.1074/jbc.273.35.22402	http://dx.doi.org/10.1074/jbc.273.35.22402			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712862	hybrid			2022-12-25	WOS:000075616600038
J	Gee, SH; Sekely, SA; Lombardo, C; Kurakin, A; Froehner, SC; Kay, BK				Gee, SH; Sekely, SA; Lombardo, C; Kurakin, A; Froehner, SC; Kay, BK			Cyclic peptides as non-carboxyl-terminal ligands of syntrophin PDZ domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; DENSITY PROTEIN PSD-95; NMDA RECEPTOR SUBUNITS; BINDING CONSTANTS; GUANYLATE KINASES; SURFACE; IDENTIFICATION; RECOGNITION; LIBRARIES; DISPLAY	Syntrophins, a family of intracellular peripheral membrane proteins of the dystrophin-associated protein complex (DAPC), each contain a single PDZ domain. Syntrophin PDZ domains bind C-terminal peptide sequences with the consensus R/K-E-S/T-X-V-COOH, an interaction that mediates association of skeletal muscle sodium channels with the DAPC. Here, we have isolated cyclic peptide ligands for syntrophin PDZ domains from a library of combinatorial peptides displayed at the N terminus of protein III of bacteriophage M13, Affinity selection from a library of X(10)G peptides yielded ligands with the consensus X-(R/K)-E-T-C-L/M-A-G-X-Psi-C, where Psi represents any hydrophobic amino acid. These peptides contain residues (underlined) similar to the C-terminal consensus sequence for binding to syntrophin PDZ domains and bind to the same site on syntrophin PDZ domains as C-terminal peptides, but do not bind to other closely related PDZ domains. PDZ binding is dependent on the formation of an intramolecular disulfide bond ire the peptides, since treatment with dithiothreitol, or substitution of either of the two cysteines with alanines, eliminated this activity. Furthermore, amino acid replacements revealed that most residues in the phage-selected peptides are required for binding. Our results define a new mode of binding to PDZ domains and suggest that proteins containing similar conformationally constrained sequences may be ligands for PDZ domains.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Univ N Carolina, Dept Physiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Macromol Interact Facil, Chapel Hill, NC 27599 USA	University of Wisconsin System; University of Wisconsin Madison; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Kay, BK (corresponding author), Univ Wisconsin, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.							ADAMS ME, 1995, J BIOL CHEM, V270, P25859, DOI 10.1074/jbc.270.43.25859; Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cowburn D, 1996, STRUCTURE, V4, P1005, DOI 10.1016/S0969-2126(96)00106-2; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Gee SH, 1998, J NEUROSCI, V18, P128; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KALININ NL, 1995, ANAL BIOCHEM, V228, P238, DOI 10.1006/abio.1995.1345; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; MORELOCK MM, 1995, J MED CHEM, V38, P1309, DOI 10.1021/jm00008a009; Myszka DG, 1996, PROTEIN SCI, V5, P2468, DOI 10.1002/pro.5560051209; Niethammer M, 1996, J NEUROSCI, V16, P2157; Oligino L, 1997, J BIOL CHEM, V272, P29046, DOI 10.1074/jbc.272.46.29046; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; Pierce HH, 1996, MOL DIVERS, V1, P259, DOI 10.1007/BF01715530; Ponting CP, 1997, PROTEIN SCI, V6, P464; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Saras J, 1997, J BIOL CHEM, V272, P24333, DOI 10.1074/jbc.272.39.24333; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SMITH GP, 1993, GENE, V128, P1, DOI 10.1016/0378-1119(93)90145-S; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; Yamabhai M, 1997, ANAL BIOCHEM, V247, P143, DOI 10.1006/abio.1997.2040; Yanagisawa J, 1997, J BIOL CHEM, V272, P8539, DOI 10.1074/jbc.272.13.8539	38	60	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21980	21987		10.1074/jbc.273.34.21980	http://dx.doi.org/10.1074/jbc.273.34.21980			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705339	hybrid, Green Published			2022-12-25	WOS:000075492600073
J	Muller-Weeks, S; Mastran, B; Caradonna, S				Muller-Weeks, S; Mastran, B; Caradonna, S			The nuclear isoform of the highly conserved human uracil-DNA glycosylase is an M-r 36,000 phosphoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; PROTEIN-KINASE; GENE; PURIFICATION; REPLICATION; SEQUENCE; BACTERIOPHAGE-PBS2; PHOSPHORYLATION; TRANSCRIPTION; SPECIFICITY	We have previously demonstrated that human cells contain multiple forms of uracil-DNA glycosylase (Caradonna, S, J,, Ladner, R., Hansbury, M,, Kosciuk, RI., Lynch, F,, and Muller, S, J, (1996) Exp, Cell Res. 222, 345-359), One of these is an M, 29,000 processed form of the highly conserved uracil-DNA glycosylase (UDG1) located in the mitochondria. The others are located in the nucleus and migrate as a group of at least three distinct bands within the 35,000-37,000 molecular weight range. In this report, we perform a detailed characterization of the M, 35,000-37,000 purified proteins. To accomplish this, uracil-DNA glycosylases were affinity purified from HeLa cell nuclear extracts. The proteins were separated by SDS-PAGE, and their identities were verified by renaturation and activity assays. The three protein bands were individually digested with cyanogen bromide, and the resulting peptide fragments were analyzed by direct amino acid sequencing. Peptide sequence, derived from each band, was identical and corresponded to a recently identified isoform of UDG1, This isoform (UDG1A) has a unique 44-amino acid N-terminal region and a C-terminal region that is identical to UDG1, To bean to study the signals required for nuclear targeting, the N-terminal regions of UDG1 and UDG1A were isolated and cloned into pEGFP-N2 to generate fusions with a redshifted variant of green fluorescent protein (GFP), When these constructs were transfected into NIH3T3 cells, UDG1/pEGFP was targeted to the mitochondria, and UDG1A/pEGFP was targeted to the nucleus, Further studies, using deletion mutants, demonstrate that the nuclear localization signal resides within the first 20 amino acids of UDG1A, To investigate the possibility that the heterogeneity observed on SDS-PAGE results from post-translational modification(s), the UDC/pEGFP fusion constructs were transfected into NIH3T3 cells, and the cells were metabolically labeled with [P-32]orthophosphate. Results from these experiments show that UDG1A is a phosphoprotein, Subsequent phosphoamino acid analysis revealed that UDG1A is phosphorylated on both serine and threonine residues. As a final characterization, RNase protection assays were performed to examine expression of each of these isoforms, These studies demonstrate that UDG1A is expressed in a wide variety of cell types and that message levels are elevated in transformed cells.	Univ Med & Dent New Jersey, Dept Biol Mol, SOM, Sch Osteopath Med, Stratford, NJ 08084 USA	Rowan University; Rowan University School of Osteopathic Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center	Muller-Weeks, S (corresponding author), Univ Med & Dent New Jersey, Dept Biol Mol, SOM, Sch Osteopath Med, 2 Med Ctr Dr, Stratford, NJ 08084 USA.	muller@umdnj.edu	Caradonna, Salvatore/AFU-8514-2022	Caradonna, Salvatore/0000-0002-2104-581X	NCI NIH HHS [CA42605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; Caradonna S, 1996, EXP CELL RES, V222, P345, DOI 10.1006/excr.1996.0044; CONE R, 1980, J BIOL CHEM, V255, P354; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMENA JD, 1988, BIOCHEMISTRY-US, V27, P6742, DOI 10.1021/bi00418a015; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; Haug T, 1996, GENOMICS, V36, P408, DOI 10.1006/geno.1996.0485; ISAYA G, 1995, METHOD ENZYMOL, V248, P556; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; Krokan HE, 1997, BIOCHEM J, V325, P1; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MILLNS AK, 1994, VIROLOGY, V198, P504, DOI 10.1006/viro.1994.1061; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MULLER SJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P197, DOI 10.1016/0167-4781(91)90055-Q; MULLER SJ, 1993, J BIOL CHEM, V268, P1310; MullerWeeks SJ, 1996, EXP CELL RES, V226, P346, DOI 10.1006/excr.1996.0235; Nagelhus TA, 1997, J BIOL CHEM, V272, P6561, DOI 10.1074/jbc.272.10.6561; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; PEREZ L, 1993, P NATL ACAD SCI USA, V90, P8113, DOI 10.1073/pnas.90.17.8113; Prichard MN, 1996, J VIROL, V70, P3018, DOI 10.1128/JVI.70.5.3018-3025.1996; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STUART DT, 1993, J VIROL, V67, P2503, DOI 10.1128/JVI.67.5.2503-2512.1993; TAKAHASHI I, 1963, NATURE, V197, P794, DOI 10.1038/197794a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	34	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21909	21917		10.1074/jbc.273.34.21909	http://dx.doi.org/10.1074/jbc.273.34.21909			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705330	hybrid			2022-12-25	WOS:000075492600064
J	Berhane, K; Ray, AA; Khanapure, SP; Rokach, J; Powell, WS				Berhane, K; Ray, AA; Khanapure, SP; Rokach, J; Powell, WS			Calcium/calmodulin-dependent conversion of 5-oxoeicosanoids to 6,7-dihydro metabolites by a cytosolic olefin reductase in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; LEUKOTRIENE B-4; 5-OXO-6,8,11,14-EICOSATETRAENOIC ACID; PROSTAGLANDIN DEHYDROGENASE; ARACHIDONIC-ACID; DIHYDRO PRODUCTS; HUMAN MONOCYTES; FATTY-ACIDS; CELLS; PURIFICATION	We previously showed that 6-trans isomers of leukotriene B-4 but not leukotriene B-4 itself are converted to dihydro metabolites by human neutrophils. The first step in the formation of these metabolites is oxidation of the 5-hydroxyl group by 5-hydroxyeicosanoid dehydrogenase, The objective of the present investigation was to characterize the second step in the formation of the dihydro metabolites, reduction of an olefinic double bond. We found that the olefin reductase reduces the 6,7-double bond of 8-oxoeicosanoids, is localized in the cytosolic fraction of neutrophils, and requires NADPH as a cofactor. Neutrophil cytosol converts a variety of both 5-oxo- and 15-oxoeicosanoids to dihydro products. However, conversion of 5-oxoeicosanoids to their 6,7-dihydro metabolites is inhibited by EGTA and a calmodulin antagonist and stimulated by the addition of calcium and calmodulin, whereas the reduction of 15-oxoeicosanoids to their 13,14-dihydro metabolites is slightly inhibited by calcium. Furthermore, eicosanoid Delta(6)- and Delta(13)-reductases could be separated by chromatography on DEAE-Sepharose. 5-Oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is converted by the Delta(6)-reductase to 6,7-dihydro-5-oxo-ETE, which is 1000 times less potent than 5-oxo-ETE in mobilizing calcium in neutrophils. We conclude that neutrophils contain both 5-oxo-eicosanoid Delta(6)-reductase and prostaglandin Delta(13)-reductase, Metabolism of 5-oxo-ETE by the Delta(6)-reductase results in loss of its biological activity.	McGill Univ, Dept Med, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Florida Inst Technol, Claude Pepper Inst, Melbourne, FL 32901 USA; Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA	McGill University; Florida Institute of Technology; Florida Institute of Technology	Powell, WS (corresponding author), McGill Univ, Dept Med, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	Bill@Meakins.LAN.McGill.ca	Powell, William/AAE-9000-2020	Powell, William/0000-0002-8507-4038; Rokach, Joshu/0000-0003-1814-7505	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044730] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44730] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGGARD E, 1971, ACTA PHYSIOL SCAND, V81, P396, DOI 10.1111/j.1748-1716.1971.tb04914.x; BERGHOLTE JM, 1987, ARCH BIOCHEM BIOPHYS, V257, P444, DOI 10.1016/0003-9861(87)90589-3; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAITHWAITE SS, 1975, J BIOL CHEM, V250, P2315; FILIPOVIC I, 1987, LIPIDS, V22, P261, DOI 10.1007/BF02533989; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; HAMBERG M, 1971, J BIOL CHEM, V246, P1073; KAEVER V, 1988, FEBS LETT, V231, P385, DOI 10.1016/0014-5793(88)80855-X; Khanapure SP, 1998, J ORG CHEM, V63, P337, DOI 10.1021/jo9716993; Khanapure SP, 1998, J ORG CHEM, V63, P4098, DOI 10.1021/jo980280p; Kitamura S, 1996, PROSTAGLANDINS, V52, P35, DOI 10.1016/0090-6980(96)00050-0; KUMLIN M, 1990, BIOCHEM BIOPH RES CO, V170, P23, DOI 10.1016/0006-291X(90)91235-K; MAAS RL, 1982, J BIOL CHEM, V257, P7056; Maddox JE, 1996, J EXP MED, V183, P137, DOI 10.1084/jem.183.1.137; MASFERRER JL, 1991, EXP EYE RES, V52, P417, DOI 10.1016/0014-4835(91)90037-F; OFLAHERTY JT, 1993, BIOCHEM BIOPH RES CO, V192, P129, DOI 10.1006/bbrc.1993.1391; OFLAHERTY JT, 1994, BBA-GEN SUBJECTS, V1201, P505, DOI 10.1016/0304-4165(94)90083-3; OFLaherty JT, 1996, J IMMUNOL, V157, P336; Okita RT, 1996, CRIT REV BIOCHEM MOL, V31, P101, DOI 10.3109/10409239609106581; Powell WS, 1996, J PHARMACOL EXP THER, V276, P728; POWELL WS, 1980, PROSTAGLANDINS, V20, P947, DOI 10.1016/0090-6980(80)90144-6; POWELL WS, 1993, J BIOL CHEM, V268, P9280; Powell WS, 1996, J IMMUNOL, V156, P336; POWELL WS, 1992, J BIOL CHEM, V267, P19233; POWELL WS, 1988, J BIOL CHEM, V263, P2170; POWELL WS, 1986, BIOCHEM BIOPH RES CO, V136, P707, DOI 10.1016/0006-291X(86)90497-3; POWELL WS, 1995, J IMMUNOL, V154, P4123; POWELL WS, 1987, ANAL BIOCHEM, V164, P117, DOI 10.1016/0003-2697(87)90375-7; SCHONFELD W, 1991, J LEUKOCYTE BIOL, V50, P303, DOI 10.1002/jlb.50.3.303; SCHWENK U, 1995, J BIOL CHEM, V270, P15029, DOI 10.1074/jbc.270.25.15029; SERHAN CN, 1993, BIOCHEMISTRY-US, V32, P6313, DOI 10.1021/bi00076a002; SHIMIZU T, 1990, METHOD ENZYMOL, V187, P296; SUN FF, 1974, PROSTAGLANDINS, V7, P327, DOI 10.1016/S0090-6980(74)80088-2; WAINWRIGHT S, 1990, BIOCHEMISTRY-US, V29, P10126, DOI 10.1021/bi00495a017; WAINWRIGHT SL, 1991, J BIOL CHEM, V266, P20899; WHEELAN P, 1995, J BIOL CHEM, V270, P19845, DOI 10.1074/jbc.270.34.19845; YOKOMIZO T, 1993, J BIOL CHEM, V268, P18128	38	14	14	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20951	20959		10.1074/jbc.273.33.20951	http://dx.doi.org/10.1074/jbc.273.33.20951			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694844	hybrid			2022-12-25	WOS:000075386100037
J	Bird, AJ; Turner-Cavet, JS; Lakey, JH; Robinson, NJ				Bird, AJ; Turner-Cavet, JS; Lakey, JH; Robinson, NJ			A carboxyl-terminal Cys/His(2)-type zinc-finger motif in DNA primase influences DNA content in Synechococcus PCC 7942	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR-SYNTHESIS OPERON; ESCHERICHIA-COLI PRIMASE; TRANSFER-RNA SYNTHETASE; TRANSCRIPTION FACTOR; REPLICATION FORK; METALLOTHIONEIN LOCUS; BINDING DOMAIN; METAL-BINDING; HELICASE; PROTEIN	The DNA primase gene, dnaG, has been isolated from the cyanobacterium Synechococcus PCC 7942, It is not part of a macromolecular synthesis operon but is cotranscribed with pheT and located adjacent to the metallothionein divergon, smt. At the carboxyl terminus of this DnaG is a Cys(2)/His(2) zinc-finger motif. The carboxyl-terminal 91 residues bound Zn-65 and 0.95 g atom of Zn2+ mol(-1) were detected with 4-(2-pyridylazo)resorcinol. Following exposure to Cd2+, 0.95 g atom of Cd2+ was displaced by 2 equivalents of p-(hydroxymercuri) phenylsulfonate mol(-1), while only 0.03 g atom of Cd2+ was displaced mol(-1) polypeptide missing the carboxyl-terminal (residue 592 onward) zinc-finger motif, Zn2+ caused an increase in intensity, and a reduction in wavelength, of Trp fluorescence at the tip of the predicted zinc-finger, while EDTA caused the converse. Cells containing a single chromosomal codon substitution (C597S), altering the zinc-finger, were generated by exploiting Zn2+-sensitive smt mutants and the proximity of dnaG to smt, Cells in which smt and dnaG(C597S) had integrated into the chromosome were selected via restored Zn2+ tolerance. Synechococcus PCC 7942 and its dnaG(C597S) mutant grew at equivalent rates, but the latter had a reduced number of chromosomes.	Univ Newcastle Upon Tyne, Sch Med, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Robinson, NJ (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Robinson, Nigel J/J-6363-2012	Robinson, Nigel J/0000-0001-5586-1092; Cavet, Jennifer/0000-0001-5913-7157				AYROA S, 1997, MOL MICROBIOL, V23, P639; BERG JM, 1990, J BIOL CHEM, V265, P6513; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BINDER BJ, 1995, APPL ENVIRON MICROB, V61, P708, DOI 10.1128/AEM.61.2.708-717.1995; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; BURTON ZF, 1983, CELL, V32, P335, DOI 10.1016/0092-8674(83)90453-1; CanoGauci DF, 1996, FEBS LETT, V386, P1, DOI 10.1016/0014-5793(96)00356-0; GRIEP A, 1997, BIOCHEMISTRY-US, V36, P544; Griep MA, 1996, BIOCHEMISTRY-US, V35, P8260, DOI 10.1021/bi952948p; GROMPE M, 1991, J BACTERIOL, V173, P1268, DOI 10.1128/jb.173.3.1268-1278.1991; HUCKLE JW, 1993, MOL MICROBIOL, V7, P177, DOI 10.1111/j.1365-2958.1993.tb01109.x; HUNT JB, 1984, J BIOL CHEM, V259, P4793; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; JEZOREK JR, 1979, ANAL CHEM, V51, P373, DOI 10.1021/ac50039a012; Kalenik JL, 1997, NUCLEIC ACIDS RES, V25, P843, DOI 10.1093/nar/25.4.843; KLEMBA M, 1995, BIOCHEMISTRY-US, V34, P10094, DOI 10.1021/bi00031a034; Kusakabe T, 1996, J BIOL CHEM, V271, P19563, DOI 10.1074/jbc.271.32.19563; KUWAHARA J, 1990, BIOCHEMISTRY-US, V29, P8627, DOI 10.1021/bi00489a019; LANDRO JA, 1994, J BIOL CHEM, V269, P20217; LARK KG, 1972, NATURE-NEW BIOL, V240, P237, DOI 10.1038/newbio240237a0; LIU JH, 1995, J BIOL CHEM, V270, P15162, DOI 10.1074/jbc.270.25.15162; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; LUISI B, 1992, NATURE, V356, P379, DOI 10.1038/356379a0; LUPSKI JR, 1984, CELL, V39, P251, DOI 10.1016/0092-8674(84)90001-1; MANN N, 1974, J GEN MICROBIOL, V83, P399; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; Masuyama H, 1997, MOL ENDOCRINOL, V11, P218, DOI 10.1210/me.11.2.218; MELY Y, 1993, BIOCHIM BIOPHYS ACTA, V1161, P6, DOI 10.1016/0167-4838(93)90189-X; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; METZGER R, 1994, GENE, V151, P161, DOI 10.1016/0378-1119(94)90649-1; MURPHY RC, 1990, J BACTERIOL, V172, P967, DOI 10.1128/jb.172.2.967-976.1990; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; Poutney Dean L., 1997, Protein Science, V6, P892; ROSE PE, 1995, J VIROL, V69, P2842, DOI 10.1128/JVI.69.5.2842-2849.1995; Sambrook J., 2002, MOL CLONING LAB MANU; SHI YG, 1995, SCIENCE, V268, P282, DOI 10.1126/science.7536342; STAMFORD NPJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P17, DOI 10.1016/0167-4781(92)90047-4; TOMMEY AM, 1991, FEBS LETT, V292, P49; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; Tougu K, 1996, J BIOL CHEM, V271, P21391, DOI 10.1074/jbc.271.35.21391; TOUGU K, 1994, J BIOL CHEM, V269, P4675; TSUJIKAWA K, 1991, FEBS LETT, V283, P239, DOI 10.1016/0014-5793(91)80597-V; TURNER JS, 1995, J IND MICROBIOL, V14, P259, DOI 10.1007/BF01569937; TURNER JS, 1993, J BIOL CHEM, V268, P4494; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; VANDERPLAS J, 1990, GENE, V95, P39, DOI 10.1016/0378-1119(90)90411-J; VERSALOVIC J, 1993, MOL MICROBIOL, V8, P343, DOI 10.1111/j.1365-2958.1993.tb01578.x; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; XU B, 1994, BIOCHEMISTRY-US, V29, P398; YU W, 1994, J BIOL CHEM, V269, P21010; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984	52	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21246	21252		10.1074/jbc.273.33.21246	http://dx.doi.org/10.1074/jbc.273.33.21246			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694883	hybrid			2022-12-25	WOS:000075386100076
J	Vijapurkar, U; Cheng, KR; Koland, JG				Vijapurkar, U; Cheng, KR; Koland, JG			Mutation of a Shc binding site tyrosine residue in ErbB3/HER3 blocks heregulin-dependent activation of mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOTYROSINE BINDING; SIGNAL TRANSDUCTION; FUSION PROTEINS; EGF RECEPTOR; DOMAIN; PHOSPHORYLATION	The ErbB2 and ErbB3 proteins together constitute a functional coreceptor for heregulin (neuregulin). Heregulin stimulates the phosphorylation of both coreceptor constituents and initiates a variety of other signaling events, which include phosphorylation of the Shc protein. The role of Shc in heregulin-stimulated signal transduction through the ErbB2-.ErbB3 coreceptor was investigated here. Heregulin was found to promote ErbB3/Shc association in NIH-3T3 cells expressing endogenous ErbB2 and recombinant ErbB3. A mutant ErbB3 protein was generated in which Tyr-1325 in a consensus Shc phosphotyrosine-binding domain recognition site was mutated to Phe (ErbB3-Y/F). This mutation abolished the association of Shc with ErbB3 and blocked the activation of mitogen-activated protein kinase by heregulin. Whereas heregulin induced mitogenesis in NIH-3T3 cells transfected with wild-type ErbB3 cDNA, this mitogenic response was markedly attenuated in NIH-3T3 cells transfected with the ErbB3-Y/F cDNA. These results showed a specific interaction of Shc with the ErbB3 receptor protein and demonstrated the importance of this interaction in the activation of mitogenic responses by the ErbB2.ErbB3 heregulin coreceptor complex.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Koland, JG (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA.			Koland, John/0000-0002-5028-4297	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044684, R01DK044684, P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25295, DK44684] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HELLYER NJ, 1995, GENE, V165, P279, DOI 10.1016/0378-1119(95)00436-A; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HORAN T, 1995, J BIOL CHEM, V270, P24604, DOI 10.1074/jbc.270.41.24604; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KIM HH, 1994, J BIOL CHEM, V269, P24747; Kim HH, 1998, BIOCHEM J, V334, P189, DOI 10.1042/bj3340189; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; KOLAND JG, 1988, J BIOL CHEM, V263, P2230; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEGATTO O, 1993, ONCOGENE, V8, P2105; Sierke SL, 1997, BIOCHEM J, V322, P757, DOI 10.1042/bj3220757; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20996	21002		10.1074/jbc.273.33.20996	http://dx.doi.org/10.1074/jbc.273.33.20996			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694850	hybrid			2022-12-25	WOS:000075386100043
J	Xie, LJ; Smith, JA; Gross, SS				Xie, LJ; Smith, JA; Gross, SS			GTP cyclohydrolase I inhibition by the prototypic inhibitor 2,4-diamino-6-hydroxypyrimidine - Mechanisms and unanticipated role of GTP cyclohydrolase I feedback regulatory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE GENERATION; VASCULAR SMOOTH-MUSCLE; MESSENGER-RNA; TETRAHYDROBIOPTERIN; PURIFICATION; SYNTHASE; CLONING; CELLS	2,4-Diamino-6-hydroxypyrimidine (DAHP) is considered to be a selective and direct-acting inhibitor of GTP cyclohydrolase I (GTPCH), the first and rate-limiting enzyme in the pathway for synthesis of tetrahydrobiopterin (BH4). Accordingly, DAHP has been widely employed to distinguish whether de novo BH4 synthesis is required in a given biological system. Although it has been assumed that DAHP inhibits GTPCH by direct competition with substrate GTP, this has never been formally demonstrated. In view of apparent structural homology between DAHP and BH4, we questioned whether DAHP may mimic BH4 in its inhibition of GTPCH by an indirect mechanism, involving interaction with a recently cloned 9.5-kDa protein termed GTPCH Feedback Regulatory Protein (GFRP). We show by reverse transcription-polymerase chain reaction that GFRP mRNA is constitutively expressed in rat aortic smooth muscle cells and further induced by treatment with immunostimulants. Moreover, functional GFRP is expressed and immunostimulant-induced BH4 accumulates in sufficient quantity to trigger feedback inhibition of GTPCH. Studies with DAHP reveal that GFRP is also essential to achieve potent inhibition of GTPCH. Indeed, DAHP inhibits GTPCH by dual mechanisms. At a relatively low concentration DAHP emulates BH4 and engages the GFRP-dependent feedback inhibitory system; at higher concentrations, DAHP competes directly for binding with GTP substrate. This knowledge predicts that DAHP would preferably target GTPCH in tissues with abundant GFRP.	Cornell Univ, Coll Med, Dept Pharmacol, New York, NY 10021 USA; Cornell Univ, Coll Med, Program Biochem & Struct Biol, New York, NY 10021 USA	Cornell University; Cornell University	Gross, SS (corresponding author), Cornell Univ, Coll Med, Dept Pharmacol, 1300 York Ave, New York, NY 10021 USA.				NHLBI NIH HHS [HL50656, HL 46403] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050656, P01HL046403] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMOAHAPRAKU B, 1995, J AM SOC NEPHROL, V5, P1630; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HATTORI Y, 1993, BIOCHEM BIOPH RES CO, V195, P435, DOI 10.1006/bbrc.1993.2062; KAUFMAN S, 1993, ANNU REV NUTR, V13, P261, DOI 10.1146/annurev.nu.13.070193.001401; KELLEY MR, 1993, ALCOHOL, V10, P185, DOI 10.1016/0741-8329(93)90033-K; LEEMING RJ, 1976, ARCH DIS CHILD, V51, P771, DOI 10.1136/adc.51.10.771; Milstien S, 1996, J BIOL CHEM, V271, P19743, DOI 10.1074/jbc.271.33.19743; MUHL H, 1994, KIDNEY INT, V46, P1302, DOI 10.1038/ki.1994.398; NAR H, 1995, STRUCTURE, V3, P459, DOI 10.1016/S0969-2126(01)00179-4; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NIEDERWIESER A, 1986, EUR J PEDIATR, V145, P176, DOI 10.1007/BF00446058; Oddis CV, 1996, AM J PHYSIOL-HEART C, V270, pH1864, DOI 10.1152/ajpheart.1996.270.5.H1864; OZELIUS LJ, 1994, NAT GENET, V8, P207, DOI 10.1038/ng1194-207; SHEN R, 1988, BIOCHIM BIOPHYS ACTA, V965, P9, DOI 10.1016/0304-4165(88)90144-4; Werner-Felmayer G, 1996, METHODS NITRIC OXIDE, P271; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; Yoneyama T, 1997, J BIOL CHEM, V272, P9690	20	43	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21091	21098		10.1074/jbc.273.33.21091	http://dx.doi.org/10.1074/jbc.273.33.21091			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694862	hybrid			2022-12-25	WOS:000075386100055
J	Dickens, M; Svitek, CA; Culbert, AA; O'Brien, RM; Tavare, JM				Dickens, M; Svitek, CA; Culbert, AA; O'Brien, RM; Tavare, JM			Central role for phosphatidylinositide 3-kinase in the repression of glucose-6-phosphatase gene transcription by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; ACTIVATED PROTEIN-KINASE; FACTOR-BINDING PROTEIN-1; MAP KINASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; PEPCK GENE; EXPRESSION; INHIBITION; RAPAMYCIN; RECEPTOR	Transcription of the gene encoding the catalytic subunit of glucose-6-phosphatase (G6Pase) is stimulated by glucocorticoids and strongly repressed by insulin. We have explored the signaling pathways by which insulin mediates the repression of G6Pase transcription in H4IIE cells. Wortmannin, a phosphatidylinositide 3-kinase (PtdIns 3-kinase) inhibitor blocked the repression of G6Pase mRNA expression by insulin. However, both rapamycin, which inhibits p70S6 kinase activation, and PD98059, an inhibitor of mitogen-activated protein kinase activation, were without effect. Insulin inhibited dexamethasone-induced luciferase expression from a transiently transfected plasmid that places the luciferase gene under the control of the G6Pase promoter. This effect of insulin was mimicked by the overexpression of a constitutively active PtdIns 3-kinase but not by a constitutively active protein kinase B. Taken together, these data demonstrate that PtdIns 3-kinase activation is both necessary and at least partly sufficient for the repression of G6Pase expression by insulin, but neither mitogen-activated protein kinase nor p70S6 kinase are involved. In addition, activation of protein kinase B alone is not sufficient for repression of the G6Pase gene. These results imply the existence of a novel signaling pathway downstream of PtdIns 3 kinase that is involved in the regulation of G6Pase expression by insulin.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	University of Bristol; Vanderbilt University	Tavare, JM (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.	j.tavare@bristol.ac.uk	Dickens, Martin/B-2001-2012					Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FERRARI S, 1993, J BIOL CHEM, V268, P16091; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P736, DOI 10.1210/en.134.2.736; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; Schmoll D, 1996, FEBS LETT, V383, P63, DOI 10.1016/0014-5793(96)00224-4; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TOKER A, 1994, J BIOL CHEM, V269, P32358; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Welsh GI, 1997, ANAL BIOCHEM, V244, P16, DOI 10.1006/abio.1996.9838; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015	43	78	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20144	20149		10.1074/jbc.273.32.20144	http://dx.doi.org/10.1074/jbc.273.32.20144			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685358	hybrid			2022-12-25	WOS:000075305400035
J	Hess, JA; Ji, QS; Carpenter, G; Exton, JH				Hess, JA; Ji, QS; Carpenter, G; Exton, JH			Analysis of platelet-derived growth factor-induced phospholipase D activation in mouse embryo fibroblasts lacking phospholipase C-gamma 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL-LIPID HYDROLYSIS; SWISS 3T3 CELLS; SIGNAL TRANSDUCTION; FACTOR RECEPTOR; PHOSPHATIDYLCHOLINE HYDROLYSIS; FACTOR INCREASES; KINASE-ACTIVITY; C ACTIVATION; STIMULATION; DIACYLGLYCEROL	Platelet-derived growth factor (PDGF) activates phospholipase D (PLD) in mouse embryo fibroblasts (MEFs). In order to investigate a role for phospholipase C-yl (PLC-gamma 1), we used targeted disruption of the Plcg1 gene in the mouse to develop Plcg1(+/+) and Plcg1(-/-) cell lines. Plcg1(+/+) MEFs treated with PDGF showed a time- and dose-dependent increase in the production of total inositol phosphates that was substantially reduced in Plcg1(-/-) cells, PLcg1(+/+) cells also showed a PDGF-induced increase in PLD activity that had a similar dose dependence to the PLC response but was down-regulated after 15 min. Phospholipase D activity, however, was markedly reduced in PLcg1(-/-) cells. The PDGF-induced inositol phosphate formation and the FLD activity that remained in the Plcg1(-/-) cells could be attributed to the presence of phospholipase C-gamma 2 (PLC-gamma S) in the Plcg1(-/-) cells, The PLC-gamma 2 expressed ire the Plcg1(-/-) cells was phosphorylated on tyrosine in response to PDGF treatment, and a small but significant fraction of the Plcg1(-/-) cells showed Ca2+ mobilization in response to PDGF, suggesting that the PLC-gamma 2 expressed in the Plcg1(-/-) cells was activated in response to PDGF. The inhibition of PDGF-induced phospholipid hydrolysis in Plcg1(-/-) cells was not due to differences in the level of PDGF receptor or in the ability of PDGF to cause autophosphorylation of the receptor. Upon treatment of the Plcg1(-/-) cells with oleoyalacetylglycerol and the Ca2+ ionophore ionomycin to mimic the effect of PLC-gamma 1, PLD activity was restored. The targeted disruption of Plcg1 did not result in universal changes in the cell signaling pathways of Plcg(1-/)- cells, because the phosphorylation of mitogen-activated protein kinase was similar in PLcg1(+/+) and Plcg1(-/-) cells. Because increased plasma membrane ruffles occurred in both Plcg1(+/+) and Pbcg1(-/-) cells following PDGF treatment, it is possible neither PLC nor PLD are necessary for this growth factor response. In summary, these data indicate that PLC-gamma is required for growth factor-induced activation of PLD in MEFs.	Vanderbilt Univ, Dept Physiol & Mol Biophys, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Dept Physiol & Mol Biophys, Sch Med, Nashville, TN 37232 USA.	john.exton@mcmail.vanderbilt.edu			NATIONAL CANCER INSTITUTE [R01CA075195] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA75195] Funding Source: Medline; PHS HHS [T32KD07061-24] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHMED A, 1994, AM J PHYSIOL, V266, pC206, DOI 10.1152/ajpcell.1994.266.1.C206; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BENAV P, 1993, EUR J BIOCHEM, V215, P455, DOI 10.1111/j.1432-1033.1993.tb18054.x; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COOK SJ, 1992, BIOCHEM J, V285, P247, DOI 10.1042/bj2850247; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; delPeso L, 1997, BIOCHEM J, V322, P519; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; HA KS, 1993, J BIOL CHEM, V268, P10534; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; Heller M, 1978, Adv Lipid Res, V16, P267; Hess JA, 1997, J BIOL CHEM, V272, P1615, DOI 10.1074/jbc.272.3.1615; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; Kim BY, 1996, BBA-MOL CELL RES, V1311, P33; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; Min DS, 1998, J BIOL CHEM, V273, P7044, DOI 10.1074/jbc.273.12.7044; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PLEVIN R, 1992, BIOCHEM J, V279, P559; Rani CSS, 1997, J BIOL CHEM, V272, P10777; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SIMPSON CMF, 1987, NEUROCHEMISTRY PRACT, P193; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TOTZKE F, 1992, FEBS LETT, V308, P125, DOI 10.1016/0014-5793(92)81258-N; vanDijk MCM, 1997, J BIOL CHEM, V272, P11011; WAKELAM MJO, 1993, BIOCHEM SOC T, V21, P873; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; YEO EJ, 1994, J BIOL CHEM, V269, P27823	42	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20517	20524		10.1074/jbc.273.32.20517	http://dx.doi.org/10.1074/jbc.273.32.20517			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685408	hybrid			2022-12-25	WOS:000075305400085
J	Krueger, S; Gorshkova, I; Brown, J; Hoskins, J; McKenney, KH; Schwarz, FP				Krueger, S; Gorshkova, I; Brown, J; Hoskins, J; McKenney, KH; Schwarz, FP			Determination of the conformations of cAMP receptor protein and its T127L,S128A mutant with and without cAMP from small angle neutron scattering measurements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE BINDING; GENE ACTIVATOR PROTEIN; ESCHERICHIA-COLI; RESOLUTION; MECHANISM; MUTATIONS; DNA	Small angle neutron scattering (SANS) measurements were performed on solutions of cAMP receptor protein (CRP) and on solutions of the T127L,S128A double mutant of CRP (CRPQ*) in D2O K3PO4 buffer containing 0.5 M KCI, in the absence and presence of 3',5' cyclic adenosine monophosphate (cAMP). Energy-minimized structures of the CRP were calculated by minimization of the x-ray crystallographic structure of CRP in either the exclusively "closed" form where the alpha-helices of the carboxyl-terminal domain are folded close to the amino-terminal domain and in the exclusively "open" form where the alpha-helices of the carboxyl-terminal domain are folded away from the amino-terminal domain. Neutron scattering models show that the CRP SANS data follow closely the data curve predicted for unligated CRP in the open form, whereas the cAMP-ligated data are more in agreement with the data predicted for the minimized cAMP-ligated CRP structure in the closed form, Thus, it appears that CRP undergoes a conformational change from the open form to the closed form in solution upon ligation with cAMP. The SANS data from the CRP* and cAMP-ligated CRP*: are coincidental, which implies that there is very little structural difference between the two species of CRP*. This is in agreement with in vivo results, which show that whereas CRP activates transcription in the cell only in the presence of cAMP, CRP* activates transcription in the absence of cAMP, implying that CRP* is already in the correct conformation for the activation of transcription.	NIST, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; NIST, Ctr Neutron Res, Gaithersburg, MD 20899 USA	National Institute of Standards & Technology (NIST) - USA; National Institute of Standards & Technology (NIST) - USA	Schwarz, FP (corresponding author), NIST, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA.							CHENG XD, 1995, BIOCHEMISTRY-US, V34, P10816, DOI 10.1021/bi00034a014; DEGRAZIA H, 1990, BIOCHEMISTRY-US, V29, P3557, DOI 10.1021/bi00466a019; Garcia AE, 1996, PROTEIN SCI, V5, P62; GARGES S, 1988, J BACTERIOL, V170, P1417, DOI 10.1128/jb.170.4.1417-1422.1988; GHOSAINI LR, 1988, BIOCHEMISTRY-US, V27, P5257, DOI 10.1021/bi00414a046; GLATTER O, 1977, J APPL CRYSTALLOGR, V10, P415, DOI 10.1107/S0021889877013879; GORSHKOVA I, 1995, J BIOL CHEM, V270, P21679, DOI 10.1074/jbc.270.37.21679; GRONENBORN AM, 1982, BIOCHEMISTRY-US, V21, P4040, DOI 10.1021/bi00260a020; GRUINIER A, 1955, SMALL ANGLE SCATTERI; HAMMOUDA B, 1993, J RES NATL INST STAN, V98, P31, DOI 10.6028/jres.098.003; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HEYDUK E, 1992, J BIOL CHEM, V267, P3200; HINDS MG, 1992, BIOCHEM J, V287, P627, DOI 10.1042/bj2870627; KUMAR SA, 1980, FEBS LETT, V109, P121, DOI 10.1016/0014-5793(80)81324-X; KYPR J, 1985, BIOCHEM BIOPH RES CO, V131, P780, DOI 10.1016/0006-291X(85)91307-5; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; Moore JL, 1996, J BIOL CHEM, V271, P21273, DOI 10.1074/jbc.271.35.21273; MOORE JL, 1993, THESIS G WASHINGTON; PEDERSEN JS, 1990, J APPL CRYSTALLOGR, V23, P321, DOI 10.1107/S0021889890003946; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; TIMMINS PA, 1988, EUR BIOPHYS J BIOPHY, V15, P257, DOI 10.1007/BF00256476; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9	23	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20001	20006		10.1074/jbc.273.32.20001	http://dx.doi.org/10.1074/jbc.273.32.20001			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685337	hybrid			2022-12-25	WOS:000075305400014
J	Larcher, F; Murillas, R; Bolontrade, M; Conti, CJ; Jorcano, JL				Larcher, F; Murillas, R; Bolontrade, M; Conti, CJ; Jorcano, JL			VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development	ONCOGENE			English	Article						angiogenesis; skin carcinogenesis; epidermis; transgenic mice	ENDOTHELIAL GROWTH-FACTOR; V-HA-RAS; RECEPTOR TYROSINE KINASE; MOUSE SKIN; PERMEABILITY FACTOR; MALIGNANT PROGRESSION; EPIDERMAL-KERATINOCYTES; ALPHA-6-BETA-4 INTEGRIN; FACTOR EXPRESSION; CARCINOGENESIS	Upregulation of keratinocyte-derived VEGF-A expression has recently been established in non-neoplastic processes of skin such as wound healing, blistering diseases and psoriasis, as well as in skin neoplasia, To further characterize the effects of VEGF-A in skin in vivo, we have developed transgenic mice expressing the mouse VEGF(120) under the control of a 2,4 kb 5' fragment of keratin K6 gene regulatory sequences that confers transgene inducibility upon hyperproliferative stimuli. As expected from the inducible nature of the transgene, two of the three founder mice obtained (V27 and V208), showed no apparent phenotype, However, one founder (V2), mosaic for transgene integration, developed scattered red spots throughout the skin at birth, The transgenic offspring derived from this founder developed a striking phenotype characterized by swelling and erythema, resulting in early postnatal lethality. Histological examination of the skin of these transgenics demonstrated highly increased vascularization and edema leading to disruption of skin architecture. Expression of the transgene was silent in adult animals of lines derived from founders V27 and V208, Phorbol ester-induced hyperplasia resulted in transgene induction and increased cutaneous vascularization in adult transgenic mice of these lines. Skin carcinogenesis experiments performed on hemizygous crosses of V208 mice with activated H-ras-carrying transgenic mice (TG.AC) resulted in accelerated papilloma development and increased tumor burden. Previous results from our laboratory showed that VEGF upregulation is a major angiogenic stimulus in mouse epidermal carcinogenesis. By overexpressing VEGF in the skin of transgenic mice we now move a step further toward showing that VEGF mediated angiogenesis is a rate-limiting step in the genesis of premalignant lesions, such as mouse skin papilloma, Our transgenic mice constitute an interesting :model system for in vivo study of the cutaneous angiogenic process and its relevance in tumorigenesis and other skin diseases.	Ctr Invest Energet Mediamnientales & Tecnol, Dept Cell & Mol Biol, Madrid 28040, Spain; Univ Texas, Md Anderson Canc Ctr, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Jorcano, JL (corresponding author), Ctr Invest Energet Mediamnientales & Tecnol, Dept Cell & Mol Biol, Madrid 28040, Spain.		Larcher, Fernando/J-1527-2016; MURILLAS, RODOLFO/H-8121-2017	Larcher, Fernando/0000-0002-6771-3561; MURILLAS, RODOLFO/0000-0001-9813-1006; Bolontrade, Marcela/0000-0002-8664-5541	NATIONAL CANCER INSTITUTE [R01CA076540] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1987, P NATL ACAD SCI USA, V84, P2029, DOI 10.1073/pnas.84.7.2029; ALDAZ CM, 1988, CANCER RES, V48, P3253; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; BALLAUN C, 1995, J INVEST DERMATOL, V104, P7, DOI 10.1111/1523-1747.ep12613450; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1995, J INVEST DERMATOL, V104, P744, DOI 10.1111/1523-1747.ep12606974; Cano A, 1996, INT J CANCER, V65, P254; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Detmar M, 1996, J INVEST DERMATOL, V106, P207, DOI 10.1111/1523-1747.ep12340457; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DETMAR M, 1995, J INVEST DERMATOL, V105, P44, DOI 10.1111/1523-1747.ep12312542; FERRARA N, 1996, EUR J CANCER, V32, P2143; FERRARA N, 1996, NATURE, V380, P389; FLAMME I, 1995, DEV BIOL, V171, P399, DOI 10.1006/dbio.1995.1291; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FOWLIS D, 1996, CELL GROWTH DIFFER, V3, P81; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GIMENEZCONTI I, 1990, CARCINOGENESIS, V11, P1995, DOI 10.1093/carcin/11.11.1995; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOMEZ M, 1992, EXP CELL RES, V201, P250, DOI 10.1016/0014-4827(92)90272-A; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; HANNAHAN D, 1996, CELL, V86, P353; HANSEN LA, 1994, P NATL ACAD SCI USA, V91, P7822, DOI 10.1073/pnas.91.16.7822; HOGAN B, 1986, MANIPULATING MOUSE E; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; Larcher F, 1996, CANCER RES, V56, P5391; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; MALHOTRA R, 1989, LAB INVEST, V61, P162; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MORBIDELLI L, 1998, IN PRESS ANGIOGENEIS, V1; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; RAK J, 1995, CANCER RES, V55, P4575; Ramirez A, 1998, DNA CELL BIOL, V17, P177, DOI 10.1089/dna.1998.17.177; RAMIREZ A, 1995, P NATL ACAD SCI USA, V92, P4783, DOI 10.1073/pnas.92.11.4783; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schweizer Juergen, 1993, P33; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; SmithMcCune K, 1997, CANCER RES, V57, P1294; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; TENNENBAUM T, 1993, CANCER RES, V53, P4803; WANG XJ, 1995, ONCOGENE, V10, P279; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; YUSPA SH, 1994, CANCER RES, V54, P1178	58	185	199	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					303	311		10.1038/sj.onc.1201928	http://dx.doi.org/10.1038/sj.onc.1201928			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690512				2022-12-25	WOS:000074947500005
J	von Knethen, A; Lotero, A; Brune, B				von Knethen, A; Lotero, A; Brune, B			Etoposide and cisplatin induced apoptosis in activated RAW264.7 macrophages is attenuated by cAMP-induced gene expression	ONCOGENE			English	Article						cisplatin; etoposide; resistance; macrophages; p53; cAMP	PROSTAGLANDIN-H SYNTHASE-2; OXIDE-INDUCED APOPTOSIS; CELL-DEATH; CYCLOOXYGENASE EXPRESSION; INDUCIBLE CYCLOOXYGENASE; ALVEOLAR MACROPHAGES; TRANSCRIPTION FACTOR; THYMOCYTE APOPTOSIS; COLORECTAL-CANCER; DNA-REPAIR	Previous observations suggest expression of cyclooxygenase-2 to convey macrophage protection towards apoptotic cell death. We reasoned prostaglandin formation and in turn a cAMP increase as the underlying protective principle. Here we report that exposure of macrophages to lipopolysaccharide/interferon-gamma or lipophilic cAMP analogs such as dibutyryl-cAMP or 8-bromo-cAMP for 15 h attenuated DNA fragmentation and accumulation of the tumor suppressor p53 in response to the chemotherapeutic agents cisplatin and etoposide, compared to cells that received chemotherapeutic agents only. In contrast, a Ih lasting preexposure period revealed no protection. The demand for a long incubation period with cAMP-derivates implied cAMP-mediated gene activation as the underlying principle, Therefore, we treated cells with oligonucleotides containing a cAMP-response element (CRE) binding site. Using this decoy-approach we scavanged activated cAMP response element binding protein prior to its promoter activating ability. Incubating macrophages with decoy, but not with control oligonucleotides, reduced cAMP evoked protection and simultanously restored p53 accumulation in response to chemotherapeutic agents. Our studies demonstrate that cAMP-initiated gene activation regulates the sensitivity towards DNA damaging agents via inhibition of a p53 dependent pathway.	Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, D-91054 Erlangen, Germany; Univ Alcala de Henares, Fac Med, Dept Biochem & Mol Biol, Alcala De Henares 28871, Spain	University of Erlangen Nuremberg; Universidad de Alcala	Brune, B (corresponding author), Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, Loschgestr 8, D-91054 Erlangen, Germany.							ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; Brune B, 1996, BIOCHEM BIOPH RES CO, V229, P396, DOI 10.1006/bbrc.1996.1816; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; Chen ZH, 1996, CANCER RES, V56, P5224; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; DiBattista JA, 1997, J CELL BIOCHEM, V65, P408, DOI 10.1002/(SICI)1097-4644(19970601)65:3<408::AID-JCB10>3.3.CO;2-H; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DuBois RN, 1996, CANCER RES, V56, P733; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Eischen Christine M., 1997, Blood, V90, P935; Fladmark KE, 1997, BIOCHEM BIOPH RES CO, V232, P20, DOI 10.1006/bbrc.1997.6214; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; Fulda S, 1997, CANCER RES, V57, P3823; Gallagher WM, 1997, ONCOGENE, V14, P185; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; Karim S, 1997, BIOCHEM J, V326, P593, DOI 10.1042/bj3260593; KAUFMANN WK, 1993, FASEB J, V7, P1188, DOI 10.1096/fasebj.7.12.8375618; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1992, J BIOL CHEM, V267, P25934; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJNO G, 1995, AM J PATHOL, V146, P3; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MCDONNELL TJ, 1995, SEMIN CANCER BIOL, V6, P53, DOI 10.1006/scbi.1995.0007; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSULLIVAN MG, 1992, BIOCHEM BIOPH RES CO, V187, P1123, DOI 10.1016/0006-291X(92)91313-F; Pang LH, 1997, BIOCHEM PHARMACOL, V53, P493, DOI 10.1016/S0006-2952(96)00737-X; Perego P, 1996, CANCER RES, V56, P556; PETERSON HI, 1983, INVAS METAST, V3, P151; Quinn MR, 1996, IMMUNOL LETT, V50, P185, DOI 10.1016/0165-2478(96)02542-4; Ramanathan RK, 1997, SEMIN ONCOL, V24, P440; REDDY BS, 1987, CANCER RES, V47, P5340; REDDY ST, 1994, J BIOL CHEM, V269, P15473; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; Ruchaud S, 1997, ONCOGENE, V15, P827, DOI 10.1038/sj.onc.1201248; Sandler AB, 1997, SEMIN ONCOL, V24, P463; SANO H, 1995, CANCER RES, V55, P3785; SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Sharma HW, 1996, ANTICANCER RES, V16, P589; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Torgersen KM, 1997, J BIOL CHEM, V272, P5495, DOI 10.1074/jbc.272.9.5495; Tortora G, 1997, P NATL ACAD SCI USA, V94, P12586, DOI 10.1073/pnas.94.23.12586; Tortora G, 1997, CANCER RES, V57, P5107; Trump BF, 1997, TOXICOL PATHOL, V25, P82, DOI 10.1177/019262339702500116; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VASSAULT A, 1983, METHOD ENZYMAT AN, V1, P118; VonKnethen A, 1997, FASEB J, V11, P887; Walker BAM, 1997, J IMMUNOL, V158, P2926; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang YM, 1996, ONCOGENE, V12, P2223; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7; ZHANG F, 1995, BIOCHEM J, V312, P135, DOI 10.1042/bj3120135	73	53	54	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	1998	17	3					387	394		10.1038/sj.onc.1201926	http://dx.doi.org/10.1038/sj.onc.1201926			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690520				2022-12-25	WOS:000074947500013
J	Migdal, M; Huppertz, B; Tessler, S; Comforti, A; Shibuya, M; Reich, R; Baumann, H; Neufeld, G				Migdal, M; Huppertz, B; Tessler, S; Comforti, A; Shibuya, M; Reich, R; Baumann, H; Neufeld, G			Neuropilin-1 is a placenta growth factor-2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VEIN ENDOTHELIAL-CELLS; EXON 7-ENCODED DOMAIN; HIGH-AFFINITY BINDING; TYROSINE KINASE; FACTOR VEGF; PLASMINOGEN-ACTIVATOR; SIGNAL-TRANSDUCTION; IN-VIVO; FLT-1; IDENTIFICATION	Placenta growth factor (PIGF) belongs to the family of vascular endothelial growth factors (VEGFs). It binds to the flt-1 VEGF receptor but not to the KDR/flk-1 receptor which is thought to mediate most of the angiogenic and proliferative effects of VEGF, Three PIGF isoforms are produced by alternative splicing. PlGF-1 and PlGF-3 differ from PlGF-2 since they lack the exon 6 encoded peptide which bestows upon PlGF-2 its heparin binding properties. Cross-linking experiments revealed that I-125-PlGF-2 binds to two endothelial cell surface receptors in a heparin dependent fashion. The binding of I-125-PlGF-2 to these receptors was inhibited by an excess of PlGF-2 and by the 165-amino acid form of VEGF (VEGF(165)), but not at all by VEGF(165) and very marginally if at all by PlGF-1, The apparent molecular weight and the binding characteristics of these receptors correspond to those of the recently identified VEGF(165) specific receptor neuropilin-1, and we therefore conclude that neuropilin-1 is a receptor for PlGF-2. The binding of I-125-PlGF-2 as well as the binding of I-125-VEGF(165) to these receptors was inhibited by a synthetic peptide derived from exon 6 of PlGF. Furthermore, the binding of I-125-PIGF-2, but not that of I-125-VEGF(165), was also inhibited by a synthetic peptide derived from exon 7 of PlGF. These observations indicate that the peptides encoded by these exons probably participate in the formation of the domain which mediates the binding of PlGF-2 to these receptors, We have also determined, using chemically modified heparin species, that the presence of sulfate moieties on the glucosamine-O-6 and on the iduronic acid-O-2 groups of heparin was required for the potentiation of I-125-PlGF-2 binding to these receptors. To determine if PlGF-2 is able to induce biological responses that are not induced by PlGF-1, we compared the effects of PlGF-1 and PlGF-2 on the migration and proliferation of endothelial cells. Both PlGF forms induced migration of endothelial cells. However, there was no quantitative difference between the response to PIGF-2 and the response to PIGF-1. Furthermore, neither PIGF-1 nor PlGF-2 had any effect upon the proliferation of the endothelial cells.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Hebrew Univ Jerusalem, Dept Pharmacol, IL-91120 Jerusalem, Israel; RWTH Aachen, D-52074 Aachen, Germany; Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 108, Japan	Technion Israel Institute of Technology; Hebrew University of Jerusalem; University of Tokyo	Neufeld, G (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	gera@techunix.technion.ac.il	Neufeld, Gera/F-1524-2019					AYOTTE L, 1986, CARBOHYD RES, V145, P267, DOI 10.1016/S0008-6215(00)90434-8; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Cao YH, 1997, BIOCHEM BIOPH RES CO, V235, P493, DOI 10.1006/bbrc.1997.6813; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; CASU B, 1983, ARZNEIMITTELFORSCH, V33-1, P135; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DETHLEFSEN SM, 1994, INVAS METAST, V14, P395; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HUPPERTZ B, 1998, IN PRESS FRONTIERS B, V2; Jonca F, 1997, J BIOL CHEM, V272, P24203, DOI 10.1074/jbc.272.39.24203; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kodama J, 1997, EUR J GYNAECOL ONCOL, V18, P508; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Malinda KM, 1997, FASEB J, V11, P474, DOI 10.1096/fasebj.11.6.9194528; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Neufeld G, 1996, CANCER METAST REV, V15, P153, DOI 10.1007/BF00437467; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; PARK JE, 1994, J BIOL CHEM, V269, P25646; QU ZH, 1995, AM J PATHOL, V147, P564; REICH R, 1988, CANCER RES, V48, P3307; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; TAKAHASHI A, 1994, CANCER RES, V54, P4233; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Yates EA, 1996, CARBOHYD RES, V294, P15; Ziche M, 1997, LAB INVEST, V76, P517	48	258	275	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22272	22278		10.1074/jbc.273.35.22272	http://dx.doi.org/10.1074/jbc.273.35.22272			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712843	hybrid			2022-12-25	WOS:000075616600019
J	Mills, EM; Takeda, K; Yu, ZX; Ferrans, V; Katagiri, Y; Jiang, H; Lavigne, MC; Leto, TL; Guroff, G				Mills, EM; Takeda, K; Yu, ZX; Ferrans, V; Katagiri, Y; Jiang, H; Lavigne, MC; Leto, TL; Guroff, G			Nerve growth factor treatment prevents the increase in superoxide produced by epidermal growth factor in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; SIGNAL-TRANSDUCTION; FACTOR RECEPTORS; RAS; GENERATION; PATHWAYS; RESPOND; KINASE; LIPIDS; LINE	Stimulation of pheochromocytoma (PC12) cells with the mitogen epidermal growth factor (EGF) produced a rapid and robust accumulation of intracellular reactive oxygen species (ROS), an accumulation which, in other systems, has been shown to be essential for mitogenesis, Brief pretreatment of the cells with nerve growth factor (NGF) suppressed the EGF-mediated ROS increase. EGF failed to produce elevations in ROS in a PC12 variant stably expressing a dominant-negative p2(ras) construct (PC12-N17) or in cells pretreated with the MEK inhibitor PD098059, NGF failed to suppress the increase in ROS in the PC12 variant nnr5, which lacks p140(trk) receptors, The suppression of the increase in ROS by NGF was restored in nnr5 cells stably expressing p140(trk) (nnr5-trk), but NGF failed to prevent the increase in ROS in nnr cells expressing mutant p140(trk) receptors that lack binding sites for Shc and phospholipase C gamma, Among several inhibitors of superoxide-generating enzymes, only the lipoxygenase inhibitor, nordihydroguaiaretic acid reduced EGF-mediated ROS accumulation. The inhibitory action of NGF on ROS production was mimicked by the nitric oxide donor, sodium nitroprusside, and was blocked by an inhibitor of nitric-oxide synthetase, L-nitroarginine methyl ester, These results suggest a novel mechanism for the rapid interruption of mitogenic signaling by the neurotrophin NGF.	NICHD, Growth Factors Sect, NIH, Bethesda, MD 20892 USA; NHLBI, Pathol Sect, Bethesda, MD 20892 USA; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Guroff, G (corresponding author), NICHD, Growth Factors Sect, NIH, Bldg 49,Rm 5A64, Bethesda, MD 20892 USA.	gordong@helix.nih.gov						Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BROWN AB, 1991, J NEUROCHEM, V57, P1740, DOI 10.1111/j.1471-4159.1991.tb06376.x; BURSTEIN DE, 1982, DEV BIOL, V94, P477, DOI 10.1016/0012-1606(82)90364-5; Chen BK, 1997, BBA-LIPID LIPID MET, V1344, P270, DOI 10.1016/S0005-2760(96)00151-8; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P4086, DOI 10.1073/pnas.94.8.4086; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Lazarovici P, 1997, J BIOL CHEM, V272, P11026, DOI 10.1074/jbc.272.17.11026; Maccarrone M, 1996, BIOCHEM BIOPH RES CO, V219, P128, DOI 10.1006/bbrc.1996.0193; MOTHE I, 1993, MOL BIOL CELL, V4, P737, DOI 10.1091/mbc.4.7.737; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RALASCA M, 1995, ONCOGENE, V10, P2113; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Shibutani M, 1998, J BIOL CHEM, V273, P6878, DOI 10.1074/jbc.273.12.6878; STEPHENS RM, 1994, NEURON, V12, P791; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683	25	59	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22165	22168		10.1074/jbc.273.35.22165	http://dx.doi.org/10.1074/jbc.273.35.22165			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712826	hybrid			2022-12-25	WOS:000075616600002
J	Ishiguro, H; Yamada, K; Ichino, N; Nagatsu, T				Ishiguro, H; Yamada, K; Ichino, N; Nagatsu, T			Identification and characterization of a novel phorbol ester-responsive DNA sequence in the 5 '-flanking region of the human dopamine beta-hydroxylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATOR YY1; BINDING PROTEIN; CYCLIC-AMP; SOMATOSTATIN GENE; PROXIMAL PROMOTER; SILENCER ELEMENT; GLOBIN GENE; EXPRESSION; REPRESSION; CELLS	The phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), enhances transcription of many eukaryotic genes, including that for dopamine P-hydroxylase (DBH). In the present study, we report identification and characterization of a novel sequence motif residing in the 5'-flanking region of the human DBH gene, which mediates transcriptional induction by TPA. Deletional analyses indicated the promoter region between -223 and -187 base pairs to be critical. Whereas this region does not contain any putative regulatory motifs with significant sequence homology to the AP-1 motif, extensive deletional and site-directed mutational analyses indicated that a sequence between -210 and -199 base pairs, B'-ATCCGCCTGTCT-3', may represent a novel TPA-response element (TRE), In addition, alteration of the YY1-binding site decreased TPA-mediated induction of the DBH promoter activity, suggesting that contiguous cis-regulatory element(s) cooperate with this novel sequence motif, Furthermore, insertional mutation analyses between the YY1-binding site and the cyclic AMP-responsive element indicated that the stereospecificity of these motifs is important for intact transcriptional induction by TPA, Taken together, these data suggest that transcriptional up-regulation of the human DBH gene in response to TPA requires coordination of a novel TRE (human DBH TRE, hDTRE), cyclic AMP-responsive element, and the YY1-binding site.	Fujita Hlth Univ, Inst Comprehens Med Sci, Toyoake, Aichi 4701192, Japan	Fujita Health University	Nagatsu, T (corresponding author), Fujita Hlth Univ, Inst Comprehens Med Sci, Toyoake, Aichi 4701192, Japan.	tnagatsu@fujita-hu.ac.jp						Afar R, 1996, MOL BRAIN RES, V36, P79, DOI 10.1016/0169-328X(95)00247-P; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; BAUKNECHT T, 1992, EMBO J, V11, P4607, DOI 10.1002/j.1460-2075.1992.tb05563.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GASTON K, 1994, FEBS LETT, V347, P289, DOI 10.1016/0014-5793(94)00567-2; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRECO D, 1995, J NEUROCHEM, V65, P510; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; IANNELLO RC, 1993, J BIOL CHEM, V268, P22581; Ishiguro H, 1995, MOL BRAIN RES, V34, P251, DOI 10.1016/0169-328X(95)00170-W; ISHIGURO H, 1993, J BIOL CHEM, V268, P17984; Kim JS, 1996, NUCLEIC ACIDS RES, V24, P4341, DOI 10.1093/nar/24.21.4341; KIM KS, 1994, J NEUROSCI, V14, P7200; KIM KS, 1993, J BIOL CHEM, V268, P15689; KOBAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P1089, DOI 10.1093/nar/17.3.1089; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LAMOUROUX A, 1993, J NEUROCHEM, V60, P364, DOI 10.1111/j.1471-4159.1993.tb05861.x; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE YM, 1994, DNA CELL BIOL, V13, P1029, DOI 10.1089/dna.1994.13.1029; LIU R, 1994, NUCLEIC ACIDS RES, V22, P2453, DOI 10.1093/nar/22.13.2453; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MARGOLIS DM, 1994, J VIROL, V68, P905, DOI 10.1128/JVI.68.2.905-910.1994; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MOMOEDA M, 1994, J VIROL, V68, P7159, DOI 10.1128/JVI.68.11.7159-7168.1994; MONTALVO EA, 1991, J VIROL, V65, P3647, DOI 10.1128/JVI.65.7.3647-3655.1991; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PETERS B, 1993, J BIOL CHEM, V268, P3430; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Seo HM, 1996, J NEUROSCI, V16, P4102; SHASKUS J, 1995, J NEUROCHEM, V64, P52; SHASKUS J, 1992, J BIOL CHEM, V267, P18821; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; TODA K, 1994, J BIOL CHEM, V269, P8099; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264; WILLIAMS TM, 1989, ANAL BIOCHEM, V176, P28, DOI 10.1016/0003-2697(89)90267-4; Ye JP, 1996, MOL CELL BIOL, V16, P4744; YE JP, 1994, J BIOL CHEM, V269, P25728; YE JP, 1994, NUCLEIC ACIDS RES, V22, P5672, DOI 10.1093/nar/22.25.5672; YOST SE, 1993, MOL CELL BIOL, V13, P5439, DOI 10.1128/MCB.13.9.5439; Zellmer E, 1995, J NEUROSCI, V15, P8109	54	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21941	21949		10.1074/jbc.273.34.21941	http://dx.doi.org/10.1074/jbc.273.34.21941			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705334	hybrid			2022-12-25	WOS:000075492600068
J	Bein, K; Ware, JA; Simons, M				Bein, K; Ware, JA; Simons, M			Myb-dependent regulation of thrombospondin 2 expression - Role of mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; C-MYB; MESSENGER-RNA; ONCOGENE PRODUCT; PROTO-ONCOGENE; DNA-BINDING; FIBROBLASTS; GENE; PROLIFERATION; PROTOONCOGENE	The nuclear transcription factor c-Myb, which is highly expressed in hematopoietic cells, has been shown to be functional in NIH 3T3 cells: cells that do not possess detectable levels of c-Myb, To identify endogenous target genes of c-Myb in fibroblasts, RNA isolated from NIH 3T3 cells stably transfected with a full-length or a dominant negative c-myb construct (GREMyb and GREMEn, respectively) was subjected to differential display analysis, 5'-Rapid amplification of cDNA ends of a selected band, sequencing, and a nucleotide homology search led to the identification of thrombospondin 2 (TSP 2) as the gene product repressed in GREMyb and induced in GREMEn cells. The pattern of TSP 2 expression during the cell cycle was consistent with c-myb-dependent regulation. The possibility that the identified transcript was TSP I, a homologous product known to be repressed by v-Src, c-Jun, and v-Myc, was ruled out by using a TSP 2-specific DNA probe and by showing a distinct pattern of regulation of TSP 1 and TSP 2 expression. Nuclear run-on and TSP 2 promoter-reporter (chloramphenicol acetyltransferase) assays showed similar transcriptional levels in GREMyb and NIH 3T3 cells. However, mRNA stability studies showed a much shorter TSP 2 mRNA half-life in GREMyb compared with wild type NIH 3T3 cells, suggesting that c-myb affects TSP 2 expression via a post-transcriptional mechanism. The implications of a protooncogene-mediated suppression of TSP expression are discussed.	Beth Israel Deaconess Med Ctr, Div Cardiovasc, Angiogenesis Res Ctr, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Simons, M (corresponding author), Beth Israel Deaconess Med Ctr, Div Cardiovasc, Angiogenesis Res Ctr, Dept Med, RW-453,330 Brookline Ave, Boston, MA 02215 USA.		Simons, Michael/G-8553-2014	Simons, Michael/0000-0003-0348-7734; Bein, Kiflai/0000-0002-5206-0801	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056993, R01HL047032, R01HL053793] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-47032, R01-HL-53793, P50-HL56993] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARLETTA C, 1992, European Journal of Gynaecological Oncology, V13, P53; Bein K, 1997, J CELL PHYSIOL, V173, P319, DOI 10.1002/(SICI)1097-4652(199712)173:3<319::AID-JCP3>3.0.CO;2-Q; BELASO J, 1993, EXPT APPROACHES STUD, P475; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BROWN KE, 1992, J BIOL CHEM, V267, P4625; CATRON KM, 1992, J IMMUNOL, V148, P934; CHEN H, 1994, J BIOL CHEM, V269, P32226; DESBIENS X, 1991, DEVELOPMENT, V111, P699; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUERIN M, 1990, ONCOGENE, V5, P131; Husain M, 1997, AM J PHYSIOL-CELL PH, V272, pC1947, DOI 10.1152/ajpcell.1997.272.6.C1947; Husain M, 1997, CIRC RES, V80, P617, DOI 10.1161/01.RES.80.5.617; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; KANEIISHII C, 1994, J BIOL CHEM, V269, P15768; KENNEY SC, 1992, MOL CELL BIOL, V12, P136, DOI 10.1128/MCB.12.1.136; KU DH, 1993, J BIOL CHEM, V268, P2255; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lipsick JS, 1996, ONCOGENE, V13, P223; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; MUMBY SM, 1984, J CELL PHYSIOL, V120, P280, DOI 10.1002/jcp.1041200304; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J., 2002, MOL CLONING LAB MANU; SCHACHNER J, 1988, LEUKEMIA, V2, P749; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; SIMONS M, 1995, AM J PHYSIOL-CELL PH, V268, pC856, DOI 10.1152/ajpcell.1995.268.4.C856; Sitzmann J, 1995, ONCOGENE, V11, P2273; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; SZCZYLIK C, 1993, J EXP MED, V178, P997, DOI 10.1084/jem.178.3.997; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TORELLI G, 1987, CANCER RES, V47, P5266; TRAVALI S, 1991, ONCOGENE, V6, P887; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; Weston K M, 1990, Semin Cancer Biol, V1, P371; WINQVIST R, 1985, CANCER GENET CYTOGEN, V18, P251, DOI 10.1016/0165-4608(85)90090-1; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	55	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21423	21429		10.1074/jbc.273.33.21423	http://dx.doi.org/10.1074/jbc.273.33.21423			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694906	hybrid			2022-12-25	WOS:000075386100099
J	Kovalsky, OI; Grossman, L				Kovalsky, OI; Grossman, L			Accessibility of epitopes on UvrB protein in intermediates generated during incision of UV-irradiated DNA by the Escherichia coli Uvr(A)BC endonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; UVRABC ENDONUCLEASE; (A)BC EXCINUCLEASE; MONOCLONAL-ANTIBODIES; ENZYMATIC-PROPERTIES; PREINCISION COMPLEX; ATPASE ACTIVITY; DAMAGED DNA; BINDING; REGION	Structural intermediates generated during incision of damaged DNA by the Uvr(A)BC endonuclease were probed with monoclonal antibodies (mAbs) raised against the Escherichia coli UvrB protein. It was found that the epitope of B2C5 mAb, mapped at amino acids (aa) 171-278 of UvrB, is not accessible in any of the preformed Uvr intermediates. Preformed B2C5-UvrB immunocomplexes, however, inhibited formation of those intermediates. B2C5 mAb seems to interfere with the formation of the UvrA-UvrB complex due to overlapping of its epitope and the UvrA binding region of UvrB, Conversely, the epitope of B3C1 mAb (aa 1-7 and/or 62-170) was accessible in all Uvr intermediates. The epitope of B*2E3 mAb (aa 171-278) was not accessible in any of the nucleoprotein intermediates preceding UvrB-DNA preincision complex. However, B*2E3 was able to immunoprecipitate this complex and to inhibit overall incision. B2A1 mAb (aa 8-61) inhibited formation of those Uvr intermediates requiring ATP binding and/or hydrolysis by UvrB, B*2B9 mAb (aa 473-630) inhibited Uvr nucleoprotein complexes involving UvrB, B*2B9 seems to prevent the binding of the UvrA-UvrB complex to DNA, The epitope of the B*3E11 mAb (aa 379-472) was not accessible in Uvr complexes formed at damaged sites. These results are discussed in terms of structure-functional mapping of UvrB protein.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA	Johns Hopkins University	Grossman, L (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem, 615 N Wolfe St, Baltimore, MD 21205 USA.	lg@welchlink.welch.jhu.edu			NIGMS NIH HHS [GM 22846] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022846, R01GM022846] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN B, 1995, THESIS J HOPKINS U; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P10891, DOI 10.1093/nar/16.22.10891; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; Harlow E., 1988, ANTIBODIES LAB MANUA; HSU DS, 1995, J BIOL CHEM, V270, P8319, DOI 10.1074/jbc.270.14.8319; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; KOVALSKY OI, 1994, J BIOL CHEM, V269, P27421; Kovalsky OI, 1998, BBA-GENE STRUCT EXPR, V1397, P91, DOI 10.1016/S0167-4781(98)00002-5; Lin CLG, 1997, NUCLEIC ACIDS RES, V25, P3151, DOI 10.1093/nar/25.15.3151; LIN JJ, 1992, MOL MICROBIOL, V6, P2219, DOI 10.1111/j.1365-2958.1992.tb01398.x; LLOYD RS, 1995, DNA REPAIR MECH IMPA, P25; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; Moolenaar GF, 1995, J BIOL CHEM, V270, P30508, DOI 10.1074/jbc.270.51.30508; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3824, DOI 10.1021/bi00230a004; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; THIAGALINGAM S, 1993, J BIOL CHEM, V268, P18382; VANHOUTEN B, 1993, BIOESSAYS, V15, P51, DOI 10.1002/bies.950150108; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1992, J BIOL CHEM, V267, P6736; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	30	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21009	21014		10.1074/jbc.273.33.21009	http://dx.doi.org/10.1074/jbc.273.33.21009			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694852	hybrid			2022-12-25	WOS:000075386100045
J	Udalova, IA; Knight, JC; Vidal, V; Nedospasov, SA; Kwiatkowski, D				Udalova, IA; Knight, JC; Vidal, V; Nedospasov, SA; Kwiatkowski, D			Complex NF-kappa B interactions at the distal tumor necrosis factor promoter region in human monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA GENE; HUMAN TNF PROMOTER; IFN-BETA GENE; TRANSCRIPTIONAL ACTIVATION; VIRUS INDUCTION; CELL-LINE; LIPOPOLYSACCHARIDE; ELEMENT; MACROPHAGES; PROTEIN	We describe a dense cluster of DNA-protein interactions located 600 nucleotides upstream of the transcriptional start site of the human tumor necrosis factor (TNF) gene. This area was identified as being of potential importance for lipopolysaccharide-inducible TNF expression in the human monocyte cell line Mono Mac 6, based on reporter gene analysis of point mutations at a number of nuclear factor kappa B (NF-kappa B)-like motifs within the human TNF promoter region. The area contains two NF-kappa B sites, which are here shown by DNase I and methylation interference footprinting to flank a novel binding site. UV cross-linking studies reveal that the novel site can also bind NF-kappa B as well as an unknown protein(s) of approximately 40 kDa. We show that these three adjacent kappa B-binding sites differ markedly in their relative affinities for p50/p50, p65/p65, and p65/p50, yet this 39-nucleotide segment of DNA appears capable of binding up to three NF-kappa B heterodimers simultaneously. Reporter gene studies indicate that each element of the cluster contributes to lipopolysaccharide-induced transcriptional activation in Mono Mac 6 cells. These findings suggest that NF-kappa B acts in a complex manner to activate TNF transcription in human monocytes.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Dept Paediat, Oxford OX3 9DS, England; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow, Russia; Moscow State Univ, Belozersky Inst Physicochem Biol, Moscow, Russia; SAIC Frederick, Intramural Res Support Program, Frederick, MD 21702 USA	University of Oxford; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Lomonosov Moscow State University; Science Applications International Corporation (SAIC); SAIC-Frederick	Udalova, IA (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Dept Paediat, Oxford OX3 9DS, England.		Nedospasov, Sergei/C-3043-2018; Nedospasov, Sergei/L-1990-2015; Nedospasov, Sergei/J-5936-2013; Knight, Julian Charles/W-2399-2019; Knight, Julian/C-7242-2009; Nedospasov, Sergei/Q-7319-2016	Knight, Julian Charles/0000-0002-0377-5536; Knight, Julian/0000-0002-0377-5536; Udalova, Irina/0000-0002-6716-2528; Kwiatkowski, Dominic/0000-0002-5023-0176				BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BEUTLER B, 1992, TUMOR NECROSIS FACTO, P561; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; ECONOMOU JS, 1989, J EXP MED, V170, P321, DOI 10.1084/jem.170.1.321; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; HAAS JG, 1990, P NATL ACAD SCI USA, V87, P9563, DOI 10.1073/pnas.87.24.9563; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HENSEL G, 1989, LYMPHOKINE RES, V8, P347; JONGENEEL CV, 1992, TUMOR NECROSIS FACTO, P539; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KRAMER B, 1995, J BIOL CHEM, V270, P6577; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUPRASH DV, 1995, ONCOGENE, V11, P97; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; POPE RM, 1994, J CLIN INVEST, V94, P1449, DOI 10.1172/JCI117482; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; SANDALTZOPOULOS R, 1994, NUCLEIC ACIDS RES, V22, P1511, DOI 10.1093/nar/22.8.1511; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAKHOV AN, 1990, GENE, V95, P215, DOI 10.1016/0378-1119(90)90364-W; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950; Stuber F, 1996, J INFLAMM, V46, P42; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TREDE NS, 1995, J IMMUNOL, V155, P902; Tsai EY, 1996, MOL CELL BIOL, V16, P459; UDALOVA IA, 1995, DOKL AKAD NAUK+, V342, P413; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324; ZIEGLERHEITBROCK HWL, 1994, J BIOL CHEM, V269, P17001	33	115	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21178	21186		10.1074/jbc.273.33.21178	http://dx.doi.org/10.1074/jbc.273.33.21178			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694874	hybrid			2022-12-25	WOS:000075386100067
J	Viswanathan, A; Doetsch, PW				Viswanathan, A; Doetsch, PW			Effects of nonbulky DNA base damages on Escherichia coli RNA polymerase-mediated elongation and promoter clearance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCISION REPAIR; PYRBI OPERON EXPRESSION; TRANSCRIPTIONAL INITIATION; REITERATIVE TRANSCRIPTION; TEMPLATE DNA; STRAND; GENE; REPLICATION; MECHANISM; CLEAVAGE	DNA base damage products either formed spontaneously or as a result of exposure to various genotoxic agents were examined for their effects on Escherichia coli RNA polymerase-mediated transcription in vitro, Uracil, O-6-methylguanine (O-6-meG), and 8-oxoguanine (8-oxoG) were placed at specific sites downstream from the transcriptional start site on the transcribed strand of a duplex template under the control of the strong too promoter. In vitro, single-round transcription experiments carried out with purified E. coli RNA polymerase revealed efficient bypass at the three lesions examined and subsequent generation of full-length runoff transcripts. Transcript sequence analysis revealed that E, coli RNA polymerase inserted primarily adenine into the transcript opposite to uracil, uracil opposite to O-6-meG, and either adenine or cytosine opposite to 8-oxoG. Thus, a uracil in the DNA template resulted in a G-to-A transition mutation in the lesion bypass product whereas O-6-meG: produced a C-to-U transition mutation and 8-oxoG; generated either the correct transcriptional product or a C-to-A transversion mutation. When 8-oxoG was placed within close proximity to the transcriptional start site (within the region required for effective promoter clearance), a reduced of full-length, runoff transcript was observed, indicative of lower promoter clearance. Taken together, these results demonstrate that the DNA base damages studied here may exert significant in vivo effects on gene expression and DNA repair with respect to the production of mutant proteins (transcriptional mutagenesis), or decreased levels of expressed proteins.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Doetsch, PW (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.	medpwd@ernory.edu			NATIONAL CANCER INSTITUTE [R01CA073041] Funding Source: NIH RePORTER; NCI NIH HHS [CA73041] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; BOHR VA, 1987, CARCINOGENESIS, V8, P1333, DOI 10.1093/carcin/8.9.1333; BRIDGES BA, 1995, NATURE, V375, P741, DOI 10.1038/375741a0; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CHEN YH, 1993, J BIOL CHEM, V268, P5849; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; ELLINGER T, 1994, J MOL BIOL, V239, P455, DOI 10.1006/jmbi.1994.1388; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Hernandez VJ, 1996, J BIOL CHEM, V271, P18775, DOI 10.1074/jbc.271.31.18775; JACQUES JP, 1990, GENE DEV, V4, P1801, DOI 10.1101/gad.4.10.1801; Jin DJ, 1996, J BIOL CHEM, V271, P11659; LIU CG, 1994, GENE DEV, V8, P2904, DOI 10.1101/gad.8.23.2904; LIU J, 1995, MOL CELL BIOL, V15, P6729; Liu J, 1998, NUCLEIC ACIDS RES, V26, P1707, DOI 10.1093/nar/26.7.1707; Liu J, 1996, BIOCHEMISTRY-US, V35, P14999, DOI 10.1021/bi961455x; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; Qi FX, 1996, METHOD ENZYMOL, V273, P71; QI FX, 1995, J MOL BIOL, V254, P552, DOI 10.1006/jmbi.1995.0638; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SHI YB, 1988, J BIOL CHEM, V263, P527; SNOW ET, 1984, J BIOL CHEM, V259, P8095; TURNBOUGH CL, 1983, P NATL ACAD SCI-BIOL, V80, P368, DOI 10.1073/pnas.80.2.368; VOIGT JM, 1995, CARCINOGENESIS, V16, P1775, DOI 10.1093/carcin/16.8.1775; ZHOU W, 1993, P NATL ACAD SCI USA, V90, P6601, DOI 10.1073/pnas.90.14.6601	28	96	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21276	21281		10.1074/jbc.273.33.21276	http://dx.doi.org/10.1074/jbc.273.33.21276			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694887	hybrid			2022-12-25	WOS:000075386100080
J	Zierath, JR; Tsao, TS; Stenbit, AE; Ryder, JW; Galuska, D; Charron, MJ				Zierath, JR; Tsao, TS; Stenbit, AE; Ryder, JW; Galuska, D; Charron, MJ			Restoration of hypoxia-stimulated glucose uptake in GLUT4-deficient muscles by muscle-specific GLUT4 transgenic complementation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; INSULIN-INDUCED TRANSLOCATION; CELL-SURFACE GLUT4; OVEREXPRESSING GLUT4; EXERCISE INCREASES; RESPONSIVE TISSUES; INTRACELLULAR POOL; TRANSPORT ACTIVITY; PLASMA-MEMBRANE; MICE	To investigate whether GLUT4 is required for exercise/hypoxia-induced glucose uptake, we assessed glucose uptake under hypoxia and normoxia in extensor digitorum longus (EDL) and soleus muscles from GLUT4-deficient mice. In EDL and soleus from wild type control mice, hypoxia increased a-deoxyglucose uptake 2-3 fold. Conversely, hypoxia did not alter a-deoxyglucose uptake in either EDL or soleus from either male or female GLUT4-null mice. Next we introduced the fast-twitch skeletal muscle-specific MLC-GLUT4 transgene into GLUT4-null mice to determine whether changes in the metabolic milieu accounted for the lack of hypoxia-mediated glucose transport. Transgenic complementation of GLUT4 in EDL was sufficient to restore hypoxia-mediated glucose uptake. Soleus muscles from MLC-GLUT4-null mice were transgene-negative, and hypoxia-stimulated a-deoxyglucose uptake was not restored. Although ablation of GLUT4 in EDL did not affect normoxic glycogen levels, restoration of GLUT4 to EDL led to an increase in glycogen under hypoxic conditions. Male GLUT4-null soleus displayed reduced normoxic glycogen stores, but female null soleus contained significantly more glycogen under normoxia and hypoxia, Reduced normoxic levels of ATP and phosphocreatine were measured in male GLUT4-null soleus but not in EDL, However, transgenic complementation of GLUT4 prevented the decrease in hypoxic ATP and phosphocreatine levels noted in male GLUT4-null and control EDL. In conclusion, we have demonstrated that GLUT4 plays an essential role in the regulation of muscle glucose uptake in response to hypoxia, Because hypoxia is a useful model for exercise, our results suggest that stimulation of glucose transport in response to exercise in skeletal muscle is totally dependent upon GLUT4, Furthermore, the compensatory glucose transport system that exists in GLUT4-null soleus muscle is not sensitive to hypoxia/muscle contraction.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Karolinska Hosp, Dept Clin Physiol, S-17176 Stockholm, Sweden	Yeshiva University; Albert Einstein College of Medicine; Karolinska Institutet; Karolinska University Hospital	Charron, MJ (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Zierath, Juleen/0000-0001-6891-7497; Tsao, Tsu-Shuen/0000-0002-1041-9687	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58119] Funding Source: Medline; NIDDK NIH HHS [DK47425] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07491] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bao SC, 1997, METABOLISM, V46, P1349, DOI 10.1016/S0026-0495(97)90243-2; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; Brozinick JT, 1997, BIOCHEM J, V321, P75, DOI 10.1042/bj3210075; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; CARTEE GD, 1990, AM J PHYSIOL, V258, pE390, DOI 10.1152/ajpendo.1990.258.2.E390; CARTEE GD, 1992, AM J PHYSIOL, V263, pR70, DOI 10.1152/ajpregu.1992.263.1.R70; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CHARRON MJ, 1996, BIOCHEM SOC T, V25, P963; CODERRE L, 1995, J BIOL CHEM, V270, P27584, DOI 10.1074/jbc.270.46.27584; DOUEN AG, 1990, FEBS LETT, V261, P256, DOI 10.1016/0014-5793(90)80566-2; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GAO JP, 1994, J APPL PHYSIOL, V77, P1597, DOI 10.1152/jappl.1994.77.4.1597; HANSEN P, 1995, AM J PHYSIOL-CELL PH, V268, pC30, DOI 10.1152/ajpcell.1995.268.1.C30; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; HENRIKSEN EJ, 1989, AM J PHYSIOL, V256, pE662, DOI 10.1152/ajpendo.1989.256.5.E662; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HIRSHMAN MF, 1988, FEBS LETT, V238, P235, DOI 10.1016/0014-5793(88)80486-1; HOLLOSZY JO, 1965, J BIOL CHEM, V240, P3493; IDSTROM JP, 1986, BIOCHEM J, V233, P131, DOI 10.1042/bj2330131; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; Leturque A, 1996, DIABETES, V45, P23, DOI 10.2337/diabetes.45.1.23; LUND S, 1994, AM J PHYSIOL, V267, pE461, DOI 10.1152/ajpendo.1994.267.3.E461; LUND S, 1993, FEBS LETT, V330, P312, DOI 10.1016/0014-5793(93)80895-2; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; Roy D, 1996, BIOCHEM BIOPH RES CO, V223, P147, DOI 10.1006/bbrc.1996.0860; Stenbit AE, 1996, J CLIN INVEST, V98, P629, DOI 10.1172/JCI118833; TREADWAY JL, 1994, J BIOL CHEM, V269, P29956; Tsao TS, 1997, J CLIN INVEST, V100, P671, DOI 10.1172/JCI119579; Tsao TS, 1996, DIABETES, V45, P28, DOI 10.2337/diabetes.45.1.28; WALLBERGHENRIKS.H, 1987, ACTA PHYSL SCAND S, V131, P564; WALLBERGHENRIKSSON H, 1987, J BIOL CHEM, V262, P7665; WALLBERGHENRIKSSON H, 1988, J APPL PHYSIOL, V65, P909, DOI 10.1152/jappl.1988.65.2.909; WILSON CM, 1994, BIOCHEM J, V299, P755, DOI 10.1042/bj2990755; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; YOUN JH, 1994, AM J PHYSIOL-REG I, V267, pR888, DOI 10.1152/ajpregu.1994.267.4.R888; YOUN JH, 1991, AM J PHYSIOL, V260, pC555, DOI 10.1152/ajpcell.1991.260.3.C555; Zierath JB, 1997, DIABETES, V46, P215, DOI 10.2337/diabetes.46.2.215	43	27	29	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20910	20915		10.1074/jbc.273.33.20910	http://dx.doi.org/10.1074/jbc.273.33.20910			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694838	hybrid			2022-12-25	WOS:000075386100031
J	Ishigami, M; Swertfeger, DK; Granholm, NA; Hui, DY				Ishigami, M; Swertfeger, DK; Granholm, NA; Hui, DY			Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL CORONARY ANGIOPLASTY; ACTIVATED PROTEIN-KINASE; CYCLIN D1 EXPRESSION; PLASMA-LIPOPROTEINS; DENSITY-LIPOPROTEIN; TRANSGENIC MICE; INTIMAL HYPERPLASIA; CHOLESTEROL EFFLUX; ALZHEIMER-DISEASE; RECEPTOR	The anti-atherogenic effects of apolipoprotein (apo) E have been attributed to its ability to reduce plasma cholesterol level and to limit foam cell formation. The purpose of this study was to ascertain if apoE also may have cytostatic functions that could attenuate vascular occlusive diseases. Purified apoE inhibited smooth muscle cell migration directed to platelet-derived growth factor (PDGF) or oxidized LDL (oxLDL) (p < 0.0001). The purified apoE also suppressed PDGF- and oxLDL-induced smooth muscle cell proliferation (p < 0.001). These apoE inhibitory effects were not because of suppression of PDGF binding to its receptors on the smooth muscle cells, but was correlated with a significant reduction in agonist-stimulated mitogen-activated protein kinase activity (p < 0.01), ApoE also inhibited PDGF-induced cyclin DI mRNA expression, suggesting that the apoE effect was mediated by growth arrest at the G(0) to G(1) phase. Taken together, these results suggest that apoE has cytostatic functions in the vessel wall and may protect against vascular diseases through inhibition of cell signaling events associated with growth factor-induced smooth muscle cell migration and proliferation.	Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Hui, DY (corresponding author), Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, 231 Bethesda Ave, Cincinnati, OH 45267 USA.		Swertfeger, Debi/AAN-6490-2021	Swertfeger, Debi/0000-0002-0570-0271	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040917] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40917] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABIEU A, 1996, J CELL SCI, V109, P239; AUSTIN GE, 1985, J AM COLL CARDIOL, V6, P369, DOI 10.1016/S0735-1097(85)80174-1; AUTRIO I, 1990, FEBS LETT, V277, P247; BIANCHI S, 1994, BIOCHEM BIOPH RES CO, V204, P691, DOI 10.1006/bbrc.1994.2515; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; CHATTERJEE S, 1992, MOL CELL BIOCHEM, V111, P143; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COCKS BG, 1992, J BIOL CHEM, V267, P12307; Dansky HM, 1997, P NATL ACAD SCI USA, V94, P4642, DOI 10.1073/pnas.94.9.4642; DeGeest B, 1997, CIRCULATION, V96, P4349; DYER CA, 1988, J BIOL CHEM, V263, P10965; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GIRALDO AA, 1985, ARCH PATHOL LAB MED, V109, P173; Graf K, 1997, HYPERTENSION, V29, P334, DOI 10.1161/01.HYP.29.1.334; Graves LM, 1996, J BIOL CHEM, V271, P505, DOI 10.1074/jbc.271.1.505; GROTENDORST GR, 1982, J CELL PHYSIOL, V113, P261, DOI 10.1002/jcp.1041130213; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HUI DY, 1980, J BIOL CHEM, V255, P1775; HUI DY, 1980, BIOCHEM J, V192, P91, DOI 10.1042/bj1920091; HUI DY, 1979, J BIOL CHEM, V254, P4666; JACKSON CL, 1993, ARTERIOSCLER THROMB, V13, P1218, DOI 10.1161/01.ATV.13.8.1218; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; KRUTH HS, 1994, J BIOL CHEM, V269, P24511; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LaFerla FM, 1997, J CLIN INVEST, V100, P310, DOI 10.1172/JCI119536; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAJACK RA, 1988, J CELL BIOL, V107, P1207, DOI 10.1083/jcb.107.3.1207; Marques M, 1997, ALZHEIMER RES, V3, P1; MAZZONE T, 1994, J LIPID RES, V35, P1345; MISRA UK, 1994, J BIOL CHEM, V269, P18303; MISTRY MJ, 1995, CELL IMMUNOL, V160, P14, DOI 10.1016/0008-8749(95)80004-3; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1986, METHOD ENZYMOL, V128, P273; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; REYLAND ME, 1991, J BIOL CHEM, V266, P21099; REYLAND ME, 1991, P NATL ACAD SCI USA, V88, P2375, DOI 10.1073/pnas.88.6.2375; Riddell DR, 1997, J BIOL CHEM, V272, P89; Russell PS, 1996, AM J PATHOL, V149, P91; Schneider WJ, 1997, CURR OPIN LIPIDOL, V8, P315, DOI 10.1097/00041433-199710000-00011; Seo HS, 1997, ARTERIOSCL THROM VAS, V17, P3593, DOI 10.1161/01.ATV.17.12.3593; SETH A, 1992, J BIOL CHEM, V267, P24796; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SHIMANO H, 1992, J CLIN INVEST, V90, P2084, DOI 10.1172/JCI116091; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; VANBOCKXMEER FM, 1994, ATHEROSCLEROSIS, V110, P195, DOI 10.1016/0021-9150(94)90204-6; Vitek MP, 1997, BIOCHEM BIOPH RES CO, V240, P391, DOI 10.1006/bbrc.1997.7408; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Yamamoto T, 1996, CURR OPIN LIPIDOL, V7, P298, DOI 10.1097/00041433-199610000-00007; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHANG SH, 1994, J CLIN INVEST, V94, P937, DOI 10.1172/JCI117460	63	125	128	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20156	20161		10.1074/jbc.273.32.20156	http://dx.doi.org/10.1074/jbc.273.32.20156			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685360	hybrid			2022-12-25	WOS:000075305400037
J	Matsuda, S; Hisatomi, O; Ishino, T; Kobayashi, Y; Tokunagati, F				Matsuda, S; Hisatomi, O; Ishino, T; Kobayashi, Y; Tokunagati, F			The role of calcium-binding sites in S-modulin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSIN PHOSPHORYLATION; LIGHT ADAPTATION; RECOVERIN; RODS; TERMINUS; VISION	S-modulin controls rhodopsin phosphorylation in a calcium-dependent manner, and it has been suggested that it modulates the light sensitivity of the photoreceptor cell, S-modulin binds to the ROS membrane at high Ca2+ concentration, and N-terminal myristoylation is necessary for this property (the calcium-myristoyl switch). S-modulin has four EF-hand motifs, of which two (EF-2 and -3) are functional. Here, we report on the roles of EF-2 and -3 in S-modulin function (calcium binding, membrane association, and inhibition of rhodopsin phosphorylation) by site-directed mutants (E85M and E121M), Surprisingly, E121M, which has a mutation in EF-3, neither binds Ca2+ nor inhibits phosphorylation, In contrast, E85M binds one Ca2+ and has the same membrane affinity as wild-type S-modulin, but has lost the ability to inhibit rhodopsin phosphorylation, It is suggested that the binding of Ca2+ to EF-3 is probably required for EF-2 to be a functional Ca2+-binding site and to induce exposure of the myristoyl group; and that the binding of Ca2+ to EF-2 is important for the interaction with rhodopsin kinase.	Osaka Univ, Fac Pharmaceut Sci, Suita, Osaka 5650043, Japan	Osaka University	Tokunagati, F (corresponding author), Osaka Univ, Grad Sch Sci, Dept Earth & Space Sci, Machikaneyama Chyo 1-1, Toyonaka, Osaka 5600043, Japan.		Matsuda, Shinji/GRR-5226-2022; Matsuda, Shinji/L-4727-2013					AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BABU A, 1992, J BIOL CHEM, V267, P15469; BLATT WF, 1968, ANAL BIOCHEM, V26, P151, DOI 10.1016/0003-2697(68)90039-0; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; Hisatomi O, 1997, BIOCHEM BIOPH RES CO, V234, P173, DOI 10.1006/bbrc.1997.6609; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; SANADA K, 1995, J BIOL CHEM, V270, P15459, DOI 10.1074/jbc.270.26.15459; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	24	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20223	20227		10.1074/jbc.273.32.20223	http://dx.doi.org/10.1074/jbc.273.32.20223			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685370	hybrid			2022-12-25	WOS:000075305400047
J	Menguy, T; Corre, F; Bouneau, L; Deschamps, S; Moller, JV; Champeil, P; le Maire, M; Falson, P				Menguy, T; Corre, F; Bouneau, L; Deschamps, S; Moller, JV; Champeil, P; le Maire, M; Falson, P			The cytoplasmic loop located between transmembrane segments 6 and 7 controls activation by Ca2+ of sarcoplasmic reticulum Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; FUNCTIONAL CONSEQUENCES; CALCIUM-BINDING; AMINO-ACIDS; TRANSPORT SITES; ATPASE; CA-2+-ATPASE; CA-2+; PHOSPHORYLATION; DISSOCIATION	During active cation transport, sarcoplasmic reticulum Ca2+-ATPase, like other P-type ATPases, undergoes major conformational changes, some of which are dependent on Ca2+ binding to high affinity transport sites. me here report that, in addition to previously described residues of the transmembrane region (Clarke, D. M., Loo, T. W., Inesi, G., and MacLennan, D. H. (1989) Nature 339, 476-478), the region located in the cytosolic L6-7 loop connecting transmembrane segments M6 and M7 has a definite influence on the sensitivity of the Ca2+-ATPase to Ca2+, i.e. on the affinity of the ATPase for Ca2+. Cluster mutation of aspartic residues in this loop results in a strong reduction of the affinity for Ca2+, as shown by the Ca2+ dependence of ATPase phosphorylation from either ATP or P-i. The reduction in Ca2+ affinity for phosphorylation from P-i is observed both at acidic and neutral pH, suggesting that these mutations interfere with binding of the first Ca2+, as proposed for some of the intramembranous residues essential for Ca2+ binding (Andersen, J. P. (1995) Biosci. Rep. 15, 243-261). Treatment of the mutated Ca2+-ATPase with proteinase K, in the absence or presence of various Ca2+ concentrations, leads to Ca2+-dependent changes in the proteolytic degradation pattern similar to those in the wild type but observed only at higher Ca2+ concentrations. This implies that these effects are not due to changes in the conformational state of Ca2+-free ATPase but that changes affecting the proteolytic digestion pattern require higher Ca2+ concentrations. We conclude that aspartic residues in the L6-7 loop might interact with Ca2+ during the initial steps of Ca2+ binding.	CE Saclay, CEA, DBCM, Sect Biophys Proteines & Membranes, F-91191 Gif Sur Yvette, France; CE Saclay, CNRS URA 2096, F-91191 Gif Sur Yvette, France; Aarhus Univ, Dept Biophys, Danish Biomembrane Res Ctr, DK-8000 Aarhus, Denmark	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Aarhus University	Falson, P (corresponding author), CE Saclay, CEA, DBCM, Sect Biophys Proteines & Membranes, Bat 528, F-91191 Gif Sur Yvette, France.	falson@dsvidf.cea.fr		Falson, Pierre/0000-0002-9760-4577				ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1994, FEBS LETT, V354, P93, DOI 10.1016/0014-5793(94)01100-1; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1985, J MEMBRANE BIOL, V88, P187, DOI 10.1007/BF01868432; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CENTENO F, 1994, FEBS LETT, V354, P117, DOI 10.1016/0014-5793(94)01104-4; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; ENOUF J, 1988, J BIOL CHEM, V263, P13922; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; FUJIMORI T, 1992, J BIOL CHEM, V267, P18475; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; HANEL AM, 1991, BIOCHEMISTRY-US, V30, P11320, DOI 10.1021/bi00111a019; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1980, J BIOL CHEM, V255, P3025; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; LACAPERE JJ, 1981, J BIOL CHEM, V256, P2302; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LEVY D, 1990, J BIOL CHEM, V265, P19524; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUND S, 1988, J BIOL CHEM, V263, P1654; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Moller JV, 1997, J BIOL CHEM, V272, P29015, DOI 10.1074/jbc.272.46.29015; NAKAMURA Y, 1984, J BIOL CHEM, V259, P8183; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; ORLOWSKI S, 1988, J BIOL CHEM, V263, P17576; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P11331, DOI 10.1021/bi00111a020; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soulie S, 1996, ANAL BIOCHEM, V236, P363, DOI 10.1006/abio.1996.0183; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; TAKISAWA H, 1981, NATURE, V290, P271, DOI 10.1038/290271a0; TANFORD C, 1987, P NATL ACAD SCI USA, V84, P7094, DOI 10.1073/pnas.84.20.7094; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WATANABE T, 1981, BIOCHEMISTRY-US, V20, P6617, DOI 10.1021/bi00526a015; YAMADA S, 1986, J BIOCHEM-TOKYO, V100, P1329, DOI 10.1093/oxfordjournals.jbchem.a121839; YAMAGUCHI M, 1985, J BIOL CHEM, V260, P4896; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; [No title captured]	54	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20134	20143		10.1074/jbc.273.32.20134	http://dx.doi.org/10.1074/jbc.273.32.20134			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685357	hybrid			2022-12-25	WOS:000075305400034
J	Pacini, S; Ulivieri, C; Maddalena, M; Di Somma, MM; Isacchi, A; Lanfrancone', L; Pelicci, PG; Telford, JL; Baldari, CT				Pacini, S; Ulivieri, C; Maddalena, M; Di Somma, MM; Isacchi, A; Lanfrancone', L; Pelicci, PG; Telford, JL; Baldari, CT			Tyrosine 474 of ZAP-70 is required for association with the Shc adaptor and for T-cell antigen receptor-dependent gene activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; KINASE ZAP-70; ZETA-CHAIN; SIGNAL TRANSDUCTION; VAV PROTOONCOGENE; PROTEIN; PHOSPHORYLATION; DOMAIN; TCR; THYMOCYTES	The protein tyrosine kinase ZAP-70 plays a central role in T-cell activation. Following receptor engagement, ZAP-70 is recruited to the phosphorylated subunits of the T-cell antigen receptor (TCR). This event results in ZAP-70 activation and in association of ZAP-70 with a number of signaling proteins. Among these is the Shc adaptor, which couples the activated TCR to Ras, Shc interaction with ZAP-70 is mediated by the Shc PTB domain. The inhibitory effect of a Shc mutant containing the isolated PTB domain suggests that Shc interaction with ZAP-70 might be required for TCR signaling. Here, we show that a point mutation (Phe(474)) of the putative Shc binding site on ZAP-70, spanning tyrosine 474, prevented ZAP-70 interaction with Shc and the subsequent binding of Shc to phospho-zeta. Neither ZAP-70 catalytic activity nor the pattern of protein phosphorylation induced by TCR triggering was affected by this mutation. However expression of the phe(474) ZAP-70 mutant resulted in impaired TCR-dependent gene activation. ZAP-70 could effectively phosphorylate Shc in vitro. Only the CH domain, which contains the two Grb2 binding sites on Shc, was phosphorylated by ZAP-70. Both Grb2 binding sites were excellent substrates for ZAP-70, The data show that Tyr(474) On ZAP-70 is required for TCR signaling and suggest that Shc association with ZAP-70 and the resulting phosphorylation of Shc might be an obligatory step in linking the activated TCR to the Ras pathway.	Univ Siena, Dept Evolutionary Biol, I-53100 Siena, Italy; Pharmacia & Upjohn Inc, I-20014 Nerviano, Italy; European Inst Oncol, I-20141 Milan, Italy; Chiron SPA, I-53100 Siena, Italy	University of Siena; Pfizer; IRCCS European Institute of Oncology (IEO); Novartis	Baldari, CT (corresponding author), Univ Siena, Dept Evolutionary Biol, Via Mattioli 4, I-53100 Siena, Italy.	baldari@unisi.it	Lanfrancone, Luisa/AAC-8671-2019; Telford, John Laird/ABG-8144-2020; Ulivieri, Cristina/AAH-7543-2020; Pelicci, Pier Giuseppe/AAL-6572-2020	Lanfrancone, Luisa/0000-0002-4523-3815; Ulivieri, Cristina/0000-0002-1710-7977; Baldari, Cosima/0000-0002-4414-6744				ADAMS JM, 1992, ONCOGENE, V7, P611; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BALDARI CT, 1992, FEBS LETT, V304, P261, DOI 10.1016/0014-5793(92)80633-R; BALDARI CT, 1995, ONCOGENE, V10, P1141; BALDARI CT, 1998, IN PRESS BIOLOGICALS, V25; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BORST J, 1990, HUM IMMUNOL, V29, P175, DOI 10.1016/0198-8859(90)90113-4; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Graef IA, 1997, EMBO J, V16, P5618, DOI 10.1093/emboj/16.18.5618; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Kong GH, 1996, MOL CELL BIOL, V16, P5026; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; Mege D, 1996, J BIOL CHEM, V271, P32644, DOI 10.1074/jbc.271.51.32644; Milia E, 1996, ONCOGENE, V13, P767; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; OSMAN N, 1995, EUR J IMMUNOL, V25, P2863, DOI 10.1002/eji.1830251023; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WATTS JD, 1994, J BIOL CHEM, V269, P29520; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; Yamasaki S, 1996, MOL CELL BIOL, V16, P7151; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; Zhao QH, 1996, MOL CELL BIOL, V16, P6765	48	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20487	20493		10.1074/jbc.273.32.20487	http://dx.doi.org/10.1074/jbc.273.32.20487			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685404	hybrid			2022-12-25	WOS:000075305400081
J	Coppee, F; Depoortere, F; Bartek, J; Ledent, C; Parmentier, M; Dumont, JE				Coppee, F; Depoortere, F; Bartek, J; Ledent, C; Parmentier, M; Dumont, JE			Differential patterns of cell cycle regulatory proteins expression in transgenic models of thyroid tumours	ONCOGENE			English	Review						cyclins; cdk(s); CKI; thyroid; HPV 16 E7; cAMP	PAPILLOMAVIRUS TYPE-16 E7; GROWTH-FACTOR-BETA; 10T1/2 MOUSE FIBROBLASTS; D-CDK COMPLEXES; INHIBITOR P27(KIP1); RETINOBLASTOMA GENE; DEPENDENT KINASES; P53-INDEPENDENT EXPRESSION; SUBCELLULAR-LOCALIZATION; MYOGENIC DIFFERENTIATION	Cell cycle proteins regulate the transitions from G1 to S and G2 to M phases. In higher eukaryotes, their function is controlled by intracellular cascades regulated by extracellular growth factors, We have studied m previously described transgenic mouse models for thyroid proliferative diseases the expression of the key proteins regulating the cell cycle by Western blotting and immunohistochemistry, and have correlated the observations with the known actions of the transgenes on the signal transduction cascades. In the adenosine A(2a) receptor model, the cyclic AMP pathway, upstream of the Rb family cell division block, is constitutively activated. In the model expressing HPV 16 E7 protein, the Rb-like proteins are inhibited, Cyclin-dependent kinases cdk4, cdk2 and cdc2, and the associated cyclins D, E and A have been studied. Cyclin D3 appears as the major cyclin D subtype expressed in mouse thyroid epithelial cells in normal and transgenic mice. In the adenosine A(2a)R model, all cell cycle proteins tested were accumulated. In the E7 model, all cell cycle proteins except for D-type cyclins and cdk4 were also accumulated. A similar pattern was observed in thyroids coexpressing both transgenes, suggesting a dominant effect of E7 over the consequences of the cAMP cascade activation. The cyclin-dependent kinase inhibitors p21(cip1/waf1) and pt27(kip1) were not downregulated in these proliferating thyroids which suggest other roles than the inhibition of the cell cycle progression.	Free Univ Brussels, IRIBHN, B-1070 Brussels, Belgium; Danish Canc Soc, Div Canc Biol, DK-2100 Copenhagen, Denmark	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Danish Cancer Society	Coppee, F (corresponding author), Free Univ Brussels, IRIBHN, 808 Route Lennik,Campus Erasme, B-1070 Brussels, Belgium.		Bartek, Jiri/G-5870-2014	Parmentier, Marc/0000-0001-8081-4685				Akagi M, 1996, JPN J CANCER RES, V87, P377, DOI 10.1111/j.1349-7006.1996.tb00233.x; Akiyama T, 1997, CANCER RES, V57, P1495; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Baptist M, 1996, J CELL PHYSIOL, V166, P256; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BATES S, 1994, ONCOGENE, V9, P1633; Botz J, 1996, MOL CELL BIOL, V16, P3401; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHRISTOPHE D, 1990, TRENDS ENDOCRIN MET, V1, P351, DOI 10.1016/1043-2760(90)90083-F; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Coppee F, 1996, ONCOGENE, V13, P1471; Coulonval K, 1997, EXP CELL RES, V233, P395, DOI 10.1006/excr.1997.3582; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Depoortere F, 1996, J CELL SCI, V109, P1759; DEPOORTERE F, 1998, J CELL SCI, V140, P1; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; GRANA X, 1995, ONCOGENE, V11, P211; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; Ishida A, 1997, J BIOL CHEM, V272, P10050; JARKUS J, 1996, ONCOGENE, V12, P2369; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIESS M, 1995, ONCOGENE, V10, P159; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOTANI S, 1995, ONCOGENE, V10, P663; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1995, ONCOGENE, V10, P1789; LEDENT C, 1990, P NATL ACAD SCI USA, V87, P6176, DOI 10.1073/pnas.87.16.6176; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lloyd RV, 1997, AM J PATHOL, V150, P401; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, ONCOGENE, V10, P2125; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; Marchetti A, 1996, ONCOGENE, V12, P1319; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; NADEL A, 1997, J PATHOL, V183, P156; NEVINS JR, 1992, SCIENCE, V258, P424; OTHANI K, 1995, P NATL ACAD SCI USA, V92, P12146; OTHSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Palmero I, 1996, CANCER SURV, V27, P351; PALMERO I, 1993, ONCOGENE, V8, P1049; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Pei XF, 1996, CARCINOGENESIS, V17, P1395, DOI 10.1093/carcin/17.7.1395; Pirson I, 1996, J CELL PHYSIOL, V168, P59, DOI 10.1002/(SICI)1097-4652(199607)168:1<59::AID-JCP8>3.0.CO;2-7; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Qian X, 1996, ENDOCRINOLOGY, V137, P3051, DOI 10.1210/en.137.7.3051; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; Ravitz MJ, 1996, J CELL PHYSIOL, V168, P510, DOI 10.1002/(SICI)1097-4652(199609)168:3<510::AID-JCP3>3.0.CO;2-S; RAVITZ MJ, 1995, CANCER RES, V55, P1413; ROGER PP, 1985, EUR J BIOCHEM, V152, P239, DOI 10.1111/j.1432-1033.1985.tb09189.x; ROGER PP, 1984, MOL CELL ENDOCRINOL, V36, P79, DOI 10.1016/0303-7207(84)90087-X; ROGER PP, 1982, MOL CELL ENDOCRINOL, V26, P165, DOI 10.1016/0303-7207(82)90014-4; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; SUAREZ HG, 1991, ONCOGENE, V6, P677; Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951; TAM SW, 1994, ONCOGENE, V9, P2663; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; Tikoo R, 1997, J BIOL CHEM, V272, P442; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Tron VA, 1996, AM J PATHOL, V149, P1139; Usuda H, 1996, VIRCHOWS ARCH, V428, P159; Vassart G, 1996, ANN ENDOCRINOL-PARIS, V57, P50; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang ZY, 1996, GENOMICS, V35, P156, DOI 10.1006/geno.1996.0334; Ward AC, 1996, BIOCHEM BIOPH RES CO, V224, P10, DOI 10.1006/bbrc.1996.0976; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZerfassThome K, 1996, ONCOGENE, V13, P2323	104	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					631	641		10.1038/sj.onc.1201966	http://dx.doi.org/10.1038/sj.onc.1201966			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704929				2022-12-25	WOS:000075195300011
J	Ferguson, AT; Lapidus, RG; Davidson, NE				Ferguson, AT; Lapidus, RG; Davidson, NE			Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression	ONCOGENE			English	Article						breast cancer; CpG island; DNA methylation; estrogen receptor; histone acetyltransferase; progesterone receptor	BREAST-CANCER CELLS; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; BINDING-PROTEIN; ESTROGEN-RECEPTOR; TRANSCRIPTION; SEQUENCE; INACTIVATION	Progesterone receptor (PR) is an estrogen-stimulated gene which has a CpG island that is heavily methylated in a significant fraction of estrogen receptor (ER)negative/PR-negative human breast cancers and cell lines, including MDA-MB-231 cells. Treatment of MDA-MB-231 cells with the demethylating agent, 5-aza-2'-deoxycytidine (deoxyC) led to demethylation and expression of ER and PR, However, simultaneous treatment with antiestrogen prevented PR transcription, suggesting that demethylation of PR alone is not sufficient to reactivate the PR gene. To examine the effects of ER on the methylation status of the PR CpG island, we stably transfected MDA-MB-231 cells with an inducible expression vector for ER, Surprisingly, in two cell clones, we found that induction of PR gene expression by ligand-bound ER does not require demethylation of the PR CpG island. In contrast, induction of PR transcription was inhibited by blocking the interaction of ER with SRC-1A, a coactivator of ER function. For the first time, we show that a transcription factor with the potential to remodel heterochromatin can activate gene expression without altering the methylation status of the CpG island. These results raise the possibility that demethylation and histone acetylation are distinct but complementary mechanisms for destabilizing heterochromatin and activating transcription.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Davidson, NE (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, 422 N Bond St, Baltimore, MD 21231 USA.							ABRAHAM SE, 1993, ONCOGENE, V8, P1639; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; Beato M, 1996, J STEROID BIOCHEM, V56, P47, DOI 10.1016/0960-0760(95)00223-5; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; FERGUSON AT, 1995, CANCER RES, V55, P2279; Graham JD, 1995, J BIOL CHEM, V270, P30693, DOI 10.1074/jbc.270.51.30693; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Hsieh CL, 1997, MOL CELL BIOL, V17, P5897, DOI 10.1128/MCB.17.10.5897; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KLEMPNAUER KH, 1993, ONCOGENE, V8, P111; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; LEVINE A, 1993, J BIOL CHEM, V268, P21754; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; ONATE SA, 1995, SCIENCE, V270, P1354; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; XING LP, 1995, J BIOL CHEM, V270, P17488, DOI 10.1074/jbc.270.29.17488; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	37	32	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					577	583		10.1038/sj.onc.1201961	http://dx.doi.org/10.1038/sj.onc.1201961			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704923				2022-12-25	WOS:000075195300005
J	Lin, HM; Hutchcroft, JE; Andoniou, CE; Kamoun, M; Band, H; Bierer, BE				Lin, HM; Hutchcroft, JE; Andoniou, CE; Kamoun, M; Band, H; Bierer, BE			Association of p59(fyn) with the T lymphocyte costimulatory receptor CD2 - Binding of the Fyn Src homology (SH) 3 domain is regulated by the Fyn SH2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-TYROSINE KINASE; NATURAL-KILLER-CELLS; CYTOPLASMIC DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; ALTERNATIVE PATHWAY; PHOSPHATASE CD45; LIGAND AVIDITY; SURFACE LIGAND	Human CD2 is a 50-55-kDa cell surface receptor specifically expressed on the surface of T lymphocytes and NK cells. Stimulation of human peripheral blood T cells with mitogenic pairs of anti-CD2 monoclonal antibodies (mAbs) is sufficient to induce interleukin-a production and T cell proliferation in the absence of an antigen-specific signal through the T cell receptor. CD2 has been shown previously to associate physically with the Src family protein-tyrosine kinases p56(lck) and p59(fyn). We now report that stimulation of T cells with mitogenic pairs of anti-CD2 mAbs enhanced the association of the Fyn polypeptide with the CD2 complex, whereas stimulation with single anti-CD2 mAb had minimal effect. Using glutathione S-transferase (GST) fusion proteins, we found that CD2 bound to the Src homology (SH) 3 domain of Fyn. Interestingly, the CD2-Fyn association was negatively regulated by the Fyn SH2 domain; CD2 bound poorly to GST fusion proteins expressing both the SH2 and SH3 domains of Fyn. However, the inhibitory effect of the Fyn SH2 domain on binding of the Fyn SH3 domain to CD2 was relieved by peptides containing a phosphorylated YEEI sequence that bound directly to the Fyn SH2 domain. In addition, we found that the ability of the Fyn SH2 domain to precipitate tyrosine-phosphorylated proteins, including the CD3 zeta chain, was enhanced after T cell stimulation with mitogenic pairs of CD2 mAbs. Finally, overexpression of a mutated Fyn molecule, in which the ability of the Fyn SH2 domain to bind phosphotyrosine-containing proteins was abrogated, inhibited CD2-induced transcriptional activation of the nuclear factor of activated T cells (NFAT), suggesting a functional involvement of the Fyn SH2 domain in CD2-induced T cell signaling. We thus propose that stimulation through the CD2 receptor leads to the tyrosine phosphorylation of intracellular proteins, including CD3 zeta itself, which in turn bind to the Fyn-SH2 domain, allowing the direct association of the Fyn SH3 domain with CD2 and the initiation of downstream signaling events.	Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Med Sci, Comm Immunol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Rheumatol & Immunol, Lymphocyte Biol Sect, Boston, MA 02115 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; University of Pennsylvania; Harvard University; Harvard Medical School	Bierer, BE (corresponding author), NHLBI, NIH, Bldg 10,Rm 5D49,10 Ctr Dr, Bethesda, MD 20892 USA.	biererb@nih.gov	Andoniou, Christopher/B-6296-2013	Bierer, Barbara/0000-0001-6448-8170; Andoniou, Christopher/0000-0003-0566-3180				ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BELL GM, 1992, MOL CELL BIOL, V12, P5548, DOI 10.1128/MCB.12.12.5548; Bell GM, 1996, J EXP MED, V183, P169, DOI 10.1084/jem.183.1.169; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BIERER BE, 1988, J EXP MED, V168, P1145, DOI 10.1084/jem.168.3.1145; BOUSSIOTIS VA, 1994, J EXP MED, V180, P1665, DOI 10.1084/jem.180.5.1665; CARMO AM, 1993, EUR J IMMUNOL, V23, P2196, DOI 10.1002/eji.1830230922; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHANG SC, 1989, SENSORS COMPREHENSIV, V1, P169; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; DECKERT M, 1992, EUR J IMMUNOL, V22, P2943, DOI 10.1002/eji.1830221128; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUSAKI N, 1994, INT IMMUNOL, V6, P1245, DOI 10.1093/intimm/6.8.1245; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; GASSMANN M, 1994, EUR J IMMUNOL, V24, P139, DOI 10.1002/eji.1830240121; GOLLOB JA, 1995, J EXP MED, V182, P721, DOI 10.1084/jem.182.3.721; GUCKEL B, 1991, J EXP MED, V174, P957, DOI 10.1084/jem.174.5.957; HAHN WC, 1993, J EXP MED, V178, P1831, DOI 10.1084/jem.178.5.1831; HAHN WC, 1992, P NATL ACAD SCI USA, V89, P7179, DOI 10.1073/pnas.89.15.7179; HAHN WC, 1992, SCIENCE, V256, P1805, DOI 10.1126/science.1377404; HOWARD FD, 1992, J EXP MED, V176, P139, DOI 10.1084/jem.176.1.139; Hubert P, 1996, J IMMUNOL, V157, P4322; HUNIG T, 1987, NATURE, V326, P298, DOI 10.1038/326298a0; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MILLER GT, 1993, J EXP MED, V178, P211, DOI 10.1084/jem.178.1.211; MOINGEON P, 1989, NATURE, V339, P312, DOI 10.1038/339312a0; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; OFFRINGA R, 1993, J BIOL CHEM, V268, P4979; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; QUILL H, 1992, J IMMUNOL, V149, P2887; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SANDRIN MS, 1993, J IMMUNOL, V151, P4606; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SCHRAVEN B, 1993, EUR J IMMUNOL, V23, P119, DOI 10.1002/eji.1830230119; SCHRAVEN B, 1994, J EXP MED, V180, P897, DOI 10.1084/jem.180.3.897; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Steeg C, 1997, EUR J IMMUNOL, V27, P2233, DOI 10.1002/eji.1830270917; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Warren HS, 1996, J IMMUNOL, V156, P2866; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	65	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19914	19921		10.1074/jbc.273.31.19914	http://dx.doi.org/10.1074/jbc.273.31.19914			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677430	hybrid			2022-12-25	WOS:000075125200082
J	Li, RZ; Sutphin, PD; Schwartz, D; Matas, D; Almog, N; Wolkowicz, R; Goldfinger, N; Pei, HP; Prokocimer, M; Rotter, V				Li, RZ; Sutphin, PD; Schwartz, D; Matas, D; Almog, N; Wolkowicz, R; Goldfinger, N; Pei, HP; Prokocimer, M; Rotter, V			Mutant p53 protein expression interferes with p53-independent apoptotic pathways	ONCOGENE			English	Article						p53-dependent; p53-independent; apoptosis; chemotherapeutic drugs	WILD-TYPE P53; MYELOID LEUKEMIC-CELLS; P53-DEPENDENT APOPTOSIS; INDEPENDENT PATHWAYS; CANCER-CHEMOTHERAPY; DNA-DAMAGE; IONIZING-RADIATION; GAMMA-IRRADIATION; FUNCTIONAL P53; LYMPHOID-CELLS	Loss of normal p53 function was found frequently to interfere with response of cancer cells to conventional anticancer therapies. Since more than half of all human cancers possess p53 mutations, we decided to explore the involvement of mutant p53 in drug induced apoptosis. To further evaluate the relationship between the p53-dependent and p53-independent apoptotic pathways, and to elucidate the function of mutant p53 in modulating these processes, we investigated the role of a p53 temperature-sensitive (ts) mutant in a number of apoptotic pathways induced by chemotherapeutic drugs that are currently used in cancer therapy. To that end, me studied the M1/2, myeloid p53 non-producer cells, and M1/2-derived temperature-sensitive I; mutant p53 expressing clones. Apoptosis caused by DIVA damage induced with gamma-irradiation, doxorubicin or cisplatin, was enhanced in cells expressing wild type p53 as compared to that seen in parental p53 non-producer cells; mutant p53 expressing clones mere found to be more resistant to apoptosis induced by these factors. Actinomycin D, a potent inhibitor of transcription, as well as a DNA. damaging agent, abrogated the restraint apoptosis mediated by mutant p53. These observations suggest that while loss of wild type p53 function clearly reduces the rate of apoptosis, p53 mutations may result in a gain of function which significantly interferes with chemotherapy induced apoptosis. Therefore, to achieve a successful cancer therapy, it is critical to consider the specific relationship between a given mutation in p53 and the chemotherapy selected.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.							Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Allred D. C., 1993, BREAST CANCER RES TR, V27, P131; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BELLOC F, 1994, CYTOMETRY, V17, P59, DOI 10.1002/cyto.990170108; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CAPRANICO G, 1992, EUR J CANCER, V28A, P2055, DOI 10.1016/0959-8049(92)90255-Z; Chresta CM, 1996, CANCER RES, V56, P1834; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORY S, 1994, PHILOS T R SOC B, V345, P289, DOI 10.1098/rstb.1994.0108; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DARZYNKIEWICZ Z, 1994, CELL BIOL LAB HDB, V1, P261; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIJIT FJ, 1988, CANCER RES, V48, P6058; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; EASTMAN A, 1995, METHOD CELL BIOL, V46, P41; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; GLYNN JM, 1991, BIOCHEM SOC T, V20, pS84; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; Hamada M, 1996, J CANCER RES CLIN, V122, P360, DOI 10.1007/BF01220804; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; Harris CC, 1996, BRIT J CANCER, V73, P261, DOI 10.1038/bjc.1996.47; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; HICKMAN JA, 1994, PHILOS T ROY SOC B, V345, P319, DOI 10.1098/rstb.1994.0112; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; Iwamoto KS, 1996, CANCER RES, V56, P3862; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; LANE DP, 1994, PHILOS T ROY SOC B, V345, P277, DOI 10.1098/rstb.1994.0106; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LEVINE JA, 1997, CELL, V88, P323; LEWIS JG, 1995, J LEUKOCYTE BIOL, V57, P635, DOI 10.1002/jlb.57.4.635; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LING YH, 1993, CANCER RES, V53, P1845; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOTEM J, 1994, CELL GROWTH DIFFER, V5, P321; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAKRIS A, 1995, LANCET, V345, P1181, DOI 10.1016/S0140-6736(95)91014-X; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MASTERS JRW, 1993, INT J CANCER, V53, P340, DOI 10.1002/ijc.2910530228; Oliver R T, 1996, Curr Opin Oncol, V8, P252; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Peled A, 1996, CANCER RES, V56, P2148; Peled A, 1996, EXP HEMATOL, V24, P728; ROSENBERG B, 1985, CANCER, V55, P2303, DOI 10.1002/1097-0142(19850515)55:10<2303::AID-CNCR2820551002>3.0.CO;2-L; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; Soddu S, 1996, J CELL BIOL, V134, P1; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; WYLLIE AH, 1994, PHILOS T R SOC B, V345, P237, DOI 10.1098/rstb.1994.0099; WYLLIE FS, 1995, ONCOGENE, V10, P49; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZALESKIS G, 1994, MOL PHARMACOL, V46, P901; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7; ZHUANG SM, 1995, CANCER RES, V55, P486	81	123	127	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3269	3277		10.1038/sj.onc.1201867	http://dx.doi.org/10.1038/sj.onc.1201867			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681825				2022-12-25	WOS:000074343600007
J	Maier, D; Zhang, ZW; Taylor, E; Hamou, MF; Gratzl, O; Van Meir, EG; Scott, RJ; Merlo, A				Maier, D; Zhang, ZW; Taylor, E; Hamou, MF; Gratzl, O; Van Meir, EG; Scott, RJ; Merlo, A			Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas	ONCOGENE			English	Article						deletion mapping; chromosome 10q23.3 and 10q25-26; PTEN/MMAC1	GLIOBLASTOMA-MULTIFORME; LONG ARM; HETEROZYGOSITY; CANCER; LOCI; PROGRESSION; METHYLATION; CARCINOMA; 10Q23-25	The l0q25-26 region between the dinucleotide markers D10S587 and D10S216 is deleted in glioblastomas and, as we have recently shown, in low-grade oligodendrogliomas. We further refined somatic mapping on 10q23-tel and simultaneously assessed the role of the candidate tumor suppressor gene PTEN/MMAC1 in glial neoplasms by sequence analysis of eight low-grade and 24 high-grade gliomas. These tumors were selected for partial or complete loss of chromosome 10 based on deletion mapping with increased microsatellite marker density at 10q23-tel. Three out of eight (38%) low-grade and 3/24 (13%) high-grade gliomas exclusively target 10q25-26.We did not find a tumor only targeting 10q23.3, and most tumors (23/32, 72%) showed large deletions on 10q including both regions. The sequence analysis of PTEN/MMAC1 revealed nucleotide alterations in 1/8 (12.5%) low-grade gliomas in a tumor with LOH at l0q21-qtel and in 5/21 (24%) high-grade gliomas displaying LOH that always included 10q23-26. Our refined mapping data point to the 10q25-26 region as the primary target on 10q, an area that also harbors the DMBT1 candidate tumor suppressor gene. The fact that we find hemizygous deletions at 10q25-qtel in low-grade astrocytomas and oligodendrogliomas - two histologically distinct entities of gliomas - suggests the existence of a putative suppressor gene involved early in glial tumorigenesis.	Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; Univ Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland	University of Basel; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Merlo, A (corresponding author), Univ Basel Hosp, Dept Res, Schanzenstr 46, CH-4031 Basel, Switzerland.		Scott, Rodney J/B-2827-2013	Scott, Rodney J/0000-0001-7724-3404; Van Meir, Erwin G./0000-0003-2444-7707				Albarosa R, 1996, AM J HUM GENET, V58, P1260; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; FULTS D, 1990, CANCER RES, V50, P5784; GRAY IC, 1995, CANCER RES, V55, P4800; HERBST RA, 1994, CANCER RES, V54, P3111; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; JAMES CD, 1988, CANCER RES, V48, P5546; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MERLO A, 1994, CANCER RES, V54, P640; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MORITA R, 1991, CANCER RES, V51, P5817; Moschonas N. K., 1996, Cytogenetics and Cell Genetics, V72, P99, DOI 10.1159/000134172; Nagase S, 1997, CANCER RES, V57, P1630; PEIFFER SL, 1995, CANCER RES, V55, P1922; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RASHEED BKA, 1995, ONCOGENE, V10, P2243; REMPEL SA, 1993, CANCER RES, V53, P2386; SPEAKS SL, 1992, GENE CHROMOSOME CANC, V5, P239, DOI 10.1002/gcc.2870050311; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Wang SI, 1997, CANCER RES, V57, P4183	31	74	80	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3331	3335		10.1038/sj.onc.1201832	http://dx.doi.org/10.1038/sj.onc.1201832			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681833				2022-12-25	WOS:000074343600015
J	Akiyama, Y; Kihara, A; Mori, H; Ogura, T; Ito, K				Akiyama, Y; Kihara, A; Mori, H; Ogura, T; Ito, K			Roles of the periplasmic domain of Escherichia coli FtsH (HflB) in protein interactions and activity modulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; BACTERIOPHAGE-LAMBDA; MEMBRANE-PROTEINS; SECY; GENE; EXPORT; COMPLEX; FORMS; CELL; INVOLVEMENT	FtsH is a membrane-bound and ATP-dependent protease of Escherichia coli, known to degrade SecY, a membrane protein for protein translocation, and CII, a soluble transcription factor for lysis/lysogeny decision of phage lambda. FtsH forms a homo-oligomeric complex as well as a hetero-oligomeric complex with HflKC, a putative modulator of FtsH. Although FtsH has a small periplasmic region, HflKC is mostly exposed to the periplasmic space. We studied the roles of the periplasmic region of FtsH by engineering mutations in this protein. FtsH Delta 236, lacking most of the periplasmic region, retained the in vivo ability to degrade SecY but not CII, resulting in high frequency lysogenization of lambda. Several insertion mutations in the periplasmic region of FtsH also differentially affected the proteolytic activities of FtsH. interestingly purified and detergent-solubilized FtsH Delta 236 was as active as the wild-type enzyme in degrading SecY and CII, although its ATPase activity was lowered 5-fold. Affinity chromatography using histidine-tagged derivatives showed that the periplasmic domain-deleted FtsH no longer interacted with FtsH or HflKC. Although FtsH Delta 236-His(6)-Myc lost the static FtsH-FtsH interaction, it retained the ability to change its conformation in an ATP-dependent manner at 37 degrees C, leading to a limited oligomerization. These results suggest that the periplasmic region of FtsH has crucial roles in the protein-protein interactions of this complex and in the modulation of its proteolytic functions against different substrates.	Kyoto Univ, Inst Virus Res, Dept Cell Biol, Kyoto 6068507, Japan; Kumamoto Univ, Sch Med, Inst Mol Embryol & Genet, Dept Mol Cell Biol, Kumamoto 8620976, Japan	Kyoto University; Kumamoto University	Akiyama, Y (corresponding author), Kyoto Univ, Inst Virus Res, Dept Cell Biol, Kyoto 6068507, Japan.	yaidyama@virus.kyoto-u.ac.jp	KIHARA, AKIO/A-3802-2012	KIHARA, AKIO/0000-0001-5889-0788; Mori, Hiroyuki/0000-0002-0429-1269; Ogura, Teru/0000-0003-3784-0970				Akiyama Y, 1998, MOL MICROBIOL, V28, P803, DOI 10.1046/j.1365-2958.1998.00843.x; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5225; AKIYAMA Y, 1995, J BIOL CHEM, V270, P23485, DOI 10.1074/jbc.270.40.23485; Akiyama Y, 1996, FEBS LETT, V399, P26, DOI 10.1016/S0014-5793(96)01283-5; Akiyama Y, 1996, J BIOL CHEM, V271, P31196, DOI 10.1074/jbc.271.49.31196; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; BANUETT F, 1986, J MOL BIOL, V187, P213, DOI 10.1016/0022-2836(86)90229-9; HERMAN C, 1993, P NATL ACAD SCI USA, V90, P10861, DOI 10.1073/pnas.90.22.10861; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; HOMMA T, 1995, BIOCHEM BIOPH RES CO, V215, P452, DOI 10.1006/bbrc.1995.2486; HOYT MA, 1982, CELL, V31, P565, DOI 10.1016/0092-8674(82)90312-9; ITO K, 1983, CELL, V32, P789, DOI 10.1016/0092-8674(83)90065-X; ITO K, 1984, MOL GEN GENET, V197, P204, DOI 10.1007/BF00330964; Kihara A, 1996, EMBO J, V15, P6122, DOI 10.1002/j.1460-2075.1996.tb01000.x; Kihara A, 1997, P NATL ACAD SCI USA, V94, P5544, DOI 10.1073/pnas.94.11.5544; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; Kihara A, 1998, J MOL BIOL, V279, P175, DOI 10.1006/jmbi.1998.1781; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; Manoil C, 1997, J MOL BIOL, V267, P250, DOI 10.1006/jmbi.1996.0881; MATSUZAWA H, 1984, J BACTERIOL, V160, P733, DOI 10.1128/JB.160.2.733-739.1984; Miller J.H., 1972, EXPT MOL GENETICS; OGURA T, 1991, RES MICROBIOL, V142, P279, DOI 10.1016/0923-2508(91)90041-8; Qu JN, 1996, J BACTERIOL, V178, P3457, DOI 10.1128/jb.178.12.3457-3461.1996; SHIBA K, 1984, J BACTERIOL, V160, P696, DOI 10.1128/JB.160.2.696-701.1984; SHIMOIKE T, 1995, J BIOL CHEM, V270, P5519, DOI 10.1074/jbc.270.10.5519; Shotland Y, 1997, MOL MICROBIOL, V24, P1303, DOI 10.1046/j.1365-2958.1997.4231796.x; Silhavy T.J., 1984, EXPT GENE FUSIONS; TAURA T, 1993, J BACTERIOL, V175, P7771, DOI 10.1128/JB.175.24.7771-7775.1993; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; Wang RF, 1998, J BACTERIOL, V180, P1929, DOI 10.1128/JB.180.7.1929-1938.1998	34	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22326	22333		10.1074/jbc.273.35.22326	http://dx.doi.org/10.1074/jbc.273.35.22326			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712851	hybrid			2022-12-25	WOS:000075616600027
J	Taylor, WH; Sinha, A; Khan, IA; McDaniel, ST; Esko, JD				Taylor, WH; Sinha, A; Khan, IA; McDaniel, ST; Esko, JD			Primers of glycosaminoglycan biosynthesis from Peruvian Rain Forest plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-D-XYLOSIDE; HUMAN SKIN FIBROBLASTS; GENE-SPECIFIED GLYCOSYLTRANSFERASES; CHONDROITIN SULFATE PROTEOGLYCAN; HAMSTER OVARY CELLS; BLOOD-GROUP-A; GLYCOSIDASE INHIBITORS; HEPARAN-SULFATE; HUMAN-MELANOMA; TUMOR-CELLS	We have developed a rapid, high throughput screening assay for compounds that alter the assembly of glycosaminoglycan chains in Chinese hamster ovary cells. The assay uses autoradiography to measure the binding of newly synthesized [S-35]proteoglycans and [S-35]glycosaminoglycans to a positively charged membrane. Screening over 1000 extracts from a random plant collection obtained from the Amazon rain forest yielded five plants that stimulated glycosaminoglycan assembly in both wild-type cells and a mutant cell line defective in xylosyltransferase (the first committed enzyme involved in glycosaminoglycan biosynthesis). Fractionation of an extract of Maieta guianensis by silica gel and reverse-phase chromatography yielded two pure compounds with stimulatory activity. Spectroscopic analysis by NMR and mass spectrometry revealed that the active principles were xylosides of dimethylated ellagic acid. One of the compounds also contained a galloyl group at C-3 of the xylose moiety. These findings suggest that plants and other natural products may be a source of agents that can potentially alter glycosaminoglycan and proteoglycan formation in animal cells.	Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Glycobiol Program, La Jolla, CA 92093 USA; Univ Mississippi, Pharmaceut Sci Res Inst, Natl Ctr Dev Nat Prod, University, MS 38677 USA; Mississippi State Univ, Dept Biol Sci, Inst Bot Explorat, Mississippi State, MS 39762 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Mississippi; Mississippi State University	Esko, JD (corresponding author), Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA.				NATIONAL CANCER INSTITUTE [R01CA046462] Funding Source: NIH RePORTER; NCI NIH HHS [CA46462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asano N, 1997, GLYCOBIOLOGY, V7, P1085, DOI 10.1093/glycob/7.8.1085; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BELLAMY F, 1993, J MED CHEM, V36, P898, DOI 10.1021/jm00059a015; BELLAMY F, 1995, EUR J MED CHEM, V30, P101; Binari RC, 1997, DEVELOPMENT, V124, P2623; CAMBIAZO V, 1990, COMP BIOCHEM PHYS B, V97, P307, DOI 10.1016/0305-0491(90)90286-3; CASTANEDA P, 1993, J NAT PROD, V56, P1575, DOI 10.1021/np50099a017; DENNIS JW, 1989, J NATL CANCER I, V81, P1028, DOI 10.1093/jnci/81.13.1028; DENNIS JW, 1993, BIOCHEM PHARMACOL, V46, P1459, DOI 10.1016/0006-2952(93)90112-A; DENNIS JW, 1990, CANCER RES, V50, P1867; Duke J. A., 1994, AMAZONIAN ETHNOBOTAN; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; ESKO JD, 1996, CURRENT PROTOCOLS S, V32; Freeze HH, 1996, TRENDS GLYCOSCI GLYC, V8, P65, DOI 10.4052/tigg.8.65; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; FRITZ TA, 1994, J BIOL CHEM, V269, P300; GALLIGANI L, 1975, J BIOL CHEM, V250, P5400; GOSS PE, 1994, CANCER RES, V54, P1450; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; HAM RG, 1965, P NATL ACAD SCI USA, V53, P288, DOI 10.1073/pnas.53.2.288; HEIMER R, 1987, ANAL BIOCHEM, V162, P330, DOI 10.1016/0003-2697(87)90400-3; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; HUMPHRIES MJ, 1986, CANCER RES, V46, P5215; HUMPHRIES MJ, 1986, P NATL ACAD SCI USA, V83, P1752, DOI 10.1073/pnas.83.6.1752; HUMPHRIES MJ, 1990, CLIN EXP METASTAS, V8, P89, DOI 10.1007/BF00155595; IZUMI J, 1994, J BIOCHEM-TOKYO, V116, P524, DOI 10.1093/oxfordjournals.jbchem.a124556; Jackson SM, 1997, DEVELOPMENT, V124, P4113; KHAC DD, 1990, PHYTOCHEMISTRY, V29, P251, DOI 10.1016/0031-9422(90)89044-A; KHAN SH, 1993, J BIOL CHEM, V268, P2468; KOLSET SO, 1986, BIOCHEM J, V238, P209, DOI 10.1042/bj2380209; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LOWARY TL, 1993, CARBOHYD RES, V249, P163, DOI 10.1016/0008-6215(93)84068-H; LOWARY TL, 1994, CARBOHYD RES, V251, P33, DOI 10.1016/0008-6215(94)84275-2; LOWARY TL, 1994, CARBOHYD RES, V256, P257, DOI 10.1016/0008-6215(94)84212-4; Lugemwa FN, 1996, J BIOL CHEM, V271, P19159, DOI 10.1074/jbc.271.32.19159; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; MANZI A, 1995, J BIOL CHEM, V270, P9154, DOI 10.1074/jbc.270.16.9154; Martin NB, 1996, SEMIN THROMB HEMOST, V22, P247, DOI 10.1055/s-2007-999015; MASSON PJ, 1995, J BIOL CHEM, V270, P2662, DOI 10.1074/jbc.270.6.2662; Miura Y, 1997, BIOCHEM BIOPH RES CO, V241, P698, DOI 10.1006/bbrc.1997.7876; MOHLA S, 1990, ANTICANCER RES, V10, P1515; MOLYNEUX RJ, 1993, ARCH BIOCHEM BIOPHYS, V304, P81, DOI 10.1006/abbi.1993.1324; NAKAMURA T, 1994, BIOCHEM J, V304, P731, DOI 10.1042/bj3040731; NAKATO H, 1995, DEVELOPMENT, V121, P3687; NEVILLE DCA, 1995, BIOCHEM J, V307, P791, DOI 10.1042/bj3070791; NEWTON SA, 1989, JNCI-J NATL CANCER I, V81, P1024, DOI 10.1093/jnci/81.13.1024; NICOLAS G, 1995, PHYTOCHEMISTRY, V38, P225, DOI 10.1016/0031-9422(94)00622-Z; Pakulski G, 1996, PHYTOCHEMISTRY, V41, P775, DOI 10.1016/0031-9422(96)89675-0; PAULSEN H, 1995, CARBOHYD RES, V275, P403, DOI 10.1016/0008-6215(95)00056-Y; PEI Y H, 1990, Yaoxue Xuebao, V25, P798; PLATT FM, 1994, J BIOL CHEM, V269, P27108; PLATT FM, 1994, J BIOL CHEM, V269, P8362; Platt FM, 1997, J BIOL CHEM, V272, P19365, DOI 10.1074/jbc.272.31.19365; Portner A, 1996, GLYCOBIOLOGY, V6, P7, DOI 10.1093/glycob/6.1.7; PULVERER G, 1988, J CANCER RES CLIN, V114, P217, DOI 10.1007/BF00417842; RAPRAEGER A, 1989, ANAL BIOCHEM, V179, P361, DOI 10.1016/0003-2697(89)90145-0; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; ROBINSON JA, 1985, BIOCHEM J, V227, P805, DOI 10.1042/bj2270805; Roden L., 1972, METHODS ENZYMOLOGY, V28, P73; Sarkar AK, 1997, J BIOL CHEM, V272, P25608, DOI 10.1074/jbc.272.41.25608; SARKAR AK, 1995, P NATL ACAD SCI USA, V92, P3323, DOI 10.1073/pnas.92.8.3323; Schultes R. E., 1990, HEALING FOREST MED T; SCHWARTZ NB, 1977, J BIOL CHEM, V252, P6316; SCHWARTZ NB, 1976, BIOCHEM BIOPH RES CO, V71, P851, DOI 10.1016/0006-291X(76)90909-8; SHIBATA S, 1995, J BIOL CHEM, V270, P13794, DOI 10.1074/jbc.270.23.13794; Takagaki K, 1996, J BIOCHEM-TOKYO, V119, P697; THOMAS SS, 1995, BBA-MOL BASIS DIS, V1272, P37, DOI 10.1016/0925-4439(95)00065-C; URZUA A, 1995, PHYTOCHEMISTRY, V39, P1489, DOI 10.1016/0031-9422(95)00109-K; URZUA A, 1995, PHYTOCHEMISTRY, V38, P555, DOI 10.1016/0031-9422(94)00590-P; WINCHESTER B, 1992, BIOCHEM SOC T, V20, P699, DOI 10.1042/bst0200699; WINCHESTER B, 1992, GLYCOBIOLOGY, V2, P199, DOI 10.1093/glycob/2.3.199; WOYNAROWSKA B, 1994, J BIOL CHEM, V269, P22797; Woynarowska B, 1996, GLYCOCONJUGATE J, V13, P663, DOI 10.1007/BF00731455; YAGEL S, 1989, INT J CANCER, V44, P685, DOI 10.1002/ijc.2910440422; Yu BY, 1996, PHYTOCHEMISTRY, V43, P201, DOI 10.1016/0031-9422(96)00228-2; ZACHARIAS C, 1994, J BIOL CHEM, V269, P13313; Zhong XN, 1997, PHYTOCHEMISTRY, V46, P943, DOI 10.1016/S0031-9422(97)00366-X; ZHUANG D, 1991, Glycobiology, V1, P425, DOI 10.1093/glycob/1.4.425	81	8	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22260	22266		10.1074/jbc.273.35.22260	http://dx.doi.org/10.1074/jbc.273.35.22260			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712841	hybrid			2022-12-25	WOS:000075616600017
J	Khvotchev, M; Sudhof, TC				Khvotchev, M; Sudhof, TC			Newly synthesized phosphatidylinositol phosphates are required for synaptic norepinephrine but not glutamate or gamma-aminobutyric acid (GABA) release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED SECRETION; PHOSPHOINOSITIDES; EXPRESSION; REGULATORS; EXOCYTOSIS; ISOFORMS; BINDING; DOMAINS; BRAIN	Newly synthesized phosphatidylinositol phosphates have been implicated in many membrane-trafficking reactions. They are essential for exocytosis of norepinephrine in PC12 cells and chromaffin cells, suggesting a function in membrane fusion. We have now studied the role of phosphatidylinositol phosphates in synaptic vesicle exocytosis using synaptosomes. Under conditions where phosphorylation of phosphatidylinositols is blocked, norepinephrine secretion was nearly abolished whereas glutamate and GABA release was still elicited. Thus phosphatidylinositides are essential only for some membrane fusion reactions, and exocytotic release mechanisms differ between neurotransmitters.	Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75235 USA.		Khvotchev, Mikhail/G-5411-2013	Khvotchev, Mikhail/0000-0001-9328-8549	PHS HHS [R01-50824] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAJJALIEH SM, 1994, J NEUROSCI, V14, P5223, DOI 10.1523/jneurosci.14-09-05223.1994; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; FAIN JN, 1979, BIOCHEM J, V178, P45, DOI 10.1042/bj1780045; FYKSE EM, 1993, J NEUROSCI, V13, P4997; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HOKIN MR, 1954, J BIOL CHEM, V209, P549; Katz B., 1969, RELEASE NEURAL TRANS; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Loyet KM, 1998, J BIOL CHEM, V273, P8337, DOI 10.1074/jbc.273.14.8337; Martin TFJ, 1997, CURR OPIN NEUROBIOL, V7, P331, DOI 10.1016/S0959-4388(97)80060-8; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; Mehrotra B, 1997, J BIOL CHEM, V272, P4237, DOI 10.1074/jbc.272.7.4237; NAGY A, 1984, J NEUROCHEM, V43, P1114, DOI 10.1111/j.1471-4159.1984.tb12851.x; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; SCHAEFER T, 1994, ANN NY ACAD SCI, V710, P356, DOI 10.1111/j.1749-6632.1994.tb26642.x; SCHELLER RH, 1995, NEURON, V14, P893; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; TURNER TJ, 1993, P NATL ACAD SCI USA, V90, P9518, DOI 10.1073/pnas.90.20.9518; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; Willars GB, 1998, J BIOL CHEM, V273, P5037, DOI 10.1074/jbc.273.9.5037	27	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21451	21454		10.1074/jbc.273.34.21451	http://dx.doi.org/10.1074/jbc.273.34.21451			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705272	hybrid			2022-12-25	WOS:000075492600006
J	Vanhamme, L; Perez-Morga, D; Marchal, C; Speijer, D; Lambert, L; Geuskens, M; Alexandre, S; Ismaili, N; Goringer, U; Benne, R; Pays, E				Vanhamme, L; Perez-Morga, D; Marchal, C; Speijer, D; Lambert, L; Geuskens, M; Alexandre, S; Ismaili, N; Goringer, U; Benne, R; Pays, E			Trypanosoma brucei TBRGG1, a mitochondrial oligo(U)-binding protein that co-localizes with an in vitro RNA editing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUIDE RNA; GENE-EXPRESSION; IN-VITRO; MESSENGER-RNA; RIBONUCLEOPROTEIN COMPLEXES; POSTTRANSCRIPTIONAL CONTROL; CRITHIDIA-FASCICULATA; AFRICAN TRYPANOSOMES; SURFACE GLYCOPROTEIN; BINDING PROTEIN	We report the characterization of a Trypanosoma brucei 75-kDa protein of the RGG (Arg-Gly-Gly) type, termed TBRGG1, Dicistronic and monocistronic transcripts of the TBRGG1 gene were produced by both alternative splicing and polyadenylation, TBRGG1 was found in two or three forms that differ in their electrophoretic mobility on SDS-polyacrylamide gel electrophoresis gels, one of which was more abundant in the procyclic form of the parasite. TBRGG1 was localized to the mitochondrion and appeared to be more abundant in bloodstream intermediate and stumpy forms in which the mitochondrion reactivates and during the procyclic stage, which possesses a fully functional mitochondrion. This protein was characterized to display oligo(U) binding characteristics and was found to co-localize with an in vitro RNA editing activity in a sedimentation analysis. TBRGG1 most likely corresponds to the 83-kDa oligo (U)-binding protein previously identified by UV cross-linking of guide RNA to mitochondrial lysates (Leegwater, P,, Speijer, D,, and Benne, R, (1995) fur. J, Biochem, 227, 780-786).	Free Univ Brussels, Dept Biol Mol, B-1640 Rhode St Genese, Belgium; Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands; Max Planck Inst Biochem, Gene Ctr Munich, D-82152 Martinsried, Germany	University of Amsterdam; Academic Medical Center Amsterdam; Max Planck Society	Pays, E (corresponding author), Free Univ Brussels, Dept Biol Mol, 67 Rue Chevaux, B-1640 Rhode St Genese, Belgium.	epays@dbm.ulb.ac.be	Speijer, Dave/AAE-4613-2019	Speijer, Dave/0000-0002-2340-2753; Perez-Morga, David/0000-0002-7168-1865				ADLER BK, 1991, MOL CELL BIOL, V11, P5878, DOI 10.1128/MCB.11.12.5878; BENAMAR MF, 1988, MOL CELL BIOL, V8, P2166, DOI 10.1128/MCB.8.5.2166; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUN R, 1979, ACTA TROP, V36, P289; Byrne EM, 1996, EMBO J, V15, P6758, DOI 10.1002/j.1460-2075.1996.tb01065.x; CHUNG HM, 1992, PARASITOL TODAY, V8, P414, DOI 10.1016/0169-4758(92)90194-7; Clayton C, 1996, MOL BIOCHEM PARASIT, V77, P1, DOI 10.1016/0166-6851(96)02587-X; Corell RA, 1996, MOL CELL BIOL, V16, P1410; CruzReyes J, 1996, P NATL ACAD SCI USA, V93, P8901, DOI 10.1073/pnas.93.17.8901; Das A, 1996, J BIOL CHEM, V271, P15675, DOI 10.1074/jbc.271.26.15675; ERONDU NE, 1992, MOL BIOCHEM PARASIT, V51, P111, DOI 10.1016/0166-6851(92)90206-Y; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; GORINGER HU, 1994, P NATL ACAD SCI USA, V91, P1776, DOI 10.1073/pnas.91.5.1776; GRAHAM SV, 1995, PARASITOL TODAY, V11, P217, DOI 10.1016/0169-4758(95)80081-6; HAJDUK SL, 1996, MOL BIOL PARASITIC P, P134; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; HEHL A, 1994, PARASITOL TODAY, V10, P442, DOI 10.1016/0169-4758(94)90180-5; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KOLLER J, 1994, NUCLEIC ACIDS RES, V22, P1988, DOI 10.1093/nar/22.11.1988; Koller J, 1997, J BIOL CHEM, V272, P3749, DOI 10.1074/jbc.272.6.3749; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LEEGWATER P, 1995, EUR J BIOCHEM, V227, P780, DOI 10.1111/j.1432-1033.1995.tb20201.x; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; PAYS E, 1993, MOL BIOCHEM PARASIT, V61, P107, DOI 10.1016/0166-6851(93)90163-R; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; PAYS E, 1989, MOL CELL BIOL, V9, P4018, DOI 10.1128/MCB.9.9.4018; PAYS E, 1996, MOL BIOL PARASITIC P, P88; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; READ LK, 1994, MOL CELL BIOL, V14, P2629, DOI 10.1128/MCB.14.4.2629; REVELARD P, 1993, MOL BIOCHEM PARASIT, V62, P93, DOI 10.1016/0166-6851(93)90181-V; RODITI I, 1989, J CELL BIOL, V108, P737, DOI 10.1083/jcb.108.2.737; Rusche LN, 1997, EMBO J, V16, P4069, DOI 10.1093/emboj/16.13.4069; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; Sloof P, 1997, TRENDS MICROBIOL, V5, P189, DOI 10.1016/S0966-842X(97)01034-2; STUART K, 1984, J PARASITOL, V70, P747, DOI 10.2307/3281757; ULLU E, 1996, MOL BIOL PARASITIC P, P115	41	85	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21825	21833		10.1074/jbc.273.34.21825	http://dx.doi.org/10.1074/jbc.273.34.21825			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705321	hybrid			2022-12-25	WOS:000075492600055
J	Lohi, O; Poussu, A; Merilainen, J; Kellokumpu, S; Wasenius, VM; Lehto, VP				Lohi, O; Poussu, A; Merilainen, J; Kellokumpu, S; Wasenius, VM; Lehto, VP			EAST, an epidermal growth factor receptor- and Eps15-associated protein with Src homology 3 and tyrosine-based activation motif domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE SUBSTRATE EPS15; ZINC-FINGER DOMAIN; SIGNAL-TRANSDUCTION; BINDING DOMAIN; EGF RECEPTOR; SH2 DOMAINS; PHOSPHORYLATION; IDENTIFICATION; ASSOCIATION; RECOGNITION	We describe the cloning and characterization of a new cytoplasmic protein designated epidermal growth factor receptor-associated protein with SH3- and TAM domains (EAST). It contains an Src homology 3 domain in its midregion and a tyrosine-based activation motif in its COOH terminus. Antibodies to EAST recognize a 68-kDa protein that is present in most chicken tissues. An epidermal growth factor (EGF) dependent association between the EGF receptor (EGFR) and EAST was shown by reciprocal immunoprecipitation/immunoblotting studies with specific antibodies. Activated EGFR catalyzed the tyrosine phosphorylation of EAST, as judged by an in vitro kinase assay with both immunoprecipitated and purified EGFR Immunoprecipitation/immunoblotting experiments also demonstrated an association between EAST and eps15, an EGFR substrate associated with clathrin-coated pits and vesicles, which is essential in the endocytotic pathway. The association between EAST and eps15 was not affected by EGF treatment. In immunofluorescence microscopy, EAST was shown to partially colocalize with clathrin. The sequence of the NH2-terminal portion of EAST shows a high degree of similarity with a group of proteins involved in endocytosis or vesicle trafficking. Thus, EAST is a novel signal transduction component probably involved in EGF signaling and in the endocytotic machinery.	Univ Oulu, Dept Pathol, FIN-90220 Oulu, Finland; Univ Oulu, Dept Anat, FIN-90220 Oulu, Finland; Univ Helsinki, Cent Hosp, Dept Radiotherapy & Oncol, FIN-00290 Helsinki, Finland	University of Oulu; University of Oulu; University of Helsinki; Helsinki University Central Hospital	Lehto, VP (corresponding author), Univ Oulu, Dept Pathol, Kajaanintie 52 D, FIN-90220 Oulu, Finland.	lehto@csc.fi	Lohi, Olli/AAW-6157-2021	Lohi, Olli/0000-0001-9195-0797				ALVAREZ CV, 1995, J BIOL CHEM, V270, P16271, DOI 10.1074/jbc.270.27.16271; Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Carbone R, 1997, CANCER RES, V57, P5498; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Merilainen J, 1997, J BIOL CHEM, V272, P23278, DOI 10.1074/jbc.272.37.23278; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; REIZMAN H, 1997, CELL, V91, P731; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Seaman MNJ, 1996, CURR OPIN CELL BIOL, V8, P549, DOI 10.1016/S0955-0674(96)80034-2; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	32	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21408	21415		10.1074/jbc.273.33.21408	http://dx.doi.org/10.1074/jbc.273.33.21408			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694904	hybrid			2022-12-25	WOS:000075386100097
J	Yu, JM; Wessling-Resnick, M				Yu, JM; Wessling-Resnick, M			Structural and functional analysis of SFT, a stimulator of Fe transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT IRON TRANSPORT; CELLS; EXPRESSION; PROTEIN; BINDING; SYSTEM	Previous studies demonstrated that SFT (Stimulator of Fe Transport) facilitates both transferrin and nontransferrin-bound iron uptake in HeLa cells (Yu, J,, and Wessling-Resnick, M, (1998) J, Biol. Chem, 273, 6909-6915), To further characterize the structure and function of SFT, we studied this human factor in rodent BHR cells. Kyte-Doolittle analysis suggests that SFT has six transmembrane-spanning segments. This transport protein also displays an REXXE motif resembling domains involved in iron binding by ferritin and in iron uptake mediated by the yeast transporter Ftr1, Using N- and C-terminal epitope tags, we have identified that modification of either protein terminus does not interfere with SFT function in nontransferrin-bound iron uptake. The N- and C-terminal domains are intracellularly disposed since antibodies against these epitopes fail to recognize expressed proteins unless BHK cells are solubilized with detergents. To define the topology of two large extramembranous loop domains, anti-peptide antibodies were employed; anti-loop 4 antibodies show no immunoreactivity unless cells are permeabilized but anti-loop 5 antibodies recognize and bind surface SFT. Thus, loop 4 must be intracellular while loop 5 is extracellular, These topological studies situate the putative iron-binding REXXE domain on the cytosolic face of the plasma membrane, However, Fe-55-binding studies reveal that the ability of SFT to bind and mediate transport of extracellular iron is defective in mutants with Glu --> Ala conversions in this motif, Curiously, we also find that depletion of intracellular iron by desferrioxamine impairs SFT transport and iron-binding functions. These observations lead to the speculation that the REXXE motif may play an important role in regulating SFT activity through interaction with intracellular iron and demonstrate that iron transport mediated by SFT is itself an iron-dependent process.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Wessling-Resnick, M (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.				NIDDK NIH HHS [DK52371] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052371] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Askwith C, 1997, J BIOL CHEM, V272, P401; BASSET P, 1986, CANCER RES, V46, P1644; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Gutierrez JA, 1997, J CELL BIOL, V139, P895, DOI 10.1083/jcb.139.4.895; INMAN RS, 1993, J BIOL CHEM, V268, P8521; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; Luo C, 1996, MOL CELL BIOL, V16, P3955; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; STURROCK A, 1990, J BIOL CHEM, V265, P3139; TEICHMANN R, 1990, J CLIN INVEST, V86, P2145, DOI 10.1172/JCI114953; TRIKHA J, 1995, J MOL BIOL, V248, P949, DOI 10.1006/jmbi.1995.0274; Yu JM, 1998, J BIOL CHEM, V273, P6909, DOI 10.1074/jbc.273.12.6909	16	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21380	21385		10.1074/jbc.273.33.21380	http://dx.doi.org/10.1074/jbc.273.33.21380			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694900	hybrid			2022-12-25	WOS:000075386100093
J	Yuan, Y; Mead, D; Schroeder, BG; Zhu, YQ; Barry, CE				Yuan, Y; Mead, D; Schroeder, BG; Zhu, YQ; Barry, CE			The biosynthesis of mycolic acids in Mycobacterium tuberculosis - Enzymatic methyl(ene) transfer to acyl carrier protein bound meromycolic acid in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE-EXTRACTS; FATTY-ACIDS; AURUM; WALL; IDENTIFICATION; CONDENSATION; SMEGMATIS; SYSTEM	A closely related family of enzymes from Mycobacterium tuberculosis has been shown by heterologous expression to catalyze the modification of mycolic acids through the addition of a methyl (or methylene) group derived from S-adenosyl-L-methionine (SAM). Overproduction of all six of these enzymes in Escherichia coli and subsequent in vitro reactions with heat-inactivated acceptor fractions derived from Mycobacterium smegmatis in the presence of [methyl-H-3]SAM demonstrated that the immediate substrate to which methyl group addition occurs was a family of very long-chain fatty acids. Inhibitors of methyl transfer, such as S-adenosyl-L-homocysteine and sinefungin, were shown to inhibit this reaction but had no effect on whole cells of either M. smegmatis or M. tuberculosis. Purified mycolic acids from M. tuberculosis were pyrolyzed, and the resulting meroaldehyde was oxidized and methylated to produce full-length methyl meromycolates. These esters were shown to comigrate with a fraction of the acceptor from the in vitro reactions, suggesting that methyl group addition occurs up to the level of the meromycolate, Protease and other treatments destroyed the activity of the acceptor fraction, which was also found to be extremely sensitive to basic pH. Antibody to the acyl carrier protein AcpM, which has recently been shown to be the carrier of full-length meromycolate produced by a unique type II fatty acid synthase system, inhibited the cell-free methyl(en)ation of these acids. These results suggest that mycolate modification reactions occur parallel with the synthesis of the AcpM-bound meromycolate chain.	NIAID, Rocky Mt Labs, TB Res Stn, Lab Intracellular Parasites,NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Barry, CE (corresponding author), NIAID, Rocky Mt Labs, TB Res Stn, Lab Intracellular Parasites,NIH, 903 S 4th St, Hamilton, MT 59840 USA.		Barry, Clifton E/ABE-7992-2020; Barry, III, Clifton/H-3839-2012	Barry, Clifton E/0000-0002-2927-270X; Barry, III, Clifton/0000-0002-2927-270X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000783] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BARRY CE, 1992, SCIENCE, V256, P377, DOI 10.1126/science.256.5055.377; BARRY CE, 1998, IN PRESS PROG LIPID; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Fersht A., 1985, ENZYME STRUCTURE MEC; GEORGE KM, 1995, J BIOL CHEM, V270, P27292, DOI 10.1074/jbc.270.45.27292; HAMID ME, 1993, J GEN MICROBIOL, V139, P2203, DOI 10.1099/00221287-139-9-2203; KREMBEL J, 1966, TETRAHEDRON, V22, P1113, DOI 10.1016/0040-4020(66)80087-X; LACAVE C, 1990, BIOCHIM BIOPHYS ACTA, V1045, P58, DOI 10.1016/0005-2760(90)90203-A; LACAVE C, 1990, BIOCHIM BIOPHYS ACTA, V1042, P315, DOI 10.1016/0005-2760(90)90159-U; Lee RE, 1997, BBA-LIPID LIPID MET, V1346, P275, DOI 10.1016/S0005-2760(97)00051-9; Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545; LIU J, 1998, MYCOBACTERIA MOL BIO, P1; LOPEZMARIN LM, 1991, BIOCHIM BIOPHYS ACTA, V1086, P22, DOI 10.1016/0005-2760(91)90150-G; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; PUGH CSG, 1982, BIOCHEMISTRY-US, V21, P1535, DOI 10.1021/bi00536a011; QURESHI N, 1984, J BACTERIOL, V157, P46, DOI 10.1128/JB.157.1.46-52.1984; QURESHI N, 1980, J BIOL CHEM, V255, P182; Ratledge C., 1982, BIOL MYCOBACTERIA, P53; Stodola FH, 1938, J BIOL CHEM, V126, P505; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAKAYAMA K, 1978, LIPIDS, V13, P575, DOI 10.1007/BF02535818; TAKAYAMA K, 1978, AM REV RESPIR DIS, V118, P113; TAKAYAMA K, 1979, BIOL BIOMEDICAL APPL, P375; TAYLOR FR, 1979, BIOCHEMISTRY-US, V18, P3292, DOI 10.1021/bi00582a015; TRAGER W, 1980, EXP PARASITOL, V50, P83, DOI 10.1016/0014-4894(80)90010-7; WHEELER PR, 1993, BIOCHIM BIOPHYS ACTA, V1167, P182, DOI 10.1016/0005-2760(93)90160-B; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630; Yuan Y, 1996, P NATL ACAD SCI USA, V93, P12828, DOI 10.1073/pnas.93.23.12828; Yuan Y, 1997, J BIOL CHEM, V272, P10041	31	58	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21282	21290		10.1074/jbc.273.33.21282	http://dx.doi.org/10.1074/jbc.273.33.21282			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694888	hybrid			2022-12-25	WOS:000075386100081
J	Pierce, A; Owen-Lynch, PJ; Spooncer, E; Dexter, TM; Whetton, AD				Pierce, A; Owen-Lynch, PJ; Spooncer, E; Dexter, TM; Whetton, AD			P210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia	ONCOGENE			English	Article						Bcr-Abl; chronic myeloid leukaemia; stem cell line	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; PHILADELPHIA-CHROMOSOME; TRANSFORMATION; GROWTH; PROTEIN; GENE; PROLIFERATION; INTERLEUKIN-3; CONSEQUENCES	Chronic myeloid leukaemia (CML) is a clonal disorder of the pluripotent haemopoietic stem cell, the hallmark of which is the constitutively activated Bcr-Abl protein tyrosine kinase. During the initial chronic phase of CML the primitive multipotent leukaemic progenitor cells remain growth factor dependant and are capable of producing terminally differentiated cells. Although the available evidence suggests that Bcr-Abl directly affects signalling pathways involved in controlling the development of primitive haemopoietic progenitors the identification of the specific biological consequences of Bcr - Abl activity in these progenitors has been hampered by the lack of suitable systems modelling CML, By transfecting the multipotent haemopoietic cell line FDCP-Mix with a temperature sensitive mutant of Bcr-Abl we have developed the first working model that mirrors the chronic phase of CML, FDCP-Mix cells expressing Bcr-Abl tyrosine kinase activity remain growth factor dependent and retain their ability to differentiate. Normal neutrophilic cells are formed in response to CSF and GM-CSF, In addition, the transfected FDCP-Mix cells grown at the permissive temperature for Bcr-Abl tyrosine kinase activity display enhanced survival and proliferation in low concentrations of growth factor, These findings are consistent with the initial subtle changes seen in CML progenitor cells during the chronic phase and confirm that Bcr-Abl effects are context specific, i.e, they depend on the origin and developmental potential of the transfected cells, This questions the significance of studies in non-haemopoietic and differentiation blocked haemopoietic cells.	Univ Manchester, Leukaemia Res Fund Cellular Dev Unit, Manchester M60 1QD, Lancs, England; Univ Manchester, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Expt Haematol, Manchester M20 9BX, Lancs, England	University of Manchester; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Whetton, AD (corresponding author), Univ Manchester, Leukaemia Res Fund Cellular Dev Unit, Sackville St, Manchester M60 1QD, Lancs, England.			WHETTON, ANTHONY D/0000-0002-1098-3878; Owen-Lynch, Penelope Jane/0000-0002-5928-2327; Pierce, Andrew/0000-0001-5995-2469				BEDI A, 1994, BLOOD, V83, P2038; CARLESSO N, 1994, ONCOGENE, V9, P149; CLARKSON B, 1993, LEUKEMIA, V7, P1683; COTTER TG, 1995, LEUKEMIA LYMPHOMA, V18, P231, DOI 10.3109/10428199509059612; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; DALEY GQ, 1991, ADV CANCER RES, V57, P151; Eaves C, 1985, Prog Clin Biol Res, V184, P403; EAVES C, 1994, BLOOD CELLS, V20, P83; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; Gotoh A, 1997, Curr Opin Hematol, V4, P3; Hariharan I K, 1988, Oncogene Res, V3, P387; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LANEUVILLE P, 1992, BLOOD, V80, P1788; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; RASKIND WH, 1987, ADV CANCER RES, V49, P127, DOI 10.1016/S0065-230X(08)60796-4; SAWYERS CL, 1993, LEUKEMIA LYMPHOMA, V11, P101, DOI 10.3109/10428199309064268; SCHERLE PA, 1990, P NATL ACAD SCI USA, V87, P1908, DOI 10.1073/pnas.87.5.1908; SPOONCER E, 1994, LEUKEMIA, V8, P620; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; WANG J Y J, 1992, Current Biology, V2, P70, DOI 10.1016/0960-9822(92)90198-J; WETZLER M, 1993, LEUKEMIA LYMPHOMA, V11, P47, DOI 10.3109/10428199309047863; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079	30	32	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	1998	17	5					667	672		10.1038/sj.onc.1201969	http://dx.doi.org/10.1038/sj.onc.1201969			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704934				2022-12-25	WOS:000075195300016
J	Dang, A; Frost, JA; Cobb, MH				Dang, A; Frost, JA; Cobb, MH			The MEK1 proline-rich insert is required for efficient activation of the mitogen-activated protein kinases ERK1 and ERK2 in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASES; MAP KINASE; PHOSPHORYLATION; IDENTIFICATION; RAF; TRANSFORMATION; CLONING; STE5	MEK1 and MEK2 contain a proline-rich insert not present in any other known MER. (MAP (mitogen-activated protein)/ERK (extracellular signal-regulated kinase) kinase) family members. We examined the effect of removing the MEK1 polyproline insert on MEK activity, its binding to Raf, and its ability to activate ERKs in cells. Deletion of the insert had no effect on either the activity of MEK1 or on its ability to bind to Raf-l. Both wild type and constitutively active MEK1 coimmunoprecipitated with Raf-l whether or not the insert was present. Deletion of the insert did not reduce activation of MEK1 by EGF or activated Raf in cells. The proline-rich insert enhanced the ability of an otherwise equally active MEK1 protein to regulate endogeneous ERKs in mammalian cells. Overexpression of either constitutively active MEK1 lacking the insert or ERK2 compensates for the weaker in vivo activity of the MEK1 deletion mutant. Expression of the insert in cells reduced activation of ERKs by EGF. We conclude that the proline-rich insert is not the site of the MEK-Raf interaction and that the polyproline insert is required for its efficient activation of downstream ERKs in cells.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Dang, A (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.			Frost, Jeffrey/0000-0001-9722-1536; Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK34128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CHIYING FH, 1996, P NATL ACAD SCI USA, V93, P10078; CHOI KY, 1994, CELL, V78, P499; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT A, 1995, J BIOL CHEM, V270, P24540, DOI 10.1074/jbc.270.41.24540; SEGER R, 1992, J BIOL CHEM, V267, P25628; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	32	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19909	19913		10.1074/jbc.273.31.19909	http://dx.doi.org/10.1074/jbc.273.31.19909			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677429	hybrid			2022-12-25	WOS:000075125200081
J	Schroeder, SC; Weil, PA				Schroeder, SC; Weil, PA			Genetic tests of the role of Abf1p in driving transcription of the yeast TATA box bindng protein-encoding gene, SPT15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL PREINITIATION COMPLEX; SACCHAROMYCES-CEREVISIAE; MULTISUBUNIT COMPLEX; SHUTTLE VECTORS; BINDING PROTEIN; QCR8 GENE; DNA; ACTIVATION; ELEMENTS; CIS	In this report we describe studies which utilized yeast strains bearing gain and loss of function alleles of ABF1 in order to attempt to directly implicate Abf1p in modulating transcription of the TBP-encoding gene, SPT15, in vivo. We found that overexpression of Abf1p in a yeast cell increased transcription of the TBP-encoding gene and that this stimulation depended upon the exact sequence of the Abf1p binding site (ABF1) present in the gene. Further, in a yeast strain expressing a temperature sensitive form of Abf1p, occupancy of the chromosomal ABF1 site in the TBP-encoding gene was immediately lost following a temperature shift. Both results suggest that Abf1p drives transcription of the TBP-encoding gene. Surprisingly though we found that continuous ABF1 cis-element occupancy by Abf1p was not acutely required for normal levels of transcription of either the TBP-encoding gene or other "Abf1p-driven" genes tested. We propose a model to explain these results and suggest mechanisms by which Abf1p could activate gene transcription.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Weil, PA (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.				NIGMS NIH HHS [GM52461] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM052461, R01GM052461] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOSTI DN, 1993, EMBO J, V12, P157, DOI 10.1002/j.1460-2075.1993.tb05641.x; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; CHODER M, 1991, GENE DEV, V5, P2315, DOI 10.1101/gad.5.12a.2315; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DELLASETA F, 1990, MOL CELL BIOL, V10, P2437, DOI 10.1128/MCB.10.5.2437; DEWINDE JH, 1993, YEAST, V9, P847, DOI 10.1002/yea.320090805; DEWINDE JH, 1992, MOL CELL BIOL, V12, P2872, DOI 10.1128/MCB.12.6.2872; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FRANCESCONI SC, 1991, P NATL ACAD SCI USA, V88, P4089, DOI 10.1073/pnas.88.10.4089; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P398; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAMIL KG, 1988, MOL CELL BIOL, V8, P4328, DOI 10.1128/MCB.8.10.4328; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; Holmes SG, 1996, GENE DEV, V10, P1021, DOI 10.1101/gad.10.8.1021; Kim S, 1997, P NATL ACAD SCI USA, V94, P820, DOI 10.1073/pnas.94.3.820; Klebanow ER, 1996, J BIOL CHEM, V271, P13706, DOI 10.1074/jbc.271.23.13706; LOO S, 1995, GENETICS, V141, P889; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MCBROOM LDB, 1994, J BIOL CHEM, V269, P16461; MIRKOVITCH J, 1992, MOL CELL BIOL, V12, P1; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; SCHROEDER SC, 1994, J BIOL CHEM, V269, P28335; SIKORSKI RS, 1989, GENETICS, V122, P19; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; UPTON T, 1995, J BIOL CHEM, V270, P16153, DOI 10.1074/jbc.270.27.16153; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; Werner MH, 1997, CELL, V88, P733, DOI 10.1016/S0092-8674(00)81917-0; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167	44	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19884	19891		10.1074/jbc.273.31.19884	http://dx.doi.org/10.1074/jbc.273.31.19884			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677425	hybrid			2022-12-25	WOS:000075125200077
J	Naruse, K; Yamada, T; Sai, XR; Hamaguchi, M; Sokabe, M				Naruse, K; Yamada, T; Sai, XR; Hamaguchi, M; Sokabe, M			Pp125(FAK) is required for stretch dependent morphological response of endothelial cells	ONCOGENE			English	Article						uni-axial cyclic stretch; HVJ-liposome; antisense phosphorothioate oligodeoxynucleotides; stretch-activated ion channel	PROTEIN-TYROSINE KINASE; ACTIVATED ION CHANNELS; FOCAL ADHESIONS; HERBIMYCIN-A; PHOSPHORYLATION; ANTIBODIES; INHIBITOR; PAXILLIN; VINCULIN	In this study, critical signaling pathway required for the stretch induced morphological changes of human umbilical endothelial cells (HUVECs) was investigated. Uniaxial cyclic stretch (1 Hz, 20% in length) of the cells cultured on an elastic silicon membrane induced a gradual morphological change in the cells from a polygonal shape to an elongated spindle-like shape whose long axis was aligned perpendicular to the stretch axis, We found that protein tyrosine phosphorylation of cellular proteins increased and peaked at 20 min in response to cyclic stretch. Either treatment of cells with gadolinium (Gd3+), a potent blocker for stretch-activated channels, or removal of extracellular Ca2+ blocked the tyrosine phosphorylation of the proteins, suggesting that stretch-activated (SA) ion channels regulated stretch specific tyrosine phosphorylation, The major phosphorylated proteins had molecular masses of approximately 120-135 kDa, and 70 kDa, Immunoprecipitation experiments revealed that paxillin, focal adhesion kinase (pp125(FAK)) and pp130(CAS) were included in the 70 kDa and 120-135 kDa bands, respectively, The morphological change was inhibited by herbimycin A and genistein, inhibitors of tyrosine kinases, suggesting that tyrosine phosphorylation was required for the morphological change, In addition, the kinase activation of pp125(FAK) was observed in response to cyclic stretch, Moreover, suppression of pp125(FAK) expression by the antisense phosphorothioate oligodeoxynucleotides (S-ODN) in HUVECs resulted in inhibition of tyrosine phosphorylation of paxillin and the stretch-dependent morphological changes. These results suggest that an activation of tyrosine kinase(s) by an increase in intracellular Ca2+ and pp125(FAK) play a critical role in the unique morphological change specifically observed in endothelial cells subjected to uni-axial cyclic stretch.	Nagoya Univ, Sch Med, Dept Physiol, Showa Ku, Nagoya, Aichi 466, Japan; Nagoya Univ, Sch Med, Dis Mechanism & Control Res Inst, Showa Ku, Nagoya, Aichi 466, Japan	Nagoya University; Nagoya University	Naruse, K (corresponding author), Nagoya Univ, Sch Med, Dept Physiol, Showa Ku, 65 Tsuramai Cho, Nagoya, Aichi 466, Japan.		NARUSE, Keiji/B-1620-2011; Sokabe, Masahiro/I-1565-2012	naruse, keiji/0000-0003-4100-6444				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BIALECKI RA, 1992, AM J PHYSIOL, V263, pL602, DOI 10.1152/ajplung.1992.263.5.L602; BOWMAN CL, 1992, BRAIN RES, V584, P272, DOI 10.1016/0006-8993(92)90906-P; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CEMERIKIC D, 1993, AM J PHYSIOL, V264, pF697, DOI 10.1152/ajprenal.1993.264.4.F697; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; FRANKE RP, 1984, NATURE, V307, P648, DOI 10.1038/307648a0; GRIMBRONE MA, 1976, PROGR HEMOSTASIS THR, P1; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; IBA T, 1991, MICROVASC RES, V42, P245, DOI 10.1016/0026-2862(91)90059-K; ILLE D, 1995, NATURE, V377, P539; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MASUDA M, 1990, MORPHOGENESIS FUNCTI, P325; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037, DOI 10.1152/ajpcell.1993.264.4.C1037; NARUSE K, 1998, IN PRESS AM J PHYSL; OHMORI H, 1985, J PHYSIOL-LONDON, V359, P189, DOI 10.1113/jphysiol.1985.sp015581; Okada Y, 1990, Neurosci Res Suppl, V12, pS5, DOI 10.1016/0921-8696(90)90004-M; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SATOH T, 1992, J BIOL CHEM, V267, P2537; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; SHIRINSKY VP, 1989, J CELL BIOL, V109, P331, DOI 10.1083/jcb.109.1.331; SOKABE M, 1997, PROGR CELL RES, V6, P139; TURNER CE, 1989, J BIOL CHEM, V264, P11938; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	36	87	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	1998	17	4					455	463		10.1038/sj.onc.1201950	http://dx.doi.org/10.1038/sj.onc.1201950			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696039				2022-12-25	WOS:000075043000008
J	Sithanandam, G; Ramakrishna, G; Diwan, BA; Anderson, LM				Sithanandam, G; Ramakrishna, G; Diwan, BA; Anderson, LM			Selective mutation of K-ras by N-ethylnitrosourea shifts from codon 12 to codon 61 during fetal mouse lung maturation	ONCOGENE			English	Article						fetal lung; lung tumor; gestation stage; N-ethylnitrosourea; K-ras; mutation; K-ras p21	ONCOGENE ACTIVATION; GENE-MUTATIONS; DNA-DAMAGE; A/J MICE; TUMORS; 1-ETHYL-1-NITROSOUREA; CARCINOGENESIS; ADENOCARCINOMA; NITROSAMINES; MUTAGENESIS	Fetal mouse lung before gestation day 17 shows unique sensitivity to causation of rapidly growing tumors by N-ethylnitrosourea (ENU). Since mouse lung tumors present a mutated K-ras oncogene, we hypothesized that this special susceptibility might reflect an unusual vulnerability of the K-ras gene. Of the lung tumors caused by ENU exposure of BALB/c mice on gestation day 14, 8/25 had a codon 12 mutation in K-ras, vs 4/25 in codon 61, Of 15 tumors after day 16 exposure, three had codon 12 and four codon 61 changes. Tumors from day 18 exposure had only codon 61 mutations (11/16), all A:T to G:C changes (CGA), By contrast, codon 12 (GGT) changes included G:C to T:A, to A:T,and to C:G, These results show significant (P<0.01) shift in the sensitivity of particular K-ras codons to ENU mutation, during fetal mouse lung maturation. In a test of a possible relationship to expression of K-ras, K-ras p21 was measured in lungs of fetal mice, and found to increase markedly on day 18 in comparison to days 14 and 16, Both alkylation of DIVA and base damage due to reactive oxygen species are postulated as mechanisms for mutation by ENU, whose efficacies vary with state of fetal lung maturation and K-rns expression.	SAIC Frederick, Intramural Res Support Program, Frederick, MD 21702 USA; NCI, Comparat Carcinogenesis Lab, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Sithanandam, G (corresponding author), SAIC Frederick, Intramural Res Support Program, Frederick, MD 21702 USA.							AHOTUPA M, 1987, BIOCHEM BIOPH RES CO, V146, P1047, DOI 10.1016/0006-291X(87)90753-4; AKASAKA S, 1994, MUTAT RES-DNA REPAIR, V315, P105, DOI 10.1016/0921-8777(94)90011-6; ANDERSON LM, 1989, FUND APPL TOXICOL, V12, P604, DOI 10.1016/0272-0590(89)90033-X; ANDERSON LM, 1985, NEW APPROACHES TOXIC, P179; Bal W, 1996, CHEM RES TOXICOL, V9, P535, DOI 10.1021/tx950157i; BARTSCH H, 1989, FREE RADICAL BIO MED, V7, P637, DOI 10.1016/0891-5849(89)90144-5; BRANSTETTER DG, 1987, CANCER RES, V47, P348; BRANSTETTER DG, 1988, CANCER RES, V48, P379; CHUNG FL, 1992, CARCINOGENESIS, V13, P1269, DOI 10.1093/carcin/13.7.1269; CORREA P, 1983, LANCET, V2, P595; Driscoll KE, 1997, CARCINOGENESIS, V18, P423, DOI 10.1093/carcin/18.2.423; Enright H, 1996, CARCINOGENESIS, V17, P1175, DOI 10.1093/carcin/17.5.1175; FRENKEL K, 1992, PHARMACOL THERAPEUT, V53, P127, DOI 10.1016/0163-7258(92)90047-4; Hanawalt PC, 1996, ENVIRON HEALTH PERSP, V104, P547, DOI 10.2307/3432821; Harty LC, 1996, CANCER EPIDEM BIOMAR, V5, P997; HILL DL, 1975, CANCER RES, V35, P296; Hoffmann D, 1996, CRIT REV TOXICOL, V26, P199, DOI 10.3109/10408449609017931; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; Horio Y, 1996, MOL CARCINOGEN, V17, P217, DOI 10.1002/(SICI)1098-2744(199612)17:4<217::AID-MC5>3.0.CO;2-A; HUANG X, 1995, CARCINOGENESIS, V16, P1753, DOI 10.1093/carcin/16.8.1753; Ichikawa T, 1996, CANCER LETT, V107, P165, DOI 10.1016/0304-3835(96)04351-0; JACKSON JH, 1997, ONCOGENE, V14, P2083; KAMIYA H, 1995, CARCINOGENESIS, V16, P833; KAUFFMAN SL, 1976, J NATL CANCER I, V57, P821, DOI 10.1093/jnci/57.4.821; KAWANO R, 1995, JPN J CANCER RES, V86, P802, DOI 10.1111/j.1349-7006.1995.tb03089.x; Keohavong P, 1996, CLIN CANCER RES, V2, P411; LEPAGE F, 1995, CARCINOGENESIS, V16, P2779; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MALKINSON AM, 1992, CANCER RES, V52, pS2670; Marker PC, 1997, GENETICS, V145, P435; MATZINGER SA, 1994, MOL CARCINOGEN, V11, P42, DOI 10.1002/mc.2940110108; Mooney LA, 1997, CARCINOGENESIS, V18, P503, DOI 10.1093/carcin/18.3.503; Munoz EF, 1996, CARCINOGENESIS, V17, P2741, DOI 10.1093/carcin/17.12.2741; Nakae D, 1997, CANCER RES, V57, P1281; OHMORI H, 1992, CARCINOGENESIS, V13, P851, DOI 10.1093/carcin/13.5.851; Ramakrishna G, 1998, CARCINOGENESIS, V19, P463, DOI 10.1093/carcin/19.3.463; RE FC, 1992, MOL CARCINOGEN, V5, P155, DOI 10.1002/mc.2940050211; REHM S, 1991, TOXICOL PATHOL, V19, P35, DOI 10.1177/019262339101900105; REID TM, 1994, ENVIRON HEALTH PERSP, V102, P57, DOI 10.2307/3431764; RICE JM, 1969, ANN NY ACAD SCI, V163, P813, DOI 10.1111/j.1749-6632.1969.tb24900.x; RICE JM, 1969, TRANSPLACENTAL CARCI, P71; Rodriguez H, 1997, CANCER RES, V57, P2394; Samson L, 1997, CARCINOGENESIS, V18, P919, DOI 10.1093/carcin/18.5.919; SHIBUYA T, 1993, MUTAT RES, V297, P3, DOI 10.1016/0165-1110(93)90005-8; SILINI EM, 1994, VIRCHOWS ARCH, V424, P367; SILLS RC, 1995, CARCINOGENESIS, V16, P1623, DOI 10.1093/carcin/16.7.1623; Sipowicz MA, 1997, CANCER LETT, V117, P87, DOI 10.1016/S0304-3835(97)00208-5; STORM SM, 1993, TOXICOL LETT, V67, P201, DOI 10.1016/0378-4274(93)90056-4; THOMALE J, 1994, J BIOL CHEM, V269, P1681; Thrane EV, 1997, EXP LUNG RES, V23, P35, DOI 10.3109/01902149709046046; VESSELINOVITCH S D, 1973, P14; WARNER RL, 1995, AM J RESP CELL MOL, V12, P649, DOI 10.1165/ajrcmb.12.6.7539274; Westra WH, 1996, CANCER RES, V56, P2224; YOU M, 1992, CARCINOGENESIS, V13, P1583, DOI 10.1093/carcin/13.9.1583; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; Ziegler RG, 1996, CANCER CAUSE CONTROL, V7, P157, DOI 10.1007/BF00115646	56	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					493	502		10.1038/sj.onc.1201958	http://dx.doi.org/10.1038/sj.onc.1201958			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696043				2022-12-25	WOS:000075043000012
J	Tang, XX; Pleasure, DE; Brodeur, GM; Ikegaki, N				Tang, XX; Pleasure, DE; Brodeur, GM; Ikegaki, N			A variant transcript encoding an isoform of the human protein tyrosine kinase EPHB2 is generated by alternative splicing and alternative use of polyadenylation signals	ONCOGENE			English	Article						ephrin; functional diversity; neurodevelopment	RECEPTOR; FAMILY; EXPRESSION; LIGAND; GENE; SEQUENCES; REGION; MOUSE; FORMS; EHK-1	We previously isolated and characterized cDNA clones of DRT (EPHB2), encoding a receptor protein-tyrosine kinase of the EPH family, Northern blot analysis showed that EPHB2 transcripts are expressed in three sizes of approximately 4, 5, and 11 kb, suggesting that these transcripts are generated by alternative splicing and/or alternative use of polyadenylation sites. To explore this possibility, we isolated additional EPHB2 cDNA clones, including clone 5K-1, by re-screening the human fetal brain cDNA library. Nucleotide sequence analysis of clone 5K-1 revealed that it represents a variant transcript of EPHB2 (EPHB2v), Relative to the EPHB2 cDNA sequence previously reported, clone 5K-1 has two coding region deletions of 3 and 93 nucleotides. Nucleotide sequence analyses of EPHB2 genomic DNA fragments corresponding to these deletions suggest that the EPHB2v transcript is generated by alternative splicing. The 3' end of clone 5K-1 contains a polyadenosine stretch preceded by a potential polyadenylation signal, which is not used to generate the EPHB2 transcript, Taken together, these data indicate that EPHB2v is generated by both alternative splicing and alternative use of polyadenylation sites. The EPHB2v protein lacks one arginine residue that resides immediately following the EPHB2 transmembrane domain, In contrast, as a result of the frame shift caused by the 93 nucleotide deletion, the C-terminus of the EPHB2v protein is longer by 70 amino acids than that of EPHB2. We also show that the human neuroblastoma cell line SY5Y and NTera-2N neurons express high levels of EPHB2 and lower levels of EPHB2v, These structural variations found between the EPHB2 and EPHB2v proteins may reflect functional heterogeneity of EPHB2.	Childrens Hosp, Div Neurol Res, Philadelphia, PA 19104 USA; Childrens Hosp, Div Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania	Ikegaki, N (corresponding author), Childrens Hosp, Div Neurol Res, Philadelphia, PA 19104 USA.				NCI NIH HHS [F32 CA75748] Funding Source: Medline; NINDS NIH HHS [NS08075, NS25044] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA075748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS008075, P50NS008075, R01NS025044] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Connor RJ, 1995, ONCOGENE, V11, P2429; Flanagan JG, 1997, CELL, V90, P403; IKEGAKI N, 1995, HUM MOL GENET, V4, P2033, DOI 10.1093/hmg/4.11.2033; Magal E, 1996, J NEUROSCI RES, V43, P735, DOI 10.1002/(SICI)1097-4547(19960315)43:6<735::AID-JNR10>3.0.CO;2-X; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PROUDFOOT N, 1982, NATURE, V298, P516, DOI 10.1038/298516a0; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SAJJADI FG, 1991, NEW BIOL, V3, P769; TAHIRA T, 1990, ONCOGENE, V5, P97; TAYLOR V, 1994, NEUROSCIENCE, V63, P163, DOI 10.1016/0306-4522(94)90014-0; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Xing YD, 1996, BIOTECHNIQUES, V21, P186	17	7	10	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					521	526		10.1038/sj.onc.1201960	http://dx.doi.org/10.1038/sj.onc.1201960			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696046				2022-12-25	WOS:000075043000015
J	Huang, P				Huang, P			Excision of mismatched nucleotides from DNA: a potential mechanism for enhancing DNA replication fidelity by the wild-type p53 protein	ONCOGENE			English	Article						p53; 3 '-> 5 ' exonuclease; DNA replication fidelity; nucleotide excision	C-TERMINAL DOMAIN; POLYMERASE-ALPHA; TRANSCRIPTIONAL ACTIVATION; P53-DEPENDENT APOPTOSIS; INVITRO REPLICATION; T-ANTIGEN; CELLS; EPSILON; CYTOTOXICITY; DELTA	The tumor suppressor p53 plays a critical role in the regulation of the cell cycle and the maintenance of genetic stability. The 3'-->5' exonuclease activity of p53 has recently been recognized as a novel biochemical function of this molecule, but the biological significance of this activity remains elusive. Using an in vitro DNA replication assay with purified human DNA polymerases, p53 protein, and defined DNA primer/templates, we demonstrated that the wild-type (wt) p53 protein, but not the mutant p53 protein, specifically enhanced the DNA replication fidelity of polymerase (pol) alpha, an enzyme that lacks 3'-->5' exonuclease activity. The misincorporation of non-complementary deoxynucleotides into DNA by pol alpha was substantially decreased by p53. In contrast, wt p53 showed no significant effect on replication fidelity or the rates of DNA synthesis by human pol epsilon or the bacterial enzyme pol I. Inhibition of 3'-->5' exonuclease activity by guanosine monophosphate (GMP) abolished the ability of p53 to enhance the replication fidelity of pol alpha. Quantitative analyses revealed that the 3'-->5' exonuclease activity of p53 effectively removed mismatched nucleotides from DNA in preference over matched nucleotides. Furthermore, study in intact cells revealed that the wt p53 protein was co-localized with DNA synthesis activity in S phase cells. These results suggest a possibility that the 3'-->5' exonuclease of the wt p53 protein might provide the proof-reading function for DNA pol alpha. The preferential excision of mismatched nucleotides from the replicating DNA strand appears to be a potential biochemical mechanism by which p53 enhances DNA replication fidelity and thereby helps to maintain genomic integrity.	Univ Texas, Md Anderson Canc Ctr, Dept Clin Invest, Sect Mol & Cellular Pharmacol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Huang, P (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Clin Invest, Sect Mol & Cellular Pharmacol, Houston, TX 77030 USA.				NCI NIH HHS [CA28596, CA77339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA077339, R01CA028596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Arita D, 1997, JPN J CANCER RES, V88, P39, DOI 10.1111/j.1349-7006.1997.tb00299.x; BAKER CH, 1991, J MED CHEM, V34, P1879, DOI 10.1021/jm00110a019; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BOYER JC, 1993, CANCER RES, V53, P3270; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CLARKE AR, 1994, ONCOGENE, V9, P1767; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; COX LS, 1991, CELL, V66, P271, DOI 10.1016/0092-8674(91)90617-8; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ECKERT KA, 1993, NUCLEIC ACIDS RES, V21, P5212, DOI 10.1093/nar/21.22.5212; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GANDHI V, 1990, CANCER RES, V50, P3675; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; HARPER JW, 1993, CELL, V75, P805; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; HUANG P, 1991, CANCER RES, V51, P6110; Huang P, 1997, CANCER RES, V57, P3407; HUANG P, 1990, J BIOL CHEM, V265, P16617; HUANG P, 1991, MOL PHARMACOL, V39, P449; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; Kamiya K, 1996, J BIOL CHEM, V271, P19428, DOI 10.1074/jbc.271.32.19428; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUNKEL TA, 1992, BIOESSAYS, V14, P303, DOI 10.1002/bies.950140503; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERRIL CR, 1990, METHOD ENZYMOL, V182, P477; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; Miller SD, 1997, MOL CELL BIOL, V17, P2194, DOI 10.1128/MCB.17.4.2194; MILLS AD, 1989, J CELL SCI, V94, P471; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NEVINS JR, 1992, SCIENCE, V258, P424; Peled A, 1996, CANCER RES, V56, P2148; PENG H, 1995, AM J PATHOL, V148, P643; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; Staib C, 1996, VIROLOGY, V219, P237, DOI 10.1006/viro.1996.0241; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; vanLaar T, 1996, CYTOMETRY, V25, P21, DOI 10.1002/(SICI)1097-0320(19960901)25:1<21::AID-CYTO3>3.0.CO;2-H; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALDMAN T, 1995, CANCER RES, V55, P5187; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	62	68	71	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					261	270		10.1038/sj.onc.1201946	http://dx.doi.org/10.1038/sj.onc.1201946			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690508				2022-12-25	WOS:000074947500001
J	Song, JS; Swann, PG; Szallasi, Z; Blank, U; Blumberg, PM; Rivera, J				Song, JS; Swann, PG; Szallasi, Z; Blank, U; Blumberg, PM; Rivera, J			Tyrosine phosphorylation-dependent and -independent associations of protein kinase C-delta with Src family kinases in the RBL-2H3 mast cell line: regulation of Src family kinase activity by protein kinase C-delta	ONCOGENE			English	Article						PKC-delta; Src; Lyn; mast cell; Fc epsilon RI	HIGH-AFFINITY RECEPTOR; FOCAL ADHESION KINASE; BASOPHILIC LEUKEMIA-CELLS; N-TERMINAL REGION; IGE-RECEPTOR; IMMUNOGLOBULIN-E; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; CROSS-LINKING; GAMMA-CHAIN	Src kinases and protein kinase C (PKC) have been well studied for their role in oncogenic and normal cellular processes. Herein we report on a novel regulatory pathway mediated by the interaction of PKC-delta with p53/56(Lyn) (Lyn) and with p6o(Src) (Src) that results in the phosphorylation and increased activity of Lyn and Src, In the RBL-2H3 mast cell line, the interaction of PKC-delta with Lyn required the activation of the high affinity receptor for IgE (Fc epsilon RI) while the interaction with Src was constitutive. Increased complex formation of PKC-delta with Lyn or Src led to increased serine phosphorylation and activity of the Src family kinases, Conversely, Lyn was found to phosphorylate Lyn-associated and recombinant PKC-delta in vitro and the tyrosine 52 phosphorylated PKC-delta was recruited to associate with the Lyn SH2 domain. The constitutive association of PKC-delta with Src did not result in the tyrosine phosphorylation of PKC-delta prior to or after Fc epsilon RI engagement, However in cells over-expressing PKC-delta, Fc epsilon RI engagement resulted in the dramatic inhibition of Src activity and some inhibition of Lyn activity, Thus, the interaction and cross-talk of PKC-delta with Src family kinases suggests a novel and inter-dependent mechanism for regulation of enzymatic activity that may serve an important role in cellular responses.	NIAMS, Sect Chem Immunol, Bethesda, MD 20892 USA; NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; Inst Pasteur, F-75724 Paris 15, France	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Rivera, J (corresponding author), NIAMS, Sect Chem Immunol, Bethesda, MD 20892 USA.			Blank, Ulrich/0000-0002-2661-2983; Szallasi, Zoltan/0000-0001-5395-7509				ALEXANDER D R, 1990, New Biologist, V2, P1049; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CHACKALAPARAMPIL I, 1994, ONCOGENE, V9, P1947; Chang EY, 1997, J IMMUNOL, V159, P2624; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; DANIELSEN AG, 1995, J BIOL CHEM, V270, P21600, DOI 10.1074/jbc.270.37.21600; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Draberova L, 1996, IMMUNOLOGY, V87, P141; EISEMAN E, 1992, NATURE, V355, P78; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; FURUICHI K, 1984, J IMMUNOL, V133, P1513; Galron D, 1997, CELL IMMUNOL, V178, P141, DOI 10.1006/cimm.1997.1120; GERMANO P, 1994, J BIOL CHEM, V269, P23102; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HAMAWY MM, 1994, J IMMUNOL, V153, P4655; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HOLOWKA D, 1982, MOL IMMUNOL, V19, P219, DOI 10.1016/0161-5890(82)90334-0; Holowka D, 1996, ANNU REV BIOPH BIOM, V25, P79; JOUNG I, 1995, P NATL ACAD SCI USA, V92, P5778, DOI 10.1073/pnas.92.13.5778; Kawakami Y, 1996, IMMUNOL LETT, V54, P113, DOI 10.1016/S0165-2478(96)02659-4; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; LAROSE L, 1995, J BIOL CHEM, V270, P3858, DOI 10.1074/jbc.270.8.3858; Lee JE, 1997, J IMMUNOL, V159, P61; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; LIU F, 1994, BIOCHEM BIOPH RES CO, V200, P1570, DOI 10.1006/bbrc.1994.1630; LIU FT, 1980, J IMMUNOL, V124, P2728; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; MAO SY, 1995, BIOCHEMISTRY-US, V34, P1968, DOI 10.1021/bi00006a018; Mayer BJ, 1997, CURR BIOL, V7, pR295, DOI 10.1016/S0960-9822(06)00141-2; MIMNAUGH EG, 1995, J BIOL CHEM, V270, P28654, DOI 10.1074/jbc.270.48.28654; Moriya K, 1997, P NATL ACAD SCI USA, V94, P12539, DOI 10.1073/pnas.94.23.12539; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; Pathan NI, 1996, J BIOL CHEM, V271, P27517, DOI 10.1074/jbc.271.44.27517; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; PRIBLUDA VS, 1992, P NATL ACAD SCI USA, V89, P11446, DOI 10.1073/pnas.89.23.11446; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; SCHARENBERG AM, 1995, CHEM IMMUNOL, V61, P72; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; Singer WD, 1996, J BIOL CHEM, V271, P4504; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; Song JS, 1996, J BIOL CHEM, V271, P26962, DOI 10.1074/jbc.271.43.26962; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yuan ZM, 1996, ONCOGENE, V13, P939; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	65	98	100	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3357	3368		10.1038/sj.onc.1201886	http://dx.doi.org/10.1038/sj.onc.1201886			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692543				2022-12-25	WOS:000074544100002
J	Takahashi, K; Sasaki, T; Mammoto, A; Hotta, I; Takaishi, K; Imamura, H; Nakano, K; Kodama, A; Takai, Y				Takahashi, K; Sasaki, T; Mammoto, A; Hotta, I; Takaishi, K; Imamura, H; Nakano, K; Kodama, A; Takai, Y			Interaction of radixin with Rho small G protein GDP/GTP exchange protein Dbl	ONCOGENE			English	Article						Rho; ERM; Dbl; Rho GEP; Rho GDI	GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEIN; GDP-DISSOCIATION INHIBITOR; SIGNAL-TRANSDUCTION; ONCOGENE PRODUCT; STRUCTURAL SIMILARITIES; HEMATOPOIETIC-CELLS; EXPRESSION CLONING; MEMBRANE; FAMILY	The Rho small G protein family, consisting of the Rho, Rac, and Cdc42 subfamilies, regulates various actin cytoskeleton-dependent cell functions. The Rho subfamily members regulate ERM (ezrin, radixin and moesin)dependent association of the actin cytoskeleton,vith the plasma membrane. Moreover, the N-terminal regions of ERM interact with Rho GDI, an inhibitory regulator of all the Rho family members, and reduce its inhibitory action, finally initiating the activation of the Rho family members. We show here that the N-terminal region of radixin furthermore interacts with DM, a stimulatory GDP/GTP exchange protein of the Rho family members. This interaction does not affect the Dbl activity to stimulate the GDP/GTP exchange reaction of RhoA, a member of the Rho subfamily. DM does not interact with radixin which is precomplexed with Rho GDI, and Rho GDI displaces Dbl from radixin. Thus, radixin plays an important role in activation of the Rho family members by recruiting their positive and negative regulators.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 565, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 565, Japan.							Adra CN, 1997, P NATL ACAD SCI USA, V94, P4279, DOI 10.1073/pnas.94.9.4279; ANDREOLI C, 1994, J CELL SCI, V107, P2509; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; GRAZIANI G, 1989, ONCOGENE, V4, P823; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; PASTERIS NG, 1994, CELL, V79, P669; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TOKSOZ D, 1994, ONCOGENE, V9, P621; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; UEDA T, 1990, J BIOL CHEM, V265, P9373; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	48	102	102	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3279	3284		10.1038/sj.onc.1201874	http://dx.doi.org/10.1038/sj.onc.1201874			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681826				2022-12-25	WOS:000074343600008
J	Chouinard, RA; Luo, Y; Osborne, TF; Walsh, A; Tall, AR				Chouinard, RA; Luo, Y; Osborne, TF; Walsh, A; Tall, AR			Sterol regulatory element binding protein-1 activates the cholesteryl ester transfer protein gene in vivo but is not required for sterol up-regulation of gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; LIPOPROTEIN RECEPTOR GENE; LEUCINE ZIPPER PROTEIN; COENZYME-A REDUCTASE; TRANSGENIC MICE; CULTURED-CELLS; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; ADIPOCYTE DETERMINATION; HDL LEVELS; PLASMA	The plasma cholesteryl ester transfer protein (CETP) plays a central role in high density lipoprotein metabolism and reverse cholesterol transport. Plasma CETP levels are increased in response to dietary or endogenous hypercholesterolemia as a result of increased gene transcription in liver and periphery. Deletional analysis in human CETP transgenic mice localized this response to a region of the proximal promoter which contains a tandem repeat of the sterol regulatory element (SRE) of the 3-hydroxy-3-methylglutaryl-CoA reductase gene. The purpose of the present study was to evaluate the role of the SRE-like element in CETP promoter activity. Gel shift assays using CETP promoter fragments containing these elements showed binding of the transcription factors, sterol regulatory element-binding protein-1 (SREBP-1) and Yin Yang-1 (YY-1), Point mutations in the SRE-like element, designated MUT1 and MUT2, resulted in decreased binding of SREBP-1 (MUT1) or SREBP-1 and YY-1 (MUT2), To determine the in vivo significance of this binding activity, CETP transgenic mice were prepared containing these promoter point mutations. MUT1 and MUTE transgenic mice expressed CETP activity and mass in plasma, In response to high fat, high cholesterol diets, both MUT1-CETP and MUT2-CETP transgenic mice displayed induction of plasma CETP activity similar to that observed in natural flanking region (NFR) CETP transgenic mice. Moreover, in stably transfected adipocyte cell lines, MUT1 and MUTE CETP promoter-reporter genes showed significant induction of reporter activity in response to sterols, To evaluate transactivation by SREBP-1, NFR- and MUT1-CETP transgenic mice were crossed with SREBP-1 transgenic mice. Induction of the SREBP transgene in the liver with a low carbohydrate diet resulted in a 3-fold increase in plasma CETP activity in NFR-CETP/SREBP transgenic mice, but there was no significant change in activity in MUT1-CETP/SREBP transgenic mice. Thus, SREBP-1 transactivates the NFR-CETP transgene in vivo, as a result of interaction with the CETP promoter SREs, However, this interaction is not required for positive sterol induction of CETP gene transcription. The results suggest independent regulation of the CETP gene by SREBP-1 and a distinct positive sterol response factor.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA; Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA; Rockefeller Univ, Biochem Genet & Metab Lab, New York, NY 10021 USA	Columbia University; University of California System; University of California Irvine; Rockefeller University	Tall, AR (corresponding author), Columbia Univ, Dept Med, Div Mol Med, 630 W 168th St,PH 8-101, New York, NY 10032 USA.		Tall, Alan/AAT-8528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1992, J BIOL CHEM, V267, P22336; AGELLON LB, 1991, J BIOL CHEM, V266, P10796; Atger V, 1995, J CLIN INVEST, V96, P2613, DOI 10.1172/JCI118326; AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V2; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Escriva H, 1997, P NATL ACAD SCI USA, V94, P6803, DOI 10.1073/pnas.94.13.6803; Francone OL, 1996, J LIPID RES, V37, P1268; GIL G, 1988, J BIOL CHEM, V263, P19009; HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JIANG XC, 1995, J BIOL CHEM, V270, P17133, DOI 10.1074/jbc.270.29.17133; JIANG XC, 1992, J CLIN INVEST, V90, P1290, DOI 10.1172/JCI115993; Kawabe Y, 1996, BIOCHEM BIOPH RES CO, V219, P515, DOI 10.1006/bbrc.1996.0265; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; MasucciMagoulas L, 1996, J CLIN INVEST, V97, P154, DOI 10.1172/JCI118384; Oliveira HCF, 1996, J BIOL CHEM, V271, P31831, DOI 10.1074/jbc.271.50.31831; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; PAPE ME, 1991, ARTERIOSCLER THROMB, V11, P1759, DOI 10.1161/01.ATV.11.6.1759; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SON YSC, 1986, ARTERIOSCLEROSIS, V6, P345, DOI 10.1161/01.ATV.6.3.345; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TALL A, 1987, J CLIN INVEST, V79, P1217, DOI 10.1172/JCI112940; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; WALSH A, 1989, J BIOL CHEM, V264, P6488; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; Zhong SB, 1996, J CLIN INVEST, V97, P2917, DOI 10.1172/JCI118751	43	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22409	22414		10.1074/jbc.273.35.22409	http://dx.doi.org/10.1074/jbc.273.35.22409			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712863	hybrid			2022-12-25	WOS:000075616600039
J	Godon, C; Lagniel, G; Lee, J; Buhler, JM; Kieffer, S; Perrot, R; Boucherie, H; Toledano, MB; Labarre, J				Godon, C; Lagniel, G; Lee, J; Buhler, JM; Kieffer, S; Perrot, R; Boucherie, H; Toledano, MB; Labarre, J			The H2O2 stimulon in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENTOSE-PHOSPHATE PATHWAY; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; MOLECULAR CHAPERONES; HEAT-SHOCK; GLUTATHIONE-REDUCTASE; SUPEROXIDE-DISMUTASE; DEPENDENT ACTIVATION; ADAPTIVE RESPONSE; ALDOSE REDUCTASE	The changes in gene expression underlying the yeast adaptive stress response to H2O2 were analyzed by comparative two-dimensional gel electrophoresis of total cell proteins. The synthesis of at least 115 proteins is stimulated by H2O2, whereas 52 other proteins are repressed by this treatment. We have identified 71 of the stimulated and 44 of the repressed targets. The kinetics and dose-response parameters of the H2O2, genomic response were also analyzed. Identification of these proteins and their mapping into specific cellular processes give a distinct picture of the way in which yeast cells adapt to oxidative stress. As expected, H2O2-responsive targets include an important number of heat shock proteins and proteins with reactive oxygen intermediate scavenging activities. Exposure to H2O2 also results in a slowdown of protein biosynthetic processes and a stimulation of protein degradation pathways. Finally, the most remarkable result inferred from this study is the resetting of carbohydrate metabolism minutes after the exposure to H2O2. Carbohydrate fluxes are redirected to the regeneration of NADPH at the expense of glycolysis. This study represents the first genome-wide characterization of a H2O2-inducible stimulon in a eukaryote.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; Rutgers State Univ, Coll Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ 08855 USA; CNRS, Inst Biochim & Genet Cellulaires, UPR 9026, F-33077 Bordeaux, France; CEA, Dept Biol Mol & Struct, F-38054 Grenoble 09, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Rutgers State University New Brunswick; Centre National de la Recherche Scientifique (CNRS); CEA	Labarre, J (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Bat 142, F-91191 Gif Sur Yvette, France.	labarre@jonas.saclay.cea.fr						Ahn SM, 1996, BIOCHEM MOL BIOL INT, V39, P1007; BABIYCHUK E, 1995, J BIOL CHEM, V270, P26224, DOI 10.1074/jbc.270.44.26224; BERTHON HA, 1992, BIOCHEMISTRY-US, V31, P12792, DOI 10.1021/bi00166a012; Boucherie H, 1996, ELECTROPHORESIS, V17, P1683, DOI 10.1002/elps.1150171106; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, BIOFACTORS, V4, P177; Ciechanover A, 1995, COLD SPRING HARB SYM, V60, P491, DOI 10.1101/SQB.1995.060.01.053; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P329, DOI 10.1099/00221287-138-2-329; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CRAWFORD DR, 1994, ENVIRON HEALTH PERSP, V102, P25, DOI 10.2307/3432208; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DEVIRGILIO C, 1994, EUR J BIOCHEM, V219, P179; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FLATTERYOBRIEN J, 1993, J GEN MICROBIOL, V139, P501, DOI 10.1099/00221287-139-3-501; GAN ZR, 1992, BIOCHEM BIOPH RES CO, V187, P949, DOI 10.1016/0006-291X(92)91289-3; GARRARD LJ, 1989, J BIOL CHEM, V264, P13929; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; HALLIWELL B, 1994, NUTR REV, V52, P253; Halliwell B., 1989, FREE RADICAL BIO MED, P1; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Izawa S, 1996, BIOCHEM J, V320, P61, DOI 10.1042/bj3200061; James P, 1997, SCIENCE, V275, P387, DOI 10.1126/science.275.5298.387; JAMIESON DJ, 1994, MICROBIOL-UK, V140, P3277, DOI 10.1099/13500872-140-12-3277; JAMIESON DJ, 1992, J BACTERIOL, V174, P6678, DOI 10.1128/JB.174.20.6678-6681.1992; Juhnke H, 1996, MOL GEN GENET, V252, P456, DOI 10.1007/BF02173011; KREMS B, 1995, CURR GENET, V27, P427, DOI 10.1007/BF00311211; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; KULLIK I, 1994, REDOX REP, P1; Liu HD, 1996, GENE DEV, V10, P592; MAGER WH, 1995, MICROBIOL REV, V59, P506, DOI 10.1128/MMBR.59.3.506-531.1995; MAGER WH, 1993, BIOCHEM J, V290, P1; Maillet I, 1996, J BIOL CHEM, V271, P10263, DOI 10.1074/jbc.271.17.10263; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MoradasFerreira P, 1996, MOL MICROBIOL, V19, P651, DOI 10.1046/j.1365-2958.1996.403940.x; MORTIMER RK, 1986, GENETICS, V113, P35; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; Norbeck J, 1997, J BIOL CHEM, V272, P5544, DOI 10.1074/jbc.272.9.5544; Parrou JL, 1997, MICROBIOL-UK, V143, P1891, DOI 10.1099/00221287-143-6-1891; RAMACHA M, 1995, MOL CELL BIOL, V15, P4754; RIBEIRO MJS, 1994, BBA-GEN SUBJECTS, V1200, P139, DOI 10.1016/0304-4165(94)90128-7; SCHAAFFGERSTENSCHLAGER I, 1993, CURR GENET, V24, P373, DOI 10.1007/BF00351843; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHIMANUKI M, 1995, J CELL SCI, V108, P569; SIKORSKI RS, 1989, GENETICS, V122, P19; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; Spycher SE, 1997, FASEB J, V11, P181, DOI 10.1096/fasebj.11.2.9039961; Srivastava S, 1995, BIOCHEM BIOPH RES CO, V217, P741, DOI 10.1006/bbrc.1995.2835; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; THOMAS D, 1991, EMBO J, V10, P547, DOI 10.1002/j.1460-2075.1991.tb07981.x; VANLOON AP, 1991, P NATL ACAD SCI USA, V83, P3820; WIEMKEN A, 1990, ANTON LEEUW INT J G, V58, P209, DOI 10.1007/BF00548935; ZHRINGER H, 1997, FEBS LETT, V412, P615	60	477	492	3	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22480	22489		10.1074/jbc.273.35.22480	http://dx.doi.org/10.1074/jbc.273.35.22480			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712873	hybrid			2022-12-25	WOS:000075616600049
J	Hoshino, S; Imai, M; Mizutani, M; Kikuchi, Y; Hanaoka, F; Ui, M; Katada, T				Hoshino, S; Imai, M; Mizutani, M; Kikuchi, Y; Hanaoka, F; Ui, M; Katada, T			Molecular cloning of a novel member of the eukaryotic polypeptide chain-releasing factors (eRF) - Its identification as eRF3 interacting with eRF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; OMNIPOTENT SUPPRESSOR-45; HIGH HOMOLOGY; SUP35 GENE; HUMAN CDNA; TERMINATION; PROTEIN; TRANSLATION; DETERMINANT	Yeast GST1 gene, whose product is a GTP-binding protein structurally related to polypeptide chain elongation factor-1 alpha (EF1 alpha), was first described to be essential for the (G) under bar(1) to (S) under bar phase transition (GSPT) of the cell cycle, and the product was recently reported to function as a polypeptide chain release factor 3 (eRF3) in yeast. Although we previously cloned a human homologue (renamed as GSPT1) of the yeast gene, it has remained to be determined whether GSPT1 also functions as eRF3 or if another GSPT may have such a function in mammalian cells. In the present study, we isolated two mouse GSPT genes, the counterpart of human GSPT1 and a novel member of the GSPT gene family, GSPT2. Both the mouse GSPTs had a two domain structure characterized as an amino-terminal no-homologous region (approximately 200 amino acids) and a carboxyl-terminal conserved eukaryotic elongation factor-1 alpha-like domain (428 amino acids), Messenger RNAs of the two GSPTs could be detected in all mouse tissues surveyed, although the level of GSPT2 message appeared to be relatively abundant in the brain. The mouse GSPT1 was expressed in a proliferation-dependent manner in Swiss 3T3 cells, whereas the expression of GSPT2 was constant during the cell-cycle progression. Immunoprecipitation assays in COS-7 cells expressing flag epitope-tagged proteins demonstrated that not only GSPT1 but also GSPT2 was capable of interacting with eRF1. Such interaction between GSPT2 and eRF1 was also confirmed by yeast two-hybrid analysis. Taken together, these data indicated that the novel GSPT2 may interact with eRF1 to function as eRF3 in mammalian cells.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Hoshino, S (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo 1130033, Japan.			Hoshino, Shinichi/0000-0001-6135-7896				BEAUDET AL, 1971, P NATL ACAD SCI USA, V68, P619, DOI 10.1073/pnas.68.3.619; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIGEN WJ, 1990, MOL MICROBIOL, V4, P861, DOI 10.1111/j.1365-2958.1990.tb00658.x; EUSTICE DC, 1986, J MOL BIOL, V188, P207, DOI 10.1016/0022-2836(86)90305-0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINKELSTEIN DB, 1983, MOL CELL BIOL, V3, P1625, DOI 10.1128/MCB.3.9.1625; FROLOVA L, 1994, NATURE, V372, P701, DOI 10.1038/372701a0; GRENETT HE, 1992, GENE, V110, P239, DOI 10.1016/0378-1119(92)90655-9; GRENETT HE, 1992, SOMAT CELL MOLEC GEN, V18, P97, DOI 10.1007/BF01233452; GRENTZMANN G, 1995, J BIOL CHEM, V270, P10595, DOI 10.1074/jbc.270.18.10595; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOSHINO S, 1989, EMBO J, V8, P3807, DOI 10.1002/j.1460-2075.1989.tb08558.x; INGEVECHTOMOV SG, 1994, GENETIKA+, V30, P1022; JeanJean O, 1996, CR ACAD SCI III-VIE, V319, P487; KIKUCHI Y, 1988, EMBO J, V7, P1175, DOI 10.1002/j.1460-2075.1988.tb02928.x; Kisselev LL, 1995, BIOCHEM CELL BIOL, V73, P1079, DOI 10.1139/o95-116; KONECKI DS, 1977, J BIOL CHEM, V252, P4514; KUSHNIROV VV, 1988, GENE, V66, P45, DOI 10.1016/0378-1119(88)90223-5; Maniatis T., 1982, MOL CLONING LAB MANU; MIKUNI O, 1994, P NATL ACAD SCI USA, V91, P5798, DOI 10.1073/pnas.91.13.5798; Miller J.H., 1972, EXPT MOL GENETICS; OZAWA K, 1992, SOMAT CELL MOLEC GEN, V18, P189, DOI 10.1007/BF01233164; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; STANSFIELD I, 1994, CURR GENET, V25, P385, DOI 10.1007/BF00351776; SURGUCHOV AP, 1980, FEBS LETT, V111, P175, DOI 10.1016/0014-5793(80)80786-1; SURGUCHOV AP, 1988, TRENDS BIOCHEM SCI, V13, P120, DOI 10.1016/0968-0004(88)90062-X; TERAVANESYAN MD, 1994, GENETICS, V137, P671; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	34	96	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22254	22259		10.1074/jbc.273.35.22254	http://dx.doi.org/10.1074/jbc.273.35.22254			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712840	hybrid			2022-12-25	WOS:000075616600016
J	Obermoeller, LM; Chen, Z; Schwartz, AL; Bu, G				Obermoeller, LM; Chen, Z; Schwartz, AL; Bu, G			Ca2+ and receptor-associated protein are independently required for proper folding and disulfide bond formation of the low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; CYSTEINE-RICH REPEAT; LDL-RECEPTOR; ENDOPLASMIC-RETICULUM; FAMILIAL HYPERCHOLESTEROLEMIA; MOLECULAR CHAPERONE; IN-VIVO; CALCIUM; LRP; SUGGEST	The low density lipoprotein receptor-related protein (LRP) is a cysteine-rich, multifunctional receptor that binds and endocytoses a diverse array of ligands. Recent studies have shown that a 39-kDa receptor-associated protein (RAP) facilitates the proper folding and subsequent trafficking of LRP within the early secretory pathway. In the current study, we have examined the potential role of Ca2+ and its relationship to RAP during LRP folding. We found that depletion of Ca2+ following either ionomycin or thapsigargin treatment significantly disrupts the folding process of LRP. The misfolded LRP molecules migrate as high molecular weight aggregates under nonreducing SDS-polyacrylamide gel electrophoresis, suggesting the formation of intermolecular disulfide bonds. This misfolding is reversible because misfolded LRP can be re-folded into functional receptor molecules upon Ca2+ restoration. Using an LRP minireceptor representing the fourth ligand binding domain of LRP, we also observed significant variation in the conformation of monomeric receptor upon Ca2+ depletion. The role of Ca2+ in LRP folding is independent from that of RAP because RAP remains bound to LRP and its minireceptor following Ca2+ depletion. Furthermore, Ca2+ depletion-induced LRP misfolding occurs in RAP-deficient cells. Taken together, these results clearly demonstrate that Ca2+ and RAP independently participate in LRP folding.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Physiol & Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Bu, G (corresponding author), Washington Univ, Sch Med, Dept Pediat, CB 8116,1 Childrens Pl, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059150] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59150] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIERI S, 1995, BIOCHEMISTRY-US, V34, P13059, DOI 10.1021/bi00040a017; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; BU GJ, 1993, J BIOL CHEM, V268, P13002; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LODISH HF, 1992, J BIOL CHEM, V267, P12753; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; WARSHAWSKY I, 1995, BIOCHEMISTRY-US, V34, P3404, DOI 10.1021/bi00010a032; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537	27	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22374	22381		10.1074/jbc.273.35.22374	http://dx.doi.org/10.1074/jbc.273.35.22374			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712858	hybrid			2022-12-25	WOS:000075616600034
J	Schlott, B; Guhrs, KH; Hartmann, M; Rocker, A; Collen, D				Schlott, B; Guhrs, KH; Hartmann, M; Rocker, A; Collen, D			NH2-terminal structural motifs in staphylokinase required for plasminogen activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT STAPHYLOKINASE; THROMBOLYTIC THERAPY; ESCHERICHIA-COLI; HUMAN PLASMA; GENE; PURIFICATION; MECHANISM	Staphylokinase (Sak) forms an inactive 1:1 stoichiometric complex with plasminogen which requires both conversion of plasminogen to plasmin and hydrolysis of the Lys(10)-Lys(11) peptide bond of Sak to become a potent plasminogen activator (Schlott, B., Guhrs, K.-H., Hartmann, M,, Rocker, A, and Collen, D, (1997) J. Biol. Chem. 272, 6067-6072). Exposure of a positively charged NH2-terminal amino acid after hydrolysis of Sak is a major determinant of the plasminogen-activating potential, but in itself is neither necessary nor sufficient, Here, the structural motifs of the NH2-terminal region Lys(11)-Gly-Asp-Asp-Ala-Ser(16)-Tyr-Phe-Glu of processed Sak, required for plasminogen activating potential, were studied by deletion and substitution mutagenesis. Expression in Escherichia coli of variants with deletion of 11, 14, 15, or 16 NH2-terminal amino acids yielded correctly processed but inactive molecules. Expression of their homologues with the NH2-terminal amino acid substituted with Lys generated derivatives from which the NH2-terminal initiation Met was no longer removed, yielding inactive (less than or equal to 10%) Sak42D Delta N11(M),G12K, active (>50%) Sak42D Delta N14(M),A15K and Sak42D Delta N15(M), S16K, and inactive Sak42D Delta N16(M),Y17K. Lys variants without NH2-terminal Met, generated from fusion proteins in which a Hiss tag and a factor Xa recognition sequence were linked to the NH, terminus of the Sak variants, were indistinguishable from their NH2-terminal Met-containing counterparts. All variants studied had intact affinities for plasminogen as measured by biospecific interaction analysis. The activity of Sak42D Delta N11(M),G12K could be restored by additional substitution of both Asp(13) and Asp(14) With Asn, yielding active Sak42D Delta N11(M),G12K, D13N, D14N, whereas substitution in Sak42D Delta N16(M),Y17K. of Phe(18) and Glu(19) with Asn yielded inactive Sak42D Delta N16(M),Y17K,F18N,E19N. These data, in combination with the recent finding that the 20 NH2-terminal amino acids of Sak lack secondary structure, suggest that the NH2-terminal region of Sak is not required for binding to plasmin/plasminogen, but that a positively charged amino acid in the ultimate or penultimate NH2-terminal position corresponding to amino acids 11-16 of this flexible region participates in the reconfiguration of the active site of the plasmin molecule to endow it with plasminogen-activating potential.	Inst Mol Biotechnol, D-07745 Jena, Germany; Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven	Schlott, B (corresponding author), Inst Mol Biotechnol, Beukenbergstr 11, D-07745 Jena, Germany.	bschlott@sanger.imb-jena.de		Guehrs, Karl-Heinz/0000-0001-8847-1365				BEHNKE D, 1987, MOL GEN GENET, V210, P528, DOI 10.1007/BF00327208; COLLEN D, 1992, FIBRINOLYSIS, V6, P226, DOI 10.1016/0268-9499(92)90075-S; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Gase A, 1996, THROMB HAEMOSTASIS, V76, P755; GASE A, 1994, EUR J BIOCHEM, V223, P303, DOI 10.1111/j.1432-1033.1994.tb18995.x; Jonsson U., 1992, ADV BIOSENSOR, P291; KEILER KC, 1995, J BIOL CHEM, V270, P28864, DOI 10.1074/jbc.270.48.28864; LACK CH, 1948, NATURE, V161, P559, DOI 10.1038/161559b0; Ohlenschlager O, 1997, J BIOMOL NMR, V9, P273, DOI 10.1023/A:1018678925512; Rabijns A, 1997, NAT STRUCT BIOL, V4, P357, DOI 10.1038/nsb0597-357; SACHAROV DV, 1996, J BIOL CHEM, V271, P27912; SAKO T, 1983, NUCLEIC ACIDS RES, V11, P7679, DOI 10.1093/nar/11.22.7679; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLOTT B, 1994, BIO-TECHNOL, V12, P185, DOI 10.1038/nbt0294-185; Schlott B, 1997, J BIOL CHEM, V272, P6067, DOI 10.1074/jbc.272.9.6067; SILENCE K, 1995, J BIOL CHEM, V270, P1; SLILATY SN, 1987, P NATL ACAD SCI USA, V84, P3987, DOI 10.1073/pnas.84.12.3987; Tachias K, 1997, J BIOL CHEM, V272, P28; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; UESHIMA S, 1993, THROMB HAEMOSTASIS, V70, P495; VANDERSCHUEREN S, 1995, CIRCULATION, V92, P2044, DOI 10.1161/01.CIR.92.8.2044; VANDERSCHUEREN S, 1995, CIRCULATION, V92, P2050, DOI 10.1161/01.CIR.92.8.2050	22	24	28	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22346	22350		10.1074/jbc.273.35.22346	http://dx.doi.org/10.1074/jbc.273.35.22346			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712854	hybrid			2022-12-25	WOS:000075616600030
J	Illidge, C; Kielty, C; Shuttleworth, A				Illidge, C; Kielty, C; Shuttleworth, A			The alpha 1(VIII) and alpha 2(VIII) chains of type VIII collagen can form stable homotrimeric molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE DESCEMETS-MEMBRANE; TRIPLE-HELICAL DOMAIN; SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; X COLLAGEN; IN-VITRO; EXPRESSION; PROTEINS; CULTURE; TISSUE	Type VIII collagen is a short chain collagen. Two chains have been described, alpha 1(VIII) and alpha 2(VIII), but the chain composition of type VIII collagen is far from resolved. To address this question, we have expressed full-length alpha 1(VIII) and alpha 2(VIII) chains in an in vitro translation system supplemented with semipermeabilized cells. Both chains gave a translation product of similar to 80 kDa that could be shown to produce a chymotrypsin/trypsin-resistant product of similar to 60 kDa, indicating that both chains could form homotrimers. Hydroxylation of proline residues was a prerequisite for stable trimer formation. The melting temperature for the alpha 1(VIII) homotrimer was 45 degrees C, whereas that for alpha 2(VIII) was 42 degrees C. The ability of both chains of type VIII collagen to form stable triple helices suggests that there may be different forms of this collagen and that cells may modulate the chain composition in response to different biological conditions.	Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Shuttleworth, A (corresponding author), Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	ashuttle@fs1.scg.man.ac.uk						Bendeck MP, 1996, CIRC RES, V79, P524, DOI 10.1161/01.RES.79.3.524; BENYA P D, 1980, Renal Physiology, V3, P30; BENYA PD, 1986, J BIOL CHEM, V261, P4160; BRASS A, 1991, BIOCHEM SOC T, V19, P365; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; Chan VC, 1997, J BIOL CHEM, V272, P31441, DOI 10.1074/jbc.272.50.31441; Frischholz S, 1998, J BIOL CHEM, V273, P4547, DOI 10.1074/jbc.273.8.4547; JUVA K, 1966, SCIENCE, V152, P92, DOI 10.1126/science.152.3718.92; KAPOOR R, 1986, BIOCHEMISTRY-US, V25, P3930, DOI 10.1021/bi00361a029; KITTELBERGER R, 1990, CONNECT TISSUE RES, V24, P303, DOI 10.3109/03008209009152157; KITTELBERGER R, 1989, BIOCHEM BIOPH RES CO, V159, P414, DOI 10.1016/0006-291X(89)90007-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacBeath JRE, 1996, BIOCHEM J, V319, P993, DOI 10.1042/bj3190993; Mann K, 1996, J MOL BIOL, V261, P255, DOI 10.1006/jmbi.1996.0457; MANN K, 1990, FEBS LETT, V273, P168, DOI 10.1016/0014-5793(90)81076-Z; MIDDLETON RB, 1993, BIOCHEM J, V296, P511, DOI 10.1042/bj2960511; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; PAULUS W, 1991, BRIT J CANCER, V63, P367, DOI 10.1038/bjc.1991.87; ROONEY P, 1993, J CELL SCI, V105, P213; Rosenblum ND, 1996, BIOCHEM BIOPH RES CO, V227, P205, DOI 10.1006/bbrc.1996.1490; RUGER B, 1994, INT J EXP PATHOL, V75, P397; SAGE H, 1983, J BIOL CHEM, V258, P3391; SAGE H, 1990, ANN NY ACAD SCI, V580, P17, DOI 10.1111/j.1749-6632.1990.tb17914.x; SAGE H, 1984, LAB INVEST, V50, P219; SAGE H, 1980, BIOCHEMISTRY-US, V19, P5747, DOI 10.1021/bi00566a013; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; Sibinga NES, 1997, CIRC RES, V80, P532, DOI 10.1161/01.RES.80.4.532; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; YAMAGUCHI N, 1989, J BIOL CHEM, V264, P16022; Yang W, 1997, J BIOL CHEM, V272, P28837, DOI 10.1074/jbc.272.46.28837	33	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22091	22095		10.1074/jbc.273.34.22091	http://dx.doi.org/10.1074/jbc.273.34.22091			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705353	hybrid			2022-12-25	WOS:000075492600087
J	Seidenbecher, CI; Langnaese, K; Sanmarti-Vila, L; Boeckers, TM; Smalla, KH; Sabel, BA; Garner, CC; Gundelfinger, ED; Kreutz, MR				Seidenbecher, CI; Langnaese, K; Sanmarti-Vila, L; Boeckers, TM; Smalla, KH; Sabel, BA; Garner, CC; Gundelfinger, ED; Kreutz, MR			Caldendrin, a novel neuronal calcium-binding protein confined to the somato-dendritic compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CAM KINASE-II; RAT-BRAIN; CA2+-BINDING PROTEINS; POSTSYNAPTIC DENSITY; CALMODULIN; PHOSPHATASE; VILIP; ALPHA; PARVALBUMIN	Using antibodies against synaptic protein preparations, we cloned the cDNA of a new Ca2+-binding protein. Its C-terminal portion displays significant similarity with calmodulin and contains two EF-hand motifs. The corresponding mRNA is highly expressed in rat brain, primarily in cerebral cortex, hippocampus, and cerebellum; its expression appears to be restricted to neurons. Transcript levels increase during postnatal development. A recombinant C-terminal protein fragment binds Ca2+ as indicated by a Ca2+-induced mobility shift in SDS-polyacrylamide gel electrophoresis. Antisera generated against the bacterial fusion protein recognize a brain-specific protein doublet with apparent molecular masses of 33 and 36 kDa, These data are confirmed by in vitro translation, which generates a single 36-kDa polypeptide, and by the heterologous expression in 293 cells, which yields a 33/36-kDa doublet comparable to that found in brain. On two-dimensional gels, the 33-kDa band separates into a chain of spots plausibly due to differential phosphorylation. This view is supported by in situ phosphorylation studies in hippocampal slices. Most of the immunoreactivity is detectable in cytoskeletal preparations with a further enrichment in the synapse-associated cytomatrix. These biochemical data, together with the ultra-structural localization in dendrites and the postsynaptic density, strongly suggest an association with the somato-dendritic cytoskeleton, Therefore, this novel Ca2+-binding protein was named caldendrin.	Otto Von Guericke Univ, Inst Med Psychol, AG Mol & Cellular Neurobiol, D-39120 Magdeburg, Germany; Leibniz Inst Neurobiol, Dept Neurochem & Mol Biol, D-39118 Magdeburg, Germany; Westfalische Wilhelms Universitat, Inst Anat, AG Mol Neuroendocrinol, D-48149 Munster, Germany; Otto Von Guericke Univ, Inst Pharmacol & Toxicol, D-39120 Magdeburg, Germany; Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA	Otto von Guericke University; Leibniz Institut fur Neurobiologie (LIN); Otto von Guericke University; University of Alabama System; University of Alabama Birmingham	Kreutz, MR (corresponding author), Leibniz Inst Neurobiol, Dept Neurochem & Mol Biol, POB 1860, D-39008 Magdeburg, Germany.		Sabel, Bernhard A./E-6579-2013; Smalla, Dr. Karl-Heinz/C-3950-2012	Smalla, Dr. Karl-Heinz/0000-0002-0269-0311; Garner, Craig/0000-0003-1970-5417; Sabel, Bernhard/0000-0002-4472-5543; Seidenbecher, Constanze/0000-0002-7433-2716				BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; Bearer EL, 1996, P NATL ACAD SCI USA, V93, P6064, DOI 10.1073/pnas.93.12.6064; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; Braunewell KH, 1997, J NEUROCHEM, V68, P2129; BURNS ME, 1995, CELL, V83, P187, DOI 10.1016/0092-8674(95)90160-4; CARLIN RK, 1983, J CELL BIOL, V96, P443, DOI 10.1083/jcb.96.2.443; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COOPER NGF, 1985, J CELL BIOL, V101, P1212, DOI 10.1083/jcb.101.4.1212; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Fukunaga K, 1996, NEUROCHEM INT, V28, P343, DOI 10.1016/0197-0186(95)00097-6; GARRIGOS M, 1991, ANAL BIOCHEM, V194, P82, DOI 10.1016/0003-2697(91)90154-L; GARRISON JC, 1982, J BIOL CHEM, V257, P3135; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; GRAB DJ, 1979, J BIOL CHEM, V254, P8690; Guerini D, 1997, BIOCHEM BIOPH RES CO, V235, P271, DOI 10.1006/bbrc.1997.6802; Heizmann C. W., 1995, CALCIUM REGULATION C; HENDRICKSON AE, 1991, J COMP NEUROL, V307, P626, DOI 10.1002/cne.903070409; JUNGBLUT P, 1993, ELECTROPHORESIS, V14, P638, DOI 10.1002/elps.1150140199; KENNEDY MB, 1989, TRENDS NEUROSCI, V12, P417, DOI 10.1016/0166-2236(89)90089-1; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KLAUCK TM, 1995, CELL SIGNAL, V7, P747, DOI 10.1016/0898-6568(95)02003-9; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langnaese K, 1996, MOL BRAIN RES, V42, P118, DOI 10.1016/S0169-328X(96)00147-7; Langnaese K, 1997, J BIOL CHEM, V272, P821, DOI 10.1074/jbc.272.2.821; Lenz SE, 1996, NEUROSCI LETT, V206, P133, DOI 10.1016/S0304-3940(96)12444-7; Lenz SE, 1996, BIOCHEM BIOPH RES CO, V225, P1078, DOI 10.1006/bbrc.1996.1298; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; MURACHI T, 1989, BIOCHEM INT, V18, P263; Pauls TL, 1996, BBA-GENE STRUCT EXPR, V1306, P39, DOI 10.1016/0167-4781(95)00221-9; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; SAITOH S, 1994, DEV BRAIN RES, V80, P199, DOI 10.1016/0165-3806(94)90105-8; SEIDENBECHER CI, 1995, J BIOL CHEM, V270, P27206, DOI 10.1074/jbc.270.45.27206; Seidenbecher CI, 1998, EUR J NEUROSCI, V10, P1621, DOI 10.1046/j.1460-9568.1998.00166.x; STAAK S, 1995, BRAIN RES, V682, P55, DOI 10.1016/0006-8993(95)00319-L; TRAVE G, 1995, EUR J BIOCHEM, V227, P35, DOI 10.1111/j.1432-1033.1995.tb20357.x; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Wyszynski M, 1998, J NEUROSCI, V18, P1383; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	44	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21324	21331		10.1074/jbc.273.33.21324	http://dx.doi.org/10.1074/jbc.273.33.21324			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694893	hybrid			2022-12-25	WOS:000075386100086
J	Shahied-Milam, L; Soltaninassab, SR; Iyer, GV; LeStourgeon, WM				Shahied-Milam, L; Soltaninassab, SR; Iyer, GV; LeStourgeon, WM			The heterogeneous nuclear ribonucleoprotein C protein tetramer binds U1, U2, and U6 snRNAs through its high affinity RNA binding domain (the bZIP-like motif)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SINGLE-STRANDED-DNA; HNRNP PROTEINS; PREMESSENGER RNA; CROSS-LINKING; PARTICLES; COMPLEXES; PHOSPHORYLATION; PURIFICATION; SPECIFICITY	Eased on UV cross-linking experiments, it has been reported that the C protein tetramer of 40 S heterogeneous nuclear ribonucleoprotein complexes specifically interacts with stem-loop I of U2 small nuclear RNA (snRNA) (Temsamani, J., and Pederson, T. (1996) J. Biol. Chem. 271, 24922-24926), that C protein disrupts U4:U6 snRNA complexes (Forne, T., Rossi, F., Labourier, E., Antoine, E., Cathala, G., Brunel, C., and Tazi, J. (1995) J. Biol. Chem. 270, 16476-16481), that U6 snRNA may modulate C protein phosphorylation (Mayrand, S. H., Fung, P. A., and Pederson, T. (1996) Mol. Cel. Biol. 16, 1241-1246), and that hyperphosphorylated C protein lacks pre-mRNA binding activity. These findings suggest that snRNA-C protein interactions may function to recruit snRNA to, or displace C protein from, splice junctions. In this study, both equilibrium and non-equilibrium RNA binding assays reveal that purified native C protein binds U1, U2, and U6 snRNA with significant affinity (similar to 7.5-50 nM) although nonspecifically. Competition binding assays reveal that U2 snRNA (the highest affinity snRNA substrate) is ineffective in C protein displacement from branch-point/splice junctions or as a competitor of C protein's self-cooperative RNA binding mode. Additionally, C protein binds snRNA through its high affinity bZLM and mutations in the RNA recognition motif at suggested RNA binding sites primarily affect protein oligomerization.	Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA	Vanderbilt University	LeStourgeon, WM (corresponding author), Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA.	lestouwm@ctrvax.vanderbilt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048567] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48567] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbdulMana N, 1996, BIOCHEMISTRY-US, V35, P3545, DOI 10.1021/bi952298p; AMRUTE SB, 1994, BIOCHEMISTRY-US, V33, P8282, DOI 10.1021/bi00193a015; BARNETT SF, 1988, J BIOCHEM BIOPH METH, V16, P87, DOI 10.1016/0165-022X(88)90106-6; BARNETT SF, 1989, MOL CELL BIOL, V9, P492, DOI 10.1128/MCB.9.2.492; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BUJALOWSKI W, 1988, J BIOL CHEM, V263, P4629; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P7799, DOI 10.1021/bi00372a003; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BUSCH SJ, 1990, ONCOGENE, V5, P1549; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHAMPIONARNAUD P, 1994, GENE DEV, V8, P1974, DOI 10.1101/gad.8.16.1974; CONWAY G, 1988, MOL CELL BIOL, V8, P2884, DOI 10.1128/MCB.8.7.2884; FORNE T, 1995, J BIOL CHEM, V270, P16476, DOI 10.1074/jbc.270.27.16476; Fung PA, 1997, P NATL ACAD SCI USA, V94, P1064, DOI 10.1073/pnas.94.4.1064; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HUANG M, 1994, MOL CELL BIOL, V14, P518, DOI 10.1128/MCB.14.1.518; HUANG M, 1994, HDB CELL BIOL, V1; KANAAR R, 1995, EMBO J, V14, P4530, DOI 10.1002/j.1460-2075.1995.tb00132.x; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; LU JR, 1995, J MOL BIOL, V247, P739, DOI 10.1016/S0022-2836(05)80152-4; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; MAYRAND SH, 1990, NUCLEIC ACIDS RES, V18, P3307, DOI 10.1093/nar/18.11.3307; Mayrand SH, 1996, MOL CELL BIOL, V16, P1241; McAfee JG, 1996, RNA, V2, P1139; McAfee JG, 1996, BIOCHEMISTRY-US, V35, P1212, DOI 10.1021/bi951974k; MCAFEE JG, 1997, PACKAGING PREMRNA FR, P68; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PU WT, 1991, P NATL ACAD SCI USA, V88, P6901, DOI 10.1073/pnas.88.16.6901; RECH JE, 1995, J STRUCT BIOL, V114, P77, DOI 10.1006/jsbi.1995.1007; RECH JE, 1996, J STRUCT BIOL, V114, P84; REVZIN A, 1991, GEL RETARDATION ASSA, P205; Sakashita E, 1996, J BIOCHEM, V120, P1028; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SMITH KC, 1969, BIOCHEM BIOPH RES CO, V34, P354, DOI 10.1016/0006-291X(69)90840-7; SMITH KC, 1968, BIOCHEMISTRY-US, V7, P1033, DOI 10.1021/bi00843a023; SOLTANINASSAB S, 1996, MOL BIOL; SOLTANINASSAB S, 1998, IN PRESS NUCL ACIDS; STEINER RF, 1973, BIOCHIM BIOPHYS ACTA, V294, P24, DOI 10.1016/0005-2787(73)90311-0; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Temsamani J, 1996, J BIOL CHEM, V271, P24922, DOI 10.1074/jbc.271.40.24922; VONHIPPE PH, 1972, ANNU REV BIOCHEM, V41, P231, DOI 10.1146/annurev.bi.41.070172.001311; WILK HE, 1983, BIOCHEMISTRY-US, V22, P4592, DOI 10.1021/bi00288a038; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; WILUSZ J, 1988, MOL CELL BIOL, V8, P4477, DOI 10.1128/MCB.8.10.4477; WOOLEY J, 1986, BIOPHYS J, V49, P17, DOI 10.1016/S0006-3495(86)83575-5; [No title captured]	56	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21359	21367		10.1074/jbc.273.33.21359	http://dx.doi.org/10.1074/jbc.273.33.21359			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694897	hybrid			2022-12-25	WOS:000075386100090
J	Darnay, BG; Haridas, V; Ni, J; Moore, PA; Aggarwal, BB				Darnay, BG; Haridas, V; Ni, J; Moore, PA; Aggarwal, BB			Characterization of the intracellular domain of receptor activator of NF-kappa B (RANK) - Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappa B and c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD40; PROTEIN; FAMILY	Various members of the tumor necrosis factor (TNF) receptor superfamily interact directly with signaling molecules of the TNF receptor-associated factor (TRAF) family to activate nuclear factor kappa B (NF-kappa B) and the c-Jun N-terminal kinase (JNK) pathway. The receptor activator of NF-kappa B (RANK), a recently described TNF receptor family member, and its ligand, RANKL, promote survival of dendritic cells and differentiation of osteoclasts. RANK contains 383 amino acids in its intracellular domain (residues 234-616), which contain three putative TRAF-binding domains (termed I, II, and III). In this study, we set out to identify the region of RANK needed for interaction with TRAF molecules and for stimulation of NF-kappa B and JNK activity. We constructed epitope-tagged RANK (F-RANK616) and three C-terminal truncations, F-RANK330, F-RANK427, and F-RANK530, lacking 85, 188, and 285 amino acids, respectively. From this deletion analysis, we determined that TRAF2, TRAF6, and TRAF6 interact with RANK at its C-terminal 85-amino acid tail; the binding affinity appeared to be in the order of TRAF2 > TRAF5 > TRAF6, Furthermore, overexpression of RANK stimulated JNK and NF-kappa B activation. When the C-terminal tail, which is necessary for TRAF binding, was deleted, the truncated RANK receptor was still capable of stimulating JNK activity but not NF-kappa B, suggesting that interaction with TRAFs is necessary for NF-kappa B activation but not necessary for activation of the JNK pathway.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Cytokine Res Lab, Houston, TX 77030 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	University of Texas System; UTMD Anderson Cancer Center; GlaxoSmithKline; Human Genome Sciences Inc	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Cytokine Res Lab, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@audumla.mdacc.tmc.edu	Aggarwal, Bharat B/G-3388-2013					Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; Haridas V, 1998, J IMMUNOL, V160, P3152; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Miller WE, 1998, MOL CELL BIOL, V18, P2835, DOI 10.1128/MCB.18.5.2835; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Singh A, 1998, J INTERF CYTOK RES, V18, P439, DOI 10.1089/jir.1998.18.439; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	23	349	366	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20551	20555		10.1074/jbc.273.32.20551	http://dx.doi.org/10.1074/jbc.273.32.20551			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685412	hybrid			2022-12-25	WOS:000075305400089
J	Zhang, Q; Cox, D; Tseng, CC; Donaldson, JG; Greenberg, S				Zhang, Q; Cox, D; Tseng, CC; Donaldson, JG; Greenberg, S			A requirement for ARF6 in Fc gamma receptor-mediated phagocytosis in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PERIPHERAL MEMBRANE-PROTEIN; BREFELDIN-A; GOLGI MEMBRANES; NUCLEOTIDE-EXCHANGE; GUANINE-NUCLEOTIDE; MOUSE MACROPHAGES; CELLS; APPARATUS; BINDING	Phagocytosis requires extension of F-actin-rich pseudopods and is accompanied by membrane fusion events. Members of the ARF family of GTPases are essential for many aspects of membrane trafficking. To test a role for this family of proteins in Fc gamma receptor-mediated phagocytosis, we utilized the fungal metabolite brefeldin A (BFA). The addition of 100 mu M BFA to a subclone of RAW 264.7 macrophages disrupted the appearance and function of the Golgi apparatus as indicated by altered immunofluorescent distribution of P-COP and reduced efflux of BODIPY C-5-ceramide, a phospholipid that normally accumulates in the Gels apparatus. In contrast, BFA had no effect on phagocytosis of IgG-coated erythrocytes. These results suggested that activation of BFA-sensitive ARFs is not required for phagocytosis, ARF6 is unique among members of the ARF family in that its membrane association is unaffected by BFA. Expression of ARF6 mutants defective in either GTP hydrolysis (Q67L) or binding (T27N) inhibited phagocytosis of IgG-coated erythrocytes and attenuated the focal accumulation of F-actin beneath the test particles. These results indicate a requirement for ARF6 in Fc gamma receptor-mediated phagocytosis and suggest that ARF6 is an important mediator of cytoskeletal alterations after Fc gamma receptor activation.	Columbia Univ, Dept Med & Pharmacol, Coll Phys & Surg, New York, NY 10032 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	Columbia University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Greenberg, S (corresponding author), Columbia Univ, Dept Med & Pharmacol, Coll Phys & Surg, PH8C,630 W 168th St, New York, NY 10032 USA.	greenberg@cuccfa.ccc.columbia.edu		Cox, Dianne/0000-0002-0591-9767				Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DSOUZASCHOREY C, 1997, EMBO J, V16, P5448; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; GREENBERG S, 1990, J EXP MED, V172, P1853, DOI 10.1084/jem.172.6.1853; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; GREENBERG S, 1995, TRENDS CELL BIOL, V5, P93, DOI 10.1016/S0962-8924(00)88957-6; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; KTISTAKIS NT, 1995, MOL BIOL CELL, V6, P135, DOI 10.1091/mbc.6.2.135; MICHL J, 1983, J EXP MED, V157, P1746, DOI 10.1084/jem.157.6.1746; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; ORCI L, 1991, CELL, V64, P1183; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006	35	168	170	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19977	19981		10.1074/jbc.273.32.19977	http://dx.doi.org/10.1074/jbc.273.32.19977			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685333	hybrid			2022-12-25	WOS:000075305400010
J	Adachi, S; Gottlieb, RA; Babior, BM				Adachi, S; Gottlieb, RA; Babior, BM			Lack of release of cytochrome c from mitochondria into cytosol early in the course of fas-mediated apoptosis of jurkat cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2; MEMBRANE	Several groups have reported that during apoptosis, cytochrome c is released from the mitochondria into the cytosol, but we have found that in apoptotic cells the cytochrome appears to remain with the mitochondria. In hopes of reconciling these findings, we compared the results obtained from cells disrupted by our method (nitrogen cavitation) with those obtained using the cell-disruption method employed by others (homogenization). We observed that at 2 h, cytochrome c levels in apoptotic cytosols from homogenized cells exceeded control levels, whereas cytochrome c levels in apoptotic cytosols from cavitated cells were similar to control. Outer membranes of homogenized mitochondria appeared damaged because the mitochondria had become permeable to cytochrome c, whereas outer membranes of cavitated mitochondria excluded the cytochrome. 4 h after Fas ligation, both cavitated and homogenized mitochondria had released small amounts of cytochrome c into the cytosol, whereas after 6 h the cytochrome had disappeared from the cell lysate. We believe that the differences between our results and those reported by others were due to 1) our examining the cells after a short (2 h) incubation with the anti-Fas antibody, and 2) our use of nitrogen cavitation instead of homogenization to disrupt the cells.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Adachi, S (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.				NIAID NIH HHS [AI-01345] Funding Source: Medline; NIA NIH HHS [AG-13501] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013501] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; DUKE RC, 1992, CURRENT PROTOCOLS IM; Errede B, 1978, Methods Enzymol, V53, P40; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; WANG HG, 1996, BLOOD, V88, P449; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	13	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19892	19894		10.1074/jbc.273.31.19892	http://dx.doi.org/10.1074/jbc.273.31.19892			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677426	hybrid			2022-12-25	WOS:000075125200078
J	Beitner-Johnson, D; Millhorn, DE				Beitner-Johnson, D; Millhorn, DE			Hypoxia induces phosphorylation of the cyclic AMP response element-binding protein by a novel signaling mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-HYDROXYLASE GENE; C-FOS TRANSCRIPTION; MAPKAP KINASE-2; GROWTH-FACTOR; MEMBRANE DEPOLARIZATION; REGULATE CREB; EXPRESSION; ACTIVATION; STRESS; IDENTIFICATION	To investigate signaling mechanisms by which hypoxia regulates gene expression, we examined the effect of hypoxia on the cyclic AMP response element-binding protein (CREB) in PC12 cells. Exposure to physiological levels of hypoxia (5% O-2, similar to 50 mm Hg) rapidly induced a persistent phosphorylation of CREB on Ser(133), an event that is required for CREB-mediated transcriptional activation. Hypoxia-induced phosphorylation of CREB was more robust than that induced by any other stimulus tested, including forskolin, depolarization, and osmotic stress. Furthermore, this effect was not mediated by any of the previously known signaling pathways that lead to phosphorylation of CREB, including protein kinase A, calcium/calmodulin-dependent protein kinase, protein kinase C, ribosomal Se kinase-2, and mitogen-activated protein kinase-activated protein kinase-a. Hypoxic activation of a CRE-containing reporter (derived from the 5'-flanking region of the tyrosine hydroxylase gene) was attenuated markedly by mutation of the CRE. Thus, a physiological reduction in O-2 levels induces a functional phosphorylation of CREB at Ser(133) via a novel signaling pathway.	Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA	University of Cincinnati	Beitner-Johnson, D (corresponding author), Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, POB 67-0576, Cincinnati, OH 45267 USA.	dana.johnson@uc.edu			PHS HHS [RH37 L 33831] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Beitner-Johnson D, 1998, BIOCHEM BIOPH RES CO, V242, P61, DOI 10.1006/bbrc.1997.7907; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; Conforti L, 1997, J PHYSIOL-LONDON, V502, P293, DOI 10.1111/j.1469-7793.1997.293bk.x; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; GIBSON GE, 1981, AM J MED, V70, P1247, DOI 10.1016/0002-9343(81)90834-2; GINTY DD, 1991, J BIOL CHEM, V266, P15325; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gudi T, 1996, J BIOL CHEM, V271, P4597; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P933; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KIM KS, 1993, J BIOL CHEM, V268, P15689; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LAZAROFF M, 1995, J BIOL CHEM, V270, P21579, DOI 10.1074/jbc.270.37.21579; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; NagamotoCombs K, 1997, J BIOL CHEM, V272, P6051, DOI 10.1074/jbc.272.9.6051; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; Pende M, 1997, J NEUROSCI, V17, P1291; Raymond R, 1997, KIDNEY INT, V51, P536, DOI 10.1038/ki.1997.74; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sato N, 1997, BIOCHEM BIOPH RES CO, V232, P637, DOI 10.1006/bbrc.1997.6341; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Walton M, 1996, MOL BRAIN RES, V43, P21, DOI 10.1016/S0169-328X(96)00144-1; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; XIE HJ, 1995, J IMMUNOL, V154, P1717; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOON SO, 1992, NEURON, V14, P241; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; Zhu WH, 1996, AM J PHYSIOL-CELL PH, V271, pC658, DOI 10.1152/ajpcell.1996.271.2.C658	56	112	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19834	19839		10.1074/jbc.273.31.19834	http://dx.doi.org/10.1074/jbc.273.31.19834			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677418	hybrid			2022-12-25	WOS:000075125200070
J	Wower, IK; Wower, J; Zimmermann, RA				Wower, IK; Wower, J; Zimmermann, RA			Ribosomal protein L27 participates in both 50 S subunit assembly and the peptidyl transferase reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; TRANSFER-RNA; CROSS-LINKING; A-SITE; PEPTIDYLTRANSFERASE ACTIVITY; PUROMYCIN REACTION; 23S RNA; 2-IMINOTHIOLANE; COMPONENTS; RECONSTITUTION	Protein L27 has been implicated as a constituent of the peptidyl transferase center of the Escherichia coli 50 S ribosomal subunit by a variety of experimental observations. To define better the functional role! of this protein, we constructed a strain in which the rpmA gene, which encodes L27, was replaced by a kanamycin resistance marker. The deletion mutant grows five to six times slower than the wild-type parent and is both cold-and temperature-sensitive. This phenotype is reversed when L27 is expressed from a plasmid-borne copy of the rpmA gene. Analysis of ribosomes from the L27-lacking strain revealed deficiencies in both the assembly and activity of the 50 S ribosomal subunits. Although functional 50 S subunits are formed in the mutant, an assembly "bottleneck" was evidenced by the accumulation of a prominent 40 S precursor to the 50 S subunit which was deficient in proteins Lie, L20, and L21, as web as L27. In addition, the peptidyl transferase activity of 70 S ribosomes containing mutant 50 S subunits was determined to be three to four times lower than for wild-type ribosomes, Ribosomes lacking L27 were found to be impaired in the enzymatic binding of Phe-tRNA(Phe) to the A site, although the interaction of N-acetyl-Phe-tRNA(Phe) with the P site was largely unperturbed. We therefore infer that L27 contributes to peptide bond formation by facilitating the proper placement of the acceptor end of the A-site tRNA at the peptidyl transferase center.	Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Zimmermann, RA (corresponding author), Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA.	zimmermann@biochem.umass.edu			NIGMS NIH HHS [GM22807] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022807] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN PN, 1991, CELL, V66, P141, DOI 10.1016/0092-8674(91)90146-P; AREVALO MA, 1989, J MED CHEM, V32, P2200, DOI 10.1021/jm00129a027; BISCHOF O, 1995, J BIOL CHEM, V270, P23060, DOI 10.1074/jbc.270.39.23060; CHEN R, 1975, FEBS LETT, V59, P96, DOI 10.1016/0014-5793(75)80349-8; COOPERMAN BS, 1988, METHOD ENZYMOL, V164, P341; DABBS ER, 1983, MOL GEN GENET, V192, P301, DOI 10.1007/BF00392166; GEYL D, 1981, MOL GEN GENET, V181, P309, DOI 10.1007/BF00425603; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GULLE H, 1988, NUCLEIC ACIDS RES, V16, P815, DOI 10.1093/nar/16.3.815; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HAMPL H, 1981, J BIOL CHEM, V256, P2284; HEROLD M, 1987, J BIOL CHEM, V262, P8826; JEONG JH, 1993, DNA SEQUENCE, V4, P59, DOI 10.3109/10425179309015624; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEDER P, 1966, BIOCHEM BIOPH RES CO, V25, P233, DOI 10.1016/0006-291X(66)90586-9; Mason TL, 1996, EXPERIENTIA, V52, P1148, DOI 10.1007/BF01952114; MONRO RE, 1967, J MOL BIOL, V25, P347, DOI 10.1016/0022-2836(67)90146-5; NICHOLSON AW, 1978, FEBS LETT, V90, P203, DOI 10.1016/0014-5793(78)80369-X; NIERHAUS KH, 1973, J MOL BIOL, V74, P587; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OSSWALD M, 1990, NUCLEIC ACIDS RES, V18, P6755; Rappoport S, 1974, Methods Enzymol, V29, P685; RODNINA MV, 1992, J MOL BIOL, V228, P450, DOI 10.1016/0022-2836(92)90834-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHULZE H, 1982, EMBO J, V1, P609, DOI 10.1002/j.1460-2075.1982.tb01216.x; SEMENKOV Y, 1992, FEBS LETT, V296, P207, DOI 10.1016/0014-5793(92)80380-Y; SEMENKOV YP, 1992, BIOCHIMIE, V74, P411, DOI 10.1016/0300-9084(92)90080-X; SONENBERG N, 1973, P NATL ACAD SCI USA, V70, P1423, DOI 10.1073/pnas.70.5.1423; STOFFLER G, 1986, STRUCTURE FUNCTION G, P28; SYLVERS LA, 1989, FEBS LETT, V245, P9, DOI 10.1016/0014-5793(89)80180-2; SZER W, 1972, BIOCHIM BIOPHYS ACTA, V259, P357, DOI 10.1016/0005-2787(72)90310-3; TEJEDOR F, 1985, BIOCHEMISTRY-US, V24, P467, DOI 10.1021/bi00323a033; TOTH MJ, 1986, J BIOL CHEM, V261, P6643; WALLECZEK J, 1989, J BIOL CHEM, V264, P4231; WALLECZEK J, 1989, BIOCHEMISTRY-US, V28, P4099, DOI 10.1021/bi00435a071; WOWER I, 1981, NUCLEIC ACIDS RES, V9, P4285, DOI 10.1093/nar/9.17.4285; WOWER J, 1988, BIOCHEMISTRY-US, V27, P8114, DOI 10.1021/bi00421a021; WOWER J, 1993, TRANSLATIONAL APPARATUS, P455; Wower J, 1995, BIOCHEM CELL BIOL, V73, P1041, DOI 10.1139/o95-111; WOWER J, 1993, EMBO J, V12, P617, DOI 10.1002/j.1460-2075.1993.tb05694.x; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232; Zimmermann R. A., 1980, RIBOSOMES STRUCTURE, P135	45	62	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19847	19852		10.1074/jbc.273.31.19847	http://dx.doi.org/10.1074/jbc.273.31.19847			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677420	hybrid			2022-12-25	WOS:000075125200072
J	Giani, C; Casalini, P; Pupa, SM; De Vecchi, R; Ardini, E; Colnaghi, MI; Giordano, A; Menard, S				Giani, C; Casalini, P; Pupa, SM; De Vecchi, R; Ardini, E; Colnaghi, MI; Giordano, A; Menard, S			Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation	ONCOGENE			English	Article						c-erbB-2; oncogene; breast cancer; estrogens; proliferation; differentiation	RECEPTOR TYROSINE KINASES; NEU-ONCOGENE; RETINOBLASTOMA PROTEIN; OVARIAN-CANCER; PC12 CELLS; IN-VIVO; OVEREXPRESSION; HEREGULIN; ESTROGEN; ERBB-2	c-erbB-2, a member of the tyrosine kinase oncogene family, is overexpressed in about 30% of human breast tumors where it correlates with poor prognosis. In vitro studies have suggested that increased expression of the receptor plays an important role in malignant progression. To better understand the direct effects of p185(HER2) overexpression, a human c-erbB-2 expression vector was transfected into the hormone-dependent MCF-7 human breast carcinoma cell line and cell growth was analysed. Unexpectedly, colony formation assay revealed a reduction in the number and size of colonies as compared with mock-transfected cells. In hormone-deprived medium, c-erbB-2 transfected cells acquired growth capability, consistent with previous reports. By contrast, two c-erbB-2-transfected clones grown in complete medium showed a reduced proliferation rate despite the activation of a fully functional oncoprotein capable of autophosphorylation and induction of the MAPK pathway. The number of c-erbB-2-overexpressing cells in the S phase of the cell cycle was about one-half the number of control and mock-transfected cells. Also, overexpression of c-erbB-2 induced overexpression of p21(WAF1), pRB hypophosphorylation and a mature differentiated cell phenotype with production of lipid droplets. Functional inactivation of p185(HER2) by means of a specific single chain antibody indicated the c-erbB-2-dependence of the observed alterations. These data show that the exogenous overexpression of the c-erbB-2 gene in hormone-dependent breast cancer cells inhibits proliferation and induces differentiation.	Ist Nazl Tumori, Div Expt Oncol E, I-20133 Milan, Italy; Thomas Jefferson Univ, Jefferson Med Coll, S Barro Inst Canc Res & Mol Med, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; Jefferson University	Colnaghi, MI (corresponding author), Ist Nazl Tumori, Div Expt Oncol E, Via Venezian 1, I-20133 Milan, Italy.		Pupa, Serenella/K-6388-2016; Giordano, Antonio/F-1927-2010; menard, sylvie mm/C-7940-2011	Pupa, Serenella/0000-0002-4592-6830; Giordano, Antonio/0000-0002-5959-016X; 				BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; Bacus SS, 1996, ONCOGENE, V12, P2535; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Carlomagno C, 1996, J CLIN ONCOL, V14, P2702, DOI 10.1200/JCO.1996.14.10.2702; CENTIS F, 1992, HYBRIDOMA, V11, P267, DOI 10.1089/hyb.1992.11.267; CHEN PL, 1995, CRIT REV EUKAR GENE, V5, P79; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOUGALL WC, 1994, ONCOGENE, V9, P2109; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; FELIP E, 1995, CANCER, V75, P2147, DOI 10.1002/1097-0142(19950415)75:8<2147::AID-CNCR2820750818>3.0.CO;2-8; Gorospe M, 1996, CELL GROWTH DIFFER, V7, P1609; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JANES PW, 1994, ONCOGENE, V9, P3601; KERN JA, 1994, J CLIN INVEST, V93, P516, DOI 10.1172/JCI117001; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; POLLER DN, 1992, BRIT J CANCER, V66, P583, DOI 10.1038/bjc.1992.318; RILKE F, 1991, INT J CANCER, V49, P44, DOI 10.1002/ijc.2910490109; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; TODD DM, 1992, DIAGN ONCOL, V2, P313; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	43	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					425	432		10.1038/sj.onc.1201954	http://dx.doi.org/10.1038/sj.onc.1201954			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696035				2022-12-25	WOS:000075043000004
J	Loetscher, P; Gong, JH; Dewald, B; Baggiolini, M; Clark-Lewis, I				Loetscher, P; Gong, JH; Dewald, B; Baggiolini, M; Clark-Lewis, I			N-terminal peptides of stromal cell-derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE CHEMOATTRACTANT; CHROMOSOMAL LOCALIZATION; HIV-1 ENTRY; 7-TRANSMEMBRANE; INTERLEUKIN-8; INFECTION; CLONING; SDF-1; LESTR/FUSIN; INHIBITOR	Peptides corresponding to the N-terminal 9 residues of stromal cell-derived factor-1 (SDF-1) have SDF-1 activity. SDF-1, 1-8, 1-9, 1-9 dimer, and 1-17 induced intracellular calcium and chemotaxis in T lymphocytes and CEM cells and bound to CXC chemokine receptor 4 (CXCR4). The peptides had similar activities to SDF-1 but were less potent. Whereas native SDF-1 had half-maximal chemoattractant activity at 5 nM, the 1-9 dimer required 500 nM and was therefore 100 fold less potent, The 1-17 and a 1-9 monomer analog were 4 and 36-fold, respectively, less potent than the 1-9 dimer, Both the chemotactic and calcium response of the 1-9 dimer was inhibited by an antibody to CXCR4. The basis for the enhanced activity of the dimer form of SDF-1, 1-9 is uncertain, but it could involve an additional fortuitous binding site on the 1-9 peptide in addition to the normal SDF-1, 1-9 site. A 1-9 analog, 1-9[P2G] dimer, was found to be a CXCR4 antagonist, Overall this study shows that the N-terminal peptides are CXCR4 agonists or antagonists, and these could be leads for high affinity ligands.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ Bern, Theodor Kocher Inst, CH-3000 Bern, Switzerland; Univ Hosp Bern, Div Rheumatol, CH-3010 Bern, Switzerland	University of British Columbia; University of British Columbia; University of Bern; University of Bern; University Hospital of Bern	Clark-Lewis, I (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	ian@brc.ubc.ca						Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; Jones SA, 1997, J BIOL CHEM, V272, P16166, DOI 10.1074/jbc.272.26.16166; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; LOETSCHER P, 1994, FASEB J, V8, P1055, DOI 10.1096/fasebj.8.13.7926371; Lowman HB, 1996, J BIOL CHEM, V271, P14344, DOI 10.1074/jbc.271.24.14344; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Murakami T, 1997, J EXP MED, V186, P1389, DOI 10.1084/jem.186.8.1389; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0	24	125	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22279	22283		10.1074/jbc.273.35.22279	http://dx.doi.org/10.1074/jbc.273.35.22279			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712844	hybrid			2022-12-25	WOS:000075616600020
J	Wang, KKW; Posmantur, R; Nath, R; McGinnis, K; Whitton, M; Talanian, RV; Glantz, SB; Morrow, JS				Wang, KKW; Posmantur, R; Nath, R; McGinnis, K; Whitton, M; Talanian, RV; Glantz, SB; Morrow, JS			Simultaneous degradation of alpha II- and beta II-spectrin by caspase 3 (CPP32) in apoptotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEASE-I; SH-SY5Y NEUROBLASTOMA-CELLS; ICE/CED-3 PROTEASE; NEURONAL APOPTOSIS; CYSTEINE PROTEASE; FAMILY PROTEASES; BRAIN SPECTRIN; BINDING-SITE; FODRIN; CALPAIN	The degradation of alpha II- and beta II-spectrin during apoptosis in cultured human neuroblastoma SH-SY5Y cells was investigated. Immunofluorescent staining showed that the collapse of the cortical spectrin cytoskeleton is an early event following staurosporine challenge. This collapse correlated with the generation of a series of prominent spectrin breakdown products (BDPs) derived from both alpha II- and beta II-subunits. Major C-terminal alpha II-spectrin BDPs were detected at approximate to 150, 145, and 120 kDa (alpha II-BDP150, alpha II-BDP145, and alpha II-BDP120, respectively); major C-terminal PII-spectrin BDPs were at approximate to 110 and 85 kDa (beta II-BDP110 and beta II-BDP85, respectively). N-terminal sequencing of the major fragments produced in vitro by caspase 3 revealed that alpha II-BDP150 and alpha II-BDP120 were generated by cleavages at DETD1185*S-1186 and DSLD1478*S-1479, respectively. For PII-spectrin, a major caspase site was detected at DEVD1457*S-1458, and both beta II-BDP110 and beta II-BDP85 shared a common N-terminal sequence starting with Ser(1458). An additional cleavage site near the C terminus, at ETVD2146*S-2147, was found to account for beta II-BDP85. Studies using specific caspase or calpain inhibitors indicate that the pattern of spectrin breakdown during apoptosis differs from that during non-apoptotic cell death. We postulate that in concert with calpain, caspase rapidly targets critical sites in both alpha II- and PII-spectrin and thereby initiates a rapid dissolution of the spectrin-actin cortical cytoskeleton with apoptosis.	Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Neurosci Therapeut, Lab Neurobiochem, Ann Arbor, MI 48105 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Immunopathol, Ann Arbor, MI 48105 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Chem, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48106 USA; BASF Biores Corp, Worcester, MA 01605 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Pfizer; Pfizer; Pfizer; University of Michigan System; University of Michigan; BASF; Yale University	Wang, KKW (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Neurosci Therapeut, Lab Neurobiochem, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.	Kevin.Wang@WL.com		Wang, Kevin/0000-0002-9343-6473				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; DELCERRO S, 1994, NEUROSCI LETT, V167, P149, DOI 10.1016/0304-3940(94)91049-9; DENG HY, 1995, J CELL BIOL, V128, P71, DOI 10.1083/jcb.128.1.71; Devarajan P, 1996, CURR TOP MEMBR, V43, P97; DISTASI AMM, 1991, NEURON, V6, P445, DOI 10.1016/0896-6273(91)90252-U; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GLANTZ SB, 1996, LUNG BIOL HEALTH DIS, V95, P153; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Greidinger EL, 1996, FEBS LETT, V390, P299, DOI 10.1016/0014-5793(96)00678-3; HARRIS AS, 1986, J CELL BIOCHEM, V30, P51, DOI 10.1002/jcb.240300107; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; HARRIS AS, 1989, J BIOL CHEM, V264, P17401; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; HARRIS AS, 1988, J NEUROSCI, V8, P2640; HU RJ, 1992, J BIOL CHEM, V267, P18715; HU RJ, 1991, J BIOL CHEM, V266, P18200; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LEE JK, 1993, J CELL BIOL, V123, P1797, DOI 10.1083/jcb.123.6.1797; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; LYNCH G, 1987, BRAIN RES BULL, V18, P809, DOI 10.1016/0361-9230(87)90220-6; LYNCH G, 1990, PROG BRAIN RES, V83, P233; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MORROW JS, 1997, HDB PHYSL, V11, P485; MURACHI T, 1989, BIOCHEM INT, V18, P263; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Posmantur R, 1997, J NEUROCHEM, V68, P2328; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; SARIN A, 1994, J IMMUNOL, V153, P862; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SIMAN R, 1989, J NEUROSCI, V9, P1579; SMITH DB, 1986, P NATL ACAD SCI USA, V83, P8703, DOI 10.1073/pnas.83.22.8703; SPEICHER DW, 1993, J BIOL CHEM, V268, P4227; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Stabach PR, 1997, BIOCHEMISTRY-US, V36, P57, DOI 10.1021/bi962034i; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; Wang KKW, 1996, BIOTECHNIQUES, V20, P662; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	53	265	269	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22490	22497		10.1074/jbc.273.35.22490	http://dx.doi.org/10.1074/jbc.273.35.22490			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712874	hybrid			2022-12-25	WOS:000075616600050
J	Bosch, M; Gil, J; Bachs, O; Agell, N				Bosch, M; Gil, J; Bachs, O; Agell, N			Calmodulin inhibitor W13 induces sustained activation of ERK2 and expression of p21(cip1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; CELL-CYCLE ARREST; DUAL-SPECIFICITY PHOSPHATASE; NUCLEOTIDE EXCHANGE FACTOR; PROTEIN-KINASE ACTIVATION; DNA-POLYMERASE-ALPHA; SMOOTH-MUSCLE CELLS; MAP KINASE; TYROSINE KINASE; GENE-PRODUCT	One of the major signaling pathways by which extracellular signals induce cell proliferation and differentiation involves the activation of extracellular signal-regulated kinases (ERKs), Because calmodulin is essential for quiescent cells to enter cell cycle, the role of calmodulin on ERK2 activation was studied in cultured fibroblasts. Serum, phorbol esters, or active Ras induced ERK2 activation in NIH 3T3 fibroblasts. This activation was not inhibited by calmodulin blockade. Surprisingly, inhibition of calmodulin prior to fetal bovine serum addition prolonged activation of ERK2, Furthermore, inactivation of calmodulin in serum-starved cells induced ERK2 phosphorylation that was dependent on MAP kinase kinase (MEK). Inactivation of calmodulin in serum-starved cells also induced activation of Ras, Raf, and MEK. On the contrary, tyrosine phosphorylation of tyrosine kinase receptors was not observed. These results indicate that calmodulin inhibits ERK2 activation pathway at the level of Ras. Calmodulin inhibition induced overexpression of p21(cip1) which was dependent on MEK activity. We propose that inhibition of Ras by calmodulin prevents the activation of ERK2 at low serum concentration. Thus, entering into the cell cycle after serum addition would imply the overcoming of the inhibitory effect of calmodulin and consequently ERK2 activation. Furthermore, down-regulation of Ras by calmodulin may be also important to determine the duration of ERK2 activation and to prevent a high p21(cip1) expression that would lead to an inhibition of cell proliferation.	Univ Barcelona, Fac Med, Inst Invest Biomed August Pi & Sunyer, Dept Biol Cellular & Anat Patol, Barcelona 08036, Spain; Univ Barcelona, Dept Ciencies Fisiol 2, Barcelona 08907, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona	Agell, N (corresponding author), Univ Barcelona, Fac Med, Dept Cellular Biol, C-Casanova 143, Barcelona 08036, Spain.		Bosch, Marta/AAU-9099-2020; Agell, Neus/E-9640-2016	Agell, Neus/0000-0002-1205-6074; Gil, Joan/0000-0002-3686-3903; Bosch, Marta/0000-0003-3934-6781				AGELL A, CELL CALCIUM, V23, P115; AGELL N, 1995, CALCIUM CALMODULIN F; Baouz S, 1997, J BIOL CHEM, V272, P6671, DOI 10.1074/jbc.272.10.6671; BOYNTON AL, 1980, BIOCHEM BIOPH RES CO, V95, P745, DOI 10.1016/0006-291X(80)90849-9; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; CHAFOULEAS JG, 1984, CELL, V36, P73, DOI 10.1016/0092-8674(84)90075-8; COFFER P, 1994, ONCOGENE, V9, P911; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; EILAM Y, 1988, GEN MICROBIOL, V143, P1063; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Guerrero C, 1996, ONCOGENE, V12, P1097; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HARPER JW, 1993, CELL, V75, P805; HERGET T, 1994, EUR J BIOCHEM, V225, P549, DOI 10.1111/j.1432-1033.1994.t01-1-00549.x; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; KAHAN C, 1992, J BIOL CHEM, V267, P13369; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOPEZGIRONA A, 1992, BIOCHEM BIOPH RES CO, V184, P1517, DOI 10.1016/S0006-291X(05)80055-5; LopezGirona A, 1995, BIOCHEM BIOPH RES CO, V217, P566, DOI 10.1006/bbrc.1995.2813; LOPEZGIRONA A, 1995, CELL CALCIUM, V18, P30, DOI 10.1016/0143-4160(95)90043-8; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martin-Nieto J, 1998, BIOCHEMISTRY-US, V37, P227, DOI 10.1021/bi971765v; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MCKENZIE FR, 1998, IN PRESS ANAL BIOCH; MEDEMA JP, 1994, MOL CELL BIOL, V14, P7078, DOI 10.1128/MCB.14.11.7078; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Mineo C, 1997, J BIOL CHEM, V272, P10345; MORRISON DK, 1995, METHOD ENZYMOL, V255, P301; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SANJOSE E, 1992, J BIOL CHEM, V267, P15237; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; TAKUWA N, 1993, J BIOL CHEM, V268, P138; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WATMANN M, 1994, J BIOL CHEM, V269, P6695; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598	71	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22145	22150		10.1074/jbc.273.34.22145	http://dx.doi.org/10.1074/jbc.273.34.22145			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705360	hybrid, Green Published			2022-12-25	WOS:000075492600094
J	Drmota, T; Novotny, J; Kim, GD; Eidne, KA; Milligan, G; Svoboda, P				Drmota, T; Novotny, J; Kim, GD; Eidne, KA; Milligan, G; Svoboda, P			Agonist-induced internalization of the G protein G(11)alpha and thyrotropin-releasing hormone receptors proceed on different time scales	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PITUITARY-CELLS; DOWN-REGULATION; ALPHA-SUBUNITS; BETA(2)-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTORS; COUPLED RECEPTOR; PHOSPHOLIPASE-C; BETA-ARRESTIN; CHOLECYSTOKININ RECEPTOR; ACETYLCHOLINE-RECEPTOR	Using a combination of confocal immunofluorescence microscopy and subcellular fractionation, we demonstrate for the first time active internalization, trafficking, and down-regulation of a G protein alpha subunit subsequent to agonist occupation of a receptor, This proceeds on a much slower time scale than internalization of the corresponding receptor. In intact E2M11 HEK293 cells that express high levels of murine G(11)alpha and the rat thyrotropin-releasing hormone (TRH) receptor, the immunofluorescence signal of G(11)alpha was restricted almost exclusively to the plasma membrane. Exposure to TRH (10 mu M) resulted first in partial relocation of G(11)alpha to discrete, segregated patches within the plasma membrane (10-60 min). Further exposure to TRH caused internalization of G(11)alpha to discrete, punctate, intracellular bodies (2-4 h) and subsequently to a virtually complete loss of G(11)alpha from plasma membranes and the cells (8-16 h), Short-term treatment with TRH followed by wash-out of the ligand allowed G(11)alpha immunofluorescence to be restored to the plasma membrane within 12 h. In subcellular membrane fractions, G(11)alpha was centered on plasma membranes, and this was not altered by up to 1-2 h of incubation with TRH. Further exposure to TRH (2-4 h) resulted in transfer of a significant portion of G(11)alpha to light-vesicular and cytosol fractions. At longer time intervals (4-16 h), an overall decrease in G(11)alpha content was observed.	Acad Sci Czech Republ, Inst Physiol, CR-14220 Prague 4, Czech Republic; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland; MRC, Reprod Biol Unit, Edinburgh EH3 9EW, Midlothian, Scotland	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; University of Glasgow	Svoboda, P (corresponding author), Acad Sci Czech Republ, Inst Physiol, Videnska 1083, CR-14220 Prague 4, Czech Republic.		Svoboda, Petr/C-2619-2012; Milligan, Graeme/F-9426-2011; Novotny, Jiri/B-2163-2012	Svoboda, Petr/0000-0002-3076-4672; Milligan, Graeme/0000-0002-6946-3519; Novotny, Jiri/0000-0002-6372-0131	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CROUCH MF, 1989, P NATL ACAD SCI USA, V86, P1776, DOI 10.1073/pnas.86.6.1776; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Gaudriault G, 1997, J BIOL CHEM, V272, P2880, DOI 10.1074/jbc.272.5.2880; GERSHENGORN MC, 1994, ENDOCRINOLOGY, V94, P5; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GREEN A, 1990, J BIOL CHEM, V265, P5206; HARAGUCHI K, 1990, P NATL ACAD SCI USA, V87, P1208, DOI 10.1073/pnas.87.3.1208; HEIN L, 1994, J BIOL CHEM, V269, P27719; HINKLE PM, 1982, J BIOL CHEM, V257, P5462; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; IBARRONDO J, 1995, P NATL ACAD SCI USA, V92, P8413, DOI 10.1073/pnas.92.18.8413; KIM GD, 1994, J BIOL CHEM, V269, P19933; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MCKENZIE FR, 1990, J BIOL CHEM, V265, P17084; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P413, DOI 10.1016/0165-6147(93)90064-Q; MITCHELL FM, 1991, FEBS LETT, V287, P171, DOI 10.1016/0014-5793(91)80043-3; MITCHELL FM, 1993, BIOCHEM J, V293, P495, DOI 10.1042/bj2930495; Molino M, 1997, J BIOL CHEM, V272, P6011, DOI 10.1074/jbc.272.9.6011; MOORE RH, 1995, J CELL SCI, V108, P2983; Muntz Kathryn H., 1994, Trends in Cell Biology, V4, P354, DOI 10.1016/0962-8924(94)90077-9; NEGISHI M, 1992, J BIOL CHEM, V267, P2364; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; PALMER TM, 1995, J BIOL CHEM, V270, P16895, DOI 10.1074/jbc.270.28.16895; Petrou C, 1997, J BIOL CHEM, V272, P2326; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Raposo G, 1994, Trends Cell Biol, V4, P418, DOI 10.1016/0962-8924(94)90096-5; Roettger BF, 1997, MOL PHARMACOL, V51, P357; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; RuizGomez A, 1997, J BIOL CHEM, V272, P9601; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SELLAR RE, 1993, J MOL ENDOCRINOL, V10, P199, DOI 10.1677/jme.0.0100199; SHAH BH, 1995, P NATL ACAD SCI USA, V92, P1886, DOI 10.1073/pnas.92.6.1886; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; Svoboda P, 1996, MOL PHARMACOL, V49, P646; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; VANDEWESTERLO E, 1995, BIOCHEM J, V310, P559, DOI 10.1042/bj3100559; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WANG N, 1990, J BIOL CHEM, V265, P1239; WISE A, 1995, J BIOL CHEM, V270, P17196, DOI 10.1074/jbc.270.29.17196; YAJIMA Y, 1993, MOL CELL ENDOCRINOL, V92, P143, DOI 10.1016/0303-7207(93)90001-Z; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	55	43	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21699	21707		10.1074/jbc.273.34.21699	http://dx.doi.org/10.1074/jbc.273.34.21699			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705305	hybrid			2022-12-25	WOS:000075492600039
J	Essler, M; Amano, M; Kruse, HJ; Kaibuchi, K; Weber, PC; Aepfelbacher, M				Essler, M; Amano, M; Kruse, HJ; Kaibuchi, K; Weber, PC; Aepfelbacher, M			Thrombin inactivates myosin light chain phosphatase via Rho and its target Rho kinase in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; SMOOTH-MUSCLE MYOSIN; ACTIN STRESS FIBERS; ADP-RIBOSYLTRANSFERASE; FOCAL ADHESIONS; CYTOPLASMIC DIVISION; RECEPTOR ACTIVATION; PUTATIVE TARGET; GENE-PRODUCT; PHOSPHORYLATION	The role of Rho GTPase and its downstream targets Rho kinase and myosin light chain phosphatase in thrombin-induced endothelial cell contraction was investigated. The specific Rho inactivator C3-transferase from Clostridium botulinum as well as microinjection of the isolated Rho-binding domain of Rho kinase or active myosin light chain phosphatase abolished thrombin-stimulated endothelial cell contraction. Conversely, microinjection of constitutively active V14Rho, constitutively active catalytic domain of Rho kinase, or treatment with the phosphatase inhibitor tautomycin caused contraction. These data are consistent with the notion that thrombin activates Rho/Rho kinase to inactivate myosin light chain phosphatase in endothelial cells. In fact, we demonstrate that thrombin transiently inactivated myosin light chain phosphatase, and this correlated with a peak in myosin light chain phosphorylation. C3-transferase abolished the decrease in myosin light chain phosphatase activity as well as the subsequent increase in myosin light chain phosphorylation and cell contraction. These data suggest that thrombin activates the Rho/Rho kinase pathway to inactivate myosin light chain phosphatase as part of a signaling network that controls myosin light chain phosphorylation/contraction in human endothelial cells.	Univ Munich, Inst Prophylaxe & Epidemiol Kreislaufkrankheiten, D-80336 Munchen, Germany; Max Von Pettenkofer Inst Hyg & Med Microbiol, D-80336 Munchen, Germany; Nara Inst Sci & Technol, Div Signal Transduct, Nara 63001, Japan	University of Munich; University of Munich; Nara Institute of Science & Technology	Essler, M (corresponding author), Univ Munich, Inst Prophylaxe & Epidemiol Kreislaufkrankheiten, Pettenkoferstr 9, D-80336 Munchen, Germany.		Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524				AEPFELBACHER M, 1995, BIOCHEM J, V308, P853, DOI 10.1042/bj3080853; Aepfelbacher M, 1996, J IMMUNOL, V157, P5070; Aepfelbacher M, 1997, ARTERIOSCL THROM VAS, V17, P1623, DOI 10.1161/01.ATV.17.9.1623; AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Allen WE, 1997, J CELL SCI, V110, P707; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FERNANDEZ A, 1990, J CELL BIOL, V111, P103, DOI 10.1083/jcb.111.1.103; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Leung T, 1996, MOL CELL BIOL, V16, P5313; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MORII N, 1992, J BIOL CHEM, V267, P20921; NODA M, 1995, FEBS LETT, V367, P246, DOI 10.1016/0014-5793(95)00573-R; PATERSON CE, 1994, MICROVASC RES, V48, P212; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; SAADI S, 1995, J EXP MED, V181, P21, DOI 10.1084/jem.181.1.21; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; TAKAISHI K, 1993, MOL CELL BIOL, V13, P1935; TAPON N, 1997, CURR OPIN CELL BIOL, V9, P89; TOMINAGA T, 1993, J CELL BIOL, V120, P1525; VERIN AD, 1995, AM J PHYSIOL, V269, pL199; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WYSOLMERSKI RB, 1990, P NATL ACAD SCI USA, V87, P16, DOI 10.1073/pnas.87.1.16	53	308	317	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21867	21874		10.1074/jbc.273.34.21867	http://dx.doi.org/10.1074/jbc.273.34.21867			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705325	hybrid			2022-12-25	WOS:000075492600059
J	Reed, AL; Yamazaki, H; Kaufman, JD; Rubinstein, Y; Murphy, B; Johnson, AC				Reed, AL; Yamazaki, H; Kaufman, JD; Rubinstein, Y; Murphy, B; Johnson, AC			Molecular cloning and characterization of a transcription regulator with homology to GC-binding factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTOR GENE; PROTO-ONCOGENE; CELL-LINES; REPRESSES TRANSCRIPTION; MESSENGER-RNA; RETINOIC ACID; HUMAN P53; PROMOTER; IDENTIFICATION	GC-binding factor (GCF) represses transcription of certain genes and is encoded by a 3.0-kilobase mRNA (Kageyama, R., and Pastan, I. (1989) Cell 59, 815-825). The GCF cDNA hybridizes to two additional mRNA species, 4.2 and 1.2 kilobases. We have used differential hybridization to identify a cDNA clone (termed GCF2) for the 4.2-kilobase mRNA and find that it is highly expressed in HUT-102 cells. The open reading frame consists of 2256 nucleotides and encodes a protein of 752 amino acids with a calculated molecular mass of 83 kilodaltons. GCF2 expressed in vitro using reticulocyte lysates and Escherichia coli migrates as a 160-kilodalton protein in SDS-polyacrylamide gel electrophoresis but has a molecular mass of 83 kilodaltons as determined by mass spectrum analysis. GCF2 binds to epidermal growth factor receptor promoter fragments, and the major binding site is located between nucleotides -249 and -233. Cotransfection assays show that GCF2 acts to repress transcription from the epidermal growth factor receptor promoter in constructs containing the major GCF2 binding site and not when the site had been mutated. Thus, GCF2 is a newly identified transcriptional repressor with aberrant electrophoretic mobility.	NCI, Mol Biol Lab, DBS, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Johnson, AC (corresponding author), NCI, Mol Biol Lab, DBS, NIH, Bldg 37,Rm 2D18,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3097, DOI 10.1093/nar/21.13.3097; BURTON Z, 1981, NUCLEIC ACIDS RES, V9, P2889, DOI 10.1093/nar/9.12.2889; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN LL, 1993, CELL GROWTH DIFFER, V4, P975; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DEB SP, 1994, ONCOGENE, V9, P1341; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HERNANDEZSOTOMAYOR SMT, 1992, J MEMBRANE BIOL, V128, P81; HOU XY, 1994, CELL GROWTH DIFFER, V5, P801; HOU XY, 1994, J BIOL CHEM, V269, P4307; Hudson L G, 1991, Genet Eng (N Y), V13, P137; HUDSON LG, 1990, P NATL ACAD SCI USA, V87, P7536, DOI 10.1073/pnas.87.19.7536; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; JOHNSON AC, 1988, BIOCHEM BIOPH RES CO, V150, P412, DOI 10.1016/0006-291X(88)90536-0; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; JOHNSON AC, 1992, J BIOL CHEM, V267, P1689; Johnson AC, 1996, J BIOL CHEM, V271, P3033; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8477, DOI 10.1093/nar/13.23.8477; KITADAI Y, 1993, CELL GROWTH DIFFER, V4, P291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Merlino G T, 1990, Semin Cancer Biol, V1, P277; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; Shibutani M, 1998, J BIOL CHEM, V273, P6878, DOI 10.1074/jbc.273.12.6878; SUBLER MA, 1994, ONCOGENE, V9, P1351; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; XU YH, 1984, P NATL ACAD SCI-BIOL, V81, P7308, DOI 10.1073/pnas.81.23.7308; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; ZHENG ZS, 1992, CELL GROWTH DIFFER, V3, P225	45	49	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21594	21602		10.1074/jbc.273.34.21594	http://dx.doi.org/10.1074/jbc.273.34.21594			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705290	hybrid			2022-12-25	WOS:000075492600024
J	Smith, CA; Baeten, J; Taylor, JS				Smith, CA; Baeten, J; Taylor, JS			The ability of a variety of polymerases to synthesize past site-specific cis-syn, trans-syn-II, (6-4), and Dewar photoproducts of thymidylyl-(3 '-> 5 ')-thymidine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T7 RNA-POLYMERASE; BACTERIOPHAGE-T7 DNA-POLYMERASE; THYMINE CYCLOBUTANE DIMER; SINGLE-TURNOVER KINETICS; CHAIN-REACTION ASSAY; HUMAN CELL-EXTRACTS; ESCHERICHIA-COLI; SKIN-CANCER; IN-VITRO; EXONUCLEASE ACTIVITY	The role of photoproduct structure, 3' --> 5' exonuclease activity, and processivity on polynucleotide synthesis past photoproducts of thymidylyl-(3' --> S')-thymidine was investigated. Both Moloney murine leukemia virus reverse transcriptase and 3' --> 5' exonuclease-deficient (exo(-)) Vent polymerase were blocked by all photoproducts, whereas Tag polymerase could slowly bypass the cis-syn dimer, T7 RNA polymerase was able to bypass all the photoproducts in the order cis-syn > Dewar > (6-4) > trans-syn-II. Klenow fragment could not bypass any of the photoproducts, but an exo- mutant could bypass the cis-syn dimer to a greater extent than the others. Likewise T7 DNA polymerase, composed of the T7 gene 5 protein and Escherichia call thioredoxin, was blocked by all the photoproducts, but the exo- mutant Sequenase 2.0 was able to bypass them all in the order cis-syn > Dewar > trans-syn-II > (6-4), No bypass occurred with an exo- gene 5 protein in the absence of the thioredoxin processivity factor. Bypass of the cis-syn and trans-syn-II products by Sequenase 2.0 was essentially non-mutagenic, whereas about 20% dTMP was inserted opposite the 5'-T of the Dewar photoproduct. A mechanism involving a transient abasic site is proposed to account for the preferential incorporation of dAMP opposite the 3'-T of the photoproducts.	Washington Univ, Dept Chem, St Louis, MO 63130 USA	Washington University (WUSTL)	Taylor, JS (corresponding author), Washington Univ, Dept Chem, St Louis, MO 63130 USA.	taylor@wuchem.wustl.edu	Taylor, John-Stephen/AAA-3218-2020	Taylor, John-Stephen/0000-0002-8615-7257; Smith, Colin/0000-0001-5652-0855	NCI NIH HHS [CA40463] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040463, R01CA040463] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AXELROD JD, 1989, NUCLEIC ACIDS RES, V17, P171, DOI 10.1093/nar/17.1.171; BANERJEE SK, 1990, J BACTERIOL, V172, P2105, DOI 10.1128/jb.172.4.2105-2112.1990; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BARAK Y, 1995, J BIOL CHEM, V270, P24174, DOI 10.1074/jbc.270.41.24174; BELGUISEVALLADIER P, 1994, J MOL BIOL, V236, P151, DOI 10.1006/jmbi.1994.1125; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CADET J, 1990, BIOORGANIC PHOTOCHEM, V1, P1; Carty MP, 1996, J BIOL CHEM, V271, P9637, DOI 10.1074/jbc.271.16.9637; CHANDRASEKHAR D, 1994, J MOL BIOL, V238, P319, DOI 10.1006/jmbi.1994.1295; Chary P, 1997, J BIOL CHEM, V272, P5805, DOI 10.1074/jbc.272.9.5805; CHEN YH, 1993, J BIOL CHEM, V268, P5849; CHOI DJ, 1994, BIOCHEMISTRY-US, V33, P780, DOI 10.1021/bi00169a020; CHRISTNER DF, 1994, BIOCHEMISTRY-US, V33, P14297, DOI 10.1021/bi00251a043; CLARK JM, 1989, BIOCHEMISTRY-US, V28, P775, DOI 10.1021/bi00428a054; COMESS KM, 1992, BIOCHEMISTRY-US, V31, P3975, DOI 10.1021/bi00131a013; DAY CL, 1989, THESIS WASHINGTON U; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; DOSANJH MK, 1990, BIOCHEMISTRY-US, V29, P4698, DOI 10.1021/bi00471a026; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; EGER BT, 1992, BIOCHEMISTRY-US, V31, P9227, DOI 10.1021/bi00153a016; Fasman GD., 1975, HDB BIOCH MOL BIOL N, V1, P589; FREIDBERG EC, 1995, DNA REPAIR MUTAGENES; GIBBS PEM, 1993, J BACTERIOL, V175, P2607, DOI 10.1128/JB.175.9.2607-2612.1993; Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493; GREVATT PC, 1992, BIOCHEMISTRY-US, V31, P4181, DOI 10.1021/bi00132a005; GUSCHLBAUER W, 1991, NUCLEIC ACIDS RES, V19, P1753, DOI 10.1093/nar/19.8.1753; Hess MT, 1997, BIOCHEMISTRY-US, V36, P2332, DOI 10.1021/bi961689g; Holmquist GP, 1997, MUTAT RES-REV MUTAT, V386, P69, DOI 10.1016/S1383-5742(96)00045-2; HORSFALL MJ, 1994, J MOL BIOL, V235, P465, DOI 10.1006/jmbi.1994.1006; Horsfall MJ, 1997, J BACTERIOL, V179, P2835, DOI 10.1128/jb.179.9.2835-2839.1997; HRUSZKEWYCZ A, 1992, CARCINOGENESIS, V13, P2347, DOI 10.1093/carcin/13.12.2347; HUBER HE, 1987, J BIOL CHEM, V262, P16224; JIANG N, 1993, BIOCHEMISTRY-US, V32, P472, DOI 10.1021/bi00053a011; KALINOWSKI DP, 1992, NUCLEIC ACIDS RES, V20, P3485, DOI 10.1093/nar/20.13.3485; KAO JLF, 1993, CHEM RES TOXICOL, V6, P561, DOI 10.1021/tx00034a027; KEMMINK J, 1987, NUCLEIC ACIDS RES, V15, P4645, DOI 10.1093/nar/15.11.4645; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KIM JK, 1995, PHOTOCHEM PHOTOBIOL, V62, P44, DOI 10.1111/j.1751-1097.1995.tb05236.x; LATHAM GJ, 1995, CHEM RES TOXICOL, V8, P422, DOI 10.1021/tx00045a014; LAWRENCE CW, 1990, MOL GEN GENET, V222, P166, DOI 10.1007/BF00283040; LAWRENCE CW, 1993, MUTAT RES, V299, P157, DOI 10.1016/0165-1218(93)90093-S; LECLERC JE, 1991, P NATL ACAD SCI USA, V88, P9685, DOI 10.1073/pnas.88.21.9685; LINDSLEY JE, 1994, BIOCHEMISTRY-US, V33, P764, DOI 10.1021/bi00169a018; LIU FT, 1978, BIOCHEMISTRY-US, V17, P4865, DOI 10.1021/bi00616a003; Liu J, 1996, BIOCHEMISTRY-US, V35, P14999, DOI 10.1021/bi961455x; LIVNEH Z, 1986, J BIOL CHEM, V261, P9526; MATTILA P, 1991, NUCLEIC ACIDS RES, V19, P4967, DOI 10.1093/nar/19.18.4967; McCarthy MJ, 1996, MUTAT RES-DNA REPAIR, V363, P57, DOI 10.1016/0921-8777(95)00061-5; MICHAELS ML, 1987, J BIOL CHEM, V262, P14648; MIKITA T, 1994, BIOCHEMISTRY-US, V33, P9195, DOI 10.1021/bi00197a023; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MOORE PD, 1981, P NATL ACAD SCI-BIOL, V78, P110, DOI 10.1073/pnas.78.1.110; Moran S, 1997, J AM CHEM SOC, V119, P2056, DOI 10.1021/ja963718g; Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126; NATARAJ AJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P218, DOI 10.1111/j.1751-1097.1995.tb05262.x; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PazElizur T, 1997, BIOCHEMISTRY-US, V36, P1766, DOI 10.1021/bi9621324; Peng W, 1996, BIOCHEMISTRY-US, V35, P10172, DOI 10.1021/bi960001x; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SELBY CP, 1993, SCIENCE, V360, P53; SHIBUTANI S, 1993, CHEM RES TOXICOL, V6, P625, DOI 10.1021/tx00035a006; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P7531, DOI 10.1021/bi00080a027; Shibutani S, 1997, BIOCHEMISTRY-US, V36, P1755, DOI 10.1021/bi962275q; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; SMITH CA, 1993, J BIOL CHEM, V268, P11143; Smith CA, 1996, BIOCHEMISTRY-US, V35, P4146, DOI 10.1021/bi951975c; Spector TI, 1997, J AM CHEM SOC, V119, P7095, DOI 10.1021/ja964372c; STRAUSS B, 1982, BIOCHIMIE, V64, P829, DOI 10.1016/S0300-9084(82)80138-7; STRAUSS BS, 1985, CANCER SURV, V4, P493; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; STRAUSS BS, 1990, CARCINOGENESIS, V11, P2103, DOI 10.1093/carcin/11.12.2103; SVOBODA DL, 1993, J BIOL CHEM, V268, P10694; SZYMKOWSKI DE, 1993, P NATL ACAD SCI USA, V90, P9823, DOI 10.1073/pnas.90.21.9823; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1989, J BIOL CHEM, V264, P6447; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P1624, DOI 10.1021/bi00458a038; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TAYLOR JS, 1994, ACCOUNTS CHEM RES, V27, P76, DOI 10.1021/ar00039a003; TAYLOR JS, 1988, BIOCHEMISTRY-US, V27, P7206, DOI 10.1021/bi00419a007; TAYLOR JS, 1995, PURE APPL CHEM, V67, P183, DOI 10.1351/pac199567010183; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P6298, DOI 10.1074/jbc.270.11.6298; WANG CI, 1992, BIOCHEMISTRY-US, V31, P3671, DOI 10.1021/bi00129a016; Wellinger RE, 1996, NUCLEIC ACIDS RES, V24, P1578, DOI 10.1093/nar/24.8.1578; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; ZHAO XD, 1995, BIOCHEMISTRY-US, V34, P1386, DOI 10.1021/bi00004a033; ZHOU W, 1994, BIOCHEMISTRY-US, V33, P14926, DOI 10.1021/bi00253a032; ZHOU W, 1995, CELL, V82, P577, DOI 10.1016/0092-8674(95)90030-6; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	97	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21933	21940		10.1074/jbc.273.34.21933	http://dx.doi.org/10.1074/jbc.273.34.21933			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705333	hybrid			2022-12-25	WOS:000075492600067
J	Godbout, R; Packer, M; Bie, WJ				Godbout, R; Packer, M; Bie, WJ			Overexpression of a DEAD box protein (DDX1) in neuroblastoma and retinoblastoma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOGENEOUSLY STAINING REGIONS; DEPENDENT RNA HELICASE; N-MYC; AMPLIFICATION UNITS; MESSENGER-RNAS; GENE DDX1; COAMPLIFICATION; INITIATION; AMPLICON; ENCODES	The DEAD box gene, DDX1, is a putative RNA helicase that is co-amplified with MYCN in a subset of retinoblastoma (RE) and neuroblastoma (NB) tumors and cell lines. Although gene amplification usually involves hundreds to thousands of kilobase pairs of DNA, a number of studies suggest that co amplified genes are only overexpressed if they provide a selective advantage to the cells in which they are amplified. Here, we further characterize DDX1 by identifying its putative transcription and translation initiation sites. We analyze DDX1 protein levels in MYCN/DDX1-amplified NE and RE cell lines using polyclonal antibodies specific to DDX1 and show that there is a good correlation with DDXI gene copy number, DDXI transcript levels, and DDXI protein levels in all cell lines studied. DDXI protein is found in both the nucleus and cytoplasm of DDX1-amplified lines but is localized primarily to the nucleus of nonamplified cells. Our results indicate that DDX1 may be involved in either the formation or progression of a subset of NE and RE tumors and suggest that DDXI normally plays a role in the metabolism of RNAs located in the nucleus of the cell.	Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Edmonton, AB T6G 1Z2, Canada	University of Alberta; University of Alberta	Godbout, R (corresponding author), Cross Canc Inst, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.		Godbout, Roseline/I-4639-2016	Godbout, Roseline/0000-0002-4779-9265				AKAO Y, 1992, CANCER RES, V52, P6083; AKIYAMA K, 1991, NUCLEIC ACIDS RES, V19, P6887, DOI 10.1093/nar/19.24.6887; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amler LC, 1996, GENE CHROMOSOME CANC, V15, P134, DOI 10.1002/(SICI)1098-2264(199602)15:2<134::AID-GCC9>3.0.CO;2-4; Arai Y, 1997, BLOOD, V89, P3936, DOI 10.1182/blood.V89.11.3936; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BUELT MK, 1994, J BIOL CHEM, V269, P29367; COHN SL, 1991, PROG CLIN BIOL RES, V366, P21; COWELL JK, 1982, ANNU REV GENET, V16, P21, DOI 10.1146/annurev.ge.16.120182.000321; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; DAN L, 1992, NUCLEIC ACIDS RES, V20, P1967, DOI 10.1093/nar/20.8.1967; DEVALOIR T, 1991, P NATL ACAD SCI USA, V88, P2113, DOI 10.1073/pnas.88.6.2113; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; Dubey P, 1997, J EXP MED, V185, P695, DOI 10.1084/jem.185.4.695; Favaloro J, 1980, Methods Enzymol, V65, P718; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; George RE, 1996, ONCOGENE, V12, P1583; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; GODBOUT R, 1994, GENE, V138, P243, DOI 10.1016/0378-1119(94)90816-8; GODBOUT R, 1995, EXP EYE RES, V60, P645, DOI 10.1016/S0014-4835(05)80006-5; Graham J., 1984, CENTRIFUGATION PRACT, P161; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GURURAJAN R, 1994, P NATL ACAD SCI USA, V91, P2056, DOI 10.1073/pnas.91.6.2056; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; IOST I, 1994, NATURE, V372, P193, DOI 10.1038/372193a0; JAMIESON DJ, 1991, NATURE, V349, P715, DOI 10.1038/349715a0; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kuroda H, 1996, ONCOGENE, V13, P1561; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MANOHAR CF, 1995, GENE CHROMOSOME CANC, V14, P196, DOI 10.1002/gcc.2870140307; MILLER KG, 1981, CELL, V27, P165, DOI 10.1016/0092-8674(81)90370-6; Missel A, 1997, MOL CELL BIOL, V17, P4895, DOI 10.1128/MCB.17.9.4895; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; Noguchi T, 1996, GENE CHROMOSOME CANC, V15, P129, DOI 10.1002/(SICI)1098-2264(199602)15:2<129::AID-GCC8>3.3.CO;2-M; Pandita A, 1997, GENE CHROMOSOME CANC, V20, P243, DOI 10.1002/(SICI)1098-2264(199711)20:3<243::AID-GCC4>3.0.CO;2-2; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Rafti F, 1996, GENE, V171, P225, DOI 10.1016/0378-1119(96)00034-0; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Reiter JL, 1996, GENOMICS, V32, P97, DOI 10.1006/geno.1996.0081; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SQUIRE JA, 1995, ONCOGENE, V10, P1417; STRAUSS EJ, 1994, NUCLEIC ACIDS RES, V22, P3187, DOI 10.1093/nar/22.15.3187; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; ZEHNBAUER BA, 1988, MOL CELL BIOL, V8, P522, DOI 10.1128/MCB.8.2.522	56	68	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21161	21168		10.1074/jbc.273.33.21161	http://dx.doi.org/10.1074/jbc.273.33.21161			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694872	hybrid			2022-12-25	WOS:000075386100065
J	Howe, L; Ranalli, TA; Allis, CD; Ausio, J				Howe, L; Ranalli, TA; Allis, CD; Ausio, J			Transcriptionally active Xenopus laevis somatic 5 S ribosomal RNA genes are packaged with hyperacetylated histone H4, whereas transcriptionally silent oocyte genes are net	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLATION; NUCLEOSOME; CHROMATIN	The relationship between histone acetylation and transcription of the Xenopus laevis oocyte and somatic 5 S ribosomal RNA genes was investigated, Chromatin fragments from a X. laevis kidney cell line were immunoprecipitated with an antibody specific for hyperacetylated histone H4. The DNA from the hyperacetylated chromatin was probed with both oocyte- and somatic gene-specific sequences, and the results showed that the upstream, nontranscribed region of the transcriptionally active somatic genes is packaged with acetylated histone H4. In contrast, the corresponding region of the transcriptionally silent oocyte genes is packaged with hypoacetylated histone H4 in this cells line. Further study also showed that this region of the oocyte genes was less sensitive to digestion with the enzyme, micrococcal nuclease, Together these results suggest that, as described for both RNA polymerase I and II transcribed genes, there is a correlation between histone acetylation and transcription of the RNA polymerase III transcribed 5 S ribosomal RNA genes in X. laevis.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Univ Rochester, Dept Biol, Rochester, NY 14627 USA	University of Victoria; University of Rochester	Ausio, J (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055, Victoria, BC V8W 3P6, Canada.							AUSIO J, 1992, J CELL SCI, V102, P1; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CHIPEV CC, 1992, MOL CELL BIOL, V12, P45, DOI 10.1128/MCB.12.1.45; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON AL, 1993, FEBS LETT, V336, P23, DOI 10.1016/0014-5793(93)81601-U; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; ENGELKE DR, 1990, NUCLEIC ACIDS RES, V18, P6031, DOI 10.1093/nar/18.20.6031; FORD PJ, 1976, NATURE, V261, P433, DOI 10.1038/261433a0; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; Mutskov VJ, 1996, J BIOL CHEM, V271, P11852, DOI 10.1074/jbc.271.20.11852; PECK LJ, 1994, NUCLEIC ACIDS RES, V11, P443; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; PETERSON RC, 1980, CELL, V20, P131, DOI 10.1016/0092-8674(80)90241-X; REYNOLDS WF, 1982, CELL NUCLEUS, V11, P63; ROMANIUK PJ, 1987, NUCLEIC ACIDS RES, V15, P2737, DOI 10.1093/nar/15.6.2737; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; TURNER BM, 1991, J CELL SCI, V99, P13; Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096; WOLFFE AP, 1990, J BIOL CHEM, V265, P4592; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WORMINGTON WM, 1983, DEV BIOL, V99, P248, DOI 10.1016/0012-1606(83)90273-7	27	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20693	20696		10.1074/jbc.273.33.20693	http://dx.doi.org/10.1074/jbc.273.33.20693			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694810	hybrid			2022-12-25	WOS:000075386100003
J	Jonk, LJC; Itoh, S; Heldin, CH; ten Dijke, P; Kruijer, W				Jonk, LJC; Itoh, S; Heldin, CH; ten Dijke, P; Kruijer, W			Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; FAMILY; ACTIVATION; EXPRESSION; MEMBERS; ANTAGONIST; CELLS; GENE; SP1; BMP	Smad proteins have been identified as mediators of intracellular signal transduction by members of the transforming growth factor-beta (TGF-beta) superfamily, which affect cell proliferation, differentiation, as well as pattern formation during early vertebrate development. Following receptor activation, Smads are assembled into heteromeric complexes consisting of a pathway-restricted Smad and the common Smad4 that are subsequently translocated into the nucleus where they are thought to play an important role in gene transcription. Here we report the identification of Smad Binding Elements (SBEs) composed of the sequence CAGACA in the promoter of the JunB gene, an immediate early gene that is potently induced by TGF-beta, activin, and bone morphogenetic protein (BMP) 2, Two JunB SBEs are arranged as an inverted repeat that is transactivated in response to Smad3 and Smad4 co-overexpression and shows inducible binding of a Smad3- and Smad4-containing complex in nuclear extracts from TGF-beta-treated cells. Bacterial-expressed Smad proteins bind directly to the SEE. Multimerization of the SEE creates a powerful TGF-beta-inducible enhancer that is also responsive to activin and BMPs. The identification of the sequence CAGACA as a direct binding site for Smad proteins will facilitate the identification of regulatory elements in genes that are activated by members of the TGF-beta superfamily.	Groningen Biomol Sci & Biotechnol Inst, Dept Dev Genet, NL-9750 AA Haren, Netherlands; Ludwig Inst Canc Res, Biomed Ctr, S-7524 Uppsala, Sweden	University of Groningen; Ludwig Institute for Cancer Research	Kruijer, W (corresponding author), Groningen Biomol Sci & Biotechnol Inst, Dept Dev Genet, POB 14, NL-9750 AA Haren, Netherlands.	w.kruijer@biol.rug.nl	Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Itoh, Susumu/0000-0002-7967-0730				Alevizopoulos A, 1997, BIOESSAYS, V19, P581, DOI 10.1002/bies.950190709; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P128; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; HASHIMOTO M, 1993, ENDOCRINOLOGY, V133, P1934, DOI 10.1210/en.133.5.1934; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LI L, 1990, J BIOL CHEM, V265, P1556; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Meersseman G, 1997, MECH DEVELOP, V61, P127, DOI 10.1016/S0925-4773(96)00629-6; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Nishitoh H, 1996, J BIOL CHEM, V271, P21345, DOI 10.1074/jbc.271.35.21345; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; ROBERTS AB, 1996, PEPTIDE GROWTH FACTO, V95, P419; Schutte M, 1996, CANCER RES, V56, P2527; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	34	499	515	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21145	21152		10.1074/jbc.273.33.21145	http://dx.doi.org/10.1074/jbc.273.33.21145			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694870	hybrid			2022-12-25	WOS:000075386100063
J	Kenneth, KR; James, AA				Kenneth, KR; James, AA			Isolation and characterization of the gene encoding a novel factor Xa-directed anticoagulant from the yellow fever mosquito, Aedes aegypti	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-XA; SALIVARY-GLANDS; INHIBITOR; PROTEINS; APYRASE; ALPHA-1-ANTITRYPSIN; CULICIDAE; SEQUENCE; SERPINS; DIPTERA	Mosquito salivary glands secrete a number of proteins that inhibit mammalian hemostasis and facilitate blood feeding, We have isolated the protein product and corresponding cDNA of a gene designated Anticoagulant-factor Xa (AFXa), that encodes the factor Xa (FXa)-directed anticoagulant of the yellow fever mosquito, Aedes aegypti. The protein was purified partially by cation exchange chromatography and shown by enzyme activity profiles and SDS polyacrylamide gel electrophoresis analysis to have an M-r = 54,000, The protein was purified further by preparative SDS-polyacrylamide gel electrophoresis and subjected to internal protein sequencing, and the sequence of five peptides was determined. Degenerate oligonucleotides were designed based on three of the peptide sequences, and these were used to screen an adult female salivary gland cDNA library from A. aegypti. A 1,8-kilobase pair cDNA was isolated and shown to encode a 415-amino acid conceptual translation product with a predicted molecular mass of 47.8 kDa that contains the five sequenced peptides. Hydrophobicity analysis predicts a 19-amino acid signal peptide typical for secreted proteins. Northern analysis demonstrated that AFXa is expressed only in female salivary glands, Baculovirus-expressed AFXa protein has the appropriate size and expected FXa-directed anticoagulant activity, Analysis of the primacy amino acid sequence shows that the AFXa gene product has similarities to the serpin superfamily of serine protease inhibitors and may represent a novel, highly diverged member of this family.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	James, AA (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Bio Sci 2,Rm 3205, Irvine, CA 92697 USA.			James, Anthony/0000-0001-5577-3308	NIAID NIH HHS [AI29746] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029746, R37AI029746] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM, 1992, CURRENT PROTOCOLS MO; CHAMPAGNE DE, 1994, P NATL ACAD SCI USA, V91, P138, DOI 10.1073/pnas.91.1.138; CHAMPAGNE DE, 1995, P NATL ACAD SCI USA, V92, P694, DOI 10.1073/pnas.92.3.694; Collins FH., 1996, SCI MED, V3, P52; CORNWALL J. W., 1914, Indian Journal of Medical Research, V2, P569; DUNWIDDIE C, 1984, J BIOL CHEM, V264, P1694; FRIEDRICH T, 1993, J BIOL CHEM, V268, P16216; Grossman G.L., 1993, Insect Molecular Biology, V1, P223, DOI 10.1111/j.1365-2583.1993.tb00095.x; Grossman GL, 1997, INSECT BIOCHEM MOLEC, V27, P769, DOI 10.1016/S0965-1748(97)00063-5; HOPKINS PCR, 1994, SCIENCE, V265, P1893; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Ibrahim MS, 1996, J MED ENTOMOL, V33, P955, DOI 10.1093/jmedent/33.6.955; JORDAN SP, 1992, BIOCHEMISTRY-US, V31, P5374, DOI 10.1021/bi00138a019; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONG GL, 1984, BIOCHEMISTRY-US, V23, P4828, DOI 10.1021/bi00316a003; MARKWARDT F, 1991, HAEMOSTASIS, V21, P11; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Metcalf R. L., 1945, JOUR NATION MALARIA SOC, V4, P271; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RIBEIRO JMC, 1984, COMP BIOCHEM PHYS B, V79, P81, DOI 10.1016/0305-0491(84)90081-6; RIBEIRO JMC, 1992, J EXP BIOL, V165, P61; RIBIERO JMC, 1995, BIOCHEM J, V308, P243; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI T, 1991, EUR J BIOCHEM, V202, P255, DOI 10.1111/j.1432-1033.1991.tb16370.x; Smartt CT, 1995, EXP PARASITOL, V81, P239, DOI 10.1006/expr.1995.1114; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; Stark KR, 1996, PARASITOL TODAY, V12, P430, DOI 10.1016/0169-4758(96)10064-8; Stark KR, 1996, J MED ENTOMOL, V33, P645, DOI 10.1093/jmedent/33.4.645; Stark KR, 1995, EXP PARASITOL, V81, P321, DOI 10.1006/expr.1995.1123; TITUS RG, 1990, PARASITOL TODAY, V6, P157, DOI 10.1016/0169-4758(90)90338-5; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YE RD, 1987, J BIOL CHEM, V262, P3718; YENBUTR P, 1995, INFECT IMMUN, V63, P1745, DOI 10.1128/IAI.63.5.1745-1753.1995	37	120	128	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20802	20809		10.1074/jbc.273.33.20802	http://dx.doi.org/10.1074/jbc.273.33.20802			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694825	hybrid			2022-12-25	WOS:000075386100018
J	Meijberg, W; Schuurman-Wolters, GK; Boer, H; Scheek, RM; Robillard, GT				Meijberg, W; Schuurman-Wolters, GK; Boer, H; Scheek, RM; Robillard, GT			The thermal stability and domain interactions of the mannitol permease of Escherichia coli - A differential scanning calorimetry study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHOTRANSFERASE SYSTEM; CYTOCHROME-C-OXIDASE; ENZYME-IIMTL; TRANSPORT PROTEIN; PHOSPHOENOLPYRUVATE; PHOSPHORYLATION; PURIFICATION; DENATURATION; TRANSITIONS; EXPRESSION	The thermal stability and domain interactions in the mannitol transporter from Escherichia coli, enzyme IImtl, have been studied by differential scanning calorimetry. To this end, the wild type enzyme, IICBA(mtl), as well as IICBmtl and IICmtl, were reconstituted into a dimyristoylphosphatidylcholine lipid bilayer, The changes in the gel to liquid crystalline transition of the lipid indicated that the protein was inserted into the membrane, disturbing a total of approximately 40 lipid molecules/protein molecule, The thermal unfolding profile of EIImtl exhibited three separate transitions, two of which were overlapping, that could be assigned to structural domains in the protein. Treatment with trypsin, resulting in the degradation of the water-soluble part of the enzyme while leaving the binding and translocation capability of the enzyme intact, resulted in a decrease of the T-m and enthalpy of unfolding of the membrane-embedded C domain. This effect was much more apparent in the presence of the substrate but only partly so in the presence of the substrate analog perseitol, These results are consistent with a recently proposed model (Meijberg, W., Schuurman-Wolters, G. K., and Robillard, G, T, (1998) J. Biol Chem. 273, 7949-7946), in which the B domain takes part in the conformational changes during the substrate binding process.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Biochem, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen	Robillard, GT (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	G.T.Robillard@chem.rug.nl		Boer, Harry/0000-0002-1685-2270				BOER H, 1995, BIOCHEMISTRY-US, V34, P3239, DOI 10.1021/bi00010a013; BOER H, 1994, J BIOL CHEM, V269, P17863; BOER H, 1996, THESIS U GRONINGEN; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; CONEJEROLARA F, 1991, BIOCHEMISTRY-US, V30, P2067, DOI 10.1021/bi00222a010; CORREAFREIRE MC, 1979, BIOCHEMISTRY-US, V18, P442, DOI 10.1021/bi00570a008; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; GALISTEO ML, 1993, EUR BIOPHYS J BIOPHY, V22, P25, DOI 10.1007/BF00205809; HALTIA T, 1994, BIOCHEMISTRY-US, V33, P9731, DOI 10.1021/bi00198a044; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P309; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE CA, 1983, J BIOL CHEM, V258, P761; LOLKEMA JS, 1990, BIOCHEMISTRY-US, V29, P10120, DOI 10.1021/bi00495a016; LOLKEMA JS, 1992, BIOCHEMISTRY-US, V31, P5514, DOI 10.1021/bi00139a013; LOLKEMA JS, 1991, BIOCHEMISTRY-US, V30, P6716, DOI 10.1021/bi00241a012; LOLKEMA JS, 1993, BIOCHEMISTRY-US, V32, P5848, DOI 10.1021/bi00073a018; LOLKEMA JS, 1992, NEW COMPR BIOCH, V21, P135; LUMRY R, 1954, J PHYS CHEM-US, V58, P110, DOI 10.1021/j150512a005; MCELHANEY RN, 1986, BIOCHIM BIOPHYS ACTA, V864, P361, DOI 10.1016/0304-4157(86)90004-3; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Meijberg W, 1996, BIOCHEMISTRY-US, V35, P2759, DOI 10.1021/bi952567b; Meijberg W, 1998, J BIOL CHEM, V273, P7949, DOI 10.1074/jbc.273.14.7949; MORIN PE, 1990, BIOCHEMISTRY-US, V29, P781, DOI 10.1021/bi00455a028; MURPHY KP, 1992, J MOL BIOL, V227, P293, DOI 10.1016/0022-2836(92)90699-K; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; RIGELL CW, 1987, BIOCHEMISTRY-US, V26, P4366, DOI 10.1021/bi00388a027; RIGELL CW, 1985, BIOCHEMISTRY-US, V24, P5638, DOI 10.1021/bi00341a053; ROBILLARD GT, 1987, BIOCHEMISTRY-US, V26, P5796, DOI 10.1021/bi00392a032; ROBILLARD GT, 1993, BIOCHEMISTRY-US, V32, P9553, DOI 10.1021/bi00088a006; ROBILLARD GT, 1996, HDB BIOL PHYS, V2, P549; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SANCHEZRUIZ JM, 1992, BIOPHYS J, V61, P921, DOI 10.1016/S0006-3495(92)81899-4; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUSTER R, 1988, J CHROMATOGR-BIOMED, V431, P271, DOI 10.1016/S0378-4347(00)83096-0; STEPHAN MM, 1986, BIOCHEMISTRY-US, V25, P8230, DOI 10.1021/bi00373a016; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; VANWEEGHEL RP, 1990, P NATL ACAD SCI USA, V87, P2613, DOI 10.1073/pnas.87.7.2613; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P9478, DOI 10.1021/bi00103a013; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1774, DOI 10.1021/bi00221a007	41	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20785	20794		10.1074/jbc.273.33.20785	http://dx.doi.org/10.1074/jbc.273.33.20785			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694823	Green Published, hybrid			2022-12-25	WOS:000075386100016
J	Orlandini, M; Semplici, F; Ferruzzi, R; Meggio, F; Pinna, LA; Oliviero, S				Orlandini, M; Semplici, F; Ferruzzi, R; Meggio, F; Pinna, LA; Oliviero, S			Protein kinase CK2 alpha ' is induced by serum as a delayed early gene and cooperates with Ha-ras in fibroblast transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITE THEILERIA-PARVA; II ALPHA-SUBUNIT; CASEIN KINASE-2; GROWTH-FACTOR; CELLULAR-REGULATION; C-MYC; ACTIVATION; PHOSPHORYLATION; INDUCTION; CLONING	Protein kinase CK2 is an ubiquitous and pleiotropic Ser/Thr protein kinase composed of two catalytic (alpha and/or alpha') and two noncatalytic (beta) subunits forming a heterotetrameric holoenzyme involved in-cell growth and differentiation. Here we report the identification, cloning, and oncogenic activity of the murine CK2 alpha' subunit. Serum treatment of quiescent mouse fibroblasts induces CK2 alpha' mRNA expression, which peaks at 4 h. The kinetics of CK2 alpha' expression correlate with increased kinase activity toward a specific CK2 holoenzyme peptide substrate. The ectopic expression of CK2 alpha' (or CK2 alpha) cooperates with Ha-ras in foci formation of rat primary embryo fibroblasts. Moreover; we observed that BALB/c 3T3 fibroblasts transformed with Ha-ras and CK2 alpha' show a faster growth rate than cells transformed with Ha-ras alone. In these cells the higher growth rate correlates with an increase in calmodulin phosphorylation, a protein substrate specifically affected by isolated CK2 catalytic subunits but not by CK2 holoenzyme, suggesting that unbalanced expression of a CK2 catalytic subunit synergizes with Ha-ras in cell transformation.	Univ Siena, Dipartimento Biol Mol, IRIS, I-53100 Siena, Italy; Univ Padua, Dipartimento Chim Biol, CNR, I-35121 Padua, Italy; Univ Padua, Ctr Studio Biomembrane, CNR, I-35121 Padua, Italy	Novartis; University of Siena; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Oliviero, S (corresponding author), Univ Siena, Dipartimento Biol Mol, IRIS, Via Fiorentina 1, I-53100 Siena, Italy.		Orlandini, Maurizio/AAF-8247-2020; oliviero, salvatore/R-6657-2019	Orlandini, Maurizio/0000-0002-6112-4889; oliviero, salvatore/0000-0002-3405-765X				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Antonelli M, 1996, EUR J BIOCHEM, V241, P272, DOI 10.1111/j.1432-1033.1996.0272t.x; BODENBACH L, 1994, EUR J BIOCHEM, V220, P263, DOI 10.1111/j.1432-1033.1994.tb18622.x; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FRETER RR, 1995, MOL CELL BIOL, V15, P315, DOI 10.1128/MCB.15.1.315; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; OLEMOIYOI OK, 1995, SCIENCE, V267, P834, DOI 10.1126/science.7846527; OLEMOIYOI OK, 1993, EMBO J, V12, P1621, DOI 10.1002/j.1460-2075.1993.tb05807.x; OLEMOIYOI OK, 1992, BIOCHEMISTRY-US, V31, P6193, DOI 10.1021/bi00142a004; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; Rethinaswamy A, 1998, J BIOL CHEM, V273, P5869, DOI 10.1074/jbc.273.10.5869; Sarno S, 1997, BIOCHEMISTRY-US, V36, P11717, DOI 10.1021/bi9705772; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532	39	105	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21291	21297		10.1074/jbc.273.33.21291	http://dx.doi.org/10.1074/jbc.273.33.21291			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694889	hybrid			2022-12-25	WOS:000075386100082
J	Choi, KB; Wong, F; Harlan, JM; Chaudhary, PM; Hood, L; Karsan, A				Choi, KB; Wong, F; Harlan, JM; Chaudhary, PM; Hood, L; Karsan, A			Lipopolysaccharide mediates endothelial apoptosis by a FADD-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DOMAIN-CONTAINING RECEPTOR; NF-KAPPA-B; CELL-DEATH; BACTERIAL LIPOPOLYSACCHARIDE; CD95 FAS/APO-1; SOLUBLE CD14; FACTOR-ALPHA; ACTIVATION; ENDOTOXIN	Endothelial cells play a pivotal role in the inflammatory process by coordinating the recruitment of inflammatory cells to sites of tissue injury. Lipopolysaccharide (LPS) activates many of the proinflammatory and procoagulant responses of endothelial cells, and endothelial injury is thought to play a crucial role in the pathogenesis of septic shock due to Gram-negative bacteria. The receptor used by LPS to signal endothelial responses has not been identified. It is also not known how LPS induces endothelial injury/death. In this study, me demonstrate that LPS mediates endothelial apoptosis by a FADD-dependent pathway. FADD is a death domain-containing protein that binds to certain members of the tumor necrosis factor receptor family, namely TNFR1, Fas, and DR3. However, none of these receptors appear to be involved in LPS-mediated death, suggesting that LPS may utilize a novel death domain-containing protein to transduce a death signal.	St Pauls Hosp, McDonald Res Labs, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6Z 1Y6, Canada; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	St. Paul's Hospital; University of Saskatchewan; University of British Columbia; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Karsan, A (corresponding author), St Pauls Hosp, McDonald Res Labs, 1081 Burrand St, Vancouver, BC V6Z 1Y6, Canada.		Chaudhary, Preet/E-1970-2018; Karsan, Aly/K-2067-2015					ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; ARDITI M, 1995, J IMMUNOL, V155, P3994; ARDITI M, 1993, INFECT IMMUN, V61, P3149, DOI 10.1128/IAI.61.8.3149-3156.1993; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CARMICHAEL J, 1987, CANCER RES, V47, P943; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CYBULSKY MI, 1988, LAB INVEST, V58, P365; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; DELUDE RL, 1995, P NATL ACAD SCI USA, V92, P9288, DOI 10.1073/pnas.92.20.9288; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; EISSNER G, 1995, BLOOD, V86, P4184, DOI 10.1182/blood.V86.11.4184.bloodjournal86114184; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HerreraVelit P, 1996, J IMMUNOL, V156, P1157; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473; Ingalls RR, 1997, J IMMUNOL, V159, P433; JOSEPH CK, 1994, J BIOL CHEM, V269, P17606; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1998, TRENDS CARDIOVAS MED, V8, P19, DOI 10.1016/S1050-1738(97)00126-6; Karsan A, 1997, AM J PATHOL, V151, P1775; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; MEYRICK B, 1989, J CELL PHYSIOL, V138, P165, DOI 10.1002/jcp.1041380122; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; READ MA, 1993, P NATL ACAD SCI USA, V90, P9887, DOI 10.1073/pnas.90.21.9887; RICHARDSON BC, 1994, EUR J IMMUNOL, V24, P2640, DOI 10.1002/eji.1830241111; SATO I, 1995, MECH AGEING DEV, V81, P27, DOI 10.1016/0047-6374(94)01579-B; Thieblemont N, 1997, J EXP MED, V185, P2095, DOI 10.1084/jem.185.12.2095; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	40	135	140	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20185	20188		10.1074/jbc.273.32.20185	http://dx.doi.org/10.1074/jbc.273.32.20185			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685365	hybrid			2022-12-25	WOS:000075305400042
J	Engel, M; Seifert, M; Theisinger, B; Seyfert, U; Welter, C				Engel, M; Seifert, M; Theisinger, B; Seyfert, U; Welter, C			Glyceraldehyde-3-phosphate dehydrogenase and Nm23-H1/Nucleoside diphosphate kinase A - Two old enzymes combine for the novel Nm23 protein phosphotransferase function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URACIL DNA-GLYCOSYLASE; LYMPH-NODE METASTASIS; X-RAY STRUCTURE; ENZYMATIC-ACTIVITY; MELANOMA-CELLS; GROWTH-FACTOR; GENE-PRODUCT; EXPRESSION; DROSOPHILA; CARCINOMA	We have recently discovered an alternative function of the putative metastasis suppressor protein Nm23, which is identical to nucleoside diphosphate kinase, as a protein phosphotransferase in vitro, While purified native Nm23 protein did not phosphorylate other proteins, we could purify a Nm23-associated protein that activates the protein phosphotransferase function; it was identified as a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) isoenzyme. Go-expression and purification of (His)(6)-tagged GAPDH in combination with either Nm23-H1 or Nm23-H2 in baculovirus-infected Sf9 cells showed that only Nm23-H1, but not Nm23-H2, forms a stable complex with GAPDH. Protein phosphotransferase activity was confirmed for the recombinant GAPDH-Nm23-H1 complex but not for either of the enzymes alone, nor was this activity observed after simple mixing of the purified proteins in vitro. The molecular mass of the highly purified recombinant GAPDH Nm23-H1 complex suggests that a dimer of GAPDH interacts with a dimer of Nm23-H1. In contrast to the complex with GAPDH, co-expression of Nm23-H1 with antioxidant protein (MER-5) or creatine kinase did not activate the protein phosphotransferase function, indicating that this activation may specifically require GAPDH as a binding partner.	Univ Saarlandes, Inst Humangenet, Dept Human Genet, D-66421 Homburg, Germany; Univ Saarlandes, Dept Hemostaseol & Transfus Med, D-66421 Homburg, Germany	Saarland University; Saarland University	Engel, M (corresponding author), Univ Saarlandes, Inst Humangenet, Dept Human Genet, Geb 68, D-66421 Homburg, Germany.							Ann KS, 1996, J EUKARYOT MICROBIOL, V43, P365, DOI 10.1111/j.1550-7408.1996.tb05045.x; ARAI T, 1995, MODERN PATHOL, V8, P252; ASHMARINA LI, 1985, EUR J BIOCHEM, V149, P67, DOI 10.1111/j.1432-1033.1985.tb08894.x; Avilan L, 1997, EUR J BIOCHEM, V246, P78, DOI 10.1111/j.1432-1033.1997.00078.x; BAXI MD, 1995, BIOCHEMISTRY-US, V34, P9700, DOI 10.1021/bi00030a007; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; CHEREDNIKOVA TV, 1980, BIOCHIM BIOPHYS ACTA, V613, P292, DOI 10.1016/0005-2744(80)90084-4; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; De BP, 1996, J BIOL CHEM, V271, P24728, DOI 10.1074/jbc.271.40.24728; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; DUNBAR B, 1994, ANAL BIOCHEM, V216, P227, DOI 10.1006/abio.1994.1029; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; ENGEL M, 1993, INT J CANCER, V55, P375, DOI 10.1002/ijc.2910550306; EPNER DE, 1993, CANCER RES, V53, P1995; Federici C, 1996, EUR J BIOCHEM, V238, P173, DOI 10.1111/j.1432-1033.1996.0173q.x; Gervasi F, 1996, CELL GROWTH DIFFER, V7, P1689; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GLASER PE, 1995, BIOCHEMISTRY-US, V34, P12193, DOI 10.1021/bi00038a013; GOLDEN A, 1993, ONCOGENES TUMOR SUPP, P345; GROSSE F, 1986, EUR J BIOCHEM, V160, P459, DOI 10.1111/j.1432-1033.1986.tb10062.x; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; HSU S, 1994, CELL GROWTH DIFFER, V5, P909; Inoue H, 1996, BIOCHEM BIOPH RES CO, V218, P887, DOI 10.1006/bbrc.1996.0158; KANTOR JD, 1993, CANCER RES, V53, P1971; Karlsson A, 1996, J BIOL CHEM, V271, P19928, DOI 10.1074/jbc.271.33.19928; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KONISHI N, 1993, JPN J CANCER RES, V84, P1050, DOI 10.1111/j.1349-7006.1993.tb02800.x; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; LASCU I, 1992, J BIOL CHEM, V267, P12775; Lebreton S, 1997, EUR J BIOCHEM, V246, P85, DOI 10.1111/j.1432-1033.1997.t01-2-00085.x; Lebreton S, 1997, EUR J BIOCHEM, V250, P286, DOI 10.1111/j.1432-1033.1997.0286a.x; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; Lu Q, 1996, J BIOL CHEM, V271, P32886, DOI 10.1074/jbc.271.51.32886; MEJEAN C, 1989, BIOCHEM J, V264, P671, DOI 10.1042/bj2640671; Mesnildrey S, 1997, FEBS LETT, V418, P53, DOI 10.1016/S0014-5793(97)01292-1; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; Michelotti EF, 1997, J BIOL CHEM, V272, P22526, DOI 10.1074/jbc.272.36.22526; Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405; MORERA S, 1995, BIOCHEMISTRY-US, V34, P11062, DOI 10.1021/bi00035a011; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; Mukhopadhyay S, 1997, J BIOL CHEM, V272, P17815, DOI 10.1074/jbc.272.28.17815; MURONETZ VI, 1983, BIOCHEM INT, V6, P443; MURONETZ VI, 1994, ARCH BIOCHEM BIOPHYS, V313, P253, DOI 10.1006/abbi.1994.1385; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NAKAMORI S, 1993, CLIN EXP METASTAS, V11, P151, DOI 10.1007/BF00114973; Otero AD, 1997, J BIOL CHEM, V272, P14690, DOI 10.1074/jbc.272.23.14690; PARHAR RS, 1995, INT J CANCER, V60, P204; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; ROBINSON JB, 1981, J BIOL CHEM, V256, P769; Schultz DE, 1996, J BIOL CHEM, V271, P14134, DOI 10.1074/jbc.271.24.14134; Shankar S, 1997, MOL MICROBIOL, V24, P477, DOI 10.1046/j.1365-2958.1997.3491724.x; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Teng DHF, 1997, CANCER RES, V57, P4177; Timmons L, 1997, ADV GENET, V35, P207, DOI 10.1016/S0065-2660(08)60451-4; TOKUNAGA Y, 1993, INT J CANCER, V55, P66, DOI 10.1002/ijc.2910550113; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; Xu J, 1996, DEV BIOL, V177, P544, DOI 10.1006/dbio.1996.0184; Xu Y, 1997, PROTEINS, V28, P150; YAMAGUCHI A, 1994, CANCER, V73, P2280, DOI 10.1002/1097-0142(19940501)73:9<2280::AID-CNCR2820730908>3.0.CO;2-3	63	112	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20058	20065		10.1074/jbc.273.32.20058	http://dx.doi.org/10.1074/jbc.273.32.20058			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685345	hybrid			2022-12-25	WOS:000075305400022
J	Avalle, B; Thomas, D; Friboulet, A				Avalle, B; Thomas, D; Friboulet, A			Functional mimicry: elicitation of a monoclonal anti-idiotypic antibody hydrolizing beta-lactams	FASEB JOURNAL			English	Article						mimicry; catalytic antibody; abzyme; anti-idiotype; beta-lactamase	CATALYTIC ANTIBODIES; ANTIIDIOTYPIC ANTIBODIES; HYDROLYSIS; AUTOANTIBODY; PEPTIDE	Antigen mimicry by anti-idiotypic antibodies is investigated as a reliable strategy to achieve molecular imprinting of an enzymatic activity. A monoclonal anti-idiotypic antibody (Ab2-9G4H9) was elicited by using a monoclonal antibody (Ab1-7AF9) specific for the beta-lactamase active site. Catalytic features of Ab2 were characterized with beta-lactamase substrates, The antibody combining site appeared to have retained a part of the catalytic specificity. The relevance of the idiotypic mimicry concept for the generation of catalytic antibodies was further demonstrated by eliciting a third generation antibody (Ab3), which was shown to recognize p-lactamase: the complete internal image properties of Ab2 9G4H9, including binding and catalytic properties, were thus checked.	Univ Technol Compiegne, CNRS, UPRES A 6022, Technol Enzymat Lab, F-60205 Compiegne, France	Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne	Friboulet, A (corresponding author), Univ Technol Compiegne, CNRS, UPRES A 6022, Technol Enzymat Lab, BP 20529, F-60205 Compiegne, France.							Ban N, 1996, J MOL BIOL, V255, P617, DOI 10.1006/jmbi.1996.0051; Benkovic SJ, 1996, NATURE, V383, P23, DOI 10.1038/383023a0; BRANNIGAN J, 1991, BIOCHEM J, V278, P673, DOI 10.1042/bj2780673; BRONSHTEIN IB, 1992, FEBS LETT, V314, P259, DOI 10.1016/0014-5793(92)81484-4; Bronstein IB, 1996, ONCOL RES, V8, P17; COURAUD PO, 1986, J IMMUNOL, V136, P3365; DANISHEFSKY S, 1993, SCIENCE, V259, P469, DOI 10.1126/science.8424168; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; GALLACHER G, 1992, BIOCHEM J, V284, P675, DOI 10.1042/bj2840675; Goldbaum FA, 1997, P NATL ACAD SCI USA, V94, P8697, DOI 10.1073/pnas.94.16.8697; IZADYAR L, 1993, P NATL ACAD SCI USA, V90, P8876, DOI 10.1073/pnas.90.19.8876; Jacobsen JR, 1995, CURR OPIN STRUC BIOL, V5, P818, DOI 10.1016/0959-440X(95)80016-6; JANDA KD, 1993, SCIENCE, V259, P490, DOI 10.1126/science.8424171; JANDA KD, 1988, SCIENCE, V241, P1188, DOI 10.1126/science.3413482; JANJIC N, 1989, J AM CHEM SOC, V111, P9109, DOI 10.1021/ja00207a022; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Magliani W, 1997, NAT BIOTECHNOL, V15, P155, DOI 10.1038/nbt0297-155; MATAGNE A, 1995, BBA-PROTEIN STRUCT M, V1246, P109, DOI 10.1016/0167-4838(94)00177-I; PAN Y, 1995, FASEB J, V9, P43, DOI 10.1096/fasebj.9.1.7821758; PAUL S, 1995, J BIOL CHEM, V270, P15257, DOI 10.1074/jbc.270.25.15257; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; Resmini M, 1997, BIOCHEM J, V326, P279, DOI 10.1042/bj3260279; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SEGE K, 1978, P NATL ACAD SCI USA, V75, P2443, DOI 10.1073/pnas.75.5.2443; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; SORENSEN K, 1987, BIOCHIM BIOPHYS ACTA, V912, P56, DOI 10.1016/0167-4838(87)90247-0; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; Tyutyulkova S, 1996, BBA-MOL BASIS DIS, V1316, P217, DOI 10.1016/0925-4439(96)00028-2; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797	32	52	54	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					1055	1060		10.1096/fasebj.12.11.1055	http://dx.doi.org/10.1096/fasebj.12.11.1055			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707178				2022-12-25	WOS:000075372600016
J	Bayewitch, ML; Avidor-Reiss, T; Levy, R; Pfeuffer, T; Nevo, I; Simonds, WF; Vogel, Z				Bayewitch, ML; Avidor-Reiss, T; Levy, R; Pfeuffer, T; Nevo, I; Simonds, WF; Vogel, Z			Inhibition of adenylyl cyclase isoforms V and VI by various G(beta gamma) subunits	FASEB JOURNAL			English	Article						G(beta gamma); signal transduction; inhibition; plasmid	BETA-GAMMA-SUBUNITS; EXPRESSION; CLONING; ACTIVATION; CELLS; SPECIFICITY; MODULATION; RECEPTORS; CHANNELS; PROTEINS	An intriguing development in the G-protein signaling field has been the finding that not only the G(alpha) subunit, but also G(beta gamma) subunits, affect a number of downstream target molecules. One of the downstream targets of G(beta gamma) is adenylyl cyclase, and it has been demonstrated that a number of isoforms of adenylyl cyclase can be either inhibited or stimulated by G(beta gamma) subunits. Until now, adenylyl cyclase type I has been the only isoform reported to be inhibited by free G(beta gamma). Here we show by transient cotransfection into COS-7 cells of either adenylyl cyclase V or VI, together with G gamma(gamma 2) and various G(beta) subunits, that these two adenylyl cyclase isozymes are markedly inhibited by G(beta gamma). In addition, we show that G(beta 1) and G(beta 5) subunits differ in their activity. G(beta 1) transfected alone markedly inhibited adenylyl cylcase V and VI (probably by recruiting endogenous G(gamma) subunits). On the other hand, G(beta 5) produced less inhibition of these isozymes, and its activity was enhanced by the addition of G(gamma 2). These results demonstrate that adenylyl cyclase types V and VI are inhibited by G(beta gamma) dimers and that G(beta 1) and G(beta 5) Subunits differ in their capacity to regulate these adenylyl cyclase isozymes.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Univ Dusseldorf, Dept Physiol Chem 2, D-40225 Dusseldorf, Germany; NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	Weizmann Institute of Science; Heinrich Heine University Dusseldorf; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Vogel, Z (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	bnvogel@weizmann.weizmann.ac.il	Avidor-Reiss, Tomer/AAK-6153-2020	Avidor-Reiss, Tomer/0000-0003-0918-526X	NIDA NIH HHS [DA-06265] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006265] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; AvidorReiss T, 1997, J BIOL CHEM, V272, P5040, DOI 10.1074/jbc.272.8.5040; Bayewitch M, 1996, J BIOL CHEM, V271, P9902, DOI 10.1074/jbc.271.17.9902; Bayewitch ML, 1998, J BIOL CHEM, V273, P2273, DOI 10.1074/jbc.273.4.2273; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; KLUXEN FW, 1993, ANAL BIOCHEM, V208, P352, DOI 10.1006/abio.1993.1060; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM K, 1989, BIOTECHNIQUES, V7, P576; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MOLLNER S, 1991, EUR J BIOCHEM, V195, P281, DOI 10.1111/j.1432-1033.1991.tb15704.x; MONS N, 1995, TRENDS NEUROSCI, V18, P536, DOI 10.1016/0166-2236(95)98375-9; PFEUFFER E, 1991, METHOD ENZYMOL, P83; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMONDS W, 1991, J BIOL CHEM, V266, P7706; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1992, COLD SPRING HARB SYM, V57, P135, DOI 10.1101/SQB.1992.057.01.017; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; UEDA N, 1994, J BIOL CHEM, V269, P4388; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Yoshimura M, 1996, MOL PHARMACOL, V50, P43; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	41	71	73	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					1019	1025		10.1096/fasebj.12.11.1019	http://dx.doi.org/10.1096/fasebj.12.11.1019			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707174				2022-12-25	WOS:000075372600012
J	Bellacosa, A; Chan, TO; Ahmed, NN; Datta, K; Malstrom, S; Stokoe, D; McCormick, F; Feng, JN; Tsichlis, P				Bellacosa, A; Chan, TO; Ahmed, NN; Datta, K; Malstrom, S; Stokoe, D; McCormick, F; Feng, JN; Tsichlis, P			Akt activation by growth factors is a multiple-step process: the role of the PH domain	ONCOGENE			English	Article						Akt; PKB; protein kinase; PH domain; PI3-kinase; PDGF	PLECKSTRIN-HOMOLOGY DOMAIN; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; C-AKT; PHOSPHORYLATION; DYNAMIN; TARGET; PHOSPHATASE	The protein kinase encoded by the Akt proto-oncogene is activated by phospholipid binding, membrane translocation and phosphorylation. To address the relative roles of these mechanisms of Akt activation, we have employed a combination of genetic and pharmacological approaches, Transient transfection of NIH3T3 cells with wild-type Akt, pleckstrin homology (PH) domain mutants, generated on the basis of a PH domain structural model, and phosphorylation site Akt mutants provided evidence for a model of Akt activation consisting of three sequential steps: (1) a PH domain-dependent, growth factor-independent step, marked by constitutive phosphorylation of threonine 450 (T450) and perhaps serine 124 (S124), that renders the protein responsive to subsequent activation events; (2) a growth factor-induced, PI3-K-dependent membrane-translocation step; and (3) a PI3-K-dependent step, characterized by phosphorylation at T308 and S473, that occurs in the cell membrane and is required for activation, When forced to translocate to the membrane, wild-type Akt and PH domain Akt mutants that are defective in the first step become constitutively active, suggesting that the purpose of this step is to prepare the protein for membrane translocation, Both growth factor stimulation and forced membrane translocation, however, failed to activate a T308A mutant, This, combined with the finding that T308D/S473D double mutant is constitutively active, suggests that the purpose of the three-step process of Akt activation is the phosphorylation of the protein at T308 and S473, The proposed model provides a framework for a comprehensive understanding of the temporal and spatial requirements for Akt activation by growth factors.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA; Catholic Univ, Sch Med, Dept Med Genet, I-00168 Rome, Italy	Fox Chase Cancer Center; University of California System; University of California San Francisco; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Tsichlis, P (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.			Chan, Tung/0000-0001-6574-9555	NATIONAL CANCER INSTITUTE [R01CA057436, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA57436, CA06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bromann PA, 1997, J BIOL CHEM, V272, P16240, DOI 10.1074/jbc.272.26.16240; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; Zhang X, 1997, LEUKEMIA RES, V21, P849, DOI 10.1016/S0145-2126(97)00055-6; ZHUO S, 1993, J BIOL CHEM, V268, P17754	54	449	457	0	16	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					313	325		10.1038/sj.onc.1201947	http://dx.doi.org/10.1038/sj.onc.1201947			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690513	Bronze			2022-12-25	WOS:000074947500006
J	Choice, CV; Howard, MJ; Poy, MN; Hankin, MH; Najjar, SM				Choice, CV; Howard, MJ; Poy, MN; Hankin, MH; Najjar, SM			Insulin stimulates pp120 endocytosis in cells co-expressing insulin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; ENDOGENOUS SUBSTRATE; INTERNALIZATION; SIGNAL; RECOGNITION; SEQUENCE; DOMAIN	pp120, a substrate of the insulin receptor tyrosine kinase, is a plasma membrane glycoprotein that is ex pressed in the hepatocyte as two spliced isoforms differing by the presence (full-length) or absence (truncated) of most of the intracellular domain including all phosphorylation sites. Go-expression of full-length pp120, but not its phosphorylation-defective isoforms, increased receptor-mediated insulin endocytosis and degradation in NIH 3T3 fibroblasts. We, herein, examined whether internalization of pp120 is required to mediate its effect on insulin endocytosis. The amount of full-length pp120 expressed at the cell surface membrane, as measured by biotin labeling, markedly decreased in response to insulin only when insulin receptors were coexpressed. In contrast, when phosphorylation-defective pp120 mutants were co-expressed, the amount of pp120 expressed at the cell surface did not decrease in response to insulin. Indirect immunofluorescence analysis revealed that upon insulin treatment of cells co-expressing insulin receptors, full-length, but not truncated, pp120 co-localized with alpha-adaptin in the adaptor protein complex that anchors endocytosed proteins to clathrin-coated pits. This suggests that full-length pp120 is part of a complex of proteins required for receptor-mediated insulin endocytosis and that formation of this complex is regulated by insulin-induced pp120 phosphorylation by the receptor tyrosine kinase. In vitro GST binding assays and co-immunoprecipitation experiments in intact cells further revealed that pp120 did not bind directly to the insulin receptor and that its association with the receptor may be mediated by other cellular proteins.	Med Coll Ohio, Dept Pharmacol & Therapeut, Toledo, OH 43614 USA; Med Coll Ohio, Dept Anat & Neurobiol, Toledo, OH 43614 USA		Najjar, SM (corresponding author), Med Coll Ohio, Dept Pharmacol & Therapeut, 3025 Arlington Ave,HSci Bldg,Rm 270, Toledo, OH 43614 USA.	snajjar@mco.edu	Poy, Matthew/F-6914-2017	Poy, Matthew/0000-0002-4904-2426	NICHD NIH HHS [HD28184] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028184, R55HD028184] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BACKER JM, 1990, J BIOL CHEM, V265, P14828; CARPENTIER JL, 1993, HISTOCHEMISTRY, V100, P169, DOI 10.1007/BF00269090; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; GORDEN P, 1978, SCIENCE, V200, P782, DOI 10.1126/science.644321; HARI J, 1987, J BIOL CHEM, V262, P15341; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LiCalzi S, 1997, AM J PHYSIOL-ENDOC M, V273, pE801, DOI 10.1152/ajpendo.1997.273.4.E801; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; SALAMOV AA, 1995, J MOL BIOL, V247, P11, DOI 10.1006/jmbi.1994.0116; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SMITH RM, 1991, J BIOL CHEM, V266, P17522; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; YAMADA K, 1995, J BIOL CHEM, V270, P3115, DOI 10.1074/jbc.270.7.3115	20	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22194	22200		10.1074/jbc.273.35.22194	http://dx.doi.org/10.1074/jbc.273.35.22194			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712832	hybrid			2022-12-25	WOS:000075616600008
J	Dong, JM; Leung, T; Manser, E; Lim, L				Dong, JM; Leung, T; Manser, E; Lim, L			cAMP-induced morphological changes are counteracted by the activated RhoA small GTPase and the Rho kinase ROK alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; NEURO-BLASTOMA CELLS; ACTIN STRESS FIBERS; LYSOPHOSPHATIDIC ACID; CYCLIC-AMP; GROWTH-FACTOR; RECEPTOR ACTIVATION; LEUKOCYTE ADHESION; FOCAL ADHESIONS; FAMILY GTPASES	Dramatic transient changes resulting in a stellate morphology are induced in many cell types on treatment with agents that enhance intracellular cAMP levels. Thrombin fully protects cells from this inductive effect of cAMP through the thrombin receptor. The protective effect of thrombin was shown to be Rho dependent. Clostridium botulinum C3 exoenzyme, which inactivates RhoA functions, abolished the ability of thrombin to protect cells fi om responding to increased cAMP levels. A constitutively activated RhoA(V14) mutant protein also prevented cells from responding to cAMP. RhoA can be specifically phosphorylated at Ser-188 by the cAMP-activated protein kinase A (PKA). We demonstrate that RhoA(V14A188), which cannot be phosphorylated by PKA in vitro, is more effective than RhoA(V14) in preventing cells from responding to cAMP and in inducing actin stress fiber formation. This suggests that PEA phosphorylation of RhoA impairs its biological activity in vivo. ROK alpha, a RhoA-associated serine/threonine kinase can also prevent cells from responding to cAMP with shape changes. Phosphorylation of RhoA by PI(A in vitro decreases the binding of RhoA to ROK alpha. These results indicate that RhoA and cAMP have antagonistic roles in regulating cellular morphology and suggest that cAMP-mediated down-regulation of RhoA binding to its effector ROKa! may be involved in this antagonism.	Glaxo IMCB Grp, Inst Mol & Cell Biol, Singapore 117609, Singapore; UCL, Inst Neurol, London WC1N 1PJ, England	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline; University of London; University College London	Lim, L (corresponding author), Glaxo IMCB Grp, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		Manser, Edward/ABD-2301-2020					Allen WE, 1997, J CELL SCI, V110, P707; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; BAORTO DM, 1992, J CELL BIOL, V117, P357, DOI 10.1083/jcb.117.2.357; BIEDLER JL, 1984, P AM ASSOC CANC RES, V25, P41; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; CICCARONE V, 1989, CANCER RES, V49, P219; EGAN JJ, 1991, J CELL BIOCHEM, V45, P101, DOI 10.1002/jcb.240450117; GOLDMAN JE, 1984, BRAIN RES, V306, P85, DOI 10.1016/0006-8993(84)90358-5; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KREISBERG JI, 1984, KIDNEY INT, V25, P874, DOI 10.1038/ki.1984.104; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Lim L, 1996, SEMIN CELL DEV BIOL, V7, P699, DOI 10.1006/scdb.1996.0086; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSS RA, 1983, J NATL CANCER I, V71, P741; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; Tigyi G, 1996, J NEUROCHEM, V66, P549; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	39	228	232	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22554	22562		10.1074/jbc.273.35.22554	http://dx.doi.org/10.1074/jbc.273.35.22554			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712882	hybrid			2022-12-25	WOS:000075616600058
J	Eichler, J; Rinard, K; Wickner, W				Eichler, J; Rinard, K; Wickner, W			Endogenous SecA catalyzes preprotein translocation at SecYEG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI SECA; PLASMA-MEMBRANE; PROTEIN TRANSLOCATION; CYTOPLASMIC MEMBRANE; STEPWISE MOVEMENT; ATP BINDING; PHOSPHOLIPIDS; INSERTION; PROOMPA; DOMAIN	SecA is found in the cytosol and bound to the plasma membrane of Escherichia coli. Binding occurs either with high affinity at SecYEG or with low affinity to lipid. Domains of 65 and 30 kDa of SecYEG-bound SecA insert into the membrane upon interaction with preprotein and ATP. Azide blocks preprotein translocation, in vivo and in vitro, through interacting with SecA and preventing SecA deinsertion. This provides a measure of the translocation relevance of each form of SecA membrane association. We now report that azide acts exclusively on SecA that is cycling at SecYEG and has no effect on SecA lipid associations. SecA molecules recovered with sucrose gradient-purified inner membrane vesicles ("endogenous" SecA) support translocation at the same rate as "added" SecA molecules bound at SecYEG. Both endogenous and added SecA yield the same proteolytic fragments, which are distinct from those obtained from SecA once it has inserted into membranes at SecYEG or from SecA at lipidic sites. Endogenous and added SecA differ, however, in their resistance to urea extraction. The translocation supported by either endogenous or added SecA is blocked by azide or by antibody to SecY. We conclude that SecA functions in preprotein translocation only through cycling at SecYEG.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, W (corresponding author), Dartmouth Med Sch, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.		EICHLER, JERRY/F-2351-2012	EICHLER, JERRY/0000-0001-9409-8026				BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; Chen XC, 1996, J BIOL CHEM, V271, P29698, DOI 10.1074/jbc.271.47.29698; Chen XC, 1998, J BACTERIOL, V180, P527, DOI 10.1128/JB.180.3.527-537.1998; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; DOLAN KM, 1991, J BIOL CHEM, V266, P23329; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1997, EMBO J, V16, P2188, DOI 10.1093/emboj/16.9.2188; EICHLER J, 1997, P NATL ACAD SCI USA, V90, P620; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KIM YJ, 1994, CELL, V78, P845; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; Price A, 1996, J BIOL CHEM, V271, P31580, DOI 10.1074/jbc.271.49.31580; Ramamurthy V, 1997, J BIOL CHEM, V272, P23239, DOI 10.1074/jbc.272.37.23239; Sato K, 1997, J BIOL CHEM, V272, P5880, DOI 10.1074/jbc.272.9.5880; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; Snyders S, 1997, J BIOL CHEM, V272, P11302; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; VANVOORTS F, 1998, IN PRESS BIOCHEMISTR; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P1895, DOI 10.1073/pnas.86.6.1895; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978	42	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21675	21681		10.1074/jbc.273.34.21675	http://dx.doi.org/10.1074/jbc.273.34.21675			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705302	hybrid			2022-12-25	WOS:000075492600036
J	Natochin, M; Granovsky, AE; Artemyev, NO				Natochin, M; Granovsky, AE; Artemyev, NO			Identification of effector residues on photoreceptor G protein, transducin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; HETEROTRIMERIC G-PROTEIN; PHOSPHODIESTERASE GAMMA-SUBUNIT; ROD OUTER SEGMENTS; ALPHA-SUBUNIT; CGMP-PHOSPHODIESTERASE; CRYSTAL-STRUCTURE; ADENYLYL-CYCLASE; BINDING-SITES; RGS PROTEIN	Transducin is a photoreceptor-specific heterotrimeric GTP-binding protein that plays a key role in the vertebrate visual transduction cascade, Here, using scanning site-directed mutagenesis of the chimeric G alpha(t)/G alpha(11);, alpha-subunit (G alpha(t/i)), we identified G alpha(t) residues critical for interaction with the effector enzyme, rod cGMP phosphodiesterase (PDE). Our evidence suggests that residue Ile(208) in the switch II region directly interacts with the effector in the active GTP-bound conformation of G alpha(t). Residues Arg(201), Arg(204), and Trp(207) are essential for the conformation-dependent, G alpha(t)/effector interaction either via direct contacts with the inhibitory PDE gamma-subunit or by forming an effector-competent conformation through the communication network between switch II and the switch III/alpha 3-helix domain of G alpha(t). Residues His(244),and Asn(247) in the alpha 3 helix of G alpha(t) are responsible for the conformatiom-independent effector-specific interaction. Insertion of these residues rendered the G alpha(t/i) chimera with the ability to bind PDE gamma-subunit and stimulate PDE activity approaching that of native G alpha(t). Comparative analysis of the interactions of G alpha(t/i) mutants with PDE and RGS16 revealed two adjacent but distinct interfaces on transducin. This indicates a possibility for a functional trimeric complex, RGS/G alpha/effector, that may play a central role in turn-off mechanisms of G protein signaling systems, particularly in phototransduction.	Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA.		Alex, Granovsky/EUV-7323-2022	Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10843] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; Artemyev NO, 1997, BIOCHEMISTRY-US, V36, P4188, DOI 10.1021/bi963002y; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FUNG BKK, 1983, J BIOL CHEM, V258, P503; Grishina G, 1997, J BIOL CHEM, V272, P20619, DOI 10.1074/jbc.272.33.20619; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Iiri T, 1997, P NATL ACAD SCI USA, V94, P5656, DOI 10.1073/pnas.94.11.5656; ITOH H, 1991, J BIOL CHEM, V266, P16226; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Li QB, 1997, J BIOL CHEM, V272, P21673, DOI 10.1074/jbc.272.35.21673; Liu Y, 1996, J BIOL CHEM, V271, P26900, DOI 10.1074/jbc.271.43.26900; Mittal R, 1996, SCIENCE, V271, P1413, DOI 10.1126/science.271.5254.1413; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Natochin M, 1998, J BIOL CHEM, V273, P4300, DOI 10.1074/jbc.273.8.4300; Natochin M, 1997, J BIOL CHEM, V272, P17444, DOI 10.1074/jbc.272.28.17444; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SPICKOFSKY N, 1994, NAT STRUCT BIOL, V1, P771, DOI 10.1038/nsb1194-771; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	52	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21808	21815		10.1074/jbc.273.34.21808	http://dx.doi.org/10.1074/jbc.273.34.21808			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705319	hybrid			2022-12-25	WOS:000075492600053
J	Ramotar, D; Belanger, E; Brodeur, I; Masson, JY; Drobetsky, EA				Ramotar, D; Belanger, E; Brodeur, I; Masson, JY; Drobetsky, EA			A yeast homologue of the human phosphotyrosyl phosphatase activator PTPA is implicated in protection against oxidative DNA damage induced by the model carcinogen 4-nitroquinoline 1-oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; APURINIC APYRIMIDINIC SITES; XENOPUS-LAEVIS OOCYTES; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PROTEIN PHOSPHATASES; FPG PROTEIN; GENES; EXPRESSION; ENDONUCLEASE	The model carcinogen 4-nitroquinoline 1-oxide (4-NQO) has historically been characterized as "UV-mimetic" with respect to its genotoxic properties. However, recent evidence indicates that 4-NQO, unlike 254-nm UV light, may exert significant cytotoxic and/or mutagenic potential via the generation of reactive oxygen species. To elucidate the response of eukaryotic cells to 4-NQO-induced oxidative stress, we isolated Saccharomyces cerevisiae mutants exhibiting hypersensitivity to the cytotoxic effects of this mutagen. One such mutant, EBY1, was cross-sensitive to the oxidative agents UVA and diamide while retaining parental sensitivities to 254-nm UV light, methyl methanesulfonate, and ionizing radiation. A complementing gene (designated yPTPA1), restoring full UVA and 4-NQO resistance to EBY1 and encoding a protein that shares 40% identity with the human phosphotyrosyl phosphatase activator hPTPA, has been isolated. Targeted deletion of yPTPA1 in wild type yeast engendered the identical pattern of mutagen hypersensitivity as that manifested by EBY1, in addition to a spontaneous mutator phenotype that was markedly enhanced upon exposure to either UVA or 4-NQO but not to 254-nm UV or methyl methanesulfonate. Moreover, the yptpa1 deletion mutant exhibited a marked deficiency in the recovery of high molecular weight DNA following 4-NQO exposure, revealing a defect at the level of DNA repair. These data (i) strongly support a role for active oxygen intermediates in determining the genotoxic outcome of 4-NQO exposure and (ii) suggest a novel mechanism in yeast involving yPtpa1p-mediated activation of a phosphatase that participates in the repair of oxidative DNA damage, implying that hPTPA may exert a similar function in humans.	Univ Montreal, Ctr Rech, Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada	Universite de Montreal	Ramotar, D (corresponding author), Univ Montreal, Ctr Rech, Hop Maison Neuve Rosemont, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada.	dramotar@hmr.qc.ca		Masson, Jean Yves/0000-0002-4403-7169				Ariza RR, 1996, NUCLEIC ACIDS RES, V24, P433, DOI 10.1093/nar/24.3.433; ARMSTRONG JD, 1992, MUTAT RES, V268, P83, DOI 10.1016/0027-5107(92)90086-H; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CAYLA X, 1994, J BIOL CHEM, V269, P15668; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DROBETSKY EA, 1995, P NATL ACAD SCI USA, V92, P2350, DOI 10.1073/pnas.92.6.2350; FELKNER C, 1968, J BACTERIOL, V96, P1448, DOI 10.1128/JB.96.4.1448-1449.1968; GALIEGUEZOUITINA S, 1986, CANCER RES, V46, P1858; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guthrie C, 1991, METHODS ENZYMOL, V194; He CH, 1996, CAN J MICROBIOL, V42, P1263, DOI 10.1139/m96-164; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P173, DOI 10.1016/0168-9525(93)90164-D; KOHDA K, 1986, BIOCHEM BIOPH RES CO, V139, P626, DOI 10.1016/S0006-291X(86)80036-5; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Masson JY, 1996, MOL CELL BIOL, V16, P2091; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; MUNBY W, 1993, PHYSIOL REV, V73, P673; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NUNOSHIBA T, 1993, CANCER RES, V53, P3250; Paques F, 1997, MOL CELL BIOL, V17, P6765, DOI 10.1128/MCB.17.11.6765; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; Ramotar D, 1997, BIOCHEM CELL BIOL, V75, P327, DOI 10.1139/bcb-75-4-327; RAMOTAR D, 1995, MOL CELL BIOCHEM, V145, P185, DOI 10.1007/BF00935491; Ramotar D, 1996, J BIOL CHEM, V271, P7368, DOI 10.1074/jbc.271.13.7368; RUIZLAGUNA J, 1994, CARCINOGENESIS, V15, P425, DOI 10.1093/carcin/15.3.425; Sander M, 1997, BIOCHEMISTRY-US, V36, P6100, DOI 10.1021/bi970048y; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sherman F., 1983, METHODS YEAST GENETI; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; SUGIMURA T, 1966, CANCER RES, V26, P1717; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; TYRRELL RM, 1990, J PHOTOCH PHOTOBIO B, V4, P349, DOI 10.1016/1011-1344(90)85014-N; TYRRELL RM, 1989, PHOTOCHEM PHOTOBIOL, V49, P407, DOI 10.1111/j.1751-1097.1989.tb09187.x; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; YAMAMOTO K, 1993, CARCINOGENESIS, V14, P1397, DOI 10.1093/carcin/14.7.1397	43	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21489	21496		10.1074/jbc.273.34.21489	http://dx.doi.org/10.1074/jbc.273.34.21489			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705277	hybrid			2022-12-25	WOS:000075492600011
J	Scott, DA; de Souza, W; Benchimol, M; Zhong, L; Lu, HG; Moreno, SNJ; Docampo, R				Scott, DA; de Souza, W; Benchimol, M; Zhong, L; Lu, HG; Moreno, SNJ; Docampo, R			Presence of a plant-like proton-pumping pyrophosphatase in acidocalcisomes of Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING INORGANIC PYROPHOSPHATASE; SUBSTRATE-BINDING SUBUNIT; VACUOLAR MEMBRANE; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; CYTOPLASMIC PH; CALCIUM-PUMP; CA2+ RELEASE; H+-ATPASE; TONOPLAST	The vacuolar-type proton-translocating pyrophosphatase (V-H+-PPase) is an enzyme previously described in detail only in plants. This paper-demonstrates its presence in the trypanosomatid Trypanosoma cruzi. Pyrophosphate promoted organellar acidification in permeabilized amastigotes, epimastigotes, and trypomastigotes of T. cruzi. This activity was stimulated by K+ ions and was inhibited by Na+ ions and pyrophosphate analogs, as is the plant activity. Separation of epimastigote extracts on Percoll gradients yielded a dense fraction that contained H+-PPase activity measured both by proton uptake and phosphate release but lacked markers for mitochondria, lysosomes, glycosomes, cytosol, and plasma membrane. Antiserum raised against specific sequences of the plant V-H+-RPase cross-reacted with a T. cruzi protein, which was also detectable in the dense Percoll fraction. The organelles in this fraction appeared by electron microscopy to consist mainly of acidocalcisomes (acidic calcium storage organelles). This identification was confirmed by x-ray microanalysis. Immunofluorescence and immunoelectron microscopy indicated that the V-H+-PPase was located in the plasma membrane and acidocalcisomes of the three different forms of the parasite. Pyrophosphate was able to drive calcium uptake in permeabilized T, cruzi, This uptake depended upon a proton gradient and was reversed by a specific V-H+-PPase inhibitor. Our results imply that the phylogenetic distribution of V-H+-PPases is much wider than previously perceived but that the enzyme has a unique subcellular location in trypanosomes.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941 Rio De Janeiro, Brazil	University of Illinois System; University of Illinois Urbana-Champaign; Universidade Federal do Rio de Janeiro	Docampo, R (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.			Scott, David/0000-0002-8668-2449	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI023259, R01AI023259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENAIM G, 1995, BIOCHEM J, V306, P299, DOI 10.1042/bj3060299; Blumwald E, 1997, ADV BOT RES, V25, P401, DOI 10.1016/S0065-2296(08)60159-7; BRIGHTMAN AO, 1992, BIOCHIM BIOPHYS ACTA, V1104, P188, DOI 10.1016/0005-2736(92)90149-G; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; CUNNINGHAM KW, 1994, J EXP BIOL, V196, P157; DOCAMPO R, 1995, BIOCHEM J, V310, P1005, DOI 10.1042/bj3101005; Drose S, 1997, J EXP BIOL, V200, P1; GordonWeeks R, 1997, PLANT PHYSIOL, V114, P901, DOI 10.1104/pp.114.3.901; Jiang SS, 1997, ARCH BIOCHEM BIOPHYS, V346, P105, DOI 10.1006/abbi.1997.0279; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; LIU CM, 1978, J BIOL CHEM, V253, P5892; Lommel C, 1997, PLANTA, V201, P477, DOI 10.1007/s004250050092; Long AR, 1997, J PLANT PHYSIOL, V151, P16, DOI 10.1016/S0176-1617(97)80031-4; LONG AR, 1995, J PLANT PHYSIOL, V146, P629, DOI 10.1016/S0176-1617(11)81925-5; Lu HG, 1998, MOL CELL BIOL, V18, P2309, DOI 10.1128/MCB.18.4.2309; Lu HG, 1997, J BIOL CHEM, V272, P9464, DOI 10.1074/jbc.272.14.9464; LUNDIN M, 1992, BIOCHIM BIOPHYS ACTA, V1098, P217, DOI 10.1016/S0005-2728(05)80339-1; MACDONALD JIS, 1988, FEBS LETT, V238, P9, DOI 10.1016/0014-5793(88)80214-X; MAESHIMA M, 1989, J BIOL CHEM, V264, P20068; MAESHIMA M, 1991, EUR J BIOCHEM, V196, P11, DOI 10.1111/j.1432-1033.1991.tb15779.x; Michels PAM, 1997, EUR J BIOCHEM, V250, P698, DOI 10.1111/j.1432-1033.1997.00698.x; Moreno SNJ, 1996, BIOCHEM J, V313, P655, DOI 10.1042/bj3130655; NORE BF, 1991, BIOCHEM BIOPH RES CO, V181, P962, DOI 10.1016/0006-291X(91)92030-N; PALMGREN MG, 1991, ANAL BIOCHEM, V192, P316, DOI 10.1016/0003-2697(91)90542-2; PEREIRADASILVA L, 1993, ARCH BIOCHEM BIOPHYS, V304, P310, DOI 10.1006/abbi.1993.1355; Rea P.A., 1990, METHODS PLANT BIOCH, V3, P385, DOI DOI 10.1016/B978-0-12-461013-2.50035-6; REA PA, 1992, PLANT PHYSIOL, V100, P723, DOI 10.1104/pp.100.2.723; REA PA, 1993, ANNU REV PLANT PHYS, V44, P157, DOI 10.1146/annurev.pp.44.060193.001105; Robinson DG, 1996, PLANTA, V198, P95, DOI 10.1007/BF00197591; SARAFIAN V, 1992, P NATL ACAD SCI USA, V89, P1775, DOI 10.1073/pnas.89.5.1775; SATO MH, 1994, J BIOL CHEM, V269, P6725; Scarpa A, 1979, Methods Enzymol, V56, P301; SCHLATTERER C, 1994, CELL CALCIUM, V16, P101, DOI 10.1016/0143-4160(94)90005-1; SCOTT DA, 1995, BIOCHEM J, V310, P789, DOI 10.1042/bj3100789; Scott DA, 1997, J BIOL CHEM, V272, P28020, DOI 10.1074/jbc.272.44.28020; Scott DA, 1998, BIOCHEM J, V331, P583, DOI 10.1042/bj3310583; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vanderheyden N, 1996, BIOCHEM J, V318, P103, DOI 10.1042/bj3180103; Vercesi AE, 1996, BIOCHEM J, V315, P265, DOI 10.1042/bj3150265; Vercesi AE, 1997, BIOCHEM J, V328, P479; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; Vianello A, 1997, PLANT CELL PHYSIOL, V38, P87, DOI 10.1093/oxfordjournals.pcp.a029090; WANG YZ, 1986, PLANT PHYSIOL, V81, P497, DOI 10.1104/pp.81.2.497; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; World Health Organization, 1991, WHO TECH REP SER; ZHEN RG, 1994, PLANT PHYSIOL, V104, P153, DOI 10.1104/pp.104.1.153; Zhen RG, 1997, ADV BOT RES, V25, P297, DOI 10.1016/S0065-2296(08)60156-1; ZIEROLD K, 1988, METHOD MICROBIOL, V20, P91, DOI 10.1016/S0580-9517(08)70049-7	50	133	136	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					22151	22158		10.1074/jbc.273.34.22151	http://dx.doi.org/10.1074/jbc.273.34.22151			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705361	hybrid			2022-12-25	WOS:000075492600095
J	Lee, WNP; Lim, S; Bassilian, S; Bergner, EA; Edmond, J				Lee, WNP; Lim, S; Bassilian, S; Bergner, EA; Edmond, J			Fatty acid cycling in human hepatoma cells and the effects of troglitazone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-OXIDATION; ISOTOPOMER; BIOSYNTHESIS; GLUCOSE; RATS	Fatty acid cycling by chain shortening/elongation in the peroxisomes is an important source of fatty acids for membrane lipid synthesis. Its role in the homeostasis of nonessential fatty acids is poorly understood. We report here a study on the cycling of saturated fatty acids and the effects of troglitazone in HepG2 cells in culture using [U-C-13]stearate or [U-C-13]oleate and mass isotopomer analysis. HepG2 cells were grown in the presence of 0.7 mmol/liter [U-C-13]stearate or [U-C-13]oleate, and in the presence and absence of 50 mu M troglitazone for 72 h. Fatty acids extracted from cell pellets after saponification were analyzed by gas chromatography/mass spectrometry. Peroxisomal beta-oxidation of uniformly C-13-labeled stearate (C18:0) and oleate (C18:1) resulted in chain shortening and produced uniformly labeled palmitate (C16:0) and palmitoleate (C16:1). In untreated cells, 16% of C16:0 was derived from C18:0 and 26% of C16:1 fi om C18:1 by chain shortening. Such contributions were significantly increased by troglitazone to 23.6 and 36.6%, respectively (p < 0.001). Desaturation of stearate contributed 67% of the oleate, while reduction of oleate contributed little to stearate (2%). The desaturation of C18:0 to C18:I was not affected by troglitazone. Our results demonstrated a high degree of recycling of C18:0 and C18:1 to C16:0 and C16:1 through chain shortening and desaturation. Chain shortening was accompanied by chain elongation in the synthesis of other long chain fatty acids. Troglitazone specifically increased recycling by peroxisomal beta-oxidation of C18 to C16 fatty acids, and the interconversion of long chain fatty acids was associated with reduced de novo lipogenesis.	Univ Calif Los Angeles, Harbor Med Ctr, Torrance, CA 90502 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lee, WNP (corresponding author), Harbor UCLA Res & Educ Inst, 1124 W Carson St, Torrance, CA 90502 USA.	lee@gcrc.humc.edu			NCI NIH HHS [P01-CA 42710] Funding Source: Medline; NCRR NIH HHS [MO1-RR 00425] Funding Source: Medline; NIDDK NIH HHS [R01-DK46353] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042710] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046353] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AJIE HO, 1995, AM J PHYSIOL-ENDOC M, V269, pE247, DOI 10.1152/ajpendo.1995.269.2.E247; ALLMANN DW, 1965, J LIPID RES, V6, P51; BLOM KF, 1988, ANAL CHEM, V60, P966, DOI 10.1021/ac00161a004; Clarke SD, 1996, LIPIDS, V31, pS7, DOI 10.1007/BF02637044; CLARKE SD, 1997, J NUTR, V10, P1170; Edmond J, 1998, J NEUROCHEM, V70, P1227; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; Fulgencio JP, 1996, DIABETES, V45, P1556, DOI 10.2337/diabetes.45.11.1556; Hajra AK, 1996, ANN NY ACAD SCI, V804, P129, DOI 10.1111/j.1749-6632.1996.tb18613.x; Hashimoto T, 1996, ANN NY ACAD SCI, V804, P86, DOI 10.1111/j.1749-6632.1996.tb18610.x; HELLERSTEIN MK, 1991, J BIOL CHEM, V266, P10920; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Inoue I, 1995, METABOLISM, V44, P1626, DOI 10.1016/0026-0495(95)90085-3; LEE WNP, 1992, BIOL MASS SPECTROM, V21, P114, DOI 10.1002/bms.1200210210; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; LEE WNP, 1995, ANAL BIOCHEM, V226, P100, DOI 10.1006/abio.1995.1197; LEE WNP, 1994, AM J PHYSIOL, V266, pE372, DOI 10.1152/ajpendo.1994.266.3.E372; LOWENSTEIN JM, 1975, METHOD ENZYMOL, V34, P279; POULOS A, 1995, LIPIDS, V30, P1, DOI 10.1007/BF02537036; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Shimabukuro M, 1998, J BIOL CHEM, V273, P3547, DOI 10.1074/jbc.273.6.3547; Sprecher H, 1995, J LIPID RES, V36, P2471	23	36	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20929	20934		10.1074/jbc.273.33.20929	http://dx.doi.org/10.1074/jbc.273.33.20929			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694841	hybrid			2022-12-25	WOS:000075386100034
J	Sepuri, NBV; Gordon, DM; Pain, D				Sepuri, NBV; Gordon, DM; Pain, D			A GTP-dependent "push" is generally required for efficient protein translocation across the mitochondrial inner membrane into the matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED PRECURSOR PROTEIN; NUCLEOSIDE TRIPHOSPHATES; INTERMEMBRANE SPACE; CYTOPLASMIC CHAPERONES; CHLOROPLASTS REQUIRES; YEAST MITOCHONDRIA; IMPORT MACHINERY; ATP HYDROLYSIS; OUTER-MEMBRANE; HSP70	Mitochondrial biogenesis requires translocation of numerous preproteins across both outer and inner membranes into the matrix of the organelle, This translocation process requires a membrane potential (Delta psi) and ATP, We have recently demonstrated that the efficient import of a urea-denatured preprotein into the matrix requires GTP hydrolysis (Sepuri, N, B, V., Schulke, N,, and Pain, D. (1998) J. Biol, Chem. 273, 1420-1424), We now demonstrate that GTP is generally required for efficient import of various preproteins, both native and urea-denatured, The GTP participation is localized to a particular stage in the protein import process. In the presence of Delta psi but no added nucleoside triphosphates, the transmembrane movement of preproteins proceeds only to a point early in their translocation across the inner membrane. The completion of translocation into the matrix is independent of Delta psi but is dependent on a GTP-mediated "push," This push is Likely mediated by a membrane-bound GTPase on the cis side of the inner membrane. This conclusion is based on two observations: (i) GTP does not readily cross the inner membrane barrier and hence, primarily acts outside the inner membrane to stimulate import, and (ii) the GTP-dependent stage of import does not require soluble constituents of the intermembrane space and can be observed in isolated mitoplasts, Efficient import into the matrix, however, is achieved only through the coordinated action of a cis GTP-dependent push and a trans ATP-dependent "pull."	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Pain, D (corresponding author), Univ Penn, Sch Med, Dept Physiol, D403 Richards Bldg,3700 Hamilton Walk, Philadelphia, PA 19104 USA.		Sepuri, Naresh/AAF-2704-2020					BECKER K, 1992, J BIOL CHEM, V267, P5637; CHEN WJ, 1987, CELL, V49, P651, DOI 10.1016/0092-8674(87)90541-1; CRAIG EA, 1989, MOL CELL BIOL, V9, P3000, DOI 10.1128/MCB.9.7.3000; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FUKUCHI T, 1993, GENE, V129, P141; GASSER SM, 1982, J BIOL CHEM, V257, P3034; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; Horst M, 1996, PROTEIN SCI, V5, P759; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; Majima E, 1998, BIOCHEMISTRY-US, V37, P424, DOI 10.1021/bi9710683; MAJIMA E, 1993, J BIOL CHEM, V268, P22181; MARTIN J, 1991, J BIOL CHEM, V266, P18051; Matouschek A, 1997, EMBO J, V16, P6727, DOI 10.1093/emboj/16.22.6727; Mihara K, 1996, TRENDS CELL BIOL, V6, P104, DOI 10.1016/0962-8924(96)81000-2; Millman JS, 1997, CELL, V89, P673, DOI 10.1016/S0092-8674(00)80248-2; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI H, 1993, P NATL ACAD SCI USA, V90, P3358, DOI 10.1073/pnas.90.8.3358; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OHBA M, 1987, EMBO J, V6, P2117, DOI 10.1002/j.1460-2075.1987.tb02478.x; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1986, FEBS LETT, V209, P152, DOI 10.1016/0014-5793(86)81101-2; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PFANNER N, 1990, J BIOL CHEM, V265, P16324; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; SCHEKMAN R, 1994, CELL, V78, P911, DOI 10.1016/0092-8674(94)90265-8; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHNELL DJ, 1995, CELL, V83, P521, DOI 10.1016/0092-8674(95)90090-X; Schulke N, 1997, P NATL ACAD SCI USA, V94, P7314, DOI 10.1073/pnas.94.14.7314; SCHULKE N, 1992, P NATL ACAD SCI USA, V89, P8011, DOI 10.1073/pnas.89.17.8011; Scott SV, 1996, J CELL BIOL, V132, P63, DOI 10.1083/jcb.132.1.63; Sepuri NBV, 1998, J BIOL CHEM, V273, P1420, DOI 10.1074/jbc.273.3.1420; SOLING HD, 1982, METABOLIC COMPARTMEN, P123; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; Tokatlidis K, 1996, NATURE, V384, P585, DOI 10.1038/384585a0; TZAGOLOFF A, 1982, CELL ORGANELLES SERI; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WICKNER WT, 1994, SCIENCE, V266, P1197, DOI 10.1126/science.7973701; ZIEGLER M, 1989, FEBS LETT, V248, P182, DOI 10.1016/0014-5793(89)80457-0	51	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20941	20950		10.1074/jbc.273.33.20941	http://dx.doi.org/10.1074/jbc.273.33.20941			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694843	hybrid			2022-12-25	WOS:000075386100036
J	Young, WJ; Lee, YF; Smith, SM; Chang, CS				Young, WJ; Lee, YF; Smith, SM; Chang, CS			A bidirectional regulation between the TR2/TR4 orphan receptors (TR2/TRA) and the ciliary neurotrophic factor (CNTF) signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; STEROID-RECEPTOR; TRANSCRIPTION FACTOR; THYROID-HORMONE; ALPHA COMPONENT; SUPERFAMILY; GENE; IDENTIFICATION; DEGENERATION; EXPRESSION	Previously, we reported that the nuclear orphan receptor TRA could induce transcriptional activity via the 5th intron of the ciliary neurotrophic factor (CNTF) alpha receptor gene (CNTFR-I5). Here we show CNTF could increase TR4 expression and enhance the DNA-binding capacity of TR4. Interestingly, the expression of TR2, a close family member of TR4, could also be induced by CNTF. In return, TR2 induced CNTFR alpha transcriptional activity through binding to a direct repeat response element of AGGTCA within CNTFR-I5. The possibility of this mutual influence between TR2 and the CNTF signaling was further strengthened by in situ hybridization. Similar expression patterns of TR2 and CNTFR alpha were observed in most of the developing neural structures such as the ganglia, neural epithelia, spinal cord, and the periventricular areas of brain. Together, our data suggest that an interaction between TR2/TR4 and the CNTF signaling pathway may occur, supporting the hypothesis that TR2/TR4 may play important roles in neurogenesis.	Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Biochem, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53792 USA	University of Rochester; University of Rochester; University of Rochester; University of Wisconsin System; University of Wisconsin Madison	Chang, CS (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	chang@pathology.rochester.edu			NATIONAL CANCER INSTITUTE [T32CA009363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09363D, CA71570] Funding Source: Medline; NIDDK NIH HHS [DK47258] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CEDARBAUM JM, 1995, CLIN NEUROPHARMACOL, V18, P515; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; FORGER NG, 1995, J NEUROBIOL, V28, P354, DOI 10.1002/neu.480280308; GUPTA SK, 1993, EUR J NEUROSCI, V5, P977, DOI 10.1111/j.1460-9568.1993.tb00949.x; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; LEE CH, 1995, GENOMICS, V30, P46, DOI 10.1006/geno.1995.0007; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; LEE HJ, 1995, J BIOL CHEM, V270, P30129; Lin DL, 1998, ENDOCRINE, V8, P123, DOI 10.1385/ENDO:8:2:123; LIN TM, 1995, J BIOL CHEM, V270, P30121; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; Lydon John P., 1992, Gene Expression, V2, P273; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1994, J NEUROBIOL, V25, P1437; VALENZUELA DM, 1995, GENOMICS, V25, P157, DOI 10.1016/0888-7543(95)80121-2; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Young WJ, 1997, J BIOL CHEM, V272, P3109, DOI 10.1074/jbc.272.5.3109	33	31	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20877	20885		10.1074/jbc.273.33.20877	http://dx.doi.org/10.1074/jbc.273.33.20877			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694834	hybrid			2022-12-25	WOS:000075386100027
J	Zhang, Y; Cao, L; Yang, BL; Yang, BB				Zhang, Y; Cao, L; Yang, BL; Yang, BB			The G3 domain of versican enhances cell proliferation via epidermal growth factor-like motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCANS; PG-M VERSICAN; SUBSTRATUM ADHESION; LINK PROTEIN; TENASCIN-R; GENE CSPG2; 3T3 CELLS; PHENOTYPE; RECEPTOR; TISSUES	Versican is a member of the large aggregating chondroitin sulfate proteoglycan family. We have expressed in NIH3T3 fibroblasts a recombinant versican mini-gene comprising the G1 and G3 domains and 15% of the CS domain. We observed that expression of the mini-versican gene stimulated cell proliferation as determined by cell counting and cell cycle analysis. Addition of exogenous mini-versican protein to cultured cells produced the same result. The effects of the mini-versican were greatly reduced when the G3 domain was deleted. Expression of the G3 domain alone promotes cell proliferation, and addition of purified G3 gene products to NIH3T3 fibroblasts and cultured chicken fibroblasts enhances cell growth. Further, deletion of the epidermal growth factor (EGF)-like motifs in the versican G3 domain reduced the effects of the mini-versican on cell proliferation. In the presence of the purified mini-versican protein, antisense oligonucleotides to the EGF receptor inhibited proliferation of NIH3T3 fibroblasts, compared with control sense oligonucleotides. Taken together, these results imply that versican enhances cell proliferation, and this effect is mediated, at least in part, by the action of versican EGF-like motifs on endogenous EGF receptor.	Univ Toronto, Sunnybrook Hlth Sci Ctr, Trauma Res Program, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Yang, BB (corresponding author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Trauma Res Program, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BINETTE F, 1994, J BIOL CHEM, V269, P19116; BITTERMAN PB, 1983, J CELL BIOL, V97, P1925, DOI 10.1083/jcb.97.6.1925; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; DEAK F, 1986, P NATL ACAD SCI USA, V83, P3766, DOI 10.1073/pnas.83.11.3766; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DONALD RGK, 1995, P NATL ACAD SCI USA, V92, P5749, DOI 10.1073/pnas.92.12.5749; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; DUCROS DL, 1995, J INVEST DERMATOL, V105, P426, DOI 10.1111/1523-1747.ep12321131; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; HAMADA H, 1995, BLOOD, V86, P225, DOI 10.1182/blood.V86.1.225.bloodjournal861225; IOZZO RV, 1992, GENOMICS, V14, P845, DOI 10.1016/S0888-7543(05)80103-X; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LANDOLT RM, 1995, DEVELOPMENT, V121, P2303; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MARGOLIS RU, 1994, METHOD ENZYMOL, V245, P105; NASO MF, 1994, J BIOL CHEM, V269, P32999; NASO MF, 1995, GENOMICS, V29, P297, DOI 10.1006/geno.1995.1251; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; Paulus W, 1996, J NEUROPATH EXP NEUR, V55, P528, DOI 10.1097/00005072-199605000-00005; Sambrook J., 2002, MOL CLONING LAB MANU; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; YAMAGATA M, 1993, J CELL SCI, V106, P55; YAMAGATA M, 1994, J CELL SCI, V107, P2581; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; YANG BB, 1997, MATRIX BIOL, V16, P541; YANG BH, 1994, J BIOL CHEM, V269, P4506; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	41	130	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21342	21351		10.1074/jbc.273.33.21342	http://dx.doi.org/10.1074/jbc.273.33.21342			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694895	hybrid			2022-12-25	WOS:000075386100088
J	Caamano, CA; Morano, MI; Dalman, FC; Pratt, WB; Akil, H				Caamano, CA; Morano, MI; Dalman, FC; Pratt, WB; Akil, H			A conserved proline in the hsp90 binding region of the glucocorticoid receptor is required for hsp90 heterocomplex stabilization and receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; GLUTATHIONE-S-TRANSFERASE; NON-DNA-BINDING; STEROID-RECEPTOR; HORMONE-BINDING; ESCHERICHIA-COLI; 90-KDA; TRANSFORMATION; COMMON; CELLS	Studies of hsp90 in yeast have supported the notion that this chaperone plays a critical role in signaling by steroid receptors. One limitation to these studies is that yeast expressing hsp90 mutants may also be deficient in fundamental cellular functions of the chaperone required for steroid-dependent induction of transcription. In this work, we have prepared mutants of the glucocorticoid receptor (GR) that permit analysis of hsp90 binding and transcriptional activity in cells with normal chaperone function. Our previous data supported a model in which hsp90 binds to the receptor steroid binding domain according to a two-site model. By amino acid mutagenesis of these two sites, we have now generated three receptor mutants and analyzed their function. Upon their translation in vitro, all three mutants interacted with hsp90 similarly to the wild-type receptor. However, one mutant, P643A (GRo), was of particular interest because, although it showed normal steroid binding and transformation to a glucocorticoid response element-specific DNA binding form, it was remarkably deficient in nuclear translocation and transcriptional function at 37 degrees C. Furthermore, GRo.hspSO heterocomplexes formed in vivo or assembled under cell-free conditions were much less stable than wild-type GR.hsp90 heterocomplexes. Our results demonstrate that Pro-643 plays a critical role in both stabilizing the receptor.hsp90 complex and in permitting an efficient nuclear translocation and, thus, support the concept that the chaperone is an integral component of the steroid-receptor signaling pathway.	Univ Michigan, Mental Hlth Res Inst, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pharmacol, Sch Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Caamano, CA (corresponding author), Univ Michigan, Mental Hlth Res Inst, Sch Med, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	ccaamano@umich.edu			NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010] Funding Source: Medline; NIDDK NIH HHS [DK34933] Funding Source: Medline; NIMH NIH HHS [MH42251] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bamberger CM, 1997, MOL CELL ENDOCRINOL, V131, P233, DOI 10.1016/S0303-7207(97)00115-9; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAAMANO CA, 1994, ANN NY ACAD SCI, V746, P68; CAAMANO CA, 1993, BIOCHEMISTRY-US, V32, P8589, DOI 10.1021/bi00084a028; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605, DOI 10.1021/bi00236a038; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOLBROOK NJ, 1983, J BIOL CHEM, V258, P6477; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MCBLAIN WA, 1981, BIOCHEMISTRY-US, V20, P6790, DOI 10.1021/bi00527a008; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1992, BIOESSAYS, V14, P841, DOI 10.1002/bies.950141209; PRATT WB, 1993, J BIOL CHEM, V268, P21455; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; PRATT WB, 1988, J BIOL CHEM, V263, P267; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHOWALTER DB, 1991, J BIOL CHEM, V266, P21165; SCHUH S, 1985, J BIOL CHEM, V260, P4292; Segnitz B, 1997, J BIOL CHEM, V272, P18694, DOI 10.1074/jbc.272.30.18694; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P17342	39	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20473	20480		10.1074/jbc.273.32.20473	http://dx.doi.org/10.1074/jbc.273.32.20473			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685402	hybrid			2022-12-25	WOS:000075305400079
J	Choi, SY; Goldberg, IJ; Curtiss, LK; Cooper, AD				Choi, SY; Goldberg, IJ; Curtiss, LK; Cooper, AD			Interaction between ApoB and hepatic lipase mediates the uptake of ApoB-containing lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; APOLIPOPROTEIN-B; CHYLOMICRON REMNANTS; RAT-LIVER; CHOLESTERYL ESTER; LDL RECEPTOR; BINDING; CELLS; PLASMA	Hepatic lipase (HL) on the surface of hepatocytes and endothelial cells lining hepatic sinusoids, the adrenal glands, and the ovary hydrolyzes triglycerides and phospholipids of circulating Lipoproteins. Its expression significantly enhances low density lipoprotein (LDL) uptake via the LDL receptor pathway. A specific interaction between LPL, a homologous molecule to HL, and apoB has been described (Choi, S. Y,, Sivaram, P,, Walker, D. E,, Curtiss, L, I,, Gretch, D, G,, Sturley, S. L,, Attie, A. D,, Deckelbaum, Il, J,, and Goldberg, I. J, (1995) J. Biol. Chem. 270, 8081-8086), The present studies tested the hypothesis that HL enhances the uptake of lipoproteins by a specific interaction of HL with apoB, On a ligand blot, HL bound to apoB26, 48, and 100 but not to apoE or apoAI, HL binding to LDL in a plate assay with LDL-coated plates was significantly greater than to bovine serum albumin-coated plates. Neither heat denatured HL nor bacterial fusion protein of HL bound to LDL in the plate assays. I-125-LDL bound to HL-saturated heparin-agarose gel with a K-d of 52 nM, and somewhat surprisingly, this binding was not inhibited by excess LPL, In cell culture experiments HL enhanced the uptake of I-125-LDL,at both 4 and 37 degrees C, The enhanced binding and uptake of LDL was significantly inhibited by monoclonal anti-apoB antibodies. In contrast to LPL, both amino- and carboxyl-terminal antibodies blocked the apoB interaction with HL to the same extent. Thus, we conclude that there is a unique interaction between HL and apoB that facilitates the uptake of apoB-containing lipoproteins by cells where HL is present.	Palo Alto Med Fdn, Res Inst, Palo Alto, CA 94301 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Palo Alto Medical Foundation Research Institute; Columbia University; Stanford University; Scripps Research Institute	Choi, SY (corresponding author), Palo Alto Med Fdn, Res Inst, 860 Bryant St, Palo Alto, CA 94301 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL045095, R01HL045095, R29HL058034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038318] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45095, HL58034] Funding Source: Medline; NIDDK NIH HHS [DK38318] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVIRAM M, 1988, J BIOL CHEM, V263, P15416; BACH JF, 1978, ANTIGEN ANTIBODY REA, P248; BRECKENRIDGE WC, 1982, ATHEROSCLEROSIS, V45, P161, DOI 10.1016/0021-9150(82)90136-8; CARDIN AD, 1984, J BIOL CHEM, V259, P8522; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHOI SSY, 1994, J LIPID RES, V35, P848; Choi SY, 1997, J LIPID RES, V38, P77; CHOI SY, 1995, J BIOL CHEM, V270, P8081, DOI 10.1074/jbc.270.14.8081; COOPER AD, 1977, BIOCHIM BIOPHYS ACTA, V488, P464, DOI 10.1016/0005-2760(77)90204-1; CURTISS LK, 1982, J BIOL CHEM, V257, P5213; deFaria E, 1996, J LIPID RES, V37, P197; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; GOLDBERG IJ, 1986, J CLIN INVEST, V78, P1523, DOI 10.1172/JCI112744; GOLDBERG IJ, 1982, J CLIN INVEST, V70, P114; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hayden M.R., 1991, CURRENT OPINION LIPI, V2, P104; HIDE WA, 1992, J LIPID RES, V33, P167; Ingram MF, 1997, J BIOL CHEM, V272, P10279; JANSEN H, 1981, BIOCHEM J, V196, P739, DOI 10.1042/bj1960739; JANSEN H, 1980, BIOCHIM BIOPHYS ACTA, V619, P119, DOI 10.1016/0005-2760(80)90248-9; JENSEN GL, 1980, J BIOL CHEM, V255, P1141; JENSEN GL, 1982, BIOCHIM BIOPHYS ACTA, V710, P464, DOI 10.1016/0005-2760(82)90130-8; JI ZS, 1994, J BIOL CHEM, V269, P13429; Komaromy M, 1996, J BIOL CHEM, V271, P16906, DOI 10.1074/jbc.271.28.16906; KOMAROMY MC, 1991, J LIPID RES, V32, P963; Krapp A, 1996, J LIPID RES, V37, P926; Kreuzer J, 1997, J LIPID RES, V38, P324; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURASE T, 1981, ATHEROSCLEROSIS, V39, P293, DOI 10.1016/0021-9150(81)90015-0; REDGRAVE TG, 1977, ATHEROSCLEROSIS, V28, P69, DOI 10.1016/0021-9150(77)90200-3; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHAFI S, 1994, J LIPID RES, V35, P709; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; VANDRIEL IR, 1989, J BIOL CHEM, V264, P9533; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035	40	25	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20456	20462		10.1074/jbc.273.32.20456	http://dx.doi.org/10.1074/jbc.273.32.20456			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685400	hybrid			2022-12-25	WOS:000075305400077
J	Engelman, JA; Lee, RJ; Karnezis, A; Bearss, DJ; Webster, M; Siegel, P; Muller, WJ; Windle, JJ; Pestell, RG; Lisanti, MP				Engelman, JA; Lee, RJ; Karnezis, A; Bearss, DJ; Webster, M; Siegel, P; Muller, WJ; Windle, JJ; Pestell, RG; Lisanti, MP			Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo - Implications for human breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; MAMMARY-TUMORS; GENE FAMILY; MEMBRANE; CELLS; INDUCTION; ONCOGENE; MUSCLE; IDENTIFICATION; PROTOONCOGENE	Neu (c-erbB2) is a proto-oncogene product that encodes an epidermal growth factor-like receptor tyrosine kinase, Amplification of wild-type c-Neu and mutational activation of Neu (Neu T) have been implicated in oncogenic transformation of cultured fibroblasts and mammary tumorigenesis in vivo. Here, we examine the relationship between Neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Recent studies have suggested that caveolins may function as negative regulators of signal transduction, Our current results show that mutational activation of c-Neu down-regulates caveolin-1 protein expression, but not caveolin-2, in cultured NIH 3T3 and Rat 1 cells. Conversely, recombinant overexpression of caveolin-1 blocks Neu-mediated signal transduction in vice. These results suggest a reciprocal relationship between c-Neu tyrosine kinase activity and caveolin-1 protein expression. We next analyzed a variety of caveolin-1 deletion mutants to map this caveolin-1-dependent inhibitory activity to a given region of the caveolin-1 molecule. Results from this mutational analysis show that this functional in vivo inhibitory activity is contained within caveolin-1 residues 82-95, in accordance with these in vivo studies, a 20-amino acid peptide derived from this region (the caveolin-1 scaffolding domain) was sufficient to inhibit Neu autophosphorylation in an in vitro kinase assay. To further confirm or refute the relevance of our findings in vivo, we next examined the expression levels of caveolin-1 in mammary tumors derived from c-Neu transgenic mice. Our results indicate that dramatic reduction of caveolin-1 expression occurs in mammary tumors derived from c-Neu-expressing transgenic mice and other transgenic mice expressing downstream effecters of Neu-mediated signal transduction, such as Src and Ras, Taken together, our data suggest that a novel form of reciprocal negative regulation exists between c-Neu and caveolin-1.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; McMaster Univ, Dept Pathol, W Hamilton, ON L8S 4K1, Canada; Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; McMaster University; Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Albert Einstein Canc Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018; Bearss, David/Q-9141-2019	Lisanti, Michael/0000-0003-2034-1382; Windle, Jolene/0000-0001-6690-385X; Bearss, David/0000-0002-4458-826X; Bearss, David/0000-0002-4280-5670	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443, T32GM007288] Funding Source: NIH RePORTER; NCI NIH HHS [5-P30-CA13330-26] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288, GM-50443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Brown D, 1996, HISTOCHEM CELL BIOL, V105, P261, DOI 10.1007/BF01463929; CACERES A, 1984, J NEUROSCI, V4, P394; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hundley JE, 1997, CANCER RES, V57, P600; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; PATERSON MC, 1991, CANCER RES, V51, P556; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; XIE YM, 1995, ONCOGENE, V10, P2409	43	190	200	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20448	20455		10.1074/jbc.273.32.20448	http://dx.doi.org/10.1074/jbc.273.32.20448			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685399	hybrid			2022-12-25	WOS:000075305400076
J	Negulescu, D; Leong, LEC; Chandy, KG; Semler, BL; Gutman, GA				Negulescu, D; Leong, LEC; Chandy, KG; Semler, BL; Gutman, GA			Translation initiation of a cardiac voltage-gated potassium channel by internal ribosome entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT-BINDING-PROTEIN; ENCEPHALOMYOCARDITIS VIRUS-RNA; MESSENGER-RNA; POLIOVIRUS RNA; K+ CHANNELS; GENE; SEQUENCE; REGION; COMPLEX; INVITRO	The mammalian Kv1.4 voltage-gated potassium channel mRNA contains an unusually long (1.2 kilobases) 5'-untranslated region (UTR) and includes 18 AUG codons upstream of the authentic site of translation initiation. Computer-predicted secondary structures of this region reveal complex stem-loop structures that would serve as barriers to 5' --> 3' ribosomal scanning. These features suggested that translation initiation in Kv1.4 might occur by the mechanism of internal ribosome entry, a mode of initiation employed by a variety of RNA viruses but only a limited number of vertebrate genes. To test this possibility we introduced the 5'-UTR of mouse Kv1.4 mRNA into the intercistronic region of a bicistronic vector containing two tandem reporter genes, chloramphenicol acetyltransferase and luciferase, The control construct translated only the upstream chloramphenicol cistron in transiently transfected mammalian cells. In contrast, the construct containing the mKv1.4 UTR efficiently translated the luciferase cistron as well, demonstrating the presence of an internal ribosome entry segment. Progressive 5' --> 3' deletions localized the activity to a 3'-proximal 200-nucleotide fragment. Suppression of cap-dependent translation by extracts from poliovirus-infected HeLa cells in an in vitro translation assay eliminated translation of the upstream cistron while allowing translation of the downstream cistron, Our results indicate that the 8'-untranslated region of mKv1.4 contains a functional internal ribosome entry segment that may contribute to unusual and physiologically important modes of translation regulation for this and other potassium channel genes.	Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Gutman, GA (corresponding author), Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.		Semler, Bert/AAV-8795-2020	Semler, Bert/0000-0002-2424-5155	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026765, R56AI026765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM054872, R01GM054221] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26765] Funding Source: Medline; NIGMS NIH HHS [GMOD54872, GM54221] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI N, 1995, J VIROL, V69, P6367, DOI 10.1128/JVI.69.10.6367-6375.1995; Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; BOROVJAGIN A, 1994, FEBS LETT, V351, P299, DOI 10.1016/0014-5793(94)00848-5; BROWN BA, 1979, VIROLOGY, V97, P396, DOI 10.1016/0042-6822(79)90350-7; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344; deQuinto SL, 1997, J VIROL, V71, P4171; Ehrenfeld E, 1995, CURR TOP MICROBIOL, V203, P65; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; GABELLE AP, 1996, TRANSLATIONAL CONTRO, P173; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Hille B., 1992, IONIC CHANNELS EXCIT; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; Jackson RJ, 1995, RNA, V1, P985; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Kaminski A, 1995, RNA, V1, P924; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; Lee TE, 1996, J MEMBRANE BIOL, V151, P225, DOI 10.1007/s002329900073; LESAGE F, 1992, FEBS LETT, V310, P162, DOI 10.1016/0014-5793(92)81320-L; LIU DX, 1992, J VIROL, V66, P6143, DOI 10.1128/JVI.66.10.6143-6154.1992; MACEJAK DG, 1990, ENZYME, V44, P310, DOI 10.1159/000468767; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Nguyen A, 1996, MOL PHARMACOL, V50, P1672; Niepmann M, 1997, J VIROL, V71, P8330, DOI 10.1128/JVI.71.11.8330-8339.1997; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PALLANCK L, 1994, HUM MOL GENET, V3, P1239, DOI 10.1093/hmg/3.8.1239; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PESOLE G, 1994, GENE, V140, P219, DOI 10.1016/0378-1119(94)90547-9; Rijnbrand R, 1997, J VIROL, V71, P451, DOI 10.1128/JVI.71.1.451-457.1997; ROEHL HH, 1995, J VIROL, V69, P2954, DOI 10.1128/JVI.69.5.2954-2961.1995; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; Stewart SR, 1997, SEMIN VIROL, V8, P242, DOI 10.1006/smvy.1997.0127; Tenenholz TC, 1997, BIOCHEMISTRY-US, V36, P2763, DOI 10.1021/bi9628432; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Wymore RS, 1996, J BIOL CHEM, V271, P15629, DOI 10.1074/jbc.271.26.15629; WYMORE RS, 1994, GENOMICS, V20, P191, DOI 10.1006/geno.1994.1153; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557	45	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20109	20113		10.1074/jbc.273.32.20109	http://dx.doi.org/10.1074/jbc.273.32.20109			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685353	hybrid			2022-12-25	WOS:000075305400030
J	Chan, SY; Lee, DCW				Chan, SY; Lee, DCW			Sex difference in immunostaining of RET in the adult mouse kidney	ONCOGENE			English	Article						c-ret; RET; kidney	EPIDERMAL GROWTH-FACTOR; MICE LACKING GDNF; TYROSINE KINASE; NUCLEAR TRANSLOCATION; FACTOR RECEPTOR; FACTOR EGF; PROTOONCOGENE; EXPRESSION; LOCALIZATION; TRAFFICKING	The c-ret proto-oncogene encodes a receptor tyrosine kinase which is important for the development of the kidney and the enteric nervous system. During nephrogenesis, c-ret is expressed in the ureteric bud epithelium and later in its derivative, the collecting duct. This takes place during 11-17.5 days post-coitum (d.p.c.) in the mouse and our immunohistochemical study showed that the RET protein co-localized with the transcript. At 18.5 d.p.c. the kidney is fully differentiated. At 18.5 d.p.c., 1 week and 10 weeks old, RET was found in the proximal convoluted tubules, which is formed from the condensed mesenchyme, This suggests that c-ret may also play a role in kidney function. For the 10 weeks old kidney, RET immunostaining in male was concentrated on the basolateral side while female had a stronger staining in the whole cell. Furthermore, cytoplasmic staining was observed in male whereas both cytoplasmic and nuclear staining was found in female. c-ret transcript was detected by RT-PCR, and in situ hybridization showed its expression throughout the kidney. The reason for the sex-specific staining and the role of RET in kidney function remain to be determined.	Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong	University of Hong Kong	Chan, SY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong.			Chan, Siu Yuen/0000-0001-7262-1293				AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BACHINSKY DR, 1993, AM J PATHOL, V143, P598; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURTIS BM, 1990, J IMMUNOL, V144, P1295; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; HARRIS RC, 1991, AM J KIDNEY DIS, V17, P627, DOI 10.1016/S0272-6386(12)80336-2; Hellmich HL, 1996, MECH DEVELOP, V54, P95, DOI 10.1016/0925-4773(95)00464-5; HOLT SJ, 1994, BIOCHEM PHARMACOL, V47, P117, DOI 10.1016/0006-2952(94)90444-8; Ivanchuk SM, 1997, ONCOGENE, V14, P1811, DOI 10.1038/sj.onc.1201016; IWAMOTO T, 1993, ONCOGENE, V8, P1087; JIANG LW, 1990, J CELL BIOL, V110, P559, DOI 10.1083/jcb.110.3.559; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kilkenny DM, 1996, ENDOCRINOLOGY, V137, P5078, DOI 10.1210/en.137.11.5078; Lee DCW, 1998, J UROLOGY, V159, P291, DOI 10.1016/S0022-5347(01)64084-9; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; MARTI U, 1991, HEPATOLOGY, V13, P15, DOI 10.1016/0270-9139(91)90210-M; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; PODLECKI DA, 1987, J BIOL CHEM, V262, P3362; PROCHIANTZ A, 1995, BIOESSAYS, V17, P39, DOI 10.1002/bies.950170109; Prudovsky IA, 1996, J BIOL CHEM, V271, P14198, DOI 10.1074/jbc.271.24.14198; RAKOWICZSZULCZYNSKA EM, 1989, ARCH BIOCHEM BIOPHYS, V268, P456, DOI 10.1016/0003-9861(89)90313-5; RUGH R, 1994, MOUSE ITS REPROD DEV; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368	35	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					661	666		10.1038/sj.onc.1201970	http://dx.doi.org/10.1038/sj.onc.1201970			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704933				2022-12-25	WOS:000075195300015
J	Echeverria, D; Aposhian, HV; Woods, JS; Heyer, NJ; Aposhian, MM; Bittner, AC; Mahurin, RK; Cianciola, M				Echeverria, D; Aposhian, HV; Woods, JS; Heyer, NJ; Aposhian, MM; Bittner, AC; Mahurin, RK; Cianciola, M			Neurobehavioral effects from exposure to dental amalgam Hg degrees: new distinctions between recent exposure and Hg body burden	FASEB JOURNAL			English	Article						behavior; elemental mercury; dentists; DMPS	ELEMENTAL MERCURY; PSYCHOLOGICAL PERFORMANCE; INORGANIC MERCURY; WORKERS; DENTISTS; VAPOR; VALIDATION; CHLORINE; SYSTEM; ACID	Potential toxicity from exposure to mercury vapor (Hg degrees) from dental amalgam fillings is the subject of current public health debate in many countries. We evaluated potential central nervous system (CNS) toxicity associated with handling Hg-containing amalgam materials among dental personnel with very low levels of Hg degrees exposure (i.e., urinary Hg <4 mu g/l), applying a neurobehavioral test battery to evaluate CNS functions in relation to both recent exposure and Hg body burden. New distinctions between subtle preclinical effects on symptoms, mood, motor function, and cognition were found associated with Hg body burden as compared with those associated with recent exposure. The pattern of results, comparable to findings previously reported among subjects with urinary Hg >50 mu g/l, presents convincing new evidence of adverse behavioral effects associated with low Hg degrees exposures within the range of that received by the general population.	Battelle Ctr Publ Hlth Res & Evaluat, Seattle, WA 98105 USA; Univ Washington, Dept Environm Hlth, Seattle, WA 98195 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Washington, Dept Psychiat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Arizona; University of Washington; University of Washington Seattle	Echeverria, D (corresponding author), Battelle Ctr Publ Hlth Res & Evaluat, 4000 NE 41st St, Seattle, WA 98105 USA.				NIDCR NIH HHS [DE11712] Funding Source: Medline; NIEHS NIH HHS [ES04696, ES04940] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004940, P42ES004696] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AASETH J, 1995, ANALYST, V120, P853, DOI 10.1039/an9952000853; ALBERS JW, 1988, ANN NEUROL, V24, P651, DOI 10.1002/ana.410240510; Anderson T. W., 1958, INTRO MULTIVARIATE S; APOSHIAN HV, 1995, TOXICOLOGY, V97, P23, DOI 10.1016/0300-483X(95)02965-B; *ATSDR, 1995, AD ENV NEUR TEST BAT, P698; BAKER EL, 1985, NEUROBEH TOXICOL TER, V7, P369; BITTNER AC, 1998, IN PRESS NEUROTOXICO; BUELLER K, 1994, THESIS U WASHINGTON; CAMERINO D, 1981, CLIN TOXICOL, V18, P1299, DOI 10.3109/00099308109035070; CLARKSON TW, 1989, J AM COLL TOXICOL, V8, P1291, DOI 10.3109/10915818909009120; *DAN PROD DEV SYST, 1995, TREM AN TEST SYST; DERUEN T, HLTH EFFECTS DENT AM; Droppelman L.F., 1971, EDITS MANUAL PROFILE; ECHEVERRIA D, 1995, NEUROTOXICOL TERATOL, V17, P161, DOI 10.1016/0892-0362(94)00049-J; ECHEVERRIA D, 1989, BRIT J IND MED, V46, P483; FAWER RF, 1983, ADV BIOSCI, V45, P137; GERSTNER HB, 1977, CLIN TOXICOL, V11, P131, DOI 10.3109/15563657708989829; GONZALEZRAMIREZ D, 1995, J PHARMACOL EXP THER, V272, P264; HALBACH S, 1978, BIOCHIM BIOPHYS ACTA, V523, P522, DOI 10.1016/0005-2744(78)90055-4; HENDERSON R, 1974, AM IND HYG ASSOC J, V38, P576; HURSH JB, 1976, ARCH ENVIRON HEALTH, V31, P302, DOI 10.1080/00039896.1976.10667240; KINGMAN A, 1994, J DENT RES; *LAF INSTR CO, HAND MOT STEAD BATT; LANGOLF GD, 1978, AM IND HYG ASSOC J, V39, P976, DOI 10.1080/0002889778507898; LANGWORTH S, 1992, BRIT J IND MED, V49, P545; LETZ R, 1985, NEUROBEHAVIORAL EVAL; MAGOS L, 1989, BIOCHIM BIOPHYS ACTA, V99, P85; MARTIN MD, 1995, J AM DENT ASSOC, V126, P1502, DOI 10.14219/jada.archive.1995.0079; NGIM CH, 1992, BRIT J IND MED, V49, P782; PIIKIVI L, 1989, SCAND J WORK ENV HEA, V15, P69, DOI 10.5271/sjweh.1880; PIIKIVI L, 1984, SCAND J WORK ENV HEA, V10, P35, DOI 10.5271/sjweh.2365; PIIKIVI L, 1981, P 2 FINN EST S EARL, P165; REITAN RM, 1986, NEUROPSYCHOLOGICAL A; ROELS H, 1982, INT ARCH OCC ENV HEA, V50, P77, DOI 10.1007/BF00432495; ROELS H, 1985, AM J IND MED, V7, P45, DOI 10.1002/ajim.4700070106; Salvendy G., 1975, INT J PROD RES, V13, P303; SCHUCKMANN F, 1979, INT ARCH OCC ENV HEA, V44, P193, DOI 10.1007/BF00381134; SHAPIRO IM, 1982, LANCET, V1, P1147; SMITH RG, 1970, AM IND HYG ASSOC J, V31, P687, DOI 10.1080/0002889708506315; SOLEO L, 1990, BRIT J IND MED, V47, P105; *SPSS INC, 1993, SPSS X; TOUTONGHI G, 1991, ADV IND ERGONOMICS S, V3, P629; *US DEP HHS, 1993, DENT AM SCI REV REC; UZZELL BP, 1986, J CLIN EXP NEUROPSYC, V8, P581, DOI 10.1080/01688638608405177; WARRINGTON EK, RECOGNITION MEMORY T; *WHO, 1986, 255 WHO OFF OCC HLTH; WILLIAMSON AM, 1982, INT ARCH OCC ENV HEA, V50, P273, DOI 10.1007/BF00378089; ZALUPS RK, 1993, J PHARMACOL EXP THER, V267, P791; 1989, FED REG, V54, P2415	49	97	102	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					971	980		10.1096/fasebj.12.11.971	http://dx.doi.org/10.1096/fasebj.12.11.971			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707169	Bronze			2022-12-25	WOS:000075372600007
J	Bisello, A; Adams, AE; Mierke, DF; Pellegrini, M; Rosenblatt, M; Suva, LJ; Chorev, M				Bisello, A; Adams, AE; Mierke, DF; Pellegrini, M; Rosenblatt, M; Suva, LJ; Chorev, M			Parathyroid hormone-receptor interactions identified directly by photocross-linking and molecular modeling studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P NK-1 RECEPTOR; (PTH)/PTH-RELATED PEPTIDE RECEPTOR; PHOTOAFFINITY CROSS-LINKING; HUMAN PTH/PTHRP RECEPTOR; OSTEOBLAST-LIKE CELLS; EXPRESSION CLONING; SUBSTANCE-P; PROTEIN-RECEPTOR; BINDING-SITE; BIMOLECULAR INTERACTIONS	Direct mapping of the interface between parathyroid hormone (PTH) and its receptor (hPTH1-Rc) was carried out by photoaffinity scanning studies. Photoreactive analogs of PTH singularly substituted with a p-benzoyl-phenylalanine (Bpa) at each of the first six N-terminal positions have been prepared. Among these, the analog [Bpa(1),Nle(8,18),Arg(13,26,27),L-2-Nal(23),Tyr(34)] bPTH-(1-34)NH2 (Bpa(1)-PTH-(1-34)) displayed in vitro activity with potency similar to that of PTH-(1-34). The radioiodinated analog I-125-Bpa(1)-PTH-(1-34) cross-linked specifically to the hPTH1-Rc stably expressed in human embryonic kidney cells. A series of chemical and enzymatic digestions of the hPTH1-Rc-I-125-Bpa(1)-PTH-(1-34) conjugate suggested that a methionine residue (either Met(414) or Met(425)) within the contact domain hPTH1-Rc-(409-437), which includes the transmembrane helix 6 and part of the third extracellular loop, as the putative contact point. Site-directed mutagenesis (M414L or M425L) identified Met(425) as the putative contact point. Molecular modeling of the hPTH1-Rc together with the NMR-derived high resolution structure of hPTH-(1-34), guided by the cross-linking data, strongly supports Met(425), at the extracellular end of transmembrane helix 6, as the residue interacting with the N-terminal residue of the hPTH-(1-34). The photocross-linking and molecular modeling studies provide insight into the topologic arrangement of the receptor-ligand complex.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr,Charles A Dana Lab, Div Bone & Mineral Metab HIM 944,Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr,Thorndike Lab, Div Bone & Mineral Metab HIM 944,Dept Med, Boston, MA 02215 USA; Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Toxicol, Worcester, MA 01655 USA; Clark Univ, Dept Chem, Worcester, MA 01610 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; Clark University	Chorev, M (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr,Charles A Dana Lab, Div Bone & Mineral Metab HIM 944,Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.		Pellegrini, Maria/W-6005-2019	Pellegrini, Maria/0000-0003-3817-4412; Suva, Larry/0000-0002-2892-9757	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054082, R01GM054082] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK47940] Funding Source: Medline; NIGMS NIH HHS [GM54082] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ADAMS AE, 1995, BIOCHEMISTRY-US, V34, P10553, DOI 10.1021/bi00033a030; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Behar V, 1996, ENDOCRINOLOGY, V137, P2748, DOI 10.1210/en.137.7.2748; Bisello A, 1996, BIOCHEMISTRY-US, V35, P15890, DOI 10.1021/bi962111+; BLANTON MP, 1994, MOL PHARMACOL, V46, P1048; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Chorev Michael, 1994, P139; Chorev Michael, 1996, P305; CIVITELLI R, 1989, ENDOCRINOLOGY, V125, P1204, DOI 10.1210/endo-125-3-1204; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; DONNELLY D, 1994, PROTEIN ENG, V7, P645, DOI 10.1093/protein/7.5.645; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; Fitzpatrick Lorraine A., 1996, P339; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Girault S, 1996, EUR J BIOCHEM, V240, P215, DOI 10.1111/j.1432-1033.1996.0215h.x; Huang ZM, 1996, J BIOL CHEM, V271, P33382, DOI 10.1074/jbc.271.52.33382; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; Juppner H, 1994, Curr Opin Nephrol Hypertens, V3, P371; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; Kage R, 1996, J BIOL CHEM, V271, P25797, DOI 10.1074/jbc.271.42.25797; KARPF DB, 1987, BIOCHEMISTRY-US, V26, P7825, DOI 10.1021/bi00398a044; KEUTMANN HT, 1993, ENDOCRINOLOGY, V132, P1305, DOI 10.1210/en.132.3.1305; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; Konopka JB, 1996, P NATL ACAD SCI USA, V93, P6764, DOI 10.1073/pnas.93.13.6764; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MILLER WT, 1988, P NATL ACAD SCI USA, V85, P5429, DOI 10.1073/pnas.85.15.5429; NAKAMOTO C, 1995, BIOCHEMISTRY-US, V34, P10546, DOI 10.1021/bi00033a029; Pellegrini M, 1997, J MED CHEM, V40, P99, DOI 10.1021/jm9605389; Pellegrini M, 1998, J BIOL CHEM, V273, P10420, DOI 10.1074/jbc.273.17.10420; Pines M, 1996, BONE, V18, P381, DOI 10.1016/8756-3282(96)00008-7; PINES M, 1994, ENDOCRINOLOGY, V135, P1713, DOI 10.1210/en.135.4.1713; ROSENBLATT M, 1976, J BIOL CHEM, V251, P159; ROUBINI E, 1992, BIOCHEMISTRY-US, V31, P4026, DOI 10.1021/bi00131a018; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SHIGENO C, 1988, J BIOL CHEM, V263, P3872; Spalding TA, 1997, BIOCHEMISTRY-US, V36, P10109, DOI 10.1021/bi970565g; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; WILLIAMS KP, 1993, J BIOL CHEM, V268, P5361; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	50	165	179	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22498	22505		10.1074/jbc.273.35.22498	http://dx.doi.org/10.1074/jbc.273.35.22498			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712875	hybrid			2022-12-25	WOS:000075616600051
J	Pike, LJ; Miller, JM				Pike, LJ; Miller, JM			Cholesterol depletion delocalizes phosphatidylinositol bisphosphate and inhibits hormone-stimulated phosphatidylinositol turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; CAVEOLAE MEMBRANE; SIGNAL-TRANSDUCTION; PROTEIN-COMPONENT; TYROSINE KINASE; CELL-SURFACE; RECEPTOR; DOMAINS; CYCLODEXTRINS; MICRODOMAINS	Caveolae and detergent-insoluble, glycosphingolipid-enriched domains (DIGs) are cholesterol-enriched membrane domains that have been implicated in signal transduction because a variety of signaling proteins as well as phosphatidylinositol bisphosphate (PtdInsP(2)) are compartmentalized in these domains. We report here that depletion of cellular cholesterol leads to the inhibition of epidermal growth factor- and bradykinin-stimulated PtdIns turnover in A431 cells. This is associated with the loss of compartmentalization of epidermal growth factor receptors, G(q), and PtdInsP(2) in the low density membrane domains. Replacement of cellular cholesterol leads to the reorganization of signaling molecules in the low density domains and the reestablishment of hormone-stimulated PtdIns hydrolysis. Oxysterol derivatives show a variable ability to functionally replace the cholesterol in this system. These data are consistent with the hypothesis that localization of signaling proteins and lipids to cholesterol-enriched domains is required for the proper function of hormone-stimulated PtdIns turnover.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Pike, LJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 So Euclid,Box 8231, St Louis, MO 63110 USA.	pike@biochem.wustl.edu						BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; FRA AM, 1994, J BIOL CHEM, V269, P30745; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; GIMPL G, 1995, BIOCHEMISTRY-US, V34, P4065; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu YM, 1998, BIOCHEM BIOPH RES CO, V245, P684, DOI 10.1006/bbrc.1998.8329; MCGUIRE TF, 1993, J BIOL CHEM, V268, P22227; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; PALADE GE, 1953, J APPL PHYS, V24, P1424; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; PITHA J, 1985, J PHARM SCI, V74, P987, DOI 10.1002/jps.2600740916; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHUH SM, 1994, MOL BIOL CELL, V5, P739, DOI 10.1091/mbc.5.7.739; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255	36	338	345	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 28	1998	273	35					22298	22304		10.1074/jbc.273.35.22298	http://dx.doi.org/10.1074/jbc.273.35.22298			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	114NY	9712847	hybrid			2022-12-25	WOS:000075616600023
J	Horton, NC; Perona, JJ				Horton, NC; Perona, JJ			Recognition of flanking DNA sequences by EcoRV endonuclease involves alternative patterns of water-mediated contacts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTION-ENDONUCLEASE; SUBSTRATE-SPECIFICITY; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; NUCLEIC-ACIDS; COGNATE DNA; BINDING; SITE; COMPLEX; PROTEINS	The 2.1-Angstrom cocrystal structure of EcoRV endonuclease bound to 5'-CGGGATATCCC, in a crystal lattice isomorphous with the cocrystallized undecamer 5'-AAAGATATCTT previously determined, shows novel base recognition in the major groove of the DNA flanking the GATATC target site. Lys(104) Of the enzyme interacts through water molecules with the exocyclic N-4 amino groups of flanking cytosines. Steric exclusion of water molecule-binding sites by the 5-methyl group of thymine drives the adoption of alternative water-mediated contacts with AT versus GC flanks. This structure provides a rare example of structural adaptability in the recognition of different DNA sequences by a protein and suggests preferred strategies for the expansion of target site specificity by EcoRV.	Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Interdepartmental Program Biochem & Mol Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Perona, JJ (corresponding author), Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA.		Horton, Nancy C/E-7881-2011	Horton, Nancy C/0000-0003-2710-8284	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053763] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53763] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL A K, 1990, Methods (Orlando), V1, P83, DOI 10.1016/S1046-2023(05)80150-1; Bozic D, 1996, J MOL BIOL, V255, P176, DOI 10.1006/jmbi.1996.0015; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; Engler LE, 1997, J MOL BIOL, V269, P82, DOI 10.1006/jmbi.1997.1027; FINZEL BC, 1995, ACTA CRYSTALLOGR D, V51, P450, DOI 10.1107/S0907444994013508; FLORES H, 1995, GENE, V157, P295, DOI 10.1016/0378-1119(94)00863-N; GEWIRTH DT, 1995, NAT STRUCT BIOL, V2, P386, DOI 10.1038/nsb0595-386; HEITMAN J, 1990, EMBO J, V9, P3369, DOI 10.1002/j.1460-2075.1990.tb07538.x; Horton NC, 1998, J MOL BIOL, V277, P779, DOI 10.1006/jmbi.1998.1655; JenJacobson L, 1997, BIOPOLYMERS, V44, P153; JenJacobson L, 1995, METHOD ENZYMOL, V259, P305; KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036; Lanio T, 1996, PROTEIN ENG, V9, P1005, DOI 10.1093/protein/9.11.1005; NEWMAN M, 1994, STRUCTURE, V2, P439, DOI 10.1016/S0969-2126(00)00045-9; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; Perona JJ, 1997, J MOL BIOL, V273, P207, DOI 10.1006/jmbi.1997.1315; PERRY KM, 1990, PROTEINS, V8, P315, DOI 10.1002/prot.340080406; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; Roberts R, 1993, NUCLEASES, P35; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCHILDKRAUT I, 1984, GENE, V27, P327, DOI 10.1016/0378-1119(84)90078-7; SCHWABE JWR, 1995, STRUCTURE, V3, P201, DOI 10.1016/S0969-2126(01)00150-2; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; TAYLOR JD, 1989, BIOCHEMISTRY-US, V28, P6198, DOI 10.1021/bi00441a011; TAYLOR JD, 1992, BIOCHEMISTRY-US, V31, P90, DOI 10.1021/bi00116a014; Thorogood H, 1996, J BIOL CHEM, V271, P8855, DOI 10.1074/jbc.271.15.8855; TuckerKellogg L, 1997, STRUCTURE, V5, P1047, DOI 10.1016/S0969-2126(97)00256-6; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; Wenz C, 1996, J BIOL CHEM, V271, P5565, DOI 10.1074/jbc.271.10.5565; WENZ C, 1994, BBA-GENE STRUCT EXPR, V1219, P73, DOI 10.1016/0167-4781(94)90248-8; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x	39	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21721	21729		10.1074/jbc.273.34.21721	http://dx.doi.org/10.1074/jbc.273.34.21721			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705308	hybrid			2022-12-25	WOS:000075492600042
J	Muskett, FW; Frenkiel, TA; Feeney, J; Freedman, RB; Carr, MD; Williamson, RA				Muskett, FW; Frenkiel, TA; Feeney, J; Freedman, RB; Carr, MD; Williamson, RA			High resolution structure of the N-terminal domain of tissue inhibitor of metalloproteinases-2 and characterization of its interaction site with matrix metalloproteinase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; COUPLING-CONSTANTS; HETERONUCLEAR NMR; CATALYTIC DOMAIN; LARGER PROTEINS; ACTIVE DOMAIN; SPECTROSCOPY; PROGRAM; ASSIGNMENT; CLONING	The high resolution structure of the N-terminal domain of tissue inhibitor of metalloproteinases-2 (N-TIMP-2) in solution has been determined using multidimensional heteronuclear NMR spectroscopy, with the structural calculations based on an extensive set of constraints, including 3132 nuclear Overhauser effect-based distance constraints, 56 hydrogen bond constraints, and 220 torsion angle constraints tan average of 26.9 constraints/residue). The core of the protein consists of a five-stranded beta-barrel that is homologous to the p-barrel found in the oligosaccharide/oligonucleotide binding protein fold. The binding site for the catalytic domain of matrix metalloproteinases-3 (N-MMP-3) on N-TIMP-2 has been mapped by determining the changes in chemical shifts on complex formation for signals from the protein backbone (N-15, C-13, and H-1). This approach identified a discrete N-MMP-3 binding site on N-TIMP-2 composed of the N terminus of the protein and the loops between beta-strands AB, CD, and EF. The beta-hairpin formed from strands A and B in N-TIMP-2 is significantly longer than the equivalent structure ire TIMP-1, allowing it to make more extensive binding interactions with the MMP catalytic domain. A detailed comparison of the N-TIMP-2 structure with that of TIMP-1 bound to N-MMP-3 (Gomis-Ruth, F.-X., Maskos, B., Betz, M., Bergner, A., Huber, R., Suzuki, K., Yoshida, N,, Nagase, H., Brew, K., Bourne, G. P., Bartunik, H. & Bode, W. (1997) Nature 389, 77-80) revealed that the core p-barrels are very similar in topology but that the loop connecting beta-strands CD (P67-C72) would need to undergo a large conformational change for TIMP-2 to bind in a similar manner to TIMP-1.	Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Natl Inst Med Res, MRC, Biomed NMR Ctr, London NW7 1AA, England; Natl Inst Med Res, Div Mol Struct, London NW7 1AA, England	University of Kent; MRC National Institute for Medical Research; MRC National Institute for Medical Research	Williamson, RA (corresponding author), Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England.			Carr, Mark/0000-0002-3939-0996	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; Carr MD, 1996, EUR J BIOCHEM, V235, P721, DOI 10.1111/j.1432-1033.1996.00721.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; GRZESIEK S, 1992, J MAGN RESON, V99, P201, DOI 10.1016/0022-2364(92)90169-8; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; GUNTERT P, 1997, MOL BIOL, V273, P283; Huang W, 1997, J BIOL CHEM, V272, P22086, DOI 10.1074/jbc.272.35.22086; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NEUHAUS D, 1992, J MOL BIOL, V228, P637, DOI 10.1016/0022-2836(92)90846-C; NORWOOD TJ, 1990, J MAGN RESON, V87, P488, DOI 10.1016/0022-2364(90)90306-T; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267; Williamson RA, 1996, EUR J BIOCHEM, V241, P476, DOI 10.1111/j.1432-1033.1996.00476.x; Williamson RA, 1997, BIOCHEMISTRY-US, V36, P13882, DOI 10.1021/bi9712091; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K, 1986, NMR PROTEIN NUCL ACI; ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P210, DOI 10.1016/0022-2364(90)90228-2	39	71	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21736	21743		10.1074/jbc.273.34.21736	http://dx.doi.org/10.1074/jbc.273.34.21736			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705310	hybrid			2022-12-25	WOS:000075492600044
J	Myslinski, E; Krol, A; Carbon, P				Myslinski, E; Krol, A; Carbon, P			ZNF76 and ZNF143 are two human homologs of the transcriptional activator Staf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; FINGER DNA RECOGNITION; CRYSTAL-STRUCTURE; SEQUENCE ELEMENT; GENE KROX-20; ZINC FINGERS; COMPLEX; ENHANCER; PROMOTER; PROTEINS	The transcriptional activator Staf, originally identified in Xenopus laevis, is implicated in the enhanced transcription of small nuclear RNA (snRNA) and snRNA-type genes by RNA polymerases II (Pol II) and III (Pol III). This zinc finger protein also possesses the capacity to stimulate expression from a Pol II mRNA promoter. Here, we report a study on two human proteins, ZNF76 and ZNF143, that are 64 and 84% identical to their Xenopus counterpart, respectively, Northern blot analysis revealed that ZNF76 and ZNF143 mRNAs were expressed in all normal adult tissues examined, By using in vivo and irt vitro assays, we have analyzed the DNA binding capacities and transcriptional properties of ZNF76 and ZNF143. The binding affinities of ZNF76 and ZNF143 for Staf divergent responsive elements were determined by gel shift assays, which revealed that the two proteins hound a same DNA motif with similar affinities, Also, polypeptide sequences containing the seven zinc fingers of ZNF76 and ZNF143 could efficiently repress in vivo the activated transcription from an snRNA-type promoter. Transfection experiments in Drosophila cells showed that ZNF76 and ZNF143 can activate transcription from an mRNA promoter through the Staf binding site. Finally, chimeric ZNF76 and ZNF143 proteins, carrying a heterologous DNA binding domain, are able to activate a Pol II mRNA promoter and snRNA Pol II and Pol III promoters in Xenopus oocytes, through the heterologous DNA binding site. Taken together, these findings demonstrate that ZNF76 and ZNF143 are two members of a same family of transactivator proteins. ZNF143 constitutes the human ortholog of the Xenopus Staf, and ZNF76 is a novel DNA binding protein related to Staf and ZNF143.	Inst Biol Mol & Cellulaire, UPR 9002 CNRS, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Carbon, P (corresponding author), Inst Biol Mol & Cellulaire, UPR 9002 CNRS, 15 Rue Rene Descartes, F-67084 Strasbourg, France.							ADACHI K, 1993, J BIOL CHEM, V273, P5598; ARES M, 1987, GENE DEV, V1, P808, DOI 10.1101/gad.1.8.808; Carey M, 1991, CURR OPIN CELL BIOL, V3, P452, DOI 10.1016/0955-0674(91)90073-8; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; HERNANDEZ N, 1992, TRANSCRIPTIONAL REGU, V1, P281; HERR W, 1992, TRANSCRIPTIONAL REGU, V1, P1103; Houbaviy HB, 1996, P NATL ACAD SCI USA, V93, P13577, DOI 10.1073/pnas.93.24.13577; JANSON L, 1987, NUCLEIC ACIDS RES, V15, P4997, DOI 10.1093/nar/15.13.4997; JOHNSON PF, 1993, J NUTR BIOCHEM, V4, P386, DOI 10.1016/0955-2863(93)90069-9; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; LESCURE A, 1992, J MOL BIOL, V228, P387, DOI 10.1016/0022-2836(92)90828-8; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; MYSLINSKI E, 1993, J MOL BIOL, V234, P311, DOI 10.1006/jmbi.1993.1588; MYSLINSKI E, 1992, NUCLEIC ACIDS RES, V20, P203, DOI 10.1093/nar/20.2.203; Omichinski JG, 1997, NAT STRUCT BIOL, V4, P122, DOI 10.1038/nsb0297-122; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; RAGOUSSIS J, 1992, GENOMICS, V14, P673, DOI 10.1016/S0888-7543(05)80167-3; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; Schuster C, 1998, MOL CELL BIOL, V18, P2650, DOI 10.1128/MCB.18.5.2650; SCHUSTER C, 1995, EMBO J, V14, P3777, DOI 10.1002/j.1460-2075.1995.tb00047.x; TEBB G, 1989, MOL CELL BIOL, V9, P1682, DOI 10.1128/MCB.9.4.1682; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; VESQUE C, 1992, NUCLEIC ACIDS RES, V20, P2485, DOI 10.1093/nar/20.10.2485; Wang Y, 1998, MOL CELL BIOL, V18, P1570, DOI 10.1128/MCB.18.3.1570; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291	36	71	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21998	22006		10.1074/jbc.273.34.21998	http://dx.doi.org/10.1074/jbc.273.34.21998			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705341	hybrid			2022-12-25	WOS:000075492600075
J	Takeshita, A; Yen, PM; Ikeda, M; Cardona, GR; Liu, Y; Koibuchi, N; Norwitz, ER; Chin, WW				Takeshita, A; Yen, PM; Ikeda, M; Cardona, GR; Liu, Y; Koibuchi, N; Norwitz, ER; Chin, WW			Thyroid hormone response elements differentially modulate the interactions of thyroid hormone receptors with two receptor binding domains in the steroid receptor coactivator-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIB; ACTIVATION FUNCTION AF-2; VITAMIN-D RECEPTORS; NUCLEAR RECEPTORS; ESTROGEN-RECEPTOR; TRANSACTIVATION DOMAIN; GENE-TRANSCRIPTION; CRYSTAL-STRUCTURE; RETINOIC ACID; CO-REPRESSOR	Ligand-dependent transcriptional activation by nuclear receptors is mediated by interactions with coactivators. Recently, a consensus interaction motif (LXXLL) has been identified in a number of coactivators such as steroid receptor coactivator-l (SRC-1). SRC-1 contains three such motifs in the central (nuclear receptor binding domain-1, NBD-1) and a single one in the C-terminal (NBD-S) regions. To define the nature and role of the two NBDs in SRC-1, interaction studies between the two NBDs and thyroid hormone receptor (TR) were performed. Although NBD-1 and NBD-S showed similar ligand- and AF-a dependent interactions with TR, in solution, these two NBDs possessed distinct interaction properties with TR when TR is bound to a thyroid hormone-response element (TRE). Both in vitro and in vivo interaction studies demonstrate that NBD-1, but not NBD-2, exhibits ligand-dependent interaction with TR in the presence of TREs. In addition, a natural isoform of SRC-1, SRC-1E, which lacks NBD-2, preserved TR as well as progesterone receptor-mediated coactivator function on reporter gene expression. Finally, we found that NBD-1 failed to interact with a TR and retinoid X receptor heterodimer complex on a transcriptionally inactive direct repeat +4 TRE in electrophoretic mobility shift assays. These observations indicate that DNA-induced, as well as ligand-induced, conformational change(s) of TR may influence the nature of its binding to SRC-1, and that the two NBDs of SRC-I may play different roles to regulate ligand-dependent transactivation of TRs.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Genet, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Takeshita, A (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Genet, GW Thorn Res Bldg,Rm 1005,20 Shattuck St, Boston, MA 02115 USA.	takeshita@rascal.med.harvard.edu	Yen, Paul M/V-9857-2019	Koibuchi, Noriyuki/0000-0002-2247-9740; Yen, Paul/0000-0002-3790-8114				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Fondell JD, 1996, MOL CELL BIOL, V16, P281; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hayashi Y, 1997, BIOCHEM BIOPH RES CO, V236, P83, DOI 10.1006/bbrc.1997.6911; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; ING NH, 1992, J BIOL CHEM, V267, P17617; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LHorset F, 1996, MOL CELL BIOL, V16, P6029; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liu Y, 1998, MOL ENDOCRINOL, V12, P34, DOI 10.1210/mend.12.1.0046; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Monden T, 1997, J BIOL CHEM, V272, P29834, DOI 10.1074/jbc.272.47.29834; ONATE SA, 1995, SCIENCE, V270, P1354; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RON D, 1992, BIOTECHNIQUES, V13, P866; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; SUEN CS, 1995, ENDOCRINOLOGY, V136, P2776, DOI 10.1210/en.136.6.2776; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; TONE Y, 1994, J BIOL CHEM, V269, P31157; TONEY JH, 1993, BIOCHEMISTRY-US, V32, P2, DOI 10.1021/bi00052a001; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VASAVADA HA, 1991, P NATL ACAD SCI USA, V88, P10686, DOI 10.1073/pnas.88.23.10686; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; YEN PM, 1992, J BIOL CHEM, V267, P3565; Yen PM, 1996, J BIOL CHEM, V271, P10910, DOI 10.1074/jbc.271.18.10910; YEN PM, 1992, J CLIN INVEST, V90, P1825, DOI 10.1172/JCI116058	52	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21554	21562		10.1074/jbc.273.34.21554	http://dx.doi.org/10.1074/jbc.273.34.21554			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705285	hybrid			2022-12-25	WOS:000075492600019
J	Atkinson, EA; Barry, M; Darmon, AJ; Shostak, I; Turner, PC; Moyer, RW; Bleackley, RC				Atkinson, EA; Barry, M; Darmon, AJ; Shostak, I; Turner, PC; Moyer, RW; Bleackley, RC			Cytotoxic T lymphocyte-assisted suicide - Caspase 3 activation is primarily the result of the direct action of granzyme B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; FAS-MEDIATED APOPTOSIS; DNA FRAGMENTATION; SERINE PROTEASES; RAPID INDUCTION; FAMILY PROTEASE; TARGET-CELLS; SERPIN CRMA; DEATH; CPP32	Cytototoxic T lymphocyte-induced apoptosis can occur either through the directed exocytosis of granzyme B and perforin or via ligation of Fas. Both pathways involve the activation of a family of cysteine proteinases, the caspases, that cleave substrates at aspartic acid and are themselves activated by cleavage at internal aspartate residues. Fas recruits caspase 8, which initiates the death program through the subsequent activation of caspase 3, Granzyme B can process both caspase 8 and 3 in vitro, suggesting that both Fas and granzyme B access the apoptotic program in the same way. Here we demonstrate that although the two mechanisms are similar, the events that lead to activation of caspase 3 can be distinguished in, vivo on the basis of their sensitivities to both pharmacological and virus-encoded caspase inhibitors. In cytotoxic T lymphocytes-mediated death the initial cleavage event on caspase 3 is insensitive to benzyloxycarbonyl-Val-Ala-Asp fluoromethyl ketone (zVAD-fmk) inhibition in both mouse and human systems. During Pas-mediated death, however, activation of caspase 3 is completely inhibited to zVAD-fmk, In addition, the viral serpin SPI-2, a homologue of cytokine response modifier A (crmA), is an effective inhibitor of the Pas but not the granzyme pathway. Our results demonstrate that whereas Fas-mediated activation of caspase 3 requires an upstream caspase activity that is zVAD-fmk-sensitive, the initial cleavage of caspase 3 during granule-mediated cell death is insensitive to zVAD-fmk, suggesting that caspase 3 is cleaved directly by granzyme B in vivo.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA	University of Alberta; State University System of Florida; University of Florida	Bleackley, RC (corresponding author), Univ Alberta, Dept Biochem, 474 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	chris.bleackley@ualberta.ca		Turner, Peter/0000-0002-7706-4593	NIAID NIH HHS [AI 25722] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025722] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Atkinson EA, 1995, CRIT REV IMMUNOL, V15, P359, DOI 10.1615/CritRevImmunol.v15.i3-4.90; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; Chinnaiyan AM, 1996, CURR BIOL, V6, P897, DOI 10.1016/S0960-9822(02)00614-0; Darmon AJ, 1996, J BIOL CHEM, V271, P21699, DOI 10.1074/jbc.271.36.21699; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Dobbelstein M, 1996, J VIROL, V70, P6479, DOI 10.1128/JVI.70.9.6479-6485.1996; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; EBNET K, 1995, EMBO J, V14, P4230, DOI 10.1002/j.1460-2075.1995.tb00097.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; GARNER R, 1994, J IMMUNOL, V153, P5413; Gu Y, 1996, J BIOL CHEM, V271, P10816, DOI 10.1074/jbc.271.18.10816; Hasegawa J, 1996, CANCER RES, V56, P1713; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kettle S, 1997, J GEN VIROL, V78, P677, DOI 10.1099/0022-1317-78-3-677; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Macen JL, 1996, P NATL ACAD SCI USA, V93, P9108, DOI 10.1073/pnas.93.17.9108; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHI L, 1996, J EXP MED, V175, P553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SHRESTA S, 1995, P NATL ACAD SCI USA, V92, P5679, DOI 10.1073/pnas.92.12.5679; SHRESTA S, 1995, IMMUNOL REV, V146, P211, DOI 10.1111/j.1600-065X.1995.tb00690.x; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	42	126	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21261	21266		10.1074/jbc.273.33.21261	http://dx.doi.org/10.1074/jbc.273.33.21261			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694885	hybrid			2022-12-25	WOS:000075386100078
J	Naylor, DJ; Stines, AP; Hoogenraad, NJ; Hoj, PB				Naylor, DJ; Stines, AP; Hoogenraad, NJ; Hoj, PB			Evidence for the existence of distinct mammalian cytosolic, microsomal, and two mitochondrial GrpE-like proteins, the co-chaperones of specific Hsp70 members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; NUCLEOTIDE-EXCHANGE FACTOR; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; MESSENGER-RNA; HOMOLOG; SYSTEM; DNAK; PURIFICATION; ATPASE	We previously reported the cDNA cloning and characterization of a mammalian mitochondrial GrpE protein (similar to 21 kDa, mt-GrpE#l) and now provide evidence for the presence of distinct cytosolic (similar to 40 kDa), microsomal (similar to 50 kDa), and additional mitochondrial (similar to 22 kDa, mt-GrpE#2) GrpE-like members. While a cytosolic GrpE-like protein has recently been identified, the demonstration of both a microsomal and a second mitochondrial GrpE-like member represents the first in any biological system, Investigation of the microsomal and two mitochondrial. GrpE-like proteins revealed that they bound specifically to Escherichia coli DnaK, and the complexes formed were not disrupted in the presence of 0.5 M salt but were readily dissociated in the presence of 5 mM ATP. The functional integrity of mt-GrpE#l and #2 was verified by their ability to specifically interact with and stimulate the ATPase activity of mammalian mitochondrial Hsp70 (mt-Hsp70), Analysis of the cDNA sequences encoding the two mammalian mitochondrial GrpE-like proteins revealed similar to 47% positional identity at the amino acid level, the presence of a highly conserved mitochondrial leader sequence, and putative destabilization elements within the 3'-untranslated region of the mt-GrpE#2 transcript which are not present in the mt-GrpE#1 transcript. A constitutive expression of both mitochondrial GrpE-like transcripts in 22 distinct mouse tissues was observed but possible different posttranscriptional regulation of the mt-GrpE#l and #2 transcripts may confer a different expression pattern of the encoded proteins.	Univ Adelaide, Dept Hort Viticulture & Oenol, Dept Agron, Glen Osmond, SA 5064, Australia; Australian Wine Res Inst, Glen Osmond, SA, Australia; La Trobe Univ, Sch Biochem, Bundoora, Vic 3083, Australia	University of Adelaide; Australian Wine Research Institute; La Trobe University	Naylor, DJ (corresponding author), Univ Adelaide, Dept Hort Viticulture & Oenol, Dept Agron, Waite Campus,PMB1, Glen Osmond, SA 5064, Australia.		Hoogenraad, Nicholas J/C-7505-2011; Hoj, Peter B/E-8526-2011					Azem A, 1997, J BIOL CHEM, V272, P20901, DOI 10.1074/jbc.272.33.20901; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; Deloche O, 1996, J BIOL CHEM, V271, P23960, DOI 10.1074/jbc.271.39.23960; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gething MJ., 1997, GUIDEBOOK MOL CHAPER; Harlow E., 1988, ANTIBODIES LAB MANUA; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HOHOFELD J, 1997, EMBO J, V16, P6209; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; IKEDA E, 1994, FEBS LETT, V339, P265, DOI 10.1016/0014-5793(94)80428-1; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LAROSA PC, 1992, PLANT PHYSIOL, V100, P409, DOI 10.1104/pp.100.1.409; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MARTINUS RD, 1995, FASEB J, V9, P371, DOI 10.1096/fasebj.9.5.7896006; MEHTA AD, 1997, GUIDEBOOK MOL CHAPER, P141; NAKAI M, 1994, BIOCHEM BIOPH RES CO, V200, P435, DOI 10.1006/bbrc.1994.1468; NAYLOR DJ, 1995, BBA-PROTEIN STRUCT M, V1248, P75, DOI 10.1016/0167-4838(95)00007-H; Naylor DJ, 1996, FEBS LETT, V396, P181, DOI 10.1016/0014-5793(96)01100-3; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Rajagopalan LE, 1997, PROG NUCLEIC ACID RE, V56, P257, DOI 10.1016/S0079-6603(08)61007-7; RAKAYAMA S, 1997, EMBO J, V16, P4887; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; RYANMT, 1997, INT REV CYTOL, V174, P127; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schlicher T, 1997, PLANT MOL BIOL, V33, P181, DOI 10.1023/A:1005784115363; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; VOOS W, 1994, MOL CELL BIOL, V14, P6627, DOI 10.1128/MCB.14.10.6627; WEBSTER TJ, 1994, DNA CELL BIOL, V13, P1213, DOI 10.1089/dna.1994.13.1213; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; Wu B, 1996, EMBO J, V15, P4806, DOI 10.1002/j.1460-2075.1996.tb00861.x; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	46	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21169	21177		10.1074/jbc.273.33.21169	http://dx.doi.org/10.1074/jbc.273.33.21169			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694873	hybrid			2022-12-25	WOS:000075386100066
J	Carrasco-Serrano, C; Campos-Caro, A; Viniegra, S; Ballesta, JJ; Criado, M				Carrasco-Serrano, C; Campos-Caro, A; Viniegra, S; Ballesta, JJ; Criado, M			GC- and E-box motifs as regulatory elements in the proximal promoter region of the neuronal nicotinic receptor alpha 7 subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; ACETYLCHOLINE-RECEPTOR; CHROMAFFIN CELLS; MOLECULAR-CLONING; NERVOUS-SYSTEM; DNA-BINDING; POU DOMAIN; EGR-1; ACTIVATION; PROTEINS	The alpha 7 subunit is a component of alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors expressed in bovine adrenomedullary chromaffin cells. The proximal promoter of the gene coding for this subunit contains several GC-boxes and one E-box, Deletion analysis and transient transfections showed that a 120-base pair region (-77 to +43) including all of these elements gave rise to similar to 70 and 95% of the maximal transcriptional activity observed in chromaffin and SHSY-5Y neuroblastoma cells, respectively. Site-directed mutagenesis of the different elements indicated that both GC and E motifs contribute to the activity of the alpha 7 gene in a very prominent way. Using electrophoretic mobility shift assays, the upstream stimulatory factor (USF) was shown to be a component of the complexes that interacted with the E-box when nuclear extracts from chromaffin and SHSY-5Y cells were used. Binding of the early growth response gene transcription factor (Egr-l) to three different GC-boxes was also demonstrated by shift assays and DNase I footprint analysis. Likewise, alpha 7 promoter activity increased by up to B-fold when alpha 7 constructs and an Egr-l expression vector were cotransfected into chromaffin cell cultures. Mutagenesis of individual GC-boxes had little effect on Egr-l activation. By contrast, pairwise suppression of GC-boxes abolished activation, especially when the most promoter-proximal of the Egr-l sites was removed. Taken together, these studies indicate that the alpha 7 gene is likely to be a target for multiple signaling pathways, in which various regulatory elements are involved.	Univ Miguel Hernandez, Dept Neurochem, Alicante 03550, Spain; Univ Miguel Hernandez, Dept Pharmacol, Alicante 03550, Spain; Univ Miguel Hernandez, Inst Neurociencias, Alicante, 03550, Spain	Universidad Miguel Hernandez de Elche; Universidad Miguel Hernandez de Elche; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Criado, M (corresponding author), Univ Miguel Hernandez, Dept Neurochem, Alicante 03550, Spain.		Campos-Caro, Antonio/T-2807-2019; Viniegra, Salvador/K-5063-2014; Criado, Manuel/K-5109-2014	Campos-Caro, Antonio/0000-0001-8532-2153; Viniegra, Salvador/0000-0002-3892-8563; Criado, Manuel/0000-0002-3953-0346				BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BESSIS A, 1993, NUCLEIC ACIDS RES, V21, P2185, DOI 10.1093/nar/21.9.2185; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; BIGGER CB, 1996, J BIOL CHEM, V271, P23842; Boyd RT, 1996, NEUROSCI LETT, V208, P73, DOI 10.1016/0304-3940(96)12561-1; BOYD RT, 1994, J NEUROBIOL, V25, P960, DOI 10.1002/neu.480250806; CamposCaro A, 1997, J NEUROCHEM, V68, P488; CAO X, 1990, MOL CELL BIOL, V9, P1931; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; CRIADO M, 1992, NEUROCHEM RES, V17, P281, DOI 10.1007/BF00966671; Criado M, 1997, J NEUROSCI, V17, P6554; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; DYODOROV D, 1998, J NEUROBIOL, V34, P151; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; Fyodorov D, 1996, MOL CELL BIOL, V16, P5004; GANDIA L, 1991, BRIT J PHARMACOL, V103, P1073, DOI 10.1111/j.1476-5381.1991.tb12302.x; GARCIAGUZMAN M, 1995, EUR J NEUROSCI, V7, P647, DOI 10.1111/j.1460-9568.1995.tb00668.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Gu HJ, 1996, J NEUROCHEM, V66, P1454; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; HALLE JP, 1995, J BIOL CHEM, V272, P1753; HERNANDEZ MC, 1995, J BIOL CHEM, V270, P3224, DOI 10.1074/jbc.270.7.3224; Jain N, 1996, J BIOL CHEM, V271, P13530, DOI 10.1074/jbc.271.23.13530; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; LUKAS RJ, 1993, MOL CELL NEUROSCI, V4, P1, DOI 10.1006/mcne.1993.1001; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MILTON NGN, 1995, J BIOL CHEM, V270, P15143, DOI 10.1074/jbc.270.25.15143; PAPKE RL, 1993, PROG NEUROBIOL, V41, P509, DOI 10.1016/0301-0082(93)90028-Q; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEGUELA P, 1993, J NEUROSCI, V13, P596; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trejo SR, 1997, J BIOL CHEM, V272, P27411, DOI 10.1074/jbc.272.43.27411; YANG XD, 1994, J BIOL CHEM, V269, P10252	48	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20021	20028		10.1074/jbc.273.32.20021	http://dx.doi.org/10.1074/jbc.273.32.20021			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685340	hybrid			2022-12-25	WOS:000075305400017
J	Hu, LA; King, SC				Hu, LA; King, SC			Functional significance of the "signature cysteine" in helix 8 of the Escherichia coli 4-aminobutyrate transporter from the amine-polyamine-choline superfamily - Restoration of Cys-300 to the Cys-less gabP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID TRANSPORTERS; LACTOSE PERMEASE; PROTEIN; SPECIFICITY; INHIBITORS; EVOLUTION; SITE	gab permease (GabP) is the exclusive mediator of 4-aminobutyrate (GABA) transport across the Escherichia coli plasma membrane. Helix 8 and a portion of the adjoining cytoplasmic region (loop 8-9) constitute the GabP "consensus amphipathic region" (CAR), a potential channel-forming domain that is found to be evolutionarily conserved within the APC (amine-polyamine-choline) transporter superfamily, Upon the polar surface of the CAR, all known gab permeases display a "signature cysteine" not found in other members of the APC superfamily, suggesting that discrete features within the CAR might play a role in imparting specificity (k(cat)/K-m) to the translocation reaction. Here we show that among the five cysteine residues in the E. coli GabP, only Cys-300, the signature cysteine, can restore wild type properties to the Cys-less GabP mutant. We conclude (i) from partial reaction studies (equilibrium exchange, counterflow) that rapid translocation of the GABA binding site from one side of the membrane to the other is greatly facilitated by Cys-300 and (ii) from pharmacological studies that loss of Cys-300 has little effect on the affinity that GabP exhibits for a structurally diverse array (kojic amine, 5-aminovaleric acid, GABA, nipecotic acid, and cis-4-aminocrotonic acid) of competitive ligands. These results raise the possibility that other GABA transporters might rely analogously upon conserved cysteine residues positioned within the amphipathic helix 8 and loop 8-9 regions.	Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	King, SC (corresponding author), Univ Texas, Med Branch, Dept Physiol & Biophys, 301 Univ Blvd, Galveston, TX 77555 USA.	steven.king@utmb.edu						Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; Brechtel CE, 1996, J BIOL CHEM, V271, P783, DOI 10.1074/jbc.271.2.783; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; HU LA, 1998, BIOCHEM J, V300, P771; JESSENMARSHALL AE, 1995, J BIOL CHEM, V270, P16251, DOI 10.1074/jbc.270.27.16251; JessenMarshall AE, 1996, J BIOL CHEM, V271, P1400, DOI 10.1074/jbc.271.3.1400; JessenMarshall AE, 1997, J BACTERIOL, V179, P2616, DOI 10.1128/jb.179.8.2616-2622.1997; KING SC, 1995, J BIOL CHEM, V270, P19893, DOI 10.1074/jbc.270.34.19893; KING SC, 1995, J BACTERIOL, V177, P5381, DOI 10.1128/jb.177.18.5381-5382.1995; KING SC, 1997, HDB PSYCHIAT GENETIC, P163; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; Miller J. H., 1972, EXPT MOL GENETICS, P398; Pazdernik NJ, 1997, J BIOL CHEM, V272, P26110, DOI 10.1074/jbc.272.42.26110; Pazdernik NJ, 1997, J BACTERIOL, V179, P735, DOI 10.1128/jb.179.3.735-741.1997; REIZER J, 1993, PROTEIN SCI, V2, P20, DOI 10.1002/pro.5560020103; ROSENBERG T, 1957, J GEN PHYSIOL, V41, P289, DOI 10.1085/jgp.41.2.289; SAIER MH, 1994, MICROBIOL REV, V58, P71, DOI 10.1128/MMBR.58.1.71-93.1994; SAIER MH, 1994, BIOESSAYS, V16, P23, DOI 10.1002/bies.950160104; SOPHIANOPOULOU V, 1995, FEMS MICROBIOL REV, V16, P53, DOI 10.1016/0168-6445(94)00091-C; TAMURA S, 1995, J BIOL CHEM, V270, P28712, DOI 10.1074/jbc.270.48.28712; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6	24	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20162	20167		10.1074/jbc.273.32.20162	http://dx.doi.org/10.1074/jbc.273.32.20162			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685361	hybrid			2022-12-25	WOS:000075305400038
J	MacLeod, RJ; Lembessis, P; James, S; Bennett, HPJ				MacLeod, RJ; Lembessis, P; James, S; Bennett, HPJ			Isolation of a member of the Neurotoxin/Cytotoxin peptide family from Xenopus laevis skin which activates dihydropyridine-sensetive Ca2+ channels in mammalian epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; REGULATORY VOLUME DECREASE; PROTEIN-KINASE-C; CALCIUM CHANNELS; P-GLYCOPROTEIN; DRUG TRANSPORT; RAT PITUITARY; MAJOR FORMS; FROG-SKIN; DOMAIN	We have used a sensitive bioassay of calcium-mediated volume changes in mammalian absorptive intestinal epithelial cells to screen extracts of the skin of the amphibian Xenopus laevis for the presence of factors affecting ion transport. A 66-residue peptide, purified using reversed-phase high performance liquid chromatography techniques, caused isotonic volume reduction of guinea pig jejunal villus cells in suspension. This volume reduction required extracellular Ca2+ and was prevented by the dihydropyridine-sensitive Ca2+ channel blocker niguldipine, Structural analysis demonstrated the presence of eight cysteines and a primary structure homologous to that of the neurotoxin/cytotoxin family found in the venom of certain poisonous snakes. The structure of the peptide was identical to that of xenoxin-1 purified from dorsal gland secretions of X. laevis (Kolbe, M., Huber A., Cordier, P., Rasmussen, U,, Bouchon, B,, Jaquinod, M,, Blasak, it,, Detot, E., and Kreil, G. (1993) J. Biol Chem, 268, 16458-16464), Xenoxin-l (10 nM) caused volume changes that required extracellular Ca2+ and were comparable in magnitude and direction to changes caused by BayK-8644 (100 nM), a dihydropyridine-sensitive Ca2+ channel agonist, The initial rate of dihydropyridine-sensitive Ca-45(2+) influx was substantially increased by xenoxin-l. Staurosporine (10 nM) prevented volume changes caused by ATP (250 mu M) but had no effect on volume changes caused by BayK-8644 or xenoxin-l. We conclude that xenoxin-l directly activated dihydropyridine-sensitive Ca2+ channels in villus cells and that a mammalian homologue to xenoxin-l may exist.	Royal Victoria Hosp, Endocrine Lab, Montreal, PQ H3A 1A1, Canada; McGill Univ, Montreal Childrens Hosp, Res Inst, Montreal, PQ H3H 1P3, Canada; McGill Univ, Fac Med, Montreal, PQ H3H 1P3, Canada	McGill University; Royal Victoria Hospital; McGill University; McGill University	Bennett, HPJ (corresponding author), Royal Victoria Hosp, Endocrine Lab, L2-05,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	bennett@pathology.lan.mcgill.ca		Lembessis, Panagiotis/0000-0001-8972-3499				BELCOURT DR, 1993, J BIOL CHEM, V268, P9230; BENNETT HPJ, 1989, ANAL BIOCHEM, V179, P222, DOI 10.1016/0003-2697(89)90119-X; BENNETT HPJ, 1981, BIOCHEMISTRY-US, V20, P4530, DOI 10.1021/bi00519a004; BENNETT HPJ, 1983, ANAL BIOCHEM, V128, P121, DOI 10.1016/0003-2697(83)90352-4; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; Boer R, 1996, BIOCHEMISTRY-US, V35, P1387, DOI 10.1021/bi951912u; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; DONOWITZ M, 1989, J CLIN INVEST, V83, P1953, DOI 10.1172/JCI114104; DONOWITZ M, 1985, AM J PHYSIOL, V248, pC726; ERSPAMER V, 1971, ANNU REV PHARMACOLOG, V11, P327, DOI 10.1146/annurev.pa.11.040171.001551; GIBSON BW, 1986, J BIOL CHEM, V261, P5341; GIOVANNINI MG, 1987, BIOCHEM J, V243, P113, DOI 10.1042/bj2430113; GRAZIADEI I, 1989, EUR J PHARM-MOLEC PH, V172, P329, DOI 10.1016/0922-4106(89)90013-8; Hamaguchi N, 1996, BIOCHEMISTRY-US, V35, P14312, DOI 10.1021/bi961024e; HOLLT V, 1992, BIOCHEM PHARMACOL, V43, P2601, DOI 10.1016/0006-2952(92)90149-D; HOMAIDAN FR, 1989, AM J PHYSIOL, V257, pG86, DOI 10.1152/ajpgi.1989.257.1.G86; KOLBE HVJ, 1993, J BIOL CHEM, V268, P16458; MACLEOD RJ, 1991, AM J PHYSIOL, V260, pG405, DOI 10.1152/ajpgi.1991.260.3.G405; MACLEOD RJ, 1994, AM J PHYSIOL, V267, pG387, DOI 10.1152/ajpgi.1994.267.3.G387; MACLEOD RJ, 1992, J MEMBRANE BIOL, V130, P23; MACLEOD RJ, 1990, AM J PHYSIOL, V258, pG665, DOI 10.1152/ajpgi.1990.258.5.G665; MACLEOD RJ, 1991, P NATL ACAD SCI USA, V88, P552, DOI 10.1073/pnas.88.2.552; MacLeod RJ, 1996, J BIOL CHEM, V271, P23138, DOI 10.1074/jbc.271.38.23138; MACLEOD RJ, 1992, AM J PHYSIOL, V262, pC950, DOI 10.1152/ajpcell.1992.262.4.C950; MASON MJ, 1991, J BIOL CHEM, V266, P20856; Palfree RGE, 1996, TISSUE ANTIGENS, V48, P71, DOI 10.1111/j.1399-0039.1996.tb02610.x; ROBINSON JP, 1990, BRIT J PHARMACOL, V100, P3, DOI 10.1111/j.1476-5381.1990.tb12041.x; ROMANIN C, 1992, PFLUG ARCH EUR J PHY, V420, P410, DOI 10.1007/BF00374478; SELSTED ME, 1987, IMMUNOLOGY, V155, P2281; SPEDDING M, 1992, PHARMACOL REV, V44, P363; SU CM, 1986, CAN J PHYSIOL PHARM, V64, P909, DOI 10.1139/y86-157; USSING HH, 1986, RENAL PHYSIOL BIOCH, V9, P38; USSING HH, 1949, ACTA PHYSIOL SCAND, V17, P1, DOI 10.1111/j.1748-1716.1949.tb00550.x; vanRhee AM, 1996, J MED CHEM, V39, P2980, DOI 10.1021/jm9600205	34	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20046	20051		10.1074/jbc.273.32.20046	http://dx.doi.org/10.1074/jbc.273.32.20046			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685343	hybrid			2022-12-25	WOS:000075305400020
J	Cartwright, P; Muller, H; Wagener, C; Holm, K; Helin, K				Cartwright, P; Muller, H; Wagener, C; Holm, K; Helin, K			E2F-6: a novel member of the E2F family is an inhibitor of E2F-dependent transcription	ONCOGENE			English	Article						E2F-6; inhibitor; cell cycle	RETINOBLASTOMA GENE-PRODUCT; UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE REGULATION; IN-VIVO; S-PHASE; GROWTH SUPPRESSION; E2F-BINDING SITE; BINDING PROTEIN; EXPRESSION; PROMOTER	The E2F family of transcription factors are essential for the regulation of genes required for appropriate progression through the cell cycle. Five members of the E2F family have been previously reported, namely E2F1-5. All five are key elements in transcriptional regulation of essential genes, and they can be divided into two functional groups, those that induce S-phase progression when overexpressed in quiescent cells (E2Fs 1-3), and those that do not (E2Fs 4-5). Here, we describe the identification of a novel member of this family, which we refer to as E2F-6, E2F-6 shares significant homology with E2Fs 1-5, especially within the DNA binding, heterodimerization and marked box domains. Unlike E2Fs 1-5, E2F-6 lacks a transactivation and a pocket protein binding domain, hence, forms a unique third group within the E2F family, E2F-6 is a nuclear protein that can form heterodimers with the DP proteins (both DP-I and DP-2) in vitro and in vivo. Our results show that the complex formed between E2F-6 and the DP proteins, possesses high DNA binding activity, displaying a preference for a TTTCCCGC E2F recognition site, which is slightly different to the E2F consensus site derived from the E2 promoter (TTTCGCGC). In contrast to the other members of the E2F family, ectopic expression of E2F-6 inhibits transcription from promoters possessing E2F recognition sites rather than activating transcription. In addition, overexpression of E2F-6 suppresses the transactivational effects of coexpression of E2F-1 and DP-1. The inhibitory effect of E2F-6 is dependent on its DIVA binding activity and its ability to form heterodimers with the DPs, Interestingly, ectopic expression of E2F-6 leads to accumulation of cells in S-phase, Our data suggest that E2F-6 expression delays the exit from S-phase rather than inducing S-phase, which further emphasizes the functional difference between E2F-6 and the previously known E2F family members.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Helin, K (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Helin, Kristian/HDM-8306-2022; Helin, Kristian/K-2526-2019	Helin, Kristian/0000-0003-1975-6097; Muller, Heiko/0000-0001-9873-3146				Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Botz J, 1996, MOL CELL BIOL, V16, P3401; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Geng Y, 1996, ONCOGENE, V12, P1173; Harlow E., 1988, ANTIBODIES LAB MANUA; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MELLILO RM, 1994, MOL CELL BIOL, V14, P8241; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Muller H, 1997, MOL CELL BIOL, V17, P5508; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; OUELLETTE MM, 1992, ONCOGENE, V7, P1075; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wu CL, 1996, MOL CELL BIOL, V16, P3698; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	61	160	164	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					611	623		10.1038/sj.onc.1201975	http://dx.doi.org/10.1038/sj.onc.1201975			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704927				2022-12-25	WOS:000075195300009
J	Lewis, ML; Reynolds, JL; Cubano, LA; Hatton, JP; Lawless, BD; Piepmeier, EH				Lewis, ML; Reynolds, JL; Cubano, LA; Hatton, JP; Lawless, BD; Piepmeier, EH			Spaceflight alters microtubules and increases apoptosis in human lymphocytes (Jurkat)	FASEB JOURNAL			English	Article						cytoskeleton; Fas/APO-1; glucose metabolism; MTOC	PROTEIN-KINASE-C; CELLS; ACTIVATION; MICROGRAVITY; MEMBRANE; ISOZYME	Alteration in cytoskeletal organization appears to underlie mechanisms of gravity sensitivity in space-flown cells. Human T lymphoblastoid cells (Jurkat) were flown on the Space Shuttle to test the hypothesis that growth responsiveness is associated with microtubule anomalies and mediated by apoptosis. Cell growth was stimulated in microgravity by increasing serum concentration. After 4 and 48 h, cells filtered from medium were fixed with formalin, Postflight, confocal microscopy revealed diffuse, shortened microtubules extending from poorly defined microtubule organizing centers (MTOCs), In comparable ground controls, discrete microtubule filaments radiated from organized MTOCs and branched toward the cell membrane. At 4 h, 30% of flown, compared to 17% of ground, cells showed DNA condensation characteristic of apoptosis. Time-dependent increase of the apoptosis-associated Fas/ APO-l protein in static flown, but not the in-flight 1 g centrifuged or ground controls, confirmed microgravity-associated apoptosis, By 48 h, ground cultures had increased by 40%, Flown populations did not increase, though some cells were cycling and actively metabolizing glucose. We conclude that cytoskeletal alteration, growth retardation, and metabolic changes in space-flown lymphocytes are concomitant with increased apoptosis and time-dependent elevation of Fas/APO-1 protein. We suggest that reduced growth response in lymphocytes during spaceflight is linked to apoptosis.	Univ Alabama, Micrograv Biotechnol Lab, Huntsville, AL 35899 USA; Estab Transfus Sanguine Strasbourg, INSERM, U311, F-67065 Strasbourg, France; Rockefeller Univ, Steinman Cohn Lab New York, New York, NY 10021 USA; Univ Texas, Dept Pharmaceut, Austin, TX 78235 USA	University of Alabama System; University of Alabama Huntsville; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Rockefeller University; University of Texas System; University of Texas Austin	Lewis, ML (corresponding author), Univ Alabama, Wilson Hall,Rm 360, Huntsville, AL 35899 USA.			Reynolds, Julie/0000-0002-6749-4514				Boise LH, 1996, SCIENCE, V274, P67, DOI 10.1126/science.274.5284.67; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Cogoli A, 1996, J Gravit Physiol, V3, P1; DEGROOT RP, 1991, EXP CELL RES, V197, P87, DOI 10.1016/0014-4827(91)90483-B; GENZEL P, 1988, ESA, P21; GRINDELAND R, 1990, FINAL REPORTS US EXP; GRUENER R, 1993, ASGSB B, V7, P65; HOEGER G, 1990, ASGSB B, V4, P42; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; HUGHESFULFORD M, 1924, ASGSB B, V731, P93; Hymer W C, 1985, Physiologist, V28, pS197; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; KAPLAN J, 1982, J CELL BIOL, V94, P12, DOI 10.1083/jcb.94.1.12; KILEY SC, 1995, J CELL SCI, V108, P1003; Klaus D, 1997, MICROBIOL-SGM, V143, P449, DOI 10.1099/00221287-143-2-449; KOLBER MA, 1990, FASEB J, V4, P3021, DOI 10.1096/fasebj.4.12.2394319; LEWIS ML, 1996, FUNDAMENTALS SPACE L, P21; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; MARTIN SJ, 1990, CELL TISSUE KINET, V23, P545, DOI 10.1111/j.1365-2184.1990.tb01345.x; MATYLEVICH N P, 1991, Radiobiologiya, V31, P27; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; Moos P. J., 1988, ASGSB B, V2, P55; MURTI KG, 1992, EXP CELL RES, V202, P36, DOI 10.1016/0014-4827(92)90401-S; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OEHM A, 1992, J BIOL CHEM, V267, P10709; OSBORN M, 1976, P NATL ACAD SCI USA, V73, P867, DOI 10.1073/pnas.73.3.867; Piepmeier EH, 1997, EXP CELL RES, V237, P410, DOI 10.1006/excr.1997.3813; RIJKENP J, 1989, ELGRA NEWS, V11, P3; Schmitt DA, 1996, FASEB J, V10, P1627, DOI 10.1096/fasebj.10.14.9002555; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Todd P, 1989, ASGSB Bull, V2, P95; WALKER PR, 1993, EXP CELL RES, V207, P142, DOI 10.1006/excr.1993.1173	33	211	232	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					1007	1018		10.1096/fasebj.12.11.1007	http://dx.doi.org/10.1096/fasebj.12.11.1007			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707173				2022-12-25	WOS:000075372600011
J	Grundy, RG; Pritchard, J; Scambler, P; Cowell, JK				Grundy, RG; Pritchard, J; Scambler, P; Cowell, JK			Loss of heterozygosity for the short arm of chromosome 7 in sporadic Wilms tumour	ONCOGENE			English	Article						Wilms tumour; LOH 7p; WT tumour suppressor gene 7p 21-15	DENYS-DRASH SYNDROME; WT1 GENE; FAMILIAL PREDISPOSITION; DISTINCT REGIONS; POINT MUTATIONS; RENAL TUMORS; TRANSLOCATION; ABNORMALITIES; CHILDHOOD; LOCUS	Cytogenetic analysis of Wilms tumours (WT) have shown that abnormalities involving chromosome 7 occur in approximately 25% of tumours, In some cases, these abnormalities involve deletions of the short arm, and are seen as the sole cytogenetic change, strongly suggesting the presence of a tumour suppressor gene in this location. Since loss of heterozygosity (LOH) studies have been crucial in defining chromosomal regions involved in Wilms tumorigenesis, we have analysed 40 sporadic Wilms tumours using a panel of 10 microsatelite polymorphic markers distributed along the length of the chromosome arm. In our series, four tumours (10%) showed allelic loss for 7p markers which is twice the background rate of LOH in WT. The shortest common region of overlap of LOH was located between markers D7S517-D7S503 in band 7p21-15. In one tumour there was evidence for a homozygous, interstitial deletion at a locus within this region. These findings provide strong evidence for the existence of a tumour suppressor gene involved in Wilms tumorigenesis and defines the critical region of the chromosome involved.	Inst Child Hlth, Hematol Oncol Unit, London WC1N 1EH, England; Inst Child Hlth, Fetal Med Unit, London WC1N 1EH, England; Hosp Sick Children, Dept Hematol Oncol, London WC1, England	University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Grundy, RG (corresponding author), Middlesex Hosp, Dept Pediat & Adolescent Oncol, Mortimer St, London W1N 8AA, England.		Scambler, Peter/AAZ-6026-2020; Scambler, Peter J/C-4998-2008	Scambler, Peter/0000-0002-1487-4628; Scambler, Peter J/0000-0002-1487-4628; Cowell, John/0000-0002-2079-5950				AUSTRUY E, 1995, GENE CHROMOSOME CANC, V14, P285, DOI 10.1002/gcc.2870140407; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BAIRD PN, 1992, ONCOGENE, V7, P2141; BARNARD JL, 1984, EUR J PEDS, V141, P175; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BRESLOW N, 1993, MED PEDIATR ONCOL, V21, P172, DOI 10.1002/mpo.2950210305; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; COPPES MJ, 1992, GENE CHROMOSOME CANC, V5, P326, DOI 10.1002/gcc.2870050408; COPPES MJ, 1994, NEW ENGL J MED, V331, P586; DANGIO GJ, 1989, CANCER-AM CANCER SOC, V64, P349, DOI 10.1002/1097-0142(19890715)64:2<349::AID-CNCR2820640202>3.0.CO;2-Q; DEVILEE P, 1991, INT J CANCER, V47, P817, DOI 10.1002/ijc.2910470604; GREEN ED, 1994, HUM MOL GENET, V3, P489, DOI 10.1093/hmg/3.3.489; GRUNDY P, 1988, NATURE, V336, P375; GRUNDY PE, 1994, CANCER RES, V54, P2331; HEWITT M, 1991, J MED GENET, V28, P411, DOI 10.1136/jmg.28.6.411; HUFF V, 1992, CANCER RES, V52, P6117; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; HUFF V, 1991, AM J HUM GENET, V49, P44; KANEKO Y, 1991, CANCER RES, V51, P5937; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1990, CANCER RES, V50, P3279; MAW M, 1986, CANCER RES, V52, P3094; MELONI AM, 1992, J UROLOGY, V148, P253, DOI 10.1016/S0022-5347(17)36565-5; Miozzo M, 1996, GENOMICS, V37, P310, DOI 10.1006/geno.1996.0565; MITLEMAN F, 1991, CYTOGENET CELL GENET, V58, P152; PEIER AM, 1995, CANCER GENET CYTOGEN, V79, P92, DOI 10.1016/0165-4608(94)00110-W; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARD J, 1995, J CLIN ONCOL, V13, P124, DOI 10.1200/JCO.1995.13.1.124; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Reynolds PA, 1996, GENE CHROMOSOME CANC, V17, P151, DOI 10.1002/(SICI)1098-2264(199611)17:3<151::AID-GCC2>3.0.CO;2-3; RIVERA H, 1985, ANN GENET-PARIS, V28, P52; RIVERA H, 1995, CANCER GENET CYTOGEN, V81, P97, DOI 10.1016/S0165-4608(94)00199-5; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SAWYER JR, 1993, CANCER GENET CYTOGEN, V69, P57, DOI 10.1016/0165-4608(93)90114-2; SCHWARTZ CE, 1991, GENOMICS, V10, P927, DOI 10.1016/0888-7543(91)90181-D; SLATER RM, 1992, CANCER GENET CYTOGEN, V61, P111, DOI 10.1016/0165-4608(92)90071-F; SLATER RM, 1985, CANCER GENET CYTOGEN, V14, P95, DOI 10.1016/0165-4608(85)90220-1; SOLIS V, 1988, CANCER GENET CYTOGEN, V34, P223, DOI 10.1016/0165-4608(88)90264-6; Tsui L C, 1995, Cytogenet Cell Genet, V71, P2; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; WADEY RB, 1990, ONCOGENE, V5, P901; WANGWUU S, 1990, CANCER RES, V50, P2786; WILMORE HP, 1994, CANCER GENET CYTOGEN, V77, P93, DOI 10.1016/0165-4608(94)90221-6	46	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					395	400		10.1038/sj.onc.1201927	http://dx.doi.org/10.1038/sj.onc.1201927			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690521				2022-12-25	WOS:000074947500014
J	Wu, RC; Hohenstein, A; Park, JM; Qiu, XB; Mueller, S; Cadenas, E; Schonthal, AH				Wu, RC; Hohenstein, A; Park, JM; Qiu, XB; Mueller, S; Cadenas, E; Schonthal, AH			Role of p53 in aziridinylbenzoquinone-induced p21(waf1) expression	ONCOGENE			English	Article						p21; p53; quinones; aziridinylbenzoquinones	CYCLIN-DEPENDENT KINASES; DT-DIAPHORASE; P53-INDEPENDENT PATHWAY; ANTICANCER AGENTS; DNA-DAMAGE; OXIDATIVE STRESS; CELL-GROWTH; P21; SENSITIVITY; METABOLISM	Quinones are the second largest family of anticancer drugs clinically used in the United States. However, their exact mode of action at the cellular and molecular level is not completely understood. We have shown earlier that the quinone 3,6-diaziridinyl-1,4-benzoquinone (DZQ) leads to the increased expression of p21(waf1/cip/sdi1) protein, an inhibitor of cyclin-dependent kinases, Because p21 has been established as an important negative regulator of the cell cycle, we further investigated the molecular basis of p21 induction by DZQ. Here we report that the induction of p21 by DZQ is regulated at the transcriptional level, and requires the activation of p53, a tumor suppressor protein. In cells that lack functional p53 protein, DZQ-mediated p21 induction is greatly diminished. However, the introduction of a wild type p53 gene into p53-negative cells restores the strong DZQ-inducibility of p21. Restoration of wild type p53 status in HL60 myeloid leukemia cells significantly increases the cells' sensitivity to the cytotoxic effects of DZQ. Thus, our results indicate that the p53-p21 pathway may play a central role in mediating the gene-regulatory and cytotoxic effects of aziridinylbenzoquinones.	Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California	Schonthal, AH (corresponding author), Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, 2011 Zonal Ave,HMR-405, Los Angeles, CA 90033 USA.		Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653; Qiu, Xiao-Bo/0000-0003-2608-9376	NCI NIH HHS [R29CA74278-01] Funding Source: Medline; NHLBI NIH HHS [R01HL53467] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074278] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053467] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BANERJEE D, 1995, CELL GROWTH DIFFER, V6, P1405; CADENAS E, 1995, BIOCHEM PHARMACOL, V49, P127, DOI 10.1016/S0006-2952(94)00333-5; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; Coursen JD, 1997, MOL CARCINOGEN, V19, P191; CRESTEIL T, 1991, BIOCHEM PHARMACOL, V42, P1021, DOI 10.1016/0006-2952(91)90284-C; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; Gansauge S, 1997, FEBS LETT, V404, P6, DOI 10.1016/S0014-5793(97)00059-8; GIBSON NW, 1992, MOL PHARMACOL, V42, P531; GUTIERREZ PL, 1989, FREE RADICAL BIO MED, V6, P405, DOI 10.1016/0891-5849(89)90087-7; Harlow E., 1988, ANTIBODIES LAB MANUA; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hawkins DS, 1996, CANCER RES, V56, P892; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; LEE CS, 1992, BIOCHEMISTRY-US, V31, P3019, DOI 10.1021/bi00126a025; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Liu Y, 1996, CANCER RES, V56, P31; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Martinez JD, 1997, CELL GROWTH DIFFER, V8, P941; MICHIELI P, 1994, CANCER RES, V54, P3391; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OConnor PM, 1997, CANCER RES, V57, P4285; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; POWIS G, 1987, PHARMACOL THERAPEUT, V35, P57, DOI 10.1016/0163-7258(87)90105-7; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; QIU X, 1997, IN PRESS FREE RADIC; Qiu XB, 1996, J BIOL CHEM, V271, P31915, DOI 10.1074/jbc.271.50.31915; Renzing J, 1996, J CELL SCI, V109, P1105; ROSS D, 1996, COMPREHENSIVE TOXICO; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITSKAMPWILMS E, 1995, BRIT J CANCER, V72, P917, DOI 10.1038/bjc.1995.433; Vile GF, 1997, FEBS LETT, V412, P70, DOI 10.1016/S0014-5793(97)00748-5; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wu GS, 1996, NAT MED, V2, P255, DOI 10.1038/nm0396-255a; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	50	6	6	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					357	365		10.1038/sj.onc.1201930	http://dx.doi.org/10.1038/sj.onc.1201930			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690517				2022-12-25	WOS:000074947500010
